In O
spite B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
medical B_PERSON/B_ORGANIZATION
help I_PERSON/I_ORGANIZATION
: O
the O
puzzle B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
eighteenth B_SEQUENCE[MEASURE]/B_LOCATION
- O
century B_PERSON
Prime I_PERSON
Minister I_PERSON
' O
s B_DISEASE
illness I_DISEASE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Medical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
History I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
1990 B_MEASURE
, O
34 B_MEASURE
: O
178 B_MEASURE
- O
184 B_MEASURE
. O

IN O
spite B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OF O
Medical B_PERSON/B_ORGANIZATION
Help I_PERSON/I_ORGANIZATION
: O
THE O
PUZZLE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
OF O
AN O
. O

eighteenth B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Century B_TIME[MEASURE]/B_PERSON
prime I_TIME[MEASURE]/I_PERSON
minister I_TIME[MEASURE]/I_PERSON
' O
S B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

illness B_DISEASE
. O

by B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

MARJORIE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
BLOY I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
* O
. O

Charles B_PERSON
Watson I_PERSON
Wentworth I_PERSON
, O
second B_PERSON
Marquis I_PERSON
of O
Rockingham B_LOCATION
, O
died O
suddenly O
and O
unexpectedly O
on O
1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
July I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
1782 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
when O
he O
was O
only O
52 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
old I_NUMBER[MEASURE]/I_ENT
. O

He O
had O
suffered O
- O
or O
enjoyed O
- O
ill B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
health B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
all O
his O
life B_TIME[MEASURE]/B_PERSON
but O
in O
1782 B_TIME[MEASURE]/B_PERSON
appeared O
to O
be O
no O
worse B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
he O
had O
ever O
been O
. O

His O
death B_PERSON/B_DISEASE
in O
London B_LOCATION/B_MEASURE
terminated O
his O
second B_TIME[MEASURE]/B_PERSON
period B_TIME[MEASURE]/I_PERSON
of O
office B_ORGANIZATION/B_PERSON
as O
Prime B_PERSON
Minister I_PERSON
, O
to O
which O
he O
had O
been O
appointed O
only O
14 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
earlier O
. O

In O
May B_TIME[MEASURE]/B_LOCATION
he O
had O
reported O
to O
the O
Duke B_PERSON/B_LOCATION
of O
Portland B_LOCATION/B_ORGANIZATION
that O
he O
had O
' O
for O
some O
weeks B_TIME[MEASURE]/B_PERSON
past O
undergone O
much B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Pain I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
much B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inconvenience I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
something B_PERSON/B_ENT
similar I_PERSON/I_ENT
to O
my O
old B_DISEASE
complaint I_DISEASE
in O
my O
Side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
stomach B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
' O
but O
that O
he O
felt O
much O
better O
than O
he O
had O
. O
' O
By O
17 B_TIME[MEASURE]
June I_TIME[MEASURE]
he O
was O
recovering O
from O
both O
influenza B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
his O
' O
old B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
complaint I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
' O
. O
2 B_MEASURE/B_LOCATION
On O
1 B_TIME[MEASURE]
July I_TIME[MEASURE]
he O
died O
and O
on O
the O
20th B_SEQUENCE[MEASURE]
he O
was O
interred O
in O
York B_LOCATION
Minster I_LOCATION
. O

The O
first O
recorded O
bout O
of O
illness O
suffered O
by O
the O
Marquis O
, O
then O
Lord O
Higham O
, O
was O
in O
July O
1741 O
when O
the O
11 O
- O
year O
- O
old O
was O
' O
a O
little O
indisposed O
, O
something O
Feaverish O
I O
guess O
it O
proceeds O
from O
worms O
and O
will O
Soon O
be O
removed O
' O
. O
3 O
He O
also O
had O
a O
rash O
and O
it O
was O
thought O
that O
the O
cause O
of O
the O
problem O
was O
that O
the O
boy B_PERSON/B_BIO
had O
overheated O
himself O
. O
4 O
He O
was O
still O
ill O
at O
the O
beginning O
of O
August O
: O
he O
had O
been O
' O
much O
out O
of O
order O
' O
for O
a O
long O
time O
but O
had O
been O
recommended O
to O
take O
warm O
baths O
by O
Dr O
Wilmot O
and O
Mr O
Ranby O
when O
they O
were O
consulted O
in O
London O
. O
5 O
Charles O
' O
s O
aunt O
, O
Lady O
Isabella O
Finch O
, O
was O
sure O
that O
the O
baths O
' O
and O
other O
Things O
They O
' O
ll O
prescribe O
will O
in O
a O
short O
Time O
entirely O
Cure O
his O
complaints O
w O
[ O
hic O
] O
h O
neither O
of O
Them O
thought O
proceed O
from O
any O
dangerous O
causes O
' O
. O
6 O
In O
spite O
of O
Lady O
Isabella O
' O
s O
hopes O
, O
Charles O
did O
not O
greatly O
improve O
, O
even O
though O
his O
mother O
believed O
that O
he O
continued O
mending O
every O
day O
. O

The O
main B_TIME[MEASURE]
reason I_TIME[MEASURE]
that O
Higham B_PERSON
and O
his O
mother B_PERSON
had O
gone O
to O
London B_LOCATION
to O
consult O
Dr B_PERSON
Wilmot I_PERSON
and O
Mr B_PERSON
. O

* B_PERSON/B_LOCATION
Marjorie I_PERSON/I_LOCATION
Bloy I_PERSON/I_LOCATION
, O
Ph B_PROTEIN[GENE]/B_LOCATION
. O
D B_OTHER/B_LOCATION
. O
, O
18 B_LOCATION/B_PERSON
Farm I_LOCATION/I_PERSON
View I_LOCATION/I_PERSON
Road I_LOCATION/I_PERSON
, O
Kimberworth B_PERSON/B_LOCATION
, O
Rotherham B_LOCATION
, O
S B_OTHER/B_LOCATION
. O

Yorks B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O

S61 B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
2BA I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

The O
Rockingham B_ENT/B_LOCATION
Papers I_ENT/I_LOCATION
are O
in O
the O
holdings B_ORGANIZATION/B_LOCATION
of O
the O
Wentworth B_LOCATION/B_ORGANIZATION
Woodhouse I_LOCATION/I_ORGANIZATION
Muniments I_LOCATION/I_ORGANIZATION
at O
Sheffield B_LOCATION/B_TIME[MEASURE]
City B_LOCATION/I_TIME[MEASURE]
Archives B_LOCATION/I_TIME[MEASURE]
Department B_LOCATION/I_TIME[MEASURE]
, O
Sheffield B_LOCATION
City I_LOCATION
Library I_LOCATION
. O

I O
am O
grateful B_PERSON/B_ORGANISM_FUNCTION
to O
Dr B_PERSON/B_LOCATION
R I_PERSON/I_LOCATION
. O

S B_OTHER/B_DISEASE
. O

Morton B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
his O
advice B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
help B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
diagnostic B_TIME[MEASURE]/B_PERSON
sections B_TIME[MEASURE]/I_PERSON
of O
this O
essay B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

' O
WWM B_LOCATION
, O
RI B_MEASURE
- O
2094 B_MEASURE/B_LOCATION
. O

Rockingham B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Portland B_LOCATION/B_ORGANIZATION
, O
25 B_LOCATION/B_PERSON
May I_LOCATION/I_PERSON
1782 I_LOCATION/I_PERSON
. O

2WWM B_LOCATION/B_PERSON
, O
RI B_MEASURE
- O
2094 B_NUMBER[MEASURE]
. O

Rockingham B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Charlemont B_LOCATION
, O
17 B_LOCATION/B_PERSON
June I_LOCATION/I_PERSON
1782 I_LOCATION/I_PERSON
. O

3 B_MEASURE
WWM I_MEASURE
, O
M8 B_MEASURE
- O
25 B_MEASURE
. O

Malton B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
Nottingham B_LOCATION
, O
after O
16 B_LOCATION/B_PERSON
June I_LOCATION/I_PERSON
1741 I_LOCATION/I_PERSON
. O

4 B_MEASURE
WWM I_MEASURE
, O
M8 B_MEASURE
- O
26 B_MEASURE
. O

Lady B_PERSON
Finch I_PERSON
to O
Lady B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
30 B_PERSON/B_LOCATION
July I_PERSON/I_LOCATION
1741 I_PERSON/I_LOCATION
. O

5 B_MEASURE/B_LOCATION
WWM I_MEASURE/I_LOCATION
, O
M8 B_MEASURE
- O
28 B_MEASURE
. O

Winchelsea B_LOCATION/B_BIO
to O
Malton B_LOCATION/B_PERSON
, O
7 B_LOCATION/B_PERSON
August I_LOCATION/I_PERSON
1741 I_LOCATION/I_PERSON
. O

6 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M8 B_MEASURE
- O
29 B_MEASURE
. O

Lady B_PERSON
Finch I_PERSON
to O
Malton B_LOCATION/B_PERSON
, O
7 B_LOCATION/B_PERSON
August I_LOCATION/I_PERSON
1741 I_LOCATION/I_PERSON
. O

178 B_NUMBER[MEASURE]
. O

An O
eighteenth B_SEQUENCE[MEASURE]
- O
century B_PERSON
Prime I_PERSON
Minister I_PERSON
' O
s B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
illness B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Ranby B_PERSON/B_LOCATION
was O
his O
mother B_PERSON
' O
s B_PERSON/B_ORGANISM_FUNCTION
concern I_PERSON/I_ORGANISM_FUNCTION
about O
a O
' O
swelling O
in O
a O
certain B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
was O
larger B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
when O
we O
left O
Wentworth B_LOCATION/B_PERSON
' I_LOCATION/I_PERSON
. O

The O
doctors B_PERSON
hoped O
that O
it O
would O
burst O
outwards B_LOCATION
' I_LOCATION
which O
they O
assure O
me O
will O
be O
the O
safest B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
way I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O
give O
the O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
monkey B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
but O
very O
little B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
pain I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
' O
7 B_TIME[MEASURE]/B_LOCATION
. O

On O
20 O
August O
Lord O
Winchelsea O
, O
Higham O
' O
s O
uncle O
, O
surprised O
to O
see O
the O
boy B_PERSON/B_LOCATION
so O
well O
and O
brisk O
, O
hoped O
that O
Charles O
was O
' O
now O
safe O
from O
this O
complaint O
' O
- O
the O
same O
one O
from O
which O
he O
had O
suffered O
in O
1738 O
- O
39 O
- O
but O
thought O
that O
he O
would O
never O
be O
safe O
' O
if O
he O
continues O
the O
practice O
of O
overheating O
himself O
and O
then O
drinking O
Cold O
Water O
' O
. O

He O
said O
that O
Charles B_PERSON
was O
of O
a O
' O
pretty O
healthy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strong B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Constitution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O
8 B_PERSON
Lady I_PERSON
Malton I_PERSON
was O
not O
so O
sure B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
same B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
she O
wrote O
a O
progress B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
her O
husband B_PERSON
saying O
that O
Charles B_PERSON
' I_PERSON
s O
swelling O
continued O
to O
grow O
, O
as O
did O
the O
pain B_DISEASE/B_PERSON
' O
in O
that O
part B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
but O
not O
the O
lease B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sic I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trouble I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
making O
Water B_LOCATION/B_BIO
or O
going O
to O
stool O
) O
& O
less B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fever B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
c B_OTHER/B_LOCATION
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oulJd B_PERSON/B_LOCATION
be O
imagined O
where O
Matter B_PERSON/B_LOCATION
is O
as O
they O
now O
imagine O
certainly O
gathering O
and O
must O
end O
in O
an O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
' O
. O

In O
spite O
of O
it O
all O
, O
Charles O
was O
in O
fine O
spirits O
. O
9 O
Lady O
Malton O
dosed O
the O
boy B_PERSON/B_BIO
with O
cinchona B_BIO/B_COLOR
bark O
, O
which O
removed O
the O
pains O
in O
his O
legs O
and O
reduced O
his O
fever O
, O
and O
she O
was O
convinced O
that O
they O
would O
soon O
have O
' O
a O
clear O
Stage O
to O
act O
in O
a O
proper O
manner O
a O
[ O
bou O
] O
t O
his O
other O
complaints O
w O
[ O
hic O
] O
h O
the O
learned O
assure O
me O
are O
to O
be O
conquered O
also O
' O
. O

10 B_PERSON
Charles I_PERSON
was O
soon O
allowed O
to O
eat O
meat B_BIO/B_TIME[MEASURE]
and O
Mr B_PERSON
Ranby I_PERSON
still O
assured O
her O
that O
the O
swelling O
would O
break O
outwards B_LOCATION
. O

1 B_MEASURE
' O
Three B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
later O
he O
decided O
to O
lance O
it O
, O
even O
though O
Dr B_PERSON
Bourne I_PERSON
disagreed O
. O

The O
boy B_PERSON
' O
s O
mother O
was O
puzzled O
because O
the O
swelling O
' O
sometimes O
pushes O
forward O
very O
fast O
then O
retires O
a O
little O
' O
but O
the O
doctor O
and O
Ranby O
seemed O
happy O
with O
his O
condition O
. O
' O
2 O
At O
this O
point O
the O
letters O
cease O
, O
presumably O
because O
Malton O
arrived O
in O
London O
with O
his O
daughters O
, O
to O
have O
them O
inoculated O
against O
smallpox B_DISEASE/B_PERSON
, O
but O
a O
later O
letter O
states O
that O
surgery O
to O
open O
the O
swelling O
was O
not O
undertaken O
. O

13 B_NUMBER[MEASURE]
. O

By O
the O
end B_SEQUENCE[MEASURE]/B_LOCATION
of O
October B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
correspondence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
recommenced O
. O

Charles B_PERSON
was O
ill B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
again O
. O

He O
was O
just O
the O
same O
as O
when O
he O
left O
Kensington O
, O
so O
John O
Bourne O
had O
bled O
him O
and O
the O
child B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
started O
on O
Sir O
Edward O
Hulse O
' O
s O
prescription O
, O
unfortunately O
not O
defined O
in O
the O
letter O
, O
but O
which O
was O
apparently O
as O
bad O
as O
the O
last O
one O
, O
if O
not O
worse O
. O

Lady B_PERSON
Malton I_PERSON
thought O
that O
' O
with O
such O
a O
State B_LOCATION/B_PERSON
of O
Blood B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
continuation B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Health B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cannot I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
be O
expected O
' O
but O
was O
hopeful B_PERSON
that O
the O
' O
Cinnabar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O
prove O
a O
more O
Efficacious B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remedie I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
any O
than O
has O
been O
tryed O
yet O
' O
' O
. O
' O
4 B_MEASURE
That O
night B_TIME[MEASURE]
she O
applied O
' O
a O
Blister B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O
. O
. O
without O
the O
least B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Symptom I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
tendency B_TIME[MEASURE]/B_DISEASE
to O
anything B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O
Strangury B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

He O
bore O
the O
treatment O
well O
, O
as O
he O
had O
done O
three O
years O
previously O
, O
and O
it O
seemed O
so O
successful O
that O
Lady O
Malton O
was O
' O
determined O
to O
keep O
it O
running O
full O
as O
long O
as O
I O
did O
last O
time O
by O
the O
help O
of O
John O
borne O
[ O
sic O
] O
with O
much O
ease O
to O
the O
Dear O
Child B_PERSON
' O
. O
' O
5 O
She O
. O

7 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
51 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
18 B_PERSON/B_LOCATION
August B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

8 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M2 B_MEASURE
- O
84 B_NUMBER[MEASURE]
. O

Winchelsea B_LOCATION/B_BIO
to O
Malton B_LOCATION/B_PERSON
, O
20 B_LOCATION/B_PERSON
August I_LOCATION/I_PERSON
1741 I_LOCATION/I_PERSON
. O

9 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
52 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
20 B_PERSON/B_LOCATION
August B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

' O
0 B_MEASURE
WWM I_MEASURE
, O
M7 B_MEASURE
- O
53 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
25 B_PERSON/B_LOCATION
August B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

WWM B_MEASURE/B_LOCATION
, O
M7 B_MEASURE
- O
54 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
29 B_PERSON/B_LOCATION
August B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

WWM B_MEASURE/B_LOCATION
, O
M7 B_MEASURE
- O
55 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton I_PERSON/I_LOCATION
, O
1 B_PERSON/B_LOCATION
September B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

3 B_MEASURE
WWM I_MEASURE
, O
R170 B_MEASURE/B_LOCATION
- O
20 B_MEASURE
. O

Nicol6 B_PERSON/B_LOCATION
Scanagati I_PERSON/I_LOCATION
of O
Padua B_LOCATION
, O
20 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
July I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1750 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

I O
am O
grateful B_PERSON
to O
Fr B_PERSON
John I_PERSON
McMahon I_PERSON
and O
Dr B_PERSON
Stephen I_PERSON
Bemrose I_PERSON
for O
their O
translations B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
letter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

4 B_MEASURE
WWM I_MEASURE
, O
M7 B_MEASURE
- O
14 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
31 B_PERSON/B_LOCATION
October B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

5 B_MEASURE/B_LOCATION
WWM I_MEASURE/I_LOCATION
, O
M7 B_MEASURE
- O
19 B_MEASURE
. O

Lady B_PERSON
Malton I_PERSON
to O
Lady B_LOCATION/B_PERSON
Finch I_LOCATION/I_PERSON
, O
2 B_PERSON/B_LOCATION
November I_PERSON/I_LOCATION
1741 I_PERSON/I_LOCATION
. O

179 B_NUMBER[MEASURE]
. O

Marjorie B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Bloy I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

continued O
with O
the O
blister B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
applied O
' O
ointment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
flyes B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
apparently O
some O
sort B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
irritant B_DISEASE
potion I_DISEASE
, O
with O
no O
sign B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
strangury B_DISEASE
. O

Charles B_PERSON
found O
her O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
' O
not O
near O
the O
pain B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
he O
expected O
' O
and O
she O
was O
' O
full B_MEASURE/B_PERSON
of O
hopes B_PERSON/B_LANGUAGE
that O
he O
will O
rec O
[ B_LOCATION/B_PERSON
eiv I_LOCATION/I_PERSON
] I_LOCATION/I_PERSON
e O
great B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
benefit B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
from O
it O
' O
. O
1 B_TIME[MEASURE]/B_PERSON
. O

Apart O
from O
his O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
troubles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
one B_NUMBER[MEASURE]/B_PERSON
of O
Charles B_PERSON
' I_PERSON
s I_PERSON
knees I_PERSON
had O
swollen O
but O
this O
had O
much O
abated O
since O
the O
application B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
the O
blisters B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
which O
Lady B_PERSON
Malton I_PERSON
believed O
' O
must O
be O
acting O
upon O
the O
whole B_LOCATION/B_PERSON
Mass I_LOCATION/I_PERSON
of O
Blood B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
' O
since O
it O
had O
' O
reached O
the O
remote B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
part I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
' O
. O

She O
thought O
that O
Sir O
Edward O
Hulse O
' O
s O
powders O
were O
too O
slow O
in O
taking O
effect O
although O
the O
boy B_PERSON
took O
them O
very O
quietly O
. O
' O
7 O
Sir O
Edward O
did O
not O
' O
apprehend O
any O
great O
danger O
from O
the O
Siziness O
[ O
thickness O
] O
of O
Charles O
' O
blood O
' O
; O
Lady O
Malton O
thought O
that O
the O
condition O
was O
the O
cause O
of O
all O
the O
child B_PERSON/B_LOCATION
' O
s O
problems O
, O
which O
would O
not O
end O
until O
it O
was O
set O
to O
rights O
. O

At O
any O
rate B_MEASURE/B_PERSON
, O
he O
was O
fit B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enough O
to O
go O
hunting B_PERSON/B_LOCATION
. O
' O
8 B_PERSON
Charles I_PERSON
continued O
in O
the O
same B_LOCATION/B_PERSON
state I_LOCATION/I_PERSON
of O
health B_PERSON/B_DISEASE
. O

He O
slept O
well O
at O
night B_TIME[MEASURE]/B_LOCATION
, O
ate O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
his O
mother B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
thought O
was O
good B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
for O
him O
, O
and O
was O
able B_TIME[MEASURE]/B_PERSON
to O
exercise O
strenuously O
without O
tiring O
. O

He O
put O
on O
no O
weight B_MEASURE/B_PRODUCT[OBJECT]
though O
, O
and O
' O
as O
for O
them O
swellings B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
at O
his O
throat B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
they O
are O
almost O
gone O
one B_TIME[MEASURE]/B_LOCATION
day B_TIME[MEASURE]/I_LOCATION
and O
rise O
the O
next B_TIME[MEASURE]/B_LOCATION
' O
. O

His O
mother B_PERSON
did O
not O
expect O
a O
speedy B_PERSON/B_ORGANIZATION
recovery I_PERSON/I_ORGANIZATION
and O
' O
if O
the O
D B_PERSON
[ I_PERSON
octo I_PERSON
] I_PERSON
RS I_PERSON
think O
him O
in O
a O
good B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
state B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
health B_PERSON/B_DISEASE
now O
, O
I O
s O
[ B_PERSON/B_LOCATION
houl I_PERSON/I_LOCATION
] I_PERSON/I_LOCATION
d I_PERSON/I_LOCATION
be O
glad B_TIME[MEASURE]/B_PERSON
to O
see O
him O
in O
a O
better B_PERSON/B_LOCATION
' O
. O
' O
9 B_MEASURE
He O
began O
to O
improve O
and O
by O
the O
end B_LOCATION/B_TIME[MEASURE]
of O
November B_TIME[MEASURE]
even O
she O
thought O
he O
was O
on O
the O
mend B_LOCATION/B_PERSON
and O
gaining O
weight B_MEASURE/B_LOCATION
. O
20 B_MEASURE
Unfortunately O
, O
Lady B_PERSON
Malton I_PERSON
again O
had O
cause B_DISEASE/B_PERSON
for O
concern B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
his O
health B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
in O
January B_TIME[MEASURE]/B_PERSON
1742 I_TIME[MEASURE]/I_PERSON
when O
he O
began O
to O
suffer O
from O
an O
intermittent B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hoarseness I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
2 B_MEASURE
' O
Otherwise O
he O
was O
as O
well O
as O
one O
could O
expect O
, O
with O
no O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complaints B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
22 B_MEASURE
It O
was O
not O
to O
last O
. O

In O
May B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1742 I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Charles I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
his O
mother B_PERSON/B_ORGANIZATION
were O
again O
in O
Bristol B_LOCATION/B_PERSON
, O
taking O
the O
waters B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
he O
had O
been O
indisposed O
. O

Lady B_PERSON
Malton I_PERSON
thought O
the O
waters B_LOCATION/B_PERSON
were O
doing O
them O
good B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
because O
they O
were O
both O
being O
violently O
sick B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O
23 B_MEASURE
However O
, O
Charles B_PERSON
had O
had O
no O
dinner B_TIME[MEASURE]/B_LOCATION
on O
25 B_SEQUENCE[MEASURE]
or O
26 B_TIME[MEASURE]/B_PERSON
May I_TIME[MEASURE]/I_PERSON
and O
was O
hot B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
lazy B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
inclined B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
stir O
, O
' O
from O
which O
I O
conclude O
he O
is O
not O
well O
, O
. O

. O
. O
and O
therefore O
intend O
to O
give O
him O
a O
gentle O
vomit O
. O
. O
. O
and O
to O
let O
him O
take O
his O
old O
Remedie O
the O
Salt O
Draughts O
for O
a O
few O
Daies O
which O
I O
dare O
say O
will O
set O
him O
quite O
to O
rights O
' O
. O
24 O
By O
29 O
May O
Dr O
Boume O
had O
bled O
the O
boy B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
which O
succeeded O
very O
well O
but O
. O
. O
. O
found O
it O
[ O
his O
blood O
] O
as O
bad O
as O
ever O
' O
. O

The O
waters B_LOCATION/B_PERSON
were O
not O
working O
' O
but O
there O
is O
a O
great B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
deal I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
for O
them O
to O
do O
which O
grant O
God B_PERSON/B_LOCATION
they O
may O
effect O
' O
. O

The O
weather B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
had O
turned O
warm B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
so O
Lady B_PERSON/B_LOCATION
Malton I_PERSON/I_LOCATION
had O
' O
shorn O
him O
. O
. O
. O
which O
has O
display B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
d B_OTHER/B_LOCATION
a O
most O
scabby B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
head I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
indeed O
several B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
other I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
untoward I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blotches I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
he O
has O
out O
upon O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
his O
Body B_BODY_PART_OR_ORGAN_COMPONENT
' O
, O
which O
made O
her O
uneasy B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O
25 B_TIME[MEASURE]/B_LOCATION
The O
blotches B_DISEASE/B_BIO
on O
his O
head B_BODY_PART_OR_ORGAN_COMPONENT
were O
not O
numerous B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O
yet O
they O
made O
up O
in O
quality B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
so O
virulent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
a O
Corrosive B_PERSON/B_BIO
humour I_PERSON/I_BIO
is O
not O
easily O
conceived O
without O
seeing O
it O
' O
. O

The O
pustules B_DISEASE
on O
his O
body B_BODY_PART_OR_ORGAN_COMPONENT
were O
of O
the O
same B_PERSON/B_BIO
sort B_PERSON/I_BIO
. O

16 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
17 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
4 B_PERSON/B_LOCATION
November B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

7 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
18 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
4 B_PERSON/B_LOCATION
November B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

18 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
16 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
7 B_PERSON/B_LOCATION
November B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

' O
9WWM B_NUMBER[MEASURE]/B_PERSON
, O
M7 B_MEASURE
- O
15 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
9 B_PERSON/B_LOCATION
November B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

20 B_MEASURE
WWM I_MEASURE
, O
M7 B_MEASURE
- O
22 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
25 B_PERSON/B_LOCATION
November B_PERSON/I_LOCATION
1741 B_PERSON/I_LOCATION
. O

21 B_NUMBER[MEASURE]/B_PERSON
WWM I_NUMBER[MEASURE]/I_PERSON
, O
M7 B_PROTEIN[GENE]/B_DISEASE
- O
1 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
25 B_PERSON/B_LOCATION
January B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

22 B_NUMBER[MEASURE]/B_PERSON
WWM I_NUMBER[MEASURE]/I_PERSON
, O
M7 B_MEASURE/B_PROTEIN[GENE]
- O
4 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton I_PERSON/I_LOCATION
, O
8 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
February B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
1742 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
WWM B_LOCATION/B_TIME[MEASURE]
, O
M7 B_MEASURE
- O
9 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
22 B_PERSON/B_LOCATION
February B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

23 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
29 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
12 B_PERSON/B_LOCATION
May B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

24 B_MEASURE/B_ORGANIZATION
WWM I_MEASURE/I_ORGANIZATION
, O
M7 B_MEASURE
- O
35 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton I_PERSON/I_LOCATION
, O
26 B_PERSON/B_LOCATION
May B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

25 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
36 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
29 B_PERSON/B_LOCATION
May B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

180 B_NUMBER[MEASURE]
. O

An O
eighteenth B_SEQUENCE[MEASURE]
- O
century B_PERSON
Prime I_PERSON
Minister I_PERSON
' O
s B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
illness B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

and O
his O
mother B_PERSON/B_ORGANIZATION
intended O
to O
put O
plasters B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
them O
to O
prevent O
them O
from O
spreading O
. O

Charles B_PERSON
was O
also O
feverish B_DISEASE_ADJECTIVE[DISEASE]
; O
his O
glands B_BODY_PART_OR_ORGAN_COMPONENT
were O
swollen B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
his O
pulse B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
erratic B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O
but O
out O
of O
compassion B_PERSON
to O
you O
I O
must O
tell O
you O
that O
he O
is O
with O
me O
as O
Brisk B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
lively B_TIME[MEASURE]/B_PERSON
as O
you O
ever O
Saw O
him O
' O
. O

Lady O
Malton O
had O
called O
in O
two O
eminent O
Bristol O
men B_PERSON
, O
Dr O
Logan O
and O
Mr O
Pye O
, O
to O
treat O
the O
boy B_PERSON/B_DISEASE
; O
Mr O
Pye O
prescribed O
' O
the O
Precipitate O
Per O
se O
' O
as O
the O
cure O
for O
the O
' O
hectic O
' O
. O

Pye B_PERSON
made O
it O
himself O
and O
said O
that O
it O
was O
the O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
remedy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
would O
work O
. O

Clearly O
Charles B_PERSON
was O
impatient B_TIME[MEASURE]
to O
be O
cured O
because O
he O
told O
his O
mother B_PERSON
to O
give O
him O
the O
medicine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O
to O
cure O
me O
which O
I O
am O
sure B_PERSON
it O
will O
do O
or O
shoot O
me O
through O
the O
head B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
once O
' O
. O

She O
thought O
that O
this O
attitude B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
' O
odd B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
from O
one B_NUMBER[MEASURE]/B_PERSON
of O
his O
Age B_TIME[MEASURE]/B_PERSON
and O
[ O
it O
] O
does O
not O
a O
little B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disturb I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
' O
. O
26 B_MEASURE
The O
blotches B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
began O
to O
burst O
and O
indent O
but O
the O
doctor B_PERSON
thought O
that O
all O
would O
be O
well O
in O
the O
end B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
27 B_TIME[MEASURE]/B_PERSON
Meanwhile I_TIME[MEASURE]
, O
Charles B_PERSON
was O
still O
losing O
weight B_MEASURE/B_PERSON
even O
though O
' O
he O
had O
none B_PERSON/B_TIME[MEASURE]
to O
spare O
before O
' O
and O
he O
was O
inclined O
to O
be O
lazy B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
which O
was O
not O
his O
natural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
turn I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

His O
father B_PERSON
recommended O
some O
unknown B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
cure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
which O
he O
called O
Gascoin B_PERSON
' O
s B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
powder I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
a O
dose B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
five B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
grains I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
made O
up O
with O
syrup B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
a O
pill B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- O
every O
night B_TIME[MEASURE]
. O

To O
make O
matters B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
worse I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
doctors B_PERSON/B_ORGANIZATION
disagreed O
about O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

' O
Dr B_PERSON
Pye I_PERSON
is O
Vehemently O
for O
the O
P B_OTHER/B_PERSON
. O

Per O
se O
, O
Dr O
Logan O
saies O
that O
it O
is O
a O
Medicine O
that O
may O
prove O
too O
rough O
in O
its O
operation O
for O
his O
Constitution O
& O
therefore O
begs O
a O
tryal O
of O
Beazor O
mineral O
[ O
gall O
stones O
from O
a O
goat B_BIO/B_PERSON
] O
and O
Viper O
Broth O
' O
. O

The O
Bristol O
water O
had O
not O
yet O
acted O
' O
because O
his O
case O
is O
of O
too O
obstinate O
a O
Nature O
' O
and O
Lady O
Malton O
herself O
was O
satisfied O
that O
since O
nothing O
else O
had O
worked O
to O
cure O
the O
boy B_PERSON/B_DISEASE
, O
the O
time O
had O
come O
to O
try O
mercurials O
, O
even O
though O
she O
knew O
that O
they O
were O
' O
powerful O
and O
perhaps O
in O
some O
cases O
hazardous O
medicines O
' O
. O
28 O
She O
wanted O
to O
see O
some O
remedy O
succeed O
but O
was O
' O
afraid O
of O
violent O
ones O
and O
at O
the O
same O
time O
vastly O
distrustfull O
[ O
sic O
] O
of O
mild O
ones O
' O
. O

It O
would O
appear O
that O
the O
' O
precipitate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Per I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
se I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
' O
, O
probably O
mercury B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
based O
, O
could O
be O
a O
kill O
- O
or O
- O
cure O
remedy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Her O
' O
terrors B_DISEASE_ADJECTIVE[DISEASE]
' I_DISEASE_ADJECTIVE[DISEASE]
did O
not O
arise O
from O
any O
immediate B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
danger I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
her O
son B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
her O
' O
perfect B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Knowledge I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
of O
his O
disorder B_DISEASE/B_PERSON
convinced O
her O
that O
whatever O
remedies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
he O
took O
, O
the O
cure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
in O
the O
hands B_LOCATION/B_MEASURE
of O
God B_PERSON/B_RELIGION[SOCIAL_CIRCUMSTANCES]
. O
29 B_TIME[MEASURE]/B_PERSON
. O

To O
add O
to O
charles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disorders I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
on O
12 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
June I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
he O
developed O
a O
' O
very O
inflamed B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bad I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Eye I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
. O
. O
the O
same B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Eye B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
. O
. O
. O

he O
did O
not O
see O
so O
well O
of O
[ O
as O
] B_OTHER/B_LOCATION
the O
other B_PERSON/B_LOCATION
. O
. O
. O

He O
sais O
[ B_LOCATION/B_PERSON
sic I_LOCATION/I_PERSON
] O
that O
from O
that O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Alone O
he O
can O
scarcely O
distinguish O
anything B_PERSON/B_ORGANIZATION
' O
. O

The O
doctors B_PERSON
suggested O
bathing O
the O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
: O
Lady B_PERSON
Malton I_PERSON
knew O
that O
the O
' B_DISEASE_ADJECTIVE[DISEASE]
frightful I_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
' I_DISEASE_ADJECTIVE[DISEASE]
which O
were O
' O
shocking B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
behold O
' O
were O
a O
result B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
' O
the O
same B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
as O
produces O
all O
the O
rest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
his O
complaints B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
whichever O
shape B_MEASURE/B_LOCATION
they O
appear O
' O
. O

30 B_MEASURE
The O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
very O
bloodshot B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
inflamed O
; O
the O
eyelid B_BODY_PART_OR_ORGAN_COMPONENT
was O
swollen B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
so O
he O
could O
hardly O
open O
it O
. O

The O
other B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
eye I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
dull B_DISEASE_ADJECTIVE[DISEASE]
and O
' O
he O
had O
very O
little B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sight I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O
it O
' O
. O
31 B_MEASURE
By O
14 B_TIME[MEASURE]
June I_TIME[MEASURE]
the O
eye B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
problem B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
had O
eased O
somewhat O
but O
Lady B_PERSON
Malton I_PERSON
could O
find O
no O
cause B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
attribute O
the O
improvement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
any O
of O
the O
' O
cures B_PERSON/B_ORGANIZATION
' I_PERSON/I_ORGANIZATION
. O

Charles O
was O
still O
being O
subjected O
to O
Bristol O
water O
, O
Beazor O
mineral O
, O
Viper O
broth O
, O
cinnabar O
and O
the O
precipitate O
per O
se O
. O
32 O
She O
decided O
to O
take O
the O
boy B_PERSON/B_BIO
home O
to O
Wentworth O
because O
he O
was O
. O

26 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
38 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
1 B_PERSON/B_LOCATION
June B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

27 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
39 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton I_PERSON/I_LOCATION
, O
2 B_PERSON/B_LOCATION
June B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

28 B_MEASURE
WWM I_MEASURE
, O
M7 B_MEASURE
- O
41 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
5 B_PERSON/B_LOCATION
June B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

29 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
43 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
7 B_PERSON/B_LOCATION
June B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

30 B_MEASURE
WWM I_MEASURE
, O
M7 B_MEASURE
- O
45 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
12 B_PERSON/B_LOCATION
June B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

31 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
56 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON
Malton I_PERSON
, O
undated B_TIME[MEASURE]/B_LOCATION
: O
12 B_TIME[MEASURE]/B_PERSON
June B_TIME[MEASURE]/I_PERSON
. O

1742 B_NUMBER[MEASURE]
. O

32 B_MEASURE
WWM I_MEASURE
, O
M7 B_MEASURE
- O
46 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton I_PERSON/I_LOCATION
, O
14 B_TIME[MEASURE]/B_LOCATION
June B_TIME[MEASURE]/I_LOCATION
. O

1742 B_NUMBER[MEASURE]
. O

181 B_NUMBER[MEASURE]
. O

Marjorie B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Bloy I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

more O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
recover O
there O
than O
anywhere O
else O
. O
33 B_TIME[MEASURE]/B_LOCATION
He O
still O
ate O
and O
slept O
well O
and O
was O
' O
pretty O
cheerful B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O
his O
looks B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
are O
bitter B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bad I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O
. O

The O
flesh B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
he O
lost O
in O
the O
accidental B_TIME[MEASURE]/B_DISEASE
Feavour I_TIME[MEASURE]/I_DISEASE
he O
has O
not O
recover O
' O
d B_OTHER/B_DISEASE
and O
his O
complexion B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
of O
the O
most O
sickly O
sort B_MEASURE/B_LOCATION
his O
hands B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
of O
the O
same B_PERSON/B_TIME[MEASURE]
Hue B_PERSON/I_TIME[MEASURE]
his O
legs B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
are O
tollerable B_PERSON/B_LOCATION
[ B_PERSON/I_LOCATION
sic B_PERSON/I_LOCATION
] O
well B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
. O
34 B_TIME[MEASURE]/B_PERSON
. O

They O
returned O
to O
Wentworth B_TIME[MEASURE]/B_LOCATION
in O
short B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
stages I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
by O
6 B_TIME[MEASURE]/B_PERSON
September I_TIME[MEASURE]/I_PERSON
Higham I_TIME[MEASURE]/I_PERSON
was O
' O
perfectly O
recovered O
. O

. O
. O
after O
the O
long O
and O
successful O
Care O
that O
Lady O
Malton O
has O
taken O
' O
of O
him O
. O
35 O
In O
May O
1743 O
he O
was O
inoculated O
against O
smallpox B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
and O
made O
a O
perfect O
recovery O
after O
which O
he O
caught O
cold O
' O
by O
stripping O
when O
He O
was O
hot O
' O
. O
36 O
Lord O
Higham O
does O
not O
seem O
to O
have O
been O
seriously O
ill O
after O
that O
until O
, O
at O
the O
age O
of O
19 O
, O
he O
undertook O
his O
Grand O
Tour O
in O
1749 O
. O

In O
July B_TIME[MEASURE]/B_LOCATION
1750 I_TIME[MEASURE]/I_LOCATION
, O
by O
then O
lord B_TIME[MEASURE]/B_LOCATION
Malton B_TIME[MEASURE]/I_LOCATION
, O
he O
had O
cause B_DISEASE/B_PERSON
to O
consult O
Nicolo B_PERSON
Scanagati I_PERSON
in O
Padua B_LOCATION
for O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
gonorrhoea B_DISEASE/B_BIO
. O

Scanagati O
produced O
a O
lengthy O
medical O
report O
of O
Malton O
' O
s O
treatment O
, O
presumably O
for O
his O
English O
doctor O
' O
s O
Enlightenment O
. O
37 O
The O
initial O
treatment O
was O
an O
' O
electuary O
, O
consisting O
of O
three O
ounces O
of O
emollient O
, O
three O
drams O
of O
powdered O
jalap B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
a O
half O
[ O
dram O
] O
of O
purified O
nitre O
, O
bound O
together O
with O
lemon B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
juice O
taken O
twice O
a O
day O
' O
. O

The O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
satisfactory B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
: O
' O
The O
dark B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
greenish I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poison I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
oozing O
slowly O
from O
his O
penis B_BODY_PART_OR_ORGAN_COMPONENT
, O
which O
was O
all O
contracted O
and O
the O
sharp B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
constant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pain I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended O
from O
the O
perineum B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
up O
to O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bladder I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
producing O
small B_DISEASE_ADJECTIVE[DISEASE]
swellings I_DISEASE_ADJECTIVE[DISEASE]
now O
in O
this O
place B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
now O
in O
that O
. O
' O
There O
was O
a O
fierce B_DISEASE
burning I_DISEASE
sensation I_DISEASE
in O
the O
glands B_BODY_PART_OR_ORGAN_COMPONENT
, O
which O
prevented O
him O
from O
sleeping O
. O

Because O
of O
this O
, O
it O
seemed O
reasonable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
bathe O
that O
part B_TIME[MEASURE]/B_BIO
in O
tepid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
milk B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
to O
apply O
poultices B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
areas B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affected O
by O
swelling O
and O
contractions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
together O
with O
cold B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
drinks I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
a O
few B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
grains I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
laudanum B_BIO
at O
night B_TIME[MEASURE]/B_LOCATION
. O

Malton B_PERSON
was O
blooded O
regularly O
besides O
being O
given O
purgatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
then O
moved O
on O
to O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
mercury B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
both O
internal B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O
on O
the O
gums B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
since O
it O
was O
widely O
believed O
at O
the O
time B_TIME[MEASURE]/B_LOCATION
that O
gonorrhoea B_DISEASE/B_BIO
and O
syphilis B_DISEASE
were O
steps B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
same B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
, O
' O
the O
Venereal B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
' B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O

Scanagati B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
at O
this O
point B_LOCATION
ruled O
out O
the O
suggestion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
syphilitic B_DISEASE
chancre I_DISEASE
because O
Malton B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
urine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
fine B_PERSON/B_COLOR
and O
light B_COLOR/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
a O
pungent B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
odour I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Scanagati B_PERSON
did O
ask O
if O
Malton B_PERSON
had O
previously O
ever O
had O
a O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peculiarity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
his O
urine B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
. O

Malton B_PERSON
replied O
that O
when O
he O
was O
very O
young B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
still O
inexperienced B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sexually O
, O
for O
some O
time B_TIME[MEASURE]
following O
a O
fever B_DISEASE/B_TIME[MEASURE]
he O
had O
had O
the O
same B_DISEASE
unusual I_DISEASE
urine I_DISEASE
, O
and O
indeed O
that O
on O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occasion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O
symptom B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coincided O
with O
certain B_DISEASE
tumours I_DISEASE
on O
the O
testicles B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

It O
was O
only O
by O
chance B_PERSON/B_TIME[MEASURE]
that O
he O
had O
not O
had O
recourse B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
, O
the O
reason B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
being O
that O
he O
was O
also O
afflicted O
with O
a O
throat B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infection B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
to O
which O
he O
was O
prone B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
and O
therefore O
had O
his O
vein B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
opened O
four B_TIME[MEASURE]/B_ENT
times I_TIME[MEASURE]/I_ENT
. O

Thereupon O
the O
inflammation B_DISEASE/B_BACTERIUM[BIO]
subsided O
, O
and O
equally O
the O
tumours B_DISEASE
and O
sediment B_DISEASE/B_BIO
disappeared O
. O

He O
told O
me O
that O
as O
a O
youth B_PERSON
he O
had O
sometimes O
experienced O
some O
difficulty B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
burning O
sensation B_DISEASE
when O
urinating B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
which O
subsided O
when O
his O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
let O
and O
with O
the O
application B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
poultices B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

I O
observed O
that O
from O
time B_TIME[MEASURE]/B_LOCATION
to O
time B_TIME[MEASURE]/B_LOCATION
his O
face B_BODY_PART_OR_ORGAN_COMPONENT
and O
body B_BODY_PART_OR_ORGAN_COMPONENT
were O
covered O
with O
purplish B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spots B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
which O
, O
having O
produced O
a O
little B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
fluid I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
would O
disappearas O
indeed O
happened O
in O
the O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
cure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
, O
at O
the O
end B_LOCATION/B_MEASURE
of O
which O
his O
face B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
entirely O
. O

33 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
47 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
15 B_PERSON/B_LOCATION
June B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

34 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M7 B_MEASURE
- O
48 B_MEASURE
. O

Lady B_PERSON
to O
Lord B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
16 B_PERSON/B_LOCATION
June B_PERSON/I_LOCATION
1742 B_PERSON/I_LOCATION
. O

35 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M2 B_MEASURE/B_PROTEIN[GENE]
- O
104 B_MEASURE
/ O
5 B_MEASURE
. O

Lady B_PERSON
Finch I_PERSON
to O
Lady B_PERSON/B_LOCATION
Malton B_PERSON/I_LOCATION
, O
6 B_PERSON/B_LOCATION
September I_PERSON/I_LOCATION
1742 I_PERSON/I_LOCATION
. O

36 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
M2 B_MEASURE
- O
135 B_MEASURE
. O

Lady B_PERSON
Finch I_PERSON
to O
Malton B_LOCATION/B_PERSON
, O
18 B_LOCATION/B_PERSON
June I_LOCATION/I_PERSON
1742 I_LOCATION/I_PERSON
. O

37 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
R170 B_MEASURE/B_LOCATION
- O
20 B_MEASURE
. O

Nicol6 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Scanagati I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

182 B_NUMBER[MEASURE]
. O

An O
eighteenth B_SEQUENCE[MEASURE]
- O
century B_PERSON
Prime I_PERSON
Minister I_PERSON
' O
s B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
illness B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

free B_MEASURE/B_LOCATION
from O
these O
spots B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
this O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
it O
seemed O
to O
me O
simple B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
deduce O
both O
the O
original B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cause I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
the O
more O
immediate B_DISEASE_ADJECTIVE[DISEASE]
cause I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
said O
sediment B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
: O
namely O
a O
natural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
humours B_DISEASE_ADJECTIVE[DISEASE]
which O
are O
exacerbated O
by O
muriatic B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
[ O
i O
. O
e O
. O
, O
acidic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sourness I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
together O
with O
the O
marked B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inflammation B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
motion B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
contracted O
poison B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Scanagati O
then O
recommended O
the O
continuation O
of O
the O
electuary O
made O
of O
emollient O
, O
guaiacum O
resin O
, O
balsam O
, O
rhubarb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
nitre O
. O

What O
does O
all O
this O
add O
up O
to O
in O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
early B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
illness B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
mystery B_DISEASE
. O

Did O
he O
have O
an O
inguinal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hernia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
; O
or O
perhaps O
mumps B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
epididymitis B_DISEASE
. O

His O
was O
a O
childless B_PERSON
marriage I_PERSON
. O

He O
seems O
to O
have O
been O
too O
fit B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
illness B_DISEASE/B_PERSON
to O
have O
been O
rheumatic B_DISEASE_ADJECTIVE[DISEASE]
fever I_DISEASE_ADJECTIVE[DISEASE]
. O

cystitis B_DISEASE
was O
not O
uncommon B_DISEASE_ADJECTIVE[DISEASE]
and O
this O
could O
certainly O
lead O
to O
' O
strangury B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O
. O

Perhaps O
Rockingham B_PERSON/B_LOCATION
suffered O
from O
a O
congenital B_DISEASE_ADJECTIVE[DISEASE]
defect I_DISEASE_ADJECTIVE[DISEASE]
of O
his O
urinogenitary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
which O
would O
result O
in O
recurrent B_DISEASE_ADJECTIVE[DISEASE]
attacks I_DISEASE_ADJECTIVE[DISEASE]
of O
cystitis B_DISEASE
and O
might O
cause O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
eventual B_DISEASE
destruction I_DISEASE
of O
the O
kidneys B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
precipitating O
sudden B_DISEASE
and O
unexpected B_DISEASE_ADJECTIVE[DISEASE]
death I_DISEASE_ADJECTIVE[DISEASE]
. O

Another O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O
be O
diabetes B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Rockingham B_PERSON/B_LOCATION
had O
a O
urinary B_DISEASE/B_PERSON
infection I_DISEASE/I_PERSON
and O
certainly O
suffered O
from O
recurrent B_DISEASE
skin I_DISEASE
infections I_DISEASE
, O
although O
it O
appears O
from O
Scanagati B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
these O
cleared O
up O
when O
mercury B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
. O

Certainly O
the O
Marquis B_PERSON
complained O
often O
about O
pains B_DISEASE
in O
his O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
stomach B_BODY_PART_OR_ORGAN_COMPONENT
and O
made O
no O
secret B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
his O
' O
old B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
complaint I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
' O
. O

He O
was O
noticeably O
less O
physically O
active B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
he O
moved O
into O
his O
thirties B_LOCATION/B_ENT
and O
only O
occasionally O
exerted O
himself O
by O
riding O
any O
distance B_TIME[MEASURE]/B_LOCATION
, O
even O
though O
he O
had O
enjoyed O
hunting B_PERSON/B_SPORT[ENT]
when O
he O
was O
younger B_NUMBER[MEASURE]/B_PERSON
. O

He O
found O
the O
pains B_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
his O
' B_DISEASE/B_PERSON
old B_DISEASE/I_PERSON
complaint B_DISEASE/I_PERSON
' O
made O
him O
feel O
so O
ill B_DISEASE_ADJECTIVE[DISEASE]
that O
he O
was O
unable B_PERSON/B_TIME[MEASURE]
to O
concentrate O
on O
' O
any O
manner B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Business B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
and O
on O
occasion B_TIME[MEASURE]/B_PERSON
it O
seemed O
likely B_DISEASE_ADJECTIVE[DISEASE]
to O
prevent O
him O
from O
attending O
Parliament B_ORGANIZATION/B_PERSON
. O
38 B_MEASURE
He O
may O
well O
have O
suffered O
from O
a O
problem B_TIME[MEASURE]/B_DISEASE
with O
gallstones B_DISEASE/B_LOCATION
from O
an O
early B_DISEASE
age I_DISEASE
. O
39 B_MEASURE
He O
appears O
to O
have O
suffered O
from O
a O
nervous B_DISEASE
disorder I_DISEASE
which O
manifested O
itself O
in O
severe B_DISEASE
palpitations I_DISEASE
, O
trembling B_DISEASE
, O
and O
other B_DISEASE
types I_DISEASE
of O
physical B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discomforts I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
boils B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
headaches B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
with O
which O
he O
was O
frequently O
afflicted O
. O
40 B_MEASURE
He O
probably O
had O
constipation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
too O
, O
since O
he O
was O
always O
dosing O
himself O
with O
purgatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
fact B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
April B_TIME[MEASURE]
1772 I_TIME[MEASURE]
the O
Duke B_PERSON/B_LOCATION
of O
Richmond B_LOCATION
decided O
that O
Rockingham B_PERSON/B_ENT
' I_PERSON/I_ENT
s I_PERSON/I_ENT
real I_PERSON/I_ENT
problem I_PERSON/I_ENT
was O
a O
' O
surfeit B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
physick B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
41 B_TIME[MEASURE]/B_LOCATION
although O
Edmund B_PERSON/B_LOCATION
Burke I_PERSON/I_LOCATION
noted O
in O
June B_MEASURE/B_ENT
1772 I_MEASURE/I_ENT
that O
the O
Marquis B_PERSON
had O
had O
a O
long B_DISEASE_ADJECTIVE[DISEASE]
and O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
illness B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O
42 B_MEASURE
Whatever O
his O
many B_NUMBER[MEASURE]/B_DISEASE
and O
varied B_NUMBER[MEASURE]/B_PERSON
ailments I_NUMBER[MEASURE]/I_PERSON
, O
Rockingham B_LOCATION/B_PERSON
survived O
until O
he O
was O
52 B_NUMBER[MEASURE]
in O
spite B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
attentions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
doctors B_PERSON/B_BIO
and O
quacks B_PERSON
and O
that O
, O
for O
the O
mid B_SEQUENCE[MEASURE]/B_LOCATION
- O
eighteenth B_TIME[MEASURE]/B_ENT
century I_TIME[MEASURE]/I_ENT
, O
was O
a O
good B_PERSON
age I_PERSON
. O

The O
mystery B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O
remains O
, O
however O
. O

Contemporary B_PERSON
opinion I_PERSON
had O
it O
that O
he O
died O
of O
pneumonia B_DISEASE/B_PERSON
but O
it O
must O
have O
struck O
. O

38 B_MEASURE/B_PERSON
WWM I_MEASURE/I_PERSON
, O
R153 B_MEASURE/B_DISEASE
- O
1 B_MEASURE
. O

Rockingham B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Burke B_PERSON/B_LOCATION
, O
31 B_LOCATION/B_PERSON
October I_LOCATION/I_PERSON
1767 I_LOCATION/I_PERSON
; O
WWM B_LOCATION/B_PERSON
, O
RI B_MEASURE
- O
1238 B_MEASURE/B_LOCATION
. O

Rockingham B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Dowdeswell B_LOCATION
, O
20 B_LOCATION/B_PERSON
October I_LOCATION/I_PERSON
1769 I_LOCATION/I_PERSON
; O
WWM O
, O
RI B_MEASURE
- O
1928 B_MEASURE/B_LOCATION
. O

Rockingham B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Savile B_LOCATION/B_PERSON
, O
September B_LOCATION/B_ENT
1780 I_LOCATION/I_ENT
. O

39 B_PERSON/B_MEASURE
Ross I_PERSON/I_MEASURE
J I_PERSON/I_MEASURE
. O

S B_OTHER/B_DISEASE
. O

Hoffman B_PERSON/B_LOCATION
, O
The O
Marquis B_PERSON/B_LOCATION
. O

A O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
Lord B_PERSON/B_LOCATION
Rockingham B_PERSON/I_LOCATION
, O
1730 B_MEASURE
- O
1782 B_MEASURE
, O
New B_LOCATION/B_PERSON
York I_LOCATION/I_PERSON
, O
Fordham B_LOCATION/B_PERSON
University I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
, O
1973 B_MEASURE
, O
p B_OTHER/B_LOCATION
. O

35 B_NUMBER[MEASURE]
. O

This O
is O
the O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
recent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
biography I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
second B_PERSON
Marquis I_PERSON
of O
Rockingham B_LOCATION/B_PERSON
, O
and O
does O
not O
deal O
with O
his O
illnesses B_PERSON
. O

Although O
he O
does O
not O
give O
the O
source B_PERSON/B_LOCATION
of O
his O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
Hoffman B_PERSON/B_LOCATION
asserts O
that O
Rockingham B_PERSON/B_LOCATION
was O
in O
Bath B_LOCATION
between O
March B_TIME[MEASURE]/B_LOCATION
and O
August B_TIME[MEASURE]/B_PERSON
1761 I_TIME[MEASURE]/I_PERSON
suffering O
from O
gallstones B_DISEASE
. O

The O
Marquis B_PERSON
would O
then O
have O
been O
31 B_ENT/B_TIME[MEASURE]
years B_ENT/I_TIME[MEASURE]
old B_ENT/I_TIME[MEASURE]
. O

40 B_MEASURE/B_LOCATION
Historical I_MEASURE/I_LOCATION
manuscripts I_MEASURE/I_LOCATION
Commission I_MEASURE/I_LOCATION
, O
Lindley B_MEASURE/B_LOCATION
Wood I_MEASURE/I_LOCATION
, O
p B_OTHER/B_LOCATION
. O

184 B_NUMBER[MEASURE]
. O

41 B_LOCATION/B_PERSON
WWM I_LOCATION/I_PERSON
, O
RI B_MEASURE/B_PROTEIN[GENE]
- O
1403 B_MEASURE/B_LOCATION
. O

Richmond B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O
Rockingham B_LOCATION
, O
26 B_LOCATION/B_PERSON
April I_LOCATION/I_PERSON
1772 I_LOCATION/I_PERSON
. O

42 B_PERSON
Burke I_PERSON
to O
James B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
de I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lancey I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
30 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
June I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1772 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
correspondence B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Edmund B_PERSON/B_LOCATION
Burke B_PERSON/I_LOCATION
, O
vol B_LOCATION/B_MEASURE
. O

2 B_TIME[MEASURE]/B_PERSON
, O
ed O
. O

T B_OTHER/B_GENE
. O

W B_OTHER/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Copeland B_PERSON
and O
others B_PERSON
, O
Cambridge B_PERSON/B_LOCATION
University B_PERSON/I_LOCATION
Press B_PERSON/I_LOCATION
, O
1958 B_MEASURE
- O
1978 B_MEASURE
, O
p B_OTHER/B_MEASURE
. O

311 B_NUMBER[MEASURE]
. O

183 B_NUMBER[MEASURE]
. O

Marjorie B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Bloy I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

suddenly O
: O
it O
was O
only O
two B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
from O
him O
' O
recovering O
' O
to O
dying O
. O

Another O
almost O
contemporary B_TIME[MEASURE]/B_PERSON
account B_TIME[MEASURE]/I_PERSON
of O
the O
marquis B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
s I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
death I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
came O
from O
the O
Earl B_PERSON/B_LOCATION
of O
Albemarle B_LOCATION
. O

He O
noted O
that O
Rockingham B_PERSON/B_LOCATION
had O
' O
for O
some O
time B_TIME[MEASURE]
past O
been O
afflicted O
with O
water B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
chest B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
: O
and O
to O
this O
well O
- O
known O
malady B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
was O
superadded O
the O
then O
novel B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
of O
influenza B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' O
. O
43 B_MEASURE
This O
conceivably O
could O
be O
an O
uninformed B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
account I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
handed O
down O
orally O
by O
surviving O
members B_PERSON
of O
the O
Marquis B_ORGANIZATION/B_PERSON
' I_ORGANIZATION/I_PERSON
s I_ORGANIZATION/I_PERSON
family I_ORGANIZATION/I_PERSON
, O
of O
emphysema B_DISEASE
. O

More O
fascinating B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
cause B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
death B_DISEASE
, O
however O
, O
is O
- O
what O
was O
wrong B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
him O
during O
his O
lifetime B_TIME[MEASURE]/B_PERSON
. O

Or O
is O
it O
yet O
another O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
' B_DISEASE/B_PERSON
English I_DISEASE/I_PERSON
disease I_DISEASE/I_PERSON
' O
: O
hypochondria B_DISEASE/B_LOCATION
. O

43Albemarle O
, O
George B_PERSON
Thomas I_PERSON
, O
Earl B_PERSON
of O
, O
memoirs B_TIME[MEASURE]/B_PERSON
of O
the O
Marquis B_PERSON
of O
Rockingham B_LOCATION
and O
his O
contemporaries B_PERSON/B_LOCATION
, O
London B_LOCATION/B_PERSON
, O
Richard B_MEASURE/B_LOCATION
Bentley I_MEASURE/I_LOCATION
, O
2 B_TIME[MEASURE]/B_LOCATION
vols B_TIME[MEASURE]/I_LOCATION
. O
, O
1852 B_MEASURE
, O
vol B_GENE/B_LOCATION
. O

2 B_NUMBER[MEASURE]
, O
p O
. O

483 B_NUMBER[MEASURE]
. O

This O
is O
the O
only B_TIME[MEASURE]/B_ENT
contemporary I_TIME[MEASURE]/I_ENT
work I_TIME[MEASURE]/I_ENT
concerning O
Rockingham B_PERSON/B_LOCATION
, O
but O
does O
not O
mention O
his O
early B_DISEASE_ADJECTIVE[DISEASE]
life I_DISEASE_ADJECTIVE[DISEASE]
and O
illnesses B_DISEASE/B_PERSON
. O

184 B_NUMBER[MEASURE]
. O

Tissue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
mammalian B_GENE/B_BIO
Fox I_GENE/I_BIO
- O
1 B_PROTEIN[GENE]/B_MEASURE
homologs I_PROTEIN[GENE]/I_MEASURE
are O
associated O
with O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]
splicing I_DISEASE_ADJECTIVE[DISEASE]
activities I_DISEASE_ADJECTIVE[DISEASE]
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

An O
intronic B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hexanucleotide I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
UGCAUG I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
shown O
to O
play O
a O
critical B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
regulation B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
wide B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
tissues B_DISEASE/B_BIO
. O

vertebrate B_PROTEIN[GENE]/B_BIO
Fox I_PROTEIN[GENE]/I_BIO
- O
1 B_MEASURE
has O
been O
shown O
to O
bind O
to O
this O
element B_GENE/B_LOCATION
, O
in O
a O
highly O
sequence B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
through O
its O
RNA B_GENE/B_TIME[MEASURE]
recognition I_GENE/I_TIME[MEASURE]
motif I_GENE/I_TIME[MEASURE]
( O
RRM B_DISEASE/B_GENE
) O
. O

In O
mammals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
there O
are O
at O
least O
two B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fox I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
- O
related O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ataxin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_PROTEIN[GENE]/B_MEASURE
binding I_PROTEIN[GENE]/I_MEASURE
protein I_PROTEIN[GENE]/I_MEASURE
1 I_PROTEIN[GENE]/I_MEASURE
( O
A2BP1 B_GENE/B_DISEASE
) O
/ O
Fox B_GENE/B_BIO
- O
1 B_NUMBER[MEASURE]
and O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Rbm9 B_GENE
, O
which O
encode O
an O
identical B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RRM I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
, O
we O
demonstrate O
that O
both O
mouse B_SPECIES[BIO]/B_DISEASE
Fxh O
and O
A2BP1 O
transcripts O
undergo O
tissue O
- O
specific O
alternative O
splicing O
, O
generating O
protein O
isoforms O
specific O
to O
brain O
and O
muscle O
. O

These O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
characterized O
for O
their O
abilities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
regulate O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- O
specific B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
cassette B_GENE
exon I_GENE
, O
N30 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
in O
the O
non B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
muscle B_GENE/B_DISEASE
myosin I_GENE/I_DISEASE
heavy I_GENE/I_DISEASE
chain I_GENE/I_DISEASE
II I_GENE/I_DISEASE
- O
B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mRNA B_GENE
, O
previously O
shown O
to O
be O
regulated O
through O
an O
intronic B_PROTEIN[GENE]
distal I_PROTEIN[GENE]
downstream I_PROTEIN[GENE]
enhancer I_PROTEIN[GENE]
( O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

All O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_NUMBER[MEASURE]/B_LOCATION
isoforms B_NUMBER[MEASURE]/I_LOCATION
with O
the O
RRM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
capable B_PERSON
of O
binding O
to O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
through O
the O
UGCAUG B_GENE/B_BIO
elements I_GENE/I_BIO
. O

Each O
isoform B_GENE/B_LOCATION
, O
however O
, O
shows O
quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
splicing O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
nuclear B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distribution I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
transfected B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

All O
Fxh B_GENE/B_BIO
isoforms I_GENE/I_BIO
and O
a O
brain B_GENE/B_MEASURE
isoform I_GENE/I_MEASURE
of O
A2BP1 B_GENE
show O
a O
predominant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclear B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localization B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Brain B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
isoforms I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
both O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
promote O
N30 B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
splicing B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
much O
more O
efficiently O
than O
do O
the O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
isoforms I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

skeletal B_PERSON
muscles I_PERSON
express O
additional B_GENE
isoforms I_GENE
that O
lack O
a O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
RRM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
isoforms B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
incapable B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
activating O
neural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_GENE/B_DISEASE
splicing I_GENE/I_DISEASE
and O
, O
Moreover O
, O
can O
inhibit O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
N30 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
play O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
determining O
tissue B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mediated O
alternative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Alternative B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
splicing B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
pre B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mRNA B_GENE
is O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
fundamental B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
for O
the O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
higher B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
eukaryotes I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
1 B_NUMBER[MEASURE]
, O
2 B_MEASURE
) O
. O

Developmentally O
regulated O
, O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
type I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
- O
or O
tissue B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
signal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
alternative B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
takes O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
in O
multicellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
organisms I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
throughout O
their O
lifetimes B_TIME[MEASURE]/B_LOCATION
. O

Misregulation O
or O
abnormalities O
in O
pre O
- O
mRNA O
splicing O
, O
in O
some O
instances O
, O
leads O
to O
cellular O
dysfunctions O
found O
in O
human B_PERSON/B_SPECIES[BIO]
and O
animal O
diseases O
( O
3 O
- O
5 O
) O
. O

Using O
various B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
regulated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alternative I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
number B_MEASURE/B_LOCATION
of O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mRNA B_GENE/B_LOCATION
features I_GENE/I_LOCATION
that O
influence O
alternative B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
splice B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
site B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
selection B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
have O
been O
defined O
( O
1 B_NUMBER[MEASURE]
, O
2 B_MEASURE
) O
. O

These O
include O
enhancer B_GENE/B_PERSON
and O
repressor B_GENE/B_MEASURE
RNA I_GENE/I_MEASURE
sequences I_GENE/I_MEASURE
located O
in O
exons B_GENE/B_LOCATION
and O
introns B_GENE/B_LOCATION
. O

Identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
RNA B_GENE/B_BIO
- O
binding O
proteins B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
targeting O
these O
cis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
regulatory B_GENE/B_LOCATION
elements I_GENE/I_LOCATION
is O
currently O
in O
progress B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
vertebrates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
participation B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
SR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
family I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
hnRNP B_GENE/B_BIO
proteins I_GENE/I_BIO
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
PTB B_GENE/B_DISEASE
and O
hnRNPA1 B_PROTEIN[GENE]/B_DISEASE
, O
in O
alternative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
via O
binding O
to O
the O
cis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
regulatory B_GENE
elements I_GENE
have O
been O
shown O
in O
many B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
splicing I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
models I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
6 B_NUMBER[MEASURE]
, O
7 B_MEASURE
) O
. O

Although O
these O
RNA B_GENE/B_BIO
- O
binding O
proteins B_LOCATION/B_PROTEIN[GENE]
are O
ubiquitously O
expressed O
, O
their O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abundance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
different B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
their O
post B_DISEASE
- O
translational B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifications I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
different B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
contexts B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
their O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abilities B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
assemble O
multiprotein B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
complexes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
different B_DISEASE/B_GENE
pre B_DISEASE/I_GENE
- O
mRNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contexts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
thought O
to O
contribute O
to O
the O
determination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
cell B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
type I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alternative B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
the O
last B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
few I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
years I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
enriched O
RNA B_GENE/B_BIO
- O
binding O
proteins B_LOCATION/B_PROTEIN[GENE]
have O
begun O
to O
be O
identified O
as O
splicing B_GENE/B_PERSON
regulators I_GENE/I_PERSON
. O

These O
include O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
or O
enriched O
) O
Nova B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
, O
nPTB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
brPTB B_MEASURE
) O
and O
some O
of O
the O
CELF B_MEASURE/B_GENE
family I_MEASURE/I_GENE
proteins I_MEASURE/I_GENE
( O
8 B_MEASURE/B_LOCATION
- O
12 B_MEASURE
) O
. O

discovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
proteins B_LOCATION/B_GENE
has O
had O
a O
great B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
impact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
aimed O
at O
understanding O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alternative B_DISEASE/B_GENE
splicing I_DISEASE/I_GENE
regulation I_DISEASE/I_GENE
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
the O
intronic B_PROTEIN[GENE]/B_DISEASE
cis I_PROTEIN[GENE]/I_DISEASE
- O
elements B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
are O
involved O
in O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
differentiation B_GENE/B_DISEASE
stage I_GENE/I_DISEASE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
regulation I_DISEASE_ADJECTIVE[DISEASE]
of O
alternative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
the O
hexanucleotide B_GENE
UGCAUG I_GENE
. O

The O
importance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
element B_LOCATION
was O
originally O
recognized O
in O
fibronectin B_PROTEIN[GENE]/B_DISEASE
pre I_PROTEIN[GENE]/I_DISEASE
- O
mRNA B_GENE
by O
Huh B_PERSON
and O
Hynes B_PERSON
( O
13 B_MEASURE
) O
. O

Since O
then O
, O
alternative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
splicing I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
specific I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
a O
variety B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tissues B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
or O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
including O
neural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
muscles B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
epithelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
erythrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
has O
been O
shown O
to O
be O
modulated O
via O
this O
element B_GENE/B_LOCATION
( O
14 B_MEASURE/B_LOCATION
- O
21 B_MEASURE
) O
. O

Recently O
, O
Jin B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
. O

( O
21 O
) O
discovered O
that O
a O
zebrafish B_SPECIES[BIO]
homolog O
of O
Caenorhabditis B_SPECIES[BIO]/B_PROTEIN[GENE]
elegans B_SPECIES[BIO]/I_PROTEIN[GENE]
Fox O
- O
1 O
( O
22 O
) O
could O
bind O
specifically O
to O
the O
pentanucleotide O
GCAUG O
by O
in O
vitro O
selection O
from O
randomized O
RNA O
sequences O
. O

This O
pentanucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
almost O
identical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
the O
hexanucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
UGCAUG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
except O
for O
the O
first B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
, O
the O
zebrafish B_SPECIES[BIO]
Fox O
- O
1 O
homolog O
, O
as O
well O
as O
the O
mouse B_SPECIES[BIO]/B_DISEASE
Fox O
- O
1 O
homolog O
, O
are O
capable O
of O
repressing O
the O
inclusion O
of O
an O
alternative O
cassette O
exon O
of O
the O
ATP O
synthase O
F1 O
gamma O
pre O
- O
mRNA O
via O
binding O
to O
GCAUG O
, O
which O
mimics O
muscle O
- O
specific O
exclusion O
of O
this O
exon O
. O

This O
mouse B_SPECIES[BIO]/B_DISEASE
homolog O
is O
identical O
to O
the O
ataxin O
- O
2 O
binding O
protein O
1 O
( O
A2BP1 O
) O
, O
which O
has O
been O
previously O
cloned O
in O
humans B_SPECIES[BIO]
and O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
cDNA O
encoding O
a O
protein O
, O
which O
interacts O
with O
ataxin O
- O
2 O
, O
the O
product O
of O
the O
causative O
gene O
for O
spinocerebellar O
ataxia O
type O
2 O
( O
23 O
, O
24 O
) O
. O

In O
addition O
to O
A2BP1 O
/ O
Fox O
- O
1 O
, O
another O
mouse B_SPECIES[BIO]/B_DISEASE
homolog O
of O
C B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
elegans I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
Fox O
- O
1 O
, O
Fxh O
, O
has O
been O
independently O
cloned O
as O
a O
cDNA O
, O
which O
is O
induced O
by O
androgen O
in O
motor O
neurons O
( O
25 O
) O
. O

Of O
note B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
that O
A2BP1 B_GENE/B_LOCATION
/ O
Fox B_GENE/B_BIO
- O
1 B_NUMBER[MEASURE]
and O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
share O
an O
identical B_GENE/B_MEASURE
RNA I_GENE/I_MEASURE
recognition I_GENE/I_MEASURE
motif I_GENE/I_MEASURE
( O
RRM B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
at O
the O
amino B_MEASURE/B_GENE
acid B_MEASURE/I_GENE
level B_MEASURE/I_GENE
. O

Therefore O
, O
two O
genes O
in O
the O
mouse B_SPECIES[BIO]/B_DISEASE
genome O
encode O
homologs O
of O
nematode O
Fox O
- O
1 O
. O

According O
to O
the O
names B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
given O
by O
the O
first B_PERSON/B_ORGANIZATION
cDNA I_PERSON/I_ORGANIZATION
cloning I_PERSON/I_ORGANIZATION
, O
we O
used O
the O
nomenclature B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
A2BP1 B_GENE/B_LOCATION
and O
Fxh B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

A2BP1 O
and O
Fxh O
have O
been O
named O
A2BP1 O
and O
Rbm9 O
, O
respectively O
, O
in O
the O
human B_SPECIES[BIO]
and O
mouse B_SPECIES[BIO]/B_DISEASE
genomes O
. O

We O
have O
been O
studying O
regulatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanisms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- O
specific B_DISEASE/B_ORGANISM_FUNCTION
alternative I_DISEASE/I_ORGANISM_FUNCTION
splicing I_DISEASE/I_ORGANISM_FUNCTION
using O
the O
non B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
muscle B_GENE
myosin I_GENE
heavy I_GENE
chain I_GENE
II I_GENE
- O
B B_PROTEIN[GENE]/B_DISEASE
( O
NMHC B_MEASURE/B_DISEASE
- O
B B_PROTEIN[GENE]/B_DISEASE
) O
gene B_GENE/B_LOCATION
as O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
14 B_MEASURE
, O
26 B_MEASURE
) O
. O

NMHC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
B B_PROTEIN[GENE]/B_MEASURE
mRNA I_PROTEIN[GENE]/I_MEASURE
is O
expressed O
ubiquitously O
. O

However O
, O
an O
alternative B_GENE
exon I_GENE
, O
N30 B_MEASURE/B_LOCATION
, O
which O
encodes O
a O
30 B_GENE
nt I_GENE
coding I_GENE
sequence I_GENE
, O
is O
included O
in O
the O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O
some O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
is O
skipped O
in O
those O
from O
all O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
in O
mammals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
birds B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
27 B_MEASURE
, O
28 B_MEASURE
) O
. O

In O
cultured O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
a O
switch B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
N30 B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
exclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
to O
inclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
be O
seen O
in O
neural B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
retinoblastoma I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Y79 I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
during O
the O
post B_DISEASE
- O
mitotic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
differentiated O
stages B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
triggered O
by O
butyrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
have O
previously O
defined O
an O
intronic B_PROTEIN[GENE]
distal I_PROTEIN[GENE]
downstream I_PROTEIN[GENE]
enhancer I_PROTEIN[GENE]
( O
IDDE B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
which O
confers O
neural B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
using O
this O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
line I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
14 B_TIME[MEASURE]/B_LOCATION
) O
. O

The O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
includes O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
copies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
UGCAUG B_PERSON/B_ENT
. O

Mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
these O
hexanucleotides B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
skipping O
in O
post B_DISEASE/B_LOCATION
- O
mitotic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
differentiated O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
investigated O
the O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
involvement I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O
A2BP1 B_GENE
and O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
N30 B_DISEASE/B_GENE
splicing I_DISEASE/I_GENE
. O

To O
this O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
we O
have O
isolated O
cDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
A2BP1 B_GENE
and O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cDNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cloning I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
enriched O
) O
isoforms B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
A2BP1 B_GENE
and O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
importance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
isoforms I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
A2BP1 B_GENE
and O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
respect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
different B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
subcellular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
localizations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Database B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disposition I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
sequences B_DISEASE/B_GENE
reported O
in O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
have O
been O
deposited O
in O
the O
GenBank B_LOCATION/B_ORGANIZATION
database I_LOCATION/I_ORGANIZATION
with O
accession B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
numbers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
AY659951 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
AY659952 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
F411 B_PROTEIN[GENE]
) O
, O
AY659953 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
F402 B_PROTEIN[GENE]
) O
, O
AY659954 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
AY659955 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
A030 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
AY659956 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
A713 B_PROTEIN[GENE]
) O
, O
AY659957 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
A715 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
AY659958 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
A704 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

RNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
preparation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Total O
RNAs O
were O
isolated O
from O
mouse B_BIO/B_DISEASE
tissues O
and O
cultured O
cells O
using O
an O
RNA O
isolation O
kit O
( O
Stratagene O
) O
or O
an O
RNeasy O
mini O
kit O
( O
Qiagen O
) O
. O

To O
obtain O
the O
full B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
length B_GENE/B_MEASURE
coding I_GENE/I_MEASURE
regions I_GENE/I_MEASURE
of O
cDNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
for O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
, O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCRs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
performed O
using O
Superscript B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
reverse O
transcriptase B_GENE
( O
Invitrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
Pfu B_GENE/B_SPECIES[BIO]
Turbo I_GENE/I_SPECIES[BIO]
DNA I_GENE/I_SPECIES[BIO]
polymerase I_GENE/I_SPECIES[BIO]
( O
Stratagene B_BIO/B_GENE
) O
. O

The O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
primers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
used O
to O
obtain O
all O
Fxh B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
5 B_NUMBER[MEASURE]/B_PROTEIN[GENE]
' I_NUMBER[MEASURE]/I_PROTEIN[GENE]
- O
ctcaggcctccactagttATGGAGAAAAAGAAAATGGTAACTC B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
and O
5 B_MEASURE
' I_MEASURE
- O
ctcaggcctcctctagaaGTAGGGGGCAAATCGGCTGTA B_PROTEIN[GENE]/B_LOCATION
- O
3 B_MEASURE
' O
. O

The O
upstream B_GENE
primers I_GENE
for O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
( O
A713 B_PROTEIN[GENE]
, O
A715 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A704 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
A2BP1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
5 B_NUMBER[MEASURE]/B_PROTEIN[GENE]
' I_NUMBER[MEASURE]/I_PROTEIN[GENE]
- O
ctcaggcctccactagtgATGAATTGTGAAAGAGAGCAGCT B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
and O
5 B_MEASURE
' I_MEASURE
- O
ctcaggcctccactagtcATGTTGGCGTCGCAAGGAGTCC B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
, O
respectively O
, O
and O
the O
downstream B_GENE/B_PERSON
primer I_GENE/I_PERSON
for O
all O
A2BP1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
5 B_NUMBER[MEASURE]
' I_NUMBER[MEASURE]
- O
ctcaggcctcctctagagATATGGAGCAAAACGGTTGTATCC B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
. O

Lower B_MEASURE/B_PERSON
case B_MEASURE/I_PERSON
letters B_MEASURE/I_PERSON
represent O
adapter B_LOCATION/B_PERSON
sequences I_LOCATION/I_PERSON
including O
restriction B_PERSON/B_MEASURE
enzyme I_PERSON/I_MEASURE
sites I_PERSON/I_MEASURE
. O

5 O
' O
Rapid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amplification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
cDNA B_GENE
ends I_GENE
( O
Race B_ENT/B_DISEASE
) O
was O
performed O
using O
Marathon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
Ready B_MEASURE/B_LOCATION
cDNA B_MEASURE/I_LOCATION
( O
BD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Biosciences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Clontech I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

For O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
minigene B_GENE
and O
NMHC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCRs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
performed O
as O
described O
previously O
( O
14 B_MEASURE
, O
26 B_MEASURE
) O
. O

sequences B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
primers B_PROTEIN[GENE]
P1 I_PROTEIN[GENE]
- O
P9 B_PROTEIN[GENE]
shown O
in O
figures B_PROTEIN[GENE]
1 I_PROTEIN[GENE]
, O
4 B_NUMBER[MEASURE]
and O
6 B_NUMBER[MEASURE]
are O
as O
follows O
: O
P1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_NUMBER[MEASURE]
' O
- O
AATTCACCCAGCAACCAGAAT B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_NUMBER[MEASURE]
' O
; O
P2 B_PROTEIN[GENE]
, O
5 B_NUMBER[MEASURE]
' O
- O
TAGAGGGATGTAAGTGTTGATGCC B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
; O
P3 B_PROTEIN[GENE]
, O
5 B_NUMBER[MEASURE]
' O
- O
CAGAGGGCGGACAGTGTATGGT B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
; O
P4 B_PROTEIN[GENE]
, O
5 B_NUMBER[MEASURE]
' O
- O
GGCGGCAGGGGCGAGGGCAT B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
; O
P5 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_NUMBER[MEASURE]
' O
- O
CCGTGGTCGCACCGTGTACAAC B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
; O
P6 B_PROTEIN[GENE]
, O
5 B_NUMBER[MEASURE]
' O
- O
CAGCGGCAGTGGCAGGGGTG B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_NUMBER[MEASURE]
' O
; O
P7 B_MEASURE/B_GENE
, O
5 B_NUMBER[MEASURE]
' O
- O
AGGAAGAAAGGACCATAATATTCC B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_NUMBER[MEASURE]
' O
; O
P8 B_MEASURE/B_PROTEIN[GENE]
, O
5 B_NUMBER[MEASURE]
' O
- O
CCTCCACCCAGCTCCAGTTGT B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
; O
and O
P9 B_MEASURE/B_GENE
, O
5 B_NUMBER[MEASURE]
' O
- O
CCTGTAGTTATTAAATCCTTCAAG B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
. O

preparation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
expression B_GENE/B_SPECIES[BIO]
constructs I_GENE/I_SPECIES[BIO]
and O
minigenes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
cDNAs O
of O
Fxh O
and O
A2BP1 O
were O
introduced O
into O
a O
plasmid O
pCS3 O
+ O
Mt O
, O
which O
contains O
a O
myc O
- O
epitope O
, O
and O
its O
modified O
version O
pCS3 O
+ O
Mt O
+ O
NLS O
, O
which O
in O
addition O
contains O
the O
nuclear O
localization O
signal O
( O
NLS O
) O
of O
the O
SV40 B_SPECIES[BIO]/B_DISEASE
large O
T O
antigen O
( O
26 O
) O
. O

Minigenes B_PROTEIN[GENE]
G I_PROTEIN[GENE]
, O
J B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
, O
and O
H B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
IDDE B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
the O
same B_MEASURE/B_PERSON
as O
minigenes B_PROTEIN[GENE]
W I_PROTEIN[GENE]
, O
D4 B_PROTEIN[GENE]
and O
Cm0 B_PROTEIN[GENE]
, O
respectively O
in O
ref B_SPECIES[BIO]/B_DISEASE
. O

( O
14 B_MEASURE
) O
. O

The O
201 B_GENE
nt I_GENE
IDDEs I_GENE
with O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O
generated O
by O
recombinant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
the O
appropriate B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
primers B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
which O
included O
mutated O
sequences B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
hexanucleotide B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
TGCATG I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequences O
at O
the O
5 B_MEASURE
' O
and O
3 B_MEASURE
' O
sides B_LOCATION
were O
changed O
to O
GTTACT B_ORGANIZATION/B_LOCATION
and O
ACCTAC B_LOCATION/B_ORGANIZATION
, O
respectively O
. O

electrophoresis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mobility I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shift O
assay O
. O

template O
DNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
for O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transcription I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
prepared O
by O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
using O
the O
wild B_BIO
- O
type B_MEASURE/B_LOCATION
and O
mutant B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
IDDEs I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
the O
minigenes B_GENE/B_BIO
as O
templates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
an O
upstream B_GENE
primer I_GENE
that O
included O
the O
T7 B_GENE
promoter I_GENE
sequence I_GENE
at O
the O
5 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
competitor B_GENE/B_BIO
RNAs I_GENE/I_BIO
were O
transcribed O
by O
T7 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
32P B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
UTP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
a O
trace B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amount B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
UTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
respectively O
, O
using O
a O
MAXIscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
( O
Ambion B_DISEASE/B_PROTEIN[GENE]
) O
. O

mole B_MEASURE/B_LOCATION
concentrations I_MEASURE/I_LOCATION
of O
synthesized B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RNAs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
estimated O
by O
radioactivities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
with O
a O
myc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tag B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
synthesized O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
by O
using O
a O
TNT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
quick O
- O
coupled O
transcription B_GENE
/ O
translation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Promega B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
from O
pCS3 B_SPECIES[BIO]/B_GENE
+ I_SPECIES[BIO]/I_GENE
MT I_SPECIES[BIO]/I_GENE
constructs I_SPECIES[BIO]/I_GENE
, O
which O
include O
the O
SP6 B_GENE/B_MEASURE
promoter I_GENE/I_MEASURE
. O

Binding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
carried O
out O
in O
a O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mu I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
contains O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HEPES I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
pH B_MEASURE/B_LOCATION
7 I_MEASURE/I_LOCATION
. O
9 B_MEASURE
) O
, O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MgCl2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
50 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycerol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_MEASURE
. O
5 B_MEASURE
mm I_MEASURE
DTT I_MEASURE
, O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mu I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
g I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tRNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mu I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reticulocyte I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lysate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
15 B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fmol I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
on O
ice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
20 B_MEASURE
- O
30 B_TIME[MEASURE]
min I_TIME[MEASURE]
. O

An O
aliquot B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
5 B_MEASURE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Mu B_MEASURE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
g B_MEASURE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
added O
to O
the O
reaction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
reaction B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixtures B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
analyzed O
by O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polyacrylamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O
a O
0 B_MEASURE
. O
5 B_MEASURE
x O
TBE B_MEASURE
buffer I_MEASURE
( O
Invitrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

Cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
transfection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
human B_SPECIES[BIO]/B_DISEASE
retinoblastoma O
cell O
line O
Y79 O
was O
cultured O
and O
transfected O
with O
DNAs O
as O
described O
previously O
( O
14 O
, O
26 O
) O
. O

Total B_MEASURE/B_ORGANIZATION
amounts I_MEASURE/I_ORGANIZATION
of O
transfected B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
adjusted O
to O
be O
constant B_MEASURE
by O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
empty B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
vector I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Either O
Lipofectin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Invitrogen B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
or O
Effectene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transfection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reagent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Qiagen B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
used O
for O
the O
transfection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
stable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
pCS3 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
MT I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
expression I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
constructs I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
transfected O
with O
a O
plasmid B_GENE
carrying O
a O
neomycin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
resistant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
selected O
by O
0 B_MEASURE
. O
2 B_MEASURE
mm I_MEASURE
geneticin I_MEASURE
( O
Invitrogen B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

For O
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
plated O
on O
the O
poly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
lysine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
coated O
plates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
then O
treated O
with O
2 B_NUMBER[MEASURE]
. O
0 B_MEASURE
- O
2 B_MEASURE
. O
5 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
butyrate I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
4 B_NUMBER[MEASURE]
- O
5 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

HeLa B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
cultured O
as O
described O
and O
transfected O
with O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O
Effectene B_LOCATION/B_GENE
reagent B_LOCATION/I_GENE
( O
14 B_MEASURE
, O
26 B_MEASURE
) O
. O

immunoblot B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
that O
required O
both O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
mRNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
split O
upon O
harvesting O
. O

Total B_PERSON/B_ENT
cell I_PERSON/I_ENT
proteins I_PERSON/I_ENT
were O
subjected O
to O
SDS B_PROTEIN[GENE]/B_DISEASE
- O
PAGE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
blotted O
as O
described O
previously O
( O
26 B_MEASURE
) O
. O

The O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
are O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
myc B_PERSON/B_BIO
- O
epitope B_PROTEIN[GENE]
( O
Invitrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
green B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
GFP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
Clontech B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
. O

binding B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
detected O
with O
the O
SuperSignal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
System I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Pierce B_PERSON/B_ORGANIZATION
) O
or O
ecl B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
Amersham B_LOCATION
) O
. O

immunofluorescent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

HeLa B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
or O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
grown O
in O
a O
four B_NUMBER[MEASURE]
- O
chamber B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
glass B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
slide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
transfected O
as O
described O
above O
. O

cells O
were O
fixed O
with O
10 O
% O
formaldehyde O
24 O
- O
48 O
h O
after O
transfection O
, O
and O
permealized O
with O
0 O
. O
5 O
% O
Triton O
X O
- O
100 O
then O
blocked O
with O
5 O
% O
goat B_SPECIES[BIO]
serum O
. O

Primary O
antibodies O
used O
were O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
myc O
( O
Invitrogen O
) O
, O
rabbit B_SPECIES[BIO]
anti O
- O
NMHC O
- O
B O
( O
29 O
) O
. O

Secondary O
antibodies O
were O
Alexa O
Fluor O
594 O
goat B_SPECIES[BIO]
anti O
- O
mouse B_SPECIES[BIO]/B_DISEASE
IgG O
and O
Alexa O
Fluor O
488 O
goat B_SPECIES[BIO]
anti O
- O
rabbit B_SPECIES[BIO]
IgG O
( O
Molecular O
Probes O
) O
. O

DAPI B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
used O
for O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

specimens B_BIO/B_PERSON
were O
mounted O
in O
ProLong B_LOCATION/B_PERSON
antifed I_LOCATION/I_PERSON
kit I_LOCATION/I_PERSON
( O
Molecular B_MEASURE/B_LOCATION
probe I_MEASURE/I_LOCATION
) O
. O

The O
images B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O
collected O
using O
Leica B_PRODUCT[OBJECT]/B_ENT
SP I_PRODUCT[OBJECT]/I_ENT
confocal I_PRODUCT[OBJECT]/I_ENT
microscopy I_PRODUCT[OBJECT]/I_ENT
( O
Leica B_DISEASE/B_MEASURE
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Tissue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
and O
their O
subcellular B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
A2BP1 O
mRNAs O
are O
detected O
almost O
exclusively O
in O
brain O
and O
striated O
muscles O
( O
heart O
and O
skeletal O
muscles O
) O
in O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
the O
Fxh O
mRNAs O
are O
expressed O
in O
a O
wide O
variety O
of O
tissues O
with O
the O
highest O
expression O
in O
brain O
and O
heart O
[ O
( O
21 O
, O
25 O
) O
and O
S O
. O
Kawamoto O
, O
unpublished O
data O
] O
. O

These O
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
prompted O
us O
to O
characterize O
the O
mRNAs B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
A2BP1 B_GENE
and O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
cloned O
cDNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
skeletal B_BODY_PART_OR_ORGAN_COMPONENT
muscles I_BODY_PART_OR_ORGAN_COMPONENT
by O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
5 B_NUMBER[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Race B_SPORT[ENT]/B_ORGANIZATION
. O

The O
isolated B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNAs I_BIO/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
schematically O
presented O
with O
genomic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
structures I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
figure B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
( O
for O
amino B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
see O
also O
Figure B_LOCATION/B_ENT
8 I_LOCATION/I_ENT
) O
. O

Both O
gene B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
found O
to O
undergo O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
alternative B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

In O
both O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
striated B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
express O
unique B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splice I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variants I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generated O
by O
mutually O
exclusive B_DISEASE_ADJECTIVE[DISEASE]
splicing I_DISEASE_ADJECTIVE[DISEASE]
of O
exons B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
B40 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
M43 B_PROTEIN[GENE]
, O
respectively O
, O
which O
provide O
different B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coding B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
middle B_LOCATION/B_DISEASE
of O
the O
carboxyl B_MEASURE/B_LOCATION
half B_MEASURE/I_LOCATION
of O
the O
molecules B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Southern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
Fxh B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
different B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
probed O
by O
oligonucleotides B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corresponding O
to O
B40 B_PROTEIN[GENE]
and O
M43 B_PROTEIN[GENE]
shows O
that O
M43 B_PROTEIN[GENE]
is O
exclusively O
used O
in O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
skeletal B_BODY_PART_OR_ORGAN_COMPONENT
muscles I_BODY_PART_OR_ORGAN_COMPONENT
, O
while O
B40 O
is O
predominantly O
used O
in O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_BODY_PART_OR_ORGAN_COMPONENT
2A I_BODY_PART_OR_ORGAN_COMPONENT
) O
. O

digestion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCR B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
products I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
A2BP1 B_GENE
mRNAs I_GENE
with O
restriction B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzymes O
unique B_DISEASE_ADJECTIVE[DISEASE]
to O
B40 B_PROTEIN[GENE]
and O
M43 B_PROTEIN[GENE]
demonstrates O
that O
B40 B_PROTEIN[GENE]
and O
M43 B_PROTEIN[GENE]
are O
used O
almost O
exclusively O
in O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
( O
Figure B_MEASURE/B_LOCATION
2B I_MEASURE/I_LOCATION
) O
. O

A2BP1 B_GENE/B_PERSON
contains O
an O
additional B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cassette I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alternative I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A53 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
consisting O
of O
53 B_GENE
nt I_GENE
. O

Inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
exclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
exon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A53 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
two B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
different B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
amino B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acid B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
owing O
to O
a O
frame B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
shift B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
. O

In O
the O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
A2BP1 B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
Moreover O
, O
it O
appears O
that O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
striated B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
utilize O
alternative B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
promoters I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
, O
resulting O
in O
different B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amino B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
acid B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
at O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminus B_LOCATION
. O

The O
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
race I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
skeletal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
muscle B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
mRNAs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
yielded O
essentially O
a O
single B_BIO/B_MEASURE
species B_BIO/I_MEASURE
of O
sequence B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
29 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unique B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Race B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
brain B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
however O
, O
yielded O
multiple B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
multiple B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deduced I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
amino I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
all O
of O
which O
differ O
from O
the O
muscle B_GENE/B_LOCATION
amino I_GENE/I_LOCATION
acid I_GENE/I_LOCATION
sequence I_GENE/I_LOCATION
at O
the O
very B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminus B_LOCATION/B_MEASURE
. O

Here O
, O
we O
focus O
our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O
a O
clone B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
containing O
nine B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unique B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminus B_LOCATION
, O
which O
was O
obtained O
most O
frequently O
. O

exon B_GENE/B_PERSON
- O
intron B_MEASURE/B_ORGANIZATION
organization I_MEASURE/I_ORGANIZATION
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
shows O
remarkable B_DISEASE_ADJECTIVE[DISEASE]
similarities I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
RRM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
encoded O
in O
four B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
exons I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Figure B_NUMBER[MEASURE]/B_PERSON
1B I_NUMBER[MEASURE]/I_PERSON
) O
. O

Of O
note B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
that O
the O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amounts B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
mRNAs I_GENE
from O
skeletal B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
are O
missing O
a O
part B_MEASURE/B_LOCATION
of O
the O
RRM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
exon B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
skipping I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Typically O
, O
as O
shown O
in O
figure B_SPECIES[BIO]
2C I_SPECIES[BIO]
, O
they O
lack O
the O
93 B_GENE
nt I_GENE
exon I_GENE
that O
encodes O
RNP1 B_GENE
, O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
two B_NUMBER[MEASURE]
most O
critical B_MEASURE/B_LOCATION
motifs I_MEASURE/I_LOCATION
of O
the O
RRM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 B_NUMBER[MEASURE]/B_BIO
) O
. O

Some O
of O
them O
lack O
almost O
the O
entire B_LOCATION/B_MEASURE
RRM I_LOCATION/I_MEASURE
( O
e B_OTHER/B_PROTEIN[GENE]
. O
g B_LOCATION/B_MEASURE
. O
F402 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Figure B_LOCATION
1A I_LOCATION
) O
. O

To O
examine O
the O
subcellular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
distribution I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
each O
isoform B_GENE/B_MEASURE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
, O
myc B_GENE/B_SPECIES[BIO]
- O
tagged O
proteins B_GENE/B_DISEASE
were O
transiently O
expressed O
in O
cultured O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
immunostained O
with O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
myc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Initially O
, O
HeLa B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O
used O
to O
investigate O
subcellular B_DISEASE/B_GENE
localization I_DISEASE/I_GENE
, O
since O
these O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
more O
suited O
for O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

representative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
confocal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
images I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
shown O
in O
figure B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3A I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

DAPI B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
NMHC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
serve O
as O
markers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
nuclei B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
cytoplasm B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
respectively O
. O

As O
noted O
, O
the O
ratio B_MEASURE/B_PERSON
of O
protein B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
distributed O
between O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
differs O
among O
the O
proteins B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

All O
isoforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
a O
predominant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
nuclear I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
localization I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
brain B_GENE/B_DISEASE
isoform I_GENE/I_DISEASE
of O
A2BP1 B_GENE
without O
the O
A53 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
localizes B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
both O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
whereas O
the O
other B_GENE/B_MEASURE
brain I_GENE/I_MEASURE
isoform I_GENE/I_MEASURE
with O
the O
A53 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
A030 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
localizes B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
predominantly O
to O
cytoplasm O
with O
only O
a O
minimum B_MEASURE/B_PERSON
being I_MEASURE/I_PERSON
in O
the O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O

The O
relative B_MEASURE
amounts I_MEASURE
of O
both O
muscle B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
A2BP1 B_GENE
( O
A713 B_PROTEIN[GENE]
and O
A715 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
are O
somewhat O
between O
the O
amounts B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
two B_GENE/B_MEASURE
brain I_GENE/I_MEASURE
isoforms I_GENE/I_MEASURE
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
summarized O
in O
Figure B_MEASURE/B_LOCATION
1A I_MEASURE/I_LOCATION
. O

The O
subcellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
representative B_GENE
isoforms I_GENE
( O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
also O
examined O
in O
retinoblastoma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Y79 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
were O
used O
as O
host B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cells I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
the O
transfection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
order B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
characterize O
splicing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP B_GENE
proteins I_GENE
( O
see O
below O
) O
. O

Although O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
have O
a O
spherical B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
shape I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O
have O
only O
thin B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cytoplasm I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O
exogenously O
expressed O
isoforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
show O
a O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
subcellular B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
distribution B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O
in O
HeLa B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Figure B_MEASURE/B_LOCATION
3B I_MEASURE/I_LOCATION
) O
. O

F011 B_MEASURE/B_PROTEIN[GENE]
localizes I_MEASURE/I_PROTEIN[GENE]
predominantly O
to O
nuclei O
, O
A016 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
both O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
A030 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predominantly O
to O
cytoplasm O
. O

Specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
with O
IDDE B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O
a O
hexanucleotide B_GENE
UGCAUG I_GENE
. O

Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_TIME[MEASURE]/B_LOCATION
share I_TIME[MEASURE]/I_LOCATION
an O
identical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RRM I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
A2BP1 B_GENE/B_MEASURE
has O
been O
reported O
to O
bind O
specifically O
to O
the O
pentanucleotide B_GENE
GCAUG I_GENE
through O
this O
RRM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
21 B_NUMBER[MEASURE]/B_LOCATION
) O
. O

We O
have O
previously O
reported O
that O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
NMHC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
B B_GENE/B_LOCATION
transcript I_GENE/I_LOCATION
, O
which O
is O
indispensable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
regulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cassette B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
type B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
exon B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
N30 B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
has O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
copies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
GCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
14 B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
. O

Therefore O
, O
we O
investigated O
whether O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
/ O
or O
A2BP1 B_GENE
bound O
to O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

electrophoretic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shift I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assays I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
EMSAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
were O
carried O
out O
using O
labeled O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
in O
vitro B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcribed O
and O
translated O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
, O
which O
include O
a O
myc B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
epitope B_GENE/B_LOCATION
. O

Since O
all O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
isoforms I_GENE
, O
except O
F402 B_PROTEIN[GENE]
and O
A704 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
contain O
the O
identical B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RRM I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
representative B_NUMBER[MEASURE]/B_PERSON
isoforms B_NUMBER[MEASURE]/I_PERSON
were O
analyzed O
. O

The O
expression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
reticulocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
lysate I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
causes O
the O
formation B_PERSON/B_DISEASE
of O
a O
RNA B_GENE/B_BIO
- O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whose O
migration B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shift B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distinguishes O
it O
from O
those O
of O
the O
control B_BIO/B_GENE
reticulocyte I_BIO/I_GENE
lysate I_BIO/I_GENE
( O
C B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
figure B_MEASURE
4B I_MEASURE
, O
lanes O
3 B_NUMBER[MEASURE]
and O
10 B_NUMBER[MEASURE]
) O
. O

The O
unlabeled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
wild B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IDDE I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
competes O
with O
the O
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
efficiently O
for O
the O
formation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
specific B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complex I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
C I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_MEASURE
4B I_MEASURE
, O
lane B_TIME[MEASURE]/B_LOCATION
4 I_TIME[MEASURE]/I_LOCATION
) O
. O

On O
the O
other B_PERSON/B_LOCATION
hand B_PERSON/I_LOCATION
, O
the O
mutant B_PERSON/B_GENE
MC I_PERSON/I_GENE
( O
Figure B_NUMBER[MEASURE]/B_PERSON
4A I_NUMBER[MEASURE]/I_PERSON
) O
, O
which O
has O
a O
mutation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
both O
copies B_GENE/B_LOCATION
of O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
does O
not O
( O
Figure O
4B B_MEASURE/B_LOCATION
, O
lane B_LOCATION/B_PROTEIN[GENE]
7 B_LOCATION/I_PROTEIN[GENE]
) O
. O

The O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
has O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
the O
hexanucleotide B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
5 B_NUMBER[MEASURE]
' O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
shows O
less O
efficient B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
competition I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
compared O
with O
MB B_LOCATION/B_GENE
, O
which O
has O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
the O
3 B_LOCATION/B_MEASURE
' I_LOCATION/I_MEASURE
side I_LOCATION/I_MEASURE
of O
the O
hexanucleotide B_GENE
( O
figure B_PROTEIN[GENE]/B_LOCATION
4B I_PROTEIN[GENE]/I_LOCATION
, O
lanes B_NUMBER[MEASURE]/B_PROTEIN[GENE]
5 I_NUMBER[MEASURE]/I_PROTEIN[GENE]
and O
6 B_MEASURE
) O
, O
indicating O
that O
the O
nucleotides B_DISEASE
at O
the O
5 B_DISEASE/B_LOCATION
' B_DISEASE/I_LOCATION
side B_DISEASE/I_LOCATION
are O
more O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
those O
at O
the O
3 B_LOCATION/B_SEQUENCE[MEASURE]
' I_LOCATION/I_SEQUENCE[MEASURE]
side I_LOCATION/I_SEQUENCE[MEASURE]
. O

The O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
myc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
a O
non B_DISEASE/B_GENE
- O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
inhibits O
the O
formation B_PERSON/B_DISEASE
of O
the O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
figure B_PROTEIN[GENE]/B_MEASURE
4B I_PROTEIN[GENE]/I_MEASURE
, O
lane B_TIME[MEASURE]/B_LOCATION
8 I_TIME[MEASURE]/I_LOCATION
) O
. O

synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
full B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
length B_GENE/B_MEASURE
F011 I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
using O
a O
reticulocyte B_GENE
lysate I_GENE
and O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
myc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
expressed O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
are O
verified O
by O
immunoblot B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
figure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4B I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lanes B_SEQUENCE[MEASURE]/B_LOCATION
11 I_SEQUENCE[MEASURE]/I_LOCATION
and O
12 B_NUMBER[MEASURE]
) O
. O

A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_MEASURE/B_PROTEIN[GENE]
show O
essentially O
identical B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
those O
with O
F011 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
can O
bind O
to O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
that O
the O
hexanucleotide B_GENE/B_LOCATION
UGCAUG I_GENE/I_LOCATION
is O
required O
for O
their O
binding B_TIME[MEASURE]/B_GENE
. O

Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enhance O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
a O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

To O
study O
whether O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
regulate O
neural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_DISEASE/B_GENE
splicing I_DISEASE/I_GENE
via O
binding O
to O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
expression I_GENE
constructs I_GENE
were O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
transfected O
into O
retinoblastoma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Y79 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
number B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
reporter B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minigene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constructs I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
include O
the O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE/B_MEASURE
or O
a O
mutant B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
version I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
of O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
figure B_GENE
4A I_GENE
) O
. O

Minigenes B_PROTEIN[GENE]/B_LOCATION
H I_PROTEIN[GENE]/I_LOCATION
and O
J B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consist O
of O
the O
exons B_PROTEIN[GENE]
E5 I_PROTEIN[GENE]
, O
N30 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
E6 B_PROTEIN[GENE]
and O
their O
flanking B_GENE/B_LOCATION
introns I_GENE/I_LOCATION
with O
some O
deletions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
the O
introns B_GENE/B_MEASURE
. O

The O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
or O
without O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
hexanucleotide B_GENE
is O
included O
or O
excluded O
between O
N30 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
E6 B_PROTEIN[GENE]
. O

As O
described O
above O
, O
each O
isoform B_GENE/B_MEASURE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
enters O
the O
nucleus B_BODY_PART_OR_ORGAN_COMPONENT
to O
a O
different B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
extent B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

To O
see O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O
itself O
, O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
their O
differential B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
properties I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
in O
nuclear B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
localization I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
an O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
added O
to O
the O
expressed O
proteins B_GENE/B_DISEASE
. O

Since O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
contain O
the O
identical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RRM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
F011 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_PROTEIN[GENE]/B_MEASURE
all O
show O
the O
same B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
UGCAUG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_GENE/B_LOCATION
were O
used O
for O
these O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Host B_PERSON/B_GENE
cells I_PERSON/I_GENE
Y79 I_PERSON
at O
the O
proliferating O
stage B_MEASURE/B_LOCATION
exclude O
the O
N30 B_DISEASE_ADJECTIVE[DISEASE]
exon I_DISEASE_ADJECTIVE[DISEASE]
in O
~ B_MEASURE
90 I_MEASURE
% I_MEASURE
of O
the O
endogenous B_GENE/B_DISEASE
NMHC I_GENE/I_DISEASE
- O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
e B_OTHER/B_GENE
. O
g B_PROTEIN[GENE]/B_LOCATION
. O
see O
figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
6A I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
lane B_TIME[MEASURE]/B_LOCATION
1 I_TIME[MEASURE]/I_LOCATION
) O
. O

As O
shown O
in O
figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4C I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
minigene B_PROTEIN[GENE]/B_LOCATION
J I_PROTEIN[GENE]/I_LOCATION
exclude O
N30 B_DISEASE_ADJECTIVE[DISEASE]
without O
exogenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
A2BP1 B_GENE
in O
Y79 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
endogenous B_GENE/B_DISEASE
NMHC I_GENE/I_DISEASE
- O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_MEASURE
4C I_MEASURE
, O
upper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
panel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
lanes O
1 B_NUMBER[MEASURE]
- O
5 B_MEASURE
) O
. O

However O
, O
in O
the O
presence B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
expression B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
increased O
( O
figure B_MEASURE/B_LOCATION
4C I_MEASURE/I_LOCATION
, O
upper B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lanes O
7 B_NUMBER[MEASURE]
and O
12 B_NUMBER[MEASURE]
) O
. O

The O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
absolutely O
dependent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
Figure B_LOCATION/B_PERSON
4C I_LOCATION/I_PERSON
, O
upper B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lanes O
6 B_NUMBER[MEASURE]
and O
11 B_NUMBER[MEASURE]
) O
. O

Moreover O
, O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
either O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
two B_GENE/B_LOCATION
copies I_GENE/I_LOCATION
of O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ma B_LOCATION/B_MEASURE
, O
Mb B_GENE/B_TIME[MEASURE]
) O
abolishes O
the O
inclusion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_MEASURE/B_LOCATION
4C I_MEASURE/I_LOCATION
, O
upper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
panel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
lanes O
8 B_MEASURE
- O
10 B_NUMBER[MEASURE]
, O
13 B_MEASURE
- O
15 B_MEASURE
) O
. O

In O
the O
context B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
minigene B_SPECIES[BIO]/B_GENE
H I_SPECIES[BIO]/I_GENE
, O
which O
contains O
shorter B_GENE
introns I_GENE
, O
the O
larger B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extent B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
is O
induced O
by O
either O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
A030 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
overexpression I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_MEASURE/B_LOCATION
4C I_MEASURE/I_LOCATION
, O
middle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
panel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
lanes O
7 B_NUMBER[MEASURE]
and O
12 B_NUMBER[MEASURE]
) O
. O

The O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
minigene B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNAs I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
depends O
on O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
IDDE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
figure B_MEASURE/B_LOCATION
4C I_MEASURE/I_LOCATION
, O
middle B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lanes O
6 B_NUMBER[MEASURE]
and O
11 B_NUMBER[MEASURE]
) O
. O

Mutation B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
copies B_ENT/B_GENE
of O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MC B_LOCATION/B_MEASURE
) O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
complete B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
loss I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
figure B_MEASURE/B_LOCATION
4C I_MEASURE/I_LOCATION
, O
middle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
panel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
lanes O
10 B_MEASURE
and O
15 B_MEASURE
) O
. O

The O
mutant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ma I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shows O
stronger B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
compared O
with O
MB B_LOCATION/B_GENE
( O
Figure B_LOCATION/B_MEASURE
4C I_LOCATION/I_MEASURE
, O
middle B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lanes O
8 B_NUMBER[MEASURE]
and O
9 B_NUMBER[MEASURE]
) O
. O

This O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
competition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
EMSA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O
in O
figure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
4B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
indicating O
that O
the O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hexanucleotide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
more O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
the O
3 B_MEASURE
' O
hexanucleotide B_LOCATION
for O
binding B_TIME[MEASURE]/B_GENE
of O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
A2BP1 B_GENE/B_LOCATION
to O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
well O
as O
an O
activation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

comparable B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
expressed O
in O
each O
transfection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
as O
verified O
by O
immunoblots B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
myc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Figure B_MEASURE/B_PERSON
4C I_MEASURE/I_PERSON
, O
lower B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
panel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
lanes B_MEASURE/B_LOCATION
6 I_MEASURE/I_LOCATION
- O
17 B_NUMBER[MEASURE]
) O
. O

Since O
minigenes B_LOCATION
J I_LOCATION
and O
H B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lack O
a O
portion B_MEASURE/B_LOCATION
of O
the O
intron B_GENE/B_LOCATION
between O
exons B_PROTEIN[GENE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
N30 I_PROTEIN[GENE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
and O
E6 B_PROTEIN[GENE]
and O
, O
therefore O
, O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
located O
~ B_LOCATION
100 I_LOCATION
nt I_LOCATION
downstream I_LOCATION
of O
N30 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
instead O
of O
1 B_MEASURE
. O
5 B_MEASURE/B_LOCATION
kb I_MEASURE/I_LOCATION
as O
in O
the O
native B_GENE/B_PERSON
gene I_GENE/I_PERSON
, O
we O
also O
analyzed O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
on O
the O
N30 B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
wild B_SPECIES[BIO]
- O
type B_GENE/B_MEASURE
minigene B_GENE/I_MEASURE
G B_GENE/I_MEASURE
, O
which O
includes O
full B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
length B_GENE/B_MEASURE
introns I_GENE/I_MEASURE
among O
E5 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N30 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
E6 B_PROTEIN[GENE]
( O
figure B_PROTEIN[GENE]
4A I_PROTEIN[GENE]
) O
. O

As O
shown O
in O
figure B_SPECIES[BIO]
4C I_SPECIES[BIO]
( O
right B_MEASURE/B_LOCATION
panel I_MEASURE/I_LOCATION
) O
, O
both O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
capable B_PERSON/B_LOCATION
of O
promoting O
N30 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
with O
F011 B_PERSON
showing O
a O
higher B_MEASURE/B_LOCATION
activity I_MEASURE/I_LOCATION
( O
figure B_MEASURE
4C I_MEASURE
, O
lanes B_MEASURE/B_LOCATION
16 I_MEASURE/I_LOCATION
and O
17 B_MEASURE
) O
. O

Although O
A030 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
promote O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
as O
efficiently O
as O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
contexts B_LOCATION
of O
the O
minigene B_PROTEIN[GENE]/B_LOCATION
J I_PROTEIN[GENE]/I_LOCATION
and O
H B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
can O
do O
so O
less O
efficiently O
than O
F011 B_PROTEIN[GENE]/B_PERSON
in O
the O
context B_LOCATION
of O
the O
minigene B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcript I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
discussed O
below O
. O

taken O
together O
, O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
activate O
N30 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inclusion I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
an O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_LOCATION
manner I_LOCATION
. O

The O
hexanucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
motif B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
UGCAUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
indispensable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
this O
activation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
alternatively O
spliced O
isoforms B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
in O
promoting O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Both O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
mRNAs I_GENE
are O
expressed O
in O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
A2BP1 B_GENE/B_PERSON
is O
also O
expressed O
in O
striated B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
Fxh B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
expressed O
in O
an O
even O
wider B_MEASURE/B_LOCATION
variety I_MEASURE/I_LOCATION
of O
tissues B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

As O
demonstrated O
above O
, O
however O
, O
both O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
undergo O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
producing O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O
enriched O
isoforms B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
the O
relative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
individual B_GENE/B_MEASURE
isoform I_GENE/I_MEASURE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
in O
promoting O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
compared O
using O
minigene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
G I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

First O
, O
in O
order B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
evaluate O
the O
relative B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specific I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
activity I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
each O
isoform B_GENE/B_MEASURE
in O
the O
splicing B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reaction I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
separately O
from O
its O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
localize O
to O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
an O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
included O
in O
the O
expressed O
protein B_GENE/B_BACTERIUM[BIO]
to O
equalize O
the O
nuclear B_MEASURE
concentration I_MEASURE
of O
the O
expressed O
protein B_GENE/B_BACTERIUM[BIO]
in O
these O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

essentially O
, O
all O
of O
the O
expressed O
proteins B_GENE/B_DISEASE
with O
the O
exogenous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
NLS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
localized O
to O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

Therefore O
, O
the O
relative B_MEASURE/B_LOCATION
nuclear I_MEASURE/I_LOCATION
concentrations I_MEASURE/I_LOCATION
of O
the O
expressed O
proteins B_GENE/B_DISEASE
can O
be O
estimated O
easily O
by O
immunoblots B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
shown O
in O
immunoblots B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
figure B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
5A I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O
similar B_MEASURE/B_LOCATION
quantities I_MEASURE/I_LOCATION
of O
proteins B_GENE/B_DISEASE
are O
expressed O
in O
a O
dose B_MEASURE/B_LOCATION
- O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
manner B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Expression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
the O
brain B_GENE
isoform I_GENE
F011 I_BIO
causes O
a O
dose B_MEASURE/B_LOCATION
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
extent B_MEASURE/B_LOCATION
of O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
reaches O
a O
plateau B_LOCATION/B_MEASURE
with O
~ O
85 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
mRNAs B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
including O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
inclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoted O
by O
F411 B_GENE
, O
the O
predominant B_GENE
isoform I_GENE
from O
skeletal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
muscles I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O
reaches O
a O
plateau B_LOCATION/B_MEASURE
with O
only O
40 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
mRNAs B_MEASURE/B_BIO
. O

With O
respect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
A2BP1 B_GENE
, O
the O
brain B_GENE
isoform I_GENE
A030 I_GENE
shows O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
activity B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
than O
the O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
isoform I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
A715 I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
, O
which O
shows O
almost O
no O
activation B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
shown O
in O
figure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
5A B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

Including O
additional B_MEASURE/B_PERSON
isoforms I_MEASURE/I_PERSON
, O
the O
activities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
individual B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
with O
an O
exogenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
NLS I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
promoting O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
are O
shown O
in O
Figure B_PERSON/B_LOCATION
5B I_PERSON/I_LOCATION
( O
lanes B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
- O
13 B_MEASURE
) O
and O
are O
also O
summarized O
in O
Figure B_LOCATION/B_PERSON
1A B_LOCATION/I_PERSON
( O
nls B_MEASURE
) O
. O

Special B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
taken O
to O
ensure O
that O
a O
similar B_MEASURE/B_LOCATION
quantity I_MEASURE/I_LOCATION
of O
each O
protein B_GENE/B_BACTERIUM[BIO]
was O
expressed O
and O
, O
if O
not O
, O
different B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
tested O
to O
obtain O
comparable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NLS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
nls B_PROTEIN[GENE]/B_MEASURE
) O
, O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
the O
highest B_MEASURE/B_LOCATION
activities I_MEASURE/I_LOCATION
among O
all O
isoforms B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tested O
. O

A30 B_PROTEIN[GENE]
shows O
a O
considerably O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
activity B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Each O
of O
the O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
F411 B_PROTEIN[GENE]
, O
A713 B_PROTEIN[GENE]
and O
A715 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
has O
a O
lower B_MEASURE
activity I_MEASURE
than O
that O
of O
their O
brain B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
counterparts I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A030 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
) O
. O

As O
expected O
, O
isoforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacking O
a O
part B_MEASURE/B_LOCATION
or O
all O
of O
the O
RRM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
F402 B_PROTEIN[GENE]
and O
A704 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
have O
no O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Next B_TIME[MEASURE]/B_LOCATION
, O
the O
splicing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
wild B_BIO/B_GENE
- O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
without O
an O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
examined O
. O

Representative B_ORGANIZATION/B_PERSON
data I_ORGANIZATION/I_PERSON
are O
shown O
in O
figure B_MEASURE/B_LOCATION
5B I_MEASURE/I_LOCATION
( O
lanes B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
- O
7 B_MEASURE
) O
and O
the O
relative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
summarized O
in O
figure B_MEASURE/B_LOCATION
1A I_MEASURE/I_LOCATION
( O
wt B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

The O
protein B_MEASURE/B_BACTERIUM[BIO]
amounts O
detected O
by O
immunoblots B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
these O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represent O
the O
total B_MEASURE
amounts I_MEASURE
of O
the O
proteins B_PROTEIN[GENE]/B_DISEASE
distributed O
to O
both O
the O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
splicing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
wild B_BIO
- O
type B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
activities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
combine O
the O
splicing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
the O
proteins B_GENE/B_DISEASE
with O
the O
exogenous B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
NLS I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
activities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
native B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
localize O
to O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

In O
the O
absence B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
wt B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
, O
the O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
A016 B_GENE/B_LOCATION
to O
a O
lesser B_MEASURE/B_DISEASE
extent I_MEASURE/I_DISEASE
, O
are O
still O
capable B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
activating O
N30 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inclusion I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficiently O
. O

The O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
isoforms O
for O
both O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
( O
F411 B_GENE
, O
A713 B_PROTEIN[GENE]
and O
A715 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
as O
well O
as O
the O
brain B_GENE/B_BIO
isoform I_GENE/I_BIO
A030 I_GENE/I_BIO
, O
show O
only B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minimal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A016 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O
to O
have O
the O
most O
physiological B_DISEASE_ADJECTIVE[DISEASE]
relevance I_DISEASE_ADJECTIVE[DISEASE]
to O
N30 B_DISEASE/B_BIO
splicing I_DISEASE/I_BIO
activation I_DISEASE/I_BIO
. O

Overexpression B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
activates O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
endogenous B_GENE/B_DISEASE
NMHC I_GENE/I_DISEASE
- O
B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
human B_SPECIES[BIO]/B_MEASURE
NMHC O
- O
B O
gene O
consists O
of O
41 O
constitutive O
exons O
and O
3 O
alternative O
exons O
. O

Its O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mRNA B_GENE
is O
~ O
156 B_MEASURE/B_PERSON
kb I_MEASURE/I_PERSON
in O
length B_MEASURE/B_LOCATION
and O
it O
is O
much O
more O
complex B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mRNA B_GENE
from O
the O
minigenes B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
the O
minigene B_GENE/B_LOCATION
pre I_GENE/I_LOCATION
- O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O
driven O
by O
a O
heterologous B_GENE
promoter I_GENE
. O

Therefore O
, O
we O
next O
examined O
if O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
were O
capable B_PERSON
of O
promoting O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
endogenous B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transcript B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Y79 O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
stably O
transfected O
with O
the O
expression B_GENE
construct I_GENE
for O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
A016 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
enriched O
in O
the O
brain B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
show O
higher B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
N30 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inclusion I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
minigene B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding O
endogenous B_GENE
NMHC I_GENE
- O
B B_PROTEIN[GENE]/B_DISEASE
were O
analyzed O
by O
using O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

As O
shown O
in O
Figure B_MEASURE/B_PERSON
6 I_MEASURE/I_PERSON
, O
the O
inclusion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
exon B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
N30 I_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
with O
and O
without O
another O
alternative B_GENE
exon I_GENE
, O
R18 O
, O
in O
the O
endogenous B_GENE
mRNAs I_GENE
is O
markedly O
increased O
in O
the O
clones B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
which O
were O
stably O
transfected O
with O
the O
construct B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
A016 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
an O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
figure B_MEASURE/B_GENE
6 B_MEASURE/I_GENE
, O
lanes B_NUMBER[MEASURE]/B_LOCATION
4 I_NUMBER[MEASURE]/I_LOCATION
and O
5 B_NUMBER[MEASURE]
) O
. O

Although O
to O
a O
lesser B_MEASURE/B_DISEASE
extent I_MEASURE/I_DISEASE
, O
transfection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
wild B_BIO/B_GENE
- O
type B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
constructs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
without O
an O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O
results O
in O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
figure B_MEASURE/B_PROTEIN[GENE]
6 B_MEASURE/I_PROTEIN[GENE]
, O
lanes B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_NUMBER[MEASURE]
and O
3 B_NUMBER[MEASURE]
) O
. O

Thus O
, O
exogenously O
expressed O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
are O
capable B_PERSON/B_LOCATION
of O
activating O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
not O
only O
in O
the O
transcripts B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
the O
minigenes B_GENE/B_BIO
, O
but O
also O
in O
those O
from O
the O
native B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NMHC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
B B_GENE
gene I_GENE
in O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

Fxh B_PERSON
may O
cooperate O
with O
other B_PERSON/B_DISEASE
factor I_PERSON/I_DISEASE
( O
s O
) O
to O
promote O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

To O
address O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
endogenous B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fxh I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
its O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
with O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
promoting O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
we O
made O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
isoform B_GENE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
F402 B_PROTEIN[GENE]
, O
which O
lacks O
the O
RRM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lacking O
an O
RRM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
other B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
binding O
proteins B_LOCATION/B_PROTEIN[GENE]
have O
previously O
been O
reported O
to O
function O
in O
a O
dominant B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fashion B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
inhibit O
the O
activities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
wild B_SPECIES[BIO]
- O
type B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
26 B_MEASURE
, O
31 B_MEASURE
) O
. O

Therefore O
, O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
F402 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inclusion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
minigene B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
H I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
examined O
in O
the O
context B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
of O
the O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
treated O
with O
butyrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Upon O
butyrate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
as O
reported O
previously O
, O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
enter O
in O
a O
post B_DISEASE/B_MEASURE
- O
mitotic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
differentiated B_DISEASE
stage I_DISEASE
, O
and O
importantly O
, O
the O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
well O
as O
the O
minigene B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNAs B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
those O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
include O
N30 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
to O
a O
large B_MEASURE/B_LOCATION
extent I_MEASURE/I_LOCATION
, O
unlike O
those O
in O
the O
untreated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
that O
predominantly O
exclude O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
14 B_NUMBER[MEASURE]
) O
. O

As O
shown O
in O
figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
7 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
in O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
exogenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
F402 B_GENE
, O
large B_NUMBER[MEASURE]/B_PERSON
quantities I_NUMBER[MEASURE]/I_PERSON
of O
the O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
minigene B_PROTEIN[GENE]/B_DISEASE
H I_PROTEIN[GENE]/I_DISEASE
- O
wt B_MEASURE/B_LOCATION
, O
which O
contains O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
IDDE B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
include O
N30 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
figure B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
7 I_SEQUENCE[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
upper B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panel I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lane B_LOCATION/B_MEASURE
4 I_LOCATION/I_MEASURE
) O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
only O
small B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
quantities I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
are O
detected O
in O
the O
mRNAs B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
from O
minigene B_PROTEIN[GENE]/B_DISEASE
H I_PROTEIN[GENE]/I_DISEASE
- O
MC B_MEASURE/B_LOCATION
, O
which O
has O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
both O
copies B_GENE/B_LOCATION
of O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
IDDE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
figure B_MEASURE/B_LOCATION
7 I_MEASURE/I_LOCATION
, O
upper B_MEASURE/B_LOCATION
panel I_MEASURE/I_LOCATION
, O
lane B_LOCATION/B_MEASURE
8 I_LOCATION/I_MEASURE
) O
. O

Therefore O
, O
the O
butyrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
contain O
factor B_GENE
( O
s B_PROTEIN[GENE]/B_DISEASE
) O
, O
which O
are O
capable B_PERSON/B_LOCATION
of O
activating O
the O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
transfection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
wild B_BIO
- O
type B_GENE/B_MEASURE
minigene B_GENE/I_MEASURE
H B_GENE/I_MEASURE
- O
wt B_MEASURE/B_LOCATION
with O
the O
F402 B_GENE
expression I_GENE
construct I_GENE
causes O
a O
dose B_MEASURE/B_LOCATION
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
( O
Figure B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
7 B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
lanes O
1 B_NUMBER[MEASURE]
- O
3 B_MEASURE
) O
, O
indicating O
that O
F402 B_GENE
has O
an O
antagonistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
endogenous B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
respect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

notably O
, O
the O
UGCAUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N30 B_LOCATION
inclusion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
seen O
in O
the O
mutant B_GENE/B_DISEASE
minigene B_GENE/I_DISEASE
H B_GENE/I_DISEASE
- O
MC B_MEASURE/B_LOCATION
is O
not O
affected O
by O
the O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
expression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
F402 B_GENE/B_DISEASE
( O
Figure B_TIME[MEASURE]/B_LOCATION
7 B_TIME[MEASURE]/I_LOCATION
, O
lanes O
5 B_NUMBER[MEASURE]
- O
7 B_MEASURE
) O
, O
indicating O
that O
the O
inhibitory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
F402 B_GENE
depends O
on O
the O
UGCAUG B_GENE/B_LOCATION
element I_GENE/I_LOCATION
. O

The O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
F011 B_GENE
expression I_GENE
construct I_GENE
does O
not O
show O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]
effect I_DISEASE_ADJECTIVE[DISEASE]
on O
N30 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
in O
either O
the O
wild B_BIO
- O
type B_DISEASE/B_MEASURE
or O
mutant B_GENE
minigene I_GENE
( O
figure B_MEASURE/B_PROTEIN[GENE]
7 B_MEASURE/I_PROTEIN[GENE]
, O
lanes B_MEASURE/B_LOCATION
9 I_MEASURE/I_LOCATION
- O
16 B_MEASURE
) O
. O

This O
may O
be O
due B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_GENE
minigene I_GENE
mRNAs I_GENE
has O
already O
reached O
a O
maximal B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
and O
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
butyrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
contain O
sufficient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amounts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
protein B_GENE/B_BACTERIUM[BIO]
( O
s B_PROTEIN[GENE]/B_DISEASE
) O
functionally O
equivalent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
F011 B_GENE/B_PERSON
, O
which O
can O
promote O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
in O
a O
UGCAUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
dependent B_GENE/B_LOCATION
manner I_GENE/I_LOCATION
. O

Since O
F402 B_GENE
does O
not O
bind O
to O
the O
UGCAUG B_GENE
element I_GENE
, O
and O
has O
a O
UGCAUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonistic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
most O
probably O
disrupts O
protein B_GENE/B_BACTERIUM[BIO]
- O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
endogenous B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
required O
for O
the O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

endogenous B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fxh I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
and O
/ O
or O
A2BP1 B_GENE/B_BIO
) O
would O
be O
a O
good B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
candidate I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whose O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
could O
be O
antagonized O
by O
exogenously O
expressed O
F402 B_GENE
. O

Thus O
, O
this O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O
that O
the O
endogenous B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fxh I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
an O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
activation B_GENE/B_MEASURE
of O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
that O
other B_GENE/B_BIO
proteins I_GENE/I_BIO
cooperate O
with O
Fxh B_GENE/B_BIO
for O
N30 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Since O
muscle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
express O
the O
RRM B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
defective B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O
a O
significant B_MEASURE/B_PERSON
extent I_MEASURE/I_PERSON
( O
figure B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
2C I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
) O
and O
the O
wild B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
F402 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
localize I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
nuclei O
efficiently O
, O
this O
also O
raises O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
RRM B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
defective B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_DISEASE_ADJECTIVE[DISEASE]
may O
have O
an O
inhibitory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
muscle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
major I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
described O
in O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

First O
, O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
facilitate O
neural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inclusion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
cassette B_ENT/B_PROTEIN[GENE]
- O
type B_GENE/B_LOCATION
exon I_GENE/I_LOCATION
via O
binding O
to O
the O
specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
intronic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UGCAUG I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
a O
minigene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
, O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
are O
capable B_PERSON/B_LOCATION
of O
facilitating O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
the O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pre I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
mRNA B_GENE
. O

This O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
physiological B_PROTEIN[GENE]
relevance I_PROTEIN[GENE]
and O
supports O
the O
notion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
NMHC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mRNA B_GENE
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
the O
true B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
A2BP1 B_GENE
- O
mediated O
regulation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
whether O
the O
endogenous B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fxh I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
A2BP1 B_GENE
regulates O
endogenous B_PROTEIN[GENE]/B_LOCATION
NMHC I_PROTEIN[GENE]/I_LOCATION
- O
B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mRNA B_GENE
splicing I_GENE
needs O
to O
be O
determined O
in O
a O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
vertebrates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
small B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interfering I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
gene B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
targeting I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strategies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
recently O
been O
used O
successfully O
to O
address O
the O
roles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
endogenous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulators I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
alternative B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
target I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
pre I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
8 B_MEASURE
, O
32 B_MEASURE
- O
36 B_MEASURE
) O
. O

A O
second B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
novel I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
finding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_LOCATION
with O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
splicing I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activities I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O
well O
as O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subcellular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
raises O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
products B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
genes I_GENE
can O
contribute O
to O
a O
mechanism B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
as O
to O
how O
tissue B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
specificity B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
alternative B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
achieved O
. O

Many B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
splicing I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
are O
detected O
not O
only O
in O
the O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O
but O
also O
in O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( O
37 B_TIME[MEASURE]/B_BIO
) O
. O

They O
are O
shuttling O
between O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
, O
in O
some O
instances B_LOCATION/B_BIO
, O
extracellular B_DISEASE_ADJECTIVE[DISEASE]
stimuli I_DISEASE_ADJECTIVE[DISEASE]
trigger I_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
subcellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
proteins B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
translocations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
have O
been O
reported O
for O
hnRNPA1 B_LOCATION/B_ORGANIZATION
and O
PTB B_GENE/B_DISEASE
( O
38 B_MEASURE
, O
39 B_MEASURE
) O
. O

Moreover O
, O
a O
number B_MEASURE/B_PERSON
of O
RNA B_GENE/B_BIO
- O
binding O
proteins B_LOCATION/B_PROTEIN[GENE]
have O
been O
demonstrated O
to O
play O
a O
role B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
steps B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
during O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
subcellular B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
compartments B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
pre B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mRNA B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
mRNA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
export I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
from O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
to O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
mRNA B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
localization B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
stability B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
translation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
( O
37 B_MEASURE
, O
40 B_MEASURE
) O
. O

Therefore O
, O
not O
surprisingly O
, O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
isoforms I_GENE
were O
found O
to O
be O
distributed O
in O
both O
the O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O
HeLa B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O
Y79 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
the O
relative B_MEASURE/B_LOCATION
ratios I_MEASURE/I_LOCATION
of O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
distributed O
between O
the O
two B_LOCATION/B_BIO
subcellular I_LOCATION/I_BIO
compartments I_LOCATION/I_BIO
at O
steady B_DISEASE/B_MEASURE
- O
state B_LOCATION/B_MEASURE
differ O
among O
the O
isoforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
agreement B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Jin B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al O
. O

( O
21 O
) O
, O
substantial B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
brain B_GENE
isoform I_GENE
A016 I_GENE
are O
detected O
in O
nuclei B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Other B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
A2BP1 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
isoform I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
A030 I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
and O
the O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
isoforms O
A713 B_PROTEIN[GENE]
and O
A715 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
only O
poorly O
detected O
in O
nuclei B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

This O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
where O
endogenous B_GENE
A2BP1 I_GENE
in O
cerebellar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Purkinje I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
neurons I_BODY_PART_OR_ORGAN_COMPONENT
and O
cardiac B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
myocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
shown O
to O
be O
localized O
essentially O
to O
the O
cytoplasm B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O
23 B_MEASURE
, O
24 B_MEASURE
) O
. O

Thus O
, O
inclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
exclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
A53 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
differences B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
very B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
A2BP1 B_PROTEIN[GENE]/B_LOCATION
isoforms I_PROTEIN[GENE]/I_LOCATION
with O
a O
distinct B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subcellular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localization B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
likely B_DISEASE_ADJECTIVE[DISEASE]
that O
A2BP1 B_GENE
proteins I_GENE
have O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
roles B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
involving O
both O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
cytoplasmic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
all O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fxh I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
predominantly O
localized O
to O
the O
nuclei B_BODY_PART_OR_ORGAN_COMPONENT
. O

Therefore O
, O
in O
terms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
their O
localization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
Fxh B_PERSON/B_GENE
proteins I_PERSON/I_GENE
are O
better B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
candidates I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
regulators B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
mRNA B_GENE
splicing I_GENE
that O
takes O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
nuclei B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

Of O
note B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
however O
, O
our O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
5 B_MEASURE
' O
race B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
as O
well O
as O
the O
EST B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
detect O
multiple B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
end I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
both O
Fxh B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
mRNAs I_GENE
, O
which O
are O
presumably O
generated O
by O
alternative B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
promoters I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
and O
alternative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
diversity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
end I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O
to O
the O
generation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
a O
number B_MEASURE/B_LOCATION
of O
unique B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_GENE/B_LOCATION
amino I_GENE/I_LOCATION
acid I_GENE/I_LOCATION
sequences I_GENE/I_LOCATION
. O

Therefore O
, O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
exclude O
the O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
existence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subcellular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
both O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
. O

Our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
does O
not O
exclude O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
some O
of O
the O
isoforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
translocate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
following O
stimuli B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
main B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
aim I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
to O
determine O
the O
relative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_DISEASE
in O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
UGCAUG B_GENE/B_LOCATION
element I_GENE/I_LOCATION
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
alternative I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
splicing I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

To O
obtain O
an O
indication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
relative B_MEASURE/B_LOCATION
specific I_MEASURE/I_LOCATION
activity I_MEASURE/I_LOCATION
of O
each O
isoform B_GENE/B_MEASURE
in O
transfected B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O
the O
same B_MEASURE/B_LOCATION
amounts B_MEASURE/I_LOCATION
of O
the O
expressed O
proteins B_GENE/B_DISEASE
should O
be O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
splicing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
nuclei B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

For O
this O
reason B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
an O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NLS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
included O
in O
the O
expressed O
proteins B_GENE/B_DISEASE
. O

essentially O
, O
all O
of O
the O
expressed O
proteins B_GENE/B_DISEASE
with O
the O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
NLS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
localized O
to O
nuclei B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Thus O
, O
the O
amounts B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
expressed O
proteins B_PROTEIN[GENE]/B_DISEASE
determined O
by O
immunoblots B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represent O
the O
nuclear B_MEASURE
concentrations I_MEASURE
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
proteins B_GENE/B_DISEASE
expressed O
with O
the O
exogenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
NLS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
allowed O
us O
to O
compare O
directly O
the O
splicing B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
these O
proteins B_GENE/B_DISEASE
. O

Furthermore O
, O
this O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
also O
allowed O
us O
to O
define O
the O
critical B_LOCATION
regions I_LOCATION
of O
the O
proteins B_GENE/B_DISEASE
for O
splicing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

As O
shown O
in O
Figure B_MEASURE/B_PERSON
5 I_MEASURE/I_PERSON
, O
the O
splicing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
various B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_LOCATION
are O
intrinsically O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
regardless O
of O
the O
subcellular B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
localization B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
properties B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
wild B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
type B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Among O
the O
isoforms B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tested O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
include O
B40 B_GENE
, O
are O
found O
to O
have O
higher B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
promoting O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

When O
the O
primary B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O
, O
outside O
of O
the O
RRM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
of O
these O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
compared O
, O
the O
C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_LOCATION
regions I_LOCATION
( O
amino B_MEASURE
acids I_MEASURE
190 I_MEASURE
- O
377 B_MEASURE
of O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
show O
a O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
homology B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
with O
71 B_GENE/B_PERSON
% I_GENE/I_PERSON
identity I_GENE/I_PERSON
, O
whereas O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
terminal B_LOCATION
regions I_LOCATION
( O
amino B_MEASURE
acids I_MEASURE
1 I_MEASURE
- O
112 B_MEASURE
of O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
show O
only O
53 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
identity I_MEASURE/I_PERSON
. O

The O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_LOCATION/B_ORGANIZATION
region I_LOCATION/I_ORGANIZATION
includes O
four B_LOCATION/B_ORGANIZATION
subregions I_LOCATION/I_ORGANIZATION
of O
nearly O
identical B_MEASURE
stretches I_MEASURE
of O
amino B_LOCATION/B_GENE
acids I_LOCATION/I_GENE
( O
Figure B_TIME[MEASURE]/B_LOCATION
8 I_TIME[MEASURE]/I_LOCATION
, O
I B_OTHER/B_PROTEIN[GENE]
- O
IV B_SEQUENCE[MEASURE]
) O
. O

One B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
subregion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
II B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
includes O
13 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoded O
by O
exon B_GENE
B40 I_GENE
. O

substitution B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
subregion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O
exon B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M43 B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Fxh B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O
substantial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
amino B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resulting O
in O
only O
a O
21 B_PERSON/B_LOCATION
% B_PERSON/I_LOCATION
identity B_PERSON/I_LOCATION
in O
this O
region B_LOCATION/B_BIO
between O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
F411 B_GENE
. O

Another O
subregion B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IV B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
located O
at O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_DISEASE/B_LOCATION
end B_DISEASE/I_LOCATION
and O
A030 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacks O
this O
homologous B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
by O
the O
inclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
exon B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A53 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
results O
in O
a O
frame B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
shift B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Since O
F411 B_GENE
and O
A030 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
with O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
, O
these O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subregions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O
to O
serve O
as O
activation B_GENE/B_PERSON
domains I_GENE/I_PERSON
, O
presumably O
by O
interacting O
with O
other B_GENE/B_BIO
proteins I_GENE/I_BIO
. O

This O
notion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
supported O
by O
the O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
RRM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
lacking O
isoform B_GENE/B_LOCATION
F402 I_GENE/I_LOCATION
, O
which O
includes O
the O
same B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
subregions I_SEQUENCE[MEASURE]/I_PROTEIN[GENE]
II I_SEQUENCE[MEASURE]/I_PROTEIN[GENE]
and O
IV B_TIME[MEASURE]/B_PROTEIN[GENE]
as O
F011 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
functions B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apparently O
as O
a O
dominant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
Fxh B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
mutant B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
and O
wild B_BIO/B_DISEASE
- O
type B_DISEASE/B_PROTEIN[GENE]
are O
competing O
to O
interact O
with O
other B_PROTEIN[GENE]/B_BIO
protein I_PROTEIN[GENE]/I_BIO
( O
s B_OTHER/B_DISEASE
) O
. O

To O
date B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Fyn B_GENE
tyrosine I_GENE
kinase I_GENE
and O
estrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
alpha B_PROTEIN[GENE]/B_LOCATION
have O
been O
reported O
to O
interact O
with O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
ataxin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]
with O
A2BP1 B_GENE/B_MEASURE
( O
23 B_MEASURE
, O
41 B_MEASURE
, O
42 B_MEASURE
) O
. O

Whether O
these O
proteins B_LOCATION/B_GENE
participate O
in O
the O
regulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
pre B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mRNA B_GENE/B_ORGANISM_FUNCTION
splicing B_GENE/I_ORGANISM_FUNCTION
is O
currently O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

Of O
interest B_PERSON/B_NUMBER[MEASURE]
, O
A030 O
with O
the O
exogenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
NLS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
activates O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
efficiently O
as O
F011 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
minigenes B_PROTEIN[GENE]/B_LOCATION
J I_PROTEIN[GENE]/I_LOCATION
and O
H B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
contain O
the O
shorter B_GENE/B_MEASURE
intron I_GENE/I_MEASURE
, O
whereas O
this O
isoform B_PROTEIN[GENE]/B_LOCATION
poorly O
activates O
N30 B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mRNA B_GENE
from O
minigene B_LOCATION/B_PROTEIN[GENE]
G I_LOCATION/I_PROTEIN[GENE]
, O
which O
contains O
the O
full B_MEASURE/B_COLOR
- O
length B_GENE
intron I_GENE
. O

This O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
implies O
that O
the O
interactions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
A030 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
different B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
required O
in O
the O
different B_DISEASE/B_GENE
pre B_DISEASE/I_GENE
- O
mRNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contexts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Therefore O
, O
the O
isoforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_LOCATION
described O
here O
may O
have O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
UGCAUG I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
regulated O
alternative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
involvement B_PERSON/B_DISEASE
of O
the O
hexanucleotide B_GENE
UGCAUG I_GENE
in O
regulated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alternative I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
experimentally O
demonstrated O
in O
a O
number B_MEASURE/B_LOCATION
of O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
as O
well O
as O
other B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
tissue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
model B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
13 B_MEASURE/B_LOCATION
- O
21 B_MEASURE
) O
. O

This O
hexanucleotide B_LOCATION/B_GENE
element B_LOCATION/I_GENE
plays O
a O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
most B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
an O
enhancer B_GENE/B_PERSON
in O
regulating O
alternative B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cassette B_LOCATION/B_GENE
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
exons I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
as O
well O
as O
mutually O
exclusive B_GENE
exons I_GENE
. O

Furthermore O
, O
computational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
revealed O
that O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
over O
- O
represented O
in O
the O
introns B_GENE/B_LOCATION
in O
which O
splicing B_GENE
is O
regulated O
, O
compared O
with O
the O
constitutively O
spliced O
introns B_GENE/B_LOCATION
( O
43 B_NUMBER[MEASURE]/B_BIO
) O
. O

This O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
pointed O
to O
the O
UGCAUG B_GENE/B_LOCATION
element I_GENE/I_LOCATION
as O
playing O
a O
role B_MEASURE/B_PERSON
in O
the O
regulation B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
wide B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
tissues B_DISEASE/B_BIO
, O
but O
not O
in O
specific B_DISEASE/B_BIO
tissues I_DISEASE/I_BIO
. O

To O
date B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
KH B_PERSON/B_GENE
- O
type B_MEASURE/B_GENE
splicing I_MEASURE/I_GENE
regulatory I_MEASURE/I_GENE
protein I_MEASURE/I_GENE
( O
KSRP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
( O
44 B_MEASURE
) O
, O
A2BP1 B_GENE
( O
21 B_MEASURE
) O
and O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
this O
study B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
are O
known O
to O
be O
capable B_PERSON/B_LOCATION
of O
binding O
to O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

KSRP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
expressed O
ubiquitously O
and O
tissue B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variants B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
gene B_GENE
have O
not O
been O
described O
so O
far O
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
have O
described O
the O
existence B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tissue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
, O
which O
, O
while O
not O
identical B_DISEASE_ADJECTIVE[DISEASE]
in O
some O
areas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
molecule B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
, O
may O
contain O
the O
same B_MEASURE/B_PROTEIN[GENE]
RRM I_MEASURE/I_PROTEIN[GENE]
. O

The O
physiological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relevance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
isoforms B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
that O
they O
have O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
splicing I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activities I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subcellular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
isoforms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
promote O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
more O
efficiently O
than O
the O
muscle B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
. O

The O
isoforms B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacking O
the O
RRM B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
are O
normally O
expressed O
to O
a O
significant B_MEASURE/B_LOCATION
extent I_MEASURE/I_LOCATION
in O
skeletal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
muscles I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

This O
isoform B_GENE/B_LOCATION
is O
incapable B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
activating O
N30 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
, O
Moreover O
, O
can O
inhibit O
N30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
properties B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
isoforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE
acting O
as O
regulators B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
N30 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
since O
N30 B_GENE/B_LOCATION
is O
included O
in O
neuronal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
but O
excluded O
in O
muscles B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
despite O
the O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
independent B_DISEASE_ADJECTIVE[DISEASE]
occurrence I_DISEASE_ADJECTIVE[DISEASE]
of O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
regulatory B_GENE
element I_GENE
, O
given O
the O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
binding O
proteins B_BIO/B_LOCATION
( O
Fxh B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2BP1 B_GENE/B_LOCATION
) O
with O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
hexanucleotide B_PROTEIN[GENE]/B_LOCATION
UGCAUG I_PROTEIN[GENE]/I_LOCATION
could O
confer O
tissue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specificity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
regulated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
the O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problems B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
understanding O
the O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responsible I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
alternative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pre I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
mRNA B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
manner B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
which O
tissue B_MEASURE/B_GENE
specificity I_MEASURE/I_GENE
is O
determined O
. O

In O
vertebrates B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
date B_TIME[MEASURE]
, O
only O
a O
few B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O
specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
identified O
as O
splicing B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulators I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
8 B_MEASURE/B_LOCATION
- O
12 B_MEASURE
) O
. O

Here O
, O
we O
have O
shown O
that O
the O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
sequence B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
RNA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O
binding O
proteins B_GENE/B_DISEASE
, O
which O
themselves O
are O
generated O
by O
alternative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
have O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
target B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
mRNA B_GENE
. O

Therefore O
, O
these O
isoforms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
play O
a O
role B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
determination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
tissue B_MEASURE
specificity I_MEASURE
of O
target B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pre I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
mRNA B_GENE
splicing I_GENE
. O

The O
discovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
isoforms I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
binding O
proteins B_BIO/B_LOCATION
with O
different B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activities B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
adds O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
new I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
dimension I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
the O
molecular B_LOCATION
mechanisms I_LOCATION
responsible I_LOCATION
for O
regulating O
tissue B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
via O
UGCAUG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PIK3CA B_GENE
in O
gastric B_DISEASE
adenocarcinoma I_DISEASE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Activation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
the O
phosphatidylinositol B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
kinase B_ENZYME[GENE]
( O
PI3K B_GENE/B_LOCATION
) O
through O
mutational B_DISEASE_ADJECTIVE[DISEASE]
inactivation I_DISEASE_ADJECTIVE[DISEASE]
of O
PTEN B_GENE
tumour I_GENE
suppressor I_GENE
gene I_GENE
is O
common B_DISEASE_ADJECTIVE[DISEASE]
in O
diverse B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
types I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
rarely O
reported O
in O
gastric B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
. O

Recently O
, O
mutations O
in O
PIK3CA O
, O
which O
encodes O
the O
p110 O
alpha O
catalytic O
subunit O
of O
PI3K O
, O
have O
been O
identified O
in O
various O
human B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
cancers O
, O
including O
3 O
of O
12 O
gastric O
cancers O
. O

eighty B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
of O
these O
reported O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
clustered O
within O
2 B_LOCATION/B_BIO
regions I_LOCATION/I_BIO
involving O
the O
helical B_ENZYME[GENE]/B_DISEASE
and O
kinase B_LOCATION/B_GENE
domains I_LOCATION/I_GENE
. O

In O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O
the O
' B_PERSON/B_NUMBER[MEASURE]
hot I_PERSON/I_NUMBER[MEASURE]
- O
spot B_LOCATION/B_BIO
' O
mutants B_DISEASE/B_BIO
has O
demonstrated O
it O
as O
an O
activating O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_PROTEIN[GENE]
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
these O
data O
, O
we O
initiated O
PIK3CA O
mutation O
screening O
in O
94 O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
gastric O
cancers O
by O
direct O
sequencing O
of O
the O
gene O
regions O
in O
which O
80 O
% O
of O
all O
the O
known O
PIK3CA O
mutations O
were O
found O
. O

We O
also O
examined O
PIK3CA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
level I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
extracting O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
scale B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
profiling O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Using O
significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
microarrays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Sam B_PERSON/B_DISEASE
) O
, O
we O
further O
searched O
for O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
show O
correlating B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
PIK3CA B_DISEASE/B_GENE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
identified O
PIK3CA B_DISEASE/B_LOCATION
mutations I_DISEASE/I_LOCATION
in O
4 B_NUMBER[MEASURE]/B_BIO
cases B_NUMBER[MEASURE]/I_BIO
( O
4 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
) O
, O
all O
involving O
the O
previously O
reported O
hotspots B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Among O
these O
4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
3 B_NUMBER[MEASURE]/B_ENT
tumours I_NUMBER[MEASURE]/I_ENT
demonstrated O
microsatellite B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
instability B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
2 B_NUMBER[MEASURE]/B_ENT
tumours I_NUMBER[MEASURE]/I_ENT
harboured O
concurrent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
KRAS B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
extracted O
from O
microarray B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
an O
increased O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PIK3CA B_GENE
in O
gastric B_DISEASE
cancers I_DISEASE
when O
compared O
with O
the O
non B_DISEASE/B_LOCATION
- O
neoplastic B_DISEASE/B_PERSON
gastric I_DISEASE/I_PERSON
mucosae I_DISEASE/I_PERSON
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Sam B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
further O
identified O
2910 B_GENE
genes I_GENE
whose O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
positively O
associated O
with O
that O
of O
PIK3CA B_GENE/B_DISEASE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggested O
that O
activation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
PI3K B_GENE/B_LOCATION
signalling I_GENE/I_LOCATION
pathway I_GENE/I_LOCATION
in O
gastric B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
may O
be O
achieved O
through O
up O
- O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
or O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
PIK3CA B_GENE
, O
in O
which O
the O
latter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
a O
consequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
mismatch B_DISEASE/B_GENE
repair I_DISEASE/I_GENE
deficiency I_DISEASE/I_GENE
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
phosphatidylinositol B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
kinase B_ENZYME[GENE]
( O
PI3K B_GENE
) O
- O
AKT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
involved O
in O
the O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
diverse B_DISEASE
cellular I_DISEASE
processes I_DISEASE
, O
including O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
growth B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
survival B_DISEASE/B_ORGANISM_FUNCTION
and O
motility B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Abnormal B_DISEASE_ADJECTIVE[DISEASE]
activation I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
pathway B_LOCATION
is O
frequently O
observed O
in O
various B_DISEASE
cancer I_DISEASE
types I_DISEASE
, O
leading O
to O
aberrant B_DISEASE
cell I_DISEASE
cycle I_DISEASE
progression I_DISEASE
, O
altered B_DISEASE
adhesion I_DISEASE
and O
motility B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
apoptosis B_DISEASE
and O
induction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
angiogenesis B_DISEASE/B_GENE
[ O
1 B_DISEASE
] I_DISEASE
. O

It O
has O
been O
previously O
reported O
that O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
alterations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
involving O
various B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
members B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
along O
this O
signalling O
pathway B_LOCATION/B_ORGANIZATION
could O
lead O
to O
its O
activation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
cancer B_DISEASE/B_LOCATION
. O

These O
include O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O
allelic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
loss B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O
promoter B_DISEASE_ADJECTIVE[DISEASE]
methylation I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
negative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PTEN I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
2 B_NUMBER[MEASURE]
] O
; O
or O
alternatively O
, O
chromosomal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
amplification B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
or O
over O
- O
expression B_GENE
of O
the O
positive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulators I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PIK3CA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
3 B_MEASURE
- O
5 B_MEASURE
] I_MEASURE
and O
the O
various B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AKT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
6 B_NUMBER[MEASURE]
, O
7 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Furthermore O
, O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
other B_DISEASE/B_GENE
related O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
that O
are O
commonly O
altered O
in O
cancer B_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
those O
involved O
in O
growth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
factor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
via O
the O
G B_GENE
- O
protein B_GENE/B_BACTERIUM[BIO]
- O
coupled O
receptors B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
through O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
with O
the O
activated O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
small B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GTPase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RAS I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
can O
also O
lead O
to O
PI3K B_GENE
- O
AKT B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
pathway I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
[ O
8 B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Activation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
this O
pathway B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
phosphorylation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
AKT B_GENE
at O
Thr B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
308 B_MEASURE
/ O
309 B_MEASURE
and O
Ser B_LOCATION/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
473 B_MEASURE
/ O
474 B_MEASURE
. O

These O
phosphorylated O
forms B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
AKT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
detected O
by O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
immunohistochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
various B_DISEASE
cancer I_DISEASE
types I_DISEASE
, O
suggesting O
the O
frequent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
PI3K B_GENE
- O
AKT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
carcinogenic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
process B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
7 B_NUMBER[MEASURE]
, O
9 B_MEASURE
] O
. O

Although O
genetic B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
along O
the O
PI3K B_GENE
- O
AKT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
repeatedly O
documented O
in O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
ovarian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
endometrial B_BODY_PART_OR_ORGAN_COMPONENT
, O
breast B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
prostate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
thyroid B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancers B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
1 B_NUMBER[MEASURE]
, O
2 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
, O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
its O
mechanism B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
activation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
gastric B_DISEASE/B_BIO
cancer I_DISEASE/I_BIO
are O
limited O
. O

Gastric B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
is O
the O
second B_SEQUENCE[MEASURE]
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cancer I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
worldwide I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
but O
its O
molecular B_LOCATION
basis I_LOCATION
of O
tumourigenesis B_DISEASE_ADJECTIVE[DISEASE]
is O
still O
poorly O
understood O
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
immunohistochemical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
has O
demonstrated O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
phosphorylated B_ENZYME[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_ENZYME[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
AKT B_GENE
in O
78 B_LOCATION/B_PERSON
% I_LOCATION/I_PERSON
of O
gastric B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
[ I_DISEASE/I_PERSON
10 I_DISEASE/I_PERSON
] I_DISEASE/I_PERSON
, O
suggesting O
that O
activation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
this O
pathway B_ENZYME[GENE]/B_DISEASE
may O
also O
be O
common B_DISEASE_ADJECTIVE[DISEASE]
in O
gastric B_DISEASE/B_BIO
cancer I_DISEASE/I_BIO
. O

Though O
loss B_DISEASE_ADJECTIVE[DISEASE]
of O
heterozygosity B_GENE/B_DISEASE
( O
LOH B_DISEASE/B_PROTEIN[GENE]
) O
involving O
the O
PTEN B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
demonstrated O
in O
47 B_PERSON
% I_PERSON
of O
gastric B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
in O
a O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
mutation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O
promoter B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
methylation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
even O
in O
cases B_PERSON/B_DISEASE
with O
LOH B_DISEASE/B_GENE
[ I_DISEASE/I_GENE
11 I_DISEASE/I_GENE
] I_DISEASE/I_GENE
. O

Thus O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
could O
not O
support O
the O
two B_NUMBER[MEASURE]/B_LOCATION
- O
hit B_DISEASE_ADJECTIVE[DISEASE]
inactivation I_DISEASE_ADJECTIVE[DISEASE]
of O
PTEN B_GENE
in O
gastric B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
, O
while O
the O
biological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
PTEN B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
haploinsufficiency B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
remains O
controversial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Alternatively O
, O
amplification B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
AKT1 B_GENE
has O
been O
reported O
in O
a O
single B_MEASURE
case I_MEASURE
of O
gastric B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
[ I_DISEASE/I_LOCATION
12 I_DISEASE/I_LOCATION
] I_DISEASE/I_LOCATION
, O
and O
amplification B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PIK3CA B_GENE
associated O
with O
elevated B_DISEASE/B_GENE
mRNA I_DISEASE/I_GENE
levels I_DISEASE/I_GENE
has O
been O
found O
in O
36 B_PERSON
% I_PERSON
of O
gastric B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
[ I_DISEASE/I_PERSON
11 I_DISEASE/I_PERSON
] I_DISEASE/I_PERSON
. O

More O
recently O
, O
Samuels O
et O
al O
. O
screened O
a O
diverse O
spectrum O
of O
human B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
cancers O
for O
mutation O
in O
16 O
PI3K O
or O
PI3K O
- O
like O
genes O
and O
found O
a O
high O
frequency O
of O
somatic O
mutation O
in O
PIK3CA O
, O
which O
encodes O
the O
p110 O
alpha O
catalytic O
subunit O
. O

Major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
colorectal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CRC B_DISEASE/B_LOCATION
) O
identified O
PIK3CA B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
in O
74 B_MEASURE
out O
of O
234 B_MEASURE
( O
32 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
cases B_PERSON/B_DISEASE
, O
while O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
were O
also O
noted O
in O
3 B_NUMBER[MEASURE]
out O
of O
12 B_MEASURE
( O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
gastric B_DISEASE/B_PERSON
cancers I_DISEASE/I_PERSON
. O

reported O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O
mostly O
of O
missense B_DISEASE/B_GENE
type B_DISEASE/I_GENE
, O
and O
clustered O
within O
2 B_LOCATION/B_BIO
regions I_LOCATION/I_BIO
in O
the O
helical B_ENZYME[GENE]/B_DISEASE
and O
kinase B_GENE/B_LOCATION
domains I_GENE/I_LOCATION
. O

Expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
a O
' B_PERSON/B_COLOR
hot B_PERSON/I_COLOR
- O
spot B_LOCATION/B_BIO
' O
mutant B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O
H1047R B_TIME[MEASURE]/B_GENE
, O
conferred O
a O
significant B_LOCATION
up I_LOCATION
- O
regulation B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
lipid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
PIK3CA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
suggesting O
it O
as O
an O
activating O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_ENZYME[GENE]
[ O
13 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

In O
this O
study O
, O
we O
have O
examined O
a O
series O
of O
94 O
human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
gastric O
adenocarcinomas O
for O
PIK3CA O
mutation O
. O

We O
have O
also O
examined O
PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
expression I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
level I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
by O
extracting O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
a O
large B_GENE/B_MEASURE
- O
scale B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profiling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
previously O
performed O
for O
these O
cases B_PERSON/B_DISEASE
[ O
14 B_MEASURE
, O
15 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Using O
Sam B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlating I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
PIK3CA B_DISEASE/B_GENE
have O
also O
been O
identified O
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Patient B_PERSON/B_LOCATION
samples O
preparation O
. O

DNA O
samples O
used O
for O
sequencing O
were O
prepared O
from O
frozen O
tumour O
and O
non O
- O
tumour O
gastric O
mucosae O
from O
94 O
gastric O
cancer O
patients B_PERSON
who O
underwent O
gastrectomy O
in O
the O
Department O
of O
Surgery O
, O
Queen O
Mary O
Hospital O
, O
The O
University O
of O
Hong O
Kong O
, O
as O
previously O
described O
[ O
16 O
] O
. O

majority B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O
the O
frozen O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
n B_OTHER/B_MEASURE
= O
81 B_MEASURE
) O
showed O
tumour B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component B_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
over O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
whereas O
in O
13 B_MEASURE/B_LOCATION
cases B_MEASURE/I_LOCATION
a O
lower B_MEASURE
proportion I_MEASURE
between O
50 B_MEASURE
to O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
was O
accepted O
due O
to O
the O
tumours B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inherent I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diffuse I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infiltrative I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
entrapment B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
non B_DISEASE
- O
neoplastic B_DISEASE
components I_DISEASE
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
microsatellite B_DISEASE/B_LOCATION
instability I_DISEASE/I_LOCATION
( O
MSI B_DISEASE/B_LOCATION
) O
, O
BRAF B_GENE/B_DISEASE
and O
KRAS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
performed O
and O
reported O
previously O
[ O
16 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

RNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
preparation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiling O
using O
a O
cDNA B_MEASURE/B_LOCATION
microarray B_MEASURE/I_LOCATION
containing O
44 B_MEASURE
, O
500 B_MEASURE
cDNA I_MEASURE
clones I_MEASURE
, O
representing O
around O
30 B_MEASURE
, O
300 B_MEASURE
unique I_MEASURE
genes I_MEASURE
, O
has O
been O
performed O
and O
reported O
in O
90 B_NUMBER[MEASURE]
of O
these O
tumours B_DISEASE/B_BIO
in O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
22 B_PERSON/B_PROTEIN[GENE]
non B_PERSON/I_PROTEIN[GENE]
- O
tumour B_DISEASE/B_BIO
gastric I_DISEASE/I_BIO
mucosae I_DISEASE/I_BIO
[ O
14 B_MEASURE
, O
15 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
approved O
by O
the O
Ethics B_PERSON/B_ORGANIZATION
Committee I_PERSON/I_ORGANIZATION
of O
the O
University B_LOCATION/B_ORGANIZATION
of O
Hong B_LOCATION
Kong I_LOCATION
. O

mutational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mutation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
PIK3CA B_GENE/B_DISEASE
was O
performed O
for O
exons B_MEASURE
9 I_MEASURE
and O
20 B_NUMBER[MEASURE]
, O
covering O
the O
mutational B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hotspots I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
and O
for O
exon B_GENE
18 I_GENE
, O
from O
which O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
was O
found O
in O
a O
gastric B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
. O

Mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_PERSON
in O
these O
3 B_GENE/B_BIO
exons I_GENE/I_BIO
constituted O
80 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
all O
PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
detected O
in O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O
13 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
intron I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
external B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
amplification B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
primers B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
internal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
primers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
designed O
according O
to O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O
13 B_LOCATION/B_MEASURE
] I_LOCATION/I_MEASURE
with O
some O
modifications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
[ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
see O
Additional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
file I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
primers B_GENE
for O
exon B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
modified O
to O
avoid O
amplification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
homologous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
located O
in O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chromosomes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
products I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O
generated O
using O
the O
external B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
directly O
sequenced O
using O
the O
internal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
the O
DYEnamic B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(TM) I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ET I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Terminator I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cycle I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sequencing I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Kit I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Amersham B_MEASURE/B_LOCATION
Biosciences I_MEASURE/I_LOCATION
, O
Freiburg B_LOCATION
, O
Germany B_LOCATION/B_MEASURE
) O
according O
to O
the O
manufacturer B_PERSON
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
instruction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

electrophoresis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
performed O
in O
the O
ABI B_LOCATION
Prism I_LOCATION
(R) I_LOCATION
3700 I_LOCATION
DNA I_LOCATION
Analyzer I_LOCATION
( O
Applied B_MEASURE/B_ORGANIZATION
Biosystems I_MEASURE/I_ORGANIZATION
, O
Foster B_LOCATION/B_PERSON
City I_LOCATION/I_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

For O
each O
exon B_GENE/B_PERSON
, O
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
generated O
from O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
independent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reactions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
forward B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reverse B_LOCATION/B_GENE
strands I_LOCATION/I_GENE
. O

For O
exon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
9 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
independent I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
followed O
by O
sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
forward B_GENE
strand I_GENE
were O
performed O
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
chromatograms B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
was O
performed O
using O
the O
mutation B_PRODUCT[OBJECT]/B_ORGANIZATION
analysis I_PRODUCT[OBJECT]/I_ORGANIZATION
software I_PRODUCT[OBJECT]/I_ORGANIZATION
mutation I_PRODUCT[OBJECT]/I_ORGANIZATION
Explorer I_PRODUCT[OBJECT]/I_ORGANIZATION
(TM) I_PRODUCT[OBJECT]/I_ORGANIZATION
( O
SoftGenetics B_MEASURE/B_ORGANIZATION
, O
State B_LOCATION
College I_LOCATION
, O
PA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

extraction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
extracted O
from O
the O
microarray B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
containing O
126 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
90 B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
gastric I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
14 B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lymph I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
node I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
metastasis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
22 B_DISEASE/B_LOCATION
non I_DISEASE/I_LOCATION
- O
tumour B_DISEASE
gastric I_DISEASE
mucosae I_DISEASE
) O
based O
on O
a O
3 B_NUMBER[MEASURE]
- O
fold B_TIME[MEASURE]/B_LOCATION
signal I_TIME[MEASURE]/I_LOCATION
above O
background B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
for O
either O
channel B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
with O
80 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
good I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
14 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

Gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
20 B_MEASURE
, O
336 B_MEASURE/B_PERSON
cDNA I_MEASURE/I_PERSON
clones I_MEASURE/I_PERSON
satisfied O
this O
selection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
extracted O
, O
which O
included O
a O
cDNA B_MEASURE/B_GENE
clone I_MEASURE/I_GENE
corresponding I_MEASURE/I_GENE
to O
PIK3CA B_GENE
( O
Image B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
clone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
number B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
345430 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
GenBank B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accession I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
no O
. O
W72473 B_MEASURE
) O
. O

Expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
PIK3CA B_GENE
was O
extracted O
and O
the O
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
tumour B_DISEASE
and O
non B_DISEASE/B_LOCATION
- O
tumour B_DISEASE
tissues I_DISEASE
were O
examined O
using O
the O
Student B_LOCATION/B_PERSON
' I_LOCATION/I_PERSON
s I_LOCATION/I_PERSON
t I_LOCATION/I_PERSON
- O
Test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

SAM B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
performed O
to O
identify O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlating I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
PIK3CA B_GENE/B_DISEASE
[ O
17 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
missing B_MEASURE
values I_MEASURE
in O
the O
dataset B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
estimated O
by O
a O
K B_OTHER/B_NUMBER[MEASURE]
- O
nearest B_LOCATION/B_MEASURE
neighbours B_LOCATION/I_MEASURE
impute O
algorithm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
10 B_PERSON/B_LOCATION
nearest I_PERSON/I_LOCATION
neighbour I_PERSON/I_LOCATION
[ I_PERSON/I_LOCATION
18 I_PERSON/I_LOCATION
] I_PERSON/I_LOCATION
followed O
by O
5000 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
permutations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
the O
SAM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Among O
the O
94 B_DISEASE/B_GENE
gastric B_DISEASE/I_GENE
adenocarcinoma B_DISEASE/I_GENE
analysed O
, O
we O
have O
detected O
PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
4 B_MEASURE
cases I_MEASURE
. O

Two B_PERSON
cases I_PERSON
harboured O
the O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
A3140G I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O
H1047R B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O
in O
exon B_GENE
20 I_GENE
, O
and O
the O
other B_SEQUENCE[MEASURE]/B_PERSON
2 I_SEQUENCE[MEASURE]/I_PERSON
cases I_SEQUENCE[MEASURE]/I_PERSON
with O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
G1624A B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
E542K B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
G1633A B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
( O
E545K B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O
in O
exon B_GENE/B_PERSON
9 I_GENE/I_PERSON
. O

Representative B_PERSON
sequence I_PERSON
chromatograms I_PERSON
are O
shown O
in O
figure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
four B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
corresponding B_DISEASE/B_GENE
non I_DISEASE/I_GENE
- O
neoplastic B_DISEASE/B_PERSON
mucosae I_DISEASE/I_PERSON
and O
thus O
were O
confirmed O
as O
somatic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Though O
the O
overall B_MEASURE
mutation I_MEASURE
frequency I_MEASURE
( O
4 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
) O
was O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
nature B_LOCATION/B_DISEASE
of O
the O
4 B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
found O
were O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
those O
identified O
at O
the O
reported O
hotspots B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
H1047R B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O
been O
reported O
in O
2 B_NUMBER[MEASURE]/B_DISEASE
gastric I_NUMBER[MEASURE]/I_DISEASE
cancers I_NUMBER[MEASURE]/I_DISEASE
and O
15 B_DISEASE
colorectal I_DISEASE
cancers I_DISEASE
[ O
13 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

While O
the O
E542K B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
E545K B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
not O
found O
in O
gastric B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
in O
the O
previous B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
large B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
colorectal B_DISEASE/B_PERSON
tumours I_DISEASE/I_PERSON
did O
harbour O
these O
2 B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O

PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
spectrum I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
their O
corresponding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
clinico I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
pathological B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
listed O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

We O
noted O
a O
higher B_MEASURE
tendency I_MEASURE
of O
high B_GENE
- O
level B_DISEASE/B_MEASURE
MSI I_DISEASE/I_MEASURE
in O
gastric B_PERSON/B_ORGANIZATION
cancers I_PERSON/I_ORGANIZATION
with O
PIK3CA B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
( O
3 B_MEASURE
in O
4 B_MEASURE
, O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
than O
in O
those O
without O
( O
18 B_NUMBER[MEASURE]
in O
90 B_NUMBER[MEASURE]
, O
20 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
. O

Moreover O
, O
though O
the O
overall B_MEASURE
incidence I_MEASURE
of O
KRAS B_DISEASE/B_GENE
mutation I_DISEASE/I_GENE
in O
the O
studied B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
population I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
was O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
8 B_NUMBER[MEASURE]
in O
94 B_MEASURE/B_PERSON
) O
, O
2 B_NUMBER[MEASURE]/B_PERSON
of O
the O
4 B_PERSON/B_DISEASE
gastric I_PERSON/I_DISEASE
cancers I_PERSON/I_DISEASE
with O
PIK3CA B_DISEASE
mutation I_DISEASE
also O
harboured O
a O
KRAS B_DISEASE/B_GENE
mutation I_DISEASE/I_GENE
. O

Since O
over O
- O
expression B_GENE
of O
PIK3CA B_GENE
has O
been O
reported O
in O
gastric B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
[ I_DISEASE/I_LOCATION
11 I_DISEASE/I_LOCATION
] I_DISEASE/I_LOCATION
, O
we O
have O
also O
extracted O
PIK3CA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
our O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cDNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
microarray I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
these O
cases B_PERSON/B_DISEASE
[ O
14 B_MEASURE
, O
15 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

We O
have O
confirmed O
that O
expression B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
of O
PIK3CA B_GENE
was O
significantly O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
gastric B_DISEASE
cancers I_DISEASE
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
87 B_MEASURE
, O
mean B_MEASURE/B_LOCATION
= O
0 B_MEASURE
. O
099 B_MEASURE
, O
SD B_DISEASE/B_PROTEIN[GENE]
= O
0 B_NUMBER[MEASURE]
. O
428 B_MEASURE
) O
when O
compared O
with O
non B_DISEASE/B_LOCATION
- O
neoplastic B_DISEASE/B_PERSON
gastric I_DISEASE/I_PERSON
mucosae I_DISEASE/I_PERSON
( O
n B_MEASURE/B_LOCATION
= O
22 B_MEASURE
, O
mean B_MEASURE/B_LOCATION
= O
- O
0 B_MEASURE
. O
418 B_MEASURE
, O
SD B_DISEASE/B_MEASURE
= O
0 B_NUMBER[MEASURE]
. O
426 B_MEASURE
; O
Student B_PERSON
' O
s B_PERSON/B_LOCATION
t B_PERSON/I_LOCATION
- O
Test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Using O
PIK3CA B_GENE/B_MEASURE
expression I_GENE/I_MEASURE
level I_GENE/I_MEASURE
as O
a O
continuous B_MEASURE/B_PERSON
variable B_MEASURE/I_PERSON
for O
SAM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
17 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
we O
found O
2910 B_GENE/B_BIO
cDNA I_GENE/I_BIO
clones I_GENE/I_BIO
( O
corresponding O
to O
about O
2546 B_MEASURE
unique I_MEASURE
genes I_MEASURE
) O
whose O
expression B_GENE/B_MEASURE
associated O
positively O
with O
PIK3CA B_DISEASE/B_GENE
expression I_DISEASE/I_GENE
( O
median B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
false B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
= O
0 B_MEASURE
. O
372 B_MEASURE
, O
Delta B_PROTEIN[GENE]/B_MEASURE
= O
1 B_MEASURE
. O
107 B_MEASURE
) O
[ B_OTHER/B_LOCATION
see O
Additional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
file I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Interestingly O
, O
no O
gene B_GENE/B_DISEASE
was O
found O
to O
be O
negatively O
associated O
with O
PIK3CA B_DISEASE
expression I_DISEASE
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
have O
reported O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
4 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
of O
gastric B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
. O

A O
high B_MEASURE
tendency I_MEASURE
( O
3 B_SEQUENCE[MEASURE]
in O
4 B_MEASURE
) O
of O
mismatch B_DISEASE/B_GENE
repair I_DISEASE/I_GENE
deficiency I_DISEASE/I_GENE
was O
noted O
in O
cases B_PERSON/B_DISEASE
harbouring O
PIK3CA B_DISEASE
mutation I_DISEASE
. O

Though O
the O
small B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O
not O
justify O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
claim I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
significance B_TIME[MEASURE]/B_DISEASE
; O
suggestion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O
such B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
despite O
of O
its O
not O
being O
mentioned O
by O
the O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
can O
be O
found O
from O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
CRC B_MEASURE
by O
Samuels B_PERSON
et I_PERSON
al I_PERSON
. O
. O

From O
their O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
33 B_MEASURE
MSI I_MEASURE
and O
201 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
microsatellite I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
stable I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
MSS B_DISEASE/B_PROTEIN[GENE]
) O
CRC B_DISEASE/B_MEASURE
cases I_DISEASE/I_MEASURE
, O
PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
48 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
MSI B_DISEASE/B_PERSON
tumours I_DISEASE/I_PERSON
, O
but O
only O
in O
29 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
MSS B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tumours I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

A O
significant B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
association I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
have O
been O
revealed O
if O
statistical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O
been O
applied O
( O
Fisher B_MEASURE/B_LOCATION
' I_MEASURE/I_LOCATION
s I_MEASURE/I_LOCATION
exact I_MEASURE/I_LOCATION
test I_MEASURE/I_LOCATION
, O
p O
= O
0 B_MEASURE
. O
014 B_MEASURE
) O
[ O
13 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

Gastrointestinal B_DISEASE/B_PERSON
tract I_DISEASE/I_PERSON
cancers I_DISEASE/I_PERSON
with O
MSI B_DISEASE
are O
known O
to O
have O
a O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
molecular B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
tumour B_DISEASE_ADJECTIVE[DISEASE]
evolution I_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
their O
MSS B_PERSON/B_LOCATION
counterparts I_PERSON/I_LOCATION
[ O
19 B_MEASURE
, O
20 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

This O
can O
be O
attributed O
to O
their O
propensity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
frameshift B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
repeat B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
resulting O
in O
selective B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disruption B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
such B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
within O
their O
coding B_GENE/B_LOCATION
regions I_GENE/I_LOCATION
. O

With O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
poly I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
adenine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
its O
coding B_LOCATION/B_PERSON
region I_LOCATION/I_PERSON
, O
PTEN B_GENE
can O
be O
inactivated O
through O
frameshift B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
MSI B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CRC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
resulting O
in O
the O
selective B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
targeting I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
PI3K B_GENE
- O
AKT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
21 B_MEASURE
, O
22 B_MEASURE
] O
. O

It O
is O
also O
known O
that O
mismatch B_DISEASE
repair I_DISEASE
deficiency I_DISEASE
would O
lead O
to O
an O
elevated B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
missense B_DISEASE
mutation I_DISEASE
due O
to O
impaired B_DISEASE/B_GENE
single I_DISEASE/I_GENE
nucleotide I_DISEASE/I_GENE
mismatch I_DISEASE/I_GENE
repair I_DISEASE/I_GENE
[ O
23 B_DISEASE/B_GENE
] B_DISEASE/I_GENE
. O

Thus O
, O
the O
observed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
higher I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PIK3CA B_DISEASE/B_GENE
missense I_DISEASE/I_GENE
mutation I_DISEASE/I_GENE
in O
MSI B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
colorectal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
gastric B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancers I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
suggests O
yet O
another O
mechanism B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
activation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
the O
PI3K B_GENE
- O
AKT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O
mismatch B_DISEASE/B_GENE
repair B_DISEASE/I_GENE
deficiency B_DISEASE/I_GENE
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O
showed O
a O
higher B_MEASURE
tendency I_MEASURE
of O
KRAS B_DISEASE/B_GENE
mutation I_DISEASE/I_GENE
in O
cases B_PERSON/B_DISEASE
with O
PIK3CA B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
( O
2 B_NUMBER[MEASURE]
in O
4 B_MEASURE
) O
than O
in O
those O
without O
( O
6 B_NUMBER[MEASURE]
in O
90 B_NUMBER[MEASURE]
) O
. O

Yet O
again O
due O
to O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
mutations B_DISEASE
in O
our O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O
not O
be O
claimed O
. O

In O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
by O
Samuels B_LOCATION/B_PERSON
et I_LOCATION/I_PERSON
al O
. O
, O
some O
of O
the O
colorectal B_DISEASE/B_PERSON
tumours I_DISEASE/I_PERSON
with O
PIK3CA B_DISEASE
mutation I_DISEASE
also O
harboured O
KRAS B_GENE/B_LOCATION
or O
BRAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
13 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
PI3K B_GENE
- O
AKT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
known O
to O
have O
a O
close B_PERSON/B_MEASURE
association I_PERSON/I_MEASURE
with O
the O
RAS B_GENE/B_DISEASE
- O
MEKK B_GENE/B_LOCATION
signalling I_GENE/I_LOCATION
pathway I_GENE/I_LOCATION
[ O
8 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Constitutively O
active B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
RAS I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
interact O
with O
the O
catalytic B_ENZYME[GENE]
subunit I_ENZYME[GENE]
of O
PI3K B_GENE
and O
lead O
to O
its O
activation B_GENE
. O

Ras B_GENE/B_DISEASE
- O
dependent B_GENE
PI3K I_GENE
activation I_GENE
contributes O
to O
the O
transforming O
phenotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
mediating O
anchorage B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
independent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cytoskeletal B_DISEASE/B_ORGANISM_FUNCTION
reorganisation I_DISEASE/I_ORGANISM_FUNCTION
and O
apoptosis B_DISEASE_ADJECTIVE[DISEASE]
evasion I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
has O
been O
observed O
that O
genes B_BIO/B_DISEASE
involved O
in O
the O
same B_DISEASE/B_LOCATION
signalling I_DISEASE/I_LOCATION
pathway I_DISEASE/I_LOCATION
may O
manifest O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
cancer B_GENE/B_BIO
cells I_GENE/I_BIO
in O
a O
mutually O
exclusive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
presumably O
due O
to O
the O
lack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
selective B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
growth I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
advantage I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
having O
a O
second B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
hit I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
the O
already O
altered O
pathway B_DISEASE/B_GENE
. O

A O
prominent B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
example I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
mutually O
exclusive B_DISEASE_ADJECTIVE[DISEASE]
occurrence I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
BRAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hotspot I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
V600E B_MEASURE/B_GENE
) O
and O
KRAS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
colorectal B_MEASURE
cancer I_MEASURE
[ I_MEASURE
24 I_MEASURE
, O
25 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

However O
, O
there O
exist O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
examples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
alterations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
components I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
same B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
may O
lead O
to O
a O
multi B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
level B_DISEASE_ADJECTIVE[DISEASE]
modulation I_DISEASE_ADJECTIVE[DISEASE]
of O
its O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
non B_GENE/B_DISEASE
- O
V600E B_DISEASE/B_GENE
BRAF I_DISEASE/I_GENE
mutations I_DISEASE/I_GENE
tend O
to O
occur O
together O
with O
KRAS B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
[ O
26 B_MEASURE
] I_MEASURE
, O
and O
inactivation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
secreted B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
frizzled O
- O
related O
proteins B_GENE/B_DISEASE
( O
antagonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Wnt B_GENE
) O
by O
promoter B_GENE/B_BIO
methylation I_GENE/I_BIO
frequently O
coincides O
with O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
the O
adenomatous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polyposis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coli I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
achieve O
multi B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
level B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Wnt B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
colorectal B_DISEASE/B_BIO
cancers I_DISEASE/I_BIO
[ O
27 B_MEASURE
] I_MEASURE
. O

Whether O
PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independently O
from O
RAS B_GENE/B_DISEASE
, O
or O
acts O
synergistically O
with O
RAS B_GENE/B_DISEASE
to O
produce O
additive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
the O
activation B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
same B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
awaits O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clarification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
extracting O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
we O
have O
confirmed O
the O
up B_LOCATION/B_LANGUAGE
- O
regulation B_MEASURE/B_LOCATION
of O
PIK3CA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
gastric B_DISEASE
cancer I_DISEASE
tissues I_DISEASE
compared O
with O
the O
non B_DISEASE/B_LOCATION
- O
neoplastic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
gastric I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
mucosae I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
identified O
a O
large B_MEASURE/B_PERSON
number B_MEASURE/I_PERSON
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
showed O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
expression B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
PIK3CA B_DISEASE/B_GENE
. O

These O
genes B_BIO/B_GENE
participate O
in O
diverse B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
177 B_MEASURE/B_PERSON
as O
putative B_TIME[MEASURE]/B_DISEASE
cell B_TIME[MEASURE]/I_DISEASE
cycle B_TIME[MEASURE]/I_DISEASE
- O
regulated O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
28 B_MEASURE
] I_MEASURE
and O
126 B_TIME[MEASURE]/B_LOCATION
mapped O
to O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
known O
functions B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
regulation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proliferation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O
DNA B_DISEASE_ADJECTIVE[DISEASE]
replication I_DISEASE_ADJECTIVE[DISEASE]
[ I_DISEASE_ADJECTIVE[DISEASE]
see O
Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
file B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

While O
some O
of O
these O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
maybe O
induced O
by O
PIK3CA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
others B_PERSON/B_LOCATION
maybe O
co O
- O
ordinately O
regulated O
by O
common B_GENE
upstream I_GENE
signals I_GENE
. O

Expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
set O
at O
one B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
point I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
limited O
in O
differentiating O
the O
above B_DISEASE
cause I_DISEASE
and O
consequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
yet O
it O
certainly O
revealed O
the O
complexity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
carcinogenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
the O
intricate B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
relationship I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O
PIK3CA B_GENE
signalling O
with O
other B_DISEASE/B_ORGANISM_FUNCTION
cellular I_DISEASE/I_ORGANISM_FUNCTION
processes I_DISEASE/I_ORGANISM_FUNCTION
. O

contrary B_PERSON/B_MEASURE
to O
our O
expectation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
the O
incidence B_MEASURE
of O
PIK3CA B_DISEASE/B_LOCATION
mutation I_DISEASE/I_LOCATION
found O
in O
the O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
is O
much O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
that O
observed O
by O
Samuel B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
. O

( O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
[ O
13 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

The O
reason B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
discrepancy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O
simply O
be O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sample B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bias B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
involved O
only O
a O
small B_MEASURE
number I_MEASURE
of O
gastric B_PERSON/B_ORGANIZATION
cancers I_PERSON/I_ORGANIZATION
( O
n B_OTHER/B_MEASURE
= O
12 B_MEASURE
) O
. O

However O
, O
ethnic B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
differences I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
can O
also O
be O
another O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
diverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrum I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
aetiological B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gastric B_DISEASE
cancers I_DISEASE
in O
different B_LOCATION/B_PERSON
geographical I_LOCATION/I_PERSON
locations I_LOCATION/I_PERSON
may O
be O
paralleled O
by O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
tumour B_DISEASE/B_GENE
development I_DISEASE/I_GENE
. O

Since O
our O
current O
study O
is O
only O
based O
on O
a O
Chinese O
population O
with O
an O
intermediate O
gastric O
cancer O
incidence O
, O
further O
studies O
involving O
patients B_PERSON
from O
different O
ethnic O
groups O
will O
be O
able O
to O
address O
this O
possibility O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

Large B_MEASURE/B_LOCATION
- O
scale B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gastric B_DISEASE/B_PERSON
adenocarcinomas I_DISEASE/I_PERSON
for O
PIK3CA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
revealed O
a O
mutation B_MEASURE
incidence I_MEASURE
of O
4 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
. O

increased O
PIK3CA B_DISEASE/B_GENE
expression I_DISEASE/I_GENE
level I_DISEASE/I_GENE
was O
observed O
in O
gastric B_DISEASE
tumours I_DISEASE
compared O
with O
non B_DISEASE/B_LOCATION
- O
neoplastic B_DISEASE/B_BIO
mucosae I_DISEASE/I_BIO
. O

This O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
PIK3CA B_GENE/B_DISEASE
level I_GENE/I_DISEASE
was O
associated O
with O
the O
elevated B_GENE
expression I_GENE
of O
a O
large B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
may O
constitute O
the O
upstream B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
regulators I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or O
downstream B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targets I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PIK3CA B_GENE
along O
the O
PI3K B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
signalling I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
pathway I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

competing O
interests B_DISEASE
. O

The O
author B_PERSON/B_LOCATION
( O
s O
) O
declare O
that O
they O
have O
no O
competing O
interests B_PERSON/B_ORGANIZATION
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

VSWL B_PERSON
carried O
out O
the O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
performed O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
drafted O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

CWW B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
TLC B_LOCATION/B_ORGANIZATION
, O
WZ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assisted O
in O
the O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

KMC B_PERSON/B_ORGANIZATION
provided O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

ASWC B_PERSON
assisted O
in O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
edited O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

SS B_LOCATION/B_ORGANIZATION
and O
XC B_LOCATION/B_ORGANIZATION
participated O
in O
the O
microarray B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

STY B_PERSON/B_ORGANIZATION
and O
SYL B_PERSON/B_ORGANIZATION
conceived O
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
participated O
in O
its O
design B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
coordination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
edited O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

All O
authors B_PERSON/B_NUMBER[MEASURE]
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

Pre B_LOCATION/B_PERSON
- O
publication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
pre B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
publication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
accessed O
here O
: O

supplementary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
material I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

Identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
novel B_PERSON/B_DISEASE
Beh I_PERSON/I_DISEASE
c I_PERSON/I_DISEASE
et I_PERSON/I_DISEASE
' O
s B_DISEASE/B_GENE
disease B_DISEASE/I_GENE
autoantigen B_DISEASE/I_GENE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
has O
been O
some O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
Beh B_DISEASE/B_GENE
c I_DISEASE/I_GENE
et I_DISEASE/I_GENE
' O
s O
disease B_DISEASE
( O
BD B_DISEASE/B_PROTEIN[GENE]
) O
has O
a O
significant B_DISEASE/B_LOCATION
autoimmune I_DISEASE/I_LOCATION
component I_DISEASE/I_LOCATION
but O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
putative B_DISEASE/B_LOCATION
autoantigens I_DISEASE/I_LOCATION
has O
not O
been O
well O
characterized O
. O

In O
the O
initial O
analysis O
of O
the O
autoantibody O
profile O
in O
39 O
Chinese O
BD O
patients B_PERSON/B_LOCATION
, O
autoantibodies O
to O
cellular O
proteins O
were O
uncovered O
in O
23 O
% O
as O
determined O
by O
immunoblotting O
. O

We O
have O
now O
identified O
one B_NUMBER[MEASURE]
of O
the O
major B_GENE/B_MEASURE
autoantibody I_GENE/I_MEASURE
specificities I_GENE/I_MEASURE
using O
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cloning I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

serum O
from O
a O
BD O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
as O
a O
probe O
to O
immunoscreen O
a O
lambda O
ZAP O
expression O
cDNA O
library O
. O

candidate B_PERSON/B_GENE
autoantigen I_PERSON/I_GENE
cDNAs I_PERSON/I_GENE
were O
characterized O
by O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
their O
expressed O
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
examined O
for O
reactivity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
entire B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
panel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
BD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sera I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
immunoprecipitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Reactivity O
was O
also O
examined O
with O
normal O
control O
sera O
and O
disease O
control O
sera O
from O
patients B_PERSON/B_BIO
with O
lupus O
and O
Sj O
o O
gren O
' O
s O
syndrome O
. O

Six O
independent O
candidate O
clones O
were O
isolated O
from O
the O
cDNA O
library O
screen O
and O
were O
identified O
as O
overlapping O
partial O
human B_SPECIES[BIO]/B_GENE
kinectin O
cDNAs O
. O

The O
finding O
that O
kinectin O
was O
an O
autoantigen O
was O
verified O
in O
9 O
out O
of O
39 O
( O
23 O
% O
) O
BD O
patient B_PERSON/B_LOCATION
sera O
by O
immunoprecipitation O
of O
the O
in O
vitro O
translation O
products O
. O

Sera B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
from O
controls B_LOCATION
showed O
no O
reactivity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
participant B_PERSON/B_MEASURE
in O
autoimmune B_DISEASE
pathogenesis I_DISEASE
in O
BD B_DISEASE/B_PERSON
and O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
autoantibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
kinectin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
serodiagnostics B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Beh B_PERSON/B_LOCATION
c I_PERSON/I_LOCATION
et I_PERSON/I_LOCATION
' O
s O
disease B_DISEASE/B_LOCATION
( O
BD B_DISEASE/B_PROTEIN[GENE]
) O
is O
a O
systemic B_DISEASE_ADJECTIVE[DISEASE]
vasculitic I_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
typified O
by O
a O
triad B_DISEASE/B_MEASURE
of O
symptoms B_DISEASE
including O
recurrent B_DISEASE
oral I_DISEASE
ulcers I_DISEASE
, O
genital B_DISEASE
ulcers I_DISEASE
and O
uveitis B_DISEASE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
skin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
joint B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
large B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vessels I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
nervous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
gastrointestinal B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
systems I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O
be O
involved O
. O

BD B_DISEASE
is O
a O
global B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
but O
has O
the O
highest B_MEASURE/B_LOCATION
prevalence I_MEASURE/I_LOCATION
in O
the O
region B_LOCATION
along O
the O
ancient B_TIME[MEASURE]/B_LOCATION
' I_LOCATION
Silk B_LOCATION/B_PERSON
Road I_LOCATION
' O
in O
China B_LOCATION
. O

The O
etiopathogenesis B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
disease B_DISEASE
remains O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
microbial B_DISEASE/B_BACTERIUM[BIO]
agent I_DISEASE/I_BACTERIUM[BIO]
triggers I_DISEASE/I_BACTERIUM[BIO]
, O
environmental B_DISEASE_ADJECTIVE[DISEASE]
factors I_DISEASE_ADJECTIVE[DISEASE]
, O
genetic B_DISEASE/B_GENE
predisposition I_DISEASE/I_GENE
, O
neutrophil B_DISEASE/B_GENE
hyperfunction I_DISEASE/I_GENE
, O
endothelial B_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_DISEASE_ADJECTIVE[DISEASE]
and O
immunological B_DISEASE
abnormalities I_DISEASE
involving O
both O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
implicated O
. O

increasing O
amounts B_MEASURE
of O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
supports O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
it O
is O
an O
immune B_DISEASE
- O
mediated O
vasculitis B_DISEASE
, O
and O
that O
abnormal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
- O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
B B_OTHER/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reactions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
autoantigen B_GENE
- O
driven O
autoimmunity B_DISEASE
play O
pivotal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
roles I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
[ O
1 B_DISEASE/B_LOCATION
] I_DISEASE/I_LOCATION
. O

Systemic B_DISEASE
lupus I_DISEASE
erythematosus I_DISEASE
( O
SLE B_LOCATION/B_ORGANIZATION
) O
is O
the O
prototypic B_DISEASE/B_PERSON
systemic I_DISEASE/I_PERSON
autoimmune I_DISEASE/I_PERSON
rheumatic I_DISEASE/I_PERSON
disease I_DISEASE/I_PERSON
with O
autoantibodies B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
cellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O
particularly O
nuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
) O
antigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
some O
of O
which O
are O
critically O
implicated O
in O
the O
autoimmune B_DISEASE
pathology I_DISEASE
while O
others B_PERSON
provide O
valuable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serodiagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
markers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
the O
disease B_DISEASE
. O

Unlike O
the O
picture B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
in O
SLE B_DISEASE/B_LOCATION
and O
other B_DISEASE/B_PROTEIN[GENE]
related B_DISEASE/I_PROTEIN[GENE]
rheumatic B_DISEASE/I_PROTEIN[GENE]
diseases B_DISEASE/I_PROTEIN[GENE]
, O
in O
BD B_DISEASE/B_PERSON
, O
antinuclear B_DISEASE
antibodies I_DISEASE
and O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
neutrophil O
cytoplasmic B_GENE/B_DISEASE
antigens I_GENE/I_DISEASE
etc I_GENE/I_DISEASE
. O
are O
not O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
date B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
since O
neither O
a O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantibody B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
pathognomonic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
help O
establish O
the O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BD B_DISEASE/B_LOCATION
, O
it O
is O
largely O
or O
solely O
based O
on O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestations B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
2 B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
a O
dilemma B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
a O
rare B_DISEASE/B_MEASURE
occurrence I_DISEASE/I_MEASURE
in O
clinical B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
practice I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nevertheless O
, O
since O
the O
1960s O
, O
there O
have O
been O
reports O
of O
autoantibodies O
against O
certain O
unknown O
components O
of O
human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oral O
mucosa O
in O
sera O
of O
patients B_PERSON/B_BIO
with O
BD O
. O

Since O
then O
, O
sporadic O
reports O
on O
findings O
of O
autoantibodies O
in O
this O
disease O
have O
been O
described O
, O
such O
as O
antibodies O
to O
retinal O
antigen O
( O
s O
) O
, O
heat O
shock O
protein O
( O
HSP O
) O
of O
some O
strains O
of O
Streptococcus B_SPECIES[BIO]
sanguis I_SPECIES[BIO]
cross O
- O
reactive O
with O
human B_PERSON/B_SPECIES[BIO]
HSP O
polypeptide O
[ O
3 O
] O
, O
antibodies O
to O
endothelial O
cell O
antigens O
( O
AECA O
) O
and O
antibodies O
to O
alpha O
- O
tropomyosin O
[ O
4 O
, O
5 O
] O
, O
attesting O
to O
the O
complicated O
humoral O
immune O
disorders O
in O
this O
disease O
. O

This O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
aimed O
at O
defining O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
autoantigens B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O
time B_TIME[MEASURE]/B_LOCATION
- O
tested O
and O
well O
- O
established O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Immunoscreening O
of O
expression B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
libraries B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O
BD B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sera I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
used O
since O
this O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O
been O
successfully O
employed O
in O
the O
characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
many B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinically O
relevant B_DISEASE_ADJECTIVE[DISEASE]
antigens I_DISEASE_ADJECTIVE[DISEASE]
in O
systemic B_DISEASE/B_BIO
rheumatic I_DISEASE/I_BIO
diseases I_DISEASE/I_BIO
such I_DISEASE/I_BIO
as O
SS B_LOCATION
- O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Ro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
9 B_MEASURE
] I_MEASURE
and O
SS B_LOCATION
- O
B B_PROTEIN[GENE]/B_DISEASE
/ O
La B_LOCATION
[ O
10 B_MEASURE
] O
antigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
Sj B_DISEASE/B_LOCATION
o O
gren B_LOCATION/B_MEASURE
' O
s B_DISEASE
syndrome I_DISEASE
( O
SjS B_MEASURE/B_DISEASE
) O
and O
centromere B_LOCATION
antigen I_LOCATION
CENP I_LOCATION
- O
B B_OTHER/B_MEASURE
[ O
11 B_MEASURE
] O
in O
scleroderma B_DISEASE/B_BIO
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
have O
been O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
using O
this O
strategy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
identify O
interesting B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
autoantigens I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O
have O
other B_DISEASE_ADJECTIVE[DISEASE]
biological I_DISEASE_ADJECTIVE[DISEASE]
significance I_DISEASE_ADJECTIVE[DISEASE]
. O

Examples B_NUMBER[MEASURE]/B_PERSON
of O
these O
include O
NOR90 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
hUBF B_MEASURE
[ O
12 B_MEASURE
] O
, O
p80 O
- O
coilin B_MEASURE/B_GENE
[ O
13 B_MEASURE
] I_MEASURE
, O
Golgi B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
autoantigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
14 B_MEASURE
- O
16 B_MEASURE
] I_MEASURE
and O
, O
more O
recently O
, O
GW182 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O
17 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Patients B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
sera O
. O

The O
currently O
used O
empirical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BD B_DISEASE
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
the O
criteria B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
proposed O
by O
the O
International B_ORGANIZATION/B_LOCATION
Study I_ORGANIZATION/I_LOCATION
Group I_ORGANIZATION/I_LOCATION
for O
BD B_DISEASE/B_MEASURE
( O
abbreviated O
as O
' B_LOCATION/B_ORGANIZATION
International I_LOCATION/I_ORGANIZATION
criteria I_LOCATION/I_ORGANIZATION
' I_LOCATION/I_ORGANIZATION
) O
[ O
2 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
study O
subjects O
of O
39 O
Chinese O
BD O
patients B_PERSON
comprised O
17 O
males O
and O
22 O
females O
, O
mean O
age O
37 O
+/- O
11 O
. O
3 O
years O
old O
, O
who O
were O
divided O
into O
two O
subgroups O
: O
25 O
typical O
BD O
patients B_PERSON
( O
Group O
I O
, O
satisfying O
the O
International O
criteria O
) O
and O
14 O
clinically O
diagnosed O
BD O
patients B_PERSON
who O
had O
recurrent O
oral O
ulcers O
and O
one O
of O
the O
symptoms O
of O
genital O
ulcers O
, O
eye O
symptoms O
or O
skin O
lesions O
as O
defined O
by O
the O
International O
criteria O
, O
as O
well O
as O
additional O
symptom O
( O
s O
) O
closely O
related O
to O
BD O
as O
listed O
in O
the O
International O
criteria O
, O
that O
is O
, O
gastrointestinal O
ulcerations O
, O
deep O
vein O
thrombosis O
or O
arthralgia O
/ O
arthritis O
without O
evidence O
that O
the O
latter O
symptoms O
might O
be O
related O
to O
any O
other O
disease O
( O
Group O
II O
, O
defined O
as O
' O
probable O
BD O
' O
in O
this O
study O
) O
. O

Disease O
controls O
included O
10 O
patients B_PERSON
with O
SLE O
and O
10 O
with O
SjS O
, O
all O
satisfying O
corresponding O
international O
classification O
criteria O
. O

All O
BD O
patients B_PERSON
and O
disease O
controls O
involved O
in O
the O
study O
were O
patients B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
treated O
at O
the O
Rheumatology O
Department O
of O
Ren O
Ji O
Hospital O
, O
Shanghai O
, O
China O
, O
where O
their O
clinical O
data O
and O
serum O
samples O
were O
collected O
. O

Twenty B_PERSON
normal I_PERSON
control I_PERSON
sera I_PERSON
were O
randomly O
selected O
from O
healthy B_PERSON
blood I_PERSON
donors I_PERSON
working O
in O
the O
same B_LOCATION
hospital I_LOCATION
. O

This O
study O
was O
approved O
by O
the O
institution O
review O
board O
of O
Ren O
Ji O
Hospital O
which O
is O
affiliated O
with O
Shanghai O
Second O
Medical O
University O
, O
and O
each O
patient B_PERSON/B_LOCATION
involved O
gave O
informed O
consent O
. O

All O
serum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
preserved O
at O
- O
20 B_MEASURE
degrees I_MEASURE
C I_MEASURE
or O
- O
70 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
until O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Cell B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
lines B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
and O
cell B_BIO/B_LOCATION
extracts I_BIO/I_LOCATION
. O

HeLa O
( O
ATCC O
CCL O
2 O
. O
2 O
) O
and O
T24 O
( O
human B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
transitional O
cell O
bladder O
carcinoma O
) O
were O
obtained O
from O
the O
American O
Type O
Culture O
Collection O
( O
Rockville O
, O
MD O
, O
USA O
) O
. O

A O
bovine B_PERSON/B_SPECIES[BIO]
aortic O
endothelial O
cell O
line O
was O
kindly O
provided O
by O
Dr O
Eugene O
G O
Levin O
from O
the O
Scripps O
Research O
Institute O
( O
La O
Jolla O
, O
CA O
, O
USA O
) O
. O

cells O
were O
cultured O
in O
DMEM O
containing O
10 O
% O
calf B_SPECIES[BIO]/B_PERSON
serum O
, O
harvested O
and O
extracted O
in O
buffer O
A O
( O
150 O
mm O
NaCl O
, O
10 O
mm O
Tris O
- O
HCl O
, O
pH7 O
. O
2 O
, O
0 O
. O
5 O
% O
Nonidet O
P O
- O
40 O
) O
with O
protease O
inhibitor O
( O
Complete O
(TM) O
; O
Boehringer O
Mannheim O
, O
Indianapolis O
, O
IN O
, O
USA O
) O
. O

For O
the O
preparation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
whole B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extract I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
10 B_MEASURE/B_BIO
volumes B_MEASURE/I_BIO
of O
Laemmli B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
buffer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
18 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
added O
to O
the O
cell B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pellet I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
boiled O
for O
3 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
stored O
at O
- O
20 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
until O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Western B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
blot I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Whole O
cell O
lysates O
from O
bovine B_SPECIES[BIO]/B_PROTEIN[GENE]
aortic O
endothelial O
cell O
, O
HeLa O
and O
T24 O
cells O
were O
resolved O
individually O
by O
discontinuous O
7 O
. O
5 O
% O
gel O
SDS O
- O
Page O
according O
to O
Laemmli O
' O
s O
method O
[ O
18 O
] O
. O

Immunoblotting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
performed O
as O
described O
by O
Towbin B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

[ O
19 B_TIME[MEASURE]
] O
with O
modifications B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Nitrocellulose O
strips O
were O
blocked O
with O
3 O
% O
nonfat O
milk O
in O
PBS O
containing O
0 O
. O
05 O
% O
Tween O
- O
20 O
( O
PBS O
- O
T O
) O
and O
then O
incubated O
with O
BD O
patient B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
sera O
and O
normal O
control O
sera O
( O
1 O
: O
100 O
dilution O
) O
at O
room O
temperature O
for O
1 O
h O
. O

filters B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
washed O
extensively O
with O
PBS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
T B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
remove O
any O
unbound B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

bound O
antibodies O
were O
detected O
with O
polyvalent O
, O
peroxidase O
- O
conjugated O
goat B_SPECIES[BIO]
anti O
- O
human B_SPECIES[BIO]
Ig O
and O
visualized O
by O
incubating O
the O
nitrocellulose O
strips O
in O
chemiluminescent O
reagents O
( O
NEN O
Life O
Science O
Products O
Inc O
. O
, O
Boston O
, O
MA O
, O
USA O
) O
and O
exposing O
to O
Kodak O
XAR O
- O
5 O
films O
. O

Screening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phage B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
antibody B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
probes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

serum O
from O
a O
BD O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O
the O
highest O
antibody O
titer O
in O
immunoblotting O
was O
selected O
as O
a O
probe O
and O
used O
at O
a O
dilution O
of O
1 O
: O
300 O
for O
initial O
immunoscreening O
of O
approximately O
106 O
recombinants O
from O
a O
T24 O
cDNA O
expression O
library O
. O

The O
latter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
constructed O
in O
lambda B_MEASURE
ZAPExpress I_MEASURE
vector I_MEASURE
( O
Stratagene B_MEASURE
, O
La B_LOCATION/B_PERSON
Jolla I_LOCATION/I_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
and O
screened O
as O
previously O
described O
[ O
20 B_MEASURE
- O
22 B_MEASURE
] I_MEASURE
. O

All O
screenings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
on O
duplicate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isopropyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
thiogalactoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
IPTG B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
impregnated O
nitrocellulose B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
filters I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
, O
and O
immunoreactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
detected O
by O
chemiluminescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Positive B_BIO/B_PERSON
phages I_BIO/I_PERSON
were O
subsequently O
plaque B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
purified O
to O
100 B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
two B_NUMBER[MEASURE]
repeated O
rounds B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
screening B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
low B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
plaque I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
densities I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

Before O
screening O
the O
cDNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
the O
BD B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serum I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
extensively O
adsorbed O
against O
bacteria B_SPECIES[BIO]/B_GENE
and O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_BIO/B_GENE
lambda I_BIO/I_GENE
ZAP I_BIO/I_GENE
phage I_BIO/I_GENE
mixture I_BIO/I_GENE
to O
reduce O
background B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
candidate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cDNAs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Purified B_PERSON/B_BIO
candidate I_PERSON/I_BIO
plaques I_PERSON/I_BIO
were O
subcloned O
in O
vivo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
into O
pBK B_PROTEIN[GENE]/B_DISEASE
- O
CMV B_NUMBER[MEASURE]/B_BIO
plasmids I_NUMBER[MEASURE]/I_BIO
using O
ExAssist B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
(TM) I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
helper I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
phage I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
as O
recommended O
in O
the O
manufacturer B_PERSON/B_ORGANIZATION
' O
s B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instructions I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Stratagene B_MEASURE/B_BIO
) O
. O

The O
recombinant B_DISEASE
pBK I_DISEASE
- O
CMV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasmids I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
then O
purified O
using O
QIAprep B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
spin I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Minprep I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Kit I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Qiagen B_MEASURE/B_PERSON
, O
Valencia B_LOCATION/B_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

restriction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
digestion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
plasmids B_GENE/B_BACTERIUM[BIO]
with O
EcoRI B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
XhoI B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
standard B_MEASURE
1 I_MEASURE
. O
0 B_MEASURE
% I_MEASURE
agarose I_MEASURE
gel I_MEASURE
was O
used O
to O
analyze O
the O
length B_MEASURE/B_LOCATION
of O
cDNA B_GENE
insert I_GENE
of O
each O
candidate B_GENE/B_BIO
plasmid I_GENE/I_BIO
. O

The O
complete B_GENE
nucleotide I_GENE
sequence I_GENE
was O
determined O
using O
Bigdye B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
terminator I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
a O
semi B_DISEASE/B_PROTEIN[GENE]
- O
automated O
sequencer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
377 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
ABI B_MEASURE
, O
Foster B_LOCATION/B_PERSON
City I_LOCATION/I_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

Both O
nucleotide O
and O
deduced O
amino B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
analyzed O
for O
similarity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
known O
sequences B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
using O
blast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
23 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
ExPASy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteomics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tools I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
coiled O
- O
coil B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motifs B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
with O
the O
software B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coils I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
24 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

immunoprecipitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
in O
vitro B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
translation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
products I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

candidate B_GENE/B_PERSON
cDNA I_GENE/I_PERSON
clones I_GENE/I_PERSON
were O
used O
as O
templates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
in O
vitro B_GENE
transcription I_GENE
and O
translation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
used O
as O
substrates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
immunoprecipitation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
confirm O
the O
specificity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
reaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
BD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sera B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
brief O
, O
1 O
Mu O
g O
of O
the O
pBK O
- O
CMV O
plasmid O
identified O
in O
the O
screening O
outlined O
above O
was O
added O
as O
template O
in O
a O
50 O
- O
Mu O
l O
reaction O
for O
the O
coupled O
in O
vitro O
transcription O
and O
translation O
reaction O
with O
a O
rabbit B_SPECIES[BIO]/B_DISEASE
reticulocyte O
lysate O
system O
( O
Promega O
, O
Madison O
, O
WI O
, O
USA O
) O
in O
the O
presence O
of O
35S O
- O
methionine O
( O
Trans O
- O
35S O
label O
; O
ICN O
Biochemicals O
, O
Costa O
Mesa O
, O
CA O
, O
USA O
) O
and O
RNasin O
(R) O
Ribonuclease O
inhibitor O
( O
Stratagene O
) O
as O
recommended O
by O
the O
manufacturer O
( O
Promega O
) O
. O

translation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
at O
30 B_TIME[MEASURE]/B_LOCATION
degrees B_TIME[MEASURE]/I_LOCATION
C B_TIME[MEASURE]/I_LOCATION
for O
1 B_MEASURE
. O
5 B_MEASURE
h O
. O

Products B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
analyzed O
in O
a O
12 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
gel I_MEASURE
SDS I_MEASURE
- O
PAGE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
stored O
at O
- O
80 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
for O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immunoprecipitation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
translation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
proteins B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
were O
examined O
for O
reactivity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
sera B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
using O
immunoprecipitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
described O
[ O
8 B_MEASURE
, O
25 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Autoantibody O
detection O
in O
sera O
from O
BD O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Initial O
examination O
of O
a O
group O
of O
39 O
BD O
patients B_PERSON/B_BIO
using O
indirect O
immunofluorescence O
( O
IIF O
) O
on O
a O
HEp O
- O
2 O
cell O
substrate O
did O
not O
yield O
any O
characteristic O
nuclear O
or O
cytoplasmic O
staining O
patterns O
. O

BD B_DISEASE
is O
thought O
by O
some O
to O
be O
a O
vasculitic B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
involving O
pathophysiology B_DISEASE
of O
endothelial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cells I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
endothelial B_DISEASE/B_GENE
cell I_DISEASE/I_GENE
antigen I_DISEASE/I_GENE
( O
AECA B_DISEASE/B_GENE
) O
has O
been O
reported O
. O

Reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
prevalence B_DISEASE_ADJECTIVE[DISEASE]
of O
AECA B_DISEASE
have O
varied O
largely O
and O
alpha B_PROTEIN[GENE]
- O
enolase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
reported O
as O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
putative B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
26 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

In O
this O
study O
, O
the O
use O
of O
bovine B_PERSON/B_SPECIES[BIO]
aortic O
endothelial O
cells O
as O
substrate O
for O
IIF O
did O
not O
provide O
any O
additional O
data O
. O

However O
, O
Western O
blot O
analysis O
of O
the O
BD O
sera O
began O
to O
show O
some O
interesting O
autoreactivity O
using O
cell O
lysates O
from O
both O
HeLa O
and O
bovine B_SPECIES[BIO]/B_PROTEIN[GENE]
aortic O
endothelial O
cells O
. O

HeLa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
initially O
used O
for O
this O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
they O
are O
commonly O
used O
in O
the O
laboratory B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
Western B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
substrate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Fig B_BIO/B_GENE
. O

1 B_NUMBER[MEASURE]/B_PERSON
illustrates O
the O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactivity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
49 B_MEASURE
kDa I_MEASURE
and O
120 B_GENE
kDa I_GENE
proteins I_GENE
in O
the O
endothelial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lysates I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
antigens B_GENE/B_DISEASE
were O
also O
detected O
in O
HeLa B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O
T24 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
; O
the O
latter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
analyzed O
because O
our O
laboratory B_LOCATION/B_PERSON
at O
The O
Scripps B_LOCATION/B_PERSON
Research I_LOCATION/I_PERSON
Institute I_LOCATION/I_PERSON
has O
produced O
an O
excellent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cDNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
library I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
the O
T24 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
the O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
result I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
T24 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extracts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
allowed O
us O
to O
screen O
the O
T24 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Ig B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
isotype I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
all O
reactivity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
largely O
IgG B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
antibodies I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Since O
the O
49 O
kDa O
and O
120 O
kDa O
bands O
were O
observed O
in O
cell O
extracts O
from O
bovine B_SPECIES[BIO]/B_PROTEIN[GENE]
as O
well O
as O
human B_SPECIES[BIO]
cell O
lines O
, O
these O
autoantigens O
might O
be O
evolutionarily O
conserved O
. O

In O
total B_MEASURE
, O
nine B_NUMBER[MEASURE]
out O
of O
39 B_NUMBER[MEASURE]/B_PERSON
BD I_NUMBER[MEASURE]/I_PERSON
sera I_NUMBER[MEASURE]/I_PERSON
( O
23 B_MEASURE
% I_MEASURE
) O
had O
autoantibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
the O
49 B_MEASURE/B_GENE
kDa I_MEASURE/I_GENE
antigen I_MEASURE/I_GENE
and O
eight B_NUMBER[MEASURE]
( O
20 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
to O
the O
120 B_GENE/B_DISEASE
kDa I_GENE/I_DISEASE
antigen I_GENE/I_DISEASE
. O

Four B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BD I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sera I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE/B_BIO
% B_MEASURE/I_BIO
) O
reacted O
with O
both O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Additionally O
, O
sera B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
showed O
common B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactivity B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
120 B_PROTEIN[GENE]
kDa I_PROTEIN[GENE]
protein I_PROTEIN[GENE]
also O
demonstrated O
a O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
band B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O
migrated O
at O
~ B_PROTEIN[GENE]/B_TIME[MEASURE]
150 B_PROTEIN[GENE]/I_TIME[MEASURE]
kDa B_PROTEIN[GENE]/I_TIME[MEASURE]
, O
although O
it O
appeared O
weaker B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
the O
120 B_MEASURE/B_BIO
kDa I_MEASURE/I_BIO
band I_MEASURE/I_BIO
. O

These O
antigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
appeared O
to O
have O
different B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
molecular B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
weights B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
those O
of O
the O
known O
autoantigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
rheumatic B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
diseases B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
other B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reactive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
bands I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
detected O
but O
they O
were O
not O
as O
commonly O
shared O
as O
the O
49 B_MEASURE
kDa I_MEASURE
and O
120 B_GENE/B_MEASURE
kDa I_GENE/I_MEASURE
bands I_GENE/I_MEASURE
. O

The O
49 B_PROTEIN[GENE]/B_MEASURE
kDa I_PROTEIN[GENE]/I_MEASURE
protein I_PROTEIN[GENE]/I_MEASURE
was O
shown O
to O
be O
distinct B_DISEASE_ADJECTIVE[DISEASE]
from O
48 B_PROTEIN[GENE]/B_LOCATION
kDa I_PROTEIN[GENE]/I_LOCATION
SS I_PROTEIN[GENE]/I_LOCATION
- O
B B_OTHER/B_MEASURE
/ O
La B_PROTEIN[GENE]/B_MEASURE
or O
50 B_LOCATION/B_PERSON
kDa I_LOCATION/I_PERSON
Jo I_LOCATION/I_PERSON
- O
1 B_PROTEIN[GENE]/B_MEASURE
proteins I_PROTEIN[GENE]/I_MEASURE
( O
Fig B_MEASURE/B_LOCATION
. O
1 B_NUMBER[MEASURE]
) O
. O

The O
120 B_PROTEIN[GENE]
kDa I_PROTEIN[GENE]
antigen I_PROTEIN[GENE]
was O
also O
shown O
to O
migrate O
differently O
from O
alanyl B_GENE/B_PERSON
tRNA I_GENE/I_PERSON
synthetase I_GENE/I_PERSON
in O
another O
Western B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O
shown O
) O
and O
did O
not O
share O
any O
apparent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
crossreactive I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
epitopes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
the O
49 B_PROTEIN[GENE]/B_BIO
kDa I_PROTEIN[GENE]/I_BIO
antigen I_PROTEIN[GENE]/I_BIO
. O

Western B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
blot B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
of O
20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
normal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sera B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
did O
not O
show O
the O
reactivities B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
with O
BD B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sera I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
order O
to O
further O
characterize O
these O
autoreactivities O
, O
a O
serum O
sample O
from O
the O
Group O
I O
definitive O
BD O
patients B_PERSON/B_GENE
with O
the O
strongest O
reactivity O
to O
49 O
kDa O
and O
120 O
kDa O
antigens O
( O
Fig O
. O
1 O
, O
lane O
2 O
) O
was O
selected O
as O
antibody O
probe O
for O
expression O
library O
screening O
. O

Kinectin B_TIME[MEASURE]/B_LOCATION
identified O
as O
a O
novel B_PERSON/B_GENE
BD I_PERSON/I_GENE
autoantigen I_PERSON/I_GENE
. O

After O
screening O
500 B_MEASURE
, O
000 B_MEASURE/B_ENT
clones I_MEASURE/I_ENT
from O
the O
T24 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cell I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
lambda I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
ZAPExpress I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
seven B_GENE/B_NUMBER[MEASURE]
immunoreactive I_GENE/I_NUMBER[MEASURE]
clones I_GENE/I_NUMBER[MEASURE]
were O
isolated O
and O
plaque B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
purified O
in O
two B_NUMBER[MEASURE]/B_LOCATION
to O
three B_NUMBER[MEASURE]
rounds I_NUMBER[MEASURE]
to O
achieve O
100 B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homogeneity B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cDNA B_GENE/B_BIO
inserts I_GENE/I_BIO
were O
subcloned O
in O
vivo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O
pBK B_PROTEIN[GENE]/B_DISEASE
- O
CMV B_NUMBER[MEASURE]/B_BIO
plasmids I_NUMBER[MEASURE]/I_BIO
, O
analyzed O
by O
restriction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
digestion I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
EcoRI B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
XhoI B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzymes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
submitted O
to O
direct B_GENE
nucleotide I_GENE
sequencing O
across O
the O
polylinker B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
arms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
cDNA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inserts I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represented O
six B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
independent I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
clones I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
designated O
BD41 B_PROTEIN[GENE]/B_DISEASE
( O
identical B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
BD44 B_GENE/B_MEASURE
) O
, O
BD481 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
BD42 B_GENE
, O
BD47 B_PROTEIN[GENE]
, O
BD482 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
BD49 B_GENE
. O

Their O
identities O
were O
established O
as O
overlapping O
partial O
cDNAs O
of O
human B_SPECIES[BIO]/B_GENE
kinectin O
, O
ranging O
from O
1 O
. O
9 O
kb O
to O
3 O
kb O
( O
Fig O
. O
2a O
) O
. O

The O
full O
- O
length O
human B_SPECIES[BIO]/B_GENE
kinectin O
( O
GenBank O
accession O
number O
nm O
_ O
182926 O
[ O
27 O
] O
) O
has O
4 O
, O
816 O
bases O
containing O
an O
open O
reading O
frame O
coding O
1 O
, O
357 O
amino O
acid O
residues O
with O
molecular O
mass O
156 O
kDa O
. O

All O
six B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cDNAs B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
lacked O
the O
5 B_MEASURE/B_LOCATION
' I_MEASURE/I_LOCATION
portion I_MEASURE/I_LOCATION
of O
the O
kinectin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
different B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
but O
spanned O
a O
sequence B_LOCATION/B_GENE
of O
kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
extended O
to O
the O
3 B_TIME[MEASURE]/B_LOCATION
' I_TIME[MEASURE]/I_LOCATION
- O
untranslated B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
. O

Secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
kinectin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O
the O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coils I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identified O
a O
long B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
alpha B_NUMBER[MEASURE]/B_GENE
- O
helical B_GENE/B_DISEASE
coiled O
- O
coil B_LOCATION/B_PERSON
domain I_LOCATION/I_PERSON
that O
extended O
from O
amino B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
acid I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
residue I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
327 I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
to O
the O
C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminus B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fig B_MEASURE/B_PROTEIN[GENE]
. O
2a B_MEASURE
, O
hatched O
boxes B_LOCATION/B_MEASURE
) O
. O

In O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
coupled O
transcription B_GENE
and O
translation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BD44 B_GENE
and O
BD42 B_GENE
clones I_GENE
directed O
the O
synthesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
[ O
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
methionine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
labeled O
polypeptides B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
migrated O
at O
95 B_MEASURE
and O
60 B_MEASURE
kDa I_MEASURE
, O
respectively O
, O
in O
addition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
smaller B_GENE
polypeptides I_GENE
( O
Fig B_PROTEIN[GENE]/B_MEASURE
. O
2b B_MEASURE
) O
. O

These O
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
had O
predicted O
molecular B_MEASURE
weights I_MEASURE
of O
103 B_MEASURE
kDa I_MEASURE
and O
75 B_MEASURE
kDa I_MEASURE
. O

Kinectin O
was O
initially O
identified O
in O
chick B_SPECIES[BIO]/B_DISEASE
embryo O
brain O
microsome O
as O
an O
integral O
membrane O
protein O
anchored O
in O
endoplasmic O
reticulum O
and O
involved O
in O
kinesin O
- O
driven O
vesicle O
motility O
along O
microtubules O
[ O
28 O
, O
29 O
] O
. O

Kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consists O
of O
a O
120 B_MEASURE
- O
kDa B_PROTEIN[GENE]
and O
a O
160 B_MEASURE
- O
kDa B_PROTEIN[GENE]/B_MEASURE
polypeptide I_PROTEIN[GENE]/I_MEASURE
interacting O
through O
the O
alpha B_NUMBER[MEASURE]/B_GENE
- O
helical B_GENE/B_DISEASE
coiled O
- O
coil B_LOCATION/B_PERSON
domain I_LOCATION/I_PERSON
to O
form O
a O
heterodimer B_GENE/B_LOCATION
[ O
30 B_GENE
] I_GENE
. O

The O
full B_MEASURE/B_COLOR
- O
length B_GENE/B_MEASURE
kinectin I_GENE/I_MEASURE
is O
the O
160 B_MEASURE/B_LOCATION
kDa B_MEASURE/I_LOCATION
polypeptide B_MEASURE/I_LOCATION
containing O
an O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_LOCATION/B_PROTEIN[GENE]
transmembrane I_LOCATION/I_PROTEIN[GENE]
helix I_LOCATION/I_PROTEIN[GENE]
followed O
by O
a O
bipartite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
nuclear I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
localization I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
sequence I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_LOCATION
leucine I_LOCATION
zipper I_LOCATION
motifs I_LOCATION
. O

We O
presume O
that O
the O
120 B_PROTEIN[GENE]/B_MEASURE
kDa I_PROTEIN[GENE]/I_MEASURE
polypeptide I_PROTEIN[GENE]/I_MEASURE
detected O
in O
Western B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Fig B_MEASURE/B_LOCATION
. O
1 B_NUMBER[MEASURE]
) O
is O
the O
truncated B_MEASURE/B_PERSON
version B_MEASURE/I_PERSON
of O
the O
160 B_MEASURE
- O
kDa B_PROTEIN[GENE]/B_MEASURE
polypeptide I_PROTEIN[GENE]/I_MEASURE
, O
lacking O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
terminal B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
first I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
232 I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminus B_LOCATION/B_MEASURE
of O
the O
160 B_MEASURE
- O
kDa B_PROTEIN[GENE]/B_LOCATION
polypeptide I_PROTEIN[GENE]/I_LOCATION
consists O
of O
a O
transmembrane B_LOCATION
domain I_LOCATION
that O
anchors B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinectin I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
endoplasmic B_MEASURE/B_BIO
reticulum I_MEASURE/I_BIO
[ I_MEASURE/I_BIO
30 I_MEASURE/I_BIO
, O
31 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

This O
120 B_PROTEIN[GENE]/B_LOCATION
kDa I_PROTEIN[GENE]/I_LOCATION
polypeptide I_PROTEIN[GENE]/I_LOCATION
is O
probably O
the O
predominant B_MEASURE
form I_MEASURE
detected O
in O
the O
Western B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
blot I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
Fig B_MEASURE/B_LOCATION
. O
1 B_NUMBER[MEASURE]
) O
because O
of O
its O
preferential B_MEASURE/B_LOCATION
solubility B_MEASURE/I_LOCATION
due O
to O
the O
omission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_PROTEIN[GENE]
transmembrane I_PROTEIN[GENE]
domain I_PROTEIN[GENE]
. O

Other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
kinectin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
have O
been O
reported O
. O

Yeast B_SPECIES[BIO]/B_NUMBER[MEASURE]
two O
- O
hybrid O
screen O
studies O
from O
several O
laboratories O
have O
revealed O
the O
interaction O
of O
the O
Rho O
family O
of O
GTPase O
with O
kinectin O
, O
and O
have O
shown O
the O
functional O
links O
among O
RhoG O
, O
kinectin O
and O
kinesin O
, O
with O
kinectin O
as O
a O
key O
effector O
of O
RhoG O
microtubule O
- O
dependent O
cellular O
activity O
[ O
32 O
] O
. O

Kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
identified O
as O
an O
important B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
constituent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
integrin B_GENE
- O
based O
adhesion B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
which O
link O
integrins B_GENE/B_BIO
to O
the O
cytoskeleton B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
recruit O
signaling B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
33 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
] B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

A O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O
that O
a O
kinectin B_GENE
isoform I_GENE
lacking O
a O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
portion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
kinesin B_GENE/B_BIO
- O
binding O
domain B_LOCATION/B_GENE
is O
very O
probably O
the O
most O
conservative B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
form I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
it O
does O
not O
bind O
kinesin B_GENE/B_BIO
but O
act O
as O
a O
membrane B_PERSON/B_GENE
anchor I_PERSON/I_GENE
for O
the O
translation B_PROTEIN[GENE]/B_DISEASE
elongation I_PROTEIN[GENE]/I_DISEASE
factor I_PROTEIN[GENE]/I_DISEASE
- O
1 B_TIME[MEASURE]/B_LOCATION
delta I_TIME[MEASURE]/I_LOCATION
in O
the O
endoplasmic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
34 B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
] I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

prevalence B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
kinectin B_DISEASE/B_GENE
autoantibodies I_DISEASE/I_GENE
. O

The O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
methionine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
labeled O
translation B_PROTEIN[GENE]
product I_PROTEIN[GENE]
of O
BD44 B_GENE
, O
representing O
the O
largest B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recombinant I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinectin I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
used O
as O
the O
antigen B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrate B_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
an O
immunoprecipitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Out O
of O
39 O
BD O
patient B_PERSON/B_MEASURE
sera O
, O
nine O
( O
23 O
% O
) O
recognized O
the O
BD44 O
translation O
product O
( O
Fig O
. O
3 O
) O
, O
whereas O
sera O
from O
20 O
normal O
controls O
, O
10 O
SLE O
and O
10 O
SjS O
patients B_PERSON/B_BIO
did O
not O
show O
reactivity O
. O

Among O
the O
nine O
anti O
- O
kinectin O
positive O
patients B_PERSON
, O
six O
( O
6 O
/ O
25 O
, O
24 O
% O
) O
were O
from O
Group O
I O
( O
definitive O
BD O
) O
including O
the O
BD O
patient B_PERSON/B_BIO
whose O
serum O
was O
used O
in O
the O
immunoscreening O
of O
expression O
cDNA O
library O
, O
and O
three O
( O
3 O
/ O
14 O
, O
21 O
. O
4 O
% O
) O
patients B_PERSON/B_LOCATION
were O
from O
the O
Group O
II O
( O
probable O
BD O
) O
in O
this O
study O
. O

According O
to O
the O
Fisher B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exact I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
probability I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
calculation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
P B_OTHER/B_PROTEIN[GENE]
= O
1 B_MEASURE
. O
00 B_MEASURE
) O
, O
there O
is O
no O
statistically O
significant B_MEASURE
difference I_MEASURE
for O
antibody B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
kinectin O
between O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
combined O
data O
substantiated O
the O
finding O
that O
kinectin O
is O
an O
autoantigen O
that O
can O
be O
recognized O
by O
sera O
from O
23 O
% O
of O
Chinese O
BD O
patients B_PERSON/B_BIO
in O
this O
study O
with O
at O
least O
one O
immunoreactive O
region O
or O
autoepitope O
residing O
within O
the O
BD44 O
encoded O
polypeptide O
. O

Currently O
, O
there O
are O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
six B_NUMBER[MEASURE]
diagnostic I_NUMBER[MEASURE]
/ O
classification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
BD B_DISEASE/B_LOCATION
, O
among O
which O
the O
International B_NUMBER[MEASURE]
criteria I_NUMBER[MEASURE]
have O
been O
applied O
most O
extensively O
due O
to O
its O
relatively O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sensitivity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
91 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
96 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
[ O
2 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
discussed O
above O
, O
differential O
diagnosis O
of O
BD O
might O
be O
confusing O
in O
clinical O
practice O
since O
no O
specific O
laboratory O
test O
is O
available O
, O
and O
some O
patients B_PERSON/B_DISEASE
may O
have O
symptoms O
and O
signs O
strongly O
suggestive O
of O
BD O
but O
do O
not O
fully O
satisfy O
the O
International O
criteria O
, O
as O
in O
the O
Group O
II O
( O
probable O
BD O
) O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
our O
study O
group O
. O

A O
number O
of O
investigators O
have O
pointed O
out O
that O
a O
comprehensive O
analysis O
of O
the O
clinical O
data O
for O
a O
given O
patient B_PERSON
is O
very O
important O
for O
correct O
clinical O
diagnosis O
of O
BD O
, O
and O
that O
classification O
/ O
diagnosis O
criteria O
, O
including O
the O
International O
criteria O
, O
should O
be O
followed O
but O
should O
not O
be O
exclusive O
. O

The O
observation O
that O
three O
out O
of O
14 O
patients B_PERSON/B_BIO
in O
the O
probable O
BD O
group O
also O
had O
antibody O
to O
kinectin O
and O
the O
similar O
percentage O
of O
positive O
reactors O
between O
this O
group O
and O
Group O
I O
( O
21 O
. O
4 O
% O
versus O
24 O
% O
) O
supports O
this O
notion O
. O

The O
further O
use O
of O
non O
- O
clinical O
parameters O
such O
as O
immunological O
biomarkers O
as O
adjuncts O
to O
identify O
BD O
patients B_PERSON/B_LOCATION
could O
be O
of O
help O
in O
the O
classification O
of O
this O
disease O
entity O
. O

While O
our O
work O
was O
ongoing O
, O
anti O
- O
kinectin O
antibodies O
were O
reported O
in O
sera O
from O
patients B_PERSON/B_BIO
with O
hepatocellular O
carcinoma O
( O
HCC O
) O
[ O
35 O
, O
36 O
] O
and O
aplastic O
anemia O
[ O
37 O
, O
38 O
] O
. O

The O
first O
HCC O
report O
[ O
35 O
] O
identified O
kinectin O
as O
a O
tumor O
- O
associated O
antigen O
from O
the O
screening O
of O
an O
autologous O
cDNA O
library O
constructed O
from O
the O
cancer O
of O
a O
30 O
- O
year O
- O
old O
patient B_PERSON
from O
Guangxi O
, O
China O
. O

This O
report O
stated O
that O
four O
out O
of O
five O
HCC O
patients B_PERSON/B_BIO
tested O
were O
positive O
for O
anti O
- O
kinectin O
antibody O
[ O
35 O
] O
. O

In O
2004 O
, O
another O
laboratory O
also O
reported O
the O
cloning O
of O
kinectin O
as O
a O
tumor O
- O
associated O
antigen O
from O
a O
( O
presumably O
) O
different O
30 O
- O
year O
- O
old O
Chinese O
HCC O
patient B_PERSON/B_BIO
[ O
36 O
] O
. O

In O
contrast O
, O
anti O
- O
kinectin O
antibodies O
were O
not O
detected O
in O
other O
studies O
of O
HCC O
patients B_PERSON/B_BIO
associated O
with O
our O
laboratory O
[ O
39 O
, O
40 O
] O
. O

The O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
kinectin B_DISEASE/B_GENE
antibodies B_DISEASE/I_GENE
in O
aplastic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
anemia B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
also O
very O
interesting B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
37 B_MEASURE
, O
38 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
initial O
report O
by O
Hirano O
et O
al O
. O
identified O
kinectin O
by O
screening O
an O
aplastic O
anemia O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
candidate O
antigens O
using O
a O
Clontech O
human B_SPECIES[BIO]/B_PERSON
fetal O
liver O
cDNA O
expression O
library O
and O
it O
was O
concluded O
that O
seven O
out O
of O
18 O
aplastic O
anemia O
patients B_PERSON
were O
positive O
for O
anti O
- O
kinectin O
while O
none O
of O
the O
normal O
or O
disease O
controls O
had O
this O
antibody O
[ O
37 O
] O
. O

In O
their O
recent O
report O
, O
Hirano O
et O
al O
. O
reported O
that O
anti O
- O
kinectin O
antibodies O
were O
found O
in O
39 O
% O
of O
aplastic O
anemia O
patients B_PERSON/B_DISEASE
from O
the O
United O
States O
but O
only O
in O
three O
out O
of O
30 O
( O
10 O
% O
) O
cases O
in O
Japan O
[ O
38 O
] O
. O

In O
our O
study O
reported O
here O
, O
kinectin O
antibodies O
were O
only O
detected O
in O
BD O
patients B_PERSON/B_LOCATION
and O
not O
in O
normal O
controls O
and O
SLE O
and O
SjS O
disease O
controls O
. O

None O
of O
the O
BD O
patients B_PERSON/B_BIO
with O
anti O
- O
kinectin O
had O
signs O
of O
HCC O
or O
aplastic O
anemia O
at O
the O
time O
of O
diagnosis O
and O
at O
up O
to O
4 O
years O
of O
follow O
- O
up O
. O

mapping B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
epitope B_PROTEIN[GENE]
( O
s O
) O
recognized O
by O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
kinectin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
shed O
light B_COLOR/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
question B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
whether O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
autoepitopes I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
reside O
within O
the O
kinectin B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecule I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognized O
by O
sera B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
different B_DISEASE/B_BIO
diseases I_DISEASE/I_BIO
. O

Kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
a O
new B_PERSON/B_LOCATION
member I_PERSON/I_LOCATION
of O
coiled B_DISEASE/B_NUMBER[MEASURE]
- O
coil B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytoplasmic B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantigens B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
recently O
reviewed O
the O
literature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
growing O
number B_MEASURE/B_LOCATION
of O
cytoplasmic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
autoantigens I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
rich I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
alpha B_NUMBER[MEASURE]/B_GENE
- O
helical B_GENE/B_DISEASE
coiled O
- O
coil B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
domains B_MEDICAL_DEVICE[OBJECT]/I_BODY_PART_OR_ORGAN_COMPONENT
as O
typified O
from O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Golgi B_DISEASE/B_BIO
autoantigens I_DISEASE/I_BIO
[ O
41 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

Golgi B_PERSON/B_GENE
autoantigens I_PERSON/I_GENE
are O
generally O
high B_DISEASE_ADJECTIVE[DISEASE]
molecular I_DISEASE_ADJECTIVE[DISEASE]
weight I_DISEASE_ADJECTIVE[DISEASE]
proteins I_DISEASE_ADJECTIVE[DISEASE]
between O
100 B_MEASURE
and O
350 B_MEASURE
kDa I_MEASURE
and O
rich B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
coiled B_NUMBER[MEASURE]/B_DISEASE
- O
coil B_LOCATION/B_MEDICAL_DEVICE[OBJECT]
domains I_LOCATION/I_MEDICAL_DEVICE[OBJECT]
in O
the O
central B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
with O
non B_DISEASE
- O
coiled O
- O
coil B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
globular B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
domains B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
at O
both O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
C B_PROTEIN[GENE]/B_LOCATION
termini I_PROTEIN[GENE]/I_LOCATION
. O

Golgi B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
autoantigens I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
are O
displayed O
on O
the O
cytoplasmic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
face B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
of O
the O
Golgi B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
complex I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
are O
not O
localized O
to O
apoptotic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blebs I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
during O
apoptosis B_DISEASE
[ I_DISEASE
42 I_DISEASE
] I_DISEASE
. O

Giantin O
, O
the O
highest O
molecular O
weight O
Golgi O
autoantigen O
reported O
, O
is O
the O
predominant O
target O
of O
human B_PERSON/B_SPECIES[BIO]
anti O
- O
Golgi O
complex O
antibodies O
and O
multiple O
non O
- O
cross O
- O
reactive O
epitopes O
have O
been O
mapped O
spanning O
the O
350 O
kDa O
protein O
[ O
43 O
] O
. O

Other B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
high I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
molecular I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
weight I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
autoantigens I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
reported O
in O
cytoplasmic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
mitotic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
organelles I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
suggesting O
that O
these O
selected O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
become O
autoimmunogenic B_DISEASE_ADJECTIVE[DISEASE]
based O
on O
their O
subcellular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
association I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
41 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
in O
the O
endosomal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
compartment I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
known I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
autoantigens I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
early B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endosomal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EEA1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
180 B_NUMBER[MEASURE]/B_LOCATION
kDa I_NUMBER[MEASURE]/I_LOCATION
) O
[ O
44 B_MEASURE
] I_MEASURE
and O
clip B_LOCATION/B_PROTEIN[GENE]
- O
170 B_MEASURE/B_BIO
( O
170 B_PROTEIN[GENE]/B_MEASURE
kDa B_PROTEIN[GENE]/I_MEASURE
) O
[ O
45 B_MEASURE
] I_MEASURE
. O

There O
is O
also O
a O
series B_SPORT[ENT]/B_LOCATION
of O
centrosomal B_GENE/B_BIO
autoantigens I_GENE/I_BIO
identified O
as O
coiled B_DISEASE/B_MEASURE
- O
coil B_MEDICAL_DEVICE[OBJECT]/B_PROTEIN[GENE]
- O
rich B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
including O
pericentrin B_GENE
, O
a O
220 B_ENZYME[GENE]/B_MEASURE
kDa I_ENZYME[GENE]/I_MEASURE
protein I_ENZYME[GENE]/I_MEASURE
[ O
46 B_MEASURE
] I_MEASURE
, O
ninein B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
protein B_BIO/B_PROTEIN[GENE]
with O
alternatively O
spliced O
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O
245 B_MEASURE
and O
249 B_MEASURE
kDa I_MEASURE
[ I_MEASURE
47 I_MEASURE
] I_MEASURE
, O
Cep250 B_GENE
( O
250 B_MEASURE
kDa I_MEASURE
) O
and O
Cep110 B_GENE
( O
110 B_MEASURE/B_GENE
kDa I_MEASURE/I_GENE
) O
[ O
48 B_MEASURE
] I_MEASURE
. O

Centromere B_NUMBER[MEASURE]/B_PERSON
autoantigens I_NUMBER[MEASURE]/I_PERSON
have O
been O
described O
but O
the O
two B_NUMBER[MEASURE]/B_PERSON
interesting I_NUMBER[MEASURE]/I_PERSON
ones I_NUMBER[MEASURE]/I_PERSON
related O
to O
this O
discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
are O
CENP B_LOCATION
- O
E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
49 B_MEASURE
] I_MEASURE
and O
CENP B_LOCATION
- O
F B_OTHER/B_PROTEIN[GENE]
[ O
50 B_MEASURE
] I_MEASURE
; O
both O
are O
high B_DISEASE_ADJECTIVE[DISEASE]
molecular I_DISEASE_ADJECTIVE[DISEASE]
weight I_DISEASE_ADJECTIVE[DISEASE]
proteins I_DISEASE_ADJECTIVE[DISEASE]
( O
312 B_MEASURE/B_LOCATION
to O
400 B_MEASURE
kDa I_MEASURE
) O
and O
have O
the O
same B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
type I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
overall B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
discussed O
above O
. O

NuMA B_GENE/B_BACTERIUM[BIO]
is O
another O
large B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
coiled O
- O
coil B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
protein B_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
located O
at O
the O
mitotic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
spindle I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
pole I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
is O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
target I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
autoantigen I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
sera B_PERSON/B_DISEASE
with O
mitotic B_DISEASE_ADJECTIVE[DISEASE]
spindle I_DISEASE_ADJECTIVE[DISEASE]
apparatus I_DISEASE_ADJECTIVE[DISEASE]
staining O
[ O
51 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Non B_DISEASE/B_PERSON
- O
muscle B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
myosin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
~ B_MEASURE/B_PROTEIN[GENE]
200 I_MEASURE/I_PROTEIN[GENE]
kDa I_MEASURE/I_PROTEIN[GENE]
) O
is O
a O
cytoskeletal B_GENE
autoantigen I_GENE
[ I_GENE
52 I_GENE
] O
that O
falls O
in O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
high B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
molecular B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
weight B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
coiled B_DISEASE
- O
coil B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
rich B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
autoantigens I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

These O
endosomal B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
centrosomal B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
mitotic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
apparatus I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
intracellular B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
autoantigens I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O
, O
like O
the O
golgins B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O
proteins B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
high B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weights B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
an O
overall B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
coiled O
- O
coil B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
domains I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
these O
two B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
physical I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
features I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
autoantigens B_DISEASE
may O
contribute O
to O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
production B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
autoimmune B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
certain B_DISEASE/B_PERSON
disease I_DISEASE/I_PERSON
states I_DISEASE/I_PERSON
. O

Kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
an O
integral B_GENE
membrane I_GENE
protein I_GENE
largely O
confined O
to O
the O
endoplasmic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
28 B_MEASURE
, O
31 B_MEASURE
] I_MEASURE
and O
it O
fits O
into O
this O
new B_MEASURE/B_LOCATION
category B_MEASURE/I_LOCATION
of O
autoantigens B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
are O
large B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
coiled I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
coil B_LOCATION/B_GENE
rich I_LOCATION/I_GENE
proteins I_LOCATION/I_GENE
( O
>= B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
100 I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kDa I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
in O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

Here O
we O
report O
the O
detection O
of O
kinectin O
autoantibody O
in O
23 O
% O
of O
Chinese O
patients B_PERSON
with O
BD O
. O

The O
identity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
BD B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
related O
autoantigen B_GENE
has O
not O
been O
reported O
to O
date B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

autoantibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O
kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
BD B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
observed O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
further O
confirms O
the O
autoimmune B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
BD B_DISEASE
and O
may O
provide O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inroads I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
into O
elucidating O
the O
immunopathogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
of O
the O
disease B_DISEASE
. O

In O
an O
effort O
to O
clarify O
the O
association O
of O
BD O
with O
antibody O
to O
kinectin O
, O
it O
is O
essential O
to O
measure O
antibody O
to O
kinectin O
in O
larger O
patient B_PERSON/B_DISEASE
populations O
including O
both O
BD O
, O
probable O
BD O
and O
important O
autoimmune O
rheumatic O
diseases O
such O
as O
SLE O
, O
SjS O
, O
rheumatoid O
arthritis O
etc O
. O
, O
as O
well O
as O
those O
diseases O
not O
easily O
differentiated O
from O
BD O
, O
such O
as O
recurrent O
aphthous O
oral O
ulcer O
, O
Reiter O
' O
s O
syndrome O
, O
inflammatory O
bowel O
diseases O
etc O
. O

On O
the O
other B_PERSON/B_LOCATION
hand B_PERSON/I_LOCATION
, O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
different B_DISEASE_ADJECTIVE[DISEASE]
manifestations I_DISEASE_ADJECTIVE[DISEASE]
or O
disease B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' O
subtypes B_DISEASE_ADJECTIVE[DISEASE]
' I_DISEASE_ADJECTIVE[DISEASE]
of O
BD B_DISEASE/B_LOCATION
is O
another O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
kinectin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
clearly O
only O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
antigen B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
identified O
because O
there O
were O
many B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
other I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
observed O
in O
the O
Western B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
BD B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sera I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Using O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sera I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
immunoscreening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
probably O
lead O
to O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
potentially O
important B_DISEASE/B_SPECIES[BIO]
antigen I_DISEASE/I_SPECIES[BIO]
- O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Abbreviations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

AECA B_LOCATION/B_DISEASE
= O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
endothelial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
BD B_LOCATION
= O
Beh B_DISEASE/B_GENE
c I_DISEASE/I_GENE
et I_DISEASE/I_GENE
' O
s B_DISEASE/B_BIO
disease I_DISEASE/I_BIO
; O
DMEM B_LOCATION
= O
Dulbecco B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
s B_DISEASE/B_LOCATION
modified O
Eagle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O
s B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
medium I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
; O
HCC B_LOCATION
= O
hepatocellular B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carcinoma B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
HSP B_DISEASE/B_LOCATION
= O
heat B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
shock B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O
IIF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
= O
indirect B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immunofluorescence I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O
PBS B_ORGANIZATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
= O
phosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
buffered B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O
SjS B_LOCATION
= O
Sj B_PERSON/B_DISEASE
o I_PERSON/I_DISEASE
gren I_PERSON/I_DISEASE
' O
s B_DISEASE
syndrome I_DISEASE
; O
SLE B_LOCATION
= O
systemic B_DISEASE/B_PERSON
lupus I_DISEASE/I_PERSON
erythematosus I_DISEASE/I_PERSON
. O

competing O
interests B_DISEASE
. O

The O
authors B_PERSON
declare O
that O
they O
have O
no O
competing O
interests B_PERSON/B_ORGANIZATION
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

YL B_PERSON
performed O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
drafted O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

PY B_PERSON
provided O
technical B_PERSON/B_TIME[MEASURE]
help I_PERSON/I_TIME[MEASURE]
throughout O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

SLC B_PERSON
and O
EMT B_ORGANIZATION/B_PERSON
conceived O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
participated O
in O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
helped O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

EKLC B_PERSON/B_ORGANIZATION
participated O
in O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
interpreted O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
helped O
to O
draft O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
authors B_PERSON/B_NUMBER[MEASURE]
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
: O
an O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resource I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O
endocrine B_DISEASE/B_ORGANISM_FUNCTION
networks I_DISEASE/I_ORGANISM_FUNCTION
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

EndoNet B_PERSON/B_LOCATION
is O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
provides O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O
the O
components B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
endocrine B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
networks I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
their O
relations B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
focuses O
on O
the O
endocrine O
cell O
- O
to O
- O
cell O
communication O
and O
enables O
the O
analysis O
of O
intercellular O
regulatory O
pathways O
in O
humans B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
the O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
, O
two B_LOCATION/B_MEASURE
classes I_LOCATION/I_MEASURE
of O
components B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
span O
a O
bipartite B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
directed O
graph B_LOCATION
. O

One B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
class B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
represents O
the O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
in O
the O
broadest B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sense I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
secreted O
by O
defined O
donor B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O

The O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
class I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
consists O
of O
the O
acceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
or O
target B_PERSON/B_LOCATION
cells I_PERSON/I_LOCATION
expressing O
the O
corresponding B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
identity B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anatomical B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
environment I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
types B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
tissues B_LOCATION/B_DISEASE
and O
organs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
is O
defined O
through O
references B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
CYTOMER B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
(R) I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ontology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

With O
the O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
user I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
interface I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
query O
the O
database B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
tissues B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
to O
combine O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
items I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
from O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
search I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rounds I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
result I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
set O
, O
from O
which O
a O
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O
be O
reconstructed O
and O
visualized O
. O

For O
each O
entity B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
page I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Some O
well O
- O
established O
endocrine B_LOCATION/B_ENT
pathways B_LOCATION/I_ENT
are O
offered O
as O
showcases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
predefined B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
result I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sets I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

These O
sets B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
used O
as O
a O
starting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
point I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
a O
more O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
query I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
for O
obtaining O
a O
quick B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
overview I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
EndoNet B_LOCATION/B_ORGANIZATION
database I_LOCATION/I_ORGANIZATION
is O
accessible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Theoretical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
post B_DISEASE/B_GENE
- O
sequencing O
era B_TIME[MEASURE]/B_LOCATION
, O
in O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
context B_LOCATION/B_PERSON
of O
systems B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
biology I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
approaches I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
increasingly O
investigate O
the O
properties B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
all O
kinds B_MEASURE/B_LOCATION
of O
pathways B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
networks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
metabolic B_GENE/B_DISEASE
and O
signaling O
pathways B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

It O
is O
commonly O
accepted O
that O
we O
need O
formal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
descriptions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
networks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
make O
systematic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
overwhelming B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
body I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
facts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
gathered O
over O
decades B_TIME[MEASURE]/B_LOCATION
of O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
both O
in O
narrow B_MEASURE/B_LOCATION
or O
global B_MEASURE/B_ORGANIZATION
scale I_MEASURE/I_ORGANIZATION
. O

corresponding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
databases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
have O
been O
created O
and O
are O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
now O
for O
metabolic B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
networks I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
KEGG B_PROTEIN[GENE]/B_LOCATION
) O
( O
1 B_NUMBER[MEASURE]
, O
2 B_MEASURE
) O
, O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
networks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
bind B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dip B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
) O
and O
signaling O
pathways B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
CSNDB B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Patika B_LOCATION/B_PERSON
and O
TRANSPATH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
(R) I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
( O
5 B_NUMBER[MEASURE]
- O
8 B_MEASURE
) O
, O
just O
to O
name O
a O
few B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

So O
far O
, O
however O
, O
their O
main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
focus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
on O
intracellular B_DISEASE_ADJECTIVE[DISEASE]/B_SPORT[ENT]
processes I_DISEASE_ADJECTIVE[DISEASE]/I_SPORT[ENT]
. O

intercellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
signaling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
addressed O
only O
insofar O
as O
usually O
the O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
modeled O
start B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
extracellular B_BIO/B_GENE
ligands I_BIO/I_GENE
, O
and O
as O
there O
exist O
catalogs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
databases B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O
secreted B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
, O
or O
the O
' O
secretome B_BACTERIUM[BIO]/B_LOCATION
' O
, O
of O
certain B_GENE/B_BIO
systems I_GENE/I_BIO
( O
9 B_NUMBER[MEASURE]
- O
12 B_MEASURE
) O
. O

This O
shortcoming B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
more O
comprehensive B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
problem I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
the O
genotype B_GENE
- O
phenotype B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gap B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
from O
a O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genotype I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
are O
able B_TIME[MEASURE]/B_PERSON
to O
infer O
a O
' B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
, O
but O
for O
correlating O
it O
with O
a O
more O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
phenotype I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
such I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O
a O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
or O
even O
a O
certain B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
and O
its O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
appearance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
still O
depend O
largely O
on O
the O
mere B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
an O
observed B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

There O
is O
no O
way B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
infer O
such O
a O
phenotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
through O
all O
the O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
layers B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
increasing O
complexity B_ORGANIZATION/B_MEASURE
between O
genomic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
DNA I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
sequences I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
the O
physiological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
whole B_GENE/B_BIO
organs I_GENE/I_BIO
and O
their O
interplay B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
within O
an O
organism B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

There O
may O
be O
principal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
barriers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preventing O
such O
an O
inference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
complexity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
levels I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
but O
even O
to O
explore O
these O
limits B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
have O
to O
make O
attempts B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
bridge O
the O
genotype B_GENE/B_MEASURE
- O
phenotype B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
gap B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

We O
have O
to O
do O
the O
next B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
towards O
modeling O
intercellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
networks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
are O
inextricably O
linked O
to O
the O
physiology B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
multicellular B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
organisms B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O
13 B_MEASURE/B_BIO
) O
. O

Being O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
most O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
constructs I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
the O
endocrine B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
comprises O
numerous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
tissues B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
that O
secrete O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
pass O
through O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT
, O
activate O
specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
target B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
initiate O
there O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intracellular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
, O
we O
present O
a O
new O
database O
, O
EndoNet O
, O
which O
provides O
information O
about O
the O
components O
of O
endocrine O
networks O
and O
their O
relations O
, O
and O
enables O
the O
analysis O
of O
intercellular O
regulatory O
pathways O
in O
humans B_BIO/B_DISEASE
. O

The O
EndoNet B_LOCATION/B_ORGANIZATION
database I_LOCATION/I_ORGANIZATION
is O
accessible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
schema I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
endocrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
actions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Development B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
organs B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
as O
well O
as O
the O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
whole B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
multicellular I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
organism I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
to O
its O
environment B_LOCATION
is O
coordinated O
through O
a O
complex B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
communication I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
specialized B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
its O
organs B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

This O
communication B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
mostly O
mediated O
by O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
a O
broader B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sense B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
this O
functional B_MEASURE/B_LOCATION
class B_MEASURE/I_LOCATION
of O
biomolecules B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
also O
comprises O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
chemokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
signal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transmitters B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

This O
generic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
view I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
is O
supported O
, O
for O
instance B_TIME[MEASURE]/B_DISEASE
, O
by O
the O
definition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
for O
' O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
' O
by O
Gene B_ORGANIZATION/B_LOCATION
Ontology I_ORGANIZATION/I_LOCATION
( O
GO O
) O
( O
14 B_MEASURE
) O
: O
' O
Any O
substance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
formed O
in O
very O
small B_DISEASE_ADJECTIVE[DISEASE]
amounts I_DISEASE_ADJECTIVE[DISEASE]
in O
one B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
specialized I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
organ I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
or O
group B_ORGANIZATION/B_MEASURE
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
carried O
( O
sometimes O
in O
the O
bloodstream B_BODY_PART_OR_ORGAN_COMPONENT
) O
to O
another O
organ B_ENT/B_BODY_PART_OR_ORGAN_COMPONENT
or O
group B_ORGANIZATION/B_MEASURE
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
in O
the O
same B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
organism I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O
upon O
which O
it O
has O
a O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regulatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
action I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
' O
. O

This O
definition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O
also O
broad B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
enough O
to O
include O
modes B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
actions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
diverse B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
endocrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
paracrine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
autocrine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Accordingly O
, O
with O
the O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hormone I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
' O
one B_NUMBER[MEASURE]/B_PERSON
might O
refer O
to O
any O
extracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
substance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
induces O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
target B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O
helps O
to O
coordinate O
growth B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
activities B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
various B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
tissues B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
organs B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
in O
multicellular B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
organisms I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
15 B_MEASURE/B_BIO
) O
. O

hormones B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
can O
be O
classified O
based O
on O
their O
chemical B_MEASURE/B_ORGANIZATION
nature I_MEASURE/I_ORGANIZATION
, O
solubility B_TIME[MEASURE]/B_LOCATION
, O
the O
distance B_MEASURE/B_LOCATION
over O
which O
the O
signal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
acts O
and O
so O
on O
( O
15 B_MEASURE
, O
16 B_MEASURE
) O
. O

From O
the O
viewpoint B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
phenotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
relations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
it O
is O
reasonable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
distinguish O
between O
polypeptide B_GENE/B_PERSON
, O
thus O
, O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
encoded O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
on O
one B_PERSON/B_NUMBER[MEASURE]
hand B_PERSON/I_NUMBER[MEASURE]
, O
and O
those O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormones B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
with O
only O
the O
machinery B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
their O
synthesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
being O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
encoded O
, O
on O
the O
other B_PERSON/B_SEQUENCE[MEASURE]
hand B_PERSON/I_SEQUENCE[MEASURE]
. O

Another O
classification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
seems O
to O
be O
overlapping O
with O
the O
previous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
one I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
refers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
the O
intracellular B_LOCATION
location I_LOCATION
of O
their O
receptors B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
, O
thus O
, O
how O
the O
subsequent B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signal B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
further O
transduced O
: O
membrane B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
bound O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usually O
trigger O
more B_TIME[MEASURE]
or O
less O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
signaling B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cascades B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
towards O
the O
nucleus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
whereas O
nuclear B_GENE/B_BIO
receptors I_GENE/I_BIO
, O
mainly O
bound O
by O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
molecular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
weight B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
have O
a O
very O
short B_DISEASE_ADJECTIVE[DISEASE]
signaling I_DISEASE_ADJECTIVE[DISEASE]
pathway I_DISEASE_ADJECTIVE[DISEASE]
downstream I_DISEASE_ADJECTIVE[DISEASE]
since O
they O
act O
as O
transcription B_GENE/B_BIO
factors I_GENE/I_BIO
themselves O
( O
15 B_MEASURE/B_PERSON
, O
16 B_MEASURE
) O
. O

In O
intercellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
communication I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
we O
can O
basically O
differentiate O
between O
two B_MEASURE/B_LOCATION
kinds I_MEASURE/I_LOCATION
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O
donor B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
which O
synthesize O
and O
secrete O
a O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
acceptor B_PERSON/B_BIO
cells I_PERSON/I_BIO
which O
express O
a O
hormone B_GENE
receptor I_GENE
( O
figure B_PROTEIN[GENE]/B_LOCATION
1a I_PROTEIN[GENE]/I_LOCATION
) O
. O

donor B_PERSON/B_BIO
cells I_PERSON/I_BIO
become O
active B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O
the O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
an O
external B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
mostly O
environmental B_DISEASE_ADJECTIVE[DISEASE]
, O
stimulus B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

In O
the O
acceptor B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
receptor B_GENE
triggers O
an O
intracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
signal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
transduction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cascade I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinds B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
end B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nodes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
effects B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
transcription B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affecting O
the O
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
the O
acceptor B_PERSON/B_BIO
cell I_PERSON/I_BIO
, O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
enzymes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
controlling O
the O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
' O
s B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
structural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
components I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
which O
define O
the O
acceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
' O
s B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
morphological B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
features B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
or O
components B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
secretory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
apparatus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
regulating O
the O
release B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extracellular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

If O
synthesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
secretion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
another O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
among O
the O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exerted O
by O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
acceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O
turned O
into O
a O
donor B_LOCATION
cell I_LOCATION
, O
thus O
becoming O
an O
internal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
node B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
organism B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
endocrine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Acceptor B_PERSON/B_BIO
cells I_PERSON/I_BIO
which O
do O
not O
become O
producers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
another O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
called O
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
terminal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
target I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cells I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
endocrine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
finally O
constitute O
the O
overall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
physiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
respective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormonal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
simply O
the O
phenotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
figure B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1a I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

The O
EndoNet B_PERSON/B_EDU[ORGANIZATION]
data I_PERSON/I_EDU[ORGANIZATION]
model I_PERSON/I_EDU[ORGANIZATION]
. O

In O
the O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
two B_LOCATION/B_MEASURE
classes I_LOCATION/I_MEASURE
of O
entities B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
-- O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
in O
the O
broadest B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sense I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
and O
their O
acceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
or O
target B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
expressing O
the O
corresponding B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-- O
span O
a O
bipartite B_MEASURE/B_BACTERIUM[BIO]
directed O
graph B_ORGANIZATION/B_LOCATION
. O

Since O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
the O
same B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
may O
be O
secreted O
by O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cell I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
types I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O
donor B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
) O
, O
each O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
secretion I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
event I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O
represented O
by O
a O
hormone B_DISEASE/B_PROTEIN[GENE]
node B_DISEASE/I_PROTEIN[GENE]
on O
its O
own B_PERSON/B_LOCATION
. O

Similarly O
, O
each O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
type I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
known O
to O
express O
a O
hormone B_GENE
receptor I_GENE
( O
acceptor B_PERSON/B_PROTEIN[GENE]
cell B_PERSON/I_PROTEIN[GENE]
) O
leads O
to O
an O
individual B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
node B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
graph B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s B_LOCATION/B_PERSON
edges I_LOCATION/I_PERSON
represent O
hormone B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transport B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
binding O
to O
a O
receptor B_GENE
( O
intercellular B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
edges I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
on O
one B_PERSON/B_MEASURE
hand B_PERSON/I_MEASURE
, O
and O
triggering B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
or O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hormone B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
secretion B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
by O
a O
receptor B_GENE
activated O
by O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
intracellular B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
edges I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
on O
the O
other B_PERSON/B_SEQUENCE[MEASURE]
hand B_PERSON/I_SEQUENCE[MEASURE]
. O

Optionally O
, O
an O
edge B_PERSON/B_LOCATION
representing O
the O
transport B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
subdivided O
by O
introducing O
the O
transport B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
usually O
blood B_BODY_PART_OR_ORGAN_COMPONENT
) O
as O
an O
additional B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O
intermediary B_LOCATION/B_MEASURE
node I_LOCATION/I_MEASURE
. O

Thus O
, O
in O
the O
conceptual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
schema B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Figure B_MEASURE/B_LOCATION
1b I_MEASURE/I_LOCATION
) O
, O
the O
links B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
organs B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
define O
donor B_PERSON/B_LOCATION
cells B_PERSON/I_LOCATION
( O
' O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
) O
, O
those O
between O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
organs B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acceptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
' O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O
) O
. O

If O
an O
acceptor B_PERSON/B_BIO
cell I_PERSON/I_BIO
synthesizes O
another O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
an O
incoming B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signal I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
it O
becomes O
an O
internal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
node B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
emerging O
hormonal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
network I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
the O
pathway B_LOCATION/B_MEASURE
between O
a O
hormone B_GENE
receptor I_GENE
expressed O
in O
an O
acceptor B_PERSON/B_BIO
cell I_PERSON/I_BIO
and O
a O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
synthesized O
in O
the O
same B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
( O
intracellular B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
edge I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
is O
handled O
as O
a O
black B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
box I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
encoded O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
references B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
entries B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
TRANSPATH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
(R) I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
which O
describe O
the O
signaling O
Cascade B_LOCATION
starting O
from O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
s B_GENE
receptor I_GENE
and O
ending O
at O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O
s B_GENE/B_PERSON
gene I_GENE/I_PERSON
, O
are O
provided O
, O
if O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

datasets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
non B_DISEASE
- O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
in O
future B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
be O
enriched O
by O
a O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
metabolic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
add I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
on O
which O
will O
include O
references B_PERSON/B_LOCATION
to O
the O
databases B_DISEASE/B_GENE
KEGG I_DISEASE/I_GENE
( O
1 B_MEASURE
) O
and O
Brenda B_PERSON/B_LOCATION
( O
17 B_NUMBER[MEASURE]
) O
, O
allowing O
for O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characterization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
steps B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
performed O
during O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
s B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
enzymes B_GENE
involved O
. O

By O
now O
, O
the O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
already O
allows O
for O
including O
descriptions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
physiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
see O
below O
, O
Future B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developments I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
contents B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
EndoNet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

In O
the O
present O
version O
of O
EndoNet O
, O
and O
as O
a O
first O
approach O
, O
we O
consider O
the O
endocrine O
( O
hormonal O
) O
network O
of O
the O
human B_PERSON/B_SPECIES[BIO]
body O
. O

For O
each O
molecule B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
or O
receptor B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
a O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
name I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
synonyms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
given O
. O

In O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
the O
sequence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
processed O
polypeptide B_PROTEIN[GENE]
, O
rather O
than O
that O
of O
the O
protein B_GENE/B_BIO
precursor I_GENE/I_BIO
, O
is O
specified O
. O

For O
a O
multimeric B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
hormone I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
subunit B_MEASURE/B_LOCATION
composition B_MEASURE/I_LOCATION
as O
well O
as O
the O
sequences B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
all O
subunits B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
stored O
; O
the O
same B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
holds O
true B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Additionally O
, O
all O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O
receptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
datasets I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
links B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
HumanPSD B_DISEASE/B_LOCATION
(TM) B_DISEASE/I_LOCATION
( O
18 B_MEASURE/B_LOCATION
) O
and O
to O
the O
Swiss B_LOCATION/B_PROTEIN[GENE]
- O
Prot B_LOCATION/B_ORGANIZATION
database I_LOCATION/I_ORGANIZATION
, O
The O
structures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
non B_DISEASE/B_PROTEIN[GENE]
- O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
can O
be O
accessed O
through O
the O
corresponding B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyperlinks I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
KEGG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Compound I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
section I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Finally O
, O
all O
molecules B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
have O
links B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
the O
TRANSPATH B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
database I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
described O
, O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
utilizes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
about O
the O
tissues B_LOCATION/B_DISEASE
from O
which O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
secreted O
and O
in O
which O
receptors B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
expressed O
to O
define O
donor B_PERSON
and O
acceptor B_PERSON/B_LOCATION
cells I_PERSON/I_LOCATION
, O
respectively O
. O

The O
identity O
and O
anatomical O
environment O
of O
cell O
types O
, O
tissues O
and O
organs O
is O
defined O
through O
references O
to O
the O
CYTOMER O
(R) O
ontology O
( O
19 O
, O
20 O
) O
; O
in O
the O
numerous O
cases O
where O
the O
receptors O
are O
ubiquitously O
expressed O
, O
just O
the O
root O
term O
' O
human B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
body O
' O
is O
linked O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
whether O
a O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' O
s B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
triggered O
or O
inhibited O
by O
another O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
its O
respective B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
particular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
obtained O
by O
manual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
selection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
textbooks B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
e B_OTHER/B_PROTEIN[GENE]
. O
g B_OTHER/B_GENE
. O
( O
16 B_MEASURE
) O
, O
] B_OTHER/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
monographies B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
21 B_MEASURE
) O
, O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
literature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
the O
est B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
linked O
databases B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TRANSPATH B_ORGANIZATION/B_LOCATION
(R) I_ORGANIZATION/I_LOCATION
, O
HumanPSD B_DISEASE/B_ORGANIZATION
(TM) I_DISEASE/I_ORGANIZATION
and O
Swiss B_LOCATION
- O
Prot B_LOCATION/B_PERSON
) O
. O

The O
contents B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
EndoNet B_ORGANIZATION/B_PERSON
are O
summarized O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Web B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interface I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
queries B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
visualization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
can O
be O
accessed O
through O
the O
www B_ORGANIZATION/B_LOCATION
via O
a O
JSP B_MEASURE/B_ORGANIZATION
- O
based O
web B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interface I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
tissues B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O
be O
queried O
for O
their O
names B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
detailed O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
all O
identified O
components B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
individual B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pages I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Each O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
individual I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
entry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
page I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
displays O
its O
source B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
target B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tissues I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
donor B_PERSON/B_BIO
and O
acceptor B_PERSON/B_LOCATION
cells I_PERSON/I_LOCATION
) O
as O
well O
as O
its O
receptors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
along O
with O
some O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Similarly O
, O
each O
receptor B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
entry I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
exhibits O
the O
tissues B_LOCATION/B_DISEASE
in O
which O
the O
receptor B_GENE
is O
expressed O
, O
and O
the O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
it O
interacts O
with O
. O

Finally O
, O
each O
tissue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
entry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lists O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
found O
in O
, O
as O
well O
as O
the O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
synthesized O
and O
secreted O
by O
the O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
also O
indicated O
whether O
the O
corresponding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tissue I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
exerts O
gender B_PERSON/B_LOCATION
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
properties I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
; O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O
on O
the O
CYTOMER B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
(R) I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
ontology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
through O
the O
corresponding B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
link I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
tissue B_LOCATION/B_PERSON
detail I_LOCATION/I_PERSON
page I_LOCATION/I_PERSON
. O

Instead O
of O
searching O
for O
a O
name B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
a O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
one O
can O
also O
browse O
the O
hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hormone I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
featured O
by O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
( O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
' O
Search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O
page B_LOCATION/B_MEASURE
) O
. O

Each O
query B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
result I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
can O
be O
used O
as O
starting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
point B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
an O
extended B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
query I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
items I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
interest B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
selected O
and O
added O
to O
a O
common B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
result I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
set O
. O

Since O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O
be O
combined O
, O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
create O
sets B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
multiple B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
search I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
parameters I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

At O
any O
step B_MEASURE/B_LOCATION
of O
this O
incremental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
retrieval I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
sets B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
tissues B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
obtained O
so O
far O
can O
be O
used O
as O
starting O
points B_LOCATION/B_BIO
for O
reconstructing O
a O
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
a O
depth B_MEASURE/B_LOCATION
- O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
graph I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
traversal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
maximum B_MEASURE/B_LOCATION
number B_MEASURE/I_LOCATION
of O
steps B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
can O
be O
selected O
separately O
for O
the O
upstream B_LOCATION/B_MEASURE
and O
downstream B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
reconstruction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Subsequently O
, O
the O
graph B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
displayed O
using O
a O
Graphviz B_PERSON/B_LOCATION
- O
based O
visualization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
22 B_TIME[MEASURE]/B_ENT
) O
, O
] O
. O

In O
the O
resulting O
image B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
represented O
as O
nodes B_LOCATION/B_PERSON
grouped O
together O
into O
subgraphs B_LOCATION/B_ORGANIZATION
representing O
the O
tissues B_LOCATION/B_DISEASE
( O
cells B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
/ O
organs B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
) O
they O
are O
secreted O
from O
or O
expressed O
in O
, O
respectively O
( O
figure B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
2 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
) O
. O

autocrine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
loops I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
donor B_PERSON
and O
acceptor B_PERSON/B_BIO
cell I_PERSON/I_BIO
being O
identical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
are O
treated O
specially O
for O
visualization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
. O

On O
demand B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
the O
hormones B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
transport I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
media I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
can O
be O
included O
in O
the O
visualization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
intercellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
edges I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
, O
enabling O
the O
user B_PERSON/B_BIO
to O
choose O
between O
different B_LOCATION
complexities I_LOCATION
of O
output B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Intracellular B_LOCATION/B_ENT
edges I_LOCATION/I_ENT
, O
which O
connect O
a O
receptor B_GENE
to O
a O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
represent O
the O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
receptor B_GENE
' O
s B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
secretion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
a O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
the O
same B_BODY_PART_OR_ORGAN_COMPONENT
cell I_BODY_PART_OR_ORGAN_COMPONENT
and O
are O
displayed O
differently O
, O
depending O
on O
whether O
this O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
triggering O
or O
inhibitory B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
nature B_LOCATION/B_DISEASE
. O

The O
graph B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
displayed O
as O
a O
clickable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
image I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
map I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
linking O
each O
entity B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
its O
detailed B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
page I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
thus O
making O
the O
database B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
entries I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
accessible I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O
the O
graphical B_LOCATION/B_PERSON
overview I_LOCATION/I_PERSON
of O
a O
network B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
too O
. O

The O
graph B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
two B_MEASURE/B_LOCATION
different B_MEASURE/I_LOCATION
formats B_MEASURE/I_LOCATION
: O
PNG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
SVG B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

While O
virtually O
every O
browser B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supports O
PNG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
a O
' O
pixel B_MEASURE/B_ENT
' O
or O
' O
bitmap B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
' O
format B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
, O
only O
a O
few B_MEASURE/B_PERSON
of O
them O
provide O
a O
zoom B_LOCATION/B_PERSON
functionality I_LOCATION/I_PERSON
for O
bitmap B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
pictures I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Scalable B_TIME[MEASURE]/B_LOCATION
vector I_TIME[MEASURE]/I_LOCATION
graphics I_TIME[MEASURE]/I_LOCATION
, O
( O
SVG B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
provides O
more B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
functionality I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
including O
perfect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
image I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
quality I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
throughout O
all O
zoom B_LOCATION/B_ENT
factors B_LOCATION/I_ENT
) O
, O
but O
until O
now O
most B_PERSON
browsers I_PERSON
do O
not O
support O
SVG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
natively O
and O
require O
an O
SVG B_PERSON/B_LOCATION
plugin I_PERSON/I_LOCATION
( O
) O
for O
displaying O
this O
vector B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
based O
format B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Some O
well O
- O
established O
endocrine B_LOCATION/B_ENT
pathways B_LOCATION/I_ENT
are O
offered O
as O
showcases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
predefined B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
result I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sets I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

For O
instance B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sets O
representing O
the O
hypothalamic B_BODY_PART_OR_ORGAN_COMPONENT
- O
hypophyseal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
focus B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
either O
thyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
adrenal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
provided O
. O

These O
predefined O
sets B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
used O
for O
obtaining O
a O
quick B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
overview I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
or O
as O
starting O
points B_LOCATION/B_ENT
for O
more O
complex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
queries I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Future B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Among O
the O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
improvements I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
which O
we O
are O
currently O
working O
on O
is O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
represent O
intercellular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
communication B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O
different B_MEASURE/B_LOCATION
levels B_MEASURE/I_LOCATION
of O
the O
hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
organization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
organs B_BODY_PART_OR_ORGAN_COMPONENT
, O
tissues B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O
the O
organism B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O
as O
well O
as O
to O
distinguish O
between O
such B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
communications I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
male B_PERSON
and O
female B_PERSON
organisms I_PERSON
. O

These O
options B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O
be O
introduced O
by O
a O
tighter B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
integration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
the O
CYTOMER B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
based O
ontology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
19 B_MEASURE
, O
20 B_MEASURE
) O
. O

The O
next B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
step I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
will O
be O
to O
expand O
the O
contents B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
towards O
the O
details B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
processes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
occurring O
in O
the O
transport B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
usually O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Since O
not O
all O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
transported O
as O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
molecules I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
some O
hydrophobic B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hormones I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
e O
. O
g B_GENE/B_MEASURE
. O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
thyroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
need O
to O
be O
bound O
to O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
carrier I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
proper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
such B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transporters I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
their O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
the O
corresponding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
will O
be O
required O
. O

It O
is O
planned O
to O
involve O
quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
about O
the O
regular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
pathological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
overall B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kinetics I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
each O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O
monotonous B_LOCATION/B_MEASURE
decay B_LOCATION/I_MEASURE
, O
oscillating B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
concentrations B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
increase O
in O
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
etc B_GENE/B_DISEASE
. O
) O
, O
its O
turnover B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
products B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
etc B_LOCATION/B_DISEASE
. O

That O
will O
allow O
utilization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
EndoNet B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contents I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
diagnostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
purposes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

In O
future B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
extended O
in O
order B_LOCATION/B_DISEASE
to O
incorporate O
external B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
e O
. O
g B_GENE/B_MEASURE
. O
light B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
and O
physiological B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
states I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
stress B_DISEASE/B_ORGANISM_FUNCTION
, O
age B_DISEASE/B_ORGANISM_FUNCTION
, O
etc B_LOCATION/B_DISEASE
. O
) O
in O
a O
formalized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manner I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
allowing O
to O
determine O
whether O
or O
not O
and O
in O
which O
quantity B_MEASURE/B_LOCATION
a O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
will O
be O
secreted O
under O
the O
given O
circumstances B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O
then O
link O
the O
physiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O
the O
intracellular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
molecular I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leading O
to O
its O
synthesis B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_GENE
and O
secretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
donor B_BODY_PART_OR_ORGAN_COMPONENT
cells I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
to O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
its O
acceptor B_PERSON/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
cells B_PERSON/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

At O
many B_MEASURE/B_LOCATION
places B_MEASURE/I_LOCATION
of O
these O
intracellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
intercellular B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
networks B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
genetically O
determined O
aberrations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
may O
cause O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
sometimes O
pathological B_DISEASE_ADJECTIVE[DISEASE]
phenotypes I_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O
enable O
to O
bridge O
the O
gap B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
between O
known O
genotypes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
their O
molecular B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
phenotypes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
this O
area B_LOCATION/B_MEASURE
of O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
its O
applications B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
its O
present B_LOCATION
state I_LOCATION
, O
EndoNet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
provides O
a O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
coverage I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
molecules B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
are O
conventionally O
considered O
as O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
well O
as O
other B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
molecules I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
are O
involved O
in O
intercellular B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
communication I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
lymphokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
chemokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
their O
known O
receptors B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
database B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
to O
provide O
a O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resource I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
studying O
the O
principal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
features I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
hormonal B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
networks I_ORGANIZATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
comprehensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
way B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
as O
it O
was O
done O
more O
exemplarily O
in O
the O
past B_TIME[MEASURE]/B_LOCATION
for O
these O
kinds B_MEASURE/B_LOCATION
of O
networks B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
23 B_MEASURE
) O
, O
but O
was O
done O
globally O
for O
many B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
other I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
intracellular I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
network I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
types I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
metabolic B_ENZYME[GENE]/B_DISEASE
, O
protein B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
transcription B_ORGANIZATION/B_GENE
networks I_ORGANIZATION/I_GENE
[ O
reviewed O
in O
( O
24 B_MEASURE
, O
25 B_MEASURE
) O
] B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

EndoNet B_PERSON/B_ORGANIZATION
database I_PERSON/I_ORGANIZATION
certainly O
is O
not O
yet O
complete B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O
will O
grow O
rapidly O
. O

Gender B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
influencing O
insulin B_DISEASE/B_GENE
resistance I_DISEASE/I_GENE
in O
elderly B_DISEASE/B_MEASURE
hyperlipemic I_DISEASE/I_MEASURE
non I_DISEASE/I_MEASURE
- O
diabetic B_PERSON
subjects I_PERSON
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
prevalence B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
insulin B_DISEASE
resistance I_DISEASE
- O
related O
metabolic B_DISEASE
syndrome I_DISEASE
, O
a O
disorder B_DISEASE
that O
greatly O
increases O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
diabetes B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
heart B_DISEASE
attack I_DISEASE
and O
stroke B_DISEASE
, O
is O
alarming B_DISEASE_ADJECTIVE[DISEASE]
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
the O
most O
frequent B_DISEASE_ADJECTIVE[DISEASE]
and O
early B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
of O
metabolic B_DISEASE
syndrome I_DISEASE
is O
hypertriglyceridemia B_DISEASE
. O

We O
examined O
the O
gender O
differences O
between O
various O
metabolic O
factors O
related O
to O
insulin O
resistance O
in O
elderly O
non O
- O
diabetic O
men B_PERSON
and O
postmenopausal O
women B_PERSON
of O
comparable O
age O
suffering O
from O
hypertriglyceridemia O
, O
and O
compared O
them O
with O
healthy O
subjects O
of O
equal O
age O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
indexes O
of O
insulin O
resistance O
HOMA O
IR O
and O
QUICKI O
were O
significantly O
higher O
in O
both O
hyperlipemic O
men B_PERSON
and O
women B_PERSON/B_BIO
than O
in O
controls O
; O
95 O
% O
confidence O
limits O
of O
hyperlipemic O
subjects O
did O
not O
overlap O
with O
controls O
. O

In O
both O
normolipemic O
and O
hyperlipemic O
men B_PERSON
and O
women B_PERSON/B_BIO
serum O
leptin O
correlated O
significantly O
with O
insulin O
resistance O
, O
while O
HDL O
- O
cholesterol O
correlated O
inversely O
with O
HOMA O
- O
IR O
only O
in O
women B_PERSON/B_BIO
( O
both O
normo O
- O
and O
hyperlipemic O
) O
, O
and O
serum O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
alpha O
) O
only O
in O
hyperlipemic O
women B_PERSON/B_BIO
. O

According O
to O
results O
of O
multiple O
regression O
analysis O
with O
HOMA O
- O
IR O
as O
a O
dependent O
variable O
, O
leptin O
played O
a O
significant O
role O
in O
determining O
insulin O
resistance O
in O
both O
genders O
, O
but O
- O
aside O
from O
leptin O
- O
triglycerides O
, O
TNF O
alpha O
and O
decreased O
HDL O
- O
cholesterol O
were O
significant O
determinants O
in O
women B_PERSON/B_BIO
, O
while O
body O
mass O
index O
and O
decreased O
HDL O
- O
cholesterol O
were O
significant O
determinants O
in O
men B_PERSON
. O

The O
coefficient O
of O
determination O
( O
R2 O
) O
of O
HOMA O
IR O
by O
above O
mentioned O
metabolic O
variables O
was O
in O
women B_PERSON/B_BIO
above O
60 O
% O
, O
in O
men B_PERSON
only O
about O
40 O
% O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

The O
significant O
role O
of O
serum O
leptin O
in O
determination O
of O
insulin O
resistance O
in O
both O
elderly O
men B_PERSON
and O
postmenopausal O
women B_PERSON
of O
equal O
age O
was O
confirmed O
. O

However O
, O
the O
study O
also O
revealed O
significant O
gender O
differences O
: O
in O
women B_PERSON/B_BIO
a O
strong O
influence O
of O
triglycerides O
, O
TNF O
alpha O
and O
decreased O
HDL O
- O
cholesterol O
, O
in O
men B_PERSON
only O
a O
mild O
role O
of O
BMI O
and O
decreased O
HDL O
- O
cholesterol O
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
association B_ORGANIZATION/B_PERSON
with O
pandemic B_DISEASE/B_ORGANISM_FUNCTION
obesity I_DISEASE/I_ORGANISM_FUNCTION
the O
prevalence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
insulin B_DISEASE
resistance I_DISEASE
- O
related O
metabolic B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
is O
constantly O
growing O
[ O
1 B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
] I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

As O
a O
consequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
type B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
2 I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
diabetes I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
mellitus I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
cardiovascular B_DISEASE
mortality I_DISEASE
occurs O
in O
much O
younger B_PERSON/B_MEASURE
age I_PERSON/I_MEASURE
groups I_PERSON/I_MEASURE
[ O
2 B_MEASURE/B_DISEASE
] I_MEASURE/I_DISEASE
. O

A O
typical B_DISEASE
hyperlipemia I_DISEASE
, O
consisting O
of O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triglycerides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
serum B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HDL I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
cholesterol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
a O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
an O
early B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptom B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
syndrome B_DISEASE/B_PERSON
[ O
3 B_LOCATION/B_TIME[MEASURE]
] B_LOCATION/I_TIME[MEASURE]
. O

With O
increasing O
age B_MEASURE/B_DISEASE
, O
body B_MEASURE/B_DISEASE
mass B_MEASURE/I_DISEASE
index B_MEASURE/I_DISEASE
( O
BMI B_MEASURE/B_DISEASE
) O
and O
adiposity B_DISEASE/B_MEASURE
, O
insulin B_DISEASE/B_MEASURE
sensitivity I_DISEASE/I_MEASURE
declines I_DISEASE/I_MEASURE
and O
the O
number B_MEASURE
of O
cardiovascular B_DISEASE/B_PERSON
risk I_DISEASE/I_PERSON
factors I_DISEASE/I_PERSON
increases I_DISEASE/I_PERSON
in O
both O
genders B_PERSON/B_MEASURE
[ O
4 B_TIME[MEASURE]
- O
6 B_MEASURE
] I_MEASURE
. O

It O
was O
repeatedly O
demonstrated O
that O
plasma O
concentration O
of O
leptin O
- O
a O
hormone O
produced O
mainly O
by O
adipose O
tissue O
- O
is O
substantially O
higher O
in O
all O
age O
groups O
of O
women B_PERSON/B_BIO
than O
in O
men B_PERSON/B_BIO
[ O
7 O
- O
10 O
] O
. O

This O
may O
be O
caused O
by O
different B_MEASURE/B_LOCATION
size B_MEASURE/I_LOCATION
and O
/ O
or O
distribution B_ORGANIZATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fat B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
tissue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
compartments I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
influenced O
by O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
estrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulate O
, O
whereas O
testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibits B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leptin O
secretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
women B_PERSON/B_BIO
subcutaneous O
fat O
mass O
prevails O
- O
and O
during O
augmentation O
of O
overweight O
it O
increases O
- O
while O
in O
men B_PERSON
intra O
- O
abdominal O
fat O
mass O
prevails O
[ O
11 O
- O
13 O
] O
. O

subcutaneous B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
fat I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
in O
particular B_DISEASE/B_SPECIES[BIO]
serves O
as O
a O
substantial B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
source I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
which O
represents O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
interfere O
with O
insulin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
signal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
transduction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
into O
the O
cells B_BODY_PART_OR_ORGAN_COMPONENT
[ O
14 B_MEASURE/B_LOCATION
- O
16 B_MEASURE
] I_MEASURE
. O

Leptin B_MEASURE/B_GENE
, O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
some O
other B_MEASURE/B_GENE
factors I_MEASURE/I_GENE
are O
abundantly O
expressed O
in O
adipose B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
contribute O
to O
the O
insulin B_DISEASE
resistance I_DISEASE
that O
accompanies O
overweight B_DISEASE/B_ORGANISM_FUNCTION
and O
obesity B_DISEASE
. O

leptin B_GENE/B_BIO
correlates O
positively O
with O
hyperinsulinemia B_DISEASE
, O
BMI B_DISEASE/B_GENE
, O
fat B_DISEASE
mass I_DISEASE
and O
hypertriglyceridemia B_DISEASE/B_PROTEIN[GENE]
, O
respectively O
, O
and O
correlates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inversely O
with O
HDL B_GENE
- O
cholesterol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
lean B_MEASURE/B_PROTEIN[GENE]
body B_MEASURE/I_PROTEIN[GENE]
mass B_MEASURE/I_PROTEIN[GENE]
[ B_MEASURE/I_PROTEIN[GENE]
17 B_MEASURE/I_PROTEIN[GENE]
- O
25 B_MEASURE
] I_MEASURE
. O

The O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
mortality B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
ischemic B_DISEASE
heart I_DISEASE
disease I_DISEASE
and O
of O
other B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
consequences I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
atherosclerosis B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increases I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
age B_TIME[MEASURE]/B_PERSON
in O
both O
genders B_PERSON/B_LOCATION
, O
especially O
after O
the O
age B_TIME[MEASURE]/B_LOCATION
of O
sixty B_NUMBER[MEASURE]
. O

In O
premenopausal O
women B_PERSON
, O
however O
, O
the O
incidence O
of O
these O
disorders O
is O
considerably O
less O
frequent O
than O
in O
men B_PERSON
of O
appropriate O
age O
. O

After O
the O
menopause O
the O
prevalence O
of O
metabolic O
syndrome O
and O
cardiovascular O
mortality O
in O
women B_PERSON/B_BIO
gradually O
increases O
, O
attaining O
values O
comparable O
to O
men B_PERSON/B_MEASURE
at O
about O
the O
age O
of O
70 O
[ O
2 O
, O
26 O
] O
. O

Paradoxically O
, O
it O
takes O
place O
at O
the O
time O
when O
serum O
leptin O
concentration O
in O
women B_PERSON/B_BIO
has O
relatively O
decreased O
[ O
27 O
, O
28 O
] O
. O

The O
aim O
of O
this O
study O
was O
to O
analyze O
the O
interrelations O
between O
several O
metabolic O
variables O
and O
factors O
related O
to O
insulin O
resistance O
in O
groups O
of O
both O
normal O
and O
hyperlipemic O
postmenopausal O
women B_PERSON
and O
men B_PERSON
of O
appropriate O
age O
, O
and O
to O
attempt O
to O
elucidate O
the O
gender O
differences O
and O
some O
pathophysiologic O
mechanisms O
of O
these O
differences O
. O

We O
compared O
homeostatic B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indexes B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
insulin B_GENE/B_DISEASE
resistance B_GENE/I_DISEASE
HOMA B_GENE/I_DISEASE
IR B_GENE/I_DISEASE
and O
QUICKI B_LOCATION/B_ORGANIZATION
, O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lipid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
uric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
leptin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
groups B_ORGANIZATION/B_PERSON
of O
subjects B_PERSON/B_BIO
without O
apparent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
metabolic B_DISEASE/B_LOCATION
syndrome I_DISEASE/I_LOCATION
, O
and O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
hypertriglyceridemia B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
decreased O
HDL B_GENE
- O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition B_MEASURE/B_LOCATION
, O
serum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
heart B_MEASURE/B_LOCATION
fraction B_MEASURE/I_LOCATION
of O
fatty B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
hFATP B_GENE/B_DISEASE
) O
was O
explored O
as O
a O
factor B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
might O
reflect O
the O
regulative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PPAR B_GENE
gamma I_GENE
in O
lipid B_DISEASE
homeostasis I_DISEASE
[ O
29 B_MEASURE
, O
30 B_MEASURE
] I_MEASURE
, O
and O
serum O
IgG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anticardiolipin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ACL B_DISEASE/B_LOCATION
- O
IgG B_PROTEIN[GENE]/B_LOCATION
) O
was O
investigated O
as O
an O
indirect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicator I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
oxidized B_DISEASE_ADJECTIVE[DISEASE]
lipid I_DISEASE_ADJECTIVE[DISEASE]
fractions I_DISEASE_ADJECTIVE[DISEASE]
related O
to O
atherosclerotic B_DISEASE
complications I_DISEASE
[ O
31 B_MEASURE
, O
32 B_MEASURE
] I_MEASURE
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

subjects B_PERSON
. O

The O
study O
was O
carried O
out O
on O
70 O
out O
- O
patients B_PERSON/B_LOCATION
of O
the O
metabolic O
Center O
at O
the O
hospital O
in O
Sternberk O
, O
Czech O
Republic O
. O

From O
these O
, O
40 O
patients B_PERSON
( O
20 O
men B_PERSON
and O
20 O
women B_PERSON/B_BIO
) O
were O
selected O
with O
mild O
hyperlipidemia O
, O
i O
. O
e O
. O
with O
plasma O
triglyceride O
concentration O
exceeding O
2 O
. O
0 O
mmol O
/ O
l O
, O
total O
cholesterol O
exceeding O
6 O
. O
0 O
mmol O
/ O
l O
, O
LDL O
cholesterol O
exceeding O
4 O
. O
0 O
mmol O
/ O
l O
, O
and O
with O
HDL O
cholesterol O
concentration O
in O
men B_PERSON/B_BIO
under O
1 O
. O
0 O
mmol O
/ O
l O
, O
and O
in O
women B_PERSON/B_BIO
under O
1 O
. O
2 O
mmol O
/ O
l O
. O

These O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O
denominated O
as O
' O
hyperlipemic B_PERSON/B_ORGANIZATION
' O
. O

Two O
other O
groups O
( O
10 O
men B_PERSON
and O
20 O
women B_PERSON/B_BIO
) O
with O
approximately O
normal O
serum O
values O
of O
these O
variables O
were O
taken O
as O
' O
controls O
' O
. O

The O
average O
age O
in O
men B_PERSON/B_LOCATION
was O
59 O
. O
1 O
+/- O
10 O
. O
6 O
y O
, O
and O
in O
women B_PERSON/B_BIO
59 O
. O
4 O
+/- O
10 O
. O
1 O
y O
, O
respectively O
. O

The O
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
lipid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
hyperlipemic B_DISEASE/B_PERSON
and O
control B_DISEASE/B_MEASURE
groups I_DISEASE/I_MEASURE
were O
highly O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
while O
the O
age B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
insignificant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

None O
of O
the O
patients B_PERSON/B_DISEASE
had O
clinically O
apparent O
diabetes O
mellitus O
, O
but O
some O
of O
the O
hyperlipemic O
patients B_PERSON/B_BIO
exerted O
impaired O
glucose O
tolerance O
or O
impaired O
fasting O
glucose O
( O
values O
between O
6 O
. O
1 O
and O
7 O
. O
0 O
mmol O
/ O
l O
, O
or O
between O
6 O
. O
1 O
and O
7 O
. O
8 O
mmol O
/ O
l O
, O
respectively O
) O
. O

None O
of O
the O
patients B_PERSON/B_DISEASE
was O
treated O
with O
insulin O
, O
peroral O
antidiabetics O
or O
antihyperlipemic O
drugs O
; O
some O
of O
them O
were O
treated O
with O
antihypertensive O
therapy O
. O

No O
signs O
of O
major O
clinical O
or O
laboratory O
symptoms O
of O
other O
diseases O
were O
present O
in O
any O
group O
of O
the O
explored O
patients B_PERSON/B_LOCATION
. O

Blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
obtained O
in O
the O
morning B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
via O
a O
venipuncture B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
after O
overnight B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasting I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

After O
clotting O
the O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
separated O
and O
stored O
at O
- O
20 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
until O
used O
. O

An O
informed B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
consent I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O
obtained O
from O
all O
probands B_PERSON
. O

Body B_MEASURE/B_LOCATION
mass I_MEASURE/I_LOCATION
indexes I_MEASURE/I_LOCATION
( O
BMI B_MEASURE/B_ORGANIZATION
) O
, O
defined O
as O
weight B_MEASURE/B_PERSON
in O
kilograms B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
divided O
by O
the O
square B_MEASURE/B_LOCATION
of O
height B_MEASURE/B_LOCATION
in O
meters B_MEASURE/B_PERSON
, O
were O
calculated O
. O

Biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

serum O
leptin O
concentrations O
were O
measured O
by O
a O
sandwich O
ELISA O
test O
kit O
( O
Human B_PERSON/B_SPECIES[BIO]
Leptin O
ELISA O
, O
BioVendor O
Laboratory O
Medicine O
, O
Inc O
, O
Czech O
Republic O
) O
. O

Its O
sensitivity B_MEASURE/B_ENT
limit I_MEASURE/I_ENT
was O
0 B_MEASURE
. O
2 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
, O
intraassay B_MEASURE
CV I_MEASURE
6 I_MEASURE
. O
1 B_MEASURE
% I_MEASURE
at O
the O
level B_MEASURE/B_LOCATION
of O
7 B_MEASURE
. O
5 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
m B_OTHER/B_MEASURE
, O
inter B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
assay B_MEASURE
CV I_MEASURE
8 I_MEASURE
. O
5 B_MEASURE
% I_MEASURE
at O
the O
level B_MEASURE/B_LOCATION
of O
4 B_MEASURE
. O
8 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
. O

Tetramethylbenzidine O
was O
used O
as O
a O
substrate O
; O
quality O
controls O
were O
human B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
. O

Several B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
were O
estimated O
by O
routine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immunochemical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tests I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
C B_GENE/B_LOCATION
- O
peptide B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
IMMULITE B_LOCATION/B_ORGANIZATION
, O
diagnostic B_LOCATION/B_ORGANIZATION
Products I_LOCATION/I_ORGANIZATION
Corporation I_LOCATION/I_ORGANIZATION
, O
Los B_LOCATION/B_PERSON
Angeles I_LOCATION/I_PERSON
, O
CA B_LOCATION
, O
U B_OTHER/B_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
) O
, O
proinsulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
intact I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
DAKO B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Denmark B_LOCATION
) O
, O
IgG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anticardiolipin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ACL B_LOCATION
- O
IgG B_GENE/B_MEASURE
, O
IMMCO B_LOCATION/B_ORGANIZATION
Diagnostics B_LOCATION/I_ORGANIZATION
, O
Buffalo B_LOCATION
, O
NY B_LOCATION
, O
U B_OTHER/B_LOCATION
. O
S B_OTHER/B_LOCATION
. O
A B_OTHER/B_LOCATION
. O
) O
and O
heart B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fatty I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
hFABP B_LOCATION/B_GENE
, O
Hbt B_LOCATION
Human I_LOCATION
H I_LOCATION
- O
FABP B_GENE/B_MEASURE
, O
HyCult B_LOCATION
Biotechnology I_LOCATION
, O
Uden B_LOCATION
, O
the O
Netherlands B_LOCATION/B_PERSON
) O
. O

Serum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
glucose B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cholesterol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
triglycerides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
HDL B_GENE
- O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
LDL B_PROTEIN[GENE]
- O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Apoprotein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
uric B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
on O
a O
ILAB B_MEASURE/B_PROTEIN[GENE]
- O
600 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
biochemical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
analyzer I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O
instrumentation B_LOCATION
Laboratory I_LOCATION
, O
Lexington B_LOCATION/B_PERSON
, O
Ma B_LOCATION
, O
U B_OTHER/B_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
A B_OTHER/B_LOCATION
. O
) O
using O
BioVendor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sets I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
processed O
and O
examined O
according O
to O
principles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
good B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
laboratory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
practice I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
under O
constant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
intralaboratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
external B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quality I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
homeostatic B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indexes B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
insulin B_DISEASE
resistance I_DISEASE
( O
HOMA B_LOCATION/B_ORGANIZATION
IR I_LOCATION/I_ORGANIZATION
and O
QUICKI B_LOCATION/B_ORGANIZATION
) O
were O
calculated O
according O
to O
the O
homeostasis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O
33 B_MEASURE
- O
35 B_MEASURE
] O
as O
follows O
: O

HOMA B_PROTEIN[GENE]/B_DISEASE
IR I_PROTEIN[GENE]/I_DISEASE
= O
fasting O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
mu B_MEASURE/B_GENE
U I_MEASURE/I_GENE
/ O
ml B_MEASURE/B_PERSON
) O
* O
fasting B_MEASURE/B_LOCATION
glucose I_MEASURE/I_LOCATION
( O
mmol B_MEASURE/B_LOCATION
/ O
l B_MEASURE/B_DISEASE
) O
/ O
22 B_MEASURE
. O
5 B_MEASURE
; O

QUICKI B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
1 B_MEASURE
/ O
[ B_MEASURE/B_LOCATION
log I_MEASURE/I_LOCATION
fasting I_MEASURE/I_LOCATION
insulin I_MEASURE/I_LOCATION
( O
Mu B_MEASURE/B_PERSON
U I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
) O
+ B_MEASURE
log I_MEASURE
fasting I_MEASURE
glucose I_MEASURE
( O
mg B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
100 B_MEASURE
ml I_MEASURE
) O
] O
. O

Statistics B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
using O
the O
Version B_LOCATION/B_ORGANIZATION
6 I_LOCATION/I_ORGANIZATION
SAS I_LOCATION/I_ORGANIZATION
/ O
STAT B_NUMBER[MEASURE]/B_PERSON
software I_NUMBER[MEASURE]/I_PERSON
( O
SAS B_ORGANIZATION/B_LOCATION
Institute I_ORGANIZATION/I_LOCATION
, O
Inc B_ORGANIZATION/B_LOCATION
. O
, O
Cary B_PERSON/B_LOCATION
, O
NC B_LOCATION
, O
U B_OTHER/B_LOCATION
. O
S B_PROTEIN[GENE]/B_DISEASE
. O
A B_OTHER/B_LOCATION
. O
) O
. O

The O
Shapiro B_PERSON
- O
Wilks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
used O
in O
testing O
the O
normality B_MEASURE
of O
distribution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Some O
of O
the O
data B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
were O
not O
normally O
distributed O
. O

The O
statistical B_MEASURE
significance I_MEASURE
of O
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
the O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
hyperlipemic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
control B_DISEASE/B_MEASURE
groups I_DISEASE/I_MEASURE
were O
evaluated O
using O
the O
unpaired B_LOCATION/B_MEASURE
Student I_LOCATION/I_MEASURE
' I_LOCATION/I_MEASURE
s I_LOCATION/I_MEASURE
T I_LOCATION/I_MEASURE
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
normal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sets I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
using O
the O
Kolmogorov B_PERSON/B_COLOR
- O
Smirnov B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
when O
at O
least O
in O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sets I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
the O
normal B_MEASURE/B_PERSON
distribution I_MEASURE/I_PERSON
was O
excluded O
. O

Spearman B_PERSON
' O
s O
rank B_PERSON/B_SEQUENCE[MEASURE]
- O
order B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
for O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
performed O
using O
HOMA B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IR B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indexes B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
insulin B_DISEASE/B_GENE
resistance I_DISEASE/I_GENE
as O
dependent B_MEASURE
variables I_MEASURE
, O
and O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hormonal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
lipid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
BMI B_MEASURE/B_GENE
, O
leptin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
hFABP B_GENE
, O
ACL B_DISEASE/B_GENE
- O
IgG B_PROTEIN[GENE]/B_MEASURE
) O
as O
independent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
so O
- O
called O
step B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
down O
regression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
used O
to O
select O
dominant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
independent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Various B_NUMBER[MEASURE]/B_ENT
four I_NUMBER[MEASURE]/I_ENT
- O
member B_PERSON/B_MEASURE
groups I_PERSON/I_MEASURE
of O
independent B_NUMBER[MEASURE]
( O
explanatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
variables B_MEASURE/B_PERSON
were O
used O
for O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
the O
non B_MEASURE/B_LOCATION
- O
zero B_MEASURE
intercept I_MEASURE
was O
taken O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
then O
dropped O
, O
one B_NUMBER[MEASURE]/B_LOCATION
at O
a O
time B_MEASURE/B_LOCATION
; O
at O
each O
stage B_MEASURE/B_LOCATION
one I_MEASURE/I_LOCATION
variable I_MEASURE/I_LOCATION
making O
the O
least B_MEASURE/B_PERSON
contribution I_MEASURE/I_PERSON
to O
the O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
i O
. O
e B_DISEASE/B_PROTEIN[GENE]
. O
that O
showed O
the O
least B_MEASURE/B_LOCATION
p I_MEASURE/I_LOCATION
- O
value B_MEASURE
in O
the O
test B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
regression B_MEASURE
coefficient I_MEASURE
being O
zero B_MEASURE
) O
was O
excluded O
. O

The O
coefficient B_MEASURE
of O
determination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
R2 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
which O
can O
be O
viewed O
as O
a O
percentage B_MEASURE
explaining O
the O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variance B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
simultaneously O
monitored O
. O

A O
great B_MEASURE
drop I_MEASURE
in O
R2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O
excluding O
some O
independent B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variable I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enabled O
selection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
those O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
could O
be O
thought O
to O
be O
the O
most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
determinants I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
dependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrates O
mean B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
subjects B_PERSON/B_BIO
matched O
according O
to O
sex B_PERSON/B_DISEASE
, O
lipid B_MEASURE/B_PERSON
parameters I_MEASURE/I_PERSON
and O
age B_MEASURE/B_DISEASE
. O

While O
the O
age B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
all O
four B_PERSON/B_BIO
groups I_PERSON/I_BIO
did O
not O
differ O
substantially O
, O
the O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
triglycerides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
HDL B_PROTEIN[GENE]
- O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
LDL B_PROTEIN[GENE]
- O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differ O
very O
significantly O
in O
both O
male B_PERSON
and O
female B_PERSON/B_BIO
hyperlipemic I_PERSON/I_BIO
groups I_PERSON/I_BIO
as O
compared O
with O
controls B_PERSON
. O

In O
addition O
, O
the O
concentration O
of O
triglycerides O
in O
control O
women B_PERSON
was O
significantly O
higher O
than O
in O
control O
men B_PERSON
, O
the O
concentration O
of O
triglycerides O
in O
hyperlipemic O
women B_PERSON
was O
lower O
than O
in O
hyperlipemic O
men B_PERSON
, O
and O
the O
concentration O
of O
HDL O
- O
cholesterol O
in O
hyperlipemic O
women B_PERSON
was O
very O
significantly O
higher O
when O
compared O
with O
hyperlipemic O
men B_PERSON
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O
the O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
other B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolic B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
parameters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
factors B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O
to O
insulin B_DISEASE/B_ORGANISM_FUNCTION
resistance I_DISEASE/I_ORGANISM_FUNCTION
and O
indexes B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
insulin B_DISEASE/B_GENE
resistance I_DISEASE/I_GENE
, O
respectively O
. O

Body O
mass O
indexes O
and O
uric O
acid O
concentration O
were O
significantly O
higher O
in O
hyperlipemic O
men B_PERSON
as O
compared O
to O
controls O
, O
but O
not O
in O
hyperlipemic O
women B_PERSON
. O

Uric O
acid O
concentration O
was O
substantially O
lower O
in O
hyperlipemic O
women B_PERSON/B_BIO
than O
in O
hyperlipemic O
men B_PERSON
. O

plasma O
concentrations O
of O
glycemia O
, O
insulin O
and O
intact O
proinsulin O
were O
significantly O
higher O
in O
both O
hyperlipemic O
men B_PERSON
and O
women B_PERSON/B_BIO
as O
compared O
with O
controls O
of O
identical O
gender O
, O
while O
the O
concentration O
of O
leptin O
increased O
only O
in O
hyperlipemic O
men B_PERSON/B_BIO
. O

However O
, O
serum O
leptin O
concentrations O
of O
both O
control O
and O
hyperlipemic O
women B_PERSON/B_BIO
were O
significantly O
higher O
than O
in O
corresponding O
groups O
of O
men B_PERSON
. O

serum O
concentrations O
of O
TNF O
alpha O
, O
hFABP O
and O
ACL O
- O
IgG O
in O
hyperlipemic O
groups O
of O
both O
men B_PERSON
and O
women B_PERSON/B_BIO
were O
not O
significantly O
different O
from O
control O
groups O
. O

On O
the O
other O
hand O
, O
the O
indexes O
of O
insulin O
resistance O
HOMA O
IR O
and O
QUICKI O
differed O
very O
significantly O
in O
hyperlipemic O
groups O
of O
both O
men B_PERSON/B_BIO
and O
women B_PERSON/B_BIO
as O
compared O
with O
corresponding O
control O
groups O
, O
more O
distinctly O
in O
women B_PERSON/B_BIO
. O

From O
Fig B_LOCATION
. O

1 O
, O
presenting O
95 O
% O
confidence O
limits O
of O
insulin O
resistance O
indexes O
HOMA O
IR O
and O
QUICKI O
, O
we O
concluded O
that O
in O
groups O
of O
hyperlipemic O
patients B_PERSON/B_BIO
of O
both O
genders O
the O
insulin O
resistance O
was O
substantially O
higher O
than O
in O
control O
groups O
; O
the O
groups O
did O
not O
overlap O
each O
other O
. O

In O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Spearman B_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
insulin B_MEASURE/B_DISEASE
resistance I_MEASURE/I_DISEASE
index I_MEASURE/I_DISEASE
HOMA I_MEASURE/I_DISEASE
IR I_MEASURE/I_DISEASE
and O
various B_DISEASE/B_GENE
metabolic B_DISEASE/I_GENE
parameters B_DISEASE/I_GENE
are O
presented O
. O

In O
the O
control O
group O
of O
men B_PERSON/B_BIO
, O
positive O
significant O
correlation O
between O
HOMA O
IR O
and O
serum O
leptin O
concentration O
, O
and O
inverse O
significant O
correlation O
between O
HOMA O
IR O
and O
ACL O
IgG O
, O
respectively O
, O
were O
found O
. O

In O
the O
control O
group O
of O
women B_PERSON/B_BIO
, O
the O
significance O
of O
Spearman O
' O
s O
correlation O
between O
HOMA O
IR O
and O
leptin O
was O
more O
expressive O
; O
inverse O
correlation O
between O
HOMA O
IR O
and O
HDL O
- O
cholesterol O
was O
also O
present O
. O

In O
the O
hyperlipemic O
group O
of O
men B_PERSON/B_BIO
, O
the O
significance O
of O
the O
correlation O
between O
HOMA O
IR O
was O
more O
expressive O
in O
relation O
to O
the O
control O
group O
, O
and O
no O
significant O
correlation O
between O
HOMA O
IR O
and O
ACL O
IgG O
was O
found O
. O

In O
the O
hyperlipemic O
group O
of O
women B_PERSON/B_BIO
, O
however O
, O
the O
significance O
of O
Spearman O
' O
s O
correlation O
between O
HOMA O
IR O
and O
serum O
leptin O
concentration O
weakened O
, O
the O
inverse O
correlation O
between O
HOMA O
IR O
and O
HDL O
- O
cholesterol O
remained O
approximately O
unchanged O
, O
and O
a O
positive O
correlation O
between O
HOMA O
IR O
and O
serum O
concentration O
of O
TNF O
alpha O
appeared O
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
when O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
both O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
hyperlipemic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
groups I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O
each O
gender B_PERSON/B_MEASURE
were O
judged O
together O
. O

HOMA B_DISEASE/B_MEASURE
IR I_DISEASE/I_MEASURE
was O
considered O
as O
a O
dependent B_MEASURE
variable I_MEASURE
and O
differently O
changed O
constellations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
metabolic B_DISEASE
and O
other B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
taken O
as O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
men B_PERSON/B_MEASURE
, O
BMI O
and O
leptin O
seemed O
to O
play O
a O
main O
role O
in O
influencing O
the O
insulin O
resistance O
index O
HOMA O
IR O
, O
while O
TGL O
, O
ACL O
IgG O
and O
LDL O
- O
cholesterol O
didn O
' O
t O
play O
any O
significant O
role O
( O
see O
left O
columns O
of O
Table O
4 O
) O
. O

The O
decreasing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
HDL B_GENE
- O
cholesterol B_MEASURE
concentration I_MEASURE
may O
also O
have O
some O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
see O
a O
significant B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drop B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
R2 B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
exclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
this O
factor B_MEASURE
in O
Table B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4A I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
4B B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

But O
in O
the O
presence B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
leptin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
group B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
independent B_PERSON/B_MEASURE
factors I_PERSON/I_MEASURE
, O
the O
drop B_MEASURE/B_DISEASE
of O
R2 B_GENE
after O
exclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HDL B_GENE
- O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
from O
these O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O
minimal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
4C I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

On O
the O
other B_PERSON/B_LOCATION
hand B_PERSON/I_LOCATION
, O
after O
the O
exclusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
from O
the O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
independent B_PERSON/B_BIO
variables I_PERSON/I_BIO
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
4D B_TIME[MEASURE]/B_LOCATION
) O
the O
value B_MEASURE
of O
R2 B_PROTEIN[GENE]/B_DISEASE
has O
unexpectedly O
risen O
, O
which O
could O
reflect O
the O
interference B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increasing O
the O
insulin B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
women B_PERSON/B_MEASURE
( O
see O
right O
columns O
of O
Table O
4 O
) O
, O
the O
maximal O
values O
of O
R2 O
were O
achieved O
with O
combination O
of O
independent O
variables O
containing O
TGL O
, O
leptin O
and O
HDL O
- O
cholesterol O
( O
about O
60 O
% O
influence O
on O
HOMA O
IR O
! O
- O
see O
Table O
4A O
, O
4B O
, O
4C O
) O
. O

TNF O
alpha O
seemed O
to O
play O
quite O
a O
different O
role O
than O
in O
men B_PERSON/B_BIO
: O
after O
exclusion O
of O
this O
factor O
from O
the O
group O
of O
independent O
factors O
R2significantly O
decreased O
( O
see O
Table O
4B O
, O
4D O
) O
. O

In O
contrast O
to O
men B_PERSON/B_ORGANIZATION
, O
the O
role O
of O
BMI O
seemed O
to O
be O
minimal O
. O

As O
in O
men B_PERSON/B_BIO
, O
the O
role O
of O
ACL O
IgG O
and O
LDL O
- O
cholesterol O
in O
influencing O
HOMA O
IR O
was O
negligible O
, O
but O
in O
contrast O
to O
men B_PERSON/B_BIO
, O
hFABP O
might O
play O
a O
certain O
role O
in O
this O
process O
( O
see O
Table O
4D O
) O
. O

Generally O
, O
the O
insulin O
resistance O
( O
represented O
by O
HOMA O
IR O
) O
was O
in O
men B_PERSON/B_BIO
much O
less O
influenced O
by O
metabolic O
variables O
than O
in O
women B_PERSON/B_BIO
; O
while O
in O
women B_PERSON/B_BIO
in O
some O
combinations O
of O
dependent O
variables O
R2 O
reached O
64 O
% O
, O
in O
men B_PERSON/B_BIO
the O
maximal O
value O
of O
R2 O
was O
only O
39 O
% O
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
our O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
paper I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O
36 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
mean B_MEASURE
value I_MEASURE
of O
HOMA B_DISEASE
IR I_DISEASE
in O
healthy B_PERSON/B_LOCATION
subjects I_PERSON/I_LOCATION
of O
both O
genders B_PERSON/B_MEASURE
and O
of O
age B_PERSON/B_MEASURE
comparable I_PERSON/I_MEASURE
with O
our O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
1 B_MEASURE
. O
57 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
. O
87 B_MEASURE
, O
and O
the O
mean B_MEASURE/B_LOCATION
value I_MEASURE/I_LOCATION
of O
index B_MEASURE
QUICKI I_MEASURE
0 I_MEASURE
. O
366 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
. O
029 B_MEASURE
, O
respectively O
. O

These O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
as O
well O
as O
the O
95 B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confidence B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
limits B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
correspond O
to O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
found O
in O
controls B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
accordance O
with O
many O
previous O
papers O
, O
serum O
concentrations O
of O
leptin O
in O
women B_PERSON/B_BIO
( O
both O
control O
and O
hyperlipemic O
) O
were O
substantially O
higher O
than O
in O
men B_PERSON/B_BIO
. O

In O
the O
control O
group O
of O
women B_PERSON/B_BIO
the O
correlation O
between O
leptin O
and O
HOMA O
IR O
was O
highly O
significant O
. O

However O
, O
in O
hyperlipemic O
women B_PERSON/B_DISEASE
the O
significance O
of O
this O
correlation O
lessened O
, O
because O
HOMA O
IR O
increased O
considerably O
( O
and O
significantly O
) O
but O
serum O
concentration O
of O
leptin O
only O
slightly O
( O
insignificantly O
) O
. O

In O
men B_PERSON/B_MEASURE
the O
significance O
of O
correlations O
between O
serum O
leptin O
and O
HOMA O
IR O
was O
high O
and O
approximately O
the O
same O
in O
both O
the O
control O
and O
hyperlipemic O
groups O
, O
because O
the O
values O
of O
HOMA O
IR O
as O
well O
as O
serum O
leptin O
have O
nearly O
doubled O
in O
hyperlipemic O
in O
relation O
to O
control O
groups O
. O

In O
non O
- O
hyperlipemic O
postmenopausal O
women B_PERSON
the O
high O
concentration O
of O
serum O
leptin O
was O
not O
associated O
with O
higher O
insulin O
resistance O
: O
HOMA O
IR O
did O
not O
differ O
substantially O
from O
men B_PERSON/B_DISEASE
. O

A O
significant O
increase O
of O
insulin O
resistance O
in O
hyperlipemic O
women B_PERSON/B_BIO
was O
associated O
by O
only O
slight O
and O
insignificant O
increase O
of O
leptin O
concentration O
. O

According O
to O
Spearman B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
correlations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
serum B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
TNF I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HDL B_GENE
- O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
might O
also O
play O
a O
distinct B_PERSON/B_MEASURE
role I_PERSON/I_MEASURE
in O
this O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
see O
Table B_LOCATION/B_ENT
3 I_LOCATION/I_ENT
) O
. O

In O
contrast O
to O
women B_PERSON/B_DISEASE
, O
in O
hyperlipemic O
men B_PERSON/B_DISEASE
the O
increase O
of O
insulin O
resistance O
index O
was O
approximately O
proportional O
with O
the O
increase O
of O
leptin O
concentration O
. O

Multiple B_PERSON/B_EDU[ORGANIZATION]
regression I_PERSON/I_EDU[ORGANIZATION]
analysis I_PERSON/I_EDU[ORGANIZATION]
affirmed O
the O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
leptin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
increasing O
of O
insulin B_DISEASE/B_GENE
resistance I_DISEASE/I_GENE
in O
both O
genders B_PERSON/B_MEASURE
. O

In O
men B_PERSON/B_MEASURE
, O
only O
BMI O
and O
HDL O
- O
cholesterol O
from O
other O
factors O
studied O
seemed O
to O
play O
a O
certain O
role O
, O
but O
the O
maximal O
values O
of O
influencing O
HOMA O
IR O
reached O
only O
39 O
% O
, O
with O
leptin O
and O
BMI O
being O
the O
more O
important O
factors O
. O

On O
the O
other O
hand O
, O
in O
women B_PERSON/B_MEASURE
the O
maximal O
determination O
of O
HOMA O
IR O
as O
high O
as O
60 O
% O
was O
registered O
in O
combination O
of O
serum O
leptin O
, O
TGL O
and O
decreased O
HDL O
- O
cholesterol O
as O
independent O
factors O
; O
the O
role O
of O
BMI O
was O
insignificant O
. O

It O
is O
not O
known O
how O
leptin B_GENE/B_BIO
is O
regulated O
. O

A O
strong O
correlation O
between O
plasma O
leptin O
and O
fasting O
insulin O
undoubtedly O
exists O
, O
but O
hyperleptinemia O
in O
both O
obese O
and O
lean O
humans B_PERSON/B_BIO
is O
not O
likely O
the O
result O
of O
hyperinsulinemia O
[ O
37 O
] O
. O

A O
relationship B_PERSON/B_MEASURE
between O
leptin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
insulin B_DISEASE_ADJECTIVE[DISEASE]
dependent I_DISEASE_ADJECTIVE[DISEASE]
on O
sex B_PERSON
or O
BMI B_MEASURE/B_DISEASE
was O
reported O
, O
but O
relationship B_PERSON/B_MEASURE
between O
triglyceride B_GENE
concentrations I_GENE
and O
leptin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
independent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
sex B_PERSON
, O
BMI B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
insulin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
18 B_MEASURE
, O
24 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Hyperleptinemia B_DISEASE
, O
as O
an O
early B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sign B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
obesity B_DISEASE
, O
was O
closely O
linked O
to O
subcutaneous B_DISEASE
fat I_DISEASE
mass I_DISEASE
[ O
39 B_MEASURE
, O
40 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

percentage O
of O
body O
fat O
has O
been O
shown O
to O
be O
the O
strongest O
predictor O
of O
leptin O
levels O
even O
in O
lean O
women B_PERSON/B_BIO
[ O
41 O
] O
. O

Leptin O
was O
highly O
correlated O
with O
percentage O
of O
body O
fat O
and O
with O
fat O
mass O
in O
adults O
irrespective O
of O
gender O
and O
age O
; O
however O
, O
the O
mean O
determinant O
of O
leptin O
plasma O
concentration O
in O
men B_PERSON
and O
postmenopausal O
women B_PERSON
was O
BMI O
, O
while O
in O
premenopausal O
women B_PERSON
it O
was O
only O
the O
fat O
mass O
[ O
42 O
] O
. O

These O
findings O
contrast O
with O
our O
results O
showing O
minimal O
influence O
of O
BMI O
on O
HOMA O
IR O
in O
postmenopausal O
women B_PERSON
. O

All O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
mentioned O
are O
connected O
with O
fat B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
: O
leptin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
directly O
produced O
chiefly O
by O
adipocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O
BMI B_DISEASE/B_GENE
growth I_DISEASE/I_GENE
is O
obviously O
accompanied O
by O
fat B_DISEASE/B_GENE
mass I_DISEASE/I_GENE
increase I_DISEASE/I_GENE
, O
and O
the O
typical B_DISEASE/B_MEASURE
hypertriglyceridemia I_DISEASE/I_MEASURE
associated O
with O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
HDL B_GENE
- O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
goes O
along O
with O
obesity B_DISEASE/B_GENE
and O
fat B_DISEASE
mass I_DISEASE
growth I_DISEASE
. O

The O
gender B_DISEASE_ADJECTIVE[DISEASE]
differences I_DISEASE_ADJECTIVE[DISEASE]
in O
circulating O
leptin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
best O
explained O
by O
percentage B_MEASURE
of O
body B_DISEASE/B_MEASURE
fat I_DISEASE/I_MEASURE
and O
- O
inversely O
- O
by O
lean B_MEASURE/B_PERSON
body I_MEASURE/I_PERSON
mass I_MEASURE/I_PERSON
[ O
25 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
both O
genders B_PERSON/B_MEASURE
the O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
abdominal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fat I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
correlated O
with O
insulin B_DISEASE/B_GENE
resistance B_DISEASE/I_GENE
, O
while O
the O
subcutaneous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
fat I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
correlated O
with O
circulating O
leptin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
12 B_MEASURE
] I_MEASURE
. O

In O
men B_PERSON/B_BIO
obesity O
led O
to O
a O
prevalent O
increase O
of O
intra O
- O
abdominal O
fat O
, O
while O
in O
women B_PERSON
of O
subcutaneous O
fat O
[ O
13 O
] O
. O

influences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compartments B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adipose B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissues I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
could O
elucidate O
the O
variability B_MEASURE/B_LOCATION
of O
correlations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
insulin B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resistance I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
high B_DISEASE
leptin I_DISEASE
concentrations I_DISEASE
in O
lean B_DISEASE/B_PERSON
and O
obese B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
subjects I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
of O
both O
genders B_PERSON/B_MEASURE
[ O
43 B_MEASURE/B_PERSON
] B_MEASURE/I_PERSON
. O

In O
our O
non O
- O
hyperlipemic O
postmenopausal O
women B_PERSON
the O
content O
of O
subcutaneous O
fat O
mass O
might O
be O
higher O
than O
in O
non O
- O
hyperlipemic O
men B_PERSON
of O
appropriate O
age O
, O
which O
indicated O
a O
higher O
serum O
concentration O
of O
leptin O
. O

However O
, O
the O
insulin O
resistance O
- O
related O
to O
intra O
- O
abdominal O
fat O
mass O
- O
did O
not O
differ O
from O
men B_PERSON/B_DISEASE
. O

The O
significant O
increase O
of O
insulin O
resistance O
and O
leptin O
concentration O
in O
hyperlipemic O
men B_PERSON/B_BIO
might O
reflect O
the O
growing O
content O
of O
both O
subcutaneous O
and O
intra O
- O
abdominal O
fat O
mass O
( O
see O
the O
significant O
increase O
of O
BMI O
) O
. O

In O
hyperlipemic O
women B_PERSON/B_DISEASE
the O
significant O
increase O
of O
insulin O
resistance O
accompanying O
only O
minimal O
insignificant O
increase O
of O
leptin O
could O
be O
caused O
by O
prevalent O
growing O
of O
intra O
- O
abdominal O
fat O
mass O
. O

In O
elderly O
postmenopausal O
women B_PERSON/B_BIO
, O
an O
association O
between O
leptin O
and O
plasma O
lipoprotein O
concentration O
was O
found O
which O
depended O
on O
adiposity O
[ O
17 O
] O
, O
and O
inverse O
correlations O
between O
serum O
leptin O
and O
HDL O
- O
cholesterol O
were O
described O
[ O
44 O
] O
. O

In O
our O
study O
, O
insulin O
resistance O
in O
women B_PERSON/B_BIO
seemed O
to O
be O
more O
notably O
than O
in O
men B_PERSON/B_LOCATION
influenced O
by O
lipid O
disorders O
, O
i O
. O
e O
. O
positively O
by O
serum O
triglycerides O
and O
inversely O
by O
HDL O
- O
cholesterol O
. O

These O
findings O
might O
be O
important O
in O
considering O
the O
concept O
of O
treatment O
of O
insulin O
resistance O
- O
related O
disorders O
in O
postmenopausal O
women B_PERSON
. O

The O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
insulin B_DISEASE/B_GENE
resistance I_DISEASE/I_GENE
, O
caused O
by O
inhibiting O
the O
transduction B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
insulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
by O
down B_LOCATION/B_DISEASE
- O
regulation B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
glucose B_GENE
transporter I_GENE
GLUT I_GENE
- O
4 B_NUMBER[MEASURE]
and O
insulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
substrate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
1 B_TIME[MEASURE]
, O
has O
been O
repeatedly O
confirmed O
[ B_MEASURE/B_LOCATION
45 I_MEASURE/I_LOCATION
- O
48 B_MEASURE
] I_MEASURE
. O

Our O
results O
supported O
these O
findings O
unambiguously O
only O
in O
women B_PERSON/B_BIO
, O
while O
in O
men B_PERSON/B_BIO
TNF O
alpha O
seemed O
paradoxically O
to O
interfere O
with O
other O
factors O
- O
mainly O
BMI O
and O
leptin O
- O
in O
influencing O
insulin O
resistance O
, O
thus O
playing O
a O
quite O
different O
role O
. O

Previously O
it O
was O
found O
[ O
46 O
] O
that O
correlation O
between O
serum O
TNF O
alpha O
on O
the O
one O
side O
, O
and O
insulin O
, O
HOMA O
IR O
, O
serum O
triglycerids O
, O
respectively O
, O
on O
the O
other O
side O
, O
was O
substantially O
more O
significant O
in O
women B_PERSON/B_BIO
than O
in O
men B_PERSON
. O

serum O
concentration O
of O
TNF O
alpha O
in O
patients B_PERSON/B_BIO
with O
type O
2 O
diabetes O
of O
both O
genders O
correlated O
only O
with O
the O
quantity O
of O
intra O
- O
abdominal O
fat O
compartment O
[ O
50 O
] O
. O

Visceral O
obesity O
correlated O
with O
plasmatic O
aldosterone O
and O
with O
insulin O
resistance O
only O
in O
premenopausal O
women B_PERSON
, O
but O
not O
in O
men B_PERSON
[ O
51 O
] O
. O

From O
all O
these O
data O
we O
might O
support O
our O
above O
mentioned O
conclusion O
- O
that O
rising O
of O
insulin O
resistance O
in O
hyperlipemic O
women B_PERSON/B_BIO
was O
associated O
with O
an O
increase O
of O
intra O
- O
abdominal O
fat O
, O
because O
this O
fat O
mass O
in O
particular O
is O
a O
source O
of O
TNF O
alpha O
, O
which O
interfered O
with O
insulin O
sensitivity O
only O
in O
women B_PERSON/B_BIO
. O

We O
came O
to O
this O
conclusion O
irrespective O
of O
the O
finding O
that O
the O
increase O
of O
serum O
TNF O
alpha O
in O
hyperlipemic O
women B_PERSON/B_BIO
was O
statistically O
insignificant O
; O
results O
of O
Spearman O
' O
s O
correlation O
( O
Table O
3 O
) O
and O
multiple O
regression O
analysis O
confirm O
a O
distinct O
role O
of O
this O
factor O
. O

In O
hyperlipemic O
men B_PERSON/B_BIO
not O
only O
the O
serum O
concentration O
of O
TNF O
alpha O
has O
decreased O
instead O
of O
increasing O
, O
but O
according O
to O
multiple O
regression O
analysis O
it O
played O
a O
quite O
different O
role O
in O
influencing O
insulin O
sensitivity O
, O
interfering O
with O
factors O
that O
determined O
insulin O
resistance O
( O
leptin O
and O
BMI O
) O
. O

In O
the O
control O
group O
of O
men B_PERSON/B_BIO
IgG O
anticardiolipin O
was O
inversely O
correlated O
to O
HOMA O
IR O
. O

The O
significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
clear B_DISEASE_ADJECTIVE[DISEASE]
. O

These O
antibodies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
vascular B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
thrombotic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oxidative B_DISEASE_ADJECTIVE[DISEASE]
modification I_DISEASE_ADJECTIVE[DISEASE]
of O
lipoproteins B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
[ O
52 B_MEASURE
, O
53 B_MEASURE
] I_MEASURE
and O
may O
represent O
an O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
atherogenic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
inflammatory B_DISEASE
complications I_DISEASE
. O

In O
this O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
, O
their O
growing O
might O
be O
connected O
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
insulin B_DISEASE/B_MEASURE
sensitivity I_DISEASE/I_MEASURE
. O

Anyway O
, O
ACL B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
IgG I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
evidently O
did O
not O
participate O
significantly O
in O
influencing O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
insulin B_DISEASE/B_GENE
resistance B_DISEASE/I_GENE
associated O
with O
hyperlipidemia B_DISEASE
, O
although O
other B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
cardiolipin B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
masked O
by O
the O
relatively O
large B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inter I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
individual B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
parameter B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Neither O
serum B_MEASURE/B_LOCATION
concentration I_MEASURE/I_LOCATION
of O
hFABP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
factor B_MEASURE/B_PROTEIN[GENE]
ensuring O
transmembrane B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
transport I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
and O
oxidative B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
metabolisation I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
of O
long B_MEASURE
- O
chain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fatty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
54 B_MEASURE
, O
55 B_MEASURE
] I_MEASURE
, O
was O
significantly O
changed O
in O
hyperlipemic B_DISEASE/B_PERSON
and O
insulin B_DISEASE/B_PERSON
resistant I_DISEASE/I_PERSON
subjects I_DISEASE/I_PERSON
of O
both O
genders B_PERSON/B_MEASURE
. O

This O
factor O
was O
very O
weakly O
associated O
only O
with O
HOMA O
IR O
in O
women B_PERSON/B_BIO
( O
see O
Table O
4D O
) O
, O
indicating O
that O
enhanced O
metabolisation O
of O
fatty O
acids O
in O
cells O
might O
to O
some O
degree O
contribute O
to O
insulin O
resistance O
. O

Conclusions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
postmenopausal O
women B_PERSON/B_BIO
as O
well O
as O
in O
men B_PERSON
of O
approximately O
equal O
age O
serum O
leptin O
plays O
a O
significant O
role O
as O
an O
important O
determinant O
of O
insulin O
resistance O
. O

In O
addition O
to O
this O
factor O
, O
in O
women B_PERSON/B_BIO
the O
grade O
of O
insulin O
resistance O
is O
very O
considerably O
influenced O
by O
serum O
triglycerides O
, O
tumor O
necrosis O
factor O
alpha O
, O
and O
by O
decreased O
concentration O
of O
HDL O
- O
cholesterol O
, O
while O
in O
men B_PERSON/B_BIO
only O
a O
mild O
influence O
of O
BMI O
and O
decreased O
HDL O
- O
cholesterol O
is O
observed O
. O

These O
findings O
are O
explained O
as O
a O
consequence O
of O
gender O
- O
related O
differences O
in O
adipose O
tissue O
composition O
and O
/ O
or O
distribution O
in O
both O
normal O
- O
weight O
and O
over O
- O
weight O
subjects O
and O
should O
be O
taken O
into O
account O
in O
treatment O
of O
patients B_PERSON/B_BIO
with O
metabolic O
risk O
factors O
of O
cardiovascular O
diseases O
. O

list B_LOCATION/B_MEASURE
of O
abbreviations B_PERSON/B_ENT
. O

HDL B_GENE
- O
Cholesterol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
density B_MEASURE
cholesterol I_MEASURE
. O

LDL B_PROTEIN[GENE]/B_DISEASE
- O
cholesterol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
density B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

HOMA B_MEASURE/B_DISEASE
IR I_MEASURE/I_DISEASE
= O
homeostasis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Insulin B_DISEASE
Resistance I_DISEASE
. O

= O
fasting O
insulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Mu B_MEASURE/B_PERSON
U I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
) O
* O
fasting B_MEASURE
glucose I_MEASURE
( O
mmol B_MEASURE/B_LOCATION
/ O
l B_MEASURE/B_OTHER
) O
/ O
22 B_MEASURE
, O
5 B_MEASURE/B_LOCATION
. O

QUICKI B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
1 B_MEASURE
/ O
[ B_MEASURE/B_LOCATION
log I_MEASURE/I_LOCATION
fasting I_MEASURE/I_LOCATION
insulin I_MEASURE/I_LOCATION
( O
Mu B_MEASURE/B_PERSON
U I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
) O
+ B_MEASURE
log I_MEASURE
fasting I_MEASURE
glucose I_MEASURE
( O
mg B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
100 B_MEASURE
ml I_MEASURE
) O
] O
. O

TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
tumor B_MEASURE/B_LOCATION
necrosis I_MEASURE/I_LOCATION
factor I_MEASURE/I_LOCATION
alpha I_MEASURE/I_LOCATION
. O

BMI B_LOCATION/B_ORGANIZATION
= O
body B_MEASURE/B_LOCATION
mass B_MEASURE/I_LOCATION
index B_MEASURE/I_LOCATION
. O

R2 O
= O
coefficient B_MEASURE/B_LOCATION
of O
determination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

hFABP B_GENE/B_DISEASE
= O
heart B_MEASURE/B_LOCATION
fatty I_MEASURE/I_LOCATION
acid I_MEASURE/I_LOCATION
binding I_MEASURE/I_LOCATION
protein I_MEASURE/I_LOCATION
. O

ACL B_DISEASE/B_GENE
- O
IgG B_MEASURE/B_GENE
= O
IgG B_TIME[MEASURE]/B_PERSON
fraction I_TIME[MEASURE]/I_PERSON
of O
anticardiolipin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

TGL B_DISEASE/B_GENE
= O
triglycerides B_PERSON/B_LOCATION
. O

GLUT B_GENE
- O
4 B_NUMBER[MEASURE]/B_LOCATION
= O
glucose B_GENE
transporter I_GENE
- O
4 B_NUMBER[MEASURE]/B_BIO
. O

PPAR B_GENE/B_LOCATION
gamma I_GENE/I_LOCATION
= O
peroxisome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
Associated O
Receptor B_PROTEIN[GENE]/B_MEASURE
gamma I_PROTEIN[GENE]/I_MEASURE
. O

CV B_LOCATION/B_DISEASE
= O
coefficient B_MEASURE/B_LOCATION
of O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Dr B_PERSON
. O
Radka B_PERSON/B_LOCATION
Lichnovsk I_PERSON/I_LOCATION
a O
collected O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
material I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
performed O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
values I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
edited O
the O
manuscript B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Dr B_PERSON
. O
Simona B_PERSON
Gwozdziewiczov I_PERSON
a O
performed O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
edited O
the O
manuscript B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Prof B_PERSON
. O

Jir B_PERSON/B_LOCATION
i O
Hreb O
i O
cek O
initiated O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
participated O
in O
its O
design B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
coordination B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
wrote O
and O
edited O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

Alexithymia O
and O
anxiety O
in O
female O
chronic O
pain O
patients B_PERSON/B_DISEASE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Alexithymia O
is O
highly O
prevalent O
among O
chronic O
pain O
patients B_PERSON/B_DISEASE
. O

Pain B_DISEASE
is O
a O
remarkable B_DISEASE/B_MEASURE
cause B_DISEASE/I_MEASURE
for O
high B_DISEASE_ADJECTIVE[DISEASE]
levels I_DISEASE_ADJECTIVE[DISEASE]
of O
chronic B_DISEASE_ADJECTIVE[DISEASE]
anxiety I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
prevalence O
of O
alexithymia O
and O
to O
determine O
anxiety O
levels O
among O
DSM O
- O
IV O
somatoform O
pain O
disorder O
( O
chronic O
pain O
) O
female O
patients B_PERSON
and O
to O
examine O
the O
relationship O
between O
alexithymia O
and O
the O
self O
- O
reporting O
of O
pain O
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thirty B_PERSON
adult I_PERSON
females I_PERSON
( O
mean B_TIME[MEASURE]/B_PERSON
age B_TIME[MEASURE]/I_PERSON
: O
34 B_MEASURE
, O
63 B_MEASURE
+/- O
10 B_MEASURE
, O
62 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
) O
, O
who O
applied O
to O
the O
outpatient B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psychiatry I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinic I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
public B_LOCATION/B_PERSON
hospital I_LOCATION/I_PERSON
with O
the O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
disorder I_DISEASE/I_LOCATION
( O
DSM B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
IV B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
, O
were O
included O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thirty O
seven O
healthy O
females O
( O
mean O
age O
: O
34 O
, O
46 O
+/- O
7 O
, O
43 O
years O
) O
, O
who O
matched O
for O
sociodemographic O
features O
with O
the O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
, O
consisted O
the O
control O
group O
. O

A O
sociodemographic O
data O
form O
, O
26 O
- O
item O
Toronto O
Alexithymia O
Scale O
( O
TAS O
- O
26 O
) O
, O
Spielberger O
trait O
anxiety O
inventory O
( O
STAI O
) O
were O
administered O
to O
each O
subject O
and O
information O
was O
obtained O
on O
several O
aspects O
of O
the O
patients B_PERSON/B_DISEASE
' O
pain O
, O
including O
intensity O
( O
measured O
by O
VAS O
) O
, O
and O
duration O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

chronic O
pain O
patients B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
found O
significantly O
more O
alexithymic O
than O
controls O
. O

There O
was O
a O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
TAS B_MEASURE/B_DISEASE
- O
26 B_MEASURE
scores I_MEASURE
and O
the O
duration B_MEASURE
of O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
alexithymic B_DISEASE/B_PERSON
and O
nonalexithymic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
did O
not O
differ O
in O
their O
perception B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
pain B_DISEASE/B_PERSON
. O

Neither O
positive O
correlation O
nor O
significant O
difference O
was O
found O
between O
alexithymia O
and O
trait O
anxiety O
in O
pain O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Alexithymia B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
may O
be O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
addressing O
the O
diversity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
subjective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
involved O
in O
pain B_DISEASE
. O

The O
conceptualization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
alexithymia B_DISEASE/B_LOCATION
as O
a O
personality B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trait I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O
well O
as O
a O
secondary B_DISEASE_ADJECTIVE[DISEASE]
state I_DISEASE_ADJECTIVE[DISEASE]
reaction I_DISEASE_ADJECTIVE[DISEASE]
is O
underlined O
by O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
original B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
definition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alexithymia B_DISEASE
is O
the O
inability B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
identify O
and O
use O
verbal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
language I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
describe O
feelings B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O
1 B_NUMBER[MEASURE]
, O
2 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

Alexithymia B_DISEASE
has O
been O
associated O
with O
a O
variety B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
psychiatric B_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
physical B_DISEASE
illness I_DISEASE
[ O
3 B_MEASURE
- O
10 B_SEQUENCE[MEASURE]/B_LOCATION
] I_SEQUENCE[MEASURE]/I_LOCATION
. O

As O
a O
measure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
Toronto B_DISEASE/B_TIME[MEASURE]
Alexithymia I_DISEASE/I_TIME[MEASURE]
Scale I_DISEASE/I_TIME[MEASURE]
was O
significantly O
correlated O
with O
the O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
tendency B_TIME[MEASURE]/B_DISEASE
to O
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O
report O
physical B_DISEASE_ADJECTIVE[DISEASE]
signs I_DISEASE_ADJECTIVE[DISEASE]
and O
symptoms B_DISEASE
[ O
11 B_DISEASE/B_MEASURE
] I_DISEASE/I_MEASURE
. O

Several O
studies O
have O
found O
a O
high O
prevalence O
of O
alexithymia O
in O
pain O
patients B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

chronic O
pain O
patients B_PERSON/B_DISEASE
frequently O
exhibit O
many O
of O
the O
core O
features O
of O
alexithymia O
, O
such O
as O
problems O
in O
identifying O
and O
describing O
subjective O
feelings O
, O
impoverished O
imaginative O
abilities O
, O
and O
excessive O
preoccupation O
with O
physical O
symptoms O
and O
external O
events O
. O

Although O
several O
studies O
have O
found O
a O
high O
prevalence O
of O
alexithymia O
in O
pain O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
way O
alexithymia O
may O
possibly O
influence O
pain O
experience O
is O
still O
unclear O
[ O
12 O
, O
13 O
] O
. O

DSM B_LOCATION
- O
IV B_NUMBER[MEASURE]
- O
TR B_MEASURE/B_PROTEIN[GENE]
defines O
pain B_DISEASE
disorder I_DISEASE
as O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pain B_DISEASE
that O
is O
' O
the O
predominant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
focus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
attention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
' O
[ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
chronic O
pain O
disorder O
, O
patients B_PERSON
complain O
of O
chronic O
pain O
, O
for O
which O
no O
physical O
etiology O
could O
be O
found O
or O
the O
underlying O
disorder O
is O
insufficient O
in O
explaining O
the O
symptoms O
. O

The O
pain B_DISEASE
causes O
clinically O
significant B_DISEASE_ADJECTIVE[DISEASE]
distress I_DISEASE_ADJECTIVE[DISEASE]
or O
impairment B_DISEASE_ADJECTIVE[DISEASE]
in O
social B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
, O
occupational B_EDU[ORGANIZATION]/B_DISEASE
, O
or O
other B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
important I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
areas I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
functioning O
. O

Psychological B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
judged O
to O
have O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]
, O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
exacerbation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
or O
maintenance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
pain B_DISEASE
[ O
15 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

The O
alexithymic O
person B_PERSON
' O
s O
difficulty O
in O
identifying O
and O
describing O
feelings O
may O
increase O
symptom O
reporting O
by O
several O
mechanisms O
. O

Consequently O
, O
due O
to O
the O
difficulty B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
experience O
and O
express O
emotions B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
alexithymia B_DISEASE
has O
been O
linked O
with O
somatosensory B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplification I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
the O
tendency B_MEASURE/B_DISEASE
to O
focus O
on O
benign B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
somatic I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensations I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Alexithymic B_PERSON
subjects I_PERSON
are O
considered O
to O
focus O
on O
somatic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
emotional B_DISEASE
arousal I_DISEASE
, O
resulting O
in O
misinterpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
somatic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensations I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
physical B_DISEASE
illness I_DISEASE
[ O
12 B_MEASURE
, O
13 B_SEQUENCE[MEASURE]
, O
16 B_MEASURE
] I_MEASURE
. O

Accordingly O
, O
previous O
studies O
have O
found O
evidence O
of O
an O
association O
between O
alexithymia O
and O
the O
development O
of O
functional O
somatic O
symptoms O
, O
as O
seen O
in O
patients B_PERSON/B_BIO
with O
somatoform O
disorders O
. O

On O
the O
other B_PERSON/B_MEASURE
hand I_PERSON/I_MEASURE
, O
alexithymia B_DISEASE/B_PERSON
may O
also O
occur O
as O
a O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
state B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
severe B_DISEASE
and O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
medical B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
illness B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
[ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
17 B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O
21 B_MEASURE
] I_MEASURE
. O

Based O
on O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
these O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
are O
worth B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
terms B_LOCATION/B_DISEASE
of O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
research I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
prevalence O
of O
alexithymia O
among O
DSM O
- O
IV O
somatoform O
pain O
disorder O
( O
chronic O
pain O
) O
female O
patients B_PERSON
and O
to O
examine O
the O
relationship O
between O
alexithymia O
and O
the O
self O
- O
reporting O
of O
pain O
in O
this O
group O
of O
patients B_PERSON
. O

Besides O
, O
the O
study O
searched O
for O
the O
anxiety O
levels O
of O
chronic O
pain O
patients B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
with O
or O
without O
alexithymia O
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
consisted O
of O
30 B_PERSON
females I_PERSON
who O
applied O
to O
the O
outpatient B_LOCATION
psychiatry I_LOCATION
clinic I_LOCATION
at O
a O
public B_LOCATION/B_MEASURE
hospital I_LOCATION/I_MEASURE
and O
who O
met O
DSM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
IV B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
chronic B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
disorder I_DISEASE/I_LOCATION
. O

Patients B_PERSON
with O
concomitant O
psychiatric O
disorders O
, O
such O
as O
major O
depression O
, O
anxiety O
disorders O
and O
somatoform O
disorders O
other O
than O
pain O
disorder O
were O
excluded O
. O

Patients B_PERSON
either O
directly O
applied O
to O
the O
psychiatry O
clinic O
themselves O
or O
were O
referred O
for O
psychiatric O
assessment O
from O
another O
outpatient O
clinic O
, O
mainly O
physical O
medicine O
and O
rehabilitation O
. O

After O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
description I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
written O
informed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
consent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
obtained O
from O
each O
subject B_PERSON
. O

The O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
was O
37 B_PERSON
healthy I_PERSON
females I_PERSON
, O
who O
matched O
for O
age B_TIME[MEASURE]
, O
and O
education B_PERSON/B_TIME[MEASURE]
with O
the O
subjects B_PERSON/B_LOCATION
. O

All O
subjects B_PERSON
participated O
voluntarily O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
gave O
consent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
after O
the O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
had O
been O
fully O
explained O
to O
them O
. O

The O
mean O
age O
of O
the O
patients B_PERSON/B_BIO
and O
the O
healthy O
controls O
was O
34 O
, O
63 O
+/- O
10 O
, O
62 O
( O
range O
: O
16 O
- O
62 O
) O
and O
34 O
, O
46 O
+/- O
7 O
, O
43 O
( O
range O
: O
22 O
- O
57 O
) O
years O
and O
the O
educational O
level O
was O
6 O
, O
13 O
+/- O
3 O
, O
03 O
( O
range O
: O
5 O
- O
11 O
) O
and O
6 O
, O
59 O
+/- O
2 O
, O
9 O
( O
range O
: O
5 O
- O
14 O
) O
years O
, O
respectively O
. O

There O
were O
no O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
age B_MEASURE/B_PERSON
( O
t B_PROTEIN[GENE]/B_DISEASE
= O
0 B_MEASURE
, O
79 B_MEASURE
, O
DF B_PROTEIN[GENE]/B_DISEASE
= O
65 B_MEASURE
, O
P B_OTHER/B_LOCATION
> O
0 B_MEASURE
, O
05 B_MEASURE
) O
, O
educational B_MEASURE/B_PERSON
level I_MEASURE/I_PERSON
( O
t B_PROTEIN[GENE]/B_DISEASE
= O
1 B_MEASURE
, O
02 B_MEASURE
, O
DF B_PROTEIN[GENE]/B_DISEASE
= O
65 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
> O
0 B_MEASURE
, O
05 B_MEASURE
) O
, O
and O
marital B_PERSON/B_ORGANIZATION
status I_PERSON/I_ORGANIZATION
( O
x2 B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
, O
51 B_MEASURE
, O
df B_MEASURE/B_PROTEIN[GENE]
= O
1 B_MEASURE
, O
P B_MEASURE
> I_MEASURE
0 I_MEASURE
, O
05 B_MEASURE
) O
. O

Measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sociodemographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
used O
for O
all O
subjects B_PERSON/B_ORGANIZATION
. O

All O
participants B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
applied O
structured O
Clinical O
Interview O
for O
DSM O
- O
IV O
( O
SCID O
- O
I O
) O
[ O
22 O
] O
, O
Turkish O
version O
[ O
23 O
] O
. O

Regarding O
the O
pain O
assessment O
, O
information O
was O
first O
obtained O
on O
several O
aspects O
of O
the O
patients B_PERSON/B_DISEASE
' O
pain O
, O
such O
as O
intensity O
, O
and O
duration O
. O

Pain B_DISEASE
intensity I_DISEASE
was O
measured O
by O
Visual B_MEASURE
analogue I_MEASURE
Scale I_MEASURE
( O
VAS B_MEASURE/B_DISEASE
) O
, O
using O
a O
horizontal B_MEASURE/B_LOCATION
10 I_MEASURE/I_LOCATION
- O
cm B_MEASURE/B_LOCATION
line I_MEASURE/I_LOCATION
with O
the O
statement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O
no O
pain B_DISEASE
at O
all O
' O
at O
the O
extreme B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
left I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
- O
hand B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
' O
the O
worst B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
possible I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pain I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
' O
or O
' O
unbearable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' O
at O
the O
right B_SEQUENCE[MEASURE]/B_LOCATION
- O
hand B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
extreme I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

VAS O
is O
scored O
by O
measuring O
the O
distance O
from O
the O
end O
of O
the O
scale O
indicating O
absence O
of O
pain O
( O
or O
no O
distress O
or O
no O
pain O
relief O
) O
to O
the O
place O
marked O
by O
the O
patient B_PERSON/B_MEASURE
[ O
24 O
] O
. O

The O
psychometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scales I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
used O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
the O
26 B_NUMBER[MEASURE]
- O
item B_MEASURE
Toronto I_MEASURE
Alexithymia I_MEASURE
Scale I_MEASURE
( O
TAS B_MEASURE/B_DISEASE
- O
26 B_MEASURE
] I_MEASURE
and O
the O
trait B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Anxiety I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Inventory I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
STAI B_LOCATION/B_ORGANIZATION
) O
, O
which O
were O
both O
validated O
in O
Turkish B_MEASURE/B_PERSON
population I_MEASURE/I_PERSON
studies I_MEASURE/I_PERSON
[ O
25 B_MEASURE
- O
28 B_MEASURE
] I_MEASURE
. O

TAS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
psychometrically O
well O
validated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
reliable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
alexithymia B_DISEASE
. O
TAS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
validated O
in O
Turkish B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
a O
true B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
or O
false B_DISEASE_ADJECTIVE[DISEASE]
scale I_DISEASE_ADJECTIVE[DISEASE]
. O

Twenty B_NUMBER[MEASURE]
- O
six B_NUMBER[MEASURE]/B_PERSON
items I_NUMBER[MEASURE]/I_PERSON
are O
scored O
either O
as O
1 B_MEASURE
or O
0 B_MEASURE
and O
the O
higher B_MEASURE
scores I_MEASURE
indicate O
higher B_MEASURE/B_DISEASE
degrees I_MEASURE/I_DISEASE
of O
alexithymia B_DISEASE_ADJECTIVE[DISEASE]
. O

TAS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
an O
interval B_MEASURE
consistency I_MEASURE
of O
0 B_MEASURE
. O
65 B_MEASURE/B_PERSON
[ I_MEASURE/I_PERSON
Kuder I_MEASURE/I_PERSON
- O
Richardson B_MEASURE
) O
and O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
retest B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reliability I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
r B_PROTEIN[GENE]/B_DISEASE
= O
0 B_MEASURE
. O
71 B_MEASURE
, O
p O
< O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
in O
Turkish B_MEASURE
reliability I_MEASURE
and O
validity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
divided O
into O
nonalexithymic B_DISEASE_ADJECTIVE[DISEASE]
and O
alexityhmic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
the O
recommended O
cut O
- O
off O
score B_MEASURE
of O
11 B_MEASURE
[ I_MEASURE
27 I_MEASURE
] I_MEASURE
. O

Spielberger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trait I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Anxiety I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Inventory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
STAI B_LOCATION/B_ORGANIZATION
) O
is O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
two B_MEASURE/B_LOCATION
sections B_MEASURE/I_LOCATION
of O
the O
Spielberger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Anxiety I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Inventory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
the O
other B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
measuring O
state B_DISEASE
anxiety I_DISEASE
) O
. O

' O
trait B_DISEASE
anxiety I_DISEASE
' O
has O
been O
defined O
as O
anxiety B_DISEASE_ADJECTIVE[DISEASE]
proneness I_DISEASE_ADJECTIVE[DISEASE]
, O
that O
is O
, O
the O
tendency B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
respond O
to O
situations B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
perceived O
as O
threatening O
with O
elevations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
intensity B_MEASURE/B_LOCATION
of O
state B_DISEASE_ADJECTIVE[DISEASE]
anxiety I_DISEASE_ADJECTIVE[DISEASE]
[ O
26 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

In O
order B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
determine O
the O
relative B_MEASURE/B_PERSON
importance B_MEASURE/I_PERSON
of O
a O
number B_MEASURE/B_LOCATION
of O
factors B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pain B_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
used O
both O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
alexithymic B_DISEASE/B_PERSON
and O
nonalexithymic B_DISEASE/B_ORGANIZATION
groups I_DISEASE/I_ORGANIZATION
were O
compared O
using O
the O
independent B_LOCATION/B_DISEASE
sample I_LOCATION/I_DISEASE
t I_LOCATION/I_DISEASE
- O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
scores B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
psychological B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
was O
carried O
out O
by O
a O
SPSS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
package I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
windows B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
using O
Chi B_PERSON/B_NUMBER[MEASURE]
- O
square B_LOCATION/B_MEASURE
, O
Fisher B_MEASURE/B_LOCATION
' I_MEASURE/I_LOCATION
s I_MEASURE/I_LOCATION
exact I_MEASURE/I_LOCATION
test I_MEASURE/I_LOCATION
, O
two B_MEASURE/B_PERSON
tailed O
t B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
Pearson B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
also O
used O
to O
determine O
group B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
alexithymics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
versus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
nonalexithymics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
in O
sociodemographic B_DISEASE_ADJECTIVE[DISEASE]
variables I_DISEASE_ADJECTIVE[DISEASE]
and O
various B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pain B_DISEASE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
chronic O
pain O
group O
, O
56 O
. O
7 O
% O
of O
patients B_PERSON/B_BIO
( O
n O
= O
17 O
) O
had O
a O
score O
greater O
than O
11 O
on O
the O
TAS O
- O
26 O
, O
and O
were O
considered O
alexithymic O
. O

The O
mean B_MEASURE
TAS I_MEASURE
- O
26 B_MEASURE
score I_MEASURE
of O
the O
alexithymic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
17 B_MEASURE
) O
was O
17 B_MEASURE
. O
88 B_MEASURE
+/- I_MEASURE
3 I_MEASURE
. O
43 B_MEASURE
and O
the O
nonalexithymic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_LOCATION
= O
13 B_MEASURE
) O
was O
8 B_MEASURE
. O
39 B_MEASURE
+/- I_MEASURE
2 I_MEASURE
. O
02 B_MEASURE
. O

Age B_TIME[MEASURE]/B_PERSON
( O
t O
= O
1 B_MEASURE
, O
38 B_MEASURE
, O
DF B_PROTEIN[GENE]/B_DISEASE
= O
28 B_MEASURE
, O
p B_OTHER/B_LOCATION
> O
0 B_MEASURE
, O
18 B_MEASURE
) O
, O
education B_PERSON/B_LOCATION
( O
t B_PROTEIN[GENE]/B_DISEASE
= O
- O
0 B_MEASURE
, O
21 B_MEASURE
, O
DF B_PROTEIN[GENE]/B_DISEASE
= I_MEASURE
28 I_MEASURE
, O
p B_MEASURE/B_PROTEIN[GENE]
> O
0 B_MEASURE
, O
16 B_MEASURE
) O
and O
marital B_PERSON/B_ORGANIZATION
status I_PERSON/I_ORGANIZATION
( O
x2 B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
, O
27 B_MEASURE
, O
DF B_PROTEIN[GENE]/B_DISEASE
= O
1 B_MEASURE
, O
p B_MEASURE/B_LOCATION
> I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
, O
87 B_MEASURE
) O
were O
not O
associated O
with O
alexithymia B_DISEASE_ADJECTIVE[DISEASE]
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

In O
the O
control O
group O
, O
24 O
, O
3 O
% O
of O
patients B_PERSON/B_BIO
( O
n O
= O
9 O
) O
were O
alexithymic O
according O
to O
TAS O
- O
26 O
. O

The O
mean B_MEASURE
TAS I_MEASURE
- O
26 B_MEASURE
score I_MEASURE
of O
the O
alexithymic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
n B_MEASURE
= O
9 B_MEASURE
) O
was O
13 B_MEASURE
, O
82 B_MEASURE
+/- I_MEASURE
1 I_MEASURE
, O
93 B_MEASURE
and O
the O
nonalexithymic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
n B_MEASURE/B_LOCATION
= O
28 B_MEASURE
) O
was O
10 B_MEASURE
, O
33 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
, O
86 B_MEASURE
. O

Alexithymia B_DISEASE
was O
not O
associated O
with O
age B_MEASURE/B_PERSON
( O
t O
= O
- O
1 B_MEASURE
, O
08 B_MEASURE
, O
DF B_PROTEIN[GENE]/B_DISEASE
= O
35 B_MEASURE
, O
p B_PROTEIN[GENE]/B_LOCATION
> O
0 B_MEASURE
, O
29 B_MEASURE
) O
, O
educational B_MEASURE/B_PERSON
level I_MEASURE/I_PERSON
( O
t B_MEASURE/B_DISEASE
= O
1 B_MEASURE
, O
1 B_MEASURE
, O
df B_MEASURE/B_PROTEIN[GENE]
= O
35 B_MEASURE
, O
p B_MEASURE/B_LOCATION
> O
0 B_MEASURE
, O
28 B_MEASURE
) O
, O
or O
marital B_DISEASE
status I_DISEASE
( O
x2 B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
, O
74 B_MEASURE
, O
DF B_DISEASE/B_PROTEIN[GENE]
= O
1 B_MEASURE
, O
p B_MEASURE/B_LOCATION
> I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
, O
79 B_MEASURE
) O
or O
anxiety B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
control B_PERSON/B_LOCATION
subjects I_PERSON/I_LOCATION
( O
Table B_MEASURE
1 I_MEASURE
) O
. O

The O
duration O
and O
severity O
of O
pain O
, O
TAS O
- O
26 O
scores O
, O
and O
STAI O
scores O
of O
the O
female O
pain O
patients B_PERSON/B_ORGANIZATION
are O
shown O
in O
Table O
2 O
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
alexithymics B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
nonalexithymics B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
either O
the O
severity B_MEASURE/B_PERSON
of O
pain B_DISEASE
or O
pain B_DISEASE
duration I_DISEASE
showed O
no O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t B_PROTEIN[GENE]/B_DISEASE
= O
0 B_MEASURE
, O
64 B_MEASURE
, O
DF B_PROTEIN[GENE]/B_DISEASE
= O
28 B_MEASURE
, O
p B_MEASURE/B_LOCATION
> I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
, O
52 B_MEASURE
, O
t O
= O
2 B_MEASURE
, O
05 B_MEASURE
, O
DF B_PROTEIN[GENE]/B_DISEASE
= O
28 B_MEASURE
, O
p B_MEASURE
> I_MEASURE
0 B_MEASURE
, O
05 B_MEASURE
, O
respectively O
) O
. O

TAS B_MEASURE/B_DISEASE
- O
26 B_MEASURE
score I_MEASURE
and O
duration B_MEASURE
of O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
found O
positively O
correlated O
( O
r B_OTHER/B_GENE
= O
0 B_MEASURE
, O
50 B_MEASURE
, O
n B_OTHER/B_MEASURE
= O
30 B_MEASURE
, O
p B_MEASURE/B_LOCATION
> I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
, O
005 B_MEASURE
) O
. O

STAI B_DISEASE/B_MEASURE
( O
trait B_MEASURE/B_DISEASE
) O
scores B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
alexithymics B_PERSON/B_BIO
in O
the O
pain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
did O
not O
significantly O
differ O
from O
the O
nonlalexithymics B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
t B_PROTEIN[GENE]/B_DISEASE
= O
0 B_MEASURE
, O
06 B_MEASURE
, O
DF B_DISEASE/B_PROTEIN[GENE]
= O
28 B_MEASURE
, O
p B_MEASURE/B_PROTEIN[GENE]
> O
0 B_MEASURE
, O
95 B_MEASURE
) O
and O
besides O
, O
TAS B_LOCATION/B_ORGANIZATION
- O
26 B_MEASURE/B_LOCATION
and O
STAI B_DISEASE/B_GENE
scores I_DISEASE/I_GENE
were O
not O
correlated O
( O
r B_PROTEIN[GENE]/B_DISEASE
= O
0 B_MEASURE
, O
06 B_MEASURE
, O
p B_MEASURE/B_LOCATION
> I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
, O
72 B_MEASURE
) O
. O

In O
summary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
are O
three B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
points I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
be O
emphasized O
. O

First O
, O
chronic O
pain O
patients B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
found O
significantly O
more O
alexithymic O
than O
controls O
( O
56 O
, O
7 O
% O
to O
24 O
, O
3 O
% O
) O
. O

Second B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
positive B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
between O
TAS B_MEASURE/B_DISEASE
- O
26 B_MEASURE
scores I_MEASURE
and O
duration B_MEASURE
of O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Third O
, O
neither O
positive O
correlation O
nor O
significant O
difference O
was O
found O
between O
alexithymia O
and O
trait O
anxiety O
in O
pain O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results O
of O
the O
present O
study O
suggest O
that O
patients B_PERSON
with O
chronic O
pain O
disorder O
are O
more O
alexithymic O
than O
individuals O
with O
no O
pain O
. O

This O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
obtained O
with O
earlier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
alexithymia B_DISEASE/B_MEASURE
[ O
11 B_MEASURE
- O
13 B_MEASURE
] I_MEASURE
. O

Although O
they O
may O
share O
common B_DISEASE_ADJECTIVE[DISEASE]
clinical I_DISEASE_ADJECTIVE[DISEASE]
features I_DISEASE_ADJECTIVE[DISEASE]
, O
alexithymia B_DISEASE
and O
somatoform B_DISEASE
pain I_DISEASE
are O
independent B_DISEASE_ADJECTIVE[DISEASE]
constructs I_DISEASE_ADJECTIVE[DISEASE]
. O

Alexithymia B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
may O
be O
a O
consequence B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
effects B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
physical B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
reduced B_DISEASE_ADJECTIVE[DISEASE]
quality I_DISEASE_ADJECTIVE[DISEASE]
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
daily B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Besides O
, O
alexithymia B_DISEASE/B_LOCATION
may O
be O
conceptualized O
as O
a O
personality B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trait I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O
well O
as O
a O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
state B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
, O
15 B_MEASURE
- O
17 B_MEASURE
] I_MEASURE
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
question B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigated O
was O
whether O
alexithymia B_DISEASE/B_PERSON
has O
any O
correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
duration B_MEASURE/B_LOCATION
or O
severity B_MEASURE/B_LOCATION
of O
the O
pain B_DISEASE
itself O
. O

There O
were O
no O
significant O
differences O
between O
alexithymic O
and O
nonalexitymic O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
self O
reports O
of O
current O
pain O
severity O
. O

This O
is O
in O
accordance O
with O
Cox O
' O
s O
study O
[ O
1994 O
] O
in O
which O
it O
was O
further O
pointed O
out O
that O
alexithymic O
patients B_PERSON
were O
found O
to O
use O
significantly O
more O
verbal O
descriptors O
of O
pain O
compared O
to O
nonalexithymic O
patients B_PERSON/B_DISEASE
[ O
13 O
] O
. O

In O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
pain B_DISEASE
intensity I_DISEASE
was O
only O
evaluated O
by O
using O
VAS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
trying O
to O
measure O
the O
intensity B_MEASURE/B_DISEASE
of O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
the O
lack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
an O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
way I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Pain O
is O
a O
subjective O
experience O
and O
each O
patient B_PERSON
may O
communicate O
in O
a O
different O
way O
, O
verbally O
or O
nonverbally O
[ O
29 O
] O
. O

Patients B_PERSON
in O
this O
sample O
were O
sufferers O
of O
chronic O
pain O
, O
who O
had O
already O
chosen O
an O
approved O
way O
of O
expressing O
their O
distress O
. O

Since O
this O
is O
true B_DISEASE_ADJECTIVE[DISEASE]
regardless O
of O
alexithymia B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O
alexithymic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
nonalexithymic B_PERSON/B_LOCATION
groups I_PERSON/I_LOCATION
in O
this O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O
no O
difference B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
pain B_DISEASE/B_GENE
severity I_DISEASE/I_GENE
. O

The O
positive B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O
alexithymia B_DISEASE
and O
the O
duration B_MEASURE
of O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
this O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
supports O
the O
assumption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
a O
two B_NUMBER[MEASURE]
- O
way B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

It O
is O
often O
assumed O
that O
pain B_DISEASE
can O
be O
caused O
by O
alexithymic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
personality I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
traits I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
also O
that O
severe B_DISEASE_ADJECTIVE[DISEASE]
and O
chronic B_DISEASE_ADJECTIVE[DISEASE]
pain I_DISEASE_ADJECTIVE[DISEASE]
may O
cause O
emotional B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
the O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
that O
because O
of O
the O
cross B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sectional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
we O
are O
unable B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
draw O
conclusions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O
the O
direction B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
causality B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O
alexithymia B_DISEASE
and O
pain B_DISEASE
. O

The O
duration O
of O
the O
patients B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O
pain O
could O
approximately O
be O
determined O
, O
yet O
the O
preexisting O
level O
of O
alexithymia O
was O
not O
known O
. O

In O
the O
usual O
absence O
of O
internal O
stimuli O
, O
alexithymic O
person B_PERSON/B_BIO
may O
be O
expected O
to O
maintain O
an O
external O
focus O
of O
attention O
, O
such O
as O
pain O
. O

Symptom O
chronicity O
may O
force O
the O
alexithymic O
person B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
to O
attent O
to O
and O
amplify O
this O
somatic O
sensation O
. O

difficulties B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
identify O
and O
differentiate O
emotions B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
somatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
experiences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
core B_DISEASE_ADJECTIVE[DISEASE]
features I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
alexithymic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
construct I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Therefore O
, O
alexithymic O
patients B_PERSON/B_BIO
might O
be O
expected O
to O
differ O
from O
nonalexithymic O
ones O
in O
their O
anxiety O
levels O
. O

Yet O
, O
in O
our O
pain O
group O
alexithymic O
patients B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
no O
significant O
difference O
from O
the O
nonalexithymics O
on O
trait O
anxiety O
. O

Besides O
, O
alexithymia B_DISEASE/B_MEASURE
and O
anxiety B_DISEASE/B_PERSON
were O
not O
correlated O
at O
all O
. O

The O
reasons O
may O
be O
lying O
in O
the O
specific O
characteristics O
of O
this O
patient B_PERSON/B_EDU[ORGANIZATION]
group O
itself O
. O

The O
study O
included O
patients B_PERSON
suffering O
from O
chronic O
symptoms O
; O
with O
an O
average O
of O
7 O
, O
44 O
+/- O
6 O
, O
82 O
years O
of O
pain O
in O
the O
alexithymic O
and O
3 O
, O
31 O
+/- O
2 O
, O
79 O
years O
in O
the O
nonalexithymic O
groups O
. O

Persistency B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
any O
physical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
symptom B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O
bring O
along O
alexithymia B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
coping O
strategy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
their O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Crook B_PERSON/B_COLOR
and O
Tunks B_PERSON/B_COLOR
( O
1988 B_MEASURE
) O
examined O
the O
types B_MEASURE/B_DISEASE
of O
coping O
strategies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
used O
by O
persistent B_PERSON/B_ORGANIZATION
pain I_PERSON/I_ORGANIZATION
sufferers I_PERSON/I_ORGANIZATION
and O
addressed O
to O
the O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
alter O
their O
attitudes B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
behavior B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
tend O
toward O
catastrophizing B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
avoidance B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
rather O
than O
simply O
concentrate O
on O
trying O
to O
teach O
them O
techniques B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
for O
' O
coping O
with O
stress B_DISEASE/B_PERSON
' O
to O
help O
persistent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pain I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
sufferers I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
[ O
30 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
] I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Sufferers B_PERSON/B_ORGANIZATION
of O
chronic B_DISEASE/B_LOCATION
symptoms I_DISEASE/I_LOCATION
in O
this O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
members B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
subgroup B_MEASURE/B_PERSON
who O
have O
been O
seeking O
medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O
a O
long B_TIME[MEASURE]/B_DISEASE
time I_TIME[MEASURE]/I_DISEASE
and O
besides O
given O
the O
chance B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
being O
referred O
to O
a O
psychiatrist B_PERSON/B_LOCATION
. O

Therefore O
, O
alexithymic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
not O
, O
their O
anxiety B_DISEASE/B_PERSON
might O
have O
induced O
unique B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
coping O
strategies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
illness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Alexithymia B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
may O
be O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
addressing O
the O
diversity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
subjective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
involved O
in O
pain B_DISEASE
[ O
31 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
] I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

It O
is O
not O
known O
whether O
it O
should O
be O
addressed O
in O
the O
treatment O
of O
pain O
patients B_PERSON/B_DISEASE
, O
but O
a O
high O
level O
of O
alexithymia O
may O
effect O
the O
nature O
of O
assessment O
. O

In O
summary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
conceptualization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
alexithymia B_DISEASE/B_LOCATION
as O
a O
personality B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
trait I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O
well O
as O
a O
secondary B_DISEASE_ADJECTIVE[DISEASE]
state I_DISEASE_ADJECTIVE[DISEASE]
reaction I_DISEASE_ADJECTIVE[DISEASE]
is O
underlined O
by O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

However O
, O
regarding O
the O
cross B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sectional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
design I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
only O
limited O
conclusions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
can O
be O
drawn O
about O
the O
nature B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
causal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
relationship I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
between O
alexithymia B_DISEASE
and O
chronic B_DISEASE
pain I_DISEASE
. O

Therefore O
, O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
longitudinal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
assessing O
the O
cause B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alexithymic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
required O
to O
fully O
elucidate O
the O
concepts B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
alexithymia I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Molecular O
polymorphism O
, O
differentiation O
and O
introgression O
in O
the O
period O
gene O
between O
Lutzomyia B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
intermedia I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
Lutzomyia B_SPECIES[BIO]/B_LOCATION
whitmani I_SPECIES[BIO]/I_LOCATION
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Lutzomyia B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
intermedia I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
and O
Lutzomyia B_SPECIES[BIO]/B_LOCATION
whitmani I_SPECIES[BIO]/I_LOCATION
( O
Diptera O
: O
Psychodidae O
) O
are O
important O
and O
very O
closely O
related O
vector O
species O
of O
cutaneous O
leishmaniasis O
in O
Brazil O
, O
which O
are O
distinguishable O
by O
a O
few O
morphological O
differences O
. O

There O
is O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introgression I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_BIO/B_PERSON
species I_BIO/I_PERSON
but O
it O
is O
not O
clear B_DISEASE_ADJECTIVE[DISEASE]
whether O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flow I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
also O
occurs O
in O
nuclear B_SPECIES[BIO]/B_GENE
genes I_SPECIES[BIO]/I_GENE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
analyzed O
the O
molecular B_GENE/B_MEASURE
variation B_GENE/I_MEASURE
within O
the O
clock B_MEASURE/B_BIO
gene I_MEASURE/I_BIO
period I_MEASURE/I_BIO
( O
per O
) O
of O
these O
two B_BIO/B_GENE
species I_BIO/I_GENE
in O
five B_MEASURE
different I_MEASURE
localities I_MEASURE
in O
Eastern B_LOCATION
Brazil I_LOCATION
. O

AMOVA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
Fst B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
estimates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O
no O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
geographical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O
species B_BIO/B_LOCATION
. O

On O
the O
other B_PERSON/B_MEASURE
hand I_PERSON/I_MEASURE
, O
the O
values B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
highly O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
both O
analyses B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
species B_BIO/B_PERSON
. O

The O
two B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
no O
fixed B_MEASURE
differences I_MEASURE
and O
a O
higher B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
shared B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphisms I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
compared O
to O
exclusive B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_MEASURE/B_LOCATION
, O
some O
haplotypes B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
that O
are O
' B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
typical I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
' O
of O
one B_PERSON/B_BIO
species I_PERSON/I_BIO
were O
found O
in O
some O
individuals B_PERSON/B_LOCATION
of O
the O
other B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
species I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
suggesting O
either O
the O
persistence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
old B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
of O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
linkage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disequilibrium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
MCMC B_SEQUENCE[MEASURE]/B_ORGANIZATION
analysis I_SEQUENCE[MEASURE]/I_ORGANIZATION
based O
on O
coalescence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
suggest O
that O
the O
two B_BIO/B_PERSON
species I_BIO/I_PERSON
might O
be O
exchanging O
alleles B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
per O
locus B_GENE/B_MEASURE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

Introgression O
might O
be O
occurring O
between O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
intermedia I_SPECIES[BIO]/I_PERSON
and O
L B_SPECIES[BIO]/B_PROTEIN[GENE]
. B_SPECIES[BIO]/I_PROTEIN[GENE]
whitmani B_SPECIES[BIO]/I_PROTEIN[GENE]
in O
period O
, O
a O
gene O
controlling O
behavioral O
rhythms O
in O
Drosophila O
. O

This O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
raises O
the O
question B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
whether O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenomena I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
are O
occurring O
at O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
loci B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
controlling O
important B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
behavior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
vectorial B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
capacity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Phlebotominae O
sand O
flies O
Lutzomyia B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
intermedia I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Lutz O
& O
Neiva O
1912 O
and O
Lutzomyia B_PERSON/B_LOCATION
whitmani I_PERSON/I_LOCATION
Antunes O
& O
Coutinho O
1912 O
are O
vectors O
of O
cutaneous O
leishmaniasis O
in O
Brazil O
. O

These O
are O
closely O
related O
species B_BIO
that O
can O
be O
only O
distinguished O
by O
a O
few B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphological I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
1 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
and O
both O
show O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
anthropophily O
and O
reported O
natural B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Leishmania B_SPECIES[BIO]/B_DISEASE
in O
different B_LOCATION/B_MEASURE
regions I_LOCATION/I_MEASURE
of O
Brazil B_LOCATION
[ I_LOCATION
2 I_LOCATION
] I_LOCATION
. O

Despite O
their O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
vectors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
only O
a O
handful B_SEQUENCE[MEASURE]/B_PERSON
of O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
have O
been O
carried O
out O
in O
these O
two B_BIO/B_LOCATION
species I_BIO/I_LOCATION
using O
molecular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
techniques B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
6 B_MEASURE
] I_MEASURE
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
the O
most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
findings I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
from O
an O
epidemiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
the O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
for O
introgression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O
the O
two B_BIO/B_PERSON
species I_BIO/I_PERSON
using O
mitochondrial B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
4 B_LOCATION/B_GENE
] I_LOCATION/I_GENE
. O

This O
was O
particularly O
interesting O
because O
apparently O
, O
only O
lineages O
of O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
whitmani I_SPECIES[BIO]
sympatric O
with O
L B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
intermedia I_SPECIES[BIO]/I_LOCATION
have O
been O
involved O
in O
cutaneous O
leishmaniasis O
transmission O
in O
the O
peridomestic O
environment O
[ O
4 O
] O
, O
which O
suggests O
that O
genes O
controlling O
aspects O
of O
vectorial O
capacity O
could O
be O
passing O
from O
one O
species O
to O
the O
other O
. O

In O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introgression I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
reported O
in O
other B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
sand I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
fly I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
species I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
7 B_MEASURE
, O
8 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
suggesting O
that O
might O
be O
a O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenomenon B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
insect B_BIO/B_PERSON
vectors I_BIO/I_PERSON
. O

However O
, O
because O
mitochondrial B_GENE/B_BIO
genes I_GENE/I_BIO
can O
introgress O
relatively O
easily O
between O
closely O
related B_BIO/B_PERSON
species I_BIO/I_PERSON
[ O
9 B_MEASURE/B_SPECIES[BIO]
] I_MEASURE/I_SPECIES[BIO]
, O
it O
becomes O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
examine O
whether O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
occur O
with O
nuclear B_MEASURE/B_GENE
genes I_MEASURE/I_GENE
. O

The O
Drosophila B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
period I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
per O
) O
gene B_GENE/B_BIO
homologue I_GENE/I_BIO
was O
isolated O
in O
sand B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
flies I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
by O
Peixoto B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
et I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
al I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
circadian O
clock O
gene O
was O
originally O
identified O
using O
mutagenesis O
by O
Konopka O
and O
Benzer O
[ O
11 O
] O
, O
but O
is O
also O
known O
to O
control O
the O
differences O
in O
the O
' O
lovesong O
' O
rhythms O
between O
D B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
melanogaster I_SPECIES[BIO]/I_PERSON
and O
D B_SPECIES[BIO]
. I_SPECIES[BIO]
simulans I_SPECIES[BIO]
[ O
12 O
] O
, O
that O
are O
important O
to O
the O
sexual O
isolation O
between O
these O
two O
species O
[ O
13 O
- O
15 O
] O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
per O
was O
implicated O
in O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
species B_BIO/B_PERSON
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
circadian I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mating I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rhythms I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
Drosophila B_SPECIES[BIO]
and O
Bractocera B_SPECIES[BIO]
, O
which O
might O
also O
constitute O
a O
reproductive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
isolation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mechanism B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
[ O
16 B_NUMBER[MEASURE]
- O
18 B_MEASURE
] I_MEASURE
. O

Thus O
per O
may O
possibly O
represent O
an O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
a O
Drosophila B_GENE/B_BIO
speciation I_GENE/I_BIO
gene I_GENE/I_BIO
[ O
19 B_MEASURE
] I_MEASURE
, O
and O
in O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
it O
has O
been O
used O
as O
a O
molecular B_GENE/B_PERSON
marker I_GENE/I_PERSON
in O
a O
number B_MEASURE/B_LOCATION
of O
speciation B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
evolutionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
not O
only O
in O
Drosophila B_SPECIES[BIO]
( O
reviewed O
in O
[ B_TIME[MEASURE]
20 I_TIME[MEASURE]
] O
) O
but O
also O
in O
other B_SPECIES[BIO]
insects I_SPECIES[BIO]
( O
e B_OTHER/B_DISEASE
. O
g B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O
[ O
21 B_MEASURE
] I_MEASURE
) O
including O
sand B_BIO/B_LOCATION
flies O
[ B_TIME[MEASURE]
22 I_TIME[MEASURE]
- O
24 B_MEASURE
] I_MEASURE
. O

Because O
per O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
the O
circadian B_MEASURE/B_ORGANISM_FUNCTION
clock B_MEASURE/I_ORGANISM_FUNCTION
in O
different B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
insects I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
25 B_MEASURE
] I_MEASURE
, O
it O
is O
almost O
certainly O
involved O
in O
the O
rhythms B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
biting B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sand B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
flies I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
[ I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
26 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
] I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
are O
very O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
leishmaniasis B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
transmission B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

In O
addition O
, O
per O
might O
be O
involved O
in O
reproductive O
isolation O
in O
sand O
flies O
, O
via O
mating O
rhythms O
, O
or O
via O
their O
' O
lovesongs O
' O
[ O
2 O
, O
27 O
] O
. O
per O
is O
thus O
a O
particularly O
interesting O
marker O
, O
among O
the O
few O
available O
, O
for O
an O
introgression O
analysis O
in O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
whitmani I_SPECIES[BIO]
. O

Evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
per O
might O
suggest O
that O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
flow I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
between O
these O
two B_BIO/B_LOCATION
vector B_BIO/I_LOCATION
species B_BIO/I_LOCATION
is O
occurring O
at O
other B_TIME[MEASURE]/B_LOCATION
genes I_TIME[MEASURE]/I_LOCATION
controlling O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
behavior B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
vectorial B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
capacity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
might O
also O
suggest O
that O
per O
does O
not O
have O
a O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
their O
reproductive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
isolation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
the O
current O
study O
, O
we O
analyzed O
the O
molecular O
variation O
within O
the O
per O
gene O
of O
L B_SPECIES[BIO]/B_DISEASE
. I_SPECIES[BIO]/I_DISEASE
intermedia I_SPECIES[BIO]/I_DISEASE
and O
L B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whitmani B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
five O
different O
localities O
in O
Eastern O
Brazil O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Polymorphism O
and O
divergence O
between O
L B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
intermedia I_SPECIES[BIO]/I_LOCATION
and O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
. O

A O
total O
of O
68 O
sequences O
from O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
intermedia I_SPECIES[BIO]/I_PERSON
and O
53 O
from O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
homologue O
to O
a O
fragment O
of O
the O
period O
gene O
were O
analyzed O
from O
populations O
of O
five O
localities O
in O
Eastern O
Brazil O
( O
Fig O
1 O
) O
. O

The O
alignment B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
72 B_MEASURE/B_LOCATION
variable I_MEASURE/I_LOCATION
sites I_MEASURE/I_LOCATION
is O
shown O
in O
Fig B_MEASURE/B_COLOR
2 I_MEASURE/I_COLOR
. O

Although O
most B_NUMBER[MEASURE]/B_PERSON
of O
the O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
are O
either O
synonymous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
occur O
within O
the O
58 B_GENE/B_LOCATION
bp I_GENE/I_LOCATION
intron I_GENE/I_LOCATION
, O
non B_DISEASE
- O
synonymous B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
substitutions B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
observed O
causing O
9 B_MEASURE
amino I_MEASURE
acid I_MEASURE
differences I_MEASURE
among O
the O
sequences B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
Fig B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
) O
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O
the O
number B_MEASURE
of O
sequences B_LOCATION/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O
each O
population B_PERSON/B_BIO
of O
the O
two B_BIO
species I_BIO
, O
the O
number B_MEASURE/B_LOCATION
of O
polymorphic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
S B_PROTEIN[GENE]/B_DISEASE
) O
and O
the O
estimates B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
molecular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymorphism I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
theta O
( O
based O
on O
the O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
mutations B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
) O
and O
pi B_PROTEIN[GENE]/B_DISEASE
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O
shows O
the O
Tajima B_PERSON/B_ORGANIZATION
' I_PERSON/I_ORGANIZATION
s I_PERSON/I_ORGANIZATION
[ I_PERSON/I_ORGANIZATION
28 I_PERSON/I_ORGANIZATION
] I_PERSON/I_ORGANIZATION
and O
Fu B_PERSON/B_LOCATION
& O
Li B_PERSON/B_LOCATION
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
29 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
statistics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Within O
each O
species O
, O
all O
populations O
present O
similar O
levels O
of O
polymorphism O
with O
the O
exception O
of O
L B_BIO/B_PERSON
. I_BIO/I_PERSON
whitmani I_BIO/I_PERSON
from O
Ilh O
e O
us O
, O
which O
seems O
to O
be O
less O
polymorphic O
than O
the O
others O
. O

This O
population B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
the O
only B_PERSON/B_MEASURE
one I_PERSON/I_MEASURE
presenting O
a O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
value B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
Fu B_PERSON/B_LOCATION
& O
Li B_PERSON/B_LOCATION
test I_PERSON/I_LOCATION
but O
only O
at O
the O
5 B_MEASURE/B_LOCATION
% B_MEASURE/I_LOCATION
level B_MEASURE/I_LOCATION
. O

Finally O
, O
the O
last B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
column I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
presents O
the O
recombination B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
estimator I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
indicating O
that O
both O
species B_BIO/B_GENE
show O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
intragenic B_DISEASE_ADJECTIVE[DISEASE]
recombination I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
per O
gene B_GENE/B_BIO
. O

To O
investigate O
the O
level B_MEASURE/B_LOCATION
of O
intra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
interspecific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
initially O
an O
AMOVA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
as O
shown O
in O
Table B_LOCATION/B_PERSON
2 I_LOCATION/I_PERSON
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
show O
a O
non B_DISEASE/B_MEASURE
- O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
within O
species B_BIO/B_PERSON
and O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
between O
species B_MEASURE/B_BIO
molecular I_MEASURE/I_BIO
variation I_MEASURE/I_BIO
at O
the O
per O
locus B_PERSON/B_LOCATION
. O

Table O
3 O
shows O
a O
more O
detailed O
analysis O
of O
the O
intraspecific O
differentiation O
among O
populations O
of O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
. O

None O
of O
the O
pairwise O
and O
overall O
fixation O
indexes O
( O
Fst O
) O
are O
significant O
in O
the O
case O
of O
L B_BIO/B_PERSON
. I_BIO/I_PERSON
intermedia I_BIO/I_PERSON
and O
only O
one O
( O
Posse O
x O
Ilh O
e O
us O
) O
has O
a O
borderline O
significant O
value O
in O
L B_BIO/B_PERSON
. I_BIO/I_PERSON
whitmani I_BIO/I_PERSON
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therefore O
show O
that O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
geographical I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heterogeneity I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
detected O
among O
the O
populations B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
two B_LOCATION/B_BIO
species I_LOCATION/I_BIO
. O

The O
estimated O
number O
of O
migrants O
per O
generation O
, O
based O
on O
the O
overall O
Fst O
values O
, O
is O
20 O
. O
683 O
for O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
intermedia I_SPECIES[BIO]/I_PERSON
and O
23 O
. O
125 O
for O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
divergence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O
species B_BIO/B_GENE
( O
Dxy B_LOCATION
and O
Da B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
as O
well O
as O
the O
Fst B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
nm B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considering O
each O
species B_BIO/B_GENE
as O
a O
unique B_PERSON/B_BIO
population B_PERSON/I_BIO
. O

Dxy B_MEASURE/B_LOCATION
is O
the O
average B_MEASURE
number I_MEASURE
of O
nucleotide B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitutions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O
site B_LOCATION/B_BIO
between O
alleles B_BIO/B_GENE
from O
two B_LOCATION/B_PERSON
different I_LOCATION/I_PERSON
populations I_LOCATION/I_PERSON
and O
Da B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
number B_MEASURE
of O
net B_LOCATION/B_GENE
nucleotide B_LOCATION/I_GENE
substitutions B_LOCATION/I_GENE
between O
two B_NUMBER[MEASURE]/B_GENE
populations I_NUMBER[MEASURE]/I_GENE
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O
shows O
the O
number B_MEASURE
of O
polymorphisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exclusive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
each O
species B_BIO/B_GENE
( O
Sint B_LOCATION/B_PERSON
and O
Swhit B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
the O
number B_MEASURE
of O
shared O
polymorphisms B_GENE
( O
SS B_LOCATION
) O
and O
the O
number B_MEASURE/B_LOCATION
of O
fixed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
sF B_PROTEIN[GENE]/B_LOCATION
) O
between O
species B_BIO/B_GENE
. O

As O
one B_NUMBER[MEASURE]/B_PERSON
can O
note O
, O
there O
is O
a O
high B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
shared O
polymorphisms B_GENE
between O
species B_BIO/B_PERSON
, O
and O
no O
fixed O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
them O
suggesting O
either O
the O
persistence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
ancestral B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphisms I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
of O
introgression B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
. O

In O
fact O
, O
there O
is O
one O
shared O
haplotype O
between O
the O
two O
species O
( O
IPO13 O
, O
WPO10 O
and O
WPO19 O
) O
and O
three O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
sequences O
( O
WAC02 O
, O
WPO13 O
and O
WPO14 O
) O
which O
show O
only O
one O
nucleotide O
difference O
to O
' O
typical O
' O
L B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
intermedia I_SPECIES[BIO]/I_LOCATION
haplotypes O
( O
see O
also O
below O
) O
. O

Genealogy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
period B_LOCATION
sequences I_LOCATION
. O

A O
phylogenetic O
analysis O
of O
the O
period O
gene O
sequences O
from O
L B_PERSON/B_LOCATION
. I_PERSON/I_LOCATION
intermedia I_PERSON/I_LOCATION
and O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
was O
carried O
out O
with O
the O
minimum O
Evolution O
method O
using O
the O
Kimura O
2 O
- O
parameter O
distance O
( O
Fig O
3 O
) O
. O

A O
sequence O
from O
L B_SPECIES[BIO]/B_MEASURE
. I_SPECIES[BIO]/I_MEASURE
umbratilis I_SPECIES[BIO]/I_MEASURE
, O
a O
related O
species O
from O
the O
same O
subgenus O
Nyssomyia O
, O
was O
used O
as O
outgroup O
[ O
24 O
] O
. O

The O
tree O
shows O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
whitmani I_SPECIES[BIO]
as O
non O
- O
monophyletic O
. O

However O
, O
despite O
the O
low O
bootstrap O
values O
, O
which O
are O
below O
50 O
% O
in O
most O
cases O
, O
there O
is O
a O
large O
group O
that O
contains O
most O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
sequences O
and O
a O
second O
large O
group O
with O
most O
L B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
whitmani B_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
sequences O
. O

A O
few B_MEASURE/B_PERSON
other I_MEASURE/I_PERSON
sequences I_MEASURE/I_PERSON
are O
clustered O
outside O
these O
two B_LOCATION
main I_LOCATION
groups I_LOCATION
. O

It O
is O
interesting O
to O
note O
that O
there O
are O
three O
L B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
. I_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
whitmani I_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
alleles O
( O
WAC2 O
, O
WPO13 O
and O
WPO14 O
) O
inside O
L B_PERSON/B_LOCATION
. I_PERSON/I_LOCATION
intermedia I_PERSON/I_LOCATION
main O
group O
, O
as O
well O
as O
one O
L B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
intermedia I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
allele O
( O
ICP16 O
) O
inside O
the O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
main O
group O
. O

In O
addition O
, O
a O
second O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
intermedia I_SPECIES[BIO]/I_PERSON
allele O
( O
IPO13 O
) O
is O
a O
shared O
haplotype O
between O
the O
two O
species O
as O
mentioned O
above O
. O

Again O
, O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggest O
either O
the O
persistence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
ancestral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polymorphisms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
the O
occurrence B_DISEASE/B_MEASURE
of O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_BIO/B_PERSON
species I_BIO/I_PERSON
. O

Very O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
obtained O
using O
the O
maximum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
likelihood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
implemented O
in O
PAUP B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
0b10 B_MEASURE/B_ORGANIZATION
software I_MEASURE/I_ORGANIZATION
[ O
31 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

As O
mentioned O
before O
, O
there O
is O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intragenic B_DISEASE_ADJECTIVE[DISEASE]
recombination I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
per O
gene B_GENE
fragment I_GENE
of O
both O
species B_BIO/B_GENE
( O
see O
Table B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
) O
and O
for O
that O
reason B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
bifurcating O
tree B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
shown O
in O
Fig B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
to O
be O
viewed O
with O
caution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
as O
different B_DISEASE/B_LOCATION
regions I_DISEASE/I_LOCATION
of O
the O
gene B_GENE/B_BIO
might O
have O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
phylogenetic I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
histories I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
[ O
32 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Therefore O
, O
we O
constructed O
Minimum B_GENE/B_BIO
evolution I_GENE/I_BIO
trees I_GENE/I_BIO
with O
the O
two B_NUMBER[MEASURE]/B_LOCATION
most O
polymorphic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
non O
- O
recombining O
blocks B_LOCATION/B_PERSON
of O
the O
per O
gene B_GENE/B_LOCATION
fragment I_GENE/I_LOCATION
identified O
using O
the O
Hudson B_PERSON
and O
Kaplan B_PERSON
[ O
33 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
DNAsp B_GENE/B_MEASURE
4 I_GENE/I_MEASURE
. O
1 B_MEASURE/B_ORGANIZATION
program I_MEASURE/I_ORGANIZATION
[ O
34 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

We O
did O
not O
observed O
major O
changes O
in O
the O
genealogy O
of O
the O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
per O
sequences O
, O
especially O
regarding O
the O
five O
haplotypes O
( O
ICP16 O
, O
IPO13 O
, O
WAC2 O
, O
WPO13 O
and O
WPO14 O
) O
that O
clearly O
cluster O
with O
sequences O
of O
the O
other O
species O
( O
data O
not O
shown O
) O
. O

Finally O
, O
a O
haplotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
estimated O
from O
per O
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
using O
statistical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
parsimony I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
as O
described O
by O
Templeton B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O
. O

[ O
35 B_MEASURE
] I_MEASURE
and O
implemented O
in O
the O
TCS1 B_GENE/B_MEASURE
. O
21 B_MEASURE/B_ORGANIZATION
software I_MEASURE/I_ORGANIZATION
[ I_MEASURE/I_ORGANIZATION
36 I_MEASURE/I_ORGANIZATION
] I_MEASURE/I_ORGANIZATION
( O
Fig B_MEASURE
4 I_MEASURE
) O
. O

A O
small B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
ambiguities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
resolved O
as O
suggested O
by O
Crandall B_PERSON/B_LOCATION
and O
Templeton B_PERSON
[ O
37 B_TIME[MEASURE]/B_PERSON
] B_TIME[MEASURE]/I_PERSON
. O

The O
haplotype O
network O
shows O
connections O
between O
sequences O
from O
each O
species O
, O
separating O
most O
of O
the O
sequences O
of O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
in O
two O
groups O
. O

No O
intraspecific B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
geographical I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structuring I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
. O

Once O
again O
, O
some O
of O
the O
L B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whitmani B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences O
( O
WAC2 O
, O
WAC10 O
, O
WPO13 O
and O
WPO14 O
) O
appear O
more O
closely O
related O
to O
L B_SPECIES[BIO]/B_TIME[MEASURE]
. I_SPECIES[BIO]/I_TIME[MEASURE]
intermedia I_SPECIES[BIO]/I_TIME[MEASURE]
haplotypes O
. O

In O
addition O
, O
one O
L B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
. I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
intermedia I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
allele O
( O
ICP16 O
) O
is O
connected O
by O
a O
small O
number O
of O
mutations O
to O
some O
of O
the O
main O
L B_SPECIES[BIO]/B_GENE
. I_SPECIES[BIO]/I_GENE
whitmani I_SPECIES[BIO]/I_GENE
haplotypes O
and O
IPO13 O
is O
a O
shared O
haplotype O
between O
the O
two O
species O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
confirm O
the O
same B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
putative I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introgressed O
sequences B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
indicated O
by O
the O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reconstructions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

LD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
tested O
the O
hypothesis O
of O
gene O
flow O
between O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
whitmani I_SPECIES[BIO]
using O
a O
method O
based O
on O
linkage O
disequilibrium O
( O
LD O
) O
developed O
by O
Machado O
et O
al O
. O

[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
38 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
x O
is O
the O
difference B_MEASURE/B_LOCATION
between O
the O
average B_MEASURE/B_LOCATION
LD B_MEASURE/I_LOCATION
found O
among O
all O
pairs B_PERSON/B_LOCATION
of O
shared B_GENE/B_LOCATION
polymorphisms I_GENE/I_LOCATION
( O
DSS B_LOCATION/B_ORGANIZATION
) O
between O
the O
two B_PERSON/B_LOCATION
species I_PERSON/I_LOCATION
and O
the O
average B_MEASURE/B_PERSON
LD I_MEASURE/I_PERSON
among O
all O
pairs B_PERSON/B_LOCATION
of O
sites B_GENE
for O
which O
one B_PERSON/B_NUMBER[MEASURE]
member B_PERSON/I_NUMBER[MEASURE]
is O
a O
shared O
polymorphism B_GENE/B_MEASURE
and O
the O
other B_SEQUENCE[MEASURE]/B_LOCATION
is O
an O
exclusive B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
polymorphism I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O
DSX B_LOCATION
) O
. O

In O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
tend O
to O
be O
positive B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
see O
[ O
38 B_MEASURE/B_LOCATION
] O
for O
more B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
details I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Because O
of O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
the O
total B_MEASURE
number I_MEASURE
of O
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
could O
be O
handled O
by O
the O
WH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O
could O
not O
perform O
the O
simulations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
all O
sequences B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
we O
carried O
out O
the O
LD O
test O
of O
introgression O
between O
each O
pair O
of O
sympatric O
populations O
of O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_BIO/B_PERSON
. I_BIO/I_PERSON
whitmani I_BIO/I_PERSON
from O
the O
localities O
of O
Posse O
, O
Afonso O
Claudio O
and O
Corte O
de O
Pedra O
. O

The O
input B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
files I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
prepared B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
using O
the O
values B_MEASURE
of O
recombination B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
and O
linkage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disequilibrium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
calculated O
by O
the O
sites B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
30 B_TIME[MEASURE]
] O
for O
each O
population B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
not O
shown O
) O
. O

Although O
no O
significant O
values O
were O
found O
for O
the O
smaller O
samples O
of O
Afonso O
Claudio O
and O
Corte O
de O
Pedra O
, O
the O
results O
( O
Table O
5 O
) O
present O
evidence O
for O
introgression O
in O
the O
period O
gene O
in O
both O
directions O
( O
from O
L B_SPECIES[BIO]/B_LOCATION
. B_SPECIES[BIO]/I_LOCATION
intermedia B_SPECIES[BIO]/I_LOCATION
to O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
and O
vice O
- O
versa O
) O
in O
the O
locality O
of O
Posse O
. O

isolation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
migration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
further O
examine O
the O
gene O
flow O
between O
L B_BIO
. I_BIO
intermedia I_BIO
and O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
whitmani I_SPECIES[BIO]
we O
used O
the O
im O
software O
[ O
39 O
] O
. O

The O
isolation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
migration B_LOCATION/B_PERSON
model I_LOCATION/I_PERSON
has O
six B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
demographic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
parameters I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
include O
two B_MEASURE/B_PERSON
migration B_MEASURE/I_PERSON
rates B_MEASURE/I_PERSON
, O
one B_NUMBER[MEASURE]/B_PERSON
for O
each O
population B_PERSON/B_LOCATION
. O

The O
IM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
estimates O
the O
posterior B_MEASURE
probability I_MEASURE
for O
each O
of O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
fitting O
the O
isolation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
migration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
the O
assumptions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
that O
the O
loci B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
studied O
do O
not O
have O
internal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
recombination B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Therefore O
, O
we O
identified O
four B_NUMBER[MEASURE]/B_ENT
different I_NUMBER[MEASURE]/I_ENT
non O
- O
recombining O
blocks B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
our O
fragment B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
per B_GENE/B_DISEASE
, O
which O
were O
then O
treated O
as O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
loci I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
four B_NUMBER[MEASURE]
- O
gametes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
33 B_NUMBER[MEASURE]
] O
implemented O
in O
DnaSP4 B_GENE
. O
1 B_MEASURE
was O
used O
for O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
possible B_DISEASE/B_BIO
recombination I_DISEASE/I_BIO
events I_DISEASE/I_BIO
. O

Since O
the O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
estimates O
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
a O
pair B_PERSON/B_LOCATION
of O
closely O
related O
populations B_LOCATION/B_BIO
or O
species B_BIO/B_GENE
, O
all O
sequences B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
each O
species B_BIO/B_GENE
were O
used O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

We O
performed O
MCMC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
runs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
IM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
with O
different B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seed B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
order B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
guarantee O
convergence B_TIME[MEASURE]/B_PERSON
of O
the O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Maximum O
likelihood O
estimates O
of O
migration O
parameters O
revealed O
a O
non O
- O
zero O
value O
for O
both O
species O
, O
M1 O
= O
1 O
. O
398 O
and O
m2 O
= O
1 O
. O
014 O
( O
M1 O
- O
from O
L B_BIO/B_LOCATION
. I_BIO/I_LOCATION
whitmani I_BIO/I_LOCATION
towards O
L B_LOCATION/B_PERSON
. I_LOCATION/I_PERSON
intermedia I_LOCATION/I_PERSON
; O
m2 O
- O
from O
L B_BIO
. I_BIO
whitmani I_BIO
towards O
L B_LOCATION/B_PERSON
. I_LOCATION/I_PERSON
intermedia I_LOCATION/I_PERSON
) O
. O

Fig O
5 O
shows O
the O
posterior O
distributions O
for O
migration O
rates O
and O
reveals O
a O
null O
probability O
for O
the O
absence O
of O
migration O
from O
L B_BIO/B_LOCATION
. I_BIO/I_LOCATION
whitmani I_BIO/I_LOCATION
towards O
L B_LOCATION
. I_LOCATION
intermedia I_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
migration B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
opposite B_LOCATION
direction I_LOCATION
is O
not O
included O
in O
the O
95 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
values B_MEASURE/B_DISEASE
range O
from O
0 B_MEASURE
. O
222 B_MEASURE
to O
8 B_MEASURE
. O
898 B_MEASURE
) O
, O
thus O
supporting O
the O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
migration B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
directions B_LOCATION/B_PERSON
. O

The O
conversion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
migration B_MEASURE
rate I_MEASURE
estimate I_MEASURE
to O
population B_MEASURE/B_PERSON
migration I_MEASURE/I_PERSON
rate I_MEASURE/I_PERSON
per O
generation B_MEASURE/B_LOCATION
( O
M1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
m2 B_PROTEIN[GENE]
) O
is O
not O
accurate B_DISEASE_ADJECTIVE[DISEASE]
when O
the O
population B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
size B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
based O
on O
a O
single B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locus B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
the O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
of O
the O
migrant B_MEASURE
number I_MEASURE
per O
generation B_TIME[MEASURE]/B_BIO
for O
both O
species B_BIO
was O
very O
close B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
nm B_MEASURE/B_LOCATION
estimate I_MEASURE/I_LOCATION
based O
on O
Fst B_MEASURE
values I_MEASURE
( O
NM B_PROTEIN[GENE]/B_DISEASE
~ O
0 B_MEASURE
. O
49 B_MEASURE
in O
Table B_MEASURE
4 I_MEASURE
, O
M1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
~ O
0 B_MEASURE
. O
52 B_MEASURE
and O
m2 B_PROTEIN[GENE]/B_LOCATION
~ O
0 B_MEASURE
. O
34 B_MEASURE
) O
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
is O
some O
evidence O
that O
L B_SPECIES[BIO]/B_DISEASE
. I_SPECIES[BIO]/I_DISEASE
intermedia I_SPECIES[BIO]/I_DISEASE
and O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
whitmani I_SPECIES[BIO]
might O
represent O
sibling O
- O
species O
complexes O
in O
Brazil O
. O

Lutzomyia B_BIO/B_MEASURE
neivai B_BIO/I_MEASURE
Pinto O
1926 O
, O
a O
sibling O
of O
L B_SPECIES[BIO]/B_LOCATION
. B_SPECIES[BIO]/I_LOCATION
intermedia B_SPECIES[BIO]/I_LOCATION
is O
found O
in O
parts O
of O
Southern O
and O
Western O
Brazil O
and O
some O
other O
countries O
of O
South O
America O
[ O
40 O
] O
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
include O
populations B_LOCATION/B_BIO
of O
this O
species B_BIO/B_MEASURE
. O

In O
the O
case O
of O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
whitmani I_SPECIES[BIO]
, O
mitochondrial O
data O
[ O
3 O
, O
6 O
] O
indicates O
three O
main O
lineages O
in O
Brazil O
: O
an O
Amazonian O
group O
, O
a O
North O
- O
South O
group O
and O
a O
Northeast O
group O
. O

We O
did O
not O
find O
strong O
evidence O
of O
a O
geographical O
differentiation O
in O
the O
period O
gene O
among O
populations O
of O
L B_SPECIES[BIO]/B_LOCATION
. B_SPECIES[BIO]/I_LOCATION
whitmani B_SPECIES[BIO]/I_LOCATION
although O
one O
of O
the O
pairwise O
Fst O
comparisons O
( O
Posse O
x O
Ilh O
e O
us O
) O
was O
significant O
at O
the O
5 O
% O
level O
. O

When O
we O
compare O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
intermedia I_SPECIES[BIO]/I_PERSON
and O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
, O
we O
find O
a O
highly O
significant O
Fst O
value O
( O
0 O
. O
3373 O
) O
, O
which O
is O
however O
smaller O
than O
that O
observed O
for O
the O
period O
gene O
between O
sympatric O
siblings O
of O
Lutzomyia B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
longipalpis I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Fst O
= O
0 O
. O
3952 O
) O
[ O
23 O
] O
, O
a O
complex O
of O
cryptic O
species O
that O
are O
vectors O
of O
American O
visceral O
leishmaniasis O
. O

Therefore O
, O
despite O
the O
presence O
of O
diagnostic O
morphological O
characters O
to O
identify O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
intermedia I_SPECIES[BIO]/I_PERSON
and O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
[ O
1 O
] O
the O
level O
of O
molecular O
divergence O
in O
period O
is O
not O
as O
high O
as O
the O
cryptic O
L B_SPECIES[BIO]/B_NUMBER[MEASURE]
. I_SPECIES[BIO]/I_NUMBER[MEASURE]
longipalpis I_SPECIES[BIO]/I_NUMBER[MEASURE]
siblings O
. O

Even O
though O
it O
is O
hard O
to O
distinguish O
introgression O
from O
the O
persistence O
of O
ancestral O
polymorphisms O
, O
a O
test O
of O
gene O
flow O
based O
on O
the O
signature O
introgression O
leaves O
on O
the O
patterns O
of O
linkage O
disequilibrium O
[ O
38 O
] O
as O
well O
as O
simulations O
that O
fit O
the O
' O
isolation O
with O
migration O
' O
model O
to O
the O
data O
suggest O
that O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
intermedia I_SPECIES[BIO]/I_PERSON
and O
L B_BIO
. I_BIO
whitmani I_BIO
might O
be O
exchanging O
alleles O
at O
the O
per O
locus O
. O

This O
is O
further O
supported O
by O
the O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
shared O
haplotypes B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
between O
the O
two B_BIO/B_PERSON
species I_BIO/I_PERSON
in O
Posse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
very O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sequences I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
all O
sympatric B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
populations I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
is O
mounting O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plays O
a O
major B_ENT/B_LOCATION
role I_ENT/I_LOCATION
in O
the O
evolution B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
closely O
related O
insect B_BIO/B_GENE
vector I_BIO/I_GENE
species I_BIO/I_GENE
. O

Introgression B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
vectors B_PROTEIN[GENE]/B_PERSON
may O
have O
important B_DISEASE_ADJECTIVE[DISEASE]
epidemiological I_DISEASE_ADJECTIVE[DISEASE]
consequences I_DISEASE_ADJECTIVE[DISEASE]
. O

Gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
loci B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
affect O
vectorial B_DISEASE/B_ORGANISM_FUNCTION
capacity I_DISEASE/I_ORGANISM_FUNCTION
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
those O
controlling O
host B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
susceptibility B_DISEASE/B_MEASURE
to O
parasite O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
can O
change O
the O
transmission B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
consequently O
make O
the O
disease B_DISEASE/B_BIO
control O
a O
harder B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Introgression O
of O
genes O
that O
control O
adaptation O
to O
particular O
types O
of O
environment O
can O
also O
have O
a O
major O
impact O
on O
the O
spread O
of O
vector O
- O
borne O
diseases O
as O
was O
proposed O
for O
the O
major O
African O
malaria O
vector O
Anopheles B_SPECIES[BIO]/B_LOCATION
gambiae I_SPECIES[BIO]/I_LOCATION
[ O
41 O
] O
. O

The O
same B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
said O
about O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
controlling O
insecticide B_DISEASE/B_ORGANISM_FUNCTION
resistance I_DISEASE/I_ORGANISM_FUNCTION
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
Weill B_LOCATION/B_PERSON
et I_LOCATION/I_PERSON
al O
. O

[ O
42 O
] O
found O
a O
kdr O
mutation O
responsible O
for O
pyrethroid O
resistance O
in O
the O
Mopti O
form O
of O
Anopheles B_SPECIES[BIO]/B_LOCATION
gambiae I_SPECIES[BIO]/I_LOCATION
, O
a O
normally O
susceptible O
taxon O
of O
this O
species O
complex O
. O

Sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O
that O
this O
resistant B_GENE/B_BIO
allele I_GENE/I_BIO
probably O
originates O
through O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
Savanna B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
L B_PERSON/B_COLOR
. I_PERSON/I_COLOR
intermedia I_PERSON/I_COLOR
and O
L B_BIO/B_PERSON
. I_BIO/I_PERSON
whitmani I_BIO/I_PERSON
are O
closely O
related O
and O
only O
distinguished O
by O
a O
few O
morphological O
differences O
, O
they O
do O
show O
differentiation O
in O
some O
other O
important O
traits O
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
in O
Posse B_LOCATION/B_PERSON
, O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
localities B_LOCATION/B_ENT
we O
studied O
, O
the O
two B_BIO
species I_BIO
show O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
abundance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
year B_TIME[MEASURE]/B_LOCATION
. O

L B_BACTERIUM[BIO]/B_DISEASE
. I_BACTERIUM[BIO]/I_DISEASE
intermedia I_BACTERIUM[BIO]/I_DISEASE
is O
more O
abundant O
in O
the O
summer O
while O
L B_BACTERIUM[BIO]/B_PERSON
. I_BACTERIUM[BIO]/I_PERSON
whitmani I_BACTERIUM[BIO]/I_PERSON
is O
more O
frequent O
in O
the O
winter O
months O
[ O
2 O
] O
. O

They O
also O
show O
differences O
in O
microhabitat O
preferences O
, O
L B_PERSON
. I_PERSON
intermedia I_PERSON
being O
more O
common O
in O
the O
peridomestic O
area O
while O
L B_BACTERIUM[BIO]/B_PERSON
. I_BACTERIUM[BIO]/I_PERSON
whitmani I_BACTERIUM[BIO]/I_PERSON
is O
found O
mainly O
in O
the O
surrounding O
forest O
[ O
2 O
] O
. O

In O
addition O
, O
the O
two O
species O
show O
marked O
differences O
in O
their O
tendencies O
to O
bite O
humans B_BIO
in O
the O
early O
morning O
, O
with O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
showing O
higher O
feeding O
rates O
than O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
intermedia I_SPECIES[BIO]/I_PERSON
[ O
26 O
] O
. O

Therefore O
, O
despite O
the O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
this O
locality B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O
there O
are O
important B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ecological B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
behavioral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O
the O
two B_BIO/B_PERSON
species I_BIO/I_PERSON
in O
Posse B_LOCATION/B_PERSON
suggesting O
that O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flow I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
probably O
rather O
limited O
in O
loci B_LOCATION
controlling O
these O
traits B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Hence O
, O
it O
is O
yet O
not O
clear O
whether O
introgression O
has O
played O
an O
important O
role O
in O
the O
evolution O
of O
L B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
intermedia I_SPECIES[BIO]/I_LOCATION
and O
L B_BIO
. I_BIO
whitmani I_BIO
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
other B_NUMBER[MEASURE]/B_PERSON
genes B_NUMBER[MEASURE]/I_PERSON
might O
help O
clarify O
the O
issue B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

Evidence O
for O
introgression O
between O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_BIO
. I_BIO
whitmani I_BIO
obtained O
using O
mitochondrial O
DNA O
[ O
4 O
] O
seems O
to O
be O
corroborated O
by O
our O
data O
on O
the O
period O
gene O
, O
a O
nuclear O
marker O
. O

Nevertheless O
, O
considering O
that O
period B_TIME[MEASURE]/B_GENE
is O
potentially O
involved O
in O
reproductive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
isolation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
might O
be O
, O
therefore O
, O
less O
prone B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
introgression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
the O
' O
average B_TIME[MEASURE]/B_PERSON
' O
gene B_PERSON/B_GENE
[ O
43 B_TIME[MEASURE]/B_LOCATION
] B_TIME[MEASURE]/I_LOCATION
, O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
much O
higher B_MEASURE/B_LOCATION
levels I_MEASURE/I_LOCATION
of O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flow I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
the O
two B_BIO/B_PERSON
species I_BIO/I_PERSON
occur O
at O
other B_TIME[MEASURE]/B_PERSON
genes I_TIME[MEASURE]/I_PERSON
. O

It O
might O
, O
on O
the O
other O
hand O
, O
suggest O
that O
this O
behavioral O
gene O
, O
or O
at O
least O
the O
fragment O
we O
analyzed O
, O
did O
not O
play O
a O
role O
in O
speciation O
between O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_BIO
. I_BIO
whitmani I_BIO
. O

In O
fact O
the O
same O
has O
been O
suggested O
for O
some O
Drosophila O
species O
[ O
44 O
] O
despite O
per O
' O
s O
role O
controlling O
lovesong O
and O
mating O
rhythm O
differences O
between O
D B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
melanogaster I_SPECIES[BIO]/I_PERSON
and O
D B_SPECIES[BIO]
. I_SPECIES[BIO]
simulans I_SPECIES[BIO]
[ O
13 O
- O
16 O
] O
. O

Although O
the O
evidence O
for O
introgression O
in O
the O
per O
gene O
between O
L B_SPECIES[BIO]
. I_SPECIES[BIO]
intermedia I_SPECIES[BIO]
and O
L B_BIO
. I_BIO
whitmani I_BIO
is O
not O
overwhelming O
, O
it O
does O
indicate O
the O
need O
to O
extend O
this O
analysis O
to O
other O
loci O
in O
the O
future O
. O

We O
are O
currently O
isolating O
new B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
molecular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
markers B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
two B_BIO/B_LOCATION
species B_BIO/I_LOCATION
to O
carry O
out O
a O
multi B_NUMBER[MEASURE]/B_ENT
- O
locus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O
39 B_TIME[MEASURE]/B_LOCATION
] O
that O
might O
help O
determining O
how O
much B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
differentiation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
there O
is O
across O
the O
genome B_BIO/B_LOCATION
of O
these O
two B_NUMBER[MEASURE]/B_LOCATION
very O
important B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
leishmaniasis I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
vectors I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

sand B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
fly I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
samples I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

sand B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
fly I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
samples I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
used O
in O
this O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
all O
the O
F1 B_PERSON/B_ORGANIZATION
generation I_PERSON/I_ORGANIZATION
from O
wild B_PERSON/B_BIO
collected O
females B_PERSON/B_BIO
from O
the O
Brazilian B_LOCATION
localities I_LOCATION
of O
Posse B_PERSON/B_LOCATION
( O
Petr B_PERSON/B_LOCATION
o I_PERSON/I_LOCATION
polis I_PERSON/I_LOCATION
, O
Rio B_LOCATION/B_PERSON
de I_LOCATION/I_PERSON
Janeiro I_LOCATION/I_PERSON
State I_LOCATION/I_PERSON
, O
22 B_TIME[MEASURE]
degrees I_TIME[MEASURE]
30 I_TIME[MEASURE]
' O
S B_MEASURE
43 I_MEASURE
degrees I_MEASURE
10 I_MEASURE
' O
W B_OTHER/B_LOCATION
) O
, O
Jacarepagu B_PERSON/B_LOCATION
a O
( O
Rio B_LOCATION/B_PERSON
de B_LOCATION/I_PERSON
Janeiro B_LOCATION/I_PERSON
, O
Rio B_LOCATION/B_PERSON
de I_LOCATION/I_PERSON
Janeiro I_LOCATION/I_PERSON
State I_LOCATION/I_PERSON
, O
22 B_TIME[MEASURE]
degrees I_TIME[MEASURE]
55 I_TIME[MEASURE]
' O
S B_TIME[MEASURE]
43 I_TIME[MEASURE]
degrees I_TIME[MEASURE]
21 I_TIME[MEASURE]
' O
W B_OTHER/B_LOCATION
) O
, O
Afonso B_PERSON/B_LOCATION
Claudio I_PERSON/I_LOCATION
( O
Esp B_PERSON/B_LOCATION
i O
rito B_LOCATION
Santo I_LOCATION
State I_LOCATION
, O
20 B_TIME[MEASURE]
degrees I_TIME[MEASURE]
04 I_TIME[MEASURE]
' O
S B_MEASURE/B_LOCATION
41 I_MEASURE/I_LOCATION
degrees I_MEASURE/I_LOCATION
07 I_MEASURE/I_LOCATION
' O
W B_OTHER/B_LOCATION
) O
, O
Corte B_LOCATION/B_PERSON
de B_LOCATION/I_PERSON
Pedra B_LOCATION/I_PERSON
( O
Presidente B_PERSON/B_LOCATION
Tancredo B_PERSON/I_LOCATION
Neves B_PERSON/I_LOCATION
, O
Bahia B_LOCATION/B_PERSON
State I_LOCATION/I_PERSON
, O
13 B_TIME[MEASURE]
degrees I_TIME[MEASURE]
27 I_TIME[MEASURE]
' O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
39 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
degrees B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
25 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
' O
W B_OTHER/B_LOCATION
) O
and O
Ilh B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
e I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
us O
( O
Bahia B_LOCATION/B_PERSON
State I_LOCATION/I_PERSON
, O
14 B_TIME[MEASURE]
degrees I_TIME[MEASURE]
50 I_TIME[MEASURE]
' O
S B_MEASURE/B_LOCATION
39 I_MEASURE/I_LOCATION
degrees I_MEASURE/I_LOCATION
06 I_MEASURE/I_LOCATION
' O
W B_OTHER/B_LOCATION
) O
. O

L B_BACTERIUM[BIO]/B_PERSON
. I_BACTERIUM[BIO]/I_PERSON
intermedia I_BACTERIUM[BIO]/I_PERSON
and O
L B_BACTERIUM[BIO]/B_PERSON
. I_BACTERIUM[BIO]/I_PERSON
whitmani I_BACTERIUM[BIO]/I_PERSON
were O
identified O
according O
to O
Young O
and O
Duncan O
[ O
1 O
] O
. O

The O
progeny B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O
each O
wild B_PERSON/B_TIME[MEASURE]
caught O
female B_PERSON/B_BIO
was O
raised O
separately O
according O
to O
Souza B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

[ O
45 O
] O
and O
only O
one O
F1 O
male O
of O
each O
female O
was O
used O
for O
the O
molecular O
analysis O
, O
which O
included O
68 O
individuals O
of O
L B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
intermedia I_SPECIES[BIO]/I_LOCATION
( O
12 O
from O
Afonso O
Claudio O
, O
18 O
from O
Posse O
, O
20 O
from O
Corte O
de O
Pedra O
and O
18 O
from O
Jacarepagu O
a O
) O
and O
51 O
individuals O
of O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
( O
12 O
from O
Afonso O
Claudio O
, O
17 O
from O
Posse O
, O
3 O
from O
Corte O
de O
Pedra O
and O
19 O
from O
Ilh O
e O
us O
) O
. O

Note O
that O
, O
although O
the O
distribution B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
two B_BIO
species I_BIO
shows O
considerable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
overlap B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
Eastern B_LOCATION/B_MEASURE
Brazil I_LOCATION/I_MEASURE
, O
in O
many B_LOCATION
localities I_LOCATION
only O
one B_SPECIES[BIO]/B_PERSON
species I_SPECIES[BIO]/I_PERSON
is O
found O
or O
is O
far O
more O
abundant B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
than O
the O
other B_SEQUENCE[MEASURE]/B_LOCATION
. O

There O
are O
also O
seasonal B_LOCATION/B_DISEASE
and O
microhabitat B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
abundance B_MEASURE/B_LOCATION
between O
them O
in O
areas B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sympatry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Genomic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
prepared O
according O
to O
Jowett B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
46 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
slight B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
modifications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
for O
30 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cycles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O
95 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
for O
30 B_LOCATION/B_ORGANIZATION
SEC I_LOCATION/I_ORGANIZATION
, O
60 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
for O
30 B_MEASURE/B_LOCATION
SEC I_MEASURE/I_LOCATION
and O
72 B_MEASURE
degrees I_MEASURE
C I_MEASURE
for O
30 B_LOCATION/B_ORGANIZATION
SEC I_LOCATION/I_ORGANIZATION
, O
using O
Abgene B_GENE/B_PERSON
, O
Amersham B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Biosciences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
Biotools B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reagents I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
according O
to O
manufacturers B_PERSON
directions I_PERSON
. O

The O
per O
primer B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
: O
5llper2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
5 B_NUMBER[MEASURE]
' O
- O
AGCATCCTTTTGTAGCAAAC B_DISEASE/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
( O
forward O
) O
and O
3llper2 B_NUMBER[MEASURE]
: O
5 B_NUMBER[MEASURE]
' O
- O
TCAGATGAACTCTTGCTGTC B_PROTEIN[GENE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
' O
( O
reverse O
) O
. O

These O
primers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amplify O
a O
486 B_GENE/B_LOCATION
bp B_GENE/I_LOCATION
fragment B_GENE/I_LOCATION
of O
the O
sand B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fly I_BIO
per O
gene B_GENE/B_LOCATION
homologue I_GENE/I_LOCATION
that O
includes O
part B_MEASURE/B_LOCATION
of O
the O
PAS B_LOCATION
/ O
CLD B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
an O
intron B_GENE
( O
58 B_TIME[MEASURE]
BP I_TIME[MEASURE]
) O
and O
the O
beginning B_MEASURE/B_LOCATION
of O
the O
Pers B_GENE
domain I_GENE
[ O
24 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

The O
amplified B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
cloned O
using O
the O
pMOSBlue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blunt I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ended O
cloning B_GENE/B_LOCATION
kit B_GENE/I_LOCATION
( O
Amersham B_LOCATION/B_ORGANIZATION
Biosciences B_LOCATION/I_ORGANIZATION
) O
and O
plasmid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
using O
the O
' O
Flexiprep B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' O
Kit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Amersham B_LOCATION/B_ORGANIZATION
Biosciences I_LOCATION/I_ORGANIZATION
) O
. O

Cloned O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
sequenced O
at O
Funda B_PERSON/B_LOCATION
c I_PERSON/I_LOCATION
a O
o O
Oswaldo B_LOCATION/B_PERSON
Cruz I_LOCATION/I_PERSON
and O
at O
University B_LOCATION/B_PERSON
of O
Leicester B_LOCATION
using O
ABI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
377 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

With O
the O
exception O
of O
two O
L B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
whitmani I_SPECIES[BIO]/I_PERSON
individuals O
from O
Corte O
de O
Pedra O
( O
see O
below O
) O
, O
only O
one O
sequence O
of O
each O
sand O
fly O
( O
representing O
one O
of O
the O
two O
possible O
alleles O
) O
was O
used O
in O
the O
analysis O
but O
an O
average O
of O
three O
sequences O
per O
individual O
were O
obtained O
in O
order O
to O
check O
possible O
PCR O
induced O
mutations O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
PCR B_GENE/B_MEASURE
fragments I_GENE/I_MEASURE
were O
also O
sequenced O
directly O
in O
some O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
same B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reason I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
the O
case O
of O
the O
two O
L B_BIO/B_PERSON
. I_BIO/I_PERSON
whitmani I_BIO/I_PERSON
mentioned O
above O
6 O
and O
9 O
clones O
were O
sequenced O
respectively O
from O
specimens O
WCP01 O
and O
WCP03 O
to O
determine O
both O
alleles O
simply O
to O
increase O
the O
size O
of O
this O
small O
sample O
. O

Negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
performed O
for O
all O
amplification B_PERSON
reactions I_PERSON
. O

In O
addition B_MEASURE/B_LOCATION
, O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cloning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
repeated O
for O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
individuals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
to O
confirm O
putative B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
introgressed O
sequences B_DISEASE/B_GENE
and O
to O
exclude O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
they O
were O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
PCR B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contamination I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Finally O
, O
for O
at O
least O
two B_PERSON/B_NUMBER[MEASURE]
individuals I_PERSON/I_NUMBER[MEASURE]
with O
putative B_GENE
introgressed I_GENE
sequences I_GENE
, O
we O
could O
define O
the O
other B_GENE/B_BIO
allele B_GENE/I_BIO
from O
additional B_PERSON/B_ENT
clones I_PERSON/I_ENT
( O
not O
included O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
which O
showed O
to O
be O
typical B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
species B_BIO/B_PERSON
, O
indicating O
no O
identification B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
problems I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

The O
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
submitted O
to O
GenBank B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
accession B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
numbers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
AY927062 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
AY927182 B_MEASURE/B_LOCATION
) O
. O

Sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
editing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
carried O
out O
using O
the O
Wisconsin B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
package I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Version I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
1 B_MEASURE
, O
genetics O
Computer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
GCG B_ORGANIZATION/B_LOCATION
) O
, O
Madison B_PERSON/B_ORGANIZATION
, O
and O
ClustalX B_LOCATION/B_PERSON
[ O
47 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
was O
used O
to O
perform O
the O
multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
population B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
differentiation B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
between O
populations B_LOCATION/B_PERSON
were O
carried O
out O
using O
DNAsp4 B_PROTEIN[GENE]/B_MEASURE
. O
1 B_MEASURE/B_ORGANIZATION
[ I_MEASURE/I_ORGANIZATION
34 I_MEASURE/I_ORGANIZATION
] I_MEASURE/I_ORGANIZATION
and O
ProSeq B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
48 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
softwares B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
while O
Arlequin B_PERSON
v O
. O

2 O
. O
0 B_MEASURE
[ O
49 B_MEASURE
] I_MEASURE
was O
used O
for O
an O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
molecular B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variance B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AMOVA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
between O
populations B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
minimum B_LOCATION/B_PERSON
Evolution I_LOCATION/I_PERSON
phylogenetic I_LOCATION/I_PERSON
tree I_LOCATION/I_PERSON
was O
constructed O
using O
MEGA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O
1 B_MEASURE/B_ORGANIZATION
software I_MEASURE/I_ORGANIZATION
[ O
50 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

The O
haplotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
estimated O
using O
TCS1 B_GENE/B_MEASURE
. O
21 B_MEASURE
[ I_MEASURE
36 I_MEASURE
] I_MEASURE
. O

Recombination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
linkage B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disequilibrium I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
using O
the O
DNAsp4 B_PROTEIN[GENE]/B_MEASURE
. O
1 B_MEASURE/B_ORGANIZATION
and O
sites B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O
30 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

linkage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disequilibrium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simulations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
carried O
out O
by O
the O
WH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O
51 B_MEASURE
, O
52 B_MEASURE
] O
and O
Markov B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
chain I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Monte I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Carlo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
MCMC B_LOCATION/B_ORGANIZATION
) O
simulations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
isolation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
migration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
using O
the O
algorithm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implemented O
in O
the O
IM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
39 B_MEASURE
] I_MEASURE
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

CJM B_PERSON/B_LOCATION
generate O
and O
analyzed O
all O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
drafted O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

NAS B_ORGANIZATION/B_PERSON
and O
CAC B_ORGANIZATION/B_LOCATION
collected O
and O
maintained B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sand B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fly I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

CPK B_PERSON/B_LOCATION
helped O
to O
write O
the O
manuscript B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
supervised B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
CJM I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
during O
her O
stay B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
Leicester B_LOCATION
. O

AAP B_PERSON/B_LOCATION
is O
the O
principal B_PERSON
investigator I_PERSON
, O
participated O
in O
its O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
coordination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
and O
helped O
to O
write O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

All O
authors B_PERSON/B_NUMBER[MEASURE]
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

presence O
of O
antibodies O
against O
cyclic O
citrullinated O
peptides O
in O
patients B_PERSON/B_BIO
with O
' O
rhupus O
' O
: O
a O
cross O
- O
sectional O
study O
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

' O
Rhupus B_DISEASE/B_GENE
' O
is O
a O
rare B_DISEASE/B_MEASURE
condition I_DISEASE/I_MEASURE
sharing O
features B_ENT/B_DISEASE
of O
rheumatoid B_DISEASE
arthritis I_DISEASE
( O
RA B_LOCATION/B_ORGANIZATION
) O
and O
systemic B_DISEASE
lupus I_DISEASE
erythematosus I_DISEASE
( O
SLE B_LOCATION
) O
. O

If O
rhupus B_DISEASE
is O
a O
distinctive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
entity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
an O
overlap B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
RA B_DISEASE
and O
SLE B_DISEASE
or O
a O
subset B_DISEASE
of O
SLE B_DISEASE/B_MEASURE
is O
currently O
debated O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
to O
explore O
the O
prevalence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
against O
cyclic B_DISEASE/B_GENE
citrullinated I_DISEASE/I_GENE
peptides I_DISEASE/I_GENE
( O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
CCP B_DISEASE/B_GENE
antibodies I_DISEASE/I_GENE
) O
in O
rhupus B_DISEASE/B_BIO
. O

Patients B_PERSON/B_LOCATION
meeting O
American O
College O
of O
Rheumatology O
criteria O
for O
RA O
, O
SLE O
, O
or O
both O
were O
included O
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
and O
radiographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
recorded O
and O
sera B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
searched O
for O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
CCP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
rheumatoid B_GENE/B_DISEASE
factor I_GENE/I_DISEASE
, O
antinuclear B_DISEASE/B_GENE
antibodies B_DISEASE/I_GENE
, O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
extractable B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O
double B_MEASURE
- O
stranded O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dsDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Seven O
patients B_PERSON
for O
each O
group O
were O
included O
. O

Clinical O
and O
serological O
features O
for O
RA O
or O
SLE O
were O
similar O
between O
rhupus O
and O
RA O
patients B_PERSON/B_DISEASE
, O
and O
between O
rhupus O
and O
SLE O
patients B_PERSON
, O
respectively O
. O

values O
for O
anti O
- O
CCP O
antibodies O
obtained O
were O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
higher O
in O
RA O
( O
6 O
/ O
7 O
) O
and O
rhupus O
( O
4 O
/ O
7 O
) O
than O
in O
SLE O
patients B_PERSON/B_BIO
( O
0 O
/ O
7 O
) O
and O
healthy O
subjects O
( O
0 O
/ O
7 O
) O
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
rhupus B_LOCATION/B_PERSON
is O
an O
overlap B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O
RA B_LOCATION
and O
SLE B_LOCATION/B_ORGANIZATION
, O
because O
highly O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantibodies B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
RA B_DISEASE/B_LOCATION
( O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
CCP B_LOCATION/B_ORGANIZATION
) O
and O
for O
SLE B_LOCATION/B_ORGANIZATION
( O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dsDNA B_LOCATION/B_ORGANIZATION
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
Sm B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
) O
are O
detected O
in O
coexistence B_DISEASE/B_BIO
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
clinical B_DISEASE/B_MEASURE
coexistence I_DISEASE/I_MEASURE
of O
rheumatoid B_DISEASE
arthritis I_DISEASE
( O
RA B_LOCATION/B_ORGANIZATION
) O
and O
systemic B_DISEASE
lupus I_DISEASE
erythematosus I_DISEASE
( O
SLE B_DISEASE/B_LOCATION
) O
was O
first O
described O
in O
1969 B_MEASURE
by O
Kantor B_PERSON
and O
was O
termed O
' O
rhupus B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
' O
by O
Schur B_PERSON
( O
both O
cited O
in O
[ B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
] I_MEASURE/I_LOCATION
) O
. O

Since O
then O
, O
fewer B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
100 B_MEASURE
cases I_MEASURE
of O
rhupus B_DISEASE/B_GENE
have O
been O
published O
[ O
1 B_NUMBER[MEASURE]
- O
3 B_MEASURE
] I_MEASURE
. O

In O
an O
epidemiological O
study O
including O
about O
7 O
, O
000 O
new O
patients B_PERSON/B_BIO
, O
the O
prevalence O
of O
RA O
was O
15 O
% O
and O
for O
SLE O
it O
was O
8 O
. O
9 O
% O
. O

The O
expected O
coincidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
RA B_LOCATION
and O
SLE B_LOCATION
by O
chance B_PERSON/B_MEASURE
would O
therefore O
be O
1 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
. O

However O
, O
the O
observed B_MEASURE/B_DISEASE
prevalence I_MEASURE/I_DISEASE
of O
rhupus B_DISEASE
was O
0 B_MEASURE
. O
09 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
less B_MEASURE
than O
one B_NUMBER[MEASURE]/B_PERSON
- O
tenth B_SEQUENCE[MEASURE]
of O
that O
expected O
[ O
1 B_LOCATION/B_PERSON
] I_LOCATION/I_PERSON
. O

Previous O
reports O
have O
shown O
that O
the O
patients B_PERSON/B_BIO
with O
rhupus O
display O
an O
array O
of O
autoantibodies O
including O
anti O
- O
double O
- O
stranded O
DNA O
( O
anti O
- O
dsDNA O
) O
, O
anti O
- O
SM O
( O
both O
highly O
specific O
for O
SLE O
) O
, O
anti O
- O
SSA O
, O
anti O
- O
SSB O
, O
anti O
- O
ribonucleoprotein O
, O
antinuclear O
antibodies O
( O
Ana O
) O
, O
anti O
- O
cardiolipins O
, O
and O
rheumatoid O
factor O
( O
RF O
) O
[ O
1 O
, O
2 O
] O
. O

However O
, O
no O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
yet O
been O
performed O
to O
investigate O
the O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O
cyclic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
citrullinated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
peptides I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
CCP B_DISEASE/B_GENE
antibodies I_DISEASE/I_GENE
) O
, O
which O
have O
a O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
RA B_DISEASE/B_LOCATION
of O
96 B_MEASURE/B_LOCATION
to O
98 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
for O
second B_SEQUENCE[MEASURE]
- O
generation B_MEASURE/B_ENT
assays I_MEASURE/I_ENT
( O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
CCP2 B_GENE/B_DISEASE
) O
) O
[ O
4 B_MEASURE
, O
5 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
confirmed O
that O
these O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
rarely O
if O
ever O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
other B_DISEASE/B_PERSON
autoimmune I_DISEASE/I_PERSON
diseases I_DISEASE/I_PERSON
such I_DISEASE/I_PERSON
as O
SLE B_DISEASE/B_LOCATION
, O
Sj B_PERSON/B_LOCATION
o I_PERSON/I_LOCATION
gren I_PERSON/I_LOCATION
' O
s O
syndrome B_DISEASE/B_MEASURE
( O
SS B_DISEASE/B_LOCATION
) O
, O
scleroderma B_DISEASE/B_LOCATION
and O
myositis B_DISEASE
[ O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Nowadays O
, O
it O
is O
a O
matter O
of O
debate O
whether O
rhupus O
is O
a O
clinically O
and O
immunologically O
distinctive O
entity O
[ O
2 O
] O
, O
a O
true O
overlap O
between O
SLE O
and O
RA O
[ O
7 O
] O
, O
or O
a O
subgroup O
of O
patients B_PERSON/B_BIO
with O
lupus O
[ O
8 O
] O
. O

This O
descriptive O
, O
cross O
- O
sectional O
study O
was O
performed O
to O
investigate O
the O
frequency O
of O
anti O
- O
CCP O
antibodies O
in O
a O
cohort O
of O
patients B_PERSON/B_BIO
with O
rhupus O
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
included O
all O
patients B_PERSON
fulfilling O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
classification O
criteria O
for O
both O
RA O
[ O
9 O
] O
and O
SLE O
[ O
10 O
] O
who O
belonged O
to O
our O
cohorts O
of O
patients B_PERSON
with O
RA O
and O
with O
SLE O
. O

comparisons O
were O
made O
with O
age O
- O
and O
gender O
- O
matched O
patients B_PERSON
with O
RA O
and O
with O
SLE O
, O
and O
healthy O
subjects O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
approved O
by O
the O
local B_ORGANIZATION/B_LOCATION
ethics I_ORGANIZATION/I_LOCATION
committee I_ORGANIZATION/I_LOCATION
, O
and O
informed O
consent B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
obtained O
. O

Serum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
obtained O
and O
stored O
at O
- O
75 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
until O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Sera B_PERSON/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
were O
analyzed O
for O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CCP2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
ELISA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
Inova B_MEASURE/B_DISEASE
Diagnostics I_MEASURE/I_DISEASE
, O
San B_LOCATION/B_PERSON
Diego I_LOCATION/I_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
with O
a O
cutoff B_MEASURE
value I_MEASURE
of O
60 B_MEASURE
U I_MEASURE
/ O
ml B_MEASURE/B_PERSON
. O

fine B_DISEASE/B_GENE
antinuclear B_DISEASE/I_GENE
reactivities B_DISEASE/I_GENE
( O
ELISA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O
Inova B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnostics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
RF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
nephelometry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
ANA B_PROTEIN[GENE]/B_DISEASE
( O
indirect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
immunofluorescence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
Hep B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE/B_LOCATION
slides I_MEASURE/I_LOCATION
) O
, O
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
dsDNA B_GENE/B_DISEASE
( O
indirect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
immunofluorescence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
Crithidia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
luciliae I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
substrate I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
) O
antibodies B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
also O
determined O
. O

Except O
for O
healthy B_PERSON
individuals I_PERSON
, O
standard B_MEASURE/B_PERSON
radiographs I_MEASURE/I_PERSON
of O
hands B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
were O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ANOVA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
the O
Mann B_PERSON/B_LOCATION
- O
Whitney B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
U B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
performed O
as O
appropriate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
GraphPad B_MEASURE
Prism I_MEASURE
4 I_MEASURE
. O
0 B_MEASURE/B_ORGANIZATION
software I_MEASURE/I_ORGANIZATION
( O
GraphPad B_MEASURE/B_ORGANIZATION
Inc I_MEASURE/I_ORGANIZATION
, O
San B_LOCATION/B_PERSON
Diego I_LOCATION/I_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Seven O
female O
patients B_PERSON
with O
a O
median O
age O
of O
44 O
years O
( O
range O
25 O
to O
64 O
) O
met O
our O
inclusion O
criteria O
. O

The O
major B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinical I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
presented O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

healthy O
individuals O
and O
all O
patients B_PERSON/B_LOCATION
belonged O
to O
cohorts O
from O
the O
same O
ethnic O
group O
( O
Hispanic O
mestizo O
) O
. O

No O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
demographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
found O
between O
groups B_ORGANIZATION/B_LOCATION
. O

Mean B_MEASURE/B_PERSON
ACR B_MEASURE/I_PERSON
criteria B_MEASURE/I_PERSON
for O
SLE B_DISEASE/B_LOCATION
were O
5 B_MEASURE
. O
57 B_MEASURE
( O
range B_NUMBER[MEASURE]/B_LOCATION
4 I_NUMBER[MEASURE]/I_LOCATION
to O
8 B_NUMBER[MEASURE]
) O
in O
the O
SLE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
5 B_MEASURE
. O
57 B_MEASURE
( O
4 B_NUMBER[MEASURE]
to O
8 B_NUMBER[MEASURE]
) O
in O
the O
rhupus B_LOCATION/B_PERSON
group I_LOCATION/I_PERSON
. O

In O
the O
same O
way O
, O
mean O
ACR O
criteria O
for O
RA O
were O
6 O
( O
4 O
to O
7 O
) O
in O
the O
RA O
group O
, O
and O
5 O
. O
14 O
( O
4 O
to O
6 O
) O
for O
the O
patients B_PERSON/B_ORGANIZATION
with O
rhupus O
. O

In O
all O
patients B_PERSON/B_BIO
with O
rhupus O
, O
RA O
was O
presented O
as O
the O
initial O
disease O
, O
as O
has O
been O
described O
previously O
[ O
2 O
] O
. O

In O
accordance O
with O
another O
report O
, O
in O
two O
patients B_PERSON/B_LOCATION
the O
disease O
started O
during O
their O
childhood O
as O
juvenile O
chronic O
arthritis O
[ O
1 O
] O
. O

Anti O
- O
CCP O
antibodies O
were O
found O
in O
four O
of O
seven O
( O
57 O
% O
) O
patients B_PERSON
with O
rhupus O
, O
and O
in O
six O
of O
seven O
( O
86 O
% O
) O
patients B_PERSON/B_DISEASE
with O
RA O
, O
whereas O
neither O
patients B_PERSON
with O
SLE O
nor O
healthy O
individuals O
showed O
reactivity O
. O

When O
the O
concentrations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
each O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
, O
a O
statistical B_MEASURE/B_PERSON
significant I_MEASURE/I_PERSON
difference I_MEASURE/I_PERSON
between O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
( O
ANOVA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

The O
mean O
concentration O
of O
anti O
- O
CCP O
antibodies O
was O
584 O
U O
/ O
ml O
( O
range O
0 O
to O
1 O
, O
237 O
) O
in O
patients B_PERSON
with O
rhupus O
( O
Figure O
1 O
) O
, O
875 O
U O
/ O
ml O
( O
0 O
to O
1 O
, O
178 O
) O
in O
the O
RA O
group O
( O
not O
significant O
compared O
with O
rhupus O
) O
, O
1 O
U O
/ O
ml O
( O
0 O
to O
10 O
) O
for O
SLE O
individuals O
( O
p O
< O
0 O
. O
05 O
compared O
with O
rhupus O
) O
, O
and O
0 O
U O
/ O
ml O
( O
0 O
to O
2 O
) O
for O
healthy O
controls O
( O
p O
< O
0 O
. O
05 O
compared O
with O
rhupus O
) O
. O

Two O
of O
three O
patients B_PERSON
with O
rhupus O
who O
were O
negative O
for O
anti O
- O
CCP O
antibodies O
were O
also O
negative O
for O
anti O
- O
dsDNA O
antibodies O
, O
RF O
and O
anti O
- O
extractable O
nuclear O
antigen O
antibodies O
, O
although O
both O
patients B_PERSON/B_LOCATION
met O
RA O
and O
SLE O
classification O
criteria O
, O
including O
Ana O
and O
erosive O
arthritis O
. O

differences O
in O
Ana O
, O
anti O
- O
dsDNA O
and O
anti O
- O
extractable O
nuclear O
antigen O
autoantibodies O
between O
patients B_PERSON/B_BIO
with O
rhupus O
and O
those O
with O
SLE O
were O
not O
found O
. O

We O
also O
found O
no O
difference O
in O
the O
prevalence O
of O
RF O
between O
patients B_PERSON/B_BIO
with O
rhupus O
and O
those O
with O
RA O
. O

surprisingly O
, O
one B_PERSON
healthy I_PERSON
subject I_PERSON
was O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
RF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
ANA B_DISEASE/B_PROTEIN[GENE]
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
SSA B_DISEASE/B_GENE
antibodies B_DISEASE/I_GENE
, O
although O
she O
was O
asymptomatic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
no O
features B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
any O
disease B_DISEASE
were O
found O
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
close O
association O
between O
different O
type O
II O
human B_SPECIES[BIO]
leukocyte O
antigen O
( O
HLA O
) O
molecules O
and O
the O
risk O
of O
RA O
is O
well O
established O
. O

These O
major B_GENE/B_BIO
histocompatibility I_GENE/I_BIO
complex I_GENE/I_BIO
( O
MHC B_LOCATION/B_ORGANIZATION
) O
class B_GENE/B_LOCATION
II I_GENE/I_LOCATION
molecules I_GENE/I_LOCATION
share O
the O
same B_GENE/B_LOCATION
amino I_GENE/I_LOCATION
acid I_GENE/I_LOCATION
sequence I_GENE/I_LOCATION
( O
QKRAA B_LOCATION/B_ORGANIZATION
or O
QRRAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
in O
positions B_MEASURE
69 I_MEASURE
to O
74 B_MEASURE
of O
the O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
chain B_LOCATION/B_GENE
, O
namely O
the O
' O
shared O
epitope B_PROTEIN[GENE]/B_LOCATION
' O
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
works I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O
demonstrated O
that O
this O
' O
shared O
epitope B_PROTEIN[GENE]/B_LOCATION
' I_PROTEIN[GENE]/I_LOCATION
preferentially O
binds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
peptides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
containing O
the O
non B_DISEASE/B_LOCATION
- O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amino I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
citrulline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
deiminated B_MEASURE/B_LOCATION
arginine I_MEASURE/I_LOCATION
) O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
11 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
addition O
, O
an O
abnormally O
increased O
function O
of O
the O
enzyme O
peptidylarginine O
deiminase O
4 O
( O
PAD4 O
; O
responsible O
for O
the O
deimination O
of O
arginine O
) O
and O
an O
elevated O
anti O
- O
CCP O
autoantibody O
production O
in O
patients B_PERSON/B_BIO
with O
RA O
have O
been O
demonstrated O
[ O
12 O
] O
. O

These O
facts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
built O
the O
first B_LOCATION/B_PERSON
bridge I_LOCATION/I_PERSON
between O
cellular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
humoral B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
autoimmunity B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O
a O
major B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rheumatic I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
supporting O
a O
pathogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
an O
abnormal B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_DISEASE_ADJECTIVE[DISEASE]
of O
citrulline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
RA B_DISEASE/B_LOCATION
[ I_DISEASE/I_LOCATION
13 I_DISEASE/I_LOCATION
, O
14 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Patients B_PERSON/B_BIO
with O
SLE O
are O
often O
part O
of O
the O
control O
group O
when O
determining O
the O
specificity O
of O
anti O
- O
CCP O
antibodies O
for O
RA O
[ O
15 O
] O
, O
although O
some O
studies O
have O
been O
performed O
specifically O
on O
patients B_PERSON/B_DISEASE
with O
SLE O
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
contribute O
some O
clues B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CCP B_DISEASE/B_GENE
antibodies B_DISEASE/I_GENE
in O
rhupus B_DISEASE/B_LOCATION
. O

Mediwake O
and O
colleagues O
[ O
16 O
] O
, O
in O
a O
study O
exploring O
the O
predictive O
value O
of O
anti O
- O
CCP O
antibodies O
to O
distinguish O
erosive O
arthritis O
in O
SLE O
, O
found O
ten O
patients B_PERSON
( O
out O
of O
231 O
) O
with O
erosive O
arthritis O
, O
two O
of O
whom O
had O
anti O
- O
CCP O
antibodies O
. O

In O
Concord O
with O
this O
, O
Hoffman O
and O
colleagues O
[ O
15 O
] O
demonstrate O
that O
three O
patients B_PERSON/B_BIO
with O
erosive O
arthritis O
, O
included O
in O
a O
cohort O
of O
235 O
patients B_PERSON
with O
SLE O
, O
were O
positive O
for O
anti O
- O
CCP O
antibodies O
. O

These O
authors O
suggest O
that O
the O
presence O
of O
anti O
- O
CCP O
antibodies O
can O
predispose O
for O
a O
chronic O
RA O
- O
like O
arthritis O
in O
patients B_PERSON/B_BIO
with O
SLE O
. O

Additionally O
Weissman O
and O
colleagues O
[ O
17 O
] O
demonstrated O
that O
patients B_PERSON/B_BIO
with O
SLE O
can O
display O
radiographic O
abnormalities O
similar O
to O
those O
of O
RA O
, O
although O
the O
presence O
of O
marginal O
erosions O
is O
a O
rare O
finding O
. O

In O
the O
present O
study O
we O
demonstrate O
that O
the O
patients B_PERSON/B_BIO
with O
rhupus O
show O
a O
very O
similar O
arthritis O
pattern O
( O
including O
erosive O
disease O
) O
and O
similar O
autoantibody O
production O
( O
RF O
and O
anti O
- O
CCP O
antibodies O
) O
to O
those O
in O
patients B_PERSON/B_ORGANIZATION
with O
RA O
. O

In O
addition O
, O
patients B_PERSON/B_BIO
with O
rhupus O
display O
a O
clinical O
and O
serological O
profile O
indistinguishable O
from O
patients B_PERSON
with O
SLE O
. O

Moreover O
, O
the O
presence O
of O
other O
coexistent O
autoimmune O
diseases O
was O
similar O
in O
all O
groups O
of O
patients B_PERSON
( O
two O
patients B_PERSON/B_DISEASE
with O
rhupus O
, O
three O
patients B_PERSON/B_DISEASE
with O
RA O
, O
and O
three O
patients B_PERSON
with O
SLE O
also O
had O
SS O
) O
. O

We O
found O
high O
titers O
of O
anti O
- O
CCP O
antibodies O
in O
four O
of O
seven O
( O
57 O
% O
) O
patients B_PERSON/B_LOCATION
with O
rhupus O
, O
a O
frequency O
similar O
to O
that O
reported O
for O
RA O
[ O
4 O
] O
. O

This O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
together O
with O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
similarity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
supports O
the O
contention B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
rhupus B_DISEASE/B_LOCATION
belongs O
to O
the O
RA B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
spectrum B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

The O
high O
prevalence O
of O
anti O
- O
CCP O
antibodies O
in O
RA O
found O
in O
our O
study O
could O
be O
explained O
by O
a O
selection O
bias O
because O
only O
patients B_PERSON/B_BIO
with O
RA O
with O
an O
aggressive O
disease O
( O
namely O
erosive O
arthritis O
and O
RF O
+ O
) O
were O
included O
. O

In O
contrast O
, O
the O
mean O
ACR O
criterion O
for O
SLE O
was O
similar O
between O
patients B_PERSON/B_BIO
with O
rhupus O
and O
those O
with O
SLE O
, O
including O
the O
' O
robust O
' O
features O
of O
SLE O
such O
as O
renal O
and O
neurological O
involvement O
, O
and O
anti O
- O
dsDNA O
and O
anti O
- O
SM O
antibodies O
. O

These O
clinical O
and O
serological O
features O
shared O
between O
patients B_PERSON
with O
rhupus O
and O
those O
with O
SLE O
also O
place O
rhupus O
in O
the O
SLE O
spectrum O
. O

titration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CCP B_DISEASE/B_GENE
antibodies B_DISEASE/I_GENE
in O
the O
rhupus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
clearly O
shows O
a O
bimodal B_MEASURE/B_LOCATION
distribution I_MEASURE/I_LOCATION
, O
suggesting O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
of O
two B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subpopulations B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Because O
of O
the O
small O
number O
of O
patients B_PERSON/B_LOCATION
, O
we O
are O
unable O
to O
define O
the O
differential O
features O
underlying O
each O
subset O
. O

However O
, O
two O
of O
three O
patients B_PERSON
negative O
for O
anti O
- O
CCP O
antibodies O
were O
also O
negative O
for O
both O
RF O
and O
anti O
- O
dsDNA O
antibodies O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

On O
the O
basis O
of O
the O
presence O
of O
shared O
clinical O
features O
of O
RA O
( O
mainly O
erosive O
arthritis O
) O
and O
SLE O
( O
including O
renal O
and O
neurological O
involvement O
) O
along O
with O
the O
presence O
of O
anti O
- O
dsDNA O
and O
anti O
- O
CCP O
autoantibodies O
in O
our O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
rhupus O
, O
our O
findings O
strongly O
support O
the O
contention O
that O
rhupus O
is O
a O
true O
overlap O
between O
RA O
and O
SLE O
, O
not O
merely O
a O
part O
of O
the O
clinical O
spectrum O
of O
the O
articular O
involvement O
seen O
in O
SLE O
. O

Moreover O
, O
on O
the O
basis O
of O
the O
mean O
ACR O
criteria O
for O
both O
diseases O
, O
we O
have O
confirmed O
that O
patients B_PERSON/B_BIO
with O
rhupus O
have O
more O
RA O
- O
associated O
and O
less O
SLE O
- O
associated O
damage O
, O
an O
issue O
that O
has O
been O
suggested O
previously O
[ O
2 O
] O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
exploring O
the O
prevalence O
of O
anti O
- O
CCP O
antibodies O
specifically O
in O
patients B_PERSON/B_BIO
with O
rhupus O
. O

More B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
are O
needed O
to O
expand O
the O
pathogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
knowledge I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
overlap B_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
. O

Abbreviations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Ana B_PERSON/B_LOCATION
= O
antinuclear B_DISEASE/B_GENE
antibodies I_DISEASE/I_GENE
; O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
CCP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
= O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
cyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
citrullinated O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dsDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
= O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
double B_MEASURE
- O
stranded O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O
ELISA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
= O
enzyme B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
linked O
immunosorbent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O
RA B_LOCATION
= O
rheumatoid B_DISEASE/B_PERSON
arthritis I_DISEASE/I_PERSON
; O
RF B_LOCATION
= O
rheumatoid B_DISEASE
factor I_DISEASE
; O
SLE B_LOCATION
= O
systemic B_DISEASE
lupus I_DISEASE
erythematosus I_DISEASE
; O
SS B_LOCATION
= O
Sj B_GENE/B_LOCATION
o O
gren B_LOCATION/B_PROTEIN[GENE]
' O
s B_DISEASE
syndrome I_DISEASE
. O

competing O
interests B_DISEASE
. O

The O
authors B_PERSON
declare O
that O
they O
have O
no O
competing O
interests B_PERSON/B_ORGANIZATION
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

LA B_LOCATION/B_PERSON
- O
G B_OTHER/B_PROTEIN[GENE]
participated O
in O
the O
conception B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
in O
the O
acquisition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
and O
was O
involved O
in O
drafting O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RS B_PERSON/B_LOCATION
performed O
the O
immunoassays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

RM B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
V B_OTHER/B_NUMBER[MEASURE]
participated O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
performed O
the O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

LG B_LOCATION/B_PROTEIN[GENE]
- O
G B_OTHER/B_NUMBER[MEASURE]
participated O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

AV O
participated O
in O
the O
recruitment O
of O
patients B_PERSON
and O
the O
acquisition O
of O
data O
. O

RB B_PROTEIN[GENE]/B_PERSON
participated O
in O
the O
interpretation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
revising O
the O
manuscript B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
intellectual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
content I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
giving O
the O
final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
approval I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
version B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
to O
be O
published O
. O

All O
authors B_PERSON/B_NUMBER[MEASURE]
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

identification O
of O
a O
human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O
blood O
monocyte O
subset O
that O
differentiates O
into O
osteoclasts O
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

increased O
bone B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
resorption B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
mediated O
by O
osteoclasts B_DISEASE/B_GENE
causes O
various B_DISEASE_ADJECTIVE[DISEASE]
diseases I_DISEASE_ADJECTIVE[DISEASE]
such I_DISEASE_ADJECTIVE[DISEASE]
as O
osteoporosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
bone B_DISEASE
erosion I_DISEASE
in O
rheumatoid B_DISEASE/B_PERSON
arthritis I_DISEASE/I_PERSON
( O
RA B_DISEASE/B_PROTEIN[GENE]
) O
. O

osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
are O
derived O
from O
the O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
macrophage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lineage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
the O
precise B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
origin B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
present O
study O
, O
we O
show O
that O
the O
purified O
CD16 O
- O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
peripheral O
blood O
monocyte O
subset O
, O
but O
not O
the O
CD16 O
+ O
monocyte O
subset O
, O
differentiates O
into O
osteoclast O
by O
stimulation O
with O
receptor O
activator O
of O
NF O
- O
Kappa O
B O
ligand O
( O
RANKL O
) O
in O
combination O
with O
macrophage O
colony O
- O
stimulating O
factor O
( O
M O
- O
CSF O
) O
. O

integrin B_GENE
- O
beta B_PROTEIN[GENE]/B_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
mRNA I_PROTEIN[GENE]/I_MEASURE
and O
the O
integrin B_GENE
- O
alpha B_GENE
v I_GENE
beta I_GENE
3 I_GENE
heterodimer I_GENE
were O
only O
expressed O
on O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
when O
they O
were O
stimulated O
with O
RANKL B_PROTEIN[GENE]/B_LOCATION
+ I_PROTEIN[GENE]/I_LOCATION
M I_PROTEIN[GENE]/I_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

downregulation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
beta B_GENE
3 I_GENE
- O
subunit B_GENE
expression I_GENE
by O
small B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
interfering B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
RNA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
targeting O
beta B_GENE
3 I_GENE
abrogated O
osteoclastogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocyte B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocyte I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
subset I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
expressed O
larger B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
amounts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
than O
the O
CD16 B_GENE
- O
subset B_MEASURE/B_PERSON
, O
which O
was O
further O
enhanced O
by O
RANKL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
RA B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovial I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
showed O
accumulation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE/B_DISEASE
- O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
consist O
of O
two B_NUMBER[MEASURE]
functionally O
heterogeneous B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subsets I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O
distinct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
RANKL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
seem O
to O
originate O
from O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
integrin B_GENE
beta I_GENE
3 I_GENE
is O
necessary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
osteoclastogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

blockade B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
accumulation B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
activation B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CD16 B_PROTEIN[GENE]/B_DISEASE
- O
monocytes B_GENE
could O
therefore O
be O
a O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
bone B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resorptive I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
especially O
for O
RA B_DISEASE/B_LOCATION
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

rheumatoid B_DISEASE
arthritis I_DISEASE
( O
RA B_LOCATION/B_ORGANIZATION
) O
is O
an O
autoimmune B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
characterized O
by O
chronic B_DISEASE_ADJECTIVE[DISEASE]
inflammation I_DISEASE_ADJECTIVE[DISEASE]
and O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
synovium B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
in O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
joints I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

A O
large B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
inflammatory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
dendritic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
accumulate O
in O
the O
affected B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
these O
inflammatory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O
together O
with O
fibroblast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
- O
like B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synoviocytes B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
express O
various B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
) O
, O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
and O
receptor B_GENE
activator I_GENE
of O
NF B_DISEASE/B_GENE
- O
kappa B_PROTEIN[GENE]/B_MEASURE
B I_PROTEIN[GENE]/I_MEASURE
ligand I_PROTEIN[GENE]/I_MEASURE
( O
RANKL B_GENE
) O
, O
which O
are O
known O
to O
induce O
differentiation B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
activation B_GENE/B_ORGANISM_FUNCTION
of O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

The O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
synovial B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
tissue B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
known O
as O
pannus B_LOCATION/B_DISEASE
, O
invades O
the O
articular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
bone I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
causes O
focal B_DISEASE
bone I_DISEASE
erosion I_DISEASE
, O
which O
is O
the O
hallmark B_DISEASE_ADJECTIVE[DISEASE]
of O
RA B_DISEASE/B_LOCATION
. O

Histopathologically O
, O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
are O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
the O
interface B_LOCATION
of O
the O
pannus B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
and O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Interestingly O
, O
the O
deletion O
of O
RANKL O
or O
c O
- O
Fos O
gene O
, O
which O
is O
important O
for O
osteoclastogenesis O
, O
results O
in O
minimal O
bone O
destruction O
in O
mouse B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
models O
of O
arthritis O
[ O
1 O
, O
2 O
] O
. O

Furthermore O
, O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O
that O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
osteoclastogenesis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
by O
osteoprotegerin B_GENE
, O
a O
decoy B_GENE
receptor I_GENE
for O
RANKL B_GENE
, O
limits O
bone B_DISEASE
destruction I_DISEASE
in O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
arthritis B_DISEASE
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
are O
involved O
in O
focal B_DISEASE
bone I_DISEASE
erosion I_DISEASE
in O
RA B_DISEASE
[ I_DISEASE
3 I_DISEASE
] I_DISEASE
. O

osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
are O
derived O
from O
the O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
macrophage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lineage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
reported O
that O
osteoclast O
precursors O
reside O
in O
human B_PERSON/B_SPECIES[BIO]
peripheral O
blood O
monocytes O
[ O
4 O
, O
5 O
] O
. O

A O
marked O
increase O
of O
the O
circulating O
osteoclast O
precursors O
was O
demonstrated O
in O
patients B_PERSON/B_BIO
with O
erosive O
psoriatic O
arthritis O
as O
well O
as O
in O
arthritic O
TNF O
alpha O
transgenic O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
6 O
, O
7 O
] O
. O

It O
was O
also O
shown O
that O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
differentiate O
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
when O
seeded O
on O
RANKL B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
osteoclast B_LOCATION/B_ORGANIZATION
differentiation I_LOCATION/I_ORGANIZATION
factor I_LOCATION/I_ORGANIZATION
- O
producing O
RA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
fibroblasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
8 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
RA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
thought O
to O
originate O
from O
peripheral B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
shown O
to O
differentiate O
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
[ O
9 B_MEASURE
, O
10 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
are O
therefore O
involved O
not O
only O
in O
synovial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
inflammation I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
also O
in O
bone B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
remodeling B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O
potential B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precursors I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
synovial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

Human B_PERSON/B_MEASURE
peripheral O
blood O
monocytes O
consist O
of O
two O
major O
subsets O
, O
CD16 O
+ O
and O
CD16 O
- O
, O
comprising O
5 O
- O
10 O
% O
and O
90 O
- O
95 O
% O
of O
the O
monocytes O
, O
respectively O
. O

These O
two B_MEASURE/B_PROTEIN[GENE]
subsets B_MEASURE/I_PROTEIN[GENE]
exhibit O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemotaxis B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activities B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
potential B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
cytokine B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
production B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
[ O
11 B_MEASURE
, O
12 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Moreover O
, O
activation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
Toll B_GENE
- O
like B_PROTEIN[GENE]/B_LOCATION
receptor I_PROTEIN[GENE]/I_LOCATION
induces O
distinct B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
subsets I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
CD1b B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
dendritic B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
DC B_GENE/B_LOCATION
- O
Sign B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
+ B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
dendritic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
C B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
type B_PROTEIN[GENE]/B_LOCATION
lectin I_PROTEIN[GENE]/I_LOCATION
ICAM I_PROTEIN[GENE]/I_LOCATION
- O
3 B_MEASURE/B_BIO
- O
grabbing O
nonintegrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE
- O
monocytes B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
respectively O
[ O
13 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
has O
not O
been O
revealed O
, O
however O
, O
which O
monocyte B_DISEASE
subset I_DISEASE
develops O
into O
osteoclasts B_DISEASE/B_LOCATION
. O

In O
the O
present O
study O
, O
we O
determined O
the O
human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O
blood O
monocyte O
subset O
that O
differentiates O
into O
osteoclasts O
, O
and O
revealed O
that O
each O
subset O
exhibits O
a O
different O
response O
for O
osteoclastogenic O
stimuli O
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

purification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
peripheral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
blood I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
monocytes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
healthy B_PERSON/B_BIO
donors I_PERSON/I_BIO
were O
collected O
using O
Ficoll B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
Conray B_PERSON/B_LOCATION
( O
Imuuno B_BIO/B_LOCATION
- O
Biological B_LOCATION/B_PERSON
Laboratories I_LOCATION/I_PERSON
, O
Gunma B_LOCATION
, O
Japan B_LOCATION/B_MEASURE
) O
gradient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
centrifugation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
selection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
monocytes B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
using O
MACS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
microbeads I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O
Miltenyi B_MEASURE/B_PERSON
Biotec I_MEASURE/I_PERSON
, O
Auburn B_LOCATION/B_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
according O
to O
the O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supplied O
by O
the O
manufacturer B_PERSON/B_ORGANIZATION
. O

The O
purified B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
separated O
into O
two B_MEASURE
subsets I_MEASURE
, O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE
- O
monocytes B_GENE/B_MEASURE
, O
using O
CD16 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MicroBeads I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Miltenyi B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Biotec I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Flow O
cytometry O
analysis O
using O
FITC O
- O
conjugated O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
CD14 O
mAb O
( O
MY4 O
; O
Bechman O
Coulter O
, O
Fullerton O
, O
CA O
, O
USA O
) O
and O
phycoerythin O
- O
conjugated O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
CD16 O
mAb O
( O
3G8 O
; O
BD O
Biosciences O
, O
San O
Jose O
, O
CA O
, O
USA O
) O
showed O
that O
the O
purities O
of O
the O
CD16 O
+ O
and O
CD16 O
- O
monocytes O
were O
more O
than O
90 O
% O
and O
92 O
% O
, O
respectively O
. O

For O
the O
other O
experiment O
, O
monocytes O
were O
purified O
using O
CD14 O
MicroBeads O
( O
Miltenyi O
Biotec O
) O
, O
and O
then O
stained O
either O
with O
FITC O
- O
conjugated O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
CD33 O
mAb O
( O
MY9 O
; O
Bechman O
Coulter O
) O
or O
phycoerythin O
- O
conjugated O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
CD16 O
mAb O
( O
3G8 O
) O
. O

Cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sorting I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
stained O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
performed O
using O
a O
FACS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Vantage B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytometer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
BD B_LOCATION/B_ORGANIZATION
Biosciences I_LOCATION/I_ORGANIZATION
) O
or O
a O
MoFlo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cell I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sorter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Dako B_PERSON/B_MEASURE
, O
Glostrup B_LOCATION/B_PERSON
, O
Denmark B_LOCATION/B_MEASURE
) O
. O

osteoclast B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Purified O
CD16 O
+ O
and O
CD16 O
- O
monocytes O
( O
5 O
x O
104 O
cells O
/ O
well O
) O
were O
incubated O
in O
96 O
- O
well O
plates O
in O
alpha O
MEM O
( O
Sigma O
, O
St O
Louis O
, O
Mo O
, O
USA O
) O
with O
heat O
- O
inactivated O
10 O
% O
fetal O
bovine B_SPECIES[BIO]/B_PROTEIN[GENE]
serum O
( O
FBS O
) O
( O
Sigma O
) O
or O
with O
Ultra O
- O
Low O
IgG O
FBS O
( O
IgG O
< O
5 O
Mu O
g O
/ O
ml O
; O
Invitrogen O
, O
Carlsbad O
, O
CA O
, O
USA O
) O
, O
and O
where O
indicated O
with O
M O
- O
CSF O
+ O
RANKL O
( O
Peprotech O
, O
Rocky O
Hill O
, O
NJ O
, O
USA O
) O
. O

For O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
varied O
numbers B_MEASURE/B_LOCATION
of O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O
1 B_MEASURE
x O
103 B_MEASURE
, O
2 B_MEASURE
. O
5 B_MEASURE
x O
103 B_MEASURE
, O
5 B_MEASURE
x O
103 B_MEASURE
) O
were O
mixed O
with O
CD16 B_GENE/B_LOCATION
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
5 B_MEASURE
x O
104 B_MEASURE
cells I_MEASURE
/ O
well O
) O
, O
and O
were O
cultured O
in O
96 B_MEASURE/B_LOCATION
- O
well O
plates B_PRODUCT[OBJECT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Mem I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
heat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
inactivated O
10 B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
% B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
FBS B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
replaced O
with O
fresh B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
later O
, O
and O
after O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
for O
7 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
stained O
for O
tartrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
resistant B_ENZYME[GENE]/B_DISEASE
acid I_ENZYME[GENE]/I_DISEASE
phosphatase I_ENZYME[GENE]/I_DISEASE
( O
TRAP B_GENE/B_LOCATION
) O
expression B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
a O
commercial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kit I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Hokudo B_MEASURE/B_PERSON
, O
Sapporo B_LOCATION/B_ORGANIZATION
, O
Japan B_LOCATION/B_MEASURE
) O
. O

The O
number B_MEASURE/B_PERSON
of O
TRAP B_GENE/B_DISEASE
- O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
multinucleated O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
MNC B_DISEASE/B_LOCATION
) O
in O
three B_NUMBER[MEASURE]/B_LOCATION
randomly O
selected O
fields B_LOCATION
examined O
at O
100 B_NUMBER[MEASURE]
x O
magnification B_MEASURE
or O
the O
total B_MEASURE
number I_MEASURE
of O
TRAP B_GENE/B_DISEASE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O
well O
was O
counted O
under O
light B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

resorption B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
seeded O
onto O
plates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coated O
with O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
thin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
films I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Biocoat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Osteologic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O
BD B_LOCATION/B_ORGANIZATION
Biosciences I_LOCATION/I_ORGANIZATION
) O
and O
were O
incubated O
with O
RANKL B_GENE
( O
40 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
) O
+ B_DISEASE/B_PROTEIN[GENE]
M B_DISEASE/I_PROTEIN[GENE]
- O
CSF B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
25 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
) O
for O
7 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cells B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O
then O
lysed O
in O
bleach B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaOCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
NaCl I_MEASURE
) O
. O

The O
resorption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
lacunae B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
examined O
under O
light B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

enzyme O
- O
linked O
immunosorbent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Purified B_PERSON/B_GENE
monocytes I_PERSON/I_GENE
were O
cultured O
in O
96 B_MEASURE/B_LOCATION
- O
well O
plates B_PRODUCT[OBJECT]/B_LOCATION
where O
indicated O
either O
with O
RANKL B_LOCATION/B_ORGANIZATION
or O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
for O
24 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
in O
the O
culture B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
supernatant I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_BACTERIUM[BIO]
were O
measured O
with O
an O
ELISA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kit I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
BioSourse B_MEASURE/B_LOCATION
International I_MEASURE/I_LOCATION
, O
Camarillo B_LOCATION/B_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

For O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
matrix B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
metalloproteinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MMP B_GENE/B_BIO
) O
- O
9 B_NUMBER[MEASURE]
and O
TRAP B_GENE/B_DISEASE
- O
5b B_NUMBER[MEASURE]
, O
culture B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
supernatants I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
collected O
on O
day B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
7 I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
the O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
enzymes B_ENZYME[GENE]
were O
measured O
using O
an O
MMP B_GENE/B_BIO
- O
9 B_MEASURE
ELISA I_MEASURE
kit I_MEASURE
( O
Amersham B_LOCATION/B_PERSON
Biosciences I_LOCATION/I_PERSON
, O
Piscataway B_LOCATION/B_PERSON
, O
NJ B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
or O
a O
TRAP B_GENE/B_DISEASE
- O
5b B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ELISA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kit I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Suomen B_LOCATION/B_ORGANIZATION
, O
Turku B_LOCATION
, O
Finland B_LOCATION
) O
. O

Reverse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcriptase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
polymerase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
( O
1 B_MEASURE
x O
106 B_MEASURE
cells I_MEASURE
/ O
well O
) O
were O
cultured O
in O
six B_MEASURE/B_LOCATION
- O
well B_TIME[MEASURE]/B_LOCATION
plates I_TIME[MEASURE]/I_LOCATION
with O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
alone O
or O
with O
M B_OTHER/B_LOCATION
- O
CSF B_GENE
+ I_GENE
RANKL I_GENE
for O
3 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Total B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
extracted O
using O
RNeasy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Micro I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Qiagen B_MEASURE/B_PERSON
, O
Valencia B_LOCATION/B_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

The O
RNA B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
then O
treated O
with O
DNase B_GENE
I I_GENE
( O
Qiagen B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O
. O

The O
oligo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
dT B_PROTEIN[GENE]/B_LOCATION
) O
- O
primed O
cDNA B_GENE
was O
synthesized O
using O
Superscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reverse O
transcriptase B_GENE
( O
Invitrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
amount B_MEASURE
of O
cDNA B_GENE
for O
amplification B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
adjusted O
by O
the O
amount B_MEASURE
of O
RNA B_GENE/B_BIO
measured O
by O
an O
optical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
density I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
meter I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
also O
by O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
actin B_GENE/B_BACTERIUM[BIO]
or O
GAPDH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PCR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

One B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microliter B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cDNA B_GENE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
was O
amplified O
in O
a O
50 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mu I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
l I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
final I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
volume I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
containing O
25 B_GENE
pmol I_GENE
appropriate I_GENE
primer I_GENE
pair I_GENE
, O
10 B_NUMBER[MEASURE]
pmol O
each O
of O
the O
four B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
deoxynucleotide I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
triphosphates I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
and O
5 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
units I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FastStart I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Taq I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Roche B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
Manheim B_LOCATION
, O
Germany B_LOCATION
) O
in O
a O
thermal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cycler I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
PTC B_LOCATION/B_ORGANIZATION
- O
200 B_NUMBER[MEASURE]
; O
MJ B_LOCATION/B_PERSON
GeneWorks B_LOCATION/I_PERSON
, O
Waltham B_LOCATION/B_PERSON
, O
MA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

The O
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
25 B_MEASURE
- O
40 B_TIME[MEASURE]
cycles I_TIME[MEASURE]
of O
denaturation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
95 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
for O
30 B_MEASURE
s I_MEASURE
) O
, O
annealing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
60 B_MEASURE
- O
62 B_MEASURE
degrees I_MEASURE
C I_MEASURE
for O
1 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
) O
and O
extension B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
72 B_MEASURE
degrees I_MEASURE
C I_MEASURE
for O
1 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
) O
. O

The O
sequences B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
primers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
are O
presented O
in O
Table B_MEASURE/B_LOCATION
1 B_MEASURE/I_LOCATION
. O

The O
PCR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
separated O
by O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
agarose I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gel I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Western B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
immunoblot I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
analysis I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Purified B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
cultured O
for O
3 B_TIME[MEASURE]
days I_TIME[MEASURE]
in O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
40 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_GENE
M I_MEASURE/I_GENE
- O
CSF B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
with O
or O
without O
25 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
RANKL I_MEASURE/I_PERSON
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
lysed O
in O
RIPA B_LOCATION
Lysis I_LOCATION
buffer I_LOCATION
( O
upstate B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Lake B_LOCATION
Placid I_LOCATION
, O
NY B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
containing O
protease B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Roche B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
for O
15 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
4 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
. O

A O
total B_MEASURE
of O
20 B_MEASURE
Mu I_MEASURE
g I_MEASURE
protein I_MEASURE
was O
boiled O
in O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
6 B_MEASURE
x O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dodecyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sample I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
buffer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
was O
separated O
on O
7 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
or O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
dodecyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
polyacrylamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
gel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
ATTO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
Tokyo B_LOCATION/B_ORGANIZATION
, O
Japan B_LOCATION/B_MEASURE
) O
. O

proteins B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
then O
electrotransferred O
to O
a O
polyvinylidene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microporous I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Millipore B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Billerica B_LOCATION/B_PERSON
, O
MA B_LOCATION
, O
USA B_LOCATION
) O
in O
a O
semidry B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
system B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

membranes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
incubated O
in O
10 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
skim I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
milk I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prepared O
in O
phosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
buffered O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PBS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O
containing O
0 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
Tween I_MEASURE
20 I_MEASURE
, O
and O
were O
subjected O
to O
immunoblotting B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

antibodies O
used O
were O
goat B_SPECIES[BIO]
anti O
- O
Rank O
antibody O
( O
Techne O
Corporation O
, O
Minneapolis O
, O
MN O
, O
USA O
) O
, O
goat B_SPECIES[BIO]
anti O
- O
c O
- O
fms O
antibody O
( O
R O
& O
D O
systems O
, O
Minneapolis O
, O
MN O
, O
USA O
) O
, O
and O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
beta O
- O
actin O
mAb O
( O
AC O
- O
15 O
; O
Sigma O
) O
. O

Peroxidase O
- O
conjugated O
rabbit B_SPECIES[BIO]
anti O
- O
goat B_SPECIES[BIO]
IgG O
antibody O
( O
Dako O
) O
or O
peroxidase O
- O
conjugated O
rabbit B_SPECIES[BIO]
anti O
- O
mouse B_SPECIES[BIO]/B_DISEASE
IgG O
antibody O
( O
Dako O
) O
was O
used O
as O
the O
second O
antibody O
. O

The O
signals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
visualized O
by O
chemiluminescence B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reagent I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
( O
ECL B_MEASURE/B_DISEASE
; O
Amersham B_MEASURE/B_LOCATION
Biocsiences I_MEASURE/I_LOCATION
, O
Little B_LOCATION
Chalfont I_LOCATION
, O
UK B_LOCATION/B_MEASURE
) O
. O

Cell B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
surface I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
expression I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
c B_GENE/B_DISEASE
- O
fms B_GENE/B_DISEASE
. O

The O
following B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mAbs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
for O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
c B_GENE/B_DISEASE
- O
fms B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
Alexa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
647 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
conjugated O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CD14 B_GENE
mAb I_GENE
( O
UCHM1 B_GENE
; O
Serotec B_LOCATION/B_PERSON
, O
Oxford B_LOCATION
, O
UK B_LOCATION/B_MEASURE
) O
, O
FITC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
conjugated O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CD16 B_GENE
mAb I_GENE
( O
3G8 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Bechman B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Coulter I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
phycoerythin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
conjugated O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
c B_DISEASE/B_GENE
- O
fms B_GENE
mAb I_GENE
( O
61708 B_TIME[MEASURE]/B_LOCATION
; O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O
D B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

Alexa O
647 O
- O
conjugated O
mouse B_SPECIES[BIO]/B_DISEASE
IgG2a O
( O
Serotec O
) O
, O
FITC O
- O
conjugated O
mouse B_SPECIES[BIO]/B_DISEASE
IgG1 O
( O
BD O
Biosciences O
) O
and O
phycoerythin O
- O
conjugated O
mouse B_SPECIES[BIO]/B_DISEASE
IgG1 O
( O
Bechman O
Coulter O
) O
were O
used O
as O
isotype O
controls O
. O

peripheral O
blood O
monocytes O
( O
1 O
x O
105 O
cells O
) O
were O
incubated O
with O
1 O
Mu O
g O
human B_SPECIES[BIO]
IgG O
for O
15 O
minutes O
, O
and O
were O
then O
stained O
with O
three O
fluorochrome O
- O
labeled O
mAbs O
for O
45 O
minutes O
on O
ice O
. O

The O
stained O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
analyzed O
with O
a O
FACS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Calibur I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
BD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Biosciences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O
. O

immunofluorescent B_DISEASE_ADJECTIVE[DISEASE]
staining I_DISEASE_ADJECTIVE[DISEASE]
. O

monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
( O
8 B_MEASURE
x O
104 B_MEASURE
cells I_MEASURE
/ O
well O
) O
were O
allowed O
to O
adhere O
on O
96 B_MEASURE/B_LOCATION
- O
well O
plates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
overnight O
or O
were O
cultured O
with O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
RANKL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
2 B_NUMBER[MEASURE]/B_LOCATION
- O
4 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

The O
cells O
were O
fixed O
in O
acetone O
and O
then O
stained O
with O
anti O
- O
alpha O
v O
beta O
3 O
mAb O
( O
LM609 O
; O
Chemicon O
, O
Temecula O
, O
CA O
, O
USA O
) O
or O
mouse B_DISEASE/B_SPECIES[BIO]
IgG1 O
( O
11711 O
; O
R O
& O
D O
Systems O
) O
as O
an O
isotype O
- O
matched O
control O
. O

Alexa O
fluor546 O
- O
conjugated O
goat B_SPECIES[BIO]/B_GENE
anti O
- O
mouse B_SPECIES[BIO]/B_DISEASE
IgG1 O
antibody O
( O
Molecular O
Probes O
, O
Eugene O
, O
OR O
, O
USA O
) O
was O
used O
as O
the O
second O
antibody O
. O

TOTO B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_NUMBER[MEASURE]/B_LOCATION
( O
Molecular B_NUMBER[MEASURE]/B_ORGANIZATION
Probes I_NUMBER[MEASURE]/I_ORGANIZATION
) O
was O
used O
for O
nuclear B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometric I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
p38 B_GENE/B_DISEASE
MAPK I_GENE/I_DISEASE
and O
ERK1 B_GENE
/ O
2 B_GENE/B_MEASURE
phosphorylation I_GENE/I_MEASURE
. O

Purified B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
cultured O
in O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
25 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_LOCATION
M I_MEASURE/I_LOCATION
- O
CSF B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
for O
3 B_TIME[MEASURE]
days I_TIME[MEASURE]
, O
and O
were O
either O
left O
unstimulated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
or O
were O
stimulated O
with O
40 B_MEASURE/B_LOCATION
ng I_MEASURE/I_LOCATION
/ O
ml B_MEASURE/B_PERSON
RANKL I_MEASURE/I_PERSON
at O
37 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
. O

Stimulations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
stopped O
by O
adding O
an O
equal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
volume I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
PhosFlow B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fix I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
buffer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
I O
solution O
( O
BD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Biosciences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
to O
the O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

After O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
for O
10 B_TIME[MEASURE]
minutes I_TIME[MEASURE]
at O
37 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
, O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
permeabilized O
by O
washing O
twice O
at O
room B_TIME[MEASURE]/B_LOCATION
temperature I_TIME[MEASURE]/I_LOCATION
in O
PhosFlow B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perm I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
wash B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
buffer I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BD B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Biosciences I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

A O
total O
of O
1 O
x O
105 O
cells O
was O
then O
FC O
blocked O
with O
1 O
Mu O
g O
human B_SPECIES[BIO]
IgG O
for O
15 O
minutes O
, O
and O
was O
stained O
with O
Alexa O
Fluor O
647 O
- O
conjugated O
mAb O
either O
to O
phospho O
- O
p38 O
MAPK O
( O
T180 O
/ O
Y182 O
) O
or O
to O
phospho O
- O
ERK1 O
/ O
2 O
( O
T202 O
/ O
Y204 O
) O
( O
BD O
Biosciences O
) O
for O
30 O
minutes O
at O
room O
temperature O
. O

Alexa O
Fluor O
647 O
- O
conjugated O
mouse B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
IgG1 O
( O
BD O
Biosciences O
) O
was O
used O
as O
an O
isotype O
control O
. O

The O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
washed O
in O
PhosFlow B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perm I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
wash B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
buffer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
I O
, O
and O
were O
analyzed O
by O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
already O
described O
. O

RNA B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interference I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RNA B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
oligonucleotides I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
iGENE B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Tsukuba B_PERSON/B_LOCATION
, O
Japan B_LOCATION/B_MEASURE
) O
were O
designed O
based O
on O
the O
algorithm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
that O
incorporates O
single B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nucleotide B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
homology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
ensure O
a O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interference I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
sense I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
and O
antisense B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oligonucleotides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
used O
: O
integrin B_GENE
beta I_GENE
3 I_GENE
, O
5 B_NUMBER[MEASURE]
' O
- O
GCU B_LOCATION/B_PERSON
UCA I_LOCATION/I_PERSON
Aug I_LOCATION/I_PERSON
AGG I_LOCATION/I_PERSON
AAG I_LOCATION/I_PERSON
UGA I_LOCATION/I_PERSON
AGA I_LOCATION/I_PERSON
AGC I_LOCATION/I_PERSON
A I_LOCATION/I_PERSON
- O
AG B_LOCATION/B_PROTEIN[GENE]
and O
3 B_NUMBER[MEASURE]
' O
- O
UA B_LOCATION/B_MEASURE
- O
CGA B_LOCATION/B_ORGANIZATION
AGU I_LOCATION/I_ORGANIZATION
UAC I_LOCATION/I_ORGANIZATION
UCC I_LOCATION/I_ORGANIZATION
UUC I_LOCATION/I_ORGANIZATION
ACU I_LOCATION/I_ORGANIZATION
UCU I_LOCATION/I_ORGANIZATION
UCG I_LOCATION/I_ORGANIZATION
U I_LOCATION/I_ORGANIZATION
; O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
5 B_NUMBER[MEASURE]
' O
- O
CGA B_LOCATION
UUC I_LOCATION
GCU I_LOCATION
AGA I_LOCATION
CCG I_LOCATION
GCU I_LOCATION
UCA I_LOCATION
UUG I_LOCATION
C I_LOCATION
- O
AG B_LOCATION/B_PROTEIN[GENE]
and O
3 B_NUMBER[MEASURE]/B_LOCATION
' I_NUMBER[MEASURE]/I_LOCATION
- O
UA B_LOCATION
- O
GCU B_LOCATION/B_ORGANIZATION
AAG I_LOCATION/I_ORGANIZATION
CGA I_LOCATION/I_ORGANIZATION
UCU I_LOCATION/I_ORGANIZATION
GGC I_LOCATION/I_ORGANIZATION
CGA I_LOCATION/I_ORGANIZATION
AGU I_LOCATION/I_ORGANIZATION
AAC I_LOCATION/I_ORGANIZATION
G I_LOCATION/I_ORGANIZATION
; O
and O
lamin B_PERSON/B_PROTEIN[GENE]
, O
5 B_NUMBER[MEASURE]
' O
- O
gag B_LOCATION/B_ORGANIZATION
GAA I_LOCATION/I_ORGANIZATION
CUG I_LOCATION/I_ORGANIZATION
GAC I_LOCATION/I_ORGANIZATION
UUC I_LOCATION/I_ORGANIZATION
CAG I_LOCATION/I_ORGANIZATION
AAG I_LOCATION/I_ORGANIZATION
AAC I_LOCATION/I_ORGANIZATION
A I_LOCATION/I_ORGANIZATION
- O
AG B_LOCATION/B_ORGANIZATION
and O
3 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
UA B_PROTEIN[GENE]/B_LOCATION
- O
CUC B_LOCATION/B_ORGANIZATION
CUU I_LOCATION/I_ORGANIZATION
GAC I_LOCATION/I_ORGANIZATION
CUG I_LOCATION/I_ORGANIZATION
AAG I_LOCATION/I_ORGANIZATION
GUC I_LOCATION/I_ORGANIZATION
UUC I_LOCATION/I_ORGANIZATION
UUG I_LOCATION/I_ORGANIZATION
U I_LOCATION/I_ORGANIZATION
. O

CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
8 B_MEASURE
x O
104 B_MEASURE
cells I_MEASURE
/ O
well O
) O
were O
incubated O
in O
96 B_MEASURE/B_LOCATION
- O
well O
plates B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O
optimem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Invitrogen B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

After O
1 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hour I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
siRNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O
transfected O
into O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
using O
oligofectamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Qiagen B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O
based O
on O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
recommended O
by O
the O
manufacturer B_PERSON/B_ORGANIZATION
. O

After O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
washed O
once O
with O
PBS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
followed O
by O
the O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Mem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
supplemented O
with O
10 B_GENE
% I_GENE
FBS I_GENE
, O
M B_PROTEIN[GENE]
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
RANKL B_GENE
. O

After O
a O
2 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_LOCATION
incubation I_TIME[MEASURE]/I_LOCATION
, O
the O
beta B_GENE
3 I_GENE
mRNA I_GENE
expression I_GENE
was O
analyzed O
by O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cycles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
described O
earlier O
. O

immunofluorescent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
alpha B_PROTEIN[GENE]/B_DISEASE
v O
beta B_GENE
3 I_GENE
heterodimer I_GENE
was O
also O
performed O
as O
described O
above O
, O
and O
numbers B_MEASURE/B_LOCATION
of O
alpha B_PROTEIN[GENE]/B_DISEASE
v O
beta B_GENE
3 I_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
counted O
in O
randomly O
selected O
three B_LOCATION/B_MEASURE
fields I_LOCATION/I_MEASURE
at O
100 B_MEASURE
x I_MEASURE
magnification I_MEASURE
. O

Seven B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
the O
transfection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
siRNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
the O
number B_MEASURE
of O
TRAP B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
five B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fields B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
examined O
at O
100 B_MEASURE
x O
magnification B_MEASURE
was O
counted O
under O
light B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Inhibition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
osteoclastogenesis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
with O
cyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RGDfV I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O
incubated O
in O
96 B_MEASURE/B_LOCATION
- O
well B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
plates B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
RANKL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
2 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
containing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
either O
cyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
RGDfV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
( O
Arg B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
D B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Phe B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
Val B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
Calbiochem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
San B_LOCATION/B_PERSON
Diego I_LOCATION/I_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
or O
dimethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sulfoxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
then O
added O
. O

After O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
for O
a O
further B_TIME[MEASURE]
5 I_TIME[MEASURE]
days I_TIME[MEASURE]
, O
the O
number B_MEASURE
of O
TRAP B_GENE
- O
positive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MNC I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
five B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fields B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
examined O
at O
100 B_MEASURE
x O
magnification B_MEASURE
was O
counted O
under O
light B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Immunohistochemistry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Synovial O
tissue O
samples O
were O
obtained O
during O
total O
knee O
joint O
replacement O
surgery O
from O
four O
RA O
patients B_PERSON/B_LOCATION
. O

signed O
consent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
obtained O
before O
the O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
approved O
by O
the O
ethics B_PERSON/B_ORGANIZATION
committee I_PERSON/I_ORGANIZATION
of O
the O
Tokyo B_PERSON/B_LOCATION
Medical I_PERSON/I_LOCATION
and O
Dental B_LOCATION
University I_LOCATION
. O

RA B_LOCATION/B_PERSON
was O
diagnosed O
according O
to O
the O
American B_LOCATION/B_ORGANIZATION
College B_LOCATION/I_ORGANIZATION
of O
Rheumatology B_PERSON/B_DISEASE
criteria I_PERSON/I_DISEASE
[ O
14 B_TIME[MEASURE]/B_LOCATION
] B_TIME[MEASURE]/I_LOCATION
. O

Double B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
immunofluorescent I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
staining O
for O
CD68 B_GENE
and O
CD16 B_GENE
antigens I_GENE
was O
conducted O
on O
optimal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cutting O
temperature B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
embedded O
sections B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
frozen B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synovial I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Eight B_NUMBER[MEASURE]
- O
micrometer B_MEASURE
- O
thick B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cryostat B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sections B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
RA B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
fixed O
in O
acetone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minutes B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
then O
rehydrated O
in O
PBS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O
5 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minutes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
incubated O
in O
5 B_MEASURE/B_LOCATION
Mu I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
ml B_MEASURE/B_PERSON
proteinase I_MEASURE/I_PERSON
K I_MEASURE/I_PERSON
( O
Roche B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
50 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethylenediamine I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetraacetic I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
100 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tris I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
HCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pH O
8 B_MEASURE
. O
0 B_MEASURE
, O
for O
15 B_TIME[MEASURE]
minutes I_TIME[MEASURE]
at O
room B_TIME[MEASURE]/B_LOCATION
temperature I_TIME[MEASURE]/I_LOCATION
followed O
by O
a O
wash B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
PBS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
samples O
were O
then O
blocked O
with O
10 O
% O
goat B_SPECIES[BIO]
serum O
in O
PBS O
for O
60 O
minutes O
at O
room O
temperature O
, O
and O
were O
incubated O
with O
anti O
- O
CD16 O
mAb O
( O
3G8 O
; O
Immunotech O
, O
Marseille O
, O
France O
) O
or O
mouse B_SPECIES[BIO]/B_DISEASE
IgG1 O
( O
11711 O
) O
as O
an O
isotype O
- O
matched O
control O
in O
1 O
% O
bovine B_SPECIES[BIO]/B_PROTEIN[GENE]
serum O
albumin O
/ O
PBS O
for O
60 O
minutes O
at O
room O
temperature O
. O

The O
samples O
were O
then O
washed O
three O
times O
in O
PBS O
, O
for O
5 O
minutes O
each O
, O
and O
incubated O
with O
Alexa O
fluor546 O
- O
conjugated O
goat B_SPECIES[BIO]/B_GENE
anti O
- O
mouse B_SPECIES[BIO]/B_DISEASE
IgG1 O
antibody O
( O
Molecular O
Probes O
) O
in O
1 O
% O
bovine B_PERSON/B_SPECIES[BIO]
serum O
albumin O
/ O
PBS O
for O
60 O
minutes O
at O
room O
temperature O
. O

The O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
then O
sequentially O
stained O
for O
CD68 B_GENE
antigen I_GENE
in O
a O
manner B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
similar I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
that O
used O
for O
CD16 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
samples O
were O
stained O
with O
anti O
- O
CD68 O
mAb O
( O
PGM1 O
; O
Immunotech O
) O
or O
mouse B_SPECIES[BIO]/B_DISEASE
IgG3 O
( O
6A3 O
; O
MBL O
, O
Nagoya O
, O
Japan O
) O
followed O
by O
labeling O
with O
Alexa O
fluor488 O
- O
conjugated O
goat B_SPECIES[BIO]
anti O
- O
mouse B_SPECIES[BIO]/B_DISEASE
IgG3 O
antibody O
( O
Molecular O
Probes O
) O
. O

The O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O
examined O
by O
confocal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laser I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scanning I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscope I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Olympus B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Tokyo B_LOCATION
, O
Japan B_LOCATION/B_MEASURE
) O
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
expressed O
as O
the O
mean B_MEASURE
+/- O
standard B_MEASURE
error I_MEASURE
of O
the O
mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
nonpaired B_PERSON
Student I_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
t I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
used O
for O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
using O
the O
StatView B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
Abacus B_MEASURE/B_EDU[ORGANIZATION]
concepts I_MEASURE/I_EDU[ORGANIZATION]
, O
Berkeley B_LOCATION/B_PERSON
, O
CA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

P B_OTHER/B_MEASURE
< O
0 B_MEASURE
. O
05 B_MEASURE
was O
considered O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

induction B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
osteoclasts B_DISEASE/B_GENE
from O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
peripheral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
blood I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
monocytes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
identify O
the O
monocyte O
subset O
that O
differentiates O
into O
osteoclasts O
, O
we O
examined O
osteoclast O
formation O
from O
CD16 O
+ O
and O
CD16 O
- O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
peripheral O
blood O
monocytes O
. O

The O
monocyte B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subsets B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
purified O
using O
magnetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beads I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O
M B_GENE/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
alone O
did O
not O
induce O
osteoclast B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
either O
subset B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
figure B_PROTEIN[GENE]
1a I_PROTEIN[GENE]
) O
. O

Culture B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
M B_PROTEIN[GENE]/B_DISEASE
- O
CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
RANKL B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
induced O
a O
significant B_MEASURE/B_ORGANIZATION
number I_MEASURE/I_ORGANIZATION
of O
TRAP B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
the O
CD16 B_GENE
- O
subset B_MEASURE/B_LOCATION
, O
whereas O
only O
few B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
CD16 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
differentiated O
into O
TRAP B_GENE/B_DISEASE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
MNC I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
figure B_PROTEIN[GENE]/B_DISEASE
1a I_PROTEIN[GENE]/I_DISEASE
, O
b O
) O
. O

We O
then O
assessed O
the O
bone B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resorptive B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ability B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
culturing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
on O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
phosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
coated O
plates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
M B_PROTEIN[GENE]
- O
CSF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RANKL B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Resorption B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacunae I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
detected O
only O
in O
the O
CD16 B_GENE
- O
subset B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O
figure B_MEASURE
1c I_MEASURE
) O
, O
indicating O
the O
TRAP B_GENE
- O
positive B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
CD16 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
- O
derived O
MNC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
possessed O
the O
osteoclast B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
obtained O
using O
purified O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
by O
FACS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sorting O
( O
purities B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
: O
CD16 B_GENE
+ I_GENE
, O
96 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
CD16 B_GENE
- O
, O
97 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

The O
number B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TRAP B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
induced O
were O
36 B_MEASURE
+/- I_MEASURE
3 I_MEASURE
cells I_MEASURE
/ O
well O
and O
348 B_MEASURE
+/- O
13 B_MEASURE/B_BIO
cells I_MEASURE/I_BIO
/ O
well O
from O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE
- O
monocytes B_MEASURE
, O
respectively O
. O

To O
exclude O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
CD16 B_GENE
antibody I_GENE
used O
for O
isolation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
inhibits I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
osteoclast I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
formation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
separated O
the O
two B_MEASURE/B_BIO
subsets B_MEASURE/I_BIO
, O
CD33low B_GENE
monocytes I_GENE
and O
CD33high B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
using O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CD33 B_GENE
mAb I_GENE
and O
a O
fluorescent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sorter I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
since O
it O
was O
reported O
that O
CD33low B_GENE/B_PERSON
monocytes I_GENE/I_PERSON
correspond O
to O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
that O
CD33high B_LOCATION/B_GENE
correspond O
to O
CD16 B_GENE/B_LOCATION
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
[ O
15 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

On O
average B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
CD33low B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
population I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
contained O
CD16 B_GENE
- O
( O
10 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
/ O
CD16 B_GENE
+ I_GENE
( O
89 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
and O
the O
CD33high B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
population I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
contained O
CD16 B_GENE
- O
( O
86 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
) O
/ O
CD16 B_GENE
+ O
( O
13 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Culture B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RANKL B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
TRAP B_GENE/B_DISEASE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
CD33high B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
whereas O
no O
or O
few B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
CD33low I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
monocytes I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
differentiated O
into O
TRAP B_GENE/B_DISEASE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]
MNC I_DISEASE_ADJECTIVE[DISEASE]
( O
CD33low B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
CD33high I_MEASURE/I_SPORT[ENT]
, O
2 B_MEASURE
+/- O
1 B_MEASURE
vs I_MEASURE
192 I_MEASURE
+/- O
71 B_MEASURE
cells I_MEASURE
/ O
well O
; O
n B_OTHER/B_MEASURE
= O
3 B_MEASURE
) O
. O

TRAP B_GENE/B_LOCATION
- O
5b B_MEASURE
and O
MMP B_GENE/B_BIO
- O
9 B_MEASURE
in O
the O
culture B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
supernatants I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
both O
of O
which O
are O
known O
to O
be O
produced O
by O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O
were O
measured O
by O
ELISA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
both O
enzymes B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
culture B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
supernatant I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_BACTERIUM[BIO]
of O
CD16 B_GENE/B_LOCATION
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
than O
in O
that O
of O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
figure B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1D B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
the O
CD16 B_GENE/B_DISEASE
- O
peripheral B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocyte B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
not O
the O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
differentiate O
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
by O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O
RANKL B_PROTEIN[GENE]/B_LOCATION
+ I_PROTEIN[GENE]/I_LOCATION
M I_PROTEIN[GENE]/I_LOCATION
- O
CSF B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
do O
not O
affect O
the O
osteoclastogenesis B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

To O
examine O
whether O
CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
affect O
osteoclastogenesis B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
CD16 B_GENE/B_DISEASE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
varied O
numbers B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O
mixed B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
CD16 B_GENE/B_DISEASE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
5 B_MEASURE
x O
104 B_MEASURE
cells I_MEASURE
/ O
well O
) O
, O
and O
were O
cultured O
for O
7 B_TIME[MEASURE]
days I_TIME[MEASURE]
in O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE
+ I_GENE
RANKL I_GENE
. O

The O
number B_MEASURE
of O
TRAP B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
not O
altered O
by O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
CD16 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_GENE
monocytes B_BIO/B_MEASURE
( O
figure B_MEASURE/B_LOCATION
2 B_MEASURE/I_LOCATION
) O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O
that O
CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
did O
not O
hamper O
or O
enhance O
the O
osteoclastogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cytokine B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
production B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
RANKL B_GENE
- O
stimulated O
or O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
stimulated O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

To O
compare O
the O
biological B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE
- O
subsets B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
either O
RANKL B_GENE
or O
M B_OTHER/B_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
stimulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
we O
measured O
the O
amount B_MEASURE
of O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE/B_ORGANIZATION
production I_MEASURE/I_ORGANIZATION
after O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
RANKL B_GENE/B_DISEASE
or O
M B_OTHER/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
with O
an O
ELISA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Without O
RANKL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
subset I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
produced O
a O
significant B_MEASURE/B_LOCATION
amount I_MEASURE/I_LOCATION
of O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
, O
whereas O
the O
CD16 B_GENE
- O
subset B_MEASURE/B_PERSON
produced O
undetectable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Figure B_MEASURE/B_PERSON
3a I_MEASURE/I_PERSON
) O
. O

RANKL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O
TNF B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
alpha B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
production B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
from O
both O
subsets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
a O
dose B_MEASURE/B_LOCATION
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
although O
the O
CD16 B_GENE
+ I_GENE
subset I_GENE
produced O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
TNF B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
alpha B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
did O
the O
CD16 B_GENE
- O
subset B_MEASURE/B_LOCATION
. O

RANKL B_PERSON/B_LOCATION
stimulation I_PERSON/I_LOCATION
also O
enhanced O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE/B_ORGANIZATION
production I_MEASURE/I_ORGANIZATION
from O
the O
CD16 B_GENE
+ I_GENE
subset I_GENE
, O
but O
not O
from O
the O
CD16 B_GENE
- O
subset B_MEASURE/B_LOCATION
. O

M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE/B_ORGANIZATION
production I_MEASURE/I_ORGANIZATION
from O
both O
subsets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
although O
the O
CD16 B_GENE/B_MEASURE
+ I_GENE/I_MEASURE
subset I_GENE/I_MEASURE
produced O
more B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
CD16 B_GENE
- O
subset B_MEASURE/B_PERSON
( O
Figure B_MEASURE/B_LOCATION
3b I_MEASURE/I_LOCATION
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
also O
respond O
both O
to O
RANKL B_GENE
and O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
although O
such B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
does O
not O
result O
in O
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O
also O
noted O
to O
express O
higher B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
amounts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
CD16 B_GENE/B_LOCATION
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
with O
or O
without O
RANKL B_GENE
or O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
molecules B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
involved O
in O
osteoclastogenesis B_DISEASE
between O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
CD16 B_GENE/B_LOCATION
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
. O

diverse B_PERSON/B_GENE
molecules I_PERSON/I_GENE
are O
involved O
in O
RANKL B_GENE
/ O
RANK B_GENE
and O
its O
costimulatory B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signal B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transduction B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O
16 B_GENE/B_DISEASE
] I_GENE/I_DISEASE
. O

The O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
RANKL B_GENE
+ O
M B_PROTEIN[GENE]/B_DISEASE
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
the O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocyte B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
the O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subset I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
might O
be O
explained O
by O
the O
expression B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
molecules B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

We O
therefore O
examined O
the O
mRNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
molecules B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O
receptor B_GENE/B_BIO
activator I_GENE/I_BIO
of O
NF B_DISEASE/B_GENE
- O
kappa B_PROTEIN[GENE]/B_MEASURE
B I_PROTEIN[GENE]/I_MEASURE
( O
RANK B_GENE
) O
, O
the O
receptor B_GENE
for O
RANKL B_GENE
; O
c O
- O
fms B_GENE/B_DISEASE
, O
the O
receptor B_GENE
for O
M B_GENE
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
; O
tumor B_DISEASE/B_GENE
necrosis B_DISEASE/I_GENE
factor B_DISEASE/I_GENE
receptor B_DISEASE/I_GENE
- O
associated O
factor B_PROTEIN[GENE]/B_MEASURE
6 I_PROTEIN[GENE]/I_MEASURE
( O
TRAF B_LOCATION/B_ORGANIZATION
- O
6 B_SEQUENCE[MEASURE]/B_LOCATION
) O
, O
the O
adaptor B_GENE
protein I_GENE
for O
RANK B_GENE
; O
c O
- O
Fos B_GENE
and O
nuclear B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
activated O
T B_GENE
cells I_GENE
C1 I_GENE
( O
NFATc1 B_GENE/B_DISEASE
) O
, O
transcription B_GENE/B_BIO
factors I_GENE/I_BIO
that O
are O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
osteoclastogenesis B_DISEASE/B_GENE
; O
DNAX B_GENE/B_DISEASE
- O
activation B_MEASURE/B_PERSON
protein I_MEASURE/I_PERSON
12 I_MEASURE/I_PERSON
( O
DAP12 B_GENE/B_PERSON
) O
and O
Fc B_GENE
receptor I_GENE
gamma I_GENE
chain I_GENE
( O
FcR B_GENE/B_PERSON
gamma I_GENE/I_PERSON
) O
, O
adaptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O
to O
deliver O
costimulatory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
RANKL B_GENE
- O
induced O
osteoclastogenesis B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O
signal B_GENE
regulatory I_GENE
protein I_GENE
beta I_GENE
1 I_GENE
( O
SIRP B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- O
beta B_GENE
1 I_GENE
) O
, O
triggering O
receptor B_PROTEIN[GENE]/B_LOCATION
expressed O
on O
myeloid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O
TREM B_LOCATION
- O
2 B_MEASURE
) O
and O
osteoclast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
associated O
receptor B_GENE/B_LOCATION
( O
Oscar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
transmembrane B_GENE/B_BIO
receptors I_GENE/I_BIO
that O
associate B_PROTEIN[GENE]/B_LOCATION
with O
either O
DAP12 B_LOCATION/B_GENE
or O
FcR B_GENE
gamma I_GENE
; O
and O
alpha B_GENE
v O
and O
beta B_GENE
3 I_GENE
, O
integrins B_PROTEIN[GENE]/B_DISEASE
known O
to O
be O
expressed O
as O
the O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
heterodimer I_GENE
on O
osteoclasts B_DISEASE/B_PROTEIN[GENE]
. O

The O
mRNA B_MEASURE
levels I_MEASURE
of O
RANK B_GENE
, O
c B_OTHER/B_GENE
- O
fms B_GENE/B_DISEASE
, O
TRAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
6 B_MEASURE
, O
DAP12 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
SIRP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
beta B_MEASURE/B_PROTEIN[GENE]
1 I_MEASURE/I_PROTEIN[GENE]
under O
the O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
no O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
) O
varied O
between O
the O
donors B_PERSON/B_BIO
; O
however O
, O
we O
did O
not O
find O
consistent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
mRNA B_MEASURE/B_LOCATION
levels I_MEASURE/I_LOCATION
of O
these O
molecules B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
between O
the O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocyte I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
subset I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
the O
CD16 B_GENE
- O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subset I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
among O
three B_NUMBER[MEASURE]/B_LOCATION
to O
six B_NUMBER[MEASURE]/B_PERSON
donors I_NUMBER[MEASURE]/I_PERSON
( O
figure B_MEASURE/B_PERSON
4a I_MEASURE/I_PERSON
) O
. O

The O
mRNA B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
apart O
from O
integrin B_GENE
beta I_GENE
3 I_GENE
, O
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
under O
the O
no O
- O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
condition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

Although O
the O
mRNA B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
RANK B_GENE
, O
c O
- O
fms B_GENE/B_DISEASE
, O
DAP12 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
FcR B_GENE
gamma I_GENE
, O
trem B_GENE/B_DISEASE
- O
2 B_MEASURE
and O
OSCAR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
in O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
alone O
or O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
+ O
RANKL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
subsets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
not O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_MEASURE/B_LOCATION
subsets B_MEASURE/I_LOCATION
. O

expressions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
TRAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
6 B_MEASURE/B_PROTEIN[GENE]
, O
c O
- O
Fos B_GENE
and O
SIRP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
beta B_MEASURE/B_GENE
1 I_MEASURE/I_GENE
mRNA I_MEASURE/I_GENE
did O
not O
change O
following O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE
+ I_GENE
RANKL I_GENE
. O

Of O
note B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
expression B_GENE
of O
NFATc1 B_GENE
mRNA I_GENE
was O
enhanced O
by O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
RANKL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
only O
in O
the O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
subset B_MEASURE/B_LOCATION
. O

Furthermore O
, O
expression B_GENE
of O
integrin B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
v O
in O
both O
subsets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
enhanced O
by O
M B_PROTEIN[GENE]/B_DISEASE
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
with O
or O
without O
RANKL B_GENE
; O
however O
, O
the O
expression B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
was O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
CD16 B_GENE
- O
subset B_MEASURE/B_LOCATION
. O

It O
was O
noted O
that O
integrin B_GENE
- O
beta B_GENE
3 I_GENE
mRNA I_GENE
was O
detected O
only O
in O
the O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
subset B_MEASURE/B_LOCATION
and O
was O
increased O
by O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
RANKL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
but O
not O
by O
M B_OTHER/B_LOCATION
- O
CSF B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
alone O
. O

The O
protein B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
RANK B_GENE
under O
the O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
weakly O
detected O
in O
both O
subsets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
the O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
varied O
between O
donors B_PERSON/B_LOCATION
by O
western B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
immunoblotting B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
protein B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
c B_GENE/B_DISEASE
- O
fms B_GENE/B_DISEASE
was O
weakly O
detected O
in O
unstimulated B_GENE
CD16 I_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
but O
not O
in O
CD16 B_GENE/B_DISEASE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
figure B_MEASURE/B_GENE
4b B_MEASURE/I_GENE
) O
. O

Flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
c B_GENE/B_DISEASE
- O
fms B_GENE/B_DISEASE
in O
fresh B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O
however O
, O
showed O
that O
both O
subsets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
express O
the O
molecule B_PROTEIN[GENE]
on O
the O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
surface I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O
figure B_GENE/B_LOCATION
4c I_GENE/I_LOCATION
) O
. O

expressions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
both O
RANK B_GENE
and O
c B_GENE/B_DISEASE
- O
fms B_GENE/B_DISEASE
were O
upregulated O
by O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
alone O
and O
by O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE
+ I_GENE
RANKL I_GENE
, O
and O
we O
did O
not O
find O
consistent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
protein B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
molecules B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
monocyte I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subsets I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
profiles B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
expression B_GENE
levels I_GENE
of O
molecules B_BIO/B_GENE
involved O
in O
RANKL B_GENE
/ O
RANK B_GENE
and O
its O
costimulatory B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
are O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_MEASURE/B_PERSON
subsets B_MEASURE/I_PERSON
, O
except O
for O
NFATc1 B_GENE
, O
integrin B_GENE
alpha I_GENE
v O
and O
integrin B_GENE
beta I_GENE
3 I_GENE
. O

We O
therefore O
assumed O
that O
the O
distinct B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
NFATc1 B_GENE
, O
integrin B_GENE
alpha I_GENE
v O
and O
integrin B_GENE
beta I_GENE
3 I_GENE
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
RANKL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
among O
the O
two B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocyte I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
subsets I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
might O
explain O
the O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
their O
abilities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
differentiate O
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

RANKL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induces O
alpha B_GENE/B_LOCATION
v O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
integrin B_GENE/B_DISEASE
- O
beta B_PROTEIN[GENE]/B_LOCATION
3 I_PROTEIN[GENE]/I_LOCATION
subunit I_PROTEIN[GENE]/I_LOCATION
binds O
to O
integrin O
alpha B_PROTEIN[GENE]
v O
only O
and O
is O
expressed O
as O
the O
heterodimeric B_PROTEIN[GENE]
protein I_PROTEIN[GENE]
alpha I_PROTEIN[GENE]
v O
beta B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
3 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
[ O
17 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
examined O
the O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
alpha B_GENE/B_LOCATION
v O
beta B_GENE
3 I_GENE
on O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
by O
immunofluorescent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Neither O
unstimulated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nor O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
stimulated O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subsets I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
expressed O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
( O
figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4D I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
not O
shown O
) O
. O

After O
48 B_MEASURE
and O
72 B_TIME[MEASURE]
hours I_TIME[MEASURE]
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
with O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE
+ I_GENE
RANKL I_GENE
, O
alpha B_GENE/B_LOCATION
v O
beta B_GENE
3 I_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mononuclear B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
observed O
in O
CD16 B_GENE
- O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
but O
not O
in O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocyte I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cultures I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

At O
96 B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
, O
both O
alpha B_GENE/B_LOCATION
v O
beta B_GENE/B_DISEASE
3 I_GENE/I_DISEASE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mononuclear B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
multinucleated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocyte B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
culture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
was O
selectively O
expressed O
on O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
the O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE
+ I_GENE
RANKL I_GENE
, O
and O
the O
expression B_GENE
was O
revealed O
before O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
differentiate O
into O
typical B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
multinucleated I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
osteoclasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

RANKL B_GENE
activates O
ERK B_GENE
and O
p38 O
kinases O
only O
in O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Since O
ERK B_GENE
and O
p38 B_GENE
MAPK I_GENE
are O
essential B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
RANKL B_GENE
- O
induced O
osteoclastogenesis B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
[ O
18 B_MEASURE/B_LOCATION
- O
20 B_MEASURE
] O
, O
we O
next O
examined O
whether O
these O
kinases B_GENE/B_LOCATION
were O
activated O
differently O
in O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
in O
CD16 B_GENE/B_DISEASE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Purified B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O
precultured O
with O
25 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_GENE/B_MEASURE
M B_GENE/I_MEASURE
- O
CSF B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
for O
3 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
enhance O
RANK B_DISEASE/B_GENE
expression I_DISEASE/I_GENE
, O
and O
were O
then O
treated O
with O
RANKL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
RANKL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induced O
phosphorylation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
both O
ERK B_GENE
and O
p38 O
MAPK B_GENE
in O
CD16 B_GENE/B_DISEASE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
at O
5 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
postexposure I_TIME[MEASURE]/I_ENT
, O
although O
the O
p38 B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MAPK B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
weak B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Both O
phosphorylations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
declined O
to O
a O
basal B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
within O
20 B_TIME[MEASURE]
minutes I_TIME[MEASURE]
( O
Figure B_MEASURE/B_PERSON
5 I_MEASURE/I_PERSON
) O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ERK B_GENE
and O
p38 B_GENE
MAPK I_GENE
were O
not O
detectably O
phosphorylated O
in O
CD16 B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
monocytes B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
RANKL B_GENE/B_DISEASE
. O

siRNA O
targeting O
integrin B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
osteoclastogenesis I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
integrin B_GENE/B_DISEASE
- O
beta B_LOCATION/B_PROTEIN[GENE]
3 B_LOCATION/I_PROTEIN[GENE]
cytoplasmic B_LOCATION/I_PROTEIN[GENE]
domain B_LOCATION/I_PROTEIN[GENE]
is O
essential B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
activation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
intracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signals I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
alpha B_GENE/B_DISEASE
v O
beta B_GENE
3 I_GENE
heterodimers I_GENE
[ O
17 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
therefore O
examined O
the O
involvement O
of O
alpha O
v O
beta O
3 O
in O
RANKL O
+ O
M O
- O
CSF O
- O
induced O
osteoclastogenesis O
in O
human B_PERSON/B_SPECIES[BIO]
CD16 O
- O
monocytes O
using O
siRNA O
targeting O
the O
integrin O
- O
beta O
3 O
subunit O
. O

The O
integrin B_GENE/B_LOCATION
- O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
siRNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
control B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
randomized O
siRNA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
transfected O
into O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

At O
48 B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
transfection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
we O
determined O
the O
integrin B_GENE/B_LOCATION
- O
beta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
3 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
level I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
alpha B_GENE
v O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
integrin B_GENE
- O
beta B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
in O
the O
integrin B_GENE
- O
beta B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
siRNA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
transfected O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
compared O
with O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
siRNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
transfected O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
( O
figure B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
6a B_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

The O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
heterodimer I_GENE
expression I_GENE
was O
evaluated O
by O
immunofluorescent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
number B_MEASURE
of O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
decreased O
in O
integrin B_GENE/B_DISEASE
- O
beta B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
siRNA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
transfected O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
compared O
with O
that O
in O
control B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
siRNA I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Figure B_MEASURE/B_BIO
6b B_MEASURE/I_BIO
) O
. O

After O
7 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
, O
the O
number B_MEASURE
of O
TRAP B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
counted O
. O

transfection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
integrin B_GENE/B_LOCATION
- O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
siRNA I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
reduced O
the O
number B_MEASURE
of O
TRAP B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
dose B_MEASURE/B_LOCATION
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
compared O
with O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
siRNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transfection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Figure B_LOCATION/B_MEASURE
6c I_LOCATION/I_MEASURE
) O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
siRNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
directed O
toward O
a O
different B_MEASURE/B_GENE
site B_MEASURE/I_GENE
of O
integrin B_GENE/B_LOCATION
- O
beta B_GENE/B_MEASURE
3 I_GENE/I_MEASURE
mRNA I_GENE/I_MEASURE
also O
inhibited O
osteoclast B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
from O
CD16 B_PROTEIN[GENE]/B_DISEASE
- O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

On O
the O
other B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hand I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
siRNA O
that O
targeted O
lamin B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
which O
was O
used O
as O
a O
negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
did O
not O
inhibit O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
osteoclasts B_GENE/B_DISEASE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
the O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
integrin B_GENE
beta I_GENE
3 I_GENE
in O
RANKL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
osteoclast B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
from O
CD16 B_GENE/B_DISEASE
- O
peripheral B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

cyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
RGDfV I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
inhibits O
the O
osteoclastogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
from O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

integrin B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
v O
beta B_GENE/B_LOCATION
3 I_GENE/I_LOCATION
recognizes O
a O
common B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tripeptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
sequence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
RGD B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Arg B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
which O
is O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
matrix I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
such I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
as O
vitronectin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
fibronectin B_GENE
[ O
21 B_GENE/B_LOCATION
] I_GENE/I_LOCATION
. O

cyclic B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RGDfV I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Arg B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
D B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Phe B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
Val B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
inhibits O
binding B_TIME[MEASURE]/B_PERSON
of O
the O
RGD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
containing O
molecules B_LOCATION/B_PROTEIN[GENE]
to O
alpha B_GENE
v O
beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
22 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
investigate O
the O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ligand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
heterodimer I_GENE
in O
the O
osteoclastogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
examined O
whether O
cyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RGDfV I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibits O
the O
formation B_DISEASE/B_ORGANISM_FUNCTION
of O
osteoclasts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

cyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
RGDfV I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
significantly O
reduced O
the O
number B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TRAP B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MNC B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
a O
dose B_MEASURE/B_LOCATION
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
figure B_MEASURE/B_LOCATION
6d I_MEASURE/I_LOCATION
) O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
imply O
possible B_DISEASE_ADJECTIVE[DISEASE]
involvement I_DISEASE_ADJECTIVE[DISEASE]
of O
ligand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
bindings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
in O
the O
osteoclastogenesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Knockdown B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
integrin B_GENE
beta I_GENE
3 I_GENE
did O
not O
affect O
the O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
NFATc1 B_GENE
mRNA I_GENE
. O

In O
the O
next B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
determined O
whether O
integrin B_GENE/B_LOCATION
- O
beta B_PROTEIN[GENE]/B_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
- O
siRNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
induced O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
osteoclastogenesis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reflects O
downregulation B_GENE
of O
NFATc1 B_GENE
, O
which O
is O
a O
key B_GENE/B_MEASURE
transcription I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
in O
osteoclastogenesis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
[ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
23 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
this O
purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
compared O
NFATc1 B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
integrin B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
beta I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
3 I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
control O
siRNA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
transfected O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Interestingly O
, O
integrin B_GENE
- O
beta B_PROTEIN[GENE]/B_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
knockdown I_PROTEIN[GENE]/I_MEASURE
did O
not O
alter O
the O
NFATc1 B_GENE/B_MEASURE
mRNA I_GENE/I_MEASURE
level I_GENE/I_MEASURE
( O
Figure B_TIME[MEASURE]/B_LOCATION
7 I_TIME[MEASURE]/I_LOCATION
) O
, O
suggesting O
that O
signal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transduction B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mediated O
by O
integrin B_GENE
beta I_GENE
3 I_GENE
does O
not O
affect O
the O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
NFATc1 B_GENE
. O

detection O
of O
CD16 O
+ O
and O
CD16 O
- O
macrophages O
in O
synovium O
of O
RA O
patients B_PERSON/B_BIO
. O

RA B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synovial I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
macrophages I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
derived O
from O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
their O
recruitment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
into O
the O
synovium B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
is O
facilitated O
by O
various B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adhesion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
chemokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O
24 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
] B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

To O
analyze O
CD16 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
synovial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
RA B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
synovial I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tissues I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
double B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
stained O
for O
CD16 B_GENE
and O
a O
macrophage B_GENE/B_MEASURE
marker B_GENE/I_MEASURE
, O
CD68 B_GENE
. O

CD16 B_GENE
- O
/ O
CD68 B_GENE
+ O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O
widespread B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
synovium B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
. O

Although O
less O
frequent B_DISEASE_ADJECTIVE[DISEASE]
, O
CD16 B_GENE
+ I_GENE
/ O
CD68 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
also O
observed O
both O
in O
the O
synovial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
intima I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
subintima B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_MEASURE/B_LOCATION
8 B_MEASURE/I_LOCATION
) O
. O

The O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
two B_MEASURE/B_LOCATION
subsets B_MEASURE/I_LOCATION
of O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE
- O
, O
in O
RA B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
synovium B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
indicates O
that O
both O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE
- O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
are O
recruited O
into O
the O
synovium B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Human B_PERSON
peripheral O
blood O
monocytes O
are O
a O
heterogeneous O
population O
, O
and O
they O
are O
divided O
into O
two O
subsets O
based O
on O
the O
expression O
of O
CD16 O
. O

The O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE
- O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subsets I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
show O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
migration B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
cytokine B_DISEASE_ADJECTIVE[DISEASE]
production I_DISEASE_ADJECTIVE[DISEASE]
and O
differentiation B_PROTEIN[GENE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
into O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
dendritic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
11 B_SEQUENCE[MEASURE]
- O
13 B_MEASURE
, O
15 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

We O
focused O
on O
the O
heterogeneity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
monocytes B_BIO/B_GENE
, O
and O
the O
primary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
question I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
addressed O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O
which O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
subset I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
could O
be O
the O
source B_PERSON/B_LOCATION
of O
osteoclasts B_DISEASE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrated O
that O
CD16 B_GENE/B_DISEASE
- O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
differentiated O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
by O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
RANKL B_PROTEIN[GENE]/B_LOCATION
+ I_PROTEIN[GENE]/I_LOCATION
M I_PROTEIN[GENE]/I_LOCATION
- O
CSF B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

To O
investigate O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
RANKL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
between O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
, O
we O
examined O
the O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
molecules B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
known O
to O
be O
involved O
in O
osteoclastogenesis B_DISEASE
. O

The O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
integrin B_GENE
alpha I_GENE
v O
, O
integrin B_PROTEIN[GENE]/B_MEASURE
beta I_PROTEIN[GENE]/I_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
and O
NFATc1 B_GENE
were O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_MEASURE/B_PERSON
subsets B_MEASURE/I_PERSON
. O

integrin B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
v O
beta B_GENE
3 I_GENE
heterodimer I_GENE
was O
expressed O
only O
on O
RANKL B_GENE/B_BIO
and O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
stimulated O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

It O
is O
known O
that O
alpha B_GENE/B_LOCATION
v O
beta B_GENE
3 I_GENE
expressed O
on O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
bone B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
resorption B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
as O
well O
as O
in O
attachment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
to O
the O
bone B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
25 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
was O
recently O
reported O
that O
bone O
marrow O
macrophages O
of O
integrin O
- O
beta O
3 O
- O
deficient O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
not O
differentiate O
into O
mature O
osteoclasts O
in O
vitro O
, O
suggesting O
that O
alpha O
v O
beta O
3 O
is O
involved O
not O
only O
in O
activation O
, O
but O
also O
in O
differentiation O
, O
of O
osteoclasts O
in O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
26 O
, O
27 O
] O
. O

The O
authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
showed O
that O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
and O
c B_GENE/B_DISEASE
- O
fms B_GENE/B_BIO
share I_GENE/I_BIO
a O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
intracellular I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
signaling O
pathway B_LOCATION
, O
including O
the O
activation B_GENE
of O
ERK B_GENE
and O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
c B_GENE/B_DISEASE
- O
Fos B_GENE
[ O
27 B_MEASURE
] I_MEASURE
, O
both O
of O
which O
are O
essential B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
osteoclastogenesis B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
28 I_DISEASE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
29 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

In O
addition O
, O
it O
was O
reported O
that O
echistatin O
, O
an O
alpha O
v O
beta O
3 O
antagonist O
, O
inhibited O
osteoclast O
formation O
of O
mouse B_SPECIES[BIO]/B_DISEASE
bone O
marrow O
cells O
[ O
30 O
] O
. O

In O
accordance O
with O
these O
reports O
, O
our O
data O
showed O
that O
knockdown O
of O
integrin O
- O
beta O
3 O
expression O
resulted O
in O
downregulation O
of O
the O
alpha O
v O
beta O
3 O
heterodimer O
, O
and O
abrogated O
osteoclastogenesis O
from O
human B_PERSON/B_SPECIES[BIO]
peripheral O
blood O
CD16 O
- O
monocytes O
. O

We O
also O
showed O
that O
blocking O
of O
adhesive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ligands I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
bind O
to O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
by O
RGDfV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibited O
osteoclast B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
from O
CD16 B_GENE
- O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

taken O
together O
, O
the O
process B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
ligand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
alpha B_GENE/B_LOCATION
v O
beta B_GENE
3 I_GENE
may O
be O
involved O
in O
the O
osteoclastogenesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

blockade B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
alpha B_GENE/B_LOCATION
v O
beta B_GENE
3 I_GENE
could O
therefore O
be O
a O
therapeutically O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
modulate O
osteoclastogenesis B_DISEASE/B_ORGANISM_FUNCTION
. O

Indeed O
, O
integrin O
alpha O
v O
beta O
3 O
antagonists O
effectively O
treated O
osteoporosis O
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
humans B_PERSON/B_SPECIES[BIO]
, O
and O
protected O
bone O
destruction O
in O
rat O
adjuvant O
- O
induced O
arthritis O
in O
vivo O
[ O
31 O
- O
34 O
] O
. O

Of O
note O
, O
it O
is O
reported O
that O
patients B_PERSON/B_BIO
with O
Iraqi O
- O
Jewish O
- O
type O
Glanzmann O
thrombasthenia O
who O
are O
deficient O
in O
integrin O
beta O
3 O
do O
not O
develop O
osteopetrosis O
because O
of O
the O
upregulation O
of O
alpha O
2 O
beta O
1 O
expression O
on O
osteoclasts O
, O
although O
the O
bone O
- O
resorptive O
ability O
of O
the O
osteoclasts O
was O
decreased O
in O
vitro O
[ O
35 O
] O
. O

The O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alpha B_GENE/B_LOCATION
v O
beta B_GENE
3 I_GENE
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
osteoclast B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
resorptive B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
function B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
could O
therefore O
be O
partially O
compensated O
by O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
integrins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
all O
the O
multinucleated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
osteoclasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
expressed O
alpha B_PROTEIN[GENE]
v O
beta B_PROTEIN[GENE]/B_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
( O
Figure B_MEASURE/B_LOCATION
4d I_MEASURE/I_LOCATION
) O
[ O
36 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
, O
a O
small B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE
+ I_GENE
RANKL I_GENE
- O
stimulated O
mononuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CD16 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
expressed O
alpha B_PROTEIN[GENE]
v O
beta B_PROTEIN[GENE]/B_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
( O
Figure B_MEASURE/B_LOCATION
4d I_MEASURE/I_LOCATION
) O
. O

Multinucleated B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
osteoclasts I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
formed O
by O
fusion B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
osteoclast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
precursor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
[ O
37 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

It O
was O
reported O
that O
alpha B_GENE
v O
beta B_GENE
3 I_GENE
is O
involved O
in O
the O
migration B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
osteoclast B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
precursors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
30 B_GENE/B_LOCATION
] I_GENE/I_LOCATION
. O

The O
alpha B_PROTEIN[GENE]/B_DISEASE
v O
beta B_PROTEIN[GENE]
3 I_PROTEIN[GENE]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cells B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
could O
therefore O
be O
forced O
to O
migrate O
by O
the O
ligands B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
may O
fuse O
with O
closed B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
v O
beta B_PROTEIN[GENE]
3 I_PROTEIN[GENE]
- O
negative B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Alternatively O
, O
only O
alpha B_GENE/B_NUMBER[MEASURE]
v O
beta B_GENE
3 I_GENE
- O
positive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
fused O
with O
each O
other B_NUMBER[MEASURE]/B_DISEASE
. O

It O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
consider O
that O
signaling O
from O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CD16 B_GENE
mAb I_GENE
- O
coated O
magnetic B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
beads B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
were O
used O
for O
the O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
separation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
by O
IgG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contained O
in O
FBS B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
might O
inhibit O
osteoclastogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
from O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

We O
therefore O
separated O
the O
two B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CD33 B_GENE
mAb I_GENE
and O
a O
fluorescent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sorter I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
stimulated O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
M B_GENE/B_LOCATION
- O
CSF B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
+ O
RANKL B_GENE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
CD33low B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
which O
correspond O
to O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
still O
could O
not O
differentiate O
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

CD16 B_GENE
is O
a O
heterodimer B_GENE
consisting O
of O
Fc B_GENE
gamma I_GENE
IIIa I_GENE
and O
Fc B_GENE
gamma I_GENE
, O
and O
has O
low B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affinity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
the O
Fc B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region B_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
IgG B_GENE
. O

aggregation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CD16 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
immune B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O
to O
transmission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
activating O
signals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
via O
the O
immunoreceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tyrosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
based O
activation B_LOCATION/B_BIO
motif I_LOCATION/I_BIO
in O
the O
gamma B_GENE
chain I_GENE
[ O
38 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
also O
assessed O
osteoclastogenesis O
from O
the O
two O
monocyte O
subsets O
using O
IgG O
- O
depleted O
bovine B_PERSON/B_SPECIES[BIO]
serum O
. O

Even O
in O
the O
IgG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
free B_LOCATION/B_MEASURE
medium I_LOCATION/I_MEASURE
, O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
but O
not O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
differentiated O
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

We O
could O
therefore O
exclude O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
signal B_GENE
transduction I_GENE
through O
CD16 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibits I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
osteoclastogenesis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

NFATc1 B_GENE
is O
a O
key B_GENE/B_MEASURE
transcription I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
in O
osteoclastogenesis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
M B_PROTEIN[GENE]/B_DISEASE
- O
CSF B_GENE
+ I_GENE
RANKL I_GENE
increased O
the O
NFATc1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
subset B_MEASURE/B_LOCATION
only O
, O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
integrin B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
v O
and O
integrin B_GENE
beta I_GENE
3 I_GENE
. O

The O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
NFATc1 B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
induction B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
might O
therefore O
also O
explain O
the O
difference B_MEASURE
in O
osteoclastogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
monocyte I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subsets I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

It O
is O
of O
interest B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
knockdown B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
integrin B_GENE
beta I_GENE
3 I_GENE
did O
not O
lower O
the O
mRNA B_MEASURE
level I_MEASURE
of O
NFATc1 B_GENE
. O

This O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
supports O
the O
notion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
NFATc1 B_GENE
is O
located O
upstream O
of O
integrin B_GENE
- O
beta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
3 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
expression I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
39 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

It O
is O
also O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
two B_NUMBER[MEASURE]
signaling O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
mediated O
by O
integrin B_GENE
beta I_GENE
3 I_GENE
and O
NFATc1 B_GENE
contributes O
to O
osteoclastogenesis O
independently O
or O
cooperatively O
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
to O
determine O
the O
mechanisms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
integrin B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
beta B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
3 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
involvement B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
RANKL B_GENE/B_PERSON
/ O
RANK B_GENE
- O
mediated O
osteoclast B_DISEASE
differentiation I_DISEASE
. O

It O
has O
been O
demonstrated O
that O
MAPK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
families I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
ERK B_GENE
and O
p38 O
MAPK B_GENE/B_BIO
, O
were O
activated O
by O
RANKL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
intracellular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
signalings B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
osteoclast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
precursors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
18 B_NUMBER[MEASURE]
, O
19 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
these O
kinases B_GENE
are O
involved O
in O
the O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
[ O
20 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
showed O
that O
RANKL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induced O
phosphorylation B_GENE
of O
ERK B_GENE
and O
p38 O
MAPK B_GENE
only O
in O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

It O
is O
suggested O
that O
differential B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
activation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
these O
kinases B_GENE
may O
partially O
explain O
the O
distinct B_DISEASE_ADJECTIVE[DISEASE]
properties I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
two B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocyte B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
upon O
RANKL B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
produce O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
compared O
with O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O
that O
CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
produced O
larger B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
amounts B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
upon O
lipopolysaccharide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
lipopeptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
than O
did O
CD16 B_GENE
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
[ O
40 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Interestingly O
, O
we O
showed O
that O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
either O
with O
RANKL B_GENE
or O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
upregulated O
the O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE/B_ORGANIZATION
production I_MEASURE/I_ORGANIZATION
by O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

A O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
is O
reported O
in O
inflammatory B_DISEASE/B_LOCATION
diseases I_DISEASE/I_LOCATION
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
infection B_DISEASE
, O
malignancy B_DISEASE
, O
Kawasaki B_DISEASE
disease I_DISEASE
and O
RA B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
41 I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
44 B_MEASURE
] I_MEASURE
. O

taken O
together O
, O
CD16 B_GENE
+ O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O
be O
an O
important B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
source I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
mice B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
peripheral O
blood O
Ly O
- O
6Chigh O
monocytes O
, O
which O
are O
thought O
to O
correspond O
to O
human B_PERSON/B_SPECIES[BIO]
CD16 O
- O
monocytes O
, O
increase O
in O
inflammatory O
conditions O
, O
and O
these O
cells O
are O
recruited O
into O
sites O
of O
inflammation O
[ O
45 O
] O
. O

In O
contrast O
, O
Ly O
- O
6Clow O
monocytes O
, O
which O
are O
thought O
to O
correspond O
to O
human B_PERSON/B_SPECIES[BIO]
CD16 O
+ O
, O
migrate O
into O
noninflamed O
tissues O
[ O
12 O
] O
. O

These O
data O
on O
mouse B_SPECIES[BIO]/B_DISEASE
monocytes O
seem O
to O
be O
in O
contrast O
to O
the O
data O
on O
human B_SPECIES[BIO]
monocytes O
, O
which O
show O
expansion O
of O
CD16 O
+ O
monocytes O
in O
inflammatory O
conditions O
where O
they O
produce O
larger O
amounts O
of O
inflammatory O
cytokines O
. O

At O
present O
, O
it O
is O
not O
clear O
whether O
mouse B_SPECIES[BIO]/B_DISEASE
monocyte O
subsets O
, O
Ly O
- O
6Clow O
/ O
Ly O
- O
6Chigh O
, O
represent O
human B_PERSON/B_SPECIES[BIO]
monocyte O
subsets O
, O
CD16 O
+ O
/ O
CD16 O
- O
monocytes O
, O
and O
whether O
the O
biologic O
functions O
of O
mouse B_SPECIES[BIO]/B_DISEASE
monocytes O
are O
analogous O
to O
those O
of O
human B_PERSON/B_SPECIES[BIO]
monocytes O
. O

In O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
blood O
monocytes O
newly O
released O
from O
the O
bone O
marrow O
are O
exclusively O
Ly O
- O
6Chigh O
and O
the O
level O
of O
Ly O
- O
6C O
is O
downregulated O
while O
in O
circulation O
[ O
45 O
] O
. O

It O
is O
thus O
suggested O
that O
in O
mice B_BIO/B_DISEASE
the O
two O
monocyte O
subsets O
differing O
in O
Ly O
- O
6C O
expression O
represent O
different O
stages O
in O
the O
maturation O
pathway O
. O

In O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
, O
transition O
from O
CD16 O
- O
monocytes O
to O
CD16 O
+ O
monocytes O
is O
observed O
upon O
culture O
with O
IL O
- O
10 O
, O
M O
- O
CSF O
and O
transforming O
growth O
factor O
beta O
in O
vitro O
[ O
42 O
, O
46 O
] O
. O

Similar O
to O
mouse B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O
, O
therefore O
, O
human B_PERSON/B_SPECIES[BIO]
peripheral O
blood O
CD16 O
- O
monocytes O
may O
also O
maturate O
into O
CD16 O
+ O
monocytes O
. O

It O
is O
reported O
that O
a O
significant B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
RA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
intima B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
express O
CD16 B_GENE
, O
suggesting O
that O
CD16 B_GENE
+ O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
synovial B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_DISEASE_ADJECTIVE[DISEASE]
[ O
47 B_MEASURE/B_DISEASE
] I_MEASURE/I_DISEASE
. O

We O
confirmed O
that O
both O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
CD16 B_GENE
- O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
accumulate O
in O
the O
RA B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O
double B_NUMBER[MEASURE]/B_COLOR
- O
color B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunohistochemical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
CD68 B_GENE
and O
CD16 B_GENE
. O

A O
number B_MEASURE/B_PERSON
of O
chemokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O
abundantly O
expressed O
in O
the O
RA B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O
24 B_MEASURE
, O
48 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Among O
these O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
MCP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
, O
MIP B_GENE
- O
1 B_MEASURE/B_PROTEIN[GENE]
alpha I_MEASURE/I_PROTEIN[GENE]
, O
SDF B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
1 B_MEASURE
, O
RANTES B_GENE
and O
fractalkine B_GENE/B_BACTERIUM[BIO]
can O
induce O
migration B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
[ O
11 B_MEASURE
, O
12 B_TIME[MEASURE]
] I_TIME[MEASURE]
and O
unpublished B_MEASURE
data I_MEASURE
) O
. O

On O
the O
other B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
hand I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
migration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
is O
induced O
only O
by O
fractalkine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

These O
chemokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
therefore O
seem O
to O
play O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
recruitment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
CD16 B_GENE
+ I_GENE
and O
CD16 B_GENE/B_LOCATION
- O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O
the O
circulating O
pool B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
into O
the O
RA B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
osteoclast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inducers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
also O
produced O
in O
the O
RA B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

RANKL B_GENE/B_LOCATION
is O
expressed O
by O
synovial B_DISEASE_ADJECTIVE[DISEASE]
fibroblasts I_DISEASE_ADJECTIVE[DISEASE]
and O
activated O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
[ O
49 B_MEASURE
- O
51 B_MEASURE
] I_MEASURE
, O
while O
M B_PROTEIN[GENE]/B_LOCATION
- O
CSF B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
is O
expressed O
on O
RA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
fibroblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
52 B_MEASURE
, O
53 B_MEASURE
] I_MEASURE
. O

TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
, O
which O
are O
mainly O
expressed O
on O
RA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synovial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
fibroblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
respectively O
, O
could O
also O
enhance O
osteoclast B_DISEASE/B_GENE
differentiation I_DISEASE/I_GENE
[ O
54 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

collectively O
, O
it O
is O
probable B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
recruited O
CD16 B_PROTEIN[GENE]/B_DISEASE
- O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
differentiate O
into O
osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O
the O
RA B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
synovium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
contribute O
to O
bone B_DISEASE
destruction I_DISEASE
. O

On O
the O
other B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
hand I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
CD16 B_GENE
+ O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
might O
also O
be O
involved O
in O
RA B_DISEASE
pathogenesis I_DISEASE
by O
producing O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
. O

Since O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
enhance O
osteoclast B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
formation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
[ O
54 B_MEASURE
, O
55 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
, O
CD16 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
/ O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
may O
also O
contribute O
to O
osteoclastogenesis B_DISEASE
in O
RA B_DISEASE/B_LOCATION
synovium I_DISEASE/I_LOCATION
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

We O
have O
shown O
that O
human B_PERSON/B_SPECIES[BIO]
peripheral O
blood O
monocytes O
consist O
of O
two O
functionally O
heterogeneous O
subsets O
with O
distinct O
response O
to O
osteoclastogenic O
stimuli O
. O

osteoclasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
seem O
to O
originate O
from O
CD16 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
monocytes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
integrin B_GENE
beta I_GENE
3 I_GENE
is O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
osteoclastogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
blockade B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
accumulation B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
activation B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CD16 B_PROTEIN[GENE]/B_DISEASE
- O
monocytes B_GENE
could O
therefore O
be O
a O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
bone B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resorptive I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
especially O
for O
RA B_DISEASE/B_LOCATION
. O

Abbreviations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

DAP O
= O
DNAX O
- O
activation O
protein O
; O
ELISA O
= O
enzyme O
- O
linked O
immunosorbent O
assay O
; O
FBS O
= O
fetal O
bovine B_SPECIES[BIO]/B_PROTEIN[GENE]
serum O
; O
FcR O
gamma O
= O
FC O
receptor O
gamma O
chain O
; O
IL O
= O
interleukin O
; O
FITC O
= O
fluorescein O
isothiocianate O
; O
mAb O
, O
monoclonal O
antibody O
; O
M O
- O
CSF O
= O
macrophage O
colony O
- O
stimulating O
factor O
; O
MEM O
= O
modified O
Eagle O
' O
s O
medium O
; O
MMP O
= O
matrix O
metalloproteinase O
; O
MNC O
= O
multinucleated O
cells O
; O
NF O
= O
nuclear O
factor O
; O
Oscar O
= O
osteoclast O
- O
associated O
receptor O
; O
PBS O
= O
phosphate O
- O
buffered O
saline O
; O
PCR O
= O
polymerase O
chain O
reaction O
; O
RA O
= O
rheumatoid O
arthritis O
; O
Rank O
= O
receptor O
activator O
of O
NF O
- O
Kappa O
B O
; O
RANKL O
= O
receptor O
activator O
of O
NF O
- O
Kappa O
B O
ligand O
; O
RT O
= O
reverse O
transcriptase O
; O
siRNA O
= O
small O
interfering O
RNA O
; O
SIRP O
- O
beta O
1 O
= O
signal O
regulatory O
protein O
- O
beta O
1 O
; O
TNF O
alpha O
= O
tumor O
necrosis O
factor O
alpha O
; O
TRAF O
= O
tumor O
necrosis O
factor O
receptor O
- O
associated O
factor O
; O
trap O
= O
tartrate O
- O
resistant O
acid O
phosphatase O
; O
TREM O
= O
triggering O
receptor O
expressed O
on O
myeloid O
cells O
. O

competing O
interests B_DISEASE
. O

The O
authors B_PERSON
declare O
that O
they O
have O
no O
competing O
interests B_PERSON/B_ORGANIZATION
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

YK B_PERSON
participated O
in O
the O
design B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
carried O
out O
the O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
drafted O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

KH B_PERSON/B_LOCATION
and O
KT B_PERSON/B_LOCATION
participated O
in O
the O
design B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
its O
coordination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

TN B_PERSON/B_ORGANIZATION
and O
nm B_MEASURE/B_ORGANIZATION
conceived O
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
participated O
in O
its O
design B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
coordination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
and O
helped O
to O
draft O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
authors B_PERSON/B_NUMBER[MEASURE]
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

embryonic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathoblasts B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transiently O
express O
TrkB B_GENE
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
proliferate O
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
brain B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- O
derived O
neurotrophic B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nerve B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
neurotrophin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_MEASURE
are O
involved O
in O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
sympathetic B_DISEASE
neurons I_DISEASE
; O
however O
, O
whether O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
derived O
neurotrophic B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
plays O
a O
role B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
known O
. O

The O
purpose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
whether O
BDNF B_GENE
and O
its O
receptor B_GENE
, O
TrkB B_GENE/B_LOCATION
, O
are O
expressed O
during O
the O
development B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
of O
paravertebral B_DISEASE
sympathetic I_DISEASE
ganglia I_DISEASE
in O
vivo B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
to O
determine O
the O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
vitro B_LOCATION/B_SPECIES[BIO]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
neural O
crest O
cells O
coalesce O
to O
form O
sympathetic O
ganglia O
, O
TrkB O
- O
positive O
cells O
are O
seen O
in O
both O
chicken B_SPECIES[BIO]
and O
mouse B_SPECIES[BIO]/B_DISEASE
embryos O
. O

In O
chicken B_SPECIES[BIO]
embryos O
, O
TrkB O
- O
expressing O
cells O
first O
appear O
at O
Hamburger O
- O
Hamilton O
Stage O
( O
St O
) O
27 O
and O
they O
co O
- O
express O
HNK O
- O
1 O
, O
confirming O
that O
they O
are O
migrating O
neural O
crest O
cells O
. O

The O
TrkB B_GENE/B_MEASURE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lack O
neural B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
markers B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O
this O
stage B_ENT/B_MEASURE
; O
however O
, O
they O
migrate O
with O
other B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
neurally O
differentiating O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O
are O
TrkA B_GENE
and O
TrkC B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

By O
St B_LOCATION/B_PERSON
. O

29 B_MEASURE
/ O
30 B_MEASURE
, O
TrkB B_GENE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
begin O
to O
express O
the O
neural B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
specific I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
markers I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Hu I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_OTHER/B_PROTEIN[GENE]
and O
Islet B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
1 B_TIME[MEASURE]/B_LOCATION
; O
eventually O
, O
all O
TrkB B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
positive I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
commence O
neural B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
St B_LOCATION/B_PERSON
. O

34 B_MEASURE/B_LOCATION
, O
TrkB B_GENE
and O
TrkC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
staining I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
lost O
. O

BDNF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
transcript I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
parallels O
that O
of O
TrkB B_GENE
. O

In O
the O
mouse B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O
TrkB O
- O
positive O
cells O
surround O
newly O
formed O
sympathetic O
ganglia O
and O
a O
small O
number O
of O
TrkB O
positive O
cells O
that O
co O
- O
express O
tyrosine O
hydroxylase O
are O
seen O
within O
ganglia O
between O
E13 O
. O
5 O
- O
15 O
. O

In O
cell B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
many B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O
St B_LOCATION/B_BIO
. O

29 O
- O
30 O
chicken B_SPECIES[BIO]/B_MEASURE
lumbar O
sympathetic O
ganglia O
express O
neural O
markers O
and O
are O
dividing O
, O
indicating O
that O
they O
are O
sympathoblasts O
. O

Sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
require O
both O
nerve B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
neurotrophin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_MEASURE
for O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O

BDNF B_GENE
increases O
the O
number B_MEASURE/B_PERSON
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expressing O
neural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
markers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
culture B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
increasing O
number B_MEASURE/B_PERSON
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O
incorporate O
bromodeoxyuridine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
most B_GENE
TrkB I_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
actively O
proliferating O
between O
E6 B_PROTEIN[GENE]
- O
E8 B_MEASURE/B_PROTEIN[GENE]
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

developing O
paravertebral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
ganglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
avian B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
murine B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
embryos I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
contain O
a O
subpopulation B_MEASURE/B_LOCATION
of O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
that O
transiently O
express O
TrkB B_GENE
and O
ultimately O
commence O
neuronal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

These O
TrkB B_GENE/B_DISEASE
expressing O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
are O
not O
actively O
dividing O
in O
vivo B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O
yet O
, O
when O
placed O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
will O
divide O
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
BDNF B_GENE
. O

This O
suggests O
that O
the O
availability B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
BDNF B_GENE
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fails O
to O
reach O
a O
threshold B_MEASURE/B_LOCATION
necessary B_MEASURE/I_LOCATION
to O
induce O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
suggest O
that O
excess B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
TrkB I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
lead O
to O
the O
genesis B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
neuroblastoma B_DISEASE
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
crest I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
destined O
to O
become O
paravertebral B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neurons B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
proliferate O
and O
differentiate O
during O
migration B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
gangliogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O

In O
chicken B_SPECIES[BIO]
embryos O
, O
migrating O
neural O
crest O
cells O
express O
catecholamines O
at O
Hamburger O
/ O
Hamilton O
Stage O
( O
St O
. O
) O
19 O
, O
and O
these O
cells O
form O
the O
primary O
sympathetic O
chain O
dorsolateral O
to O
the O
aorta O
at O
St O
. O

22 B_NUMBER[MEASURE]
( O
E3 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
) O
[ O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Between O
St B_LOCATION/B_PERSON
. O

23 B_TIME[MEASURE]/B_PERSON
( O
E4 B_MEASURE
) O
and O
St B_PROTEIN[GENE]/B_MEASURE
. O

28 O
( O
E6 B_MEASURE
) O
, O
these O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
disperse O
and O
undergo O
a O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
migration I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
form O
the O
paravertebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
chain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
resides O
ventral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT
root I_BODY_PART_OR_ORGAN_COMPONENT
ganglion I_BODY_PART_OR_ORGAN_COMPONENT
[ O
1 B_PROTEIN[GENE]/B_LOCATION
] I_PROTEIN[GENE]/I_LOCATION
. O

After O
ganglia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
coalesce I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
, O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
express O
markers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
neuronal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
Q211 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
tyrosine B_GENE
hydroxylase I_GENE
( O
TH B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
, O
at O
a O
time B_TIME[MEASURE]/B_LOCATION
when O
they O
also O
incorporate O
[ O
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
thymidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O
2 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Time O
lapse O
photography O
has O
shown O
that O
cultured O
E15 O
. O
5 O
- O
E16 O
. O
5 O
sympathetic O
neurons O
from O
rat B_SPECIES[BIO]/B_GENE
embryos O
extend O
axons O
while O
they O
divide O
[ O
3 O
- O
5 O
] O
. O

Although O
proliferation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
appears O
to O
be O
an O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
expand O
the O
sympathetic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neuron I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
population I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O
differentiation B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
, O
the O
mechanisms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
guide O
sympathoblast B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
proliferation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
have O
not O
been O
identified O
. O

The O
development B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
guided O
by O
neurotrophins B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Neurotrophin B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_NUMBER[MEASURE]/B_LOCATION
( O
NT B_LOCATION/B_ORGANIZATION
- O
3 B_NUMBER[MEASURE]/B_LOCATION
) O
binds B_TIME[MEASURE]/B_PERSON
to O
its O
receptor B_GENE
, O
TrkC B_GENE
, O
to O
promote O
the O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathoblasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
early B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lumbar B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
paravertebral B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
ganglia B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
6 B_GENE/B_LOCATION
] I_GENE/I_LOCATION
. O

Nerve B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
signals B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
through O
its O
receptor B_GENE
, O
TrkA B_GENE/B_LOCATION
, O
to O
promote O
the O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
upon O
target B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
innervation I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
7 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

There O
are O
severe O
sympathetic O
defects O
in O
the O
superior O
cervical O
ganglion O
of O
individual O
NT O
- O
3 O
and O
NGF O
knockout O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
8 O
- O
10 O
] O
. O

Furthermore O
, O
there O
is O
no O
additional O
cell O
death O
in O
the O
superior O
cervical O
ganglion O
of O
NT O
- O
3 O
and O
NGF O
double O
knockout O
mouse B_SPECIES[BIO]/B_DISEASE
embryos O
, O
suggesting O
that O
all O
of O
the O
neurons O
are O
dependent O
on O
both O
neurotrophins O
for O
survival O
[ O
11 O
] O
. O

There O
is O
also O
an O
increase O
in O
sympathetic O
neuron O
cell O
death O
in O
TrkA O
knockout O
mice B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
12 O
] O
. O

However O
, O
in O
TrkB O
and O
BDNF O
knockout O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
is O
no O
apparent O
phenotype O
in O
the O
superior O
cervical O
ganglion O
, O
and O
there O
is O
little O
evidence O
that O
TrkB O
or O
BDNF O
is O
expressed O
in O
sympathetic O
ganglia O
. O

Thus O
, O
it O
is O
generally O
thought O
that O
TrkB B_GENE
and O
BDNF B_GENE/B_LOCATION
have O
little B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
no O
roles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O
guiding O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
sympathetic B_DISEASE
neurons I_DISEASE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
their O
developmental B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
neurotrophin B_GENE/B_PERSON
receptors I_GENE/I_PERSON
regulate O
cell B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
behavior B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
neuroblastoma B_DISEASE
, O
a O
tumor B_DISEASE
found O
in O
sympathetic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
adrenal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
medulla I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

Tumors B_DISEASE/B_PERSON
that O
express O
TrkA B_GENE
often O
spontaneously O
regress O
, O
while O
those O
that O
express O
TrkB B_GENE
and O
its O
ligand B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O
derived O
neurotrophic B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BDNF B_GENE
) O
, O
grow O
aggressively O
, O
are O
invasive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
fail O
to O
respond O
to O
chemotherapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
13 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
] I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
TrkA B_GENE
in O
neuroblastoma B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tumors B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
its O
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
developing O
sympathetic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
suggests O
that O
regressive B_DISEASE/B_PERSON
neuroblastoma I_DISEASE/I_PERSON
tumors I_DISEASE/I_PERSON
arise O
from O
early B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
that O
express O
TrkA B_GENE
. O

The O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TrkB B_GENE
in O
early B_DISEASE
sympathetic I_DISEASE
development I_DISEASE
is O
unknown B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
which O
makes O
understanding O
the O
etiology B_DISEASE
of O
aggressive B_DISEASE
neuroblastoma I_DISEASE
tumors I_DISEASE
difficult I_DISEASE
. O

Based O
on O
its O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
neuroblastoma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
tumors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O
we O
hypothesize O
that O
BDNF B_GENE
and O
TrkB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
differentiating O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
is O
responsible B_DISEASE_ADJECTIVE[DISEASE]
for O
expanding O
the O
neuronal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
population I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
through O
proliferation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
. O

We O
sought O
to O
determine O
whether O
BDNF B_GENE
and O
TrkB B_GENE
are O
involved O
in O
sympathetic B_DISEASE
development I_DISEASE
. O

We O
report O
that O
during O
early B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
embryonic B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
TrkB B_GENE
is O
expressed O
in O
a O
subset B_MEASURE/B_LOCATION
of O
differentiating O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
in O
both O
avian B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
murine B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
embryos I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
also O
find O
that O
BDNF B_GENE
promotes O
the O
proliferation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
TrkB B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathoblasts B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
culture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

However O
, O
the O
majority B_PERSON/B_MEASURE
of O
TrkB B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
positive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
fail O
to O
take O
up O
bromodeoxyuridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
BrdU B_PROTEIN[GENE]/B_LOCATION
) O
over O
a O
24 B_TIME[MEASURE]/B_LOCATION
hr I_TIME[MEASURE]/I_LOCATION
period I_TIME[MEASURE]/I_LOCATION
, O
suggesting O
that O
endogenous B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
BDNF I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
concentrations I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
do O
not O
reach O
a O
threshold B_MEASURE/B_LOCATION
necessary I_MEASURE/I_LOCATION
to O
stimulate O
proliferation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Shortly O
after O
all O
of O
the O
TrkB B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
positive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
commence O
neuronal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
TrkB B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoreactivity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
lost O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
prolonged O
expression B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
activation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
TrkB B_GENE
signaling I_GENE
at O
these O
early B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stages B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
may O
be O
an O
early B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triggering O
the O
formation B_DISEASE/B_ORGANISM_FUNCTION
of O
neuroblastoma B_DISEASE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

TrkB B_GENE
is O
expressed O
during O
migration B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
crest I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
ganglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
first O
determined O
whether O
TrkB B_GENE
is O
expressed O
in O
neural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
crest I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
region B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventral I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
root I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ganglia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
where O
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ganglia B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coalesce B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
Hamburger B_PERSON
/ O
Hamilton B_PERSON
stages I_PERSON
( O
St B_LOCATION/B_PERSON
. O
) O
25 B_MEASURE
- O
28 B_MEASURE
/ O
29 B_MEASURE
. O

To O
identify O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
that O
have O
commenced O
neuronal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
transverse B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
sections I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
of O
the O
lumbar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
spinal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
column I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
were O
stained O
with O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O
Hu B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_MEASURE/B_GENE
[ I_MEASURE/I_GENE
14 I_MEASURE/I_GENE
] I_MEASURE/I_GENE
, O
a O
neuronal B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O
specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
binding O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
or O
Islet B_LOCATION
- O
1 B_NUMBER[MEASURE]
, O
a O
transcription B_GENE
factor I_GENE
found O
in O
sympathetic B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neurons I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
15 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

We O
found O
that O
Hu B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Islet B_LOCATION/B_GENE
- O
1 B_MEASURE/B_LOCATION
are O
expressed O
in O
the O
same B_BODY_PART_OR_ORGAN_COMPONENT
cells I_BODY_PART_OR_ORGAN_COMPONENT
both O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
in O
vitro B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
throughout O
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

In O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
done O
between O
St B_LOCATION/B_PERSON
. O

25 O
and O
28 B_MEASURE/B_LOCATION
, O
islet B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
1 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
staining B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
appeared O
weaker B_MEASURE/B_DISEASE
than O
Hu B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
thus O
we O
used O
Hu B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
identify O
differentiating O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O
these O
stages B_DISEASE/B_TIME[MEASURE]
. O

At O
later B_TIME[MEASURE]/B_LOCATION
stages I_TIME[MEASURE]/I_LOCATION
, O
islet B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
1 B_NUMBER[MEASURE]
was O
used O
to O
facilitate O
the O
identification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
because O
of O
the O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
location B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
its O
immunoreactivity B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expressing O
Hu B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
/ O
D B_OTHER/B_PROTEIN[GENE]
are O
first O
detected O
at O
St B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

25 B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
ventral I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
to O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
dorsal B_MEASURE/B_LOCATION
root B_MEASURE/I_LOCATION
ganglion B_MEASURE/I_LOCATION
and O
lateral B_MEASURE/B_LOCATION
to O
the O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT
aorta I_BODY_PART_OR_ORGAN_COMPONENT
( O
figure B_PROTEIN[GENE]
1A I_PROTEIN[GENE]
, O
1B B_MEASURE/B_PROTEIN[GENE]
) O
. O

By O
St B_LOCATION/B_PERSON
. O

26 O
, O
the O
number B_MEASURE/B_PERSON
of O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
express O
Hu B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_OTHER/B_PROTEIN[GENE]
in O
this O
region B_LOCATION
increases O
dramatically O
( O
Figure B_MEASURE/B_LOCATION
1C I_MEASURE/I_LOCATION
) O
. O

TrkB O
- O
expressing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
first O
appear O
at O
St B_LOCATION/B_ORGANISM_FUNCTION
. O

27 B_TIME[MEASURE]/B_LOCATION
in O
the O
same B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O
are O
adjacent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
Hu B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_LOCATION/B_MEASURE
cells I_LOCATION/I_MEASURE
( O
figure B_PROTEIN[GENE]
1D I_PROTEIN[GENE]
, O
2A B_PROTEIN[GENE]/B_DISEASE
, O
2H B_PROTEIN[GENE]/B_MEASURE
) O
. O

TrkB B_GENE
- O
positive B_DISEASE/B_LOCATION
cells I_DISEASE/I_LOCATION
co I_DISEASE/I_LOCATION
- O
localize B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
a O
neural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
crest I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
marker I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
HNK B_LOCATION/B_GENE
- O
1 B_NUMBER[MEASURE]
( O
figures B_PROTEIN[GENE]/B_MEASURE
2B I_PROTEIN[GENE]/I_MEASURE
, O
2C B_PROTEIN[GENE]/B_DISEASE
, O
2D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
Hu B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_OTHER/B_PROTEIN[GENE]
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
this O
region B_LOCATION
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neurons B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
since O
they O
appear O
in O
the O
region B_LOCATION/B_BIO
where O
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ganglia I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
form I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
express O
tyrosine B_ENZYME[GENE]
hydroxylase I_ENZYME[GENE]
, O
a O
rate B_MEASURE
- O
limiting O
enzyme B_ENZYME[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
synthesis B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_GENE
of O
catecholamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
figures B_PROTEIN[GENE]/B_LOCATION
2E I_PROTEIN[GENE]/I_LOCATION
, O
2F B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
2G B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

At O
St B_LOCATION/B_MEASURE
. O

28 B_MEASURE
/ O
29 B_MEASURE
, O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
begin O
to O
coalesce O
ventral B_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
to O
the O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
root I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
ganglion I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O
the O
Hu B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
TrkB B_GENE
- O
positive B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
remain O
as O
two B_MEASURE/B_PERSON
separate B_MEASURE/I_PERSON
cell B_MEASURE/I_PERSON
populations B_MEASURE/I_PERSON
( O
figure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1E B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
; O
however O
, O
shortly O
afterwards O
, O
all O
of O
the O
TrkB B_GENE/B_MEASURE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
begin O
to O
express O
Islet B_LOCATION/B_PERSON
- O
1 B_NUMBER[MEASURE]/B_PERSON
( O
figure B_GENE/B_LOCATION
3B I_GENE/I_LOCATION
) O
and O
Hu B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

Developmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
TrkA B_GENE
, O
TrkB B_GENE/B_LOCATION
, O
TrkC B_GENE
, O
and O
BDNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
TrkB B_GENE
, O
the O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neurotrophin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
TrkA B_GENE
and O
TrkC B_GENE
, O
are O
co B_LOCATION/B_MEASURE
- O
expressed O
in O
both O
Hu B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Hu B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_DISEASE_ADJECTIVE[DISEASE]
cells I_DISEASE_ADJECTIVE[DISEASE]
at O
St B_MEASURE
. O

27 O
( O
figures B_MEASURE/B_PROTEIN[GENE]
2I I_MEASURE/I_PROTEIN[GENE]
, O
2J B_TIME[MEASURE]
) O
. O

We O
find O
that O
approximately O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
the O
Islet B_LOCATION/B_PROTEIN[GENE]
- O
1 B_MEASURE/B_DISEASE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
express O
TrkA B_GENE
( O
figure B_MEASURE/B_DISEASE
3A I_MEASURE/I_DISEASE
) O
, O
while O
50 B_PERSON/B_NUMBER[MEASURE]
% B_PERSON/I_NUMBER[MEASURE]
express O
TrkB B_GENE
( O
figure B_MEASURE/B_PROTEIN[GENE]
3B B_MEASURE/I_PROTEIN[GENE]
) O
and O
100 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
express O
TrkC B_GENE
( O
figure B_MEASURE/B_LOCATION
3C I_MEASURE/I_LOCATION
) O
at O
St B_MEASURE
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_TIME[MEASURE]/B_LOCATION
. O
5 B_MEASURE
) O
. O

Thus O
, O
all O
developing O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
express O
TrkC B_GENE
in O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
either O
TrkA B_GENE
or O
TrkB B_GENE
. O

By O
St B_LOCATION/B_PERSON
. O

31 B_MEASURE/B_LOCATION
( O
E7 B_MEASURE
) O
, O
the O
number B_MEASURE/B_PERSON
of O
TrkA B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Islet B_LOCATION
- O
1 B_NUMBER[MEASURE]/B_LOCATION
- O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
increases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
100 B_MEASURE
% I_MEASURE
( O
figure B_PROTEIN[GENE]
3D I_PROTEIN[GENE]
) O
and O
immunoreactivities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
both O
TrkB B_GENE/B_LOCATION
and O
TrkC B_GENE
appear O
dispersed O
( O
figure B_PROTEIN[GENE]
3E I_PROTEIN[GENE]
, O
3F B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

By O
St B_LOCATION/B_PERSON
. O

34 B_MEASURE/B_LOCATION
( O
E8 B_MEASURE/B_GENE
) O
, O
TrkA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
well O
- O
sustained O
( O
figure B_PROTEIN[GENE]
3G I_PROTEIN[GENE]
) O
and O
TrkB B_LOCATION
and O
TrkC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoreactivities I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
lost O
( O
figure B_PROTEIN[GENE]
3H I_PROTEIN[GENE]
, O
3I B_MEASURE/B_PROTEIN[GENE]
) O
. O

We O
also O
examined O
the O
early B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
development I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
murine B_PERSON/B_EDU[ORGANIZATION]
sympathetic B_PERSON/I_EDU[ORGANIZATION]
ganglia B_PERSON/I_EDU[ORGANIZATION]
( O
Figure B_TIME[MEASURE]/B_LOCATION
4 I_TIME[MEASURE]/I_LOCATION
) O
. O

At O
E13 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
, O
the O
newly O
formed O
lumbar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
ganglia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
observed O
ventral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
notochord B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
their O
staining B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
Hu B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_OTHER/B_PROTEIN[GENE]
and O
TH B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Figure B_MEASURE/B_PERSON
4A I_MEASURE/I_PERSON
) O
. O

TrkB B_GENE/B_DISEASE
- O
positive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
seen O
surrounding O
developing O
ganglia B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
well O
as O
in O
occasional B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
within O
the O
ganglia B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
figure B_PROTEIN[GENE]/B_LOCATION
4C I_PROTEIN[GENE]/I_LOCATION
, O
D B_OTHER/B_MEASURE
) O
. O

These O
TrkB B_GENE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
ganglia B_DISEASE/B_PROTEIN[GENE]
co B_DISEASE/I_PROTEIN[GENE]
- O
express B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
TH I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
are O
seen O
at O
a O
frequency B_MEASURE
of O
1 B_MEASURE/B_LOCATION
- O
2 B_MEASURE
cells I_MEASURE
per O
section B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
starting O
at O
E13 B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
( O
figure B_MEASURE/B_PROTEIN[GENE]
4A B_MEASURE/I_PROTEIN[GENE]
- O
D B_OTHER/B_MEASURE
) O
and O
are O
still O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
E15 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
5 B_MEASURE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
not O
shown O
) O
. O

In O
neuroblastoma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
BDNF B_GENE
is O
co B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
expressed O
with O
TrkB B_GENE
, O
suggesting O
that O
autocrine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
a O
means B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
which O
proliferation B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
sustained O
in O
the O
transformed O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O

To O
test O
whether O
BDNF O
, O
the O
ligand O
for O
TrkB O
, O
was O
present O
in O
embryonic O
chick B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
sympathetic O
ganglia O
, O
we O
used O
quantitative O
real O
- O
time O
PCR O
with O
TaqMan O
probes O
to O
determine O
the O
relative O
abundance O
of O
BDNF O
transcripts O
in O
total O
RNA O
extracted O
from O
lumbar O
sympathetic O
ganglia O
at O
St O
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_TIME[MEASURE]/B_LOCATION
. O
5 B_MEASURE
) O
, O
St B_LOCATION/B_PERSON
. O

31 B_TIME[MEASURE]/B_PERSON
( O
E7 B_MEASURE
) O
, O
St B_GENE/B_MEASURE
. O

34 B_NUMBER[MEASURE]
( O
E8 B_MEASURE/B_PROTEIN[GENE]
) O
, O
and O
E9 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

BDNF B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
ganglia B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parallels O
that O
of O
TrkB B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
: O
BDNF B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
highest B_MEASURE
at O
St B_MEASURE/B_LOCATION
29 I_MEASURE/I_LOCATION
/ O
30 B_MEASURE
( O
E6 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
) O
, O
and O
these O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decrease O
2 B_NUMBER[MEASURE]
- O
fold B_SEQUENCE[MEASURE]
at O
St B_PROTEIN[GENE]
. O

31 B_TIME[MEASURE]/B_PERSON
( O
E7 B_MEASURE
) O
and O
St B_LOCATION/B_GENE
. O

34 B_TIME[MEASURE]/B_LOCATION
( O
E8 O
; O
Figure B_MEASURE/B_PERSON
5 I_MEASURE/I_PERSON
) O
. O

By O
E9 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
BDNF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
7 B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
times B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lower B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O
at O
St B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_TIME[MEASURE]/B_LOCATION
. O
5 B_MEASURE
; O
Figure B_MEASURE/B_PERSON
5 I_MEASURE/I_PERSON
) O
. O

NT3 B_GENE
and O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promote O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
differentiating O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
culture B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
determine O
the O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
neurotrophins B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
cultured O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
dispersed O
from O
lumbar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
ganglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O
St B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
) O
because O
, O
at O
this O
stage B_MEASURE/B_ENT
, O
ganglion B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
formation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
the O
number B_MEASURE/B_LOCATION
of O
TrkA B_GENE
- O
, O
TrkB B_GENE
- O
, O
and O
TrkC B_GENE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
have O
peaked O
, O
and O
all O
Trk B_GENE/B_LOCATION
- O
expressing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
have O
initiated O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

First O
, O
we O
identified O
markers B_GENE/B_DISEASE
expressed O
by O
acutely O
isolated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
. O

As O
shown O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
80 B_MEASURE
- O
91 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
p75 O
neurotrophin B_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
( O
NTR B_LOCATION/B_ORGANIZATION
) O
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
indicating O
that O
most B_NUMBER[MEASURE]/B_PERSON
of O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
crest I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
derived O
and O
little B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mesenchymal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contamination I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
introduced O
by O
the O
isolation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
28 B_MEASURE
- O
33 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
express O
the O
neural B_GENE
marker I_GENE
Hu I_GENE
C I_GENE
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Approximately O
half B_MEASURE
of O
these O
Hu B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_OTHER/B_PROTEIN[GENE]
- O
positive B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
express O
TrkB B_GENE/B_DISEASE
. O

Conversely O
, O
all O
of O
the O
TrkB B_DISEASE/B_LOCATION
positive I_DISEASE/I_LOCATION
cells I_DISEASE/I_LOCATION
express O
Hu B_LOCATION/B_GENE
C I_LOCATION/I_GENE
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
TrkB B_GENE/B_MEASURE
- O
positive B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
comprise O
approximately O
14 B_NUMBER[MEASURE]
- O
17 B_SEQUENCE[MEASURE]/B_PERSON
% I_SEQUENCE[MEASURE]/I_PERSON
of O
the O
total B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
population I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O

We O
then O
determined O
how O
many B_NUMBER[MEASURE]/B_PERSON
of O
the O
acutely O
isolated O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
proliferating O
by O
incubating O
them O
for O
12 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
BrdU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
containing O
medium B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

For O
these O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
identified O
differentiating O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
with O
the O
transcription B_GENE/B_DISEASE
factor I_GENE/I_DISEASE
islet I_GENE/I_DISEASE
- O
1 B_NUMBER[MEASURE]
because O
this O
marker B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
labels I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nuclei O
, O
thus O
it O
co O
localizes B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
any O
BrdU B_GENE
that O
has O
been O
incorporated O
into O
the O
DNA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
allowing O
us O
to O
determine O
whether O
the O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
had O
undergone O
S B_DISEASE/B_PROTEIN[GENE]
- O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
cell B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
12 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
BrdU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
59 B_PERSON/B_MEASURE
% I_PERSON/I_MEASURE
of O
islet B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
1 B_MEASURE/B_DISEASE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclei B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stain B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
BrdU B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoreactivity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
cultures B_LOCATION/B_PERSON
of O
St B_LOCATION/B_PERSON
. O

29 B_MEASURE
/ O
30 B_MEASURE/B_PERSON
sympathetic I_MEASURE/I_PERSON
ganglia I_MEASURE/I_PERSON
contain O
many B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
proliferate O
while O
exhibiting O
markers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
neuronal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
confirming O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
call O
these O
dividing O
neuronal B_LOCATION
precursors I_LOCATION
sympathoblasts I_LOCATION
. O

The O
remaining O
non B_DISEASE_ADJECTIVE[DISEASE]
- O
BrdU B_DISEASE_ADJECTIVE[DISEASE]
incorporating I_DISEASE_ADJECTIVE[DISEASE]
, O
islet B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
1 B_NUMBER[MEASURE]/B_LOCATION
positive I_NUMBER[MEASURE]/I_LOCATION
cells I_NUMBER[MEASURE]/I_LOCATION
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
post O
mitotic B_DISEASE_ADJECTIVE[DISEASE]
neurons I_DISEASE_ADJECTIVE[DISEASE]
. O

Finally O
, O
we O
determined O
the O
trophic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
St B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
) O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
monitored O
cultures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
over O
a O
three B_TIME[MEASURE]
day I_TIME[MEASURE]
period I_TIME[MEASURE]
after O
plating O
and O
counted O
the O
number B_MEASURE
of O
phase B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
bright I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
neurites B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
a O
morphological B_MEASURE
feature I_MEASURE
of O
both O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
trophic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
more B_MEASURE
than O
2 B_NUMBER[MEASURE]
/ O
3 B_SEQUENCE[MEASURE]
of O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
die O
by O
24 B_TIME[MEASURE]/B_DISEASE
hours B_TIME[MEASURE]/I_DISEASE
in O
culture B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
BDNF B_GENE
, O
NT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
, O
or O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
is O
not O
sufficient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
promote O
survival B_DISEASE/B_ORGANISM_FUNCTION
( O
figure B_MEASURE/B_DISEASE
6 B_MEASURE/I_DISEASE
) O
. O

However O
, O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
together O
with O
NT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE/B_BIO
supports O
the O
survival B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
significantly O
larger B_MEASURE
number I_MEASURE
of O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
Figure B_MEASURE/B_PERSON
6 I_MEASURE/I_PERSON
) O
. O

For O
the O
subsequent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
all O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
cultured O
with O
25 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE
NT I_MEASURE
- O
3 B_NUMBER[MEASURE]/B_LOCATION
and O
1 B_MEASURE/B_LOCATION
Mu I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
ml B_MEASURE
7S I_MEASURE
NGF I_MEASURE
to O
optimize O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

BDNF B_GENE
promotes O
proliferation B_DISEASE/B_ORGANISM_FUNCTION
of O
TrkB B_GENE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
culture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

To O
determine O
the O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
cultures B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
St B_LOCATION/B_SPECIES[BIO]
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_MEASURE
. O
5 B_MEASURE
) O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
ganglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
supplemented O
with O
200 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_GENE
BDNF I_MEASURE/I_GENE
and O
the O
number B_MEASURE/B_LOCATION
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
were O
counted O
at O
24 B_MEASURE
, O
48 B_MEASURE
, O
and O
72 B_TIME[MEASURE]
hours I_TIME[MEASURE]
using O
phase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Figure B_LOCATION/B_PROTEIN[GENE]
7A I_LOCATION/I_PROTEIN[GENE]
) O
. O

A O
1 B_MEASURE
. O
6 B_MEASURE
- O
fold B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
the O
number B_MEASURE
of O
neurons B_BIO/B_DISEASE
due O
to O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
observed O
by O
24 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hours I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
and O
this O
number B_MEASURE/B_PERSON
does O
not O
increase O
further O
at O
48 B_MEASURE
or O
72 B_MEASURE/B_LOCATION
hours I_MEASURE/I_LOCATION
. O

This O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
concentration B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
with O
an O
EC50 B_MEASURE
of O
75 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
( O
Figure B_MEASURE/B_PERSON
7B I_MEASURE/I_PERSON
) O
. O

To O
test O
whether O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
number B_MEASURE/B_PERSON
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
BDNF B_GENE
is O
due O
to O
the O
differentiation B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
pluripotent B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
neural I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
crest I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O
we O
quantified O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BDNF B_GENE
on O
the O
number B_MEASURE/B_LOCATION
of O
neurally O
differentiating O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
Hu B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
versus O
the O
number B_MEASURE
of O
non B_DISEASE
- O
neuronal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
( O
Hu B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
/ O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative O
) O
after O
identifying O
all O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
crest I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
staining O
for O
p75NTR B_GENE
in O
St B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_TIME[MEASURE]/B_LOCATION
. O
5 B_MEASURE
) O
cultures B_LOCATION/B_RELIGION[SOCIAL_CIRCUMSTANCES]
. O

If O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increases O
the O
number B_MEASURE/B_LOCATION
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
by O
inducing O
a O
non B_DISEASE
- O
neuronal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O
express O
Hu B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
then O
we O
expected O
that O
the O
total B_MEASURE
cell I_MEASURE
number I_MEASURE
would O
remain O
the O
same B_MEASURE/B_LOCATION
and O
that O
there O
would O
be O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
number B_MEASURE/B_PERSON
of O
non B_DISEASE
- O
neuronal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
as O
well O
as O
a O
corresponding B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
number B_MEASURE/B_PERSON
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

After O
24 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hours I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O
increases O
the O
number B_MEASURE/B_PERSON
of O
p75NTR B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
the O
number B_MEASURE
of O
Hu B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
D B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8A I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

However O
, O
there O
was O
no O
statistically O
significant B_MEASURE
change I_MEASURE
in O
the O
number B_MEASURE
of O
non B_DISEASE
- O
neuronal B_PERSON
cells I_PERSON
. O

Thus O
, O
it O
is O
unlikely B_DISEASE_ADJECTIVE[DISEASE]
that O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increases O
the O
number B_MEASURE
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
by O
inducing O
differentiation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O
non B_DISEASE
- O
neuronal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O

To O
determine O
whether O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
total B_MEASURE/B_ENT
number I_MEASURE/I_ENT
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
is O
caused O
by O
BDNF B_GENE
- O
induced O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
BDNF B_GENE
- O
treated O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
exposed O
to O
BrdU B_GENE
for O
12 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
plating O
, O
and O
the O
number B_MEASURE/B_LOCATION
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
incorporated O
BrdU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O
their O
DNA B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O
determined O
after O
24 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
culture B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Even O
in O
the O
control B_LOCATION
condition I_LOCATION
, O
a O
number B_MEASURE/B_PERSON
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
culture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
are O
dividing O
, O
giving O
a O
high B_MEASURE
baseline I_MEASURE
of O
BrdU B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
incorporation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
8B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

When O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
added O
, O
the O
total B_MEASURE
number I_MEASURE
of O
BrdU B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
positive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
increases O
approximately O
1 B_MEASURE
. O
6 B_MEASURE
- O
fold B_MEASURE/B_LOCATION
( O
Figure B_TIME[MEASURE]/B_PERSON
8B I_TIME[MEASURE]/I_PERSON
) O
. O

This O
BDNF B_GENE
- O
induced O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
total B_MEASURE/B_ENT
number I_MEASURE/I_ENT
of O
BrdU B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
positive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
occurs O
in O
sympathoblasts B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
because O
the O
number B_MEASURE/B_ENT
of O
Islet B_LOCATION
- O
1 B_NUMBER[MEASURE]
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cultures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
label B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
BrdU B_GENE
is O
268 B_MEASURE
+/- I_MEASURE
59 I_MEASURE
and O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
raises O
this O
number B_MEASURE/B_PERSON
to O
424 B_MEASURE
+/- O
80 B_MEASURE
, O
which O
corresponds O
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]
of O
1 B_MEASURE
. O
6 B_MEASURE
- O
fold B_MEASURE
. O

This O
accounts O
for O
the O
1 B_MEASURE
. O
6 B_MEASURE
- O
fold B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
total B_MEASURE/B_PERSON
neuron I_MEASURE/I_PERSON
number I_MEASURE/I_PERSON
and O
total B_GENE
BrdU I_GENE
- O
positive B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
described O
above O
. O

We O
then O
confirmed O
that O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
TrkB B_GENE
- O
positive B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
BDNF B_GENE
increases O
the O
number B_MEASURE
of O
TrkB B_GENE
- O
expressing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
incorporate O
BrdU B_MEASURE
2 I_MEASURE
. O
6 B_MEASURE
- O
4 B_NUMBER[MEASURE]
- O
fold B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
over O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
and O
it O
also O
increases O
the O
overall B_MEASURE
number I_MEASURE
of O
TrkB B_GENE
- O
positive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
2 B_MEASURE
. O
5 B_MEASURE
- O
fold B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
over O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O
not O
increase O
the O
number B_MEASURE/B_PERSON
of O
BrdU B_GENE
- O
positive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
TrkB B_GENE
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
the O
overall B_MEASURE
number I_MEASURE
of O
TrkB B_GENE
- O
negative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

In O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
BDNF B_GENE
acts O
directly O
on O
TrkB B_GENE
- O
expressing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O
an O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
directed O
against O
the O
extracellular B_PROTEIN[GENE]/B_LOCATION
domain I_PROTEIN[GENE]/I_LOCATION
of O
TrkB B_GENE
completely O
prevents O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BDNF B_GENE
in O
promoting O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
TrkB B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
TrkB B_GENE/B_LOCATION
- O
negative B_DISEASE_ADJECTIVE[DISEASE]
cells I_DISEASE_ADJECTIVE[DISEASE]
( O
compare B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Figure B_MEASURE
9A I_MEASURE
to O
9B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Thus O
, O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BDNF B_GENE
is O
restricted O
to O
the O
population B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
expresses O
TrkB B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O
which O
are O
developing O
sympathoblasts B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

To O
determine O
whether O
TrkB B_GENE/B_MEASURE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O
actively O
proliferating O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
embryos B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
injected O
with O
BrdU B_GENE
at O
St B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
. O

27 B_TIME[MEASURE]/B_PERSON
and O
harvested O
at O
St B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

29 B_TIME[MEASURE]/B_LOCATION
, O
approximately O
24 B_TIME[MEASURE]
hrs I_TIME[MEASURE]
later O
. O

The O
majority B_PERSON/B_MEASURE
( O
85 B_MEASURE
- O
90 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
of O
TrkB B_GENE
- O
positive B_DISEASE/B_BIO
cells I_DISEASE/I_BIO
do O
not O
incorporate O
BrdU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O
their O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
under O
basal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
Figure B_MEASURE
10 I_MEASURE
) O
, O
although O
a O
few B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TrkB I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
labeled O
nuclei B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
observed O
( O
arrows B_MEASURE/B_BIO
) O
. O

This O
contrasts O
with O
our O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
71 B_MEASURE
- O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
TrkB B_GENE
- O
positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
incorporate O
BrdU B_GENE
in O
culture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
BDNF B_GENE
( O
Table B_NUMBER[MEASURE]/B_LOCATION
2 I_NUMBER[MEASURE]/I_LOCATION
) O
, O
suggesting O
that O
endogenous B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BDNF I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
achieve O
a O
threshold B_MEASURE
sufficient I_MEASURE
to O
support O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sympathoblast B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proliferation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
report O
that O
the O
neurotrophin O
receptor O
TrkB O
is O
expressed O
in O
a O
subset O
of O
embryonic O
sympathoblasts O
during O
the O
early O
development O
of O
lumbar O
paravertebral O
sympathetic O
ganglia O
in O
chicken B_SPECIES[BIO]
and O
mouse B_SPECIES[BIO]/B_DISEASE
embryos O
. O

In O
the O
chicken B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O
TrkB O
expression O
is O
transient O
, O
and O
completely O
lost O
by O
St O
34 O
( O
E8 O
) O
. O

Since O
BDNF B_GENE
induces O
the O
proliferation B_TIME[MEASURE]/B_DISEASE
of O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
in O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
yet O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
there O
is O
little B_DISEASE_ADJECTIVE[DISEASE]
proliferation I_DISEASE_ADJECTIVE[DISEASE]
observed O
in O
TrkB B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
nascent B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ganglia I_BIO/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
propose O
that O
if O
TrkB B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
becomes O
unregulated B_DISEASE_ADJECTIVE[DISEASE]
by O
excess B_DISEASE_ADJECTIVE[DISEASE]
BDNF I_DISEASE_ADJECTIVE[DISEASE]
or O
constitutive B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
phosphorylation B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
TrkB B_GENE
[ O
16 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
] I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
this O
transient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TrkB B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sympathoblasts I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
may O
trigger O
the O
genesis B_DISEASE/B_ORGANISM_FUNCTION
of O
neuroblastoma B_DISEASE/B_GENE
, O
a O
childhood B_DISEASE_ADJECTIVE[DISEASE]
tumor I_DISEASE_ADJECTIVE[DISEASE]
found O
in O
the O
paravertebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
chain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
adrenal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
medulla I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

The O
two B_MEASURE/B_LOCATION
populations B_MEASURE/I_LOCATION
of O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
that O
we O
observe O
support O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
heterogeneity B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
among O
developing O
sympathetic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
crest I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Early B_PERSON/B_DISEASE
sympathetic I_PERSON/I_DISEASE
ganglia I_PERSON/I_DISEASE
contain O
at O
least O
two B_NUMBER[MEASURE]/B_LOCATION
subpopulations I_NUMBER[MEASURE]/I_LOCATION
: O
early B_DISEASE_ADJECTIVE[DISEASE]
differentiating O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
lack O
TrkB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
express O
TrkA B_LOCATION/B_ORGANIZATION
and O
TrkC B_GENE
, O
and O
late B_DISEASE_ADJECTIVE[DISEASE]
differentiating O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
that O
express O
TrkB B_GENE/B_LOCATION
. O

Explant O
cultures O
of O
sympathetic O
ganglia O
from O
E16 O
chick B_SPECIES[BIO]
embryos O
give O
rise O
to O
two O
neuronal O
populations O
: O
one O
that O
remains O
close O
to O
the O
explant O
, O
and O
one O
that O
migrates O
away O
from O
the O
explant O
[ O
1 O
] O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
early B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuronal I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subpopulations I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
observed O
in O
cultures B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
crest I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
St B_LOCATION/B_SPECIES[BIO]
. O

13 B_MEASURE
/ O
14 B_MEASURE
quail I_MEASURE
embryos I_MEASURE
as O
evidenced O
by O
the O
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
neuronal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
type I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O
specific B_MEASURE/B_PROTEIN[GENE]
gangliosides I_MEASURE/I_PROTEIN[GENE]
[ O
17 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Perhaps O
these O
different B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subpopulations B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
will O
ultimately O
give O
rise B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
the O
two B_NUMBER[MEASURE]
neurochemically O
distinct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
populations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
found O
in O
lumbar B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
ganglia I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
: O
the O
noradrenergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
NPY B_GENE
- O
containing O
neurons B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
innervate B_TIME[MEASURE]/B_PERSON
internal I_TIME[MEASURE]/I_PERSON
organs I_TIME[MEASURE]/I_PERSON
and O
enteric B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
cholinergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
VIP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
neurons B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
innervate B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
vasculature I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
hind B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
limbs I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

The O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
BDNF B_GENE
and O
TrkB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deletion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
over O
expression B_GENE
have O
been O
studied O
on O
superior B_BODY_PART_OR_ORGAN_COMPONENT
cervical I_BODY_PART_OR_ORGAN_COMPONENT
ganglion I_BODY_PART_OR_ORGAN_COMPONENT
and O
preganglionic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
thoracic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
segments B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
spinal B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
column I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
on O
paravertebral B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
sympathetic I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
neurons I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
. O

In O
the O
superior O
cervical O
ganglion O
, O
an O
increase O
in O
the O
number O
of O
neurons O
of O
BDNF O
null O
mice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
likely O
due O
to O
apoptosis O
induced O
by O
BDNF O
via O
p75NTR O
[ O
18 O
] O
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
the O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
paravertebral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
complex B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
subtype O
dependent B_DISEASE_ADJECTIVE[DISEASE]
. O

Over O
expression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
BDNF B_GENE
leads O
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
number B_MEASURE
of O
noradrenergic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
fibers I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
innervating O
the O
erector B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pilli B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
muscles B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
hair B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
follicles I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
while O
noradrenergic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
fibers I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
innervating O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
vessels I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
were O
unaffected B_DISEASE_ADJECTIVE[DISEASE]
[ I_DISEASE_ADJECTIVE[DISEASE]
19 I_DISEASE_ADJECTIVE[DISEASE]
] I_DISEASE_ADJECTIVE[DISEASE]
. O

If O
our O
results O
indicating O
that O
BDNF O
promotes O
proliferation O
of O
TrkB O
- O
positive O
sympathoblasts O
in O
the O
chicken B_SPECIES[BIO]/B_DISEASE
embryo O
can O
be O
extrapolated O
to O
the O
subset O
of O
TrkB O
- O
positive O
sympathoblasts O
in O
murine O
ganglia O
, O
then O
these O
TrkB O
- O
positive O
cells O
may O
be O
neurons O
destined O
to O
innervate O
the O
erector O
pilli O
. O

In O
other O
studies O
, O
TrkB O
null O
mice B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O
no O
changes O
in O
morphology O
or O
cell O
number O
in O
superior O
cervical O
ganglia O
[ O
12 O
] O
or O
in O
the O
intermediolateral O
column O
[ O
20 O
] O
; O
but O
this O
may O
not O
be O
predictive O
of O
a O
phenotype O
in O
the O
lumbar O
paravertebral O
chain O
. O

It O
is O
thus O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
BDNF B_GENE/B_LOCATION
/ O
TrkB B_GENE/B_LOCATION
signaling I_GENE/I_LOCATION
could O
play O
a O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
other B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
regions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
paravertebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
chain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
the O
lumbar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

However O
, O
if O
TrkB O
- O
positive O
cells O
are O
not O
normally O
actively O
proliferating O
in O
vivo O
, O
then O
it O
would O
not O
be O
surprising O
that O
the O
development O
of O
the O
paravertebral O
sympathetic O
chain O
is O
not O
disrupted O
in O
TrkB O
or O
BDNF O
null O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
may O
be O
more O
informative O
to O
examine O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
over O
express O
BDNF O
on O
a O
promoter O
that O
targets O
expression O
to O
embryonic O
lumbar O
ganglia O
. O

Unfortunately O
, O
such O
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
do O
not O
exist O
. O

Our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
St B_LOCATION/B_PERSON
. O

29 O
/ O
30 O
( O
E6 O
. O
5 O
) O
sympathoblasts O
are O
dependent O
on O
both O
NT O
- O
3 O
and O
NGF O
for O
survival O
in O
culture O
are O
consistent O
with O
previous O
work O
on O
mouse B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
sympathoblasts O
from O
the O
superior O
cervical O
ganglion O
[ O
11 O
] O
. O

In O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
NT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
and O
NGF B_GENE/B_DISEASE
deletion I_GENE/I_DISEASE
separately O
led O
to O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
number B_MEASURE/B_ENT
of O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O
E17 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
5 B_MEASURE
compared O
to O
control O
. O

Deletion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O
both O
NT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE/B_LOCATION
and O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
together O
did O
not O
enhance O
cell B_DISEASE
death I_DISEASE
. O

In O
contrast O
, O
cultured O
rat B_SPECIES[BIO]/B_GENE
superior O
cervical O
ganglion O
sympathetic O
neurons O
respond O
to O
NT O
- O
3 O
at O
E14 O
. O
5 O
and O
then O
to O
NGF O
at O
E19 O
. O
5 O
, O
although O
time O
points O
in O
between O
were O
not O
analyzed O
[ O
6 O
] O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
promoting O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
, O
NT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
, O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
BDNF B_GENE/B_LOCATION
also O
induce O
proliferation B_TIME[MEASURE]/B_ORGANISM_FUNCTION
of O
various B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neuronal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
precursors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stages I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
development B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
. O

NT O
- O
3 O
can O
promote O
the O
incorporation O
of O
[ O
3H O
] O
- O
thymidine O
into O
cultured O
quail O
neural O
crest O
cells O
from O
the O
trunk O
region O
[ O
21 O
, O
22 O
] O
, O
Later O
in O
rat B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
sympathetic O
development O
, O
NT O
- O
3 O
supports O
survival O
of O
neurons O
, O
but O
does O
not O
promote O
proliferation O
[ O
6 O
] O
, O
which O
is O
consistent O
with O
our O
results O
. O

NGF O
promotes O
an O
increase O
in O
BrdU O
incorporation O
from O
25 O
% O
to O
35 O
% O
in O
the O
DRG O
cervical O
segment O
2 O
in O
the O
chick B_SPECIES[BIO]/B_DISEASE
embryo O
[ O
23 O
] O
. O

In O
chicken B_SPECIES[BIO]
embryos O
that O
are O
treated O
with O
NGF O
in O
ovo O
at O
St O
. O

18 O
and O
21 B_TIME[MEASURE]/B_LOCATION
, O
there O
is O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
BrdU B_DISEASE/B_MEASURE
uptake B_DISEASE/I_MEASURE
after O
formation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
primary B_LOCATION/B_PERSON
sympathetic I_LOCATION/I_PERSON
chain I_LOCATION/I_PERSON
at O
St B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
. O

23 B_MEASURE
[ O
24 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

Since O
NGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
does O
not O
appear O
to O
affect O
proliferation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
St B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

29 O
/ O
30 O
( O
E6 O
. O
5 O
) O
chick B_PERSON/B_MEASURE
sympathoblasts O
, O
NGF O
may O
only O
promote O
proliferation O
in O
primary O
, O
but O
not O
secondary O
chain O
sympathoblasts O
. O

Motor O
neuron O
progenitors O
in O
the O
ventral O
neural O
tube O
from O
the O
chick B_SPECIES[BIO]/B_DISEASE
embryo O
express O
TrkB O
and O
when O
ventral O
neural O
tube O
explants O
are O
treated O
with O
BDNF O
, O
there O
is O
an O
increase O
in O
the O
number O
of O
motor O
neurons O
produced O
and O
BrdU O
incorporation O
[ O
25 O
] O
. O

BDNF B_GENE/B_LOCATION
also O
promotes O
the O
proliferation B_DISEASE/B_ORGANISM_FUNCTION
of O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
neuroblastoma I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
[ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
13 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O

taken O
together O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
NT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
and O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O
not O
promote O
proliferation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
St B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
) O
sympathoblasts B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
support O
the O
assertion B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
BDNF B_GENE
promotes O
proliferation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
TrkB B_GENE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sympathoblasts B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
culture B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
a O
transient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
TrkB B_GENE
during O
early B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
supporting O
proliferation B_MEASURE/B_ORGANISM_FUNCTION
of O
this O
early B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
subpopulation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
the O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
labeling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
suggests O
that O
only O
a O
minority B_PERSON/B_SEQUENCE[MEASURE]
( O
10 B_NUMBER[MEASURE]
- O
20 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
of O
this O
population B_PERSON/B_MEASURE
is O
dividing O
during O
the O
window B_LOCATION/B_TIME[MEASURE]
that O
TrkB B_GENE
is O
expressed O
. O

In O
light B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
very O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proliferative B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
in O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
culture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
these O
TrkB B_GENE
expressing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
could O
respond O
more O
strongly O
if O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
rises O
to O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
levels B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
or O
if O
the O
mechanism B_GENE/B_DISEASE
that O
down O
regulates O
TrkB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
becomes O
nonfunctional B_DISEASE_ADJECTIVE[DISEASE]
. O

Such B_DISEASE/B_GENE
events B_DISEASE/I_GENE
could O
trigger O
an O
early B_DISEASE_ADJECTIVE[DISEASE]
proliferative I_DISEASE_ADJECTIVE[DISEASE]
event I_DISEASE_ADJECTIVE[DISEASE]
that O
leads O
to O
a O
cascade B_DISEASE/B_MEASURE
of O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
initiates O
transformation B_DISEASE/B_ORGANISM_FUNCTION
of O
cells B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
neuroblastoma B_DISEASE
. O

Thus O
, O
these O
early B_GENE
TrkB I_GENE
expressing O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
help O
solve O
the O
puzzle B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
to O
why O
TrkB B_GENE/B_LOCATION
is O
expressed O
in O
aggressive B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
invasive B_DISEASE_ADJECTIVE[DISEASE]
forms I_DISEASE_ADJECTIVE[DISEASE]
of O
neuroblastoma B_DISEASE
, O
particularly O
because O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
cultured O
neuroblastoma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
become O
more O
proliferative B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
invasive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
angiogenic B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
resistant B_DISEASE_ADJECTIVE[DISEASE]
to O
chemotherapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reagents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
than O
untreated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cultures I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
13 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Future O
studies O
will O
determine O
whether O
constitutive O
expression O
of O
BDNF O
and O
TrkB O
in O
the O
chick B_SPECIES[BIO]/B_DISEASE
embryo O
sustains O
proliferation O
of O
differentiating O
sympathoblasts O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

We O
have O
identified O
a O
time B_MEASURE/B_LOCATION
point B_MEASURE/I_LOCATION
during O
development B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
when O
differentiating O
lumbar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
transiently O
express O
TrkB B_GENE
and O
proliferate O
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
culture B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
elevated O
BDNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
above O
basal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
levels I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O
signaling O
through O
TrkB B_GENE
may O
be O
a O
mechanism B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
contributes O
to O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
neuroblastoma B_DISEASE
. O

A O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
populations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
fate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
TrkB B_GENE/B_MEASURE
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cells B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
will O
provide O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
insight I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
into O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
paravertebral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
sympathetic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
ganglia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
genesis B_DISEASE/B_PERSON
of O
neuroblastoma B_DISEASE
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

preparation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
tissue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
immunohistochemistry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
lumbar O
spinal O
column O
and O
surrounding O
tissues O
were O
dissected O
from O
chicken B_SPECIES[BIO]
embryos O
at O
the O
indicated O
stages O
and O
placed O
in O
Zamboni O
' O
s O
fixative O
( O
4 O
% O
( O
w O
/ O
v O
) O
paraformaldehyde O
, O
15 O
% O
( O
v O
/ O
v O
) O
picric O
acid O
in O
0 O
. O
1 O
M O
sodium O
phosphate O
buffer O
, O
pH O
7 O
. O
4 O
) O
for O
two O
hours O
at O
room O
temperature O
. O

Mouse B_BIO/B_PERSON
embryos O
at O
13 O
- O
15 O
days O
post O
- O
coitus O
were O
collected O
according O
to O
an O
IACUC O
- O
approved O
protocol O
to O
Dr O
. O
L O
. O

Sherman B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
Oregon B_EDU[ORGANIZATION]/B_PERSON
Health I_EDU[ORGANIZATION]/I_PERSON
and O
Science B_LOCATION/B_EDU[ORGANIZATION]
University B_LOCATION/I_EDU[ORGANIZATION]
. O

The O
mouse B_DISEASE/B_SPECIES[BIO]
embryos O
were O
immersion O
- O
fixed O
in O
Zamboni O
' O
s O
fixative O
overnight O
at O
4 O
degrees O
C O
then O
washed O
with O
phosphate O
buffered O
saline O
( O
PBS O
; O
130 O
mm O
NaCl O
, O
20 O
mm O
sodium O
phosphate O
buffer O
, O
pH O
7 O
. O
4 O
) O
. O

fixed O
tissues B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
were O
equilibrated O
in O
30 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sucrose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
buffered O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PBS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
) O
. O

fixed O
mouse B_SPECIES[BIO]/B_DISEASE
embryos O
were O
shipped O
to O
Vermont O
in O
sucrose O
. O

transverse B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
30 B_LOCATION/B_BIO
mu I_NUMBER[MEASURE]/I_LOCATION
M I_NUMBER[MEASURE]/I_LOCATION
sections I_NUMBER[MEASURE]/I_LOCATION
of O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
columns I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
cut O
at O
on O
a O
microm B_LOCATION/B_MEASURE
HM I_LOCATION/I_MEASURE
cryostat I_LOCATION/I_MEASURE
( O
knife B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperature I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
16 B_MEASURE
degrees I_MEASURE
C I_MEASURE
; O
object B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
temperature I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
: O
23 B_MEASURE
degrees I_MEASURE
C I_MEASURE
) O
and O
collected O
on O
Superfrost B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Plus I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
slides I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Fisher B_PERSON/B_MEASURE
) O
. O

sections O
were O
dried O
at O
room O
temperature O
, O
washed O
in O
1 O
x O
PBS O
and O
incubated O
overnight O
in O
blocking O
buffer O
( O
1 O
x O
PBS O
consisting O
of O
10 O
% O
( O
v O
/ O
v O
) O
heat O
- O
inactivated O
horse B_SPECIES[BIO]
serum O
( O
Invitrogen O
/ O
Gibco O
) O
, O
0 O
. O
5 O
% O
Triton O
X O
- O
100 O
( O
Sigma O
) O
, O
and O
0 O
. O
1 O
% O
sodium O
azide O
( O
Fisher O
) O
) O
. O

Immunohistochemistry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

sections B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
incubated O
with O
primary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
overnight O
at O
4 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
, O
followed O
by O
incubation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O
secondary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
2 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
room B_MEASURE/B_LOCATION
temperature I_MEASURE/I_LOCATION
. O

Primary O
antibodies O
used O
were O
: O
rabbit B_SPECIES[BIO]/B_GENE
anti O
- O
p75 O
( O
1 O
: O
1500 O
, O
generous O
gift O
from O
Louis O
Reichardt O
, O
UCSF O
[ O
26 O
] O
) O
, O
mouse B_SPECIES[BIO]/B_DISEASE
IgG2b O
anti O
- O
Hu O
C O
/ O
D O
, O
( O
1 O
: O
250 O
, O
Molecular O
Probes O
) O
; O
mouse B_SPECIES[BIO]/B_DISEASE
IgG1 O
anti O
- O
Islet O
- O
1 O
, O
( O
1 O
: O
10 O
, O
developmental O
Studies O
Hybridoma O
Bank O
) O
; O
rabbit B_SPECIES[BIO]
anti O
- O
chicken B_SPECIES[BIO]
TrkA O
( O
1 O
: O
500 O
) O
; O
rabbit B_SPECIES[BIO]
anti O
- O
chicken B_SPECIES[BIO]
TrkB O
( O
1 O
: O
500 O
) O
; O
rabbit B_SPECIES[BIO]
anti O
- O
chicken B_SPECIES[BIO]
TrkC O
( O
1 O
: O
500 O
) O
( O
all O
Trk O
antibodies O
were O
generous O
gifts O
of O
Dr O
. O
Louis O
Reichardt O
, O
UCSF O
[ O
26 O
- O
28 O
] O
) O
; O
mouse B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O
- O
HNK O
- O
1 O
( O
1 O
: O
50 O
, O
developmental O
Studies O
Hybridoma O
Bank O
) O
; O
mouse B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IgG2a O
anti O
- O
tyrosine O
hydroxylase O
( O
1 O
: O
10 O
, O
developmental O
Studies O
Hybridoma O
Bank O
) O
, O
sheep B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
anti O
- O
BrdU O
( O
1 O
: O
100 O
, O
Biodesign O
International O
) O
, O
rabbit B_MEASURE
anti O
- O
tyrosine O
hydroxylase O
( O
1 O
: O
100 O
, O
Chemicon O
) O
, O
and O
goat B_SPECIES[BIO]/B_LOCATION
anti O
- O
TrkB O
( O
1 O
: O
1000 O
, O
R O
& O
D O
Systems O
) O
. O

immunofluorescence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
imaged O
using O
a O
Nikon B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
C1 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
confocal I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mounted O
on O
a O
Nikon B_LOCATION/B_PERSON
Eclipse I_LOCATION/I_PERSON
E800 I_LOCATION/I_PERSON
microscope I_LOCATION/I_PERSON
with O
a O
10 B_MEASURE
x O
Plan B_MEASURE/B_LOCATION
Apo I_MEASURE/I_LOCATION
( O
Na B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
. O
785 B_MEASURE
) O
air B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
objective I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
a O
60 B_MEASURE
x O
Plan B_MEASURE/B_LOCATION
Apo I_MEASURE/I_LOCATION
( O
Na B_MEASURE/B_LOCATION
1 B_MEASURE/I_LOCATION
. O
4 B_MEASURE
) O
oil B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
objective I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
lens I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
, O
E7 B_PROTEIN[GENE]/B_LOCATION
- O
C1 B_MEASURE/B_ORGANIZATION
software I_MEASURE/I_ORGANIZATION
, O
and O
UV B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
argon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
and O
He O
/ O
NE B_PERSON/B_ORGANIZATION
lasers I_PERSON/I_ORGANIZATION
exciting I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
408 B_MEASURE
, O
488 B_MEASURE
, O
and O
543 B_MEASURE
nm I_MEASURE
and O
emitting O
at O
404 B_MEASURE
500 I_MEASURE
- O
530 B_MEASURE
, O
and O
555 B_MEASURE
- O
615 B_MEASURE
nm I_MEASURE
, O
respectively O
. O

A O
Nikon B_ORGANIZATION/B_TIME[MEASURE]
Eclipse B_ORGANIZATION/I_TIME[MEASURE]
E800 O
microscope B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
nearby B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
COBRE I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Molecular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
cellular B_LOCATION/B_ORGANIZATION
Core I_LOCATION/I_ORGANIZATION
Facility I_LOCATION/I_ORGANIZATION
was O
used O
for O
counting O
immunofluorescent B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O
200 B_MEASURE/B_LOCATION
x I_MEASURE/I_LOCATION
using O
epifluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
optics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

RNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
extraction I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
cDNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

sympathetic O
ganglia O
were O
removed O
from O
chick B_PERSON/B_SPECIES[BIO]
embryos O
and O
RNA O
was O
isolated O
using O
TriReagent O
( O
Molecular O
Research O
Center O
) O
, O
an O
acidified O
guanidinium O
with O
phenol O
extraction O
method O
[ O
29 O
] O
. O

RNA B_GENE/B_BIO
was O
transcribed O
to O
cDNA B_GENE
using O
oligo B_GENE
- O
dT B_GENE
with O
Superscript B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Reverse I_GENE
Transcriptase B_TIME[MEASURE]/B_PERSON
( O
Invitrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
at O
42 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
for O
1 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hour I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Real B_PERSON/B_MEASURE
- O
time B_TIME[MEASURE]/B_LOCATION
PCR B_TIME[MEASURE]/I_LOCATION
. O

Relative B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RNA I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
determined O
using O
quantitative B_MEASURE
real I_MEASURE
- O
time B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
an O
ABI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7500 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Fast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Real B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
System B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

TaqMan O
probes O
were O
used O
to O
quantify O
the O
progression O
of O
the O
PCR O
reaction O
and O
reactions O
were O
normalized O
using O
the O
constitutively O
expressed O
gene O
chick B_BIO/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
ribosomal O
binding O
protein O
s17 O
( O
CHRPS O
) O
. O

The O
sequences O
were O
used O
for O
primer O
/ O
probes O
sets O
: O
for O
BDNF O
: O
forward O
: O
5 O
' O
- O
AGCCCAGTGAGGAAAACAAG O
- O
3 O
' O
, O
reverse O
: O
5 O
' O
- O
ACTCCTCGAGCAGAAAGAGC O
- O
3 O
' O
, O
probe O
: O
5 O
' O
- O
[ O
6 O
- O
FAM O
] O
- O
TACACATCCCGAGTCATGCTGAGCA O
- O
[ O
BHQ O
] O
- O
3 O
' O
; O
for O
CHRPS O
( O
chick B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
ribosomal O
binding O
protein O
S O
- O
17 O
) O
: O
5 O
' O
AACGACTTCCACACCAACAA3 O
' O
, O
reverse O
: O
5 O
' O
CTTCATCAGGTGGGTGACAT3 O
' O
, O
probe O
: O
5 O
' O
- O
[ O
6 O
- O
FAM O
] O
- O
CGCCATCATCCCCAGCAAGA O
[ O
BHQ O
] O
- O
3 O
' O
. O

primers B_GENE
and O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
were O
synthesized O
by O
Operon B_ORGANIZATION/B_DISEASE
Technologies I_ORGANIZATION/I_DISEASE
, O
Inc B_ORGANIZATION/B_LOCATION
( O
Alameda B_LOCATION/B_PERSON
, O
CA B_LOCATION
) O
. O

The O
primers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
BDNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
validated O
against O
primers B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
CHRPS B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
according O
to O
an O
Applied B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
BioSystems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
by O
serially O
diluting O
the O
target B_MEASURE/B_PERSON
cDNA I_MEASURE/I_PERSON
1 I_MEASURE/I_PERSON
: O
10 B_MEASURE
, O
determining O
the O
cycle B_MEASURE/B_LOCATION
threshold I_MEASURE/I_LOCATION
( O
CT B_LOCATION/B_PROTEIN[GENE]
) O
for O
each O
reaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
plotting O
the O
CT B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
log B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

slopes B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
resulting O
lines B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
calculated O
and O
primers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
accepted O
if O
their O
CT B_MEASURE/B_LOCATION
slopes I_MEASURE/I_LOCATION
were O
between O
- O
3 B_NUMBER[MEASURE]
. O
2 B_MEASURE
and O
- O
3 B_NUMBER[MEASURE]
. O
4 B_MEASURE
( O
a O
perfect B_MEASURE/B_LOCATION
efficiency I_MEASURE/I_LOCATION
of O
1 B_MEASURE
. O
0 B_MEASURE/B_LOCATION
yields I_MEASURE/I_LOCATION
a O
slope B_MEASURE
of O
- O
3 B_NUMBER[MEASURE]
. O
3 B_MEASURE
) O
. O

To O
analyze O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
the O
delta B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Ct I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
relative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
quantification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
used O
, O
where O
the O
Ct B_MEASURE
of O
Chrps B_GENE/B_BACTERIUM[BIO]
was O
subtracted O
from O
the O
Ct B_MEASURE
of O
the O
gene B_GENE
of O
interest B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Delta B_GENE
Ct I_GENE
) O
and O
the O
arbitrary B_MEASURE
units I_MEASURE
of O
mRNA B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
expressed O
as O
10000 B_MEASURE/B_LOCATION
/ O
2 B_MEASURE
^ O
( O
Delta B_MEASURE/B_LOCATION
CT B_MEASURE/I_LOCATION
) O
. O

Cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

sympathetic B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O
cultured O
as O
previously O
described O
[ O
30 B_TIME[MEASURE]/B_LOCATION
] O
with O
a O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

sympathetic B_PERSON
ganglia I_PERSON
were O
removed O
from O
the O
lumbar B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
region I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
paravertebral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
chain B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
St B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

29 O
/ O
30 O
( O
E6 O
. O
5 O
) O
chick B_PERSON/B_NUMBER[MEASURE]
embryos O
and O
placed O
in O
modified O
Puck O
' O
s O
solution O
with O
glucose O
( O
MPG O
) O
. O

The O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
dissociated O
by O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
ganglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
0 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
trypsin I_MEASURE
in O
MPG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
37 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
for O
10 B_TIME[MEASURE]
minutes I_TIME[MEASURE]
followed O
by O
triturating O
with O
a O
fire B_LOCATION/B_TIME[MEASURE]
polished O
9 B_NUMBER[MEASURE]/B_PERSON
' O
Pasteur B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pipette I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

cells O
were O
then O
resuspended O
in O
Dulbecco O
' O
s O
modified O
Eagle O
Medium O
( O
DMEM O
) O
consisting O
of O
10 O
% O
horse B_SPECIES[BIO]/B_PERSON
serum O
, O
2 O
% O
fetal O
calf O
serum O
, O
and O
10 O
mg O
/ O
ml O
penicillin O
/ O
streptomycin O
. O

For O
neurotrophin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
culture B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
medium I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
was O
supplemented O
with O
25 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_LOCATION
NT I_MEASURE/I_LOCATION
- O
3 B_NUMBER[MEASURE]/B_LOCATION
( O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Systems I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
1 B_MEASURE/B_LOCATION
Mu I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
ml B_MEASURE/B_LOCATION
7S I_MEASURE/I_LOCATION
NGF I_MEASURE/I_LOCATION
( O
Alomone B_LOCATION
Labs I_LOCATION
) O
upon O
plating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
50 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
, O
100 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
, O
or O
200 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE
BDNF I_MEASURE
( O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Systems I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
once O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
adhered O
to O
the O
wells B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
plated O
on O
poly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
lysine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
laminin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
coated O
wells B_PERSON/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
cover B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
slips I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fisher B_PERSON/B_MEASURE
) O
as O
previously O
described O
[ O
30 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

quantification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
sympathoblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
using O
phase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

embryonic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sympathoblasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
neurons B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
small B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
phase B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
bright I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
cells I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O
neurites B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

The O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
with O
neurites B_MEASURE/B_LOCATION
the O
length B_MEASURE/B_COLOR
of O
two B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
bodies I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
counted O
in O
10 B_NUMBER[MEASURE]
non O
- O
overlapping O
fields B_LOCATION
of O
view B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evenly O
spaced O
in O
a O
grid B_LOCATION/B_BIO
- O
like B_LOCATION/B_PERSON
pattern I_LOCATION/I_PERSON
across O
the O
bottom B_LOCATION/B_MEASURE
of O
a O
well B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
a O
24 B_MEASURE/B_LOCATION
well I_MEASURE/I_LOCATION
plate I_MEASURE/I_LOCATION
at O
200 B_MEASURE/B_LOCATION
x I_MEASURE/I_LOCATION
using O
a O
Nikon B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Eclipse I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
TE200 I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
microscope I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

BrdU B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labeling I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
approximately O
2 B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
after O
plating O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
St B_LOCATION/B_BIO
. O

29 B_MEASURE
/ O
30 B_MEASURE
( O
E6 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
) O
sympathetic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_TIME[MEASURE]
ganglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_TIME[MEASURE]
, O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
labeled O
with O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mu I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
M I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bromodeoxyuridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
BrdU B_LOCATION/B_PROTEIN[GENE]
, O
sigma B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
12 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
37 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
. O

Following O
this O
labeling B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
period I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
incubated O
in O
complete B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
BrdU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
an O
additional B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
then O
fixed O
in O
Zamboni B_BIO/B_LOCATION
' I_LOCATION
s I_LOCATION
fixative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
30 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
room B_TIME[MEASURE]/B_LOCATION
temperature I_TIME[MEASURE]/I_LOCATION
and O
rinsed O
with O
1 B_MEASURE
x O
PBS B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
in O
vivo O
studies O
, O
25 O
Mu O
g O
BrdU O
was O
injected O
into O
the O
amnion O
of O
chick B_SPECIES[BIO]
embryos O
at O
St O
. O

27 B_NUMBER[MEASURE]
. O

The O
cells B_BODY_PART_OR_ORGAN_COMPONENT
and O
sections B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
denatured O
with O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
37 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
for O
1 B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hr B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
were O
then O
neutralized O
with O
0 B_MEASURE
. O
1 B_MEASURE
M I_MEASURE
borate I_MEASURE
buffer I_MEASURE
, O
pH B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
. O
5 B_MEASURE
, O
for O
10 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
room B_MEASURE/B_LOCATION
temperature I_MEASURE/I_LOCATION
. O

Immunochemistry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
as O
described O
above O
. O

Abbreviations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

BDNF O
, O
brain O
- O
derived O
neurotrophic O
factor O
; O
BrdU O
, O
Bromodeoxyuridine O
; O
Da O
, O
dorsal O
aorta O
; O
DMEM O
, O
Dulbecco O
' O
s O
modified O
Eagle O
' O
s O
Medium O
; O
DRG O
, O
dorsal O
root O
ganglion O
; O
E O
, O
embryonic O
day O
; O
HS O
, O
horse B_BIO/B_PERSON
serum O
; O
MPG O
, O
modified O
Puck O
' O
s O
solution O
with O
glucose O
; O
NGF O
, O
nerve O
growth O
factor O
; O
NC O
, O
notochord O
; O
NT O
, O
neural O
tube O
; O
NT O
- O
3 O
, O
neurotrophin O
- O
3 O
; O
NTR O
, O
neurotrophin O
receptor O
; O
PBS O
, O
phosphate O
- O
buffered O
saline O
; O
SC O
, O
spinal O
cord O
; O
SCG O
, O
superior O
cervical O
ganglion O
; O
SEM O
, O
standard O
error O
of O
the O
mean O
; O
SG O
, O
sympathetic O
ganglion O
; O
St O
. O
, O
stage O
; O
w O
/ O
v O
, O
weight O
/ O
volume O
; O
v O
/ O
v O
, O
volume O
/ O
volume O
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

JAS B_PERSON/B_LOCATION
designed O
the O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
performed O
the O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
analyzed O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
and O
wrote O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

GLSS B_PERSON
contributed O
intellectually O
to O
the O
conception B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
design B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
assisted O
in O
the O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RN B_PERSON
supervised O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
participated O
in O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
edited O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
and O
obtained O
funding B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
project B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

All O
authors B_PERSON/B_NUMBER[MEASURE]
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

Video O
analysis O
of O
the O
escape O
flight O
of O
Pileated B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Woodpecker I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Dryocopus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
pileatus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
: O
does O
the O
Ivory B_BIO
- I_BIO
billed I_BIO
Woodpecker I_BIO
Campephilus I_BIO
principalis I_BIO
persist O
in O
continental O
North O
America O
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
apparent O
rediscovery O
of O
the O
Ivory B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
- I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
billed I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
Woodpecker I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
Campephilus I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
principalis I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
in O
Arkansas O
, O
USA O
, O
previously O
feared O
extinct O
, O
was O
supported O
by O
video O
evidence O
of O
a O
single O
bird O
in O
flight O
( O
Fitzpatrick O
et O
al O
, O
Science O
2005 O
, O
308 O
: O
1460 O
- O
1462 O
) O
. O

Plumage O
patterns O
and O
wingbeat O
frequency O
of O
the O
putative O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
said O
to O
be O
incompatible O
with O
the O
only O
possible O
confusion O
species O
native O
to O
the O
area O
, O
the O
Pileated B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Woodpecker I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Dryocopus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
pileatus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

New O
video O
analysis O
of O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Woodpeckers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O
escape O
flights O
comparable O
to O
that O
of O
the O
putative O
Ivory B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
filmed O
in O
Arkansas O
shows O
that O
Pileated B_PERSON/B_BIO
Woodpeckers I_PERSON/I_BIO
can O
display O
a O
wingbeat O
frequency O
equivalent O
to O
that O
of O
the O
Arkansas O
bird O
during O
escape O
flight O
. O

The O
critical O
frames O
from O
the O
Arkansas O
video O
that O
were O
used O
to O
identify O
the O
bird O
as O
an O
Ivory B_BIO/B_PERSON
- I_BIO/I_PERSON
billed I_BIO/I_PERSON
Woodpecker I_BIO/I_PERSON
are O
shown O
to O
be O
equally O
, O
or O
more O
, O
compatible O
with O
the O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

The O
identification O
of O
the O
bird O
filmed O
in O
Arkansas O
in O
April O
2004 O
as O
an O
Ivory B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
billed I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
Woodpecker I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O
best O
regarded O
as O
unsafe O
. O

The O
similarities O
between O
the O
Arkansas O
bird O
and O
known O
Pileated B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
suggest O
that O
it O
was O
most O
likely O
a O
Pileated B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
reported O
rediscovery O
of O
the O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
2004 O
- O
5 O
in O
the O
Big O
Woods O
of O
Arkansas O
gave O
new O
impetus O
to O
efforts O
to O
conserve O
the O
mature O
bottomland O
woodlands O
of O
the O
south O
- O
eastern O
USA O
. O

Several B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sightings I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
have O
been O
reported O
without O
photographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
being O
obtained O
[ O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Unless O
sightings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
are O
, O
however O
, O
independently O
verifiable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
photographic B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
other B_TIME[MEASURE]/B_LOCATION
recorded O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
mistakes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
been O
made O
cannot O
be O
eliminated O
. O

crucial O
to O
the O
scientific O
case O
for O
the O
persistence O
of O
the O
Ivory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
billed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
a O
4 O
s O
video O
of O
a O
large O
woodpecker O
in O
flight O
recorded O
by O
M O
. O
D O
. O

Luneau O
on O
25 O
April O
2004 O
( O
henceforth O
referred O
to O
as O
the O
' O
Luneau O
video O
' O
) O
and O
published O
in O
2005 O
[ O
1 O
] O
, O
which O
was O
claimed O
to O
be O
inconsistent O
with O
the O
plumage O
patterns O
of O
the O
superficially O
similar O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
a O
common O
resident O
bird O
of O
the O
area O
) O
. O

Both O
species B_BIO/B_PERSON
are O
large B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
black B_COLOR/B_LOCATION
- O
and O
- O
white B_COLOR/B_BIO
woodpeckers I_COLOR/I_BIO
[ O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
upperwing O
of O
the O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
black O
, O
with O
white O
secondary O
feathers O
and O
white O
on O
some O
inner O
primary O
feathers O
. O

Pileated B_PERSON/B_BIO
Woodpeckers I_PERSON/I_BIO
have O
a O
largely O
black O
upperwing O
, O
with O
white O
restricted O
to O
the O
' O
wrist O
' O
due O
to O
white O
bases O
to O
the O
primary O
feathers O
. O

The O
underwing O
of O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
all O
- O
white O
underwing O
coverts O
, O
giving O
an O
appearance O
of O
a O
white O
underwing O
with O
a O
broad O
black O
outline O
( O
the O
black O
flight O
feathers O
) O
. O

These O
plumage O
differences O
result O
in O
the O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O
a O
white O
trailing O
edge O
to O
the O
wings O
( O
upper O
and O
lower O
sides O
) O
, O
whereas O
the O
Pileated B_PERSON/B_LOCATION
Woodpecker I_PERSON/I_LOCATION
has O
a O
black O
trailing O
edge O
to O
the O
wings O
. O

Both O
species B_BIO/B_PERSON
have O
black B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
wing B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
- O
tips B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
and O
other B_MEASURE/B_PERSON
plumage B_MEASURE/I_PERSON
characteristics B_MEASURE/I_PERSON
are O
shown O
in O
[ B_LOCATION/B_MEASURE
1 B_LOCATION/I_MEASURE
, O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
wingbeat O
frequency O
of O
the O
bird O
in O
the O
Luneau O
video O
was O
measured O
at O
8 O
. O
6 O
beats O
s O
- O
1 O
, O
similar O
to O
that O
inferred O
from O
archival O
sound O
recording O
of O
a O
single O
Ivory B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
claimed O
to O
be O
outside O
the O
range O
of O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
which O
generally O
have O
slower O
wingbeats O
) O
[ O
1 O
, O
3 O
] O
. O

Sibley B_PERSON
et I_PERSON
al I_PERSON
[ O
4 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
questioned O
the O
video B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
in O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
providing O
alternative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
explanations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
plumage B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Luneau B_BIO
bird I_BIO
in O
flight B_LOCATION
and O
at O
rest B_LOCATION/B_TIME[MEASURE]
. O

They O
pointed O
out O
individual O
frames O
of O
the O
Luneau O
video O
that O
appear O
to O
show O
three O
features O
that O
are O
each O
inconsistent O
with O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
( O
1 O
) O
apparently O
black O
secondary O
feathers O
on O
the O
upper O
surface O
of O
the O
left O
wing O
, O
( O
2 O
) O
particularly O
bright O
white O
primary O
bases O
, O
and O
( O
3 O
) O
a O
black O
band O
curving O
smoothly O
round O
the O
wing O
tip O
( O
see O
Figure O
3 O
in O
[ O
4 O
] O
) O
. O

They O
hypothesized O
that O
flexing O
of O
a O
Pileated B_BIO/B_PERSON
Woodpecker I_BIO/I_PERSON
' O
s O
wings O
during O
flight O
could O
produce O
the O
appearance O
of O
white O
trailing O
edges O
on O
both O
wings O
in O
low O
- O
quality O
videos O
[ O
4 O
] O
. O

They O
offered O
, O
however O
, O
no O
direct O
evidence O
to O
show O
that O
this O
could O
cause O
a O
video O
of O
a O
Pileated B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
look O
like O
the O
bird O
in O
the O
Luneau O
video O
. O

Fitzpatrick O
et O
al O
[ O
5 O
] O
in O
turn O
rebutted O
some O
aspects O
of O
the O
hypothesis O
of O
Sibley O
et O
al O
[ O
4 O
] O
, O
publishing O
video O
stills O
of O
Pileated B_PERSON/B_BIO
Woodpeckers I_PERSON/I_BIO
, O
and O
a O
model O
of O
a O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpecker B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
that O
appeared O
to O
show O
a O
black O
trailing O
edge O
to O
the O
wings O
inconsistent O
with O
Ivory B_PERSON
- I_PERSON
billed I_PERSON
Woodpecker I_PERSON
and O
the O
Luneau O
video O
. O

Fitzpatrick B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
[ O
5 B_MEASURE
] O
neither O
rebutted O
nor O
discussed O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
key I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inconsistencies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
described O
above O
. O

Without O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
this O
became O
largely O
a O
theoretical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
debate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
over O
interpretation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
field B_LOCATION/B_ENT
characters I_LOCATION/I_ENT
that O
were O
barely O
visible B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
very O
small B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
images I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
originally O
obtained O
. O

On O
one O
hand O
, O
as O
pointed O
out O
in O
Sibley O
et O
al O
[ O
4 O
] O
, O
some O
of O
the O
frames O
of O
the O
bird O
in O
the O
Luneau O
video O
do O
appear O
to O
be O
inconsistent O
with O
Ivory B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
the O
other O
hand O
, O
the O
flight O
pattern O
of O
the O
bird O
in O
the O
Luneau O
video O
is O
asserted O
to O
be O
atypical O
for O
Pileated B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
but O
matching O
anecdotal O
descriptions O
of O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Furthermore O
, O
the O
general O
impression O
of O
the O
bird O
in O
the O
Luneau O
video O
was O
that O
there O
is O
far O
too O
much O
white O
in O
the O
wings O
for O
it O
to O
be O
a O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
that O
if O
it O
was O
a O
Pileated O
, O
then O
it O
must O
be O
an O
aberrant O
one O
with O
abnormally O
extensive O
white O
plumage O
. O

Such B_DISEASE/B_PERSON
birds I_DISEASE/I_PERSON
occasionally O
occur O
, O
and O
have O
been O
observed O
in O
the O
Arkansas B_LOCATION
study I_LOCATION
area I_LOCATION
[ O
6 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

This O
study O
was O
undertaken O
to O
determine O
whether O
the O
flight O
and O
plumage O
of O
the O
bird O
in O
the O
Luneau O
video O
really O
was O
inconsistent O
with O
either O
a O
normal O
or O
partial O
albino O
Pileated B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Woodpecker I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Independent O
analyses O
of O
the O
plumage O
patterns O
and O
wingbeat O
frequencies O
observable O
in O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Woodpeckers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
presented O
, O
and O
it O
is O
concluded O
that O
the O
identification O
of O
the O
bird O
in O
the O
Luneau O
video O
as O
definite O
Ivory B_BIO/B_PERSON
- I_BIO/I_PERSON
billed I_BIO/I_PERSON
Woodpecker I_BIO/I_PERSON
is O
probably O
unsafe O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
January O
28 O
and O
February O
5 O
, O
2006 O
, O
David O
Nolin O
( O
DN O
) O
video O
- O
recorded O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpeckers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Dryocopus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
pileatus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
at O
a O
bird O
- O
feeder O
in O
Dayton O
, O
Ohio O
, O
USA O
. O

A O
Hi B_PROTEIN[GENE]/B_MEASURE
- O
8 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
Sony B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
Handycam B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
was O
used O
, O
hand B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
- O
held O
, O
at O
approximately O
5 B_MEASURE/B_LOCATION
m I_MEASURE/I_LOCATION
from O
the O
feeder B_LOCATION/B_ENT
. O

Birds B_BIO/B_PERSON
on O
the O
tree B_LOCATION
trunk I_LOCATION
were O
alarmed O
by O
movement B_ORGANIZATION/B_BIO
, O
and O
their O
escape B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
flights I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
recorded O
. O

Four O
escape O
flights O
were O
captured O
that O
approximate O
to O
that O
recorded O
for O
the O
putative O
Ivory B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Campephilus B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
principalis B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
Luneau O
in O
April O
2004 O
and O
published O
in O
Fitzpatrick O
et O
al O
[ O
1 O
] O
. O

The O
videos O
are O
not O
directly O
equivalent O
because O
the O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
made O
only O
short O
escape O
flights O
to O
nearby O
trees O
, O
whereas O
the O
putative O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
Luneau O
video O
showed O
little O
sign O
of O
coming O
to O
rest O
before O
being O
lost O
from O
view O
. O

Nevertheless O
, O
interesting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparisons I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
made O
. O

Wingbeat O
frequency O
of O
Pileated B_BIO/B_DISEASE
Woodpecker I_BIO/I_DISEASE
. O

The O
woodpecker B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
Luneau B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
video I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
maintains O
a O
steady B_MEASURE
rapid I_MEASURE
wingbeat I_MEASURE
rate I_MEASURE
of O
8 B_MEASURE
. O
6 B_MEASURE
beats I_MEASURE
s O
- O
1 B_MEASURE/B_LOCATION
for O
at O
least O
8 B_TIME[MEASURE]/B_ENT
wingbeats I_TIME[MEASURE]/I_ENT
[ O
1 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
, O
a O
figure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
was O
confirmed O
by O
independent B_PERSON
analysis I_PERSON
during O
preparation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
this O
paper B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Pileated B_PERSON/B_BIO
woodpeckers I_PERSON/I_BIO
in O
DN O
' O
s O
video O
do O
not O
do O
this O
- O
after O
initial O
rapid O
flapping O
immediately O
after O
take O
- O
off O
, O
they O
settle O
into O
a O
more O
relaxed O
level O
flight O
. O

As O
shown O
in O
tables O
1 O
and O
2 O
, O
although O
the O
mean O
wingbeat O
frequencies O
of O
the O
Pileated B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
in O
DN O
' O
s O
video O
are O
slower O
than O
the O
8 O
. O
6 O
s O
- O
1 O
recorded O
for O
the O
bird O
in O
the O
Luneau O
video O
[ O
1 O
, O
3 O
, O
5 O
] O
the O
first O
four O
wingbeats O
, O
the O
initial O
escape O
response O
, O
are O
faster O
than O
those O
claimed O
for O
Pileated B_BIO/B_PERSON
Woodpeckers I_BIO/I_PERSON
in O
the O
literature O
[ O
1 O
, O
3 O
, O
5 O
] O
. O

For O
the O
four B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
escape I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
flights I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
mean B_MEASURE
frequency I_MEASURE
values I_MEASURE
for O
the O
first B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
four I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
wingbeats I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
7 B_NUMBER[MEASURE]
. O
1 B_MEASURE
, O
6 B_NUMBER[MEASURE]
. O
7 B_MEASURE
, O
8 B_NUMBER[MEASURE]
. O
6 B_MEASURE
, O
and O
8 B_MEASURE
. O
0 B_MEASURE/B_LOCATION
s I_MEASURE/I_LOCATION
- O
1 B_MEASURE/B_LOCATION
, O
respectively O
. O

The O
8 O
. O
6 O
beats O
s O
- O
1 O
of O
the O
bird O
identified O
in O
the O
Luneau O
video O
, O
while O
consistent O
with O
the O
limited O
data O
( O
n O
= O
1 O
; O
see O
discussion O
) O
for O
Ivory B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
equally O
consistent O
with O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
its O
initial O
escape O
flight O
. O

The O
bird O
in O
the O
Luneau O
video O
maintains O
a O
frequency O
of O
8 O
. O
6 O
s O
- O
1 O
for O
the O
next O
four O
wingbeats O
too O
, O
whereas O
the O
Pileated B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
recorded O
here O
all O
slowed O
their O
flight O
as O
they O
prepared O
to O
land O
in O
nearby O
trees O
. O

There O
are O
no O
data O
to O
suggest O
whether O
Pileated B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
can O
maintain O
a O
wingbeat O
frequency O
approaching O
8 O
. O
6 O
s O
- O
1 O
for O
eight O
or O
more O
wingbeats O
, O
like O
the O
bird O
in O
the O
Luneau O
video O
. O

It O
remains O
possible O
that O
the O
flight O
pattern O
of O
the O
bird O
in O
the O
Luneau O
video O
is O
unusual O
for O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
a O
frequency O
of O
8 O
. O
6 O
s O
- O
1 O
is O
consistent O
with O
a O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Woodpecker B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
gaining O
initial O
speed O
and O
height O
in O
escape O
flight O
, O
and O
by O
itself O
cannot O
be O
taken O
as O
strong O
evidence O
that O
the O
Luneau O
video O
bird O
was O
an O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
discussed O
further O
below O
. O

Plumage O
pattern O
of O
Pileated B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
in O
flight O
. O

The O
video O
of O
Pileated B_PERSON
Woodpeckers I_PERSON
in O
flight O
was O
obtained O
in O
avi O
format O
, O
decompiled O
and O
examined O
frame O
by O
frame O
. O

comparisons O
of O
Pileated B_PERSON/B_LOCATION
Woodpecker I_PERSON/I_LOCATION
images O
with O
key O
images O
of O
Luneau O
video O
are O
shown O
in O
figures O
1 O
and O
2 O
, O
and O
suggest O
a O
genuine O
resemblance O
between O
the O
bird O
in O
the O
Luneau O
video O
and O
a O
Pileated B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
complicated O
by O
the O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
digital I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
two B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
videos I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
in O
the O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Nolin B_ENT
videos I_ENT
it O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
concentrate O
only O
on O
those O
frames B_TIME[MEASURE]/B_ENT
or O
part B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
frames B_TIME[MEASURE]/B_LOCATION
where O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plumage I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
an O
artifact B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
blurred B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
images I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Thirty B_NUMBER[MEASURE]
- O
six B_NUMBER[MEASURE]/B_ENT
frames I_NUMBER[MEASURE]/I_ENT
from O
the O
fourth B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
example I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Pileated B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
escape I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
flight I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
most B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
resembled O
the O
flight B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
path B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
Luneau B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
video I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
bird I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
were O
analysed O
systematically O
frame B_TIME[MEASURE]/B_ENT
by O
frame B_LOCATION/B_ENT
. O

They O
represent O
seven B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
complete I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
wingbeats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
( O
1 B_MEASURE/B_LOCATION
. O
20 B_MEASURE
s I_MEASURE
from O
the O
middle B_SEQUENCE[MEASURE]/B_LOCATION
of O
the O
second B_ENT/B_LOCATION
wingbeat I_ENT/I_LOCATION
to O
middle B_SEQUENCE[MEASURE]/B_LOCATION
of O
wingbeat B_SEQUENCE[MEASURE]/B_PERSON
9 I_SEQUENCE[MEASURE]/I_PERSON
) O
and O
were O
directly O
compared O
frame B_LOCATION/B_TIME[MEASURE]
- O
by O
- O
frame B_LOCATION/B_TIME[MEASURE]
with O
the O
equivalent B_SEQUENCE[MEASURE]/B_LOCATION
fields I_SEQUENCE[MEASURE]/I_LOCATION
( O
middle B_LOCATION/B_MEASURE
wingbeat I_LOCATION/I_MEASURE
2 I_LOCATION/I_MEASURE
- O
middle B_MEASURE
wingbeat I_MEASURE
9 I_MEASURE
) O
of O
the O
Luneau B_LOCATION/B_TIME[MEASURE]
video B_LOCATION/I_TIME[MEASURE]
. O

This O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
shown O
in O
Figure B_MEASURE/B_LOCATION
3 I_MEASURE/I_LOCATION
. O

The O
images O
of O
the O
birds O
are O
not O
identical O
, O
but O
in O
every O
frame O
of O
the O
36 O
frames O
available O
, O
there O
are O
sufficient O
similarities O
to O
suggest O
that O
the O
bird O
in O
the O
Luneau O
video O
is O
consistent O
with O
the O
known O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Further O
comparisons O
of O
the O
Luneau O
bird O
with O
the O
other O
three O
Pileated B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
escape O
flights O
recorded O
are O
presented O
in O
the O
supplementary O
material O
( O
see O
Additional O
file O
1 O
) O
. O

Key B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
video B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
: O

1 B_NUMBER[MEASURE]
. O

Pileated B_PERSON/B_BIO
Woodpeckers I_PERSON/I_BIO
flying O
near O
- O
horizontally O
away O
from O
the O
observer O
show O
much O
more O
white O
in O
poor O
- O
quality O
video O
than O
would O
be O
expected O
from O
their O
general O
plumage O
pattern O
. O

They O
present O
an O
appearance B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
black B_COLOR/B_DISEASE_ADJECTIVE[DISEASE]
- O
bodied B_BIO/B_LOCATION
bird I_BIO/I_LOCATION
with O
largely O
white B_COLOR/B_DISEASE_ADJECTIVE[DISEASE]
wings I_COLOR/I_DISEASE_ADJECTIVE[DISEASE]
and O
black B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wingtips I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
very O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
bird B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
Luneau B_ENT/B_LOCATION
video I_ENT/I_LOCATION
; O
compare O
in O
particular B_MEASURE/B_ENT
figure I_MEASURE/I_ENT
1B I_MEASURE/I_ENT
, O
frame B_TIME[MEASURE]/B_LOCATION
758 I_TIME[MEASURE]/I_LOCATION
, O
with O
figure B_PROTEIN[GENE]
1A I_PROTEIN[GENE]
, O
frame B_GENE/B_DISEASE
283 I_GENE/I_DISEASE
. O
3 B_MEASURE
. O

The O
expected O
appearance O
of O
the O
upperwing O
of O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mostly O
black O
with O
a O
small O
white O
patch O
at O
the O
base O
of O
the O
primaries O
- O
is O
often O
not O
seen O
, O
and O
is O
only O
clearly O
resolvable O
when O
birds O
are O
flying O
near O
- O
vertically O
before O
landing O
on O
a O
tree O
trunk O
; O
something O
the O
bird O
in O
the O
Luneau O
video O
did O
not O
do O
. O

2 B_NUMBER[MEASURE]
. O

The O
black O
trailing O
edge O
to O
the O
underwing O
of O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Woodpecker B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O
often O
very O
inconspicuous O
and O
may O
disappear O
completely O
. O

Due O
to O
motion B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
flexion B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
the O
wing B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
black B_DISEASE/B_MEASURE
trailing I_DISEASE/I_MEASURE
edge I_DISEASE/I_MEASURE
is O
much O
more O
obvious B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
towards O
the O
wingtips B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

This O
produces O
an O
apparent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plumage I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pattern I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
matches O
the O
patterns B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shown O
by O
the O
Luneau B_ENT/B_PERSON
video I_ENT/I_PERSON
bird I_ENT/I_PERSON
( O
compare O
figure B_PROTEIN[GENE]/B_MEASURE
1B I_PROTEIN[GENE]/I_MEASURE
, O
frames B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
175 B_MEASURE
and O
457 B_MEASURE
with O
Figure B_ENT/B_LOCATION
1A I_ENT/I_LOCATION
, O
frames B_MEASURE
300 I_MEASURE
and O
416 B_MEASURE
. O
7 B_MEASURE
) O
. O

In O
many O
frames O
of O
Pileated B_ENT/B_LOCATION
Woodpecker I_ENT/I_LOCATION
, O
a O
black O
trailing O
edge O
to O
the O
wing O
is O
discernable O
( O
though O
due O
to O
bleeding O
of O
white O
as O
a O
video O
artifact O
, O
it O
appears O
narrower O
than O
it O
really O
is O
) O
. O

However O
, O
analysis O
of O
the O
bird O
in O
the O
Luneau O
video O
in O
light O
of O
images O
of O
known O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confirms O
that O
a O
similar O
black O
trailing O
edge O
to O
the O
wing O
is O
discernable O
in O
some O
frames O
of O
the O
Luneau O
video O
( O
compare O
Figure O
1B O
, O
frame O
775 O
with O
Figure O
1A O
, O
frame O
366 O
. O
7 O
: O
the O
apparent O
plumage O
patterns O
are O
similar O
, O
and O
inconsistent O
with O
Ivory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
billed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
) O
. O

It O
is O
argued O
here O
that O
the O
hypothesis O
put O
forward O
in O
Sibley O
et O
al O
[ O
4 O
] O
is O
correct O
, O
and O
that O
the O
black O
trailing O
edge O
of O
the O
underwing O
of O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
indeed O
, O
due O
to O
flexion O
of O
the O
wings O
during O
the O
downstroke O
, O
be O
misinterpreted O
as O
the O
black O
leading O
edge O
and O
wingtips O
of O
the O
upperwing O
of O
an O
Ivory B_BIO/B_LOCATION
- I_BIO/I_LOCATION
billed I_BIO/I_LOCATION
Woodpecker I_BIO/I_LOCATION
. O

3 B_NUMBER[MEASURE]
. O

Figure O
3 O
shows O
that O
the O
plumage O
patterns O
shown O
by O
the O
Luneau O
bird O
, O
throughout O
several O
wingbeat O
cycles O
, O
are O
compatible O
with O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Woodpecker B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

The O
three O
plumage O
features O
described O
in O
Sibley O
et O
al O
[ O
4 O
] O
that O
are O
incompatible O
with O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
black O
secondary O
feathers O
on O
upper O
surface O
of O
left O
wing O
, O
brighter O
white O
primary O
bases O
, O
and O
a O
black O
band O
curling O
round O
the O
wing O
tip O
) O
are O
seen O
consistently O
in O
the O
Luneau O
video O
and O
are O
recapitulated O
throughout O
the O
video O
of O
Pileated B_PERSON/B_LOCATION
Woodpecker I_PERSON/I_LOCATION
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Evidence O
is O
presented O
here O
to O
show O
that O
the O
distinctive O
plumage O
features O
of O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
surprisingly O
difficult O
to O
resolve O
in O
poor O
- O
quality O
video O
of O
birds O
in O
escape O
flight O
away O
from O
the O
camera O
, O
and O
that O
they O
can O
show O
apparent O
plumage O
patterns O
that O
might O
more O
readily O
be O
associated O
with O
Ivory B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Irrespective O
of O
the O
identity O
of O
the O
bird O
in O
the O
Luneau O
video O
, O
this O
knowledge O
will O
be O
critical O
to O
assessment O
of O
further O
claims O
of O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
current O
intensive O
search O
effort O
. O

It O
is O
, O
however O
, O
suggested O
here O
that O
critical O
frames O
used O
for O
identification O
of O
the O
Luneau O
video O
woodpecker O
as O
an O
Ivory B_BIO/B_PERSON
- I_BIO/I_PERSON
billed I_BIO/I_PERSON
Woodpecker I_BIO/I_PERSON
are O
also O
consistent O
with O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

The O
wingbeat O
frequency O
of O
the O
bird O
in O
the O
Luneau O
video O
is O
also O
perhaps O
consistent O
with O
Pileated B_MEASURE/B_LOCATION
Woodpecker I_MEASURE/I_LOCATION
, O
at O
least O
for O
short O
periods O
of O
flight O
. O

Analysis O
of O
the O
videos O
of O
Pileated B_PERSON/B_LOCATION
Woodpecker I_PERSON/I_LOCATION
has O
supported O
the O
hypothesised O
interpretations O
of O
key O
frames O
of O
the O
Luneau O
video O
by O
Sibley O
et O
al O
[ O
4 O
] O
. O

Although O
the O
rebuttal O
of O
that O
comment O
in O
Fitzpatrick O
et O
al O
[ O
5 O
] O
asserted O
that O
flexion O
and O
motion O
of O
wings O
of O
Pileated B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
could O
not O
produce O
the O
images O
seen O
in O
the O
Luneau O
video O
, O
it O
has O
been O
shown O
here O
that O
they O
can O
. O

The O
Luneau O
video O
as O
presented O
in O
Fitzpatrick O
et O
al O
[ O
1 O
] O
, O
shows O
features O
that O
are O
consistent O
with O
Pileated B_PERSON/B_LOCATION
Woodpecker I_PERSON/I_LOCATION
, O
and O
inconsistent O
with O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
argued O
in O
this O
paper O
that O
, O
in O
fact O
, O
the O
black O
trailing O
edge O
of O
the O
wing O
of O
a O
Pileated B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
seen O
clearly O
in O
the O
Luneau O
video O
, O
during O
the O
downstroke O
of O
the O
wingbeat O
cycle O
, O
but O
that O
it O
has O
been O
misinterpreted O
as O
black O
wingtips O
( O
Figure O
1 O
, O
2 O
, O
3 O
) O
. O

A O
fuller B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
Luneau B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
video I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
by O
the O
Cornell B_PERSON/B_ORGANIZATION
University I_PERSON/I_ORGANIZATION
team I_PERSON/I_ORGANIZATION
is O
presented O
online B_TIME[MEASURE]/B_ORGANIZATION
[ I_TIME[MEASURE]/I_ORGANIZATION
7 I_TIME[MEASURE]/I_ORGANIZATION
] I_TIME[MEASURE]/I_ORGANIZATION
. O

Although O
it O
is O
not O
peer B_PERSON/B_LOCATION
- O
reviewed O
, O
the O
points B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O
article B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
makes O
should O
be O
taken O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
authors O
summarise O
nine O
diagnostic O
traits O
from O
their O
analysis O
of O
the O
Luneau O
video O
that O
identify O
the O
bird O
as O
Ivory B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
are O
listed O
and O
discussed O
point B_LOCATION/B_MEASURE
- O
by O
point B_LOCATION/B_PERSON
below O
. O

1 B_NUMBER[MEASURE]
. O

' O
The O
underwing B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
pattern B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
in O
flight B_BIO
consistently O
appears O
largely O
white B_COLOR/B_LOCATION
, O
giving O
the O
appearance B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
having O
black B_COLOR/B_BIO
wingtips I_COLOR/I_BIO
but O
lacking O
any O
black B_COLOR/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O
the O
rear B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
, O
or O
trailing B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
edge I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O
' O
. O

Data O
presented O
in O
this O
paper O
show O
that O
this O
statement O
is O
not O
wholly O
supported O
, O
and O
in O
any O
case O
the O
underwing O
of O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Woodpeckers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O
present O
the O
same O
appearance O
. O

2 B_NUMBER[MEASURE]
. O

' O
The O
upperwing O
pattern O
in O
flight O
consistently O
shows O
a O
broad O
, O
white O
trailing O
edge O
, O
with O
no O
frames O
demonstrating O
the O
conspicuous O
dark O
rear O
border O
to O
be O
expected O
of O
normal O
Pileated B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpeckers I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
' O
. O

Notwithstanding O
that O
certain O
frames O
of O
the O
Luneau O
video O
( O
e O
. O
g O
. O
frame O
350 O
) O
do O
appear O
to O
show O
a O
black O
trailing O
edge O
to O
the O
upperwing O
, O
data O
presented O
in O
this O
paper O
shows O
that O
, O
at O
this O
angle O
of O
view O
and O
resolution O
of O
video O
, O
Pileated B_PERSON/B_ENT
Woodpeckers I_PERSON/I_ENT
also O
may O
fail O
to O
show O
this O
feature O
. O

This O
analysis O
has O
shown O
that O
the O
hypothesis O
presented O
in O
Sibley O
et O
al O
[ O
4 O
] O
is O
plausible O
, O
i O
. O
e O
. O
that O
some O
of O
the O
frames O
interpreted O
by O
[ O
1 O
] O
to O
show O
the O
upperwing O
of O
an O
Ivory B_BIO/B_LOCATION
- I_BIO/I_LOCATION
billed I_BIO/I_LOCATION
Woodpecker I_BIO/I_LOCATION
may O
in O
fact O
show O
large O
amounts O
of O
white O
and O
the O
black O
trailing O
edge O
from O
the O
underwing O
of O
a O
Pileated B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

3 B_NUMBER[MEASURE]
. O

' O
The O
wings O
are O
longer O
relative O
to O
the O
body O
diameter O
than O
in O
Pileated B_PERSON/B_BIO
Woodpecker I_PERSON/I_BIO
and O
consistent O
with O
the O
wing O
shape O
of O
Ivory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
billed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Woodpecker B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O
' O
. O

Fitzpatrick B_PERSON/B_ORGANIZATION
et I_PERSON/I_ORGANIZATION
al I_PERSON/I_ORGANIZATION
[ O
5 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
agreed O
that O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
not O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
video B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
images I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O
in O
their O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
paper I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
[ O
1 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
, O
and O
it O
seems O
unlikely B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
that O
much B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
confidence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
placed O
in O
the O
wing B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
length B_MEASURE/B_LOCATION
measurements I_MEASURE/I_LOCATION
of O
the O
bird B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
Luneau B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
video I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
, O
for O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
figure B_PROTEIN[GENE]
1A I_PROTEIN[GENE]
, O
frame B_MEASURE/B_LOCATION
283 I_MEASURE/I_LOCATION
. O
3 B_MEASURE
with O
figure B_MEASURE/B_LOCATION
1B I_MEASURE/I_LOCATION
, O
frame B_LOCATION
578 I_LOCATION
suggests O
that O
any O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O
be O
very O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
prove O
. O

4 B_NUMBER[MEASURE]
. O

' O
Reenactment O
of O
the O
scene O
using O
life O
- O
sized O
, O
realistically O
painted O
, O
dynamically O
flapping O
models O
produced O
images O
remarkably O
similar O
to O
those O
of O
the O
Luneau O
video O
using O
the O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O
, O
and O
images O
clearly O
identifiable O
as O
Pileated B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
Woodpecker I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
using O
a O
model O
of O
that O
species O
. O
' O
. O

interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
re B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
enactments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
is O
hampered O
by O
the O
fact B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
the O
stiff B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
flat B_NUMBER[MEASURE]/B_DISEASE
- O
winged B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
cannot B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
reflect O
the O
wing B_MEASURE/B_LOCATION
flexion I_MEASURE/I_LOCATION
and O
curvature B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
real B_BIO/B_ENT
birds I_BIO/I_ENT
. O

Reenactment O
of O
the O
scene O
using O
real O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
Woodpeckers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
has O
produced O
images O
remarkably O
similar O
to O
the O
Luneau O
video O
. O

5 B_NUMBER[MEASURE]
. O

' O
The O
wingbeat O
frequency O
is O
8 O
. O
6 O
beats O
per O
second O
, O
which O
is O
almost O
identical O
to O
that O
recorded O
for O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
as O
documented O
by O
one O
acoustic O
record O
from O
1935 O
) O
. O

The O
wing O
- O
beat O
frequencies O
of O
Pileated B_PERSON/B_ENT
Woodpecker B_PERSON/I_ENT
are O
not O
known O
to O
exceed O
7 O
. O
5 O
beats O
per O
second O
, O
and O
more O
typically O
range O
between O
3 O
and O
6 O
beats O
per O
second O
. O
' O
. O

The O
fact O
that O
in O
only O
four O
recorded O
escape O
flights O
of O
Pileated B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
two O
were O
recorded O
for O
which O
the O
initial O
escape O
flight O
wingbeat O
frequency O
( O
8 O
. O
0 O
s O
- O
1 O
and O
8 O
. O
6 O
s O
- O
1 O
) O
exceeded O
that O
previously O
recorded O
for O
this O
species O
shows O
that O
previous O
datasets O
were O
too O
limited O
to O
make O
this O
conclusion O
. O

Birds O
flap O
more O
rapidly O
at O
take O
off O
to O
gain O
altitude O
and O
speed O
than O
they O
do O
in O
sustained O
level O
flight O
: O
Pileated B_TIME[MEASURE]/B_LOCATION
Woodpecker I_TIME[MEASURE]/I_LOCATION
flight O
data O
in O
the O
literature O
[ O
1 O
, O
4 O
, O
5 O
] O
was O
derived O
from O
the O
work O
of O
Tobalske O
[ O
8 O
] O
, O
which O
explicitly O
excluded O
the O
initial O
take O
- O
off O
period O
, O
and O
therefore O
cannot O
be O
used O
to O
support O
the O
elimination O
of O
Pileated B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
Luneau O
video O
. O

Furthermore O
, O
the O
bird B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
Luneau B_LOCATION/B_ENT
video I_LOCATION/I_ENT
is O
consistently O
gaining O
height B_MEASURE/B_LOCATION
from O
a O
low B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
position I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
above O
water B_LOCATION/B_BIO
and O
, O
whatever O
its O
species B_MEASURE/B_BIO
, O
might O
be O
expected O
to O
flap O
more O
rapidly O
than O
if O
it O
were O
in O
level B_LOCATION
flight I_LOCATION
. O

Tanner O
[ O
9 O
] O
noted O
that O
Pileated B_PERSON
Woodpeckers I_PERSON
can O
maintain O
extended O
fast O
direct O
flight O
. O

He O
was O
of O
the O
opinion O
that O
flight O
pattern O
was O
not O
a O
useful O
character O
for O
separating O
the O
two O
species O
in O
the O
field O
, O
and O
that O
Pileated B_BIO/B_PERSON
Woodpeckers I_BIO/I_PERSON
frequently O
fly O
in O
a O
manner O
that O
was O
in O
no O
way O
different O
to O
Ivory B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
billed I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
figure O
of O
8 O
. O
6 O
wingbeats O
per O
second O
for O
the O
Luneau O
bird O
( O
data O
reanalysed O
here O
) O
is O
taken O
as O
consistent O
with O
Ivory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
billed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
on O
the O
basis O
of O
analysis O
of O
a O
single O
archival O
audio O
recording O
[ O
3 O
] O
. O

The O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
that O
audio O
tape O
is O
clearly O
flapping O
its O
wings O
, O
but O
without O
accompanying O
visual O
confirmation O
it O
is O
not O
clear O
that O
it O
is O
in O
flight O
. O

In O
general B_PERSON/B_LOCATION
, O
larger B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
birds I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
are O
expected O
to O
flap O
their O
wings B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
more O
slowly O
than O
smaller B_PERSON/B_BIO
birds I_PERSON/I_BIO
of O
comparable B_BIO/B_LOCATION
wing I_BIO/I_LOCATION
morphology I_BIO/I_LOCATION
. O

Tobalske B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
8 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
showed O
that O
, O
across O
species B_BIO/B_LOCATION
, O
smaller B_BIO/B_PERSON
woodpeckers I_BIO/I_PERSON
tend O
to O
flap O
more O
quickly O
than O
larger B_MEASURE/B_PERSON
ones B_MEASURE/I_PERSON
, O
and O
that O
there O
was O
considerable B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intraspecific B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
assertion O
that O
Ivory B_BIO/B_PERSON
- I_BIO/I_PERSON
billed I_BIO/I_PERSON
Woodpeckers I_BIO/I_PERSON
flap O
their O
wings O
more O
quickly O
than O
Pileated B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
is O
therefore O
counterintuitive O
. O

Further O
comment O
is O
conjecture O
: O
while O
the O
flight O
pattern O
and O
wing O
posture O
of O
the O
bird O
in O
the O
Luneau O
video O
may O
be O
unusual O
, O
it O
has O
not O
been O
shown O
that O
it O
is O
outside O
the O
range O
of O
variability O
of O
Pileated B_SPECIES[BIO]/B_LOCATION
Woodpecker I_SPECIES[BIO]/I_LOCATION
, O
and O
cannot O
therefore O
be O
used O
to O
eliminate O
the O
possibility O
that O
it O
was O
the O
commoner O
species O
. O

6 B_NUMBER[MEASURE]
. O

' O
White B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
plumage B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
on O
the O
back B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
is O
visible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O
the O
retreating O
bird B_LOCATION/B_SPECIES[BIO]
as O
it O
begins O
to O
gain O
altitude B_LOCATION/B_MEASURE
. O

Ivory B_BIO/B_PERSON
- I_BIO/I_PERSON
billed I_BIO/I_PERSON
Woodpecker I_BIO/I_PERSON
has O
white O
on O
the O
back O
; O
Pileated B_PERSON/B_LOCATION
Woodpecker I_PERSON/I_LOCATION
has O
entirely O
black O
back O
. O
' O
. O

This O
was O
discussed O
by O
Sibley B_PERSON
et I_PERSON
al I_PERSON
[ O
4 B_MEASURE
] I_MEASURE
, O
who O
argued O
that O
the O
images B_ENT/B_BODY_PART_OR_ORGAN_COMPONENT
thought O
to O
show O
white B_DISEASE
on O
the O
dorsum B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
were O
too O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
be O
accepted O
uncritically O
. O

In O
all O
the O
frames B_TIME[MEASURE]/B_ENT
of O
the O
Luneau B_ENT/B_LOCATION
video I_ENT/I_LOCATION
that O
appear O
to O
show O
white B_COLOR/B_PERSON
on O
the O
dorsum B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
bird B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
is O
distant B_LOCATION/B_DISEASE
( O
dorsal B_COLOR/B_LOCATION
white B_COLOR/I_LOCATION
is O
not O
visible B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
resolution B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
images B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
earlier O
in O
the O
video B_ENT
) O
and O
partially O
obscured O
, O
making O
it O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
distinguish O
dorsum B_BIO/B_LOCATION
from O
wing B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Spurious B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
areas I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
white B_DISEASE
pixels I_DISEASE
appear O
as O
artifacts B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
videos B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nevertheless O
, O
this O
remains O
the O
best O
evidence O
that O
the O
Luneau O
bird O
was O
not O
a O
standard O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

7 B_NUMBER[MEASURE]
. O

' O
The O
dorsal O
view O
of O
the O
right O
wing O
as O
it O
begins O
to O
unfold O
shows O
a O
triangle O
of O
white O
that O
matches O
in O
size O
and O
position O
the O
white O
on O
the O
folded O
wing O
of O
an O
Ivory B_BIO/B_PERSON
- I_BIO/I_PERSON
billed I_BIO/I_PERSON
Woodpecker I_BIO/I_PERSON
beginning O
to O
launch O
into O
flight O
. O
' O
. O

No O
further B_LOCATION
comment I_LOCATION
is O
provided O
here O
. O

An O
alternative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
explanation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
offered O
by O
Sibley B_PERSON
et I_PERSON
al I_PERSON
[ O
4 B_MEASURE
] I_MEASURE
and O
rebutted O
by O
Fitzpatrick B_PERSON
et I_PERSON
al I_PERSON
[ O
5 B_MEASURE
] I_MEASURE
. O

The O
statement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
requires O
a O
degree B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
certainty B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O
the O
position B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
wing B_PERSON/B_ORGANIZATION
. O

( O
8 O
) O
' O
The O
distance O
between O
the O
wrist O
area O
and O
the O
tip O
of O
the O
tail O
( O
32 O
- O
36 O
cm O
, O
as O
measured O
when O
the O
bird O
begins O
to O
take O
flight O
) O
is O
comparable O
to O
known O
measurements O
of O
Ivory B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
considerably O
larger O
than O
even O
the O
largest O
Pileated B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
measured O
. O
' O
. O

As O
stated O
under O
( O
3 B_MEASURE
) O
, O
above O
, O
there O
is O
general B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agreement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
not O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
Luneau B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
video I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
too O
many B_NUMBER[MEASURE]/B_PERSON
uncontrolled I_NUMBER[MEASURE]/I_PERSON
variables I_NUMBER[MEASURE]/I_PERSON
are O
involved O
[ O
4 B_NUMBER[MEASURE]
, O
5 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

9 B_NUMBER[MEASURE]
. O

' O
Only O
20 O
seconds O
before O
the O
woodpecker O
flees O
, O
a O
bird O
with O
the O
size O
and O
color O
pattern O
of O
an O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
perched O
within O
3 O
m O
of O
the O
site O
from O
which O
the O
woodpecker O
took O
flight O
. O
' O
. O

This O
would O
be O
a O
strong B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
argument I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
if O
it O
could O
be O
shown O
that O
the O
object B_PERSON/B_LOCATION
in O
question B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
a O
bird B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O
not O
, O
as O
is O
now O
apparently O
thought O
likely O
, O
a O
section B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
branch B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
or O
tree B_BIO/B_DISEASE
stump I_BIO/I_DISEASE
[ I_BIO/I_DISEASE
10 I_BIO/I_DISEASE
] I_BIO/I_DISEASE
. O

The O
Luneau B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
video I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
reveals O
several B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
white B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triangular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patches B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apparently O
visible B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
on O
or O
around O
tree B_PERSON/B_LOCATION
trunks B_PERSON/I_LOCATION
, O
most B_NUMBER[MEASURE]/B_LOCATION
or O
all O
of O
which O
must O
therefore O
be O
images B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
tree B_ENT/B_LOCATION
topography I_ENT/I_LOCATION
or O
video B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
artifacts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

This O
was O
discussed O
in O
the O
literature B_PERSON/B_TIME[MEASURE]
( O
see O
[ B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_MEASURE
] I_MEASURE
) O
. O

Central O
to O
the O
identification O
of O
the O
flying O
bird O
seen O
in O
the O
Luneau O
video O
was O
the O
evidence O
that O
plumage O
and O
flight O
patterns O
were O
inconsistent O
with O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
very O
basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
video I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
presented O
here O
has O
suggested O
that O
this O
may O
not O
be O
the O
case B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
that O
further B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
research I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
is O
needed O
. O

Any O
identification O
of O
the O
bird O
in O
the O
Luneau O
video O
as O
an O
Ivory B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
bill I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
must O
take O
into O
account O
the O
data O
presented O
here O
and O
in O
Sibley O
et O
al O
[ O
4 O
] O
, O
which O
shows O
it O
is O
largely O
consistent O
with O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
points O
out O
apparent O
inconsistencies O
with O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
does O
not O
of O
course O
necessarily O
imply O
that O
the O
Ivory B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
extinct O
, O
nor O
indeed O
entirely O
rule O
out O
the O
possibility O
that O
the O
bird O
in O
the O
Luneau O
video O
was O
one O
. O

There O
appears O
to O
be O
no O
reason O
to O
question O
the O
anecdotal O
sight O
records O
of O
Ivory B_PERSON
- I_PERSON
billed I_PERSON
Woodpecker I_PERSON
presented O
in O
Fitzpatrick O
et O
al O
[ O
1 O
] O
( O
or O
in O
many O
online O
sources O
) O
, O
because O
some O
of O
them O
appear O
credible O
, O
albeit O
brief O
. O

audio B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
has O
since O
been O
published O
[ O
11 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
although O
this O
too O
is O
far O
from O
conclusive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
to O
regard O
the O
Luneau B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
video I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
by O
itself O
as O
presenting O
anything B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
other B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
than O
an O
unidentified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
falls O
below O
the O
standards B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
proof B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
normally O
required O
for O
scientific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
publication I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
the O
images B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
good B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
enough O
. O

The O
Ivory B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
billed I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
Woodpecker I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
may O
persist O
in O
continental O
North O
America O
, O
and O
there O
is O
enough O
anecdotal O
evidence O
to O
make O
this O
a O
possibility O
, O
but O
the O
Luneau O
video O
does O
not O
support O
the O
case O
. O

The O
balance O
of O
evidence O
would O
suggest O
that O
the O
bird O
in O
the O
Luneau O
video O
is O
more O
likely O
to O
have O
been O
a O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
the O
search O
for O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
continue O
. O

While O
this O
paper O
was O
under O
review O
, O
a O
report O
of O
sight O
records O
and O
sound O
recordings O
of O
Ivory B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
- I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
billed I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O
published O
from O
a O
location O
in O
Florida O
[ O
12 O
] O
. O

This O
very O
exciting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
claim I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
strengthened O
by O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sighting B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
white B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
dorsal I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
stripes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
on O
one B_BIO/B_PERSON
bird I_BIO/I_PERSON
in O
flight B_LOCATION
. O

Unfortunately O
, O
several B_PERSON/B_ENT
sightings I_PERSON/I_ENT
were O
made O
without O
optical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
aids I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
cannot B_PERSON/B_LOCATION
be O
considered O
proven O
. O

The O
' O
Kent O
' O
calls O
recorded O
from O
the O
Florida O
location O
are O
spectrographically O
similar O
to O
the O
' O
bleat O
' O
calls O
of O
young O
White B_BIO/B_PERSON
- B_BIO/I_PERSON
tailed B_BIO/I_PERSON
Deer B_BIO/I_PERSON
, O
as O
described O
in O
Richardson O
et O
al O
[ O
13 O
] O
. O

A O
clear O
photograph O
will O
be O
required O
from O
this O
location O
too O
before O
the O
presence O
of O
Ivory B_DISEASE
- I_DISEASE
billed I_DISEASE
Woodpeckers I_DISEASE
can O
be O
considered O
confirmed O
. O

It O
is O
hoped O
that O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
help O
with O
assessment B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
any O
further B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
low I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quality I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
photographs I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
videos B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

Flight O
and O
plumage O
patterns O
of O
the O
putative O
Ivory B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
billed I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recorded O
in O
Arkansas O
in O
2005 O
are O
recapitulated O
by O
confirmed O
Pileated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Woodpeckers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
bird O
in O
the O
Arkansas O
video O
is O
best O
regarded O
as O
not O
fully O
identified O
, O
and O
is O
probably O
a O
Pileated B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Woodpecker I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

video B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
recording I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

Pileated B_PERSON/B_BIO
Woodpeckers I_PERSON/I_BIO
were O
attracted O
to O
a O
bird O
feeder O
containing O
suet O
at O
grants O
Trail O
, O
Dayton O
, O
OH O
45459 O
. O

The O
suet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
feeder B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O
placed O
approximately O
2 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
m I_MEASURE/I_LOCATION
high I_MEASURE/I_LOCATION
on O
a O
tree B_LOCATION
trunk I_LOCATION
, O
and O
the O
distance B_MEASURE/B_LOCATION
to O
the O
suet B_LOCATION
feeder I_LOCATION
from O
the O
observation B_LOCATION/B_BIO
point I_LOCATION/I_BIO
was O
approximately O
5 B_MEASURE
m I_MEASURE
. O

Birds B_BIO/B_PERSON
on O
the O
feeder B_LOCATION/B_BIO
were O
startled O
by O
movement B_ORGANIZATION/B_LOCATION
of O
window B_PERSON/B_BIO
blinds B_PERSON/I_BIO
on O
January B_TIME[MEASURE]
28 I_TIME[MEASURE]
and O
February B_TIME[MEASURE]
5 I_TIME[MEASURE]
, O
2006 B_MEASURE
, O
and O
their O
escape B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
flights B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
filmed O
using O
a O
Sony B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
Hi I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O
8 B_PERSON/B_LOCATION
SteadyShot I_PERSON/I_LOCATION
video I_PERSON/I_LOCATION
camera I_PERSON/I_LOCATION
at O
29 B_MEASURE
. O
97 B_MEASURE
frames I_MEASURE
s I_MEASURE
- O
1 B_MEASURE/B_LOCATION
. O

At O
least O
two B_NUMBER[MEASURE]/B_ENT
birds I_NUMBER[MEASURE]/I_ENT
feature O
in O
the O
videos B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
male B_PERSON/B_COLOR
and O
female B_PERSON
. O

analogue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
tape I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
was O
converted O
to O
digital B_PRODUCT[OBJECT]/B_ENT
by O
connecting O
the O
Hi B_PROTEIN[GENE]/B_BACTERIUM[BIO]
- O
8 B_PRODUCT[OBJECT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
camera I_PRODUCT[OBJECT]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directly O
to O
a O
Sony B_DISEASE/B_LOCATION
DCR B_DISEASE/I_LOCATION
- O
HC30 B_MEASURE/B_LOCATION
digital I_MEASURE/I_LOCATION
video I_MEASURE/I_LOCATION
camera I_MEASURE/I_LOCATION
and O
recording O
onto O
that O
camera B_ENT/B_PRODUCT[OBJECT]
' O
s B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
mini I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
DV I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
cassette I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O

The O
resulting O
images B_ENT/B_RELIGION[SOCIAL_CIRCUMSTANCES]
were O
converted O
to O
an O
avi B_ENT/B_ORGANIZATION
file I_ENT/I_ORGANIZATION
using O
windows B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
movie I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Maker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
a O
Windows B_PRODUCT[OBJECT]/B_PERSON
XP I_PRODUCT[OBJECT]/I_PERSON
PC I_PRODUCT[OBJECT]/I_PERSON
. O

The O
video B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
freely O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
wmv B_MEASURE/B_ENT
format I_MEASURE/I_ENT
[ O
14 B_TIME[MEASURE]/B_ENT
] B_TIME[MEASURE]/I_ENT
and O
in O
avi B_ENT/B_PERSON
format B_ENT/I_PERSON
from O
the O
author B_PERSON/B_ORGANIZATION
or O
David B_PERSON
Nolin I_PERSON
( O
via O
the O
author B_PERSON/B_ORGANIZATION
) O
. O

The O
video B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
decompiled O
using O
Blaze B_ORGANIZATION/B_LOCATION
Media B_ORGANIZATION/I_LOCATION
Pro B_ORGANIZATION/I_LOCATION
( O
Mystik B_MEASURE/B_PERSON
Media I_MEASURE/I_PERSON
, O
Hampstead B_LOCATION/B_PERSON
, O
NC B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
for O
a O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

import B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
Avid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
(R) I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Xpress I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Pro I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
HD I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
deinterlacing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
did O
not O
reduce O
the O
wing B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
flicker I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
seen O
in O
the O
images B_ENT/B_RELIGION[SOCIAL_CIRCUMSTANCES]
, O
and O
further B_TIME[MEASURE]/B_LOCATION
professional I_TIME[MEASURE]/I_LOCATION
processing I_TIME[MEASURE]/I_LOCATION
could O
not O
improve O
the O
resolution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
so O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
decompiled I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
file I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
was O
used O
for O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hence O
some O
frames B_TIME[MEASURE]/B_ENT
contain O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
overlaid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
images I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
which O
may O
lower O
the O
resolution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
some O
cases B_PERSON/B_LOCATION
. O

The O
decompiled O
file O
was O
examined O
frame O
by O
frame O
and O
compared O
to O
the O
decompiled O
images O
of O
the O
putative O
Ivory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
billed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
Woodpecker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
presented O
in O
Fitzpatrick O
et O
al O
[ O
1 O
] O
. O

Wingbeat B_TIME[MEASURE]/B_PERSON
frequencies I_TIME[MEASURE]/I_PERSON
were O
calculated O
by O
noting O
the O
frame B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
the O
midpoint B_LOCATION/B_MEASURE
of O
the O
downstroke B_DISEASE_ADJECTIVE[DISEASE]/B_SPORT[ENT]
of O
each O
wingbeat B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
e B_DISEASE/B_PROTEIN[GENE]
. O
g B_PROTEIN[GENE]/B_MEASURE
. O
Figure B_MEASURE/B_PERSON
1B I_MEASURE/I_PERSON
, O
frame B_TIME[MEASURE]
758 I_TIME[MEASURE]
) O
and O
calculating O
the O
length B_MEASURE/B_ORGANIZATION
of O
time B_TIME[MEASURE]/B_LOCATION
taken O
per O
wingbeat B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
( O
number B_MEASURE
of O
frames B_TIME[MEASURE]/B_LOCATION
between O
downstroke B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
midpoints B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
/ O
29 B_MEASURE
. O
97 B_MEASURE
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

JMC B_PERSON/B_ORGANIZATION
performed O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
drafted O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

supplementary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
material I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

A O
global B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
evolution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
Vibrionaceae B_BIO
family I_BIO
using O
phylogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
profile I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Vibrionaceae B_BACTERIUM[BIO]/B_PERSON
represent O
a O
significant B_MEASURE/B_PERSON
portion I_MEASURE/I_PERSON
of O
the O
cultivable B_BACTERIUM[BIO]/B_LOCATION
heterotrophic B_BACTERIUM[BIO]/I_LOCATION
sea B_BACTERIUM[BIO]/I_LOCATION
bacteria B_BACTERIUM[BIO]/I_LOCATION
; O
they O
strongly O
affect O
nutrient B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cycling I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
some O
species B_BIO/B_PERSON
are O
devastating B_DISEASE_ADJECTIVE[DISEASE]
pathogens I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
work B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
propose O
an O
improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
phylogenetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
on O
14 B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
Vibrionaceae I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
genomes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
to O
study O
the O
evolution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O
this O
family B_PERSON/B_BIO
on O
the O
basis B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
based O
on O
the O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
genes O
involved B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
e B_GENE/B_DISEASE
. O
g B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O
metabolic B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
structural B_GENE/B_BIO
complex I_GENE/I_BIO
) O
tend O
to O
be O
concurrently O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
within O
different B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
genomes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
allows O
the O
prediction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
hypothetical B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
basis B_PERSON/B_LOCATION
of O
a O
shared O
phylogenetic B_MEASURE/B_LOCATION
profiles I_MEASURE/I_LOCATION
. O

Moreover O
this O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
identify O
putative B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
laterally O
transferred O
elements B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
basis B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
their O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
distantly O
phylogenetically O
related O
bacteria B_BIO/B_GENE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Vibrionaceae B_PERSON/B_BIO
ORFs I_PERSON/I_BIO
were O
aligned O
against O
all O
the O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bacterial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
proteomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
profile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
defined O
as O
an O
array B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
distances B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
based O
on O
aminoacid B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitution I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrixes I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
from O
single B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
all O
their O
orthologues B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Final B_MEASURE
phylogenetic I_MEASURE
profiles I_MEASURE
, O
derived O
from O
non B_DISEASE/B_MEASURE
- O
redundant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
list I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
all O
ORFs B_BIO
, O
was O
defined O
as O
the O
median B_MEASURE
of O
all O
the O
profiles B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O
to O
the O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
resulting O
phylogenetic B_BIO/B_GENE
profiles O
matrix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contains O
gene B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
clusters I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
rows B_LOCATION
and O
organisms B_BIO/B_LOCATION
on O
the O
columns B_LOCATION
. O

cluster B_PERSON
analysis I_PERSON
identified O
groups B_ORGANIZATION/B_MEASURE
of O
' B_GENE/B_BIO
core I_GENE/I_BIO
genes I_GENE/I_BIO
' I_GENE/I_BIO
with O
a O
widespread B_MEASURE/B_LOCATION
high I_MEASURE/I_LOCATION
similarity I_MEASURE/I_LOCATION
across O
all O
the O
organisms B_BIO/B_LOCATION
and O
several B_LOCATION/B_MEASURE
clusters I_LOCATION/I_MEASURE
that O
contain O
genes B_GENE/B_PERSON
homologous I_GENE/I_PERSON
only O
to O
a O
limited O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
organisms B_GENE/B_BIO
. O

On O
each O
of O
these O
clusters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
COG B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
class B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
enrichment B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
been O
calculated O
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
reveals O
that O
clusters B_LOCATION/B_NUMBER[MEASURE]
of O
core B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
have O
the O
highest B_MEASURE/B_LOCATION
number B_MEASURE/I_LOCATION
of O
enriched B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classes I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
the O
others B_PERSON/B_LOCATION
are O
enriched O
just O
for O
few B_NUMBER[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
them O
like O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
replication B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
recombination B_GENE/B_TIME[MEASURE]
and O
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

We O
found O
that O
mobile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
elements I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
have O
heterogeneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O
only O
across O
the O
entire B_MEASURE/B_PERSON
set B_MEASURE/I_PERSON
of O
organisms B_BIO/B_GENE
, O
but O
also O
within O
Vibrionaceae B_BIO/B_PERSON
; O
this O
confirms O
their O
great B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
bacteria B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
evolution I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
even O
inside O
the O
same B_PERSON/B_BIO
family B_PERSON/I_BIO
. O

Furthermore O
, O
several B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
hypothetical I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
highly O
correlate B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
mobile B_GENE/B_PERSON
elements I_GENE/I_PERSON
profiles I_GENE/I_PERSON
suggesting O
a O
possible B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
horizontal I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
evolution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
these O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Finally O
, O
we O
suggested O
the O
putative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
some O
ORFs B_GENE/B_BIO
having O
an O
unknown B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
the O
basis B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
their O
phylogenetic B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similarity I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
well O
characterized O
genes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Over O
the O
past B_TIME[MEASURE]/B_ORGANIZATION
ten I_TIME[MEASURE]/I_ORGANIZATION
years I_TIME[MEASURE]/I_ORGANIZATION
, O
a O
great B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
microbial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
sequenced O
covering O
a O
wide B_MEASURE/B_LOCATION
representation I_MEASURE/I_LOCATION
of O
prokaryots B_BIO/B_GENE
as O
well O
as O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
strains I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
some O
species B_BIO/B_PERSON
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
these O
genomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
both O
by O
computational B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
experimental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
highly O
improved O
our O
understanding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
physiology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
phylogenetic B_DISEASE_ADJECTIVE[DISEASE]/B_EDU[ORGANIZATION]
relationship I_DISEASE_ADJECTIVE[DISEASE]/I_EDU[ORGANIZATION]
and O
pathogenicity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
many B_BIO
organisms I_BIO
. O

Furthermore O
, O
it O
has O
provided O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
knowledge I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
microbial B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
genome B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
evolution B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
revealing O
a O
gene B_GENE/B_LOCATION
core I_GENE/I_LOCATION
shared O
by O
the O
great B_PERSON/B_GENE
majority I_PERSON/I_GENE
of O
bacteria B_BIO/B_GENE
, O
genes B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
characteristic I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O
particular B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
' B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
novel I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
possibly O
originated O
by O
lateral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
transfer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
from O
some O
unknown B_PERSON/B_BIO
source I_PERSON/I_BIO
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O
on O
closely O
related B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
genomes B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
revealed O
that O
a O
substantial B_MEASURE/B_PERSON
fraction I_MEASURE/I_PERSON
of O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
any O
genome B_BIO/B_GENE
seem O
to O
be O
strain O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O
sometime O
arise O
by O
gene B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duplication I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
followed O
by O
a O
rapid B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
divergence I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
or O
by O
lineage B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
loss I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
one B_SPECIES[BIO]/B_PERSON
strain I_SPECIES[BIO]/I_PERSON
, O
resulting O
in O
a O
unique B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
gene B_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
other B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
strains I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
there O
are O
several B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
lines B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicating O
that O
lateral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transfer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
may O
be O
the O
main B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
acquire O
novel B_DISEASE/B_GENE
genes I_DISEASE/I_GENE
. O

Indeed O
, O
this O
could O
be O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
forces I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
driving O
bacterial B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
adaptation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
evolution B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
. O

phage B_GENE
DNA I_GENE
is O
thought O
to O
be O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
main B_LOCATION/B_PERSON
vectors I_LOCATION/I_PERSON
for O
lateral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
bacteria B_BACTERIUM[BIO]
[ O
1 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
and O
many B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
virulence B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factors B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
from O
bacterial B_BACTERIUM[BIO]/B_PERSON
pathogen I_BACTERIUM[BIO]/I_PERSON
are O
phage B_BACTERIUM[BIO]/B_TIME[MEASURE]
encoded O
[ O
2 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

For O
example O
, O
the O
genes O
for O
CT O
, O
the O
most O
important O
virulence O
factor O
of O
V B_BACTERIUM[BIO]/B_GENE
. I_BACTERIUM[BIO]/I_GENE
cholerae I_BACTERIUM[BIO]/I_GENE
, O
are O
encoded O
in O
the O
genome O
of O
phage O
CTX O
Phi O
, O
integrated O
in O
the O
bacterial O
chromosome O
1 O
. O

Since O
lateral B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plays O
a O
relevant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
bacterial B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
evolution I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
reconstruction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
phylogeny B_BIO/B_GENE
is O
very O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
trees I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
built O
by O
standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
may O
not O
lead O
to O
a O
reliable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
picture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
evolutionary B_PERSON/B_BIO
history B_PERSON/I_BIO
. O

In O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
alternative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
trees I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
obtained O
when O
different B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
considered O
. O

For O
many B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
the O
classification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bacteria B_BIO/B_GENE
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
their O
global B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
give O
a O
better B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
their O
evolutionary B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
may O
be O
particularly O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
bacteria B_BIO/B_PERSON
of O
the O
same B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
compared O
, O
since O
newly O
acquired O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
could O
be O
relevant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
confer O
peculiar B_DISEASE_ADJECTIVE[DISEASE]
features I_DISEASE_ADJECTIVE[DISEASE]
that O
allows O
the O
exploitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
different B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ecological I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
niches I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
we O
propose O
a O
bioinformatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
investigate O
bacterial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genome I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
evolution I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
taking O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O
global B_MEASURE/B_LOCATION
gene B_MEASURE/I_LOCATION
content B_MEASURE/I_LOCATION
, O
as O
well O
as O
sequence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similarity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
based O
our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
modified O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
however O
, O
we O
do O
not O
consider O
only O
the O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
absence B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
orthologue B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
, O
but O
also O
their O
distance B_MEASURE/B_LOCATION
, O
based O
on O
a O
substitution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
matrix I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

A O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
a O
non B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
sequence B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
homology B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
based O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
developed O
to O
infer O
a O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
functional I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
relationship I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O
genes B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
based O
on O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
proteins B_BIO/B_LOCATION
that O
are O
involved O
in O
the O
same B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
metabolic B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
or O
structural B_LOCATION
complex I_LOCATION
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
evolve O
in O
a O
correlate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fashion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
during O
evolution B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
appear O
phylogenetically O
linked O
, O
showing O
a O
tendency B_MEASURE/B_DISEASE
to O
be O
either O
preserved O
or O
eliminated O
as O
a O
whole B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
genes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phylogenetic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
functionally O
related O
. O

We O
extended O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
produce O
an O
evolutionary B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tree B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
a O
hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
clusterization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
organisms B_BIO/B_GENE
with O
similar B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
phylogenetic I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
profiles I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O
took O
the O
whole B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dataset I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
320 B_SPECIES[BIO]/B_GENE
prokaryotic I_SPECIES[BIO]/I_GENE
genomes I_SPECIES[BIO]/I_GENE
, O
however O
, O
we O
limited O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
orthologous B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
groups I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O
are O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
at O
least O
one B_NUMBER[MEASURE]
of O
the O
14 B_NUMBER[MEASURE]
considered O
species B_BIO/B_GENE
of O
the O
Vibrionaceae B_BIO/B_LOCATION
family I_BIO/I_LOCATION
. O

These O
bacteria B_BIO/B_PERSON
belong O
to O
the O
Gammaproteobacteria B_BACTERIUM[BIO]/B_MEASURE
group I_BACTERIUM[BIO]/I_MEASURE
and O
are O
highly O
abundant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
aquatic B_LOCATION/B_BIO
environment I_LOCATION/I_BIO
, O
they O
strongly O
influence O
nutrient B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cycling I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
various B_TIME[MEASURE]/B_ENT
species I_TIME[MEASURE]/I_ENT
are O
also O
devastating B_DISEASE_ADJECTIVE[DISEASE]
pathogens I_DISEASE_ADJECTIVE[DISEASE]
. O

Since O
we O
focused O
our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
this O
particular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O
not O
the O
construction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
global B_BIO
evolutionary I_BIO
tree I_BIO
, O
but O
rather O
a O
Vibrionaceae B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O
bacterial B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
diversity I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
based O
on O
phylogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Phylogenetic B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
on O
14 B_BIO/B_PERSON
bacteria I_BIO/I_PERSON
belonging O
to O
the O
Vibrionaceae B_BIO/B_LOCATION
family I_BIO/I_LOCATION
( O
Table B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

The O
redundant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
list I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
Vibrionaceae B_BIO/B_GENE
ORFs B_BIO/I_GENE
was O
clustered O
to O
reduce O
the O
number B_MEASURE/B_PERSON
of O
proteins B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
analyze O
and O
the O
phylogenetic B_MEASURE
profile I_MEASURE
for O
each O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
calculated O
as O
described O
in O
the O
Method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
section I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Many B_PERSON
authors I_PERSON
proposed O
and O
successfully O
applied O
different B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
measure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methods I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
calculate O
the O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
values B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Pellegrini B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
et I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
al I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

[ O
3 O
] O
firstly O
proposed O
a O
phylogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
described O
as O
a O
string B_ENT/B_MEASURE
of O
bits B_BIO/B_LOCATION
, O
each O
bit B_MEASURE
representing O
the O
absence B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
an O
homologous B_GENE/B_BIO
gene I_GENE/I_BIO
in O
a O
given O
genome B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

This O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lacks O
a O
weighting B_MEASURE/B_LOCATION
procedure I_MEASURE/I_LOCATION
, O
giving O
the O
same B_MEASURE
weight I_MEASURE
( O
value B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
) O
to O
all O
the O
sequences B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
are O
considered O
homologous B_TIME[MEASURE]/B_LOCATION
given O
a O
similarity B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
threshold I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Enault B_PERSON/B_LOCATION
and O
colleagues B_PERSON
proposed O
an O
improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phylogenetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O
on O
a O
normalized B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blastp B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bit B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
score B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
4 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

This O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
compared O
to O
the O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
implemented O
by O
Pellegrini B_PERSON/B_ORGANIZATION
, O
allows O
weighting O
each O
point B_LOCATION/B_MEASURE
of O
the O
profile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
proportionally O
to O
the O
length B_MEASURE/B_LOCATION
and O
the O
quality B_MEASURE/B_LOCATION
of O
the O
alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Jingchun B_PERSON/B_LOCATION
and O
colleagues B_PERSON
optimized O
the O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
by O
integrating O
phylogenetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relationships I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
among O
reference B_BIO/B_LOCATION
organisms I_BIO/I_LOCATION
and O
sequence B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homology I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
based O
on O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
value B_MEASURE/B_LOCATION
score B_MEASURE/I_LOCATION
, O
to O
improve O
prediction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
accuracy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
5 B_MEASURE/B_PERSON
] B_MEASURE/I_PERSON
. O

The O
measure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
index I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
I O
proposed O
in O
this O
work B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
others B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
described O
above O
, O
taking O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
both O
the O
quality B_MEASURE/B_LOCATION
and O
the O
length B_MEASURE
of O
the O
alignment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
a O
substitution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
matrix I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Moreover O
our O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considers O
also O
the O
total B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
of O
the O
sequences B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
penalizing O
good B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurring O
between O
ORFs B_GENE/B_LOCATION
having O
different B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
lengths I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O
taking O
into O
consideration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
ORFs B_PERSON/B_BIO
could O
differentiate O
mainly O
for O
the O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
domains B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

The O
final B_MEASURE/B_LOCATION
phylogenetic B_MEASURE/I_LOCATION
profile B_MEASURE/I_LOCATION
for O
each O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
defined O
as O
the O
median B_MEASURE
of O
all O
the O
profiles B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O
to O
the O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
named O
' B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meta I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
profile B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
, O
which O
describes O
the O
profile B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
conserved B_GENE/B_LOCATION
ORFs I_GENE/I_LOCATION
belonging O
to O
an O
entire B_PERSON/B_LOCATION
family B_PERSON/I_LOCATION
. O

hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cluster I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cluster I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O
performed O
on O
the O
entire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phylogenetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
matrix I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
it O
was O
calculated O
a O
statistical B_MEASURE/B_LOCATION
support I_MEASURE/I_LOCATION
based O
on O
bootstrap B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
for O
the O
nodes B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
columns B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
tree I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
Fig B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
branch B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tree I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
colors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
represent O
the O
bootstrap B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
percentage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
support B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

This O
constitutes O
a O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tree I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
based O
on O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O
Vibrionaceae B_BIO/B_GENE
ORFs B_BIO/I_GENE
as O
a O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

genomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O
to O
the O
same B_BIO/B_ORGANIZATION
taxonomic I_BIO/I_ORGANIZATION
group I_BIO/I_ORGANIZATION
tend O
to O
cluster O
together O
and O
the O
Vibrionaceae B_BIO/B_NUMBER[MEASURE]
species B_BIO/I_NUMBER[MEASURE]
are O
closely O
related O
. O

As O
expected O
, O
according O
to O
the O
Vibrionaceae B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
branch I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lengths I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
it O
is O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
variability B_MEASURE/B_BIO
within O
this O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
compared O
to O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
dataset B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
used O
for O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calculation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
indeed O
composed O
by O
Vibrionaceae B_BIO/B_GENE
ORFs I_BIO/I_GENE
. O

This O
implies O
that O
the O
similarity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures O
between O
these O
ORFs B_GENE/B_BIO
and O
the O
corresponding B_GENE/B_BIO
orthologues I_GENE/I_BIO
will O
be O
nearly O
zero B_MEASURE
in O
most B_NUMBER[MEASURE]/B_DISEASE
of O
the O
other B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
species I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
significantly O
higher B_MEASURE
in O
the O
Vibrionaceae B_SPECIES[BIO]/B_MEASURE
family I_SPECIES[BIO]/I_MEASURE
, O
increasing O
the O
variability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
into O
this O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
the O
average B_MEASURE/B_PERSON
percentage I_MEASURE/I_PERSON
of O
clusters B_LOCATION/B_BIO
shared O
by O
the O
Vibrionaceae B_PERSON/B_BIO
members I_PERSON/I_BIO
is O
only O
47 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
( O
average B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
shared O
clusters B_LOCATION/B_BIO
divided O
by O
the O
total B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
clusters B_LOCATION/B_PERSON
) O
that O
again O
indicates O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inside O
this O
family B_PERSON/B_LOCATION
. O

It O
is O
also O
interesting B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
note O
that O
organisms B_BIO/B_PERSON
belonging O
to O
the O
same B_MEASURE/B_LOCATION
or O
closely O
related O
taxa B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
split I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
into O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
subgroups I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

This O
highlights O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
variability B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
among O
lineages B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
due O
to O
genetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
evolutionary B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
processes I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
such I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
as O
lateral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
concerted B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evolution B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
duplication B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
6 B_BIO/B_LOCATION
] I_BIO/I_LOCATION
. O

In O
terms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
content I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
the O
organisms B_BIO/B_PERSON
more O
related B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
Vibrionaceae B_BIO
belong O
to O
the O
gamma B_PROTEIN[GENE]
and O
beta B_PROTEIN[GENE]/B_BACTERIUM[BIO]
proteobacteria I_PROTEIN[GENE]/I_BACTERIUM[BIO]
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
Altermonadales I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
Enterobacteriales B_BACTERIUM[BIO]
and O
Burkholderiales B_BACTERIUM[BIO]
are O
closely O
related B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
Vibrionaceae B_BACTERIUM[BIO]/B_PERSON
, O
and O
share O
the O
higher B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
genes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
average B_MEASURE/B_LOCATION
percentage I_MEASURE/I_LOCATION
of O
20 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
% I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

As O
expected O
, O
Archea B_PERSON/B_BIO
are O
the O
most O
distant B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
group I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sharing O
just O
3 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
clusters B_GENE/B_DISEASE
. O

clusters B_LOCATION/B_ORGANIZATION
and O
genes B_GENE/B_LOCATION
distribution I_GENE/I_LOCATION
, O
as O
shown O
in O
Fig B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reveals O
that O
the O
number B_MEASURE/B_PERSON
of O
clusters B_LOCATION/B_BIO
and O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O
by O
the O
organisms B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
decreases I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O
the O
number B_MEASURE/B_LOCATION
of O
organisms B_BIO/B_GENE
considered O
increases B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

The O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
performed O
considering O
for O
each O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
the O
number B_MEASURE/B_LOCATION
of O
organisms B_BIO/B_GENE
sharing O
the O
same B_MEASURE/B_LOCATION
numbers I_MEASURE/I_LOCATION
of O
clusters B_LOCATION/B_BIO
( O
and O
genes B_PROTEIN[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
majority B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gene B_BIO/B_PERSON
cluster I_BIO/I_PERSON
groups I_BIO/I_PERSON
no O
more B_MEASURE/B_PERSON
than O
21 B_NUMBER[MEASURE]/B_LOCATION
species I_NUMBER[MEASURE]/I_LOCATION
on O
a O
total B_MEASURE/B_LOCATION
of O
320 B_NUMBER[MEASURE]/B_LOCATION
. O

The O
highest B_MEASURE
blue I_MEASURE
spike I_MEASURE
corresponds O
to O
the O
higher B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O
by O
105 B_NUMBER[MEASURE]
groups I_NUMBER[MEASURE]
of O
14 B_BIO/B_GENE
organisms I_BIO/I_GENE
. O

Among O
these O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
expected O
, O
Vibrionaceae B_PERSON
are O
highly O
represented O
. O

Other O
species O
represented O
are O
Colwellia B_BACTERIUM[BIO]
psychrerythraea I_BACTERIUM[BIO]
34H I_BACTERIUM[BIO]
and O
Shewanella B_MEASURE/B_BACTERIUM[BIO]
oneidensis I_MEASURE/I_BACTERIUM[BIO]
, O
that O
belong O
to O
the O
Alteromonadales O
family O
. O

The O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O
on O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
shown O
in O
Fig B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

3 B_NUMBER[MEASURE]
. O

From O
now O
on O
, O
to O
avoid O
confusing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O
clusters B_LOCATION/B_BIO
derived O
from O
the O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O
from O
the O
ORFs B_GENE/B_MEASURE
clustering O
we O
will O
use O
the O
term B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
in O
place B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ORFs B_GENE/B_BIO
. O

The O
different B_DISEASE_ADJECTIVE[DISEASE]
gradient I_DISEASE_ADJECTIVE[DISEASE]
of O
color B_ENT/B_MEASURE
, O
from O
bright B_COLOR/B_PERSON
to O
dark B_COLOR
red I_COLOR
, O
represents O
decreasing O
similarity B_MEASURE/B_COLOR
values I_MEASURE/I_COLOR
. O

The O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
allows O
the O
detection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
three B_MEASURE/B_LOCATION
main B_MEASURE/I_LOCATION
groups B_MEASURE/I_LOCATION
of O
genes B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
( O
Fig B_MEASURE/B_PROTEIN[GENE]
3 I_MEASURE/I_PROTEIN[GENE]
, O
panel B_MEASURE/B_LOCATION
B I_MEASURE/I_LOCATION
) O
contains O
the O
most O
conserved B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
established B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
genes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
shared O
almost O
by O
all O
the O
organisms B_BIO/B_PERSON
. O

These O
core B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
can O
be O
defined O
as O
the O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
all O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O
as O
orthologous B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
by O
all O
members B_PERSON/B_LOCATION
of O
an O
evolutionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
coherent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

In O
our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
we O
identify O
four B_NUMBER[MEASURE]/B_LOCATION
clusters I_NUMBER[MEASURE]/I_LOCATION
, O
for O
a O
total B_MEASURE/B_LOCATION
of O
145 B_NUMBER[MEASURE]
genes I_NUMBER[MEASURE]
, O
shared O
by O
all O
the O
320 B_BIO/B_MEASURE
organisms I_BIO/I_MEASURE
. O

The O
ORFs B_GENE/B_LOCATION
belonging O
to O
these O
clusters B_LOCATION/B_BIO
are O
predicted O
to O
codify O
for O
the O
ATP B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ABC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transporters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
annotated O
as O
ABC B_ORGANIZATION/B_LOCATION
- O
type B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
polar I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
amino I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transport I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
system I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
ABC B_ORGANIZATION/B_LOCATION
- O
type B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
antimicrobial I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
peptide I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
transport I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
system I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
ABC B_ORGANIZATION/B_LOCATION
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
histidine I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
transport I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
system I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
ABC B_ORGANIZATION/B_LOCATION
- O
type B_MEASURE/B_LOCATION
transport B_MEASURE/I_LOCATION
system B_MEASURE/I_LOCATION
involved O
in O
lysophospholipase B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_GENE
L1 I_CELL_FUNCTION[ORGANISM_FUNCTION]/I_GENE
biosynthesis I_CELL_FUNCTION[ORGANISM_FUNCTION]/I_GENE
) O
. O

This O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
surprising B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O
this O
is O
the O
first B_LOCATION/B_MEASURE
report I_LOCATION/I_MEASURE
where O
these O
ORFs B_GENE/B_BIO
are O
assigned O
to O
the O
core B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
. O

Anyway O
two B_PERSON/B_LOCATION
different I_PERSON/I_LOCATION
explanations I_PERSON/I_LOCATION
can O
be O
traced O
. O

First O
, O
it O
is O
known O
that O
the O
ABC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transporters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
represent O
an O
essential B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transport I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
prokaryotes B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
and O
that O
their O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O
subunits B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
apparently O
overrepresented O
compared O
to O
the O
other B_GENE/B_NUMBER[MEASURE]
two I_GENE/I_NUMBER[MEASURE]
subunits I_GENE/I_NUMBER[MEASURE]
( O
ligand B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
permease B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
subunit B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
) O
in O
all O
genomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequenced O
thus O
far O
[ O
7 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

Second O
, O
one O
organism O
, O
Buchnera B_BIO/B_LOCATION
aphidicola B_BIO/I_LOCATION
, O
presents O
these O
genes O
with O
a O
similarity O
just O
below O
the O
cut O
- O
off O
used O
for O
the O
analysis O
, O
but O
they O
have O
been O
considered O
since O
it O
is O
well O
known O
that O
in O
this O
mutualistic O
endosymbiont O
the O
accelerated O
evolution O
and O
AT O
bias O
affect O
all O
its O
genes O
, O
including O
the O
16S O
rRNA O
[ O
8 O
, O
9 O
] O
. O

The O
dataset O
used O
for O
the O
analysis O
includes O
genomes O
in O
draft O
quality O
( O
Vibrio B_BACTERIUM[BIO]/B_GENE
cholerae I_BACTERIUM[BIO]/I_GENE
0395 I_BACTERIUM[BIO]/I_GENE
, O
Vibrio B_BACTERIUM[BIO]/B_PROTEIN[GENE]
cholerae B_BACTERIUM[BIO]/I_PROTEIN[GENE]
MO10 B_BACTERIUM[BIO]/I_PROTEIN[GENE]
, O
Vibrio B_MEASURE/B_BACTERIUM[BIO]
cholerae I_MEASURE/I_BACTERIUM[BIO]
RC385 I_MEASURE/I_BACTERIUM[BIO]
, O
Vibrio B_BACTERIUM[BIO]
cholerae I_BACTERIUM[BIO]
V51 I_BACTERIUM[BIO]
, O
Vibrio B_BACTERIUM[BIO]/B_GENE
cholerae B_BACTERIUM[BIO]/I_GENE
V52 B_BACTERIUM[BIO]/I_GENE
, O
Photobacterium B_BACTERIUM[BIO]
profundum I_BACTERIUM[BIO]
3TCK I_BACTERIUM[BIO]
, O
Vibrio B_BACTERIUM[BIO]/B_GENE
MED222 I_BACTERIUM[BIO]/I_GENE
, O
Vibrio B_MEASURE/B_BACTERIUM[BIO]
splendidus12B01 I_MEASURE/I_BACTERIUM[BIO]
) O
. O

wrong B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
ORFs I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
prediction I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
or O
missing O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
incomplete B_DISEASE_ADJECTIVE[DISEASE]
genome I_DISEASE_ADJECTIVE[DISEASE]
sequences I_DISEASE_ADJECTIVE[DISEASE]
can O
explain O
the O
low B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
core B_GENE
genes I_GENE
identified O
. O

To O
avoid O
such B_DISEASE_ADJECTIVE[DISEASE]
problems I_DISEASE_ADJECTIVE[DISEASE]
we O
repeated O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
excluding O
the O
draft B_GENE/B_BIO
genomes I_GENE/I_BIO
and O
thus O
considering O
312 B_GENE/B_PERSON
genomes I_GENE/I_PERSON
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
reported O
in O
Table B_MEASURE
2 I_MEASURE
, O
show O
an O
increased O
number B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
core B_GENE
genes I_GENE
and O
in O
particular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ribosomal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
tRNA B_GENE
synthetase I_GENE
, O
as O
reported O
by O
Charlesbois B_PERSON
and O
Doolittle B_PERSON
[ O
10 B_GENE/B_TIME[MEASURE]
] I_GENE/I_TIME[MEASURE]
. O

This O
could O
be O
considered O
as O
a O
sort B_MEASURE/B_LOCATION
of O
' O
minimal B_MEASURE/B_BIO
genome B_MEASURE/I_BIO
' O
containing O
the O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
maintain O
a O
free B_TIME[MEASURE]/B_LOCATION
- O
living B_BACTERIUM[BIO]/B_LOCATION
organism I_BACTERIUM[BIO]/I_LOCATION
. O

The O
low B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O
by O
all O
the O
organisms B_BIO/B_PERSON
can O
be O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
many B_DISEASE_ADJECTIVE[DISEASE]
factors I_DISEASE_ADJECTIVE[DISEASE]
. O

First O
of O
all O
we O
used O
the O
Vibrionaceae B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ORFs B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
limiting O
the O
number B_MEASURE/B_LOCATION
of O
genes B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
were O
able B_TIME[MEASURE]/B_PERSON
to O
identify O
. O

It O
was O
further O
demonstrated O
that O
the O
core B_MEASURE
gene I_MEASURE
size I_MEASURE
decreases O
as O
more B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genome I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
analyzed O
[ O
10 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
considered O
to O
belong O
to O
the O
core B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
set O
when O
close B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
organisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
compared O
, O
are O
classified O
as O
flexible B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
genes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
when O
distantly O
related O
genomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
analyzed O
[ O
6 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

Finally O
, O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
within O
core B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
genomes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
might O
be O
transferred O
or O
replaced O
, O
introducing O
new B_MEASURE/B_LOCATION
versions I_MEASURE/I_LOCATION
of O
existing O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
genomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Such B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
transfers I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
can O
replace O
even O
highly O
conserved B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
genes I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
by O
non B_DISEASE/B_GENE
- O
homologous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
counterparts I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
but O
the O
advantages B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provided O
are O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
explain O
. O

It O
is O
also O
to O
take O
into O
consideration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
many B_SPECIES[BIO]
symbiotic I_SPECIES[BIO]
and O
parasitic B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
bacteria I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
undergo O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
their O
genomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
loosing O
many B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
by O
free B_MEASURE/B_PERSON
- O
living B_PERSON/B_MEASURE
cell I_PERSON/I_MEASURE
. O

The O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
( O
Fig B_MEASURE/B_PROTEIN[GENE]
3 I_MEASURE/I_PROTEIN[GENE]
, O
panel B_MEASURE/B_LOCATION
C I_MEASURE/I_LOCATION
) O
represents O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O
mainly O
among O
Vibrionaceae B_BACTERIUM[BIO]
and O
other B_BACTERIUM[BIO]/B_PERSON
gamma I_BACTERIUM[BIO]/I_PERSON
proteobacteria I_BACTERIUM[BIO]/I_PERSON
( O
as O
Altermonadales B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O
Burkholderiales B_BACTERIUM[BIO]
and O
Enterobactidiales B_BACTERIUM[BIO]
) O
. O

Finally O
, O
the O
third B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Fig B_MEASURE/B_PROTEIN[GENE]
. O
3 B_NUMBER[MEASURE]
, O
panel B_MEASURE/B_LOCATION
D I_MEASURE/I_LOCATION
) O
is O
composed O
by O
genes B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
mainly O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
Vibrionaceae B_BIO/B_DISEASE
. O

k O
- O
mean B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enrichment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
performed O
a O
k B_OTHER/B_NUMBER[MEASURE]
- O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cluster I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
setting O
the O
k B_MEASURE
value I_MEASURE
to O
14 B_MEASURE
. O

As O
shown O
in O
Fig B_MEASURE/B_LOCATION
. O

4 O
, O
the O
clusters B_SEQUENCE[MEASURE]/B_PERSON
3 I_SEQUENCE[MEASURE]/I_PERSON
, O
4 B_NUMBER[MEASURE]
, O
11 B_NUMBER[MEASURE]
, O
13 B_NUMBER[MEASURE]
and O
14 B_MEASURE
contain O
the O
higher B_MEASURE
percentage I_MEASURE
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
accounting O
for O
more B_MEASURE/B_LOCATION
that O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
total B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
, O
while O
clusters B_NUMBER[MEASURE]/B_PERSON
9 I_NUMBER[MEASURE]/I_PERSON
and O
10 B_NUMBER[MEASURE]
contain O
the O
lower B_MEASURE
number I_MEASURE
of O
ORFs B_GENE/B_BIO
( O
3 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
variance B_MEASURE/B_LOCATION
in O
each O
k B_OTHER/B_MEASURE
- O
means B_LOCATION/B_MEASURE
cluster I_LOCATION/I_MEASURE
is O
very O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
Fig B_MEASURE
. O
4 B_NUMBER[MEASURE]
) O
, O
meaning O
that O
the O
clusters B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contain O
genes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
compact B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
similar B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
profiles I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

As O
described O
in O
Fig B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

4 B_TIME[MEASURE]/B_LOCATION
, O
the O
majority B_PERSON/B_MEASURE
of O
the O
clusters B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_NUMBER[MEASURE]
, O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
, O
7 B_NUMBER[MEASURE]
, O
9 B_NUMBER[MEASURE]
, O
12 B_NUMBER[MEASURE]
, O
13 B_MEASURE
) O
contains O
genes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
a O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
with O
the O
average B_MEASURE/B_LOCATION
values I_MEASURE/I_LOCATION
( O
red B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
near O
zero B_MEASURE
, O
except O
for O
the O
presence B_LOCATION/B_DISEASE
of O
some O
spikes B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correspondent I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
an O
increasing O
similarity B_MEASURE
with O
some O
isolated B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
organisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

As O
shown O
in O
Table B_MEASURE
3 I_MEASURE
, O
clusters B_PROTEIN[GENE]/B_MEASURE
1 I_PROTEIN[GENE]/I_MEASURE
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
, O
and O
9 B_NUMBER[MEASURE]
contains O
genes B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
have O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
similarity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
a O
small B_LOCATION/B_MEASURE
subset B_LOCATION/I_MEASURE
of O
organisms B_BIO/B_GENE
. O

The O
majority B_PERSON/B_LOCATION
of O
these O
ORFs B_GENE/B_BIO
are O
annotated O
as O
hypothetical B_SPECIES[BIO]/B_GENE
proteins I_SPECIES[BIO]/I_GENE
or O
phage O
related O
proteins B_BIO/B_GENE
. O

clusters B_NUMBER[MEASURE]/B_PERSON
8 I_NUMBER[MEASURE]/I_PERSON
, O
10 B_NUMBER[MEASURE]
and O
14 B_MEASURE
present I_MEASURE
genes I_MEASURE
shared O
among O
almost O
all O
the O
organisms B_BIO/B_PERSON
. O

In O
particular B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cluster I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
10 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
is O
composed O
by O
the O
core B_GENE/B_BIO
genes I_GENE/I_BIO
described O
before O
having O
an O
high B_MEASURE
value I_MEASURE
of O
similarity B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
widespread I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
all O
the O
organisms B_BIO/B_PERSON
; O
cluster B_NUMBER[MEASURE]
8 I_NUMBER[MEASURE]
contains O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shared O
mainly O
by O
gamma B_BACTERIUM[BIO]
proteobacteria I_BACTERIUM[BIO]
and O
cluster B_TIME[MEASURE]/B_LOCATION
14 I_TIME[MEASURE]/I_LOCATION
is O
composed O
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
common B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
between O
Vibrionaceae B_BACTERIUM[BIO]
and O
Enterobacteriaceae B_BACTERIUM[BIO]
. O

A O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
annotation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
performed O
on O
each O
gene B_GENE/B_MEASURE
cluster I_GENE/I_MEASURE
using O
COG B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
cluster B_LOCATION/B_ORGANIZATION
of O
Orthologous B_GENE/B_MEASURE
Genes I_GENE/I_MEASURE
) O
, O
KEGG B_LOCATION/B_ORGANIZATION
pathway I_LOCATION/I_ORGANIZATION
map I_LOCATION/I_ORGANIZATION
and O
GO B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
databases I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
each O
k B_OTHER/B_MEASURE
- O
mean B_LOCATION/B_MEASURE
cluster I_LOCATION/I_MEASURE
the O
enrichment B_MEASURE
probability I_MEASURE
with O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
clusters B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
obtained O
with O
the O
hypergeometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distribution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Fig B_BIO/B_GENE
. O

5 B_MEASURE/B_PERSON
shows O
COG O
enrichment B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
each O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

As O
expected O
clusters B_LOCATION/B_DISEASE
represented O
by O
conserved B_BIO/B_NUMBER[MEASURE]
genes I_BIO/I_NUMBER[MEASURE]
( O
cluster B_MEASURE
8 I_MEASURE
, O
10 B_NUMBER[MEASURE]
and O
14 B_MEASURE
) O
have O
the O
higher B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
enriched B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
COG I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
codes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
while O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
specific I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
few B_BIO/B_GENE
organisms B_BIO/I_GENE
are O
characterized O
by O
a O
small B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
enriched B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
COGs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
majority B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
clusters B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presents O
COG B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
codes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enrichment O
for O
S B_OTHER/B_LOCATION
( O
function B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
unknown I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
, O
R B_OTHER/B_PROTEIN[GENE]
( O
poorly O
characterized O
) O
and O
- O
( O
absence B_DISEASE/B_LOCATION
of O
COG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
categories B_LOCATION
. O

This O
is O
due O
to O
the O
large B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
abundance I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
unknown B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
hypothetical B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
presents I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
Vibrionaceae B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
proteomes B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O

It O
is O
worth O
noting O
that O
cluster O
3 O
, O
mainly O
represented O
by O
Photobacterium B_NUMBER[MEASURE]/B_PERSON
profundum I_NUMBER[MEASURE]/I_PERSON
SS9 I_NUMBER[MEASURE]/I_PERSON
ORFs O
, O
is O
enriched O
only O
by O
C O
( O
Energy O
production O
and O
conversion O
) O
, O
L O
( O
DNA O
replication O
, O
recombination O
and O
repair O
) O
and O
M O
( O
Cell O
envelope O
biogenesis O
, O
outer O
membrane O
) O
. O

Probably O
the O
L B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overrepresentation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
determined O
by O
the O
high B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
transposons B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
that O
are O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
SS9 B_GENE
genome I_GENE
[ I_GENE
11 I_GENE
] I_GENE
. O

The O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
played O
by O
these O
transposable B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
elements B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O
the O
survival B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
this O
deep B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O
sea B_LOCATION/B_BIO
bacterium I_LOCATION/I_BIO
it O
is O
still O
a O
matter B_PERSON/B_LOCATION
of O
debate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
12 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition O
V B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
vulnificus I_BACTERIUM[BIO]
YJ016 I_BACTERIUM[BIO]
and O
V B_TIME[MEASURE]/B_BACTERIUM[BIO]
. I_TIME[MEASURE]/I_BACTERIUM[BIO]
vulnificus I_TIME[MEASURE]/I_BACTERIUM[BIO]
CMCP6 I_TIME[MEASURE]/I_BACTERIUM[BIO]
( O
cluster O
13 O
) O
seem O
to O
share O
genes O
belonging O
to O
the O
enriched O
COG O
classes O
K O
( O
transcription O
) O
, O
L O
and O
T O
( O
Signal O
transduction O
mechanisms O
) O
. O

It O
was O
previously O
reported O
an O
enrichment O
in O
genes O
belonging O
to O
the O
transcription O
class O
in O
the O
genome O
of O
V B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
vulnificus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
respect O
to O
the O
V B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
cholerae I_SPECIES[BIO]/I_PERSON
genome O
[ O
13 O
] O
. O

This O
class B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
clearly O
related O
to O
the O
T B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
class I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
seems O
to O
indicate O
that O
this O
organism B_BIO/B_GENE
is O
able B_TIME[MEASURE]/B_PERSON
to O
receive O
and O
translate O
in O
a O
transcriptional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
response I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
environmental I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
signals I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Despite O
this O
, O
the O
large B_SEQUENCE[MEASURE]/B_PERSON
majority I_SEQUENCE[MEASURE]/I_PERSON
of O
the O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
clusters B_NUMBER[MEASURE]/B_PERSON
3 I_NUMBER[MEASURE]/I_PERSON
and O
13 B_NUMBER[MEASURE]
lacks O
COG B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
annotation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Cluster B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
7 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
shown O
in O
Table B_MEASURE/B_LOCATION
3 I_MEASURE/I_LOCATION
, O
accounts O
organisms B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
with O
large B_MEASURE/B_BIO
genome I_MEASURE/I_BIO
size I_MEASURE/I_BIO
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

This O
can O
explain O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
this O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
contains O
almost O
all O
the O
COG B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enriched O
and O
suggests O
a O
more O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
flexible B_PERSON/B_LOCATION
life I_PERSON/I_LOCATION
- O
style B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
these O
organisms B_BIO/B_GENE
compared O
to O
the O
other B_TIME[MEASURE]/B_LOCATION
Vibrionaceae I_TIME[MEASURE]/I_LOCATION
members I_TIME[MEASURE]/I_LOCATION
. O

KEGG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
annotation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
limited O
to O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
or O
structural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
network I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
so O
a O
reduced B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
have O
a O
KEGG B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
entry B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
causes O
the O
presence B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
clusters B_LOCATION
without O
enriched B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
map I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
cluster B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
5 B_NUMBER[MEASURE]
, O
7 B_NUMBER[MEASURE]
, O
13 B_SEQUENCE[MEASURE]
, O
see O
Fig B_MEASURE/B_LOCATION
5 B_MEASURE/I_LOCATION
) O
. O

Also O
in O
this O
case B_PERSON/B_LOCATION
, O
the O
clusters B_LOCATION/B_BIO
presenting O
the O
higher B_MEASURE/B_LOCATION
number B_MEASURE/I_LOCATION
of O
significant B_LOCATION/B_GENE
KEGG I_LOCATION/I_GENE
map I_LOCATION/I_GENE
are O
those O
containing O
the O
conserved B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
. O

The O
most O
enriched B_DISEASE_ADJECTIVE[DISEASE]
KEGG I_DISEASE_ADJECTIVE[DISEASE]
clusters I_DISEASE_ADJECTIVE[DISEASE]
are O
cluster B_NUMBER[MEASURE]
14 I_NUMBER[MEASURE]
, O
10 B_MEASURE
and O
8 B_MEASURE
accounting I_MEASURE
for O
the O
majority B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cluster B_GENE/B_LOCATION
1 I_GENE/I_LOCATION
is O
enriched O
for O
map3080 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
type B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
IV B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
system B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) O
. O

In O
fact O
V B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
fischeri I_PERSON/I_SPECIES[BIO]
genome O
contains O
10 O
separate O
pilus O
gene O
clusters O
, O
including O
eight O
type O
- O
IV O
pilus O
loci O
. O

The O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pilus I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
gene I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
clusters I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
suggests O
that O
different B_DISEASE/B_BIO
pili I_DISEASE/I_BIO
may O
be O
expressed O
in O
different B_NUMBER[MEASURE]/B_LOCATION
environments I_NUMBER[MEASURE]/I_LOCATION
or O
during O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
stages I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O
its O
development B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
symbiont B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
[ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
14 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
] B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

Cluster B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
11 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
enriched O
for O
map3090 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
type B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
II I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
secretion I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
system I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
type B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
II B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
pathway B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
is O
conserved O
among O
gram B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
bacteria I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
many B_BACTERIUM[BIO]
pathogens I_BACTERIUM[BIO]
, O
and O
secretes O
a O
variety B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
virulence B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
degradative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
enzymes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
[ O
15 B_SPECIES[BIO]/B_LOCATION
] I_SPECIES[BIO]/I_LOCATION
. O

Cluster B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
9 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
enriched O
for O
map B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
00860 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
porphyrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
chlorophyll B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

These O
genes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
involved O
in O
the O
cobalamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
coenzyme B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B12 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
biosynthetic B_LOCATION/B_ORGANIZATION
pathway I_LOCATION/I_ORGANIZATION
[ O
16 B_TIME[MEASURE]
] O
. O

Some O
organisms O
, O
such O
as O
Salmonella B_BACTERIUM[BIO]
typhimurium I_BACTERIUM[BIO]
and O
Klebsiella B_BACTERIUM[BIO]
pneumoniae I_BACTERIUM[BIO]
, O
can O
synthesize O
cobalamin O
de O
novo O
[ O
17 O
] O
, O
while O
E B_PERSON/B_BIO
. I_PERSON/I_BIO
coli I_PERSON/I_BIO
and O
large O
part O
of O
the O
Vibrionaceae O
perform O
cobalamin O
biosynthesis O
only O
when O
provided O
with O
cobinamide O
. O

It O
is O
interesting O
to O
observe O
that O
the O
genes O
belonging O
to O
the O
de O
novo O
pathway O
are O
only O
shared O
by O
Archea O
, O
some O
other O
organisms O
like O
Salmonella O
, O
Pseudomonas O
and O
Vibrio B_BACTERIUM[BIO]
MED222 I_BACTERIUM[BIO]
. O

Finally O
cluster B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
enriched O
by O
map2010 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ABC B_GENE
transporter I_GENE
) O
, O
map2020 B_GENE
( O
two B_NUMBER[MEASURE]/B_LOCATION
- O
component B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ENZYME[GENE]
system B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ENZYME[GENE]
) O
, O
map2030 B_GENE
and O
map2031 B_MEASURE/B_GENE
( O
bacterial B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
chemotaxis I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
map2040 B_GENE/B_ORGANIZATION
( O
Flagellar B_BIO/B_ENZYME[GENE]
assembly B_BIO/I_ENZYME[GENE]
) O
and O
map3090 B_GENE/B_MEASURE
( O
type B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
II B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
system B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) O
. O

This O
cluster O
contains O
genes O
shared O
with O
a O
high O
similarity O
by O
all O
Vibrio O
and O
with O
a O
lower O
similarity O
with O
Photobacterium B_BACTERIUM[BIO]
profundum I_BACTERIUM[BIO]
species O
. O

Among O
the O
Vibrio O
species O
the O
organisms O
showing O
the O
highest O
similarity O
( O
Tab O
. O
3 O
) O
are O
V B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
cholerae I_BACTERIUM[BIO]
strains O
. O

Vibrionaceae B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
specific I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
identify O
1940 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clusters I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
Vibrionaceae B_LOCATION/B_PERSON
. O

All O
the O
Vibrionaceae B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
share I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
108 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
clusters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Among O
these O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
identify O
ToxR B_LOCATION/B_GENE
and O
ToxS B_LOCATION/B_ORGANIZATION
genes I_LOCATION/I_ORGANIZATION
. O

ToxR O
gene O
encodes O
a O
transmembrane O
regulatory O
protein O
firstly O
identified O
in O
V B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
cholerae I_BACTERIUM[BIO]
, O
in O
which O
it O
co O
- O
ordinates O
many O
virulence O
factors O
in O
response O
to O
several O
environmental O
parameters O
[ O
18 O
] O
. O

V B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cholerae I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
ToxR O
activity O
is O
enhanced O
by O
a O
second O
transmembrane O
protein O
, O
ToxS O
, O
encoded O
downstream O
toxR O
[ O
19 O
] O
. O

This O
family O
of O
proteins O
is O
involved O
in O
response O
to O
temperature O
, O
pH O
, O
osmolarity O
and O
in O
Photobacterium B_BACTERIUM[BIO]/B_PERSON
profundum I_BACTERIUM[BIO]/I_PERSON
SS9 I_BACTERIUM[BIO]/I_PERSON
, O
a O
piezophilic O
bacterium O
, O
to O
hydrostatic O
pressure O
[ O
20 O
] O
. O

The O
widespread B_PERSON/B_MEASURE
presence I_PERSON/I_MEASURE
of O
these O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
the O
Vibrionaceae B_BIO/B_PERSON
suggests O
their O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
regulatory B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
identify O
two B_MEASURE/B_LOCATION
other I_MEASURE/I_LOCATION
noteworthy I_MEASURE/I_LOCATION
groups I_MEASURE/I_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composed O
by O
257 B_MEASURE
and O
160 B_MEASURE
genes I_MEASURE
respectively O
shared O
just O
by O
two B_NUMBER[MEASURE]/B_PERSON
strains I_NUMBER[MEASURE]/I_PERSON
, O
mainly O
annotated O
as O
' B_PROTEIN[GENE]
hypothetical I_PROTEIN[GENE]
protein I_PROTEIN[GENE]
' O
. O

The O
first O
group O
of O
genes O
is O
shared O
between O
Photobacterium B_BACTERIUM[BIO]
profundum I_BACTERIUM[BIO]
SS9 I_BACTERIUM[BIO]
and O
Photobacterium B_BACTERIUM[BIO]/B_PROTEIN[GENE]
profundum B_BACTERIUM[BIO]/I_PROTEIN[GENE]
3TCK B_BACTERIUM[BIO]/I_PROTEIN[GENE]
, O
while O
the O
second O
is O
shared O
between O
V B_BACTERIUM[BIO]/B_PROTEIN[GENE]
. B_BACTERIUM[BIO]/I_PROTEIN[GENE]
vulnificus B_BACTERIUM[BIO]/I_PROTEIN[GENE]
CMCP6 B_BACTERIUM[BIO]/I_PROTEIN[GENE]
and O
YJ016 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
strains B_BIO/B_GENE
are O
closely O
related O
and O
this O
explains O
the O
high B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
shared O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
while O
, O
inside O
the O
Vibrionaceae B_BIO/B_LOCATION
family I_BIO/I_LOCATION
, O
the O
number B_MEASURE/B_LOCATION
of O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
shared O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highly O
decreases O
, O
showing O
a O
high B_DISEASE/B_MEASURE
inter I_DISEASE/I_MEASURE
- O
species B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
variability I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Fig B_MEASURE/B_LOCATION
. O
6 B_NUMBER[MEASURE]
) O
. O

Prophages B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
transposases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Prophages B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recover O
different B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
biological I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
roles I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
both O
as O
quantitatively O
important B_PERSON/B_GENE
genetic I_PERSON/I_GENE
elements I_PERSON/I_GENE
of O
the O
bacterial B_BIO/B_LOCATION
chromosome I_BIO/I_LOCATION
, O
and O
as O
vectors B_PROTEIN[GENE]/B_LOCATION
of O
lateral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
bacteria B_BIO/B_GENE
, O
due O
to O
their O
characters B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mobile B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Indeed O
, O
numerous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virulence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
bacterial B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pathogens I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
are O
phage B_BACTERIUM[BIO]/B_LOCATION
encoded O
. O

It O
was O
postulated O
that O
this O
role B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
prophages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
is O
not O
limited O
to O
pathogenic O
bacteria B_BIO/B_DISEASE
but O
some O
adaptations B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nonpathogenic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
strains I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
to O
their O
ecological B_LOCATION/B_PERSON
niche I_LOCATION/I_PERSON
might O
also O
be O
mediated O
by O
prophages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
acquisition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
[ O
21 B_DISEASE/B_ORGANISM_FUNCTION
] I_DISEASE/I_ORGANISM_FUNCTION
. O

To O
better O
understand O
the O
importance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
mobile B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
elements B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
within O
Vibrionaceae B_BIO/B_GENE
family I_BIO/I_GENE
, O
we O
performed O
a O
hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cluster I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
gene B_GENE/B_MEASURE
profiles I_GENE/I_MEASURE
annotated O
as O
' O
phage B_ENZYME[GENE]
protein I_ENZYME[GENE]
' O
and O
' O
transposase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
' O
, O
for O
a O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
172 B_MEASURE
clusters I_MEASURE
of O
genes B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fig B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
7 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

We O
found O
that O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
inter B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
strain B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exists O
and O
phages B_BIO/B_GENE
and O
transposases B_BIO/B_GENE
are O
both O
shared O
by O
almost O
all O
Vibrionaceae B_BIO/B_GENE
, O
and O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
just O
some O
organisms B_BIO/B_GENE
. O

We O
identified O
five B_MEASURE/B_LOCATION
major I_MEASURE/I_LOCATION
clusters I_MEASURE/I_LOCATION
of O
mobile B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
elements B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
are O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
a O
single B_BIO/B_GENE
organism I_BIO/I_GENE
. O

A O
group O
composed O
by O
26 O
clusters O
containing O
both O
transposase O
and O
phage O
proteins O
seem O
to O
be O
unique O
to O
V B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
splendiduds I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12B01 I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fig O
7 O
) O
. O

Another O
one O
composed O
by O
16 O
clusters O
is O
specific O
of O
V B_BIO
. I_BIO
vulnificus I_BIO
CMCP6 I_BIO
( O
Fig O
7 O
) O
while O
V B_PERSON
. I_PERSON
parahaemoliticus I_PERSON
has O
a O
cluster O
of O
11 O
genes O
( O
Fig O
7 O
) O
. O

Moreover O
there O
is O
another O
group O
of O
transposases O
and O
phage O
genes O
shared O
mainly O
by O
V B_BACTERIUM[BIO]/B_GENE
. I_BACTERIUM[BIO]/I_GENE
cholerae I_BACTERIUM[BIO]/I_GENE
0395 O
, O
Shewanella B_MEASURE/B_BACTERIUM[BIO]
oneidensis I_MEASURE/I_BACTERIUM[BIO]
and O
V B_BACTERIUM[BIO]/B_DISEASE
. I_BACTERIUM[BIO]/I_DISEASE
cholerae I_BACTERIUM[BIO]/I_DISEASE
V51 O
( O
Fig O
7 O
) O
. O

Finally O
a O
big O
cluster O
of O
almost O
30 O
genes O
, O
all O
predicted O
to O
codify O
for O
transposases O
, O
was O
found O
in O
P B_BIO/B_PERSON
. I_BIO/I_PERSON
profundum I_BIO/I_PERSON
SS9 I_BIO/I_PERSON
genome O
( O
Fig O
. O
7 O
) O
. O

The O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
transposases B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
bacterium B_BIO/B_LOCATION
seems O
to O
correlate O
with O
its O
deep B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O
sea B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
habitat I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
feature B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
presumably O
shared O
with O
other B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
deep I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O
sea B_BIO/B_LOCATION
microorganisms B_BIO/I_LOCATION
[ O
12 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

As O
shown O
in O
Fig B_MEASURE
7 I_MEASURE
, O
many B_NUMBER[MEASURE]/B_PERSON
of O
the O
clusters B_LOCATION/B_BIO
well O
conserved O
in O
an O
organism B_BIO/B_GENE
, O
are O
partially O
shared O
with O
a O
low B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
similarity I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
by O
other B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
organisms I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
agrees O
with O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
prophages B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
maintained O
in O
the O
genome B_BIO/B_GENE
over O
a O
long B_MEASURE/B_LOCATION
period I_MEASURE/I_LOCATION
of O
time B_TIME[MEASURE]/B_LOCATION
and O
part B_NUMBER[MEASURE]/B_LOCATION
of O
their O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
deleted O
from O
the O
chromosome B_BIO/B_GENE
. O

Moreover O
, O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scanning I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
demonstrated O
that O
prophages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
are O
frequently O
strain O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
within O
a O
given O
bacterial B_BIO/B_GENE
species I_BIO/I_GENE
[ O
22 B_MEASURE
- O
24 B_MEASURE
] I_MEASURE
. O

According O
to O
the O
modular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
of O
phage B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
evolution I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
phage B_GENE/B_BIO
genomes I_GENE/I_BIO
are O
mosaics B_MEASURE/B_LOCATION
of O
modules B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
, O
groups B_ORGANIZATION/B_LOCATION
of O
genes B_BIO/B_GENE
functionally O
related O
, O
that O
are O
free B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
recombine O
in O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
exchanges I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
between O
distinct B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
phages I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
infecting O
the O
same B_BIO
cell I_BIO
[ O
21 B_GENE/B_BIO
] I_GENE/I_BIO
. O

This O
can O
result O
in O
the O
occurrences B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
part I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
phage B_BIO/B_GENE
distributed O
in O
far O
related O
genomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
some O
transposases B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
is O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
phage B_MEASURE/B_BIO
ones I_MEASURE/I_BIO
, O
suggesting O
a O
possible B_BIO/B_GENE
transfer B_BIO/I_GENE
mechanism B_BIO/I_GENE
phage B_BIO/I_GENE
- O
mediated O
for O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mobile I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
elements I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

In O
this O
work B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
propose O
an O
improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
phylogenetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
on O
14 B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Vibrionaceae I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
genomes I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
to O
study O
this O
family B_PERSON/B_LOCATION
on O
the O
basis B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
content I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Using O
a O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
each O
cluster B_LOCATION/B_MEASURE
of O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
defined O
as O
the O
median B_LOCATION/B_MEASURE
of O
all O
the O
profiles B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O
to O
the O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
meta B_DISEASE/B_PROTEIN[GENE]
- O
profile B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
we O
investigate O
the O
evolution B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
groups B_ORGANIZATION/B_LOCATION
of O
ORFs B_BIO/B_GENE
belonging O
to O
the O
entire B_PERSON/B_LOCATION
family I_PERSON/I_LOCATION
. O

A O
two B_NUMBER[MEASURE]
- O
way B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cluster I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
allows O
us O
to O
identify O
similarity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
structures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
on O
the O
entire B_LOCATION/B_BIO
phylogenetic B_LOCATION/I_BIO
matrix B_LOCATION/I_BIO
composed O
by O
8 B_MEASURE
, O
239 B_MEASURE
clusters I_MEASURE
of O
genes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
320 B_BIO/B_GENE
organisms B_BIO/I_GENE
. O

The O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tree I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
obtained O
with O
the O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
does O
not O
reflect O
the O
global B_BIO/B_LOCATION
evolutionary I_BIO/I_LOCATION
tree I_BIO/I_LOCATION
because O
of O
the O
Vibrionaceae B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
ORFs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
dataset I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
used O
for O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
but O
rather O
can O
be O
considered O
as O
the O
Vibrionaceae B_BIO/B_LOCATION
perspective B_BIO/I_LOCATION
of O
bacterial B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
diversity B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

The O
phylogenetic B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tree I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reflects O
the O
evolutionary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
processes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
shape O
genomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transfer B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
genes B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Genesis B_PERSON/B_TIME[MEASURE]
and O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
this O
context B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
tree B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allows O
to O
group O
together O
genomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
base B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
their O
global B_LOCATION/B_ORGANIZATION
gene I_LOCATION/I_ORGANIZATION
content I_LOCATION/I_ORGANIZATION
. O

We O
found O
that O
genomes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belonging O
to O
the O
same B_BIO/B_MEASURE
taxonomic I_BIO/I_MEASURE
group I_BIO/I_MEASURE
tend O
to O
cluster O
together O
and O
that O
Vibrionaceae B_PERSON/B_BIO
species I_PERSON/I_BIO
are O
closely O
related O
. O

Moreover O
organisms B_BIO/B_PERSON
belonging O
to O
the O
same B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
or O
closely O
related B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
taxa I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
split I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
into O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subgroups I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
confirming O
the O
existence B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variability I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
among O
lineages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
due O
to O
genetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
evolutionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
lateral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
gene I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
transfer I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
concerted B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evolution B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
genes B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duplication B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

On O
the O
other B_MEASURE/B_LOCATION
hand B_MEASURE/I_LOCATION
several B_MEASURE/I_LOCATION
groups B_MEASURE/I_LOCATION
of O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
characterised O
by O
different B_DISEASE/B_GENE
homogeneous I_DISEASE/I_GENE
profiles I_DISEASE/I_GENE
have O
been O
identified O
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
we O
found O
, O
1 B_TIME[MEASURE]
) O
a O
set B_GENE/B_LOCATION
of O
conserved B_GENE/B_BIO
genes I_GENE/I_BIO
( O
with O
a O
high B_MEASURE/B_LOCATION
similarity I_MEASURE/I_LOCATION
values I_MEASURE/I_LOCATION
across O
all O
organisms B_BIO/B_GENE
) O
that O
reflects O
the O
' B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minimal I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genome I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
composition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
defined O
in O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
previous I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
works I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O
2 B_NUMBER[MEASURE]
) O
a O
set B_PROTEIN[GENE]/B_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mainly O
shared O
by O
Vibrionaceae B_BACTERIUM[BIO]
and O
other B_SPECIES[BIO]
Gamma I_SPECIES[BIO]
proteobacteria I_SPECIES[BIO]
and O
3 B_NUMBER[MEASURE]
) O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specific I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
different B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
sets I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O
Vibrionaceae B_BIO/B_GENE
. O

Finally O
a O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
prophage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
and O
transposase B_GENE/B_BACTERIUM[BIO]
has O
confirmed O
the O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
inter I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O
strain B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genetic I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O
among O
closely O
related O
species B_BIO/B_GENE
. O

The O
increasing O
number B_MEASURE
of O
genomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
included O
in O
this O
type B_DISEASE/B_LOCATION
of O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surely O
add O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sorces I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
variability B_MEASURE/B_DISEASE
and O
noise B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
anyway O
we O
think O
that O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
meta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
profiles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
complexity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
study O
global B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
gene I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
evolution I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

datasets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
Vibrionaceae B_BIO/B_GENE
species B_BIO/I_GENE
used O
in O
this O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
selected O
among O
the O
freely O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complete I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
draft B_TIME[MEASURE]/B_GENE
genome I_TIME[MEASURE]/I_GENE
sequences I_TIME[MEASURE]/I_GENE
. O

The O
proteomes O
of O
V B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
cholerae I_BACTERIUM[BIO]
N16961 I_BACTERIUM[BIO]
, O
V B_MEASURE/B_BACTERIUM[BIO]
. I_MEASURE/I_BACTERIUM[BIO]
parahaemolyticus I_MEASURE/I_BACTERIUM[BIO]
, O
V B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
vulnificus I_BACTERIUM[BIO]
YJ016 I_BACTERIUM[BIO]
, O
V B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
vulnificus I_BACTERIUM[BIO]
CMCP6 I_BACTERIUM[BIO]
, O
V B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fischeri I_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ES114 I_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Photobacterium B_MEASURE/B_BACTERIUM[BIO]
profundum I_MEASURE/I_BACTERIUM[BIO]
SS9 I_MEASURE/I_BACTERIUM[BIO]
were O
downloaded O
from O
the O
NCBI O
ftp O
site O
[ O
25 O
] O
. O

protein O
sequences O
of O
Vibrio B_BACTERIUM[BIO]
cholerae I_BACTERIUM[BIO]
MO10 I_BACTERIUM[BIO]
, O
Vibrio B_MEASURE/B_BACTERIUM[BIO]
cholerae I_MEASURE/I_BACTERIUM[BIO]
0395 I_MEASURE/I_BACTERIUM[BIO]
, O
Vibrio B_TIME[MEASURE]/B_BACTERIUM[BIO]
cholerae I_TIME[MEASURE]/I_BACTERIUM[BIO]
RC385 I_TIME[MEASURE]/I_BACTERIUM[BIO]
, O
Vibrio B_BACTERIUM[BIO]/B_GENE
cholerae I_BACTERIUM[BIO]/I_GENE
V51 I_BACTERIUM[BIO]/I_GENE
, O
Vibrio B_MEASURE/B_BACTERIUM[BIO]
cholerae I_MEASURE/I_BACTERIUM[BIO]
V52 I_MEASURE/I_BACTERIUM[BIO]
were O
downloaded O
from O
the O
NCBI O
genome O
database O
, O
while O
sequences O
of O
Vibrio B_BACTERIUM[BIO]/B_GENE
MED222 I_BACTERIUM[BIO]/I_GENE
, O
Vibrio B_BACTERIUM[BIO]/B_GENE
splendidus B_BACTERIUM[BIO]/I_GENE
12B01 B_BACTERIUM[BIO]/I_GENE
, O
Photobacterium B_BIO/B_TIME[MEASURE]
profundum I_BIO/I_TIME[MEASURE]
3TCK I_BIO/I_TIME[MEASURE]
from O
the O
J O
. O

Craig B_LOCATION/B_ORGANIZATION
Venter B_LOCATION/I_ORGANIZATION
Institute B_LOCATION/I_ORGANIZATION
web O
site B_LOCATION/B_PERSON
. O

The O
320 B_MEASURE
complete I_MEASURE
genomes I_MEASURE
update O
at O
03 B_MEASURE
/ O
06 B_MEASURE
were O
downloaded O
from O
the O
NCBI B_LOCATION/B_ORGANIZATION
ftp I_LOCATION/I_ORGANIZATION
site I_LOCATION/I_ORGANIZATION
. O

similarity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
the O
Vibrionaceae B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ORFs B_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
merged O
generating O
a O
redundant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
list I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
59 B_MEASURE
, O
669 B_MEASURE
proteins I_MEASURE
and O
were O
compared O
to O
all O
open B_GENE/B_PERSON
reading I_GENE/I_PERSON
frame I_GENE/I_PERSON
from O
320 B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
bacterial I_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
archeal B_SPECIES[BIO]/B_GENE
genomes I_SPECIES[BIO]/I_GENE
using O
Blastp B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

To O
determine O
the O
presence B_MEASURE/B_DISEASE
of O
an O
orthologous B_DISEASE/B_BIO
we O
used O
a O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
three B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thresholds B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
a O
similarity B_MEASURE/B_LOCATION
value I_MEASURE/I_LOCATION
equal I_MEASURE/I_LOCATION
to O
or O
higher B_MEASURE
than O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
an O
alignment B_MEASURE
length I_MEASURE
equal I_MEASURE
or O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
and O
an O
Evalue B_MEASURE
score I_MEASURE
lower I_MEASURE
than O
or O
equal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
e B_OTHER/B_MEASURE
- O
6 B_MEASURE
. O

After O
determining O
the O
presence B_LOCATION/B_DISEASE
of O
an O
orthologous B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
, O
we O
computed O
a O
similarity B_MEASURE/B_LOCATION
index I_MEASURE/I_LOCATION
I O
for O
each O
pair B_PERSON/B_LOCATION
of O
orthologous B_BIO/B_GENE
( O
a O
point B_MEASURE
of O
the O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
profile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
as O
follow O
: O

I O
= O
SqsSqq B_MEASURE
. O
min B_PERSON/B_LOCATION
( O
lq B_MEASURE/B_PROTEIN[GENE]
, O
LS B_PROTEIN[GENE]/B_DISEASE
) O
max B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
lq B_MEASURE/B_PROTEIN[GENE]
, O
LS B_PROTEIN[GENE]/B_DISEASE
) O
. O

MathType B_MEASURE
@ O
MTEF B_MEASURE/B_ORGANIZATION
@ O
5 B_MEASURE
@ O
5 B_MEASURE
@ O
+ B_MEASURE/B_OTHER
= O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY B_LOCATION/B_MEASURE
= O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 B_MEASURE/B_LOCATION
= O
OqFfea0dXdd9vqai B_LOCATION/B_MEASURE
= O
hGuQ8kuc9pgc9s8qqaq B_GENE/B_LOCATION
= O
dirpe0xb9q8qiLsFr0 B_GENE/B_MEASURE
= O
vr0 B_MEASURE/B_LOCATION
= O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGjbqscqGH9aqpdaWcaaqaaiabdofatnaaBaaaleaacqWGXbqCcqWGZbWCaeqaaaGcbaGaem4uam1aaSbaaSqaaiabdghaXjabdghaXbqabaaaaOGaeyyXIC9aaSaaaeaacyGGTbqBcqGGPbqAcqGGUbGBcqGGOaakcqWGSbaBdaWgaaWcbaGaemyCaehabeaakiabcYcaSiabdYgaSnaaBaaaleaacqWGZbWCaeqaaOGaeiykaKcabaGagiyBa0MaeiyyaeMaeiiEaGNaeiikaGIaemiBaW2aaSbaaSqaaiabdghaXbqabaGccqGGSaalcqWGSbaBdaWgaaWcbaGaem4CamhabeaakiabcMcaPaaaaaa B_MEASURE
@ O
532D B_MEASURE/B_GENE
@ O
. O

where O
lq B_PROTEIN[GENE]/B_LOCATION
and O
LS B_PROTEIN[GENE]/B_DISEASE
are O
the O
query B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
subject B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
length I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
respectively O
and O
Sqs B_PROTEIN[GENE]/B_LOCATION
is O
the O
similarity B_MEASURE/B_LOCATION
score I_MEASURE/I_LOCATION
between O
the O
query B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
the O
subject B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Sqs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
defined O
as O
follow O
: O

Sqs B_PROTEIN[GENE]/B_MEASURE
= O
sum B_MEASURE/B_PROTEIN[GENE]
i O
= O
1M B_MEASURE/B_LOCATION
alpha I_MEASURE/I_LOCATION
Aqi I_MEASURE/I_LOCATION
, O
Asi B_LOCATION/B_PROTEIN[GENE]
+ I_LOCATION/I_PROTEIN[GENE]
GP I_LOCATION/I_PROTEIN[GENE]
. O

MathType B_MEASURE
@ O
MTEF B_MEASURE/B_ORGANIZATION
@ O
5 B_MEASURE
@ O
5 B_MEASURE
@ O
+ B_MEASURE/B_OTHER
= O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY B_LOCATION/B_MEASURE
= O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 B_MEASURE/B_LOCATION
= O
OqFfea0dXdd9vqai B_LOCATION/B_MEASURE
= O
hGuQ8kuc9pgc9s8qqaq B_GENE/B_LOCATION
= O
dirpe0xb9q8qiLsFr0 B_MEASURE/B_GENE
= O
vr0 B_MEASURE/B_LOCATION
= O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGtbWudaWgaaWcbaGaemyCaeNaem4Camhabeaakiabg2da9maaqahabaacciGae8xSde2aaSbaaSqaaiabdgeabjabdghaXjabdMgaPjabcYcaSiabdgeabjabdohaZjabdMgaPbqabaaabaGaemyAaKMaeyypa0JaeGymaedabaGaemyta0eaniabggHiLdGccqGHRaWkcqWGhbWrcqWGqbauaaa B_MEASURE
@ O
4620 B_MEASURE
@ O
. O

where O
M B_PROTEIN[GENE]
is O
the O
match B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
between O
the O
query B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
subject B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
; O
Aqi B_PERSON/B_LOCATION
and O
Asi B_SPECIES[BIO]/B_LOCATION
respectively O
the O
query B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
subject B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
amino I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acid I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
position B_LOCATION/B_MEASURE
i O
; O
alpha O
the O
BLOSUM B_MEASURE
substitution I_MEASURE
matrix I_MEASURE
value I_MEASURE
for O
amino B_LOCATION/B_PERSON
acid I_LOCATION/I_PERSON
pair I_LOCATION/I_PERSON
Aqi I_LOCATION/I_PERSON
, O
Asi B_PERSON/B_LOCATION
and O
GP B_PROTEIN[GENE]/B_LOCATION
the O
gap B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
penalty I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

GP B_DISEASE
is O
defined O
as O
follow O
: O

GP B_LOCATION
= O
GOP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
+ O
GEP B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
k B_MEASURE/B_OTHER
- O
1 B_MEASURE/B_LOCATION
) O
. O

where O
GOP B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
is O
the O
GAP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Penalty B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
set O
to O
- O
11 B_NUMBER[MEASURE]
, O
GEP B_MEASURE/B_ORGANIZATION
the O
Gap B_MEASURE/B_PERSON
Extension I_MEASURE/I_PERSON
penalty I_MEASURE/I_PERSON
set O
to O
- O
1 B_MEASURE
and O
k B_OTHER/B_MEASURE
the O
gap B_MEASURE/B_PERSON
length I_MEASURE/I_PERSON
. O

Sqq B_MEASURE/B_GENE
represents O
the O
score B_MEASURE/B_LOCATION
of O
the O
self B_PERSON/B_LOCATION
- O
aligned O
query B_PERSON/B_LOCATION
sequence I_PERSON/I_LOCATION
. O

Sqs B_GENE/B_LOCATION
is O
always O
smaller B_MEASURE
than O
Sqq B_MEASURE/B_LOCATION
and O
the O
score B_MEASURE
S I_MEASURE
range I_MEASURE
between O
0 B_NUMBER[MEASURE]
and O
1 B_NUMBER[MEASURE]
. O

In O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
take O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
also O
the O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lengths B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
we O
multiplied O
the O
score B_MEASURE
S I_MEASURE
by O
the O
ratio B_MEASURE/B_PERSON
between O
the O
minimum B_MEASURE
length I_MEASURE
between O
query B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
subject B_PERSON
and O
the O
maximum B_MEASURE
length I_MEASURE
between O
query B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
subjects B_PERSON
. O

In O
this O
way B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
total B_MEASURE
score I_MEASURE
is O
weighted O
on O
the O
base B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
length B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
resulting O
in O
a O
lower B_MEASURE/B_PERSON
similarity I_MEASURE/I_PERSON
value I_MEASURE/I_PERSON
if O
the O
lengths B_MEASURE/B_LOCATION
of O
the O
sequences B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
different B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
phylogenetic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
each O
ORF B_BIO/B_GENE
is O
an O
array B_LOCATION/B_MEASURE
of O
index B_MEASURE/B_GENE
I O
with O
length B_MEASURE/B_PERSON
equal I_MEASURE/I_PERSON
to O
the O
number B_MEASURE/B_LOCATION
of O
genomes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O
( O
320 B_MEASURE/B_LOCATION
) O
. O

ORFs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clustering I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
redundant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
list I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
59 B_MEASURE
, O
669 B_MEASURE
Vibrionaceae I_MEASURE
ORFs I_MEASURE
contained O
multiple B_NUMBER[MEASURE]
copies I_NUMBER[MEASURE]
of O
the O
same B_PERSON/B_BIO
genes I_PERSON/I_BIO
due O
to O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
conserved O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
considered O
genomes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
order B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
reduce O
the O
redundancy B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
clustered O
proteins B_LOCATION/B_GENE
using O
a O
two B_NUMBER[MEASURE]
- O
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
based O
on O
COG B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Othologous B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
Genes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) O
annotation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

COG B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classifies O
conserved B_BIO/B_GENE
genes I_BIO/I_GENE
according O
to O
their O
homologous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relationships I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

All O
the O
Vibrionaceae B_BIO/B_GENE
ORFs B_BIO/I_GENE
were O
annotated O
using O
COG B_ORGANIZATION/B_BIO
clusters I_ORGANIZATION/I_BIO
and O
proteins B_BIO/B_DISEASE
sharing O
the O
same B_LOCATION/B_GENE
COG I_LOCATION/I_GENE
code I_LOCATION/I_GENE
were O
considered O
belonging O
to O
the O
same B_PERSON/B_LOCATION
cluster I_PERSON/I_LOCATION
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
annotation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
consists O
of O
a O
similarity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
all O
the O
ORFs B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
the O
COG B_GENE/B_BIO
proteins I_GENE/I_BIO
using O
blast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
considering O
the O
best B_PERSON/B_MEASURE
hit O
for O
each O
protein B_GENE/B_BACTERIUM[BIO]
. O

43 O
, O
024 B_MEASURE
ORFs I_MEASURE
presented O
a O
similarity B_MEASURE/B_LOCATION
with O
a O
COG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
entry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
producing O
2 B_MEASURE
, O
463 B_MEASURE
different I_MEASURE
clusters I_MEASURE
. O

In O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
remaining O
16 B_MEASURE
, O
645 B_MEASURE/B_LOCATION
ORFs I_MEASURE/I_LOCATION
without O
similarity B_MEASURE/B_LOCATION
with O
any O
COG B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
entry I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
clustered O
using O
CD B_LOCATION/B_DISEASE
- O
HIT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
26 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

CD B_DISEASE/B_PROTEIN[GENE]
- O
HIT B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program B_LOCATION/B_PERSON
clusters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
protein I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
identity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
threshold B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
efficiently O
removes O
high B_DISEASE_ADJECTIVE[DISEASE]
sequence I_DISEASE_ADJECTIVE[DISEASE]
redundancy I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
clustering I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
produced O
9 B_MEASURE
, O
613 B_MEASURE
different I_MEASURE
groups I_MEASURE
of O
similar B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Finally O
from O
the O
12 B_MEASURE
, O
076 B_MEASURE
total I_MEASURE
clusters I_MEASURE
obtained O
by O
this O
methodology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
those O
composed O
by O
ORFs B_GENE/B_LOCATION
that O
do O
not O
have O
any O
ortologous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
with O
a O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
composed O
by O
an O
array B_LOCATION/B_GENE
with O
all O
zero B_GENE/B_LOCATION
values I_GENE/I_LOCATION
except O
for O
one B_MEASURE/B_PERSON
position I_MEASURE/I_PERSON
match I_MEASURE/I_PERSON
with O
itself O
) O
were O
eliminated O
, O
resulting O
in O
a O
dataset B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
composed O
by O
8 B_MEASURE
, O
239 B_MEASURE
distinct I_MEASURE
clusters I_MEASURE
. O

The O
final B_MEASURE/B_LOCATION
phylogenetic I_MEASURE/I_LOCATION
profile I_MEASURE/I_LOCATION
for O
each O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
meta B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
profile B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
defined O
as O
the O
median B_MEASURE
of O
all O
the O
profiles B_LOCATION/B_BIO
belonging O
to O
the O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
the O
end B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
these O
procedures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phylogenetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
matrix I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
composed O
by O
8 B_NUMBER[MEASURE]
, O
239 B_MEASURE/B_LOCATION
rows I_MEASURE/I_LOCATION
( O
cluster B_LOCATION/B_MEASURE
of O
genes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
320 B_LOCATION/B_ORGANIZATION
columns I_LOCATION/I_ORGANIZATION
( O
organisms B_BIO/B_GENE
) O
. O

In O
each O
cell B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
the O
median B_MEASURE
of O
the O
index B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reported O
. O

Cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
clustering I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
techniques I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
been O
used O
to O
identify O
the O
similarity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
underneath O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

A O
k B_OTHER/B_MEASURE
- O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
a O
two B_NUMBER[MEASURE]
- O
way B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
Euclidean B_MEASURE
distance I_MEASURE
and O
complete B_MEASURE/B_LOCATION
linkage I_MEASURE/I_LOCATION
were O
performed O
on O
the O
phylogenetic B_LOCATION
matrix I_LOCATION
. O

The O
goal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O
a O
cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
to O
partition O
the O
elements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
into O
subsets B_LOCATION/B_PERSON
without O
any O
constrains B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
a O
priori B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
so O
that O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
satisfied O
: O
homogeneity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
elements B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inside O
a O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
highly O
similar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
each O
other B_NUMBER[MEASURE]/B_PERSON
; O
and O
separation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
elements B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
different B_LOCATION/B_PERSON
clusters I_LOCATION/I_PERSON
have O
low B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
similarity I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
to O
each O
other B_NUMBER[MEASURE]/B_PERSON
. O

The O
Figure B_PERSON/B_MEASURE
of O
merit B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
FOM B_LOCATION/B_ORGANIZATION
) O
is O
a O
measure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fit B_MEASURE
of O
the O
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patterns I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
clusters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produced O
by O
a O
particular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
estimates O
the O
predictive B_MEASURE
power I_MEASURE
of O
a O
clustering B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

It O
is O
computed O
by O
removing O
each O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
turn B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
set I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
clustering O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
based O
on O
the O
remaining O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
calculating O
the O
fit B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
withheld O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
the O
clustering B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
obtained O
from O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

On O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
FOM I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
identified O
the O
best B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
k B_MEASURE/B_OTHER
- O
means B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clusters I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O
10 B_NUMBER[MEASURE]
and O
15 B_MEASURE
. O

We O
decided O
to O
set O
k B_MEASURE
( O
in O
the O
k B_MEASURE/B_OTHER
- O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
equal B_MEASURE/B_PERSON
to O
14 B_NUMBER[MEASURE]/B_LOCATION
. O

In O
each O
of O
these O
14 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
clusters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
subsequent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
hierarchical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cluster I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
performed O
with O
bootstrap B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cluster I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessment I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

All O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
with O
TMEV B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
[ O
27 B_MEASURE
] I_MEASURE
, O
freely O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
[ B_MEASURE/B_LOCATION
28 B_MEASURE/I_LOCATION
] B_MEASURE/I_LOCATION
. O

enrichment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
categories I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Each O
cluster B_LOCATION/B_MEASURE
of O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O
been O
annotated O
according O
to O
COG B_LOCATION/B_ORGANIZATION
code I_LOCATION/I_ORGANIZATION
, O
GO O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
KEGG B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maps I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Class B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
enrichment B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
with O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
entire B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
has O
been O
calculated O
according O
to O
the O
hypergeometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distribution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
was O
used O
to O
obtain O
the O
chance B_PERSON/B_MEASURE
probability B_PERSON/I_MEASURE
of O
observing O
the O
number B_MEASURE/B_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
annotated O
with O
a O
particular B_LOCATION
COG I_LOCATION
, O
GO O
and O
KEGG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
category B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
among O
the O
selected B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cluster I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
probability B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
observing O
at O
least O
k B_MEASURE/B_LOCATION
genes B_MEASURE/I_LOCATION
of O
a O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
category I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
within O
a O
group B_ORGANIZATION/B_LOCATION
of O
n B_GENE/B_PERSON
genes I_GENE/I_PERSON
is O
given O
by O
: O

P B_MEASURE/B_PROTEIN[GENE]
= O
sum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
i O
= O
kn B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
fi B_LOCATION/B_MEASURE
) O
( O
g B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
FN B_DISEASE/B_LOCATION
- O
i B_DISEASE/B_MEASURE
) O
( O
gn B_MEASURE
) O
. O

MathType B_MEASURE
@ O
MTEF B_MEASURE/B_ORGANIZATION
@ O
5 B_MEASURE
@ O
5 B_MEASURE
@ O
+ B_MEASURE/B_OTHER
= O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY B_MEASURE/B_LOCATION
= O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0 B_MEASURE/B_LOCATION
= O
OqFfea0dXdd9vqai B_MEASURE/B_LOCATION
= O
hGuQ8kuc9pgc9s8qqaq B_GENE/B_LOCATION
= O
dirpe0xb9q8qiLsFr0 B_MEASURE/B_GENE
= O
vr0 B_MEASURE/B_LOCATION
= O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGqbaucqGH9aqpdaaeWbqaamaalaaabaWaaeWaaeaafaqabeGabaaabaGaemOzaygabaGaemyAaKgaaaGaayjkaiaawMcaamaabmaabaqbaeqabiqaaaqaaiabdEgaNjabgkHiTiabdAgaMbqaaiabd6gaUjabgkHiTiabdMgaPbaaaiaawIcacaGLPaaaaeaadaqadaqaauaabeqaceaaaeaacqWGNbWzaeaacqWGUbGBaaaacaGLOaGaayzkaaaaaaWcbaGaemyAaKMaeyypa0Jaem4AaSgabaGaemOBa4ganiabggHiLdaaaa B_MEASURE
@ O
47C6 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
@ O
. O

where O
f O
is O
the O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
category I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
in O
the O
matrix B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
g B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
the O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
our O
matrix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

A O
secondary B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
common I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
ribosomal B_GENE/B_LOCATION
ITS2 I_GENE/I_LOCATION
( O
internal B_GENE/B_BIO
transcribed I_GENE/I_BIO
spacer I_GENE/I_BIO
) O
of O
. O

Culexspecies B_PERSON/B_ENT
from O
diverse B_LOCATION
geographical I_LOCATION
locations I_LOCATION
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
structural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
ITS2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
the O
spacer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
segment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
between O
5 B_MEASURE
. O
8S B_MEASURE
and O
28S B_MEASURE/B_GENE
rRNA I_MEASURE/I_GENE
of O
. O

mature O
rRNA B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
) O
of O
7 B_BIO/B_PERSON
Culex I_BIO/I_PERSON
species I_BIO/I_PERSON
belonging O
to O
5 B_LOCATION
different I_LOCATION
geographical I_LOCATION
locations I_LOCATION
was O
carried O
out O
. O

alignment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
. O

ITS2 B_GENE/B_BACTERIUM[BIO]
sequence I_GENE/I_BACTERIUM[BIO]
from O
the O
7 B_BIO/B_GENE
species I_BIO/I_GENE
revealed O
8 B_MEASURE/B_GENE
homologous I_MEASURE/I_GENE
domains I_MEASURE/I_GENE
. O

Four O
species O
namely O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
vishnui I_SPECIES[BIO]
, O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
annulus I_SPECIES[BIO]/I_PERSON
, O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
pipiens I_SPECIES[BIO]
, O

C B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
quiquefasciatusshowed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
high O
sequence O
( O
98 O
- O
100 O
% O
) O
and O
RNA O
secondary O
structure O
similarity O
. O

The O
ITS2 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
similarity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
among O
different B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

species B_BIO/B_PERSON
is O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
despite O
their O
varying O
geographical B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
locations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Several B_MEASURE/B_LOCATION
common B_MEASURE/I_LOCATION
features B_MEASURE/I_LOCATION
of O
secondary B_DISEASE/B_PERSON
structure I_DISEASE/I_PERSON
are O
shared O
among O
. O

these O
species B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O
with O
some O
of O
them O
supported O
by O
compensatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
suggesting O
the O
significant B_PERSON/B_MEASURE
role I_PERSON/I_MEASURE
by O
ITS2 B_GENE/B_BACTERIUM[BIO]
as O
an O
RNA B_GENE/B_PERSON
domain I_GENE/I_PERSON
. O

during O
ribosome B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
biogenesis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Culex B_BACTERIUM[BIO]/B_PERSON
mosquito I_BACTERIUM[BIO]/I_PERSON
species I_BACTERIUM[BIO]/I_PERSON
have O
been O
described O
from O
a O
wide B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
environments B_LOCATION/B_BIO
and O
are O
involved O
in O
pathogen B_DISEASE/B_SPECIES[BIO]
transmission B_DISEASE/I_SPECIES[BIO]
from O
. O

human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
reservoirs O
and O
vice O
- O
versa O
. O

[ B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
] O
sequence B_PERSON/B_LOCATION
similarity I_PERSON/I_LOCATION
have O
been O
. O

reported O
for O
ITS2 B_GENE/B_BACTERIUM[BIO]
( O
the O
spacer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
segments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
5 B_MEASURE
. O
8S B_MEASURE
and O
28S B_MEASURE/B_GENE
rRNA I_MEASURE/I_GENE
of O
mature B_GENE/B_SPECIES[BIO]
rRNA B_GENE/I_SPECIES[BIO]
sequences B_GENE/I_SPECIES[BIO]
) O
from O
5 B_BIO/B_PERSON
Culex I_BIO/I_PERSON
species I_BIO/I_PERSON
of O
diverse B_LOCATION/B_SPECIES[BIO]
. O

geographic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

[ O
3 B_MEASURE
- O
4 B_MEASURE
- O
. O

5 O
- O
9 B_MEASURE
- O
. O

20 O
] O
The O
Its O
spacers B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
versatile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
have O
been O
used O
for O
the O
determination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
taxonomic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

classification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

[ O
17 O
] O
Recent O
functional O
analyses O
performed O
on O
yeast B_SPECIES[BIO]
ribosomal O
. O

RNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
clearly O
show O
that O
the O
structural B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
transcribed B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
spacer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
an O
essential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prerequisite I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
correct B_TIME[MEASURE]/B_DISEASE
. O

processing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
mature B_GENE
rRNA I_GENE
and O
for O
the O
biogenesis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
active B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ribosomal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

[ B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
. O

3 O
] O
The O
derivation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
reliable B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
secondary I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
structure I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
each O
transcribed B_GENE
spacer I_GENE
. O

region B_LOCATION/B_PERSON
would O
represent O
a O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
towards O
a O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
their O
biological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
roles I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Comparative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequence I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
provides O
a O
powerful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
identifying O
biologically O
relevant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
folding I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patterns I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
RNA B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

[ O
4 O
] O
This O
involves O
collection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
sequences B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exhibiting O
substantial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
while O
retaining O
unequivocal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similarity I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
a O
high B_MEASURE
degree I_MEASURE
of O
sequence B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
variation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
transcribed B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ENT
. O

spacers B_PERSON/B_ORGANIZATION
is O
known O
even O
among O
closely O
related O
species B_BIO/B_GENE
. O

[ O
5 B_MEASURE
- O
6 B_MEASURE
- O
7 B_MEASURE
] I_MEASURE
Here O
, O
we O
analyze O
ITS2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
7 B_TIME[MEASURE]/B_LOCATION
. O

Culex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
species I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characteristic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
geographical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
locations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
to O
assemble O
common B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
structural I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
features I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

methodology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

dataset B_PERSON/B_MEASURE
. O

ITS2 B_GENE/B_BIO
nucleotide I_GENE/I_BIO
sequences O
from O
7 B_NUMBER[MEASURE]/B_LOCATION
Culex I_NUMBER[MEASURE]/I_LOCATION
mosquitoes I_NUMBER[MEASURE]/I_LOCATION
characteristic I_NUMBER[MEASURE]/I_LOCATION
of O
5 B_LOCATION/B_BIO
geographical I_LOCATION/I_BIO
locations I_LOCATION/I_BIO
( O
Italy B_LOCATION
, O
China B_LOCATION
, O
Africa B_LOCATION
, O

America B_LOCATION
, O
and O
Japan B_LOCATION
) O
were O
downloaded O
from O
GenBank B_ORGANIZATION/B_LOCATION
( O
www B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
ncbi B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
nlm B_LOCATION/B_GENE
. O
NIH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
gov B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
genbank B_LOCATION/B_ORGANIZATION
. O

) O
. O
The O
GenBank B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
accession I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
numbers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
ITS2 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

from O
C B_LOCATION/B_PERSON
. I_LOCATION/I_PERSON
pipens I_LOCATION/I_PERSON
( O
North O
America O
) O
, O
C B_LOCATION/B_PERSON
. I_LOCATION/I_PERSON
tritaeniorhynchus I_LOCATION/I_PERSON
( O
China O
) O
, O
C B_LOCATION/B_SPECIES[BIO]
. I_LOCATION/I_SPECIES[BIO]
quinquefasciatus I_LOCATION/I_SPECIES[BIO]
. O

( O
Africa O
) O
, O
C B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tarsalis I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Italy O
) O
, O
C B_PERSON/B_LOCATION
. I_PERSON/I_LOCATION
annulus I_PERSON/I_LOCATION
( O
China O
) O
, O
C B_BIO/B_LOCATION
. B_BIO/I_LOCATION
pseudovishnui B_BIO/I_LOCATION
. O

( O
China O
) O
, O
and O
C B_PERSON/B_NUMBER[MEASURE]
. B_PERSON/I_NUMBER[MEASURE]
vishnui B_PERSON/I_NUMBER[MEASURE]
( O
Japan O
) O
were O
X75817 O
, O
AF305558 O
, O
Z48468 O
, O
U33031 O
, O
AF453488 O
, O
AF453498 O
and O
AF165900 O
, O

respectively B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sequence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
alignments I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
performed O
using O
CLUSTALW B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
a O
gap B_MEASURE/B_PERSON
opening I_MEASURE/I_PERSON
penalty I_MEASURE/I_PERSON
of O
15 B_MEASURE
and O
gap B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extension B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
penalty B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
6 B_MEASURE
. O
66 B_MEASURE
. O

[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prediction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
RNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
secondary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
structures I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
ITS2 B_GENE/B_MEASURE
were O
predicted O
using O
RNADRAW B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

[ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RNADRAW B_PERSON/B_GENE
predicts O
RNA B_DISEASE_ADJECTIVE[DISEASE]
structures I_DISEASE_ADJECTIVE[DISEASE]
by O
identifying O
suboptimal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
structures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
using O
the O
free B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
energy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
optimization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
methodology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O
a O
default B_MEASURE/B_LOCATION
. O

temperature B_MEASURE/B_LOCATION
of O
370 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degrees I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
C I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
the O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
ITS2 B_GENE/B_BACTERIUM[BIO]
and O
5 B_MEASURE
. O
8S B_MEASURE
regions I_MEASURE
( O
the O
first B_GENE/B_MEASURE
170 I_GENE/I_MEASURE
nucleotides I_GENE/I_MEASURE
) O
were O
used O
for O
RNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

prediction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
minimum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
energy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
prediction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
RNADRAW B_GENE/B_BACTERIUM[BIO]
was O
ported O
from O
the O
RNAFOLD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
included O
in O
the O
. O

Vienna B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
package I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

[ O
24 O
] O
The O
dynamic B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programming I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
algorithm I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
employed O
in O
. O

RNADRAW B_PERSON/B_LOCATION
was O
based O
on O
the O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
Zuker B_PERSON
and O
Stiegler B_PERSON
[ O
25 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O
uses O
energy B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
taken O
from O
Turner B_PERSON
[ O
26 B_MEASURE
] I_MEASURE
, O
Freier B_PERSON
[ O
27 B_MEASURE
] I_MEASURE
and O
Jaeger B_PERSON
. O

[ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
28 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
phylogenetic B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Genebee I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
service I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
for O
phylogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tree I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
construction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

[ B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
22 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

] B_OTHER/B_PERSON

RNA B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fold I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Sribo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Sfold B_MEASURE
( O
Statistical B_DISEASE_ADJECTIVE[DISEASE]
folding I_DISEASE_ADJECTIVE[DISEASE]
and O
rational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O
was O
. O

used O
to O
predict O
the O
probable B_LOCATION/B_BIO
target I_LOCATION/I_BIO
accessibility I_LOCATION/I_BIO
sites I_LOCATION/I_BIO
( O
loops B_LOCATION
) O
for O
trans B_LOCATION/B_GENE
- O
cleaving O
ribozymes B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
ITS2 B_BIO
. O

[ O
24 O
] O
The O
prediction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
accessibility B_MEASURE/B_DISEASE
is O
based O
on O
a O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sample I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
Boltzmann B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

ensemble B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
secondary B_ENT/B_PERSON
structures I_ENT/I_PERSON
. O

Here O
, O
we O
assessed O
the O
likelihood B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
unpaired B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ribozyme I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
target I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Each O
mRNA B_TIME[MEASURE]/B_GENE
. O

exists O
as O
a O
population B_PERSON/B_LOCATION
of O
different B_NUMBER[MEASURE]/B_LOCATION
structures I_NUMBER[MEASURE]/I_LOCATION
. O

Hence O
, O
stochastic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
accessible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
. O

appropriate B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

[ O
29 O
] O
The O
probability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
profiling O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
Ding B_PERSON
and O
Lawrence B_PERSON
. O

[ O
30 O
] O
reveals O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sites B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
are O
commonly O
accessible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
. O

a O
large B_MEASURE/B_LOCATION
number B_MEASURE/I_LOCATION
of O
statistically O
representative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structures B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
bypasses O
the O
long B_TIME[MEASURE]/B_LOCATION
- O
standing B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
. O

difficulty B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
accessibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
limited O
representation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
probable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
due I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
high B_MEASURE/B_DISEASE
statistical B_MEASURE/I_DISEASE
confidence B_MEASURE/I_DISEASE
. O

in O
predictions B_PERSON
. O

The O
probability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
individual B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bases I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
W B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
= O
1 B_MEASURE
) O
is O
produced O
for O
the O
region B_LOCATION/B_TIME[MEASURE]
that O
. O

includes O
a O
triplet B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
two B_LOCATION/B_MEASURE
flanking I_LOCATION/I_MEASURE
sequences I_LOCATION/I_MEASURE
of O
15 B_GENE
bases I_GENE
each O
in O
every O
site B_LOCATION/B_MEASURE
of O
the O
selected O
cleavage B_GENE/B_LOCATION
triplet I_GENE/I_LOCATION
( O
e O
. O
g B_GENE/B_MEASURE
. O
, O
GUC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

ITS2 B_MEASURE/B_BIO
sequences I_MEASURE/I_BIO
showed O
a O
taxonomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trend I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
similar I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
that O
in O
phylogeny B_LOCATION/B_SPECIES[BIO]
construction B_LOCATION/I_SPECIES[BIO]
( O
Figure B_LOCATION/B_MEASURE
1A I_LOCATION/I_MEASURE
. O

) B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

of O
5 B_MEASURE
. O
8S B_MEASURE/B_GENE
rDNA I_MEASURE/I_GENE
and O
ITS2 B_GENE/B_BACTERIUM[BIO]
showed O
in O
Figure B_MEASURE/B_PERSON
1B I_MEASURE/I_PERSON
indicated O
that O
more O
distantly O
related O
species B_BIO/B_PERSON
have O
. O

lower B_MEASURE/B_LOCATION
sequence B_MEASURE/I_LOCATION
similarity B_MEASURE/I_LOCATION
in O
the O
. O

ITS2 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
region I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
predicted B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
ITS2 B_GENE/B_BACTERIUM[BIO]
using O
RNADRAW B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
are O
given O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
stems B_BIO/B_PERSON
. O

( O
double B_NUMBER[MEASURE]
stranded O
paired O
regions B_GENE/B_DISEASE
) O
. O

stabilize O
RNA B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
secondary B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
structures B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
number B_MEASURE/B_LOCATION
of O
stems B_PERSON/B_GENE
present B_PERSON/I_GENE
in O
each O
ITS2 B_GENE/B_BACTERIUM[BIO]
is O
given O
( O
Table B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
) O
. O

ITS2 B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
. O

C B_SPECIES[BIO]/B_DISEASE
. I_SPECIES[BIO]/I_DISEASE
pipiens I_SPECIES[BIO]/I_DISEASE
and O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
quinquefasciatus I_SPECIES[BIO]/I_PERSON
have O
the O
highest O
negative O
free O
energy O
( O
- O
149 O
. O
38 O
Kcal O
and O
. O

- O
148 O
. O
23 O
Kcal O
) O
followed O
by O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
tarsalis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
- O
129 O
. O
2 O
) O
, O
C B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
annulus I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
then O
by O
C B_LOCATION/B_BIO
. I_LOCATION/I_BIO
vishnui I_LOCATION/I_BIO
. O

( O
- O
115 O
. O
3 O
) O
, O
C B_BACTERIUM[BIO]/B_LOCATION
. I_BACTERIUM[BIO]/I_LOCATION
pseudovishnui I_BACTERIUM[BIO]/I_LOCATION
( O
- O
105 O
. O
66 O
) O
and O
C B_BACTERIUM[BIO]
. I_BACTERIUM[BIO]
tritaeniorhyncus I_BACTERIUM[BIO]
( O
- O
82 O
. O
57 O
) O
. O

Visual B_NUMBER[MEASURE]/B_ENT
comparison I_NUMBER[MEASURE]/I_ENT
shows O
. O

that O
this O
is O
related O
to O
the O
trend B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cladogram B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
given O
in O
Figure B_LOCATION/B_MEASURE
1A B_LOCATION/I_MEASURE
. O

A O
high B_MEASURE
degree I_MEASURE
of O
sequence B_MEASURE/B_DISEASE
similarity I_MEASURE/I_DISEASE
is O
observed O
at O
the O
. O

5 B_MEASURE
' O
end B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
the O
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
( O
Figure B_LOCATION/B_MEASURE
1A I_LOCATION/I_MEASURE
) O
. O

This O
is O
due O
to O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
genetic B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
drift I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
relative B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
and O
size B_MEASURE/B_LOCATION
of O
repeats B_TIME[MEASURE]/B_GENE
, O

rates B_MEASURE/B_LOCATION
of O
unequal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crossover I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conversion B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
immigration B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
number B_MEASURE/B_LOCATION
of O
the O
loci B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influencing O
the O
length B_MEASURE/B_DISEASE
. O

[ B_MEASURE
10 I_MEASURE
] O
Furthermore O
, O
a O
high B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sequence B_MEASURE
similarity I_MEASURE
is O
found O
between O
C B_OTHER/B_GENE
. O

annulus O
and O
C B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
vishnui I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
as O
well O
as O
C B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
quinquefasciatus B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
and O
C B_DISEASE/B_LOCATION
. B_DISEASE/I_LOCATION
. O

pipiens B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

The O
simple B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tandem I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
repeats I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shown O
in O
Figure B_LOCATION/B_COLOR
1B B_LOCATION/I_COLOR
as O
bolded B_TIME[MEASURE]/B_LOCATION
regions I_TIME[MEASURE]/I_LOCATION
are O
found O
to O
be O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
similarity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
seen O
in O
corresponding O
. O

RNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
computed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
energies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Culex B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species B_BIO/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
then O
grouped O
into O
three B_LOCATION/B_MEASURE
classes I_LOCATION/I_MEASURE
based O
on O
the O
similarity B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
. O

RNA B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
stems O
and O
loops B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Despite O
their O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
geographic I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locations I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
varying O
Eco B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
climatic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
class B_LOCATION/B_MEASURE
I I_LOCATION/I_MEASURE
. O

( O
C B_LOCATION
. I_LOCATION
annulus I_LOCATION
, O
C B_BACTERIUM[BIO]/B_LOCATION
. B_BACTERIUM[BIO]/I_LOCATION
pseudovishnui B_BACTERIUM[BIO]/I_LOCATION
and O
C B_BACTERIUM[BIO]/B_LOCATION
. I_BACTERIUM[BIO]/I_LOCATION
vishnui I_BACTERIUM[BIO]/I_LOCATION
) O
isolates O
( O
China O
and O
Japan O
) O
showed O
high O
similarity O
. O

in O
secondary B_PERSON
structural I_PERSON
features I_PERSON
. O

Similar O
observations O
were O
seen O
in O
class O
II O
( O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
pipiens I_SPECIES[BIO]
, O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
quinquefasciatus I_SPECIES[BIO]
and O
. O

C B_MEASURE/B_PERSON
. I_MEASURE/I_PERSON
tarsalis I_MEASURE/I_PERSON
) O
isolates O
from O
North O
America O
and O
Africa O
. O

[ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
19 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
high B_MEASURE/B_LOCATION
degree B_MEASURE/I_LOCATION
of O
similarity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
5 B_MEASURE
. O
8S B_MEASURE
region I_MEASURE
unlike O
the O
ITS2 B_NUMBER[MEASURE]/B_LOCATION
is O
shown O
for O
different B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolates I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
relative B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
evolutionary I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

selection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

[ O
9 B_TIME[MEASURE]
] O
The O
loops B_SEQUENCE[MEASURE]/B_LOCATION
11 I_SEQUENCE[MEASURE]/I_LOCATION
and O
12 B_NUMBER[MEASURE]
having O
sequences B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
UGUCG I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
CUUCGGUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O

respectively O
are O
highly O
conserved O
in O
all O
classes B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

figure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1c I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
shows O
the O
distribution B_ORGANIZATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
types B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
loops B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
hairpin B_LOCATION/B_MEASURE
, O
bulge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
multi B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
branched O
, O
interior B_LOCATION/B_MEASURE
and O
exterior B_LOCATION
) O
among O
. O

different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolates I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
segments B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
ITS2 B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
having O
score B_MEASURE/B_PERSON
>= B_MEASURE/I_PERSON
50 B_MEASURE/I_PERSON
are O
further O
probed O
carefully O
for O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
site I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
assess O
the O
. O

likelihood B_MEASURE/B_PERSON
of O
unpaired B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
segments I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Interestingly O
, O
the O
observed B_PERSON
phylogenetic I_PERSON
trend I_PERSON
was O
identified O
with O
respect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
target B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

accessibility B_MEASURE/B_LOCATION
sites I_MEASURE/I_LOCATION
for O
the O
seven B_LOCATION/B_ORGANIZATION
Culex I_LOCATION/I_ORGANIZATION
isolates I_LOCATION/I_ORGANIZATION
. O

The O
order B_LOCATION/B_DISEASE
of O
preference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
interior B_MEASURE
loop I_MEASURE
, O
bulge B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
loop B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
multiple B_MEASURE/B_DISEASE
. O

branched O
loop B_LOCATION/B_BIO
, O
hairpin B_LOCATION
loop I_LOCATION
and O
exterior B_LOCATION/B_BIO
loops I_LOCATION/I_BIO
in O
all O
the O
isolates B_BIO/B_LOCATION
. O

Several B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
homologous I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
domains I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
in O
the O
Its O
regions B_GENE/B_DISEASE
of O
Aedes B_BIO/B_GENE
mosquito B_BIO/I_GENE
species B_BIO/I_GENE
by O
Wesson B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

et B_MEASURE/B_LOCATION
al I_MEASURE/I_LOCATION
[ O
11 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
was O
shown O
that O
these O
domains B_MEASURE/B_GENE
base I_MEASURE/I_GENE
pair I_MEASURE/I_GENE
to O
. O

form O
a O
core B_LOCATION
region I_LOCATION
central I_LOCATION
to O
. O

several B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stem I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
features I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

This O
suggested O
that O
conserved O
core B_LOCATION/B_PERSON
region I_LOCATION/I_PERSON
of O
rDNA B_GENE/B_BIO
is O
more O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
rRNA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
folding B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

pattern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Barker O
found O
that O
ITS2 O
is O
unique O
in O
the O
16 O
populations O
of O
Boophilus B_SPECIES[BIO]
microplus I_SPECIES[BIO]
, O
Boophilus B_SPECIES[BIO]/B_LOCATION
decoloratus B_SPECIES[BIO]/I_LOCATION
, O

Rhipicephalus B_BIO/B_PERSON
appendiculatus I_BIO/I_PERSON
, O
Rhipicephalus B_SPECIES[BIO]/B_PERSON
zambesiensis I_SPECIES[BIO]/I_PERSON
, O
Rhipicephalus B_SPECIES[BIO]
evertsi I_SPECIES[BIO]
, O
Rhipicephalus B_SPECIES[BIO]/B_PERSON
sanguineus I_SPECIES[BIO]/I_PERSON
, O
Rhipicephalus O
. O

turanicus O
, O
Rhipicephalus B_SPECIES[BIO]/B_LOCATION
pumilio I_SPECIES[BIO]/I_LOCATION
and O
Rhipicephalus B_SPECIES[BIO]/B_PERSON
camicasi I_SPECIES[BIO]/I_PERSON
from O
different O
geographical O
locations O
. O

[ O
12 O
] O
These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggest O
that O
the O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
similarity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
. O

in O
the O
ITS2 B_GENE/B_MEASURE
of O
different B_SPECIES[BIO]
species I_SPECIES[BIO]
are O
not O
simply O
accumulated O
due O
to O
random B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
have O
evolved O
for O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
selection B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

in O
ribosome B_PERSON
biogenesis I_PERSON
. O

However O
, O
it O
was O
shown O
in O
three O
related O
mosquito O
genera O
( O
Aedes O
, O
Psorophora O
and O
Haemogogus B_PERSON/B_SPECIES[BIO]
) O
. O

that O
the O
intra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
spacer B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
variable I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
regions I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
appear O
to O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
evolve O
and O
that O
ITS2 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
variation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
is O
constrained O
by O
its O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

[ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
11 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Further I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
demonstrated O
that O
the O
ITS2 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

for O
the O
correct B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
efficient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
processing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
maturation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
26S B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribosomal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
units I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

[ B_OTHER/B_PERSON

13 O
] O
Furthermore O
, O
the O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
required O
for O
the O
efficient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
removal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ITS2 B_GENE/B_BACTERIUM[BIO]
from O
its O
RNA B_LOCATION/B_PERSON
precursor I_LOCATION/I_PERSON
is O
not O
. O

localized O
but O
dispersed O
throughout O
the O
ITS2 B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Thus O
, O
insertions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
and O
deletions B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
indels B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
that O
affect O
secondary B_DISEASE/B_GENE
structures I_DISEASE/I_GENE
. O

alter O
rRNA B_DISEASE_ADJECTIVE[DISEASE]
processing I_DISEASE_ADJECTIVE[DISEASE]
. O

Critical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
rRNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
folding B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
due O
to O
evolutionary B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
sequence I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
variation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
the O
Its O
spacer B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

regions B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
thus O
have O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
kinetics B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
precursor B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
rRNA B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
formation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
for O
the O
efficient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
functioning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
rDNA B_GENE/B_BIO
clusters I_GENE/I_BIO
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ITS2 B_GENE/B_BIO
sequences I_BIO
from O
different B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
isolates I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O
Culex B_BACTERIUM[BIO]
show O
similarity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
variations B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

surprisingly O
, O
species B_BIO/B_DISEASE
displaying O
. O

sequence B_PERSON/B_LOCATION
similarity I_PERSON/I_LOCATION
belong O
to O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
geographical I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
locations I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O
diverse B_LOCATION/B_EDU[ORGANIZATION]
climatic B_LOCATION/I_EDU[ORGANIZATION]
and O
ecological B_LOCATION/B_MEASURE
conditions I_LOCATION/I_MEASURE
. O

This B_LOCATION/B_PERSON
implies O
that O
. O

the O
ITS2 B_GENE/B_BIO
regions I_GENE/I_BIO
have O
less O
selective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
than O
the O
ribosomal B_MEASURE/B_LOCATION
regions I_MEASURE/I_LOCATION
. O

Several B_PERSON/B_ENT
common I_PERSON/I_ENT
structural I_PERSON/I_ENT
folds I_PERSON/I_ENT
were O
shared O
among O
the O
. O

selected O
mosquitoes B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
maintaining O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
equivalents I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

construction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
an O
evolutionary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
tree I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
using O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isolates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
. O

Culex B_BIO/B_PERSON
will O
provide O
an O
understanding B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
their O
functional B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
selection I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

integration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
in O
primary B_LOCATION/B_ORGANIZATION
community I_LOCATION/I_ORGANIZATION
care I_LOCATION/I_ORGANIZATION
networks I_LOCATION/I_ORGANIZATION
( O
PCCNs B_DISEASE/B_GENE
) O
: O
examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
governance B_EDU[ORGANIZATION]/B_PERSON
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
marketing B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
financial B_ORGANIZATION/B_PERSON
, O
and O
information B_ORGANIZATION/B_PERSON
infrastructures I_ORGANIZATION/I_PERSON
in O
a O
national B_LOCATION/B_ORGANIZATION
demonstration I_LOCATION/I_ORGANIZATION
project I_LOCATION/I_ORGANIZATION
in O
Taiwan B_LOCATION
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Taiwan O
' O
s O
primary O
community O
care O
network O
( O
PCCN O
) O
demonstration O
project O
, O
funded O
by O
the O
Bureau O
of O
National O
Health O
Insurance O
on O
March O
2003 O
, O
was O
established O
to O
discourage O
hospital O
shopping O
behavior O
of O
people B_PERSON/B_LOCATION
and O
drive O
the O
traditional O
fragmented O
health O
care O
providers O
into O
cooperate O
care O
models O
. O

Between O
2003 B_MEASURE
and O
2005 B_MEASURE
, O
268 B_NUMBER[MEASURE]/B_LOCATION
PCCNs I_NUMBER[MEASURE]/I_LOCATION
were O
established O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
profiled O
the O
individual B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
PCCNs B_ORGANIZATION/B_LOCATION
to O
study O
the O
nature B_MEASURE/B_LOCATION
and O
extent B_MEASURE
to O
which O
their O
network B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructures I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
integrated O
among O
the O
members B_PERSON/B_LOCATION
( O
clinics B_LOCATION/B_ORGANIZATION
and O
hospitals B_LOCATION/B_ORGANIZATION
) O
within O
individual B_LOCATION/B_ORGANIZATION
PCCNs I_LOCATION/I_ORGANIZATION
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
thorough B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
questionnaire I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
items I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
covering O
the O
network B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
working O
infrastructures B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O
governance B_ORGANIZATION/B_PERSON
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
marketing B_ORGANIZATION/B_SOCIAL_CIRCUMSTANCES
, O
financial B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
information B_ORGANIZATION
integration I_ORGANIZATION
in O
PCCNs B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
were O
developed O
with O
validity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
reliability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
confirmed O
. O

One B_NUMBER[MEASURE]/B_ENT
thousand I_NUMBER[MEASURE]/I_ENT
five I_NUMBER[MEASURE]/I_ENT
hundred I_NUMBER[MEASURE]/I_ENT
and O
fifty B_NUMBER[MEASURE]
- O
seven B_NUMBER[MEASURE]/B_PERSON
clinics I_NUMBER[MEASURE]/I_PERSON
that O
had O
belonged O
to O
PCCNs B_LOCATION/B_PERSON
for O
more B_MEASURE/B_PERSON
than O
one B_TIME[MEASURE]
year I_TIME[MEASURE]
, O
based O
on O
the O
2003 B_MEASURE/B_LOCATION
- O
2005 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Taiwan I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Primary I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Community I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
list I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
were O
surveyed O
by O
mail B_TIME[MEASURE]/B_PERSON
. O

Nine B_NUMBER[MEASURE]/B_LOCATION
hundred I_NUMBER[MEASURE]/I_LOCATION
and O
twenty B_NUMBER[MEASURE]
- O
eight B_NUMBER[MEASURE]/B_ORGANIZATION
clinic I_NUMBER[MEASURE]/I_ORGANIZATION
members I_NUMBER[MEASURE]/I_ORGANIZATION
responded O
to O
the O
surveys B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
giving O
a O
59 B_MEASURE
. O
6 B_MEASURE
% I_MEASURE
response I_MEASURE
rate I_MEASURE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Overall O
, O
the O
PCCNs B_ORGANIZATION/B_PERSON
' I_ORGANIZATION/I_PERSON
members I_ORGANIZATION/I_PERSON
had O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
involvement I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
the O
governance B_ORGANIZATION/B_LOCATION
infrastructure B_ORGANIZATION/I_LOCATION
, O
which O
was O
usually O
viewed O
as O
the O
most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
establishment B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
core B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
PCCNs B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organization I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
management B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
the O
early B_TIME[MEASURE]/B_LOCATION
integration I_TIME[MEASURE]/I_LOCATION
stage I_TIME[MEASURE]/I_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
it O
found O
that O
there O
existed O
a O
higher B_MEASURE
extent I_MEASURE
of O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
marketing B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
information B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructures I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
the O
hospital B_LOCATION/B_PERSON
- O
clinic B_PERSON/B_LOCATION
member I_PERSON/I_LOCATION
relationship I_PERSON/I_LOCATION
than O
those O
among O
clinic B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
within O
individual B_LOCATION/B_ORGANIZATION
PCCNs I_LOCATION/I_ORGANIZATION
. O

The O
financial B_LOCATION/B_ORGANIZATION
infrastructure I_LOCATION/I_ORGANIZATION
was O
shown O
the O
least B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrated O
relative B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
other B_ORGANIZATION/B_PERSON
functional I_ORGANIZATION/I_PERSON
infrastructures I_ORGANIZATION/I_PERSON
at O
the O
early B_TIME[MEASURE]/B_LOCATION
stage I_TIME[MEASURE]/I_LOCATION
of O
PCCN B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

There O
was O
still O
room B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
better B_DISEASE_ADJECTIVE[DISEASE]
integrated O
partnerships B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
evidenced O
by O
the O
great B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
variety I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
of O
relationships B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
extent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
provide O
how O
the O
network B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
have O
done O
for O
their O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
at O
the O
early B_TIME[MEASURE]/B_LOCATION
stage I_TIME[MEASURE]/I_LOCATION
of O
network B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forming O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
detailed B_NUMBER[MEASURE]/B_LOCATION
surveyed O
items B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
, O
the O
concepts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
proposed O
by O
the O
managerial B_PERSON
and O
theoretical B_PERSON/B_ORGANIZATION
professionals I_PERSON/I_ORGANIZATION
, O
could O
be O
a O
guide B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
those O
health B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
providers I_PERSON/I_ORGANIZATION
who O
have O
willingness B_PERSON
to O
turn O
their O
business B_ORGANIZATION/B_PERSON
into O
multi B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
organizations B_ORGANIZATION/B_PERSON
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Taiwan B_LOCATION/B_PERSON
' I_LOCATION/I_PERSON
s I_LOCATION/I_PERSON
National I_LOCATION/I_PERSON
Health I_LOCATION/I_PERSON
Insurance I_LOCATION/I_PERSON
( O
NHI B_LOCATION/B_ORGANIZATION
) O
under O
the O
control B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
Bureau B_ORGANIZATION/B_PERSON
of O
National B_ORGANIZATION/B_LOCATION
Health I_ORGANIZATION/I_LOCATION
Insurance I_ORGANIZATION/I_LOCATION
( O
BNHI B_ORGANIZATION/B_LOCATION
) O
, O
was O
launched O
in O
March B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1995 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
replace O
its O
social B_PERSON/B_ORGANIZATION
insurance I_PERSON/I_ORGANIZATION
system I_PERSON/I_ORGANIZATION
that O
was O
covering O
59 B_PERSON/B_MEASURE
% I_PERSON/I_MEASURE
of O
its O
population B_PERSON/B_LOCATION
: O
government B_PERSON
employees I_PERSON
, O
labourers B_PERSON/B_ORGANIZATION
, O
farmers B_PERSON
and O
servicemen B_PERSON
[ O
1 B_LOCATION/B_MEASURE
] B_LOCATION/I_MEASURE
. O

By O
June O
2003 O
the O
number O
of O
people B_PERSON
insured O
had O
reached O
21 O
, O
956 O
, O
729 O
( O
99 O
% O
) O
. O

There O
were O
17 B_MEASURE
, O
259 B_MEASURE
medical I_MEASURE
providers I_MEASURE
( O
92 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
including O
575 B_LOCATION/B_PERSON
hospitals B_LOCATION/I_PERSON
and O
16 B_MEASURE
, O
684 B_TIME[MEASURE]
clinics I_TIME[MEASURE]
contracted O
with O
the O
BNHI B_LOCATION/B_ORGANIZATION
for O
serving O
the O
enrolled B_LOCATION/B_PERSON
population I_LOCATION/I_PERSON
. O

The O
unique O
phenomenon O
characterized O
in O
Taiwan O
health O
care O
industry O
different O
from O
those O
in O
the O
western O
countries O
is O
the O
freedom O
of O
patients B_PERSON
to O
choose O
the O
health O
care O
providers O
they O
want O
, O
no O
matter O
what O
their O
disease O
severity O
is O
. O

Furthermore O
, O
Taiwan O
people B_PERSON/B_LOCATION
favor O
the O
larger O
scales O
of O
facilities O
and O
this O
fallacy O
leads O
to O
the O
phenomenon O
of O
big O
- O
hospital O
shopping O
. O

For O
example O
, O
people B_PERSON/B_LOCATION
choose O
the O
medical O
centers O
which O
are O
accredited O
as O
the O
highest O
level O
of O
medical O
science O
in O
Taiwan O
when O
they O
only O
suffer O
from O
a O
common O
cold O
. O

In O
the O
spring O
of O
2003 O
, O
the O
SARS O
epidemic O
viciously O
attacked O
the O
health O
of O
Taiwan O
' O
s O
people B_PERSON/B_ORGANIZATION
. O

The O
people B_PERSON/B_LOCATION
' O
s O
freedom O
to O
choose O
medical O
providers O
caused O
the O
national O
health O
authority O
to O
barely O
control O
and O
traced O
the O
flow O
of O
epidemic O
. O

This O
event B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
made O
Taiwan B_PERSON
national I_PERSON
health I_PERSON
authorities I_PERSON
rethink O
what O
happened O
and O
how O
it O
damaged O
under O
the O
traditional B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fragmented I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
health I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
care I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
providers I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
Taiwan B_LOCATION
. O

One B_TIME[MEASURE]/B_ORGANIZATION
health I_TIME[MEASURE]/I_ORGANIZATION
reform I_TIME[MEASURE]/I_ORGANIZATION
launched O
was O
named O
the O
' O
Primary B_LOCATION/B_PERSON
Community I_LOCATION/I_PERSON
Care I_LOCATION/I_PERSON
Network I_LOCATION/I_PERSON
( O
PCCN B_DISEASE/B_ORGANIZATION
) O
demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
' O
, O
a O
nationwide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
financing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
funded O
by O
the O
Bureau B_ORGANIZATION/B_PERSON
of O
National B_LOCATION/B_ORGANIZATION
Health I_LOCATION/I_ORGANIZATION
Insurance I_LOCATION/I_ORGANIZATION
( O
BNHI B_ORGANIZATION/B_LOCATION
) O
in O
March B_TIME[MEASURE]/B_LOCATION
2003 I_TIME[MEASURE]/I_LOCATION
and O
it O
was O
a O
new B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
the O
Taiwan B_ORGANIZATION/B_LOCATION
government I_ORGANIZATION/I_LOCATION
to O
redefine O
the O
role B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
family B_PERSON/B_ORGANIZATION
physicians I_PERSON/I_ORGANIZATION
in O
the O
health B_LOCATION/B_ORGANIZATION
care I_LOCATION/I_ORGANIZATION
delivery I_LOCATION/I_ORGANIZATION
system I_LOCATION/I_ORGANIZATION
. O

A O
PCCN B_LOCATION/B_PERSON
in O
Taiwan B_LOCATION
consists O
of O
a O
group B_ORGANIZATION/B_LOCATION
of O
clinic B_PERSON
physicians I_PERSON
whose O
medical B_PERSON/B_LOCATION
jobs I_PERSON/I_LOCATION
are O
viewed O
as O
family B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
and O
at O
least O
one B_LOCATION/B_NUMBER[MEASURE]
hospital B_LOCATION/I_NUMBER[MEASURE]
for O
secondary B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
tertiary B_LOCATION/B_TIME[MEASURE]
care I_LOCATION/I_TIME[MEASURE]
. O

The O
idea O
of O
member O
component O
design O
in O
PCCNs O
was O
aimed O
to O
lead O
the O
Taiwan O
citizens O
to O
choose O
one O
clinic O
physician O
as O
their O
personal O
family O
physician O
for O
health O
maintenance O
and O
this O
family O
physician O
also O
would O
have O
the O
responsibility O
of O
referring O
the O
patients B_PERSON/B_LOCATION
to O
specialty O
care O
if O
necessary O
. O

From O
a O
national O
health O
authority O
perspective O
, O
they O
expected O
the O
Taiwan O
people B_PERSON/B_ORGANIZATION
to O
put O
an O
end O
to O
their O
fallacy O
that O
' O
bigger O
is O
better O
' O
for O
health O
care O
organizations O
and O
establish O
the O
idea O
of O
' O
human B_PERSON/B_LOCATION
health O
' O
, O
starting O
with O
prevention O
and O
primary O
care O
, O
followed O
by O
secondary O
or O
tertiary O
care O
, O
emphasizing O
health O
promotion O
and O
maintenance O
instead O
of O
disease O
curing O
. O

Furthermore O
, O
it O
could O
decrease O
the O
inappropriateness B_MEASURE/B_DISEASE
of O
medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
usage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
i O
. O
e O
. O
, O
over B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
uses B_PERSON/B_ORGANIZATION
of O
secondary B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
and O
tertiary B_LOCATION/B_PERSON
medical I_LOCATION/I_PERSON
services I_LOCATION/I_PERSON
in O
the O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
tech B_LOCATION/B_MEASURE
hospitals I_LOCATION/I_MEASURE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
national B_ORGANIZATION/B_LOCATION
health I_ORGANIZATION/I_LOCATION
authority I_ORGANIZATION/I_LOCATION
was O
expected O
to O
drive O
the O
traditional B_PERSON/B_LOCATION
fragmented I_PERSON/I_LOCATION
Heath I_PERSON/I_LOCATION
care I_PERSON/I_LOCATION
providers I_PERSON/I_LOCATION
into O
coordinated B_LOCATION/B_ORGANIZATION
medical I_LOCATION/I_ORGANIZATION
multidisciplinary I_LOCATION/I_ORGANIZATION
teams I_LOCATION/I_ORGANIZATION
and O
share O
the O
limited B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resources I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
through O
the O
PCCN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
demonstration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

In O
summary O
, O
the O
PCCN O
demonstration O
project O
was O
aimed O
to O
: O
1 O
) O
change O
the O
traditional O
patients B_PERSON/B_LOCATION
' O
customs O
of O
freely O
choosing O
health O
care O
organizations O
and O
establish O
referral O
channels O
along O
the O
continuum O
of O
care O
, O
and O
2 O
) O
establish O
partnerships O
among O
the O
primary O
care O
clinics O
and O
hospitals O
to O
provide O
a O
continuum O
of O
health O
care O
services O
. O

It O
was O
also O
expected O
to O
establish O
the O
primary O
care O
system O
of O
family O
physicians O
to O
provide O
whole O
- O
people B_PERSON/B_LOCATION
health O
care O
and O
improve O
care O
quality O
[ O
1 O
] O
. O

Partnership B_ORGANIZATION/B_PERSON
structures I_ORGANIZATION/I_PERSON
in O
the O
PCCNs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
represent O
the O
virtual B_LOCATION/B_ORGANIZATION
vertical I_LOCATION/I_ORGANIZATION
( O
i O
. O
e O
. O
, O
between O
the O
member B_LOCATION/B_ORGANIZATION
clinics I_LOCATION/I_ORGANIZATION
and O
hospitals B_LOCATION/B_ORGANIZATION
) O
and O
virtual B_LOCATION/B_ORGANIZATION
horizontal I_LOCATION/I_ORGANIZATION
( O
i O
. O
e O
. O
, O
among O
the O
member B_PERSON/B_ORGANIZATION
clinics I_PERSON/I_ORGANIZATION
) O
aspects B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
organizing B_TIME[MEASURE]/B_ORGANIZATION
, O
which O
designate O
the O
formal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relationships I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O
individuals B_PERSON/B_ORGANIZATION
and O
the O
total B_ORGANIZATION/B_LOCATION
network I_ORGANIZATION/I_LOCATION
and O
include O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
ensure O
effective B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
communication I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
coordination B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
the O
total B_ORGANIZATION/B_LOCATION
network I_ORGANIZATION/I_LOCATION
. O

Each O
PCCN B_LOCATION/B_ORGANIZATION
consists O
of O
five B_NUMBER[MEASURE]/B_LOCATION
to O
ten B_NUMBER[MEASURE]
clinics I_NUMBER[MEASURE]
: O
half B_NUMBER[MEASURE]/B_PERSON
of O
them O
should O
offer O
the O
services B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
general B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
medicine I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
internal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medicine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
, O
obstetrics B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
gynecology B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
pediatric B_DISEASE/B_PERSON
, O
or O
family B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
medicine I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

And O
each O
PCCN B_ORGANIZATION/B_LOCATION
has O
a O
central B_LOCATION/B_PERSON
headquarters I_LOCATION/I_PERSON
, O
usually O
in O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
clinic B_LOCATION
facilities I_LOCATION
, O
to O
coordinate O
and O
integrate O
the O
network B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
the O
clinic O
physicians O
in O
a O
PCCN O
are O
assigned O
the O
roles O
of O
' O
family O
physicians O
' O
or O
' O
gatekeepers O
' O
who O
recruit O
people B_PERSON
from O
the O
local O
community O
, O
keep O
background O
and O
medical O
files O
on O
them O
, O
certify O
family O
physician O
education O
training O
programs O
, O
and O
hold O
office O
hours O
in O
the O
member O
hospital O
, O
where O
they O
serve O
as O
joint O
faculty O
members O
for O
further O
medical O
consultations O
or O
medical O
utilizations O
of O
labs O
and O
tests O
, O
if O
necessary O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
hospital B_PERSON/B_ORGANIZATION
member B_PERSON/I_ORGANIZATION
is O
asked O
to O
help O
clinic B_PERSON/B_LOCATION
physicians I_PERSON/I_LOCATION
in O
their O
network B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
set O
up O
a O
medical B_LOCATION/B_ORGANIZATION
information I_LOCATION/I_ORGANIZATION
system I_LOCATION/I_ORGANIZATION
, O
share B_ORGANIZATION/B_LOCATION
hospital I_ORGANIZATION/I_LOCATION
resources I_ORGANIZATION/I_LOCATION
( O
medical B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
equipment I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
library B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
literature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O
with O
the O
clinic B_PERSON/B_LOCATION
physicians I_PERSON/I_LOCATION
in O
their O
network B_ORGANIZATION/B_LOCATION
and O
establish O
referral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
channels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
among O
the O
network B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
. O

Furthermore O
, O
this O
new O
demonstration O
model O
tries O
to O
minimize O
the O
barriers O
to O
patient B_PERSON/B_PRODUCT[OBJECT]
access O
by O
setting O
up O
24 O
- O
hour O
a O
day O
, O
7 O
- O
day O
a O
week O
medical O
consultation O
telephone O
lines O
for O
providing O
urgent O
services O
onsite O
and O
for O
taking O
care O
of O
the O
patients B_PERSON
whose O
family O
physicians O
' O
practices O
are O
closed O
to O
assure O
seamless O
care O
channels O
. O

The O
BNHI B_ORGANIZATION/B_LOCATION
funded O
these O
extra B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
demonstration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
actions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
at O
around O
one B_MEASURE/B_PERSON
hundred I_MEASURE/I_PERSON
thousand I_MEASURE/I_PERSON
US I_MEASURE/I_PERSON
dollars I_MEASURE/I_PERSON
( O
i O
. O
e O
. O
, O
NT O
$ O
3 B_MEASURE
, O
500 B_MEASURE
, O
000 B_MEASURE/B_LOCATION
) O
for O
each O
PCCN B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
the O
current B_MEASURE/B_PERSON
fee I_MEASURE/I_PERSON
- O
for O
- O
service B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
payment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O
1 B_LOCATION/B_PERSON
] I_LOCATION/I_PERSON
. O

figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
describes O
the O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
individual B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCCNs I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introduced O
in O
the O
demonstration B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
project I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Taiwan B_LOCATION
. O

To O
date B_TIME[MEASURE]/B_PERSON
, O
the O
PCCN B_LOCATION/B_ORGANIZATION
demonstration I_LOCATION/I_ORGANIZATION
project I_LOCATION/I_ORGANIZATION
has O
been O
in O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
for O
more B_MEASURE
than O
three B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
. O

There O
have O
been O
268 B_LOCATION/B_ORGANIZATION
PCCNs I_LOCATION/I_ORGANIZATION
formed O
in O
the O
period B_TIME[MEASURE]/B_LOCATION
of O
2003 B_MEASURE
to O
2005 B_MEASURE
around O
Taiwan B_LOCATION
. O

The O
geographical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
distributions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
PCCNs B_PERSON/B_BIO
and O
their O
members B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
described O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

analyzing O
all O
1 B_MEASURE
, O
557 B_MEASURE
participating O
clinic B_LOCATION/B_ORGANIZATION
members I_LOCATION/I_ORGANIZATION
in O
the O
demonstration B_LOCATION/B_ORGANIZATION
project I_LOCATION/I_ORGANIZATION
in O
terms B_NUMBER[MEASURE]/B_DISEASE
of O
medical B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
specialties I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
they O
cover O
general B_DISEASE/B_PERSON
medicine I_DISEASE/I_PERSON
, O
internal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medicine I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
surgeries B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
obstetrics B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
gynecology B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pediatrics B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
family B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
medicines I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
otolaryngology B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
ophthalmology B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
rehabilitation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medicine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
dermatology B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
and O
psychiatry B_DISEASE/B_PERSON
, O
with O
237 B_NUMBER[MEASURE]/B_PERSON
clinics I_NUMBER[MEASURE]/I_PERSON
providing O
more B_MEASURE/B_PERSON
than O
two B_NUMBER[MEASURE]/B_LOCATION
specialties I_NUMBER[MEASURE]/I_LOCATION
. O

On O
the O
other B_PERSON/B_LOCATION
hand I_PERSON/I_LOCATION
, O
each O
PCCN B_LOCATION/B_ORGANIZATION
recruits O
at O
least O
one B_LOCATION
district I_LOCATION
or O
regional B_LOCATION/B_ORGANIZATION
accredited I_LOCATION/I_ORGANIZATION
hospital I_LOCATION/I_ORGANIZATION
for O
acute B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
demands I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
required O
for O
network B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
) O
and O
a O
medical B_LOCATION/B_PERSON
center B_LOCATION/I_PERSON
for O
tertiary B_PERSON
care I_PERSON
support I_PERSON
( O
not O
required O
for O
network B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
) O
. O

There O
are O
6 B_LOCATION
medical I_LOCATION
centers I_LOCATION
, O
52 B_LOCATION/B_ORGANIZATION
regional I_LOCATION/I_ORGANIZATION
hospitals I_LOCATION/I_ORGANIZATION
, O
and O
71 B_LOCATION/B_PERSON
district B_LOCATION/I_PERSON
hospitals B_LOCATION/I_PERSON
joining O
in O
the O
demonstration B_LOCATION/B_ORGANIZATION
project I_LOCATION/I_ORGANIZATION
. O

See O
Table B_LOCATION/B_ORGANIZATION
1 I_LOCATION/I_ORGANIZATION
for O
more O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
about O
the O
PCCN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
members I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

To O
date B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
have O
been O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
empirical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
working O
relationships B_PERSON/B_LOCATION
that O
have O
developed O
between O
members B_PERSON/B_LOCATION
of O
the O
PCCN B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Partnership B_ORGANIZATION/B_LOCATION
needs O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
determine O
at O
an O
early B_MEASURE/B_LOCATION
stage I_MEASURE/I_LOCATION
, O
to O
make O
sure B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whether O
they O
are O
making O
the O
most B_MEASURE/B_DISEASE
of O
collaboration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
2 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
acceptance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
contracting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
networks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O
Taiwan B_LOCATION
as O
an O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
innovation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
worthy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
greater B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diffusion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deserves O
to O
be O
explored O
. O

Therefore O
, O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
used O
a O
structured B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
questionnaire I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
characterize O
the O
relationship B_PERSON
among O
the O
members B_PERSON/B_ORGANIZATION
in O
the O
individual B_ORGANIZATION/B_LOCATION
PCCNs I_ORGANIZATION/I_LOCATION
, O
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
governance B_ORGANIZATION/B_PERSON
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
marketing B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
financing B_PERSON/B_ORGANIZATION
, O
as O
well O
as O
information B_ORGANIZATION/B_PERSON
integration I_ORGANIZATION/I_PERSON
infrastructures I_ORGANIZATION/I_PERSON
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O
descriptive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
detail B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
map O
the O
partnership B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
developments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
to O
enrich O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
knowledge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
partner B_ORGANIZATION/B_LOCATION
relationships I_ORGANIZATION/I_LOCATION
and O
to O
help O
policy B_PERSON
makers I_PERSON
understand O
the O
coordinated B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
these O
health B_ORGANIZATION/B_PERSON
care I_ORGANIZATION/I_PERSON
providers I_ORGANIZATION/I_PERSON
which O
have O
developed O
under O
this O
system B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
also O
provides O
the O
recommendations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
Heath B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
policy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
decision B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
- O
making B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
management B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
networks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
providers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
the O
future B_LOCATION/B_ORGANIZATION
involvement I_LOCATION/I_ORGANIZATION
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O
aimed O
at O
providing O
descriptive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
map O
the O
partnership B_LOCATION/B_ORGANIZATION
development I_LOCATION/I_ORGANIZATION
. O

To O
understand O
the O
actual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
integration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
actions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
done O
by O
network B_ORGANIZATION/B_PERSON
members I_ORGANIZATION/I_PERSON
, O
the O
theoretical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
concept I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
employed O
by O
network B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partnerships I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
described O
and O
then O
the O
derived O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
developed O
. O

theoretical B_TIME[MEASURE]/B_PERSON
framework B_TIME[MEASURE]/I_PERSON
for O
organization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
network B_ORGANIZATION/B_LOCATION
integration I_ORGANIZATION/I_LOCATION
. O

The O
rapid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
organizational I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
health B_LOCATION/B_ORGANIZATION
care I_LOCATION/I_ORGANIZATION
industry I_LOCATION/I_ORGANIZATION
have O
driven O
theorists B_PERSON/B_ORGANIZATION
from O
every O
discipline B_PERSON/B_LOCATION
and O
across O
the O
world B_LOCATION/B_ORGANIZATION
to O
seek O
an O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
allows O
organizations B_ORGANIZATION/B_PERSON
to O
flourish O
. O

Organization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
allows O
investigators B_PERSON
to O
profile O
an O
organization B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
aspect B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patterns B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
regularities B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
organizational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
design I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
behavior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
. O

In O
the O
early B_TIME[MEASURE]/B_LOCATION
20th I_TIME[MEASURE]/I_LOCATION
century I_TIME[MEASURE]/I_LOCATION
, O
classical B_PERSON/B_ORGANIZATION
management I_PERSON/I_ORGANIZATION
theorists I_PERSON/I_ORGANIZATION
claimed O
that O
an O
organization B_ORGANIZATION/B_PERSON
has O
' O
a O
best B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
way I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
' O
to O
be O
organized O
and O
managed O
[ O
3 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

That O
implied O
that O
all O
organizations B_ORGANIZATION/B_PERSON
would O
own O
the O
' B_LOCATION
same I_LOCATION
' I_LOCATION
organizational I_LOCATION
styles I_LOCATION
or O
structures B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
1960s B_TIME[MEASURE]/B_LOCATION
, O
several B_PERSON
theorists I_PERSON
[ O
4 B_MEASURE
- O
8 B_MEASURE
] I_MEASURE
challenged O
this O
assumption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
by O
applying O
a O
' O
contingency B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
' O
to O
propose O
that O
there O
is O
no O
best B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
way I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
organize O
an O
organization B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
that O
the O
effectiveness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
an O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
varies O
with O
the O
situation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
an O
organization B_ORGANIZATION/B_PERSON
. O

Furthermore O
, O
it O
is O
proposed O
that O
the O
best B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
way I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
organize O
an O
organization B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depends O
on O
the O
nature B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
environment B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
which O
the O
organization B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relates O
. O

Contingency B_PERSON/B_EDU[ORGANIZATION]
theory I_PERSON/I_EDU[ORGANIZATION]
delineates O
the O
concepts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
organization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
internal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
features B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
' O
' O
the O
demands B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
environments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
' O
' O
best B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
adaptation I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
' O
and O
, O
the O
most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
all O
, O
' O
best B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
match I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
[ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
9 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Lawrence B_PERSON
& O
Lorsch B_PERSON
[ O
7 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
argued O
that O
environments B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characterized O
by O
uncertainty B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
rapid B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
change B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
in O
market B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
technology B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impose O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
demands I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
constraints B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
opportunities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
on O
organizations B_ORGANIZATION/B_PERSON
than O
do O
placid B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
environments I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Similarly O
to O
Lawrence B_PERSON
and O
Lorsch B_PERSON
' I_PERSON
s I_PERSON
views I_PERSON
mentioned O
above O
, O
Galbraith B_PERSON
[ O
10 B_MEASURE
, O
11 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
stressed O
the O
contingency B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
information B_DISEASE_ADJECTIVE[DISEASE]
processing I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
processing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
emphasizes O
that O
environment B_LOCATION/B_MEASURE
, O
size B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
technology B_ORGANIZATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impose O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
processing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
requirements I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
organizations B_ORGANIZATION/B_PERSON
, O
and O
thus O
an O
organization B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O
be O
designed O
to O
encourage O
information B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
flow I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O
both O
vertical B_LOCATION/B_MEASURE
and O
horizontal B_MEASURE/B_LOCATION
directions B_MEASURE/I_LOCATION
to O
achieve O
the O
overall B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tasks I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
organization B_ORGANIZATION/B_PERSON
and O
, O
finally O
, O
organizational B_MEASURE/B_LOCATION
effectiveness I_MEASURE/I_LOCATION
[ I_MEASURE/I_LOCATION
11 I_MEASURE/I_LOCATION
- O
14 B_MEASURE
] I_MEASURE
. O

Some O
theorists B_PERSON/B_ORGANIZATION
have O
criticized O
conventional B_PERSON/B_ORGANIZATION
contingency I_PERSON/I_ORGANIZATION
theorists I_PERSON/I_ORGANIZATION
who O
presume O
that O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
driven O
by O
the O
environment B_LOCATION/B_PERSON
. O

Child B_PERSON
[ O
15 B_MEASURE
] I_MEASURE
, O
Miller B_PERSON
[ I_PERSON
16 I_PERSON
] I_PERSON
, O
Van B_PERSON
de I_PERSON
Ven I_PERSON
and O
Drazin B_PERSON
[ O
17 B_MEASURE
] I_MEASURE
, O
and O
Tushman B_PERSON
and O
Romanelli B_PERSON
[ O
18 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
raised O
such B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
criticisms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O
they O
argued O
that O
organizations B_ORGANIZATION/B_PERSON
become O
what O
they O
are O
not O
only O
because O
of O
the O
environment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
also O
because O
of O
choices B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
made O
by O
members B_PERSON/B_ORGANIZATION
, O
especially O
choices B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O
strategy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
and O
organizational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
design I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

As O
Thompson B_PERSON
' I_PERSON
s I_PERSON
words I_PERSON
in O
the O
book B_ORGANIZATION/B_PERSON
Organizations I_ORGANIZATION/I_PERSON
in O
Action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
[ O
8 B_PERSON/B_LOCATION
] I_PERSON/I_LOCATION
put O
it O
, O
' O
organizations B_ORGANIZATION/B_PERSON
are O
not O
determined O
simply O
by O
their O
environments B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_MEASURE/B_GENE
. O
27 B_MEASURE
) O
. O
' O
He O
also O
pointed O
out O
that O
' O
administration B_ORGANIZATION/B_PERSON
may O
innovate O
on O
any O
or O
all O
of O
the O
necessary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dimensions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
but O
only O
to O
the O
extent B_DISEASE/B_MEASURE
that O
innovations B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
acceptable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
those O
on O
whom O
the O
organization B_ORGANIZATION/B_PERSON
can O
and O
must O
depend O
. O
' O
Instead O
of O
assuming O
that O
administrators B_PERSON/B_ORGANIZATION
are O
highly O
constrained O
in O
their O
decisions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
strategic B_PERSON/B_ORGANIZATION
contingency I_PERSON/I_ORGANIZATION
theorists I_PERSON/I_ORGANIZATION
emphasized O
' B_DISEASE/B_LOCATION
the O
importance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
choice B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
' O
that O
is O
, O
' O
the O
freedom B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
agency B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
[ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
15 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Furthermore O
, O
Pfeffer B_PERSON
[ O
19 B_LOCATION/B_PERSON
] I_LOCATION/I_PERSON
explicitly O
pointed O
out O
that O
' O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
the O
outcomes B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
political B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
contests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
within O
organizations B_ORGANIZATION/B_LOCATION
( O
p B_MEASURE/B_GENE
. O
38 B_MEASURE
) O
. O
' O
. O

Daft B_PERSON
[ O
14 B_PERSON
] I_PERSON
proposed O
a O
top B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
delineate O
how O
' O
a O
strategy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
is O
a O
plan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
interacting O
with O
the O
competitive B_PERSON/B_LOCATION
environment I_PERSON/I_LOCATION
to O
achieve O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
' O
He O
stated O
that O
the O
major B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responsibility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
top B_ORGANIZATION/B_PERSON
management B_ORGANIZATION/I_PERSON
is O
to O
determine O
the O
goals B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
strategy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
and O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
an O
organization B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
adapt O
to O
a O
changing O
environment B_LOCATION
. O

To O
assess O
the O
external B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
internal B_LOCATION/B_ORGANIZATION
environments I_LOCATION/I_ORGANIZATION
of O
an O
organization B_ORGANIZATION/B_LOCATION
seems O
to O
be O
the O
first B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
task I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
top B_PERSON
managers I_PERSON
in O
defining O
an O
organization B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
goals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
missions B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Then O
, O
guided O
by O
the O
goals O
and O
missions O
of O
the O
organization O
, O
top O
managers O
shape O
the O
design O
of O
the O
organization O
, O
including O
structural O
forms O
, O
information O
system O
, O
technology O
, O
human B_PERSON/B_SPECIES[BIO]
resources O
, O
organizational O
culture O
, O
and O
inter O
- O
organizational O
linkages O
, O
to O
achieve O
the O
final O
organizational O
performance O
. O

Integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
refers O
to O
the O
mechanisms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
coordination B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
ways B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
guided O
to O
partnership B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
fit O
internal B_TIME[MEASURE]/B_LOCATION
and O
external B_LOCATION/B_ORGANIZATION
conditions I_LOCATION/I_ORGANIZATION
[ O
7 B_MEASURE
, O
20 B_MEASURE
, O
21 B_MEASURE
] I_MEASURE
. O

In O
the O
early B_TIME[MEASURE]/B_LOCATION
1990s I_TIME[MEASURE]/I_LOCATION
, O
proposals B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
US B_ORGANIZATION
national I_ORGANIZATION
health I_ORGANIZATION
care I_ORGANIZATION
reform I_ORGANIZATION
recognized O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
integrating O
mechanisms B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
achieve O
both O
financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
success I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
care B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
well O
- O
organized O
system B_ORGANIZATION/B_LOCATION
of O
care B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
[ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
22 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
23 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Several B_PERSON
researchers I_PERSON
also O
viewed O
inter B_LOCATION/B_PERSON
- O
organizational B_ORGANIZATION/B_LOCATION
cooperation I_ORGANIZATION/I_LOCATION
as O
resource B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchanges I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
client B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
referrals I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
money B_ORGANIZATION/B_PERSON
, O
and O
staff B_PERSON/B_ORGANIZATION
[ O
24 B_MEASURE
- O
27 B_TIME[MEASURE]
] I_TIME[MEASURE]
. O

From O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ways I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
viewing O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
success B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lies O
in O
the O
coordinative B_ORGANIZATION/B_PERSON
mechanisms I_ORGANIZATION/I_PERSON
and O
partnership B_ORGANIZATION/B_PERSON
working O
that O
support B_PERSON/B_TIME[MEASURE]
it O
[ O
28 B_TIME[MEASURE]
] I_TIME[MEASURE]
, O
including O
an O
administrative B_ORGANIZATION/B_LOCATION
organization I_ORGANIZATION/I_LOCATION
that O
coordinates O
the O
operations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
various B_ORGANIZATION/B_LOCATION
health I_ORGANIZATION/I_LOCATION
care I_ORGANIZATION/I_LOCATION
services I_ORGANIZATION/I_LOCATION
; O
a O
management B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
integrates O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
utilization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
and O
financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
follows O
clients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
settings I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
a O
care B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
coordination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
or O
disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
works O
with O
clients B_PERSON/B_ORGANIZATION
to O
arrange O
health B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
care I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
services I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
and O
a O
financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanism I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
enables O
pooling B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
funds B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
services B_MEASURE
[ I_MEASURE
29 I_MEASURE
- O
35 B_MEASURE
] I_MEASURE
. O

Fox B_PERSON/B_ORGANIZATION
[ O
36 B_ORGANIZATION/B_PERSON
] I_ORGANIZATION/I_PERSON
suggested O
the O
success B_MEASURE/B_ORGANIZATION
of O
integrated B_ORGANIZATION/B_PERSON
health I_ORGANIZATION/I_PERSON
networks I_ORGANIZATION/I_PERSON
should O
ensure O
that O
the O
new B_ORGANIZATION/B_PERSON
business I_ORGANIZATION/I_PERSON
link O
such B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
aspects I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
as O
technology B_ORGANIZATION/B_PERSON
, O
functional B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
skills I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
, O
customer B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
access I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
management B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
products B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
can O
be O
shared O
across O
both O
the O
core B_PERSON/B_ORGANIZATION
and O
the O
new B_ORGANIZATION/B_LOCATION
business I_ORGANIZATION/I_LOCATION
; O
to O
conduct O
market B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
financial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
; O
to O
share O
the O
risk B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vertical B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
integration I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
with O
outside B_PERSON/B_ORGANIZATION
entities B_PERSON/I_ORGANIZATION
, O
to O
develop O
the O
management B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
can O
reflect O
the O
degree B_MEASURE/B_ORGANIZATION
of O
coordination B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necessary I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
support O
the O
core B_ORGANIZATION/B_PERSON
business I_ORGANIZATION/I_PERSON
activities I_ORGANIZATION/I_PERSON
; O
to O
ensure O
that O
the O
integration B_ORGANIZATION/B_LOCATION
strategy I_ORGANIZATION/I_LOCATION
meets O
the O
needs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
customers B_PERSON/B_ORGANIZATION
, O
including O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
the O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
medical B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
technology I_ORGANIZATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
preferred B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
purchase B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
and O
to O
measure O
the O
new B_ORGANIZATION/B_LOCATION
business I_ORGANIZATION/I_LOCATION
by O
its O
value B_MEASURE/B_ORGANIZATION
to O
the O
enterprise B_ORGANIZATION/B_LOCATION
as O
a O
whole B_MEASURE/B_ORGANIZATION
, O
rather O
than O
by O
its O
profitability B_MEASURE/B_ORGANIZATION
as O
a O
stand O
- O
alone O
entity B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
summary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
inter B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
organizational B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
designs I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
on O
network B_ORGANIZATION/B_PERSON
management I_ORGANIZATION/I_PERSON
were O
substantial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
a O
managerial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Borrowing O
the O
ideas O
of O
strategic O
contingency O
perspective O
[ O
8 O
, O
15 O
, O
19 O
] O
and O
top O
management O
model O
[ O
14 O
] O
, O
it O
could O
be O
imply O
that O
success O
( O
organization O
performance O
) O
in O
reengineering O
a O
network O
lies O
in O
the O
integration O
of O
process O
and O
services O
( O
see O
Figure O
1 O
) O
, O
including O
leadership O
/ O
governing O
structure O
, O
teamwork O
between O
disciplines O
and O
patient B_PERSON/B_LOCATION
care O
, O
financial O
planning O
, O
and O
information O
systems O
, O
characterized O
as O
the O
constructs O
of O
governance O
, O
clinical O
, O
financial O
, O
and O
information O
infrastructures O
, O
respectively O
, O
in O
this O
study O
. O

In O
addition O
, O
another O
construct O
, O
marketing O
infrastructure O
, O
was O
especially O
important O
and O
designed O
to O
explore O
for O
PCCNs O
in O
this O
study O
because O
of O
patients B_PERSON/B_ORGANIZATION
' O
freedom O
of O
making O
healthcare O
choice O
and O
the O
traditional O
fragmented O
health O
care O
systems O
by O
individual O
health O
care O
organizations O
in O
Taiwan O
. O

One O
major O
reason O
for O
Taiwan O
people B_PERSON/B_LOCATION
' O
s O
hospital O
shopping O
preferences O
was O
that O
Taiwan O
people B_PERSON
usually O
believe O
the O
bigger O
the O
facility O
, O
the O
better O
capacities O
a O
facility O
has O
no O
matter O
on O
any O
aspect O
from O
medical O
professionals O
to O
tangible O
medical O
equipment O
and O
plants O
. O

And O
this O
fallacy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
made O
the O
public B_ORGANIZATION/B_PERSON
want O
to O
overuse O
the O
facility B_LOCATION/B_ORGANIZATION
with O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
tech B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medical I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
services I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
no O
matter B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
if O
it O
fits O
their O
needs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

From O
the O
health B_ORGANIZATION/B_PERSON
policy I_ORGANIZATION/I_PERSON
and O
management B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
perspectives I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
therefore O
, O
the O
health B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
providers I_PERSON/I_ORGANIZATION
were O
encouraged O
to O
market O
their O
services B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
new B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corporate I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identity I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
brand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O
37 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
, O
including O
offering O
tangible B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resources I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
books B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
libraries B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
medical B_ORGANIZATION/B_LOCATION
equipment I_ORGANIZATION/I_LOCATION
, O
and O
intangible B_LOCATION/B_ORGANIZATION
resources B_LOCATION/I_ORGANIZATION
such B_LOCATION/I_ORGANIZATION
as O
knowledge B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
exchanges B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
education B_PERSON/B_MEASURE
) O
and O
reputation B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
sharing O
one B_NUMBER[MEASURE]/B_LOCATION
another O
among O
PCCN B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
. O

Furthermore O
, O
through O
the O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
marketing O
resource B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
exchanges I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
therefore O
, O
each O
PCCN B_ORGANIZATION/B_PERSON
could O
establish O
the O
images B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
' B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
one B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
brand I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
quality B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
for O
the O
public B_ORGANIZATION/B_PERSON
and O
for O
the O
health B_ORGANIZATION/B_PERSON
care I_ORGANIZATION/I_PERSON
providers I_ORGANIZATION/I_PERSON
. O

It O
also O
makes O
it O
be O
more O
visible B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
public B_ORGANIZATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
five B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
integration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
infrastructures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
network B_LOCATION/B_ORGANIZATION
management I_LOCATION/I_ORGANIZATION
were O
constructed O
as O
a O
conceptual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
framework B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
help O
to O
portray O
how O
the O
PCCN B_ORGANIZATION/B_PERSON
members I_ORGANIZATION/I_PERSON
have O
done O
. O

The O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
described O
in O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
. O

Survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
integration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
infrastructures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
partnerships B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
the O
five B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
integration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
infrastructures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
network B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
management I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
structured B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
questionnaire I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
derived O
from O
extensive B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
literature I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

governance B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

governance B_ORGANIZATION/B_PERSON
assumes O
the O
broad B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responsibility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
survival B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
involves O
the O
series B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
setting B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
monitoring O
organizational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
goals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
strategy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
through O
a O
board B_ORGANIZATION/B_LOCATION
of O
representatives B_PERSON
[ O
38 B_MEASURE/B_PERSON
] B_MEASURE/I_PERSON
. O

governance O
or O
administrative O
integration O
infrastructure O
in O
establishing O
network O
partnerships O
refers O
to O
administrative O
structures O
( O
or O
responsibilities O
) O
created O
to O
facilitate O
communication O
, O
clear O
lines O
of O
authority O
, O
accountability O
, O
and O
responsibility O
for O
patient B_PERSON
care O
services O
; O
to O
negotiate O
budgets O
and O
financial O
trade O
- O
offs O
; O
and O
to O
present O
a O
cohesive O
, O
consistent O
message O
in O
interactions O
with O
external O
agencies O
and O
the O
community O
[ O
29 O
, O
39 O
- O
41 O
] O
and O
most O
important O
for O
members O
in O
contract O
agreements O
, O
to O
manage O
participation O
[ O
33 O
] O
. O

From O
a O
multidisciplinary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
Mitchell B_PERSON/B_COLOR
and O
Shortell B_PERSON/B_COLOR
[ O
42 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
applied O
the O
concepts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
governance B_ORGANIZATION/B_PERSON
and O
management B_ORGANIZATION/B_PERSON
characteristics I_ORGANIZATION/I_PERSON
in O
effective B_LOCATION/B_ORGANIZATION
community I_LOCATION/I_ORGANIZATION
health I_LOCATION/I_ORGANIZATION
partnerships I_LOCATION/I_ORGANIZATION
. O

The O
construct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
governance B_ORGANIZATION/B_PERSON
involved O
several B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tasks I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
setting O
priorities B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
strategic B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
choosing O
the O
membership B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
composition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
obtaining O
the O
necessary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
financial I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
resources I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
setting O
up O
the O
accountability B_ORGANIZATION/B_LOCATION
systems I_ORGANIZATION/I_LOCATION
, O
and O
so O
on O
. O

The O
construct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
management B_PERSON/B_ORGANIZATION
refers O
to O
the O
tasks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
engaging O
and O
maintaining O
organizational B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
' I_PERSON/I_ORGANIZATION
interest I_PERSON/I_ORGANIZATION
in O
a O
shared B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vision I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
mission B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
providing O
appropriate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
coordination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanisms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
the O
specified O
strategies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
promoting O
constructive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conflicts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
managing O
destructive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
conflicts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
implementing O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
monitor O
the O
dynamics B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
adjusting O
the O
leadership B_PERSON
in O
the O
overall B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
membership I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
so O
on O
. O

The O
issues B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
governance B_ORGANIZATION
and O
administrative B_ORGANIZATION/B_PERSON
integration I_ORGANIZATION/I_PERSON
in O
the O
PCCNs B_LOCATION/B_ORGANIZATION
could O
include O
[ B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
, O
38 B_MEASURE
, O
40 B_MEASURE
, O
41 B_MEASURE
, O
43 B_MEASURE
- O
47 B_MEASURE
] I_MEASURE
: O

* B_OTHER/B_LOCATION
planning O
the O
shared O
visions B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
missions B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

* B_OTHER/B_LOCATION
determining O
the O
shared O
service B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
cooperation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
priorities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
policies B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
principles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

* B_OTHER/B_TIME[MEASURE]
identifying O
the O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
needed O
and O
how O
to O
get O
it O
. O

* B_OTHER/B_TIME[MEASURE]
organizing O
the O
network B_ORGANIZATION/B_PERSON
dynamics I_ORGANIZATION/I_PERSON
and O
member B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
roles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

* B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
leading O
and O
managing O
the O
conflicts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
communication B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

* B_OTHER/B_LOCATION
designing O
and O
controlling O
the O
shared O
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
performance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
including O
indicator B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
settings I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
feedbacks B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
and O
accountability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Clinical B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

The O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
care B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
begins O
through O
such B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
public I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programs I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
include O
social B_PERSON/B_ORGANIZATION
workers I_PERSON/I_ORGANIZATION
in O
public B_LOCATION/B_PERSON
welfare I_LOCATION/I_PERSON
departments I_LOCATION/I_PERSON
, O
caseworkers B_PERSON/B_ORGANIZATION
in O
mental B_LOCATION/B_ORGANIZATION
health I_LOCATION/I_ORGANIZATION
, O
or O
nurses B_PERSON
in O
public B_LOCATION/B_PERSON
health I_LOCATION/I_PERSON
departments I_LOCATION/I_PERSON
. O

In O
the O
late B_TIME[MEASURE]/B_LOCATION
1980s I_TIME[MEASURE]/I_LOCATION
, O
care B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
integration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
deemed O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
streamlining B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
care B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
negotiating O
the O
maze B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
services I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

At O
that O
time B_TIME[MEASURE]/B_LOCATION
, O
it O
was O
referred O
to O
as O
service B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
coordination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
or O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
or O
in O
other B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O
29 B_TIME[MEASURE]/B_PERSON
] B_TIME[MEASURE]/I_PERSON
. O

The O
purpose O
of O
care O
integration O
is O
to O
work O
directly O
with O
patients B_PERSON
and O
their O
families O
over O
time O
to O
help O
them O
arrange O
and O
manage O
the O
complex O
resources O
that O
patients B_PERSON/B_LOCATION
may O
need O
to O
maintain O
health O
and O
independent O
functioning O
. O

At O
the O
same O
time O
, O
care O
integration O
is O
used O
to O
achieve O
the O
most O
cost O
- O
effective O
use O
possible O
of O
scarce O
resources O
, O
by O
steering O
patients B_PERSON/B_LOCATION
to O
the O
health O
, O
social O
, O
and O
support O
services O
most O
appropriate O
for O
them O
at O
a O
given O
time O
[ O
29 O
] O
. O

Conrad O
and O
Dowling O
[ O
33 O
] O
pointed O
out O
that O
to O
coordinate O
and O
integrate O
patient B_PERSON/B_DISEASE
care O
relies O
on O
connecting O
patient B_PERSON
services O
at O
the O
different O
stages O
of O
the O
patient B_PERSON
care O
processes O
. O

Care B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
coordination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
integrated B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
networks B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
can O
be O
achieved O
through O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
training B_PERSON/B_ORGANIZATION
programs I_PERSON/I_ORGANIZATION
and O
some O
clinical B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
services I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
provision B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
complementary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
capabilities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
geographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
proximity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
clear B_ORGANIZATION/B_PERSON
role I_ORGANIZATION/I_PERSON
definition I_ORGANIZATION/I_PERSON
of O
each O
institution B_ORGANIZATION/B_PERSON
, O
commitment B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
flexibility B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
leaderships B_PERSON/B_ORGANIZATION
and O
medical B_ORGANIZATION/B_PERSON
staffs B_ORGANIZATION/I_PERSON
, O
and O
the O
support B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
large B_MEASURE/B_LOCATION
referring O
physician B_ORGANIZATION/B_PERSON
groups I_ORGANIZATION/I_PERSON
embracing O
the O
affiliation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
concepts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O
48 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

The O
issues B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
integration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
PCCNs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O
include O
[ B_MEASURE/B_LOCATION
48 I_MEASURE/I_LOCATION
- O
50 B_MEASURE
] I_MEASURE
: O

* B_OTHER/B_ORGANIZATION
planning O
and O
differentiating O
target B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
markets I_ORGANIZATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
based O
on O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
services I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
network B_ORGANIZATION/B_PERSON
members B_ORGANIZATION/I_PERSON
. O

* B_DISEASE/B_LOCATION
uniting O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
professionals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
planning I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

* O
designing O
patient B_PERSON/B_LOCATION
- O
centered O
care O
or O
case O
management O
teams O
. O

* O
establishing O
committees O
responsible O
for O
patient B_PERSON
- O
centered O
case O
report O
meetings O
, O
case O
referral O
, O
transfer O
, O
and O
tracing O
, O
file O
management O
( O
record O
and O
information O
exchanges O
) O
, O
clinical O
quality O
management O
( O
quality O
assurance O
, O
improvement O
, O
risk O
and O
malpractice O
management O
, O
and O
utilization O
review O
) O
, O
and O
medical O
continuing O
education O
and O
on O
- O
job O
education O
. O

marketing B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

Marketing O
integration O
refers O
to O
how O
to O
work O
together O
as O
a O
whole O
both O
from O
the O
provider O
and O
patient B_PERSON/B_ORGANIZATION
perspectives O
. O

One B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
case B_PERSON/B_ORGANIZATION
reports I_PERSON/I_ORGANIZATION
interviewing O
developing O
integrated O
delivery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
or O
networks B_LOCATION/B_ORGANIZATION
realized O
that O
the O
most O
important B_DISEASE_ADJECTIVE[DISEASE]
thing I_DISEASE_ADJECTIVE[DISEASE]
is O
how O
an O
integrated O
system B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
network B_ORGANIZATION/B_LOCATION
is O
promoted O
and O
what O
is O
promoted O
for O
the O
consumers B_PERSON/B_ORGANIZATION
[ O
51 B_TIME[MEASURE]/B_LOCATION
] B_TIME[MEASURE]/I_LOCATION
, O
including O
focusing O
on O
product B_ORGANIZATION/B_PERSON
development B_ORGANIZATION/I_PERSON
, O
making O
sure B_PERSON/B_LOCATION
the O
branding B_PERSON/B_ORGANIZATION
holds O
together O
, O
marketing O
directly O
to O
consumers B_PERSON/B_ORGANIZATION
, O
demonstrating O
values B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
consumers B_PERSON/B_ORGANIZATION
, O
and O
even O
conducting O
marketing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
make O
efforts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
the O
long B_PERSON/B_ORGANIZATION
term I_PERSON/I_ORGANIZATION
. O

In O
a O
health O
care O
network O
with O
several O
organizational O
members O
and O
target O
patients B_PERSON/B_LOCATION
, O
the O
marketing O
infrastructure O
in O
PCCNs O
here O
refers O
to O
provider O
members O
' O
marketing O
, O
meaning O
the O
resource O
sharing O
and O
market O
development O
in O
a O
PCCN O
as O
a O
whole O
. O

The O
issues B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
marketing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
integration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
PCCNs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O
include O
[ B_NUMBER[MEASURE]/B_LOCATION
37 I_NUMBER[MEASURE]/I_LOCATION
, O
52 B_MEASURE
- O
54 B_MEASURE
] I_MEASURE
: O

* B_OTHER/B_TIME[MEASURE]
sharing O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
facility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
publications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
among O
the O
network B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
. O

* B_OTHER/B_LOCATION
uniting O
public B_ORGANIZATION/B_PERSON
promotions I_ORGANIZATION/I_PERSON
such I_ORGANIZATION/I_PERSON
as O
united B_ORGANIZATION/B_ENT
activities B_ORGANIZATION/I_ENT
, O
electronic B_PRODUCT[OBJECT]/B_ENT
and O
paper B_PERSON/B_PRODUCT[OBJECT]
media B_PERSON/I_PRODUCT[OBJECT]
for O
enhancing O
the O
network B_ORGANIZATION/B_LOCATION
reputation I_ORGANIZATION/I_LOCATION
as O
' O
one B_NUMBER[MEASURE]/B_ORGANIZATION
system I_NUMBER[MEASURE]/I_ORGANIZATION
, O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
brand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
quality B_NUMBER[MEASURE]/B_ORGANIZATION
' O
. O

* B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiating O
target B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markets B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
network B_ORGANIZATION/B_LOCATION
for O
competing O
in O
the O
medical B_ORGANIZATION/B_LOCATION
industry B_ORGANIZATION/I_LOCATION
. O

Financial B_ORGANIZATION/B_LOCATION
infrastructure I_ORGANIZATION/I_LOCATION
. O

Comprehensive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
flexible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
adequate B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
financing I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
goal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
ideal B_ORGANIZATION/B_LOCATION
continuum I_ORGANIZATION/I_LOCATION
of O
care B_PERSON/B_ORGANIZATION
. O

That O
component B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
most O
critical B_DISEASE_ADJECTIVE[DISEASE]
and O
challenging B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
manage O
under O
the O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
health B_LOCATION/B_ORGANIZATION
care I_LOCATION/I_ORGANIZATION
delivery I_LOCATION/I_ORGANIZATION
environment I_LOCATION/I_ORGANIZATION
. O

Gillies B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

[ O
30 B_NUMBER[MEASURE]/B_PERSON
] O
suggested O
that O
integrating O
financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
across O
operating B_ORGANIZATION/B_LOCATION
units I_ORGANIZATION/I_LOCATION
adds O
the O
greatest B_MEASURE
value I_MEASURE
to O
systems B_LOCATION/B_ORGANIZATION
or O
organizations B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
one B_MEASURE/B_ENT
case I_MEASURE/I_ENT
study I_MEASURE/I_ENT
, O
Bramson B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
. O

[ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
55 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O
showed O
that O
reducing O
costs B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
joint B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purchasing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
radiology B_PERSON/B_LOCATION
departments I_PERSON/I_LOCATION
of O
a O
vertically O
integrated O
health B_ORGANIZATION/B_LOCATION
system I_ORGANIZATION/I_LOCATION
could O
yield O
substantial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
savings I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
issues B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
integration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
PCCNs B_LOCATION/B_ORGANIZATION
could O
include O
: O

* B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
budgeting I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

* B_OTHER/B_TIME[MEASURE]
uniting O
equipment B_PRODUCT[OBJECT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
medical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
materials I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
purchasing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
routine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
administrative I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
stuff I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
management I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
. O

* B_DISEASE/B_LOCATION
pooling O
recruitment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
funds I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

* B_OTHER/B_TIME[MEASURE]
designing O
a O
financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
sharing B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mechanism I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Information B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

Information B_ORGANIZATION/B_PERSON
is O
an O
essential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
component I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
an O
organization B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
can O
help O
an O
organization B_ORGANIZATION/B_PERSON
to O
integrate O
its O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
units I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
efficiently O
manage O
the O
continuum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
ideal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
a O
continuum B_LOCATION/B_ORGANIZATION
of O
care B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conceived O
of O
and O
formed O
in O
the O
mid B_TIME[MEASURE]/B_DISEASE
- O
1980s B_TIME[MEASURE]
[ I_TIME[MEASURE]
56 I_TIME[MEASURE]
] I_TIME[MEASURE]
. O

During O
the O
late B_TIME[MEASURE]
1980s I_TIME[MEASURE]
, O
computer B_ORGANIZATION/B_PERSON
technology I_ORGANIZATION/I_PERSON
began O
to O
make O
an O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
feasible I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
affordable B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
through O
new B_ORGANIZATION
computer I_ORGANIZATION
chips I_ORGANIZATION
with O
expanded O
capability B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
networking B_ORGANIZATION/B_LOCATION
technology B_ORGANIZATION/I_LOCATION
. O

In O
the O
1990s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
individual B_PERSON/B_ORGANIZATION
services I_PERSON/I_ORGANIZATION
of O
the O
continuum B_LOCATION/B_ORGANIZATION
upgraded O
their O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
combine O
clinical B_ORGANIZATION/B_PERSON
, O
financial B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
utilization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O
29 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

Some O
studies O
have O
argued O
that O
the O
quality O
of O
information O
systems O
can O
drive O
costs O
down O
, O
because O
a O
good O
information O
system O
can O
give O
physicians O
easy O
electronic O
access O
to O
complete O
the O
documentation O
of O
the O
patients B_PERSON
' O
clinical O
records O
, O
better O
inform O
them O
about O
reimbursement O
and O
capitation O
issues O
, O
help O
them O
easily O
associate O
and O
manage O
cases O
together O
, O
and O
achieve O
a O
higher O
level O
of O
professional O
satisfaction O
[ O
57 O
, O
58 O
] O
. O

Using O
Inova B_ORGANIZATION/B_LOCATION
Health I_ORGANIZATION/I_LOCATION
System I_ORGANIZATION/I_LOCATION
, O
an O
integrated B_ORGANIZATION/B_LOCATION
delivery I_ORGANIZATION/I_LOCATION
system I_ORGANIZATION/I_LOCATION
in O
northern B_LOCATION
Virginia I_LOCATION
, O
as O
an O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
Wager B_PERSON
, O
Heda B_PERSON
, O
and O
Austin B_LOCATION/B_PERSON
[ O
59 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
showed O
that O
by O
developing O
a O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
within O
an O
integrated B_ORGANIZATION/B_LOCATION
delivery I_ORGANIZATION/I_LOCATION
system I_ORGANIZATION/I_LOCATION
, O
Inova B_PERSON/B_ORGANIZATION
can O
have O
a O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
transaction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
system I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O
hospitals B_LOCATION/B_PERSON
and O
other B_LOCATION/B_PERSON
entities I_LOCATION/I_PERSON
, O
a O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
repository I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O
decision B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
support I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
and O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
a O
managed O
care B_ORGANIZATION/B_LOCATION
information B_ORGANIZATION/I_LOCATION
system B_ORGANIZATION/I_LOCATION
to O
support O
managed O
care B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
capitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
contracts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
greater B_LOCATION/B_ORGANIZATION
capability I_LOCATION/I_ORGANIZATION
to O
acquire O
physicians B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
issues B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
coordination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
include O
[ B_MEASURE
60 I_MEASURE
- O
68 B_MEASURE
] I_MEASURE
: O

* O
establishing O
an O
electronic O
medical O
record O
system O
, O
regional O
information O
network O
for O
patient B_PERSON/B_TIME[MEASURE]
clinical O
and O
administrative O
data O
, O
clinical O
service O
arrangements O
and O
administrative O
work O
. O

* B_OTHER/B_LOCATION
uniting O
the O
system B_ORGANIZATION/B_ENT
information I_ORGANIZATION/I_ENT
management I_ORGANIZATION/I_ENT
and O
web B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
pages I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

The O
structured B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
questionnaire I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
developed O
with O
the O
wording B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
practical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
managerial I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
actions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
based O
on O
the O
five B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
just O
mentioned O
. O

There O
were O
19 B_MEASURE
survey I_MEASURE
items I_MEASURE
on O
governance B_ORGANIZATION/B_LOCATION
infrastructure I_ORGANIZATION/I_LOCATION
, O
25 B_MEASURE
on O
clinical B_ORGANIZATION
infrastructure I_ORGANIZATION
, O
13 B_MEASURE
on O
marketing B_ORGANIZATION/B_LOCATION
infrastructure I_ORGANIZATION/I_LOCATION
, O
20 B_MEASURE
on O
financial B_ORGANIZATION
infrastructure I_ORGANIZATION
, O
and O
7 B_NUMBER[MEASURE]
on O
information B_ORGANIZATION
infrastructure I_ORGANIZATION
. O

All O
84 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
items I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
, O
simultaneously O
, O
applied O
to O
examine O
the O
relationships B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
clinic B_LOCATION/B_ORGANIZATION
' O
s B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peer B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
relationship B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
clinic B_LOCATION/B_PERSON
and O
hospital B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
in O
a O
PCCN B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
it O
resulted O
in O
a O
total B_MEASURE
of O
168 B_NUMBER[MEASURE]
survey I_NUMBER[MEASURE]
questions I_NUMBER[MEASURE]
. O

The O
detailed B_MEASURE
information I_MEASURE
of O
the O
item B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
questions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
listed O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
. O

The O
structured B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
questionnaires I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
drafted O
from O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
literatures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
then O
examined O
by O
two B_PERSON
academic I_PERSON
professors I_PERSON
for O
theoretical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
accuracy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Then O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pilot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
pre B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tested O
for O
the O
PCCN B_ORGANIZATION/B_LOCATION
pioneers I_ORGANIZATION/I_LOCATION
( O
i O
. O
e O
. O
, O
92 B_ORGANIZATION/B_LOCATION
network B_ORGANIZATION/I_LOCATION
clinic B_ORGANIZATION/I_LOCATION
members B_ORGANIZATION/I_LOCATION
) O
and O
116 B_PERSON/B_ORGANIZATION
hospital I_PERSON/I_ORGANIZATION
providers I_PERSON/I_ORGANIZATION
which O
have O
partner B_PERSON/B_ORGANIZATION
relationships I_PERSON/I_ORGANIZATION
with O
other B_PERSON/B_LOCATION
health I_PERSON/I_LOCATION
care I_PERSON/I_LOCATION
organizations I_PERSON/I_LOCATION
( O
i O
. O
e O
. O
, O
hospitals B_LOCATION/B_ORGANIZATION
, O
clinics B_LOCATION/B_ORGANIZATION
, O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_MEASURE/B_LOCATION
care I_MEASURE/I_LOCATION
facilities I_MEASURE/I_LOCATION
) O
. O

The O
wordings B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
meanings B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
each O
question B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
item I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
revised O
to O
assure O
content B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
validity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
Cronbach B_MEASURE/B_PERSON
alpha I_MEASURE/I_PERSON
values O
for O
the O
five B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
integration I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
constructs I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
- O
governance B_ORGANIZATION/B_PERSON
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
marketing B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
finance B_ORGANIZATION
, O
and O
information B_ORGANIZATION/B_PERSON
infrastructure I_ORGANIZATION/I_PERSON
were O
0 B_MEASURE
. O
946 B_MEASURE
, O
0 B_NUMBER[MEASURE]
. O
958 B_MEASURE
, O
0 B_MEASURE/B_LOCATION
. O
932 B_MEASURE
, O
0 B_MEASURE/B_LOCATION
. O
944 B_MEASURE
, O
and O
0 B_NUMBER[MEASURE]/B_LOCATION
. O
898 B_MEASURE
for O
the O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
clinic B_LOCATION/B_PERSON
- O
clinic B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
member I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
relationships I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
; O
and O
0 B_MEASURE
. O
945 B_MEASURE
, O
0 B_MEASURE
. O
949 B_MEASURE
, O
0 B_MEASURE
. O
916 B_MEASURE
, O
0 B_MEASURE
. O
948 B_MEASURE
, O
and O
0 B_NUMBER[MEASURE]
. O
896 B_MEASURE
for O
the O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
clinic B_LOCATION/B_PERSON
- O
hospital B_PERSON/B_ORGANIZATION
member I_PERSON/I_ORGANIZATION
relationships I_PERSON/I_ORGANIZATION
. O

Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
subjects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

To O
find O
the O
member B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partnership I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
sent O
questionnaires B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
1 B_MEASURE
, O
557 B_MEASURE
individual I_MEASURE
clinics I_MEASURE
which O
had O
belonged O
to O
PCCNs B_LOCATION/B_PERSON
for O
at O
least O
one B_TIME[MEASURE]
year I_TIME[MEASURE]
, O
based O
on O
information B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
contained O
in O
the O
Taiwan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Primary I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Community I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
list I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
Bureau B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
National B_LOCATION/B_TIME[MEASURE]
Health I_LOCATION/I_TIME[MEASURE]
Insurance I_LOCATION/I_TIME[MEASURE]
2003 I_LOCATION/I_TIME[MEASURE]
, O
2004 B_MEASURE
and O
2005 B_MEASURE
) O
. O

We O
let O
clinic B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
in O
all O
PCCNs B_LOCATION/B_ORGANIZATION
point O
out O
how O
they O
coordinate O
with O
their O
peer B_PERSON/B_LOCATION
clinic I_PERSON/I_LOCATION
members I_PERSON/I_LOCATION
and O
hospital B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
within O
a O
PCCN B_ORGANIZATION/B_LOCATION
because O
individual B_PERSON/B_ORGANIZATION
clinic I_PERSON/I_ORGANIZATION
members I_PERSON/I_ORGANIZATION
could O
be O
better B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
informants I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
hospital B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
, O
which O
need O
to O
deal O
with O
multiple B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relationships I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
therefore O
might O
find O
it O
hard B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O
describe O
the O
coordination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
involvement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
one I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O
one B_NUMBER[MEASURE]/B_PERSON
with O
clinic B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
. O

Moreover O
, O
networks B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O
for O
various B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reasons I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
it O
might O
lead O
to O
the O
various B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
involvements I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O
individual B_PERSON/B_ORGANIZATION
network I_PERSON/I_ORGANIZATION
members I_PERSON/I_ORGANIZATION
( O
i O
. O
e O
. O
, O
hospital B_LOCATION/B_PERSON
and O
clinic B_ORGANIZATION/B_LOCATION
members I_ORGANIZATION/I_LOCATION
) O
. O

Therefore O
, O
using O
the O
participating O
clinics B_LOCATION/B_ORGANIZATION
as O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
survey I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
units I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
could O
portray O
the O
overall B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
processes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
more O
authentically O
and O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
throughout O
all O
PCCNs B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
demonstration B_LOCATION
project I_LOCATION
. O

Nine B_NUMBER[MEASURE]/B_LOCATION
hundred I_NUMBER[MEASURE]/I_LOCATION
and O
twenty B_NUMBER[MEASURE]
- O
eight B_NUMBER[MEASURE]
clinics I_NUMBER[MEASURE]
responded O
( O
59 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
with O
239 B_MEASURE
clinics I_MEASURE
in O
the O
Taipei B_LOCATION
region I_LOCATION
, O
165 B_MEASURE
in O
the O
northern B_LOCATION
region I_LOCATION
, O
241 B_MEASURE
in O
the O
central B_LOCATION
region I_LOCATION
, O
108 B_MEASURE
in O
the O
southern B_LOCATION
region I_LOCATION
, O
150 B_MEASURE
in O
the O
Kao B_PERSON/B_LOCATION
- O
Ping B_LOCATION/B_PERSON
region I_LOCATION/I_PERSON
, O
and O
15 B_MEASURE
in O
the O
eastern B_LOCATION
region I_LOCATION
of O
Taiwan B_LOCATION
. O

Ten B_PERSON
clinics I_PERSON
had O
not O
mentioned O
their O
practicing O
locations B_LOCATION/B_PERSON
. O

There O
is O
no O
statistically O
significant B_MEASURE
difference I_MEASURE
in O
geographical B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
respondents B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
the O
study B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
chi B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
4 B_MEASURE
. O
208 B_MEASURE
, O
p O
> O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

analytical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
first O
analyzed O
descriptively O
with O
frequency B_MEASURE
counts I_MEASURE
( O
percentage B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
each O
survey B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
item I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
instead O
of O
using O
mean O
as O
a O
statistical B_MEASURE/B_EDU[ORGANIZATION]
method I_MEASURE/I_EDU[ORGANIZATION]
, O
because O
the O
variation B_MEASURE
among O
the O
respondents B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O
not O
represent O
the O
normal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
it O
might O
ignore O
the O
extreme B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
respondents B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
answers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

To O
compare O
how O
the O
respondents B_PERSON
perceived O
the O
strength B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
existing O
in O
clinic B_LOCATION/B_PERSON
- O
clinic B_LOCATION/B_PERSON
and O
clinic B_LOCATION/B_PERSON
- O
hospital B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
paired O
t B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
performed O
for O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
survey I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
items I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
using O
the O
original B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numerical B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Profiling O
the O
partnerships B_ORGANIZATION/B_LOCATION
in O
Taiwan B_ORGANIZATION/B_LOCATION
PCCNs I_ORGANIZATION/I_LOCATION
: O
governance B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
infrastructure I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

With O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
governance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
infrastructures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
frequency B_MEASURE
was O
counted O
for O
each O
survey B_MEASURE/B_PERSON
item B_MEASURE/I_PERSON
with O
recalculated O
scales B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
disagree O
( O
Likert B_NUMBER[MEASURE]/B_LOCATION
scale I_NUMBER[MEASURE]/I_LOCATION
1 I_NUMBER[MEASURE]/I_LOCATION
and O
2 B_NUMBER[MEASURE]
) O
, O
fair B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
( O
Likert B_NUMBER[MEASURE]/B_LOCATION
scale I_NUMBER[MEASURE]/I_LOCATION
3 I_NUMBER[MEASURE]/I_LOCATION
) O
, O
and O
agree O
( O
Likert B_MEASURE
scale I_MEASURE
4 I_MEASURE
and O
5 B_NUMBER[MEASURE]
) O
with O
individual B_MEASURE
items I_MEASURE
. O

In O
clinic B_LOCATION/B_PERSON
- O
clinic B_PERSON/B_LOCATION
relationship I_PERSON/I_LOCATION
( O
Table B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
the O
majority B_PERSON/B_ORGANIZATION
of O
clinic B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
agree O
that O
the O
determined O
deals B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
obeyed O
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
item B_MEASURE
1 I_MEASURE
: O
88 B_MEASURE
. O
69 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
the O
goals B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
strategies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
members B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
well O
- O
understood O
( O
Table B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
, O
item B_MEASURE
16 I_MEASURE
: O
79 B_MEASURE
. O
74 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
and O
the O
united B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
principals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
members I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
developed O
( O
Table B_MEASURE/B_PERSON
2 I_MEASURE/I_PERSON
, O
item B_MEASURE
15 I_MEASURE
: O
79 B_MEASURE
. O
42 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

The O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
percentages I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
were O
also O
found O
in O
clinic B_LOCATION/B_PERSON
- O
hospital B_PERSON/B_LOCATION
relationship I_PERSON/I_LOCATION
in O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
items I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
Table B_MEASURE
2 I_MEASURE
) O
. O

On O
the O
other B_PERSON/B_LOCATION
hand B_PERSON/I_LOCATION
, O
establishing O
fair B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coordination I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
item B_MEASURE
11 I_MEASURE
: O
27 B_MEASURE
. O
91 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
designing O
and O
employing O
the O
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
performance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
indicators I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Table B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
item B_MEASURE
3 I_MEASURE
: O
21 B_MEASURE
. O
23 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
and O
establishing O
communication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
channels B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
item B_MEASURE
12 I_MEASURE
: O
19 B_MEASURE
. O
94 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
still O
occupied O
higher B_MEASURE/B_LOCATION
percentages B_MEASURE/I_LOCATION
not O
developed O
and O
deserved O
to O
been O
made O
the O
focus B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
future B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

paired O
t B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
all O
individual B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
survey I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
items I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
governance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infrastructure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
that O
the O
deals B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
obeyed O
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
item1 B_MEASURE/B_LOCATION
) O
and O
plans B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
goals B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
controlled O
( O
Table B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
item B_MEASURE
2 I_MEASURE
) O
were O
achieved O
more O
in O
clinic B_LOCATION/B_PERSON
- O
clinic B_PERSON/B_LOCATION
relationships B_PERSON/I_LOCATION
than O
those O
in O
clinic B_LOCATION/B_PERSON
- O
hospital B_LOCATION/B_PERSON
relationships I_LOCATION/I_PERSON
; O
however O
, O
the O
design B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
performance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
indicators I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
item B_MEASURE
3 I_MEASURE
) O
, O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
disintegration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
policy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
principals B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
item B_MEASURE
8 I_MEASURE
) O
, O
and O
the O
establishment B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fair B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
coordination I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
mechanism I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
Table B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
item B_MEASURE/B_LOCATION
11 I_MEASURE/I_LOCATION
) O
were O
reached O
more O
in O
clinic B_LOCATION/B_PERSON
- O
hospital B_PERSON/B_LOCATION
relationships B_PERSON/I_LOCATION
than O
those O
in O
clinic B_LOCATION/B_PERSON
- O
clinic B_LOCATION/B_PERSON
relationships I_LOCATION/I_PERSON
. O

Profiling O
the O
partnerships B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Taiwan B_LOCATION/B_PERSON
PCCNs I_LOCATION/I_PERSON
: O
clinical B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructure I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

examining O
the O
extent O
of O
clinical O
infrastructure O
for O
network O
members O
, O
establishing O
two O
- O
directed O
patient B_PERSON/B_LOCATION
referral O
systems O
and O
patient B_PERSON/B_LOCATION
referral O
information O
files O
( O
Table O
3 O
, O
items O
35 O
& O
37 O
) O
and O
uniting O
medical O
continuing O
education O
and O
on O
- O
job O
education O
( O
Table O
3 O
, O
item O
34 O
) O
were O
shown O
at O
a O
highly O
implemented O
rate O
in O
clinic O
- O
clinic O
( O
more O
than O
70 O
% O
) O
and O
clinic O
- O
hospital O
( O
more O
than O
80 O
% O
) O
relationships O
. O

On O
the O
other O
hand O
, O
network O
members O
had O
higher O
percentages O
( O
more O
than O
40 O
% O
) O
not O
to O
think O
about O
the O
possible O
integration O
mechanisms O
including O
establishing O
committees O
to O
deal O
with O
medical O
malpractice O
( O
Table O
3 O
, O
item O
44 O
) O
, O
planning O
and O
differentiating O
clinical O
market O
areas O
( O
Table O
3 O
, O
item O
20 O
) O
, O
and O
designing O
patient B_PERSON/B_ORGANIZATION
- O
centered O
case O
management O
teams O
( O
Table O
3 O
, O
item O
22 O
) O
. O

Overall O
, O
there O
was O
better B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
all O
the O
described O
items B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
in O
clinic B_LOCATION/B_PERSON
- O
hospital B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relationships I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
than O
those O
in O
clinic B_LOCATION/B_PERSON
- O
clinic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relationships B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
within O
a O
network B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
paired O
t B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
p B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Profiling O
the O
partnerships B_ORGANIZATION/B_LOCATION
in O
Taiwan B_ORGANIZATION/B_LOCATION
PCCNs B_ORGANIZATION/I_LOCATION
: O
marketing B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructure I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
marketing B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
planning I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
clinics B_LOCATION/B_PERSON
had O
better B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
integrated I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
marketing I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
activities I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
with O
their O
respective B_PERSON
hospitals I_PERSON
than O
with O
peer B_PERSON/B_LOCATION
clinic I_PERSON/I_LOCATION
members I_PERSON/I_LOCATION
within O
PCCNs B_LOCATION/B_PERSON
for O
all O
studied O
items B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
paired O
t B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
p B_PROTEIN[GENE]/B_MEASURE
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

examining O
the O
clinic B_LOCATION/B_PERSON
- O
clinic B_PERSON/B_LOCATION
relationships I_PERSON/I_LOCATION
, O
uniting O
social B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
activities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
Table B_MEASURE
4 I_MEASURE
, O
item B_MEASURE
53 I_MEASURE
) O
, O
sharing O
the O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
facility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O
updated O
services B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_MEASURE
4 I_MEASURE
, O
item B_MEASURE
46 I_MEASURE
) O
, O
public B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
promotion I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O
Table B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
item B_MEASURE
54 I_MEASURE
) O
, O
and O
uniting O
and O
joining O
the O
facility B_ORGANIZATION/B_LOCATION
activities I_ORGANIZATION/I_LOCATION
( O
Table B_MEASURE
4 I_MEASURE
, O
item B_MEASURE
51 I_MEASURE
) O
were O
the O
top B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
four I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
marketing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
works I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
done O
among O
clinic B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
( O
more B_MEASURE
than O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
implemented O
rate B_MEASURE/B_LOCATION
) O
; O
and O
those O
items B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
also O
showed O
a O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
implemented I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
rate I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
between O
clinic B_LOCATION/B_PERSON
and O
hospital B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
. O

On O
the O
other B_PERSON/B_MEASURE
hand I_PERSON/I_MEASURE
, O
facility B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assets I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
reports B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
Table B_MEASURE
4 I_MEASURE
, O
item B_MEASURE
49 I_MEASURE
) O
, O
and O
professional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
literatures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
books B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_MEASURE
4 I_MEASURE
, O
item B_MEASURE
45 I_MEASURE
) O
were O
not O
well O
- O
shared O
among O
clinic B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
( O
' O
never O
- O
thinking O
' O
rate B_MEASURE/B_PERSON
: O
42 B_MEASURE
. O
13 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
uniting O
the O
network B_ORGANIZATION/B_PERSON
publication B_ORGANIZATION/I_PERSON
could O
make O
more B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
efforts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
future B_TIME[MEASURE]/B_LOCATION
( O
' O
never O
- O
thinking O
' O
rate B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
item B_MEASURE/B_LOCATION
50 I_MEASURE/I_LOCATION
: O
39 B_MEASURE
. O
98 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

The O
room B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
clinic B_LOCATION/B_PERSON
- O
hospital B_PERSON/B_ORGANIZATION
partnership I_PERSON/I_ORGANIZATION
to O
think O
about O
acting O
was O
kind O
of O
different B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
those O
in O
the O
clinic B_LOCATION/B_PERSON
- O
clinic B_LOCATION/B_ORGANIZATION
relationship I_LOCATION/I_ORGANIZATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
the O
uniting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
publication I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
can O
be O
encouraged O
to O
improve O
the O
clinic B_LOCATION/B_PERSON
- O
hospital B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
relationship I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
Table B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
item B_MEASURE
50 I_MEASURE
: O
27 B_MEASURE
. O
48 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
cooperating O
in O
research B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projects I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_MEASURE
4 I_MEASURE
, O
item B_MEASURE
52 I_MEASURE
: O
25 B_MEASURE
. O
00 B_MEASURE
% I_MEASURE
) O
and O
identifying O
and O
differentiating O
target B_PERSON/B_ORGANIZATION
markets I_PERSON/I_ORGANIZATION
( O
Table B_MEASURE/B_LOCATION
4 I_MEASURE/I_LOCATION
, O
item B_MEASURE
57 I_MEASURE
: O
24 B_MEASURE
. O
57 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
had O
still O
more B_TIME[MEASURE]/B_PERSON
opportunities I_TIME[MEASURE]/I_PERSON
to O
be O
focused O
on O
in O
the O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Profiling O
the O
partnerships B_ORGANIZATION/B_LOCATION
in O
Taiwan B_LOCATION/B_ORGANIZATION
PCCNs I_LOCATION/I_ORGANIZATION
: O
financial B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructure I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
PCCN B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
were O
found O
to O
have O
a O
lower B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extent B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
financial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
evidenced O
by O
higher B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
percentage B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
' O
' O
never O
thinking B_PERSON/B_LOCATION
' O
' O
scale B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O
the O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
items I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
almost O
all O
items B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

slightly O
more B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
that O
is O
, O
' O
' O
acting O
' O
' O
rate B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
found O
in O
only O
four B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
items B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
both O
in O
clinic B_LOCATION/B_PERSON
- O
clinic B_LOCATION/B_PERSON
relationships I_LOCATION/I_PERSON
and O
in O
clinic B_LOCATION/B_PERSON
- O
hospital B_ORGANIZATION/B_PERSON
relationships I_ORGANIZATION/I_PERSON
, O
including O
uniting O
budget B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
planning I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
Table B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
item B_MEASURE
58 I_MEASURE
) O
, O
sharing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
places I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
and O
equipment B_PRODUCT[OBJECT]/B_LOCATION
( O
Table B_MEASURE/B_LOCATION
5 I_MEASURE/I_LOCATION
: O
item B_MEASURE
68 I_MEASURE
) O
, O
uniting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
budgeting I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
certain B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
services I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_NUMBER[MEASURE]/B_LOCATION
5 I_NUMBER[MEASURE]/I_LOCATION
: O
items B_MEASURE
72 I_MEASURE
) O
, O
and O
designing O
the O
resource B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
principals I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
the O
whole B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
item B_MEASURE
77 I_MEASURE
) O
. O

Further O
examining O
the O
financial B_ORGANIZATION/B_MEASURE
infrastructure I_ORGANIZATION/I_MEASURE
in O
clinic B_LOCATION/B_PERSON
- O
clinic B_PERSON/B_LOCATION
relationship I_PERSON/I_LOCATION
and O
clinic B_LOCATION/B_PERSON
- O
hospital B_PERSON/B_LOCATION
relationship I_PERSON/I_LOCATION
, O
paired O
- O
t B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
revealed O
that O
clinic B_LOCATION/B_PERSON
- O
hospital B_PERSON/B_LOCATION
partnerships I_PERSON/I_LOCATION
were O
involved O
more B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
places B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
materials B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O
and O
equipment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
sharing I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
maintenance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
items O
62 B_MEASURE
and O
68 B_MEASURE
) O
( O
p B_MEASURE
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
and O
higher B_MEASURE/B_LOCATION
financial I_MEASURE/I_LOCATION
infrastructure I_MEASURE/I_LOCATION
coordination I_MEASURE/I_LOCATION
exists O
in O
clinic B_LOCATION/B_PERSON
- O
clinic B_LOCATION/B_PERSON
relationships I_LOCATION/I_PERSON
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
items B_MEASURE
58 I_MEASURE
, O
59 B_MEASURE
, O
63 B_MEASURE
- O
65 B_MEASURE
, O
72 B_MEASURE
, O
74 B_MEASURE
, O
75 B_MEASURE
, O
and O
77 B_MEASURE
) O
( O
p B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
05 B_MEASURE
) O
. O

Profiling O
the O
partnerships B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Taiwan B_ORGANIZATION/B_LOCATION
PCCNs I_ORGANIZATION/I_LOCATION
: O
information B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructure I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
was O
significantly O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
clinic B_LOCATION/B_PERSON
- O
hospital B_LOCATION/B_PERSON
than O
clinic B_LOCATION/B_PERSON
- O
clinic B_LOCATION/B_PERSON
relationships I_LOCATION/I_PERSON
in O
all O
items B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
in O
this O
category B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
6 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
paired O
t B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
p B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

The O
greatest O
integration O
was O
found O
in O
electronic O
patient B_PERSON
records O
( O
Table O
6 O
: O
item O
78 O
) O
, O
followed O
by O
information O
integration O
for O
patient B_PERSON
data O
( O
Table O
6 O
: O
item O
79 O
) O
and O
clinical O
service O
arrangements O
( O
Table O
6 O
: O
item O
81 O
) O
. O

The O
lowest B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
information B_ORGANIZATION/B_LOCATION
infrastructure I_ORGANIZATION/I_LOCATION
was O
found O
in O
administrative B_LOCATION
works I_LOCATION
such I_LOCATION
as O
registration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
billing B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
so O
on O
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
item B_MEASURE/B_LOCATION
82 I_MEASURE/I_LOCATION
, O
' O
' O
never O
- O
thinking O
' O
' O
rate B_MEASURE
more I_MEASURE
than O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
within O
network B_LOCATION/B_ORGANIZATION
members I_LOCATION/I_ORGANIZATION
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
surveyed O
943 B_LOCATION/B_ORGANIZATION
clinics B_LOCATION/I_ORGANIZATION
that O
had O
belonged O
to O
Taiwan B_ORGANIZATION/B_LOCATION
PCCNs I_ORGANIZATION/I_LOCATION
for O
more B_MEASURE/B_PERSON
than O
a O
year B_TIME[MEASURE]
to O
understand O
the O
nature B_MEASURE/B_LOCATION
and O
extent B_MEASURE
of O
integration B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
which O
they O
and O
their O
associated O
PCCN B_ORGANIZATION/B_LOCATION
members I_ORGANIZATION/I_LOCATION
( O
clinics B_LOCATION/B_ORGANIZATION
and O
hospitals B_LOCATION/B_ORGANIZATION
) O
had O
in O
governance B_ORGANIZATION/B_PERSON
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
marketing B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
financial B_ORGANIZATION/B_PERSON
, O
and O
information B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructures I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
was O
found O
a O
wide B_MEASURE
variance I_MEASURE
in O
the O
kind B_MEASURE
and O
degree B_MEASURE
of O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
them O
and O
a O
lot B_MEASURE
of O
room B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
better B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
integration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
) O
. O

From O
the O
governance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
found O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
in O
the O
establishment B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fair B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
coordination I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
mechanism I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
item B_MEASURE
11 I_MEASURE
) O
among O
member B_PERSON/B_ORGANIZATION
clinics I_PERSON/I_ORGANIZATION
and O
member B_ORGANIZATION/B_LOCATION
hospitals I_ORGANIZATION/I_LOCATION
. O

coordination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
could O
be O
viewed O
from O
different B_LOCATION/B_PERSON
perspectives I_LOCATION/I_PERSON
, O
including O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
standardized B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
languages I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
forms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
organizational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
rules I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
procedures B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
the O
establishment B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
common B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
rules I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
policies B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
procedures B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
and O
the O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
through O
memos B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
a O
computerized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O
69 B_MEASURE
, O
70 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

facing O
the O
cumbersome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
integration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
suggests O
that O
each O
PCCN B_LOCATION/B_ORGANIZATION
' B_LOCATION/I_ORGANIZATION
s B_LOCATION/I_ORGANIZATION
headquarters B_LOCATION/I_ORGANIZATION
should O
become O
actively O
involved O
and O
clarify O
the O
authority B_ORGANIZATION/B_PERSON
, O
responsibility B_PERSON/B_ORGANIZATION
and O
accountability B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
individual B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
, O
identify O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conflict I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sources I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
and O
publicize O
the O
rules B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
regulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
network B_ORGANIZATION/B_LOCATION
integration I_ORGANIZATION/I_LOCATION
dynamics I_ORGANIZATION/I_LOCATION
covering O
decision B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
making O
processes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
market B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
planning I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
teamwork B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
designs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
members I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

These O
actions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O
enhance O
the O
trust B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
respect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
network B_NUMBER[MEASURE]/B_ORGANIZATION
members I_NUMBER[MEASURE]/I_ORGANIZATION
one I_NUMBER[MEASURE]/I_ORGANIZATION
another O
and O
could O
improve O
the O
small B_MEASURE
extent I_MEASURE
of O
integration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
found O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
about O
the O
mechanisms B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
communication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
channels B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
PCCNs B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
item B_MEASURE
12 I_MEASURE
) O
. O

From O
the O
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
communication B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
occur O
between O
the O
various B_PERSON/B_ORGANIZATION
entities B_PERSON/I_ORGANIZATION
such B_PERSON/I_ORGANIZATION
as O
between O
hospital B_LOCATION/B_PERSON
and O
clinics B_LOCATION/B_PERSON
, O
primary B_PERSON/B_LOCATION
care I_PERSON/I_LOCATION
physicians I_PERSON/I_LOCATION
and O
specialists B_PERSON/B_LOCATION
, O
managers B_PERSON/B_ORGANIZATION
and O
clinical B_PERSON
professionals I_PERSON
, O
and O
even O
among O
the O
clinical B_PERSON/B_ORGANIZATION
professionals I_PERSON/I_ORGANIZATION
in O
the O
network B_ORGANIZATION/B_LOCATION
. O

To O
develop O
effective B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
timely B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
communication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channels B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
the O
key B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
management B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
integrated B_DISEASE
organizations I_DISEASE
[ O
30 B_MEASURE
- O
32 B_MEASURE
] I_MEASURE
and O
could O
alleviate O
the O
tensions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
sometimes O
occur O
in O
the O
dynamics B_ORGANIZATION/B_LOCATION
of O
the O
multi B_MEASURE/B_DISEASE
- O
organizations B_ORGANIZATION/B_LOCATION
. O

In O
this O
study O
, O
it O
was O
found O
a O
low O
level O
of O
involvement O
of O
medical O
teams O
in O
medical O
projects O
, O
patient B_PERSON
- O
centered O
case O
management O
, O
and O
case O
report O
meetings O
among O
the O
network O
members O
( O
Table O
3 O
: O
item O
21 O
, O
22 O
, O
and O
23 O
) O
from O
a O
clinical O
integration O
perspective O
. O

Several O
researchers O
have O
addressed O
that O
clinical O
integration O
providing O
a O
process O
of O
medical O
management O
, O
care O
management O
, O
case O
management O
, O
and O
patient B_PERSON/B_ORGANIZATION
management O
designed O
to O
transform O
the O
traditionally O
fragmented O
delivery O
system O
into O
a O
more O
cohesive O
system O
[ O
71 O
] O
, O
and O
lead O
to O
higher O
service O
quality O
and O
assure O
financial O
objectives O
[ O
72 O
, O
73 O
] O
. O

More B_PERSON/B_MEASURE
attention I_PERSON/I_MEASURE
could O
be O
paid O
to O
these O
activities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
future B_TIME[MEASURE]/B_LOCATION
. O

In O
addition B_MEASURE/B_LOCATION
, O
it O
was O
also O
found O
less B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
planning O
and O
differentiating O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
market I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
areas I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
Table B_MEASURE
3 I_MEASURE
, O
item B_MEASURE
20 I_MEASURE
) O
among O
the O
network B_ORGANIZATION/B_LOCATION
members B_ORGANIZATION/I_LOCATION
in O
the O
category B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
clinical B_PERSON/B_ORGANIZATION
infrastructure I_PERSON/I_ORGANIZATION
. O

This O
may O
result O
from O
the O
existing O
specialty B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diversities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
PCCNs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
which O
might O
not O
need O
to O
involve O
planning O
and O
differentiating O
market B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
the O
members B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
services I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
at O
the O
early B_MEASURE/B_LOCATION
stage B_MEASURE/I_LOCATION
of O
network B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
development I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

There O
was O
more B_MEASURE
involvement I_MEASURE
in O
marketing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
clinic B_LOCATION/B_PERSON
- O
hospital B_ORGANIZATION/B_PERSON
relationships I_ORGANIZATION/I_PERSON
than O
in O
clinic B_LOCATION/B_PERSON
- O
clinic B_LOCATION/B_PERSON
relationships I_LOCATION/I_PERSON
. O

Generally O
speaking O
, O
hospitals O
have O
more O
resources O
( O
i O
. O
e O
. O
, O
money O
, O
human B_PERSON/B_SPECIES[BIO]
resources O
, O
materials O
, O
and O
physical O
assets O
) O
than O
clinics O
, O
which O
might O
explain O
the O
stronger O
marketing O
involvements O
between O
the O
clinic O
and O
hospital O
members O
, O
including O
the O
library O
sharing O
( O
books O
and O
literatures O
) O
, O
facility O
brochure O
dissemination O
, O
public O
promoting O
, O
and O
medical O
research O
cooperation O
. O

These O
integration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
efforts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
also O
meet O
the O
expectation B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
national B_LOCATION/B_ORGANIZATION
health B_LOCATION/I_ORGANIZATION
authority B_LOCATION/I_ORGANIZATION
for O
resource B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sharing I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
quality I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
image I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
enhancement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
among O
the O
health B_PERSON/B_LOCATION
care I_PERSON/I_LOCATION
providers I_PERSON/I_LOCATION
. O

financial B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
infrastructure I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
was O
found O
to O
be O
the O
least O
integrated O
, O
with O
most B_MEASURE/B_PERSON
items B_MEASURE/I_PERSON
never O
considered O
. O

Perhaps O
the O
only B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reason I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
score B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
budget B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
planning I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
activities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
items B_MEASURE
58 I_MEASURE
and O
77 B_MEASURE
) O
was O
that O
BHNI B_PERSON/B_LOCATION
required O
each O
PCCN B_ORGANIZATION/B_LOCATION
to O
design O
and O
determine O
its O
budgeting B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
arrangement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
advance B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
before O
joining O
the O
demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

While O
slightly O
more B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
financial I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
involvement I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
made O
among O
network B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
items B_MEASURE
68 I_MEASURE
, O
72 B_MEASURE
& O
73 B_MEASURE
) O
, O
possibly O
due O
to O
similar B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
needs I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
remains O
a O
lot B_MEASURE
of O
room B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
financial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
future B_TIME[MEASURE]/B_LOCATION
. O

There O
was O
a O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
networks B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
develop O
electronic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
though O
creating O
and O
managing O
an O
integrated B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involves O
very O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Most O
of O
the O
clinics O
surveyed O
have O
focused O
more O
on O
the O
individual O
public O
members O
' O
administrative O
works O
such O
as O
filing O
patient B_PERSON/B_LOCATION
medical O
records O
, O
collecting O
and O
managing O
network O
patient B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
clinical O
data O
, O
and O
scheduling O
clinical O
services O
, O
which O
were O
required O
by O
the O
BNHI O
. O

The O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O
the O
health B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
managers I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
adopt O
the O
integrated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
include O
the O
decision B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
make O
or O
buy O
, O
adoption B_PERSON/B_ORGANIZATION
leadership I_PERSON/I_ORGANIZATION
, O
adoption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
implementation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leadership I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
phased O
versus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
simultaneous I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
implementation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
technology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
implementation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
policies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
practices B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
use B_MEASURE
levels I_MEASURE
and O
resistance B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
realized O
benefits B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
return B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
investment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calculation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
66 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
, O
which O
might O
be O
very O
cumbersome B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
time B_TIME[MEASURE]/B_LOCATION
- O
consuming O
. O

It O
suggests O
that O
the O
network O
partners O
might O
be O
engaged O
, O
firstly O
, O
more O
in O
simpler O
network O
cooperation O
such O
as O
the O
administrative O
systems O
for O
patient B_PERSON
admission O
to O
the O
network O
members O
and O
establishing O
united O
web O
pages O
for O
patients B_PERSON
to O
access O
their O
family O
physicians O
and O
network O
members O
for O
medical O
and O
public O
promotion O
purposes O
. O

And O
for O
further B_PERSON
integrated I_PERSON
information I_PERSON
investments I_PERSON
, O
efforts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
must O
be O
redirected O
for O
network B_ORGANIZATION/B_PERSON
members B_ORGANIZATION/I_PERSON
to O
work O
together O
to O
define O
the O
approach B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
long B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
74 B_MEASURE/B_PERSON
] B_MEASURE/I_PERSON
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

This O
study O
tried O
to O
portray O
and O
trace O
how O
the O
facility O
participants B_PERSON
were O
involved O
in O
the O
Taiwan O
PCCNs O
. O

It O
was O
found O
that O
Taiwan B_PERSON/B_ORGANIZATION
PCCNs I_PERSON/I_ORGANIZATION
' I_PERSON/I_ORGANIZATION
members I_PERSON/I_ORGANIZATION
had O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
involvement I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
the O
governance B_ORGANIZATION/B_LOCATION
infrastructure I_ORGANIZATION/I_LOCATION
, O
which O
was O
usually O
viewed O
as O
the O
most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
establishment B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
core B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
PCCNs B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organization I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
management B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

There O
existed O
a O
higher B_MEASURE
extent I_MEASURE
of O
integration B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
marketing B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
information B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infrastructures I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
the O
hospital B_LOCATION/B_PERSON
- O
clinic B_PERSON/B_LOCATION
member I_PERSON/I_LOCATION
relationship I_PERSON/I_LOCATION
than O
those O
among O
clinic B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
within O
individual B_LOCATION/B_ORGANIZATION
PCCNs I_LOCATION/I_ORGANIZATION
. O

The O
financial B_LOCATION/B_ORGANIZATION
infrastructure I_LOCATION/I_ORGANIZATION
was O
shown O
the O
least B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrated O
relative B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
other B_ORGANIZATION/B_PERSON
functional I_ORGANIZATION/I_PERSON
infrastructures I_ORGANIZATION/I_PERSON
at O
the O
early B_TIME[MEASURE]/B_LOCATION
stage I_TIME[MEASURE]/I_LOCATION
of O
PCCN B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Page B_PERSON/B_LOCATION
[ O
43 B_PERSON/B_LOCATION
] I_PERSON/I_LOCATION
argued O
that O
networks B_LOCATION/B_ORGANIZATION
form O
and O
grow O
for O
various B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reasons I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
, O
only O
some O
of O
them O
could O
be O
compatible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
the O
iterative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
processes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
collaboration B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Some O
participants B_PERSON/B_ORGANIZATION
in O
the O
PCCNs O
may O
simply O
seek O
short O
- O
term O
economic O
gains O
and O
have O
little O
interest O
in O
joint O
learning O
and O
continuous O
improvement O
. O

From O
an O
organizational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
old B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phrase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
proposed O
by O
the O
wisdom B_TIME[MEASURE]/B_PERSON
of O
the O
saying B_PERSON/B_ORGANIZATION
about O
developing O
the O
integrated B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
organizations I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
networks B_LOCATION/B_ORGANIZATION
) O
should O
be O
- O
' O
coming O
together O
is O
the O
beginning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
working O
together O
is O
the O
success B_SEQUENCE[MEASURE]/B_LOCATION
. O
' O
Page B_PERSON/B_LOCATION
[ O
43 B_TIME[MEASURE]/B_PERSON
] B_TIME[MEASURE]/I_PERSON
examined O
the O
virtual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
provider I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
organizations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
such I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O
physician B_PERSON/B_LOCATION
- O
hospital B_PERSON/B_ORGANIZATION
organizations I_PERSON/I_ORGANIZATION
and O
pointed O
out O
the O
issue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
provider B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attitudes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
behaviors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
as O
the O
critically O
successful B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
continuous I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
improvements I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
health B_ORGANIZATION/B_LOCATION
care I_ORGANIZATION/I_LOCATION
environments I_ORGANIZATION/I_LOCATION
. O

A O
wide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
degree B_MEASURE
of O
network B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
integration I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Taiwan B_DISEASE/B_LOCATION
PCCNs I_DISEASE/I_LOCATION
still O
leaves O
room B_LOCATION
to O
improve O
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
thoroughly O
surveyed O
items B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
, O
that O
is O
, O
the O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
content B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
were O
employed O
. O

In O
addition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
provide O
how O
the O
network B_PERSON/B_ORGANIZATION
members I_PERSON/I_ORGANIZATION
have O
done O
their O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O
the O
early B_MEASURE/B_LOCATION
stage B_MEASURE/I_LOCATION
of O
network B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forming O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
detailed B_NUMBER[MEASURE]/B_PERSON
surveyed O
items B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
, O
the O
concepts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
proposed O
by O
the O
managerial B_PERSON
and O
theoretical B_PERSON/B_ORGANIZATION
professionals I_PERSON/I_ORGANIZATION
, O
could O
be O
also O
a O
guide B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
those O
health B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
providers I_PERSON/I_ORGANIZATION
who O
have O
a O
willingness B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
join O
multi B_MEASURE/B_DISEASE
- O
organizations B_ORGANIZATION/B_LOCATION
. O

It O
suggests O
that O
health B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
providers I_PERSON/I_ORGANIZATION
could O
take O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detailed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
looks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O
those O
surveyed O
items B_PRODUCT[OBJECT]/B_PERSON
and O
give O
some O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
opportunities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
create O
the O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
actions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
empirically O
done O
to O
explore O
the O
relative B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
integration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanisms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
the O
effectiveness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
organizational B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
partnerships I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
partnerships B_ORGANIZATION/B_PERSON
within O
each O
PCCN B_ORGANIZATION/B_LOCATION
represent O
various B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
depend O
on O
how O
much B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
the O
members B_PERSON/B_ORGANIZATION
are O
engaged O
in O
the O
projects B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition O
to O
the O
macro O
concepts O
including O
governance O
, O
clinical O
, O
marketing O
, O
financial O
, O
and O
information O
infrastructures O
explored O
in O
this O
study O
, O
other O
managerial O
issues O
for O
integrated O
organizations O
were O
also O
suggested O
such O
as O
formation O
of O
an O
integrated O
cultural O
atmosphere O
, O
human B_PERSON/B_SPECIES[BIO]
resources O
management O
, O
physician O
involvement O
, O
mission O
and O
commitment O
establishment O
, O
from O
micro O
organizational O
behavior O
perspective O
[ O
30 O
- O
32 O
, O
34 O
, O
36 O
, O
75 O
, O
76 O
] O
. O

Micro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
managerial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
longitudinal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
designs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
could O
be O
employed O
to O
more O
precisely O
catch O
the O
never O
completing O
integration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
future B_TIME[MEASURE]/B_LOCATION
. O

Abbreviations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

primary B_LOCATION/B_ORGANIZATION
community I_LOCATION/I_ORGANIZATION
care I_LOCATION/I_ORGANIZATION
network I_LOCATION/I_ORGANIZATION
( O
PCCN B_DISEASE/B_ORGANIZATION
) O
; O
Bureau B_ORGANIZATION/B_PERSON
of O
National B_LOCATION/B_PERSON
Health I_LOCATION/I_PERSON
Insurance I_LOCATION/I_PERSON
( O
BNHI B_ORGANIZATION/B_LOCATION
) O
. O

competing O
interests B_DISEASE
. O

The O
author B_PERSON/B_LOCATION
( O
s O
) O
declare O
that O
they O
have O
no O
competing O
interests B_PERSON/B_ORGANIZATION
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

BYJL B_PERSON
independently O
designed O
and O
conducted O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pre B_LOCATION/B_PERSON
- O
publication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
pre B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
publication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
accessed O
here O
: O

Recombinant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activated O
protein B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
C I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
sepsis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
endothelium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
or O
endothelium B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

endothelium B_DISEASE/B_GENE
dysfunction I_DISEASE/I_GENE
is O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
hallmarks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
sepsis B_DISEASE/B_LOCATION
. O

Looney B_PERSON
and O
Mattay B_PERSON
, O
in O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
issue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
Critical B_DISEASE/B_EDU[ORGANIZATION]
Care I_DISEASE/I_EDU[ORGANIZATION]
, O
highlight O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
activated O
protein B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
C I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
APC B_GENE/B_BACTERIUM[BIO]
) O
as O
a O
protective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
endothelial I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
septic B_DISEASE
situations I_DISEASE
. O

Nevertheless O
, O
the O
results O
of O
in O
vivo O
studies O
are O
less O
explicit O
and O
it O
remains O
uncertain O
whether O
these O
properties O
are O
relevant O
in O
human B_PERSON/B_SPECIES[BIO]
septic O
shock O
. O

Before O
considering O
recombinant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
APC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
rAPC B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
as O
a O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
endothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
we O
have O
to O
demonstrate O
its O
efficiency B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
protect O
or O
to O
reduce O
endothelium B_DISEASE
injury I_DISEASE
when O
infused O
a O
long B_TIME[MEASURE]/B_ENT
time I_TIME[MEASURE]/I_ENT
after O
the O
septic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
challenge B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Nevertheless O
, O
if O
rAPC O
is O
efficient O
when O
infused O
in O
the O
early O
phase O
of O
septic O
challenge O
, O
we O
thus O
need O
to O
treat O
our O
patients B_PERSON/B_DISEASE
earlier O
. O

At O
the O
least B_TIME[MEASURE]/B_LOCATION
, O
genetically O
engineered O
variants B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O
been O
designed O
with O
greater B_DISEASE
anti I_DISEASE
- O
apoptotic B_DISEASE/B_GENE
activity I_DISEASE/I_GENE
and O
reduced O
anticoagulant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
relative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
wild B_PERSON/B_BIO
- O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
APC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
to O
demonstrate O
the O
usefulness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
variants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
septic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
shock I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

The O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
recombinant B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activated O
protein B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
rAPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
is O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
hottest B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
topics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O
septic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
shock I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
pivotal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
placebo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- O
controlled O
Protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
C I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
worldwide I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
Severe B_DISEASE/B_LOCATION
sepsis I_DISEASE/I_LOCATION
( O
PROWESS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
a O
19 B_MEASURE
. O
4 B_MEASURE
% I_MEASURE
relative I_MEASURE
risk I_MEASURE
reduction I_MEASURE
in O
28 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_PERSON
mortality I_TIME[MEASURE]/I_PERSON
( O
6 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
absolute I_MEASURE
risk I_MEASURE
reduction I_MEASURE
) O
with O
an O
increased O
risk B_MEASURE
( O
3 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
versus I_MEASURE
2 I_MEASURE
. O
0 B_MEASURE
% I_MEASURE
) O
of O
serious B_DISEASE
bleeding I_DISEASE
events I_DISEASE
compared O
with O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two B_NUMBER[MEASURE]
recent I_NUMBER[MEASURE]
and O
important B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
articles I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
highlighted O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
APC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
as O
a O
protective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
endothelial I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O
1 B_NUMBER[MEASURE]/B_LOCATION
] I_NUMBER[MEASURE]/I_LOCATION
and O
as O
a O
cyto B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
protective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
2 B_MEASURE/B_PROTEIN[GENE]
] I_MEASURE/I_PROTEIN[GENE]
. O

beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rAPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
PROWESS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
thought O
to O
be O
related O
to O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
coagulation B_DISEASE
and O
, O
to O
a O
lesser B_DISEASE/B_MEASURE
extent B_DISEASE/I_MEASURE
, O
to O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
to O
sepsis B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
3 B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Post B_LOCATION/B_DISEASE
- O
PROWESS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O
been O
associated O
with O
a O
myriad B_MEASURE/B_LOCATION
of O
cellular B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
demonstrating O
that O
rAPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
through O
reactions B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
by O
endothelial B_GENE
protein I_GENE
C I_GENE
receptor I_GENE
and O
the O
effector B_GENE
receptor I_GENE
, O
protease B_GENE
activated O
receptor B_GENE
- O
1 B_NUMBER[MEASURE]
, O
acts O
directly O
on O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
exert O
multiple B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytoprotective I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O
: O
down B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
regulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
pro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE/B_GENE
gene I_DISEASE/I_GENE
expression I_DISEASE/I_GENE
[ I_DISEASE/I_GENE
4 I_DISEASE/I_GENE
] I_DISEASE/I_GENE
; O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
activities I_DISEASE_ADJECTIVE[DISEASE]
[ O
5 B_MEASURE
] I_MEASURE
; O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
apoptotic B_DISEASE
activity I_DISEASE
[ O
6 B_MEASURE
] O
; O
and O
protection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
endothelial B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
barrier B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
function B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
1 B_NUMBER[MEASURE]
, O
2 B_MEASURE/B_PROTEIN[GENE]
] I_MEASURE/I_PROTEIN[GENE]
. O

endothelium B_DISEASE/B_GENE
dysfunction I_DISEASE/I_GENE
is O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
hallmarks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
sepsis B_DISEASE/B_LOCATION
[ I_DISEASE/I_LOCATION
7 I_DISEASE/I_LOCATION
] I_DISEASE/I_LOCATION
. O

sepsis B_DISEASE/B_BACTERIUM[BIO]
, O
per O
se B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
may O
induce O
phenotypic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulations I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
endothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
through O
direct B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
indirect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
endothelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
layer B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
with O
components B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
bacterial B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
, O
inducing O
a O
myriad B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
host B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
- O
derived O
factors B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
endothelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

phenotypic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
modifications I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
include O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
coagulant B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
proadhesive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
increased O
endothelial B_DISEASE
permeability I_DISEASE
, O
endothelial B_DISEASE
cell I_DISEASE
apoptosis I_DISEASE
and O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vasomotor B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
; O
the O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
is O
crucial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O
vasoplegia B_DISEASE/B_PERSON
is O
directly O
related O
to O
septic B_DISEASE
shock I_DISEASE
mortality I_DISEASE
. O

Recent O
animal O
and O
human B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O
have O
suggested O
that O
rAPC O
may O
improve O
both O
vascular O
and O
myocardial O
dysfunction O
and O
vascular O
reactivity O
to O
catecholamine O
during O
endotoxin O
and O
/ O
or O
septic O
challenge O
[ O
8 O
, O
9 O
] O
. O

From O
bench B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
to O
bedside O
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
supports O
a O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
APC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O
maintaining O
the O
integrity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
endothelium B_BODY_PART_OR_ORGAN_COMPONENT
through O
both O
direct B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
indirect B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nevertheless O
, O
the O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
in O
vivo B_EDU[ORGANIZATION]/B_LOCATION
studies I_EDU[ORGANIZATION]/I_LOCATION
are O
less O
explicit B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
a O
retrospective O
study O
of O
septic O
shock O
in O
humans B_PERSON/B_SPECIES[BIO]
, O
Monnet O
and O
colleagues O
[ O
9 O
] O
demonstrated O
that O
APC O
infusion O
was O
associated O
with O
a O
decrease O
in O
the O
amount O
of O
delivered O
norepinephrine O
. O

Wiel O
and O
colleagues O
[ O
10 O
] O
demonstrated O
in O
a O
rabbit B_SPECIES[BIO]
model O
of O
endotoxin O
induced O
shock O
that O
APC O
decreased O
aorta O
endothelial O
injury O
. O

By O
contrast O
, O
in O
a O
lung O
model O
of O
endotoxin O
induced O
inflammation O
, O
Robriquet O
and O
colleagues O
[ O
11 O
] O
demonstrated O
a O
trend O
to O
an O
increased O
vascular O
permeability O
using O
high O
doses O
of O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
APC O
. O

This O
last O
result O
was O
in O
sharp O
contrast O
with O
the O
results O
obtained O
by O
Nick O
and O
colleagues O
[ O
12 O
] O
in O
a O
human B_SPECIES[BIO]
model O
of O
pulmonary O
endotoxin O
administration O
. O

APC B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
improve O
mortality B_DISEASE
in O
septic B_DISEASE/B_PERSON
shock I_DISEASE/I_PERSON
with O
a O
high B_DISEASE/B_GENE
APACHE I_DISEASE/I_GENE
2 I_DISEASE/I_GENE
score I_DISEASE/I_GENE
and O
is O
potentially O
detrimental B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sepsis B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

In O
rats O
, O
APC O
markedly O
decreased O
tumour O
necrosis O
factor O
concentrations O
whereas O
they O
remained O
unchanged O
in O
either O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
septic O
shock O
or O
endotoxemia O
. O

The O
question B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arises O
, O
therefore O
, O
as O
to O
whether O
it O
is O
truly O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
reconcile O
all O
these O
discrepancies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
, O
can O
these O
stirring O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
be O
translated O
into O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
practice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

limitations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
experimental B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
studies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O
endothelium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
versus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
endothelium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
therapy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Clearly O
, O
in O
cellular B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
rAPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
given O
either O
as O
a O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
or O
concurrent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
with O
septic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
challenge I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
mode O
of O
administration O
favours O
the O
anti O
- O
inflammatory O
effects O
of O
rAPC O
, O
which O
are O
particularly O
efficient O
in O
murine B_DISEASE
models O
in O
protecting O
the O
endothelium O
from O
cytokine O
- O
mediated O
apoptosis O
or O
upregulation O
of O
endothelial O
adhesion O
molecules O
. O

Thus O
, O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
post B_DISEASE
- O
injury B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O
needed O
in O
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
mimic O
septic B_DISEASE
shock I_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
experimental B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pneumonia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
peritonitis B_DISEASE
treated O
by O
antibiotics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
volume B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resuscitation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
where O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rAPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
would O
be O
investigated O
16 B_NUMBER[MEASURE]
to O
24 B_MEASURE/B_SPORT[ENT]
hours I_MEASURE/I_SPORT[ENT]
after O
septic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
challenge I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

If O
we O
can O
demonstrate O
the O
efficiency B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rAPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
protect O
or O
to O
reduce O
endothelium B_DISEASE/B_GENE
injury I_DISEASE/I_GENE
in O
these O
conditions B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
can O
ultimately O
postulate O
that O
rAPC B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
also O
a O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
endothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

The O
earlier B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
better B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

If O
rAPC O
is O
efficient O
when O
infused O
in O
the O
early O
phase O
of O
septic O
challenge O
, O
we O
thus O
need O
to O
treat O
our O
patients B_PERSON/B_DISEASE
earlier O
. O

At O
least O
two O
studies O
suggest O
that O
treatment O
with O
rAPC O
within O
24 O
hours O
may O
carry O
a O
larger O
survival O
advantage O
for O
patients B_PERSON/B_BIO
with O
severe O
sepsis O
, O
compared O
with O
those O
treated O
more O
than O
24 O
hours O
after O
organ O
dysfunction O
[ O
13 O
] O
. O

Interventions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
directed O
at O
specific B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
endpoints I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
when O
initiated O
early O
in O
the O
' B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
golden B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
patient B_PERSON
' O
s B_PERSON/B_TIME[MEASURE]
condition I_PERSON/I_TIME[MEASURE]
, O
seem O
to O
be O
promising B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O
14 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
] I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
beneficial O
effects O
of O
earlier O
administration O
of O
rAPC O
to O
appropriate O
patients B_PERSON/B_LOCATION
may O
fit O
into O
this O
paradigm O
. O

The O
future B_TIME[MEASURE]/B_PERSON
. O

Extensive B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
have O
focused O
on O
the O
cytoprotective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
APC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
most B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
authors I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agree O
that O
its O
anticoagulant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cytoprotective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
mediated O
by O
distinct B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
APC B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
structural B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
features B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

positively O
charged O
residues B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
surface B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
loops B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
APC B_PROTEIN[GENE]
protease I_PROTEIN[GENE]
domain I_PROTEIN[GENE]
have O
been O
identified O
as O
participating O
in O
the O
anticoagulant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
activity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
but O
not O
in O
cellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Hence O
, O
variants B_LOCATION/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
have O
been O
designed O
with O
greater B_DISEASE
anti I_DISEASE
- O
apoptotic B_DISEASE/B_GENE
activity I_DISEASE/I_GENE
and O
reduced O
anticoagulant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
relative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
wild B_PERSON/B_BIO
- O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
APC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Whether O
these O
genetically O
engineered O
variants B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
actually O
provide O
superior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O
to O
be O
elucidated O
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
allow O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
APC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
variants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
decreased B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticoagulant B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
reduce O
the O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
bleeding O
on O
the O
one B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hand I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
but O
also O
with O
normal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytoprotective I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
properties I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
retain O
full B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beneficial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
sepsis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Abbreviations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

PROWESS B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
Protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
C I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
worldwide I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
Severe B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sepsis B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
; O
rAPC B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
recombinant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activated O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

competing O
interests B_DISEASE
. O

BL B_PERSON
has O
received O
reimbursements B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
funding B_PERSON/B_ORGANIZATION
from O
Eli B_PERSON/B_LOCATION
Lilly B_PERSON/I_LOCATION
, O
France B_LOCATION/B_ORGANIZATION
. O

carbonic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Anhydrase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
inhibitors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
541 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
metal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
New I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Class I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
Antiglaucoma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
possessing O
carbonic B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CA B_LOCATION/B_ORGANIZATION
) O
inhibitory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
recently O
shown O
to O
be O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
intraocular B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IOP B_DISEASE/B_LOCATION
) O
lowering O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
and O
might O
be O
developed O
as O
a O
novel B_PERSON/B_ENT
class I_PERSON/I_ENT
of O
antiglaucoma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
we O
report O
the O
synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
a O
heterocyclic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CA O
inhibitor B_NUMBER[MEASURE]
and O
of O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
main B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metal I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
as O
Be B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
MG B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Al B_LOCATION/B_PERSON
( O
III B_TIME[MEASURE]/B_LOCATION
) O
, O
Zn B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
CD B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
Hg B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
the O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
5 B_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
ligands B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
new B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
characterized O
by O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
physico I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
chemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
assayed O
as O
inhibitors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isozymes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
CA O
I O
, O
II B_TIME[MEASURE]/B_PROTEIN[GENE]
and O
IV B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
. O

Some O
of O
them O
( O
but O
not O
the O
parent O
sulfonamides O
) O
strongly O
lowered O
IOP O
in O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
administered O
as O
a O
2 O
% O
solution O
into O
the O
eye O
. O

carbonic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
ANHYDRASE I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
inhibitors I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

Part B_MEASURE
54 I_MEASURE
Metal I_MEASURE
complexes I_MEASURE
OF O
heterocyclic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
SULFONAMIDES I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
A O
New B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Class I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
OF O
ANTIGLAUCOMA B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Agents I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Claudiu I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Supuran B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
* O
, O
Andrea B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Scozzafava I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

and O
Andrei B_PERSON/B_NUMBER[MEASURE]
Jitianu B_PERSON/I_NUMBER[MEASURE]
2 B_PERSON/I_NUMBER[MEASURE]
. O

Universit B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O
degli B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Studi I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
Dipartimento B_LOCATION
di I_LOCATION
Chimica I_LOCATION
, O
Laboratorio B_LOCATION/B_PERSON
di I_LOCATION/I_PERSON
Chimica I_LOCATION/I_PERSON
Inorganica I_LOCATION/I_PERSON
e O
Bioinorganica B_LOCATION/B_PERSON
, O
Via O
Gino B_PERSON/B_LOCATION
Capponi B_PERSON/I_LOCATION
7 B_PERSON/I_LOCATION
, O
1 B_MEASURE
- O
50121 B_MEASURE
, O
Florence B_LOCATION
, O
Italy B_MEASURE/B_ORGANIZATION
2 I_MEASURE/I_ORGANIZATION
' O
I O
. O
G B_PROTEIN[GENE]/B_LOCATION
. O

Murgulescu B_LOCATION/B_PERSON
' I_LOCATION
Institute I_LOCATION
of O
Physical B_EDU[ORGANIZATION]/B_PERSON
Chemistry I_EDU[ORGANIZATION]/I_PERSON
, O
Academia B_LOCATION
Romana I_LOCATION
, O
Spl B_LOCATION
. O

Independentei B_MEASURE/B_ORGANIZATION
202 I_MEASURE/I_ORGANIZATION
, O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
77208 B_MEASURE/B_LOCATION
Bucharest I_MEASURE/I_LOCATION
, O
Roumania B_LOCATION/B_MEASURE
abstract I_LOCATION/I_MEASURE
: O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
possessing O
carbonic B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CA B_LOCATION/B_ORGANIZATION
) O
inhibitory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
recently O
shown O
to O
be O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
intraocular B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IOP B_DISEASE/B_LOCATION
) O
lowering O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
animals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
and O
might O
be O
developed O
as O
a O
novel B_PERSON/B_ENT
class I_PERSON/I_ENT
of O
antiglaucoma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
we O
report O
the O
synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
a O
heterocyclic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CA O
inhibitor B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
of O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
main B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metal I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
as O
Be B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
MG B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
AI B_LOCATION/B_PERSON
( O
III B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
, O
Zn B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
CD B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
Hg B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
the O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
5 B_NUMBER[MEASURE]
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_MEASURE
, O
4thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
ligands B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
new B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
characterized O
by O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
physico I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
chemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
assayed O
as O
inhibitors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isozymes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
CA O
I O
, O
II B_TIME[MEASURE]/B_PROTEIN[GENE]
and O
IV B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
. O

Some O
of O
them O
( O
but O
not O
the O
parent O
sulfonamides O
) O
strongly O
lowered O
IOP O
in O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
administered O
as O
a O
2 O
% O
solution O
into O
the O
eye O
. O

Introduction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
possessing O
carbonic B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
anhydrase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CA B_LOCATION/B_MEASURE
, O
EC B_MEASURE
4 I_MEASURE
. O
2 B_MEASURE
. O
1 B_MEASURE
. O
1 B_MEASURE
) O
inhibitory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
2 B_DISEASE_ADJECTIVE[DISEASE]
] I_DISEASE_ADJECTIVE[DISEASE]
such I_DISEASE_ADJECTIVE[DISEASE]
as O
acetazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
methazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
ethoxzolamide B_NUMBER[MEASURE]
3 I_NUMBER[MEASURE]
and O
dichlorophenamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
used O
for O
more B_MEASURE/B_PERSON
than O
40 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
as O
pressure B_DISEASE
lowering O
systemic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
angle B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
glaucoma B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
3 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Their O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
due O
to O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
at O
least O
two B_NUMBER[MEASURE]/B_BIO
CA I_NUMBER[MEASURE]/I_BIO
isozymes I_NUMBER[MEASURE]/I_BIO
present I_NUMBER[MEASURE]/I_BIO
within O
cilliary B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
processes I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
of O
the O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
ie O
, O
CA B_PROTEIN[GENE]/B_LOCATION
II I_PROTEIN[GENE]/I_LOCATION
and O
CA B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
IV I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
is O
followed O
by O
lowered O
bicarbonate B_MEASURE/B_LOCATION
formation I_MEASURE/I_LOCATION
and O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
aqueous B_MEASURE/B_LOCATION
humor B_MEASURE/I_LOCATION
secretion B_MEASURE/I_LOCATION
[ B_MEASURE/I_LOCATION
5 B_MEASURE/I_LOCATION
- O
7 B_MEASURE
] I_MEASURE
. O

Their O
main B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
drawback I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O
constituted O
by O
side B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
such B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
fatigue B_DISEASE
, O
augmented B_DISEASE
diuresis I_DISEASE
, O
or O
paresthesias B_DISEASE
, O
due O
to O
CA B_DISEASE_ADJECTIVE[DISEASE]
inhibition I_DISEASE_ADJECTIVE[DISEASE]
in O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
/ O
organs B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
than O
the O
target B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ie O
, O
the O
eye B_BODY_PART_OR_ORGAN_COMPONENT
[ O
8 B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

N B_OTHER/B_PROTEIN[GENE]
- O
- O
N B_OTHER/B_MEASURE
. O

XN B_MEASURE/B_PROTEIN[GENE]
- O
- O
N B_SEQUENCE[MEASURE]/B_LOCATION
EtO I_SEQUENCE[MEASURE]/I_LOCATION
S I_SEQUENCE[MEASURE]/I_LOCATION
. O

NH B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

O B_OTHER/B_PERSON

NH B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
S B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
- O
- O
O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

NHEt B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
above O
- O
mentioned O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
case B_PERSON/B_LOCATION
in O
which O
the O
inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
topical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
is O
applied O
directly O
into O
the O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

This O
route B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
been O
demonstrated O
only O
in O
1983 B_MEASURE/B_LOCATION
by O
Maren B_MEASURE/B_ORGANIZATION
' I_MEASURE/I_ORGANIZATION
s I_MEASURE/I_ORGANIZATION
group I_MEASURE/I_ORGANIZATION
[ O
9 B_TIME[MEASURE]
] I_TIME[MEASURE]
and O
was O
followed O
by O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
first B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
type B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
10 B_NUMBER[MEASURE]
, O
11 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Trusopt B_PROTEIN[GENE]/B_LOCATION
) O
has O
been O
introduced O
in O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
1995 B_MEASURE
in O
USA B_LOCATION
and O
Europe B_LOCATION
and O
it O
constituted O
the O
beginning B_TIME[MEASURE]/B_PERSON
of O
a O
radically O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glaucoma B_DISEASE
, O
devoid B_DISEASE/B_LOCATION
of O
the O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
with O
the O
systemic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
inhibitors I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
[ O
4 B_TIME[MEASURE]/B_LOCATION
- O
6 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
success B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
topical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antiglaucoma I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
CA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inhibitors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
fostered O
much B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
types B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
such B_LOCATION/B_MEASURE
compounds I_LOCATION/I_MEASURE
[ I_LOCATION/I_MEASURE
12 I_LOCATION/I_MEASURE
- O
15 B_MEASURE
] I_MEASURE
. O

307 B_NUMBER[MEASURE]
. O

Vol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

4 O
, O
No O
. O
6 B_MEASURE
, O
1997 B_MEASURE/B_LOCATION
. O

metal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
complexes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
A O
New B_PERSON/B_ENT
Class B_PERSON/I_ENT
ofAntiglaucoma B_PERSON/I_ENT
Agents B_PERSON/I_ENT
. O

On O
the O
other B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hand I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
type B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
5 B_MEASURE
have O
been O
recently O
prepared O
by O
two B_MEASURE
groups I_MEASURE
16 I_MEASURE
- O
20 B_MEASURE
] I_MEASURE
, O
and O
it O
was O
proved O
that O
they O
possess O
much O
stronger B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
CA I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
inhibitory I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
properties I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
the O
sulfonamides B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
from O
which O
they O
were O
prepared O
18 B_MEASURE
- O
22 B_MEASURE
] I_MEASURE
. O

Although O
the O
mechanism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
CA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
complexes B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
is O
presently O
unknown B_DISEASE_ADJECTIVE[DISEASE]
, O
it O
was O
hypothesized O
that O
their O
increased O
inhibitory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
power I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O
be O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
two B_LOCATION/B_MEASURE
processes I_LOCATION/I_MEASURE
, O
occurring O
separately O
or O
in O
concert B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
ie O
, O
( O
i O
) O
dissociation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
complex B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
anions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
in O
diluted B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
, O
which O
in O
turn B_GENE/B_PERSON
both O
interact B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
thereafter O
with O
the O
enzyme B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
at O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
binding B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
sites B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
and O
( O
ii B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
the O
undissociated B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
complex I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
with O
the O
enzyme B_ENZYME[GENE]
, O
and O
more O
specifically O
with O
the O
hydrophilic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patch I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
entrance B_LOCATION
of O
CA B_LOCATION/B_BIO
II I_LOCATION/I_BIO
active I_LOCATION/I_BIO
site I_LOCATION/I_BIO
[ O
23 B_MEASURE
] I_MEASURE
, O
this O
being O
the O
isozyme B_ENZYME[GENE]/B_LOCATION
most O
susceptible B_DISEASE_ADJECTIVE[DISEASE]
to O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
this O
class B_PERSON/B_LOCATION
of O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
22 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

Whether O
initially O
the O
first B_LOCATION
mechanism I_LOCATION
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mentioned O
above O
was O
favored O
by O
us O
[ O
22 B_MEASURE
] I_MEASURE
, O
recent B_PERSON
evidences I_PERSON
suggested O
that O
the O
undissociated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
might O
be O
the O
inhibitory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
species I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
at O
least O
for O
some O
isozymes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
[ O
24 B_MEASURE
] I_MEASURE
. O

Since O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
much O
more O
inhibitory B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O
the O
parent B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sulfonamide I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
which O
they O
were O
prepared O
, O
it O
appeared O
of O
interest B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
test O
whether O
this O
property B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O
be O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
their O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
lowering O
IOP B_DISEASE/B_GENE
in O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
whence B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
as O
a O
possible B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glaucoma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recently O
we O
proved O
[ O
25 B_MEASURE
, O
26 B_MEASURE
] O
that O
some O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
which O
themselves O
do O
not O
possess O
IOP B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lowering O
properties B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
act B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
very O
powerful B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
administered O
as O
diluted B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
solutions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
directly O
into O
the O
eye B_BODY_PART_OR_ORGAN_COMPONENT
of O
experimental B_SPECIES[BIO]/B_PERSON
animals I_SPECIES[BIO]/I_PERSON
, O
and O
would O
thus O
offer O
the O
possibility B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
developing O
such B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
totally O
novel B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Here O
we O
report O
the O
synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
a O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possessing O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CA B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitory B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ie O
, O
5 B_NUMBER[MEASURE]
- O
( O
chloroacetamido B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
of O
the O
metal B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
this O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
of O
5 B_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_TIME[MEASURE]/B_PROTEIN[GENE]
, O
3 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
containing O
some O
main B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metal I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
new O
compounds O
have O
been O
characterized O
by O
standard O
physico O
- O
chemical O
procedures O
, O
and O
were O
assayed O
as O
inhibitors O
of O
three O
CA O
isozymes O
, O
hCA O
I O
, O
hCA O
II O
and O
bCA O
IV O
( O
h O
human B_PROTEIN[GENE]/B_SPECIES[BIO]
; O
b O
bovine B_SPECIES[BIO]/B_PROTEIN[GENE]
; O
these O
are O
the O
isozymes O
considered O
to O
play O
a O
critical O
role O
in O
aqueous O
humour O
secretion O
within O
the O
eye O
of O
higher O
vertebrates O
[ O
2 O
- O
5 O
] O
) O
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

melting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
points I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
recorded O
with O
a O
heating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscope I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
are O
not O
corrected O
. O

IR B_NUMBER[MEASURE]/B_ENT
spectra B_NUMBER[MEASURE]/I_ENT
were O
recorded O
in O
KBr B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pellets I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
a O
Carl B_LOCATION/B_PROTEIN[GENE]
Zeiss I_LOCATION/I_PROTEIN[GENE]
IR I_LOCATION/I_PROTEIN[GENE]
- O
80 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
instrument I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

1H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
NMR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectra I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
recorded O
in O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
d6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
solvent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
with O
a O
Bruker B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
CPX200 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Chemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shifts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
reported O
as O
values B_MEASURE
, O
relative B_PERSON/B_MEASURE
to O
Me4Si B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
internal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
standard I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Conductimetric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
done O
at O
room B_MEASURE/B_LOCATION
temperature I_MEASURE/I_LOCATION
( O
1 B_MEASURE/B_LOCATION
mm B_MEASURE/I_LOCATION
concentration B_MEASURE/I_LOCATION
of O
complex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
a O
Fisher B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conductimeter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

elemental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
done O
by O
combustion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
C B_LOCATION/B_GENE
, O
H B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N B_OTHER/B_LOCATION
with O
an O
automated O
Carlo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Erba I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyzer I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
gravimetrically O
for O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
were O
0 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
theoretical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Thermogravimetric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
done O
in O
air B_LOCATION/B_DISEASE
, O
at O
a O
heating B_MEASURE
rate I_MEASURE
of O
10C B_MEASURE/B_PERSON
/ O
min B_PERSON/B_MEASURE
. O
, O
with O
a O
Perkin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
Elmer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
3600 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
thermobalance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O

Sulfonamides B_TIME[MEASURE]/B_LOCATION
used O
as O
standards B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
the O
enzymatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
except O
for O
5 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
acetazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
chloroacetyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
for O
the O
preparation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
compound B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
solvents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
inorganic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reagents I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
from O
sigma B_GENE/B_LOCATION
, O
Merck B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
Carlo B_PERSON/B_ORGANIZATION
Erba I_PERSON/I_ORGANIZATION
. O

5 B_MEASURE
- O
Amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_MEASURE/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
prepared O
from O
acetazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O
literature B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedures B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
27 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
, O
by O
desacetylation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
with O
concentrated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrochloric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
followed O
by O
neutralization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bicarbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
corresponding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Scheme B_MEASURE
1 I_MEASURE
) O
. O

Dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
from O
Merck B_PERSON
, O
Sharp B_PERSON/B_COLOR
and O
Dohme B_PERSON
or O
was O
prepared O
as O
described O
by O
Ponticello B_LOCATION/B_MEASURE
et I_LOCATION/I_MEASURE
al O
10 B_MEASURE
, O
11 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Human B_PERSON/B_NUMBER[MEASURE]
CA O
and O
CA O
II O
cDNAs O
were O
expressed O
in O
Escherichia O
coli O
strain O
BL21 O
( O
DE3 O
) O
from O
the O
plasmids O
pACA O
/ O
hCA O
I O
and O
pACAdaCA O
II O
described O
by O
Forsman O
et O
al O
. O

[ O
28 B_TIME[MEASURE]
] O
( O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasmids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
a O
gift B_TIME[MEASURE]/B_PERSON
from O
Prof B_PERSON/B_LOCATION
. O
Sven B_PERSON
Lindskog I_PERSON
, O
Umea B_LOCATION
University I_LOCATION
, O
Sweden B_LOCATION/B_MEASURE
) O
. O

Cell B_MEASURE/B_PERSON
growth B_MEASURE/I_PERSON
conditions B_MEASURE/I_PERSON
were O
those O
described O
by O
Lindskog B_PERSON
' I_PERSON
s I_PERSON
group I_PERSON
[ O
29 B_MEASURE
] I_MEASURE
, O
and O
enzymes B_BIO/B_PROTEIN[GENE]
were O
purified O
by O
affinity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
according O
to O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Khalifah B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
30 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Enzyme B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
determined O
spectrophotometrically O
at O
280 B_TIME[MEASURE]/B_LOCATION
nm I_TIME[MEASURE]/I_LOCATION
, O
utilizing O
a O
molar B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absorptivity B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
49 B_MEASURE
mm I_MEASURE
- O
l B_MEASURE/B_DISEASE
. O
cm B_MEASURE
- O
1 B_NUMBER[MEASURE]
for O
HCA B_DISEASE/B_PROTEIN[GENE]
and O
54 B_MEASURE
mm I_MEASURE
- O
l B_MEASURE/B_DISEASE
. O
cm B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]
for O
HCA B_DISEASE/B_PROTEIN[GENE]
II B_DISEASE/I_PROTEIN[GENE]
, O
respectively O
, O
based O
on O
M B_MEASURE/B_LOCATION
28 I_MEASURE/I_LOCATION
. O
85 B_MEASURE
kDa I_MEASURE
for O
HCA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
29 B_MEASURE
. O
3 B_MEASURE
kDa I_MEASURE
for O
HCA B_DISEASE/B_LOCATION
II I_DISEASE/I_LOCATION
, O
respectively O
[ B_MEASURE
31 I_MEASURE
, O
32 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

bCA O
IV O
was O
isolated O
from O
bovine B_SPECIES[BIO]/B_PROTEIN[GENE]
lung O
microsomes O
as O
described O
by O
Maren O
et O
al O
, O
and O
its O
concentration O
has O
been O
determined O
by O
titration O
with O
ethoxzolamide O
[ O
33 O
] O
. O

synthesis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
5 B_MEASURE
- O
( O
chloroacetamido B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]/B_PERSON
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
An O
amount B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
1 B_MEASURE
. O
80 B_MEASURE
g I_MEASURE
( O
10 B_MEASURE/B_LOCATION
mmol I_MEASURE/I_LOCATION
) O
of O
5 B_NUMBER[MEASURE]
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_TIME[MEASURE]/B_PROTEIN[GENE]
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]/B_PERSON
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
suspended O
in O
20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
anhydrous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonitrile I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
0 B_MEASURE
. O
9 B_MEASURE
mL I_MEASURE
( O
0 B_MEASURE
. O
87g B_MEASURE
, O
11 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mmol I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
pyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
added O
. O

The O
mixture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
magnetically O
stirred O
at O
4 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
10 B_TIME[MEASURE]
minutes I_TIME[MEASURE]
, O
then O
10 B_MEASURE
. O
5 B_MEASURE/B_PERSON
mmol I_MEASURE/I_PERSON
of O
monochloroacetyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dissolved O
in O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonitrile I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
were O
added O
dropwise B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
5 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
min I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
stirring O
was O
continued O
for O
other B_TIME[MEASURE]
2 I_TIME[MEASURE]
hours I_TIME[MEASURE]
at O
room B_TIME[MEASURE]/B_LOCATION
temperature I_TIME[MEASURE]/I_LOCATION
. O

After O
an O
additional B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
refluxation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
followed O
by O
cooling O
, O
the O
precipitated O
crystals B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
filtered O
and O
recrystallized O
from O
ethanol B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

yield B_MEASURE/B_ENT
of O
62 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
white I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
crystals I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
MP B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
246 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
248 B_TIME[MEASURE]
o I_TIME[MEASURE]
lit I_TIME[MEASURE]
[ I_TIME[MEASURE]
34 I_TIME[MEASURE]
] O
mP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
IR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
KBr B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
cm B_LOCATION/B_PROTEIN[GENE]
- O
l B_OTHER/B_MEASURE
: O
590 B_MEASURE
, O
610 B_MEASURE
, O
660 B_MEASURE
, O
790 B_MEASURE
, O
935 B_MEASURE
, O
1090 B_MEASURE
, O
1115 B_MEASURE
, O
1170 B_MEASURE
, O
1350 B_MEASURE
, O
1400 B_MEASURE
, O
1550 B_MEASURE
, O
1650 B_MEASURE
, O
1720 B_MEASURE
, O
2870 B_MEASURE
, O
3280 B_MEASURE/B_LOCATION
3370 I_MEASURE/I_LOCATION
( O
broad B_MEASURE
) O
; O
UV B_DISEASE/B_PROTEIN[GENE]
spectrum B_DISEASE/I_PROTEIN[GENE]
, O
, O
Max B_PERSON/B_PROTEIN[GENE]
, O
nm B_MEASURE/B_DISEASE
( O
lg B_MEASURE/B_PROTEIN[GENE]
) O
: O
255 B_MEASURE
( O
3 B_MEASURE
. O
50 B_MEASURE
) O
; O
288 B_MEASURE
( O
4 B_MEASURE
. O
37 B_MEASURE
) O
H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
NMR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
d6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
i O
, O
ppm B_MEASURE/B_PROTEIN[GENE]
: O
2 B_MEASURE
. O
96 B_MEASURE
( O
s O
, O
2H B_LOCATION/B_MEASURE
, O
CH2 B_LOCATION/B_PROTEIN[GENE]
) O
; O
8 B_MEASURE
. O
20 B_MEASURE
( O
s O
, O
2H B_LOCATION
, O
SOzNH2 B_LOCATION
) O
; O
12 B_MEASURE
. O
22 B_MEASURE
( O
s O
, O
1H B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CONH B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Analysis B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
found O
: O
C B_OTHER/B_LOCATION
, O
18 B_MEASURE
. O
56 B_MEASURE
; O
H B_OTHER/B_LOCATION
, O
1 B_MEASURE
. O
88 B_MEASURE
; O
N B_OTHER/B_LOCATION
, O
21 B_MEASURE
. O
76 B_MEASURE
; O
S B_OTHER/B_LOCATION
, O
24 B_MEASURE
. O
62 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
C4HsC1N403S2 B_LOCATION
requires O
' O
C B_OTHER/B_LOCATION
, O
18 B_MEASURE
. O
72 B_MEASURE
; O
H B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
1 B_MEASURE
. O
96 B_MEASURE
; O
N B_OTHER/B_LOCATION
, O
21 B_MEASURE
. O
83 B_MEASURE
; O
S B_OTHER/B_LOCATION
, O
24 B_MEASURE
. O
98 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

General B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
for O
the O
preparation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
compounds B_MEASURE/B_LOCATION
8 B_MEASURE/I_LOCATION
- O
20 B_MEASURE
An O
amount B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
6 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mmol I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
salt B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
sulfonamides B_MEASURE
6 I_MEASURE
or O
7 B_MEASURE/B_LOCATION
was O
prepared O
by O
reacting O
the O
corresponding B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sulfonamide I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
the O
required B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
amount I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
an O
alcoholic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaOH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
solvent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
this O
308 B_TIME[MEASURE]/B_LOCATION
. O

Claudiu B_MEASURE
T I_MEASURE
. O
Supuran B_PERSON/B_LOCATION
et B_PERSON/I_LOCATION
al B_PERSON/I_LOCATION
. O

metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Based O
Drugs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
added O
the O
aqueous B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
metal I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
salt I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Zn B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
MG B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
AI B_LOCATION
( O
III B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
, O
CD B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
chlorides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
and O
Be O
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Pb B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
Hg B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
nitrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
working O
in O
molar B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ratios I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
RSOzNH I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
Mn B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
of O
2 B_MEASURE
: O
1 B_NUMBER[MEASURE]
for O
the O
divalent B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cations I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
3 B_MEASURE
: O
1 B_NUMBER[MEASURE]
for O
the O
trivalent B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cation I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
. O

The O
aqueous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
alcoholic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reaction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
mixture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
heated O
on O
a O
steam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bath B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
one B_TIME[MEASURE]/B_ENT
hour I_TIME[MEASURE]/I_ENT
, O
adjusting O
the O
pH B_MEASURE
at O
7 B_MEASURE/B_LOCATION
if O
necessary B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
after O
being O
cooled O
at O
0 B_NUMBER[MEASURE]/B_LOCATION
C I_NUMBER[MEASURE]/I_LOCATION
the O
precipitated O
complexes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
filtered O
and O
thoroughly O
washed O
with O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
water B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
: O
1 B_MEASURE
( O
v B_OTHER/B_MEASURE
/ O
v O
) O
and O
air B_DISEASE_ADJECTIVE[DISEASE]
dried O
. O

yields B_MEASURE/B_PERSON
were O
in O
the O
range B_LOCATION/B_MEASURE
of O
85 B_MEASURE
- O
90 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
. O

The O
obtained O
white B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
powders I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
compounds B_MEASURE/B_PROTEIN[GENE]
8 I_MEASURE/I_PROTEIN[GENE]
- O
20 B_MEASURE
melted O
with O
decomposition B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
temperatures B_MEASURE
higher I_MEASURE
than O
350 B_MEASURE/B_LOCATION
C I_MEASURE/I_LOCATION
, O
and O
were O
poorly O
soluble B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
but O
had O
good B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solubilities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
DMF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
mixtures B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
DMF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

pharmacology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
carbonic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
anhydrase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
inhibition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Initial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
4 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
nitrophenyl B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
hydrolysis I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
catalysed O
by O
different B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
CA B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
isozymes B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
were O
monitored O
spectrophotometrically O
, O
at O
400 B_MEASURE/B_LOCATION
rim I_MEASURE/I_LOCATION
, O
with O
a O
Cary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interfaced O
with O
an O
IBM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compatible I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PC I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
35 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Solutions B_LOCATION
of O
substrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
prepared O
in O
anhydrous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonitrile I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
the O
substrate B_MEASURE
concentrations I_MEASURE
varied O
between O
2 B_MEASURE
. O
10 B_MEASURE
- O
2 B_MEASURE
and O
1 B_MEASURE
. O
10 B_MEASURE
- O
6 B_MEASURE/B_LOCATION
M I_MEASURE/I_LOCATION
, O
working O
at O
25C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

A O
molar B_MEASURE
absorption I_MEASURE
coefficient I_MEASURE
of O
18 B_MEASURE
, O
400 B_MEASURE
M I_MEASURE
- O
l B_OTHER/B_MEASURE
. O
cm B_MEASURE/B_LOCATION
- O
1 B_MEASURE
was O
used O
for O
the O
4 B_MEASURE/B_PROTEIN[GENE]
- O
nitrophenolate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formed O
by O
hydrolysis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
the O
conditions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
pH B_MEASURE/B_LOCATION
7 I_MEASURE/I_LOCATION
. O
40 B_MEASURE
) O
, O
as O
reported O
in O
the O
literature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
[ O
35 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Non B_DISEASE
- O
enzymatic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrolysis I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
always O
subtracted O
from O
the O
observed B_MEASURE
rates I_MEASURE
. O

duplicate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
done O
for O
each O
inhibitor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
the O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reported O
throughout O
the O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
are O
the O
mean B_MEASURE/B_PERSON
of O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Stock B_PERSON/B_LOCATION
solutions B_PERSON/I_LOCATION
of O
inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
were O
prepared O
in O
distilled O
- O
deionized B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
1020 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
v B_OTHER/B_MEASURE
/ O
v O
) O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
which O
is O
not O
inhibitory B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
these O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ I_MEASURE
2 I_MEASURE
] I_MEASURE
) O
and O
dilutions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
up O
to O
0 B_MEASURE
. O
01 B_MEASURE
nm I_MEASURE
were O
done O
thereafter O
with O
distilled O
- O
deionized O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
enzyme B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
solutions B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
were O
preincubated O
together O
for O
10 B_TIME[MEASURE]
min I_TIME[MEASURE]
at O
room B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temperature I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prior I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
assay B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
order B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
allow O
for O
the O
formation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
E B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
I O
complex B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
inhibition B_MEASURE/B_LOCATION
constant B_MEASURE/I_LOCATION
Ki B_MEASURE/I_LOCATION
was O
determined O
as O
described O
by O
Pocket B_TIME[MEASURE]/B_PERSON
and O
Stone B_PERSON
[ O
35 B_LOCATION/B_GENE
] I_LOCATION/I_GENE
. O

enzyme B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
3 B_MEASURE
. O
3 B_MEASURE/B_COLOR
nm I_MEASURE/I_COLOR
for O
HCA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
l0 O
nm B_MEASURE
for O
HCA B_DISEASE/B_PROTEIN[GENE]
and O
34 B_MEASURE
nm I_MEASURE
for O
BCA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
this O
isozyme B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
decreased O
esterase B_MEASURE
activity I_MEASURE
[ O
36 B_MEASURE
] I_MEASURE
and O
higher B_TIME[MEASURE]/B_LOCATION
concentrations I_TIME[MEASURE]/I_LOCATION
had O
to O
be O
used O
for O
the O
- O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

measurement O
of O
tonometric O
lOP O
Adult O
male O
New O
Zealand O
albino O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weighing O
2 O
- O
3 O
kg O
were O
used O
in O
the O
experiments O
( O
three O
animals O
were O
used O
for O
each O
inhibitor O
studied O
) O
. O

The O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
procedures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
conform O
to O
the O
Association B_ORGANIZATION/B_LOCATION
for O
Research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
vision B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
and O
Ophthalmology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resolution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
animals B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
kept O
in O
individual O
cages O
with O
food O
and O
water O
provided O
ad O
libitum O
. O

The O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
maintained O
on O
a O
12 B_MEASURE
h O
: O
12 B_MEASURE
h O
light B_COLOR/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
dark B_TIME[MEASURE]/B_ENT
cycle I_TIME[MEASURE]/I_ENT
in O
a O
temperature B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
controlled O
room B_LOCATION
, O
at O
22 B_MEASURE
- O
26 B_TIME[MEASURE]/B_LOCATION
C I_TIME[MEASURE]/I_LOCATION
. O

solutions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
inhibitors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
by O
weight B_MEASURE
) O
were O
obtained O
in O
DMSOwater B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
2 B_MEASURE
: O
3 B_MEASURE
, O
v O
/ O
v O
) O
due O
to O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
water B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
solubility B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
some O
of O
these O
derivatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
at O
the O
same B_MEASURE/B_LOCATION
concentration I_MEASURE/I_LOCATION
as O
that O
used O
for O
obtaining O
the O
inhibitors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
solutions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
showed O
that O
it O
does O
not O
possess O
IOP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lowering I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
increasing O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

IOP B_DISEASE/B_PROTEIN[GENE]
was O
measured O
using O
a O
Digilab B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
30R B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
pneumatonometer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
( O
BioRad B_MEASURE/B_ORGANIZATION
, O
Cambridge B_LOCATION/B_PERSON
, O
MA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
as O
described O
by O
Maren B_PERSON/B_ORGANIZATION
' I_PERSON/I_ORGANIZATION
s I_PERSON/I_ORGANIZATION
group I_PERSON/I_ORGANIZATION
[ O
37 B_MEASURE
- O
39 B_MEASURE
] I_MEASURE
. O

The O
pressure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
readings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
matched O
with O
two B_NUMBER[MEASURE]/B_LOCATION
- O
point B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
pressure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
least O
twice O
each O
day B_TIME[MEASURE]/B_LOCATION
using O
a O
Digilab B_PRODUCT[OBJECT]/B_MEASURE
Calibration I_PRODUCT[OBJECT]/I_MEASURE
verifier I_PRODUCT[OBJECT]/I_MEASURE
. O

All O
IOP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
done O
by O
the O
same B_PERSON
investigator I_PERSON
with O
the O
same B_PERSON/B_MEASURE
tonometer I_PERSON/I_MEASURE
. O

One B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drop B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
0 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
oxybuprocaine I_MEASURE
hydrochloride I_MEASURE
( O
novesine B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Sandoz B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
diluted O
1 B_MEASURE
' O
1 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
instilled O
in O
each O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
immediately O
before O
each O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
pressure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

IOP B_DISEASE
was O
measured O
three B_TIME[MEASURE]/B_LOCATION
times I_TIME[MEASURE]/I_LOCATION
at O
each O
time B_LOCATION/B_MEASURE
interval I_LOCATION/I_MEASURE
, O
and O
the O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O
. O

IOP B_DISEASE/B_GENE
was O
measured O
first O
immediately O
before O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
then O
at O
30 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
after O
the O
instillation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
pharmacological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
then O
each O
30 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
for O
a O
period B_MEASURE/B_LOCATION
of O
several B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
. O

For O
all O
IOP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
experiments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
was O
administered O
to O
only O
one B_PERSON
eye I_PERSON
, O
leaving O
the O
contralateral B_PERSON/B_DISEASE
eye B_PERSON/I_DISEASE
as O
an O
untreated B_PERSON/B_ORGANIZATION
control I_PERSON/I_ORGANIZATION
. O

The O
ocular O
hypotensive O
activity O
is O
expressed O
as O
the O
average O
difference O
in O
IOP O
between O
the O
treated O
and O
control O
eye O
, O
in O
this O
way O
minimizing O
the O
diurnal O
, O
seasonal O
and O
interindividual O
variations O
commonly O
observed O
in O
the O
rabbit B_BIO/B_PERSON
[ O
37 O
- O
39 O
] O
. O

All O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
expressed O
as O
mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SE B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
using O
a O
one B_NUMBER[MEASURE]
- O
tailed O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Reaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
5 B_NUMBER[MEASURE]
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]/B_PERSON
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_LOCATION
19b I_LOCATION
] O
with O
chloroacteyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
pyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
afforded O
5 B_NUMBER[MEASURE]/B_LOCATION
- O
( O
chloroacetamido B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]/B_PERSON
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
by O
the O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
already O
reported O
by O
Young B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
. O

[ O
34 B_TIME[MEASURE]/B_ORGANIZATION
] I_TIME[MEASURE]/I_ORGANIZATION
( O
Scheme B_MEASURE
1 I_MEASURE
) O
. O

The O
sulfonamide B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
7 I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
been O
characterized O
by O
elemental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
spectroscopic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O
confirmed O
its O
structure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
only O
its O
m B_DISEASE/B_PROTEIN[GENE]
. O
p B_MEASURE/B_GENE
. O
has O
been O
reported O
in O
ref B_TIME[MEASURE]/B_PERSON
. O
[ O
34 B_MEASURE
] I_MEASURE
) O
. O

The O
sodium B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
salt I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
sulfonamides B_NUMBER[MEASURE]
6 I_NUMBER[MEASURE]
and O
7 B_NUMBER[MEASURE]
, O
obtained O
in O
situ B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
corresponding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
hydroxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O
were O
then O
used O
for O
the O
preparation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
coordination B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
containing O
the O
following O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O
Be O
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
MG B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Al B_LOCATION/B_PERSON
( O
III B_TIME[MEASURE]/B_LOCATION
) O
, O
Zn B_LOCATION
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
CD B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
Hg B_LOCATION/B_MEASURE
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

mention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
should O
be O
made O
that O
although O
5 B_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_MEASURE/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
parent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compound I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
important B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
sulfonamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
CA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
acetazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
benzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
methazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
etc B_LOCATION/B_GENE
. O
, O
its O
coordination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemistry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
scarcely O
investigated O
up O
to O
now O
[ O
22 B_MEASURE
, O
40 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
new B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
prepared O
in O
this O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
shown O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O
Both O
compounds B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
containing O
the O
sulfonamide B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
deprotonated O
species B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
LH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
as O
well O
as O
complexes B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
the O
anion B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
5amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
tda B_LOCATION/B_PROTEIN[GENE]
) O
act B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
ligands B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
have O
been O
prepared O
. O

In O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
another O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O
40 B_TIME[MEASURE]
] O
it O
was O
documented O
that O
in O
some O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sulfonamides B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
derived O
from O
this O
ring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
may O
undergo O
hydrolysis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
. O

309 B_NUMBER[MEASURE]
. O

Vol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

4 O
, O
No O
. O
6 B_MEASURE
, O
1997 B_MEASURE/B_LOCATION
. O

metal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O
' O
A B_MEASURE/B_LOCATION
New B_MEASURE/I_LOCATION
Class B_MEASURE/I_LOCATION
ofAntiglaucoma B_MEASURE/I_LOCATION
Agents B_MEASURE/I_LOCATION
. O

the O
moiety B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
substituting O
the O
5 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
the O
formation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
5 B_NUMBER[MEASURE]
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_MEASURE
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
thereafter O
coordinates O
metal B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present I_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

N B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CIH I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

I B_OTHER/B_PERSON

N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
NaHCO B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
. O

N B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

- O
NaCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

I O
S B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

N B_OTHER/B_PERSON

II B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

SO2NH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

1 B_MEASURE
_ O
12 B_TIME[MEASURE]
O I_TIME[MEASURE]
Py I_TIME[MEASURE]
/ O
MeCN B_LOCATION/B_MEASURE
. O

6Htda O
+ O
CIOCCH2CI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

0 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Cl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
CH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scheme I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

HN B_DISEASE/B_MEASURE
. O

. B_OTHER/B_MEASURE
I O
. O

N B_OTHER/B_PERSON

N B_OTHER/B_PERSON

S B_LOCATION
7 I_LOCATION
: O
LH B_MEASURE/B_PERSON
. O

II B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

SqNH B_GENE/B_MEASURE
. O

Thus O
, O
the O
X B_NUMBER[MEASURE]/B_DISEASE
- O
ray B_LOCATION/B_MEASURE
crystal I_LOCATION/I_MEASURE
structure I_LOCATION/I_MEASURE
of O
the O
complex B_LOCATION/B_BIO
[ I_LOCATION/I_BIO
Zn I_LOCATION/I_BIO
( O
tda B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
2 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NH3 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
] O
. O
H20 O
prepared O
in O
this O
way B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O
recently O
been O
reported O
by O
this O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
40 B_LOCATION/B_PERSON
] I_LOCATION/I_PERSON
. O

On O
the O
other B_PERSON/B_LOCATION
hand B_PERSON/I_LOCATION
, O
when O
the O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O
not O
been O
hydrolyzed O
( O
during O
the O
preparation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
the O
coordination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
metal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
5 B_NUMBER[MEASURE]
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_MEASURE/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
chloroacetate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
the O
metal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
complexes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
contining O
6 B_NUMBER[MEASURE]/B_PERSON
as O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
have O
been O
prepared B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
last B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
pure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
as O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
salt I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
and O
the O
corresponding B_MEASURE/B_LOCATION
metal I_MEASURE/I_LOCATION
salt I_MEASURE/I_LOCATION
, O
by O
the O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
described O
in O
the O
Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
part I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Table B_LOCATION/B_MEASURE
I O
: O
prepared O
complexes B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
- O
20 B_MEASURE
, O
containing O
the O
conjugate B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bases I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
sulfonamides B_NUMBER[MEASURE]
6 I_NUMBER[MEASURE]
and O
7 B_NUMBER[MEASURE]
as O
ligands B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
their O
elemental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

L B_PROTEIN[GENE]/B_MEASURE
stands O
for O
the O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deprotonated O
species B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O
7 B_MEASURE/B_BIO
, O
whereas O
tda B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deprotonated O
species B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
of O
5 B_NUMBER[MEASURE]
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

No O
. O
8 B_TIME[MEASURE]/B_LOCATION
9 B_TIME[MEASURE]/I_LOCATION
10 B_TIME[MEASURE]/I_LOCATION
11 B_TIME[MEASURE]/I_LOCATION
12 B_TIME[MEASURE]/I_LOCATION
13 B_TIME[MEASURE]/I_LOCATION
14 B_TIME[MEASURE]/I_LOCATION
15 B_TIME[MEASURE]/I_LOCATION
16 B_TIME[MEASURE]/I_LOCATION
17 B_TIME[MEASURE]/I_LOCATION
18 B_TIME[MEASURE]/I_LOCATION
19 B_TIME[MEASURE]/I_LOCATION
20 B_TIME[MEASURE]/I_LOCATION
. O

Complex B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

yield B_TIME[MEASURE]
. O

( O
% B_OTHER/B_MEASURE
) O
. O

% B_PERSON/B_MEASURE
Ma I_PERSON/I_MEASURE
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
calculated O
/ O
found O
) O
% B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
b O
% B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
b O
13 B_MEASURE
. O
0 B_MEASURE
/ O
13 B_MEASURE
. O
1 B_MEASURE
11 I_MEASURE
. O
0 B_MEASURE
/ O
10 B_MEASURE
. O
8 B_TIME[MEASURE]
11 I_TIME[MEASURE]
. O
3 B_MEASURE
/ O
11 B_MEASURE
. O
4 B_MEASURE
10 I_MEASURE
. O
2 B_MEASURE
/ O
10 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
. O
5 B_MEASURE
/ O
8 B_MEASURE
. O
1 B_MEASURE
7 I_MEASURE
. O
9 B_MEASURE
/ O
7 B_MEASURE
. O
9 B_TIME[MEASURE]
12 I_TIME[MEASURE]
. O
7 B_MEASURE
/ O
12 B_MEASURE
. O
8 B_TIME[MEASURE]
18 I_TIME[MEASURE]
. O
4 B_MEASURE
/ O
18 B_MEASURE
. O
1 B_MEASURE
18 I_MEASURE
. O
1 B_MEASURE
/ O
17 B_MEASURE
. O
9 B_TIME[MEASURE]
16 I_TIME[MEASURE]
. O
6 B_MEASURE
/ O
16 B_MEASURE
. O
2 B_TIME[MEASURE]
15 I_TIME[MEASURE]
. O
3 B_MEASURE
/ O
14 B_MEASURE
. O
9 B_TIME[MEASURE]
13 I_TIME[MEASURE]
. O
4 B_MEASURE
/ O
13 B_MEASURE
. O
3 B_TIME[MEASURE]
12 I_TIME[MEASURE]
. O
7 B_MEASURE
/ O
12 B_MEASURE
. O
5 B_MEASURE
1 I_MEASURE
. O
6 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
3 B_MEASURE
2 I_MEASURE
. O
7 B_MEASURE
/ O
2 B_NUMBER[MEASURE]
. O
3 B_MEASURE
1 I_MEASURE
. O
4 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
1 B_MEASURE
1 I_MEASURE
. O
2 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
2 B_MEASURE
1 I_MEASURE
. O
0 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
2 B_MEASURE
1 I_MEASURE
. O
6 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
3 B_MEASURE
1 I_MEASURE
. O
6 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
6 B_MEASURE
1 I_MEASURE
. O
5 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
5 B_MEASURE
1 I_MEASURE
. O
5 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
3 B_MEASURE
1 I_MEASURE
. O
3 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
4 B_MEASURE
1 I_MEASURE
. O
2 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
1 B_MEASURE
1 I_MEASURE
. O
1 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
2 B_MEASURE
1 I_MEASURE
. O
0 B_MEASURE
/ O
1 B_NUMBER[MEASURE]
. O
0 B_MEASURE
. O

% B_MEASURE
N I_MEASURE
b O
30 B_MEASURE
. O
4 B_MEASURE
/ O
30 B_MEASURE
. O
2 B_MEASURE
25 I_MEASURE
. O
6 B_MEASURE
/ O
25 B_MEASURE
. O
5 B_TIME[MEASURE]
26 I_TIME[MEASURE]
. O
4 B_MEASURE
/ O
26 B_MEASURE
. O
4 B_TIME[MEASURE]
13 I_TIME[MEASURE]
. O
7 B_MEASURE
/ O
23 B_MEASURE
. O
3 B_TIME[MEASURE]
20 I_TIME[MEASURE]
. O
0 B_MEASURE
/ O
19 B_MEASURE
. O
8 B_TIME[MEASURE]
18 I_TIME[MEASURE]
. O
6 B_MEASURE
/ O
18 B_MEASURE
. O
5 B_TIME[MEASURE]
29 I_TIME[MEASURE]
. O
7 B_MEASURE
/ O
29 B_MEASURE
. O
6 B_TIME[MEASURE]
21 I_TIME[MEASURE]
. O
5 B_MEASURE
/ O
21 B_MEASURE
. O
3 B_TIME[MEASURE]
21 I_TIME[MEASURE]
. O
1 B_MEASURE
/ O
20 B_MEASURE
. O
8 B_TIME[MEASURE]
19 I_TIME[MEASURE]
. O
4 B_MEASURE
/ O
19 B_MEASURE
. O
3 B_TIME[MEASURE]
17 I_TIME[MEASURE]
. O
9 B_MEASURE
/ O
17 B_MEASURE
. O
8 B_TIME[MEASURE]
15 I_TIME[MEASURE]
. O
7 B_MEASURE
/ O
15 B_MEASURE
. O
6 B_TIME[MEASURE]
14 I_TIME[MEASURE]
. O
8 B_MEASURE
/ O
14 B_MEASURE
. O
6 B_MEASURE
. O

[ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Be O
( O
tda B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Mg B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
tda B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O
3 B_LOCATION/B_ORGANIZATION
H20 I_LOCATION/I_ORGANIZATION
[ I_LOCATION/I_ORGANIZATION
Zn I_LOCATION/I_ORGANIZATION
( O
tda B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
2 B_LOCATION/B_ENT
] I_LOCATION/I_ENT
[ I_LOCATION/I_ENT
CD I_LOCATION/I_ENT
( O
tda B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2 B_PROTEIN[GENE]/B_LOCATION
] B_PROTEIN[GENE]/I_LOCATION
[ B_PROTEIN[GENE]/I_LOCATION
Hg B_PROTEIN[GENE]/I_LOCATION
( O
tda B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
tda B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
z B_MEASURE/B_LOCATION
( O
OH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Al B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
tda B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
3 B_NUMBER[MEASURE]
] O
[ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BeL2 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
[ B_NUMBER[MEASURE]/B_PERSON
ALL3 I_NUMBER[MEASURE]/I_PERSON
] O
[ B_MEASURE/B_LOCATION
ZnL2 I_MEASURE/I_LOCATION
] O
[ B_MEASURE/B_LOCATION
CdL2 I_MEASURE/I_LOCATION
] O
[ B_MEASURE/B_LOCATION
HgL2 I_MEASURE/I_LOCATION
] O
[ B_LOCATION/B_ORGANIZATION
PbLz I_LOCATION/I_ORGANIZATION
( O
OH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

78 B_MEASURE
76 I_MEASURE
83 I_MEASURE
90 I_MEASURE
95 I_MEASURE
84 I_MEASURE
72 I_MEASURE
75 I_MEASURE
59 I_MEASURE
87 I_MEASURE
88 I_MEASURE
92 I_MEASURE
95 I_MEASURE
. O

2 O
. O
4 B_MEASURE
/ O
2 B_MEASURE
. O
5 B_MEASURE
5 I_MEASURE
. O
5 B_MEASURE
/ O
5 B_MEASURE
. O
1 B_MEASURE
15 I_MEASURE
. O
4 B_MEASURE
/ O
15 B_MEASURE
. O
0 B_MEASURE
23 I_MEASURE
. O
8 B_MEASURE
/ O
24 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
35 I_MEASURE/I_LOCATION
. O
8 B_MEASURE
/ O
35 B_MEASURE
. O
7 B_TIME[MEASURE]
34 I_TIME[MEASURE]
. O
4 B_MEASURE
/ O
34 B_MEASURE
. O
7 B_MEASURE
4 I_MEASURE
. O
7 B_MEASURE
/ O
4 B_MEASURE
. O
4 B_MEASURE
1 I_MEASURE
. O
7 B_MEASURE
/ O
1 B_MEASURE
. O
6 B_MEASURE
3 I_MEASURE
. O
4 B_MEASURE
/ O
3 B_MEASURE
. O
5 B_MEASURE
11 I_MEASURE
. O
3 B_MEASURE
/ O
11 B_MEASURE
. O
5 B_TIME[MEASURE]
18 I_TIME[MEASURE]
. O
0 B_MEASURE
/ O
18 B_MEASURE
. O
1 B_MEASURE
28 I_MEASURE
. O
1 B_MEASURE
/ O
28 B_MEASURE
. O
3 B_TIME[MEASURE]
27 I_TIME[MEASURE]
. O
4 B_MEASURE
/ O
27 B_MEASURE
. O
2 B_MEASURE
. O

aBy O
gravimetry B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
bBy B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
combustion I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

The O
new B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
also O
been O
characterized O
by O
spectroscopic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
conductimetric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
thermogravimetric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
measurements I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Table B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

By O
comparing O
the O
IR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spectra I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
complexes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
the O
corresponding B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ligands I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
made O
: O
( O
i O
) O
the O
shift B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
two B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamido B_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vibrations B_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
both O
the O
symmetric B_PERSON/B_MEASURE
as O
well O
as O
the O
the O
assymetric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
towards O
lower B_DISEASE_ADJECTIVE[DISEASE]
wavenumbers I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
spectra B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
complexes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
compared O
to O
the O
spectra B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
corresponding B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ligand I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Table B_MEASURE
II I_MEASURE
) O
, O
as O
already O
documented O
previously O
for O
similar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
13 B_NUMBER[MEASURE]
- O
22 B_MEASURE
] I_MEASURE
. O

This O
is O
a O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indication I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
the O
deprotonated B_LOCATION/B_PERSON
sulfonamido I_LOCATION/I_PERSON
310 I_LOCATION/I_PERSON
. O

Claudiu B_MEASURE
T I_MEASURE
. O
Supuran B_PERSON/B_LOCATION
et B_PERSON/I_LOCATION
al B_PERSON/I_LOCATION
. O

metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Based O
Drugs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

moieties B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
ligands B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
newly O
prepared B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
coordination I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
compounds I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O
( O
ii B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O
the O
amide B_MEASURE/B_ENT
vibrations I_MEASURE/I_ENT
( O
the O
most O
intense B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bands I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
1670 B_MEASURE
- O
1680 B_MEASURE
cm I_MEASURE
- O
1 B_NUMBER[MEASURE]/B_LOCATION
) O
of O
ligand B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
7 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
appear O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O
the O
IR B_LOCATION
spectra I_LOCATION
of O
complexes B_SEQUENCE[MEASURE]/B_LOCATION
15 I_SEQUENCE[MEASURE]/I_LOCATION
- O
20 B_MEASURE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
not O
shown O
) O
, O
suggesting O
that O
these O
moieties B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
do O
not O
participate O
in O
coordination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O
( O
III B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
the O
C B_PROTEIN[GENE]/B_LOCATION
- O
N B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stretching O
vibration B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
spectra B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
prepared B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
shifted O
with O
5 B_MEASURE
- O
20 B_MEASURE
cm I_MEASURE
- O
1 B_MEASURE/B_LOCATION
towards O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wavenumbers B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
compared O
to O
the O
same B_MEASURE
vibration I_MEASURE
in O
the O
spectra B_LOCATION/B_ORGANIZATION
of O
sulfonamides B_MEASURE
6 I_MEASURE
and O
7 B_NUMBER[MEASURE]
, O
indicating O
that O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
endocyclic B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrogens I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
thiadiazolic B_LOCATION
ring I_LOCATION
( O
presumably O
N3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
acts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
as O
donor B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
atom I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
as O
already O
documented O
by O
X B_OTHER/B_DISEASE
- O
ray B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
crystallographic I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
spectroscopic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
determinations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
on O
complexes B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sulfonamides B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O
1 B_MEASURE/B_LOCATION
- O
3 B_MEASURE
) O
with O
divalent B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
metal I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
13 B_MEASURE
- O
22 B_MEASURE
] I_MEASURE
( O
Table B_MEASURE
II I_MEASURE
) O
; O
( O
IV B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
region B_MEASURE/B_LOCATION
3100 I_MEASURE/I_LOCATION
- O
3160 B_MEASURE
cm I_MEASURE
- O
, O
as O
the O
bands B_TIME[MEASURE]/B_PERSON
present I_TIME[MEASURE]/I_PERSON
in O
the O
spectra B_LOCATION/B_MEASURE
of O
sulfonamides B_NUMBER[MEASURE]
6 I_NUMBER[MEASURE]
, O
7 B_NUMBER[MEASURE]/B_PERSON
are O
present B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
spectra B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
complexes B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
20 B_MEASURE
too O
, O
but O
they O
are O
not O
well O
resolved O
, O
and O
have O
a O
smaller B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensity I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
is O
probably O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
deprotonation B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
SO2NH2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moiety I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
participation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
cations B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O
( O
v B_OTHER/B_PROTEIN[GENE]
) O
the O
amino B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vibrations B_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
3320 B_MEASURE
cm I_MEASURE
- O
in B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
spectra B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
6 B_MEASURE
appear O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
spectra B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
its O
complexes B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
14 B_MEASURE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
not O
s O
. O
hown B_MEASURE/B_PERSON
) O
. O

In O
the O
1H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
NMR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectra I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
its O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
signal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
amino B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
been O
evidenced O
as O
a O
broad B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
singlet I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
centered O
at O
4 B_MEASURE
. O
54 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
, O
which O
is O
not O
exchangeable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
D20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
NMR B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tube I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
sulfonamido B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
NH2 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
protons I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
which O
readily O
exchange O
) O
. O

This O
proves O
that O
the O
5 B_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
moiety I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
not O
involved O
in O
binding O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
already O
shown O
in O
the O
X B_PROTEIN[GENE]/B_NUMBER[MEASURE]
- O
ray B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
crystallographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
complex B_LOCATION/B_BIO
[ I_LOCATION/I_BIO
Zn I_LOCATION/I_BIO
( O
tda B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
z B_MEASURE/B_LOCATION
( O
NH3 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
] B_OTHER/B_DISEASE
. O
H20 B_LOCATION/B_PERSON
previously O
reported O
[ O
40 B_LOCATION/B_PERSON
] I_LOCATION/I_PERSON
. O

For O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
the O
CONH B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
proton I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
resonates O
as O
a O
singlet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
12 B_MEASURE
. O
22 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
. O

In O
complexes B_MEASURE/B_LOCATION
15 I_MEASURE/I_LOCATION
- O
20 B_MEASURE
only O
very O
minor B_DISEASE_ADJECTIVE[DISEASE]
shifts I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
signal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
evidenced O
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
proving O
basically O
that O
the O
CONH B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moiety I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
interact O
with O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
complexes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
spectroscopic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
thermogravimetric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
conductimetric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
compounds B_MEASURE/B_PROTEIN[GENE]
6 I_MEASURE/I_PROTEIN[GENE]
- O
20 B_MEASURE
. O

1H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
NMR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Spectrab I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Comp I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

IR B_MEASURE
Spectraa I_MEASURE
, O
cm B_MEASURE/B_LOCATION
- O
1 B_MEASURE
as O
v B_MEASURE/B_GENE
( O
C B_OTHER/B_PROTEIN[GENE]
= O
N B_OTHER/B_MEASURE
) O
CONH B_NUMBER[MEASURE]/B_ORGANIZATION
, O
i O
( O
ppm B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
v B_PROTEIN[GENE]/B_LOCATION
( O
SO2 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
S B_MEASURE/B_OTHER
; O
v B_PROTEIN[GENE]/B_LOCATION
( O
SO2 B_LOCATION/B_MEASURE
) O
6 B_LOCATION/B_PROTEIN[GENE]
8 I_LOCATION/I_PROTEIN[GENE]
9 I_LOCATION/I_PROTEIN[GENE]
10 I_LOCATION/I_PROTEIN[GENE]
11 I_LOCATION/I_PROTEIN[GENE]
. O

TG B_LOCATION/B_ORGANIZATION
analysisc I_LOCATION/I_ORGANIZATION
calc I_LOCATION/I_ORGANIZATION
. O
/ O
found O
. O

Conductimetryd B_MEASURE
AM I_MEASURE
( O
- O
1 B_MEASURE/B_LOCATION
x I_MEASURE/I_LOCATION
cm2x I_MEASURE/I_LOCATION
mol I_MEASURE/I_LOCATION
- O
) O
2 B_MEASURE/B_LOCATION
7 B_MEASURE/I_LOCATION
4 B_MEASURE/I_LOCATION
5 B_MEASURE/I_LOCATION
3 B_MEASURE/I_LOCATION
2 B_MEASURE/I_LOCATION
2 B_MEASURE/I_LOCATION
6 B_MEASURE/I_LOCATION
3 B_MEASURE/I_LOCATION
4 B_MEASURE/I_LOCATION
2 B_MEASURE/I_LOCATION
9 B_MEASURE/I_LOCATION
3 B_MEASURE/I_LOCATION
2 B_MEASURE/I_LOCATION
8 B_MEASURE/I_LOCATION
. O

12 B_TIME[MEASURE]
13 I_TIME[MEASURE]
14 I_TIME[MEASURE]
7 I_TIME[MEASURE]
15 I_TIME[MEASURE]
16 I_TIME[MEASURE]
17 I_TIME[MEASURE]
18 I_TIME[MEASURE]
19 I_TIME[MEASURE]
20 I_TIME[MEASURE]
. O

1170 B_NUMBER[MEASURE]
; O
1150 B_NUMBER[MEASURE]
; O
1150 B_NUMBER[MEASURE]
; O
1145 B_NUMBER[MEASURE]
; O
1145 B_TIME[MEASURE]
; O
1140 B_MEASURE/B_LOCATION
; O
1145 B_NUMBER[MEASURE]
; O
1150 B_SEQUENCE[MEASURE]
; O
1170 B_NUMBER[MEASURE]
; O
1130 B_TIME[MEASURE]
; O
1140 B_SEQUENCE[MEASURE]
; O
1140 B_SEQUENCE[MEASURE]/B_LOCATION
; O
1150 B_MEASURE/B_LOCATION
; O
1140 B_SEQUENCE[MEASURE]/B_LOCATION
; O
1145 B_SEQUENCE[MEASURE]
; O

1350 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1305 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1305 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1300 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1350 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1335 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1330 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1330 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1330 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1335 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1330 I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

1610 B_TIME[MEASURE]
1600 I_TIME[MEASURE]
1600 I_TIME[MEASURE]
1600 I_TIME[MEASURE]
1600 I_TIME[MEASURE]
1590 I_TIME[MEASURE]
1605 I_TIME[MEASURE]
1605 I_TIME[MEASURE]
1610 I_TIME[MEASURE]
1605 I_TIME[MEASURE]
1610 I_TIME[MEASURE]
1610 I_TIME[MEASURE]
1605 I_TIME[MEASURE]
1600 I_TIME[MEASURE]
1600 I_TIME[MEASURE]
. O

A O
A B_OTHER/B_LOCATION
A O
A O
A O
A O
A B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

e B_DISEASE
e O
. O

12 O
. O
3 B_MEASURE
/ O
12 B_MEASURE
. O
1f B_MEASURE/B_LOCATION
e O
e O
e B_MEASURE/B_LOCATION
5 I_MEASURE/I_LOCATION
. O
9 B_MEASURE
/ O
5 B_MEASURE
. O
7g B_MEASURE
. O

A O
12 B_MEASURE
. O
22 B_MEASURE
( O
1H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
12 B_NUMBER[MEASURE]
. O
19 B_MEASURE
( I_MEASURE
2H I_MEASURE
) O
12 B_NUMBER[MEASURE]
. O
18 B_MEASURE
( I_MEASURE
3H I_MEASURE
) O
12 B_NUMBER[MEASURE]
. O
20 B_MEASURE
( I_MEASURE
2H I_MEASURE
) O
12 B_NUMBER[MEASURE]
. O
18 B_MEASURE
( I_MEASURE
2H I_MEASURE
) O
12 B_NUMBER[MEASURE]
. O
19 B_MEASURE
( I_MEASURE
2H I_MEASURE
) O
12 B_NUMBER[MEASURE]
. O
21 B_MEASURE
( I_MEASURE
2H I_MEASURE
) O
. O

e O
e O
e O
e O
e O
e O
e O
4 B_NUMBER[MEASURE]
. O
7 B_MEASURE
/ O
4 B_MEASURE
. O
8g B_MEASURE
. O

a O
In O
KBr B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
; O
bin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DMSO I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
d6 B_MEASURE/B_PERSON
; O
A O
the O
signal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
of O
the O
5 B_NUMBER[MEASURE]
- O
amino B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
6 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
appearing O
in O
the O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
4 B_NUMBER[MEASURE]
. O
54 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
as O
a O
broad B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
singlet I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
appears O
at O
the O
same B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemical I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shift I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 B_MEASURE/B_LOCATION
. O
50 B_MEASURE
4 I_MEASURE
. O
55 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
) O
in O
complexes B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
- O
14 B_MEASURE
; O
cWeight B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
70 B_MEASURE
- O
250 B_MEASURE/B_PERSON
C I_MEASURE/I_PERSON
; O
d O
mm B_LOCATION
solution I_LOCATION
, O
in O
DMF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
at O
25C B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
e B_PROTEIN[GENE]/B_DISEASE
No O
weight B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
loss I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
seen O
under O
250 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O
fCorresponding O
to O
three B_LOCATION/B_BIO
lattice B_LOCATION/I_BIO
water B_LOCATION/I_BIO
molecules B_LOCATION/I_BIO
lost O
at O
70 B_MEASURE
- O
110C B_MEASURE/B_PERSON
, O
and O
gCorresponding O
to O
two B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coordinated B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecules B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lost O
at O
160 B_MEASURE
- O
180 B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thermogravimetric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
the O
presence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
uncoordinated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
molecule B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O
complex B_MEASURE/B_LOCATION
9 I_MEASURE/I_LOCATION
( O
the O
three B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
waters I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
lost O
in O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
between O
70 B_MEASURE
- O
110 B_MEASURE/B_LOCATION
C I_MEASURE/I_LOCATION
) O
and O
of O
coordinated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
molecules B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
lead B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
derivatives B_MEASURE/B_PERSON
13 I_MEASURE/I_PERSON
and O
20 B_MEASURE
. O

All O
these O
compounds B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behaved O
as O
non B_DISEASE
- O
electrolytes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
DMF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
solvent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

mention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
made O
that O
the O
Mg B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
II B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
complex B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O
not O
be O
isolated O
. O

Instead O
, O
only O
the O
correponding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
5 B_NUMBER[MEASURE]
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
l B_PROTEIN[GENE]/B_DISEASE
, O
3 B_MEASURE/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
obtained O
from O
reaction B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mixtures I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O
magnesium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
salts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
the O
sodium B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
salt I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
7 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
probably O
due O
to O
a O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion O
assisted O
hydrolysis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
7 B_NUMBER[MEASURE]
to O
6 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
chloroacetate B_MEASURE
. O

Generally O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrolytic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
involve O
highly O
acidic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prolonged B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heating B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
5 B_MEASURE/B_PROTEIN[GENE]
- O
alkylamido B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
- O
thiadiazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
41 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
, O
but O
they O
might O
become O
milder B_DISEASE_ADJECTIVE[DISEASE]
by O
taking O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O
putative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalytic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Mg2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O
ions B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reported O
here O
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
shown O
above O
lead B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
ligand O
7 B_MEASURE/B_LOCATION
shares B_MEASURE/I_LOCATION
a O
common B_LOCATION/B_ORGANIZATION
coordination I_LOCATION/I_ORGANIZATION
chemistry I_LOCATION/I_ORGANIZATION
with O
acetazolamide B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
which O
it O
is O
structurally O
related O
, O
whereas O
6 B_NUMBER[MEASURE]/B_LOCATION
probably O
also O
behaves O
similarly O
to O
acetazolamide O
in O
the O
sense B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
5 B_NUMBER[MEASURE]
- O
amino B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
seems O
not O
to O
be O
involved O
in O
coordinating O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
at O
311 B_MEASURE/B_LOCATION
. O

Vol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

4 O
, O
No O
. O
6 B_MEASURE
, O
1997 B_MEASURE/B_LOCATION
. O

metal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
complexes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
A O
New B_PERSON/B_ENT
Class B_PERSON/I_ENT
ofAntiglaucoma B_PERSON/I_ENT
Agents B_PERSON/I_ENT
. O

least B_LOCATION/B_DISEASE
in O
the O
complexes B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O
by O
us O
here O
( O
and O
also O
in O
the O
compound B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characterized O
by O
X B_PROTEIN[GENE]/B_DISEASE
- O
ray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
crystallography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mentioned O
above O
[ B_MEASURE/B_LOCATION
40 I_MEASURE/I_LOCATION
] I_MEASURE/I_LOCATION
) O
. O

Thus O
, O
in O
all O
complexes B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O
here O
these O
sulfonamides B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
as O
monodeprotonated O
species B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
at O
the O
SO2NH B_LOCATION/B_MEASURE
2 I_LOCATION/I_MEASURE
moieties I_LOCATION/I_MEASURE
) O
act B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
bidentate B_LOCATION/B_PERSON
ligands I_LOCATION/I_PERSON
, O
through O
the O
endocyclic B_LOCATION
N I_LOCATION
- O
3 B_MEASURE/B_LOCATION
and O
the O
NH B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
proposed O
formulae B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
complxes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
are O
shown O
below O
. O

Except O
for O
the O
two B_LOCATION/B_ORGANIZATION
Pb I_LOCATION/I_ORGANIZATION
( O
II B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
complexes B_MEASURE/B_LOCATION
13 I_MEASURE/I_LOCATION
and O
20 B_MEASURE
, O
as O
well O
as O
the O
AI B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
III B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
derivatives B_MEASURE/B_PERSON
14 I_MEASURE/I_PERSON
and O
16 B_MEASURE
, O
which O
presumably O
are O
pseudo B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
octahedral B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
other B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derivatives I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
supposed O
to O
contain O
tetrahedral B_LOCATION
M I_LOCATION
( O
II B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
ions B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

R B_OTHER/B_PERSON

R O
13 B_NUMBER[MEASURE]
' O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
= O
20 B_MEASURE
' O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
. O

H2N B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

CICH2CONH B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
. O

14 B_MEASURE
: O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
16 B_MEASURE
: O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
. O

H2N B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
CICH2CONH I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
compounds B_LOCATION
6 I_LOCATION
- O
20 B_MEASURE
together O
with O
the O
standard B_NUMBER[MEASURE]/B_PERSON
CA I_NUMBER[MEASURE]/I_PERSON
inhibitors O
1 B_MEASURE
- O
5 B_MEASURE
were O
assayed O
for O
inhibition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
against O
three B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isozymes B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
HCA B_DISEASE/B_GENE
I B_DISEASE/I_GENE
, O
HCA B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
BCA B_PROTEIN[GENE]/B_NUMBER[MEASURE]
IV I_PROTEIN[GENE]/I_NUMBER[MEASURE]
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
III B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

As O
seen O
from O
the O
above B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
chloracetamido B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
derivative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
is O
more O
inhibitory B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
acetazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
methazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dichlorophenamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
the O
unacylated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
less O
inhibitory B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
than O
the O
above B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O

The O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
820 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
much O
more O
inhibitory B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
than O
the O
sulfonamides B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
which O
they O
derive O
6 B_MEASURE/B_LOCATION
, O
7 B_MEASURE/B_LOCATION
and O
than O
all O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
simple I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
assayed O
. O

They O
behave O
similarly O
to O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acetazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
methazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
previously O
reported O
by O
this O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
were O
all O
more O
inhibitory B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
parent B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sulfonamide I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
which O
were O
prepared O
[ B_TIME[MEASURE]/B_LOCATION
16 B_TIME[MEASURE]/I_LOCATION
- O
22 B_MEASURE
, O
40 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

particularly O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
for O
the O
Zn B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Hg B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Pb B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
CD B_LOCATION/B_PERSON
( O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
complexes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
especially O
against O
CA B_LOCATION/B_ORGANIZATION
II I_LOCATION/I_ORGANIZATION
and O
CA O
IV B_NUMBER[MEASURE]/B_PROTEIN[GENE]
, O
the O
isozymes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
critical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O
aqueous B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
humor B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
formation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

In O
vivo O
IOP O
lowering O
experiments O
were O
done O
in O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
some O
of O
the O
new O
compounds O
prepared O
in O
the O
present O
work O
, O
such O
as O
the O
sulfonamides O
6 O
and O
7 O
, O
and O
their O
Zn O
( O
II O
) O
complexes O
, O
which O
were O
among O
the O
strong O
CA O
II O
and O
CA O
IV O
inhibitors O
in O
the O
obtained O
series O
. O

Some O
of O
the O
IOP O
lowering O
data O
at O
half O
an O
hour O
and O
one O
hour O
after O
the O
instillation O
of O
one O
drop O
of O
2 O
% O
solution O
of O
inhibitor O
within O
the O
rabbit B_BIO/B_PERSON
eye O
are O
shown O
in O
312 O
. O

Claudiu B_MEASURE
T I_MEASURE
. O
Supuran B_PERSON/B_LOCATION
et B_PERSON/I_LOCATION
al B_PERSON/I_LOCATION
. O

metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Based O
Drugs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IV I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
with O
dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
at O
the O
same B_LOCATION/B_MEASURE
concentration I_LOCATION/I_MEASURE
) O
as O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
Fig B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
the O
time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dependence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
IOP B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
lowering I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
the O
two B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Zn I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
II B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
complexes B_MEASURE/B_LOCATION
10 I_MEASURE/I_LOCATION
and O
17 B_MEASURE
is O
presented O
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CA O
inhibition O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
the O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5 B_MEASURE
, O
the O
sulfonamides B_SEQUENCE[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_SEQUENCE[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
7 B_NUMBER[MEASURE]
, O
and O
their O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
8 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
20 B_MEASURE
. O

No O
1 B_NUMBER[MEASURE]/B_LOCATION
2 I_NUMBER[MEASURE]/I_LOCATION
3 I_NUMBER[MEASURE]/I_LOCATION
4 I_NUMBER[MEASURE]/I_LOCATION
5 I_NUMBER[MEASURE]/I_LOCATION
6 I_NUMBER[MEASURE]/I_LOCATION
7 I_NUMBER[MEASURE]/I_LOCATION
8 I_NUMBER[MEASURE]/I_LOCATION
9 I_NUMBER[MEASURE]/I_LOCATION
10 I_NUMBER[MEASURE]/I_LOCATION
11 I_NUMBER[MEASURE]/I_LOCATION
12 I_NUMBER[MEASURE]/I_LOCATION
13 I_NUMBER[MEASURE]/I_LOCATION
14 I_NUMBER[MEASURE]/I_LOCATION
15 I_NUMBER[MEASURE]/I_LOCATION
16 I_NUMBER[MEASURE]/I_LOCATION
17 I_NUMBER[MEASURE]/I_LOCATION
18 I_NUMBER[MEASURE]/I_LOCATION
19 I_NUMBER[MEASURE]/I_LOCATION
20 I_NUMBER[MEASURE]/I_LOCATION
a O
. O

inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ki B_MEASURE
hCA I_MEASURE
Ia I_MEASURE
900 I_MEASURE
780 I_MEASURE
25 I_MEASURE
1200 I_MEASURE
> I_MEASURE
50 I_MEASURE
, O
000 B_MEASURE/B_LOCATION
1550 I_MEASURE/I_LOCATION
640 I_MEASURE/I_LOCATION
1050 I_MEASURE/I_LOCATION
350 I_MEASURE/I_LOCATION
50 I_MEASURE/I_LOCATION
40 I_MEASURE/I_LOCATION
12 I_MEASURE/I_LOCATION
80 I_MEASURE/I_LOCATION
240 I_MEASURE/I_LOCATION
120 I_MEASURE/I_LOCATION
80 I_MEASURE/I_LOCATION
40 I_MEASURE/I_LOCATION
40 I_MEASURE/I_LOCATION
9 I_MEASURE/I_LOCATION
15 I_MEASURE/I_LOCATION
. O

( O
nm B_MEASURE
) O
bCA B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVb I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
220 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
240 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
380 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
43 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
780 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
540 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
220 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
26 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
110 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

hCA B_MEASURE/B_ORGANIZATION
IIa O
12 B_NUMBER[MEASURE]/B_GENE
14 I_NUMBER[MEASURE]/I_GENE
8 I_NUMBER[MEASURE]/I_GENE
38 I_NUMBER[MEASURE]/I_GENE
9 I_NUMBER[MEASURE]/I_GENE
230 I_NUMBER[MEASURE]/I_GENE
5 I_NUMBER[MEASURE]/I_GENE
190 I_NUMBER[MEASURE]/I_GENE
110 I_NUMBER[MEASURE]/I_GENE
15 I_NUMBER[MEASURE]/I_GENE
14 I_NUMBER[MEASURE]/I_GENE
7 I_NUMBER[MEASURE]/I_GENE
10 I_NUMBER[MEASURE]/I_GENE
76 I_NUMBER[MEASURE]/I_GENE
5 I_NUMBER[MEASURE]/I_GENE
4 I_NUMBER[MEASURE]/I_GENE
3 I_NUMBER[MEASURE]/I_GENE
3 I_NUMBER[MEASURE]/I_GENE
2 I_NUMBER[MEASURE]/I_GENE
5 I_NUMBER[MEASURE]/I_GENE
. O

Acetazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Methazolamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ethoxzolamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Dichlorophenamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Dorzolamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Human B_SPECIES[BIO]/B_NUMBER[MEASURE]
( O
cloned O
) O
isozymes O
; O
b O
From O
bovine B_PERSON/B_SPECIES[BIO]
lung O
microsomes O
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IV I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
IOP B_MEASURE/B_ORGANIZATION
lowering O
following O
topical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
half O
an O
hour B_TIME[MEASURE]/B_ENT
and O
one B_TIME[MEASURE]/B_ENT
hour I_TIME[MEASURE]/I_ENT
after O
instillation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
into O
the O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
a O
drop B_MEASURE/B_PERSON
( O
50 B_MEASURE/B_LOCATION
L I_MEASURE/I_LOCATION
) O
of O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

lOP B_MEASURE
SE I_MEASURE
1 I_MEASURE
/ O
2 B_MEASURE
h O
. O

a B_OTHER/B_PERSON

( O
mm B_TIME[MEASURE]/B_COLOR
Hg I_TIME[MEASURE]/I_COLOR
) O
lh B_MEASURE
4 I_MEASURE
. O
1 B_MEASURE
0 I_MEASURE
. O
15 B_MEASURE
0 I_MEASURE
0 I_MEASURE
. O
09 B_MEASURE/B_SPORT[ENT]
0 I_MEASURE/I_SPORT[ENT]
0 I_MEASURE/I_SPORT[ENT]
. O
09 B_MEASURE
5 I_MEASURE
. O
0 B_MEASURE
0 I_MEASURE
. O
12 B_MEASURE
8 I_MEASURE
. O
1 B_MEASURE
0 I_MEASURE
. O
21 B_TIME[MEASURE]
Dorzolamide I_TIME[MEASURE]
5 I_TIME[MEASURE]
6 I_TIME[MEASURE]
7 I_TIME[MEASURE]
10 I_TIME[MEASURE]
17 I_TIME[MEASURE]
a O
. O

2 O
. O
2 B_MEASURE
0 I_MEASURE
. O
10 B_MEASURE/B_SPORT[ENT]
0 I_MEASURE/I_SPORT[ENT]
0 I_MEASURE/I_SPORT[ENT]
. O
10 B_MEASURE/B_SPORT[ENT]
0 I_MEASURE/I_SPORT[ENT]
0 I_MEASURE/I_SPORT[ENT]
. O
10 B_MEASURE
2 I_MEASURE
. O
00 B_MEASURE
. O
09 B_TIME[MEASURE]
8 I_TIME[MEASURE]
. O
0 B_MEASURE
0 I_MEASURE
. O
14 B_MEASURE
. O

IOP B_DISEASE/B_ORGANIZATION
. O

IOP B_MEASURE
control I_MEASURE
eye I_MEASURE
' O
IOP B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
treated O
eye B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
( O
N B_MEASURE/B_LOCATION
3 I_MEASURE/I_LOCATION
) O
. O

As O
seen O
from O
the O
above B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
the O
sulfonamides B_NUMBER[MEASURE]
6 I_NUMBER[MEASURE]
and O
7 B_NUMBER[MEASURE]
are O
totally O
ineffective B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
lOP B_DISEASE/B_PROTEIN[GENE]
lowering O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
similarly O
to O
the O
classical B_NUMBER[MEASURE]
clinically O
used O
inhibitors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
5 B_NUMBER[MEASURE]/B_PROTEIN[GENE]
[ O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]/B_LOCATION
] I_NUMBER[MEASURE]/I_LOCATION
. O

On O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
first B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
topical I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
clinically O
in O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
glaucoma B_DISEASE
is O
an O
effective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
such I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
with O
a O
decrease B_MEASURE/B_DISEASE
of O
lOP B_DISEASE/B_MEASURE
of O
around O
4 B_NUMBER[MEASURE]
mm I_NUMBER[MEASURE]
Hg I_NUMBER[MEASURE]
, O
one B_TIME[MEASURE]
hour I_TIME[MEASURE]
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
directly O
into O
the O
eye B_BODY_PART_OR_ORGAN_COMPONENT
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IV I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

From O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
is O
obvious B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
investigated O
by O
us O
behave O
as O
much O
more O
effective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
IOP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lowering O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
and O
their O
effect B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
is O
generally O
longerlasting O
( O
Fig B_MEASURE/B_LOCATION
. O
1 B_NUMBER[MEASURE]
) O
. O

A O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remark I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
made O
about O
the O
possible B_LOCATION
mechanism I_LOCATION
of O
action B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
new B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
class I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
IOP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
lowering O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Obviously O
, O
their O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
due O
to O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
isozymes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
present B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
cilliary B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
processes I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
within O
the O
eye B_BODY_PART_OR_ORGAN_COMPONENT
, O
similarly O
to O
other B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
topically O
active B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfonamides I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
2 B_MEASURE/B_LOCATION
- O
6 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O
se B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
inactive B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
via O
the O
topical B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
route B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
, O
whereas O
the O
metal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O
much O
better O
than O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

313 B_NUMBER[MEASURE]
. O

Vol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

4 O
, O
No O
. O
6 B_MEASURE
, O
1997 B_MEASURE/B_LOCATION
. O

metal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
heterocyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Sulfonamides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O
' O
A B_MEASURE/B_LOCATION
New B_MEASURE/I_LOCATION
Class B_MEASURE/I_LOCATION
ofAntiglaucoma B_MEASURE/I_LOCATION
Agents B_MEASURE/I_LOCATION
. O

dorzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
indicates O
that O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ions I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
molecules B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
these O
CA B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
essential B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
confers O
them O
completely O
new B_DISEASE_ADJECTIVE[DISEASE]
properties I_DISEASE_ADJECTIVE[DISEASE]
. O

lowering B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
IOP B_DISEASE/B_MEASURE
( O
ram B_MEASURE/B_PERSON
Hg I_MEASURE/I_PERSON
) O
. O

' O
| O
| B_OTHER/B_DISEASE
, O

/ B_OTHER/B_PERSON

' B_OTHER/B_TIME[MEASURE]
, O
, O

' B_OTHER/B_MEASURE
' O
, O
. O
, O

, O
< B_MEASURE
. O

. O
7 B_MEASURE/B_LOCATION
, O
/ O
. O

/ B_OTHER/B_PERSON

. O
6 B_MEASURE/B_LOCATION
. O

- O
0 B_MEASURE/B_LOCATION
. O

- O
10 B_MEASURE/B_LOCATION
0 B_MEASURE/I_LOCATION
. O

2 B_NUMBER[MEASURE]/B_PERSON

Time B_TIME[MEASURE]
( O
hours B_TIME[MEASURE]
) O
. O

Fig O
l O
' O
Time O
dependence O
of O
IOP O
lowering O
with O
dorzolamide O
( O
curve O
1 O
) O
; O
the O
zinc O
complex O
10 O
( O
curve O
3 O
) O
and O
the O
zinc O
complex O
17 O
( O
curve O
3 O
) O
, O
after O
topical O
administration O
of O
one O
drop O
of O
2 O
% O
solution O
of O
inhibitor O
in O
rabbit B_SPECIES[BIO]/B_DISEASE
. O

Preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
this O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
topically O
active B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
show I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
also O
increased O
lOP B_DISEASE/B_MEASURE
lowering O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
complexes B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prepared O
in O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
42 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
that O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ion I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
molecules B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
these O
complex B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induces O
a O
dramatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
change B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
their O
physico B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
chemical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
compared O
to O
those O
of O
the O
parent B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sulfonamide I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

This O
phenomenon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
certainly O
governed O
by O
the O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polarization B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
the O
metal B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
this O
way B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
is O
quite O
probable B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
right B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
balance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
lipo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
and O
hydrosolubility B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
achieved O
, O
which O
has O
been O
considered O
to O
be O
the O
critical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
not O
observing O
topical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
classical B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CA I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
as O
acetazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
methazolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ethoxzolamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
were O
either O
too O
lipophilic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
too O
hy O
. O
drosoluble B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ O
2 B_NUMBER[MEASURE]
, O
3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

So O
, O
by O
choosing O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
metal I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
ions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
diverse B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfonamides I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
much O
larger B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
possibilities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
arise O
to O
finely O
tune O
the O
pharmacological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
properties I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
which O
strongly O
influence O
the O
value B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
a O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
we O
describe O
here O
a O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
class I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
lOP B_DISEASE
lowering O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ie O
, O
the O
metal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complexes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
sulfonamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
derivatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O
to O
be O
very O
active B_DISEASE_ADJECTIVE[DISEASE]
and O
longer O
lasting B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dorzolamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
might O
constitute O
the O
premises B_LOCATION/B_PERSON
for O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
generation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O
antiglaucoma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Acknowledgments B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

We O
are O
grateful B_PERSON
to O
Prof B_PERSON/B_LOCATION
. O

S B_OTHER/B_DISEASE
. O

Lindskog B_LOCATION/B_NUMBER[MEASURE]
( O
Umea B_LOCATION/B_PERSON
Univ I_LOCATION/I_PERSON
. O
, O
Sweden B_LOCATION/B_MEASURE
) O
for O
the O
gift B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
hCA B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
and O
II B_PERSON/B_LOCATION
plasmids B_PERSON/I_LOCATION
. O

references B_PERSON/B_NUMBER[MEASURE]
preceding O
part B_TIME[MEASURE]/B_ENT
of O
this O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
' O
Supuran B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
CT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
Scozzafava B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Ilies B_LOCATION/B_PERSON
MA I_LOCATION/I_PERSON
, O
Iorga B_LOCATION/B_PERSON
B I_LOCATION/I_PERSON
, O
Cristea B_PERSON/B_LOCATION
T I_PERSON/I_LOCATION
, O
Chiraleu B_PERSON/B_ORGANIZATION
F I_PERSON/I_ORGANIZATION
, O
Banciu B_PERSON/B_LOCATION
MD I_PERSON/I_LOCATION
( O
1997 B_MEASURE
) O
Eur B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chem B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
submitted O
. O

2 B_MEASURE
Supuran I_MEASURE
CT I_MEASURE
( O
1994 B_MEASURE
) O
' O
carbonic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anhydrase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
In O
carbonic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Anhydrase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
modulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
physiologic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pathologic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
organism B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
( O
Puscas B_PERSON
I I_PERSON
, O
Ed B_PERSON/B_PROTEIN[GENE]
) O
Helicon B_PERSON/B_TIME[MEASURE]
, O
Timisoara B_MEASURE/B_LOCATION
, O
pp B_LOCATION/B_PERSON
. O

29 O
- O
111 B_MEASURE
. O

3 B_PERSON
Maren I_PERSON
th I_PERSON
( O
1991 B_MEASURE
) O
' O
The O
links B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
biochemistry B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
physiology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pharmacology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
in O
carbonic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anhydrase B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
systems B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
carbonic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Anhydrase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
From O
Biochemistry B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
genetics B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
physiology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
Medicine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
, O
( O
Botr6 B_PERSON
F I_PERSON
, O
Gros B_MEASURE/B_LOCATION
G I_MEASURE/I_LOCATION
, O
storey B_MEASURE/B_LOCATION
BT I_MEASURE/I_LOCATION
eds I_MEASURE/I_LOCATION
) O
VCH B_LOCATION/B_PERSON
, O
Weinheim B_MEASURE/B_LOCATION
, O
pp B_LOCATION/B_MEASURE
. O

186 O
- O
207 B_MEASURE
. O

4 B_PERSON/B_ORGANIZATION
Bayer I_PERSON/I_ORGANIZATION
A I_PERSON/I_ORGANIZATION
, O
Ferrari B_LOCATION/B_PERSON
F I_LOCATION/I_PERSON
, O
Maren B_PERSON/B_LOCATION
TH I_LOCATION
, O
Erb B_LOCATION/B_GENE
C I_LOCATION/I_GENE
( O
1996 B_MEASURE
) O
dFr B_MEASURE
Ophtalrnol I_MEASURE
19 I_MEASURE
, O
3 B_MEASURE
: O
57 B_MEASURE
- O
362 B_MEASURE
. O

: O
5 B_PERSON/B_LOCATION
Maren I_PERSON/I_LOCATION
TH I_LOCATION
, O
Conroy B_LOCATION/B_PERSON
CW I_LOCATION/I_PERSON
, O
Wynns B_LOCATION/B_PERSON
GC I_LOCATION/I_PERSON
, O
Levy B_PERSON/B_LOCATION
NS I_PERSON/I_LOCATION
( O
1997 B_MEASURE
) O
d B_MEASURE
Ocul I_MEASURE
Pharrnacol I_MEASURE
Therapeut I_MEASURE
13 I_MEASURE
, O
23 B_MEASURE
- O
30 B_MEASURE
. O

6 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sugrue I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MF I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1996 B_MEASURE
) O
d B_MEASURE/B_PERSON
Ocul I_MEASURE/I_PERSON
Pharmacol I_MEASURE/I_PERSON
Ther I_MEASURE/I_PERSON
12 I_MEASURE/I_PERSON
, O
363 B_MEASURE
- O
376 B_MEASURE
. O

7 B_PERSON
Bartlett I_PERSON
JD I_PERSON
, O
Jaanus B_PERSON/B_MEASURE
SD I_PERSON/I_MEASURE
( O
1989 B_MEASURE
) O
' O
Carbonic B_TIME[MEASURE]/B_PERSON
anhydrase I_TIME[MEASURE]/I_PERSON
inhibitors I_TIME[MEASURE]/I_PERSON
' I_TIME[MEASURE]/I_PERSON
. O

In O
Clinical B_TIME[MEASURE]/B_PERSON
Ocular I_TIME[MEASURE]/I_PERSON
Pharmacology I_TIME[MEASURE]/I_PERSON
, O
Second B_NUMBER[MEASURE]/B_ENT
Edition I_NUMBER[MEASURE]/I_ENT
, O
Butterworths B_MEASURE/B_LOCATION
Publishers I_MEASURE/I_LOCATION
, O
Boston B_LOCATION/B_MEASURE
, O
pp B_LOCATION/B_MEASURE
. O

2 O
: O
54 O
- O
263 B_MEASURE
. O

8 B_PERSON
Alward I_PERSON
PD I_PERSON
, O
Wilensky B_PERSON/B_MEASURE
JT I_PERSON/I_MEASURE
( O
1981 B_MEASURE/B_LOCATION
) O
Arch B_MEASURE/B_LOCATION
Ophthalmo199 I_MEASURE/I_LOCATION
, O
1973 B_MEASURE
- O
1976 B_MEASURE
. O

314 B_NUMBER[MEASURE]
. O

Claudiu B_MEASURE
T I_MEASURE
. O
Supuran B_PERSON/B_LOCATION
et B_PERSON/I_LOCATION
al B_PERSON/I_LOCATION
. O

metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Based O
Drugs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

9 B_PERSON/B_LOCATION
Maren I_PERSON/I_LOCATION
TH I_LOCATION
, O
Jankowska B_LOCATION/B_NUMBER[MEASURE]
L I_LOCATION/I_NUMBER[MEASURE]
, O
Sanyal B_PERSON/B_LOCATION
G I_PERSON/I_LOCATION
, O
Edelhauser B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
HF I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O
1983 B_MEASURE
) O
Exp B_MEASURE
Eye I_MEASURE
Res I_MEASURE
36 I_MEASURE
, O
457 B_MEASURE
- O
480 B_MEASURE
. O

10 B_NUMBER[MEASURE]/B_LOCATION
a O
) O
Ponticello B_PERSON
GS I_PERSON
, O
Freedman B_LOCATION/B_PERSON
MB I_LOCATION/I_PERSON
, O
Habecker B_LOCATION/B_PERSON
CN I_LOCATION/I_PERSON
, O
Lyle B_DISEASE/B_LOCATION
PA B_DISEASE/I_LOCATION
, O
Schwam B_LOCATION/B_PERSON
H I_LOCATION/I_PERSON
, O
Varga B_LOCATION
SL I_LOCATION
, O
Christy O
ME B_LOCATION
, O
Randall B_PERSON/B_LOCATION
WC B_PERSON/I_LOCATION
, O
Baldwin B_PERSON/B_LOCATION
JJ B_PERSON/I_LOCATION
( O
1987 B_MEASURE
) O
J B_MEASURE
Med I_MEASURE
Chem I_MEASURE
30 I_MEASURE
, O
591 B_MEASURE
- O
597 B_MEASURE
; O
b O
) O
Greer B_PERSON
J I_PERSON
, O
Erickson B_LOCATION/B_PERSON
JW I_LOCATION/I_PERSON
, O
Baldwin B_LOCATION/B_PERSON
JJ I_LOCATION/I_PERSON
, O
Varney B_PERSON/B_LOCATION
MD I_PERSON/I_LOCATION
( O
1994 B_MEASURE
) O
J B_MEASURE
Med I_MEASURE
Chem I_MEASURE
37 I_MEASURE
, O
1035 B_MEASURE
- O
1054 B_MEASURE
. O

11 B_PERSON/B_LOCATION
Baldwin I_PERSON/I_LOCATION
JJ I_PERSON/I_LOCATION
, O
Ponticello B_LOCATION/B_PERSON
GS I_LOCATION/I_PERSON
, O
Anderson B_LOCATION/B_PERSON
GS I_LOCATION/I_PERSON
, O
Christy B_PERSON/B_LOCATION
ME B_PERSON/I_LOCATION
, O
Murcko B_PERSON/B_LOCATION
MA I_PERSON/I_LOCATION
, O
Randall B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
WC I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O
Schwam B_LOCATION/B_PERSON
H I_LOCATION/I_PERSON
, O
Sugrue B_LOCATION
MF I_LOCATION
, O
Springer B_PERSON/B_LOCATION
JP B_PERSON/I_LOCATION
, O
Gautheron B_LOCATION/B_PERSON
P I_LOCATION/I_PERSON
, O
Grove B_LOCATION/B_PERSON
J I_LOCATION/I_PERSON
, O
Mallorga B_LOCATION/B_PERSON
P I_LOCATION/I_PERSON
, O
Viader B_PERSON/B_LOCATION
MP B_PERSON/I_LOCATION
, O
McKeever B_LOCATION/B_PERSON
BM I_LOCATION/I_PERSON
, O
Navia B_PERSON/B_LOCATION
MA I_PERSON/I_LOCATION
( O
1989 B_MEASURE
) O
J B_MEASURE
Med I_MEASURE
Chem I_MEASURE
32 I_MEASURE
, O
2510 B_MEASURE
- O
2513 B_MEASURE
. O

12 B_PERSON
Chow I_PERSON
K I_PERSON
, O
Lai B_LOCATION/B_PERSON
R I_LOCATION/I_PERSON
, O
Holmes B_PERSON/B_LOCATION
JM B_PERSON/I_LOCATION
, O
Wijono B_LOCATION/B_PERSON
M I_LOCATION/I_PERSON
, O
Wheeler B_LOCATION/B_PERSON
LA I_LOCATION/I_PERSON
, O
Garst B_PERSON/B_LOCATION
ME I_PERSON/I_LOCATION
( O
1996 B_MEASURE
) O
EurJMed B_MEASURE/B_PERSON
Chem I_MEASURE/I_PERSON
31 I_MEASURE/I_PERSON
, O
175 B_MEASURE
- O
186 B_MEASURE
. O

13 B_PERSON/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Supuran I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Nicolae B_PERSON/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_PERSON/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Popescu B_LOCATION/B_MEASURE
A I_LOCATION/I_MEASURE
( O
1996 B_MEASURE
) O
Eur B_MEASURE
JMed I_MEASURE
Chem I_MEASURE
31 I_MEASURE
, O
431 B_MEASURE
- O
438 B_MEASURE
. O

14 B_PERSON/B_LOCATION
Supuran I_PERSON/I_LOCATION
CT I_PERSON/I_LOCATION
, O
Popescu B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Ilisiu B_PERSON/B_LOCATION
M B_PERSON/I_LOCATION
, O
Costandache B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Banciu B_PERSON/B_LOCATION
MD I_PERSON/I_LOCATION
( O
1996 B_MEASURE
) O
Eur B_MEASURE
JMed I_MEASURE
Chem I_MEASURE
31 I_MEASURE
, O
439 B_MEASURE
- O
448 B_MEASURE
. O

15 B_PERSON/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Supuran I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CT I_PERSON/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Scozzafava B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Popescu B_PERSON/B_LOCATION
A B_PERSON/I_LOCATION
, O
Bobes B_PERSON
- O
Tureac B_LOCATION/B_PERSON
R I_LOCATION/I_PERSON
, O
Banciu B_LOCATION/B_PERSON
A B_LOCATION/I_PERSON
, O
Creanga B_LOCATION
A I_LOCATION
, O
Bobes B_PERSON
- O
Tureac B_LOCATION
G I_LOCATION
, O
Banciu B_PERSON/B_LOCATION
MD I_PERSON/I_LOCATION
( O
1997 B_MEASURE
) O
Eur B_MEASURE
JMed I_MEASURE
Chem I_MEASURE
32 I_MEASURE
, O
445 B_MEASURE
- O
452 B_MEASURE
. O

16 B_PERSON
Alzuet I_PERSON
G I_PERSON
, O
Casanova B_LOCATION
J I_LOCATION
, O
Ramirez B_PERSON
JA I_PERSON
, O
Borras B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Carugo B_LOCATION/B_MEASURE
O I_LOCATION/I_MEASURE
( O
1995 B_MEASURE
) O
J B_MEASURE
Inorg I_MEASURE
Bioehem I_MEASURE
57 I_MEASURE
, O
219 B_MEASURE
- O
234 B_MEASURE
. O

17 B_PERSON/B_LOCATION
Sumalan I_PERSON/I_LOCATION
SL I_PERSON/I_LOCATION
, O
Casanova B_LOCATION/B_PERSON
J I_LOCATION/I_PERSON
, O
Alzuet B_PERSON
G I_PERSON
, O
Borras B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Castifieiras B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Supuran B_PERSON/B_LOCATION
CT I_PERSON/I_LOCATION
( O
1996 B_MEASURE
) O
J B_MEASURE
Inorg I_MEASURE
Biochem I_MEASURE
62 I_MEASURE
, O
3139 B_MEASURE/B_LOCATION
. O

18 B_MEASURE/B_LOCATION
a O
) O
Supuran B_LOCATION/B_DISEASE
CT I_LOCATION/I_DISEASE
( O
1995 B_MEASURE
) O
Metal B_MEASURE/B_PERSON
Based I_MEASURE/I_PERSON
Drugs I_MEASURE/I_PERSON
2 I_MEASURE/I_PERSON
, O
327 B_MEASURE
- O
330 B_MEASURE
; O
b O
) O
Scozzafava B_PERSON/B_MEASURE
A I_PERSON/I_MEASURE
, O
Supuran B_LOCATION/B_MEASURE
CT I_LOCATION/I_MEASURE
( O
1997 B_MEASURE
) O
Metal B_MEASURE
Based I_MEASURE
Drugs I_MEASURE
4 I_MEASURE
, O
19 B_MEASURE
- O
26 B_MEASURE
. O

19 B_NUMBER[MEASURE]/B_LOCATION
a O
) O
Borras B_PERSON
J I_PERSON
, O
Cristea B_LOCATION
T I_LOCATION
, O
Supuran B_LOCATION
CT I_LOCATION
( O
1996 B_MEASURE
) O
, O
Main B_MEASURE/B_ORGANIZATION
Group I_MEASURE/I_ORGANIZATION
Met I_MEASURE/I_ORGANIZATION
Chem I_MEASURE/I_ORGANIZATION
19 I_MEASURE/I_ORGANIZATION
, O
339 B_MEASURE
- O
346 B_MEASURE
; O
b O
) O
Jitianu B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
, O
Ilies B_LOCATION/B_PERSON
MA B_LOCATION/I_PERSON
, O
Briganti B_LOCATION/B_PERSON
F I_LOCATION/I_PERSON
, O
Scozzafava B_PERSON
A I_PERSON
, O
Supuran B_LOCATION/B_MEASURE
CT I_LOCATION/I_MEASURE
( O
1997 B_MEASURE
) O
Metal B_MEASURE
Based I_MEASURE
Drugs I_MEASURE
4 I_MEASURE
, O
1 B_MEASURE
- O
7 B_MEASURE
. O

20 B_NUMBER[MEASURE]/B_LOCATION
a O
) O
Supuran B_LOCATION/B_PERSON
CT I_LOCATION/I_PERSON
, O
Scozzafava B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1997 B_MEASURE
) O
J B_MEASURE/B_PERSON
enzyme I_MEASURE/I_PERSON
Inhibition I_MEASURE/I_PERSON
12 I_MEASURE/I_PERSON
, O
37 B_MEASURE
- O
51 B_MEASURE
; O
b O
) O
Supuran B_PERSON/B_LOCATION
CT I_PERSON/I_LOCATION
, O
Briganti B_MEASURE/B_LOCATION
F I_MEASURE/I_LOCATION
, O
Scozzafava B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
( O
1997 B_MEASURE
) O
J B_MEASURE/B_PERSON
enzyme I_MEASURE/I_PERSON
Inhibition I_MEASURE/I_PERSON
12 I_MEASURE/I_PERSON
, O
175 B_MEASURE
- O
190 B_MEASURE
. O

21 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Mincione I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Scozzafava B_MEASURE/B_PERSON
A I_MEASURE/I_PERSON
, O
Supuran B_LOCATION
CT I_LOCATION
( O
1997 B_MEASURE
) O
Metal B_MEASURE
Based I_MEASURE
Drugs I_MEASURE
4 I_MEASURE
, O
27 B_MEASURE
- O
34 B_MEASURE
. O

22 B_PERSON
Alzuet I_PERSON
G I_PERSON
, O
Ferrer B_PERSON/B_LOCATION
S I_PERSON/I_LOCATION
, O
Borras B_PERSON
J I_PERSON
, O
Supuran B_LOCATION/B_NUMBER[MEASURE]
CT B_LOCATION/I_NUMBER[MEASURE]
( O
1994 B_MEASURE
) O
Roum B_MEASURE/B_LOCATION
Chem I_MEASURE/I_LOCATION
Quart I_MEASURE/I_LOCATION
Rev I_MEASURE/I_LOCATION
2 I_MEASURE/I_LOCATION
, O
283 B_MEASURE
- O
300 B_MEASURE
. O

23 B_PERSON/B_LOCATION
Briganti I_PERSON/I_LOCATION
F I_PERSON/I_LOCATION
, O
Mangani B_LOCATION/B_PERSON
S I_LOCATION/I_PERSON
, O
Orioli B_PERSON/B_LOCATION
P I_PERSON/I_LOCATION
, O
Scozzafava B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Vernaglione B_LOCATION
G I_LOCATION
, O
Supuran B_LOCATION/B_MEASURE
CT I_LOCATION/I_MEASURE
( O
1997 B_MEASURE
) O
Biochemistry B_MEASURE
36 I_MEASURE
, O
10384 B_MEASURE
- O
10392 B_MEASURE
. O

24 B_PERSON/B_LOCATION
Borras I_PERSON/I_LOCATION
J I_PERSON/I_LOCATION
, O
Casanova B_LOCATION
J I_LOCATION
, O
Cristea B_LOCATION/B_PERSON
T I_LOCATION/I_PERSON
, O
Gheorghe B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
, O
Scozzafava B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Supuran B_LOCATION
CT I_LOCATION
, O
Tudor B_NUMBER[MEASURE]/B_PERSON
V I_NUMBER[MEASURE]/I_PERSON
( O
1996 B_MEASURE
) O
Metal B_MEASURE
Based I_MEASURE
Drugs I_MEASURE
3 I_MEASURE
, O
143 B_MEASURE
- O
148 B_MEASURE
. O

25 B_MEASURE/B_LOCATION
Supuran I_MEASURE/I_LOCATION
CT I_MEASURE/I_LOCATION
, O
Mincione B_LOCATION/B_ORGANIZATION
F I_LOCATION/I_ORGANIZATION
, O
Scozzafava B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
, O
Briganti B_LOCATION/B_PERSON
F I_LOCATION/I_PERSON
, O
Mincione B_PERSON/B_LOCATION
G B_PERSON/I_LOCATION
, O
Ilies B_LOCATION/B_MEASURE
MA I_LOCATION/I_MEASURE
( O
1997 B_MEASURE
) O
Eur B_MEASURE/B_LOCATION
J I_MEASURE/I_LOCATION
Med I_MEASURE/I_LOCATION
Chem I_MEASURE/I_LOCATION
, O
in O
. O

press B_ENT/B_LOCATION
. O

26 B_MEASURE/B_LOCATION
Supuran I_MEASURE/I_LOCATION
CT I_MEASURE/I_LOCATION
, O
Scozzafava B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Saramet B_PERSON
I O
, O
Banciu B_PERSON/B_LOCATION
MD I_PERSON/I_LOCATION
( O
1997 B_MEASURE
) O
J B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Inhibition I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
press B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

27 B_PERSON/B_LOCATION
Jitianu I_PERSON/I_LOCATION
A I_PERSON/I_LOCATION
, O
Ilies B_LOCATION/B_PERSON
MA I_LOCATION/I_PERSON
, O
Scozzafava B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Supuran B_LOCATION/B_PERSON
CT I_LOCATION/I_PERSON
( O
1997 B_MEASURE
) O
Main B_MEASURE/B_ORGANIZATION
Group I_MEASURE/I_ORGANIZATION
Met I_MEASURE/I_ORGANIZATION
Chem I_MEASURE/I_ORGANIZATION
20 I_MEASURE/I_ORGANIZATION
, O
151 B_MEASURE
- O
156 B_MEASURE
. O

28 B_PERSON
Forsman I_PERSON
C I_PERSON
, O
Behravan B_PERSON/B_LOCATION
G I_PERSON/I_LOCATION
, O
Osterman B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Jonsson B_PERSON/B_MEASURE
BH I_PERSON/I_MEASURE
( O
1988 B_MEASURE
) O
Acta B_MEASURE
Chem I_MEASURE
Scand I_MEASURE
B42 I_MEASURE
, O
314 B_MEASURE
- O
318 B_MEASURE
. O

29 B_PERSON
Behravan I_PERSON
G I_PERSON
, O
Jonasson B_LOCATION/B_PERSON
P I_LOCATION/I_PERSON
, O
Jonsson B_PERSON/B_LOCATION
BH I_PERSON/I_LOCATION
, O
Lindskog B_NUMBER[MEASURE]/B_LOCATION
S I_NUMBER[MEASURE]/I_LOCATION
( O
1991 B_MEASURE
) O
Eur B_MEASURE
JBiochem I_MEASURE
198 I_MEASURE
, O
589 B_MEASURE
- O
592 B_MEASURE
. O

30 B_PERSON/B_LOCATION
Khalifah I_PERSON/I_LOCATION
RG I_PERSON/I_LOCATION
, O
Strader B_LOCATION
DJ I_LOCATION
, O
Bryant B_LOCATION/B_ORGANIZATION
SH I_LOCATION/I_ORGANIZATION
, O
Gibson B_LOCATION/B_PERSON
SM I_LOCATION/I_PERSON
( O
1977 B_MEASURE
) O
Biochemistry B_MEASURE
16 I_MEASURE
, O
2241 B_MEASURE
- O
2247 B_MEASURE
. O

31 B_PERSON/B_LOCATION
Nyman I_PERSON/I_LOCATION
Po I_PERSON/I_LOCATION
, O
Lindskog B_PERSON/B_LOCATION
S I_PERSON/I_LOCATION
( O
1964 B_MEASURE
) O
Biochim B_MEASURE/B_LOCATION
Biophys I_MEASURE/I_LOCATION
Acta I_MEASURE/I_LOCATION
85 I_MEASURE/I_LOCATION
, O
141 B_MEASURE
- O
151 B_MEASURE
. O

32 B_PERSON
Henderson I_PERSON
le I_PERSON
, O
Henriksson B_PERSON/B_LOCATION
D I_PERSON/I_LOCATION
, O
Nyman B_PERSON/B_LOCATION
Po B_PERSON/I_LOCATION
( O
1976 B_MEASURE
) O
JBiol B_MEASURE
Chem I_MEASURE
251 I_MEASURE
, O
5457 B_MEASURE
- O
5463 B_MEASURE
. O

33 B_MEASURE/B_LOCATION
Maren I_MEASURE/I_LOCATION
TH I_LOCATION
, O
Wynns B_PERSON/B_LOCATION
GC I_PERSON/I_LOCATION
, O
Wistrand B_PERSON/B_LOCATION
PJ I_PERSON/I_LOCATION
( O
1993 B_MEASURE
) O
Mol B_MEASURE/B_PERSON
Pharmaco144 I_MEASURE/I_PERSON
, O
901 B_MEASURE
- O
906 B_MEASURE
. O

34 B_PERSON/B_LOCATION
Young I_PERSON/I_LOCATION
RW I_PERSON/I_LOCATION
, O
Wood B_LOCATION/B_PERSON
KH I_LOCATION/I_PERSON
, O
Vaughan B_LOCATION/B_PERSON
JR I_LOCATION/I_PERSON
, O
Anderson B_PERSON/B_LOCATION
GW I_PERSON/I_LOCATION
( O
1956 B_MEASURE
) O
J B_MEASURE/B_LOCATION
Am I_MEASURE/I_LOCATION
Chem I_MEASURE/I_LOCATION
Soc I_MEASURE
78 I_MEASURE
, O
4649 B_MEASURE
- O
4654 B_MEASURE
. O

35 B_PERSON/B_LOCATION
Pocker I_PERSON/I_LOCATION
Y I_PERSON/I_LOCATION
, O
stone B_MEASURE/B_PERSON
JT I_MEASURE/I_PERSON
( O
1967 B_MEASURE
) O
Biochemistry B_MEASURE
6 I_MEASURE
, O
668 B_MEASURE
- O
678 B_MEASURE
. O

36 B_PERSON
Baird I_PERSON
TT I_PERSON
, O
Waheed B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Okuyama B_LOCATION/B_PERSON
T I_LOCATION/I_PERSON
, O
sly B_LOCATION
WS I_LOCATION
, O
Fierke B_LOCATION/B_PERSON
CA B_LOCATION/I_PERSON
( O
1997 B_MEASURE
) O
Biochemistry B_MEASURE
36 I_MEASURE
, O
2669 B_MEASURE
- O
2678 B_MEASURE
. O

37 B_MEASURE/B_LOCATION
Maren I_MEASURE/I_LOCATION
TH I_LOCATION
, O
Bar B_LOCATION/B_PERSON
- O
Ilan B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
, O
Conroy B_PERSON/B_LOCATION
CW I_PERSON/I_LOCATION
, O
Brechue B_MEASURE/B_LOCATION
WF I_MEASURE/I_LOCATION
( O
1990 B_MEASURE
) O
Exp B_MEASURE/B_LOCATION
Eye I_MEASURE/I_LOCATION
Res I_MEASURE/I_LOCATION
50 I_MEASURE/I_LOCATION
, O
27 B_MEASURE
- O
36 B_MEASURE
. O

38 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Maren I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TH I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Brechue B_MEASURE/B_LOCATION
WF I_MEASURE/I_LOCATION
, O
Bar B_LOCATION/B_PERSON
- O
Ilan B_MEASURE/B_PERSON
A I_MEASURE/I_PERSON
( O
1992 B_MEASURE
) O
Exp B_MEASURE
Eye I_MEASURE
Res I_MEASURE
55 I_MEASURE
, O
73 B_MEASURE
- O
79 B_MEASURE
. O

39 B_PERSON
Brechue I_PERSON
WF I_PERSON
, O
Maren B_NUMBER[MEASURE]/B_LOCATION
th I_NUMBER[MEASURE]/I_LOCATION
( O
1993 B_TIME[MEASURE]/B_LOCATION
) O
invest O
Ophthalmol B_MEASURE/B_PERSON
Vis I_MEASURE/I_PERSON
Sci I_MEASURE/I_PERSON
34 I_MEASURE/I_PERSON
, O
2581 B_MEASURE
- O
2587 B_MEASURE
. O

40 B_PERSON/B_LOCATION
Borja I_PERSON/I_LOCATION
P I_PERSON/I_LOCATION
, O
Alzuet B_LOCATION
G I_LOCATION
, O
Server B_PERSON
- O
Carri6 B_LOCATION/B_MEASURE
J I_LOCATION/I_MEASURE
, O
Borras B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Supuran B_PERSON/B_MEASURE
CT I_PERSON/I_MEASURE
( O
1997 B_MEASURE
) O
J B_LOCATION/B_TIME[MEASURE]
Biol B_LOCATION/I_TIME[MEASURE]
Inorg B_LOCATION/I_TIME[MEASURE]
Chem B_LOCATION/I_TIME[MEASURE]
( O
JBIC B_MEASURE
) O
, O
in O
press B_LOCATION/B_MEASURE
. O

41 B_PERSON/B_LOCATION
Supuran I_PERSON/I_LOCATION
CT I_PERSON/I_LOCATION
, O
Balaban B_NUMBER[MEASURE]/B_LOCATION
AT I_NUMBER[MEASURE]/I_LOCATION
, O
Gheorghiu B_PERSON/B_LOCATION
MD I_PERSON/I_LOCATION
, O
Schiketanz B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Dinculescu B_LOCATION
A I_LOCATION
, O
Puscas B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O
1990 B_MEASURE
) O
Rev B_MEASURE/B_LOCATION
Roum I_MEASURE/I_LOCATION
Chim I_MEASURE/I_LOCATION
35 I_MEASURE/I_LOCATION
, O
399 B_MEASURE
- O
405 B_MEASURE
. O

42 B_PERSON/B_LOCATION
Supuran I_PERSON/I_LOCATION
CT I_PERSON/I_LOCATION
, O
Scozzafava B_NUMBER[MEASURE]/B_PERSON
A I_NUMBER[MEASURE]/I_PERSON
( O
1997 B_MEASURE
) O
unpublished B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

received O
: O
September B_TIME[MEASURE]
24 I_TIME[MEASURE]
, O
1997 B_MEASURE
accepted O
: O
October B_TIME[MEASURE]
17 I_TIME[MEASURE]
, O
1997 B_MEASURE
received O
in O
revised O
camera B_SPORT[ENT]/B_ORGANIZATION
- O
ready B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
format I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O
October B_TIME[MEASURE]
23 I_TIME[MEASURE]
, O
1997 B_MEASURE
. O

315 B_NUMBER[MEASURE]
. O

synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
Characterization B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
Antitumour B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Some O
Butyltin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
IV B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O
Cysteaminates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
N B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N B_OTHER/B_PROTEIN[GENE]
- O
Dimethylcysteaminates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
synthesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
four B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
di I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
and O
tri B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
butyltin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dimethylcysteaminates B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
three B_NUMBER[MEASURE]/B_PERSON
protonated O
/ O
quaternized B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
reported O
. O

They O
all O
exhibit O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
vitro B_MEASURE/B_DISEASE
cytotoxic I_MEASURE/I_DISEASE
activity I_MEASURE/I_DISEASE
. O

Six B_NUMBER[MEASURE]
of O
seven B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds B_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O
in O
this O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
more O
active B_DISEASE_ADJECTIVE[DISEASE]
than O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
less O
active B_DISEASE_ADJECTIVE[DISEASE]
than O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Metal B_ORGANIZATION
Based I_ORGANIZATION
Drugs I_ORGANIZATION
. O

Vol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

7 B_MEASURE
, O
Nr B_MEASURE/B_BIO
. O

5 B_TIME[MEASURE]/B_LOCATION
, O
2000 B_MEASURE/B_LOCATION
. O

synthesis B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Characterization B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
AND O
ANTITUMOUR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ACTITY I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OF O
Some O
BUTYLTIN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IV B_NUMBER[MEASURE]/B_DISEASE
) O
CYSTEAMINATES B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
N B_OTHER/B_PROTEIN[GENE]
, O
N B_OTHER/B_PROTEIN[GENE]
- O
DIMETHYLCYSTEAMINATES B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Marcel I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Gielen I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Karel I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Handlir I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
2 B_NUMBER[MEASURE]/B_PERSON
, O
Martin B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hollein I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Dick B_PERSON/B_ENT
de I_PERSON/I_ENT
Vos I_PERSON/I_ENT
2 I_PERSON/I_ENT
3 I_PERSON/I_ENT
. O

Departement B_LOCATION/B_ORGANIZATION
of O
General B_PERSON/B_EDU[ORGANIZATION]
and O
Organic B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chemistry I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AOSC I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Faculty B_PERSON/B_LOCATION
of O
Applied B_EDU[ORGANIZATION]/B_PERSON
Sciences I_EDU[ORGANIZATION]/I_PERSON
, O
Free B_LOCATION
University I_LOCATION
of O
Brussels B_LOCATION/B_PERSON
VUV I_LOCATION/I_PERSON
, O
Pleinlaan B_LOCATION/B_PERSON
2 I_LOCATION/I_PERSON
, O
B B_OTHER/B_MEASURE
- O
1050 B_LOCATION/B_MEASURE
Brussels I_LOCATION/I_MEASURE
, O
Belgium B_LOCATION/B_ORGANIZATION
Departement I_LOCATION/I_ORGANIZATION
of O
General B_PERSON/B_EDU[ORGANIZATION]
and O
Inorganic B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chemistry I_EDU[ORGANIZATION]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Faculty B_PERSON/B_LOCATION
of O
Chemical B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Technology I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
University B_LOCATION/B_ORGANIZATION
of O
Pafdubice B_PERSON/B_LOCATION
, O
Nam B_PERSON/B_LOCATION
. O

CS B_LOCATION/B_PERSON
. O
legii B_NUMBER[MEASURE]/B_PERSON
565 I_NUMBER[MEASURE]/I_PERSON
, O
53210 B_LOCATION/B_MEASURE
Pardubice I_LOCATION/I_MEASURE
, O
Czech B_LOCATION
Republic I_LOCATION
Pharmachemie I_LOCATION
B I_LOCATION
. O

V B_OTHER/B_DISEASE
. O
, O
Haarlem B_LOCATION
, O
the O
Netherlands B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
abstract I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
synthesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
four B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
di I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
and O
tri B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
butyltin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
_ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
N B_OTHER/B_LOCATION
, O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
dimethylcysteaminates B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
three B_NUMBER[MEASURE]/B_PERSON
protonated O
/ O
quaternized B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
reported O
. O

They O
all O
exhibit O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
vitro B_MEASURE/B_DISEASE
cytotoxic I_MEASURE/I_DISEASE
activity I_MEASURE/I_DISEASE
. O

Six B_NUMBER[MEASURE]
of O
seven B_MEASURE/B_PERSON
compounds B_MEASURE/I_PERSON
presented O
in O
this O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
more O
active B_DISEASE_ADJECTIVE[DISEASE]
than O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
less O
active B_DISEASE_ADJECTIVE[DISEASE]
than O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
doxorubiein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Several B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organotin I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminates I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
aminoethylthiolates B_DISEASE/B_PROTEIN[GENE]
) O
have O
been O
studied O
1 B_MEASURE/B_LOCATION
- O
4 B_MEASURE
as O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
potentially O
high B_DISEASE_ADJECTIVE[DISEASE]
biological I_DISEASE_ADJECTIVE[DISEASE]
activity I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
their O
cytotoxic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
paper I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
reports O
the O
synthesis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
di B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
tri B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
butyltin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
their O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dimethyl B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analogues I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
their O
in O
vitro B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
cytotoxicity I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

It O
is O
shown O
that O
a O
correct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
biological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
organotin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
remains O
5 B_TIME[MEASURE]/B_LOCATION
often O
hampered O
by O
their O
low B_DISEASE_ADJECTIVE[DISEASE]
water I_DISEASE_ADJECTIVE[DISEASE]
solubility I_DISEASE_ADJECTIVE[DISEASE]
. O

Therefore O
, O
we O
focused O
on O
the O
synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
derivatives B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
potentially O
higher B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
solubility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
introducing O
ionic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
molecule B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
by O
protonation B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
quatemization B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
nitrogen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atom I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

3 B_NUMBER[MEASURE]/B_PERSON

2 B_NUMBER[MEASURE]/B_PERSON

4 B_NUMBER[MEASURE]/B_PERSON

( O
n O
- O
Bu B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
n B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sn I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SCH2 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
CH2 B_MEASURE/B_LOCATION
- O
NHm B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
CH3 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2 B_MEASURE/B_LOCATION
- O
m B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
4 I_MEASURE/I_LOCATION
- O
n B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

n O
= O
3 B_NUMBER[MEASURE]
, O
n O
= O
3 B_NUMBER[MEASURE]
, O
n B_OTHER/B_MEASURE
= O
2 B_NUMBER[MEASURE]
, O
n B_OTHER/B_MEASURE
= O
2 B_NUMBER[MEASURE]
, O

m O
= O
2 B_MEASURE/B_LOCATION
m I_MEASURE/I_LOCATION
= O
O B_MEASURE/B_LOCATION
m I_MEASURE/I_LOCATION
= O
2 B_MEASURE/B_LOCATION
m I_MEASURE/I_LOCATION
= O
O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1 B_MEASURE
) O
( O
2 B_NUMBER[MEASURE]
) O
( O
3 B_NUMBER[MEASURE]
) O
( O
4 B_NUMBER[MEASURE]
) O
. O

3 B_NUMBER[MEASURE]/B_PERSON

2 B_NUMBER[MEASURE]/B_PERSON

4 B_NUMBER[MEASURE]/B_PERSON

( O
n O
- O
Bu B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
3 B_MEASURE/B_PERSON
Sn I_MEASURE/I_PERSON
S I_MEASURE/I_PERSON
- O
CH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
CH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
NHm B_LOCATION/B_MEASURE
( O
CH3 B_LOCATION/B_PERSON
) O
3 B_MEASURE
. O
m B_NUMBER[MEASURE]/B_LOCATION
X I_NUMBER[MEASURE]/I_LOCATION
. O

m O
= O
3 B_NUMBER[MEASURE]
, O
x O
= O
cn3so3 B_LOCATION/B_MEASURE
( O
5 B_MEASURE
) O
m B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
, O
X B_PROTEIN[GENE]/B_DISEASE
= O
CH3SO3 B_LOCATION/B_MEASURE
( O
6 B_MEASURE
) O
m B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
, O
X B_MEASURE/B_LOCATION
I I_MEASURE/I_LOCATION
( O
7 B_MEASURE
) O
. O

n O
- O
Bu B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CH3 B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
CH2 B_PROTEIN[GENE]/B_LOCATION
- O
CH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
CH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

( O
2 B_NUMBER[MEASURE]
) O
, O
di B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
nTri B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
butyltin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_NUMBER[MEASURE]
) O
, O
tri B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
butyltin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
dimethylcysteaminate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
butyltin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
cysteaminate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
3 B_NUMBER[MEASURE]
) O
and O
di B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
butyltin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
dimethylcysteaminate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
4 B_NUMBER[MEASURE]
) O
were O
prepared O
by O
the O
reaction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteaminate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
prepared O
in O
situ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
the O
reaction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
hydrochloride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
eysteamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
with O
the O
suitable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
di I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
or O
tri B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
butyltin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
chloroform B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
following O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
the O
reactions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
The O
methanesulphonates B_SEQUENCE[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_SEQUENCE[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
6 B_NUMBER[MEASURE]
were O
respectively O
synthesized O
equimolar B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amount I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
methane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphonic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
unprotonated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
2 B_NUMBER[MEASURE]
with O
an O
chloroform B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

After O
purification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
a O
short B_LOCATION
column I_LOCATION
of O
alumina B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
evaporation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
solvent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
colourless B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
viscous I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oils I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
obtained O
. O

The O
quaternized B_TIME[MEASURE]/B_LOCATION
methyl I_TIME[MEASURE]/I_LOCATION
derivative I_TIME[MEASURE]/I_LOCATION
of O
2 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
methiodide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
7 B_TIME[MEASURE]/B_LOCATION
) O
, O
was O
prepared O
by O
its O
reaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
methyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iodide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
benzene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
purified O
by O
recrystalization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
chloroform B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

233 B_NUMBER[MEASURE]
. O

M B_OTHER/B_MEASURE
. O

Gielen B_PERSON
, O
K B_OTHER/B_PERSON
. O

Handlir B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

Hollein B_PERSON/B_COLOR
and O
D B_OTHER/B_PERSON
. O

de B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Vos I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
synthesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
Characterization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
antitumor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ofSome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Butyltin I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IV B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
Cysteaminates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
N B_OTHER/B_PROTEIN[GENE]
- O
Dimethylcysteaminates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

86 B_MEASURE
77 I_MEASURE
85 I_MEASURE
3 I_MEASURE
( O
C4H9 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2Sn B_MEASURE/B_LOCATION
( O
SCH2CH2NH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
2 B_MEASURE
90 I_MEASURE
4 I_MEASURE
( O
C4Hg B_MEASURE/B_LOCATION
) O
zSn B_MEASURE/B_LOCATION
( O
SCH2CHzN B_LOCATION
( O
CH3 B_LOCATION/B_PERSON
) O
2 B_MEASURE
) O
2 B_MEASURE
92 I_MEASURE
oil I_MEASURE
5 I_MEASURE
( O
C4H9 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
3 B_MEASURE/B_PERSON
SnSCH2CH2NH3 I_MEASURE/I_PERSON
CH3SO3 I_MEASURE/I_PERSON
94 I_MEASURE/I_PERSON
6 I_MEASURE/I_PERSON
oil I_MEASURE/I_PERSON
( O
C4H9 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
3 B_MEASURE/B_LOCATION
SnSCH2CH2NH I_MEASURE/I_LOCATION
( O
CH3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
2 B_MEASURE/B_PERSON
CH3SO3 I_MEASURE/I_PERSON
118 I_MEASURE/I_PERSON
- O
120 B_MEASURE
74 I_MEASURE
7 I_MEASURE
( O
C4H9 B_MEASURE/B_GENE
) O
. O
SnSCH B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
. O
CH B_LOCATION/B_DISEASE
. O
N B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CH3 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
31 B_MEASURE
The O
elemental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
C B_LOCATION/B_GENE
, O
H B_OTHER/B_LOCATION
, O
N B_OTHER/B_LOCATION
, O
Sn B_LOCATION/B_PERSON
) O
agree O
satisfactorily O
with O
the O
proposed O
formul B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

melting O
points B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
yields B_MEASURE
for O
. O
. O
c0mP0unds B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
) O
rmula B_PROTEIN[GENE]/B_MEASURE
, O
2 B_LOCATION/B_MEASURE
comp I_LOCATION/I_MEASURE
. O

1 B_NUMBER[MEASURE]
( O
C4H9 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
3SnSCHzCH2NH2 B_PROTEIN[GENE]/B_LOCATION
2 B_PROTEIN[GENE]/I_LOCATION
( O
C4H9 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
3SnSCHzCH2N B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CH3 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2 B_MEASURE/B_LOCATION
. O

7 B_NUMBER[MEASURE]
. O

m B_PROTEIN[GENE]/B_DISEASE
. O
p B_MEASURE/B_PROTEIN[GENE]
. O
, O
. O
. O
b O
. O
p B_MEASURE/B_PROTEIN[GENE]
. O
. O
, O
. O
C B_MEASURE
120 I_MEASURE
- O
123 B_MEASURE
/ O
40 B_TIME[MEASURE]
Pa I_TIME[MEASURE]
129 I_TIME[MEASURE]
- O
131 B_MEASURE
/ O
35 B_TIME[MEASURE]
Pa I_TIME[MEASURE]
167 I_TIME[MEASURE]
- O
169 B_MEASURE
/ O
35 B_TIME[MEASURE]
Pa I_TIME[MEASURE]
172 I_TIME[MEASURE]
- O
174 B_MEASURE
/ O
40 B_MEASURE/B_LOCATION
Pa I_MEASURE/I_LOCATION
. O

' B_OTHER/B_DISEASE
o O
' O
. O

yield B_MEASURE
, O
. O
% B_OTHER/B_MEASURE
. O

Compounds B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
4 B_NUMBER[MEASURE]
, O
and O
7 B_MEASURE/B_LOCATION
, O
are O
poorly O
soluble B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O
aqueous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solutions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
< B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
/ O
mL B_MEASURE/B_LOCATION
) O
. O

Compounds B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 B_NUMBER[MEASURE]
and O
6 B_MEASURE
exhibit O
higher B_DISEASE_ADJECTIVE[DISEASE]
water I_DISEASE_ADJECTIVE[DISEASE]
solubilities I_DISEASE_ADJECTIVE[DISEASE]
( O
ca O
. O
2 B_MEASURE
mg I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
) O
. O

Compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 B_PERSON/B_LOCATION
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
soluble B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O
a O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
0 B_MEASURE
, O
103 B_MEASURE
M I_MEASURE
solution I_MEASURE
of O
NaCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
DMSO B_MEASURE
1 I_MEASURE
/ O
9 B_NUMBER[MEASURE]
) O
. O

A O
white B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
turbidity B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
in O
these O
solutions B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
after O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
slow O
hydrolysis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

compounds B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
characterized O
by O
multinuclear B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NMR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectroscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
NMR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
given O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

resonances B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
13C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
( O
ca O
20 B_MEASURE
% I_MEASURE
Sol I_MEASURE
. O
v B_OTHER/B_PROTEIN[GENE]
/ O
v O
) O
1 B_NUMBER[MEASURE]
' O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

SN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ll9Sn B_MEASURE/B_LOCATION
NMR I_MEASURE/I_LOCATION
spectra I_MEASURE/I_LOCATION
of O
2 B_MEASURE/B_LOCATION
. O

the O
compounds B_DISEASE/B_PROTEIN[GENE]
1 B_DISEASE/I_PROTEIN[GENE]
- O
7 B_MEASURE
in O
CDCI3 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
86 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
3 B_TIME[MEASURE]
13 I_TIME[MEASURE]
. O
45 B_MEASURE
. O

6 B_MEASURE/B_LOCATION
' O
' O
S B_OTHER/B_MEASURE
' O
n B_MEASURE
) O
, O
' O
ppm B_TIME[MEASURE]/B_PROTEIN[GENE]
6 I_TIME[MEASURE]/I_PROTEIN[GENE]
( O
3c B_MEASURE/B_LOCATION
) O
a O
, O
ppm B_MEASURE/B_LOCATION
. O

x B_OTHER/B_PERSON

77 O
. O
6 B_MEASURE/B_LOCATION
12 I_MEASURE/I_LOCATION
. O
3 B_MEASURE
. O

77 O
. O
5 B_TIME[MEASURE]
12 I_TIME[MEASURE]
. O
75 B_MEASURE
. O

3 B_MEASURE
- O
28 B_MEASURE
. O
9 B_MEASURE/B_LOCATION
22 I_MEASURE/I_LOCATION
. O
38 B_MEASURE
. O

38 O
. O
' O
18 B_MEASURE/B_LOCATION
. O
78 B_TIME[MEASURE]/B_LOCATION
. O

4 B_NUMBER[MEASURE]/B_PERSON

6 B_MEASURE
' O
' O
89 B_MEASURE
. O
5 B_TIME[MEASURE]
13 I_TIME[MEASURE]
. O
45 B_MEASURE
. O

7 B_MEASURE
93 I_MEASURE
. O
2 B_MEASURE
13 I_MEASURE
. O
60 B_MEASURE
. O

( O
332 O
) O
27 B_MEASURE/B_LOCATION
. O
93 B_TIME[MEASURE]/B_LOCATION
. O

( O
331 O
) O
27 B_MEASURE/B_LOCATION
. O
97 B_MEASURE/B_LOCATION
. O

( O
495 O
) O
28 B_MEASURE/B_LOCATION
. O
27 B_MEASURE/B_LOCATION
. O

( O
438 O
) O
27 B_MEASURE/B_LOCATION
. O
51 B_TIME[MEASURE]/B_LOCATION
. O

( O
322 O
) O
28 B_MEASURE/B_LOCATION
. O
30 B_TIME[MEASURE]/B_PERSON
. O

( O
350 O
) O
28 B_MEASURE/B_LOCATION
. O
34 B_MEASURE/B_LOCATION
. O

( O
339 O
) O
28 B_MEASURE/B_LOCATION
. O
47 B_TIME[MEASURE]/B_LOCATION
. O

( O
21 O
. O
3 B_MEASURE
) O
26 B_MEASURE/B_LOCATION
. O
32 B_MEASURE
. O

( O
21 O
. O
1 B_MEASURE
) O
26 B_MEASURE/B_LOCATION
. O
38 B_MEASURE
. O

( O
28 O
. O
4 B_MEASURE
) O
26 B_MEASURE/B_LOCATION
. O
42 B_MEASURE
. O

( O
26 O
. O
4 B_MEASURE
) O
25 B_MEASURE/B_LOCATION
. O
90 B_MEASURE
. O

( O
21 O
. O
4 B_MEASURE
) O
26 B_MEASURE/B_LOCATION
. O
85 B_MEASURE
. O

( O
21 O
. O
3 B_MEASURE
) O
26 B_MEASURE/B_LOCATION
. O
81 B_MEASURE
. O

( O
22 O
. O
0 B_MEASURE
) O
26 B_MEASURE
. O
91 B_MEASURE
. O

( O
59 O
. O
6 B_MEASURE
) O
12 B_MEASURE/B_LOCATION
. O
89 B_MEASURE
. O

( O
59 O
. O
8 B_MEASURE
) O
12 B_MEASURE/B_LOCATION
. O
95 B_MEASURE
. O

( O
87 O
. O
1 B_MEASURE
) O
13 B_MEASURE/B_LOCATION
. O
35 B_MEASURE
. O

( O
83 O
. O
8 B_MEASURE
) O
12 B_MEASURE/B_LOCATION
. O
82 B_MEASURE
. O

( O
62 O
. O
7 B_MEASURE
) O
13 B_MEASURE/B_LOCATION
. O
45 B_MEASURE
. O

( O
61 O
. O
4 B_MEASURE
) O
13 B_MEASURE/B_LOCATION
. O
58 B_MEASURE
. O

62 O
. O
2 B_MEASURE
) O
14 B_MEASURE
. O
00 B_MEASURE
. O

( O
- O
) O
30 B_MEASURE
. O
31 B_TIME[MEASURE]
45 I_TIME[MEASURE]
. O
02 B_MEASURE
. O

( O
- O
) O
23 B_MEASURE
. O
59 B_TIME[MEASURE]
63 I_TIME[MEASURE]
. O
12 B_TIME[MEASURE]
44 I_TIME[MEASURE]
. O
71 B_MEASURE
. O

( O
- O
) O
30 B_MEASURE
. O
04 B_TIME[MEASURE]
44 I_TIME[MEASURE]
. O
44 B_MEASURE
. O

( O
- O
) O
23 B_MEASURE
. O
84 B_MEASURE/B_LOCATION
61 I_MEASURE/I_LOCATION
. O
84 B_TIME[MEASURE]
44 I_TIME[MEASURE]
. O
46 B_MEASURE
. O

( O
- O
) O
23 B_MEASURE
. O
92 B_MEASURE
43 I_MEASURE
. O
08 B_MEASURE
. O

( B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
- O
; O

( B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
) O
. O

20 B_MEASURE
. O
94 B_MEASURE/B_LOCATION
19 I_MEASURE/I_LOCATION
. O
70 B_MEASURE
60 I_MEASURE
. O
94 B_MEASURE
69 I_MEASURE
. O
49 B_MEASURE
43 I_MEASURE
. O
42 B_TIME[MEASURE]
54 I_TIME[MEASURE]
. O
18 B_TIME[MEASURE]
39 I_TIME[MEASURE]
. O
15 B_TIME[MEASURE]
39 I_TIME[MEASURE]
. O
16 B_MEASURE
- O
360 B_MEASURE
. O
4 B_MEASURE
- O
354 B_MEASURE
. O
0 B_SEQUENCE[MEASURE]
- O
355 B_MEASURE
. O
3 B_MEASURE
- O
354 B_MEASURE
. O
4 B_MEASURE
- O
349 B_MEASURE
. O
4 B_MEASURE
- O
344 B_MEASURE
. O
2 B_MEASURE
- O
325 B_MEASURE
. O
8 B_MEASURE
1 I_MEASURE
. O
1 B_MEASURE
6 I_MEASURE
. O
2 B_MEASURE
1 I_MEASURE
. O
5 B_MEASURE
1 I_MEASURE
. O
5 B_TIME[MEASURE]
12 I_TIME[MEASURE]
. O
7 B_TIME[MEASURE]
11 I_TIME[MEASURE]
. O
7 B_TIME[MEASURE]
30 I_TIME[MEASURE]
. O
1 B_MEASURE/B_LOCATION
13 I_MEASURE/I_LOCATION
a O
' O
values B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
NJ B_LOCATION/B_NUMBER[MEASURE]
( O
n B_LOCATION
J I_LOCATION
9 I_LOCATION
Sn I_LOCATION
, O
, O
C B_OTHER/B_MEASURE
) O
c0uplihg B_MEASURE/B_PERSON
constants I_MEASURE/I_PERSON
in O
Hz B_MEASURE
' O
for O
Carbon B_LOCATION/B_MEASURE
ato I_LOCATION/I_MEASURE
] O
ns B_MEASURE
in O
parentlee B_PERSON
' O
s B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
btween I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
N B_OTHER/B_MEASURE
) O
for O
the O
organo B_LOCATION/B_ENT
. O
i O
compound O
and O
free B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteamine I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
6 B_NUMBER[MEASURE]
( O
N B_MEASURE/B_OTHER
) O
361 B_MEASURE
. O
5 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
; O
N B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dimethylcysteamine B_LOCATION/B_MEASURE
, O
5 B_NUMBER[MEASURE]
( O
N B_OTHER/B_MEASURE
) O
- O
355 B_MEASURE
. O
9 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
) O
not O
observed O
. O

C B_LOCATION/B_PERSON
resonances I_LOCATION/I_PERSON
were O
assigned O
on O
the O
basis B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
values B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
n B_NUMBER[MEASURE]/B_LOCATION
J I_NUMBER[MEASURE]/I_LOCATION
( O
119 B_MEASURE/B_LOCATION
Sn I_MEASURE/I_LOCATION
, O
13 B_LOCATION/B_MEASURE
C I_LOCATION/I_MEASURE
) O
coupling B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
constants I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
13 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
apt B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
utilization I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
agreement B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
ref B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O
. O

The O
values B_MEASURE
of O
119 B_NUMBER[MEASURE]/B_PERSON
Sn I_NUMBER[MEASURE]/I_PERSON
chemical I_NUMBER[MEASURE]/I_PERSON
shifts I_NUMBER[MEASURE]/I_PERSON
are O
found O
in O
the O
interval B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
characteristic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
fourcoordinated B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tin I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
7 B_MEASURE/B_LOCATION
. O

The O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
coupling B_MEASURE/B_LOCATION
constants I_MEASURE/I_LOCATION
j O
( O
1 B_MEASURE/B_PROTEIN[GENE]
lqSn I_MEASURE/I_PROTEIN[GENE]
, O
13C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
agree O
with O
the O
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
proposed O
. O

compound B_PERSON
3 I_PERSON
is O
characterized O
by O
a O
somewhat O
larger B_MEASURE
upfield I_MEASURE
shift I_MEASURE
, O
close B_LOCATION/B_MEASURE
to O
the O
upper B_MEASURE/B_LOCATION
limit I_MEASURE/I_LOCATION
of O
the O
above B_TIME[MEASURE]/B_LOCATION
mentioned O
interval B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
together O
with O
a O
high B_MEASURE/B_LOCATION
value I_MEASURE/I_LOCATION
of O
1j B_MEASURE/B_PROTEIN[GENE]
( O
l B_MEASURE/B_PROTEIN[GENE]
lqSn I_MEASURE/I_PROTEIN[GENE]
, O
13C B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
495 B_MEASURE/B_LOCATION
Hz I_MEASURE/I_LOCATION
) O
. O

67 B_MEASURE
The O
C B_PROTEIN[GENE]/B_LOCATION
- O
Sn B_LOCATION/B_PERSON
- O
C B_MEASURE/B_LOCATION
angle B_MEASURE/I_LOCATION
, O
est B_LOCATION/B_PROTEIN[GENE]
' O
mated O
, O
from O
this O
value B_MEASURE
of O
coupling O
constant B_MEASURE
is O
124 B_TIME[MEASURE]
According O
to O
ref O
. O
this O
behaviour B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O
be O
due B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
intermolecular B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
association I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
increasing O
the O
coordinatitn B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
tin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
concentrated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
solutions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
as O
suggested O
by O
the O
concentration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dependence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
tS B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Sn B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
and O
cryoscopic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O
benzene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
values B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
6 B_MEASURE
( O
SN B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
chemical B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
shifts I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
compounds B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
1 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
2 B_SEQUENCE[MEASURE]
and O
4 B_NUMBER[MEASURE]
only O
slightly O
differ O
from O
the O
( O
15N B_LOCATION
) O
values B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
free B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cysteamine I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
significantly O
larger B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i O
( O
15N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
chemical B_MEASURE
shift I_MEASURE
of O
compound B_MEASURE
3 I_MEASURE
is O
however O
much O
lower B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
those O
of O
compounds B_NUMBER[MEASURE]
5 I_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
and O
7 B_NUMBER[MEASURE]
containing O
a O
N B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interaction I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tetracoordinated I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nitrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
atom I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
can O
be O
stated O
that O
the O
Sn B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
4 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
negligible B_DISEASE_ADJECTIVE[DISEASE]
or O
only O
very O
weak B_DISEASE_ADJECTIVE[DISEASE]
in O
chlorofom B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
solutions B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

This O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
not O
in O
contradiction B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
proved O
Sn B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
N I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interaction I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
found O
in O
the O
solid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
state I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

13 B_NUMBER[MEASURE]
. O


, B_OTHER/B_PERSON

234 B_NUMBER[MEASURE]
. O

Metal B_ORGANIZATION
Based I_ORGANIZATION
Drugs I_ORGANIZATION
. O

Vol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

7 B_MEASURE
, O
Nr B_MEASURE/B_BIO
. O

5 B_TIME[MEASURE]/B_LOCATION
, O
2000 B_MEASURE/B_LOCATION
. O

Antitumour B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antitumour I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
given O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
the O
inhibition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
doses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
IDs0 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
observed O
against O
a O
panel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
seven B_DISEASE
human I_DISEASE
tumour I_DISEASE
cell I_DISEASE
lines I_DISEASE
, O
MCF B_PROTEIN[GENE]/B_BIO
- O
7 B_TIME[MEASURE]/B_LOCATION
and O
EVSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
T B_MEASURE/B_OTHER
, O
two B_DISEASE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
breast B_DISEASE/I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
cancers B_DISEASE/I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
, O
WiDr B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
, O
a O
colon B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
IGROV B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
ovarian B_DISEASE
cancer I_DISEASE
, O
M19 B_DISEASE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
MEL B_DISEASE/I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
, O
a O
melanoma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
A248 B_GENE/B_DISEASE
, O
a O
renal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
H226 B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
non B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
small B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
lung I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
antitumour B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
compared O
with O
those O
obtained O
for O
clinically O
used O
reference B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds9 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Inhibition B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

comp B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

1 B_MEASURE
2 I_MEASURE
3 I_MEASURE
4 I_MEASURE
5 I_MEASURE
6 I_MEASURE
7 I_MEASURE
. O

MF B_MEASURE
- O
7 B_MEASURE
41 I_MEASURE
41 I_MEASURE
51 I_MEASURE
78 I_MEASURE
30 I_MEASURE
90 I_MEASURE
385 I_MEASURE
699 I_MEASURE
10 I_MEASURE
2 I_MEASURE
594 I_MEASURE
750 I_MEASURE
18 I_MEASURE
. O

EVSA B_MEASURE/B_GENE
- O
T B_MEASURE/B_LOCATION
33 I_MEASURE/I_LOCATION
35 I_MEASURE/I_LOCATION
45 I_MEASURE/I_LOCATION
65 I_MEASURE/I_LOCATION
< O
3 B_MEASURE/B_LOCATION
57 I_MEASURE/I_LOCATION
367 I_MEASURE/I_LOCATION
. O

IDs0 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
compounds B_PERSON/B_DISEASE
WiDr I_PERSON/I_DISEASE
39 I_PERSON/I_DISEASE
39 I_PERSON/I_DISEASE
211 I_PERSON/I_DISEASE
331 I_PERSON/I_DISEASE
19 I_PERSON/I_DISEASE
40 I_PERSON/I_DISEASE
339 I_PERSON/I_DISEASE
. O

1 B_NUMBER[MEASURE]/B_LOCATION
- O
7 B_MEASURE
and O
of O
five B_MEASURE/B_LOCATION
reference B_MEASURE/I_LOCATION
compounds B_MEASURE/I_LOCATION
. O

IGROV B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
M19MEL I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
A498 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
H226 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
67 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
44 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
85 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
39 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
46 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
78 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
88 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
39 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
68 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
70 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
118 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
72 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
110 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
129 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
108 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
112 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
31 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
29 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
36 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
42 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
83 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
133 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
77 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
111 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
327 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
758 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
576 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
411 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
169 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
60 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
580 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
297 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
7 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
558 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
16 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
505 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
442 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
23 I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
doxorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

422 B_TIME[MEASURE]
8 I_TIME[MEASURE]
317 I_TIME[MEASURE]
475 I_TIME[MEASURE]
5 I_TIME[MEASURE]
. O

methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

967 B_TIME[MEASURE]
11 I_TIME[MEASURE]
150 I_TIME[MEASURE]
225 I_TIME[MEASURE]
< O
3 B_MEASURE/B_LOCATION
. O

2 B_TIME[MEASURE]
253 I_TIME[MEASURE]
90 I_TIME[MEASURE]
314 I_TIME[MEASURE]
143 I_TIME[MEASURE]
37 I_TIME[MEASURE]
. O

3 B_MEASURE
369 I_MEASURE
199 I_MEASURE
3 I_MEASURE
934 I_MEASURE
340 I_MEASURE
2 I_MEASURE
287 I_MEASURE
. O

It O
is O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
all O
studied O
compounds B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
exhibit O
excellent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cytostatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
except O
compound B_NUMBER[MEASURE]/B_BIO
7 I_NUMBER[MEASURE]/I_BIO
showing O
only B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moderate I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 B_LOCATION
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
more O
active B_DISEASE_ADJECTIVE[DISEASE]
than O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
, O
in O
most B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
than O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Their O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
most B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
studied O
cancer B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
very O
limited B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
acquired O
activity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
the O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
tri B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
butyltin B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
those O
of O
di B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
n B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
butyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analogues I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
1 B_NUMBER[MEASURE]/B_LOCATION
> O
3 B_NUMBER[MEASURE]
, O
2 B_NUMBER[MEASURE]
> O
4 B_NUMBER[MEASURE]
) O
for O
all O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lines B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
especially O
compounds O
against O
WiDr B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dimethyl B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derivatives I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exhibit O
an O
activity B_MEASURE/B_LOCATION
comparable I_MEASURE/I_LOCATION
to O
or O
somewhat O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
unmethylated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

compound B_MEASURE
8 I_MEASURE
, O
with O
a O
quaternized B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrogen B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
exhibits O
the O
lowest B_MEASURE/B_LOCATION
cytotoxic I_MEASURE/I_LOCATION
activities I_MEASURE/I_LOCATION
, O
approximatively O
9 B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
times B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lower B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O
compound B_NUMBER[MEASURE]/B_LOCATION
2 I_NUMBER[MEASURE]/I_LOCATION
. O

It O
might O
be O
underlined O
that O
the O
ionic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
more I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
soluble B_NUMBER[MEASURE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_NUMBER[MEASURE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_NUMBER[MEASURE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
6 B_NUMBER[MEASURE]
are O
not O
more O
active B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
the O
uncharged B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analogs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
4 B_MEASURE
, O
whereas O
the O
hydrophilic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
organotin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
polyoxacarboxylates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
exhibit O
much O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
than O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
organotin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
carxylates O
51 B_NUMBER[MEASURE]
compounds I_NUMBER[MEASURE]
5 I_NUMBER[MEASURE]
and O
6 B_NUMBER[MEASURE]
( O
with O
a O
protonated O
nitrogen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
exhibit B_LOCATION/B_PERSON
activities I_LOCATION/I_PERSON
comparable I_LOCATION/I_PERSON
or O
even O
considerably O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
compound B_MEASURE
5 I_MEASURE
) O
against O
EVSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
T B_PROTEIN[GENE]/B_MEASURE
than O
the O
corresponding B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unprotonated I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Compound B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
with O
a O
quaternized B_MEASURE
nitrogen I_MEASURE
) O
exhibits O
the O
lowest B_MEASURE/B_LOCATION
cytostatic I_MEASURE/I_LOCATION
activities I_MEASURE/I_LOCATION
, O
approximately O
9 B_TIME[MEASURE]/B_LOCATION
times B_TIME[MEASURE]/I_LOCATION
should O
however O
be O
mentioned O
that O
another O
ionic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organotin I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lower I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
compound B_NUMBER[MEASURE]/B_LOCATION
2 I_NUMBER[MEASURE]/I_LOCATION
. O

It O
compound O
, O
bis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
dicyclohexyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
ammonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
- O
pyridinecarboxyla B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
to O
) O
di B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
n B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
butylstannate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
where O
the O
organotin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
moiety I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
this O
time B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
anionic I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
is O
also O
as O
active B_DISEASE_ADJECTIVE[DISEASE]
as O
the O
uncharged B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analog I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

All O
NMR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spectra I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
recorded O
on O
a O
Bruker B_MEASURE/B_PRODUCT[OBJECT]
AMX I_MEASURE/I_PRODUCT[OBJECT]
360 I_MEASURE/I_PRODUCT[OBJECT]
instrument I_MEASURE/I_PRODUCT[OBJECT]
using O
a O
5 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mm I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
multinuclear I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
tuneable I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
probe I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
residual B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CHCI3 I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resonance I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O
7 B_MEASURE
. O
24 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
was O
used O
as O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
H B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
soectra I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
central B_SEQUENCE[MEASURE]/B_LOCATION
13CDCI3 I_SEQUENCE[MEASURE]/I_LOCATION
resonance I_SEQUENCE[MEASURE]/I_LOCATION
at O
77 B_MEASURE
. O
0 B_TIME[MEASURE]
ppm I_TIME[MEASURE]
, O
for O
the O
13C B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spectra I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
119 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Sn I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chemical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
shifts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
refered O
to O
the O
external B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tetramethyltin I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
6 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
119 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sn I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
0 B_MEASURE
. O
0 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
15N B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NMR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectra I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
measur B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O
l B_DISEASE/B_LOCATION
using O
the O
INEPT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
or O
in O
inverse B_MEASURE
- O
gated O
mode B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

( O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
instrumentation B_PERSON/B_LOCATION
. O

external B_MEASURE
nitromethane I_MEASURE
, O
[ B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
' O
N B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
0 B_MEASURE
. O
0 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
) O
. O

The O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
followed O
for O
the O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antitumour I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
screenings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O
been O
already O
reported O
10 B_TIME[MEASURE]/B_LOCATION
. O

Acknowledgements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

K B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

H B_PROTEIN[GENE]/B_LOCATION
. O
and O
M B_LOCATION/B_PERSON
H I_LOCATION/I_PERSON
. O
thank O
the O
Grant B_ORGANIZATION/B_LOCATION
Agency I_ORGANIZATION/I_LOCATION
of O
the O
Czech B_LOCATION/B_ORGANIZATION
Republic I_LOCATION/I_ORGANIZATION
( O
Grant B_MEASURE/B_ORGANIZATION
No I_MEASURE
. O
203 B_MEASURE
/ O
00 B_MEASURE
/ O
0920 B_MEASURE
) O
and O
the O
Ministry B_ORGANIZATION/B_PERSON
o O
' O
Education B_PERSON/B_LOCATION
, O
Youth B_PERSON/B_EDU[ORGANIZATION]
and O
Sport B_SPORT[ENT]/B_PERSON
of O
the O
Czech B_LOCATION/B_ORGANIZATION
republic I_LOCATION/I_ORGANIZATION
, O
associated O
with O
EU B_LOCATION/B_PERSON
in O
the O
cost B_TIME[MEASURE]/B_LOCATION
8 I_TIME[MEASURE]/I_LOCATION
. O
20 B_MEASURE
program I_MEASURE
for O
financial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
this O
work B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
are O
grateful B_PERSON
to O
Mr B_PERSON/B_PROTEIN[GENE]
. O
R B_OTHER/B_PERSON
. O

G B_OTHER/B_GENE
. O

Experimental B_PERSON/B_LOCATION
Oostrum I_PERSON/I_LOCATION
, O
Dr B_PERSON/B_LOCATION
. O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
verweij B_PERSON
, O
Prof B_PERSON/B_LOCATION
. O

Dr B_TIME[MEASURE]
. O
G B_OTHER/B_PERSON
. O

Stoter B_PERSON
, O
r O
. O
K B_GENE/B_LOCATION
. O

Nooter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
Laboratory B_LOCATION/B_PERSON
of O
Chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
pharmacology B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
Department B_ORGANIZATION/B_LOCATION
of O
Medical B_EDU[ORGANIZATION]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Oncology I_EDU[ORGANIZATION]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
Rotterdam B_LOCATION
Cancer I_LOCATION
235 I_LOCATION
. O

M B_OTHER/B_MEASURE
. O

Gielen B_PERSON
, O
K B_OTHER/B_PERSON
. O

Handlir B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

HoHein B_PERSON/B_COLOR
and O
D B_OTHER/B_PERSON
. O

de B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Vos I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
synthesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
Characterization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
antitumor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ofSome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Butyltin I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IV B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
Cysteaminates B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
N B_OTHER/B_PROTEIN[GENE]
- O
Dimethylcysteaminates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Institute B_LOCATION/B_ORGANIZATION
, O
NL B_LOCATION/B_ORGANIZATION
3008 I_LOCATION/I_ORGANIZATION
AE I_LOCATION/I_ORGANIZATION
, O
Rotterdam B_LOCATION
, O
The O
Netherlands B_LOCATION
, O
for O
performing O
the O
in O
vitro B_ENT/B_ORGANIZATION
tests I_ENT/I_ORGANIZATION
. O

This O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O
supported O
by O
the O
Fund B_ORGANIZATION/B_LOCATION
for O
Scientific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Flanders I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Belgium B_LOCATION/B_MEASURE
) O
, O
grant B_MEASURE/B_LOCATION
Nr I_MEASURE/I_LOCATION
G I_MEASURE/I_LOCATION
. O
0074 B_MEASURE
. O
00 B_TIME[MEASURE]/B_PERSON
, O
M B_OTHER/B_LOCATION
. O

G B_OTHER/B_MEASURE
. O
) O
. O

references B_PERSON/B_DISEASE
. O

1 B_NUMBER[MEASURE]
. O

B B_PROTEIN[GENE]/B_DISEASE
. O
S B_OTHER/B_DISEASE
. O

Saraswat B_PERSON/B_LOCATION
, O
J B_OTHER/B_LOCATION
. O

Mason B_PERSON/B_MEASURE
, O
Polyhedron B_MEASURE/B_LOCATION
( O
9 B_NUMBER[MEASURE]
) O
, O
5 B_MEASURE
( O
1986 B_MEASURE
) O
, O
1449 B_MEASURE/B_LOCATION
. O

2 B_NUMBER[MEASURE]
. O

G B_OTHER/B_GENE
. O

Domazetis B_PERSON/B_COLOR
, O
R B_OTHER/B_PERSON
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Magee B_PERSON
, O
B B_OTHER/B_PERSON
. O

D B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

James B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

Organomet B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Chem B_MEASURE/B_PERSON
, O
162 B_MEASURE/B_PERSON
( O
1978 B_MEASURE
) O
, O
239 B_MEASURE/B_LOCATION
. O

3 B_NUMBER[MEASURE]
. O

J B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
D B_OTHER/B_PERSON
. O

Cashion B_PERSON/B_LOCATION
, O
G B_OTHER/B_PERSON
. O

Domazetis B_PERSON
, O
B B_OTHER/B_PERSON
. O

D B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

James B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

Organomet B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Chem B_MEASURE/B_PERSON
, O
185 B_MEASURE
( O
1980 B_MEASURE
) O
, O
433 B_MEASURE/B_LOCATION
. O

4 B_NUMBER[MEASURE]
. O

G B_OTHER/B_GENE
. O

Domazetis B_PERSON/B_COLOR
, O
R B_OTHER/B_PERSON
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Magee B_PERSON
, O
B B_OTHER/B_PERSON
. O

D B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

James B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

Organomet B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Chem B_MEASURE/B_PERSON
, O
148 B_MEASURE
( O
1978 B_MEASURE
) O
, O
339 B_MEASURE/B_LOCATION
. O

5 B_NUMBER[MEASURE]
. O

G B_OTHER/B_GENE
. O

Atassi B_PERSON/B_TIME[MEASURE]
, O
Rev B_PERSON/B_LOCATION
. O

Si B_MEASURE
GE I_MEASURE
Sn I_MEASURE
Pb I_MEASURE
Cpds I_MEASURE
, O
8 B_MEASURE
( O
1985 B_MEASURE
) O
, O
219 B_MEASURE
; O
M B_MEASURE
. O

Kemmer B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

Gielen B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

Biesemans B_PERSON
, O
D B_OTHER/B_PERSON
. O

de B_PERSON/B_COLOR
Vos I_PERSON/I_COLOR
, O
R B_OTHER/B_LOCATION
. O

Willem B_PERSON/B_LOCATION
, O
metal B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Based O
Drugs B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1998 B_MEASURE
) O
, O
189 B_MEASURE
; O
M B_MEASURE/B_GENE
. O

Gielen B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

Biesemans B_PERSON
, O
D B_OTHER/B_PERSON
. O

de B_PERSON/B_COLOR
Vos I_PERSON/I_COLOR
, O
R B_OTHER/B_LOCATION
. O

Willem B_PERSON/B_COLOR
, O
J B_OTHER/B_LOCATION
. O

Inorg B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

Biochem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
, O
79 B_MEASURE
( O
2000 B_MEASURE
) O
, O
139 B_MEASURE/B_LOCATION
. O

6 B_NUMBER[MEASURE]
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Holecek B_PERSON/B_COLOR
, O
A O
. O

Lycka B_PERSON/B_LOCATION
, O
Inorg B_LOCATION/B_PERSON
. O

Chim B_PERSON/B_DISEASE
. O

Acta B_MEASURE/B_PERSON
, O
118 B_NUMBER[MEASURE]
( O
1986 B_NUMBER[MEASURE]
) O
, O
L B_GENE/B_MEASURE
15 I_GENE/I_MEASURE
. O

7 B_NUMBER[MEASURE]
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Holecek B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

Nadvomik B_PERSON/B_LOCATION
, O
K B_OTHER/B_PERSON
. O

Handlir B_PERSON/B_COLOR
, O
A O
. O

Lycka B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

Organomet B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Chem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
, O
315 B_MEASURE
( O
1986 B_MEASURE
) O
, O
299 B_MEASURE/B_LOCATION
. O

8 B_NUMBER[MEASURE]
. O

B B_MEASURE/B_DISEASE
. O
D B_OTHER/B_BACTERIUM[BIO]
. O

James B_PERSON/B_COLOR
, O
R B_OTHER/B_PERSON
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Magee B_PERSON/B_LOCATION
, O
W B_OTHER/B_PERSON
. O

C B_OTHER/B_GENE
. O

Patalinghug B_PERSON/B_LOCATION
, O
B B_OTHER/B_PERSON
. O

W B_OTHER/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Skelton B_PERSON/B_COLOR
, O
A O
. O

H B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

White B_COLOR/B_PERSON
, O
J B_OTHER/B_PERSON
. O

Organomet B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Chem B_MEASURE/B_PERSON
, O
467 B_MEASURE/B_PERSON
( O
1994 B_MEASURE
) O
, O
51 B_MEASURE/B_GENE
9 I_MEASURE/I_GENE
. O

P B_OTHER/B_MEASURE
. O

Skehan B_PERSON/B_COLOR
, O
R B_OTHER/B_PERSON
. O

Storeng B_PERSON/B_LOCATION
, O
D B_OTHER/B_PERSON
. O

Scudiero B_PERSON/B_COLOR
, O
A O
. O

monks B_PERSON/B_COLOR
, O
J B_OTHER/B_LOCATION
. O

McMahon B_PERSON/B_LOCATION
, O
D B_OTHER/B_PERSON
. O

Vistica B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

T B_OTHER/B_GENE
. O

Warren B_PERSON/B_LOCATION
, O
H B_OTHER/B_PERSON
. O

Bokesh B_PERSON/B_LOCATION
, O
S B_OTHER/B_PERSON
. O

Kenney B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

R B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Boyd B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O
. O

Natl B_PERSON/B_BACTERIUM[BIO]
. O

Cancer B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lnst I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O
, O
82 B_MEASURE
( O
1990 B_MEASURE
) O
, O
1107 B_MEASURE/B_LOCATION
. O

10 B_NUMBER[MEASURE]
. O

Y B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

P B_OTHER/B_MEASURE
. O

Kepers B_PERSON/B_LOCATION
, O
G B_OTHER/B_PERSON
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Peters B_PERSON/B_ORGANIZATION
, O
J B_OTHER/B_PERSON
. O

Van B_PERSON/B_LOCATION
Ark I_PERSON/I_LOCATION
- O
Otte B_PERSON
, O
B B_OTHER/B_PERSON
. O

Winograd B_PERSON/B_LOCATION
, O
H B_OTHER/B_PERSON
. O

M B_OTHER/B_MEASURE
. O

Pinedo B_PERSON/B_LOCATION
, O
Eur B_LOCATION/B_PERSON
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cancer B_DISEASE/B_MEASURE
, O
27 B_MEASURE
( O
1991 B_MEASURE
) O
, O
897 B_MEASURE/B_LOCATION
. O

11 B_NUMBER[MEASURE]
. O

M B_OTHER/B_MEASURE
. O

Kemmer B_PERSON/B_COLOR
, O
L B_OTHER/B_PERSON
. O

Ghys B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

Gielen B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

Biesemans B_PERSON/B_COLOR
, O
E B_OTHER/B_PERSON
. O

R B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

T B_OTHER/B_GENE
. O

Tiekink B_PERSON/B_LOCATION
, O
R B_OTHER/B_PERSON
. O

Willem B_PERSON/B_COLOR
, O
J B_OTHER/B_LOCATION
. O

Organomet B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Chem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

582 B_MEASURE
( O
1999 B_MEASURE
) O
, O
195 B_MEASURE/B_LOCATION
. O

12 B_NUMBER[MEASURE]
. O

S B_OTHER/B_DISEASE
. O

W B_OTHER/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Ng B_PERSON
, O
V B_OTHER/B_PERSON
. O

G B_OTHER/B_GENE
. O

Kumar B_PERSON/B_COLOR
Das I_PERSON/I_COLOR
, O
J B_OTHER/B_PERSON
. O

Holecek B_PERSON/B_COLOR
, O
A O
. O

Lycka B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

Gielen B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

G B_OTHER/B_GENE
. O

B B_OTHER/B_DISEASE
. O

drew B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
Appl B_PERSON/B_LOCATION
. O

Organomet B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Chem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

11 B_MEASURE
( O
1997 B_MEASURE
) O
, O
3 B_MEASURE/B_PERSON
9 I_MEASURE/I_PERSON
. O

received O
' O
September B_TIME[MEASURE]
22 I_TIME[MEASURE]
, O
2000 B_MEASURE
accepted O
- O
October B_TIME[MEASURE]
19 I_TIME[MEASURE]
, O
2000 B_MEASURE
received O
in O
revised O
camera B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ready B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
format I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
October B_TIME[MEASURE]
20 I_TIME[MEASURE]
, O
2000 B_MEASURE
. O

236 B_NUMBER[MEASURE]
. O

Genomic O
- O
Bioinformatic O
Analysis O
of O
Transcripts O
Enriched O
in O
the O
Third O
- O
Stage O
Larva O
of O
the O
Parasitic O
Nematode O
Ascaris B_SPECIES[BIO]/B_DISEASE
suum I_SPECIES[BIO]/I_DISEASE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

differential O
transcription O
in O
Ascaris B_DISEASE/B_SPECIES[BIO]
suum I_DISEASE/I_SPECIES[BIO]
was O
investigated O
using O
a O
genomic O
- O
bioinformatic O
approach O
. O

A O
cDNA O
archive O
enriched O
for O
molecules O
in O
the O
infective O
third O
- O
stage O
larva O
( O
L3 O
) O
of O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
was O
constructed O
by O
suppressive O
- O
subtractive O
hybridization O
( O
SSH O
) O
, O
and O
a O
subset O
of O
cDNAs O
from O
3075 O
clones O
subjected O
to O
microarray O
analysis O
using O
cDNA O
probes O
derived O
from O
RNA O
from O
different O
developmental O
stages O
of O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
. O

The O
cDNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
n B_OTHER/B_MEASURE
= O
498 B_MEASURE
) O
shown O
by O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
be O
enriched O
in O
the O
L3 B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O
sequenced O
and O
subjected O
to O
bioinformatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
a O
semi B_DISEASE
- O
automated O
pipeline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
ESTExplorer B_LOCATION/B_ORGANIZATION
) O
. O

Using O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
ontology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
GO O
) O
, O
235 B_NUMBER[MEASURE]/B_PERSON
of O
these O
molecules B_BIO/B_LOCATION
were O
assigned O
to O
' O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
' O
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
68 B_MEASURE
) O
, O
' O
cellular B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
component B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
( O
n B_OTHER/B_MEASURE
= O
50 B_MEASURE
) O
, O
or O
' O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
function I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
' O
( O
n B_OTHER/B_MEASURE
= O
117 B_MEASURE
) O
. O

Of O
the O
91 O
clusters O
assembled O
, O
56 O
molecules O
( O
61 O
. O
5 O
% O
) O
had O
homologues O
/ O
orthologues O
in O
the O
free O
- O
living O
nematodes O
Caenorhabditis B_SPECIES[BIO]
elegans I_SPECIES[BIO]
and O
C B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
briggsae I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
other O
organisms O
, O
whereas O
35 O
( O
38 O
. O
5 O
% O
) O
had O
no O
significant O
similarity O
to O
any O
sequences O
available O
in O
current O
gene O
databases O
. O

Transcripts O
encoding O
protein O
kinases O
, O
protein O
phosphatases O
( O
and O
their O
precursors O
) O
, O
and O
enolases O
were O
abundantly O
represented O
in O
the O
L3 O
of O
A B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
suum I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
as O
were O
molecules O
involved O
in O
cellular O
processes O
, O
such O
as O
ubiquitination O
and O
proteasome O
function O
, O
gene O
transcription O
, O
protein O
- O
protein O
interactions O
, O
and O
function O
. O

In O
silico O
analyses O
inferred O
the O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
orthologues O
/ O
homologues O
( O
n O
= O
50 O
) O
to O
be O
involved O
in O
apoptosis O
and O
insulin O
signaling O
( O
2 O
% O
) O
, O
ATP O
synthesis O
( O
2 O
% O
) O
, O
carbon O
metabolism O
( O
6 O
% O
) O
, O
fatty O
acid O
biosynthesis O
( O
2 O
% O
) O
, O
gap O
junction O
( O
2 O
% O
) O
, O
glucose O
metabolism O
( O
6 O
% O
) O
, O
or O
porphyrin O
metabolism O
( O
2 O
% O
) O
, O
although O
34 O
( O
68 O
% O
) O
of O
them O
could O
not O
be O
mapped O
to O
a O
specific O
metabolic O
pathway O
. O

Small B_NUMBER[MEASURE]
numbers I_NUMBER[MEASURE]
of O
these O
50 B_GENE/B_BIO
molecules I_GENE/I_BIO
were O
predicted O
to O
be O
secreted O
( O
10 B_MEASURE
% I_MEASURE
) O
, O
anchored O
( O
2 B_MEASURE
% I_MEASURE
) O
, O
and O
/ O
or O
transmembrane B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( O
12 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
) O
proteins B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

Functionally O
, O
17 O
( O
34 O
% O
) O
of O
them O
were O
predicted O
to O
be O
associated O
with O
( O
non O
- O
wild O
- O
type O
) O
RNAi O
phenotypes O
in O
C B_BIO
. I_BIO
elegans I_BIO
, O
the O
majority O
being O
embryonic O
lethality O
( O
Emb O
) O
( O
13 O
types O
; O
58 O
. O
8 O
% O
) O
, O
larval O
arrest O
( O
Lva O
) O
( O
23 O
. O
5 O
% O
) O
and O
larval O
lethality O
( O
Lvl O
) O
( O
47 O
% O
) O
. O

A O
genetic O
interaction O
network O
was O
predicted O
for O
these O
17 O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
orthologues O
, O
revealing O
highly O
significant O
interactions O
for O
nine O
molecules O
associated O
with O
embryonic O
and O
larval O
development O
( O
66 O
. O
9 O
% O
) O
, O
information O
storage O
and O
processing O
( O
5 O
. O
1 O
% O
) O
, O
cellular O
processing O
and O
signaling O
( O
15 O
. O
2 O
% O
) O
, O
metabolism O
( O
6 O
. O
1 O
% O
) O
, O
and O
unknown O
function O
( O
6 O
. O
7 O
% O
) O
. O

The O
potential O
roles O
of O
these O
molecules O
in O
development O
are O
discussed O
in O
relation O
to O
the O
known O
roles O
of O
their O
homologues O
/ O
orthologues O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
and O
some O
other O
nematodes O
. O

The O
results O
of O
the O
present O
study O
provide O
a O
basis O
for O
future O
functional O
genomic O
studies O
to O
elucidate O
molecular O
aspects O
governing O
larval O
developmental O
processes O
in O
A B_BIO/B_ORGANISM_FUNCTION
. I_BIO/I_ORGANISM_FUNCTION
suum I_BIO/I_ORGANISM_FUNCTION
and O
/ O
or O
the O
transition O
to O
parasitism O
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

parasitic B_DISEASE/B_BIO
nematodes I_DISEASE/I_BIO
are O
of O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
socio I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O
economic B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
animals B_BIO/B_LOCATION
. O

For O
example O
, O
hundreds O
of O
millions O
of O
people B_PERSON/B_BIO
are O
infected O
with O
geohelminths O
( O
soil O
- O
transmitted O
worms O
) O
, O
such O
as O
blood O
- O
feeding O
hookworms O
Ancylostoma B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
duodenale I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
Necator B_SPECIES[BIO]/B_PERSON
americanus I_SPECIES[BIO]/I_PERSON
, O
Trichuris B_SPECIES[BIO]/B_DISEASE
trichiura I_SPECIES[BIO]/I_DISEASE
and O
Ascaris O
spp O
. O

[ O
1 O
] O
, O
causing O
serious O
adverse O
effects O
on O
human B_PERSON/B_BIO
health O
, O
particularly O
in O
children B_PERSON/B_LOCATION
. O

Similarly O
, O
parasitic O
nematodes O
of O
livestock O
, O
such O
as O
pigs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
also O
cause O
substantial O
economic O
losses O
due O
to O
subclinical O
and O
clinical O
diseases O
, O
with O
billions O
of O
dollars O
spent O
annually O
on O
the O
treatment O
and O
control O
of O
gastro O
- O
intestinal O
nematodes O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
the O
socioeconomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impact I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
these O
parasites B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
, O
there O
is O
potential B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
emergence B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
resistance B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
them O
against O
all O
of O
the O
main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
( O
nematocidal B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
to O
treat O
the O
diseases B_DISEASE
they O
cause O
[ B_LOCATION
2 I_LOCATION
] I_LOCATION
- O
[ O
5 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Therefore O
, O
there O
is O
a O
significant B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
need I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
work O
toward O
discovering O
new B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
compounds I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
control O
these O
parasites B_DISEASE
. O

gaining O
an O
improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
molecular B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
parasite B_DISEASE
development I_DISEASE
provides O
such O
an O
avenue B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Compared O
with O
the O
free O
- O
living O
nematode O
Caenorhabditis B_BIO/B_LOCATION
elegans I_BIO/I_LOCATION
, O
there O
is O
very O
little O
information O
on O
fundamental O
molecular O
aspects O
of O
development O
in O
parasitic O
nematodes O
[ O
6 O
] O
- O
[ O
8 O
] O
. O

Since O
the O
genome O
sequence O
of O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
was O
published O
in O
1998 O
[ O
9 O
] O
, O
many O
aspects O
of O
the O
molecular O
biology O
of O
this O
nematode O
have O
been O
elucidated O
. O

For O
instance O
, O
microarray O
analyses O
have O
been O
used O
to O
examine O
developmental O
and O
gender O
- O
enriched O
gene O
expression O
[ O
10 O
] O
, O
[ O
11 O
] O
, O
and O
the O
functions O
of O
more O
than O
96 O
% O
of O
the O
C B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elegans B_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O
have O
been O
assessed O
by O
double O
- O
stranded O
RNA O
interference O
( O
RNAi O
, O
or O
gene O
silencing O
; O
[ O
12 O
] O
) O
[ O
13 O
] O
- O
[ O
18 O
] O
. O

Comparative O
analyses O
of O
genetic O
data O
sets O
have O
shown O
that O
parasitic O
nematodes O
usually O
share O
~ O
50 O
- O
70 O
% O
of O
genes O
with O
C B_SPECIES[BIO]/B_GENE
. I_SPECIES[BIO]/I_GENE
elegans I_SPECIES[BIO]/I_GENE
( O
e O
. O
g O
. O
, O
[ O
19 O
] O
, O
[ O
20 O
] O
) O
. O

There O
is O
similarity O
in O
other O
features O
( O
such O
as O
basic O
body O
plan O
and O
moulting O
) O
between O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
and O
parasitic O
nematodes O
, O
suggesting O
that O
some O
molecular O
pathways O
are O
relatively O
conserved O
[ O
8 O
] O
, O
[ O
21 O
] O
. O

Understanding O
the O
pathways B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
linked O
to O
basic B_DISEASE/B_BIO
nematode I_DISEASE/I_BIO
biology I_DISEASE/I_BIO
and O
development B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
have O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
finding O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
ways I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O
disrupting O
these O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O
thus O
facilitate O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
targets I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Despite O
the O
advances O
in O
genomic O
technologies O
[ O
7 O
] O
, O
[ O
22 O
] O
- O
[ O
29 O
] O
and O
the O
study O
of O
C B_BIO/B_GENE
. I_BIO/I_GENE
elegans I_BIO/I_GENE
, O
there O
is O
a O
paucity O
of O
information O
on O
the O
genomics O
of O
parasitic O
nematodes O
of O
animals O
, O
particularly O
in O
relation O
to O
development O
. O

Also O
considering O
the O
major O
socioeconomic O
impact O
of O
Ascaris O
and O
ascariasis O
in O
humans B_SPECIES[BIO]
and O
pigs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
30 O
] O
- O
[ O
32 O
] O
, O
several O
characteristics O
, O
including O
the O
large O
size O
of O
the O
adult O
worm O
( O
providing O
the O
opportunity O
of O
investigating O
individual O
organ O
systems O
and O
tissues O
) O
, O
the O
ability O
to O
maintain O
Ascaris O
in O
the O
pig B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O
store O
eggs O
and O
culture O
larvae O
in O
vitro O
for O
relatively O
long O
periods O
of O
time O
( O
months O
to O
years O
) O
[ O
32 O
] O
as O
well O
as O
the O
discovery O
that O
RNAi O
achieves O
' O
cross O
- O
species O
' O
gene O
silencing O
for O
a O
selected O
number O
of O
genes O
[ O
33 O
] O
, O
[ O
34 O
] O
and O
the O
imminent O
genome O
sequence O
( O
http O
: O
/ O
/ O
www O
. O
sanger O
. O
AC O
. O
uk O
/ O
Projects O
/ O
Helminths O
/ O
) O
all O
indicate O
that O
Ascaris O
could O
serve O
as O
a O
powerful O
model O
system O
for O
investigating O
reproductive O
and O
developmental O
processes O
in O
nematodes O
. O

In O
the O
present O
study O
, O
Ascaris O
from O
pigs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
to O
study O
molecules O
abundantly O
transcribed O
in O
the O
infective O
third O
- O
stage O
larva O
( O
L3 O
) O
. O

Following O
the O
oral O
ingestion O
of O
Ascaris O
eggs O
by O
the O
host O
( O
human B_SPECIES[BIO]
or O
pig B_SPECIES[BIO]
) O
, O
L3s O
are O
released O
and O
then O
invade O
/ O
penetrate O
predominantly O
the O
caecal O
wall O
[ O
35 O
] O
to O
then O
undergo O
hepato O
- O
pulmonary O
migration O
, O
after O
which O
ultimately O
the O
adult O
females O
and O
males O
establish O
and O
develop O
in O
the O
small O
intestine O
[ O
36 O
] O
, O
[ O
37 O
] O
. O

The O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
linked O
to O
host B_DISEASE
invasion I_DISEASE
and O
parasite B_DISEASE_ADJECTIVE[DISEASE]
development I_DISEASE_ADJECTIVE[DISEASE]
are O
largely O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

Here O
, O
we O
constructed O
an O
L3 O
- O
enriched O
cDNA O
library O
using O
the O
method O
of O
suppressive O
- O
subtractive O
hybridization O
( O
SSH O
) O
, O
explored O
transcription O
of O
a O
representative O
subset O
of O
molecules O
by O
microarray O
analysis O
and O
conducted O
bioinformatic O
analyses O
to O
characterize O
these O
molecules O
, O
map O
them O
to O
biochemical O
pathways O
and O
predict O
genetic O
interactions O
based O
on O
comparisons O
with O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
and O
/ O
or O
other O
organisms O
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

production B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Different B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Developmental B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Ascaris B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Experimental O
pigs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
8 O
- O
12 O
weeks O
of O
age O
) O
were O
purchased O
from O
and O
maintained O
in O
the O
Experimental O
Animal O
Center O
of O
South O
China O
Agricultural O
University O
. O

These O
pigs B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
treated O
humanely O
, O
according O
to O
the O
Animal O
Ethics O
procedures O
and O
guidelines O
of O
the O
People O
' O
s O
Republic O
of O
China O
. O

Adult O
worms O
( O
males O
and O
females O
) O
of O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
were O
collected O
from O
the O
small O
intestines O
of O
pigs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
an O
abattoir O
in O
Shenzhen O
, O
China O
. O

Infective O
eggs O
and O
infective O
L3s O
of O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
were O
produced O
according O
to O
the O
methods O
described O
previously O
[ O
38 O
] O
. O

In O
brief O
, O
eggs O
from O
the O
uteri O
of O
adult O
females O
of O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
were O
collected O
and O
incubated O
at O
28 O
degrees O
C O
for O
28 O
days O
to O
allow O
them O
to O
develop O
to O
infective O
eggs O
( O
containing O
infective O
L3s O
) O
. O

To O
obtain O
pure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
L3s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
7 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
v I_MEASURE
/ O
v O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypochlorite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
to O
treat O
the O
larvated O
eggs B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
37 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
overnight O
and O
then O
the O
eggs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O
shaken O
with O
glass B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
beads B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
then O
, O
the O
exsheathed O
L3s B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
shells B_BIO/B_PERSON
were O
separated O
by O
density B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gradient I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
centrifugation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
lymphocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
separating O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LSM B_MEASURE/B_DISEASE
) O
[ O
38 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Following O
the O
experimental O
infection O
of O
helminth O
- O
free O
pigs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
infective O
Ascaris O
eggs O
as O
described O
previously O
[ O
39 O
] O
, O
the O
L3s O
from O
livers O
and O
in O
lungs O
as O
well O
as O
L4s O
in O
intestines O
were O
isolated O
according O
to O
an O
established O
method O
[ O
40 O
] O
. O

All O
parasite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
snap O
- O
frozen O
in O
liquid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
nitrogen I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
prior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
storage B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
at O
- O
70 B_LOCATION/B_MEASURE
degrees I_LOCATION/I_MEASURE
C I_LOCATION/I_MEASURE
. O

construction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
cDNA B_GENE
Library I_GENE
by O
Subtractive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
suppressive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hybridization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
SSH B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Total O
RNA O
was O
isolated O
from O
adult O
females O
and O
males O
, O
different O
larval O
stages O
or O
eggs O
of O
A B_PERSON/B_BIO
. I_PERSON/I_BIO
suum I_PERSON/I_BIO
using O
TriPure O
reagent O
( O
Roche O
) O
as O
recommended O
by O
the O
manufacturer O
. O

equal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amounts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
total B_DISEASE/B_MEASURE
RNA I_DISEASE/I_MEASURE
from O
each O
stage B_ENT/B_MEASURE
or O
sex B_PERSON/B_LOCATION
were O
pooled O
. O

The O
mRNA B_GENE
was O
isolated O
using O
the O
Oligotex B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mRNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Kit I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Qiagen B_LOCATION/B_BACTERIUM[BIO]
) O
, O
following O
the O
manufacturer B_PERSON/B_ORGANIZATION
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
protocol I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

SSH B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
carried O
out O
using O
the O
PCR B_LOCATION/B_PERSON
- O
Select B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Subtraction I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kit I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Clontech B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
according O
to O
the O
manufacturer B_PERSON/B_ORGANIZATION
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
protocol I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

In O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
cDNA B_GENE
synthesized O
from O
mRNAs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O
infective B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L3s I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
subtracted O
against O
cDNA B_GENE/B_BIO
synthesized O
from O
the O
pooled O
mRNA B_GENE/B_BIO
from O
all O
other B_TIME[MEASURE]/B_BIO
stages I_TIME[MEASURE]/I_BIO
included O
herein B_LOCATION/B_SPECIES[BIO]
. O

The O
SSH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
constructed O
using O
infective B_SPECIES[BIO]/B_DISEASE
L3s I_SPECIES[BIO]/I_DISEASE
as O
the O
tester B_PERSON
and O
pooled O
cDNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
all O
other B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
driver B_PERSON
. O

The O
effectiveness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
subtraction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O
already O
been O
demonstrated O
in O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O
41 B_MEASURE
] I_MEASURE
, O
[ O
42 B_MEASURE
] I_MEASURE
. O

The O
cDNA O
obtained O
following O
SSH O
was O
cloned O
into O
the O
pGEM O
- O
T O
Easy O
plasmid O
vector O
( O
Promega O
) O
and O
competent O
Escherichia B_BACTERIUM[BIO]
coli I_BACTERIUM[BIO]
( O
JM109 O
) O
transformed O
. O

positive B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
clones I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
, O
picked O
randomly O
( O
based O
on O
blue B_COLOR
/ O
white B_COLOR
selection I_COLOR
) O
, O
were O
grown O
overnight O
in O
Luria B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Bertani B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
lb B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
shaking O
, O
37 B_PROTEIN[GENE]/B_LOCATION
degrees I_PROTEIN[GENE]/I_LOCATION
C I_PROTEIN[GENE]/I_LOCATION
) O
. O

Individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
inserts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
amplified O
using O
' B_OTHER/B_NUMBER[MEASURE]
nested O
primers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
2R B_SEQUENCE[MEASURE]/B_LOCATION
from O
the O
Subtraction B_LOCATION/B_PERSON
kit I_LOCATION/I_PERSON
( O
Clontech B_LOCATION/B_DISEASE
) O
and O
examined O
by O
agarose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

preparation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
microarray B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
slides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Clones B_LOCATION/B_BIO
( O
n B_OTHER/B_MEASURE
= O
3075 B_MEASURE
) O
from O
the O
subtracted B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
picked O
and O
cultured O
overnight O
in O
lb B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
ampicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1000 B_MEASURE/B_LOCATION
IU I_MEASURE/I_LOCATION
/ O
ml B_MEASURE/B_PERSON
) O
in O
sealed O
96 B_MEASURE/B_LOCATION
- O
well O
blocks B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Five B_MEASURE/B_LOCATION
micro B_MEASURE/I_LOCATION
l B_MEASURE/I_LOCATION
of O
culture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
suspension B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
each O
well O
were O
transferred O
into O
individual B_NUMBER[MEASURE]/B_PERSON
wells I_NUMBER[MEASURE]/I_PERSON
thermocycling O
( O
96 B_NUMBER[MEASURE]/B_LOCATION
- O
well B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
plates B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
inserts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
amplified O
using O
primers B_LOCATION/B_ORGANIZATION
1 I_LOCATION/I_ORGANIZATION
and O
2R B_NUMBER[MEASURE]/B_LOCATION
. O

Following O
a O
10 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
denaturation I_TIME[MEASURE]/I_LOCATION
step I_TIME[MEASURE]/I_LOCATION
at O
94 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
, O
the O
amplification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proceeded O
for O
25 B_TIME[MEASURE]/B_LOCATION
cycles I_TIME[MEASURE]/I_LOCATION
of O
10 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
s I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
94 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
, O
30 B_TIME[MEASURE]
s I_TIME[MEASURE]
at O
68 B_MEASURE
degrees I_MEASURE
C I_MEASURE
and O
1 B_MEASURE
. O
5 B_TIME[MEASURE]
min I_TIME[MEASURE]
at O
72 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
, O
with O
a O
final B_SEQUENCE[MEASURE]/B_LOCATION
extension I_SEQUENCE[MEASURE]/I_LOCATION
for O
5 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
at O
72 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
. O

products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O
resolved O
in O
agarose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
precipitated O
, O
re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
suspended O
in O
16 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
micro I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
l I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
' O
spotting O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
( O
Shanghai B_ORGANIZATION/B_LOCATION
BioStar I_ORGANIZATION/I_LOCATION
Genechip I_ORGANIZATION/I_LOCATION
, O
Inc B_ORGANIZATION/B_MEASURE
) O
to O
a O
final B_MEASURE
concentration I_MEASURE
of O
~ B_MEASURE
500 I_MEASURE
ng I_MEASURE
per O
micro B_MEASURE
l I_MEASURE
, O
before O
being O
printed O
on O
to O
glass B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
slides I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
in O
duplicate O
) O
using O
a O
robotic B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arrayer I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sixteen O
blanks O
( O
using O
spotting O
solution O
only O
) O
and O
the O
same O
number O
of O
negative O
( O
irrelevant O
cDNAs O
with O
no O
relationship O
to O
Ascaris O
) O
were O
also O
printed O
on O
to O
slides O
and O
served O
as O
negative O
controls O
; O
beta O
- O
actin O
of O
A B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
suum I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
served O
as O
a O
positive O
control O
to O
assess O
the O
efficiency O
of O
labeling O
and O
hybridization O
. O

The O
slides B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
air B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dried O
for O
2 B_MEASURE
h O
, O
and O
cDNA B_GENE/B_LOCATION
in O
the O
spots B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
linked O
at O
254 B_TIME[MEASURE]/B_LOCATION
mJ I_TIME[MEASURE]/I_LOCATION
. O

The O
printed O
slides B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
stored O
at O
4 B_LOCATION/B_PERSON
degrees I_LOCATION/I_PERSON
C I_LOCATION/I_PERSON
. O

labeling B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cDNA B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
probes B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
fluorescent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dyes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cDNAs O
produced O
from O
total O
RNA O
from O
A B_PERSON/B_BIO
. B_PERSON/I_BIO
suum B_PERSON/I_BIO
eggs O
, O
infective O
L3s O
, O
L3s O
isolated O
from O
pig B_SPECIES[BIO]/B_PERSON
liver O
or O
lung O
, O
fourth O
- O
stage O
larvae O
( O
L4s O
) O
, O
adult O
males O
or O
females O
[ O
as O
described O
in O
the O
section O
' O
Construction O
of O
the O
cDNA O
Library O
by O
Subtractive O
- O
Suppressive O
Hybridization O
( O
SSH O
) O
' O
] O
were O
labeled O
with O
cyanine O
dyes O
. O

Cy3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
Cy5 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dCTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
incorporated O
into O
cDNA B_GENE
produced O
from O
30 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
micro I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
g I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
of O
total B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
labeling I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
reverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
an O
oligo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
dT B_PROTEIN[GENE]/B_LOCATION
) O
primer B_GENE
. O

labeled O
cDNA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
purified O
using O
DyeEx B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
columns I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Qiagen B_MEASURE/B_BACTERIUM[BIO]
) O
. O

Microarray O
slides O
were O
incubated O
with O
a O
pre O
- O
hybridization O
solution O
[ O
5 O
x O
SSC O
, O
1 O
% O
bovine B_PERSON/B_SPECIES[BIO]
serum O
albumin O
( O
BSA O
) O
, O
0 O
. O
1 O
% O
sodium O
dodecyl O
- O
sulphate O
( O
SDS O
) O
] O
for O
6 O
h O
at O
42 O
degrees O
C O
. O

After O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
slides B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
incubated O
with O
' O
pooled O
' O
Cy3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
Cy5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
labeled O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
hybridization B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_NUMBER[MEASURE]
x O
SSC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BSA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_NUMBER[MEASURE]
. O
1 B_MEASURE
% I_MEASURE
SDS I_MEASURE
) O
, O
in O
the O
dark B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O
42 B_MEASURE/B_PROTEIN[GENE]
degrees I_MEASURE/I_PROTEIN[GENE]
C I_MEASURE/I_PROTEIN[GENE]
for O
18 B_MEASURE
h O
, O
and O
then O
washed O
in O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
1 B_MEASURE
x O
SSC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
0 B_MEASURE
. O
2 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
SDS I_MEASURE/I_PERSON
) O
for O
10 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
, O
followed O
by O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
0 B_MEASURE
. O
1 B_MEASURE
x O
SSC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
0 B_NUMBER[MEASURE]
. O
2 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
SDS I_MEASURE/I_PERSON
) O
for O
10 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
60 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
, O
according O
to O
the O
protocols B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
provided O
by O
Shanghai B_ORGANIZATION/B_LOCATION
BioStar I_ORGANIZATION/I_LOCATION
Genechip I_ORGANIZATION/I_LOCATION
, O
Inc B_ORGANIZATION/B_LOCATION
. O

A O
' B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dye I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
flip I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O
was O
carried O
out O
to O
control O
for O
any O
bias B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
between O
the O
Cy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
labeled O
cDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
probes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
produced O
for O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distinct I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
populations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
slides B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O
dried O
and O
scanned O
( O
ScanArray B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4000 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scanner B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
using O
image B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquisition I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Shanghai B_LOCATION/B_PERSON
BioStar B_LOCATION/I_PERSON
Genechip B_LOCATION/I_PERSON
Inc B_LOCATION/I_PERSON
. O
) O
and O
a O
range B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
laser B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
power I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
photo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
multiplier B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tube B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensities B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybridization B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signal B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
derived O
from O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
replicates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
array I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
corrected O
for O
background B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
normalized O
[ O
43 B_MEASURE
] I_MEASURE
, O
log2 B_MEASURE/B_LOCATION
- O
transformed O
and O
then O
subjected O
to O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
employing O
the O
students B_MEASURE/B_PERSON
t I_MEASURE/I_PERSON
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
a O
spreadsheet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
Excel B_ORGANIZATION/B_LOCATION
, O
Microsoft B_ORGANIZATION/B_LOCATION
, O
USA B_LOCATION/B_ORGANIZATION
) O
. O

The O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
analysed O
for O
differential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hybridization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
> B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
. O
0 B_MEASURE
- O
fold B_LOCATION/B_MEASURE
to O
114 B_MEASURE
. O
3 B_MEASURE
- O
fold B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
between O
L3 B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
each O
of O
the O
other B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
eggs B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L3s I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
L4 B_PERSON/B_BIO
, O
adult B_PERSON/B_BIO
female I_PERSON/I_BIO
and O
adult B_PERSON
male I_PERSON
) O
. O

verification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Differential B_DISEASE/B_GENE
hybridization I_DISEASE/I_GENE
by O
Reverse B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Transcription I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
coupled O
polymerase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
RT B_LOCATION
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

For O
a O
subset B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_MEASURE
= O
17 B_MEASURE
) O
of O
representative B_MEASURE/B_PERSON
ESTs I_MEASURE/I_PERSON
( O
rESTs B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
used O
to O
verify O
the O
differential B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recorded O
by O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Double O
- O
stranded O
cDNA O
was O
synthesized O
from O
total O
RNA O
( O
separately O
) O
from O
each O
stage O
or O
sex O
of O
A B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
. I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANISM_FUNCTION
suum I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANISM_FUNCTION
using O
reverse O
transcriptase O
( O
Superscript O
III O
, O
Invitrogen O
) O
. O

briefly B_TIME[MEASURE]/B_LOCATION
, O
5 B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
micro I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
g I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
added O
to O
14 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
micro I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
l I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
H2O B_GENE/B_DISEASE
and O
1 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micro I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
oligo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
d I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
T B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
n B_MEASURE/B_PROTEIN[GENE]
= O
12 B_MEASURE
- O
18 B_MEASURE/B_ENT
primer I_MEASURE/I_ENT
( O
0 B_MEASURE
. O
5 B_MEASURE
micro I_MEASURE
g I_MEASURE
/ O
micro B_MEASURE/B_LOCATION
l I_MEASURE/I_LOCATION
) O
, O
heated O
to O
70 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
degrees I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
10 B_TIME[MEASURE]
min I_TIME[MEASURE]
and O
chilled O
on O
ice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

First O
- O
and O
second B_SEQUENCE[MEASURE]/B_LOCATION
- O
strand B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNAs I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
synthesized O
via O
the O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
4 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
micro I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
l I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
first B_NUMBER[MEASURE]/B_LOCATION
- O
strand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
buffer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
250 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tris I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
HCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pH B_MEASURE/B_GENE
8 B_MEASURE
. O
3 B_MEASURE
, O
375 B_MEASURE
mm I_MEASURE
KCl I_MEASURE
and O
15 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MgCl2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
2 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
micro I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
l I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
0 B_MEASURE
. O
1 B_MEASURE
M I_MEASURE
dithiothreitol I_MEASURE
, O
and O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
micro I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
l I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
of O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
each O
dNTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
followed O
by O
an O
incubation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
25 B_MEASURE
degrees I_MEASURE
C I_MEASURE
( O
10 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
) O
, O
42 B_MEASURE
degrees I_MEASURE
C I_MEASURE
( O
50 B_TIME[MEASURE]
min I_TIME[MEASURE]
) O
and O
70 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
( O
15 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
) O
. O

One B_NUMBER[MEASURE]
- O
tenth B_SEQUENCE[MEASURE]/B_LOCATION
of O
each O
double B_NUMBER[MEASURE]/B_DISEASE
- O
stranded B_GENE/B_LOCATION
cDNA I_GENE/I_LOCATION
produced O
was O
then O
used O
as O
a O
template B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
transcripts B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
amplified O
from O
individual B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
using O
oligonucleotide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
primers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upon O
request B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
designed O
to O
each O
EST B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
PCR O
amplification O
of O
a O
portion O
( O
209 O
BP O
) O
of O
the O
beta O
- O
actin O
gene O
( O
accession O
no O
. O
BI594141 O
) O
using O
forward O
primer O
( O
5 O
' O
- O
CTCGAAACAAGAATACGATG O
- O
3 O
' O
) O
and O
reverse O
primer O
( O
5 O
' O
- O
ACATGTGCCGTTGTATGATG O
- O
3 O
' O
) O
, O
previously O
determined O
to O
be O
present O
in O
all O
developmental O
stages O
and O
both O
sexes O
of O
A B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
suum I_PERSON/I_SPECIES[BIO]
[ O
44 O
] O
, O
served O
as O
a O
positive O
control O
. O

samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
without O
template B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
no O
- O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
controls I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
were O
included O
in O
each O
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
run I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
following B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cycling I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
conditions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
were O
employed O
: O
one B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
cycle I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
at O
94 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
( O
5 B_TIME[MEASURE]
min I_TIME[MEASURE]
) O
, O
94 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
( O
30 B_MEASURE
s I_MEASURE
) O
, O
60 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
( O
30 B_MEASURE
s O
) O
and O
72 B_MEASURE
degrees I_MEASURE
C I_MEASURE
( O
30 B_MEASURE/B_LOCATION
s I_MEASURE/I_LOCATION
) O
for O
30 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycles I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
followed O
by O
a O
final B_MEASURE/B_GENE
extension I_MEASURE/I_GENE
of O
70 B_NUMBER[MEASURE]/B_LOCATION
degrees I_NUMBER[MEASURE]/I_LOCATION
C I_NUMBER[MEASURE]/I_LOCATION
( O
7 B_TIME[MEASURE]
min I_TIME[MEASURE]
) O
. O

Following O
the O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_LOCATION/B_GENE
micro I_LOCATION/I_GENE
l I_LOCATION/I_GENE
of O
individual B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amplicons I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
resolved O
in O
ethidium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
bromide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
stained O
agarose B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gels I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
and O
then O
photographed O
upon O
transillumination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
relative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
band I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
intensities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
analyzed O
using O
UVIsoft B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Image I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquisition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
UVITEC B_ORGANIZATION/B_LOCATION
) O
. O

The O
specificity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
identity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amplicons I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
confirmed O
by O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O
the O
same B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
separately O
) O
as O
employed O
for O
their O
amplification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
and O
bioinformatics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Clones B_LOCATION/B_GENE
from O
the O
SSH B_LOCATION/B_BIO
cDNA I_LOCATION/I_BIO
library I_LOCATION/I_BIO
with O
increased O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
the O
infective B_BODY_PART_OR_ORGAN_COMPONENT/B_SPECIES[BIO]
L3 I_BODY_PART_OR_ORGAN_COMPONENT/I_SPECIES[BIO]
compared O
with O
other B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sequenced O
using O
standard B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
technology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O
45 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
nucleotide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O
been O
deposited O
in O
the O
GenBank B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
under O
accession B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
numbers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
ES290984 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
ES291074 B_MEASURE
. O

Following O
the O
processing O
of O
the O
sequences O
( O
i O
. O
e O
. O
, O
removal O
of O
vector O
sequences O
, O
quality O
assurance O
and O
clustering O
) O
, O
contigs O
or O
singletons O
from O
individual O
clusters O
were O
subjected O
to O
BLASTx O
( O
NCBI O
: O
www O
. O
ncbi O
. O
nlm O
. O
nih O
. O
gov O
) O
and O
BLASTn O
( O
EMBL O
- O
EBI O
parasite O
genome O
blast O
Server O
: O
www O
. O
ebi O
. O
AC O
. O
uk O
) O
analysis O
to O
identify O
putative O
homologues O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
, O
other O
nematodes O
and O
other O
organisms O
( O
e O
- O
value O
of O
<= O
1e O
- O
05 O
) O
. O

peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inferred O
from O
ESTs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
classified O
functionally O
using O
Interproscan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
http B_ORGANIZATION/B_LOCATION
: O
/ O
/ O
www B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
ebi B_BIO/B_GENE
. O
AC B_LOCATION/B_DISEASE
. O
uk B_LOCATION/B_MEASURE
/ O
InterProScan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
/ O
) O
employing O
the O
default B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

WormBase O
( O
www O
. O
wormbase O
. O
org O
) O
was O
interrogated O
extensively O
for O
relevant O
information O
on O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
homologues O
/ O
orthologues O
, O
including O
RNAi O
phenotypic O
, O
transcriptomic O
, O
proteomic O
and O
interactomic O
data O
. O

ESTs O
with O
homologues O
/ O
orthologues O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
and O
other O
nematodes O
were O
also O
subjected O
to O
analysis O
employing O
the O
KEGG O
Orthology O
- O
Based O
Annotation O
System O
( O
KOBAS O
) O
( O
www O
. O
kobas O
. O
cbi O
. O
pku O
. O
edu O
. O
cn O
) O
, O
which O
predicts O
the O
biochemical O
pathways O
in O
which O
molecules O
are O
involved O
. O

The O
open O
reading O
frames O
( O
ORFs O
) O
inferred O
from O
selected O
ESTs O
with O
orthologues O
in O
C B_SPECIES[BIO]/B_GENE
. I_SPECIES[BIO]/I_GENE
elegans I_SPECIES[BIO]/I_GENE
were O
also O
subjected O
to O
' O
secretome O
analysis O
' O
using O
the O
program O
SignalP O
v O
. O
2 O
. O
0 O
www O
. O
CBS O
. O
dtu O
. O
dk O
/ O
services O
/ O
SignalP O
/ O
) O
, O
employing O
both O
the O
neural O
network O
and O
hidden O
Markov O
models O
to O
predict O
signal O
peptides O
and O
/ O
or O
anchors O
[ O
46 O
] O
- O
[ O
48 O
] O
. O

Also O
, O
transmembrane B_LOCATION
domains I_LOCATION
were O
predicted O
using O
the O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
TMHMM I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
www B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
CBS B_ORGANIZATION/B_DISEASE
. O
dtu B_LOCATION/B_ORGANIZATION
. O
DK B_DISEASE/B_LOCATION
/ O
services B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
TMHMM B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
; O
[ B_MEASURE
49 I_MEASURE
] I_MEASURE
- O
[ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
51 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
subcellular B_TIME[MEASURE]/B_LOCATION
localization I_TIME[MEASURE]/I_LOCATION
inferred O
employing O
the O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wolf I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PSORT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
http B_ORGANIZATION/B_LOCATION
: O
/ O
/ O
wolfpsort B_LOCATION/B_ORGANIZATION
. O
org B_ORGANIZATION/B_LOCATION
/ O
; O
[ B_MEASURE
52 I_MEASURE
] I_MEASURE
) O
. O

The O
method O
established O
by O
Zhong O
and O
Sternberg O
[ O
53 O
] O
was O
used O
to O
predict O
the O
interactions O
for O
C B_NUMBER[MEASURE]/B_SPECIES[BIO]
. I_NUMBER[MEASURE]/I_SPECIES[BIO]
elegans I_NUMBER[MEASURE]/I_SPECIES[BIO]
orthologues O
of O
the O
L3 O
- O
enriched O
molecules O
from O
Ascaris O
. O

In O
brief O
, O
interaction O
, O
phenotypic O
, O
expression O
and O
gene O
ontology O
data O
from O
fruitfly B_SPECIES[BIO]
, O
yeast B_SPECIES[BIO]
, O
mouse B_SPECIES[BIO]/B_DISEASE
and O
human B_SPECIES[BIO]
were O
integrated O
using O
a O
na O
i O
ve O
Bayesian O
model O
to O
predict O
genetic O
interactions O
among O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
genes O
( O
[ O
45 O
] O
, O
[ O
53 O
] O
; O
Zhong O
and O
Sternberg O
, O
unpublished O
) O
. O

The O
predicted B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
networks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
resulting O
from O
the O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
saved O
in O
a O
graphic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
display I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
file I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
gdf B_LOCATION/B_ENT
) O
format B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
examined O
using O
the O
graph B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
exploration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
available I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
at O
http B_ORGANIZATION/B_LOCATION
: O
/ O
/ O
graphexploration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
cond B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
org B_ORGANIZATION/B_LOCATION
/ O
. O

Images B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
labeled O
and O
saved O
in O
the O
joint B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
photographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
experts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
jpeg B_DISEASE/B_GENE
) O
format B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
identify O
molecules O
transcribed O
abundantly O
in O
the O
L3 O
of O
A B_BIO
. I_BIO
suum I_BIO
, O
an O
enriched O
cDNA O
library O
was O
constructed O
by O
SSH O
. O

From O
a O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
3075 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
this O
library B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
2921 B_NUMBER[MEASURE]
( O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
shown O
to O
contain O
an O
insert B_GENE
( O
which O
could O
be O
amplified O
by O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
. O

From O
2671 B_NUMBER[MEASURE]/B_PERSON
( O
92 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
these O
clones B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
amplicons B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
representing O
single B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bands I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
~ B_MEASURE
400 I_MEASURE
to O
600 B_TIME[MEASURE]
BP I_TIME[MEASURE]
in O
size B_MEASURE
were O
produced O
. O

These O
latter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amplicons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
arrayed O
( O
in O
duplicate B_MEASURE/B_LOCATION
) O
on O
to O
slides B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
then O
hybridized O
with O
Cy3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
labeled O
L3 B_DISEASE/B_PROTEIN[GENE]
- O
cDNA B_GENE
or O
with O
Cy5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
labeled O
cDNA B_GENE
from O
eggs B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
/ O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
L3s I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
L4s B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
, O
adult B_PERSON/B_BIO
female I_PERSON/I_BIO
or O
adult B_PERSON/B_BIO
male I_PERSON/I_BIO
of O
Ascaris B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
. O

dye B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
flip I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
conducted O
to O
verify O
the O
hybridization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
the O
2671 O
( O
duplicate O
) O
spots O
, O
1526 O
had O
a O
significant O
difference O
in O
hybridization O
between O
infective O
L3 O
cDNA O
and O
cDNAs O
from O
all O
other O
stages O
or O
sexes O
of O
A B_SPECIES[BIO]/B_ORGANISM_FUNCTION
. I_SPECIES[BIO]/I_ORGANISM_FUNCTION
suum I_SPECIES[BIO]/I_ORGANISM_FUNCTION
, O
of O
which O
515 O
had O
a O
> O
2 O
. O
0 O
- O
fold O
increased O
hybridization O
for O
the O
L3 O
. O

In O
order B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
independently O
verify O
the O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
microarray B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
a O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
based O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
selected O
subset B_MEASURE
( O
n B_OTHER/B_MEASURE
= O
17 B_MEASURE
) O
clones B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
using O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
primer I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pairs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Having O
verified O
the O
specificity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
identity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
amplicons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O
sequencing O
, O
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
reproducible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
based O
on O
multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
runs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
different B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
~ O
94 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
16 B_MEASURE/B_LOCATION
of O
17 B_NUMBER[MEASURE]/B_PERSON
) O
concordant B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
those O
of O
the O
microarray B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
not O
shown O
) O
. O

There O
was O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concordance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
representative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
a O
differential B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
signal B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
>= B_MEASURE
3 I_MEASURE
. O
0 B_MEASURE
- O
fold B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
microarray B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
clones B_GENE/B_DISEASE
linked O
to O
the O
515 B_GENE/B_LOCATION
spots I_GENE/I_LOCATION
representing O
increased O
transcription B_GENE
( O
> B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
. O
0 B_MEASURE
- O
fold B_MEASURE
) O
in O
infective B_BIO/B_DISEASE
L3 I_BIO/I_DISEASE
compared O
with O
the O
other B_TIME[MEASURE]/B_PERSON
developmental I_TIME[MEASURE]/I_PERSON
stages I_TIME[MEASURE]/I_PERSON
or O
sexes B_BIO/B_PERSON
included O
were O
subjected O
to O
sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
498 B_GENE/B_LOCATION
sequences I_GENE/I_LOCATION
( O
length B_TIME[MEASURE]/B_LOCATION
: O
550 B_MEASURE
+/- I_MEASURE
115 B_MEASURE/B_BIO
BP I_MEASURE
) O
determined O
were O
then O
subjected O
to O
detailed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bioinformatic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
were O
91 B_MEASURE
unique I_MEASURE
clusters I_MEASURE
( O
accession B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
numbers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
ES290984 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
ES291074 B_MEASURE
) O
, O
of O
which O
55 B_MEASURE
were O
singletons B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
sequences B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
determined O
once O
) O
. O

Of O
56 O
molecules O
( O
61 O
. O
5 O
% O
) O
with O
significant O
similarity O
to O
sequences O
other O
than O
A B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suum I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
databases O
interrogated O
, O
50 O
( O
54 O
. O
9 O
% O
) O
had O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
elegans I_SPECIES[BIO]/I_PERSON
or O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
briggsae I_SPECIES[BIO]/I_PERSON
homologues O
, O
and O
six O
had O
similarity O
to O
ESTs O
already O
sequenced O
from O
ascaridoid O
and O
/ O
or O
other O
parasitic O
nematodes O
, O
and O
/ O
or O
other O
organisms O
( O
Table O
1 O
) O
. O

A O
significant B_SEQUENCE[MEASURE]/B_PERSON
proportion I_SEQUENCE[MEASURE]/I_PERSON
( O
38 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
did O
not O
have O
any O
similarity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
sequence B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
any O
organisms B_BIO/B_GENE
for O
which O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
presently O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Comparative O
analysis O
specifically O
against O
A B_NUMBER[MEASURE]/B_PERSON
. I_NUMBER[MEASURE]/I_PERSON
suum I_NUMBER[MEASURE]/I_PERSON
est O
data O
sets O
( O
n O
~ O
42 O
, O
000 O
) O
available O
in O
public O
databases O
confirmed O
independently O
that O
the O
majority O
of O
molecules O
( O
> O
60 O
% O
) O
were O
present O
exclusively O
in O
the O
infective O
L3 O
stage O
or O
were O
orphans O
. O

As O
gene O
ontology O
( O
GO O
) O
provides O
a O
hierarchy O
that O
unifies O
the O
descriptions O
of O
biological O
, O
cellular O
and O
molecular O
functions O
[ O
54 O
] O
, O
this O
approach O
was O
employed O
to O
predict O
the O
classification O
and O
gene O
function O
of O
molecules O
enriched O
in O
infective O
L3 O
of O
A B_SPECIES[BIO]/B_DISEASE
. I_SPECIES[BIO]/I_DISEASE
suum I_SPECIES[BIO]/I_DISEASE
. O

A O
summary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
GO B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
categories I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
these O
molecules B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
displayed O
in O
Fig B_TIME[MEASURE]/B_LOCATION
. O

1 B_NUMBER[MEASURE]
. O

Of O
the O
91 B_NUMBER[MEASURE]/B_LOCATION
contigs I_NUMBER[MEASURE]/I_LOCATION
, O
32 B_MEASURE
( O
35 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
could O
be O
functionally O
assigned O
to O
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
' O
( O
n B_OTHER/B_MEASURE
= O
38 B_MEASURE
) O
, O
' O
cellular B_GENE/B_BIO
component I_GENE/I_BIO
' O
( O
n B_OTHER/B_MEASURE
= O
17 B_MEASURE
) O
and O
' O
molecular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
function I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' O
( O
n B_OTHER/B_MEASURE
= O
64 B_MEASURE
) O
. O

The O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
subcategories I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
gluconeogenesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
13 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
metabolic B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
process I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
( O
13 B_MEASURE
% I_MEASURE
) O
within O
' O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
' O
, O
extracellular B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
region B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
( O
24 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
within O
' B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ENZYME[GENE]
cellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ENZYME[GENE]
component B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ENZYME[GENE]
' O
, O
and O
catalytic B_ENZYME[GENE]
activity I_ENZYME[GENE]
( O
11 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
phosphoenolpyruvate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
carboxykinase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
( O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
within O
' O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
' O
( O
Table B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
S1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

A O
focused O
KOBAS O
analysis O
inferred O
the O
50 O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
orthologues O
/ O
homologues O
to O
be O
involved O
in O
apoptosis O
and O
insulin O
signaling O
( O
2 O
% O
) O
, O
ATP O
synthesis O
( O
2 O
% O
) O
, O
carbon O
metabolism O
( O
6 O
% O
) O
, O
fatty O
acid O
biosynthesis O
( O
2 O
% O
) O
, O
gap O
junction O
( O
2 O
% O
) O
, O
glucose O
metabolism O
( O
6 O
% O
) O
or O
porphyrin O
metabolism O
( O
2 O
% O
) O
, O
although O
34 O
( O
68 O
% O
) O
of O
them O
could O
not O
be O
mapped O
to O
a O
specific O
metabolic O
pathway O
( O
Table O
2 O
) O
. O

Of O
these O
50 B_GENE/B_MEASURE
molecules I_GENE/I_MEASURE
, O
small B_MEASURE
numbers I_MEASURE
were O
predicted O
to O
be O
secreted O
( O
10 B_MEASURE
% I_MEASURE
) O
, O
anchored O
( O
2 B_MEASURE
% I_MEASURE
) O
and O
/ O
or O
transmembrane B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
( O
12 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
proteins B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
Table B_MEASURE/B_PERSON
2 I_MEASURE/I_PERSON
) O
. O

Functionally O
, O
17 O
( O
34 O
% O
) O
of O
the O
50 O
molecules O
were O
associated O
with O
( O
non O
- O
wild O
- O
type O
) O
RNAi O
phenotypes O
in O
C B_BIO/B_PERSON
. I_BIO/I_PERSON
elegans I_BIO/I_PERSON
, O
the O
majority O
displaying O
embryonic O
lethality O
( O
Emb O
) O
( O
13 O
types O
; O
58 O
. O
8 O
% O
) O
, O
larval O
arrest O
( O
Lva O
) O
( O
23 O
. O
5 O
% O
) O
and O
larval O
lethality O
( O
Lvl O
) O
( O
47 O
% O
) O
( O
Table O
2 O
) O
. O

extending O
this O
analysis O
, O
a O
relatively O
complex O
genetic O
interaction O
network O
was O
predicted O
for O
the O
17 O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
orthologues O
( O
i O
. O
e O
. O
, O
with O
non O
- O
wild O
- O
type O
RNAi O
phenotypes O
) O
( O
see O
Table O
S2 O
) O
. O

Statistically O
highly O
significant O
interactions O
were O
predicted O
for O
nine O
of O
the O
C B_NUMBER[MEASURE]/B_PERSON
. I_NUMBER[MEASURE]/I_PERSON
elegans I_NUMBER[MEASURE]/I_PERSON
genes O
; O
the O
top O
five O
interactors O
are O
displayed O
in O
Fig O
. O

2 B_NUMBER[MEASURE]
. O

The O
gene O
ontology O
categories O
for O
eight O
selected O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
genes O
( O
F33D11 O
. O
10 O
, O
F55A12 O
. O
8 O
, O
kin O
- O
2 O
, O
mec O
- O
12 O
, O
mup O
- O
2 O
, O
pab O
- O
1 O
, O
rpl O
- O
22 O
and O
T21B10 O
. O
2 O
) O
included O
: O
embryonic O
development O
, O
egg O
hatching O
, O
larval O
development O
and O
/ O
or O
growth O
. O

The O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
categories I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
included O
: O
positive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
rate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
( O
F55A12 B_PROTEIN[GENE]/B_MEASURE
. O
8 B_MEASURE
, O
kin B_GENE
- O
2 B_NUMBER[MEASURE]
, O
mup B_GENE/B_BACTERIUM[BIO]
- O
2 B_NUMBER[MEASURE]
, O
pab B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
, O
rpl B_PROTEIN[GENE]/B_LOCATION
- O
22 B_NUMBER[MEASURE]
and O
T21B10 B_MEASURE/B_GENE
. O
2 B_MEASURE
) O
and O
gamete B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
generation I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
and O
locomotory B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
behaviour I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
( O
kin B_PROTEIN[GENE]
- O
2 B_NUMBER[MEASURE]
, O
mup B_GENE/B_BACTERIUM[BIO]
- O
2 B_NUMBER[MEASURE]
, O
pab B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
and O
F55A12 B_MEASURE/B_PROTEIN[GENE]
. O
8 B_MEASURE
, O
kin B_GENE/B_LOCATION
- O
2 B_NUMBER[MEASURE]
, O
mup B_GENE/B_BACTERIUM[BIO]
- O
2 B_MEASURE
, O
respectively O
) O
. O

The O
C B_SPECIES[BIO]/B_GENE
. I_SPECIES[BIO]/I_GENE
elegans I_SPECIES[BIO]/I_GENE
homologue O
egl O
- O
3 O
was O
predicted O
to O
be O
involved O
in O
proteolysis O
( O
see O
www O
. O
wormbase O
. O
org O
) O
. O

All O
nine O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
orthologues O
were O
predicted O
to O
interact O
directly O
with O
a O
total O
of O
296 O
( O
range O
: O
5 O
- O
75 O
) O
other O
genes O
and O
, O
in O
particular O
, O
a O
direct O
genetic O
interaction O
was O
predicted O
between O
pab O
- O
1 O
and O
T21B10 O
. O
2 O
( O
Fig O
. O
2 O
) O
. O

The O
296 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
interactors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
associated O
with O
embryonic B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
and O
larval B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
development I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
( O
n B_OTHER/B_MEASURE
= O
198 B_MEASURE
; O
66 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
information B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
storage I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O
processing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O
n B_MEASURE/B_LOCATION
= O
15 B_MEASURE
; O
5 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
, O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
processes B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
signalling O
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
45 B_MEASURE
; O
15 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
and O
metabolism B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
18 B_MEASURE
; O
6 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
; O
the O
precise B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
some O
of O
the O
interactors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
20 B_MEASURE
; O
6 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
is O
presently O
unknown B_DISEASE_ADJECTIVE[DISEASE]
( O
Table B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
S2 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
present O
study O
investigated O
transcripts O
in O
infective O
L3s O
of O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
using O
a O
genomic O
- O
bioinformatic O
platform O
. O

The O
focus O
was O
on O
comparisons O
with O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
elegans I_SPECIES[BIO]/I_PERSON
homologues O
/ O
orthologues O
, O
because O
the O
entire O
genome O
sequence O
of O
this O
nematode O
is O
known O
[ O
9 O
] O
and O
because O
there O
is O
a O
wealth O
of O
information O
on O
the O
localization O
and O
functionality O
of O
its O
molecules O
( O
www O
. O
wormbase O
. O
org O
; O
http O
: O
/ O
/ O
elegans O
. O
bcgsc O
. O
BC O
. O
ca O
/ O
knockout O
. O
shtml O
) O
. O

The O
functions O
of O
most O
genes O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
have O
been O
assessed O
using O
RNAi O
( O
e O
. O
g O
. O
, O
[ O
14 O
] O
, O
[ O
15 O
] O
, O
[ O
17 O
] O
, O
[ O
55 O
] O
, O
[ O
56 O
] O
) O
in O
the O
hermaphroditic O
stage O
, O
whereas O
there O
is O
a O
paucity O
of O
functional O
information O
available O
for O
Ascaris O
and O
other O
parasitic O
nematodes O
of O
animals O
[ O
57 O
] O
, O
[ O
58 O
] O
. O

Following O
the O
microarray B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
analysis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
> O
2500 B_GENE
ESTs I_GENE
from O
the O
SSH B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
498 B_GENE/B_MEASURE
cDNAs I_GENE/I_MEASURE
inferred O
to O
be O
enriched O
in O
the O
L3 B_LOCATION/B_DISEASE
, O
based O
on O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
were O
sequenced O
and O
subjected O
to O
comprehensive B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
silico B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Of O
the O
91 O
clusters O
of O
molecules O
categorized O
, O
50 O
( O
54 O
. O
9 O
% O
) O
had O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
homologues O
/ O
orthologues O
with O
loss O
- O
of O
- O
function O
phenotypes O
could O
be O
mapped O
to O
key O
pathways O
. O

The O
statistically O
significant O
genetic O
interactions O
predicted O
for O
9 O
of O
the O
50 O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
orthologues O
[ O
namely O
egl O
- O
3 O
, O
F33D11 O
. O
10 O
, O
F55A12 O
. O
8 O
, O
kin O
- O
2 O
, O
mec O
- O
12 O
, O
mup O
- O
2 O
, O
pab O
- O
1 O
, O
rpl O
- O
22 O
and O
T21B10 O
. O
2 O
( O
= O
enol O
- O
1 O
) O
] O
and O
the O
interaction O
network O
included O
genes O
encoding O
kinases O
, O
alpha O
- O
tubulins O
, O
enolases O
, O
troponin O
and O
other O
named O
and O
unnamed O
proteins O
. O

Eight O
of O
these O
molecules O
( O
enol O
- O
1 O
, O
pab O
- O
1 O
, O
F33D11 O
. O
10 O
, O
rpl O
- O
22 O
, O
F55A12 O
. O
8 O
mec O
- O
12 O
, O
mup O
- O
2 O
and O
kin O
- O
2 O
) O
have O
known O
or O
predicted O
roles O
in O
embryonic O
and O
larval O
growth O
and O
development O
, O
gamete O
generation O
, O
locomotory O
behaviour O
or O
other O
biological O
processes O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
( O
see O
www O
. O
wormbase O
. O
org O
) O
. O

The O
enolase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
encoded O
by O
enol B_DISEASE/B_PROTEIN[GENE]
- O
1 B_NUMBER[MEASURE]
is O
predicted O
to O
play O
a O
role B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
glycolysis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
gluconeogenesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
phenylalanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
tyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
tryptophan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
biosynthesis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
cf B_GENE
. O
[ B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
59 I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Since O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O
the O
main B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
source I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
alteration B_DISEASE_ADJECTIVE[DISEASE]
in O
these O
key B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycolytic I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzymes I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
lead O
to O
cellular B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
impaired B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ion I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
motive B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATPase B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
to O
maintain O
potential B_MEASURE/B_BIO
gradients I_MEASURE/I_BIO
, O
operate O
pumps B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O
maintain O
membrane B_DISEASE_ADJECTIVE[DISEASE]
lipid I_DISEASE_ADJECTIVE[DISEASE]
asymmetry I_DISEASE_ADJECTIVE[DISEASE]
[ O
60 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

Bioinformatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
transmembrane B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helices I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TMHMM B_LOCATION/B_ORGANIZATION
) O
and O
peptide B_GENE/B_LOCATION
signal I_GENE/I_LOCATION
sequences I_GENE/I_LOCATION
( O
SignalP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
predicted O
ENOL B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
to O
be O
a O
non B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
secreted B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
protein I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
localized O
to O
the O
cytoplasm B_BODY_PART_OR_ORGAN_COMPONENT
( O
CF B_LOCATION/B_GENE
. O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
) O
. O

Nonetheless O
, O
enolases O
are O
often O
detected O
in O
the O
excretory O
/ O
secretory O
( O
es O
) O
products O
of O
parasitic O
helminths O
, O
including O
adult O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
[ O
61 O
] O
, O
and O
appear O
to O
play O
a O
role O
in O
the O
triggering O
of O
nitric O
oxide O
production O
by O
host O
cells O
. O

The O
enol O
- O
1 O
orthologue O
of O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
has O
been O
predicted O
to O
interact O
specifically O
with O
the O
polyadenylate O
binding O
protein O
gene O
, O
pab O
- O
1 O
, O
inferred O
to O
be O
involved O
in O
coordinated O
gene O
transcription O
and O
expression O
during O
normal O
larval O
development O
[ O
16 O
] O
. O

Poly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
A O
) O
- O
binding O
proteins B_PROTEIN[GENE]/B_DISEASE
( O
PABPs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
are O
recognized O
to O
be O
central B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
regulation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
mRNA B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
translation B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
stability B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
[ O
62 B_SPECIES[BIO]/B_GENE
] I_SPECIES[BIO]/I_GENE
. O

Present O
evidence O
suggests O
that O
the O
expression O
of O
PAB O
- O
1 O
is O
regulated O
by O
an O
oligo O
- O
pyrimidine O
tract O
in O
response O
to O
cell O
growth O
and O
relates O
to O
coordinated O
growth O
regulation O
in O
C B_BIO/B_DISEASE
. I_BIO/I_DISEASE
elegans I_BIO/I_DISEASE
[ O
62 O
] O
. O

Furthermore O
, O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
silencing B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
pab B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
and O
its O
selected O
interactors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
( O
see O
Fig B_MEASURE/B_PERSON
. O
2 B_NUMBER[MEASURE]
) O
leads O
to O
embryonic B_DISEASE/B_ORGANISM_FUNCTION
lethal I_DISEASE/I_ORGANISM_FUNCTION
( O
Emb B_LOCATION/B_PERSON
) O
, O
slow B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Slo B_PERSON/B_LOCATION
) O
and O
sterile B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
progeny I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
Stp B_LOCATION/B_ORGANIZATION
) O
phenotypes B_DISEASE/B_GENE
( O
see O
www B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
wormbase B_BIO/B_GENE
. O
org B_ORGANIZATION/B_LOCATION
) O
. O

Another O
gene O
( O
F33D11 O
. O
10 O
; O
est O
code O
4F10 O
; O
see O
Table O
2 O
) O
which O
encodes O
an O
ATP O
- O
dependent O
RNA O
helicase O
and O
is O
associated O
with O
embryonic O
lethal O
( O
Emb O
) O
and O
larval O
lethal O
( O
Lvl O
) O
RNAi O
phenotypes O
, O
was O
shown O
to O
be O
highly O
transcribed O
in O
infective O
L3s O
of O
A B_BIO
. I_BIO
suum I_BIO
. O

Helicases O
are O
involved O
in O
a O
variety O
of O
RNA O
metabolic O
processes O
, O
including O
translation O
initiation O
, O
pre O
- O
mRNA O
splicing O
, O
pre O
- O
rRNA O
processing O
, O
rRNA O
maturation O
and O
RNA O
degradation O
[ O
63 O
] O
, O
and O
are O
crucial O
for O
life O
cycle O
progression O
, O
sex O
determination O
and O
early O
embryogenesis O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
[ O
60 O
] O
. O

The O
high O
transcription O
levels O
of O
a O
homologue O
/ O
orthologue O
in O
the O
L3 O
of O
A B_BIO
. I_BIO
suum I_BIO
might O
suggest O
a O
similar O
role O
in O
this O
ascaridoid O
. O

Similarly O
, O
the O
coordination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
expression B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
large B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
required O
for O
normal B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
proliferation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
during O
larval B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

The O
high O
transcription O
level O
for O
the O
ribosomal O
protein O
gene O
homologue O
rpl O
- O
22 O
( O
large O
subunit O
family O
member O
; O
est O
code O
26G12 O
, O
see O
Table O
2 O
) O
in O
the O
infective O
L3 O
of O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
compared O
with O
other O
developmental O
stages O
is O
likely O
to O
reflect O
the O
substantial O
rate O
of O
cell O
growth O
in O
this O
stage O
[ O
64 O
] O
. O

The O
gene O
( O
F55A12 O
. O
8 O
, O
est O
code O
4G11 O
; O
see O
Table O
2 O
) O
encoding O
an O
acetyl O
- O
transferase O
with O
a O
putative O
ATPase O
domain O
, O
shown O
to O
be O
enriched O
in O
the O
L3 O
of O
A B_BIO
. I_BIO
suum I_BIO
, O
was O
predicted O
to O
interact O
with O
75 O
other O
genes O
all O
involved O
in O
energy O
production O
and O
/ O
or O
RNA O
processing O
( O
see O
Table O
S2 O
) O
. O

Several O
molecules O
involved O
in O
ATP O
synthesis O
and O
mitochondrial O
pathways O
( O
e O
. O
g O
. O
, O
cytochrome O
oxidase O
c O
subunits O
1 O
, O
2 O
and O
3 O
, O
ADP O
/ O
ATP O
translocases O
, O
NADH O
dehydrogenases O
, O
ATPases O
and O
ATP O
synthetases O
) O
have O
been O
reported O
previously O
to O
be O
highly O
represented O
in O
the O
L3 O
stage O
of O
Anisakis B_SPECIES[BIO]/B_DISEASE
simplex I_SPECIES[BIO]/I_DISEASE
[ O
65 O
] O
, O
thus O
supporting O
the O
proposal O
that O
substantial O
energy O
is O
required O
for O
larval O
development O
as O
well O
as O
the O
transition O
from O
the O
free O
- O
living O
to O
the O
parasitic O
stage O
and O
the O
invasion O
of O
the O
host O
. O

There O
is O
also O
likely O
to O
be O
a O
substantial O
energy O
requirement O
for O
muscle O
contraction O
linked O
to O
larval O
motility O
in O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
, O
as O
the O
L3s O
penetrate O
the O
caecal O
wall O
in O
the O
porcine O
host O
, O
before O
undergoing O
hepato O
- O
pulmonary O
migration O
[ O
35 O
] O
. O

Accordingly O
, O
genes O
encoding O
a O
specialized O
tubulin O
expressed O
in O
mechanoreceptors O
( O
mec O
- O
12 O
, O
est O
code O
13E09 O
) O
and O
a O
troponin O
( O
mup O
- O
2 O
, O
est O
code O
01G03 O
; O
see O
Table O
2 O
) O
, O
both O
predicted O
to O
interact O
with O
a O
total O
number O
of O
32 O
tubulin O
- O
and O
myosin O
- O
encoding O
genes O
, O
also O
supported O
a O
link O
to O
extensive O
muscle O
contraction O
and O
motility O
in O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
suum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
L3s O
. O

Also O
, O
neuroactive B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
peptides I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
are O
required O
to O
regulate O
the O
responsiveness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
nematode B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
larvae I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
mechanical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimuli I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
66 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
homologue O
encoded O
by O
egl O
- O
3 O
was O
shown O
to O
be O
highly O
transcribed O
in O
the O
L3 O
of O
A B_BIO
. I_BIO
suum I_BIO
; O
EGL O
- O
3 O
is O
predicted O
to O
be O
a O
pro O
- O
hormone O
convertase O
involved O
in O
the O
maturation O
of O
neuropeptides O
and O
could O
be O
associated O
with O
mechano O
- O
sensory O
responses O
and O
touch O
sensitivity O
linked O
to O
the O
host O
invasion O
. O

A O
regulatory B_GENE/B_PERSON
subunit I_GENE/I_PERSON
of O
a O
cAMP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_ENZYME[GENE]/B_LOCATION
protein I_ENZYME[GENE]/I_LOCATION
kinase I_ENZYME[GENE]/I_LOCATION
( O
kin B_GENE
- O
2 B_MEASURE/B_PROTEIN[GENE]
, O
EST B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
22H01 I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
was O
predicted O
to O
interact O
with O
72 B_GENE/B_MEASURE
other I_GENE/I_MEASURE
genes I_GENE/I_MEASURE
all O
involved O
in O
diverse B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
processes B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
trafficking B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
and O
DNA B_DISEASE_ADJECTIVE[DISEASE]
replication I_DISEASE_ADJECTIVE[DISEASE]
and O
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O
see O
Table B_MEASURE/B_LOCATION
S2 I_MEASURE/I_LOCATION
) O
. O

Based O
on O
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ontology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
terms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
kin B_GENE
- O
2 B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
implicated O
in O
gamete B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
generation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O
growth B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
larval B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
development I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O
post B_LOCATION/B_DISEASE
- O
embryonic B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
body I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
morphogenesis I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O
signal B_GENE
transduction I_GENE
and O
/ O
or O
protein B_DISEASE/B_GENE
amino I_DISEASE/I_GENE
acid I_DISEASE/I_GENE
phosphorylation I_DISEASE/I_GENE
( O
see O
Table B_LOCATION/B_PERSON
S2 I_LOCATION/I_PERSON
) O
. O

Gene O
silencing O
of O
kin O
- O
2 O
in O
C B_BIO
. I_BIO
elegans I_BIO
leads O
to O
phenotypes O
, O
such O
as O
larval O
lethal O
( O
Lvl O
) O
, O
larval O
arrest O
( O
Lva O
) O
, O
body O
morphology O
defect O
( O
Bmd O
) O
, O
dumpy O
( O
Dpy O
) O
, O
uncoordinated O
( O
Unc O
) O
and O
sterile O
progeny O
( O
Stp O
) O
( O
www O
. O
wormbase O
. O
org O
) O
, O
suggesting O
that O
its O
homologue O
in O
A B_SPECIES[BIO]
. I_SPECIES[BIO]
suum I_SPECIES[BIO]
is O
central O
to O
larval O
maturation O
. O

The O
KOBAS O
analysis O
predicted O
the O
protein O
kin O
- O
2 O
to O
be O
involved O
in O
the O
insulin O
- O
signaling O
pathway O
, O
previously O
implicated O
in O
controlling O
the O
exit O
from O
dauer O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
and O
the O
activation O
of O
L3s O
of O
the O
canine B_SPECIES[BIO]
hookworm I_SPECIES[BIO]
, O
Ancylostoma B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
caninum B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O
following O
exsheathment O
[ O
67 O
] O
. O

In O
a O
recent O
study O
, O
Brand O
and O
Hawdon O
[ O
68 O
] O
were O
able O
to O
inhibit O
( O
with O
a O
phosphoinositide O
- O
3 O
- O
OH O
- O
kinase O
inhibitor O
) O
the O
activation O
of O
infective O
L3s O
of O
both O
of O
the O
hookworms O
Ancylostoma B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
caninum B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
and O
Ancylostoma B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
ceylanicum I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
via O
the O
insulin O
signaling O
pathway O
, O
thus O
lending O
some O
credence O
to O
the O
hypothesis O
that O
this O
pathway O
plays O
an O
critical O
role O
in O
regulating O
the O
transition O
from O
the O
free O
- O
living O
to O
the O
parasitic O
stage O
[ O
68 O
] O
. O

Recently O
, O
it O
has O
been O
proposed O
that O
transcriptional O
and O
feeding O
responses O
to O
serum O
- O
stimulation O
in O
Ancylostoma B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
caninum B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
are O
regulated O
by O
parallel O
systems O
, O
with O
the O
insulin O
signaling O
pathway O
playing O
a O
significant O
role O
in O
the O
' O
resumption O
of O
feeding O
' O
in O
activated O
larvae O
[ O
69 O
] O
. O

protein B_PERSON/B_GENE
kinases I_PERSON/I_GENE
are O
also O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
involved O
in O
pathways B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
linked O
to O
sexual B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
maturation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
developing O
larvae B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

As O
already O
proposed O
for O
adult O
stages O
of O
H B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
. I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
contortus I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
45 O
] O
, O
the O
protein O
kinase O
gene O
cdk O
- O
1 O
is O
predicted O
to O
play O
a O
pivotal O
role O
in O
the O
germline O
, O
oogenesis O
and O
spermiogenesis O
pathways O
of O
this O
parasitic O
nematode O
. O

Other O
protein O
kinases O
, O
such O
as O
PEPCK O
, O
and O
phosphatases O
, O
were O
shown O
herein O
to O
be O
transcribed O
at O
high O
levels O
in O
the O
L3 O
stage O
compared O
with O
other O
developmental O
stages O
of O
A B_BIO
. I_BIO
suum I_BIO
( O
see O
Table O
2 O
) O
, O
which O
is O
in O
accordance O
to O
findings O
reported O
recently O
for O
Anisakis B_SPECIES[BIO]
simplex I_SPECIES[BIO]
[ O
65 O
] O
. O

Due O
to O
their O
major B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
regulatory I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
effects I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
eukaryotic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
signaling B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
events B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O
regulatory B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sensory B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
functions B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
protein B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
kinases I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
considered O
interesting B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targets I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
parasitic B_DISEASE/B_GENE
drugs I_DISEASE/I_GENE
[ O
70 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
conclusion O
, O
this O
study O
has O
given O
some O
interesting O
insights O
into O
early O
molecular O
processes O
in O
the O
L3 O
of O
A B_DISEASE
. I_DISEASE
suum I_DISEASE
. O

Approximately O
60 O
% O
of O
the O
transcripts O
enriched O
in O
the O
L3 O
stage O
of O
A B_ORGANISM_FUNCTION/B_BIO
. I_ORGANISM_FUNCTION/I_BIO
suum I_ORGANISM_FUNCTION/I_BIO
have O
homologues O
/ O
orthologues O
in O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
. O

The O
bioinformatic O
analyses O
of O
selected O
molecules O
suggest O
that O
a O
complex O
genetic O
network O
regulates O
or O
controls O
larval O
growth O
and O
development O
in O
A B_PERSON
. I_PERSON
suum I_PERSON
L3s O
, O
and O
some O
of O
these O
might O
be O
involved O
in O
or O
regulate O
the O
switch O
from O
the O
free O
- O
living O
to O
the O
parasitic O
stage O
. O

Some O
caution O
is O
warranted O
in O
drawing O
conclusions O
regarding O
molecular O
mechanisms O
regulating O
the O
transition O
to O
parasitism O
in O
parasitic O
nematodes O
from O
information O
on O
C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
, O
as O
latter O
is O
a O
free O
- O
living O
nematode O
. O

Also O
, O
while O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
reliable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prediction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
might O
limit O
the O
capacity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
somewhat O
to O
infer O
nematode B_BIO/B_GENE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

As O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
datasets I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
gene B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
functions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
become O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
various B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
parasitic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
nematodes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
more O
informed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inferences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
made O
regarding O
the O
functions B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nematode B_BIO/B_PERSON
- O
specific B_GENE/B_BIO
genes I_GENE/I_BIO
, O
particularly O
those O
involved O
in O
the O
transition B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
parasitism B_DISEASE/B_ORGANISM_FUNCTION
. O

The O
imminent O
genome O
sequence O
of O
A B_BIO
. I_BIO
suum I_BIO
( O
http O
: O
/ O
/ O
www O
. O
sanger O
. O
AC O
. O
uk O
/ O
Projects O
/ O
Helminths O
/ O
) O
should O
all O
assist O
in O
this O
endeavour O
. O

Also O
, O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
selected O
molecules B_BIO/B_GENE
representing O
selected O
ESTs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
identified O
herein B_TIME[MEASURE]/B_LOCATION
, O
utilizing O
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
silencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approaches I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
established O
recently O
[ O
33 B_MEASURE
] I_MEASURE
, O
[ O
34 B_MEASURE
] I_MEASURE
, O
could O
provide O
some O
insights B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
developmental B_DISEASE/B_GENE
processes I_DISEASE/I_GENE
in O
Ascaris B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
and O
related B_SPECIES[BIO]/B_PERSON
ascaridoid I_SPECIES[BIO]/I_PERSON
nematodes I_SPECIES[BIO]/I_PERSON
and O
provide O
avenues B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
their O
control B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Supporting O
Information B_PERSON/B_ENT
. O

Minocycline B_DISEASE_ADJECTIVE[DISEASE]
attenuates I_DISEASE_ADJECTIVE[DISEASE]
lipopolysaccharide O
( O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
- O
induced O
neuroinflammation B_DISEASE
, O
sickness B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
anhedonia B_DISEASE/B_GENE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Activation B_DISEASE/B_GENE
of O
the O
peripheral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
innate B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
immune B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
stimulates O
the O
secretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
CNS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
modulate O
the O
behavioral B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
of O
sickness B_DISEASE/B_LOCATION
. O

excessive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
production B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
by O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
however O
, O
may O
cause O
long O
- O
lasting B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
behavioral B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
purpose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
if O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
agent I_DISEASE_ADJECTIVE[DISEASE]
and O
purported O
microglial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
attenuates O
lipopolysaccharide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
- O
induced O
neuroinflammation B_DISEASE
, O
sickness B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
anhedonia B_DISEASE
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
microglia B_DISEASE/B_GENE
activation I_DISEASE/I_GENE
was O
assessed O
in O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
microglia B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cultures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
the O
second O
study O
, O
adult O
( O
3 O
- O
6 O
m O
) O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O
an O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
vehicle O
or O
minocycline O
( O
50 O
mg O
/ O
kg O
) O
for O
three O
consecutive O
days O
. O

On O
the O
third O
day O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
also O
injected O
( O
i O
. O
p O
. O
) O
with O
saline O
or O
Escherichia B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coli B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS O
( O
0 O
. O
33 O
mg O
/ O
kg O
) O
and O
behavior O
( O
i O
. O
e O
. O
, O
sickness O
and O
anhedonia O
) O
and O
markers O
of O
neuroinflammation O
( O
i O
. O
e O
. O
, O
microglia O
activation O
and O
inflammatory O
cytokines O
) O
were O
determined O
. O

In O
the O
final O
study O
, O
adult O
and O
aged O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
treated O
with O
the O
same O
minocycline O
and O
LPS O
injection O
regimen O
and O
markers O
of O
neuroinflammation O
were O
determined O
. O

All O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
analyzed O
using O
Statistical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Analysis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Systems I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
General I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Linear I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Model I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
procedures I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
were O
subjected O
to O
one B_NUMBER[MEASURE]/B_PERSON
- O
, O
two B_NUMBER[MEASURE]/B_PERSON
- O
, O
or O
three B_NUMBER[MEASURE]
- O
way B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ANOVA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
determine O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
main I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
interactions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O
LPS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cytokine B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_MEASURE
microglia I_MEASURE
- O
derived O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
reduced O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
Toll B_GENE
- O
like B_BIO/B_PROTEIN[GENE]
- O
receptor B_GENE/B_BIO
- O
2 B_MEASURE
( O
TLR2 B_GENE
) O
surface B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
brain B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
microglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
minocycline O
facilitated O
the O
recovery O
from O
sickness O
behavior O
( O
i O
. O
e O
. O
, O
anorexia O
, O
weight O
loss O
, O
and O
social O
withdrawal O
) O
and O
prevented O
anhedonia O
in O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenged O
with O
LPS O
. O

Furthermore O
, O
the O
minocycline B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
from O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
sickness B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
paralleled O
by O
reduced B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mRNA B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
1 B_MEASURE/B_PROTEIN[GENE]
beta I_MEASURE/I_PROTEIN[GENE]
, O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
, O
and O
indoleamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
3 B_MEASURE/B_ENZYME[GENE]
dioxygenase I_MEASURE/I_ENZYME[GENE]
( O
IDO B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
the O
cortex B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
. O

Finally O
, O
in O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
where O
exaggerated O
neuroinflammation O
was O
elicited O
by O
LPS O
, O
minocycline O
pretreatment O
was O
still O
effective O
in O
markedly O
reducing O
mRNA O
levels O
of O
IL O
- O
1 O
beta O
, O
TLR2 O
and O
IDO O
in O
the O
hippocampus O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mitigates O
neuroinflammation B_DISEASE/B_GENE
in O
the O
adult B_PERSON
and O
aged B_PERSON
brain I_PERSON
and O
modulates O
the O
cytokine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
motivation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
behavior B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
bi B_DISEASE/B_NUMBER[MEASURE]
- O
directional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
communication I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O
the O
immune B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
CNS B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
) O
is O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
mounting O
the O
appropriate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
immunological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
physiological B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
behavioral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
immune B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
[ O
1 B_DISEASE
] I_DISEASE
. O

CNS B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
innate O
immune B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
including O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
play O
integral B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
roles I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
receiving O
and O
propagating O
inflammatory B_DISEASE
signals I_DISEASE
that O
are O
initiated O
at O
the O
periphery B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

Activation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
innate I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
immune I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
elicits O
the O
secretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
inflammatory B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
interleukin B_GENE
( O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
1 B_MEASURE
, O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
, O
and O
tumor B_DISEASE/B_GENE
necrosis B_DISEASE/I_GENE
factor B_DISEASE/I_GENE
- O
alpha B_PROTEIN[GENE]
( O
TNF B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
) O
, O
that O
use O
neural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
[ O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
] O
, O
humoral O
[ O
4 B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
blood B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
brain B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
barrier B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
5 B_MEASURE
] O
to O
relay O
this O
signal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
the O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

This O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
signal I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
turn B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
induces O
CNS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
produce O
the O
same B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O
6 B_MEASURE
] I_MEASURE
, O
which O
target O
neuronal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
substrates I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
elicit O
a O
sickness B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
syndrome B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
normally O
adaptive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
beneficial B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
host B_PERSON/B_SPORT[ENT]
[ I_PERSON/I_SPORT[ENT]
1 I_PERSON/I_SPORT[ENT]
] I_PERSON/I_SPORT[ENT]
. O

An O
amplified B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
excessive B_DISEASE/B_MEASURE
inflammatory I_DISEASE/I_MEASURE
cytokine I_DISEASE/I_MEASURE
response I_DISEASE/I_MEASURE
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
however O
, O
is O
associated O
with O
a O
myriad B_MEASURE/B_LOCATION
of O
complications B_DISEASE_ADJECTIVE[DISEASE]
including O
cognitive B_DISEASE
dysfunction I_DISEASE
[ I_DISEASE
7 I_DISEASE
- O
10 B_NUMBER[MEASURE]/B_LOCATION
] I_NUMBER[MEASURE]/I_LOCATION
, O
prolonged B_DISEASE
sickness I_DISEASE
behavior I_DISEASE
[ O
11 B_SEQUENCE[MEASURE]
- O
14 B_MEASURE
] I_MEASURE
, O
and O
depressive B_DISEASE
- O
like B_DISEASE
behavior I_DISEASE
[ O
15 B_MEASURE
] I_MEASURE
. O

microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
are O
primarily O
involved O
in O
immune B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
16 B_MEASURE
, O
17 B_MEASURE
] I_MEASURE
, O
but O
when O
activated O
have O
macrophage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
like B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
capabilities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
including O
phagocytosis B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
cytokine I_DISEASE_ADJECTIVE[DISEASE]
production I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
antigen B_DISEASE_ADJECTIVE[DISEASE]
presentation I_DISEASE_ADJECTIVE[DISEASE]
[ O
18 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

Normally O
these O
neuroinflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
transient B_DISEASE_ADJECTIVE[DISEASE]
with O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
returning O
to O
a O
resting O
state B_LOCATION/B_MEASURE
as O
the O
immune B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
resolved O
. O

aging O
or O
neurological B_DISEASE
disease I_DISEASE
, O
however O
, O
may O
provide O
a O
brain B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
environment I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
where O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
are O
more B_DISEASE_ADJECTIVE[DISEASE]
' O
reactive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
primed O
' O
to O
a O
peripheral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immune I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
challenge I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
19 B_DISEASE
] I_DISEASE
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
indicate O
that O
several B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
markers I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
glial B_DISEASE
activation I_DISEASE
such I_DISEASE
as O
major B_GENE
histocompatibility I_GENE
complex I_GENE
( O
MHC B_LOCATION/B_ORGANIZATION
) O
class B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
complement B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
scavenger B_GENE
receptors I_GENE
are O
increased O
in O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
during O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
aging O
[ O
13 B_MEASURE
, O
20 B_MEASURE
- O
26 B_MEASURE
] I_MEASURE
. O

Furthermore O
, O
we O
and O
others B_PERSON/B_BIO
have O
reported O
that O
a O
biological B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
consequence B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
this O
reactive B_DISEASE_ADJECTIVE[DISEASE]
glial I_DISEASE_ADJECTIVE[DISEASE]
profile I_DISEASE_ADJECTIVE[DISEASE]
is O
an O
exaggerated B_DISEASE_ADJECTIVE[DISEASE]
neuroinflammatory I_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
to O
innate O
immune B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
9 B_MEASURE
, O
10 B_SEQUENCE[MEASURE]
, O
12 B_SEQUENCE[MEASURE]
- O
14 B_MEASURE
, O
27 B_MEASURE
, O
28 B_MEASURE
] I_MEASURE
. O

Active B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
microglia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
CNS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
also O
contribute O
to O
the O
production B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
oxidative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
neuroactive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediators B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
may O
influence O
behavior B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
instance B_PERSON/B_DISEASE
, O
inflammatory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upregulate I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
enzyme B_ENZYME[GENE]/B_LOCATION
IDO I_ENZYME[GENE]/I_LOCATION
[ O
29 B_MEASURE
, O
30 B_MEASURE
] I_MEASURE
, O
which O
metabolizes O
tryptophan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TRP B_PROTEIN[GENE]
) O
into O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
kynurenine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
KYN B_PROTEIN[GENE]/B_DISEASE
) O
[ O
31 B_MEASURE
] I_MEASURE
. O

TRP B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degradation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
KYN B_GENE/B_DISEASE
can O
reduce O
TRP B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
are O
required O
for O
serotonin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
32 B_MEASURE
] I_MEASURE
and O
can O
lead O
to O
the O
production B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
neuroactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mediators I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O
3 B_NUMBER[MEASURE]
- O
hydroxykynurenine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3HK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
and O
quinolinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
QUIN B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
[ O
31 B_MEASURE
] I_MEASURE
. O

High B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
3HK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
quin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induce O
neuronal B_DISEASE/B_GENE
damage I_DISEASE/I_GENE
through O
oxidative B_DISEASE_ADJECTIVE[DISEASE]
stress I_DISEASE_ADJECTIVE[DISEASE]
[ O
33 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
] I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
over O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
methyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
aspartate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
[ O
34 B_MEASURE
, O
35 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

A O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicates O
that O
while O
several B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
types I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
express I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
IDO I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
only O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_NUMBER[MEASURE]
maintain O
all O
the O
enzymes B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
to O
produce O
3HK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
quin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
36 B_TIME[MEASURE]/B_LOCATION
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Because O
IDO B_DISEASE/B_GENE
mediated O
TRP B_DISEASE/B_GENE
degradation I_DISEASE/I_GENE
impacts O
both O
serotonergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
glutamatergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathways I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
this O
may O
be O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanism I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
underlying O
mood B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
behavior B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concomitant I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
inflammation B_DISEASE/B_BACTERIUM[BIO]
[ O
37 B_MEASURE
- O
39 B_MEASURE
] I_MEASURE
. O

Because O
activated O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
suspected O
to O
cause O
or O
exacerbate O
several B_DISEASE
neurodegenerative I_DISEASE
diseases I_DISEASE
, O
pharmacological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strategies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
suppress O
microglial B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activity I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
being O
explored O
as O
therapies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
derived O
antibiotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
has O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
that O
are O
separate B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
its O
antimicrobial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
action I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O
40 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
readily O
crosses O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
barrier I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
attenuates B_DISEASE/B_LOCATION
inflammation I_DISEASE/I_LOCATION
associated O
with O
microglial B_DISEASE
activation I_DISEASE
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocks O
the O
deleterious B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neuroinflammation B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
neurogenesis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
potentiation B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
, O
and O
neuronal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
survival B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
41 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
43 B_MEASURE
] I_MEASURE
. O

The O
mechanism B_LOCATION
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abrogates O
MAPkinase B_GENE/B_DISEASE
and O
NF B_GENE
kappa I_GENE
B I_GENE
dependent I_GENE
signaling O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O
primary B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
microglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cultures I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
44 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Moreover O
, O
in O
the O
brain O
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
minocycline O
abrogates O
microglial O
expression O
of O
CD11b O
and O
MHC O
II O
through O
a O
protein O
kinase O
- O
c O
dependent O
mechanism O
[ O
45 O
] O
. O

This O
is O
relevant B_DISEASE_ADJECTIVE[DISEASE]
because O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attenuates O
neuroinflammation B_DISEASE/B_GENE
in O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
rodent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
disease B_DISEASE
including O
amyotrophic B_DISEASE/B_GENE
Lateral I_DISEASE/I_GENE
sclerosis I_DISEASE/I_GENE
[ I_DISEASE
46 I_DISEASE
] I_MEASURE/I_DISEASE
, O
Experimental B_DISEASE
autoimmune I_DISEASE
encephalomyelitis I_DISEASE
( O
EAE B_DISEASE
) O
[ O
45 B_MEASURE
] I_MEASURE
and O
MPTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
Parkinson B_DISEASE/B_GENE
' O
s B_DISEASE
disease I_DISEASE
[ O
47 B_MEASURE
] I_MEASURE
. O

However O
, O
the O
extent B_DISEASE/B_MEASURE
to O
which O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
facilitates O
the O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mediated O
sickness B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
investigated O
the O
degree B_MEASURE/B_LOCATION
to O
which O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
agent I_DISEASE_ADJECTIVE[DISEASE]
and O
purported O
microglial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
reduced O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
neuroinflammation B_DISEASE
and O
sickness B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
show O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O
LPS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cytokine B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_MEASURE
microglia I_MEASURE
- O
derived O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
reduced O
LPS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
Toll B_GENE
- O
like B_BIO/B_PROTEIN[GENE]
- O
receptor B_GENE/B_MEASURE
- O
2 B_MEASURE
( O
TLR2 B_GENE/B_LOCATION
) O
surface B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
brain B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
microglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
our O
data O
show O
that O
minocycline O
pretreatment O
attenuated O
LPS O
- O
induced O
weight O
loss O
, O
social O
withdrawal O
, O
and O
anhedonia O
in O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
attenuation O
of O
sickness O
behavior O
was O
paralleled O
with O
minocycline O
dependent O
decrease O
in O
markers O
of O
neuroinflammation O
( O
IL O
- O
1 O
beta O
, O
TLR2 O
, O
and O
IDO O
) O
in O
adult O
and O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support O
our O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
ability B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O
mitigate O
cytokine B_DISEASE/B_GENE
expression I_DISEASE/I_GENE
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
during O
systemic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflammatory I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
preventing O
cognitive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
behavioral B_DISEASE
deficits I_DISEASE
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Male O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
adults O
( O
3 O
month O
old O
) O
and O
juvenile O
( O
3 O
- O
4 O
week O
old O
) O
were O
purchased O
from O
Harlan O
( O
Indianapolis O
, O
IN O
) O
. O

For O
age O
comparisons O
, O
male O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 O
- O
4 O
and O
20 O
- O
22 O
month O
old O
) O
were O
purchased O
from O
the O
National O
Institute O
on O
aging O
specific O
pathogen O
free O
colony O
. O

Upon O
arrival O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
individually O
housed O
in O
polypropylene O
cages O
and O
maintained O
at O
21 O
degrees O
C O
under O
a O
12 O
h O
light O
: O
12 O
h O
dark O
cycle O
with O
ad O
libitum O
access O
to O
water O
and O
rodent O
Chow O
. O

At O
the O
end O
of O
each O
study O
, O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
examined O
postmortem O
for O
gross O
signs O
of O
disease O
( O
e O
. O
g O
. O
, O
splenomeglia O
or O
tumors O
) O
. O

Data O
from O
mice B_BIO/B_PERSON
determined O
to O
be O
unhealthy O
were O
excluded O
from O
analysis O
( O
< O
5 O
% O
) O
. O

All O
procedures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
in O
accordance B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
National B_ORGANIZATION/B_LOCATION
Institute I_ORGANIZATION/I_LOCATION
of O
Health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Guidelines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
the O
Care B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Laboratory B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Animals I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
approved O
by O
The O
Ohio B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
State I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
University I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
institutional I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Laboratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Animal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
Use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Committee I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microglia I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lines I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
cultured O
in O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O
DMEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
supplemented O
with O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FBS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
sodium B_MEASURE
bicarbonate I_MEASURE
3 I_MEASURE
. O
7 B_MEASURE
g I_MEASURE
/ O
l B_OTHER/B_MEASURE
, O
200 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
100 B_MEASURE/B_LOCATION
U I_MEASURE/I_LOCATION
/ O
ml B_MEASURE/B_LOCATION
penicillin I_MEASURE/I_LOCATION
G I_MEASURE/I_LOCATION
, O
100 B_MEASURE
Mu I_MEASURE
g I_MEASURE
/ O
ml B_MEASURE
streptomycin I_MEASURE
, O
0 B_MEASURE/B_LOCATION
. O
25 B_MEASURE/B_LOCATION
Mu I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
ml B_MEASURE
fungizone I_MEASURE
) O
as O
previously O
described O
[ O
12 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

cultures B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
maintained O
at O
37 B_LOCATION/B_MEASURE
degrees I_LOCATION/I_MEASURE
C I_LOCATION/I_MEASURE
with O
95 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
humidity B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
CO2 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
medium B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
was O
replenished O
every O
third B_TIME[MEASURE]
day I_TIME[MEASURE]
until O
confluence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

cultures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
washed O
twice O
and O
supplemented O
with O
warm B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
experimental B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Cell B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
viability B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
was O
measured O
by O
the O
MTS B_PERSON/B_ORGANIZATION
cell I_PERSON/I_ORGANIZATION
proliferation I_PERSON/I_ORGANIZATION
assay I_PERSON/I_ORGANIZATION
according O
to O
the O
manufacturer B_PERSON/B_ORGANIZATION
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
instructions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
Promega B_LOCATION/B_PERSON
, O
Madison B_PERSON/B_LOCATION
, O
WI B_MEASURE/B_LOCATION
) O
. O

CNS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
isolation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

CNS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
collected O
from O
whole B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
brain I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
homogenates I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
as O
described O
previously O
[ O
48 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
, O
but O
with O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
modifications I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Mice B_BIO/B_PERSON
were O
euthanized O
by O
CO2 O
asphyxiation O
and O
whole O
brains O
were O
collected O
. O

brains B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
homogenized O
in O
Hank B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_MEASURE
s I_MEASURE
balanced I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
salt I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
HBSS B_DISEASE/B_PROTEIN[GENE]
) O
pH B_MEASURE/B_LOCATION
7 I_MEASURE/I_LOCATION
. O
4 B_MEASURE
. O

Brain B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
homogenates I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
passed O
through O
a O
70 B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mu I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
m I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nylon I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strainer I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
centrifuged O
at O
400 B_MEASURE
x O
g B_OTHER/B_MEASURE
for O
10 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
min I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

supernatants B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANIZATION
were O
removed O
and O
cell B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pellets I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
re O
- O
suspended O
in O
70 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
isotonic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Percoll I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
GE B_DISEASE/B_GENE
- O
healthcare B_NUMBER[MEASURE]/B_LOCATION
, O
Uppsala B_LOCATION
, O
Sweden B_LOCATION/B_MEASURE
) O
at O
room B_MEASURE/B_LOCATION
temperature B_MEASURE/I_LOCATION
. O

A O
discontinuous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Percoll I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
density I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gradient I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
set O
up O
as O
follows O
: O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
35 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
and O
0 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
isotonic I_MEASURE/I_LOCATION
Percoll I_MEASURE/I_LOCATION
. O

This O
suspension B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
centrifuged O
for O
30 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
minutes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
400 B_MEASURE
x O
g B_OTHER/B_MEASURE
. O

A O
mixed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
CNS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
collected O
from O
the O
interphase B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
between O
the O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
and O
35 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
Percoll I_MEASURE/I_LOCATION
layers I_MEASURE/I_LOCATION
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
washed O
and O
then O
re B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
suspended O
in O
sterile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
HBSS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
number B_MEASURE/B_LOCATION
of O
viable B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
was O
determined O
using O
a O
hemacytometer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
0 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
trypan I_MEASURE
blue I_MEASURE
staining I_MEASURE
. O

Flow B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometry I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometric I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
microglial B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
surface B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
markers B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
performed O
as O
described O
previously O
, O
but O
with O
a O
few B_MEASURE/B_PERSON
modifications I_MEASURE/I_PERSON
[ O
48 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

In O
brief B_MEASURE
, O
Fc B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
blocked O
with O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
CD16 B_GENE
/ O
CD32 B_GENE/B_MEASURE
antibody I_GENE/I_MEASURE
( O
eBiosciences B_LOCATION/B_ORGANIZATION
, O
CA B_LOCATION/B_MEASURE
) O
. O

Next O
, O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
incubated O
with O
either O
Panel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_NUMBER[MEASURE]
( O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
CD11b B_GENE
APC I_GENE
, O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
CD45 B_GENE
FITC I_GENE
, O
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
MHC B_GENE
II I_GENE
PE I_GENE
from O
eBiosciences B_LOCATION/B_ORGANIZATION
, O
CA B_LOCATION
) O
or O
Panel B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE/B_PROTEIN[GENE]
antibodies I_MEASURE/I_PROTEIN[GENE]
( O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
CD11b B_GENE
APC I_GENE
, O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
CD45 B_GENE
FITC I_GENE
, O
and O
anti B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
TLR2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PE I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
eBiosciences B_LOCATION/B_ORGANIZATION
, O
CA B_LOCATION
) O
. O

Expression B_GENE/B_MEASURE
of O
these O
surface B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
determined O
by O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
a O
Becton B_PERSON/B_LOCATION
- O
Dickinson B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FACSCaliber I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
four I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
color I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Cytometer I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Thirty B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
thousand I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
events I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O
collected O
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
differentiated O
from O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
based O
on O
the O
levels B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
CD11b B_GENE
and O
CD45 B_GENE
surface I_GENE
expression I_GENE
. O

microglia B_GENE
stain I_GENE
CD11b I_GENE
+ I_GENE
/ O
CD45low B_GENE
and O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stain O
CD11b B_GENE
+ I_GENE
/ O
CD45high B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
[ O
48 B_MEASURE
, O
49 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
analyzed O
using O
FlowJo B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Tree B_MEASURE/B_ORGANIZATION
Star I_MEASURE/I_ORGANIZATION
, O
San B_LOCATION/B_PERSON
Carlos I_LOCATION/I_PERSON
, O
CA B_LOCATION/B_MEASURE
) O
. O

Behavior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Social B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exploratory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
assess O
the O
motivation B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
engage O
in O
social B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exploratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
juvenile I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conspecific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
introduced O
into O
the O
test B_PERSON/B_BIO
subject B_PERSON/I_BIO
' O
s B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
home I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
cage I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
for O
a O
10 B_NUMBER[MEASURE]
- O
min B_TIME[MEASURE]/B_LOCATION
period I_TIME[MEASURE]/I_LOCATION
. O

Behavior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
video B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
taped O
and O
the O
cumulative B_MEASURE/B_LOCATION
amount I_MEASURE/I_LOCATION
of O
time B_TIME[MEASURE]
the O
subject B_PERSON/B_ORGANIZATION
engaged O
in O
social B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
investigation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
was O
determined O
from O
the O
video B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
by O
a O
trained O
observer B_PERSON
who O
was O
blind B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Baseline B_DISEASE
social I_DISEASE
behavior I_DISEASE
was O
measured O
at O
time B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
0 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
for O
all O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Social B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
determined O
as O
the O
amount B_MEASURE
of O
time B_TIME[MEASURE]
that O
the O
experimental B_PERSON
subject I_PERSON
spent O
investigating O
( O
e O
. O
g B_GENE/B_MEASURE
. O
, O
anogenital B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sniffing B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
trailing O
) O
the O
juvenile B_PERSON/B_BIO
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
expressed O
as O
percent B_MEASURE
decrease I_MEASURE
in O
time B_TIME[MEASURE]/B_PERSON
engaged O
in O
social B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
behavior I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
compared O
to O
respective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
baseline I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
measures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

sucrose B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
assess O
sucrose O
preference O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
provided O
two O
solutions O
, O
water O
or O
water O
supplemented O
with O
2 O
% O
sucrose O
, O
in O
50 O
ml O
conical O
tubes O
with O
stoppers O
fitted O
with O
ball O
- O
type O
sipper O
tubes O
. O

Prior O
to O
testing O
conditions O
, O
all O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
acclimated O
to O
the O
two O
bottle O
test O
choice O
. O

All O
mice B_BIO/B_PERSON
drank O
both O
the O
water O
and O
the O
2 O
% O
sucrose O
solution O
, O
but O
preferred O
drinking O
the O
sucrose O
over O
the O
water O
( O
data O
not O
shown O
) O
. O

On O
the O
day O
of O
testing O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
fluid O
and O
food O
deprived O
for O
2 O
h O
prior O
to O
testing O
[ O
50 O
] O
. O

At O
the O
start B_LOCATION/B_TIME[MEASURE]
of O
the O
dark B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
phase I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
photoperiod B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
, O
drinking B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
the O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sucrose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
placed O
in O
the O
home B_LOCATION
cage I_LOCATION
overnight O
( O
15 B_MEASURE
h O
) O
. O

At O
the O
end B_LOCATION/B_DISEASE
of O
each O
testing B_TIME[MEASURE]/B_LOCATION
period B_TIME[MEASURE]/I_LOCATION
the O
fluid B_MEASURE/B_LOCATION
content I_MEASURE/I_LOCATION
of O
the O
conical B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
tubes B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O
measured O
and O
sucrose B_DISEASE/B_MEASURE
preference I_DISEASE/I_MEASURE
was O
determined O
using O
the O
equation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Sucrose B_MEASURE/B_LOCATION
intake I_MEASURE/I_LOCATION
/ O
Total B_MEASURE/B_LOCATION
fluid I_MEASURE/I_LOCATION
intake I_MEASURE/I_LOCATION
( O
water B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O
sucrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
x B_MEASURE/B_LOCATION
100 I_MEASURE/I_LOCATION
[ O
51 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Plasma B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytokine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
were O
measured O
in O
the O
plasma B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
as O
previously O
described O
[ O
52 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

In O
brief O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
euthanized O
by O
CO2 O
asphyxiation O
and O
blood O
was O
collected O
by O
cardiac O
puncture O
into O
EDTA O
coated O
syringes O
. O

samples B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
centrifuged O
( O
6000 B_MEASURE
x O
g B_OTHER/B_MEASURE
for O
15 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
4 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
) O
and O
plasma B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O
collected O
and O
stored O
frozen O
( O
- O
80 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
) O
until O
assaying O
. O

Plasma B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
assayed O
for O
IL B_LOCATION/B_GENE
- O
6 B_NUMBER[MEASURE]
using O
a O
customized O
ELISA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
we O
have O
described O
in O
detail B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
52 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
and O
for O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
using O
a O
commercial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ELISA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kit I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Systems I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Minneapolis B_LOCATION/B_PERSON
, O
MN B_LOCATION
) O
. O

Assays B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sensitive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
8 B_MEASURE
pg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
of O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
and O
1 B_MEASURE
. O
5 B_MEASURE
pg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
of O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
, O
and O
inter B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
assay B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
less B_MEASURE
than O
10 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Real B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
time I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
PCR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O

Total B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
isolated O
from O
brain B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
using O
the O
Tri B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reagent I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
protocol I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
sigma B_GENE
, O
St B_LOCATION/B_PERSON
. O
Louis B_PERSON
, O
Mo B_LOCATION/B_MEASURE
) O
. O

RNA B_PERSON/B_GENE
samples I_PERSON/I_GENE
were O
subjected O
to O
a O
DNase B_GENE/B_MEASURE
I O
digestion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
then O
reverse O
transcribed O
to O
cDNA B_GENE
using O
a O
RT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RETROscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Ambion B_PERSON/B_TIME[MEASURE]
, O
Austin B_LOCATION/B_PERSON
, O
TX B_MEASURE/B_LOCATION
) O
. O

Quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
real I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
using O
the O
Applied B_ORGANIZATION/B_TIME[MEASURE]
Biosystems B_ORGANIZATION/I_TIME[MEASURE]
( O
Foster B_PERSON/B_LOCATION
, O
CA B_LOCATION/B_MEASURE
) O
Assay B_LOCATION/B_PERSON
- O
on O
demand B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Gene I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
protocol I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
previously O
described O
[ O
13 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

In O
brief B_MEASURE
, O
cDNA B_GENE
was O
amplified O
by O
real B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
time I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
where O
a O
target B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE/B_PROTEIN[GENE]
beta I_MEASURE/I_PROTEIN[GENE]
, O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
, O
MHC B_GENE
II I_GENE
, O
TLR2 B_GENE
, O
or O
IDO B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
a O
reference B_GENE
cDNA I_GENE
( O
glyceraldehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
3 B_NUMBER[MEASURE]
- O
phosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
dehydrogenase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
) O
were O
amplified O
simultaneously O
using O
an O
oligonucleotide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
probe I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
a O
5 B_NUMBER[MEASURE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reporter I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 B_MEASURE/B_LOCATION
- O
fam B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
a O
3 B_MEASURE
' O
quencher B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NFQ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
. O

Fluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
determined O
on O
an O
ABI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PRISM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
7300 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
sequence B_MEASURE
detection I_MEASURE
system I_MEASURE
( O
Applied B_LOCATION/B_ORGANIZATION
Biosystems I_LOCATION/I_ORGANIZATION
, O
CA B_LOCATION/B_MEASURE
) O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
analyzed O
using O
the O
comparative B_MEASURE
threshold I_MEASURE
cycle I_MEASURE
( O
CT B_LOCATION
) O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
expressed O
as O
fold B_MEASURE
difference I_MEASURE
. O

Experimental B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocols I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
the O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
prepared O
in O
dimethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfoxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
and O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
were O
washed O
and O
replenished O
with O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediumsupplemented O
with O
0 B_MEASURE
, O
25 B_MEASURE
, O
50 B_MEASURE
, O
100 B_MEASURE
, O
200 B_MEASURE
, O
or O
400 B_MEASURE
Mu I_MEASURE
g I_MEASURE
/ O
ml B_MEASURE
minocycline I_MEASURE
. O

After O
30 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
min I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
LPS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
10 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
was O
added O
to O
the O
culture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

supernatants B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPORT[ENT]
were O
collected O
4 B_NUMBER[MEASURE]
h O
later O
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_NUMBER[MEASURE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
concentrations I_MEASURE
were O
determined O
by O
ELISA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Total B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
proteins I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
determined O
from O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
culture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
homogenates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
by O
the O
Bio B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
Rad B_PERSON/B_LOCATION
DC I_PERSON/I_LOCATION
protein I_PERSON/I_LOCATION
assay I_PERSON/I_LOCATION
according O
to O
the O
manufacturer B_PERSON/B_ORGANIZATION
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
instructions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
Bio B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
Rad B_ORGANIZATION/B_PERSON
Lboratories B_ORGANIZATION/I_PERSON
, O
Hercules B_PERSON/B_LOCATION
, O
CA B_LOCATION/B_ORGANIZATION
) O
. O

Each O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
replicated O
a O
minimum B_MEASURE/B_LOCATION
of O
four B_TIME[MEASURE]/B_ENT
times I_TIME[MEASURE]/I_ENT
. O

Cell B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
viability B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
confirmed O
by O
the O
MTS B_ORGANIZATION/B_PERSON
cell I_ORGANIZATION/I_PERSON
proliferation I_ORGANIZATION/I_PERSON
assay I_ORGANIZATION/I_PERSON
according O
to O
the O
manufacturer B_PERSON/B_ORGANIZATION
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
instructions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
Promega B_LOCATION/B_PERSON
, O
Madison B_PERSON/B_LOCATION
, O
WI B_MEASURE/B_LOCATION
) O
. O

For O
all O
mouse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies O
, O
minocycline O
( O
Sigma O
, O
St O
. O
Louis O
, O
Mo O
) O
was O
dissolved O
in O
sterile O
water O
and O
sonicated O
to O
ensure O
complete O
solubilization O
. O

In O
the O
first O
mouse B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
study O
, O
adult O
male O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O
an O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
vehicle O
or O
minocycline O
( O
50 O
mg O
/ O
kg O
) O
for O
three O
consecutive O
days O
. O

On O
the O
3rd O
day O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
also O
injected O
i O
. O
p O
. O
with O
saline O
or O
Escherichia B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coli B_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS O
( O
0 O
. O
33 O
mg O
/ O
kg O
; O
serotype O
0127 O
: O
B8 O
, O
Sigma O
, O
St O
. O
Louis O
, O
Mo O
) O
and O
were O
euthanized O
by O
CO2 O
asphyxiation O
24 O
h O
later O
( O
n O
= O
6 O
) O
. O

The O
LPS O
dosage O
was O
selected O
because O
it O
elicits O
a O
proinflammatory O
cytokine O
response O
in O
the O
brain O
resulting O
in O
mild O
transient O
sickness O
behavior O
in O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
13 O
, O
53 O
] O
. O

macrophage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O
microglial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
isolated O
from O
whole B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
homogenates I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
TLR2 B_GENE
and O
MHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
surface I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
determined O
by O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
minocycline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
injection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regimen I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
dosage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O
selected O
because O
a O
repeated O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
course I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
necessary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
attenuate O
neuroinflammation B_DISEASE
[ O
41 B_MEASURE
- O
43 B_MEASURE
, O
45 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

In O
the O
second O
study O
, O
adult O
male O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O
an O
i O
. O
p O
. O
injection O
with O
vehicle O
or O
minocycline O
for O
three O
consecutive O
days O
. O

On O
the O
third B_TIME[MEASURE]/B_LOCATION
day B_TIME[MEASURE]/I_LOCATION
, O
motivation B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
engage O
in O
social B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
determined O
immediately O
before O
i O
. O
p B_MEASURE/B_LOCATION
. O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
. O
33 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
) O
and O
again O
2 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
, O
8 B_NUMBER[MEASURE]
, O
12 B_MEASURE
, O
and O
24 B_MEASURE
h I_MEASURE
later O
( O
n B_OTHER/B_MEASURE
= O
8 B_MEASURE
) O
. O

Body B_TIME[MEASURE]/B_LOCATION
weight I_TIME[MEASURE]/I_LOCATION
and O
food B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
at O
each O
time B_TIME[MEASURE]/B_LOCATION
point I_TIME[MEASURE]/I_LOCATION
over O
the O
24 B_MEASURE
h O
period B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
a O
related O
, O
but O
separate O
study O
, O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
treated O
with O
minocycline O
and O
LPS O
as O
described O
and O
anhedonia O
was O
assessed O
24 O
- O
39 O
h O
following O
i O
. O
p O
. O
injection O
of O
saline O
or O
LPS O
( O
0 O
. O
33 O
mg O
/ O
kg O
) O
( O
n O
= O
15 O
) O
. O

Body B_TIME[MEASURE]/B_LOCATION
weight I_TIME[MEASURE]/I_LOCATION
, O
food B_DISEASE/B_ORGANISM_FUNCTION
intake I_DISEASE/I_ORGANISM_FUNCTION
, O
water B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
intake B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
and O
sucrose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
intake I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
were O
determined O
over O
the O
testing B_TIME[MEASURE]
period I_TIME[MEASURE]
. O

In O
the O
third O
study O
, O
adult O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
treated O
with O
minocycline O
and O
then O
LPS O
as O
described O
. O

Mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
euthanized O
by O
CO2 O
asphyxiation O
4 O
later O
. O

brains B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
removed O
and O
dissected O
to O
collect O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
brain B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
regions B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Brain B_PERSON
regions I_PERSON
were O
stored O
at O
- O
20 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
in O
RNAlater B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Qiagen B_LOCATION/B_PERSON
, O
CA B_LOCATION/B_MEASURE
) O
. O

Total B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
isolated O
from O
brain B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
assayed O
using O
quantitative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
n B_OTHER/B_MEASURE
= O
8 B_MEASURE
) O
. O

Plasma B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O
also O
collected O
and O
stored O
( O
- O
80 B_MEASURE
degrees I_MEASURE
C I_MEASURE
) O
until O
assaying O
. O

In O
a O
final O
study O
, O
adult O
( O
3 O
- O
4 O
month O
old O
) O
or O
aged O
( O
20 O
- O
22 O
month O
old O
) O
male O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
treated O
with O
minocycline O
and O
LPS O
as O
described O
and O
euthanized O
4 O
h O
later O
. O

brains B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
dissected O
to O
collect O
different B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
brain I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
regions I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
were O
stored O
at O
- O
20 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
in O
RNAlater B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Qiagen B_LOCATION/B_PERSON
, O
CA B_LOCATION/B_MEASURE
) O
. O

Total B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
isolated O
from O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
and O
assayed O
using O
quantitative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
n B_OTHER/B_MEASURE
= O
8 B_MEASURE
) O
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

All O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
analyzed O
using O
Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
SAS B_LOCATION/B_DISEASE
) O
General B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Linear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
procedures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
subjected O
to O
one B_NUMBER[MEASURE]/B_PERSON
, O
two B_NUMBER[MEASURE]/B_PERSON
- O
( O
Mino B_PERSON/B_TIME[MEASURE]
x O
LPS B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Age B_TIME[MEASURE]/B_PERSON
x O
LPS B_TIME[MEASURE]/B_PERSON
, O
Mino B_PERSON/B_TIME[MEASURE]
x O
Age B_TIME[MEASURE]/B_LOCATION
) O
or O
three B_NUMBER[MEASURE]
- O
way B_LOCATION/B_MEASURE
( O
Mino B_PERSON/B_TIME[MEASURE]
x O
LPS B_TIME[MEASURE]/B_LOCATION
x O
Time B_TIME[MEASURE]/B_PERSON
, O
Mino B_PERSON/B_TIME[MEASURE]
x O
LPS B_TIME[MEASURE]/B_LOCATION
x O
Age B_TIME[MEASURE]/B_LOCATION
) O
ANOVA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
determine O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
main I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
interactions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O
main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

When O
appropriate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
means I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
evaluated O
by O
an O
F B_OTHER/B_MEASURE
- O
protected O
t B_OTHER/B_MEASURE
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
using O
the O
least O
- O
Significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
difference I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
SAS B_LOCATION/B_DISEASE
. O

All O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
expressed O
as O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
means O
+/- O
standard B_MEASURE
error I_MEASURE
of O
the O
mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
attenuates O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cytokine B_DISEASE/B_GENE
production I_DISEASE/I_GENE
in O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_LOCATION
microglia I_LOCATION
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibiotic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
has O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
[ O
41 B_MEASURE
- O
43 B_MEASURE
, O
45 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

To O
determine O
the O
degree B_MEASURE/B_LOCATION
to O
which O
minocycline B_DISEASE_ADJECTIVE[DISEASE]
suppresses I_DISEASE_ADJECTIVE[DISEASE]
microglia O
activation B_GENE/B_DISEASE
, O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_MEASURE
microglia I_MEASURE
- O
derived O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lines I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
used O
. O

In O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
were O
treated O
with O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
IL B_LOCATION/B_GENE
- O
6 B_MEASURE/B_ORGANIZATION
production I_MEASURE/I_ORGANIZATION
was O
determined O
4 B_MEASURE
h O
later O
. O

Fig B_BIO/B_GENE
. O

1A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
shows O
that O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE/B_ORGANIZATION
production I_MEASURE/I_ORGANIZATION
in O
a O
dose B_MEASURE/B_LOCATION
dependent I_MEASURE/I_LOCATION
manner I_MEASURE/I_LOCATION
F I_MEASURE/I_LOCATION
( O
5 B_MEASURE
, O
23 B_MEASURE
) O
= O
101 B_MEASURE
, O
P B_OTHER/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

In O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
were O
incubated O
with O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
then O
stimulated O
with O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Minocycline B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE/B_ORGANIZATION
secretion I_MEASURE/I_ORGANIZATION
in O
a O
dose B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Mino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
x O
LPS B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
F B_OTHER/B_LOCATION
( O
4 B_MEASURE
, O
23 B_MEASURE
) O
= O
16 B_MEASURE
. O
87 B_MEASURE
, O
P B_OTHER/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
, O
Fig B_MEASURE/B_GENE
. O
1B B_NUMBER[MEASURE]/B_LOCATION
) O
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
had O
a O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
inflammatory B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
stimulated O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
secretion I_MEASURE
( O
Fig B_PROTEIN[GENE]/B_MEASURE
. O
1C B_MEASURE/B_PROTEIN[GENE]
) O
. O

In O
a O
third B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suppressed O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
MHC B_GENE
II I_GENE
, O
TLR2 B_GENE
, O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE/B_PROTEIN[GENE]
beta I_MEASURE/I_PROTEIN[GENE]
, O
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
mRNA I_MEASURE
levels I_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
, O
for O
each O
, O
Fig B_MEASURE/B_GENE
. O
1D B_NUMBER[MEASURE]/B_LOCATION
) O
. O

The O
MTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
verified O
that O
neither O
cell B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
survival I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
affected O
by O
the O
experimental B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

LPS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
TLR2 B_DISEASE_ADJECTIVE[DISEASE]
surface I_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
on O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
reduced O
by O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Because O
minocycline O
attenuated O
LPS O
- O
induced O
cytokine O
secretion O
and O
TLR2 O
mRNA O
expression O
in O
BV O
- O
2 O
cells O
we O
next O
sought O
to O
determine O
if O
minocycline O
suppresses O
markers O
of O
microglial O
activation O
in O
the O
brain O
of O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
injected O
i O
. O
p O
. O
with O
vehicle O
or O
minocycline O
for O
3 O
consecutive O
days O
then O
challenged O
with O
saline O
or O
LPS O
i O
. O
p O
. O

markers B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
activation B_GENE/B_DISEASE
, O
TLR2 B_GENE
and O
MHC B_GENE
II I_GENE
, O
were O
determined O
on O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
collected O
24 B_MEASURE
h O
later O
. O

The O
representative B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
bivariate O
density B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
Fig B_LOCATION/B_GENE
. O

2A B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
shows O
that O
there O
were O
two B_MEASURE/B_LOCATION
populations I_MEASURE/I_LOCATION
of O
CD11b B_GENE
/ O
CD45 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
positive B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
that O
more B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
stained O
CD11b B_GENE
+ I_GENE
/ O
CD45low B_GENE/B_DISEASE
( O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
than O
CD11b B_GENE/B_DISEASE
+ I_GENE/I_DISEASE
/ O
CD45high B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
CNS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

ANOVA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
revealed O
that O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increased O
TLR2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
20 B_MEASURE
) O
= O
17 B_MEASURE
. O
6 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
004 B_MEASURE
, O
Fig B_GENE
. O
2B B_PROTEIN[GENE]
& O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
but O
this O
induction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
abrogated O
by O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
tendency B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Mino B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x O
LPS B_DISEASE/B_GENE
interaction B_DISEASE/I_GENE
, O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
20 B_MEASURE
) O
= O
2 B_MEASURE
. O
66 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
10 B_MEASURE
, O
Fig B_MEASURE/B_GENE
. O
2C B_PROTEIN[GENE]/B_DISEASE
& O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

It O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
note O
that O
because O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
differ O
in O
their O
TLR2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
these O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
grouped O
together O
as O
the O
Control B_MEASURE/B_ORGANIZATION
group I_MEASURE/I_ORGANIZATION
( O
Fig B_PROTEIN[GENE]/B_DISEASE
. O
2B B_MEASURE/B_PROTEIN[GENE]
& O
C B_PROTEIN[GENE]
) O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
neither O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nor O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
significant B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
main I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
MHC B_DISEASE_ADJECTIVE[DISEASE]
class I_DISEASE_ADJECTIVE[DISEASE]
II I_DISEASE_ADJECTIVE[DISEASE]
surface I_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
on O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attenuated O
LPS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
TLR2 B_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
on O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
facilitates O
the O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
sickness B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CNS B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
macrophages B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
produce O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_DISEASE_ADJECTIVE[DISEASE]
and O
secondary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
messengers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
modulate O
behavioral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
we O
next O
investigated O
if O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O
the O
sickness B_DISEASE
response I_DISEASE
associated O
with O
peripheral B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LPS I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
this O
experiment O
, O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
treated O
with O
minocycline O
and O
LPS O
as O
described O
. O

Social B_DISEASE/B_PERSON
exploratory I_DISEASE/I_PERSON
behavior I_DISEASE/I_PERSON
was O
measured O
before O
i O
. O
p B_MEASURE/B_LOCATION
. O

LPS B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
again O
2 B_SEQUENCE[MEASURE]
, O
4 B_SEQUENCE[MEASURE]
, O
8 B_MEASURE
, O
and O
24 B_MEASURE
h I_MEASURE
later O
. O

Fig B_BIO/B_GENE
. O

3A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
shows O
that O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
caused O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
social B_DISEASE
exploratory I_DISEASE
behavior I_DISEASE
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
57 B_MEASURE
) O
= O
218 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
that O
was O
time B_DISEASE_ADJECTIVE[DISEASE]
dependent I_DISEASE_ADJECTIVE[DISEASE]
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
4 B_NUMBER[MEASURE]
, O
57 B_MEASURE
) O
= O
66 B_MEASURE
. O
5 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Moreover O
, O
the O
LPS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
reduction B_DISEASE_ADJECTIVE[DISEASE]
in O
social B_DISEASE/B_GENE
exploration I_DISEASE/I_GENE
was O
attenuated O
by O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Mino B_PERSON/B_LOCATION
x O
LPS B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
F B_OTHER/B_PROTEIN[GENE]
( O
1 B_MEASURE
, O
57 B_MEASURE
) O
= O
7 B_MEASURE
. O
5 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
007 B_MEASURE
) O
. O

For O
example O
, O
at O
8 O
h O
post O
LPS O
, O
social O
exploration O
was O
reduced O
by O
35 O
% O
in O
minocycline O
pretreated O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
LPS O
compared O
to O
a O
67 O
% O
reduction O
in O
vehicle O
pretreated O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
LPS O
( O
P O
< O
0 O
. O
001 O
) O
. O

While O
minocycline O
administration O
alone O
reduced O
food O
intake O
and O
body O
weight O
in O
control O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P O
< O
0 O
. O
05 O
, O
for O
each O
) O
, O
it O
also O
protected O
against O
LPS O
- O
associated O
anorexia O
( O
Mino O
x O
LPS O
interaction O
, O
F O
( O
1 O
, O
60 O
) O
= O
70 O
. O
0 O
, O
P O
< O
0 O
. O
001 O
, O
Fig O
. O
3B O
) O
and O
weight O
loss O
( O
Mino O
x O
LPS O
interaction O
, O
F O
( O
1 O
, O
60 O
) O
= O
29 O
. O
7 O
, O
P O
< O
0 O
. O
001 O
, O
Fig O
. O
3C O
) O
. O

Because O
sickness B_DISEASE
can O
also O
be O
associated O
with O
longer B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lasting I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
motivation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O
38 B_MEASURE
] I_MEASURE
, O
we O
next O
sought O
to O
determine O
if O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
abrogated O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
anhedonia B_DISEASE
[ O
54 B_MEASURE
, O
55 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

In O
this O
experiment O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
subjected O
to O
the O
same O
minocycline O
injection O
regimen O
and O
LPS O
challenge O
as O
above O
and O
sucrose O
preference O
was O
assessed O
24 O
- O
39 O
h O
post O
LPS O
injection O
. O

By O
24 O
h O
post O
LPS O
injection O
, O
food O
and O
water O
intake O
returned O
to O
baseline O
and O
LPS O
treated O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O
exhibited O
a O
marked O
reduction O
in O
sucrose O
preference O
from O
24 O
- O
39 O
h O
( O
F O
( O
1 O
, O
59 O
) O
= O
14 O
. O
3 O
, O
P O
< O
0 O
. O
003 O
) O
. O

Moreover O
, O
this O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
sucrose B_DISEASE/B_GENE
preference I_DISEASE/I_GENE
was O
prevented O
by O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Mino B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
F B_OTHER/B_PROTEIN[GENE]
( O
1 B_MEASURE
, O
59 B_MEASURE
) O
= O
9 B_MEASURE
. O
9 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
004 B_MEASURE
, O
Fig B_MEASURE/B_GENE
. O
4 B_NUMBER[MEASURE]
) O
. O

For O
example O
, O
minocycline O
pretreated O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injected O
with O
LPS O
maintained O
the O
same O
strong O
preference O
for O
sucrose O
as O
saline O
and O
minocycline O
controls O
( O
i O
. O
e O
. O
, O
approximately O
85 O
% O
preference O
) O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
interpreted O
to O
indicate O
that O
minocycline B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocks I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anhedonia O
associated O
with O
peripheral B_DISEASE
LPS I_DISEASE
challenge I_DISEASE
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reduces O
LPS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
neuroinflammation B_DISEASE
. O

Pro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
are O
partially O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
behavioral B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
of O
sickness B_DISEASE/B_LOCATION
( O
e B_PROTEIN[GENE]/B_DISEASE
. O
g B_GENE/B_MEASURE
. O
, O
anorexia B_DISEASE
, O
social B_DISEASE
withdrawal I_DISEASE
, O
and O
anhedonia B_DISEASE
) O
[ O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Therefore O
, O
we O
investigated O
the O
degree B_MEASURE/B_LOCATION
to O
which O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O
neuroinflammation B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE/B_PROTEIN[GENE]
beta I_MEASURE/I_PROTEIN[GENE]
, O
IL B_LOCATION/B_GENE
- O
6 B_MEASURE
, O
and O
IDO B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
after O
peripheral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
this O
experiment O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
subjected O
to O
the O
minocycline O
injection O
regimen O
and O
LPS O
challenge O
as O
above O
and O
cytokine O
mRNA O
levels O
were O
determined O
in O
the O
cortex O
and O
hippocampus O
4 O
h O
after O
LPS O
injection O
. O

In O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreated O
with O
vehicle O
, O
LPS O
markedly O
increased O
IL O
- O
1 O
beta O
mRNA O
levels O
in O
the O
hippocampus O
( O
F O
( O
1 O
, O
31 O
) O
= O
62 O
, O
P O
< O
0 O
. O
0001 O
) O
and O
cortex O
( O
F O
( O
1 O
, O
31 O
) O
= O
17 O
. O
25 O
, O
P O
< O
0 O
. O
0003 O
) O
. O

The O
LPS O
- O
induced O
IL O
- O
1 O
beta O
mRNA O
expression O
was O
reduced O
in O
both O
brain O
regions O
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O
minocycline O
prior O
to O
LPS O
injection O
: O
( O
hippocampus O
, O
F O
( O
1 O
, O
31 O
) O
= O
9 O
. O
63 O
, O
P O
< O
0 O
. O
01 O
) O
and O
cortex O
, O
F O
( O
1 O
, O
31 O
) O
= O
7 O
. O
23 O
, O
P O
= O
0 O
. O
08 O
, O
Fig O
. O

5A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
caused O
a O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
mRNA I_MEASURE
levels I_MEASURE
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
31 B_MEASURE
) O
= O
37 B_MEASURE
. O
2 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
and O
cortex B_BODY_PART_OR_ORGAN_COMPONENT
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
31 B_MEASURE
) O
= O
22 B_MEASURE
. O
5 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
, O
but O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
only O
significantly O
attenuated O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
mRNA I_MEASURE
levels I_MEASURE
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
31 B_MEASURE
) O
= O
10 B_MEASURE
. O
27 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
004 B_MEASURE
, O
Fig B_MEASURE
. O
5B B_NUMBER[MEASURE]/B_LOCATION
) O
. O

IDO B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mRNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
determined O
from O
the O
same B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
pool I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Fig B_BIO/B_GENE
. O

6D B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
shows O
that O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increased O
IDO B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
31 B_MEASURE
) O
= O
11 B_MEASURE
. O
69 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
002 B_MEASURE
) O
and O
cortex B_BODY_PART_OR_ORGAN_COMPONENT
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
31 B_MEASURE
) O
= O
5 B_MEASURE
. O
26 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
03 B_MEASURE
) O
. O

This O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
IDO B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
attenuated O
by O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
31 B_MEASURE
) O
= O
11 B_MEASURE
. O
69 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
002 B_MEASURE
) O
and O
cortex B_BODY_PART_OR_ORGAN_COMPONENT
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
31 B_MEASURE
) O
= O
5 B_MEASURE
. O
26 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
03 B_MEASURE
) O
. O

It O
is O
important O
to O
note O
that O
IDO O
mRNA O
was O
undetected O
in O
saline O
treated O
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Therefore O
, O
the O
fold O
IDO O
change O
was O
relative O
to O
the O
IDO O
mRNA O
levels O
in O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O
minocycline O
prior O
to O
LPS O
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
, O
but O
not O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
, O
in O
the O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
. O

Because O
cytokine B_DISEASE/B_GENE
signals I_DISEASE/I_GENE
can O
be O
relayed O
from O
the O
periphery B_BODY_PART_OR_ORGAN_COMPONENT
to O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O
humoral B_DISEASE/B_GENE
pathways B_DISEASE/I_GENE
[ O
56 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
, O
plasma B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
were O
determined O
4 B_MEASURE/B_LOCATION
h O
post B_MEASURE
LPS I_MEASURE
injection I_MEASURE
. O

As O
expected O
, O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
caused O
a O
marked O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
plasma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
1 B_MEASURE
beta I_MEASURE
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
36 B_MEASURE
) O
= O
52 B_MEASURE
. O
5 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
levels I_MEASURE
( O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
36 B_MEASURE
) O
34 B_MEASURE
. O
01 B_MEASURE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
levels I_MEASURE
in O
the O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
( O
F B_OTHER/B_PROTEIN[GENE]
( O
1 B_MEASURE
, O
36 B_MEASURE/B_LOCATION
) O
6 B_MEASURE
. O
68 B_MEASURE
, O
P B_OTHER/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
but O
had O
no O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
main I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
levels I_MEASURE
( O
Fig B_MEASURE
. O
6 B_NUMBER[MEASURE]
) O
. O

Minocycline O
attenuates O
LPS O
- O
induced O
exaggerated O
neuroinflammation O
in O
aged O
mice B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

aged O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
22 O
- O
24 O
m O
) O
have O
an O
exaggerated O
neuroinflammatory O
response O
to O
LPS O
injection O
[ O
10 O
, O
13 O
, O
14 O
] O
. O

Therefore O
, O
we O
next O
sought O
to O
determine O
if O
the O
heightened O
inflammatory O
response O
in O
the O
brain O
of O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
by O
minocycline O
. O

In O
this O
experiment O
, O
adult O
and O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
subjected O
to O
the O
minocycline O
injection O
regimen O
and O
LPS O
challenge O
as O
above O
. O

As O
we O
have O
reported O
previously O
, O
MHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
increased O
by O
age B_DISEASE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
03 B_MEASURE
, O
Fig B_MEASURE
. O
7A B_MEASURE
) O
[ O
13 B_MEASURE
, O
14 B_MEASURE
] I_MEASURE
, O
but O
MHC B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
unaffected B_DISEASE_ADJECTIVE[DISEASE]
by O
either O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
not O
shown O
) O
. O

consistent B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
with O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O
in O
Fig B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

2 B_MEASURE/B_PERSON
, O
ANOVA B_NUMBER[MEASURE]/B_LOCATION
revealed O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
main B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
TLR2 B_GENE
mRNA I_GENE
expression I_GENE
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
( O
F B_OTHER/B_LOCATION
( O
1 B_MEASURE
, O
63 B_NUMBER[MEASURE]
) O
= O
85 B_MEASURE
. O
5 B_MEASURE
, O
P B_OTHER/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Moreover O
, O
LPS O
caused O
a O
greater O
increase O
in O
TLR2 O
mRNA O
in O
the O
hippocampus O
of O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
adults O
( O
LPS O
x O
Age O
interaction O
, O
F O
( O
1 O
, O
63 O
) O
= O
12 O
. O
70 O
, O
P O
< O
0 O
. O
01 O
) O
. O

Furthermore O
, O
minocycline O
pretreatment O
attenuated O
LPS O
- O
induced O
TLR2 O
mRNA O
levels O
in O
both O
adult O
and O
aged O
mice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
Mino O
x O
LPS O
interaction O
, O
F O
( O
1 O
, O
63 O
) O
= O
9 O
. O
02 O
, O
P O
< O
0 O
. O
004 O
) O
. O

parallel O
to O
the O
results O
for O
TLR2 O
, O
LPS O
caused O
a O
greater O
increase O
in O
IL O
- O
1 O
beta O
and O
IDO O
mRNA O
levels O
in O
hippocampus O
of O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
adults O
( O
Age O
x O
LPS O
, O
F O
( O
1 O
, O
60 O
) O
= O
8 O
. O
64 O
, O
P O
< O
0 O
. O
01 O
for O
IL O
- O
1 O
beta O
and O
F O
( O
1 O
, O
60 O
) O
= O
4 O
. O
0 O
, O
P O
< O
0 O
. O
05 O
for O
IDO O
) O
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
attenuated O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
mRNA B_DISEASE_ADJECTIVE[DISEASE]
levels I_DISEASE_ADJECTIVE[DISEASE]
of O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
( O
Mino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
x O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
60 B_MEASURE
) O
= O
8 B_MEASURE
. O
76 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
, O
Fig B_MEASURE/B_GENE
. O
7C B_MEASURE/B_PROTEIN[GENE]
) O
and O
IDO B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
Mino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
x O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
F B_PROTEIN[GENE]/B_DISEASE
( O
1 B_NUMBER[MEASURE]
, O
60 B_MEASURE
) O
= O
9 B_MEASURE
. O
7 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
003 B_MEASURE
, O
Fig B_MEASURE/B_GENE
. O
7D B_MEASURE/B_PERSON
) O
. O

While O
LPS O
induced O
higher O
IL O
- O
6 O
mRNA O
levels O
in O
the O
hippocampus O
of O
both O
adult O
and O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
F O
( O
1 O
, O
59 O
) O
= O
44 O
. O
5 O
, O
P O
< O
0 O
. O
001 O
) O
, O
there O
was O
not O
an O
Age O
x O
LPS O
interaction O
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O
the O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
hippocampal B_GENE
IL I_GENE
- O
6 B_MEASURE
mRNA I_MEASURE
( O
Mino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
x O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
F B_OTHER/B_PROTEIN[GENE]
( O
1 B_MEASURE
, O
59 B_MEASURE
) O
= O
5 B_MEASURE
. O
4 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
02 B_MEASURE
, O
Fig B_MEASURE
. O
7E B_MEASURE
) O
. O

taken O
together O
these O
data O
indicate O
that O
minocycline O
pretreatment O
was O
effective O
in O
attenuating O
the O
exaggerated O
neuroinflammation O
in O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
elderly B_PERSON/B_DISEASE
, O
systemic B_DISEASE
infection I_DISEASE
is O
associated O
with O
an O
increased O
frequency B_MEASURE/B_LOCATION
of O
behavioral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cognitive B_DISEASE
complications I_DISEASE
[ I_DISEASE
57 I_DISEASE
, O
58 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

We O
have O
reported O
that O
stimulation O
of O
the O
peripheral O
immune O
system O
in O
older O
( O
20 O
- O
24 O
m O
) O
BALB O
/ O
c O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O
exaggerated O
neuroinflammation O
that O
is O
paralleled O
by O
prolonged O
sickness O
[ O
13 O
] O
, O
impaired O
working O
memory O
[ O
10 O
] O
, O
and O
depressive O
- O
like O
behaviors O
[ O
15 O
] O
. O

Therefore O
, O
it O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
understand O
the O
mechanisms B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
can O
modulate O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mediated O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Here O
we O
show O
that O
minocycline O
treatment O
reduced O
LPS O
- O
induced O
TLR2 O
expression O
in O
BV O
- O
2 O
cells O
and O
on O
microglia O
isolated O
from O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
, O
we O
demonstrate O
that O
minocycline O
was O
effective O
in O
facilitating O
the O
recovery O
from O
LPS O
- O
induced O
sickness O
and O
preventing O
anhedonia O
in O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Furthermore O
, O
we O
show O
that O
minocycline O
attenuated O
LPS O
- O
induced O
neuroinflammation O
in O
adults O
and O
normalized O
the O
exaggerated O
neuroinflammation O
in O
aged O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
using O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
support O
the O
notion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
attenuates O
microglial B_DISEASE
activation I_DISEASE
and O
limits O
production B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediators I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
instance B_PERSON/B_DISEASE
, O
minocycline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pretreatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cultures I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
stimulated O
cytokine B_DISEASE_ADJECTIVE[DISEASE]
production I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
dose B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
dependent I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
manner I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Fig B_PROTEIN[GENE]/B_LOCATION
. O
1A B_NUMBER[MEASURE]
) O
. O

In O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_LOCATION
cells I_LOCATION
, O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O
attenuated O
mRNA B_GENE
expression I_GENE
of O
inflammatory B_GENE
genes I_GENE
including O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
, O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
, O
MHC B_GENE
II I_GENE
, O
and O
TLR2 B_GENE
( O
Fig B_MEASURE/B_PROTEIN[GENE]
. O
1D B_NUMBER[MEASURE]/B_LOCATION
) O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
BV B_PROTEIN[GENE]/B_LOCATION
- O
2 B_MEASURE/B_PERSON
cells I_MEASURE/I_PERSON
[ O
44 B_MEASURE
, O
59 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Based O
on O
these O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
next O
investigated O
if O
microglial B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
could O
be O
attenuated O
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Because O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increases O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cytokine B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
production B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
we O
expected O
that O
MHC B_DISEASE
II I_DISEASE
expression I_DISEASE
would O
also O
be O
increased O
. O

contrary B_PERSON
to O
our O
predictions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
neither O
MHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Fig B_MEASURE/B_LOCATION
. O
7 B_NUMBER[MEASURE]
) O
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nor O
MHC B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
surface I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
expression I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
CD11b B_GENE
+ I_GENE
/ O
CD45low B_MEASURE/B_GENE
) O
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
were O
increased O
by O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
an O
EAE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
model I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduced O
microglial B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
MHC B_GENE
II I_GENE
[ O
45 B_MEASURE
] I_MEASURE
, O
but O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
key I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
that O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
EAE B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathology I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requires O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presentation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
MHC B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
60 B_MEASURE
] I_MEASURE
. O

It O
is O
postulated O
that O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
states I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
depend O
on O
the O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inflammatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stimulus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
61 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

Thus O
, O
in O
situations B_LOCATION
of O
transient B_DISEASE
peripheral I_DISEASE
innate I_DISEASE
immune I_DISEASE
stimulation I_DISEASE
, O
markers B_GENE/B_DISEASE
in O
the O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
such I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
as O
Toll B_GENE
- O
Like B_GENE/B_DISEASE
receptors I_GENE/I_DISEASE
[ O
6 B_GENE
] I_GENE
may O
be O
indicative B_DISEASE/B_PERSON
of O
microglia B_DISEASE
activation I_DISEASE
. O

In O
support B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
premise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O
that O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increases O
TLR2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
CD11b B_GENE
+ I_GENE
/ O
CD45low B_MEASURE/B_GENE
) O
, O
which O
is O
inhibited O
by O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Fig B_MEASURE/B_PROTEIN[GENE]
. O
2 B_NUMBER[MEASURE]
) O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showing O
that O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O
peripheral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
LPS B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
challenge B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
increases O
TLR2 B_GENE
mRNA I_GENE
in O
the O
brain B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
[ I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
6 I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
14 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

taken O
together O
our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
interpreted O
to O
suggest O
that O
minocycline B_DISEASE/B_GENE
attenuates I_DISEASE/I_GENE
pathways I_DISEASE/I_GENE
associated O
with O
microglia B_DISEASE/B_GENE
activation I_DISEASE/I_GENE
following O
peripheral B_DISEASE
LPS I_DISEASE
challenge I_DISEASE
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
the O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
that O
reduction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
neuroinflammation B_DISEASE/B_GENE
by O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
facilitated B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
sickness B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
akin B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
to O
our O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
oxidant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
alpha B_PROTEIN[GENE]
- O
tocopherol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
52 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
an O
NFKB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decoy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
62 B_NUMBER[MEASURE]/B_LOCATION
] I_NUMBER[MEASURE]/I_LOCATION
. O

Consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
our O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
52 B_MEASURE
, O
53 B_MEASURE
, O
62 B_MEASURE
, O
63 B_MEASURE
] I_MEASURE
, O
reductions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
neuroinflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fig B_MEASURE/B_GENE
. O
5 B_NUMBER[MEASURE]
) O
did O
not O
prevent O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
sickness B_DISEASE
response I_DISEASE
( O
2 B_NUMBER[MEASURE]
- O
4 B_MEASURE
h O
) O
, O
but O
rather O
facilitated O
the O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
sickness B_DISEASE
( O
8 B_MEASURE
- O
24 B_MEASURE
h I_MEASURE
) O
( O
Fig B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
3A B_MEASURE
) O
. O

Recovery B_TIME[MEASURE]/B_DISEASE
may O
be O
a O
critical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
issue I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
because O
brain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cytokines I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
corresponding B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
physiological B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
beneficial B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
host B_PERSON/B_SPORT[ENT]
[ I_PERSON/I_SPORT[ENT]
1 I_PERSON/I_SPORT[ENT]
] I_PERSON/I_SPORT[ENT]
. O

The O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
maladaptive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurs O
when O
the O
normally O
transient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neuroinflammatory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
response I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
amplified O
or O
protracted O
[ O
64 B_DISEASE_ADJECTIVE[DISEASE]
] I_DISEASE_ADJECTIVE[DISEASE]
. O

Therefore O
pharmacological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
that O
attenuate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuroinflammatory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
do O
not O
completely O
inhibit O
them O
, O
may O
be O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
preventing O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
more O
severe B_DISEASE_ADJECTIVE[DISEASE]
and O
long O
- O
lasting B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
cognitive B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
behavioral B_DISEASE
complications I_DISEASE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
sucrose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
support O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
limiting O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
to O
neuroinflammation B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O
the O
duration B_MEASURE
of O
behavioral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O
not O
inhibit O
cytokine B_DISEASE/B_ORGANISM_FUNCTION
expression I_DISEASE/I_ORGANISM_FUNCTION
( O
Fig B_GENE
. O
5 B_NUMBER[MEASURE]
) O
or O
the O
induction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sickness B_DISEASE/B_GENE
( O
Fig B_PROTEIN[GENE]/B_LOCATION
. O
3A B_MEASURE
) O
, O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
completely O
reversed O
the O
reduction B_DISEASE_ADJECTIVE[DISEASE]
in O
sucrose B_DISEASE
preference I_DISEASE
( O
i O
. O
e O
. O
, O
anhedonia B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
associated O
with O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
Fig B_GENE
. O
4 B_MEASURE
) O
. O

It O
is O
also O
important B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
to O
mention O
that O
while O
LPS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
sickness B_DISEASE
and O
anhedonia B_DISEASE_ADJECTIVE[DISEASE]
are O
interrelated B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
these O
behaviors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
be O
differentiated O
from O
one B_NUMBER[MEASURE]/B_LOCATION
another O
. O

For O
instance B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reduced O
social B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exploration B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
evident B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
- O
24 B_MEASURE
h O
post B_TIME[MEASURE]/B_LOCATION
injection I_TIME[MEASURE]/I_LOCATION
( O
Fig B_GENE
. O
3A B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
, O
but O
only O
decreased O
sucrose B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
exhibited O
24 B_MEASURE
to O
39 B_MEASURE
h O
later O
( O
Fig B_GENE
. O
4 B_NUMBER[MEASURE]
) O
. O

This O
separation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
behaviors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
investigating O
sickness B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
longer O
- O
lasting O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
motivation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O
15 B_MEASURE
, O
65 B_MEASURE
, O
66 B_MEASURE
] I_MEASURE
. O

IDO B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
TRP B_DISEASE
metabolism I_DISEASE
represents O
a O
potential B_LOCATION/B_MEASURE
connection I_LOCATION/I_MEASURE
between O
activation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
CNS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
innate B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
immune B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
longer O
lasting B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavioral I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

IDO B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
TRP B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
may O
affect O
behavior B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
impacting O
both O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathways I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
39 B_MEASURE/B_PERSON
] B_MEASURE/I_PERSON
. O

We O
have O
reported O
that O
IDO O
induction O
and O
activity O
is O
amplified O
in O
the O
brain O
of O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
is O
associated O
with O
prolonged O
depressive O
- O
like O
behavior O
[ O
15 O
] O
. O

Here O
we O
show O
that O
IDO O
mRNA O
induction O
is O
blocked O
by O
minocycline O
in O
the O
brain O
of O
both O
adult O
and O
aged O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Figs O
. O
5 O
& O
7 O
) O
. O

These O
data O
are O
consistent O
with O
a O
recent O
report O
showing O
a O
causal O
relationship O
between O
IDO O
activity O
and O
acute O
depressive O
effects O
in O
adult O
CD O
- O
1 O
mice B_BIO/B_PERSON
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
O B_OTHER/B_LOCATION
' O
connor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
et B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
al B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O
report O
that O
both O
1 B_MEASURE
- O
methyl B_LOCATION/B_PROTEIN[GENE]
tryptophan B_LOCATION/I_PROTEIN[GENE]
( O
a O
competitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
IDO B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O
IDO B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
prevented O
depressive B_DISEASE
- O
like B_DISEASE
immobility I_DISEASE
in O
the O
tail B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suspension I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
forced B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
swimming B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
66 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Thus O
, O
in O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
minocycline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blockade I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
IDO B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induction I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
explain O
the O
abrogation B_DISEASE_ADJECTIVE[DISEASE]
of O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
anhedonia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Another O
interesting O
finding O
was O
that O
while O
minocycline O
pretreatment O
in O
adult O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O
LPS O
- O
induced O
brain O
IL O
- O
1 O
beta O
at O
4 O
h O
( O
Fig O
. O
5 O
) O
, O
it O
had O
no O
effect O
on O
plasma O
IL O
- O
1 O
beta O
levels O
( O
Fig O
. O
6 O
) O
. O

Because O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
signals I_MEASURE
can O
be O
relayed O
from O
the O
periphery B_BODY_PART_OR_ORGAN_COMPONENT
to O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O
humoral B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
5 B_DISEASE/B_SPECIES[BIO]
] B_DISEASE/I_SPECIES[BIO]
, O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
related O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
readily O
crosses O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
barrier I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
to O
elicit O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE/B_GENE
effect I_DISEASE/I_GENE
[ O
41 B_MEASURE
- O
43 B_MEASURE
] I_MEASURE
. O

With O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
, O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O
both O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
4 B_MEASURE
h O
post B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LPS I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Because O
circulating O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
levels I_MEASURE
can O
be O
increased O
by O
CNS B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mediated O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
including O
activation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
the O
hypothalamus B_BODY_PART_OR_ORGAN_COMPONENT
- O
pituitary B_BODY_PART_OR_ORGAN_COMPONENT
- O
adrenal B_BODY_PART_OR_ORGAN_COMPONENT
( O
HPA B_LOCATION/B_ORGANIZATION
) O
axis B_LOCATION/B_DISEASE
[ O
67 B_MEASURE
] I_MEASURE
and O
the O
sympathetic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O
68 B_MEASURE
] I_MEASURE
, O
the O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
6 B_NUMBER[MEASURE]
by O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O
reflect O
the O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflammation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
4 B_MEASURE
h O
( O
Fig B_MEASURE
. O
5 B_NUMBER[MEASURE]
) O
. O

In O
support B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
notion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
and O
others B_PERSON/B_BIO
have O
reported O
that O
i O
. O
c O
. O
v B_PROTEIN[GENE]/B_MEASURE
. O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_PROTEIN[GENE]/B_MEASURE
beta I_PROTEIN[GENE]/I_MEASURE
increase I_PROTEIN[GENE]/I_MEASURE
plasma I_PROTEIN[GENE]/I_MEASURE
IL I_PROTEIN[GENE]/I_MEASURE
- O
6 B_MEASURE
levels I_MEASURE
, O
but O
not O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
levels I_MEASURE
[ O
14 B_MEASURE
, O
68 B_MEASURE
, O
69 B_MEASURE
] I_MEASURE
. O

The O
final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
critical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
effective B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
attenuating O
neuroinflammation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independent B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
age B_DISEASE/B_GENE
. O

consistent O
with O
other O
aging O
and O
neuroinflammation O
studies O
, O
our O
data O
show O
that O
LPS O
caused O
exaggerated O
neuroinflammation O
in O
aged O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
adults O
[ O
10 O
, O
13 O
- O
15 O
] O
. O

It O
is O
important O
to O
mention O
that O
while O
there O
was O
an O
age O
- O
related O
difference O
in O
MHC O
II O
expression O
in O
the O
hippocampus O
of O
saline O
treated O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fig O
. O
7A O
) O
there O
was O
not O
an O
age O
- O
related O
difference O
in O
IL O
- O
1 O
beta O
and O
IL O
- O
6 O
mRNA O
levels O
. O

These O
data O
differ O
from O
a O
previous O
report O
using O
BALB O
/ O
c O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showing O
an O
increase O
in O
IL O
- O
6 O
in O
older O
mice B_BIO/B_PERSON
[ O
70 O
] O
. O

This O
may O
be O
because O
the O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
in O
the O
present O
study O
were O
approximately O
4 O
months O
younger O
than O
the O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
previously O
. O

Nonetheless O
, O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
can O
be O
primed O
or O
reactive O
with O
increased O
MHC B_DISEASE_ADJECTIVE[DISEASE]
II I_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
do O
not O
necessarily O
produce O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
this O
state B_LOCATION
[ O
19 B_DISEASE
] I_DISEASE
. O

The O
key B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
that O
peripheral B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LPS I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
causes O
a O
greater B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
TLR2 B_GENE
, O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
beta I_MEASURE
, O
and O
IDO B_GENE
mRNA I_GENE
in O
the O
aged B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
brain B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
than O
in O
the O
adult B_PERSON/B_ENT
brain I_PERSON/I_ENT
and O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
normalizes O
this O
age B_TIME[MEASURE]/B_DISEASE
- O
related O
exaggerated B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuroinflammation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fig B_MEASURE/B_PROTEIN[GENE]
. O
7 B_NUMBER[MEASURE]
) O
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
also O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
an O
amplified B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuroinflammatory I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
aged B_BODY_PART_OR_ORGAN_COMPONENT
brain I_BODY_PART_OR_ORGAN_COMPONENT
is O
a O
precursor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
complications B_DISEASE
including O
deficits B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
working O
memory B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
memory B_DISEASE_ADJECTIVE[DISEASE]
consolidation I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
depressive B_DISEASE
- O
like B_DISEASE_ADJECTIVE[DISEASE]
behavior I_DISEASE_ADJECTIVE[DISEASE]
[ O
9 B_SEQUENCE[MEASURE]
, O
10 B_NUMBER[MEASURE]
, O
15 B_MEASURE
] I_MEASURE
. O

Based O
on O
the O
biochemical O
and O
behavioral O
data O
obtained O
from O
this O
study O
, O
we O
predict O
that O
minocycline O
will O
abrogate O
the O
prolonged O
LPS O
- O
induced O
sickness O
[ O
13 O
] O
and O
depressive O
- O
like O
behavior O
exhibited O
by O
aged O
BALB O
/ O
c O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
15 O
] O
. O

We O
acknowledge O
, O
however O
, O
that O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
test O
these O
predictions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrates O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
microglial B_DISEASE
activation I_DISEASE
, O
CNS B_DISEASE
cytokine I_DISEASE
production I_DISEASE
, O
and O
behavioral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
sickness B_DISEASE
( O
e B_GENE/B_DISEASE
. O
g B_GENE/B_MEASURE
. O
, O
social B_DISEASE
withdrawal I_DISEASE
and O
anhedonia B_DISEASE
) O
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
potentially O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
they O
indicate O
that O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
used O
to O
mitigate O
cytokine B_DISEASE
expression I_DISEASE
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
have O
a O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
behavioral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

taken O
together O
, O
these O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
pharmacological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strategies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aimed O
at O
decreasing O
neuroinflammation B_DISEASE
associated O
with O
microglial B_DISEASE/B_LOCATION
activation I_DISEASE/I_LOCATION
are O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
improving O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
sickness B_DISEASE
and O
reducing O
the O
frequency B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
neurobehavioral B_DISEASE
complications I_DISEASE
. O

list B_LOCATION/B_MEASURE
of O
abbreviations B_PERSON/B_ENT
. O

3 O
- O
Hydroxy O
- O
L O
- O
Kynuriene O
( O
3HK O
) O
, O
Allophycocyanin O
( O
APC O
) O
, O
Analysis O
of O
variance O
( O
ANOVA O
) O
, O
Central O
nervous O
System O
( O
CNS O
) O
, O
Dulbecco O
' O
s O
modified O
Eagle O
' O
s O
Medium O
( O
DMEM O
) O
, O
Dimethyl O
Sulfoxide O
( O
DMSO O
) O
, O
Experimental O
Autoimmune O
Encephalomyelitis O
( O
EAE O
) O
, O
enzyme O
linked O
Immmunosorbent O
Assay O
( O
ELISA O
) O
, O
Fluorescein O
Isothiocyanate O
( O
FITC O
) O
, O
Fetal O
Bovine B_PERSON/B_BIO
serum O
( O
FBS O
) O
, O
Hank O
' O
s O
balanced O
Salt O
solution O
( O
HBSS O
) O
, O
Indoleamine O
2 O
, O
3 O
dioxygenase O
( O
IDO O
) O
, O
Intraperitoneal O
( O
i O
. O
p O
. O
) O
, O
Intracerebroventricular O
( O
i O
. O
c O
. O
v O
. O
) O
, O
Interleukin O
( O
IL O
) O
, O
Kynurenine O
( O
KYN O
) O
, O
Lipopolysaccharide O
( O
LPS O
) O
, O
Major O
Histocompatibility O
Complex O
class O
II O
( O
MHC O
II O
) O
, O
Mitogen O
activated O
protein O
kinase O
( O
Map O
- O
kinase O
) O
, O
Nuclear O
factor O
Kappa O
B O
( O
NF O
Kappa O
B O
) O
, O
N O
- O
methyl O
- O
D O
- O
aspartate O
( O
NMDA O
) O
, O
R O
- O
Phycoerthrin O
( O
PE O
) O
, O
Quinolinic O
acid O
( O
QUIN O
) O
, O
Statistical O
Analysis O
Systems O
( O
SAS O
) O
, O
Standard O
error O
of O
the O
Mean O
( O
SEM O
) O
, O
toll O
- O
like O
receptor O
- O
2 O
( O
TLR2 O
) O
, O
and O
Tryptophan O
( O
TRP O
) O
. O

competing O
interests B_DISEASE
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
declare O
that O
there O
are O
no O
actual B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conflicts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
interest B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
authors O
affirm O
that O
there O
are O
no O
financial O
, O
personal O
or O
other O
relationships O
with O
other O
people B_PERSON/B_ORGANIZATION
or O
organizations O
that O
have O
inappropriately O
influenced O
or O
biased O
their O
research O
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

CJH B_PERSON
was O
involved O
in O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
experimentation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
completion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
writing O
of O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

YH B_PERSON/B_PROTEIN[GENE]
, O
AW B_LOCATION
, O
MH B_LOCATION/B_PERSON
and O
JH B_LOCATION/B_PERSON
assisted O
with O
experimentation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

MB B_LOCATION/B_PERSON
and O
JFS B_LOCATION/B_PERSON
contributed O
to O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
assisted O
in O
editing O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

JPG B_PERSON/B_ORGANIZATION
directed O
all O
aspects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
including O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
experimentation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
completion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
and O
writing O
of O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

A O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
demand B_DISEASE
ischemia I_DISEASE
from O
phendimetrazine B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Phendimetrazine O
is O
a O
medication O
currently O
being O
used O
to O
help O
patients B_PERSON
with O
weight O
loss O
. O

It O
shares O
a O
chemical B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
amphetamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

As O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
it O
shares O
some O
of O
the O
same B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
can O
include O
cardiac B_DISEASE
toxicity I_DISEASE
. O

This O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highlights O
this O
principle B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presentation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

a O
54 B_PERSON
year I_PERSON
old I_PERSON
Caucasian I_PERSON
female I_PERSON
presented O
to O
our O
urgent B_LOCATION/B_PERSON
care I_LOCATION/I_PERSON
facility I_LOCATION/I_PERSON
with O
complaints B_DISEASE_ADJECTIVE[DISEASE]
of O
chest B_DISEASE
pains I_DISEASE
and O
other B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
suggestive I_DISEASE_ADJECTIVE[DISEASE]
of O
acute B_DISEASE/B_LOCATION
coronary I_DISEASE/I_LOCATION
syndrome I_DISEASE/I_LOCATION
. O

Ultimately O
, O
she O
was O
transferred O
to O
the O
emergency B_LOCATION/B_ORGANIZATION
room I_LOCATION/I_ORGANIZATION
. O

After O
evaluation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
there O
, O
it O
appeared O
she O
was O
having O
demand B_DISEASE_ADJECTIVE[DISEASE]
ischemia I_DISEASE_ADJECTIVE[DISEASE]
from O
prescription B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pills I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

This O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrates O
the O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dangers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
based O
diet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pills I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
have O
been O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
cardiomyopathies B_DISEASE
related O
to O
phendimetrazine B_DISEASE
, O
but O
it O
is O
something B_DISEASE
that O
is O
rarely O
recognized O
in O
an O
outpatient B_PERSON/B_LOCATION
setting I_PERSON/I_LOCATION
. O

A O
case O
such O
as O
this O
demonstrates O
the O
importance O
of O
obtaining O
a O
careful O
medication O
history O
in O
all O
patients B_PERSON/B_LOCATION
and O
in O
recognizing O
diet O
pills O
with O
an O
amphetamine O
base O
can O
cause O
cardiac O
toxicity O
. O

Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presentation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
54 B_TIME[MEASURE]/B_PERSON
year I_TIME[MEASURE]/I_PERSON
- O
old B_PERSON
Caucasian I_PERSON
female I_PERSON
presented O
to O
our O
urgent B_LOCATION/B_PERSON
care I_LOCATION/I_PERSON
facility I_LOCATION/I_PERSON
complaining O
of O
nausea B_DISEASE
and O
vomiting B_DISEASE
, O
sense B_TIME[MEASURE]/B_DISEASE
of O
impending B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
doom B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
vague B_DISEASE/B_MEASURE
chest I_DISEASE/I_MEASURE
pain I_DISEASE/I_MEASURE
radiating O
toward O
her O
left B_BODY_PART_OR_ORGAN_COMPONENT
side I_BODY_PART_OR_ORGAN_COMPONENT
for O
about O
five B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
. O

She O
never O
had O
similar B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
past B_TIME[MEASURE]/B_LOCATION
. O

She O
also O
denied O
anything B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
that O
could O
have O
precipitated O
these O
symptoms B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Her O
only B_DISEASE_ADJECTIVE[DISEASE]
past I_DISEASE_ADJECTIVE[DISEASE]
medical I_DISEASE_ADJECTIVE[DISEASE]
history I_DISEASE_ADJECTIVE[DISEASE]
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
spina B_DISEASE/B_BACTERIUM[BIO]
bifida I_DISEASE/I_BACTERIUM[BIO]
. O

Her O
medications B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
occasional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fiorinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
unknown B_MEASURE
dose I_MEASURE
) O
, O
Xanax B_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
as O
needed O
, O
and O
Phendimetrazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
unclear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Her O
social B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
significant B_DISEASE_ADJECTIVE[DISEASE]
for O
smoking O
1 B_NUMBER[MEASURE]
/ O
2 B_MEASURE/B_ENT
pack I_MEASURE/I_ENT
per O
day B_TIME[MEASURE]/B_PERSON
cigarette I_TIME[MEASURE]/I_PERSON
use I_TIME[MEASURE]/I_PERSON
. O

She O
denied O
alcohol B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
use I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Family B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
non B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
worked O
from O
home B_LOCATION/B_PERSON
. O

Her O
physical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exam I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
a O
tachycardia B_DISEASE/B_MEASURE
of O
around O
100 B_MEASURE
beats I_MEASURE
per O
minute B_TIME[MEASURE]
, O
respiratory B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
of O
16 B_MEASURE
, O
temperature B_MEASURE/B_DISEASE
of O
98 B_MEASURE
. O
1 B_MEASURE
, O
and O
O2 B_MEASURE/B_ORGANISM_FUNCTION
saturation I_MEASURE/I_ORGANISM_FUNCTION
of O
100 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
room B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
air I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

She O
was O
approximately O
5 B_MEASURE
' I_MEASURE
7 I_MEASURE
' O
and O
145 B_MEASURE/B_COLOR
pounds I_MEASURE/I_COLOR
. O

In O
general O
, O
she O
was O
an O
anxious O
appearing O
, O
diaphoretic O
woman B_PERSON/B_LOCATION
in O
moderate O
distress O
, O
she O
had O
no O
elevated O
JVD O
at O
30 O
degrees O
, O
her O
heart O
was O
tachycardic O
, O
but O
otherwise O
without O
murmur O
, O
gallops O
, O
or O
rubs O
, O
her O
lungs O
were O
clear O
, O
abdomen O
soft O
, O
and O
she O
had O
no O
peripheral O
edema O
. O

An O
EKG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
checked O
which O
appears O
below O
( O
figure B_MEASURE
1 I_MEASURE
) O
. O

After O
examination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
there O
was O
concern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
acute B_DISEASE
coronary I_DISEASE
syndrome I_DISEASE
( O
ACS B_DISEASE/B_LOCATION
) O
. O

She O
was O
given O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
relief B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
her O
chest B_DISEASE
discomfort I_DISEASE
. O

She O
was O
also O
given O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
chew O
. O

EMS B_PERSON
was O
called O
and O
she O
was O
transferred O
to O
a O
local B_LOCATION/B_PRODUCT[OBJECT]
emergency B_LOCATION/I_PRODUCT[OBJECT]
room B_LOCATION/I_PRODUCT[OBJECT]
. O

She O
was O
hospitalized O
there O
for O
three B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
and O
after O
her O
discharge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
we O
got O
permission B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
her O
to O
request B_PERSON/B_LOCATION
records B_PERSON/I_LOCATION
. O

While O
hospitalized O
, O
she O
was O
ruled O
out O
for O
ACS B_DISEASE/B_LOCATION
with O
negative B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
troponins B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
was O
also O
given O
beta O
blockade B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
resolved O
her O
tachycardia B_DISEASE
and O
her O
T B_DISEASE_ADJECTIVE[DISEASE]
wave I_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
on O
EKG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
next B_TIME[MEASURE]/B_LOCATION
morning I_TIME[MEASURE]/I_LOCATION
, O
she O
had O
an O
adenosine B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
revealed O
normal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
uptake I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
no O
areas B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ischemia B_DISEASE
and O
an O
ejection B_MEASURE
fraction I_MEASURE
of O
55 B_MEASURE
% I_MEASURE
. O

She O
was O
monitored O
for O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
day B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
then O
discharged O
with O
instructions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
discontinue O
her O
diet B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pills I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Phendimetrazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
a O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
currently O
being O
used O
for O
weight B_DISEASE
loss I_DISEASE
, O
with O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
illicit B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
has O
a O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemical B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
composition B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
amphetamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
which O
is O
thought O
to O
account O
for O
its O
clinical B_DISEASE_ADJECTIVE[DISEASE]
actions I_DISEASE_ADJECTIVE[DISEASE]
[ O
1 B_LOCATION/B_DISEASE
] I_LOCATION/I_DISEASE
. O

Amphetamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
well O
recognized O
as O
an O
etiology B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiac B_DISEASE
ischemia I_DISEASE
, O
however O
phendimetrazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
more O
rarely O
described O
in O
the O
literature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
as O
causing O
cardiac B_DISEASE
events I_DISEASE
. O

[ B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
, O
3 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
include O
hyperpyrexia B_DISEASE
, O
mydriasis B_DISEASE/B_BIO
, O
chest B_DISEASE
pain I_DISEASE
, O
arrhytmias B_DISEASE
, O
delirium B_DISEASE
, O
and O
, O
rhabdomylosis B_DISEASE_ADJECTIVE[DISEASE]
, O
among O
others B_PERSON/B_DISEASE
[ O
2 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
] I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Long B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O
been O
associated O
with O
dilated B_DISEASE
cardiomyopathies I_DISEASE
, O
some O
of O
which O
have O
resolved O
with O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

In O
this O
particular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
it O
appears O
she O
may O
have O
developed O
a O
demand B_DISEASE
ischemia I_DISEASE
from O
the O
medication B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

It O
is O
not O
known O
how O
much B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
she O
was O
taking O
. O

Initially O
, O
she O
was O
resistant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
accepting O
that O
phendimetrazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
could O
induce O
side B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
there O
was O
suspicion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
she O
could O
have O
been O
taking O
more B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
recommended O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
she O
was O
not O
prescribed O
the O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
would O
not O
admit O
to O
where O
she O
obtained O
it O
. O

As O
the O
public B_ORGANIZATION/B_PERSON
seems O
to O
have O
more B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
focus I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
on O
using O
medications B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
induce O
weight B_DISEASE
loss I_DISEASE
, O
this O
may O
be O
a O
more O
recognized B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complication B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
heart B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
conditions I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
should O
likely O
be O
monitored O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
starting O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
based O
weight B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pills I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

Due O
to O
potentially O
detrimental B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
phendimetrazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
should O
be O
used O
cautiously O
in O
many B_PERSON/B_LOCATION
situations I_PERSON/I_LOCATION
. O

As O
it O
shares O
its O
chemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
amphetamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
it O
also O
shares O
many B_NUMBER[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
abuse B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
/ O
addiction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

There O
have O
been O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
literature B_PERSON/B_LOCATION
describing O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
phendimetrazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
cautious B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
warranted O
. O

Abbreviations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

ACS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Acute B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
Coronary B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
Syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O

competing O
interests B_DISEASE
. O

The O
authors B_PERSON
declare O
that O
they O
have O
no O
competing O
interests B_PERSON/B_ORGANIZATION
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

DL B_PROTEIN[GENE]/B_PERSON
, O
JJ B_LOCATION/B_PERSON
, O
GG B_PROTEIN[GENE]/B_LOCATION
have O
all O
been O
involved O
in O
and O
approve O
of O
the O
writing B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
presentation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

consent B_TIME[MEASURE]/B_PERSON
. O

Written O
informed B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consent I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
obtained O
from O
the O
patient B_PERSON/B_ORGANIZATION
for O
publication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
purposes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

A O
copy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
can O
be O
obtained O
if O
requested O
by O
the O
Editor B_PERSON
in O
Chief B_PERSON/B_LOCATION
of O
this O
journal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Advanced B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concepts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
employing O
microcomputers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O
the O
. O

laboratory B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

IIII B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

II B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

, O
Advanced B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
software I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
concepts I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
. O

employing O
microcomputers B_PERSON/B_ORGANIZATION
in O
the O
laboratory B_LOCATION/B_PERSON
Scott I_LOCATION/I_PERSON
B I_LOCATION/I_PERSON
. O
Tilden B_PERSON/B_LOCATION
and O
M B_LOCATION
. O
Bonner B_PERSON
Denton I_PERSON
, O
Department B_ORGANIZATION/B_PERSON
of O
Chemistry B_EDU[ORGANIZATION]/B_PERSON
, O
University B_LOCATION/B_ORGANIZATION
of O
Arizona B_LOCATION
, O
Tucson B_LOCATION/B_PERSON
, O
Arizona B_LOCATION
85721 I_LOCATION
, O
USA B_LOCATION/B_MEASURE
. O

Introduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
While O
a O
proliferation B_MEASURE/B_LOCATION
of O
commercial B_ORGANIZATION/B_PERSON
chemical I_ORGANIZATION/I_PERSON
instrumentation I_ORGANIZATION/I_PERSON
is O
appearing O
today B_DISEASE_ADJECTIVE[DISEASE]
employing O
microprocessors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
for O
a O
variety B_ENT/B_MEASURE
of O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
great B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
potential I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
microprocessors B_ORGANIZATION/B_PERSON
has O
not O
been O
exploited O
extensively O
for O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
custom I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
applications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

The O
primary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reason I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
this O
phenomenon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
altogether O
too O
clear B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
microprocessor I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
software I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
either O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
develop O
or O
inefficient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
memory B_MEASURE/B_LOCATION
requirements I_MEASURE/I_LOCATION
and O
speed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
. O

This O
problem B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
even O
more O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
situations B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requiring O
constant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
software I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

modification B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Initially O
, O
most B_ORGANIZATION/B_LOCATION
instrument I_ORGANIZATION/I_LOCATION
manufacturers I_ORGANIZATION/I_LOCATION
utilized O
cross B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
assemblers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
supported O
on O
large B_PERSON
' I_PERSON
number I_PERSON
cruncher I_PERSON
' O
computers B_PRODUCT[OBJECT]/B_LOCATION
to O
generate O
the O
required B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
machine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binary I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

More O
recently O
, O
the O
trend B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
toward O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
a O
' B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
( O
at O
a O
cost B_MEASURE/B_PERSON
comparable I_MEASURE/I_PERSON
to O
a O
moderate B_PRODUCT[OBJECT]/B_PERSON
minicomputer I_PRODUCT[OBJECT]/I_PERSON
- O
the O
authors B_PERSON/B_LOCATION
use O
the O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
mini B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
' O
micro B_MEASURE
' O
reluctantly O
because O
of O
the O
ever O
increasing O
overlap B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
computing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
capability I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
to O
write O
and O
debug O
assembly B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
level I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
porgrams I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O
are O
subsequently O
converted O
to O
binary B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
incorporated O
into O
an O
instrument B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
' O
read O
only B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
memory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O
( O
ROM B_DISEASE
) O
. O

While O
this O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Interpretative B_LOCATION/B_MEASURE
machine I_LOCATION/I_MEASURE
code I_LOCATION/I_MEASURE
. O

source B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
file I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

to O
execute O
Command B_PERSON
A I_PERSON
Hachine I_PERSON
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Various I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

to O
execute O
Comma B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
nd I_PERSON
B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
ne I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

' O
commands B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
making O
up O
. O

, B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lachi O
. O

to O
execute O
Command B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

users B_PERSON/B_SEQUENCE[MEASURE]
source O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

i B_OTHER/B_PERSON

machine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

to O
execute O
Command B_PERSON
D I_PERSON
. O

etc B_LOCATION/B_DISEASE
. O

figure B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
. O

The O
interpretative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
cycle I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
common B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
types I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
languages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
Basic B_PERSON/B_LOCATION
. O

After O
examining O
each O
command B_ORGANIZATION/B_PERSON
in O
the O
source B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
file I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
the O
interpreter B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
searches O
for O
and O
branches B_LOCATION/B_PERSON
to O
the O
corresponding B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
machine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
code I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
; O
thus O
, O
program B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
execution I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
always O
remains O
within O
the O
interpreter B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

128 B_NUMBER[MEASURE]
. O

The O
Journal B_ORGANIZATION
of O
Automatic B_EDU[ORGANIZATION]/B_PERSON
Chemistry I_EDU[ORGANIZATION]/I_PERSON
. O

Tilden B_PERSON/B_LOCATION
& O
Denton B_PERSON/B_LOCATION
IIII I_PERSON/I_LOCATION
. O

Advanced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

III B_NUMBER[MEASURE]
. O

Users B_ORGANIZATION
Source I_ORGANIZATION
File I_ORGANIZATION
. O

The O
compiler B_PERSON/B_LOCATION
. O

command B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Comma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
nd I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
B I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
command I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
C I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
command I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
D I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
etc I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
. O

/ O
z B_OTHER/B_PERSON
/ O
Li B_PERSON/B_MEASURE
i O
. O

II B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

. O
machine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

etc B_LOCATION/B_DISEASE
. O

. O
lachi B_LOCATION/B_PERSON
ne B_DISEASE/B_PERSON
code I_DISEASE/B_LOCATION
. O

to O
execute O
Command B_PERSON
A I_PERSON
. O

etc B_NUMBER[MEASURE]/B_LOCATION
. O
to O
execute O
. O

machine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

to O
execute O
Command B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

machine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

etc B_LOCATION/B_DISEASE
. O

figure B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
. O

Note O
that O
the O
compiler B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transforms O
each O
source B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
command B_ORGANIZATION/B_PERSON
' O
into O
executable B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
machine I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
code B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
will O
, O
subsequently O
, O
be O
loaded O
and O
executed O
independently O
of O
the O
compiler B_PERSON
. O

has O
proven O
cost B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
high B_TIME[MEASURE]/B_LOCATION
volume I_TIME[MEASURE]/I_LOCATION
mass I_TIME[MEASURE]/I_LOCATION
produced O
applications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
it O
possesses O
serious B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
limitations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
updates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
custom B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Additionally O
, O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
program O
efficiently O
at O
the O
assembly B_LOCATION
level I_LOCATION
is O
a O
talent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
requiring O
a O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
expenditure I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
time B_MEASURE/B_LOCATION
to O
develop O
. O

During O
the O
past B_TIME[MEASURE]/B_ENT
several I_TIME[MEASURE]/I_ENT
years I_TIME[MEASURE]/I_ENT
, O
a O
virtual B_MEASURE/B_LOCATION
deluge B_MEASURE/I_LOCATION
of O
sophisticated B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
flexible B_DISEASE_ADJECTIVE[DISEASE]
, O
high B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
computer I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hardware I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
introduced O
primarily O
aimed O
at O
a O
rapidly O
growing O
' B_LOCATION/B_ORGANIZATION
hobbyist B_LOCATION/I_ORGANIZATION
' B_LOCATION/I_ORGANIZATION
market B_LOCATION/I_ORGANIZATION
. O

manufacturers B_PERSON/B_ORGANIZATION
quickly O
realilsed O
that O
to O
sell O
the O
public B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
hardware I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
some O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
reasonably O
high B_ORGANIZATION/B_TIME[MEASURE]
level B_ORGANIZATION/I_TIME[MEASURE]
software B_ORGANIZATION/I_TIME[MEASURE]
must O
be O
made O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
variety B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Basic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interpreters I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
ranging O
from O
rather O
' O
dumb B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
' O
to O
' O
quite O
intelligent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
' O
have O
since O
evolved O
. O

The O
more O
intelligent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Basic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
interpreters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
have O
several B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
highly O
attractive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attributes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
' O
hobbyist B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
' O
applications B_PERSON/B_LANGUAGE
. O

The O
language B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
both O
easy B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
master B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conversational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

error B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
caution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
messages I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O
provided O
as O
aids B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
programming B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SPORT[ENT]
. O

Why O
not O
apply O
the O
' O
hobbyist B_PERSON/B_MEASURE
' O
technology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toward O
the O
implementation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
custom B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
laboratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Many B_PERSON/B_NUMBER[MEASURE]
investigators B_PERSON/I_NUMBER[MEASURE]
have O
and O
, O
no O
doubt O
, O
many B_PERSON/B_ENT
more I_PERSON/I_ENT
will O
take O
this O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
Basic B_PERSON
interpreters I_PERSON
possess O
serious B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
limitations B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
system B_MEASURE
speed I_MEASURE
, O
flexibility B_MEASURE
and O
input B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
/ O
output B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
O B_PROTEIN[GENE]/B_LOCATION
) O
capabilities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
Basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
each O
command B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O
first O
be O
interpreted O
and O
then O
executed O
( O
see O
figure B_MEASURE
1 I_MEASURE
) O
. O

In O
many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
the O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
takes O
much O
more B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
time B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O
the O
actual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
execution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

This O
problem B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
compounded O
by O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
commands B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpreted O
in O
the O
past B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O
be O
re O
- O
interpreted O
each O
time B_TIME[MEASURE]/B_LOCATION
they O
are O
used O
causing O
iterative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
programs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
be O
very O
slow B_DISEASE_ADJECTIVE[DISEASE]
. O

While O
speed B_MEASURE
is O
often O
not O
a O
serious B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
limitation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
playing O
computer B_SPORT[ENT]/B_ORGANIZATION
games I_SPORT[ENT]/I_ORGANIZATION
, O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requiring O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
speed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acquisition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manipulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
common B_DISEASE_ADJECTIVE[DISEASE]
. O

Additionally O
, O
the O
more O
intelligent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
BASICs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
make O
very O
inefficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
memory B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
often O
requiring O
minimum B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
12 B_NUMBER[MEASURE]
or O
16 B_MEASURE
K I_MEASURE
bytes I_MEASURE
( O
twelve B_NUMBER[MEASURE]
or O
sixteen B_NUMBER[MEASURE]/B_ENT
thousand I_NUMBER[MEASURE]/I_ENT
eight I_NUMBER[MEASURE]/I_ENT
bit I_NUMBER[MEASURE]/I_ENT
words I_NUMBER[MEASURE]/I_ENT
) O
' B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Volume B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CS B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

H B_OTHER/B_PERSON

A B_OTHER/B_PERSON

D B_OTHER/B_PERSON

H B_MEASURE/B_PERSON
figure I_MEASURE/I_PERSON
3 I_MEASURE/I_PERSON
. O

The O
' O
threaded O
' O
code B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
in O
convers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
' O
threaded O
' O
code B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
programming I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
modules I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
sub B_DISEASE
- O
routines B_LOCATION/B_PERSON
are O
used O
repetitively O
in O
a O
variety B_ENT/B_MEASURE
of O
combinations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
allow O
implementation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
an O
infinite B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
functions B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Note O
that O
the O
flow B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
logic B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
threads O
its O
way B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
very O
non B_DISEASE
. O
linear B_LOCATION/B_ORGANIZATION
fashion I_LOCATION/I_ORGANIZATION
through O
these O
modules B_LOCATION
. O

No O
. O
3 B_PERSON/B_MEASURE
April I_PERSON/I_MEASURE
1979 I_PERSON/I_MEASURE
. O

129 B_NUMBER[MEASURE]
. O

Tilden B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

& O
Denton B_LOCATION/B_GENE
. O

Advanced B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
software I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
concepts I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
| O
I O
. O

stack B_LOCATION
. O

Upper B_DISEASE_ADJECTIVE[DISEASE]
Memory I_DISEASE_ADJECTIVE[DISEASE]
bound O
. O

user B_PERSON/B_ORGANIZATION
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Application I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Dictionaries I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

4 O
. O
5k B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Octal I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CONVERS I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Di B_LOCATION/B_MEASURE
SK I_LOCATION/I_MEASURE
Operating I_LOCATION
System I_LOCATION
. O

3 O
. O
7k B_MEASURE/B_LOCATION
Octal I_MEASURE/I_LOCATION
Standard I_MEASURE/I_LOCATION
High I_MEASURE/I_LOCATION
. O

Level B_MEASURE
Dictionary I_MEASURE
1 I_MEASURE
. O
2k B_MEASURE/B_PERSON
Octal I_MEASURE/I_PERSON
Initial I_MEASURE/I_PERSON
Machine I_MEASURE/I_PERSON
. O

code B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Dictionary I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

I O
@ O
@ O
Octal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

figure B_MEASURE/B_LOCATION
4 I_MEASURE/I_LOCATION
. O

Memory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
map I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
Con B_LOCATION/B_PERSON
VERS I_LOCATION/I_PERSON
dictionary I_LOCATION/I_PERSON
. O

The O
stack B_LOCATION
which O
is O
composed O
of O
data B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
etc I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
acts B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
constantly O
expanding O
or O
contracting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
buffer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O
allows O
one B_PERSON/B_LOCATION
subroutine I_PERSON/I_LOCATION
to O
communicate O
with O
another O
without O
either O
needing O
to O
know O
the O
other B_TIME[MEASURE]/B_PERSON
' O
s B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
location I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
interpreters B_MEASURE/B_ORGANIZATION
, O
high B_PERSON/B_ORGANIZATION
level I_PERSON/I_ORGANIZATION
compilers I_PERSON/I_ORGANIZATION
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
as O
FORTRAN B_PERSON/B_ORGANIZATION
, O
offer O
a O
much O
faster B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
' O
run B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
time I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
execution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
speed I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

This O
is O
accomplished O
through O
generation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
the O
required O
machine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
during O
a O
series B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
programming B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
operations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Compilers B_ORGANIZATION/B_PERSON
using O
FORTRAN B_LOCATION/B_PERSON
, O
which O
are O
designed O
to O
run O
on O
many B_MEASURE/B_PRODUCT[OBJECT]
minicomputers B_MEASURE/I_PRODUCT[OBJECT]
and O
some O
micros B_PRODUCT[OBJECT]/B_PERSON
, O
often O
first O
transform O
user B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
symbolic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
source I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
into O
assembly B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
code I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

An O
assembler B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
subsequently O
, O
transforms O
this O
into O
the O
required B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
machine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

This O
ready B_MEASURE/B_PERSON
- O
to O
- O
run B_LOCATION/B_MEASURE
machine I_LOCATION/I_MEASURE
code I_LOCATION/I_MEASURE
is O
often O
loaded O
along O
with O
a O
run B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
time I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
package I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
which O
executes O
in O
the O
manner B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
shown O
in O
Figure B_LOCATION/B_ENT
2 B_LOCATION/I_ENT
. O

While O
this O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
greatly O
improves O
execution B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
speed B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
loading O
several B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
soft I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ware B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
routines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
increases O
the O
' O
hassle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O
associated O
with O
editing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
debugging B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
this O
makes O
some O
form B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
mass B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
memory I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
disk B_PRODUCT[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
magnetic B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tape I_PRODUCT[OBJECT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
almost O
mandatory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Additionally O
, O
I O
/ O
O B_LOCATION/B_PROTEIN[GENE]
algorithms I_LOCATION/I_PROTEIN[GENE]
generally O
must O
be O
implemented O
in O
assembly B_MEASURE/B_PERSON
level B_MEASURE/I_PERSON
code B_MEASURE/I_PERSON
! O

One B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
obvious I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
question I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
immediately O
arises O
- O
why O
not O
incorporate O
the O
most O
desirable B_MEASURE/B_PERSON
characteristics I_MEASURE/I_PERSON
of O
both O
interpreters B_PERSON/B_LOCATION
and O
compilers B_PERSON
into O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
language I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Additionally O
, O
due O
to O
the O
unique B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
found O
in O
many B_PERSON/B_ORGANIZATION
applications I_PERSON/I_ORGANIZATION
, O
why O
not O
allow O
the O
programmer B_PERSON/B_LOCATION
additional I_PERSON/I_LOCATION
flexibility I_PERSON/I_LOCATION
by O
providing O
him O
with O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
actually O
develop O
his O
own B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
individual I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
modifications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
additions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O
the O
language B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O
. O

Other B_MEASURE/B_PERSON
desirable B_MEASURE/I_PERSON
features B_MEASURE/I_PERSON
would O
include O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
memory I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
efficiency I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
level I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
I O
] O
O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
programming I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
ease B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
understanding O
the O
language B_PERSON/B_PRODUCT[OBJECT]
' O
s B_PERSON/B_LOCATION
' I_PERSON/I_LOCATION
inter I_PERSON/I_LOCATION
- O
working B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
' O
and O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
be O
transferred O
from O
one B_NUMBER[MEASURE]/B_PERSON
CPU I_NUMBER[MEASURE]/I_PERSON
to O
another O
with O
minimum B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effort B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Type B_TIME[MEASURE]/B_LOCATION
' O
acquire B_DISEASE_ADJECTIVE[DISEASE]
' O
. O

acquire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

- O
of O
characters B_DISEASE/B_PERSON
. O

A O
G B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

format B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
T I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
plot I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
. O

Start O
scan O
GALC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
T I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

display B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
return I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Executive B_PERSON/B_LOCATION
. O

figure B_MEASURE/B_PERSON
5 I_MEASURE/I_PERSON
. O

If O
a O
previously O
defined O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
name I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
A B_LOCATION/B_PROTEIN[GENE]
CO I_LOCATION/I_PROTEIN[GENE]
U I_LOCATION/I_PROTEIN[GENE]
R I_LOCATION/I_PROTEIN[GENE]
tQ I_LOCATION/I_PROTEIN[GENE]
is O
entered O
when O
in O
EXECUTE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mode I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
a O
dictionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
takes O
place B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locating O
the O
acquire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
entry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Once O
found O
, O
this O
entry B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O
all O
the O
required B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
machine I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
code I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
/ O
or O
calls B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
addresses B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_NUMBER[MEASURE]/B_LOCATION
previously O
compiled O
machine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
code I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
modules I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
completely O
execute O
the O
desired B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

130 B_NUMBER[MEASURE]
. O

The O
Journal B_ORGANIZATION
of O
Automatic B_EDU[ORGANIZATION]/B_PERSON
Chemistry I_EDU[ORGANIZATION]/I_PERSON
. O

Tilden B_PERSON/B_LOCATION
& O
Denton B_LOCATION/B_PERSON
. O

Advanced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

2000 B_NUMBER[MEASURE]
. O

variable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

start B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Stop B_LOCATION/B_TIME[MEASURE]
. O

5000 B_TIME[MEASURE]
20 I_TIME[MEASURE]
. O

variable B_MEASURE
variable I_MEASURE
7 I_MEASURE
. O

increment B_DISEASE/B_ORGANIZATION
. O

0 B_NUMBER[MEASURE]/B_PERSON

Location B_LOCATION
. O

A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
D7 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

INDEVICE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
start I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

INITIALIZE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

@ B_OTHER/B_PERSON

Location B_LOCATION
. O

Location B_LOCATION
. O

@ B_OTHER/B_PERSON

increment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
INDEVICE I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

@ B_OTHER/B_PERSON

+ B_MEASURE
10 I_MEASURE
. O

Location B_LOCATION
. O

delay B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
move I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scan I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

begin O
- O
Here O
Location B_LOCATION/B_PERSON
. O

AND B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O

IF O
delay B_NUMBER[MEASURE]
. O

A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
D7 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

else B_LOCATION/B_DISEASE
. O

begin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Then B_LOCATION/B_PERSON
. O

@ B_OTHER/B_PERSON

5 B_NUMBER[MEASURE]/B_PERSON

OUTDEVICE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Step B_MOUSE_GENE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

INITIALIZE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

begin B_MEASURE/B_LOCATION
- O
Here O
. O

Move B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Location B_LOCATION
. O

@ B_OTHER/B_PERSON

Stop B_LOCATION/B_DISEASE
. O

@ B_OTHER/B_PERSON

> B_OTHER/B_PERSON

IF B_LOCATION/B_DISEASE
. O

End B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

else B_LOCATION/B_DISEASE
. O

begin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Then B_LOCATION/B_PERSON
. O

3000 B_TIME[MEASURE]
6500 I_TIME[MEASURE]
10 I_TIME[MEASURE]
. O

start B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Start B_LOCATION/B_TIME[MEASURE]
. O

increment B_DISEASE/B_ORGANIZATION
. O

scan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

figure B_MEASURE/B_PERSON
6 I_MEASURE/I_PERSON
. O

Ten B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
typical B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CONVERS I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code O
to O
scan O
wavelengths B_LOCATION/B_MEASURE
between O
two B_NUMBER[MEASURE]/B_PERSON
easily O
changed O
limits B_LOCATION
and O
acquire O
data B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

By O
reference B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
notes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
the O
text B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
it O
can O
be O
easily O
understood O
. O

Note O
: O
a O
number B_MEASURE
or O
name B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pushes O
the O
number B_MEASURE/B_LOCATION
of O
address B_LOCATION/B_BIO
occupied O
by O
the O
name B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
stack B_LOCATION
. O

The O
symbol B_LOCATION/B_MEASURE
@ O
, O
pips O
the O
top B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
stack B_LOCATION/B_MEASURE
uses O
it O
as O
the O
address B_LOCATION/B_MEASURE
from O
which O
to O
obtain O
a O
number B_MEASURE
and O
pushes O
that O
number B_MEASURE/B_LOCATION
on O
the O
stack B_LOCATION/B_ENT
. O

Development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
CONVERS B_ORGANIZATION/B_PERSON
During O
the O
past B_TIME[MEASURE]
two I_TIME[MEASURE]
years I_TIME[MEASURE]
, O
a O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
software B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
taking O
place B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
the O
University B_LOCATION
of O
Arizona B_LOCATION
referred O
to O
as O
an O
' O
Interpretive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Compiler I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
called O
CONVERS B_LOCATION/B_PERSON
. O

This O
package B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
conceptually O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
forth B_PERSON/B_LOCATION
language I_PERSON/I_LOCATION
currently O
being O
used O
in O
several B_PERSON/B_LOCATION
minicomputerastronomical I_PERSON/I_LOCATION
applications I_PERSON/I_LOCATION
] I_PERSON/I_LOCATION
, O
is O
able B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
provide O
many B_NUMBER[MEASURE]/B_PERSON
of O
the O
desirable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
features I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
found O
in O
both O
interpreters B_LOCATION/B_PERSON
and O
compilers B_PERSON/B_LOCATION
by O
separating O
the O
compile B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
execute O
states B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
as O
a O
compiler B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
) O
while O
maintaining O
a O
resident B_PERSON/B_ORGANIZATION
user I_PERSON/I_ORGANIZATION
interactive I_PERSON/I_ORGANIZATION
and O
conversational B_PERSON/B_LOCATION
executive I_PERSON/I_LOCATION
which O
oversees O
system B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
operation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

The O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
realise O
such B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advanced I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
software I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
capabilities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
very O
modest B_MEASURE/B_PERSON
amount I_MEASURE/I_PERSON
of O
memory B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
less B_MEASURE
than O
4 B_MEASURE
K I_MEASURE
bytes I_MEASURE
on O
an O
8080 B_TIME[MEASURE]/B_ORGANIZATION
based O
micro B_MEASURE/B_PRODUCT[OBJECT]
) O
is O
the O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
exploiting O
threaded B_PERSON/B_LOCATION
code I_PERSON/I_LOCATION
programming I_PERSON/I_LOCATION
techniques I_PERSON/I_LOCATION
( O
see O
figure B_MEASURE/B_LOCATION
3 I_MEASURE/I_LOCATION
) O
. O

The O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
involves O
highly O
efficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
simple B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
macroinstructions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
build O
more O
complex B_LOCATION/B_PERSON
subroutines I_LOCATION/I_PERSON
which O
are O
recombined O
with O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
macroinstructions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
form O
super B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subroutines I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

This O
process B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
combining O
previously O
defined O
modules B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
form O
ever O
increasingly O
sophisticated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
routines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
for O
performing O
the O
task B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
hand B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
is O
the O
essence B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
threaded B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programming I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
initially O
loaded O
and O
running O
, O
CONVERS B_MEASURE/B_PERSON
acts O
much O
like O
an O
interpreter B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
i O
. O
e O
. O
it O
is O
conversational B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ready B_TIME[MEASURE]/B_PERSON
to O
either O
execute O
a O
previously O
programmed O
algorithm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
or O
accept O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
one I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

However O
, O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Basic B_PERSON/B_PRODUCT[OBJECT]
, O
when O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
being O
entered O
under O
convers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
it O
is O
immediately O
transformed O
into O
binary B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
machine I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
to O
the O
binary B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
starting O
addresses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
other B_NUMBER[MEASURE]/B_LOCATION
previously O
entered O
and O
compiled O
machine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
programs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

During O
this O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
operator B_PERSON
is O
kept O
informed O
of O
the O
status B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
by O
a O
series B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
error B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
diagnostic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Volume I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

messages B_ENT/B_PERSON
. O

When O
the O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O
been O
completed O
, O
it O
is O
entered O
in O
a O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
or O
dictionary B_PERSON/B_LOCATION
, O
which O
is O
constantly O
building O
up O
from O
low B_PERSON/B_LOCATION
memory I_PERSON/I_LOCATION
( O
see O
figure B_MEASURE/B_LOCATION
4 I_MEASURE/I_LOCATION
) O
. O

If O
the O
operator B_PERSON
now O
wants O
to O
execute O
this O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
he O
can O
request O
it O
from O
his O
terminal B_LOCATION/B_PERSON
. O

A O
dictionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
will O
begin O
at O
the O
last B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
entry I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
progress B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
until O
the O
requested O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O
located O
. O

Once O
located O
, O
the O
requested O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
will O
run O
in O
its O
entirety B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
without O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
for O
any O
additional B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
dictionary I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
searches I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
let O
us O
assume O
an O
algorithm B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
called O
acquire B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
has O
been O
programmed O
to O
take O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
some O
hypothetical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
experimental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

When O
acquire B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
requested O
from O
the O
terminal B_LOCATION/B_PERSON
, O
a O
dictionary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
search I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O
initiated O
. O

The O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
names I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquire O
( O
see O
figure B_MEASURE/B_LOCATION
5 I_MEASURE/I_LOCATION
) O
, O
once O
located O
, O
contains O
the O
starting O
addresses B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
series B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
previously O
defined O
modules B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
which O
implement O
the O
various B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
steps I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
necessary I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
perform O
the O
desired O
experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
module B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
scan I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O
might O
be O
intended O
to O
scan O
a O
monochromator B_PRODUCT[OBJECT]/B_PERSON
' O
s B_MEASURE/B_LOCATION
wavelength I_MEASURE/I_LOCATION
in O
some O
desired B_PERSON/B_LOCATION
manner B_PERSON/I_LOCATION
has O
been O
previously O
defined O
and O
tested O
. O

This O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
easily O
test O
each O
module B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
separately O
and O
then O
efficiently O
combine O
a O
series B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
modules B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
perform O
a O
more O
complex B_DISEASE_ADJECTIVE[DISEASE]
function I_DISEASE_ADJECTIVE[DISEASE]
, O
test O
this O
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
then O
employ O
. O
it O
in O
a O
vastly O
more O
complex B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
etc B_LOCATION/B_ORGANIZATION
. O
, O
i O
. O
e O
. O
testing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
each O
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
as O
the O
threaded B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
made O
increasingly O
complex B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
, O
is O
a O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributing O
to O
the O
speed B_TIME[MEASURE]/B_SPORT[ENT]
with O
which O
software B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
developed O
using O
convers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
software B_PRODUCT[OBJECT]/B_LOCATION
stack I_PRODUCT[OBJECT]/I_LOCATION
also O
contributes O
toward O
improved B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
memory I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
efficiency I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
simplified B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
programming I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
stack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
an O
area B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
memory B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
set O
aside O
to O
handle O
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
data B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
numbers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
etc B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

One B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
primary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advantages I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
stack B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
that O
entries B_PERSON/B_LOCATION
can O
leave O
temporary B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
stack B_LOCATION/B_ORGANIZATION
without O
having O
to O
assign O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
131 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

No O
. O
3 B_PERSON/B_MEASURE
April I_PERSON/I_MEASURE
1979 I_PERSON/I_MEASURE
. O

Tilden B_PERSON/B_LOCATION
& O
Denton B_LOCATION/B_PERSON
. O

Advanced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Dual B_TIME[MEASURE]/B_LOCATION
regulated O
Power B_GENE
supply I_GENE
I0 I_GENE
kV I_GENE
I00 I_LOCATION
. O

grating B_LOCATION/B_ENT
. O

PIEZOELECTRIC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
TRANSLATOR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

op B_ORGANIZATION
TOACOUS I_ORGANIZATION
TIC I_ORGANIZATION
Cell I_ORGANIZATION
. O

, B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
. O

C02He B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N2 B_MEASURE/B_LOCATION
. O

mirror B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
TRANSLATOR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

CHOPPER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Power B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
DE I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
TECTOR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

STEPPER B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Motor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Driver B_PERSON
. O

ADC B_DISEASE/B_MEASURE
. O

Lock B_LOCATION/B_MEASURE
- O
IN B_LOCATION
AMP I_LOCATION
. O

Controller B_PERSON/B_MEDICAL_DEVICE[OBJECT]
. O

Lock B_LOCATION/B_DISEASE
- O
IN B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

AMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

MICROFLOPPY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

disk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
24K I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ram I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

1 B_NUMBER[MEASURE]/B_PERSON

Figure B_MEASURE
7 I_MEASURE
. O

The O
optoacoustic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
which O
a O
microcomputer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
is O
used O
to O
control O
laser B_MEASURE
wavelength I_MEASURE
and O
to O
monitor O
laser B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
power B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
and O
optoacoustic B_MEASURE/B_ENT
signal I_MEASURE/I_ENT
. O

memory B_MEASURE/B_PERSON
locations B_MEASURE/I_PERSON
to O
store O
them O
. O

This O
not O
only O
can O
save O
considerable B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
memory I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
also O
allows O
programs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
be O
easily O
relocatable B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
since O
one B_PERSON/B_ORGANIZATION
algorithm I_PERSON/I_ORGANIZATION
need O
only O
know O
that O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
routine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
left O
so O
many B_MEASURE/B_ENT
words I_MEASURE/I_ENT
of O
data B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
etc B_DISEASE/B_PROTEIN[GENE]
. O
on O
the O
stack B_LOCATION
. O

It O
need O
not O
know O
where O
the O
previous B_LOCATION
routine I_LOCATION
is O
nor O
even O
where O
the O
stack B_LOCATION/B_SEQUENCE[MEASURE]
is O
located O
. O

A O
series B_SPORT[ENT]/B_MEASURE
of O
stack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
handling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
routines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
which O
should O
appear O
quite O
familiar B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
many B_PERSON
small I_PERSON
calculator I_PERSON
users I_PERSON
, O
provide O
an O
array B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
capabilities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
including O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
push O
a O
number B_MEASURE
on O
the O
stack B_LOCATION
, O
POP B_DISEASE/B_GENE
, O
it O
off O
, O
duplicate O
it O
, O
swap O
the O
top B_MEASURE/B_ENT
two I_MEASURE/I_ENT
numbers I_MEASURE/I_ENT
, O
locate O
a O
number B_MEASURE
some O
distance B_MEASURE/B_LOCATION
into O
the O
stack B_LOCATION
, O
and O
copy O
it O
on O
top B_PROTEIN[GENE]/B_LOCATION
of O
the O
stack B_LOCATION/B_MEASURE
, O
etc B_LOCATION
. O

Additionally O
, O
a O
variety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
logic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
functions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
familiar I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
the O
minicomputer B_PERSON/B_LOCATION
user I_PERSON/I_LOCATION
are O
provided O
including O
OR O
, O
AND O
, O
shift O
left O
, O
shift O
right O
, O
greater B_LOCATION/B_MEASURE
than O
, O
less O
than O
, O
etc B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

input B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
output B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
O B_PROTEIN[GENE]/B_LOCATION
) O
is O
normally O
accomplished O
using O
the O
stack B_LOCATION/B_PERSON
in O
conjunction B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
INDEVICE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
OUTDEVICE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
commands B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
to O
take O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
a O
device B_PRODUCT[OBJECT]/B_LOCATION
located O
at O
I O
/ O
O B_OTHER/B_LOCATION
, O
port B_LOCATION/B_MEASURE
7 I_LOCATION/I_MEASURE
, O
the O
number B_MEASURE/B_PERSON
seven I_MEASURE/I_PERSON
is O
' O
pushed O
' O
onto O
the O
stack B_LOCATION
( O
7 B_NUMBER[MEASURE]/B_LOCATION
) O
, O
goes O
to O
this O
I O
/ O
O B_LOCATION
port I_LOCATION
, O
takes O
in O
a O
number B_MEASURE
and O
' O
pushes O
' O
the O
number B_MEASURE
on O
the O
stack B_LOCATION
. O

OUTDEVICE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
functions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
a O
similar B_LOCATION/B_PERSON
manner I_LOCATION/I_PERSON
, O
requiring O
the O
number B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
sent O
to O
the O
desired B_PERSON
device I_PERSON
to O
be O
' O
pushed O
' O
onto O
the O
stack B_LOCATION/B_PRODUCT[OBJECT]
followed O
by O
the O
device B_PRODUCT[OBJECT]/B_PERSON
' O
s B_OTHER/B_DISEASE_ADJECTIVE[DISEASE]
I O
/ O
O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
port B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
address B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

Hence O
, O
to O
send O
the O
number B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
131 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
to O
device B_NUMBER[MEASURE]/B_PERSON
11 I_NUMBER[MEASURE]/I_PERSON
, O
the O
number B_PERSON/B_PRODUCT[OBJECT]
131 I_PERSON/I_PRODUCT[OBJECT]
is O
pushed O
on O
the O
stack B_LOCATION/B_ENT
followed O
by O
11 B_NUMBER[MEASURE]/B_PERSON
and O
then O
OUTDEVICE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

This O
' O
pops O
' O
the O
top B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
( O
11 B_MEASURE
) O
from O
the O
stack B_LOCATION/B_ENT
, O
uses O
it O
as O
the O
output B_LOCATION/B_MEASURE
port I_LOCATION/I_MEASURE
and O
then O
sends O
the O
number B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
131 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
that O
location B_LOCATION/B_MEASURE
. O

Sound B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

bell B_PERSON
. O

bell B_PERSON
. O

bell B_PERSON
. O

The O
colon B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
denotes O
changing O
from O
EXECUTE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
COMPILE B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
mode I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

After O
typing O
the O
name B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
new B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
routine I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
in O
this O
case B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
be O
called O
Sound B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
typing O
the O
name B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
earlier O
defined B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
routine I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
bell B_PERSON/B_TIME[MEASURE]
a O
previously O
defined O
simple B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
rng O
the O
terminal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
initiates O
a O
dictionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
search I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
locate O
this O
routine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O
s B_OTHER/B_DISEASE
starting O
address B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
subsequentially O
is O
entered O
three B_TIME[MEASURE]/B_LOCATION
times B_TIME[MEASURE]/I_LOCATION
. O

The O
resulting O
sound B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
routine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
contains O
machine B_NUMBER[MEASURE]
code I_NUMBER[MEASURE]
calls O
to O
the O
Be O
LL B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
routine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O
, O
itself O
, O
is O
composed O
of O
machine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Of O
course O
, O
Sound B_ENT/B_PERSON
could O
also O
have O
been O
defined O
using O
a O
Do B_LOCATION/B_MEASURE
- O
Loop B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
i O
. O
e B_DISEASE/B_LOCATION
. O
Sound B_ENT/B_LOCATION
3 I_ENT/I_LOCATION
. O

Do B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

bell B_PERSON
. O

Loop B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

where O
the O
numbers B_NUMBER[MEASURE]/B_ENT
three I_NUMBER[MEASURE]/I_ENT
and O
one B_NUMBER[MEASURE]/B_LOCATION
set O
the O
upper B_MEASURE
and O
lower B_MEASURE/B_LOCATION
indices I_MEASURE/I_LOCATION
. O

If O
it O
were O
desirable B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
change O
the O
actual B_MEASURE
number I_MEASURE
of O
bell B_PERSON/B_ENT
rings I_PERSON/I_ENT
from O
some O
other B_MEASURE/B_LOCATION
program I_MEASURE/I_LOCATION
, O
this O
value B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
defined O
as O
a O
variable B_PERSON/B_LOCATION
let I_PERSON/I_LOCATION
' O
s B_OTHER/B_DISEASE
call O
it O
Noise B_ENT/B_MEASURE
. O

3 B_NUMBER[MEASURE]/B_PERSON

variable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
noise I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
number B_PERSON/B_MEASURE
three I_PERSON/I_MEASURE
is O
first O
pushed O
on O
the O
stack B_LOCATION/B_BIO
, O
variable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
transfers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
the O
top B_MEASURE
number I_MEASURE
on O
the O
stack B_LOCATION/B_MEASURE
( O
the O
three B_MEASURE/B_LOCATION
) O
to O
a O
dictionary B_MEASURE
location I_MEASURE
named O
Noise B_ENT/B_MEASURE
. O

If O
Sound B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
now O
defined O
as O
: O
Sound B_ENT/B_LOCATION
. O

Noise B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

@ B_OTHER/B_PERSON

Do B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

bell B_PERSON
. O

Loop B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

applications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
CONVERS B_EDU[ORGANIZATION]/B_PERSON
To O
appreciate O
the O
ease B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
which O
real B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
programs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
can O
be O
written O
, O
a O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
examples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
be O
considered O
. O

A O
trivial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
called O
Sound B_MEASURE/B_ENT
, O
which O
rings O
the O
terminal B_PERSON/B_LOCATION
bell I_PERSON/I_LOCATION
three I_PERSON/I_LOCATION
times I_PERSON/I_LOCATION
, O
might O
be O
written O
: O
132 B_MEASURE/B_LOCATION
. O

the O
bell B_PERSON/B_PRODUCT[OBJECT]
would O
again O
ring O
three B_TIME[MEASURE]/B_LOCATION
times I_TIME[MEASURE]/I_LOCATION
. O

In O
this O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
when O
the O
word B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Noise I_SEQUENCE[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IS O
encountered O
, O
its O
address B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
pushed O
on O
the O
stack B_LOCATION/B_ENT
, O
the O
@ O
is O
a O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
which O
goes O
to O
the O
address B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O
on O
the O
top B_PROTEIN[GENE]/B_LOCATION
of O
the O
stack B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
that O
of O
Noise B_ENT/B_NUMBER[MEASURE]
) O
and O
replaces O
it O
with O
the O
actual B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
located O
at O
that O
address B_LOCATION/B_MEASURE
( O
the O
number B_MEASURE/B_PERSON
three I_MEASURE/I_PERSON
) O
. O

At O
any O
future B_MEASURE/B_ENT
time I_MEASURE/I_ENT
, O
the O
value B_MEASURE/B_LOCATION
of O
variable B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
changed O
by O
' O
pushing O
' O
the O
new B_MEASURE
value I_MEASURE
onto O
the O
stack B_LOCATION/B_ENT
, O
followed O
by O
the O
address B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
variable B_MEASURE
to O
be O
changed O
, O
generated O
by O
its O
name B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
an O
exclamation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mark I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

To O
change O
N B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IS I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
5 B_TIME[MEASURE]/B_LOCATION
, O
The O
Journal B_EDU[ORGANIZATION]
of O
Automatic B_EDU[ORGANIZATION]/B_PERSON
Chemistry I_EDU[ORGANIZATION]/I_PERSON
. O

Tilden B_PERSON/B_LOCATION
& O
Denton B_LOCATION/B_PERSON
. O

Advanced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

5 B_TIME[MEASURE]/B_LOCATION
Noise I_TIME[MEASURE]/I_LOCATION
a O
number B_MEASURE/B_PERSON
five I_MEASURE/I_PERSON
is O
pushed O
onto O
the O
stack B_LOCATION
, O
Noise B_ENT/B_NUMBER[MEASURE]
pushes O
its O
address B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
on O
the O
stack B_LOCATION/B_ENT
, O
and O
goes O
to O
the O
address B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
by O
the O
' O
top B_GENE/B_MEASURE
' O
number B_MEASURE/B_LOCATION
on O
the O
stack B_LOCATION/B_ENT
and O
deposits B_DISEASE/B_MEASURE
the O
next B_MEASURE
number I_MEASURE
. O

Now O
sound B_ENT/B_PERSON
would O
ring O
the O
terminal B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
bell B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
five B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
times B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

A O
much O
less O
trivial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
which O
could O
be O
written O
to O
scan O
and O
take O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
a O
monochromator B_PRODUCT[OBJECT]/B_PERSON
equipped O
with O
a O
. O

DENCO B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
SM2A I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
stepper I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
motor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
controller I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
2 B_PROTEIN[GENE]/B_MEASURE
] I_PROTEIN[GENE]/I_MEASURE
( O
the O
SM2A B_GENE/B_PERSON
takes O
a O
parallel B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
an O
address B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sends O
one B_NUMBER[MEASURE]/B_LOCATION
of O
two B_PERSON/B_NUMBER[MEASURE]
stepper B_PERSON/I_NUMBER[MEASURE]
motors B_PERSON/I_NUMBER[MEASURE]
to O
this O
location B_LOCATION/B_ORGANIZATION
and O
outputs O
an O
arrival B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flag I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
when O
the O
address B_LOCATION/B_MEASURE
is O
reached O
) O
is O
given O
in O
Figure B_MEASURE/B_PERSON
6 I_MEASURE/I_PERSON
. O

assume O
that O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
configured O
so O
the O
SM2A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
at O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
O B_OTHER/B_PROTEIN[GENE]
, O
port B_MEASURE/B_LOCATION
5 I_MEASURE/I_LOCATION
and O
an O
analog B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
digital B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
converter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
to O
acquire O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
at O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
O B_OTHER/B_LOCATION
, O
port B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Let O
us O
assume O
that O
, O
initially O
, O
a O
scan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
designed O
from O
a O
starting O
stepper B_MEASURE/B_LOCATION
motor I_MEASURE/I_LOCATION
location I_MEASURE/I_LOCATION
of O
2000 B_MEASURE
to O
a O
final B_MEASURE/B_ENT
location I_MEASURE/I_ENT
of O
5000 B_MEASURE
, O
taking O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
every O
20 B_TIME[MEASURE]/B_ENT
steps I_TIME[MEASURE]/I_ENT
. O

The O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
illustrated O
in O
figure B_MEASURE/B_LOCATION
6 I_MEASURE/I_LOCATION
acts I_MEASURE/I_LOCATION
in O
the O
following B_LOCATION/B_ENT
manner B_LOCATION/I_ENT
. O

Line B_LOCATION/B_ORGANIZATION
defines O
a O
variable B_LOCATION/B_DISEASE
called O
start B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
be O
2000 B_TIME[MEASURE]
, O
which O
is O
the O
starting B_MEASURE
location I_MEASURE
of O
fhe B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scan B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
end B_MEASURE/B_LOCATION
of O
the O
scan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
defined O
as O
5000 B_NUMBER[MEASURE]/B_LOCATION
in O
the O
next B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
line I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
defines O
the O
increment B_MEASURE/B_LOCATION
between O
data B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
points I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
variable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
called O
Location B_LOCATION/B_MEASURE
where O
the O
. O
next B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
address I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
stored O
is O
defined O
in O
line B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
. O

Colon B_PERSON/B_NUMBER[MEASURE]
, O
in O
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
5 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
puts O
the O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
compile B_LOCATION/B_PERSON
mode I_LOCATION/I_PERSON
, O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
D7 B_PROTEIN[GENE]/B_MEASURE
will O
be O
the O
name B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
module B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
which O
when O
called O
will O
cause O
a O
7 B_MEASURE/B_BIO
to O
be O
pushed O
onto O
the O
stack B_LOCATION/B_PRODUCT[OBJECT]
. O

INDEVICE B_PERSON
will O
' O
pop O
' O
it O
back O
off O
and O
use O
it O
as O
a O
device B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
address B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
go O
and O
take O
a O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
point I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
push O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
onto O
the O
stack B_LOCATION/B_PRODUCT[OBJECT]
. O

Line B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defines O
a O
module B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
INITIALIZE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
Start B_LOCATION/B_PERSON
puts O
its O
address B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
the O
stack B_LOCATION/B_PERSON
, O
@ O
replaces O
the O
address B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
value B_MEASURE
at O
that O
address B_LOCATION/B_MEASURE
, O
Location B_LOCATION
puts O
its O
address B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
stack B_LOCATION/B_MEASURE
, O
' O
! O
' O
goes O
to O
the O
address B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specified O
by O
the O
number B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
stack B_LOCATION/B_PERSON
and O
deposits B_LOCATION
the O
second B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
net B_MEASURE
result I_MEASURE
value I_MEASURE
at O
Start B_LOCATION/B_MEASURE
is O
put O
into O
Location B_LOCATION
. O

Line B_PERSON/B_LOCATION
7 I_PERSON/I_LOCATION
defines O
Step B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
take O
values B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
from O
. O

Location B_LOCATION/B_PERSON
and O
INCREMENT B_PERSON/B_ORGANIZATION
adds O
them O
together O
and O
puts O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
into O
Location B_LOCATION/B_MEASURE
, O
i O
. O
e O
. O
Location B_LOCATION/B_PERSON
puts O
its O
address B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
the O
stack B_LOCATION
, O
@ O
replaces O
the O
top B_MEASURE
value I_MEASURE
on O
the O
stack B_LOCATION/B_MEASURE
with O
the O
number B_MEASURE
stored O
at O
the O
address B_LOCATION/B_MEASURE
, O
INCREMENT B_LOCATION/B_ORGANIZATION
@ O
gets O
the O
value B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
INCREMENT B_LOCATION/B_MEASURE
and O
puts O
it O
in O
to O
the O
stack B_LOCATION/B_MEASURE
, O
and O
adds O
the O
top B_MEASURE/B_LOCATION
two I_MEASURE/I_LOCATION
stack I_MEASURE/I_LOCATION
numbers I_MEASURE/I_LOCATION
and O
pushes O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
the O
stack B_LOCATION
. O

Location B_LOCATION/B_ORGANIZATION
puts O
its O
address B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
stack B_LOCATION
and O
goes O
to O
the O
address B_LOCATION/B_MEASURE
specified O
by O
the O
top B_PERSON/B_MEASURE
number I_PERSON/I_MEASURE
on O
the O
stack B_LOCATION
and O
deposits B_DISEASE/B_MEASURE
the O
second B_MEASURE
number I_MEASURE
. O

Themodule B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
defined O
in O
line B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
8 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
takes O
a O
number B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
stepper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
motor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
controller I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
assume O
device B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbered O
5 B_NUMBER[MEASURE]
) O
pushes O
on O
the O
stack B_LOCATION/B_PERSON
, O
and O
pushes O
the O
value B_MEASURE/B_PRODUCT[OBJECT]
10 B_MEASURE/I_PRODUCT[OBJECT]
on O
the O
stack B_LOCATION/B_ORGANIZATION
and O
does O
a O
logical B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
to O
see O
if O
the O
controllers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
flag B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
set O
, O
if O
this O
is O
true B_DISEASE_ADJECTIVE[DISEASE]
the O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
D7 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
module I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
called O
to O
input O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
if O
the O
flag B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
set O
, O
the O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
returned O
to O
begin O
- O
Here O
. O

Therefore O
the O
delay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
module I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
loop B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
waiting O
for O
the O
stepper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
motor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
to O
arrive O
at O
its O
new B_LOCATION/B_PERSON
location I_LOCATION/I_PERSON
followed O
by O
a O
call B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
D7 B_LOCATION/B_PROTEIN[GENE]
data I_LOCATION/I_PROTEIN[GENE]
acquisition I_LOCATION/I_PROTEIN[GENE]
module I_LOCATION/I_PROTEIN[GENE]
. O

Move B_LOCATION/B_PERSON
defined O
in O
line B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gets O
the O
value B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stored O
at O
Location B_LOCATION/B_PERSON
pushes O
the O
device B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
code I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
onto O
the O
stack B_LOCATION/B_PRODUCT[OBJECT]
performs O
an O
outdevice B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
which O
uses O
the O
top B_LOCATION/B_MEASURE
stack I_LOCATION/I_MEASURE
number I_LOCATION/I_MEASURE
as O
a O
1 B_MEASURE/B_LOCATION
/ O
0 B_MEASURE/B_LOCATION
port I_MEASURE/I_LOCATION
address I_MEASURE/I_LOCATION
to O
send O
the O
next B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
call O
the O
Step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
module I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
ie O
the O
value B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
Location B_LOCATION
) O
, O
this O
increments B_LOCATION/B_TIME[MEASURE]
Location B_LOCATION/I_TIME[MEASURE]
by O
the O
INCREM B_MEASURE/B_LOCATION
E I_MEASURE/I_LOCATION
N I_MEASURE/I_LOCATION
T I_MEASURE/I_LOCATION
value I_MEASURE/I_LOCATION
and O
finally O
calls O
D B_LOCATION
E I_LOCATION
L I_LOCATION
A I_LOCATION
Y I_LOCATION
and O
waits O
for O
a O
flag B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
the O
stepper B_PERSON
motor I_PERSON
controller I_PERSON
to O
signal O
its O
arrival B_MEASURE
at O
the O
desired B_LOCATION
address I_LOCATION
and O
then O
takes O
a O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
line I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shown O
in O
the O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Called O
scan B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
itself O
calls O
the O
INITIALIZE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
module I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
which O
sets O
Location B_LOCATION/B_MEASURE
to O
the O
Start B_LOCATION/B_PERSON
location I_LOCATION/I_PERSON
for O
the O
scan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
it O
also O
calls O
move B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
which O
sends O
this O
value B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
motor B_PRODUCT[OBJECT]/B_PERSON
Location I_PRODUCT[OBJECT]/I_PERSON
controller I_PRODUCT[OBJECT]/I_PERSON
, O
increments O
the O
value B_MEASURE
stored O
in O
Location B_LOCATION
by O
INCREMENT B_MEASURE/B_DISEASE
and O
calls B_TIME[MEASURE]/B_LOCATION
delay I_TIME[MEASURE]/I_LOCATION
which O
waits O
for O
the O
motor B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
arrive O
and O
then O
takes O
a O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

Next O
the O
incremented B_MEASURE/B_LOCATION
value B_MEASURE/I_LOCATION
from O
Location B_LOCATION/B_MEASURE
is O
placed O
on O
the O
stack B_LOCATION/B_ENT
( O
Location B_LOCATION
) O
followed O
by O
the O
stop B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

I0 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KW I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AMPLIFIER I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matching I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

, O
NETWORKIS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PREAMP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Motor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
CON I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
TROL I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
ER I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

MICRODISK B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
90K I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
byte I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Intel B_LOCATION/B_ORGANIZATION
8080 I_LOCATION/I_ORGANIZATION
based O
MICROCOMPUTER B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
16K I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

ram B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

figure B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
. O

A O
schematic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
inductively O
coupled O
plasma B_LOCATION
emission I_LOCATION
spectrometer I_LOCATION
in O
which O
the O
microcomputer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
used O
to O
control O
radio B_MEASURE
frequency I_MEASURE
power I_MEASURE
and O
' O
flame B_PERSON/B_LOCATION
' O
positioning B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
as O
well O
as O
to O
monitor O
light B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
intensity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Volume B_MEASURE
. O

No O
. O
3 B_PERSON/B_MEASURE
April I_PERSON/I_MEASURE
1979 I_PERSON/I_MEASURE
. O

133 B_NUMBER[MEASURE]
. O

Tilden B_PERSON/B_LOCATION
& O
Denton B_LOCATION/B_PERSON
. O

Advanced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concepts I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

value B_MEASURE/B_LOCATION
( O
Stop B_LOCATION/B_MEASURE
@ O
) O
, O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
compared O
to O
to O
see O
if O
the O
incremented B_MEASURE/B_LOCATION
value I_MEASURE/I_LOCATION
at O
Location B_LOCATION
is O
larger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
then O
the O
Stop B_MEASURE/B_LOCATION
value I_MEASURE/I_LOCATION
, O
if O
it O
is O
the O
program B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ends O
, O
if O
not O
, O
it O
repeats O
the O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
starting O
at O
begin B_MEASURE/B_LOCATION
- O
- O
Here O
. O

It O
should O
be O
noted O
that O
whilst O
many B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
variables I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
have O
been O
pushed O
on O
the O
stack B_LOCATION
, O
only O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O
remain O
, O
since O
each O
time B_TIME[MEASURE]/B_LOCATION
a O
value B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
used O
it O
is O
' O
popped O
' O
( O
removed O
) O
from O
the O
stack B_LOCATION
. O

If O
a O
different B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectra I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
to O
be O
scanned O
i O
. O
e O
. O
from O
3000 B_MEASURE
to O
6500 B_MEASURE
with O
10 B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increments B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
variables B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
need O
only O
be O
. O

> B_OTHER/B_PERSON

data B_PERSON/B_ORGANIZATION
acquisition I_PERSON/I_ORGANIZATION
programs I_PERSON/I_ORGANIZATION
have O
been O
easily O
implemented O
. O

Memory B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
operating B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
speed B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
found O
to O
be O
far O
superior B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
conventional B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
approaches I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Additionally O
, O
new B_PERSON/B_ORGANIZATION
system I_PERSON/I_ORGANIZATION
users I_PERSON/I_ORGANIZATION
have O
encountered O
a O
difficulty B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
utilising O
previously O
developed O
custom B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O
a O
particular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
even O
when O
documentation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
vague B_DISEASE_ADJECTIVE[DISEASE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
The O
authors B_PERSON/B_ORGANIZATION
hope O
that O
this O
short B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
introduction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O
only O
a O
few B_MEASURE
of O
the O
concepts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
employed O
in O
CONVERS B_ORGANIZATION/B_LOCATION
will O
generate O
interest B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O
its O
capabilities B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

A O
much O
more O
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discussion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
user B_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
manual I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O
3 B_PERSON/B_MEASURE
] I_PERSON/I_MEASURE
available I_PERSON/I_MEASURE
from O
the O
authors B_PERSON/B_ORGANIZATION
. O

changed O
thus O
3000 B_TIME[MEASURE]/B_LOCATION
Start I_TIME[MEASURE]
! O

6500 B_TIME[MEASURE]/B_LOCATION
Stop O
10 B_MEASURE
increment I_MEASURE
and O
type B_MEASURE/B_LOCATION
scan B_MEASURE/I_LOCATION
, O
system B_ORGANIZATION/B_PERSON
will O
now O
scan O
from O
3000 B_NUMBER[MEASURE]
to O
6500 B_MEASURE/B_ORGANIZATION
taking I_MEASURE/I_ORGANIZATION
data I_MEASURE/I_ORGANIZATION
every O
10 B_TIME[MEASURE]/B_ENT
steps I_TIME[MEASURE]/I_ENT
. O

While O
the O
code B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O
look O
a O
little O
strange B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
first O
, O
it O
quickly O
becomes O
very O
easy O
to O
work O
with O
. O

The O
scan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
figure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
combined O
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
modules I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O
shown O
in O
Figure B_LOCATION/B_PERSON
5 I_LOCATION/I_PERSON
to O
perform O
some O
more O
complex B_DISEASE_ADJECTIVE[DISEASE]
experimental I_DISEASE_ADJECTIVE[DISEASE]
function I_DISEASE_ADJECTIVE[DISEASE]
. O

Each O
module B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
program B_ORGANIZATION/B_PRODUCT[OBJECT]
can O
be O
easily O
tried O
out O
to O
ensure O
that O
it O
is O
operational B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
proceeding O
with O
the O
next B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
. O

presently O
, O
convers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
being O
used O
in O
the O
authors B_LOCATION/B_ORGANIZATION
' I_LOCATION/I_ORGANIZATION
laboratories I_LOCATION/I_ORGANIZATION
for O
a O
variety B_ENT/B_MEASURE
of O
spectrochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
laser B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
excited O
optoacoustic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectroscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Figure B_TIME[MEASURE]/B_ENT
7 I_TIME[MEASURE]/I_ENT
) O
and O
inductively O
coupled B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
optical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emission I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectroscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Figure B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
) O
. O

Rather O
complex B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactive I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
. O

ACKNOWLEDGEMENTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
The O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
convers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
was O
partially O
supported O
by O
the O
Office B_ORGANIZATION/B_LOCATION
of O
Naval B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Research I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
Alfred B_PERSON/B_LOCATION
P I_PERSON/I_LOCATION
. O
Cloan B_PERSON/B_LOCATION
Foundation I_PERSON/I_LOCATION
Research I_PERSON/I_LOCATION
Fellowship I_PERSON/I_LOCATION
to O
M B_OTHER/B_MEASURE
. O

Bonnet B_PERSON/B_LOCATION
Denton I_PERSON/I_LOCATION
. O

references B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moore B_PERSON/B_TIME[MEASURE]
, O
Astronomical B_MEASURE/B_LOCATION
Astrophysics I_MEASURE/I_LOCATION
Supplemental I_MEASURE/I_LOCATION
, O
15 B_MEASURE
, O
( O
1974 B_MEASURE
) O
497 B_MEASURE/B_LOCATION
. O

[ O
2 B_TIME[MEASURE]
] O
M B_PROTEIN[GENE]/B_LOCATION
. O
B B_PROTEIN[GENE]/B_DISEASE
. O

Denton B_LOCATION/B_PERSON
, O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
D B_OTHER/B_PERSON
. O

Mack B_PERSON/B_LOCATION
, O
M B_LOCATION
. O
W B_OTHER/B_PROTEIN[GENE]
. O

Routh B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
B B_OTHER/B_PERSON
. O

SwartzClmerican B_PERSON/B_BIO
. O

[ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Laboratory B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
8 B_NUMBER[MEASURE]
, O
69 B_MEASURE
( O
1976 B_MEASURE
) O
. O

CONVERS B_PERSON
An O
Interpretive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Compiler I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
developed O
by O
scott B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
Tilden B_PERSON/B_COLOR
and O
M B_OTHER/B_PERSON
. O

Bonner B_PERSON/B_ORGANIZATION
Denton I_PERSON/I_ORGANIZATION
, O
Department B_ORGANIZATION/B_PERSON
of O
Chemistry B_EDU[ORGANIZATION]/B_PERSON
, O
University B_LOCATION/B_ORGANIZATION
of O
Arizona B_LOCATION
, O
Tucson B_LOCATION/B_PERSON
, O
Arizona B_LOCATION
85721 I_LOCATION
, O
USA B_LOCATION/B_MEASURE
. O

The O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
a O
microcomputer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
for O
flexible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
automation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
a O
liquid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

chromatograph B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
D B_OTHER/B_MEASURE
. O

Mills B_MEASURE/B_PERSON
, O
i O
. O

Mackenzie B_PERSON/B_COLOR
and O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
J B_OTHER/B_PERSON
. O

Dolphin B_MEASURE/B_LOCATION
* O
Philips B_LOCATION
Research I_LOCATION
Laboratories I_LOCATION
, O
Redhill B_LOCATION/B_PERSON
, O
Surrey B_LOCATION
, O
RH1 B_LOCATION
5HA I_LOCATION
, O
U B_LOCATION
. O
K B_OTHER/B_LOCATION
. O

Introduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Microprocessors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
being O
used O
to O
add O
inexpensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
automatic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
data B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
handling I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
facilities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
a O
variety B_ENT/B_MEASURE
of O
chemical B_ORGANIZATION/B_LOCATION
instruments B_ORGANIZATION/I_LOCATION
. O

With O
a O
microcomputer B_PRODUCT[OBJECT]/B_PERSON
it O
is O
now O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
realise O
the O
flexibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
formerly O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
with O
a O
relatively O
large B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
expensive B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
minicomputer B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O
an O
instrument B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
little O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
size B_MEASURE/B_LOCATION
and O
cost B_MEASURE
from O
one B_TIME[MEASURE]/B_PERSON
controlled O
by O
inflexible B_ORGANIZATION
hardware I_ORGANIZATION
. O

In O
many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ways I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chromatography I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
an O
ideal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
such B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
automation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Most B_PERSON
instruments I_PERSON
are O
given O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
workload B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
, O
although O
many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
applications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
routine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
repetitive B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
versatility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
requires O
an O
instrument B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
can O
easily O
be O
used O
in O
a O
variety B_ENT/B_MEASURE
of O
modes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
improving O
the O
convenience B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
user B_PERSON
, O
automation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PRODUCT[OBJECT]
of O
a O
liquid B_ENT
chromatrograph I_ENT
should O
enhance O
the O
performance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
instrument B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Some O
aspects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
high B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
liquid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
HPLC B_LOCATION/B_ORGANIZATION
) O
which O
can O
benefit O
in O
this O
way B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
as O
follows O
: O
( O
1 B_SEQUENCE[MEASURE]
) O
Accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
solvent B_MEASURE
flow I_MEASURE
rate I_MEASURE
will O
compensate O
for O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
pressure B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drop O
and O
lead O
to O
more O
reliable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
retention I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
times I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

( O
2 O
) O
The O
composition B_MEASURE/B_ENT
of O
the O
mobile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
can O
be O
accurately O
controlled O
in O
either O
isocratic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
gradient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
elution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chromatography B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O
, O
for O
example B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
a O
proportioning O
valve B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
the O
low B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
pressure I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
side I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
pump B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

( O
3 O
) O
automatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sampling B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O
be O
operated O
in O
a O
variety B_ENT/B_MEASURE
of O
modes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
process O
a O
number B_MEASURE
of O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
supervision B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
also O
more O
precise B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
manual B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
injection I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

( O
4 O
) O
A O
built O
- O
in O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
handling O
facility B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
present O
the O
analyst B_PERSON
with O
an O
easily O
read O
post B_LOCATION/B_MEASURE
- O
run B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
the O
analytical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
accurate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
peak B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
area B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
measurements B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
even O
for O
peaks B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
which O
are O
poorly O
resolved O
. O

Although O
liquid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatographs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incorporating O
microprocessors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
handling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
purposes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
commercially O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
these O
instruments B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
, O
so O
far O
, O
This O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
describes O
, O
in O
detail B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
relatively O
inflexible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O
automation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
of O
a O
liquid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
chromatograph I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O
an O
inexpensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
general I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
purpose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microcomputer I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
has O
previously O
been O
applied O
in O
atomic B_LOCATION/B_ORGANIZATION
absorption I_LOCATION/I_ORGANIZATION
spectrophotometry I_LOCATION/I_ORGANIZATION
[ O
1 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
for O
column B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
switching I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
HPLC B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
2 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

Figure B_PERSON/B_LOCATION
illustrates O
the O
interconnection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
chromatograph B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
and O
the O
microcomputer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
which O
controls O
the O
mobile B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
operates O
an O
automatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sampler I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
analyses O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
the O
detector B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
handling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
functions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
integrated O
in O
a O
program B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
enables O
the O
user B_PERSON
to O
communicate O
with O
the O
instrument B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
plain B_MEASURE/B_LOCATION
English I_MEASURE/I_LOCATION
, O
via O
a O
visual B_PRODUCT[OBJECT]/B_PERSON
display I_PRODUCT[OBJECT]/I_PERSON
unit I_PRODUCT[OBJECT]/I_PERSON
( O
VDU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
or O
teletypewriter B_PRODUCT[OBJECT]/B_ENT
keyboard I_PRODUCT[OBJECT]/I_ENT
. O

A O
variety B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
operational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
modes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
offered O
, O
giving O
the O
analyst B_PERSON
an O
opportunity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
establish O
the O
best B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conditions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
a O
particular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
separation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
before O
leaving O
the O
instrument B_SPORT[ENT]/B_LOCATION
to O
perform O
its O
given O
tasks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
microcomputer B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hardware I_PRODUCT[OBJECT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
The O
computer B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
purpose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
constructed O
using O
a O
set B_GENE/B_LOCATION
of O
ready B_TIME[MEASURE]/B_LOCATION
made O
circuit B_PRODUCT[OBJECT]/B_PERSON
cards I_PRODUCT[OBJECT]/I_PERSON
( O
Philips B_TIME[MEASURE]/B_EDU[ORGANIZATION]
, O
Science B_ORGANIZATION/B_LOCATION
and O
The B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Journal B_ORGANIZATION/B_LOCATION
of O
Automatic B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chemistry I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

* B_MEASURE/B_LOCATION
Present I_MEASURE/I_LOCATION
address I_MEASURE/I_LOCATION
: O
lye B_LOCATION/B_PERSON
Unicam I_LOCATION/I_PERSON
Ltd I_LOCATION/I_PERSON
. O
, O
York B_LOCATION/B_ORGANIZATION
Street I_LOCATION/I_ORGANIZATION
, O
Cambridge B_LOCATION
, O
CB1 B_LOCATION/B_PERSON
2PX I_LOCATION/I_PERSON
, O
U B_LOCATION
. O
K B_OTHER/B_LOCATION
. O

134 B_NUMBER[MEASURE]
. O

TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O
Fast B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flexible B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
constraints B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
major B_DISEASE_ADJECTIVE[DISEASE]
challenges I_DISEASE_ADJECTIVE[DISEASE]
in O
structural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
bioinformatics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

Despite O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
many B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
tools I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
algorithms B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
very O
few B_NUMBER[MEASURE]/B_PERSON
of O
them O
have O
managed O
to O
capture O
the O
intuitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
understanding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O
in O
structural B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biology I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
especially O
in O
the O
context B_LOCATION
of O
rapid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
database I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
searches I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
intuitions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
could O
help O
speed O
up O
similarity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
searches I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
make O
it O
easier B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
understand O
the O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
developed O
a O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
uses O
an O
intuitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
proteins B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
structures I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
captured O
in O
the O
popular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
diagrams I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
limit O
the O
search B_MEASURE
space I_MEASURE
of O
the O
aligned O
fragment B_LOCATION/B_BIO
pairs I_LOCATION/I_BIO
( O
AFPs B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O
by O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

The O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
faster B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
an O
order B_MEASURE/B_DISEASE
of O
magnitude B_NUMBER[MEASURE]
with O
a O
minimal B_MEASURE
cost I_MEASURE
in O
classification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
accuracy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

For O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rich B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
its O
accuracy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
better B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
because O
the O
TOPS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
+ O
strings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
contains O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O
parallel B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
hydrogen B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
- O
bond B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
patterns I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
between O
the O
beta B_GENE/B_NUMBER[MEASURE]
- O
strand B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
SSEs B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
Secondary B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Structural I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
elements I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

We O
show O
that O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
errors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rare B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
as O
they O
are O
, O
can O
be O
clearly O
linked O
to O
oversimplifications B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
of O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagrams I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
can O
be O
corrected O
by O
the O
development B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
more O
precise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secondary I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
definitions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Software B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
availability I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
benchmark B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
the O
compressed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
archive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Linux B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
platform I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O
be O
downloaded O
from O
the O
following O
web B_LOCATION/B_ORGANIZATION
site I_LOCATION/I_ORGANIZATION
: O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provides O
FATCAT B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
accuracy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
insights B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
speed B_MEASURE/B_LOCATION
comparable I_MEASURE/I_LOCATION
to O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alignments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
opening O
up O
a O
possibility B_LOCATION/B_MEASURE
of O
interactive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
protein I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
similarity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
searches I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

structural B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biology I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
most O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fields I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
modern B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biology I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Over O
50 B_MEASURE
, O
000 B_MEASURE
solved O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
illustrate O
details B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
specific I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
biological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
also O
provide O
us O
with O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O
the O
global B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
protein B_LOCATION/B_BIO
structure I_LOCATION/I_BIO
space I_LOCATION/I_BIO
and O
can O
be O
studied O
to O
discover O
the O
evolutionary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
physical B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
mathematical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
rules I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
governing O
them O
. O

How O
many B_NUMBER[MEASURE]/B_PERSON
fundamentally O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
protein B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
shapes B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
folds B_LOCATION/B_LANGUAGE
) O
are O
there O
. O

How O
do O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
structures I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
evolve O
. O

How O
do O
new B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O
, O
and O
if O
they O
are O
coupled O
with O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
how O
does O
this O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
occur O
. O

Such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
questions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O
be O
studied O
by O
classifying O
, O
comparing O
and O
analyzing O
known O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
synergistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
strategies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
are O
typically O
used O
for O
this O
purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
classification O
systems O
such O
as O
SCOP O
[ O
1 O
] O
or O
CATH O
[ O
2 O
] O
, O
human B_PERSON/B_SPECIES[BIO]
intuition O
is O
used O
to O
simplify O
the O
description O
of O
protein O
structures O
to O
a O
manageable O
size O
, O
and O
a O
human B_PERSON/B_SPECIES[BIO]
eye O
, O
sometimes O
supported O
by O
automated O
analysis O
, O
can O
recognize O
patterns O
and O
types O
of O
structures O
. O

In O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
specialized B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
comparison I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
algorithms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
DALI B_LOCATION/B_ORGANIZATION
[ O
3 B_MEASURE
] I_MEASURE
, O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O
4 B_MEASURE
] I_MEASURE
, O
or O
FATCAT B_LOCATION
[ O
5 B_MEASURE
] I_MEASURE
can O
be O
used O
to O
calculate O
a O
distance B_MEASURE/B_LOCATION
- O
like B_MEASURE/B_LOCATION
metric I_MEASURE/I_LOCATION
in O
the O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
space I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

This O
in O
turn B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
used O
to O
cluster O
proteins B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
algorithms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
have O
been O
developed O
over O
the O
past B_TIME[MEASURE]
few I_TIME[MEASURE]
decades I_TIME[MEASURE]
and O
have O
been O
mostly O
used O
for O
the O
classification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
structures I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
into O
families B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

An O
exact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
solution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
an O
alignment B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
two B_LOCATION/B_PERSON
structures I_LOCATION/I_PERSON
is O
formally O
equivalent B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
a O
threading B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
problem I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
is O
therefore O
NP B_DISEASE/B_MEASURE
- O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O
6 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

However O
, O
a O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
obtained O
by O
heuristics B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
reducing O
the O
problem B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
a O
manageable B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
size B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
human B_PERSON/B_BIO
classification O
systems O
, O
the O
protein O
is O
usually O
reduced O
to O
a O
set O
of O
several O
structural O
elements O
, O
which O
obviously O
involve O
many O
arbitrary O
thresholds O
. O

automated O
algorithms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
the O
same B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
also O
suffer O
from O
inconsistencies B_DISEASE_ADJECTIVE[DISEASE]
between O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
numerical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
protein B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
structure I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
similarity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
8 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

Interestingly O
, O
despite O
these O
problems B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
broadly O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

They O
all O
identify O
approximately O
a O
few B_MEASURE/B_LOCATION
hundred I_MEASURE/I_LOCATION
general I_MEASURE/I_LOCATION
classes I_MEASURE/I_LOCATION
of O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
structures B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
usually O
called O
folds B_LOCATION/B_LANGUAGE
[ O
1 B_NUMBER[MEASURE]/B_LOCATION
] I_NUMBER[MEASURE]/I_LOCATION
or O
topologies B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
2 B_NUMBER[MEASURE]/B_LOCATION
] I_NUMBER[MEASURE]/I_LOCATION
, O
distinguished O
by O
how O
the O
main B_LOCATION/B_MEASURE
chain I_LOCATION/I_MEASURE
of O
the O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
folds O
around O
itself O
in O
the O
three B_NUMBER[MEASURE]
- O
dimensional B_MEASURE/B_LOCATION
space I_MEASURE/I_LOCATION
. O

At O
the O
same B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
, O
the O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
both O
between O
and O
within O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
shows O
that O
fold B_LOCATION/B_ORGANIZATION
/ O
topologies B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
( O
or O
cluster B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
definitions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
somewhat O
fuzzy B_DISEASE_ADJECTIVE[DISEASE]
, O
with O
some O
proteins B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O
occasionally O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
classify O
and O
joining O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
groups I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
depending O
on O
various B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assumptions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

This O
lead B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
some O
to O
question O
the O
concept B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
fold B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
[ I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
9 I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
] I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
leaves O
little B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
doubt I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
protein B_LOCATION/B_MEASURE
structure I_LOCATION/I_MEASURE
space I_LOCATION/I_MEASURE
has O
some O
natural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
granularity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
overlaps O
well O
with O
the O
traditional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fold I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
classification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
structures B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O
significantly O
simplified O
by O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
proteins B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
naturally O
modular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
structures B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
being O
mostly O
composed O
of O
locally O
regular B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
structures I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O
alpha B_PROTEIN[GENE]/B_LOCATION
helices I_PROTEIN[GENE]/I_LOCATION
and O
beta B_LOCATION/B_BIO
strands I_LOCATION/I_BIO
. O

These O
two B_MEASURE/B_LOCATION
types I_MEASURE/I_LOCATION
of O
secondary B_LOCATION/B_GENE
structures B_LOCATION/I_GENE
constitute O
a O
little B_PERSON/B_MEASURE
over O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
an O
average B_MEASURE/B_BIO
protein B_MEASURE/I_BIO
' O
s B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
. O

With O
the O
average B_MEASURE
length I_MEASURE
of O
a O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
being O
around O
10 B_NUMBER[MEASURE]
amino I_NUMBER[MEASURE]
acids I_NUMBER[MEASURE]
, O
this O
makes O
it O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
describe O
protein B_GENE/B_LOCATION
structure I_GENE/I_LOCATION
as O
an O
arrangement B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
much O
smaller B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
elements B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

protein B_MEASURE/B_PERSON
structures B_MEASURE/I_PERSON
are O
often O
visualized O
in O
a O
simplified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
with O
the O
so O
- O
called O
ribbon B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagram I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
secondary B_LOCATION/B_PERSON
structures I_LOCATION/I_PERSON
shown O
as O
helices B_LOCATION/B_PERSON
and O
arrows B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
being O
the O
most O
popular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
see O
figure B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
) O
. O

This O
picture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
be O
simplified O
further O
by O
showing O
individual B_PERSON/B_LOCATION
secondary I_PERSON/I_LOCATION
structure I_PERSON/I_LOCATION
elements I_PERSON/I_LOCATION
as O
simple B_LOCATION/B_PERSON
symbols I_LOCATION/I_PERSON
( O
circles B_LOCATION/B_BIO
or O
boxes B_LOCATION/B_BIO
/ O
triangles B_BIO/B_LOCATION
) O
. O

These O
depictions B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
called O
fold B_LOCATION
diagrams I_LOCATION
, O
originally O
proposed O
in O
the O
70s B_SEQUENCE[MEASURE]/B_LOCATION
[ I_SEQUENCE[MEASURE]/I_LOCATION
10 I_SEQUENCE[MEASURE]/I_LOCATION
- O
12 B_MEASURE
] I_MEASURE
are O
best O
captured O
by O
a O
TOPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
topology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
protein B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
structures I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
) O
algorithm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
, O
which O
attempts O
to O
automate O
the O
process B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
creation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
the O
topology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cartoon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
13 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

While O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
, O
such B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
simplified O
descriptions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
not O
used O
in O
the O
most O
popular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
automated O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
algorithms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
DALI B_LOCATION/B_ORGANIZATION
[ I_LOCATION/I_ORGANIZATION
3 I_LOCATION/I_ORGANIZATION
] I_LOCATION/I_ORGANIZATION
or O
CE B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
4 B_MEASURE
] I_MEASURE
. O

Kleywegt B_PERSON
and O
Jones B_PERSON
developed O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
finding O
similar B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
motifs I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
comparing O
distance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
matrices I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
are O
constructed O
by O
representing O
protein B_BIO/B_GENE
as O
a O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O
SSEs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
their O
directional B_MEASURE/B_LOCATION
vectors I_MEASURE/I_LOCATION
and O
angle B_MEASURE/B_LOCATION
between O
those O
vectors B_PROTEIN[GENE]/B_LOCATION
[ O
14 B_MEASURE/B_PERSON
] B_MEASURE/I_PERSON
. O

programs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
used O
SSEs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
either O
for O
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O
on O
hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
superposition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
both O
SSEs B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
atomic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
representation I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
15 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
or O
for O
finding O
common B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substructures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
based O
on O
subgraph B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
isomorphism I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
[ B_TIME[MEASURE]
16 I_TIME[MEASURE]
, O
17 B_MEASURE
] I_MEASURE
and O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
applications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diagram I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
18 B_MEASURE
, O
19 B_MEASURE
] I_MEASURE
, O
usually O
struggle O
with O
translating O
the O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O
the O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
the O
individual B_MEASURE/B_PERSON
residue B_MEASURE/I_PERSON
level B_MEASURE/I_PERSON
. O

Although O
the O
SSM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
uses O
graph B_MEASURE/B_LOCATION
- O
matching O
procedures B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
the O
SSE B_LOCATION/B_MEASURE
level I_LOCATION/I_MEASURE
followed O
by O
an O
interactive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3D I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
protein B_DISEASE/B_PROTEIN[GENE]
C B_DISEASE/I_PROTEIN[GENE]
- O
alpha B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
atom B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
20 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
, O
it O
lacks O
the O
topological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relationships I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
the O
SSEs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
which O
are O
essential B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
identifying O
common B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scaffolds B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
distantly O
related O
proteins B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

A O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
used O
to O
guide O
the O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
for O
instance B_TIME[MEASURE]/B_DISEASE
, O
to O
build O
multiple B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structural I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignments I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
distantly O
related O
family B_PERSON/B_LOCATION
of O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rich B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
21 B_GENE/B_LOCATION
] I_GENE/I_LOCATION
. O

The O
Multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
MSAT B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
automates O
this O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
merging O
it O
with O
a O
popular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ClustalW I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O
22 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

DALI B_MEASURE
[ I_MEASURE
3 I_MEASURE
] O
, O
CE B_LOCATION
[ O
4 B_NUMBER[MEASURE]
] O
or O
FATCAT B_LOCATION/B_ORGANIZATION
[ O
5 B_MEASURE
] O
introduce O
their O
own B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
methods I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
decomposing O
the O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O
smaller B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
units B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
7 B_MEASURE
x O
7 B_MEASURE/B_LOCATION
dense I_MEASURE/I_LOCATION
distance I_MEASURE/I_LOCATION
map I_MEASURE/I_LOCATION
fragments O
( O
DALIs B_LOCATION/B_ORGANIZATION
) O
or O
aligned O
fragment B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pairs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
AFPs B_DISEASE/B_GENE
) O
( O
CE B_LOCATION
and O
FATCAT B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
large B_MEASURE/B_LOCATION
number B_MEASURE/I_LOCATION
of O
such B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fragments B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
the O
combinations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
fragments B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
need O
to O
be O
evaluated O
by O
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
programs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
the O
main B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reason I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
computational B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
algorithms I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
more O
importantly O
, O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ B_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
used O
here O
to O
enable O
a O
structural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
takes O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flexibility I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
not O
only O
classifies O
the O
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
but O
also O
can O
recognize O
such B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
rearrangements I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O
which O
is O
a O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
SSEs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
language I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

In O
this O
contribution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
we O
explore O
the O
question B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
whether O
it O
would O
be O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
combine O
insights B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provided O
by O
topology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diagrams I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
into O
automated O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignment I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
algorithms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
focusing O
on O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O
previously O
in O
our O
group B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
a O
unique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
allows O
for O
flexibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
structures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
being O
compared O
. O

It O
builds O
the O
alignment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
chaining O
aligned O
fragment B_LOCATION/B_PERSON
pairs I_LOCATION/I_PERSON
( O
AFPs B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
[ O
23 B_TIME[MEASURE]/B_LOCATION
] O
together O
using O
a O
unified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
function I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
where O
AFP B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
extensions B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
gaps B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
twists B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
each O
have O
their O
specific B_MEASURE/B_PERSON
scores B_MEASURE/I_PERSON
( O
Figure B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
) O
. O

introducing O
a O
twist B_MEASURE/B_PERSON
into O
the O
alignment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
penalized O
, O
but O
this O
penalty B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
compensated O
for O
by O
the O
gain B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
score B_MEASURE/B_LOCATION
of O
the O
resulting O
alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
i O
. O
e O
. O
, O
longer O
alignment B_DISEASE/B_MEASURE
and O
/ O
or O
better B_DISEASE/B_MEASURE
RMSD I_DISEASE/I_MEASURE
) O
. O

rigid B_PERSON
alignment I_PERSON
can O
be O
treated O
as O
a O
special B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
in O
which O
no O
twist B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
allowed O
in O
chaining O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

FATCAT B_PERSON/B_ORGANIZATION
program I_PERSON/I_ORGANIZATION
provides O
alignment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
, O
' O
rigid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' O
mode B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
' O
flexible B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
' O
( O
default B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
) O
mode B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
as O
well O
as O
most B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
structure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
comparison B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
programs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
is O
very O
slow B_DISEASE_ADJECTIVE[DISEASE]
when O
compared O
to O
sequence O
alignments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
computing B_MEASURE
time I_MEASURE
of O
FATCAT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
determined O
by O
the O
size B_MEASURE/B_LOCATION
of O
the O
collection B_LOCATION/B_MEASURE
of O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O
between O
the O
two B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O
compared O
. O

FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
a O
server B_PERSON/B_LOCATION
with O
an O
option B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O
search O
in O
SCOP B_ORGANIZATION/B_LOCATION
or O
PDB B_LOCATION/B_ORGANIZATION
databases I_LOCATION/I_ORGANIZATION
for O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
typically O
takes O
between O
8 B_NUMBER[MEASURE]
to O
16 B_MEASURE/B_ENT
hours I_MEASURE/I_ENT
of O
CPU B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
time I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
this O
is O
the O
main B_MEASURE/B_LOCATION
obstacle B_MEASURE/I_LOCATION
to O
broader B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
this O
option B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

FATCAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O
been O
used O
to O
construct O
a O
flexible B_LOCATION
Structure I_LOCATION
neighborhood I_LOCATION
( O
FSN B_LOCATION/B_ORGANIZATION
) O
database B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
contains O
pre B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
computed O
results B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
similarity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
searches I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
it O
takes O
several B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
CPU B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
update O
the O
FSN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
protein I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
resources I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
DALI B_LOCATION/B_ORGANIZATION
or O
CE B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
very O
similar B_DISEASE_ADJECTIVE[DISEASE]
problems I_DISEASE_ADJECTIVE[DISEASE]
. O

tops B_LOCATION/B_ENT
cartoons I_LOCATION/I_ENT
and O
TOPS B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
graph I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

As O
discussed O
in O
the O
Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cartoons I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
capture O
the O
simplified O
, O
fold B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O
level B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
description B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
protein B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
at O
the O
same B_TIME[MEASURE]/B_LOCATION
time B_TIME[MEASURE]/I_LOCATION
can O
be O
automated O
[ O
24 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
uses O
structural B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
hydrogen B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bonds B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
chirality B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
beta B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strands I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
provide O
a O
scoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
function I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
optimize O
the O
cartoon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
see O
figure B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
b B_OTHER/B_MEASURE
) O
) O
. O

In O
tops B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
the O
secondary B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structural I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
elements I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
SSEs B_MEASURE/B_DISEASE
) O
are O
derived O
from O
the O
DSSP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O
25 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cartoons I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
a O
formal B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
graph I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
graph B_ORGANIZATION/B_MEASURE
- O
based O
definitions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
topology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
pattern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
discovery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O
developed O
[ O
26 B_MEASURE
, O
27 B_MEASURE/B_GENE
] B_MEASURE/I_GENE
. O

The O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pattern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discovery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
matching B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
accessible B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
. O

Novel B_PERSON/B_MEASURE
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_OTHER/B_LOCATION
and O
TOPS B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ I_LOCATION
strings I_LOCATION
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
was O
further O
enhanced B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
to O
incorporate O
features B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
such I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
ligand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
more O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secondary I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structural I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
segment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
enhanced O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
called O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
see O
figure B_MEASURE/B_LOCATION
3a I_MEASURE/I_LOCATION
) O
. O

This O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
described O
formally O
in O
a O
TOPS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
+ I_LOCATION
strings I_LOCATION
language I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
figure B_MEASURE/B_PROTEIN[GENE]
3b B_MEASURE/I_PROTEIN[GENE]
) O
at O
a O
reduced O
linear B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
. O

The O
enhanced B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
can O
be O
used O
in O
fast B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
string I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
based O
structure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
matching I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
comparison B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
at O
the O
same B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
avoiding O
issues B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
NP B_DISEASE/B_MEASURE
- O
completeness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
associated O
with O
graph B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
alignments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

In O
detail B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
each O
node B_LOCATION/B_MEASURE
( O
SSE B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
segment I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
) O
of O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
described O
by O
its O
type B_MEASURE/B_LOCATION
, O
orientation B_MEASURE/B_EDU[ORGANIZATION]
, O
PDB B_MEASURE/B_LOCATION
start I_MEASURE/I_LOCATION
number I_MEASURE/I_LOCATION
, O
segment B_MEASURE/B_LOCATION
length B_MEASURE/I_LOCATION
, O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
incoming B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
InArc B_LOCATION/B_ORGANIZATION
) O
and O
outgoing B_TIME[MEASURE]/B_LOCATION
( O
OutArc B_LOCATION/B_ORGANIZATION
) O
arcs B_LOCATION/B_PERSON
( O
edges B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
, O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
ArcTypes B_LOCATION/B_ORGANIZATION
, O
and O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
ligand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arcs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
LigArc B_LOCATION/B_PERSON
) O
. O

The O
type B_MEASURE/B_LOCATION
of O
the O
segment B_LOCATION/B_PROTEIN[GENE]
( O
SSEType B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
could O
be O
one B_MEASURE/B_PERSON
of O
[ O
E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
e O
, O
H B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
h O
, O
U B_PROTEIN[GENE]/B_LOCATION
, O
u B_LOCATION/B_PROTEIN[GENE]
] I_LOCATION/I_PROTEIN[GENE]
, O
where O
, O
' O
E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
and O
' O
e O
' O
represent O
the O
' O
up O
' O
- O
and O
' O
down O
' O
- O
oriented O
beta B_LOCATION/B_PERSON
strands I_LOCATION/I_PERSON
; O
' O
H B_OTHER/B_PROTEIN[GENE]
' O
and O
' O
h O
' O
indicate O
the O
' O
up O
' O
- O
and O
' O
down O
' O
- O
oriented O
alpha B_LOCATION/B_BIO
helices I_LOCATION/I_BIO
; O
and O
' O
U B_OTHER/B_PROTEIN[GENE]
' O
and O
' O
u B_OTHER/B_PROTEIN[GENE]
' O
represent O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
bound O
and O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
free B_DISEASE_ADJECTIVE[DISEASE]
loops I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
InArcType B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O
be O
classified O
as O
an O
/ O
a O
[ O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
L B_PROTEIN[GENE]/B_LOCATION
, O
P B_PROTEIN[GENE]/B_LOCATION
, O
A O
] B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
where O
' O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
and O
' O
L B_PROTEIN[GENE]/B_LOCATION
' O
represent O
right B_SEQUENCE[MEASURE]/B_LOCATION
and O
left O
chiralities B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
; O
and O
' O
P B_PROTEIN[GENE]/B_LOCATION
' O
and O
' O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' O
represent B_PERSON/B_LOCATION
parallel B_PERSON/I_LOCATION
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
parallel B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrogen B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bonds B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
. O

The O
OutArcType B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
represented O
in O
a O
similar B_LOCATION/B_GENE
manner I_LOCATION/I_GENE
by O
[ O
R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
, O
L B_OTHER/B_LOCATION
' O
, O
P B_PROTEIN[GENE]/B_LOCATION
' O
, O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O
] B_GENE/B_DISEASE
. O

Ligand B_PERSON/B_ORGANIZATION
arcs I_PERSON/I_ORGANIZATION
are O
indicated O
by O
LT B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
= O
AA B_LOCATION/B_ORGANIZATION
, O
where O
Lt B_PERSON/B_LOCATION
is O
the O
ligand B_PROTEIN[GENE]/B_LOCATION
type I_PROTEIN[GENE]/I_LOCATION
and O
AA B_LOCATION
is O
the O
PDB B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
Figure B_NUMBER[MEASURE]/B_LOCATION
3 I_NUMBER[MEASURE]/I_LOCATION
( O
a O
) O
and O
3 B_NUMBER[MEASURE]
( O
b B_PROTEIN[GENE]/B_DISEASE
) O
contain O
visual B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
representations I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
TOPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O
TOPS B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ I_LOCATION
strings I_LOCATION
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
respectively O
, O
for O
the O
protein B_PROTEIN[GENE]/B_LOCATION
domain I_PROTEIN[GENE]/I_LOCATION
d1fnb I_PROTEIN[GENE]/I_LOCATION
_ O
1 B_MEASURE/B_LOCATION
. O

Here O
the O
triangles B_BIO/B_LOCATION
represent O
the O
beta B_LOCATION
strands I_LOCATION
; O
the O
red B_LOCATION/B_COLOR
curve I_LOCATION/I_COLOR
represents O
the O
alpha B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
helix I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
; O
gray B_COLOR/B_LOCATION
ellipsoids I_COLOR/I_LOCATION
indicate O
loops B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
and O
green B_LOCATION/B_ORGANIZATION
arcs I_LOCATION/I_ORGANIZATION
indicate O
hydrogen B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
bonds I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
between O
two B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strands B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
called O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beta B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sheets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
length B_MEASURE/B_LOCATION
of O
a O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
strings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
defined O
by O
number B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SSEs B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O
thus O
, O
the O
length B_MEASURE/B_LOCATION
of O
d1fnb B_PROTEIN[GENE]/B_LOCATION
_ O
1 B_MEASURE/B_LOCATION
is O
19 B_MEASURE
. O

For O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
details I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
see O
[ O
28 B_GENE
] I_GENE
. O

TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

tops B_MEASURE/B_PERSON
+ B_MEASURE/I_PERSON
is O
a O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
computes O
a O
distance B_MEASURE/B_LOCATION
between O
tops B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
a O
dynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programming I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
identifies O
the O
longest B_MEASURE/B_LOCATION
common B_MEASURE/I_LOCATION
subsequence B_MEASURE/I_LOCATION
( O
LCS B_DISEASE/B_PROTEIN[GENE]
) O
, O
consisting O
of O
the O
list B_ORGANIZATION/B_MEASURE
of O
the O
topologically O
equivalent B_MEASURE/B_LOCATION
SSEs B_MEASURE/I_LOCATION
between O
two B_GENE/B_MEASURE
proteins I_GENE/I_MEASURE
. O

For O
example O
, O
Figure O
3 O
( O
c O
) O
shows O
the O
tops O
+ O
strings O
alignment O
between O
Dihydropteridine O
reductase O
proteins O
from O
rat O
( O
1dhr O
) O
and O
human B_SPECIES[BIO]
( O
1hdr O
) O
. O

The O
TOPS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
+ O
strings B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
1dhr B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
1hdr B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
represented O
by O
a O
linear B_MEASURE/B_PROTEIN[GENE]
string B_MEASURE/I_PROTEIN[GENE]
- O
model B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
where O
a O
yellow B_COLOR/B_LOCATION
triangle I_COLOR/I_LOCATION
and O
red B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
curves B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
indicate O
the O
beta B_PROTEIN[GENE]
strands I_PROTEIN[GENE]
and O
alpha B_LOCATION/B_GENE
helices B_LOCATION/I_GENE
in O
their O
' O
up O
' O
or O
' O
down O
' O
orientations B_LOCATION/B_ORGANIZATION
, O
respectively O
. O

The O
grey B_COLOR/B_LOCATION
line I_COLOR/I_LOCATION
and O
purple B_BIO/B_COLOR
stubs B_BIO/I_COLOR
represent O
the O
loop B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
NAD B_LOCATION
ligand I_LOCATION
interactions I_LOCATION
, O
respectively O
. O

Note O
that O
the O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
optional B_DISEASE_ADJECTIVE[DISEASE]
and O
in O
this O
work B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
have O
not O
used O
it O
. O

The O
incoming B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
outgoing B_TIME[MEASURE]/B_PERSON
arcs I_TIME[MEASURE]/I_PERSON
are O
depicted O
in O
the O
SSEs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
top B_GENE/B_LOCATION
and O
bottom B_LOCATION/B_MEASURE
of O
the O
beta B_LOCATION/B_MEASURE
strands I_LOCATION/I_MEASURE
) O
, O
where O
red B_COLOR
and O
green B_COLOR/B_ORGANIZATION
arcs I_COLOR/I_ORGANIZATION
represent O
the O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
parallel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
bond B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
interactions I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
that O
show O
beta O
- O
sheet B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
while O
yellow B_COLOR
and O
blue B_COLOR/B_PERSON
arcs I_COLOR/I_PERSON
indicate O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O
left O
chirality B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
relationships I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
between O
the O
SSEs B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

A O
pink B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
arrow I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
the O
TOPS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
+ I_LOCATION
strings I_LOCATION
elements I_LOCATION
indicates O
the O
conserved B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
SSE I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
dotted B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arrows B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
indicate O
the O
conserved B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
helices I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
beta B_LOCATION
strands I_LOCATION
, O
while O
the O
plain B_LOCATION/B_BIO
arrows I_LOCATION/I_BIO
indicate O
the O
conserved B_LOCATION/B_MEASURE
loop I_LOCATION/I_MEASURE
regions I_LOCATION/I_MEASURE
. O

TOPS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
+ I_MEASURE
+ I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
this O
work B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
want O
to O
test O
the O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
idea I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pruning O
the O
search B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
space B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
using O
topological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
constraints I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Many B_NUMBER[MEASURE]/B_PERSON
of O
the O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
considered O
in O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
easily O
eliminated O
from O
the O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O
constraining O
the O
alignment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
we O
explore O
constraints B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
obtained O
from O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
identifies O
topologically O
equivalent B_LOCATION
secondary I_LOCATION
structure I_LOCATION
elements I_LOCATION
( O
alpha B_GENE
helices I_GENE
, O
beta B_LOCATION/B_BIO
strands I_LOCATION/I_BIO
, O
and O
loops B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
for O
this O
purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Such B_PERSON
equivalences I_PERSON
define O
blocks B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
that O
restrict O
the O
alignment B_LOCATION
region I_LOCATION
; O
AFPs B_LOCATION/B_ORGANIZATION
that O
fall O
outside O
these O
regions B_LOCATION
are O
simply O
not O
considered O
( O
see O
figure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
4 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
b B_OTHER/B_MEASURE
) O
) O
. O

We O
introduce O
a O
parameter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
r I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
control O
the O
strictness B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
constraints B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
by O
tops B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings B_ENT/B_BIO
alignments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
; O
r B_PROTEIN[GENE]/B_OTHER
equals O
0 B_MEASURE/B_LOCATION
if O
the O
alignment B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
strictly O
restrained O
by O
TOPS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
strings I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alignment I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
r B_OTHER/B_GENE
is O
set O
to O
1 B_MEASURE
by O
default B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
our O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
allow O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flexibility B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
constrained B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
region I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
figure B_PROTEIN[GENE]
4 I_PROTEIN[GENE]
( O
c B_OTHER/B_MEASURE
) O
) O
. O

We O
then O
can O
speed O
up O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
considering O
only O
the O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
within O
the O
constrained B_LOCATION/B_MEASURE
alignment I_LOCATION/I_MEASURE
area I_LOCATION/I_MEASURE
( O
Figure B_LOCATION/B_MEASURE
4 I_LOCATION/I_MEASURE
( O
d B_OTHER/B_PROTEIN[GENE]
) O
) O
. O

The O
rigid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structural I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
can O
be O
treated O
as O
a O
special B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
in O
which O
no O
twist B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
is O
allowed O
in O
chaining O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

However O
, O
the O
tops B_LOCATION/B_SPORT[ENT]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_PERSON/B_LOCATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
provides O
alignment B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
, O
' O
rigid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' O
mode B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
' O
flexible B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
' O
mode B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
default B_DISEASE/B_PROTEIN[GENE]
) O
. O

Benchmarking B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
benchmarking B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
have O
used O
the O
PDB40 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dataset I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
1 B_MEASURE
, O
901 B_MEASURE
protein I_MEASURE
domain I_MEASURE
pairs I_MEASURE
( O
DP B_PROTEIN[GENE]/B_DISEASE
) O
corresponding O
to O
SCOP B_MEASURE/B_LOCATION
version I_MEASURE/I_LOCATION
1 I_MEASURE/I_LOCATION
. O
61 B_MEASURE
from O
the O
ASTRAL B_TIME[MEASURE]/B_ORGANIZATION
database I_TIME[MEASURE]/I_ORGANIZATION
[ O
29 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
provides O
the O
SCOP B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
superfamily O
level B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
homolog B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
versus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
non B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
homolog B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
statistics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O
the O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
main I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Scop I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
i O
. O
e O
. O
, O
all O
- O
alpha B_GENE
, O
all O
- O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
alpha B_PROTEIN[GENE]/B_MEASURE
/ O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
alpha B_GENE/B_MEASURE
+ I_GENE/I_MEASURE
beta I_GENE/I_MEASURE
, O
and O
all O
proteins B_BIO/B_PROTEIN[GENE]
regardless O
of O
their O
structural B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
classes I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
performed O
the O
receiver B_LOCATION/B_ORGANIZATION
Operating I_LOCATION/I_ORGANIZATION
characteristics I_LOCATION/I_ORGANIZATION
( O
ROC B_LOCATION/B_ORGANIZATION
) O
curve B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
the O
AUC B_LOCATION/B_MEASURE
( O
Area B_LOCATION/B_ORGANIZATION
Under O
the O
ROC B_MEASURE/B_LOCATION
curve I_MEASURE/I_LOCATION
) O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
compare O
the O
performance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
using O
Scop B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
the O
superfamily B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
as O
a O
standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O
30 B_MEASURE/B_PERSON
] B_MEASURE/I_PERSON
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

ROC B_LOCATION/B_ORGANIZATION
and O
AUC B_ORGANIZATION/B_LOCATION
analyses B_ORGANIZATION/I_LOCATION
. O

We O
have O
compared O
the O
performance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
against O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O
the O
Scop B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
the O
superfamily B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
. O

We O
have O
plotted O
the O
ROC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O
on O
P B_MEASURE/B_PROTEIN[GENE]
- O
values B_MEASURE
obtained O
from O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

We O
have O
plotted O
the O
ROC B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
separately O
for O
the O
main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Scop I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
i O
. O
e B_OTHER/B_LOCATION
. O
, O
all O
- O
alpha B_PROTEIN[GENE]
, O
all O
- O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
alpha B_PROTEIN[GENE]/B_MEASURE
/ O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
alpha B_PROTEIN[GENE]/B_MEASURE
+ I_PROTEIN[GENE]/I_MEASURE
beta I_PROTEIN[GENE]/I_MEASURE
, O
and O
all O
proteins B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regardless O
of O
the O
class B_PERSON/B_MEASURE
they O
belong O
to O
( O
see O
Figure B_NUMBER[MEASURE]/B_PERSON
5 I_NUMBER[MEASURE]/I_PERSON
( O
a O
) O
to O
5 B_NUMBER[MEASURE]
( O
e B_PROTEIN[GENE]/B_DISEASE
) O
) O
. O

In O
the O
graph B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
x O
- O
and O
y B_PROTEIN[GENE]/B_MEASURE
- O
axes B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
represent O
the O
false B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
true B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
positive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rates I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
performance B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
respectively O
. O

In O
the O
legend B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
RF B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
pvalue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
FF B_PROTEIN[GENE]/B_LOCATION
- O
pvalue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
rigid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
; O
similarly O
, O
rT2F B_PROTEIN[GENE]/B_LOCATION
- O
pvalue B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fT2F B_PROTEIN[GENE]/B_LOCATION
- O
pvalue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
represent O
the O
rigid B_DISEASE_ADJECTIVE[DISEASE]
and O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
. O

We O
have O
calculated O
the O
AUC B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
all O
the O
Scop B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
based O
on O
ROC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
obtained O
from O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
the O
flexible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
/ O
rigid B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
options I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

For O
all O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
rigid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performs O
best B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
usually O
followed O
by O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
rigid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
performance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
all O
four B_NUMBER[MEASURE]
methods I_NUMBER[MEASURE]
is O
best B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
all O
alpha B_PROTEIN[GENE]
and O
all O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
all O
four B_NUMBER[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perform O
markedly O
worse B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
but O
similar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
each O
other B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
alpha B_PROTEIN[GENE]/B_DISEASE
/ O
beta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Only O
alpha B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
beta I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
proteins I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O
a O
clear B_MEASURE/B_PERSON
difference I_MEASURE/I_PERSON
between O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
TOPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ B_MEASURE
+ I_MEASURE
FATCAT I_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

It O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
note O
that O
the O
tops B_PERSON/B_ORGANIZATION
+ I_PERSON/I_ORGANIZATION
strings I_PERSON/I_ORGANIZATION
models I_PERSON/I_ORGANIZATION
consider O
the O
parallel B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
parallel B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
sheet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
the O
form B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
incoming B_TIME[MEASURE]/B_LOCATION
and O
outgoing B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arcs I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
their O
ArcTypes B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Thus O
, O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discriminates O
the O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
domain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pairs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
more O
efficiently O
compared O
to O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

For O
example B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
in O
the O
all O
- O
beta B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pairs I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
both O
the O
flexible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
the O
rigid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
perform O
well O
. O

The O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
covers O
nearly O
84 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
protein B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
domains I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
with O
0 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
false I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
positives I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
but O
the O
flexible B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
rigid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
cover O
only O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
and O
49 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
true B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
positives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
respectively O
, O
with O
0 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
false I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
positives I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
zoomed O
- O
in O
version B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
ROC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curves I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
up O
to O
10 B_MEASURE
% I_MEASURE
false I_MEASURE
positives I_MEASURE
for O
all O
- O
beta B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
rich I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
protein I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
families I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
is O
shown O
in O
Figure B_LOCATION/B_PERSON
5 I_LOCATION/I_PERSON
( O
f O
) O
; O
where O
both O
the O
rigid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
green B_COLOR
) O
and O
flexible B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
( O
red B_COLOR
) O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
have O
coverage B_MEASURE
rates I_MEASURE
of O
82 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
84 B_MEASURE
% I_MEASURE
true I_MEASURE
positives I_MEASURE
respectively O
with O
0 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
false I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
positives I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
overall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
all O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O
that O
TOPS B_DISEASE/B_GENE
+ I_DISEASE
+ B_MEASURE/B_LOCATION
FATCAT I_DISEASE/I_MEASURE
performance I_DISEASE/I_MEASURE
is O
only O
slightly O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
3 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
- O
7 B_MEASURE
% I_MEASURE
AUC I_MEASURE
value I_MEASURE
difference I_MEASURE
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
) O
as O
compared O
to O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
while O
providing O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
more B_MEASURE
than O
10 B_NUMBER[MEASURE]
- O
fold B_PERSON/B_MEASURE
speedup B_PERSON/I_MEASURE
( O
see O
next B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
section I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

AFP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
Runtime B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Analyses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

We O
tested O
both O
the O
FATCAT B_MEASURE/B_LOCATION
and O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
Mac B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OS I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
version I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
4 B_MEASURE
. O
10 B_MEASURE/B_LOCATION
computer I_MEASURE/I_LOCATION
system I_MEASURE/I_LOCATION
with O
a O
2 B_MEASURE
x O
2 B_MEASURE
. O
66 B_MEASURE
- O
GHz B_MEASURE/B_LOCATION
Dual I_MEASURE/I_LOCATION
- O
Core B_PERSON/B_LOCATION
Intel B_PERSON/I_LOCATION
Xeon B_PERSON/I_LOCATION
processor B_PERSON/I_LOCATION
and O
1 B_MEASURE
- O
GB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
667 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
MHz I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
memory I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

We O
have O
performed O
runtime B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
1 B_MEASURE
, O
901 B_MEASURE
protein I_MEASURE
domain I_MEASURE
pairs I_MEASURE
and O
counted O
the O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
and O
the O
corresponding B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
runtime B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
both O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
an O
exponential B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
AFPs B_MEASURE/B_ORGANIZATION
( O
Figure B_MEASURE/B_PERSON
6 I_MEASURE/I_PERSON
( O
b B_DISEASE/B_PROTEIN[GENE]
) O
) O
and O
corresponding B_MEASURE
runtime I_MEASURE
( O
Figure B_MEASURE/B_PERSON
6 I_MEASURE/I_PERSON
( O
a O
) O
) O
for O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
compared O
to O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
average B_MEASURE
number I_MEASURE
of O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
for O
the O
TOPS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
530 B_MEASURE
, O
but O
the O
average B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
for O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
15 B_MEASURE
, O
019 B_MEASURE
. O

This O
represents O
the O
number B_MEASURE
of O
average B_MEASURE/B_LOCATION
AFPs B_MEASURE/I_LOCATION
used O
by O
the O
FATCAT B_ORGANIZATION/B_LOCATION
method I_ORGANIZATION/I_LOCATION
is O
increased O
by O
a O
factor B_MEASURE
of O
28 B_NUMBER[MEASURE]
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

This O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
leads O
to O
the O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
TOPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ B_OTHER/B_MEASURE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
22 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
times I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
faster O
compared O
to O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
because O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O
take O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
more I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
number I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
in O
the O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

While O
the O
overall O
accuracy O
of O
both O
rigid O
and O
flexible O
FATCAT O
methods O
is O
better O
than O
their O
tops O
+ O
+ O
FATCAT O
equivalents O
, O
an O
interesting O
example O
where O
the O
opposite O
is O
true O
lies O
in O
the O
comparison O
of O
two O
proteins O
, O
d2trxa O
_ O
( O
108 O
AA O
) O
from O
Escherichia B_SPECIES[BIO]
coli I_SPECIES[BIO]
and O
d1kte O
_ O
_ O
( O
105 O
AA O
) O
from O
Sus B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
scrofa I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
pig B_PERSON/B_PROTEIN[GENE]
) O
from O
the O
thioredoxin O
- O
like O
superfamily O
. O

For O
this O
pair B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
_ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provides O
an O
alignment B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
88 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
equivalent I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
positions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
1 B_MEASURE
. O
67 B_MEASURE
A O
chain B_MEASURE/B_LOCATION
RMSD I_MEASURE/I_LOCATION
and O
3 B_MEASURE
. O
06 B_MEASURE
A I_MEASURE
of O
optimal B_MEASURE/B_LOCATION
RMSD B_MEASURE/I_LOCATION
without O
any O
twist B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
giving O
the O
alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
10 B_TIME[MEASURE]/B_LOCATION
% I_TIME[MEASURE]/I_LOCATION
sequence I_TIME[MEASURE]/I_LOCATION
identity I_TIME[MEASURE]/I_LOCATION
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

On O
the O
other B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hand I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
flexible B_LOCATION
_ O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
provides O
an O
alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
86 B_NUMBER[MEASURE]/B_PERSON
aligned O
positions B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
a O
twist B_MEASURE/B_LOCATION
in O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_LOCATION
region I_LOCATION
; O
it O
has O
a O
higher B_MEASURE
chain I_MEASURE
RMSD I_MEASURE
of O
5 B_MEASURE
. O
14 B_MEASURE
A I_MEASURE
, O
and O
its O
optimal B_MEASURE
RMSD I_MEASURE
is O
3 B_MEASURE
. O
48 B_MEASURE
A I_MEASURE
. O

For O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O
the O
chain B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
optimal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RMSDs I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
refer O
[ O
5 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

The O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
_ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
uses O
the O
twist B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
align O
a O
helix B_LOCATION/B_MEASURE
in O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_LOCATION
region I_LOCATION
, O
which O
is O
positioned O
incorrectly O
with O
a O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sheet B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
see O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
4 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

Figure B_MEASURE/B_PERSON
7 I_MEASURE/I_PERSON
( O
a O
) O
shows O
the O
superposition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
d2trxa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
_ O
( O
gray B_PERSON/B_COLOR
) O
and O
d1kte B_PROTEIN[GENE]/B_BIO
_ O
_ O
( O
orange B_COLOR/B_SPORT[ENT]
) O
domains B_LOCATION/B_BIO
from O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
_ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
where O
the O
blue B_SEQUENCE[MEASURE]/B_COLOR
color I_SEQUENCE[MEASURE]/I_COLOR
indicates O
the O
d1kte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
_ O
_ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
the O
flexible B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
_ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
TOPS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
FATCAT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
method I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_COLOR
. O

The O
incorrect B_LOCATION
alignment I_LOCATION
of O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_LOCATION/B_GENE
domain I_LOCATION/I_GENE
alpha I_LOCATION/I_GENE
helix I_LOCATION/I_GENE
of O
the O
d1kte B_PROTEIN[GENE]
_ I_PROTEIN[GENE]
_ I_PROTEIN[GENE]
domain I_PROTEIN[GENE]
( O
orange B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
visible B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
core B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sheet B_LOCATION
region I_LOCATION
. O

Figure B_MEASURE
7 I_MEASURE
( O
b O
) O
and O
7 B_NUMBER[MEASURE]
( O
c B_PROTEIN[GENE]/B_DISEASE
) O
shows O
the O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
flexible B_PROTEIN[GENE]/B_DISEASE
_ O
FATCAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
_ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
respectively O
. O

The O
hinge B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
a O
twist B_MEASURE/B_LOCATION
in O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
_ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
indicated O
by O
an O
arrow B_LOCATION/B_MEASURE
and O
the O
AFPs B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
represented O
by O
a O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
color B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
see O
figure B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
b B_OTHER/B_MEASURE
) O
) O
. O

In O
this O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constraints I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allow O
the O
tops B_LOCATION/B_MEASURE
+ I_LOCATION/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
avoid O
a O
spurious B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alignment I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
Erythrocruorin O
protein O
domain O
d1eca O
_ O
_ O
( O
136 O
AA O
) O
from O
Chironomus B_BIO
thummi I_BIO
and O
the O
Phycocyanin O
alpha O
subunit O
protein O
domain O
d1cpca O
_ O
( O
162 O
AA O
) O
from O
Fremyella B_BACTERIUM[BIO]
diplosiphon I_BACTERIUM[BIO]
( O
Cyanobacterium O
) O
belong O
to O
the O
Globin O
- O
like O
superfamily O
. O

For O
these O
protein B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
domain I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
pairs I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provides O
a O
better B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
120 B_MEASURE
and O
118 B_MEASURE
aligned O
positions B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
the O
chain B_MEASURE
RMSD I_MEASURE
of O
4 B_MEASURE
. O
02 B_MEASURE
A I_MEASURE
based O
on O
the O
flexible B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O
rigid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
options B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O
respectively O
. O

The O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
_ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gives O
an O
alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
63 B_NUMBER[MEASURE]/B_PERSON
aligned O
positions B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
the O
3 B_NUMBER[MEASURE]
. O
23 B_MEASURE
A I_MEASURE
optimal I_MEASURE
RMSD I_MEASURE
and O
the O
6 B_NUMBER[MEASURE]
. O
28 B_MEASURE
A I_MEASURE
chain I_MEASURE
RMSD I_MEASURE
. O

In O
this O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
_ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT B_TIME[MEASURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
misses O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_LOCATION/B_GENE
region I_LOCATION/I_GENE
helix I_LOCATION/I_GENE
and O
misaligns O
some O
helices B_LOCATION/B_BIO
. O

For O
example B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
figure B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
( O
a O
) O
shows O
the O
superposition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
d1eca B_PROTEIN[GENE]/B_LOCATION
_ O
_ O
( O
gray B_PERSON/B_COLOR
) O
and O
d1cpca B_PROTEIN[GENE]/B_LOCATION
_ O
( O
orange B_COLOR/B_SPORT[ENT]
) O
domains B_LOCATION
from O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
_ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
while O
d1cpca B_PROTEIN[GENE]/B_MEASURE
_ O
( O
blue B_COLOR
) O
domain B_TIME[MEASURE]/B_LOCATION
is O
from O
the O
flexible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
_ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
TOPS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
AFP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
chaining I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
the O
actual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
FATCAT B_MEASURE/B_LOCATION
are O
shown O
in O
Figure B_NUMBER[MEASURE]/B_LOCATION
8 I_NUMBER[MEASURE]/I_LOCATION
( O
b B_OTHER/B_LOCATION
) O
and O
8 B_MEASURE
( O
e B_PROTEIN[GENE]/B_DISEASE
) O
, O
respectively O
. O

Figure B_NUMBER[MEASURE]/B_LOCATION
8 I_NUMBER[MEASURE]/I_LOCATION
( O
c O
) O
shows O
the O
AFP B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
tops B_MEASURE
+ I_MEASURE
+ I_MEASURE
FATCAT I_MEASURE
, O
in O
which O
this O
method B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
misses O
the O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
terminal B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
and O
incorrectly O
aligns O
some O
of O
the O
C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_LOCATION/B_MEASURE
regions I_LOCATION/I_MEASURE
( O
see O
figure B_MEASURE/B_PERSON
8 I_MEASURE/I_PERSON
( O
d B_PROTEIN[GENE]/B_DISEASE
) O
) O
. O

However O
, O
the O
rigid B_LOCATION/B_DISEASE
_ O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
produces O
an O
alignment B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
108 B_NUMBER[MEASURE]/B_PERSON
aligned O
positions B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
optimal B_MEASURE/B_LOCATION
and O
chain B_MEASURE
RMSDs I_MEASURE
of O
3 B_MEASURE
. O
22 B_MEASURE/B_PERSON
A I_MEASURE/I_PERSON
and O
6 B_MEASURE
. O
28 B_MEASURE
A I_MEASURE
respectively O
. O

In O
general B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
TOPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
comparison I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
does O
not O
work O
well O
for O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
rich B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
due I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
the O
lack B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hydrogen B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bonds B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
SSEs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
[ O
26 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

The O
same B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
true B_DISEASE_ADJECTIVE[DISEASE]
for O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
strings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
some O
extent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O
however O
, O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
takes O
advantage B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
information I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
compare O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
more O
efficiently O
; O
for O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
the O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
motifs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
helix B_LOCATION/B_GENE
- O
turn B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
helix B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
helix B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
loop B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
helix B_LOCATION/B_TIME[MEASURE]
can O
be O
easily O
recognized O
[ O
28 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

However O
, O
we O
have O
not O
explored O
that O
ligand B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
discovery I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
option I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
tops B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings B_MEASURE/B_LOCATION
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provides O
only O
a O
basic B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
the O
scoring O
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
find O
the O
best B_MEASURE/B_ENT
alignment B_MEASURE/I_ENT
has O
not O
been O
optimized O
. O

These O
problems B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
be O
addressed O
in O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
considering O
the O
advanced B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TOPS B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
tops B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings B_ORGANIZATION/B_LOCATION
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
based O
on O
helix B_NUMBER[MEASURE]/B_LOCATION
- O
helix B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
packing B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationships B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
SSE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ligand B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interaction I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
properties I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
together O
with O
the O
right B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
left O
chiralities B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
can O
be O
optimized O
in O
both O
the O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
in O
the O
alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
take O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
insertion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
/ O
deletion B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
of O
SSEs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
exist O
in O
nature B_BIO/B_LOCATION
across O
the O
different B_MEASURE/B_LOCATION
members I_MEASURE/I_LOCATION
of O
the O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
superfamilies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
[ O
31 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

The O
overall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
all O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
classes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O
that O
TOPS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_DISEASE
+ B_MEASURE/B_LOCATION
FATCAT I_DISEASE/I_MEASURE
performance I_DISEASE/I_MEASURE
is O
only O
slightly O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
3 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
- O
7 B_MEASURE
% I_MEASURE
AUC I_MEASURE
value I_MEASURE
difference I_MEASURE
) O
as O
compared O
to O
FATCAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
while O
providing O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
more B_MEASURE
than O
10 B_NUMBER[MEASURE]
- O
fold B_PERSON/B_MEASURE
speedup B_PERSON/I_MEASURE
. O

The O
main B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reason B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
discrepancies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
that O
TOPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ I_PERSON
strings I_PERSON
alignments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
occasionally O
misalign O
the O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
elements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
subsequent B_PERSON/B_LOCATION
FATCAT I_PERSON/I_LOCATION
alignment I_PERSON/I_LOCATION
, O
constrained O
by O
the O
tops B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alignment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cannot B_PERSON/B_LOCATION
overcome O
the O
earlier B_DISEASE_ADJECTIVE[DISEASE]
errors I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
is O
a O
clear B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
trade I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
- O
off B_MEASURE/B_LOCATION
between O
the O
runtime B_MEASURE
and O
the O
accuracy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O
limiting O
the O
pool B_LOCATION/B_MEASURE
of O
fragments B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O
compared O
speeds B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
up O
the O
algorithm B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
but O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
( O
slightly O
) O
lower B_DISEASE_ADJECTIVE[DISEASE]
accuracy I_DISEASE_ADJECTIVE[DISEASE]
. O

At O
the O
same B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
offer O
clear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggestions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
future B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
development I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

Using O
a O
more O
advanced B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
version I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
remove O
some O
of O
the O
false B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
positives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
might O
be O
at O
a O
cost B_MEASURE
of O
significantly O
slowing O
the O
total B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

MV B_TIME[MEASURE]/B_PERSON
developed O
the O
TOPS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FATCAT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
algorithm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
performed O
the O
calculations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prepared O
the O
figures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
YY O
provided O
advice B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oversight B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
project B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
verified O
the O
code B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
provided O
FATCAT B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
AG B_LOCATION/B_PERSON
contributed O
to O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
idea I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
to O
writing O
of O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Are O
there O
sensitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
airborne B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
shown O
that O
particulate B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
hospitalization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
lung B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
; O
however O
, O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
what O
subpopulations B_PERSON/B_BIO
are O
most O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
this O
pollutant B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
analyzed O
Medicare B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hospital I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
admissions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
heart B_DISEASE
disease I_DISEASE
, O
chronic B_DISEASE
obstructive I_DISEASE
pulmonary I_DISEASE
disorders I_DISEASE
( O
COPD B_DISEASE
) O
and O
pneumonia B_DISEASE
in O
Chicago B_LOCATION/B_PERSON
, O
Cook B_LOCATION/B_PERSON
County I_LOCATION/I_PERSON
, O
Illinois B_LOCATION
, O
between O
1985 B_MEASURE
and O
1994 B_MEASURE
. O

We O
examined O
whether O
previous O
admissions O
or O
secondary O
diagnoses O
for O
selected O
conditions O
predisposed O
persons B_PERSON
to O
having O
a O
greater O
risk O
from O
air O
pollution O
. O

We O
also O
considered O
effect B_PERSON
modification I_PERSON
by O
age B_MEASURE/B_LOCATION
, O
sex B_PERSON/B_MEASURE
, O
and O
race B_SPORT[ENT]/B_LOCATION
. O

We O
found O
that O
the O
air B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O
pollution B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
hospital B_DISEASE/B_GENE
admissions I_DISEASE/I_GENE
for O
cardiovascular B_DISEASE
diseases I_DISEASE
was O
almost O
doubled O
in O
subjects B_PERSON/B_LOCATION
with O
concurrent B_DISEASE/B_GENE
respiratory I_DISEASE/I_GENE
infections I_DISEASE/I_GENE
. O

The O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
was O
also O
increased O
by O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admission I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
conduction B_DISEASE
disorders I_DISEASE
. O

For O
COPD B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
pneumonia B_DISEASE
admissions I_DISEASE
, O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
conduction B_DISEASE
disorders I_DISEASE
or O
dysrhythmias B_DISEASE
increased O
the O
risk B_MEASURE/B_LOCATION
of O
particulate B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
matter I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
< O
10 B_MEASURE
microm I_MEASURE
in O
aerodynamic B_MEASURE/B_LOCATION
diameter I_MEASURE/I_LOCATION
( O
PM B_LOCATION/B_PROTEIN[GENE]
( O
10 B_MEASURE/B_LOCATION
) O
) O
- O
associated O
admissions B_DISEASE
. O

Persons B_PERSON
with O
asthma O
had O
twice O
the O
risk O
of O
a O
PM O
( O
10 O
) O
- O
associated O
pneumonia O
admission O
and O
persons B_PERSON
with O
heart O
failure O
had O
twice O
the O
risk O
of O
PM O
( O
10 O
) O
- O
induced O
COPD O
admissions O
. O

The O
PM B_LOCATION/B_SEQUENCE[MEASURE]
( O
10 B_NUMBER[MEASURE]/B_LOCATION
) O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O
not O
vary O
by O
sex B_PERSON/B_LOCATION
, O
age B_MEASURE/B_LOCATION
, O
and O
race B_LOCATION/B_TIME[MEASURE]
. O

These O
results O
suggest O
that O
patients B_PERSON/B_BIO
with O
acute O
respiratory O
infections O
or O
defects O
in O
the O
electrical O
control O
of O
the O
heart O
are O
a O
risk O
group O
for O
particulate O
matter O
effects O
. O

Articles B_PERSON
. O

Are O
There O
sensitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
subgroups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
airborne B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Antonella B_MEASURE/B_BIO
Zanobetti I_MEASURE/I_BIO
, O
1 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Joel I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Schwartz I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
1 B_MEASURE
, O
2 B_MEASURE
and O
Diane B_MEASURE/B_PERSON
Gold1 I_MEASURE/I_PERSON
, O
2 B_MEASURE/B_LOCATION
1Environmental I_MEASURE/I_LOCATION
. O

Epidemiology O
Program O
, O
Department O
of O
Environmental O
Health O
, O
Harvard O
School O
of O
Public O
Health O
, O
Boston O
, O
Massachusetts O
, O
USA O
; O
2Channing O
Laboratory O
, O
Department O
of O
Medicine O
, O
Harvard O
Medical O
School O
and O
Brigham O
and O
Women B_PERSON
' O
s O
Hospital O
, O
Boston O
, O
Massachusetts O
, O
USA O
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
shown O
that O
particulate B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
hospitalization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
lung B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
; O
however O
, O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
what O
subpopulations B_PERSON/B_BIO
are O
most O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
this O
pollutant B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
analyzed O
Medicare B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hospital I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
admissions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
heart B_DISEASE
disease I_DISEASE
, O
chronic B_DISEASE
obstructive I_DISEASE
pulmonary I_DISEASE
disorders I_DISEASE
( O
COPD B_DISEASE
) O
and O
pneumonia B_DISEASE
in O
Chicago B_LOCATION/B_PERSON
, O
Cook B_LOCATION/B_PERSON
County I_LOCATION/I_PERSON
, O
Illinois B_LOCATION
, O
between O
1985 B_MEASURE
and O
1994 B_MEASURE
. O

We O
examined O
whether O
previous O
admissions O
or O
secondary O
diagnoses O
for O
selected O
conditions O
predisposed O
persons B_PERSON
to O
having O
a O
greater O
risk O
from O
air O
pollution O
. O

We O
also O
considered O
effect B_PERSON
modification I_PERSON
by O
age B_MEASURE/B_LOCATION
, O
sex B_PERSON/B_MEASURE
, O
and O
race B_SPORT[ENT]/B_LOCATION
. O

We O
found O
that O
the O
air B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O
pollution B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
hospital B_DISEASE/B_GENE
admissions I_DISEASE/I_GENE
for O
cardiovascular B_DISEASE
diseases I_DISEASE
was O
almost O
doubled O
in O
subjects B_PERSON/B_LOCATION
with O
concurrent B_DISEASE/B_GENE
respiratory I_DISEASE/I_GENE
infections I_DISEASE/I_GENE
. O

The O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
was O
also O
increased O
by O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admission I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
conduction B_DISEASE
disorders I_DISEASE
. O

For O
COPD B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
pneumonia B_DISEASE
admissions I_DISEASE
, O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
conduction B_DISEASE
disorders I_DISEASE
or O
dysrhythmias B_DISEASE
increased O
the O
risk B_MEASURE/B_LOCATION
of O
particulate B_MEASURE
matter I_MEASURE
< O
10 B_MEASURE/B_LOCATION
<FFFD> I_MEASURE/I_LOCATION
m I_MEASURE/I_LOCATION
in O
aerodynamic B_MEASURE
diameter I_MEASURE
( O
PM10 B_DISEASE/B_SPECIES[BIO]
) O
- O
associated O
admissions B_DISEASE
. O

Persons B_PERSON
with O
asthma O
had O
twice O
the O
risk O
of O
a O
PM10 O
- O
associated O
pneumonia O
admission O
and O
persons B_PERSON
with O
heart O
failure O
had O
twice O
the O
risk O
of O
PM10 O
- O
induced O
COPD O
admissions O
. O

The O
PM10 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
did O
not O
vary O
by O
sex B_PERSON/B_LOCATION
, O
age B_MEASURE/B_LOCATION
, O
and O
race B_SPORT[ENT]/B_LOCATION
. O

These O
results O
suggest O
that O
patients B_PERSON/B_BIO
with O
acute O
respiratory O
infections O
or O
defects O
in O
the O
electrical O
control O
of O
the O
heart O
are O
a O
risk O
group O
for O
particulate O
matter O
effects O
. O

Key B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
words I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
modification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
hospital B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admissions B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
particulate B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
air B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pollution B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Environ B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspect I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
108 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
841 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
845 I_MEASURE/I_PERSON
( O
2000 B_MEASURE
) O
. O

[ B_ORGANIZATION/B_PERSON
Online I_ORGANIZATION/I_PERSON
28 I_ORGANIZATION/I_PERSON
July I_ORGANIZATION/I_PERSON
2000 I_ORGANIZATION/I_PERSON
] I_ORGANIZATION/I_PERSON
http I_ORGANIZATION/I_PERSON
: O
/ O
/ O
ehpnet1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O
niehs B_PERSON/B_BIO
. O
nih B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
gov B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
docs B_PERSON/B_MEASURE
/ O
2000 B_MEASURE/B_ENT
/ O
108p841 B_MEASURE
- O
845zanobetti B_MEASURE/B_PERSON
/ O
abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
html B_MEASURE/B_GENE
. O

particulate B_DISEASE
air I_DISEASE
pollution I_DISEASE
has O
been O
associated O
with O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
daily B_DISEASE
deaths I_DISEASE
and O
hospital B_DISEASE
admissions I_DISEASE
in O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
all O
over O
the O
world B_LOCATION
( O
1 B_MEASURE/B_LOCATION
<FFFD> I_MEASURE/I_LOCATION
15 I_MEASURE/I_LOCATION
) O
. O

These O
associations O
are O
now O
well O
documented O
but O
little O
is O
known O
, O
as O
yet O
, O
of O
the O
characteristics O
of O
persons B_PERSON/B_LOCATION
that O
put O
them O
at O
increased O
risk O
of O
adverse O
events O
related O
to O
particulate O
air O
pollution O
. O

This O
has O
been O
identified O
as O
a O
key B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
gap I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
16 B_MEASURE/B_LOCATION
) O
. O

Schwartz O
and O
Dockery O
( O
17 O
) O
reported O
that O
persons B_PERSON
older O
than O
65 O
years O
of O
age O
had O
a O
somewhat O
increased O
risk O
of O
death O
, O
and O
this O
has O
been O
confirmed O
in O
other O
studies O
( O
18 O
) O
. O

A O
more O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
particulate B_DISEASE
matter I_DISEASE
- O
related O
risk B_DISEASE
by O
deciles B_TIME[MEASURE]/B_LOCATION
of O
age B_TIME[MEASURE]
( O
19 B_MEASURE
) O
showed O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
beginning O
to O
increase O
at O
approximately O
40 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
age B_TIME[MEASURE]/B_PERSON
and O
reaching O
its O
maximum B_MEASURE/B_LOCATION
for O
those O
75 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
age B_TIME[MEASURE]/B_PERSON
and O
older B_TIME[MEASURE]/B_LOCATION
. O

In O
addition O
to O
age O
, O
several O
studies O
suggest O
that O
persons B_PERSON/B_BIO
with O
respiratory O
illness O
are O
at O
increased O
risk O
for O
cardiovascular O
effects O
associated O
with O
air O
pollution O
. O

An O
examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
death B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
certificates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
air B_DISEASE_ADJECTIVE[DISEASE]
pollution I_DISEASE_ADJECTIVE[DISEASE]
days I_DISEASE_ADJECTIVE[DISEASE]
reported O
a O
substantial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
proportion B_MEASURE/B_PERSON
of O
deaths B_PERSON/B_DISEASE
from O
cardiovascular B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
causes I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
that O
had O
respiratory B_DISEASE
disease I_DISEASE
as O
a O
contributing O
cause B_DISEASE/B_PERSON
of O
death B_DISEASE
( O
19 B_MEASURE
) O
. O

A O
recent O
follow O
- O
up O
study O
of O
a O
cohort O
of O
persons B_PERSON
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
in O
Barcelona O
, O
Spain O
, O
found O
an O
association O
between O
particulate O
air O
pollution O
and O
all O
- O
cause O
mortality O
in O
the O
cohort O
( O
20 O
) O
. O

The O
magnitude B_MEASURE
of O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]
per O
microgram B_TIME[MEASURE]/B_PERSON
per O
cubic B_TIME[MEASURE]/B_PERSON
meter I_TIME[MEASURE]/I_PERSON
of O
exposure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
substantially O
greater B_MEASURE
than O
that O
for O
the O
general B_PERSON/B_MEASURE
population I_PERSON/I_MEASURE
. O

Environmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perspectives I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Controlled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
chronic B_DISEASE/B_LOCATION
bronchitis I_DISEASE/I_LOCATION
and O
control B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
concentrated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
demonstrated O
a O
potentiating B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lung B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O
airborne B_LOCATION/B_PROTEIN[GENE]
particles B_LOCATION/I_PROTEIN[GENE]
( O
21 B_MEASURE/B_LOCATION
) O
. O

This O
has O
led O
to O
the O
hypothesis O
that O
the O
cardiovascular O
effects O
of O
air O
pollution O
are O
predominantly O
in O
persons B_PERSON/B_ORGANIZATION
with O
chronic O
lung O
disease O
. O

There O
has O
been O
even O
less O
done O
to O
examine O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifiers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
airborne B_DISEASE
particles I_DISEASE
on O
hospital B_DISEASE
admissions I_DISEASE
. O

The O
existing O
literature B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
comorbidity B_DISEASE
shows O
that O
comorbidity B_DISEASE
per O
se B_LOCATION/B_TIME[MEASURE]
seems O
to O
increase O
the O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
22 B_PROTEIN[GENE]/B_DISEASE
<FFFD> I_PROTEIN[GENE]/I_DISEASE
30 I_PROTEIN[GENE]/I_DISEASE
) O
. O

Little B_PERSON/B_MEASURE
is O
known O
about O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
comorbidities B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifiers I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
air B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study O
uses O
data O
from O
the O
Medicare O
system O
to O
examine O
potential O
short O
- O
term O
and O
long O
- O
term O
medical O
conditions O
that O
may O
increase O
a O
person B_PERSON/B_LOCATION
' O
s O
risk O
of O
hospital O
admissions O
associated O
with O
particulate O
air O
pollution O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
examine O
potential B_PERSON
effect I_PERSON
modification I_PERSON
by O
age B_MEASURE/B_LOCATION
, O
race B_SPORT[ENT]/B_PERSON
, O
and O
sex B_PERSON/B_LOCATION
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Health O
Care O
financing O
Administration O
( O
Baltimore O
, O
MD O
) O
maintains O
records O
of O
every O
hospital O
admission O
for O
Medicare O
participants B_PERSON/B_ORGANIZATION
in O
the O
United O
States O
. O

Persons B_PERSON/B_ENT
in O
this O
database O
have O
a O
unique O
identifier O
. O

Using O
this O
identifier O
, O
we O
traced O
every O
hospital O
admission O
for O
heart O
and O
lung O
disease O
for O
each O
person B_PERSON/B_LOCATION
in O
Cook O
County O
, O
Illinois O
, O
between O
1985 O
and O
1994 O
. O

We O
chose O
Cook B_LOCATION/B_PERSON
County I_LOCATION/I_PERSON
because O
it O
is O
the O
most O
populous B_DISEASE_ADJECTIVE[DISEASE]
. O

county B_LOCATION/B_PERSON
in O
the O
United B_LOCATION
States I_LOCATION
with O
daily B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
monitoring I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
particulate B_PRODUCT[OBJECT]/B_LOCATION
matter I_PRODUCT[OBJECT]/I_LOCATION
with O
aerodynamic B_MEASURE/B_LOCATION
diameter I_MEASURE/I_LOCATION
< O
10 B_MEASURE/B_LOCATION
<FFFD> I_MEASURE/I_LOCATION
m I_MEASURE/I_LOCATION
( O
PM10 B_MEASURE/B_LOCATION
) O
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
then O
analyzed O
to O
look O
at O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
concurrent B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
preexisting O
conditions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
as O
well O
as O
by O
age B_MEASURE/B_LOCATION
, O
race B_SPORT[ENT]/B_PERSON
, O
and O
sex B_PERSON/B_LOCATION
. O

To O
establish O
a O
baseline B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
computed O
daily B_MEASURE
counts I_MEASURE
of O
hospital B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
cardiovascular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CVD B_DISEASE/B_LOCATION
) O
[ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
International I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Disease B_DISEASE
, O
9th B_MEASURE/B_ENT
edition I_MEASURE/I_ENT
, O
World B_MEASURE/B_LOCATION
Health I_MEASURE/I_LOCATION
Organization I_MEASURE/I_LOCATION
, O
Geneva B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ICD B_DISEASE/B_MEASURE
- O
9 B_SEQUENCE[MEASURE]
) O
code B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
390 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
<FFFD> I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
429 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
pneumonia B_DISEASE
( O
ICD B_DISEASE/B_LOCATION
- O
9 B_MEASURE
code I_MEASURE
480 I_MEASURE
<FFFD> I_MEASURE
487 I_MEASURE
) O
, O
and O
COPD B_DISEASE
( O
ICD B_DISEASE/B_LOCATION
- O
9 B_MEASURE
code I_MEASURE
490 I_MEASURE
<FFFD> I_MEASURE
496 I_MEASURE
, O
excluding O
493 B_TIME[MEASURE]/B_DISEASE
) O
. O

The O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
these O
daily B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counts B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
PM10 B_DISEASE/B_SPECIES[BIO]
was O
examined O
for O
the O
years B_TIME[MEASURE]
1988 I_TIME[MEASURE]
<FFFD> I_TIME[MEASURE]
1994 I_TIME[MEASURE]
, O
when O
daily B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PM10 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
monitoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Chicago B_LOCATION
. O

Once O
our O
baseline B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
risks I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
established O
, O
we O
examined O
three B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
classes I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
modifiers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

First O
, O
we O
looked O
at O
whether O
previous O
admissions O
for O
selected O
conditions O
predisposed O
persons B_PERSON
to O
having O
a O
greater O
risk O
from O
air O
pollution O
. O

For O
each O
of O
the O
three B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
admission I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
categories I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
CVD B_DISEASE
, O
pneumonia B_DISEASE/B_LOCATION
, O
and O
COPD B_DISEASE/B_PERSON
) O
, O
we O
considered O
10 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
causes I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
defined O
by O
a O
previous B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
as O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifiers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
COPD B_DISEASE
( O
ICD B_DISEASE/B_LOCATION
- O
9 B_MEASURE
code I_MEASURE
490 I_MEASURE
<FFFD> I_MEASURE
496 I_MEASURE
except O
493 B_TIME[MEASURE]/B_LOCATION
) O
, O
asthma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
ICD B_DISEASE/B_LOCATION
- O
9 B_MEASURE/B_LOCATION
code I_MEASURE/I_LOCATION
493 I_MEASURE/I_LOCATION
) O
, O
acute B_DISEASE
bronchitis I_DISEASE
( O
ICD B_DISEASE/B_LOCATION
- O
9 B_MEASURE/B_LOCATION
code I_MEASURE/I_LOCATION
466 I_MEASURE/I_LOCATION
) O
, O
acute B_DISEASE
respiratory I_DISEASE
illness I_DISEASE
( O
ICD B_DISEASE/B_LOCATION
- O
9 B_MEASURE
code I_MEASURE
460 I_MEASURE
<FFFD> I_MEASURE
466 I_MEASURE
) O
, O
pneumonia B_DISEASE
( O
ICD B_DISEASE/B_LOCATION
- O
9 B_MEASURE
code I_MEASURE
480 I_MEASURE
<FFFD> I_MEASURE
487 I_MEASURE
) O
, O
CVD B_DISEASE
( O
ICD B_DISEASE/B_LOCATION
- O
9 B_MEASURE
code I_MEASURE
390 I_MEASURE
<FFFD> I_MEASURE
429 I_MEASURE
) O
, O
myocardial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infarction I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
ICD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
9 B_MEASURE
code I_MEASURE
410 I_MEASURE
) O
, O
congestive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ICD B_MEASURE/B_DISEASE
- O
9 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
428 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
conduction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disorders I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
ICD B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
9 B_MEASURE/B_LOCATION
code I_MEASURE/I_LOCATION
426 I_MEASURE/I_LOCATION
) O
, O
and O
dysrhythmias B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
ICD9 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
code I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
427 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

To O
test O
the O
hypothesis O
that O
persons B_PERSON
with O
these O
conditions O
had O
higher O
risks O
of O
subsequent O
PM10 O
- O
related O
admissions O
, O
we O
computed O
separate O
daily O
counts O
of O
admissions O
for O
our O
three O
target O
causes O
, O
stratified O
by O
whether O
or O
not O
the O
person B_PERSON
admitted O
had O
been O
previously O
admitted O
for O
the O
hypothesized O
predisposing O
condition O
. O

separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
then O
performed O
within O
each O
strata B_LOCATION/B_ORGANIZATION
to O
see O
if O
the O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
PM10 B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
differed O
by O
strata B_MEASURE/B_LOCATION
. O

address O
correspondence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
A B_OTHER/B_PERSON
. O

Zanobetti B_PERSON/B_LOCATION
, O
Department B_ORGANIZATION/B_PERSON
of O
Environmental B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Environmental B_LOCATION/B_PERSON
Epidemiology I_LOCATION/I_PERSON
Program I_LOCATION/I_PERSON
, O
Harvard B_LOCATION/B_ORGANIZATION
School B_LOCATION/I_ORGANIZATION
of O
Public B_ORGANIZATION/B_LOCATION
Health I_ORGANIZATION/I_LOCATION
, O
665 B_LOCATION/B_ORGANIZATION
Huntington I_LOCATION/I_ORGANIZATION
Avenue I_LOCATION/I_ORGANIZATION
, O
Boston B_LOCATION/B_PERSON
, O
MA B_LOCATION
02115 I_LOCATION
USA I_LOCATION
. O

Telephone B_PRODUCT[OBJECT]/B_MEASURE
: O
( O
617 B_MEASURE/B_LOCATION
) O
4324642 B_MEASURE/B_LOCATION
. O

Fax B_MEASURE/B_PERSON
: O
( O
617 O
) O
277 B_MEASURE
- O
2382 B_MEASURE
. O

E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mail B_TIME[MEASURE]/B_LOCATION
: O
azanob B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
@ O
sparc6a B_LOCATION
. O
Harvard B_LOCATION/B_DISEASE
. O
edu B_PERSON/B_LOCATION
supported O
by O
NIEHS B_ORGANIZATION/B_LOCATION
grant I_ORGANIZATION/I_LOCATION
ES07937 I_ORGANIZATION/I_LOCATION
. O

received O
18 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
January I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
2000 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
; O
accepted O
18 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
April I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
2000 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

<FFFD> B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Volume I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
108 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Number I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
9 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
September I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2000 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

841 B_NUMBER[MEASURE]
. O

Articles B_PERSON
. O

<FFFD> B_PERSON/B_MEASURE
. O

Zanobetti B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
. O

The O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
predisposing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
included O
secondary B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnoses I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
the O
index B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
could O
represent O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
chronic B_DISEASE
condition I_DISEASE
( O
e B_DISEASE/B_GENE
. O
g B_GENE/B_MEASURE
. O
, O
COPD B_DISEASE
) O
that O
has O
not O
resulted O
in O
a O
previous B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hospital I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

They O
could O
also O
represent O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
may O
have O
increased O
the O
subjects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sensitivity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
air B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
example O
, O
if O
respiratory O
infections O
modified O
the O
effect O
of O
particulate O
matter O
on O
the O
cardiovascular O
health O
of O
persons B_PERSON
with O
underlying O
heart O
disease O
, O
then O
the O
risk O
of O
a O
hospital O
admission O
for O
heart O
disease O
might O
be O
different O
in O
persons B_PERSON/B_LOCATION
with O
infections O
. O

If O
this O
were O
true O
, O
then O
the O
risk O
ratio O
of O
a O
10 O
- O
<FFFD> O
g O
/ O
m3 O
increase O
of O
PM10 O
on O
cardiovascular O
admissions O
of O
persons B_PERSON
with O
a O
concurrent O
respiratory O
infection O
would O
be O
different O
from O
the O
ratio O
in O
persons B_PERSON/B_LOCATION
without O
respiratory O
infection O
. O

To O
test O
these O
hypotheses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
we O
computed O
separate B_MEASURE/B_ORGANIZATION
daily I_MEASURE/I_ORGANIZATION
counts I_MEASURE/I_ORGANIZATION
of O
admissions B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
events B_PERSON/B_LOCATION
with O
and O
without O
the O
concurrent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
conditions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
hypothesized O
to O
increase O
sensitivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
air B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pollution I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
were O
taken O
as O
the O
same B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
certain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
exclusions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
pairing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
would O
be O
illogical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

That O
is O
, O
the O
concurrent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
specific B_DISEASE
cardiac I_DISEASE
condition I_DISEASE
was O
not O
treated O
as O
an O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifier I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
admissions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
any O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
condition B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Likewise O
, O
pneumonia B_DISEASE/B_LOCATION
and O
COPD B_DISEASE
were O
not O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
concurrent I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
conditions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
each O
other B_PERSON/B_LOCATION
. O

The O
third B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
predisposing O
conditions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
considered O
was O
being O
older B_TIME[MEASURE]
than O
75 B_TIME[MEASURE]/B_PERSON
years I_TIME[MEASURE]/I_PERSON
of O
age B_TIME[MEASURE]/B_PERSON
, O
nonwhite B_PERSON/B_LOCATION
, O
and O
female B_PERSON
. O

These O
were O
examined O
for O
all O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
obtained O
weather B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
O B_OTHER/B_PERSON
' O
Hare B_PERSON/B_LOCATION
Airport I_PERSON/I_LOCATION
from O
the O
EarthInfo B_ENT/B_LOCATION
CD I_ENT/I_LOCATION
- O
ROM B_DISEASE/B_NUMBER[MEASURE]
( O
EarthInfo B_MEASURE/B_DISEASE
CD I_MEASURE/I_DISEASE
NCDC I_MEASURE/I_DISEASE
Surface I_MEASURE/I_DISEASE
Airways I_MEASURE/I_DISEASE
, O
EarthInfo B_ORGANIZATION/B_LOCATION
Inc I_ORGANIZATION/I_LOCATION
. O
, O
Boulder B_LOCATION/B_LANGUAGE
, O
CO B_LOCATION
) O
, O
and O
we O
obtained O
air B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
pollution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O
the O
U B_OTHER/B_LOCATION
. O
S B_OTHER/B_LOCATION
. O

Environmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Protection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Agency B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Aerometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
retrieval B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
System B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
network B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
31 B_MEASURE/B_ORGANIZATION
) O
. O

running O
- O
line B_MEASURE/B_LOCATION
smoother I_MEASURE/I_LOCATION
, O
loess B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
35 B_MEASURE/B_LOCATION
) O
, O
was O
chosen O
to O
estimate O
the O
smooth B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
control O
for O
weather B_TIME[MEASURE]
variables I_TIME[MEASURE]
and O
day B_TIME[MEASURE]
of O
the O
week B_TIME[MEASURE]/B_LOCATION
, O
we O
chose O
the O
smoothing B_MEASURE
parameter I_MEASURE
that O
minimized O
the O
Akaike B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
criterion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
36 B_MEASURE/B_LOCATION
) O
. O

To O
model O
seasonality B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
we O
chose O
the O
smoothing B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameter B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
minimized O
the O
sum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
autocorrelation B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
residuals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
while O
removing O
seasonal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two B_NUMBER[MEASURE]/B_LOCATION
autoregressive I_NUMBER[MEASURE]/I_LOCATION
terms I_NUMBER[MEASURE]/I_LOCATION
( O
37 B_MEASURE/B_LOCATION
) O
were O
added O
in O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
eliminate O
the O
remaining O
serial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
the O
residuals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

We O
used O
the O
mean B_MEASURE
of O
PM10 B_DISEASE/B_MEASURE
on O
the O
day B_TIME[MEASURE]
of O
the O
admission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
the O
day B_TIME[MEASURE]
before O
the O
admission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
as O
our O
exposure B_TIME[MEASURE]/B_PERSON
variable I_TIME[MEASURE]/I_PERSON
. O

This O
gives O
results B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
are O
similar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
those O
obtained O
fitting B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
full B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
distributed O
lag B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
38 B_TIME[MEASURE]/B_LOCATION
) O
. O

PM10 B_BIO/B_MEASURE
was O
treated O
linearly O
. O

Our O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
the O
daily B_MEASURE
counts I_MEASURE
of O
CVD B_DISEASE
, O
pneumonia B_DISEASE
, O
and O
COPD B_DISEASE
admissions I_DISEASE
as O
outcomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

We O
then O
subdivided O
those O
counts B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
the O
presence B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
absence B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
potential B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifier I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reestimated O
our O
regressions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
those O
subgroups B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

We O
considered O
effect O
modification O
to O
be O
indicated O
when O
the O
estimates O
of O
PM10 O
in O
the O
group O
with O
the O
condition O
was O
outside O
of O
the O
95 O
% O
confidence O
interval O
( O
CI O
) O
of O
the O
effect O
estimate O
in O
persons B_PERSON/B_ORGANIZATION
without O
the O
condition O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Table I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O
the O
mean B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
COPD B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
cardiovascular B_DISEASE
, O
and O
pneumonia B_DISEASE
both O
overall B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
in O
the O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
modifiers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

For O
some O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
modifiers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
conduction B_DISEASE
disorders I_DISEASE
or O
myocardial B_DISEASE
infarctions I_DISEASE
, O
the O
counts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
conjunction B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
our O
respiratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
. O

low B_MEASURE/B_COLOR
, O
which O
limits O
power B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

In O
general B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
numbers B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
examining O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
previous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
admissions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
for O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
concurrent B_DISEASE/B_PERSON
diagnosis I_DISEASE/I_PERSON
. O

This O
is O
as O
expected O
because O
many B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinically O
relevant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comorbidities I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
never O
have O
resulted O
in O
a O
hospital B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O
the O
25th B_SEQUENCE[MEASURE]
, O
50th B_SEQUENCE[MEASURE]
, O
and O
75th B_SEQUENCE[MEASURE]
percentile I_SEQUENCE[MEASURE]
values I_SEQUENCE[MEASURE]
for O
the O
environmental B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
variables I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
mean B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
PM10 B_MEASURE/B_SPECIES[BIO]
is O
33 B_MEASURE
<FFFD> I_MEASURE
g I_MEASURE
/ O
m3 B_MEASURE
. O

The O
daily B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
PM10 B_TIME[MEASURE]/B_PERSON
were O
computed O
as O
the O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
of O
10 B_NUMBER[MEASURE]
monitors I_NUMBER[MEASURE]
, O
two B_NUMBER[MEASURE]
of O
which O
measured O
PM10 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
almost O
every O
day B_TIME[MEASURE]
and O
the O
others B_PERSON/B_SEQUENCE[MEASURE]
less O
frequently O
( O
38 B_TIME[MEASURE]
) O
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O
the O
mean B_MEASURE
daily I_MEASURE
counts I_MEASURE
of O
CVD B_DISEASE
, O
COPD B_DISEASE
, O
and O
pneumonia B_DISEASE
by O
sex B_PERSON/B_LOCATION
, O
age B_MEASURE/B_PERSON
groups B_MEASURE/I_PERSON
, O
and O
race B_LOCATION
. O

The O
distribution B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O
sex B_PERSON
is O
almost O
even O
, O
although O
the O
counts B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
admissions B_PERSON/B_DISEASE
for O
males B_PERSON/B_DISEASE
are O
generally O
lower B_MEASURE
( O
approximately O
10 B_MEASURE
% I_MEASURE
) O
than O
for O
females B_PERSON
, O
particularly O
for O
cardiovascular B_PERSON
diseases I_PERSON
. O

The O
counts O
of O
CVD O
, O
COPD O
, O
and O
pneumonia O
admissions O
were O
similar O
for O
people B_PERSON/B_LOCATION
65 O
<FFFD> O
75 O
or O
75 O
years O
of O
age O
and O
older O
. O

tables B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
4 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
<FFFD> I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
6 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O
the O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PM10 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
overall I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
stratifying B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
concurrent B_TIME[MEASURE]/B_LOCATION
diagnosis I_TIME[MEASURE]/I_LOCATION
and O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admissions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
are O
expressed O
as O
the O
percentage B_MEASURE
increase I_MEASURE
for O
10 B_MEASURE/B_LOCATION
<FFFD> I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
m3 B_MEASURE
PM10 I_MEASURE
. O

Table B_TIME[MEASURE]/B_LOCATION
4 I_TIME[MEASURE]/I_LOCATION
shows O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
CVD B_ORGANIZATION/B_MEASURE
. O

A O
10 O
- O
<FFFD> O
g O
/ O
m3 O
increase O
in O
PM10 O
was O
associated O
with O
a O
1 O
. O
31 O
% O
( O
5 O
% O
CI O
, O
0 O
. O
97 O
% O
; O
95 O
% O
CI O
, O
1 O
. O
66 O
% O
) O
increase O
in O
hospital O
admissions O
for O
heart O
disease O
in O
all O
elderly O
persons B_PERSON/B_LOCATION
. O

A O
concurrent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
( O
not O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
COPD B_DISEASE
modified O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
PM10 B_DISEASE/B_SPECIES[BIO]
- O
associated O
admissions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
heart B_DISEASE
disease I_DISEASE
. O

However O
, O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
associations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
still O
seen O
between O
PM10 B_PERSON/B_LOCATION
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Mean O
daily B_MEASURE/B_LOCATION
counts I_MEASURE/I_LOCATION
of O
admissions B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
Chicago B_TIME[MEASURE]/B_LOCATION
1986 I_TIME[MEASURE]/I_LOCATION
<FFFD> I_TIME[MEASURE]/I_LOCATION
1994 I_TIME[MEASURE]/I_LOCATION
, O
for O
COPD B_DISEASE
, O
CVD B_DISEASE/B_GENE
, O
and O
pneumonia B_DISEASE
overall O
and O
by O
concurrent B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
diagnosis I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
by O
previous B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
admissions I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
concurrent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
COPD I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
CVD I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
pneumonia I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Overall I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Respiratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
disease I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Acute I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
bronchitis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Acute I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
respiratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
infections I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
pneumonia I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Asthma I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
COPD I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Cardiovascular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
disease I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
CVD I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
conduction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
disorders I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Cardiac I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
dysrhythmias I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
congestive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
heart I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
failure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Myocardial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
infarction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
NA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
not O
applicable B_MEASURE/B_DISEASE
. O

By O
previous B_MEASURE
admissions I_MEASURE
COPD I_MEASURE
CVD I_MEASURE
pneumonia I_MEASURE
7 I_MEASURE
. O
8 B_MEASURE
0 I_MEASURE
. O
8 B_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
1 I_MEASURE
. O
6 B_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
2 I_MEASURE
. O
7 B_MEASURE
2 I_MEASURE
. O
1 B_MEASURE
0 I_MEASURE
. O
0 B_MEASURE
0 I_MEASURE
. O
4 B_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
0 I_MEASURE
. O
3 B_MEASURE
102 I_MEASURE
. O
1 B_MEASURE
1 I_MEASURE
. O
6 B_MEASURE
1 I_MEASURE
. O
8 B_MEASURE
7 I_MEASURE
. O
3 B_MEASURE
1 I_MEASURE
. O
5 B_MEASURE
2 I_MEASURE
. O
0 B_MEASURE
54 I_MEASURE
. O
7 B_MEASURE
1 I_MEASURE
. O
0 B_MEASURE
9 I_MEASURE
. O
9 B_TIME[MEASURE]
24 I_TIME[MEASURE]
. O
2 B_MEASURE
11 I_MEASURE
. O
4 B_TIME[MEASURE]
26 I_TIME[MEASURE]
. O
5 B_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
1 I_MEASURE
. O
0 B_MEASURE
6 I_MEASURE
. O
4 B_MEASURE
0 I_MEASURE
. O
7 B_MEASURE
1 I_MEASURE
. O
4 B_MEASURE
7 I_MEASURE
. O
2 B_MEASURE
0 I_MEASURE
. O
2 B_MEASURE
1 I_MEASURE
. O
5 B_MEASURE
3 I_MEASURE
. O
1 B_MEASURE
1 I_MEASURE
. O
0 B_MEASURE
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
We O
analyzed O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
a O
generalized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
additive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
robust B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Poisson B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
32 B_TIME[MEASURE]/B_LOCATION
) O
. O

This O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
become O
the O
norm B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
14 B_MEASURE
, O
33 B_MEASURE
, O
34 B_MEASURE
) O
. O

In O
the O
generalized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
additive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
the O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
assumed O
to O
depend O
on O
a O
sum B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nonparametric B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
smooth B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
each O
variable B_TIME[MEASURE]/B_LOCATION
that O
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
potential B_MEASURE
nonlinear I_MEASURE
dependence I_MEASURE
of O
daily B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
weather B_LOCATION/B_TIME[MEASURE]
and O
season B_MEASURE/B_LOCATION
. O

The O
model B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
of O
the O
form B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
log B_PROTEIN[GENE]
[ I_PROTEIN[GENE]
E I_PROTEIN[GENE]
( O
Yt B_MEASURE/B_PROTEIN[GENE]
) O
] B_OTHER/B_DISEASE
= O
0 B_MEASURE/B_PROTEIN[GENE]
+ B_MEASURE/I_PROTEIN[GENE]
S1 B_MEASURE/I_PROTEIN[GENE]
( O
X1 B_MEASURE/B_GENE
) O
+ B_OTHER/B_GENE
. O
. O
. O

+ O
SP B_LOCATION
( O
Xp B_LOCATION/B_MEASURE
) O
where O
E B_OTHER/B_LOCATION
( O
Yt B_LOCATION/B_MEASURE
) O
is O
the O
expected B_MEASURE
value I_MEASURE
of O
the O
daily B_MEASURE/B_LOCATION
count I_MEASURE/I_LOCATION
of O
admissions B_LOCATION/B_ORGANIZATION
Yt I_LOCATION/I_ORGANIZATION
and O
Si B_LOCATION/B_PERSON
are O
the O
smooth B_MEASURE/B_LOCATION
functions I_MEASURE/I_LOCATION
of O
the O
covariates B_MEASURE/B_LOCATION
Xi I_MEASURE/I_LOCATION
. O

We O
examined O
temperature B_MEASURE/B_LOCATION
, O
previous B_TIME[MEASURE]/B_LOCATION
day B_TIME[MEASURE]/I_LOCATION
' O
s B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temperature B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
relative B_MEASURE/B_LOCATION
humidity B_MEASURE/I_LOCATION
, O
barometric B_MEASURE/B_LOCATION
pressure B_MEASURE/I_LOCATION
, O
and O
day B_TIME[MEASURE]/B_LOCATION
of O
week B_TIME[MEASURE]/B_LOCATION
covariates I_TIME[MEASURE]/I_LOCATION
. O

The B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
locally O
weighted O
. O

7 O
. O
8 B_MEASURE
0 I_MEASURE
. O
1 B_MEASURE
0 I_MEASURE
. O
3 B_MEASURE
0 I_MEASURE
. O
4 B_MEASURE
0 I_MEASURE
. O
1 B_MEASURE
Na I_MEASURE
4 I_MEASURE
. O
7 B_MEASURE
0 I_MEASURE
. O
2 B_MEASURE
1 I_MEASURE
. O
4 B_MEASURE
1 I_MEASURE
. O
8 B_MEASURE
0 I_MEASURE
. O
1 B_MEASURE
. O

102 O
. O
1 B_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
1 I_MEASURE
. O
3 B_MEASURE
4 I_MEASURE
. O
0 B_MEASURE
1 I_MEASURE
. O
8 B_TIME[MEASURE]
13 I_TIME[MEASURE]
. O
4 B_MEASURE/B_ENT
Na I_MEASURE/I_ENT
Na I_MEASURE/I_ENT
Na I_MEASURE/I_ENT
Na I_MEASURE/I_ENT
Na I_MEASURE/I_ENT
. O

26 O
. O
5 B_MEASURE
0 I_MEASURE
. O
3 B_MEASURE
0 I_MEASURE
. O
3 B_MEASURE
Na I_MEASURE
0 I_MEASURE
. O
9 B_TIME[MEASURE]
6 I_TIME[MEASURE]
. O
9 B_TIME[MEASURE]
14 I_TIME[MEASURE]
. O
7 B_MEASURE
0 I_MEASURE
. O
6 B_MEASURE
4 I_MEASURE
. O
6 B_TIME[MEASURE]
7 I_TIME[MEASURE]
. O
3 B_MEASURE
0 I_MEASURE
. O
4 B_MEASURE
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

25th O
, O
50th B_SEQUENCE[MEASURE]
, O
and O
75th B_SEQUENCE[MEASURE]
percentile I_SEQUENCE[MEASURE]
values I_SEQUENCE[MEASURE]
for O
the O
environmental B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
variables I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
Chicago B_LOCATION/B_TIME[MEASURE]
, O
1988 B_LOCATION
<FFFD> I_LOCATION
1994 I_LOCATION
. O

temperature B_MEASURE
( O
<FFFD> B_MEASURE/B_LOCATION
F I_MEASURE/I_LOCATION
) O
35 B_TIME[MEASURE]
51 I_TIME[MEASURE]
67 I_TIME[MEASURE]
relative I_TIME[MEASURE]
humidity I_TIME[MEASURE]
62 I_TIME[MEASURE]
70 I_TIME[MEASURE]
79 I_TIME[MEASURE]
Barometric I_TIME[MEASURE]
pressure I_TIME[MEASURE]
29 I_TIME[MEASURE]
. O
2 B_MEASURE
29 I_MEASURE
. O
3 B_TIME[MEASURE]
29 I_TIME[MEASURE]
. O
4 B_TIME[MEASURE]
PM10 I_TIME[MEASURE]
( O
<FFFD> B_MEASURE/B_LOCATION
g I_MEASURE/I_LOCATION
/ O
m3 B_MEASURE
) O
23 B_MEASURE/B_LOCATION
33 I_MEASURE/I_LOCATION
46 I_MEASURE/I_LOCATION
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Mean O
daily B_MEASURE/B_LOCATION
counts I_MEASURE/I_LOCATION
of O
admissions B_PERSON/B_LOCATION
by O
sex B_PERSON/B_LOCATION
, O
race B_LOCATION
, O
and O
age B_MEASURE/B_PERSON
groups B_MEASURE/I_PERSON
, O
Chicago B_LOCATION/B_DISEASE
, O
1986 B_TIME[MEASURE]/B_LOCATION
<FFFD> B_TIME[MEASURE]/I_LOCATION
1994 B_TIME[MEASURE]/I_LOCATION
. O

Group B_TIME[MEASURE]/B_LOCATION
Overall I_TIME[MEASURE]/I_LOCATION
Female I_TIME[MEASURE]/I_LOCATION
Nonwhite I_TIME[MEASURE]/I_LOCATION
Age I_TIME[MEASURE]/I_LOCATION
> O
75 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
COPD I_MEASURE/I_ENT
7 I_MEASURE/I_ENT
. O
8 B_MEASURE
4 I_MEASURE
. O
2 B_MEASURE
1 I_MEASURE
. O
6 B_MEASURE
3 I_MEASURE
. O
7 B_MEASURE
CVD I_MEASURE
102 I_MEASURE
. O
1 B_MEASURE
59 I_MEASURE
. O
4 B_TIME[MEASURE]
21 I_TIME[MEASURE]
. O
0 B_MEASURE
55 I_MEASURE
. O
1 B_TIME[MEASURE]
pneumonia I_TIME[MEASURE]
26 I_TIME[MEASURE]
. O
5 B_TIME[MEASURE]
14 I_TIME[MEASURE]
. O
7 B_MEASURE
5 I_MEASURE
. O
2 B_MEASURE
17 I_MEASURE
. O
4 B_MEASURE
. O

842 B_NUMBER[MEASURE]
. O

Volume B_MEASURE
. O

108 O
| O
Number B_TIME[MEASURE]
9 I_TIME[MEASURE]
| O
September B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2000 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
<FFFD> I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Environmental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
perspectives I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Articles B_PERSON
. O

<FFFD> B_PERSON/B_MEASURE
. O

Effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
particles B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
sensitive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroups I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

and O
heart O
disease O
admissions O
in O
persons B_PERSON/B_LOCATION
without O
COPD O
listed O
as O
either O
a O
comorbidity O
or O
a O
cause O
of O
previous O
admission O
( O
Table O
4 O
) O
. O

A O
significant O
association O
was O
also O
seen O
in O
persons B_PERSON
without O
any O
respiratory O
disease O
as O
a O
concurrent O
diagnosis O
, O
although O
the O
risk O
is O
much O
lower O
than O
in O
persons B_PERSON
with O
respiratory O
disease O
. O

However O
, O
the O
risk O
associated O
with O
PM10 O
was O
roughly O
doubled O
in O
subjects O
with O
concurrent O
respiratory O
infections O
and O
the O
risk O
estimates O
in O
those O
subjects O
were O
outside O
the O
95 O
% O
CI O
of O
the O
risk O
in O
patients B_PERSON
without O
concurrent O
respiratory O
infections O
. O

A O
previous O
admission O
for O
conduction O
disorders O
( O
e O
. O
g O
. O
, O
heart O
block O
) O
increased O
the O
risk O
of O
a O
PM10 O
- O
related O
subsequent O
admission O
for O
any O
heart O
condition O
, O
and O
a O
weaker O
indication O
of O
effect O
modification O
was O
seen O
for O
persons B_PERSON
with O
previous O
admission O
for O
dysrhythmias O
. O

In O
contrast B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
heart I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
failure I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
previous B_DISEASE/B_PERSON
myocardial I_DISEASE/I_PERSON
infarctions I_DISEASE/I_PERSON
were O
highly O
insignificant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifiers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Table B_MEASURE/B_LOCATION
5 I_MEASURE/I_LOCATION
shows O
the O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
COPD B_MEASURE/B_PERSON
. O

Overall O
, O
there O
is O
a O
1 B_MEASURE
. O
89 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
CI I_MEASURE/I_LOCATION
, O
0 B_MEASURE
. O
8 B_MEASURE
<FFFD> I_MEASURE
3 I_MEASURE
. O
0 B_MEASURE
) O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
COPD B_DISEASE/B_GENE
admissions I_DISEASE/I_GENE
for O
a O
10 B_MEASURE/B_LOCATION
<FFFD> I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
m3 B_MEASURE
increase I_MEASURE
in O
PM10 B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
stratified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
preexisting O
heart B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifies O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

percentage O
increase O
in O
hospital O
admissions O
for O
CVD O
in O
all O
persons B_PERSON/B_LOCATION
and O
by O
concurrent O
diagnosis O
and O
previous O
admissions O
. O

PM10 O
2 O
. O
5 O
% O
CI O
97 O
. O
5 O
% O
CI O
All O
persons B_PERSON/B_TIME[MEASURE]
1 O
. O
31 O
By O
concurrent O
diagnosis O
respiratory O
disease O
All O
respiratory O
disease O
With O
1 O
. O
65 O
Without O
0 O
. O
98 O
acute O
bronchitis O
With O
2 O
. O
50 O
Without O
1 O
. O
07 O
acute O
respiratory O
infections O
With O
2 O
. O
71 O
Without O
1 O
. O
06 O
pneumonia O
With O
1 O
. O
95 O
Without O
1 O
. O
03 O
COPD O
With O
1 O
. O
59 O
Without O
1 O
. O
08 O
By O
previous O
admissions O
respiratory O
disease O
All O
respiratory O
disease O
With O
1 O
. O
18 O
Without O
1 O
. O
08 O
COPD O
With O
1 O
. O
48 O
Without O
1 O
. O
09 O
Asthma O
With O
1 O
. O
71 O
Without O
1 O
. O
08 O
Cardiovascular O
disease O
Conduction O
disorders O
With O
2 O
. O
89 O
Without O
1 O
. O
07 O
cardiac O
dyshrethmias O
With O
1 O
. O
61 O
Without O
1 O
. O
04 O
0 O
. O
97 O
1 O
. O
66 O
. O

the O
risk B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
COPD B_DISEASE
admissions I_DISEASE
on O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
particle B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
days B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admissions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
any O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
increased O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
a O
PM10associated B_DISEASE
COPD I_DISEASE
admission I_DISEASE
approximately O
2 B_NUMBER[MEASURE]
. O
5 B_MEASURE
- O
fold B_TIME[MEASURE]/B_LOCATION
. O

A O
previous B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O
an O
even O
more O
striking B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
PM10 B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admissions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
dysrhythmias B_DISEASE
and O
conduction B_DISEASE
defects I_DISEASE
were O
rare B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Table B_MEASURE
1 I_MEASURE
) O
with O
no O
power B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
examine O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
modifications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Listings B_DISEASE
as O
concurrent B_DISEASE/B_PERSON
diagnoses I_DISEASE/I_PERSON
were O
more O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
here O
they O
joined O
heart B_DISEASE_ADJECTIVE[DISEASE]
failure I_DISEASE_ADJECTIVE[DISEASE]
in O
increasing O
the O
risk B_MEASURE
of O
PM B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
COPD B_DISEASE/B_LOCATION
admissions I_DISEASE/I_LOCATION
. O

For O
COPD B_DISEASE/B_PERSON
there O
was O
also O
some O
indication B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
concurrent B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pneumonia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
an O
acute B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
respiratory I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
last B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
year I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
increased O
risk B_DISEASE
. O

The O
low B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
numbers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
made O
these O
estimates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
less O
precise B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
. O

The O
percentage B_MEASURE
increase I_MEASURE
in O
pneumonia B_DISEASE/B_PROTEIN[GENE]
admission B_DISEASE/I_PROTEIN[GENE]
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
6 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
for O
10 B_MEASURE/B_LOCATION
<FFFD> I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
m3 B_MEASURE
PM10 I_MEASURE
is O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
for O
COPD B_DISEASE/B_LOCATION
or O
CVD B_DISEASE/B_LOCATION
with O
an O
increase B_PROTEIN[GENE]/B_DISEASE
of O
2 B_MEASURE
. O
34 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
CI I_MEASURE/I_LOCATION
, O
1 B_MEASURE
. O
66 B_MEASURE
<FFFD> I_MEASURE
3 I_MEASURE
. O
0 B_MEASURE
) O
. O

As O
with O
COPD O
, O
persons B_PERSON
with O
heart O
disease O
appeared O
at O
higher O
risk O
of O
pneumonia O
hospital O
admissions O
associated O
with O
particulate O
air O
pollution O
. O

Here O
diagnoses B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggestive B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
impaired B_DISEASE_ADJECTIVE[DISEASE]
autonomic I_DISEASE_ADJECTIVE[DISEASE]
control I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
conduction B_DISEASE
disorders I_DISEASE
or O
dysrhythmias B_DISEASE
, O
were O
associated O
with O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
PM B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
pneumonia B_DISEASE
admissions I_DISEASE
. O

Unlike O
COPD B_DISEASE/B_PERSON
, O
no O
difference B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
seen O
for O
congestive B_DISEASE
heart I_DISEASE
failure I_DISEASE
. O

Persons B_PERSON
with O
asthma O
Table O
5 O
. O

percentage O
increase O
in O
hospital O
admissions O
for O
COPD O
in O
all O
persons B_PERSON/B_DISEASE
and O
by O
concurrent O
diagnosis O
and O
previous O
admissions O
. O

PM10 O
2 O
. O
5 O
% O
CI O
97 O
. O
5 O
% O
CI O
All O
persons B_TIME[MEASURE]/B_DISEASE
1 O
. O
89 O
By O
concurrent O
diagnosis O
respiratory O
disease O
pneumonia O
With O
4 O
. O
00 O
Without O
1 O
. O
51 O
Cardiovascular O
disease O
Conduction O
disorders O
With O
2 O
. O
34 O
Without O
1 O
. O
60 O
cardiac O
dysrhythmias O
With O
3 O
. O
09 O
Without O
1 O
. O
43 O
Congestive O
heart O
failure O
With O
2 O
. O
90 O
Without O
1 O
. O
39 O
By O
previous O
admissions O
respiratory O
disease O
acute O
respiratory O
infections O
With O
3 O
. O
20 O
Without O
1 O
. O
70 O
Cardiovascular O
disease O
CVD O
With O
2 O
. O
90 O
Without O
1 O
. O
18 O
Congestive O
heart O
failure O
With O
4 O
. O
37 O
Without O
1 O
. O
14 O
Within O
1 O
year O
6 O
. O
04 O
0 O
. O
80 O
2 O
. O
99 O
. O

had O
twice O
the O
risk O
of O
a O
PM10 O
- O
induced O
pneumonia O
admission O
as O
persons B_PERSON/B_LOCATION
without O
asthma O
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
7 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O
sex B_PERSON/B_LOCATION
, O
age B_TIME[MEASURE]/B_LOCATION
, O
and O
race B_SPORT[ENT]/B_LOCATION
. O

None B_PERSON/B_NUMBER[MEASURE]
of O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
size I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
estimates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
any O
of O
the O
stratification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
outside B_LOCATION/B_DISEASE
of O
the O
95 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CI B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
opposite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strata I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

There O
was O
a O
tendency B_MEASURE/B_DISEASE
for O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PM10 B_DISEASE/B_SPECIES[BIO]
on O
CVD B_DISEASE
admissions I_DISEASE
to O
be O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
females B_PERSON
, O
whereas O
the O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
pneumonia B_DISEASE
admissions I_DISEASE
was O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
males B_PERSON
. O

In O
general O
, O
we O
found O
somewhat O
larger O
effects O
on O
whites O
compared O
to O
nonwhites O
, O
and O
for O
persons B_PERSON
older O
than O
75 O
years O
of O
age O
compared O
to O
younger O
persons B_PERSON
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
In O
this O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
examined O
whether O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PM10 B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
risk B_MEASURE
of O
hospital B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
lung B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O
on O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
comorbidities B_DISEASE
. O

We O
found O
that O
PM10 B_DISEASE/B_SPECIES[BIO]
was O
associated O
with O
hospital B_DISEASE_ADJECTIVE[DISEASE]
admissions I_DISEASE_ADJECTIVE[DISEASE]
for O
all O
three B_DISEASE_ADJECTIVE[DISEASE]
causes I_DISEASE_ADJECTIVE[DISEASE]
( O
CVD B_DISEASE
, O
COPD B_DISEASE
, O
and O
pneumonia B_DISEASE
) O
and O
we O
found O
not O
a O
general B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
PM10 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
related I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
risk I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
comorbidities B_DISEASE
, O
but O
a O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
is O
suggestive B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O
potential B_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]
and O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epidemiologic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
toxicologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

One B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
major I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
finding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
that O
preexisting O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
, O
particularly O
impaired O
autonomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
conduction B_DISEASE
defects I_DISEASE
and O
dysrhythmias B_DISEASE
) O
and O
heart B_DISEASE
failure I_DISEASE
, O
substantially O
increased O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
respiratory B_DISEASE
admissions I_DISEASE
associated O
with O
airborne B_DISEASE
particles I_DISEASE
. O

In O
fact O
, O
recent O
human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
studies O
have O
shown O
that O
exposure O
to O
particulate O
air O
pollution O
is O
a O
risk O
factor O
for O
reduced O
heart O
rate O
variability O
( O
39 O
<FFFD> O
41 O
) O
. O

reduced O
heart B_DISEASE/B_PROTEIN[GENE]
rate B_DISEASE/I_PROTEIN[GENE]
variability B_DISEASE/I_PROTEIN[GENE]
is O
an O
adverse B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
arrhythmia B_DISEASE
. O

A O
new O
study O
of O
defibrillator O
discharges O
in O
patients B_PERSON/B_BIO
with O
implanted O
cardioverter O
defibrillators O
found O
that O
discharges O
were O
associated O
with O
air O
pollution O
( O
42 O
) O
. O

exposure B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
combustion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Table I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

percentage O
increase O
in O
hospital O
admissions O
for O
pneumonia O
in O
all O
persons B_PERSON/B_DISEASE
and O
by O
concurrent O
diagnosis O
and O
previous O
admissions O
. O

PM10 O
All O
persons B_PERSON/B_DISEASE
By O
concurrent O
diagnosis O
respiratory O
disease O
Asthma O
With O
Without O
Cardiovascular O
disease O
Conduction O
disorders O
With O
Without O
cardiac O
dysrhythmias O
With O
Without O
By O
previous O
admissions O
Cardiovascular O
disease O
cardiac O
dysrhythmias O
With O
Without O
2 O
. O
34 O
2 O
. O
5 O
% O
CI O
97 O
. O
5 O
% O
CI O
1 O
. O
66 O
3 O
. O
02 O
. O

1 O
. O
10 B_MEASURE
0 I_MEASURE
. O
64 B_MEASURE
<FFFD> I_MEASURE
0 I_MEASURE
. O
47 B_MEASURE
0 I_MEASURE
. O
76 B_MEASURE
0 I_MEASURE
. O
18 B_MEASURE
0 I_MEASURE
. O
76 B_MEASURE
0 I_MEASURE
. O
55 B_MEASURE
0 I_MEASURE
. O
72 B_MEASURE
0 I_MEASURE
. O
85 B_MEASURE
0 I_MEASURE
. O
75 B_MEASURE
. O

2 O
. O
20 B_TIME[MEASURE]
1 I_TIME[MEASURE]
. O
33 B_MEASURE
5 I_MEASURE
. O
55 B_MEASURE
1 I_MEASURE
. O
37 B_MEASURE
5 I_MEASURE
. O
30 B_MEASURE
1 I_MEASURE
. O
37 B_MEASURE
3 I_MEASURE
. O
36 B_MEASURE
1 I_MEASURE
. O
35 B_MEASURE
2 I_MEASURE
. O
34 B_MEASURE
1 I_MEASURE
. O
41 B_MEASURE
. O

<FFFD> B_MEASURE
0 I_MEASURE
. O
45 B_MEASURE
0 I_MEASURE
. O
47 B_MEASURE
<FFFD> I_MEASURE
4 I_MEASURE
. O
42 B_MEASURE
0 I_MEASURE
. O
58 B_MEASURE
0 I_MEASURE
. O
64 B_MEASURE
0 I_MEASURE
. O
33 B_MEASURE
0 I_MEASURE
. O
77 B_MEASURE
0 I_MEASURE
. O
24 B_MEASURE
. O

8 O
. O
65 B_MEASURE
2 I_MEASURE
. O
57 B_MEASURE
9 I_MEASURE
. O
59 B_MEASURE
2 I_MEASURE
. O
64 B_MEASURE
5 I_MEASURE
. O
60 B_MEASURE
2 I_MEASURE
. O
55 B_MEASURE
5 I_MEASURE
. O
08 B_MEASURE
2 I_MEASURE
. O
55 B_MEASURE
. O

0 O
. O
45 B_MEASURE
0 I_MEASURE
. O
76 B_MEASURE
<FFFD> I_MEASURE
0 I_MEASURE
. O
40 B_MEASURE
0 I_MEASURE
. O
78 B_MEASURE
<FFFD> I_MEASURE
0 I_MEASURE
. O
43 B_MEASURE
0 I_MEASURE
. O
77 B_MEASURE
0 I_MEASURE
. O
22 B_MEASURE
0 I_MEASURE
. O
76 B_MEASURE
0 I_MEASURE
. O
75 B_MEASURE
0 I_MEASURE
. O
72 B_MEASURE
. O

1 O
. O
91 B_MEASURE
1 I_MEASURE
. O
41 B_MEASURE
3 I_MEASURE
. O
40 B_MEASURE
1 I_MEASURE
. O
40 B_MEASURE
3 I_MEASURE
. O
89 B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
. O
39 B_MEASURE
5 I_MEASURE
. O
63 B_MEASURE
1 I_MEASURE
. O
38 B_MEASURE
2 I_MEASURE
. O
48 B_MEASURE
1 I_MEASURE
. O
36 B_MEASURE
. O

4 O
. O
18 B_MEASURE
2 I_MEASURE
. O
07 B_MEASURE
7 I_MEASURE
. O
92 B_MEASURE
1 I_MEASURE
. O
99 B_MEASURE
<FFFD> I_MEASURE
<FFFD> I_MEASURE
. O

1 O
. O
01 B_MEASURE
1 I_MEASURE
. O
46 B_MEASURE
4 I_MEASURE
. O
28 B_MEASURE
1 I_MEASURE
. O
37 B_MEASURE
<FFFD> I_MEASURE
<FFFD> I_MEASURE
. O

7 O
. O
46 B_MEASURE
2 I_MEASURE
. O
69 B_MEASURE
11 I_MEASURE
. O
69 B_MEASURE
2 I_MEASURE
. O
61 B_MEASURE
<FFFD> I_MEASURE
<FFFD> I_MEASURE
. O

<FFFD> B_MEASURE
1 I_MEASURE
. O
38 B_MEASURE
0 I_MEASURE
. O
66 B_MEASURE
0 I_MEASURE
. O
99 B_MEASURE
<FFFD> I_MEASURE
0 I_MEASURE
. O
01 B_MEASURE
1 I_MEASURE
. O
43 B_MEASURE
0 I_MEASURE
. O
05 B_MEASURE
2 I_MEASURE
. O
10 B_MEASURE
. O

8 O
. O
01 B_MEASURE
2 I_MEASURE
. O
76 B_MEASURE
4 I_MEASURE
. O
85 B_MEASURE
2 I_MEASURE
. O
39 B_MEASURE
7 I_MEASURE
. O
40 B_MEASURE
2 I_MEASURE
. O
24 B_TIME[MEASURE]
10 I_TIME[MEASURE]
. O
14 B_MEASURE
. O

3 O
. O
47 B_MEASURE
2 I_MEASURE
. O
08 B_MEASURE
. O

1 O
. O
21 B_MEASURE
1 I_MEASURE
. O
45 B_MEASURE
. O

5 O
. O
79 B_MEASURE
2 I_MEASURE
. O
71 B_MEASURE
. O

Increases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
for O
a O
10 B_MEASURE
- O
<FFFD> B_MEASURE/B_LOCATION
g I_MEASURE/I_LOCATION
/ O
m3 B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
PM10 B_SPECIES[BIO]/B_PROTEIN[GENE]
. O

Increases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
for O
a O
10 B_MEASURE
- O
<FFFD> B_MEASURE/B_LOCATION
g I_MEASURE/I_LOCATION
/ O
m3 B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
PM10 B_SPECIES[BIO]/B_PROTEIN[GENE]
. O

Increases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
for O
a O
10 B_MEASURE
- O
<FFFD> B_MEASURE/B_LOCATION
g I_MEASURE/I_LOCATION
/ O
m3 B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
PM10 B_SPECIES[BIO]/B_PROTEIN[GENE]
. O

Environmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perspectives I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

<FFFD> B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Volume I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
108 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Number I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
9 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
September I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2000 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

843 B_NUMBER[MEASURE]
. O

Articles B_PERSON
. O

<FFFD> B_PERSON/B_MEASURE
. O

Zanobetti B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
7 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
sex B_PERSON/B_LOCATION
, O
race B_SPORT[ENT]/B_PERSON
, O
and O
age B_MEASURE/B_LOCATION
groups B_MEASURE/I_LOCATION
for O
10 B_MEASURE/B_LOCATION
<FFFD> I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
m3 B_MEASURE
PM10 I_MEASURE
. O

% O
All O
persons B_PERSON/B_LOCATION
Male O
Female O
White O
Non O
- O
white O
Age O
> O
75 O
Age O
75 O
1 O
. O
89 O
1 O
. O
34 O
2 O
. O
19 O
1 O
. O
65 O
1 O
. O
07 O
2 O
. O
20 O
1 O
. O
33 O
COPD O
( O
95 O
% O
CI O
) O
( O
0 O
. O
80 O
, O
2 O
. O
99 O
) O
( O
<FFFD> O
0 O
. O
14 O
, O
2 O
. O
84 O
) O
( O
0 O
. O
81 O
, O
3 O
. O
59 O
) O
( O
0 O
. O
51 O
, O
2 O
. O
81 O
) O
( O
<FFFD> O
1 O
. O
11 O
, O
3 O
. O
3 O
) O
( O
0 O
. O
72 O
, O
3 O
. O
69 O
) O
( O
0 O
. O
03 O
, O
2 O
. O
65 O
) O
% O
1 O
. O
31 O
1 O
. O
07 O
1 O
. O
21 O
1 O
. O
20 O
0 O
. O
70 O
1 O
. O
28 O
0 O
. O
93 O
CVD O
( O
95 O
% O
CI O
) O
( O
0 O
. O
97 O
, O
1 O
. O
66 O
) O
( O
0 O
. O
62 O
, O
1 O
. O
51 O
) O
( O
0 O
. O
83 O
, O
1 O
. O
6 O
) O
( O
0 O
. O
86 O
, O
1 O
. O
55 O
) O
( O
0 O
. O
1 O
, O
1 O
. O
3 O
) O
( O
0 O
. O
88 O
, O
1 O
. O
69 O
) O
( O
0 O
. O
51 O
, O
1 O
. O
35 O
) O
% O
2 O
. O
34 O
2 O
. O
65 O
1 O
. O
91 O
2 O
. O
45 O
1 O
. O
91 O
2 O
. O
12 O
2 O
. O
52 O
pneumonia O
( O
95 O
% O
CI O
) O
( O
1 O
. O
66 O
, O
3 O
. O
02 O
) O
( O
1 O
. O
81 O
, O
3 O
. O
5 O
) O
( O
1 O
. O
11 O
, O
2 O
. O
72 O
) O
( O
1 O
. O
77 O
, O
3 O
. O
14 O
) O
( O
0 O
. O
69 O
, O
3 O
. O
14 O
) O
( O
1 O
. O
38 O
, O
2 O
. O
86 O
) O
( O
1 O
. O
57 O
, O
3 O
. O
48 O
) O
. O

figures B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O
are O
the O
percentage B_MEASURE/B_PERSON
increase I_MEASURE/I_PERSON
in O
admissions B_DISEASE/B_MEASURE
( O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
CI I_MEASURE/I_LOCATION
) O
. O

particles B_DISEASE/B_LOCATION
has O
also O
been O
associated O
with O
arrhythmia B_DISEASE/B_LOCATION
in O
an O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
43 B_MEASURE
) O
and O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
ST B_DISEASE_ADJECTIVE[DISEASE]
segments I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
noted O
as O
well O
( O
44 B_MEASURE
) O
. O

This O
is O
the O
first O
study O
to O
suggest O
persons B_PERSON/B_BIO
with O
defects O
in O
the O
electrical O
control O
of O
the O
heart O
are O
also O
at O
higher O
risk O
of O
respiratory O
illness O
after O
exposure O
to O
airborne O
particles O
. O

These O
data O
also O
suggest O
that O
persons B_PERSON/B_BIO
admitted O
to O
hospitals O
for O
pneumonia O
during O
an O
air O
pollution O
episode O
may O
be O
at O
high O
risk O
for O
clinically O
significant O
conduction O
disorders O
during O
that O
hospital O
admission O
. O

Patients B_PERSON/B_BIO
with O
congestive O
heart O
failure O
were O
at O
greater O
risk O
of O
hospital O
admissions O
for O
COPD O
in O
association O
with O
airborne O
particles O
. O

Heart B_DISEASE/B_LOCATION
failure I_DISEASE/I_LOCATION
and O
COPD B_DISEASE
is O
not O
an O
uncommon B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
finding O
that O
these O
patients B_PERSON/B_BIO
are O
at O
higher O
risk O
for O
admissions O
associated O
with O
particulate O
air O
pollution O
is O
new O
but O
is O
also O
consistent O
with O
several O
other O
recent O
reports O
. O

The O
spontaneous O
hypertensive O
rat B_SPECIES[BIO]/B_GENE
develops O
a O
model O
of O
heart O
failure O
, O
and O
recent O
studies O
have O
reported O
greater O
sensitivity O
to O
particulate O
air O
pollution O
in O
these O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
include O
both O
electrocardiogram B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
abnormalities I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
44 B_MEASURE
) O
and O
pulmonary B_DISEASE
toxicity I_DISEASE
( O
45 B_MEASURE
, O
46 B_MEASURE
) O
. O

Similarly O
, O
in O
an O
epidemiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
Hoek B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
47 B_MEASURE
) O
, O
found O
a O
higher B_MEASURE
relative I_MEASURE
risk I_MEASURE
of O
death B_DISEASE
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
PM10 B_DISEASE/B_SPECIES[BIO]
for O
congestive B_DISEASE/B_PERSON
heart I_DISEASE/I_PERSON
failure I_DISEASE/I_PERSON
deaths I_DISEASE/I_PERSON
than O
other B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deaths I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
COPD B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
those O
heart B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deaths I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
examined O
. O

Another O
consistent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
of O
acute B_DISEASE_ADJECTIVE[DISEASE]
respiratory I_DISEASE_ADJECTIVE[DISEASE]
infections I_DISEASE_ADJECTIVE[DISEASE]
increasing O
susceptibility B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
airborne B_DISEASE
particles I_DISEASE
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
bronchitis I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
more O
generally O
acute B_DISEASE
upper I_DISEASE
respiratory I_DISEASE
illnesses I_DISEASE
, O
as O
well O
as O
pneumonia B_DISEASE/B_PERSON
, O
increased O
susceptibility B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
particle B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
associated O
admissions B_DISEASE
for O
CVD B_DISEASE
and O
COPD B_DISEASE
. O

The O
notion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
air B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pollution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exacerbates O
acute B_DISEASE
respiratory I_DISEASE
infections I_DISEASE
is O
well O
supported O
by O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
which O
report O
associations B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
airborne B_DISEASE
particles I_DISEASE
and O
hospital B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
respiratory B_DISEASE/B_PERSON
infections I_DISEASE/I_PERSON
( O
48 B_MEASURE/B_PERSON
, O
49 B_MEASURE
) O
. O

Zelikoff B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
50 O
) O
exposed O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infected O
with O
streptococcus O
to O
concentrated O
air O
particles O
and O
reported O
a O
significant O
increase O
in O
bacterial O
burdens O
and O
in O
the O
extent O
of O
pneumonia O
compared O
to O
animals O
exposed O
to O
filtrated O
air O
. O

This O
suggests O
an O
impaired B_DISEASE_ADJECTIVE[DISEASE]
immune I_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
. O

Similarly O
, O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
combustion B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

particles O
enhances O
influenza O
infections O
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
51 O
) O
. O

An O
impaired O
defense O
to O
respiratory O
infection O
is O
a O
major O
reason O
that O
persons B_PERSON
with O
COPD O
require O
hospital O
admission O
. O

If O
airborne B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
result O
in O
further B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
modification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
we O
observe O
makes O
good B_DISEASE_ADJECTIVE[DISEASE]
sense I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
heart B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
more O
relevant B_DISEASE_ADJECTIVE[DISEASE]
. O

This O
modification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
earlier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Schwartz B_PERSON
( O
19 B_MEASURE
) O
, O
who O
found O
greater B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
respiratory B_DISEASE/B_PERSON
complications I_DISEASE/I_PERSON
on O
death B_PERSON
certificates I_PERSON
with O
an O
underlying O
cause B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
heart B_DISEASE
disease I_DISEASE
if O
the O
death B_PERSON/B_DISEASE
occurred O
on O
a O
day B_TIME[MEASURE]/B_LOCATION
with O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
airborne B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
airborne B_DISEASE
particle I_DISEASE
exposure I_DISEASE
has O
been O
associated O
with O
increased O
exacerbation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
asthma B_DISEASE
( O
2 B_MEASURE
, O
12 B_MEASURE
, O
48 B_MEASURE
, O
52 B_MEASURE
<FFFD> I_MEASURE
59 I_MEASURE
) O
, O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
first B_SEQUENCE[MEASURE]/B_LOCATION
to O
suggest O
that O
asthmatics B_PERSON/B_BIO
are O
more O
susceptible B_DISEASE_ADJECTIVE[DISEASE]
to O
PM10 B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
pneumonia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
exacerbation I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
to O
cardiovascular B_DISEASE
effects I_DISEASE
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
pneumonia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
admissions I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O
plausible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
given O
the O
impaired B_DISEASE_ADJECTIVE[DISEASE]
ability I_DISEASE_ADJECTIVE[DISEASE]
to O
fight O
off O
infections B_DISEASE/B_BIO
in O
asthmatics B_PERSON/B_LOCATION
with O
mucus B_DISEASE
plugs I_DISEASE
and O
the O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
airborne B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
impair O
the O
lungs B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ability B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
fight O
off O
bacterial B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
viral B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
infections B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O
as O
noted O
earlier O
. O

The O
increased O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
albeit O
weaker B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
is O
interesting B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

If O
airborne B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
affect O
the O
cardiovascular B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
via O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
autonomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
asthmatics B_PERSON/B_BIO
would O
be O
more O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
those O
effects B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
asthma B_DISEASE/B_LOCATION
showed O
that O
combustion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhance O
the O
asthmatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
aeroallergen B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenges B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
59 B_TIME[MEASURE]/B_LOCATION
) O
. O

This O
suggests O
an O
enhancement B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
pulmonary B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
asthmatics B_DISEASE/B_LOCATION
. O

On O
the O
other B_PERSON/B_MEASURE
hand I_PERSON/I_MEASURE
, O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
asthma B_DISEASE/B_LOCATION
is O
problematic B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
elderly B_PERSON/B_DISEASE
, O
and O
crossover B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
with O
COPD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
this O
explains O
our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
reduced O
by O
our O
failure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
find O
previous B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hospital B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
COPD B_DISEASE/B_GENE
was O
an O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
modifier I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
particles B_DISEASE
on O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
admissions I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
must O
acknowledge O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
potential I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
limitations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

First O
, O
we O
considered O
only O
previous B_NUMBER[MEASURE]/B_PERSON
admissions B_NUMBER[MEASURE]/I_PERSON
that O
occurred O
within O
Cook B_LOCATION/B_TIME[MEASURE]
County I_LOCATION/I_TIME[MEASURE]
. O

Hence O
persons B_PERSON
with O
previous O
admissions O
elsewhere O
would O
be O
misclassified O
to O
our O
reference O
group O
. O

The O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
would O
be O
to O
reduce O
the O
difference B_MEASURE
in O
PM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
10 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Volume B_MEASURE
. O

Nevertheless O
, O
we O
identified O
some O
interesting B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
cannot O
exclude O
the O
possibility B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
there O
are O
areas B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
missed O
for O
this O
reason B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
also O
examined O
interactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
log B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
which O
is O
inherently O
multiplicative B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Although O
we O
believe O
this O
is O
justified O
because O
doubling O
the O
population B_PERSON/B_LOCATION
exposed O
would O
be O
expected O
to O
double O
the O
pollution B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
associated O
admissions B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
it O
results O
in O
a O
more O
conservative B_MEASURE/B_PERSON
definition I_MEASURE/I_PERSON
of O
interaction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O
would O
an O
additive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Finally O
, O
our O
exposure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
clearly O
measured O
with O
error B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Most B_DISEASE/B_NUMBER[MEASURE]
of O
this O
error B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
Berkson B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
error B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
60 B_MEASURE
) O
and O
hence O
will O
introduce O
no O
bias B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
Zeger B_LOCATION/B_PERSON
et I_LOCATION/I_PERSON
al O
. O

( O
60 O
) O
showed O
that O
the O
remaining O
error B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
would O
have O
to O
have O
pathologic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
other B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variables I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
result O
in O
an O
upward B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bias I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Another O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
result I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
of O
course O
, O
is O
an O
estimate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
magnitude B_MEASURE
of O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
airborne B_DISEASE
particles I_DISEASE
on O
public B_DISEASE
health I_DISEASE
. O

The O
PM10 B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_DISEASE_ADJECTIVE[DISEASE]
in O
Chicago B_LOCATION/B_PERSON
during O
this O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
were O
associated O
with O
approximately O
1 B_MEASURE
, O
600 B_MEASURE
additional I_MEASURE
admissions I_MEASURE
per O
year B_TIME[MEASURE]
for O
heart B_DISEASE
disease I_DISEASE
, O
740 B_MEASURE
additional I_MEASURE
admissions I_MEASURE
per O
year B_TIME[MEASURE]/B_PERSON
for O
pneumonia B_DISEASE
, O
and O
170 B_MEASURE
additional I_MEASURE
admissions I_MEASURE
per O
year B_TIME[MEASURE]
for O
COPD B_DISEASE
. O

These O
are O
not O
trivial B_DISEASE_ADJECTIVE[DISEASE]
increases I_DISEASE_ADJECTIVE[DISEASE]
in O
serious B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
morbidity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
replicated O
in O
additional B_TIME[MEASURE]/B_LOCATION
cities I_TIME[MEASURE]/I_LOCATION
, O
although O
they O
do O
begin O
to O
fill O
in O
some O
missing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
information I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
about O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
airborne B_DISEASE
particles I_DISEASE
on O
health B_PERSON/B_LOCATION
. O

More O
generally O
airborne B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
been O
associated O
with O
a O
broad B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
systemic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O
heart B_DISEASE
rate I_DISEASE
variability I_DISEASE
( O
39 B_MEASURE
<FFFD> I_MEASURE
41 I_MEASURE
) O
, O
increased O
peripheral B_DISEASE/B_GENE
neutrophils I_DISEASE/I_GENE
( O
61 B_MEASURE
<FFFD> I_MEASURE
63 I_MEASURE
) O
, O
increased O
plasma B_DISEASE
viscosity I_DISEASE
( O
64 B_MEASURE
) O
, O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
blood B_DISEASE/B_GENE
pressure B_DISEASE/I_GENE
( O
65 B_MEASURE
) O
, O
and O
the O
outcomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mentioned O
previously O
. O

The O
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
systemic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
potential B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sources I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
specific B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modifications I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
have O
seen O
should O
be O
an O
area B_LOCATION/B_PERSON
of O
fruitful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
future B_TIME[MEASURE]/B_LOCATION
. O

references B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
Notes B_MEASURE/B_PERSON
1 B_MEASURE/I_PERSON
. O

Katsouyanni B_PERSON/B_LOCATION
K I_PERSON/I_LOCATION
, O
Touloumi B_PERSON/B_LOCATION
G I_PERSON/I_LOCATION
, O
Spix B_PERSON/B_LOCATION
C I_PERSON/I_LOCATION
, O
Schwartz B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Balducci B_PERSON
F I_PERSON
, O
Medina B_PERSON
S I_PERSON
, O
Rossi B_PERSON
G I_PERSON
, O
Wojtyniak B_PERSON
D I_PERSON
, O
Sunyer B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Bacharova B_PERSON
L I_PERSON
, O
et B_PERSON/B_LOCATION
al I_PERSON/I_LOCATION
. O

Short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ambient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulphur I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dioxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
particulate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
matter I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
mortality B_DISEASE
in O
12 B_LOCATION/B_BIO
European I_LOCATION/I_BIO
cities I_LOCATION/I_BIO
: O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
the O
APHEA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
project B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

BR B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
314 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
1658 B_MEASURE
<FFFD> I_MEASURE
1663 I_MEASURE
( O
1997 B_MEASURE
) O
. O

Pope B_PERSON/B_MEASURE
CA B_PERSON/I_MEASURE
, O
Dockery B_MEASURE/B_LOCATION
DW I_MEASURE/I_LOCATION
, O
Schwartz B_MEASURE
J I_MEASURE
. O
Review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
epidemiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
particulate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
air I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pollution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Inhal B_MEASURE/B_PERSON
Toxicol I_MEASURE/I_PERSON
7 I_MEASURE/I_PERSON
: O
1 B_MEASURE
<FFFD> I_MEASURE
18 I_MEASURE
( O
1995 B_MEASURE
) O
. O

Schwartz B_LOCATION/B_MEASURE
J I_LOCATION/I_MEASURE
. O

Air B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pollution I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
daily B_DISEASE
mortality I_DISEASE
: O
a O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
meta B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Environ B_MEASURE
Res I_MEASURE
64 I_MEASURE
: O
36 B_MEASURE
<FFFD> I_MEASURE
52 I_MEASURE
( O
1994 B_MEASURE
) O
. O

Dominici B_PERSON/B_ORGANIZATION
F I_PERSON/I_ORGANIZATION
, O
Samet B_PERSON
J I_PERSON
, O
Zeger B_PERSON/B_LOCATION
SL I_PERSON/I_LOCATION
. O

combining O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
air B_DISEASE_ADJECTIVE[DISEASE]
pollution I_DISEASE_ADJECTIVE[DISEASE]
and O
daily B_DISEASE/B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality B_DISEASE/I_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
largest B_LOCATION
20 I_LOCATION
US I_LOCATION
cities I_LOCATION
: O
a O
hierarchical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
modeling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

R B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Stat I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Soc I_MEASURE
Ser I_MEASURE
A I_MEASURE
, O
in O
press B_PERSON/B_ENT
. O

Burnett B_MEASURE/B_LOCATION
RT I_MEASURE/I_LOCATION
, O
Dales B_PERSON/B_LOCATION
Re B_PERSON/I_LOCATION
, O
Raizenne O
ME B_LOCATION
, O
Krewski B_LOCATION
D I_LOCATION
, O
Summers B_PERSON/B_LOCATION
PW B_PERSON/I_LOCATION
, O
Roberts B_PERSON/B_LOCATION
GR B_PERSON/I_LOCATION
, O
Raad B_PERSON
- O
Young B_PERSON/B_LOCATION
M B_PERSON/I_LOCATION
, O
Dann B_PERSON
T I_PERSON
, O
Brooke B_MEASURE/B_LOCATION
T I_MEASURE/I_LOCATION
. O
Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
low B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ambient I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
ozone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sulfates B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
frequency B_MEASURE/B_PERSON
of O
respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Ontario B_LOCATION/B_ORGANIZATION
hospitals I_LOCATION/I_ORGANIZATION
. O

Environ B_MEASURE
Res I_MEASURE
65 I_MEASURE
: O
172 B_MEASURE
<FFFD> I_MEASURE
194 I_MEASURE
( O
1994 B_MEASURE
) O
. O

Anderson B_MEASURE/B_LOCATION
HR I_MEASURE/I_LOCATION
, O
Spix B_LOCATION
C I_LOCATION
, O
Medina B_LOCATION/B_PERSON
S I_LOCATION/I_PERSON
, O
Schouten B_PERSON
JP I_PERSON
, O
Castellsague B_PERSON/B_LOCATION
J B_PERSON/I_LOCATION
, O
Rossi B_PERSON/B_LOCATION
G B_PERSON/I_LOCATION
, O
Zmirou B_PERSON/B_LOCATION
D I_PERSON/I_LOCATION
, O
Touloumi B_PERSON/B_LOCATION
G I_PERSON/I_LOCATION
, O
Wojtyniak B_PERSON
B I_PERSON
, O
Ponka B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
, O
et B_PERSON/B_LOCATION
al I_PERSON/I_LOCATION
. O

Air B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
pollution I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
daily B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
admissions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
. O

2 B_NUMBER[MEASURE]
. O

3 B_NUMBER[MEASURE]
. O

4 B_NUMBER[MEASURE]
. O

5 B_NUMBER[MEASURE]
. O

6 B_NUMBER[MEASURE]
. O

844 B_NUMBER[MEASURE]
. O

108 O
| O
Number B_TIME[MEASURE]
9 I_TIME[MEASURE]
| O
September B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
2000 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
<FFFD> I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Environmental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
perspectives I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Articles B_PERSON
. O

<FFFD> B_PERSON/B_MEASURE
. O

Effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
particles B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
sensitive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subgroups I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

7 B_NUMBER[MEASURE]
. O

8 B_NUMBER[MEASURE]
. O

9 B_NUMBER[MEASURE]
. O

10 B_NUMBER[MEASURE]
. O

11 B_NUMBER[MEASURE]
. O

12 B_NUMBER[MEASURE]
. O

13 B_NUMBER[MEASURE]
. O

14 B_NUMBER[MEASURE]
. O

15 B_NUMBER[MEASURE]
. O

16 B_NUMBER[MEASURE]
. O

17 B_NUMBER[MEASURE]
. O

18 B_NUMBER[MEASURE]
. O

19 B_NUMBER[MEASURE]
. O

20 B_NUMBER[MEASURE]
. O

21 B_NUMBER[MEASURE]
. O

22 B_NUMBER[MEASURE]
. O

23 B_NUMBER[MEASURE]
. O

24 B_NUMBER[MEASURE]
. O

25 B_NUMBER[MEASURE]
. O

26 B_NUMBER[MEASURE]
. O

27 B_NUMBER[MEASURE]
. O

28 B_NUMBER[MEASURE]
. O

29 B_NUMBER[MEASURE]
. O

30 B_NUMBER[MEASURE]
. O

chronic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obstructive B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
6 B_LOCATION/B_PERSON
European I_LOCATION/I_PERSON
cities I_LOCATION/I_PERSON
: O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
the O
APHEA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Eur B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
1064 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
1071 I_MEASURE/I_PERSON
( O
1997 B_MEASURE
) O
. O

Schwartz B_MEASURE
J I_MEASURE
. O
Short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluctuations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
air B_DISEASE_ADJECTIVE[DISEASE]
pollution I_DISEASE_ADJECTIVE[DISEASE]
and O
hospital B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
elderly B_PERSON/B_DISEASE
for O
respiratory B_DISEASE
disease I_DISEASE
. O

Thorax B_MEASURE
50 I_MEASURE
: O
531 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
538 I_MEASURE/I_PERSON
( O
1995 B_MEASURE
) O
. O

Schwartz B_LOCATION/B_MEASURE
J I_LOCATION/I_MEASURE
. O

Air B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
pollution I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
hospital B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
heart B_DISEASE/B_PERSON
disease I_DISEASE/I_PERSON
in O
eight B_LOCATION/B_PERSON
U I_LOCATION/I_PERSON
. O
S B_OTHER/B_LOCATION
. O
counties B_LOCATION
. O

Epidemiology B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
17 B_MEASURE
<FFFD> I_MEASURE
22 I_MEASURE
( O
1999 B_MEASURE
) O
. O

Schwartz B_LOCATION/B_MEASURE
J I_LOCATION/I_MEASURE
. O

Air B_PERSON/B_LOCATION
pollution I_PERSON/I_LOCATION
and O
hospital B_DISEASE
admissions I_DISEASE
for O
the O
elderly B_PERSON/B_DISEASE
in O
Minneapolis B_LOCATION
. O

Arch B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Environ I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
49 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
366 B_MEASURE
<FFFD> I_MEASURE
374 I_MEASURE
( O
1994 B_MEASURE
) O
. O

Schwartz B_LOCATION/B_MEASURE
J I_LOCATION/I_MEASURE
. O

Air B_PERSON/B_LOCATION
pollution B_PERSON/I_LOCATION
and O
hospital B_DISEASE_ADJECTIVE[DISEASE]
admissions I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
elderly B_PERSON/B_LOCATION
in O
Birmingham B_LOCATION/B_PERSON
, O
Alabama B_LOCATION
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
139 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
589 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
598 I_MEASURE/I_PERSON
( O
1994 B_MEASURE
) O
. O

Schwartz B_LOCATION/B_MEASURE
J I_LOCATION/I_MEASURE
. O

Air B_PERSON/B_LOCATION
pollution B_PERSON/I_LOCATION
and O
hospital B_DISEASE
admissions I_DISEASE
for O
the O
elderly B_PERSON/B_LOCATION
in O
Detroit B_LOCATION/B_PERSON
, O
MI B_LOCATION
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Crit I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Care I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
150 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
648 B_MEASURE
<FFFD> I_MEASURE
655 I_MEASURE
( O
1994 B_MEASURE
) O
. O

Pope B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
CA I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
III I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disease B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
associated O
with O
community B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
steel B_LOCATION/B_MEASURE
mill I_LOCATION/I_MEASURE
, O
Utah B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
valley B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Am B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Public I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
79 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
623 B_MEASURE
<FFFD> I_MEASURE
628 I_MEASURE
( O
1989 B_MEASURE
) O
. O

Saldiva B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
pH I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
Pope B_MEASURE/B_DISEASE
CA I_MEASURE/I_DISEASE
, O
Schwartz B_LOCATION
J I_LOCATION
, O
Dockery B_LOCATION/B_ORGANIZATION
DW I_LOCATION/I_ORGANIZATION
, O
Lichtenfels B_LOCATION/B_PERSON
AJ I_LOCATION/I_PERSON
, O
Salge B_PERSON/B_LOCATION
JM B_PERSON/I_LOCATION
, O
Barone B_PERSON/B_LOCATION
I B_PERSON/I_LOCATION
, O
Bohm B_PERSON/B_LOCATION
GM B_PERSON/I_LOCATION
. O

Air O
pollution O
and O
mortality O
in O
elderly O
people B_PERSON/B_LOCATION
: O
a O
time O
series O
study O
in O
Sao O
Paulo O
, O
Brazil O
. O

Arch B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Environ I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
159 B_MEASURE
<FFFD> I_MEASURE
163 I_MEASURE
( O
1995 B_MEASURE
) O
. O

Schwartz B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

Air B_DISEASE_ADJECTIVE[DISEASE]
pollution I_DISEASE_ADJECTIVE[DISEASE]
and O
hospital B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admissions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
cardiovascular B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
in O
Tucson B_LOCATION/B_PERSON
. O

Epidemiology B_MEASURE
8 I_MEASURE
: O
371 B_MEASURE
<FFFD> I_MEASURE
177 I_MEASURE
( O
1997 B_MEASURE
) O
. O

Delfino B_LOCATION/B_MEASURE
RJ I_LOCATION/I_MEASURE
, O
Murphy B_LOCATION/B_PERSON
Moulton I_LOCATION/I_PERSON
AM I_LOCATION/I_PERSON
, O
Becklake B_LOCATION/B_PERSON
MR I_LOCATION/I_PERSON
. O

Emergency B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
room B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visits B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
respiratory B_DISEASE
illnesses I_DISEASE
among O
the O
elderly B_PERSON/B_LOCATION
in O
Montreal B_LOCATION/B_PERSON
: O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
low B_DISEASE/B_PERSON
level I_DISEASE/I_PERSON
ozone I_DISEASE/I_PERSON
exposure I_DISEASE/I_PERSON
. O

Environ B_MEASURE
Res I_MEASURE
76 I_MEASURE
: O
67 B_MEASURE
<FFFD> I_MEASURE
77 I_MEASURE
( O
1998 B_MEASURE
) O
. O

National B_PERSON/B_LOCATION
Research I_PERSON/I_LOCATION
Council I_PERSON/I_LOCATION
. O

Research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
priorities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
airborne B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
particulate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
matter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Washington B_LOCATION/B_PERSON
, O
DC B_LOCATION
: O
National B_PERSON/B_MEASURE
Academy I_PERSON/I_MEASURE
Press I_PERSON/I_MEASURE
, O
1998 B_MEASURE
. O

Schwartz B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Dockery B_PERSON/B_PROTEIN[GENE]
DW I_PERSON/I_PROTEIN[GENE]
. O

increased O
mortality B_DISEASE/B_ORGANISM_FUNCTION
in O
Philadelphia B_LOCATION/B_PERSON
associated O
with O
daily B_DISEASE
air I_DISEASE
pollution I_DISEASE
concentrations I_DISEASE
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rev I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dis I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
145 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
600 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
604 I_MEASURE/I_PERSON
( O
1992 B_MEASURE
) O
. O

Samet B_PERSON
JM I_PERSON
, O
Zeger B_PERSON/B_LOCATION
SL I_PERSON/I_LOCATION
, O
Berhane B_PERSON/B_MEASURE
K I_PERSON/I_MEASURE
. O

The O
association B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mortality B_DISEASE/B_LOCATION
and O
particulate B_DISEASE_ADJECTIVE[DISEASE]
air I_DISEASE_ADJECTIVE[DISEASE]
pollution I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
: O
particulate B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
Air I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
pollution I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
Daily B_DISEASE
Mortality I_DISEASE
. O

The O
Phase B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
Report O
of O
the O
particle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Epidemiology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Boston B_LOCATION/B_PERSON
, O
MA B_LOCATION
: O
Health B_PERSON/B_MEASURE
Effects I_PERSON/I_MEASURE
Institute I_PERSON/I_MEASURE
, O
1995 B_MEASURE/B_ORGANIZATION
. O

Schwartz O
J O
. O
What O
are O
people B_PERSON/B_BIO
dying O
of O
on O
high O
air O
pollution O
days O
. O

Environ B_MEASURE
Res I_MEASURE
64 I_MEASURE
: O
26 B_MEASURE
<FFFD> I_MEASURE
35 I_MEASURE
( O
1994 B_MEASURE
) O
. O

Sunyer B_PERSON
J I_PERSON
, O
Schwartz B_PERSON
J I_PERSON
, O
Tobias B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
, O
MacFarlane B_PERSON
D I_PERSON
, O
Garcia B_PERSON
J I_PERSON
, O
Anto B_PERSON/B_LOCATION
JM I_PERSON/I_LOCATION
. O

Patients B_PERSON/B_LOCATION
with O
chronic O
obstructive O
pulmonary O
disease O
are O
a O
susceptible O
population O
of O
dying O
due O
to O
urban O
particles O
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
151 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE
) O
: O
50 B_MEASURE
<FFFD> I_MEASURE
56 I_MEASURE
( O
2000 B_MEASURE
) O
. O

Godleski B_PERSON/B_LOCATION
JJ I_PERSON/I_LOCATION
, O
Sioutas B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
, O
Katler B_LOCATION/B_PERSON
M I_LOCATION/I_PERSON
, O
Koutrakis B_MEASURE/B_PERSON
P I_MEASURE/I_PERSON
. O
Death B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
inhalation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
concentrated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
air I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
in O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
pulmonary B_DISEASE
disease I_DISEASE
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Crit I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Care I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
153 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
A15 B_MEASURE/B_LOCATION
( O
1996 B_MEASURE
) O
. O

Matsui O
K O
, O
Goldman O
L O
. O
Comorbidity O
as O
a O
correlate O
of O
length O
of O
stay O
for O
hospitalized O
patients B_PERSON
with O
acute O
chest O
pain O
. O

J B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Gen I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Intern I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
262 B_MEASURE
<FFFD> I_MEASURE
268 I_MEASURE
( O
1996 B_MEASURE
) O
. O

Charlson B_LOCATION/B_MEASURE
M I_LOCATION/I_MEASURE
, O
Szatrowshi B_PERSON/B_LOCATION
TP I_PERSON/I_LOCATION
, O
Peterson B_PERSON/B_LOCATION
J B_PERSON/I_LOCATION
, O
Gold B_MEASURE/B_COLOR
J I_MEASURE/I_COLOR
. O
Validation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
a O
combined O
comorbidity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
index I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

J B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
47 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
1245 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
1251 I_MEASURE/I_PERSON
( O
1994 B_MEASURE
) O
. O

Monane B_LOCATION/B_PERSON
M I_LOCATION/I_PERSON
, O
Kanter B_LOCATION/B_PERSON
DS I_LOCATION/I_PERSON
, O
Glynn B_PERSON
RJ I_PERSON
, O
Avorn B_MEASURE/B_PERSON
J I_MEASURE/I_PERSON
. O
Variability B_MEASURE
in O
length B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hospitalization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
stroke B_DISEASE/B_GENE
. O

The O
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
managed O
care B_PERSON/B_LOCATION
in O
an O
elderly B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Arch B_MEASURE
Neurol I_MEASURE
53 I_MEASURE
: O
848 B_MEASURE
( O
1996 B_MEASURE
) O
. O

Hallstrom B_DISEASE/B_PERSON
AP I_DISEASE/I_PERSON
, O
Cobb B_LOCATION/B_PERSON
LA I_LOCATION/I_PERSON
, O
Yu B_PERSON/B_LOCATION
BH B_PERSON/I_LOCATION
. O

influence O
of O
comorbidity O
on O
the O
outcome O
of O
patients B_PERSON
treated O
for O
out O
- O
of O
- O
hospital O
ventricular O
fibrillation O
. O

circulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
93 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
2019 B_TIME[MEASURE]
<FFFD> I_TIME[MEASURE]
2022 I_TIME[MEASURE]
( O
1996 B_MEASURE/B_LOCATION
) O
. O

Malenka B_PERSON/B_COLOR
DJ I_PERSON/I_COLOR
, O
Mclerran B_PERSON/B_LOCATION
D I_PERSON/I_LOCATION
, O
Roos B_PERSON/B_LOCATION
N I_PERSON/I_LOCATION
, O
Fisher B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ES I_LOCATION
, O
Wennberg B_LOCATION/B_PROTEIN[GENE]
je B_LOCATION/I_PROTEIN[GENE]
. O

Using O
administrative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
describe O
case B_PERSON/B_LOCATION
- O
mix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
: O
a O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
the O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
record I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

J B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
47 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
1027 B_MEASURE
<FFFD> I_MEASURE
1032 I_MEASURE
( O
1994 B_MEASURE
) O
. O

Romano B_PERSON/B_COLOR
PS I_PERSON/I_COLOR
, O
Roos B_LOCATION/B_PERSON
LL I_LOCATION/I_PERSON
, O
Jollis B_LOCATION/B_PERSON
JG I_LOCATION/I_PERSON
. O

Adapting O
a O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comorbidity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
index I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
ICD B_MEASURE/B_DISEASE
- O
9 B_TIME[MEASURE]
- O
cm B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administrative I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
differing O
perspectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

J B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
46 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
1075 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
1079 I_MEASURE/I_PERSON
( O
1993 B_MEASURE
) O
. O

Deyo B_MEASURE/B_DISEASE
RA I_MEASURE/I_DISEASE
, O
Cherkin B_LOCATION/B_PERSON
DC I_LOCATION/I_PERSON
, O
Ciol B_LOCATION/B_PERSON
MA I_LOCATION/I_PERSON
. O

Adapting O
a O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comorbidity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
index I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
ICD B_DISEASE/B_LOCATION
- O
9CM B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administrative I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
databases I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

J B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
45 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
613 B_MEASURE
<FFFD> I_MEASURE
619 I_MEASURE
( O
1992 B_MEASURE
) O
. O

Charlson B_PERSON/B_PROTEIN[GENE]
ME I_PERSON/I_PROTEIN[GENE]
, O
Pompei B_LOCATION/B_PERSON
P I_LOCATION/I_PERSON
, O
Ales B_LOCATION/B_PERSON
KL I_LOCATION/I_PERSON
, O
MacKenzie B_PERSON/B_LOCATION
CR I_PERSON/I_LOCATION
. O

A O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
classifying O
prognostic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comorbidity I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
longitudinal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
: O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
validation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

J B_MEASURE/B_LOCATION
chronic I_MEASURE/I_LOCATION
Dis I_MEASURE/I_LOCATION
40 I_MEASURE/I_LOCATION
: O
373 B_MEASURE
<FFFD> I_MEASURE
383 I_MEASURE
( O
1987 B_MEASURE
) O
. O

Librero B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Peir B_PERSON/B_MEASURE
<FFFD> I_PERSON/I_MEASURE
S I_PERSON/I_MEASURE
, O
Ordi B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
<FFFD> B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ana I_LOCATION
R I_LOCATION
. O

Chronic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comorbidity B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
outcomes B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
hospital B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O
length B_MEASURE
of O
stay B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
mortality B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
readmission B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
30 B_MEASURE
and O
365 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
. O

J B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clin I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Epidemiol I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
52 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
171 B_MEASURE
<FFFD> I_MEASURE
179 I_MEASURE
( O
1999 B_MEASURE
) O
. O

31 B_NUMBER[MEASURE]
. O

Nehls B_LOCATION/B_PERSON
GJ I_LOCATION/I_PERSON
, O
Akland B_LOCATION/B_PERSON
GG I_LOCATION/I_PERSON
. O

procedures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
handling O
aerometric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O

J B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Air I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Pollut I_MEASURE
Control I_MEASURE
Assoc I_MEASURE
23 I_MEASURE
: O
180 B_MEASURE
<FFFD> I_MEASURE
184 I_MEASURE
( O
1973 B_MEASURE
) O
. O

32 B_NUMBER[MEASURE]
. O

Hastie B_PERSON
T I_PERSON
, O
Tibshirani B_MEASURE/B_PERSON
R I_MEASURE/I_PERSON
. O
Generalized B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Additive B_EDU[ORGANIZATION]/B_LOCATION
Models I_PROTEIN[GENE]/I_EDU[ORGANIZATION]
. O

London B_LOCATION
: O
Chapman B_PERSON/B_LOCATION
and O
Hall B_LOCATION/B_PERSON
, O
1990 B_MEASURE/B_ORGANIZATION
. O

33 B_NUMBER[MEASURE]
. O

Schwartz B_MEASURE
J I_MEASURE
. O
Generalized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
additive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
epidemiology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
: O
International B_PERSON/B_TIME[MEASURE]
Biometric B_PERSON/I_TIME[MEASURE]
Society B_PERSON/I_TIME[MEASURE]
, O
invited O
papers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

17th B_TIME[MEASURE]
International I_TIME[MEASURE]
Biometric I_TIME[MEASURE]
Conference I_TIME[MEASURE]
, O
8 B_TIME[MEASURE]/B_LOCATION
<FFFD> I_TIME[MEASURE]/I_LOCATION
12 I_TIME[MEASURE]/I_LOCATION
August I_TIME[MEASURE]/I_LOCATION
1994 I_TIME[MEASURE]/I_LOCATION
, O
Hamilton B_PERSON/B_LOCATION
, O
Ontario B_LOCATION
, O
Canada B_LOCATION
. O

Washington B_LOCATION/B_PERSON
, O
DC B_LOCATION
: O
International B_PERSON/B_MEASURE
Biometric I_PERSON/I_MEASURE
Society I_PERSON/I_MEASURE
, O
1994 B_MEASURE
; O
55 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
80 I_MEASURE/I_PERSON
. O

34 B_NUMBER[MEASURE]
. O

Rossi B_MEASURE/B_LOCATION
G I_MEASURE/I_LOCATION
, O
Vigotti B_PERSON/B_LOCATION
MA I_PERSON/I_LOCATION
, O
Zanobetti B_LOCATION
A I_LOCATION
, O
Repetto B_LOCATION/B_PERSON
F I_LOCATION/I_PERSON
, O
Giannelle B_PERSON
V I_PERSON
, O
Schwartz B_LOCATION/B_PERSON
J I_LOCATION/I_PERSON
. O

Air B_DISEASE/B_MEASURE
pollution I_DISEASE/I_MEASURE
and O
cause O
specific B_DISEASE_ADJECTIVE[DISEASE]
mortality I_DISEASE_ADJECTIVE[DISEASE]
in O
Milan B_LOCATION
, O
Italy B_LOCATION
, O
1980 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
<FFFD> I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1989 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Arch B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Environ I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
54 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
158 B_MEASURE
<FFFD> I_MEASURE
164 I_MEASURE
( O
1999 B_MEASURE
) O
. O

35 B_NUMBER[MEASURE]
. O

Cleveland B_PERSON/B_LOCATION
WS I_PERSON/I_LOCATION
, O
Devlin B_PERSON/B_LOCATION
SJ B_PERSON/I_LOCATION
. O

robust B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
locally O
- O
weighted O
regression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
smoothing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scatterplots I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

J B_MEASURE
Am I_MEASURE
Stat I_MEASURE
Assoc I_MEASURE
74 I_MEASURE
: O
829 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
836 I_MEASURE/I_PERSON
( O
1988 B_MEASURE
) O
. O

36 B_NUMBER[MEASURE]
. O

Akaike B_MEASURE/B_PERSON
H I_MEASURE/I_PERSON
. O
Information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
an O
extension B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
maximum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
likelihood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
principal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
: O
2nd B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
International I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Symposium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
on O
Information B_DISEASE/B_EDU[ORGANIZATION]
Theory I_DISEASE/I_EDU[ORGANIZATION]
( O
Petrov B_PERSON
BN I_PERSON
, O
Csaki B_LOCATION/B_MEASURE
F I_LOCATION/I_MEASURE
, O
eds B_MEASURE/B_LOCATION
) O
. O

Budapest B_LOCATION
: O
Akademiai B_PERSON/B_LOCATION
Kaiado I_PERSON/I_LOCATION
, O
1973 B_MEASURE
; O
267 B_PERSON/B_MEASURE
<FFFD> I_PERSON/I_MEASURE
281 I_PERSON/I_MEASURE
. O

37 B_NUMBER[MEASURE]
. O

Brumback B_PERSON/B_COLOR
BA I_PERSON/I_COLOR
, O
Ryan B_LOCATION/B_PERSON
LM I_LOCATION/I_PERSON
, O
Schwartz B_PERSON
J I_PERSON
, O
Neas B_LOCATION/B_PERSON
LM I_LOCATION/I_PERSON
, O
Stark B_PERSON
PC I_PERSON
, O
Burge B_LOCATION/B_PERSON
Ha B_LOCATION/I_PERSON
. O

transitional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
application B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
environmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
time I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

J B_MEASURE
Acoust I_MEASURE
Soc I_MEASURE
Am I_MEASURE
95 I_MEASURE
( O
449 B_MEASURE
) O
: O
16 B_MEASURE
<FFFD> I_MEASURE
28 I_MEASURE
( O
2000 B_MEASURE
) O
. O

38 B_NUMBER[MEASURE]
. O

Schwartz B_LOCATION/B_MEASURE
J I_LOCATION/I_MEASURE
. O

The O
distributed O
lag B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
between O
air B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
pollution B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
daily B_DISEASE
deaths I_DISEASE
. O

Epidemiology B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
320 B_MEASURE
<FFFD> I_MEASURE
326 I_MEASURE
( O
2000 B_MEASURE
) O
. O

39 B_NUMBER[MEASURE]
. O

Pope B_PERSON/B_LOCATION
CA I_PERSON/I_LOCATION
III I_PERSON/I_LOCATION
, O
Verrier B_LOCATION/B_PERSON
RL I_LOCATION/I_PERSON
, O
Lovett B_PERSON/B_LOCATION
EG I_PERSON/I_LOCATION
, O
Larson B_PERSON/B_LOCATION
AC I_PERSON/I_LOCATION
, O
Raizenne B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ME I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Kanner B_PERSON/B_LOCATION
Re B_PERSON/I_LOCATION
, O
Schwartz B_LOCATION/B_ORGANIZATION
J I_LOCATION/I_ORGANIZATION
, O
Villegas B_LOCATION/B_PERSON
GM I_LOCATION/I_PERSON
, O
Dockery B_LOCATION/B_ORGANIZATION
DW I_LOCATION/I_ORGANIZATION
. O

Heart B_DISEASE_ADJECTIVE[DISEASE]
rate I_DISEASE_ADJECTIVE[DISEASE]
variability I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
particulate B_DISEASE
air I_DISEASE
pollution I_DISEASE
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Heart I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
138 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
890 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
899 I_MEASURE/I_PERSON
( O
1999 B_MEASURE
) O
. O

40 B_NUMBER[MEASURE]
. O

Gold B_MEASURE/B_LOCATION
DR I_MEASURE/I_LOCATION
, O
Litonjua B_LOCATION/B_PERSON
A I_LOCATION/I_PERSON
, O
Schwartz B_PERSON
J I_PERSON
, O
Lovett B_PERSON
E I_PERSON
, O
Larson B_PERSON
A I_PERSON
, O
Nearing O
B B_OTHER/B_LOCATION
, O
Allen B_PERSON
G I_PERSON
, O
Verrier B_PERSON/B_COLOR
M I_PERSON/I_COLOR
, O
Cherry B_PERSON/B_COLOR
R I_PERSON/I_COLOR
, O
Verrier B_MEASURE/B_PERSON
R I_MEASURE/I_PERSON
. O
ambient B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pollution B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
heart B_MEASURE/B_LOCATION
rate B_MEASURE/I_LOCATION
variability B_MEASURE/I_LOCATION
. O

circulation B_TIME[MEASURE]
101 I_TIME[MEASURE]
( O
11 B_MEASURE
) O
: O
1267 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
1273 I_MEASURE/I_PERSON
( O
2000 B_MEASURE
) O
. O

41 B_NUMBER[MEASURE]
. O

Liao B_PERSON/B_COLOR
D I_PERSON/I_COLOR
, O
Creason B_PERSON
J I_PERSON
, O
shy B_PERSON/B_LOCATION
C I_PERSON/I_LOCATION
, O
Williams B_PERSON
R I_PERSON
, O
Watts B_PERSON/B_LOCATION
R I_PERSON/I_LOCATION
, O
Zweidinger B_MEASURE/B_PERSON
R I_MEASURE/I_PERSON
. O
Daily B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
variation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
particulate B_DISEASE
air I_DISEASE
pollution I_DISEASE
and O
poor B_DISEASE_ADJECTIVE[DISEASE]
cardiac I_DISEASE_ADJECTIVE[DISEASE]
autonomic I_DISEASE_ADJECTIVE[DISEASE]
control I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
elderly B_PERSON/B_DISEASE
. O

Environ B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspect I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
107 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
521 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
525 I_MEASURE/I_PERSON
( O
1999 B_MEASURE
) O
. O

42 B_NUMBER[MEASURE]
. O

Peters B_PERSON
A I_PERSON
, O
Liu B_PERSON/B_LOCATION
E B_PERSON/I_LOCATION
, O
Verrier B_PERSON/B_LOCATION
RL I_PERSON/I_LOCATION
, O
Schwartz B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Gold B_PERSON/B_LOCATION
DR I_PERSON/I_LOCATION
, O
Mittelman B_LOCATION/B_PERSON
M I_LOCATION/I_PERSON
, O
Baliff B_PERSON
J I_PERSON
, O
Allen B_PERSON/B_LOCATION
G I_PERSON/I_LOCATION
, O
Monahan B_PERSON/B_LOCATION
K I_PERSON/I_LOCATION
, O
Dockery B_PERSON/B_ORGANIZATION
DW I_PERSON/I_ORGANIZATION
. O

Air B_DISEASE_ADJECTIVE[DISEASE]
pollution I_DISEASE_ADJECTIVE[DISEASE]
and O
incidences B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
cardiac B_DISEASE
arrhythmia I_DISEASE
. O

Epidemiology B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE
) O
: O
11 B_MEASURE
<FFFD> I_MEASURE
17 I_MEASURE
( O
2000 B_MEASURE
) O
. O

43 B_NUMBER[MEASURE]
. O

Godleski B_PERSON
JJ I_PERSON
, O
Verrier B_LOCATION/B_PERSON
RL I_LOCATION/I_PERSON
, O
Koutrakis B_PERSON/B_LOCATION
P B_PERSON/I_LOCATION
, O
Catalano B_MEASURE/B_PERSON
P I_MEASURE/I_PERSON
. O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
morbidity B_DISEASE
and O
Mortality B_DISEASE
from O
Exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
ambient B_DISEASE
Air I_DISEASE
particles I_DISEASE
. O

Health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Institute I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
91 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Cambridge B_LOCATION/B_PERSON
, O
MA B_LOCATION
: O
Health B_PERSON/B_MEASURE
Effects I_PERSON/I_MEASURE
Institute I_PERSON/I_MEASURE
, O
2000 B_MEASURE/B_LOCATION
. O

44 B_NUMBER[MEASURE]
. O

Watkinson B_PERSON/B_LOCATION
WP B_PERSON/I_LOCATION
, O
Campen B_PERSON/B_LOCATION
MJ B_PERSON/I_LOCATION
, O
Kodavanti B_PERSON
UP O
, O
Ledbetter B_DISEASE/B_LOCATION
AD B_DISEASE/I_LOCATION
, O
Costa B_PERSON/B_LOCATION
DL B_PERSON/I_LOCATION
. O

Effects O
of O
inhaled O
residual O
oil O
fly O
ash O
particles O
on O
electrocardiographic O
and O
thermoregulatory O
parameters O
in O
normal O
and O
compromised O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
abstract O
] O
. O

Am B_MEASURE/B_LOCATION
J I_MEASURE/I_LOCATION
Respir I_MEASURE/I_LOCATION
Crit I_MEASURE/I_LOCATION
Care I_MEASURE/I_LOCATION
Med I_MEASURE/I_LOCATION
157 I_MEASURE/I_LOCATION
: O
A150 B_MEASURE/B_LOCATION
( O
1998 B_MEASURE
) O
. O

45 B_NUMBER[MEASURE]
. O

Watkinson B_PERSON/B_LOCATION
WP I_PERSON/I_LOCATION
, O
Campen B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MJ I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Costa B_PERSON/B_LOCATION
DL I_PERSON/I_LOCATION
. O

Cardiac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrhythmia I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
residual B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fly I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ash I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
rodent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
pulmonary B_DISEASE
hypertension I_DISEASE
. O

Toxicol B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Sci I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
41 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
209 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
216 I_MEASURE/I_PERSON
( O
1998 B_MEASURE
) O
. O

46 B_NUMBER[MEASURE]
. O

Kodavanti B_PERSON
UP O
, O
Jackson B_LOCATION/B_PERSON
MC I_LOCATION/I_PERSON
, O
Richards B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Ledbetter B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
, O
Costa B_PERSON/B_PROTEIN[GENE]
DL I_PERSON/I_PROTEIN[GENE]
. O

differential O
pulmonary O
responses O
to O
inhaled O
emission O
particulate O
matter O
( O
PM O
) O
in O
systemically O
hypertensive O
vs O
. O
normotensive O
rats B_BIO/B_PERSON
[ O
abstract O
] O
. O

Am B_MEASURE/B_LOCATION
J I_MEASURE/I_LOCATION
Respir I_MEASURE/I_LOCATION
Crit I_MEASURE/I_LOCATION
Care I_MEASURE/I_LOCATION
Med I_MEASURE/I_LOCATION
157 I_MEASURE/I_LOCATION
: O
A260 B_MEASURE
( O
1998 B_MEASURE
) O
. O

47 B_NUMBER[MEASURE]
. O

Hoek B_PERSON/B_LOCATION
G I_PERSON/I_LOCATION
, O
Brunekreef B_PERSON/B_LOCATION
B I_PERSON/I_LOCATION
, O
van B_PERSON/B_LOCATION
Wijnen I_PERSON/I_LOCATION
JH I_PERSON/I_LOCATION
. O

Cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
mortality I_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
to O
air B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
strongest B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
failure I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
thrombotic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
causes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
death B_DISEASE
[ O
abstract B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Epidemiology B_MEASURE
10 I_MEASURE
: O
S177 B_MEASURE/B_PERSON
( O
1999 B_MEASURE
) O
. O

48 B_NUMBER[MEASURE]
. O

Bates B_PERSON
DV I_PERSON
, O
Szito B_MEASURE/B_LOCATION
R I_MEASURE/I_LOCATION
. O
Hospital B_LOCATION/B_ORGANIZATION
admissions I_LOCATION/I_ORGANIZATION
and O
air B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pollutants I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
southern B_LOCATION
Ontario I_LOCATION
: O
the O
acid B_LOCATION/B_TIME[MEASURE]
summer I_LOCATION/I_TIME[MEASURE]
haze I_LOCATION/I_TIME[MEASURE]
effect I_LOCATION/I_TIME[MEASURE]
. O

Environ B_MEASURE
Res I_MEASURE
43 I_MEASURE
: O
317 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
331 I_MEASURE/I_PERSON
( O
1987 B_MEASURE
) O
. O

49 B_NUMBER[MEASURE]
. O

Pope B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
CA I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
III I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disease B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
associated O
with O
community B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
air B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
steel B_LOCATION/B_MEASURE
mill I_LOCATION/I_MEASURE
, O
Utah B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
valley B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Am B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Public I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
79 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
623 B_MEASURE
<FFFD> I_MEASURE
628 I_MEASURE
( O
1989 B_MEASURE
) O
. O

50 B_NUMBER[MEASURE]
. O

Zelikoff B_PERSON
JT I_PERSON
, O
Nadziejko B_PERSON/B_LOCATION
C I_PERSON/I_LOCATION
, O
Fang B_PERSON/B_LOCATION
T B_PERSON/I_LOCATION
, O
Gordon B_PERSON/B_LOCATION
C B_PERSON/I_LOCATION
, O
Premdass B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
, O
Cohen B_PERSON/B_LOCATION
MD I_PERSON/I_LOCATION
. O

Short B_MEASURE/B_LOCATION
term I_MEASURE/I_LOCATION
, O
low B_MEASURE/B_COLOR
- O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
inhalation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
ambient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
particulate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
matter I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
exacerbates O
ongoing B_DISEASE
pneumococcal I_DISEASE
infections I_DISEASE
in O
Streptococcus B_DISEASE/B_BACTERIUM[BIO]
pneumoniae I_DISEASE/I_BACTERIUM[BIO]
- O
infected O
rates B_MEASURE/B_PERSON
. O

In O
: O
Proceedings O
of O
the O
Third O
Colloquium O
on O
Particulate O
Air O
pollution O
and O
Human B_PERSON/B_LOCATION
Health O
( O
Phalen O
RF O
, O
Bell O
YM O
, O
eds O
) O
. O

Irvine B_LOCATION/B_PERSON
, O
CA B_LOCATION
: O
Air B_LOCATION/B_PERSON
pollution I_LOCATION/I_PERSON
Health I_LOCATION/I_PERSON
Effects I_LOCATION/I_PERSON
Laboratory I_LOCATION/I_PERSON
, O
University B_LOCATION/B_ORGANIZATION
of O
California B_LOCATION
, O
1999 B_NUMBER[MEASURE]/B_LOCATION
; O
8 B_MEASURE
- O
94 B_MEASURE
<FFFD> I_MEASURE
8 I_MEASURE
- O
101 B_MEASURE
. O

51 B_NUMBER[MEASURE]
. O

Clarke B_PERSON/B_LOCATION
RW I_PERSON/I_LOCATION
, O
Hemenway B_LOCATION
DR I_LOCATION
, O
frank B_LOCATION/B_DISEASE
R I_LOCATION/I_DISEASE
, O
Kleeberger B_LOCATION
SR I_LOCATION
, O
Longphre B_LOCATION
MV I_LOCATION
, O
Jakab B_PERSON/B_LOCATION
GJ I_PERSON/I_LOCATION
. O

particle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
associated O
sulfate B_DISEASE
exposure I_DISEASE
enhances O
murine B_DISEASE
influenza I_DISEASE
mortality I_DISEASE
[ I_DISEASE
abstract I_DISEASE
] I_DISEASE
. O

Am B_MEASURE
J I_MEASURE
Respir I_MEASURE
Crit I_MEASURE
Care I_MEASURE
Med I_MEASURE
155 I_MEASURE
: O
A245 B_MEASURE
( O
1997 B_MEASURE
) O
. O

52 B_NUMBER[MEASURE]
. O

Pope B_PERSON/B_LOCATION
CA I_PERSON/I_LOCATION
, O
Dockery B_LOCATION/B_ORGANIZATION
DW I_LOCATION/I_ORGANIZATION
, O
Spengler B_LOCATION/B_PERSON
JD I_LOCATION/I_PERSON
, O
Raizenne O
ME O
. O

Respiratory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
PM10 B_DISEASE_ADJECTIVE[DISEASE]
pollution I_DISEASE_ADJECTIVE[DISEASE]
: O
a O
daily B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rev I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dis I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
144 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
668 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
674 I_MEASURE/I_PERSON
( O
1991 B_MEASURE
) O
. O

53 B_NUMBER[MEASURE]
. O

Schwartz B_PERSON/B_COLOR
J I_PERSON/I_COLOR
, O
Koenig B_PERSON/B_LOCATION
J I_PERSON/I_LOCATION
, O
Slater B_PERSON
D I_PERSON
, O
Larson B_MEASURE/B_PERSON
T I_MEASURE/I_PERSON
. O
particulate B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
air I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pollution I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
hospital B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
emergency I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
visits I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
asthma B_PERSON
in O
Seattle B_LOCATION/B_PERSON
. O

Am B_MEASURE/B_PERSON
Rev I_MEASURE/I_PERSON
Respir I_MEASURE/I_PERSON
Dis I_MEASURE/I_PERSON
147 I_MEASURE/I_PERSON
: O
826 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
831 I_MEASURE/I_PERSON
( O
1993 B_MEASURE
) O
. O

54 B_NUMBER[MEASURE]
. O

Thurston B_PERSON
GD I_PERSON
, O
Ito B_LOCATION/B_PERSON
K I_LOCATION/I_PERSON
, O
Lippman B_LOCATION/B_PERSON
M I_LOCATION/I_PERSON
, O
Hayes B_PERSON/B_LOCATION
CG B_PERSON/I_LOCATION
, O
Bates B_PERSON/B_LOCATION
DV I_PERSON/I_LOCATION
. O

respiratory B_TIME[MEASURE]/B_LOCATION
hospital I_TIME[MEASURE]/I_LOCATION
admissions I_TIME[MEASURE]/I_LOCATION
and O
summertime B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
haze I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
air I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
pollution I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
Toronto B_LOCATION/B_PERSON
, O
Ontario B_LOCATION/B_MEASURE
: O
consideration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
role B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
acid B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
aerosols I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

Environ B_MEASURE
Res I_MEASURE
65 I_MEASURE
: O
271 B_MEASURE
<FFFD> I_MEASURE
290 I_MEASURE
( O
1994 B_MEASURE
) O
. O

55 B_NUMBER[MEASURE]
. O

Norris B_PERSON/B_ORGANIZATION
G B_PERSON/I_ORGANIZATION
, O
YoungPong B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SN I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Koenig B_PERSON/B_ORGANIZATION
JQ B_PERSON/I_ORGANIZATION
, O
Larson B_PERSON/B_ORGANIZATION
TV I_PERSON/I_ORGANIZATION
, O
Sheppard B_PERSON/B_ORGANIZATION
L B_PERSON/I_ORGANIZATION
, O
Stout B_PERSON/B_LOCATION
JW B_PERSON/I_LOCATION
. O

An O
association O
between O
fine O
particles O
and O
asthma O
emergency O
department O
visits O
for O
children B_PERSON
in O
Seattle O
. O

Environ B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspect I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
107 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
489 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
493 I_MEASURE/I_PERSON
( O
1999 B_MEASURE
) O
. O

56 B_NUMBER[MEASURE]
. O

Hamada B_PERSON/B_LOCATION
K I_PERSON/I_LOCATION
, O
Goldsmith B_PERSON/B_LOCATION
CW I_PERSON/I_LOCATION
, O
Kobzik B_LOCATION/B_PERSON
L I_LOCATION/I_PERSON
. O

Air O
pollutant O
aerosols O
allow O
airway O
sensitization O
to O
allergen O
in O
juvenile O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Am B_PERSON
J I_PERSON
Resp I_PERSON
Crit I_PERSON
Care I_PERSON
Med I_PERSON
A28 I_PERSON
( O
1999 B_MEASURE
) O
. O

57 B_NUMBER[MEASURE]
. O

Lambert B_PERSON
AL I_PERSON
, O
Selgrade B_PERSON/B_LOCATION
M I_PERSON/I_LOCATION
, O
Dong B_PERSON
W I_PERSON
, O
Winsett B_PERSON/B_LOCATION
D I_PERSON/I_LOCATION
, O
Gilmour B_MEASURE/B_PERSON
M I_MEASURE/I_PERSON
. O
Enhanced B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
allergic B_TIME[MEASURE]/B_PERSON
sensitization I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
by O
residual B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oil I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fly I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ash I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
particles I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
mediated O
by O
soluble B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
metal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
constituents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ O
abstract B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Am B_MEASURE/B_PERSON
J I_MEASURE/I_PERSON
Respir I_MEASURE/I_PERSON
Crit I_MEASURE/I_PERSON
Care I_MEASURE/I_PERSON
Med I_MEASURE/I_PERSON
159 I_MEASURE/I_PERSON
: O
A26 B_MEASURE
( O
1999 B_MEASURE
) O
. O

58 B_NUMBER[MEASURE]
. O

Dailey B_DISEASE/B_LOCATION
LA B_DISEASE/I_LOCATION
, O
Madden B_LOCATION
MC I_LOCATION
, O
Devlin B_PERSON/B_LOCATION
RB I_PERSON/I_LOCATION
. O

Do O
airway O
epithelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
normal B_PERSON/B_DISEASE
and O
asthmatic B_DISEASE/B_MEASURE
donors I_DISEASE/I_MEASURE
respond O
differently O
to O
an O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
challenge I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
a O
particulate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pollutant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

[ O
abstract B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Am B_MEASURE
J I_MEASURE
Respir I_MEASURE
Crit I_MEASURE
Care I_MEASURE
Med I_MEASURE
157 I_MEASURE
: O
A598 B_MEASURE/B_LOCATION
( O
1998 B_MEASURE
) O
. O

59 B_NUMBER[MEASURE]
. O

Gilmour B_PERSON/B_COLOR
MI I_PERSON/I_COLOR
, O
Winsett B_LOCATION/B_PERSON
D I_LOCATION/I_PERSON
, O
Selgrade B_LOCATION/B_PERSON
MJ I_LOCATION/I_PERSON
, O
Costa B_PERSON/B_LOCATION
DL I_PERSON/I_LOCATION
. O

residual O
oil O
fly O
ash O
exposure O
enhances O
allergic O
sensitization O
to O
house O
dust O
mite O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
augments O
immune O
- O
mediated O
inflammation O
[ O
abstract O
] O
. O

Am B_MEASURE
J I_MEASURE
Respir I_MEASURE
Crit I_MEASURE
Care I_MEASURE
Med I_MEASURE
155 I_MEASURE
: O
A244 B_MEASURE/B_LOCATION
( O
1997 B_MEASURE
) O
. O

60 B_NUMBER[MEASURE]
. O

Zeger B_PERSON
SL I_PERSON
, O
Thomas B_LOCATION/B_PERSON
D I_LOCATION/I_PERSON
, O
Dominici B_PERSON/B_SPECIES[BIO]
F I_PERSON/I_SPECIES[BIO]
, O
Samet B_PERSON
JM I_PERSON
, O
Schwartz B_PERSON/B_LOCATION
JM I_PERSON/I_LOCATION
, O
Dockery B_PERSON/B_ORGANIZATION
D I_PERSON/I_ORGANIZATION
, O
Cohen B_MEASURE/B_PERSON
A I_MEASURE/I_PERSON
. O
exposure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurement I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
error I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
<FFFD> I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
air B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pollution B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
concepts B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
consequences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Environ B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Perspect I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
108 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
419 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
426 I_MEASURE/I_PERSON
( O
2000 B_MEASURE
) O
. O

61 B_NUMBER[MEASURE]
. O

Salvi O
S O
, O
Blomberg O
A O
, O
Rudell O
B O
, O
Kelly O
F O
, O
Sandstrom O
T O
, O
Holgate O
ST O
, O
Frew O
A O
. O
acute O
inflammatory O
responses O
in O
the O
Airways O
and O
peripheral O
blood O
after O
short O
- O
term O
exposure O
to O
diesel O
exhaust O
in O
healthy O
human B_PERSON/B_SPECIES[BIO]
volunteers O
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Crit I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Care I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
159 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
702 B_MEASURE
<FFFD> I_MEASURE
709 I_MEASURE
( O
1999 B_MEASURE
) O
. O

62 B_NUMBER[MEASURE]
. O

Tan B_PERSON
WC I_PERSON
, O
van B_PERSON/B_LOCATION
Eeden I_PERSON/I_LOCATION
S I_PERSON/I_LOCATION
, O
Qiu B_PERSON/B_LOCATION
DW I_PERSON/I_LOCATION
, O
Liam B_PERSON/B_LOCATION
BL B_PERSON/I_LOCATION
, O
Dyachokova B_PERSON/B_LOCATION
Y B_PERSON/I_LOCATION
, O
Hogg B_PERSON/B_LOCATION
JL I_PERSON/I_LOCATION
. O

particulate B_DISEASE_ADJECTIVE[DISEASE]
air I_DISEASE_ADJECTIVE[DISEASE]
pollution I_DISEASE_ADJECTIVE[DISEASE]
, O
bone B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
marrow I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
pathogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
excess B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cardiovascular I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
deaths I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Am B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Respir I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Crit I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Care I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Med I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
155 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
1441 B_MEASURE/B_PERSON
<FFFD> I_MEASURE/I_PERSON
1447 I_MEASURE/I_PERSON
( O
1997 B_MEASURE
) O
. O

63 B_NUMBER[MEASURE]
. O

Gordon B_PERSON
T I_PERSON
, O
Nadziejko B_LOCATION/B_PERSON
C I_LOCATION/I_PERSON
, O
Schlesinger B_PERSON
R I_PERSON
, O
Chen B_PERSON/B_LOCATION
LC I_PERSON/I_LOCATION
. O

pulmonary O
and O
cardiovascular O
effects O
of O
acute O
exposure O
to O
concentrated O
ambient O
particulate O
matter O
in O
rats B_BIO/B_PERSON
. O

Toxicol B_MEASURE
Lett I_MEASURE
96 I_MEASURE
<FFFD> I_MEASURE
97 I_MEASURE
: O
285 B_MEASURE
<FFFD> I_MEASURE
288 I_MEASURE
( O
1998 B_MEASURE
) O
. O

64 B_NUMBER[MEASURE]
. O

Peters B_PERSON
A I_PERSON
, O
Doering B_PERSON
A I_PERSON
, O
Wichmann B_PERSON/B_MEASURE
He O
, O
Koenig B_MEASURE/B_PERSON
W I_MEASURE/I_PERSON
. O
Increased B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma B_MEASURE/B_DISEASE
viscosity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
during O
an O
air B_DISEASE
pollution I_DISEASE
episode I_DISEASE
: O
a O
link B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
mortality B_DISEASE
. O

Lancet B_MEASURE
349 I_MEASURE
( O
9065 B_MEASURE
) O
: O
1582 B_MEASURE
<FFFD> I_MEASURE
1587 I_MEASURE
( O
1997 B_MEASURE
) O
. O

65 B_NUMBER[MEASURE]
. O

Peters B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
, O
Stieberv B_PERSON
J I_PERSON
, O
Doering B_PERSON
A I_PERSON
, O
Wichmann B_PERSON
He O
. O

Is O
systolic B_DISEASE
blood I_DISEASE
pressure I_DISEASE
associated O
with O
air B_DISEASE
pollution I_DISEASE
. O

[ O
abstract B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Epidemiology B_MEASURE
10 I_MEASURE
( O
4 B_MEASURE
) O
: O
S177 B_MEASURE/B_PERSON
( O
1999 B_MEASURE
) O
. O

Environmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perspectives I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

<FFFD> B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Volume I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
108 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Number I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
9 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
| I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
September I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
2000 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

845 B_NUMBER[MEASURE]
. O

syndrome O
of O
arachnomelia O
in O
Simmental O
cattle B_BIO/B_PERSON
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
syndrome O
of O
arachnomelia O
is O
an O
inherited O
malformation O
mainly O
of O
limbs O
, O
back O
and O
head O
in O
cattle B_BIO/B_PERSON
. O

At O
present O
the O
arachnomelia O
syndrome O
has O
been O
well O
known O
mainly O
in O
Brown O
Swiss O
cattle B_BIO/B_DISEASE
. O

Nevertheless O
, O
the O
arachnomelia B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
had O
been O
observed O
in O
the O
Hessian B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Simmental I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
decade B_TIME[MEASURE]
1964 I_TIME[MEASURE]
- O
1974 B_MEASURE
. O

Recently O
, O
stillborn O
Simmental O
calves B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
having O
a O
morphology O
similar O
to O
the O
arachnomelia O
syndrome O
. O

The O
goal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
of O
this O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
the O
characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
morphology B_DISEASE
and O
genealogy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
syndrome B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O
Simmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
establish O
the O
basis B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
an O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
disease B_DISEASE/B_PERSON
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
first B_SEQUENCE[MEASURE]
pathologically O
confirmed O
arachnomelia B_DISEASE/B_LOCATION
syndrome I_DISEASE/I_LOCATION
- O
cases B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Simmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
appeared O
in O
the O
year B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2005 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

By O
2007 O
, O
an O
additional O
140 O
calves B_PERSON/B_BIO
with O
the O
arachnomelia O
syndrome O
were O
identified O
. O

The O
major B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pathological I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
findings I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
malformed O
bones B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
affecting O
the O
head B_BODY_PART_OR_ORGAN_COMPONENT
, O
long B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bones I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
legs B_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
vertebral B_BODY_PART_OR_ORGAN_COMPONENT
column I_BODY_PART_OR_ORGAN_COMPONENT
. O

It O
could O
be O
shown O
that O
, O
with O
the O
exception O
of O
two O
cases O
that O
were O
considered O
as O
phenocopies O
, O
all O
of O
the O
paternal O
and O
about O
two O
- O
third O
of O
the O
maternal O
pedigrees O
of O
the O
affected O
calves B_PERSON
could O
be O
traced O
back O
to O
one O
common O
founder O
. O

Together O
with O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
experimental B_MEASURE
matings I_MEASURE
, O
the O
pedigree B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
support O
an O
autosomal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recessive B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
being O
the O
etiology B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
arachnomelia B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
. O

The O
frequency B_MEASURE
of O
the O
mutation B_DISEASE/B_GENE
in O
the O
current B_PERSON/B_BIO
population B_PERSON/I_BIO
was O
estimated O
to O
be O
3 B_MEASURE
. O
32 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

We O
describe O
the O
repeated O
occurrence O
of O
the O
arachnomelia O
syndrome O
in O
Simmental O
calves B_PERSON/B_SPECIES[BIO]
. O

It O
resembles O
completely O
the O
same B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defect I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurring O
in O
the O
Brown B_BIO/B_MEASURE
Swiss I_BIO/I_MEASURE
breed I_BIO/I_MEASURE
. O

The O
mutation B_DISEASE_ADJECTIVE[DISEASE]
became O
relatively O
widespread B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
amongst O
the O
current B_PERSON/B_LOCATION
population I_PERSON/I_LOCATION
. O

Therefore O
, O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
has O
to O
be O
established O
and O
it O
is O
highly O
desirable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
map O
the O
disease B_DISEASE/B_GENE
and O
develop O
a O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
year O
2006 O
a O
syndrome O
was O
described O
in O
the O
German O
and O
Austrian O
Simmental O
( O
Fleckvieh O
, O
as O
it O
is O
locally O
called O
, O
is O
the O
main O
dual O
- O
purpose O
breed O
in O
Germany O
, O
in O
short O
called O
Simmental O
in O
the O
further O
text O
) O
population O
, O
that O
was O
pathologically O
similar O
to O
the O
arachnomelia O
syndrome O
in O
Brown O
Swiss O
cattle B_SPECIES[BIO]
[ O
1 O
] O
. O

The O
congenital O
arachnomelia O
syndrome O
( O
AS O
, O
OMIA O
Phene O
ID O
139 O
, O
Group O
000059 O
) O
is O
mainly O
a O
malformation O
of O
the O
skeletal O
system O
in O
cattle B_SPECIES[BIO]/B_PERSON
that O
was O
initially O
described O
by O
Rieck O
and O
Schade O
[ O
2 O
] O
in O
Holstein O
Friesian O
, O
Red O
Holstein O
and O
Simmental O
. O

The O
main B_DISEASE_ADJECTIVE[DISEASE]
pathological I_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
are O
skeletal B_DISEASE
malformations I_DISEASE
of O
the O
legs B_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
column I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
skull B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
legs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
are O
thinner B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
appear O
longer O
than O
normal B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
( O
dolichostenomelia B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O
arachnomelia B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
) O
since O
the O
diameter B_MEASURE/B_LOCATION
of O
the O
diaphyses B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
reduced O
. O

These O
long B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bones I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
more O
fragile B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
, O
in O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
stiffened B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
joints I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
they O
tend O
to O
fracture O
during O
calving O
. O

The O
fetlock B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
joints I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
deformed O
, O
often O
stiffened O
and O
show B_DISEASE_ADJECTIVE[DISEASE]
hyperextension I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
malformation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
column I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
leads O
to O
kyphosis B_DISEASE
and O
scoliosis B_DISEASE
. O

The O
skull B_DISEASE/B_PERSON
malformations I_DISEASE/I_PERSON
are O
characterized O
by O
a O
shortened O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
jaw I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
brachygnathia B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
inferior B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
, O
convex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rounding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
frontal B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone I_BODY_PART_OR_ORGAN_COMPONENT/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O
to O
a O
marked O
stop B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
' O
pointer B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
head I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
' O
) O
and O
rotation B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
anterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cranium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
some O
cases B_PERSON/B_BIO
, O
additional B_DISEASE_ADJECTIVE[DISEASE]
malformations I_DISEASE_ADJECTIVE[DISEASE]
like O
hydrocephalus B_DISEASE/B_PERSON
externus I_DISEASE/I_PERSON
develop O
[ B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5 B_MEASURE
] I_MEASURE
. O

Since O
the O
report O
of O
Rieck O
and O
Schade O
[ O
2 O
] O
no O
further O
cases O
were O
reported O
in O
Simmental O
cattle B_SPECIES[BIO]/B_LOCATION
, O
but O
in O
the O
1980s O
the O
syndrome O
was O
dispersed O
in O
another O
breed O
, O
the O
European O
Brown O
Swiss O
cattle B_SPECIES[BIO]/B_LOCATION
, O
by O
the O
use O
of O
American O
Brown O
Swiss O
sires O
[ O
4 O
, O
6 O
] O
. O

In O
Brown B_MEASURE/B_PERSON
Swiss I_MEASURE/I_PERSON
an O
autosomal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recessive B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mode B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
inheritance B_DISEASE
was O
supposed O
and O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
based O
on O
the O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
carriers B_PERSON/B_BIO
by O
pedigree B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
established O
[ O
5 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

Recently O
, O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
arachnomelia B_DISEASE
syndrome I_DISEASE
were O
reported O
in O
Italy B_LOCATION
[ O
3 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
we O
present O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
152 B_NUMBER[MEASURE]
pathologically O
confirmed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
arachnomelia B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
in O
Simmental B_LOCATION
that O
were O
collected O
from O
October B_TIME[MEASURE]/B_LOCATION
2005 I_TIME[MEASURE]/I_LOCATION
to O
March B_TIME[MEASURE]/B_LOCATION
2007 I_TIME[MEASURE]/I_LOCATION
. O

We O
describe O
the O
pathological O
findings O
, O
the O
familial O
occurrence O
and O
an O
estimate O
of O
the O
frequency O
of O
the O
diseases O
allele O
in O
Simmental O
cattle B_BIO/B_PERSON
. O

Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
the O
mode B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
inheritance B_DISEASE
and O
the O
genetic B_DISEASE_ADJECTIVE[DISEASE]
basis I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
arachnomelia B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
is O
given O
by O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
obligate B_PERSON/B_BIO
carriers I_PERSON/I_BIO
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

AS O
has O
not O
been O
reported O
again O
in O
Simmental B_LOCATION/B_BIO
since O
its O
first B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
description I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
1970s B_TIME[MEASURE]/B_LOCATION
, O
more B_MEASURE/B_PERSON
than O
thirteen B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
ago O
. O

In O
autumn O
2004 O
a O
number O
of O
stillborn O
calves B_PERSON/B_BIO
with O
similar O
malformations O
of O
the O
legs O
and O
head O
were O
recorded O
within O
the O
monitoring O
system O
of O
anomalies O
in O
Simmental O
. O

Some O
of O
these O
calves B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sent O
to O
the O
veterinary O
service O
laboratory O
for O
examination O
, O
and O
in O
December O
2005 O
the O
first O
15 O
cases O
of O
AS O
were O
pathologically O
confirmed O
. O

Subsequently O
, O
farmers B_PERSON
and O
veterinarians B_PERSON
had O
been O
encouraged O
to O
report O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
an O
information B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leaflet I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
various B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
articles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
local B_ORGANIZATION/B_LOCATION
trade I_ORGANIZATION/I_LOCATION
journals I_ORGANIZATION/I_LOCATION
. O

An O
increasing O
number O
of O
suspected O
cases O
was O
reported O
and O
an O
additional O
136 O
affected O
calves B_PERSON/B_BIO
were O
identified O
by O
pathological O
examination O
by O
June O
2007 O
. O

familial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
occurrence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
presentation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
syndrome B_DISEASE
of O
arachnomelia B_DISEASE/B_SPECIES[BIO]
. O

The O
geographical B_LOCATION/B_MEASURE
origins I_LOCATION/I_MEASURE
of O
the O
cases B_PERSON/B_SPECIES[BIO]
were O
the O
southern B_LOCATION/B_PERSON
part I_LOCATION/I_PERSON
of O
Germany B_LOCATION
and O
Austria B_LOCATION
, O
reflecting O
the O
regional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distribution B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Simmental B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
breed I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

Both O
sexes O
were O
equally O
represented O
in O
the O
152 O
( O
80 O
male O
, O
72 O
female O
, O
Chi O
2 O
= O
0 O
. O
21 O
, O
p O
= O
0 O
. O
64 O
) O
affected O
calves B_PERSON/B_LOCATION
. O

The O
largest B_MEASURE
number I_MEASURE
of O
cases B_PERSON/B_LOCATION
was O
registered O
in O
2006 B_MEASURE
( O
Figure B_LOCATION/B_TIME[MEASURE]
1 B_LOCATION/I_TIME[MEASURE]
) O
. O

In O
retrospect B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
could O
be O
shown O
that O
the O
main B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reason I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
rapid B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
of O
cases B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
years B_TIME[MEASURE]/B_LOCATION
2005 I_TIME[MEASURE]/I_LOCATION
and O
2006 B_TIME[MEASURE]
was O
the O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
popularity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
certain B_PERSON/B_ENT
sires I_PERSON/I_ENT
carrying O
the O
AS B_DISEASE/B_GENE
mutation I_DISEASE/I_GENE
( O
ROMEL B_LOCATION/B_ORGANIZATION
, O
ISO B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Nr B_LOCATION/B_MEASURE
. O
276000911043667 B_NUMBER[MEASURE]
, O
born O
in O
1995 B_MEASURE
; O
EGEL B_LOCATION/B_ORGANIZATION
, O
276000915512806 B_NUMBER[MEASURE]/B_LOCATION
, O
1985 B_MEASURE
; O
REXON B_ORGANIZATION/B_LOCATION
, O
276000913008210 B_NUMBER[MEASURE]/B_LOCATION
, O
1989 B_MEASURE
) O
. O

The O
latter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
two I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
sires I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
represent O
the O
key B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
nodes B_LOCATION/B_PERSON
of O
the O
pedigree B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathways I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
from O
the O
founder B_PERSON/B_TIME[MEASURE]
into O
the O
current B_PERSON
population I_PERSON
( O
Figure B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
) O
. O

ROMEL O
, O
for O
example O
, O
sired O
more O
than O
40 O
, O
000 O
cows B_BIO/B_PERSON
4 O
to O
6 O
years O
ago O
. O

Furthermore O
, O
115 B_PERSON/B_MEASURE
sons I_PERSON/I_MEASURE
of O
ROMEL B_PERSON/B_ORGANIZATION
born O
from O
2001 B_MEASURE
to O
2005 B_MEASURE
are O
registered O
and O
listed O
in O
the O
breeding O
database B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O
7 B_MEASURE/B_LOCATION
] B_MEASURE/I_LOCATION
. O

These O
progeny O
were O
now O
mated O
to O
ROMEL O
and O
sons O
or O
grandsons O
of O
EGEL O
and O
REXON O
resulting O
in O
a O
high O
probability O
for O
the O
occurrence O
of O
affected O
calves B_PERSON/B_BIO
. O

increasing O
awareness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
disease B_DISEASE/B_PERSON
and O
abandoning O
of O
selling O
the O
semen B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
carriers B_PERSON/B_BIO
led O
to O
a O
sharp B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drop I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cases B_PERSON/B_DISEASE
in O
2007 B_NUMBER[MEASURE]/B_LOCATION
. O

The O
disease B_DISEASE
was O
successfully O
managed O
by O
efficient B_PERSON/B_ORGANIZATION
collaboration I_PERSON/I_ORGANIZATION
of O
the O
Institute B_ORGANIZATION/B_LOCATION
for O
Animal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
breeding I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Bavarian B_ORGANIZATION/B_LOCATION
State I_ORGANIZATION/I_LOCATION
Research I_ORGANIZATION/I_LOCATION
Centre I_ORGANIZATION/I_LOCATION
for O
Agriculture B_EDU[ORGANIZATION]/B_LOCATION
( O
LfL B_LOCATION/B_ORGANIZATION
) O
, O
the O
Landeskuratorium B_LOCATION/B_ORGANIZATION
der I_LOCATION/I_ORGANIZATION
Erzeugerringe I_LOCATION/I_ORGANIZATION
f O
u B_EDU[ORGANIZATION]/B_GENE
r I_EDU[ORGANIZATION]/I_GENE
tierische I_EDU[ORGANIZATION]/I_GENE
Veredelung I_EDU[ORGANIZATION]/I_GENE
in O
Bayern B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
e I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
V B_OTHER/B_TIME[MEASURE]
( O
LKV B_MEASURE/B_LOCATION
) O
, O
the O
Bavarian B_ORGANIZATION/B_LOCATION
Animal I_ORGANIZATION/I_LOCATION
Health I_ORGANIZATION/I_LOCATION
Service I_ORGANIZATION/I_LOCATION
( O
TGD B_DISEASE/B_ORGANIZATION
) O
and O
breeding B_PERSON/B_ORGANIZATION
organizations I_PERSON/I_ORGANIZATION
. O

Pathological B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
findings I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Calves B_PERSON
under O
suspicion O
of O
the O
arachnomelia O
syndrome O
were O
sent O
to O
the O
pathology O
department O
of O
the O
TGD O
for O
macroscopic O
examination O
. O

The O
observed B_DISEASE_ADJECTIVE[DISEASE]
major I_DISEASE_ADJECTIVE[DISEASE]
pathological I_DISEASE_ADJECTIVE[DISEASE]
findings I_DISEASE_ADJECTIVE[DISEASE]
were O
( O
1 B_SEQUENCE[MEASURE]/B_PERSON
) O
facial B_DISEASE
deformation I_DISEASE
, O
including O
brachygnathia B_DISEASE_ADJECTIVE[DISEASE]
inferior I_DISEASE_ADJECTIVE[DISEASE]
and O
concave B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rounding I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
maxilla B_BODY_PART_OR_ORGAN_COMPONENT
forming O
a O
dent B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
' O
pointer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
head B_BODY_PART_OR_ORGAN_COMPONENT
' O
) O
; O
( O
2 B_SEQUENCE[MEASURE]
) O
abnormally O
thin B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diaphyses I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
long B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bones I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
the O
outer B_MEASURE/B_LOCATION
diameter I_MEASURE/I_LOCATION
of O
the O
diaphyses B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
is O
diminished O
, O
whereas O
the O
width B_MEASURE/B_LOCATION
of O
the O
substantia B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compacta I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
leading O
to O
frequent B_DISEASE
fractures I_DISEASE
of O
the O
metacarpus B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
and O
metatarsus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
course B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
forced O
birth B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
assistance I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
' O
spider B_BIO/B_DISEASE
- O
legs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
' I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
dolichostenomelia B_MEASURE/B_BIO
) O
. O

The O
deformations B_DISEASE_ADJECTIVE[DISEASE]
of O
other B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
bones B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
legs B_BODY_PART_OR_ORGAN_COMPONENT
were O
less O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
scapula B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
was O
usually O
unaffected O
; O
( O
3 O
) O
angular B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deformations I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
distal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
parts I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
legs B_BODY_PART_OR_ORGAN_COMPONENT
characterized O
by O
bilateral B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stiff I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
hyperextended B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fetlocks I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
the O
extremity B_LOCATION/B_BIO
of O
the O
toe B_BODY_PART_OR_ORGAN_COMPONENT
forward O
and O
parallel B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
trunk B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT
; O
and O
( O
4 B_NUMBER[MEASURE]
) O
defects B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
vertebral B_BODY_PART_OR_ORGAN_COMPONENT
column I_BODY_PART_OR_ORGAN_COMPONENT
( O
kyphosis B_DISEASE
and O
scoliosis B_DISEASE
) O
, O
but O
not O
of O
the O
ribs B_BODY_PART_OR_ORGAN_COMPONENT
( O
figure B_PROTEIN[GENE]/B_DISEASE
3A I_PROTEIN[GENE]/I_DISEASE
- O
C B_MEASURE/B_GENE
) O
. O

Additionally O
, O
inconsistent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pathological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
included O
cerebral B_DISEASE
herniation I_DISEASE
combined O
with O
a O
malformed B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
foramen I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
magnum I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
microphthalmia B_DISEASE
, O
and O
external B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
internal B_DISEASE_ADJECTIVE[DISEASE]
hydrocephalus I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
latter B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seem O
to O
develop O
secondarily O
, O
due O
to O
the O
enlarged O
foramen B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnum I_BODY_PART_OR_ORGAN_COMPONENT/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
selected O
cases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
revealed O
the O
presence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
hemorrhages B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O
the O
osteochondral B_LOCATION/B_BIO
junction I_LOCATION/I_BIO
of O
the O
epiphysis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
an O
abrupt B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transmission I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
chondral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
to O
osteogenic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
never O
showed O
isolated B_DISEASE_ADJECTIVE[DISEASE]
malformations I_DISEASE_ADJECTIVE[DISEASE]
, O
e O
. O
g B_GENE/B_MEASURE
. O
of O
the O
head B_BODY_PART_OR_ORGAN_COMPONENT
or O
legs B_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
usually O
a O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
all O
pathological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
syndrome B_DISEASE/B_PERSON
. O

Nevertheless O
, O
the O
degree B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
lesions B_DISEASE_ADJECTIVE[DISEASE]
ranged O
from O
obvious B_PERSON/B_BIO
spider I_PERSON/I_BIO
- O
leg B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cases I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
moderate O
or O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
making O
a O
definite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
difficult I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

The O
latter B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
( O
3 B_MEASURE
) O
were O
excluded O
from O
the O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pedigree I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Meanwhile O
, O
an O
indirect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
has O
been O
developed O
at O
the O
Institute B_ORGANIZATION/B_LOCATION
for O
Animal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
breeding B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Bavarian B_LOCATION/B_ORGANIZATION
State B_LOCATION/I_ORGANIZATION
Research B_LOCATION/I_ORGANIZATION
Centre B_LOCATION/I_ORGANIZATION
for O
agriculture B_LOCATION/B_DISEASE
( O
ITZ B_MEASURE/B_LOCATION
) O
and O
it O
could O
be O
shown O
that O
these O
cases B_PERSON/B_BIO
are O
most O
probably O
not O
genetically O
affected B_DISEASE_ADJECTIVE[DISEASE]
( O
Buitkamp B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al O
. O
, O
in O
preparation B_MEASURE
) O
. O

carrier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two B_NUMBER[MEASURE]/B_PERSON
criteria B_NUMBER[MEASURE]/I_PERSON
were O
used O
for O
carrier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
first O
was O
the O
presence O
of O
a O
calf B_DISEASE
that O
was O
diagnosed O
by O
pathological O
investigation O
. O

In O
many O
cases O
more O
than O
one O
affected O
calf B_BIO/B_PERSON
per O
sire O
was O
identified O
[ O
8 O
] O
. O

Some O
sires O
had O
only O
one O
affected O
calf B_PERSON/B_BIO
, O
but O
a O
large O
number O
of O
risk O
- O
matings O
. O

In O
these O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criterion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
risk B_MEASURE/B_DISEASE
- O
matings B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
was O
used O
to O
identify O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
phenocopies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

For O
this O
purpose O
, O
the O
probability O
of O
observing O
only O
a O
single O
affected O
calf B_BIO/B_PERSON
among O
a O
certain O
number O
of O
risk O
- O
matings O
of O
the O
sire O
in O
question O
was O
calculated O
. O

Risk B_MEASURE/B_LOCATION
- O
matings B_PERSON/B_LOCATION
were O
defined O
as O
matings B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
direct B_PERSON/B_ORGANIZATION
progenies I_PERSON/I_ORGANIZATION
of O
identified O
AS O
carriers B_PERSON/B_BIO
. O

The O
probability O
of O
observing O
an O
affected O
calf B_BIO/B_PERSON
depends O
also O
on O
the O
probability O
that O
such O
a O
calf B_BIO/B_PERSON
is O
reported O
to O
the O
LKV O
. O

We O
assumed O
this O
probability B_MEASURE/B_PERSON
to O
be O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

Under O
these O
conditions O
, O
the O
probability O
of O
observing O
only O
one O
affected O
calf B_BIO/B_PERSON
is O
lower O
than O
1 O
. O
0 O
percent O
, O
if O
at O
least O
104 O
risk O
- O
matings O
are O
given O
for O
a O
single O
sire O
. O

In O
this O
case O
it O
is O
very O
likely O
that O
the O
single O
affected O
calf B_PERSON/B_BIO
is O
a O
phenocopy O
. O

In O
2006 B_MEASURE
and O
2007 B_MEASURE
this O
was O
the O
case B_PERSON/B_MEASURE
for O
two B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sires I_ENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
for O
artificial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
insemination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
that O
had O
no O
pedigree B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
connection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
SEMPER B_PERSON/B_ORGANISM_FUNCTION
( O
see O
below O
) O
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
matings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
obligate B_SPECIES[BIO]/B_PERSON
carriers I_SPECIES[BIO]/I_PERSON
. O

Four O
out O
of O
seven O
cows B_BIO/B_PERSON
that O
were O
known O
AS O
carriers O
brought O
to O
the O
facilities O
of O
the O
ITZ O
were O
used O
for O
embryo O
transfer O
( O
Table O
1 O
) O
. O

33 B_NUMBER[MEASURE]
of O
the O
60 B_PERSON
recipients I_PERSON
( O
55 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
confirmed O
pregnant B_PERSON/B_LOCATION
on O
day B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
35 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Four B_NUMBER[MEASURE]
of O
the O
33 B_PERSON
pregnant I_PERSON
heifers I_PERSON
( O
12 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
aborted O
between O
days B_TIME[MEASURE]
36 I_TIME[MEASURE]
and O
49 B_MEASURE
of O
pregnancy B_TIME[MEASURE]/B_ORGANISM_FUNCTION
. O

Of O
the O
remaining O
29 B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recipients I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
6 B_MEASURE
were O
slaughtered O
on O
day B_TIME[MEASURE]/B_PERSON
150 I_TIME[MEASURE]/I_PERSON
, O
6 B_MEASURE
on O
day B_TIME[MEASURE]
200 I_TIME[MEASURE]
, O
and O
17 B_MEASURE/B_ENT
animals I_MEASURE/I_ENT
on O
day B_TIME[MEASURE]
225 I_TIME[MEASURE]
of O
pregnancy B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Table B_MEASURE
1 I_MEASURE
) O
. O

Four B_MEASURE/B_ENT
fetuses I_MEASURE/I_ENT
( O
three B_PERSON/B_NUMBER[MEASURE]
male B_PERSON/I_NUMBER[MEASURE]
and O
one B_PERSON
female I_PERSON
) O
out O
of O
29 B_NUMBER[MEASURE]
( O
14 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
showed O
the O
typical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pathological I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
arachnomelia B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
as O
described O
above O
( O
Figure B_PERSON/B_PROTEIN[GENE]
4C I_PERSON/I_PROTEIN[GENE]
, O
D B_OTHER/B_MEASURE
) O
. O

All O
other B_PERSON/B_NUMBER[MEASURE]
fetuses I_PERSON/I_NUMBER[MEASURE]
showed O
no O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
AS B_DISEASE
( O
figure B_PROTEIN[GENE]/B_LOCATION
4A I_PROTEIN[GENE]/I_LOCATION
, O
B B_OTHER/B_MEASURE
) O
. O

Male B_PERSON
fetuses I_PERSON
represented O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
( O
22 B_MEASURE/B_LOCATION
of O
29 B_MEASURE/B_PERSON
) O
of O
pregnancies B_PERSON/B_BIO
( O
Chi B_MEASURE/B_PROTEIN[GENE]
2 I_MEASURE/I_PROTEIN[GENE]
= O
3 B_MEASURE
. O
123 B_MEASURE
, O
p O
= O
0 B_MEASURE
. O
077 B_MEASURE
, O
Yates B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
corrected O
for O
sample B_MEASURE
size I_MEASURE
< O
30 B_MEASURE
) O
. O

Female B_MEASURE/B_LOCATION
weight I_MEASURE/I_LOCATION
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
, O
crown B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O
rump B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
at O
day B_TIME[MEASURE]/B_PERSON
225 I_TIME[MEASURE]/I_PERSON
and O
chest B_MEASURE/B_PERSON
circumference I_MEASURE/I_PERSON
at O
day B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
225 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
normal B_PERSON/B_BIO
fetuses I_PERSON/I_BIO
were O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
male B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
fetuses I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Fetuses B_PERSON/B_LOCATION
that O
were O
affected O
by O
the O
arachnomelia B_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
showed O
lower B_MEASURE
weight I_MEASURE
than O
normal B_PERSON
fetuses I_PERSON
. O

The O
affected O
and O
the O
normal B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
fetuses I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
had O
similar B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
crown I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
- O
rump B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
, O
but O
the O
chest B_MEASURE
circumference I_MEASURE
of O
affected O
fetuses B_PERSON/B_LOCATION
was O
higher B_TIME[MEASURE]
than O
that O
of O
normal B_PERSON/B_BIO
fetuses I_PERSON/I_BIO
( O
Table B_MEASURE/B_PERSON
2 I_MEASURE/I_PERSON
) O
. O

Due O
to O
the O
small B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
affected B_PERSON/B_BIO
female I_PERSON/I_BIO
fetuses I_PERSON/I_BIO
, O
a O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
unaffected B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
sex B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
compare O
unaffected B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
affected B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
animals I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O
total B_MEASURE/B_LOCATION
, O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
analyzed O
for O
statistical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
the O
non B_PERSON
parametric I_PERSON
Mann I_PERSON
- O
Whitney B_PERSON/B_ORGANIZATION
- O
Test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
only B_MEASURE/B_PERSON
trait I_MEASURE/I_PERSON
that O
was O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
unaffected B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
affected O
fetuses B_PERSON/B_LOCATION
was O
the O
chest B_MEASURE/B_BIO
circumference B_MEASURE/I_BIO
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
004 B_MEASURE
, O
Table B_MEASURE
2 I_MEASURE
) O
. O

The O
body O
weight O
of O
AS O
affected O
calves B_PERSON/B_SPECIES[BIO]
was O
tendentially O
lower O
than O
that O
of O
normal O
calves B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Since O
affected O
calves B_PERSON/B_BIO
did O
not O
have O
different O
crown O
- O
rump O
- O
length O
and O
their O
chest O
circumference O
was O
even O
higher O
, O
this O
can O
best O
be O
explained O
by O
a O
reduced O
bone O
mass O
. O

pedigree B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
mode B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
inheritance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Eight B_SEQUENCE[MEASURE]
- O
generation B_SEQUENCE[MEASURE]/B_ORGANIZATION
pedigrees I_SEQUENCE[MEASURE]/I_ORGANIZATION
of O
all O
cases B_PERSON
were O
extracted O
from O
the O
joint B_LOCATION/B_ORGANIZATION
German I_LOCATION/I_ORGANIZATION
and O
Austria B_PERSON/B_ORGANIZATION
pedigree I_PERSON/I_ORGANIZATION
data I_PERSON/I_ORGANIZATION
and O
screened O
for O
common B_DISEASE/B_GENE
ancestors I_DISEASE/I_GENE
. O

The O
pedigree O
of O
the O
majority O
of O
affected O
calves B_PERSON/B_SPECIES[BIO]
( O
paternal O
line O
150 O
, O
maternal O
line O
106 O
out O
of O
152 O
, O
Table O
3 O
) O
could O
be O
traced O
back O
to O
one O
founder O
, O
SEMPER O
( O
ISO O
- O
Nr O
. O
27000979299305 O
) O
, O
a O
sire O
born O
in O
1964 O
, O
6 O
- O
9 O
generations O
before O
the O
affected O
calves B_PERSON/B_BIO
were O
born O
( O
Figure O
2 O
) O
. O

Most O
of O
the O
affected O
calves B_PERSON/B_BIO
inherited O
the O
AS O
mutation O
via O
REXON O
or O
EGEL O
( O
Table O
3 O
, O
Figure O
2 O
) O
. O

In O
44 B_PERSON/B_TIME[MEASURE]
cases I_PERSON/I_TIME[MEASURE]
the O
maternal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
paths I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
not O
linked O
to O
the O
common B_PERSON
pedigree I_PERSON
( O
Table B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

One B_LOCATION/B_PERSON
explanation B_LOCATION/I_PERSON
would O
be O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
additional B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
hereto B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
unknown I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
origins I_ENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
mutation B_DISEASE
. O

This O
could O
happen O
if O
the O
AS B_GENE/B_DISEASE
mutation I_GENE/I_DISEASE
is O
much O
more O
ancient B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
additional B_LOCATION/B_PERSON
pedigree I_LOCATION/I_PERSON
paths I_LOCATION/I_PERSON
exist O
or O
if O
an O
independent B_DISEASE_ADJECTIVE[DISEASE]
mutation I_DISEASE_ADJECTIVE[DISEASE]
event I_DISEASE_ADJECTIVE[DISEASE]
happened O
leading O
to O
the O
same B_DISEASE/B_GENE
phenotype I_DISEASE/I_GENE
. O

An O
alternative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
more O
plausible B_DISEASE_ADJECTIVE[DISEASE]
explanation I_DISEASE_ADJECTIVE[DISEASE]
could O
be O
the O
occurrence B_DISEASE/B_PROTEIN[GENE]
of O
misparentages B_DISEASE
. O

It O
is O
well O
known O
that O
in O
the O
pre O
parentage O
- O
test O
era O
, O
the O
frequency O
of O
false O
paternity O
, O
especially O
of O
the O
cows B_BIO/B_PERSON
, O
was O
reasonable O
high O
( O
up O
to O
23 O
% O
[ O
9 O
] O
) O
. O

Therefore O
, O
there O
is O
a O
good B_PERSON/B_ENT
chance I_PERSON/I_ENT
of O
a O
false B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
registry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
within O
6 B_NUMBER[MEASURE]
- O
9 B_TIME[MEASURE]
generations I_TIME[MEASURE]
. O

There O
is O
strong B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
assumption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
that O
the O
AS B_DISEASE/B_GENE
is O
regulated O
by O
a O
single B_MEASURE/B_ORGANIZATION
autosomal B_MEASURE/I_ORGANIZATION
locus B_MEASURE/I_ORGANIZATION
acting O
in O
a O
recessive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
manner I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

First O
of O
all O
, O
the O
pedigree O
structure O
of O
the O
affected O
calves B_PERSON
in O
Simmental O
can O
best O
be O
explained O
by O
a O
recessive O
mode O
of O
inheritance O
. O

The O
paternal O
branch O
of O
the O
pedigree O
could O
be O
traced O
back O
to O
one O
sire O
, O
SEMPER O
, O
for O
all O
affected O
calves B_PERSON/B_BIO
, O
the O
maternal O
branch O
in O
the O
majority O
of O
the O
cases O
. O

Inbreeding O
loops O
over O
a O
few O
generations O
are O
present O
in O
several O
pedigrees O
of O
affected O
calves B_PERSON/B_BIO
, O
e O
. O
g O
. O
cases O
P3364 O
and O
P1787 O
( O
Figure O
2 O
) O
. O

Sex B_PERSON/B_LOCATION
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inheritance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
obviously O
be O
excluded O
and O
a O
dominant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mode I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
reduced O
penetrance B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
seems O
to O
be O
unlikely B_DISEASE_ADJECTIVE[DISEASE]
. O

secondly O
, O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
4 B_MEASURE
affected O
and O
25 B_PERSON/B_TIME[MEASURE]
unaffected I_PERSON/I_TIME[MEASURE]
fetuses I_PERSON/I_TIME[MEASURE]
, O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
most O
closely O
resembles O
the O
expectation B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
recessive B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mode I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
inheritance B_DISEASE/B_ORGANISM_FUNCTION
. O

Thirdly O
, O
the O
occurrence B_DISEASE/B_MEASURE
of O
cases B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corresponded O
well O
with O
the O
numbers B_MEASURE
expected O
under O
the O
assumption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
recessively O
acting O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

We O
tested O
this O
on O
the O
progeny B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ROMEL B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
largest B_MEASURE/B_PERSON
dataset I_MEASURE/I_PERSON
available I_MEASURE/I_PERSON
from O
one B_LOCATION/B_ORGANIZATION
carrier I_LOCATION/I_ORGANIZATION
. O

We O
analyzed O
the O
period B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
beginning B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
recording B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
malformations B_TIME[MEASURE]
to O
May B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2007 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
that O
period O
44 O
, O
170 O
calves B_PERSON/B_SPECIES[BIO]
were O
born O
that O
were O
sired O
by O
ROMEL O
. O

From O
these O
, O
662 O
were O
considered O
as O
risk O
pairings O
, O
i O
. O
e O
. O
the O
mother O
had O
a O
risk O
of O
0 O
. O
5 O
to O
be O
a O
carrier O
( O
i O
. O
e O
. O
one O
of O
the O
grandparents O
was O
an O
obligate O
carrier O
) O
and O
35 O
calves B_PERSON/B_MEASURE
out O
of O
these O
were O
diagnosed O
as O
affected O
. O

Since O
it O
is O
expected O
that O
about O
1 O
/ O
2 O
to O
1 O
/ O
3 O
of O
the O
affected O
calves B_PERSON/B_SPECIES[BIO]
were O
recorded O
, O
this O
result O
is O
very O
close O
to O
the O
expected O
1 O
: O
7 O
ratio O
of O
affected O
to O
unaffected O
calves B_PERSON/B_SPECIES[BIO]
. O

Moreover O
, O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
concordant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
historical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
arachnomelia B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
Simmental B_PERSON/B_LOCATION
[ O
2 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
and O
the O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cases B_PERSON/B_DISEASE
in O
Brown B_LOCATION/B_PERSON
Swiss I_LOCATION/I_PERSON
[ O
5 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Finally O
, O
when O
applying O
linkage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
microsatellite B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
markers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
evaluations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assuming O
recessive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autosomal B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inheritance B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gave O
the O
highest B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lod B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Buitkamp B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
in O
preparation B_MEASURE
) O
. O

Allelic O
frequency O
of O
carriers O
in O
the O
present O
Simmental O
cow B_BIO/B_LOCATION
population O
. O

Since O
the O
arachnomelia B_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
- O
allele B_GENE/B_PERSON
was O
passed O
to O
the O
current B_PERSON
population I_PERSON
through O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
parental I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
lines I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
REXON B_LOCATION/B_ORGANIZATION
and O
EGEL B_LOCATION/B_ORGANIZATION
) O
and O
the O
main B_GENE/B_ORGANIZATION
carriers I_GENE/I_ORGANIZATION
are O
known O
, O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
estimate O
the O
frequency B_MEASURE/B_LOCATION
of O
the O
disease B_GENE/B_DISEASE
allele I_GENE/I_DISEASE
by O
an O
allele B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
counting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
10 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

The O
allelic O
frequency O
was O
calculated O
for O
all O
cows B_BIO/B_PERSON
from O
the O
breeding O
population O
who O
were O
alive O
in O
June O
2007 O
. O

In O
10 O
. O
4 O
percent O
of O
the O
pedigrees O
of O
540 O
, O
725 O
cows B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
an O
identified O
carrier O
was O
found O
and O
the O
probability O
that O
individual O
cows B_BIO/B_PERSON
were O
carrier O
of O
the O
arachnomelia O
syndrome O
- O
allele O
was O
calculated O
. O

E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
g B_OTHER/B_PROTEIN[GENE]
. O
in O
14 B_MEASURE
, O
740 B_MEASURE
and O
41 B_MEASURE
, O
032 B_MEASURE/B_LOCATION
cases B_MEASURE/I_LOCATION
a O
known B_PERSON/B_BIO
carrier I_PERSON/I_BIO
appeared O
as O
sire B_PERSON
and O
grandsire B_PERSON/B_BIO
, O
respectively O
. O

In O
these O
cases B_PERSON
the O
probability B_MEASURE/B_PERSON
of O
transmitting O
the O
allele B_GENE/B_PERSON
is O
50 B_MEASURE
and O
25 B_MEASURE
percent I_MEASURE
, O
respectively O
, O
if O
no O
further B_PERSON/B_MEASURE
carrier I_PERSON/I_MEASURE
is O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
two B_PERSON/B_LOCATION
generation I_PERSON/I_LOCATION
pedigree I_PERSON/I_LOCATION
. O

The O
averaged O
rate O
of O
the O
arachnomelia O
syndrome O
carriers O
based O
on O
known O
carriers O
over O
all O
cows B_BIO/B_PERSON
alive O
in O
Bavarian O
Simmental O
was O
3 O
. O
32 O
percent O
. O

Using O
this O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
the O
frequency B_MEASURE/B_PERSON
of O
carriers B_PERSON/B_LOCATION
was O
calculated O
for O
each O
year B_TIME[MEASURE]/B_LOCATION
( O
always O
based O
on O
the O
actual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
datasets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
from O
August B_TIME[MEASURE]/B_LOCATION
2008 I_TIME[MEASURE]/I_LOCATION
) O
from O
2003 B_MEASURE
to O
2008 B_MEASURE
( O
Figure B_TIME[MEASURE]/B_LOCATION
1 I_TIME[MEASURE]/I_LOCATION
) O
. O

The O
calculations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
done O
twice O
, O
considering O
all O
known O
carriers B_PERSON/B_MEASURE
together O
, O
and O
also O
by O
using O
only B_PERSON/B_LOCATION
ROMEL I_PERSON/I_LOCATION
as O
a O
carrier B_PERSON
to O
show O
the O
numeric B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contribution I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
his O
progeny B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
Figure B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
) O
. O

For O
these O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
sires B_PERSON/B_BIO
that O
are O
designated O
to O
be O
non B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
carriers B_PERSON
by O
the O
number B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
risk B_PERSON
pairings I_PERSON
without O
having O
a O
case B_PERSON/B_MEASURE
or O
the O
indirect B_PERSON/B_MEASURE
gene I_PERSON/I_MEASURE
test I_PERSON/I_MEASURE
are O
set O
as O
non B_DISEASE/B_MEASURE
- O
carrier B_PERSON/B_LOCATION
. O

Therefore O
, O
these O
frequencies B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
slightly O
lower B_MEASURE
than O
the O
initial B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
estimate I_MEASURE/I_LOCATION
of O
3 B_MEASURE
. O
32 B_MEASURE/B_PERSON
percent I_MEASURE/I_PERSON
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

The O
cases O
of O
malformed O
Simmental O
calves B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O
here O
showed O
the O
same O
morphology O
described O
in O
the O
arachnomelia O
syndrome O
in O
Brown O
Swiss O
[ O
e O
. O
g O
. O
[ O
3 O
] O
] O
, O
even O
though O
there O
is O
a O
certain O
morphological O
variation O
from O
mild O
to O
severe O
malformations O
. O

The O
main B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
brachygnathia B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
inferior I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
convex B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
frontal I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
bone I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
face B_BODY_PART_OR_ORGAN_COMPONENT
, O
deformation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
vertebrae B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
dysplasia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
limbs B_BODY_PART_OR_ORGAN_COMPONENT
, O
namely O
the O
diaphyses B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
metatarsus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
- O
carpus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
fetlocks B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
can O
best O
be O
explained O
by O
irregularly O
developed O
bone B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
structure B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
at O
the O
corresponding B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
locations I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O

Without O
pathological B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
examination I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
it O
is O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
distinguish O
the O
arachnomelia B_DISEASE/B_MEASURE
syndrome I_DISEASE/I_MEASURE
from O
other B_DISEASE
malformations I_DISEASE
of O
the O
limbs B_BODY_PART_OR_ORGAN_COMPONENT
. O

Therefore O
, O
low B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
numbers I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
cases B_PERSON/B_LOCATION
in O
Simmental B_LOCATION
probably O
passed O
unrecognized B_DISEASE/B_MEASURE
before O
2005 B_TIME[MEASURE]/B_LOCATION
. O

In O
that O
year O
the O
allelic O
frequency O
of O
the O
disease O
in O
the O
cow B_BIO/B_PERSON
population O
increased O
sharply O
because O
some O
sires O
that O
had O
been O
carriers O
of O
the O
mutation O
had O
become O
very O
popular O
2 O
- O
4 O
years O
before O
. O

The O
identification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
a O
common B_PERSON/B_BIO
ancestor I_PERSON/I_BIO
, O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
matings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
the O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
numbers B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cases B_PERSON/B_BIO
from O
risk B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matings I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strongly O
support O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
an O
autosomal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
recessively O
inherited O
disease B_DISEASE/B_GENE
. O

Furthermore O
, O
this O
assumption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
concordant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
historical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
syndrome B_DISEASE
in O
Simmental B_PERSON/B_LOCATION
and O
Brown B_PERSON/B_LOCATION
Swiss I_PERSON/I_LOCATION
. O

The O
allelic B_MEASURE
frequency I_MEASURE
of O
the O
arachnomelia B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
current B_PERSON/B_LOCATION
population I_PERSON/I_LOCATION
is O
well O
above O
3 B_MEASURE/B_LOCATION
percent I_MEASURE/I_LOCATION
and O
a O
substantial B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
progeny B_PERSON/B_BIO
from O
known O
carriers B_PERSON/B_BIO
with O
superior B_DISEASE/B_GENE
genetic I_DISEASE/I_GENE
merit I_DISEASE/I_GENE
shall O
be O
used O
as O
sires B_PERSON
during O
the O
next B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
years I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

Therefore O
, O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
has O
to O
be O
established O
and O
the O
arachnomelia B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O
gene B_GENE/B_DISEASE
should O
be O
mapped O
as O
a O
prerequisite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
an O
indirect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
gene I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
carrier B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
availability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
pathologically O
well O
characterized O
cases B_PERSON/B_BIO
from O
the O
field B_LOCATION/B_PERSON
and O
from O
the O
ET B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
generated O
full B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
sib B_PERSON/B_MEASURE
families B_PERSON/I_MEASURE
will O
be O
an O
excellent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
material I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O
a O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mapping I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recording O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
for O
congenital B_ENT
malformations I_ENT
. O

A O
system O
for O
monitoring O
inherited O
congenital O
malformations O
in O
Bavarian O
cattle B_SPECIES[BIO]
populations O
was O
established O
by O
the O
Institute O
for O
Animal O
breeding O
of O
the O
Bavarian O
State O
Research O
Centre O
for O
Agriculture O
( O
ITZ O
) O
in O
cooperation O
with O
the O
Bavarian O
milk O
recording O
organization O
( O
LKV O
) O
[ O
11 O
] O
. O

In O
short O
, O
a O
questionnaire O
was O
developed O
for O
detailed O
recording O
of O
malformed O
calves B_PERSON/B_BIO
. O

The O
malformation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
described O
according O
to O
its O
location B_LOCATION/B_MEASURE
( O
e B_DISEASE/B_PROTEIN[GENE]
. O
g B_PROTEIN[GENE]/B_MEASURE
. O
head B_BODY_PART_OR_ORGAN_COMPONENT
, O
legs B_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
its O
characteristics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
e B_PROTEIN[GENE]/B_DISEASE
. O
g B_PROTEIN[GENE]/B_MEASURE
. O
hernia B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
) O
. O

The O
standardized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
stored O
in O
a O
database B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
the O
LKV B_LOCATION/B_PERSON
, O
that O
is O
evaluated O
monthly O
for O
a O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
malformations B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sires O
that O
fit O
into O
the O
pedigree O
( O
progeny O
of O
REXON O
or O
EGEL O
) O
with O
at O
least O
one O
affected O
calf B_BIO/B_PERSON
with O
confirmed O
paternity O
were O
defined O
as O
obligate O
carriers O
and O
marked O
in O
the O
breeding O
information O
system O
[ O
7 O
] O
. O

In O
cases O
without O
connection O
to O
the O
pedigree O
and O
only O
one O
recorded O
calf B_PERSON/B_BIO
the O
number O
of O
' O
risk O
pairings O
' O
( O
matings O
to O
cows B_BIO/B_PERSON
where O
at O
least O
one O
parent O
is O
a O
known O
carrier O
, O
enabling O
the O
calculation O
of O
the O
probability O
for O
the O
occurrence O
of O
cases O
) O
was O
calculated O
. O

When O
the O
probability B_MEASURE/B_PERSON
that O
a O
case B_PERSON/B_DISEASE
occurs O
was O
above O
99 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
for O
the O
sire B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
question B_LOCATION/B_BIO
the O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
considered O
to O
be O
a O
phenocopy B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

The O
number O
of O
calves B_PERSON/B_BIO
affected O
by O
the O
arachnomelia O
syndrome O
and O
their O
parentage O
is O
routinely O
published O
[ O
8 O
] O
. O

Pathological B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
examinations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Pathological B_PERSON
examinations I_PERSON
followed O
standard B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
procedures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
. O

Calves B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
photographed O
and O
size O
and O
weight O
measurements O
were O
recorded O
. O

tissue B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
condyle B_BODY_PART_OR_ORGAN_COMPONENT
( O
epiphysis B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
) O
and O
from O
the O
diaphysis B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
femur B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O
collected O
for O
histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

specimens B_BIO/B_PERSON
were O
fixed O
in O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formalin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
kept O
in O
a O
decalcifying O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Ossafixonafor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
for O
24 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thereafter O
, O
specimens B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O
processed O
in O
an O
automated O
embedding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
sectioned O
at O
4 B_MEASURE
- O
6 B_MEASURE
microns I_MEASURE
and O
finally O
stained O
with O
haematoxyline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
eosin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
embryo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Known O
carriers O
of O
the O
arachnomelia O
syndrome O
( O
seven O
cows B_BIO/B_PERSON
that O
had O
produced O
at O
least O
one O
affected O
calf B_BIO/B_PERSON
) O
were O
brought O
to O
the O
facilities O
of O
the O
ITZ O
for O
embryo O
transfer O
( O
Table O
1 O
) O
. O

Late O
morulae O
and O
blastocysts O
collected O
on O
day O
7 O
( O
day O
0 O
= O
estrus O
) O
from O
superovulated O
donor O
cows B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
nonsurgically O
transferred O
to O
heifers O
[ O
12 O
] O
. O

mode B_MEASURE/B_DISEASE
of O
inheritance B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
allele B_MEASURE/B_PERSON
frequency B_MEASURE/I_PERSON
. O

The O
pedigree B_PERSON/B_MEASURE
of O
all O
cases B_PERSON/B_BIO
was O
constructed O
from O
the O
pedigree B_PERSON/B_BIO
that O
is O
used O
for O
the O
joint B_PERSON/B_LOCATION
breeding B_PERSON/I_LOCATION
evaluation B_PERSON/I_LOCATION
of O
Germany B_LOCATION
and O
Austria B_LOCATION
. O

The O
graphical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
presentation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
the O
pedigree B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
with O
the O
Pedigraph B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
TM I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
[ O
13 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
allelic O
frequency O
of O
the O
AS O
mutation O
in O
the O
current O
cow B_BIO/B_LOCATION
population O
was O
estimated O
from O
ancestors O
with O
known O
genotypes O
following O
the O
allele O
- O
counting O
method O
[ O
10 O
] O
. O

For O
this O
reason O
two O
generation O
pedigrees O
of O
herd O
book O
cows B_BIO/B_PERSON
in O
Bavarian O
Simmental O
were O
analyzed O
for O
obligate O
carriers O
. O

We O
considered O
all O
cows B_BIO/B_PERSON
that O
were O
alive O
in O
June O
2007 O
and O
included O
in O
the O
herd O
book O
. O

All O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
bred O
by O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
artificial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
insemination I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
non B_PERSON/B_LOCATION
parametric I_PERSON/I_LOCATION
Mann I_PERSON/I_LOCATION
- O
Whitney B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
performed O
using O
SPSS B_MEASURE
Version I_MEASURE
14 I_MEASURE
. O
0 B_MEASURE/B_LOCATION
, O
the O
Chi B_PERSON/B_NUMBER[MEASURE]
- O
square B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
performed O
using O
R B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
4 B_MEASURE
. O
0 B_MEASURE
[ I_MEASURE
14 I_MEASURE
] I_MEASURE
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

JB B_PERSON
drafted O
the O
manuscript B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
analyzed O
the O
pedigrees B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

BL B_PERSON
conceived O
the O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
inherited O
diseases B_DISEASE/B_GENE
. O

Re B_PERSON
extracted O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
the O
database B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
estimated O
the O
allelic B_MEASURE
frequencies I_MEASURE
of O
the O
arachnomelia B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

HR B_LOCATION/B_ORGANIZATION
and O
MW B_MEASURE/B_LOCATION
performed O
the O
embryo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
transfer O
and O
recorded O
the O
morpho B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
metrical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
experimental B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
matings I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

BS O
examined O
the O
calves B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathologically O
. O

nm B_MEASURE/B_LOCATION
and O
kg B_MEASURE/B_LOCATION
participated O
in O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
coordination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
critically O
revised O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
authors B_PERSON/B_NUMBER[MEASURE]
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

suggestions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
concerning O
the O
Use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
which O
arises O
from O
the O
aorta B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
the O
Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
Tetralogy B_DISEASE_ADJECTIVE[DISEASE]
of O
Fallot B_LOCATION/B_PERSON
* O
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Images B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

suggestions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concerning O
THE O
Use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
OF O
THE O
subclavian B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Which O
arises O
From O
THE O
aorta B_DISEASE/B_ORGANIZATION
IN O
THE O
Treatment B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

OF O
THE O
TETRALOGY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
OF O
FALLOT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
* O
. O

HARRIS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

SHUMACKER B_PERSON/B_LOCATION
, O
JR B_LOCATION/B_PERSON
. O
* O
* O
. O

In O
Blalock B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
early I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
experience I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
the O
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
the O
tetralogy B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
Fallot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
two B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
subclavian I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
the O
innominate B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
carotid B_BODY_PART_OR_ORGAN_COMPONENT/B_NUMBER[MEASURE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_NUMBER[MEASURE]
were O
all O
used O
for O
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Soon O
, O
however O
, O
it O
became O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
innominate B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
carotid B_LOCATION
was O
followed O
by O
a O
relatively O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
complications B_DISEASE
resulting O
from O
cerebral B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Blalock B_PERSON
suggested O
, O
therefore O
, O
that O
the O
subclavian B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
be O
used O
by O
preference B_PERSON/B_TIME[MEASURE]
. O

The O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
branch I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
innominate B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
become O
kinked O
or O
badly O
angulated O
when O
it O
is O
turned O
down O
for O
the O
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
a O
good B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functional I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
result I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
almost O
invariably O
follows O
the O
completion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
a O
satisfactory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anastomosis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
which O
arises O
directly O
from O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
on O
the O
other B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
hand I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
tends O
to O
form O
a O
bad B_DISEASE/B_LOCATION
angle B_DISEASE/I_LOCATION
when O
it O
is O
brought O
down O
for O
the O
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
, O
and O
, O
indeed O
, O
near O
its O
point B_LOCATION/B_MEASURE
of O
origin B_DISEASE/B_LOCATION
it O
may O
be O
so O
flattened O
out O
against O
the O
relatively O
rigid B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aortic I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
to O
obstruct O
all O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
it O
. O

These O
considerations O
led O
Blalock O
to O
recommend O
the O
use O
of O
the O
former O
except O
in O
infants B_PERSON
under O
two O
years O
of O
age O
in O
whom O
this O
artery O
may O
be O
too O
small O
and O
in O
adults O
or O
children B_PERSON
over O
twelve O
years O
old O
or O
five O
feet O
tall O
with O
a O
left O
aortic O
arch O
in O
whom O
it O
is O
often O
too O
short O
to O
permit O
a O
satisfactory O
anastomosis O
. O
7 O
' O
. O

In O
contrast B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Paine B_PERSON
and O
Varco B_PERSON
, O
' O
Lam B_PERSON/B_NUMBER[MEASURE]
, O
6 B_MEASURE/B_PERSON
Holman I_MEASURE/I_PERSON
, O
' O
Olim B_MEASURE/B_PERSON
, O
7 B_TIME[MEASURE]/B_PERSON
and O
others B_SEQUENCE[MEASURE]
have O
preferred O
to O
use O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
which O
arises O
from O
the O
aorta B_DISEASE/B_BIO
and O
have O
obtained O
generally O
excellent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

They O
point O
out O
that O
the O
tendency B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
kinking B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
artery B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
more O
a O
theoretical B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
a O
practical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
disadvantage I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
that O
the O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
dissection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
both O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
are O
easier B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
the O
side B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
aortic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
arch B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
that O
both O
vessels B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O
generally O
longer B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
on O
the O
opposite B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
side I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
and O
that O
, O
as O
a O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
rule I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
be O
accomplished O
more O
readily O
. O

The O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
third B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
systemic I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
vessel I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
namely O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
was O
demonstrated O
by O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
technique B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
to O
- O
side B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
aortic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
pulmonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
by O
Potts B_PERSON
and O
his O
associates B_PERSON/B_ORGANIZATION
. O
' O
0 B_NUMBER[MEASURE]
In O
spite B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
preferences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
held O
by O
individual B_PERSON
operators I_PERSON
for O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
one B_NUMBER[MEASURE]/B_PERSON
vessel B_NUMBER[MEASURE]/I_PERSON
or O
another O
, O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
remains O
, O
as O
Blalock B_PERSON
has O
emphasized O
, O
that O
there O
is O
always O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
a O
usable B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
systemic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
vessel I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
provided O
a O
suitable B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
pulmonary I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
artery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
is O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nevertheless O
, O
the O
choice O
of O
the O
systemic O
artery O
in O
each O
individual O
patient B_PERSON/B_LOCATION
is O
important O
since O
in O
certain O
cases O
one O
or O
another O
is O
unsuitable O
. O

* B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
From O
the O
Department B_ORGANIZATION/B_LOCATION
of O
Surgery B_EDU[ORGANIZATION]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
the O
Indiana B_LOCATION/B_ORGANIZATION
University I_LOCATION/I_ORGANIZATION
Medical I_LOCATION/I_ORGANIZATION
Center I_LOCATION/I_ORGANIZATION
, O
Indianapolis B_LOCATION/B_PERSON
, O
Indiana B_LOCATION
. O

aided O
by O
a O
contract B_ORGANIZATION/B_PERSON
between O
the O
Office B_ORGANIZATION/B_LOCATION
of O
Naval B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Research I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Department B_ORGANIZATION/B_LOCATION
of O
the O
Navy B_ORGANIZATION/B_LOCATION
, O
and O
Indiana B_ORGANIZATION/B_LOCATION
University I_ORGANIZATION/I_LOCATION
. O

* B_PERSON
* I_PERSON
Resident I_PERSON
surgeon I_PERSON
, O
New B_LOCATION
Haven I_LOCATION
Hospital I_LOCATION
, O
1937 B_MEASURE
- O
1938 B_MEASURE
. O

received O
for O
publication B_TIME[MEASURE]/B_PERSON
April I_TIME[MEASURE]/I_PERSON
26 I_TIME[MEASURE]/I_PERSON
, O
1951 B_MEASURE
. O

Treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
OF O
TETRALOGY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
OF O
FALLOT B_PERSON/B_LOCATION
. O

It O
has O
been O
my O
custom B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
follow O
a O
policy B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rather O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
outlined O
by O
Blalock B_PERSON
. O

The O
subclavian O
branch O
of O
the O
innominate O
has O
generally O
been O
preferred O
in O
patients B_PERSON/B_BIO
ranging O
between O
two O
and O
twelve O
years O
of O
age O
and O
in O
older O
individuals O
in O
whom O
there O
is O
a O
right O
aortic O
arch O
. O

In O
others B_PERSON
the O
thoracotomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
usually O
made O
on O
the O
side B_LOCATION/B_MEASURE
of O
the O
aortic B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arch I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
either O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
itself O
or O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
arising O
from O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
used O
for O
the O
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

My O
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
originating B_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
is O
small B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
not O
been O
as O
good B_DISEASE_ADJECTIVE[DISEASE]
as O
those O
which O
others B_PERSON
have O
reported O
. O

One O
eighteen O
- O
month O
- O
old O
child B_PERSON
died O
the O
day O
after O
operation O
and O
was O
found O
at O
post O
- O
mortem O
examination O
to O
have O
an O
occluded O
anastomosis O
. O

In O
one O
three O
- O
year O
- O
old O
child B_PERSON
and O
one O
twenty O
- O
year O
- O
old O
woman B_PERSON
a O
poor O
result O
was O
obtained O
and O
a O
second O
operation O
upon O
the O
other O
side O
was O
necessary O
. O

In O
two B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
additional I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
only O
fair B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

excluding O
the O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mentioned O
in O
the O
present O
report O
, O
only O
in O
two O
was O
an O
unquestionably O
good O
result O
obtained O
. O

Recently O
, O
in O
several B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
failure B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seemed O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
modification B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
been O
required O
in O
order B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
obtain O
a O
functioning O
shunt B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Since O
these O
modifications B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
proved O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
since O
these O
threats B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
failure B_PERSON
tax I_PERSON
one I_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ingenuiity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O
the O
time B_MEASURE/B_LOCATION
of O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
I O
have O
thought O
it O
might O
be O
helpful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
describe O
the O
procedures B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
employed O
and O
to O
illustrate O
them O
with O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

One B_NUMBER[MEASURE]/B_PERSON
is O
a O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
obviously O
has O
very O
limited B_DISEASE_ADJECTIVE[DISEASE]
applicability I_DISEASE_ADJECTIVE[DISEASE]
, O
while O
the O
otlher B_PERSON/B_SEQUENCE[MEASURE]
would O
seem O
to O
be O
rather O
generally O
applicable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
consists O
of O
the O
transplantation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
origin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
to O
a O
more O
suitable B_LOCATION/B_MEASURE
portion I_LOCATION/I_MEASURE
of O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
patient B_PERSON
was O
a O
19 O
- O
year O
- O
old O
girl B_PERSON
who O
had O
been O
cyanotic O
since O
the O
age O
of O
six O
months O
. O

She O
had O
developed O
normally O
but O
was O
always O
limited O
in O
exercise B_MEASURE
capacity I_MEASURE
. O

In O
her O
early B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
school B_LOCATION/B_PERSON
she O
was O
taken O
to O
school B_LOCATION
by O
her O
parents B_PERSON
and O
carried O
to O
and O
from O
her O
seat B_LOCATION/B_PERSON
in O
the O
classroom B_LOCATION
. O

She O
did O
reasonably O
well O
in O
high B_LOCATION/B_ORGANIZATION
school I_LOCATION/I_ORGANIZATION
, O
being O
driven O
to O
and O
from O
the O
school B_LOCATION
, O
but O
she O
got O
into O
severe B_DISEASE_ADJECTIVE[DISEASE]
difficulty I_DISEASE_ADJECTIVE[DISEASE]
when O
she O
attempted O
to O
attend O
college B_LOCATION/B_PERSON
. O

The O
longer B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distances I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
classes B_PERSON/B_LOCATION
and O
the O
necessity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
climbing O
stairs B_LOCATION/B_TIME[MEASURE]
precipitated O
a O
downhill B_DISEASE_ADJECTIVE[DISEASE]
course I_DISEASE_ADJECTIVE[DISEASE]
, O
with O
increasing O
dyspnea B_DISEASE/B_MEASURE
, O
more O
marked B_DISEASE
cyanosis I_DISEASE
and O
fatigue B_DISEASE
, O
and O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
bouts B_DISEASE
of O
loss B_DISEASE_ADJECTIVE[DISEASE]
of O
consciousness B_DISEASE
. O

The O
latter B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
occurred O
several B_MEASURE/B_LOCATION
times I_MEASURE/I_LOCATION
daily O
. O

One B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
which O
was O
witnessed O
by O
her O
physician B_PERSON
lasted O
45 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
; O
he O
feared O
it O
would O
prove O
fatal B_DISEASE_ADJECTIVE[DISEASE]
. O

Ordinarily O
, O
she O
could O
not O
walk O
more B_MEASURE
than O
half O
a O
block B_LOCATION/B_TIME[MEASURE]
. O

There O
was O
marked O
cyanosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
nails B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
mucous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membranes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
to O
a O
lesser B_DISEASE
extent I_DISEASE
of O
the O
skin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Clubbing B_DISEASE/B_PERSON
was O
very O
prominent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
physical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fitted O
in O
with O
a O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tetralogy B_DISEASE/B_LOCATION
of O
Fallot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
hematocrit B_MEASURE
ranged O
between O
83 B_MEASURE
and O
90 B_MEASURE
. O

Oxygen B_MEASURE
saturation I_MEASURE
of O
arterial B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_BODY_PART_OR_ORGAN_COMPONENT/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
65 B_MEASURE
per O
cent B_MEASURE
at O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
rest I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

The O
aortic B_LOCATION
arch I_LOCATION
was O
on O
the O
left B_LOCATION
side I_LOCATION
. O

On O
October B_TIME[MEASURE]
26 I_TIME[MEASURE]
, O
1949 B_MEASURE
a O
left B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lateral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thoracotomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
performed O
, O
the O
pleural B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cavity B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
being O
entered O
through O
the O
bed B_LOCATION/B_MEASURE
of O
the O
fifth B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
rib I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

There O
was O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
greatly O
increased O
collateral B_DISEASE/B_MEASURE
circulation B_DISEASE/I_MEASURE
in O
the O
mediastinum B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
hilum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
appeared O
to O
have O
markedly O
reduced O
blood B_MEASURE/B_LOCATION
flow I_MEASURE/I_LOCATION
, O
was O
very O
short B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
and O
thin B_MEASURE
- O
walled B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Its O
diameter B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
was O
less B_MEASURE
than O
5 B_MEASURE/B_LOCATION
mm I_MEASURE/I_LOCATION
. O

The O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
seemed O
to O
be O
bowed O
out O
laterally O
in O
an O
unusual B_PERSON/B_LOCATION
fashion I_PERSON/I_LOCATION
and O
the O
short B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pulmonary I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O
not O
possibly O
be O
brought O
out O
over O
it O
. O

The O
subclavian B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
relatively O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
having O
. O

487 B_NUMBER[MEASURE]
. O

YALE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Journal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
OF O
Biology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
Medicine B_EDU[ORGANIZATION]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

a O
diameter B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
only O
about O
4 B_NUMBER[MEASURE]
mm I_NUMBER[MEASURE]
. O
but O
it O
seemed O
rather O
long O
. O

It O
was O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
a O
Pott B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
s I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
impossible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
that O
an O
end B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
to O
- O
side B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subclavian B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
artery B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
anastomosis B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
would O
be O
doomed O
to O
failure O
. O

Hence O
, O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O
divided O
at O
the O
level B_TIME[MEASURE]/B_LOCATION
of O
its O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
branch B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
divided O
proximally O
, O
and O
an O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
to O
- O
end B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
subclavian I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O
pulmonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
anastomosis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
was O
carried O
out O
. O

This O
was O
done O
with O
ease B_PERSON
. O

When O
the O
clamps B_DISEASE_ADJECTIVE[DISEASE]/B_MEDICAL_DEVICE[OBJECT]
were O
removed O
, O
however O
, O
no O
blood B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
flowed O
through O
it O
. O

The O
softwalled B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
subclavian B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
completely O
flattened O
out O
against O
the O
relatively O
rigid B_LOCATION/B_MEASURE
aorta I_LOCATION/I_MEASURE
( O
Fig B_MEASURE/B_LOCATION
. O
1 B_NUMBER[MEASURE]
) O
. O

When O
the O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
structures I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
were O
forcibly O
elevated O
in O
a O
cephalad B_LOCATION/B_ORGANIZATION
direction I_LOCATION/I_ORGANIZATION
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
immediately O
filled O
and O
pulsated O
normally O
and O
a O
thrill B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O
be O
felt O
. O

Simple B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
expansion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
lungs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
however O
, O
failed O
to O
achieve O
this O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
I O
could O
conceive O
of O
no O
way B_LOCATION/B_PERSON
in O
which O
the O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
could O
be O
held O
in O
a O
more O
cephalad B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
direction I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT
was O
then O
ligated O
at O
the O
point B_LOCATION/B_MEASURE
where O
it O
came O
off O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
its O
proximal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
end I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
was O
anastomosed O
end B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
to O
- O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
to O
the O
descending O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

It O
now O
pulsated O
vigorously O
as O
did O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O

In O
spite B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
good B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
pulsation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
no O
thrill B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
was O
palpable B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
patient B_PERSON/B_LOCATION
had O
an O
uneventful O
but O
disappointing O
convalescence O
. O

She O
remained O
markedly O
cyanotic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O
no O
continuous B_DISEASE
bruit I_DISEASE
was O
audible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
she O
left O
the O
hospital B_LOCATION/B_MEASURE
14 I_LOCATION/I_MEASURE
days I_LOCATION/I_MEASURE
after O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
there O
was O
no O
improvement B_DISEASE_ADJECTIVE[DISEASE]
in O
her O
appearance B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
hematocrit B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
or O
arterial B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

surprisingly O
enough O
she O
reported O
progress B_DISEASE
on O
each O
follow O
- O
up O
examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

By O
the O
end B_LOCATION/B_MEASURE
of O
seven B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
she O
was O
obviously O
less O
cyanotic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O
her O
hematocrit B_MEASURE/B_DISEASE
was O
77 B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
she O
was O
able B_TIME[MEASURE]/B_PERSON
to O
walk O
a O
number B_MEASURE/B_PERSON
of O
blocks B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
to O
climb O
a O
flight B_LOCATION/B_PRODUCT[OBJECT]
of O
stairs B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
without O
difficulty B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
reported O
that O
she O
had O
danced O
and O
roller B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
skated O
without O
much B_DISEASE
trouble I_DISEASE
. O

Shortly O
thereafter O
a O
continuous B_DISEASE/B_MEASURE
murmur I_DISEASE/I_MEASURE
was O
audible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
left B_LOCATION
chest I_LOCATION
. O

She O
continued O
to O
improve O
and O
in O
January B_TIME[MEASURE]
entered O
a O
southern B_LOCATION
college I_LOCATION
. O

She B_PERSON
did O
well O
. O

At O
least O
once O
a O
day B_TIME[MEASURE]
, O
often O
twice O
, O
she O
walked O
without O
difficulty B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
the O
campus B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
into O
town B_LOCATION
and O
back O
, O
a O
distance B_MEASURE/B_LOCATION
of O
ten B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
blocks I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
each O
way B_LOCATION/B_TIME[MEASURE]
. O

She O
played O
a O
little B_ENT
tennis I_ENT
, O
learned O
to O
swim O
, O
and O
began O
to O
dance O
, O
including O
jitterbugging B_ENT/B_PERSON
. O

When O
she O
xvas O
seen O
in O
June B_TIME[MEASURE]/B_ENT
, O
her O
color B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
good B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
although O
there O
was O
still O
slight B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cyanosis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
lips B_BODY_PART_OR_ORGAN_COMPONENT
and O
nail B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
beds I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
was O
a O
very O
loud B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
continuous B_DISEASE
murmur I_DISEASE
in O
the O
left B_LOCATION
chest I_LOCATION
. O

The O
following B_TIME[MEASURE]/B_ENT
fall I_TIME[MEASURE]/I_ENT
she O
transferred O
to O
a O
midwestern B_LOCATION/B_PERSON
university I_LOCATION/I_PERSON
. O

She O
got O
along O
reasonably O
well O
but O
not O
as O
well O
as O
she O
had O
in O
a O
warmer B_LOCATION
climate I_LOCATION
and O
on O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
terrain I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

She O
walked O
four B_NUMBER[MEASURE]
or O
five B_NUMBER[MEASURE]
blocks I_NUMBER[MEASURE]
up O
and O
down O
hills B_LOCATION/B_TIME[MEASURE]
between O
classes B_PERSON/B_LOCATION
without O
difficulty B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O
good B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
weather I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
but O
complained O
of O
some O
dyspnea B_DISEASE
and O
fatigue B_DISEASE
on O
cold B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
windy B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
attended O
dances B_ENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
often O
danced O
each O
number B_TIME[MEASURE]/B_ENT
throughout O
the O
evening B_TIME[MEASURE]/B_LOCATION
without O
trouble B_DISEASE
. O

When O
seen O
in O
December B_TIME[MEASURE]/B_COLOR
she O
looked O
well O
. O

Her O
color B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
good B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
clubbing B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O
definitely O
less O
marked B_DISEASE_ADJECTIVE[DISEASE]
than O
it O
had O
been O
previously O
. O

She O
had O
a O
severe B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cold I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
the O
time B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Her O
oxygen B_MEASURE
saturation I_MEASURE
of O
arterial B_BODY_PART_OR_ORGAN_COMPONENT
blood I_BODY_PART_OR_ORGAN_COMPONENT
was O
75 B_NUMBER[MEASURE]
per O
cent B_MEASURE
at O
rest B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
it O
did O
not O
fall O
when O
she O
stood O
or O
still O
- O
walked O
. O

The O
hematocrit B_BIO/B_PERSON
was O
69 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

There O
was O
audible B_PROTEIN[GENE]/B_MEASURE
the O
same B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
loud I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
continuous I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
murmur I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
left B_LOCATION
chest I_LOCATION
. O

Though O
the O
patient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
been O
markedly O
improved O
, O
it O
is O
recognized O
that O
the O
result O
is O
not O
as O
good O
as O
is O
commonly O
obtained O
when O
patients B_PERSON/B_DISEASE
with O
more O
adequate O
pulmonary O
arteries O
are O
treated O
by O
the O
conventional O
anastomosis O
of O
a O
systemic O
artery O
to O
the O
side O
of O
the O
pulmonary O
artery O
. O

Nevertheless O
, O
the O
patient B_PERSON/B_LOCATION
has O
thus O
far O
been O
given O
such O
good O
health O
and O
relatively O
normal O
capacity O
for O
ordinary O
activity O
that O
further O
operation O
has O
seemed O
unwarranted O
, O
though O
the O
possibility O
of O
some O
future O
attempt O
at O
creation O
of O
an O
additional O
shunt O
is O
being O
kept O
in O
mind O
. O

The O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
embodies O
the O
cephalad B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O
a O
plastic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O
the O
incision B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
the O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
mediastinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pleural I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
structures I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

488 B_NUMBER[MEASURE]
. O

FIG B_ORGANIZATION/B_GENE
. O

1 B_NUMBER[MEASURE]
. O

Drawing O
illustrating O
the O
condition B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
existed O
in O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
completion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
the O
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
its O
correction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
origin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
B B_PROTEIN[GENE]/B_DISEASE
) O
. O

FIG B_ORGANIZATION/B_GENE
. O

2 B_NUMBER[MEASURE]
. O

Drawing O
illustrating O
correction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
obstruction B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
to O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
through O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
by O
inverted B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
T I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
L B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
plastic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
closure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
of O
the O
defect B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
mediastinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
structures I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

Treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
OF O
TETRALOGY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
OF O
FALLOT B_PERSON/B_LOCATION
. O

Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

The O
first O
patient B_PERSON
was O
a O
fully O
grown O
young O
man B_PERSON
of O
17 O
with O
tetralogy O
of O
Fallot O
which O
caused O
considerable O
incapacity O
. O

He O
was O
admitted O
to O
the O
hospital B_LOCATION/B_ORGANIZATION
on O
July B_TIME[MEASURE]
18 I_TIME[MEASURE]
, O
1950 B_MEASURE
and O
was O
operated O
upon O
two B_TIME[MEASURE]/B_LOCATION
days I_TIME[MEASURE]/I_LOCATION
later O
. O

He O
was O
known O
to O
have O
a O
left B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
aortic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
arch I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
a O
left B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lateral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thoracotomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
performed O
. O

The O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
freed O
for O
a O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
to O
- O
side B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
anastomosis B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
with O
the O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

So O
much B_DISEASE_ADJECTIVE[DISEASE]
difficulty I_DISEASE_ADJECTIVE[DISEASE]
was O
encountered O
, O
however O
, O
in O
placing O
the O
aortic B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
clamp I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
proper B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position I_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
making O
a O
satisfactory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
incision I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
that O
the O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
abandoned O
and O
an O
end B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
to O
- O
side B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subclavian I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O
pulmonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
artery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
anastomosis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
accomplished O
instead O
. O

The O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
of O
fair B_MEASURE
size I_MEASURE
, O
having O
an O
estimated O
diameter B_MEASURE/B_LOCATION
of O
1 B_NUMBER[MEASURE]
cm I_NUMBER[MEASURE]
. O

The O
subclavian B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
appeared O
to O
be O
quite O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
it O
was O
of O
very O
satisfactory B_MEASURE/B_COLOR
size I_MEASURE/I_COLOR
, O
having O
a O
diameter B_MEASURE/B_LOCATION
of O
about O
6 B_NUMBER[MEASURE]/B_LOCATION
mm I_NUMBER[MEASURE]/I_LOCATION
. O

To O
my O
dismay B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
first B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
portion I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
soft B_NUMBER[MEASURE]/B_DISEASE
- O
walled B_BODY_PART_OR_ORGAN_COMPONENT
subclavian I_BODY_PART_OR_ORGAN_COMPONENT
artery I_BODY_PART_OR_ORGAN_COMPONENT
was O
completely O
flattened O
out O
against O
the O
rather O
rigid B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
wall I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT
and O
no O
blood B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
flow I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
through O
it O
could O
be O
demonstrated O
, O
there O
being O
no O
subclavian B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulsation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
thrill B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

If O
one B_NUMBER[MEASURE]/B_PERSON
forcefully O
elevated O
the O
hilum B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
a O
cephalad B_LOCATION/B_ORGANIZATION
direction I_LOCATION/I_ORGANIZATION
, O
the O
obstruction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disappeared O
, O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
began O
to O
pulsate O
, O
and O
a O
thrill B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
could O
be O
palpated O
. O

When O
the O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
allowed O
to O
assume O
its O
usual B_PERSON/B_MEASURE
position B_PERSON/I_MEASURE
, O
the O
subclavian B_DISEASE_ADJECTIVE[DISEASE]
obstruction I_DISEASE_ADJECTIVE[DISEASE]
was O
again O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
could O
not O
be O
prevented O
by O
full B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
expansion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

It O
was O
found O
that O
the O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
could O
be O
maintained O
in O
a O
satisfactory B_LOCATION
cephalad I_LOCATION
position I_LOCATION
by O
traction B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
upward O
upon O
the O
cuff B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pleura I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
the O
adjacent B_BODY_PART_OR_ORGAN_COMPONENT
vascular I_BODY_PART_OR_ORGAN_COMPONENT
sheath I_BODY_PART_OR_ORGAN_COMPONENT
and O
that O
these O
structures B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
were O
sufficiently O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
so O
that O
traction B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O
be O
maintained O
upon O
them O
with O
a O
small B_MEDICAL_DEVICE[OBJECT]/B_DISEASE_ADJECTIVE[DISEASE]
hemostat I_MEDICAL_DEVICE[OBJECT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
defect B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
mediastinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
then O
repaired O
using O
a O
sort B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
inverted B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
T B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
plastic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
closure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

By O
this O
maneuver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
success I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
achieved O
in O
elevating O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
cephalad B_LOCATION/B_ORGANIZATION
direction I_LOCATION/I_ORGANIZATION
so O
that O
the O
subclavian B_DISEASE/B_MEASURE
obstruction I_DISEASE/I_MEASURE
was O
relieved B_DISEASE_ADJECTIVE[DISEASE]
and O
excellent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulsation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fig B_PROTEIN[GENE]/B_MEASURE
. O
2B B_NUMBER[MEASURE]/B_LOCATION
) O
. O

A O
fairly O
good B_DISEASE/B_MEASURE
continuous I_DISEASE/I_MEASURE
thrill I_DISEASE/I_MEASURE
was O
palpable B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
patient B_PERSON
had O
an O
uneventful O
convalescence O
. O

When O
last O
seen O
on O
January B_TIME[MEASURE]
16 I_TIME[MEASURE]
, O
1951 B_MEASURE
he O
had O
excellent B_DISEASE
color I_DISEASE
without O
any O
visible B_DISEASE
cyanosis I_DISEASE
. O

The O
clubbing B_DISEASE/B_MEASURE
seemed O
to O
have O
decreased O
somewhat O
. O

A O
continuous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
murmur I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
audible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

He O
stated O
that O
he O
noted O
no O
limitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
exercise B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
outlining O
his O
activities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
he O
said O
that O
, O
among O
other B_PERSON/B_ENT
things I_PERSON/I_ENT
, O
he O
was O
doing O
a O
great B_TIME[MEASURE]/B_ORGANIZATION
deal I_TIME[MEASURE]/I_ORGANIZATION
of O
ice B_LOCATION/B_PERSON
- O
skating B_SPORT[ENT]
and O
was O
playing O
ice B_SPORT[ENT]/B_PERSON
hockey I_SPORT[ENT]/I_PERSON
regularly O
. O

He O
was O
planning O
to O
start O
college B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
work I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
following B_TIME[MEASURE]/B_LOCATION
month I_TIME[MEASURE]/I_LOCATION
. O

The O
second O
patient B_PERSON
was O
a O
16 O
- O
year O
- O
old O
boy B_PERSON
who O
had O
been O
cyanotic O
since O
birth O
. O

His O
physical B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
was O
somewhat O
retarded B_DISEASE_ADJECTIVE[DISEASE]
and O
he O
was O
slow B_DISEASE_ADJECTIVE[DISEASE]
in O
learning O
to O
sit O
and O
walk O
. O

Until O
he O
had O
grown O
old B_DISEASE_ADJECTIVE[DISEASE]
enough O
to O
be O
self B_PERSON/B_DISEASE
- O
conscious B_PERSON
about O
it O
he O
had O
always O
squatted O
when O
he O
was O
tired B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

By O
perseverance B_TIME[MEASURE]/B_PERSON
he O
had O
managed O
to O
do O
more B_MEASURE
than O
one O
would O
have O
suspected O
he O
could O
from O
the O
degree B_DISEASE_ADJECTIVE[DISEASE]
of O
his O
cyanosis B_DISEASE
. O

He O
could O
walk O
as O
much B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
five B_NUMBER[MEASURE]
or O
six B_NUMBER[MEASURE]
blocks I_NUMBER[MEASURE]
at O
a O
slow B_TIME[MEASURE]/B_LOCATION
pace I_TIME[MEASURE]/I_LOCATION
. O

He O
was O
fond B_PERSON
of O
drums B_ENT/B_DISEASE
and O
managed O
to O
play O
occasionally O
with O
an O
orchestra B_ENT/B_PERSON
in O
a O
somewhat O
restricted B_LOCATION/B_PERSON
fashion I_LOCATION/I_PERSON
. O

For O
the O
past B_TIME[MEASURE]
few I_TIME[MEASURE]
months I_TIME[MEASURE]
he O
had O
had O
more B_DISEASE
dyspnea I_DISEASE
, O
fatigability B_DISEASE
, O
and O
seemed O
to O
be O
going O
downhill O
generally O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
physical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
rather O
typical B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
tetralogy B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
Fallot B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

Clubbing B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O
marked O
, O
the O
nailbeds B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
and O
mucous B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
membranes B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
were O
a O
rather O
deep B_COLOR/B_ENT
purplish I_COLOR/I_ENT
- O
blue B_COLOR
color I_COLOR
, O
and O
the O
skin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
had O
a O
dusky B_DISEASE/B_BIO
cyanotic I_DISEASE/I_BIO
tint I_DISEASE/I_BIO
. O

The O
aortic B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arch I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
determined O
to O
be O
on O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

On O
July B_TIME[MEASURE]
21 I_TIME[MEASURE]
, O
1950 B_MEASURE
a O
left B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lateral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thoracotomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
performed O
, O
the O
pleural B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cavity B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
being O
entered O
through O
the O
bed B_LOCATION/B_MEASURE
of O
the O
fourth B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
rib I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

There O
was O
a O
rather O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
collateral B_DISEASE/B_MEASURE
circulation B_DISEASE/I_MEASURE
in O
the O
mediastinum B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
the O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

The O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
easily O
dissected O
free B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

It O
was O
fairly O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
was O
about O
1 B_MEASURE
cm I_MEASURE
. O
in O
diameter B_MEASURE/B_LOCATION
. O

The O
subclavian B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
artery I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
seemed O
quite O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
was O
of O
adequate B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
, O
having O
a O
diameter B_MEASURE/B_LOCATION
of O
about O
5 B_NUMBER[MEASURE]
mm I_NUMBER[MEASURE]
. O

An O
end B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
to O
- O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sub9lavian I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
pulmonary I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anastomosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
performed O
. O

Again O
in O
this O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
, O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
acutely O
angulated O
and O
completely O
flattened O
out O
against O
the O
aortic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

There B_LOCATION/B_PERSON
was O
no O
. O

489 B_NUMBER[MEASURE]
. O

YALE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Journal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
OF O
Biology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
Medicine B_EDU[ORGANIZATION]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

pulsation B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT
and O
no O
thrill B_DISEASE/B_MEASURE
in O
the O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
this O
instance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
also O
, O
good B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blood I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
flow I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
through O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT
artery I_BODY_PART_OR_ORGAN_COMPONENT
was O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whenever O
the O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
structures I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
elevated O
in O
a O
cephalad B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
direction B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
but O
no O
pulsation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
demonstrable B_DISEASE_ADJECTIVE[DISEASE]
simply O
by O
expanding O
fully O
the O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Again O
, O
a O
sort B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
inverted B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
T B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
plastic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
closure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O
the O
defect B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
hilum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mediastinum B_BODY_PART_OR_ORGAN_COMPONENT
brought O
about O
a O
cephalad B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
elevation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
so O
that O
tension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
released O
and O
there O
was O
excellent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulsation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT
artery I_BODY_PART_OR_ORGAN_COMPONENT
. O

A O
thrill B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
now O
palpable B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O

Convalescence B_TIME[MEASURE]/B_PERSON
was O
uneventful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Improvement B_DISEASE_ADJECTIVE[DISEASE]
in O
color B_ENT/B_DISEASE
was O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
a O
few B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
and O
his O
color B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
excellent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O
the O
time B_TIME[MEASURE]/B_LOCATION
he O
was O
discharged O
from O
the O
hospital B_LOCATION/B_ORGANIZATION
on O
the O
thirteenth B_SEQUENCE[MEASURE]
postoperative I_SEQUENCE[MEASURE]
day I_SEQUENCE[MEASURE]
. O

He O
rapidly O
found O
that O
he O
was O
now O
able B_TIME[MEASURE]/B_PERSON
to O
lead O
a O
quite O
normal B_MEASURE/B_PERSON
sort I_MEASURE/I_PERSON
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
he O
was O
seen O
on O
December B_ENT/B_LOCATION
9 I_ENT/I_LOCATION
he O
stated O
that O
he O
had O
no O
limitation B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
exercise B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
capacity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

He O
could O
walk O
rapidly O
without O
fatigue B_DISEASE
. O

He O
was O
going O
to O
school B_LOCATION
and O
was O
playing O
the O
drums B_ENT
in O
a O
professional B_TIME[MEASURE]/B_ENT
orchestra I_TIME[MEASURE]/I_ENT
three I_TIME[MEASURE]/I_ENT
or O
four B_NUMBER[MEASURE]/B_ENT
nights I_NUMBER[MEASURE]/I_ENT
each O
week B_TIME[MEASURE]
. O

There O
was O
some O
diminution B_DISEASE/B_MEASURE
in O
the O
clubbing B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
his O
color B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
excellent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

There O
was O
a O
loud B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continuous I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bruit I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
audible I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
chest B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

On O
March B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
27 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
arterial B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
oxygen B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
saturation B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
was O
88 B_MEASURE
. O
2 B_MEASURE
per O
cent B_MEASURE
. O

When O
I O
first O
used O
this O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
was O
rather O
surprised B_PERSON
that O
such B_PERSON
tissues I_PERSON
would O
hold O
sutures B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
serve O
satisfactorily O
to O
elevate O
the O
hilum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
occasions B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
had O
previously O
toyed O
with O
the O
idea B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
suturing O
hilar B_DISEASE/B_LOCATION
pleura I_DISEASE/I_LOCATION
to O
the O
mediastinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pleura I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
but O
had O
abandoned O
it O
as O
impractical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
because O
the O
sutures B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
seemed O
to O
pull O
out O
whenever O
there O
was O
any O
tension B_DISEASE
whatsoever O
. O

If O
the O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
to O
be O
successful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
it O
is O
essential B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
sutures B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
encompass O
any O
adjacent B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
areolar I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
fibrous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
especially O
the O
so O
- O
called O
vascular B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sheath I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O
surrounds O
both O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
is O
dissected O
free B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
during O
the O
course B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Fortunately O
, O
in O
its O
proximal B_LOCATION
portion I_LOCATION
the O
sheath B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
about O
the O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
artery B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
gains B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
added O
strength B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
from O
the O
extension B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
into O
it O
of O
a O
reflection B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
fibrous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pericardium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Sutures B_MEASURE/B_PERSON
through O
the O
mediastinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pleura I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
in O
the O
region B_LOCATION/B_MEASURE
of O
the O
aortic B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arch I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
purposely O
include O
the O
perivascular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
which O
have O
been O
stripped O
off O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT
and O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
also O
any O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
may O
lend O
strength B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
the O
divided O
ends B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
supreme B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
intercostal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
vein I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
vessels I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
which O
lhave O
been O
transected O
and O
ligated O
. O

The O
exact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
repair B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
vary O
from O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

By O
placing O
the O
sutures B_MEDICAL_DEVICE[OBJECT]/B_MEASURE
properly O
it O
would O
seem O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sometimes O
to O
displace O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
laterally O
as O
well O
as O
in O
a O
cephalad B_LOCATION/B_ORGANIZATION
direction I_LOCATION/I_ORGANIZATION
if O
such O
a O
maneuver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
thought O
to O
be O
desirable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fig B_MEASURE/B_GENE
. O
2C B_MEASURE
) O
. O

On O
occasions B_NUMBER[MEASURE]/B_PERSON
one B_NUMBER[MEASURE]/I_PERSON
would O
close O
the O
pleural B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
defect I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
fairly O
snugly O
, O
on O
others B_PERSON/B_TIME[MEASURE]
leave O
it O
wide B_SPORT[ENT]/B_DISEASE_ADJECTIVE[DISEASE]
open I_SPORT[ENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
places B_LOCATION/B_DISEASE
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Though O
there O
is O
always O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
some O
suitable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
systemic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
vessel I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
though O
the O
major B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concern I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
of O
the O
tetralogy B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
Fallot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
the O
adequacy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
pulmonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
artery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
from O
time B_TIME[MEASURE]/B_LOCATION
to O
time B_TIME[MEASURE]/B_LOCATION
one O
may O
find O
the O
achievement B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
satisfactory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
result I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
thwarted O
by O
the O
local B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anatomical I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regardless O
of O
one B_NUMBER[MEASURE]/B_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
choice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Consequently O
, O
those O
modifications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O
may O
add O
to O
the O
likelihood B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
successful B_DISEASE_ADJECTIVE[DISEASE]
outcome I_DISEASE_ADJECTIVE[DISEASE]
are O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Blalock B_PERSON
' O
' O
pointed O
out O
the O
practicability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
performing O
an O
end B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
toend B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
subclavian I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
- O
pulmonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
artery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
anastomosis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
whenever O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
judged O
too O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
too O
short O
for O
a O
satisfactory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
end I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

490 B_NUMBER[MEASURE]
. O

Treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
OF O
TETRALOGY B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
OF O
FALLOT B_PERSON/B_LOCATION
491 I_PERSON/I_LOCATION
. O

to O
- O
side B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
anastomosis B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Holman B_PERSON
' O
feels O
that O
a O
poorly O
functioning B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
shunt I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
after O
end B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
to O
- O
side B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
anastomosis B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
can O
usually O
be O
corrected O
by O
proximal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
division I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
thus O
in O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
converting O
the O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
into O
an O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
to O
- O
end B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
anastomosis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

If O
a O
satisfactory B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
end I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
to O
- O
side B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
suture I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT
and O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
to O
- O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aortic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
pulmonary I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
anastomosis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
seems O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
achieve O
, O
one O
may O
occasionally O
find O
it O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
divide O
the O
upper B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lobe B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
branch B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
carry O
out O
an O
end B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
to O
- O
end B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suture I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
proximal B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
end I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lobe I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
branch I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Potts B_PERSON
and O
Smith B_PERSON/B_LOCATION
' I_PERSON
performed O
an O
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O
the O
proximal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
end I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
upper B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lobe B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
branch B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
side B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
a O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
which O
complete B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
temporary B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
main B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pulmonary I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O
withstood O
poorly O
. O

I O
have O
found O
this O
principle B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
division B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lobe I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
branch I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
its O
proximal B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
value B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
obtaining O
a O
suitable B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
subclavian I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
pulmonary I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
anastomosis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
when O
the O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seemed O
to O
have O
inadequate B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
occasions B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
when O
the O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vessel B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seems O
too O
short B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
one O
may O
elect O
to O
interpose O
a O
free B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
vascular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
transplant I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
3 B_MEASURE/B_LOCATION
' O
' O
a O
modification B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
I O
first O
employed O
in O
1946 B_MEASURE
though O
unfortunately O
not O
with O
success B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
instance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
operation O
performed O
in O
my O
first O
patient B_PERSON/B_TIME[MEASURE]
constitutes O
in O
reality O
the O
use O
of O
the O
subclavian O
artery O
as O
an O
autogenous O
graft O
between O
the O
aorta O
and O
pulmonary O
artery O
. O

It O
will O
obviously O
not O
often O
be O
the O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
choice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
but O
sometimes O
may O
be O
found O
a O
useful B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
converting O
an O
apparently O
inadequate B_DISEASE_ADJECTIVE[DISEASE]
functional I_DISEASE_ADJECTIVE[DISEASE]
shunt I_DISEASE_ADJECTIVE[DISEASE]
into O
a O
good B_PRODUCT[OBJECT]/B_DISEASE
one I_PRODUCT[OBJECT]/I_DISEASE
. O

If O
my O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
plastic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
defect B_DISEASE/B_LOCATION
in O
the O
mediastinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
structures I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
what O
may O
be O
expected O
of O
this O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
it O
would O
seem O
to O
have O
wide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
applicability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whenever O
a O
poorly O
functioning O
subclavian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
shunt B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
seems O
correctable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
cephalad B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
hilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
structures I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
consequent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
release I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
tension B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

I O
was O
unaware B_PERSON
of O
any O
reference B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
in O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
its O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
until O
belatedly O
I O
discovered O
that O
I O
had O
overlooked O
a O
statement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
the O
legend B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
excellent B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drawings I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Blalock B_LOCATION/B_PERSON
' I_LOCATION/I_PERSON
s I_LOCATION/I_PERSON
paper I_LOCATION/I_PERSON
on O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
procedures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
pulmonic B_MEASURE
stenosis I_MEASURE
. O
' O
Here O
he O
states O
that O
suture B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
pleura B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
superior B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
aspect I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
hilum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
mediastinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pleura I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
may O
effectively O
elevate O
a O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
the O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Perhaps O
our O
more O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
consideration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
this O
maneuver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
add O
to O
its O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

references B_PERSON/B_DISEASE
. O

1 B_PERSON
Blalock I_PERSON
, O
A B_OTHER/B_PERSON
. O
: O
The O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
creation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
of O
an O
artificial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
ductus B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
arteriosus B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
the O
. O

treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
pulmonic B_DISEASE
stenosis I_DISEASE
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

thorac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
. O

Surg B_PERSON/B_GENE
. O
, O
1947 B_NUMBER[MEASURE]
, O
16 B_MEASURE
, O
244 B_MEASURE/B_LOCATION
. O

2 B_PERSON
Blalock I_PERSON
, O
A B_OTHER/B_PERSON
. O
: O
Surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
procedures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
employed O
and O
anatomical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variations I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encountered O
. O

in O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
congenital B_DISEASE
pulmonic I_DISEASE
stenosis I_DISEASE
. O

Surg B_LOCATION/B_PERSON
. O
, O
Gyn B_PERSON/B_LOCATION
. O

Obst B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
1948 B_MEASURE
, O
87 B_MEASURE
, O
385 B_MEASURE
. O

3 B_PERSON/B_COLOR
Gross I_PERSON/I_COLOR
, O
R B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

E O
. O
, O
Bill B_PERSON
, O
A B_OTHER/B_PERSON
. O

H B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Jr B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
and O
Pierce B_PERSON/B_ORGANIZATION
, O
E B_OTHER/B_PERSON
. O

C B_OTHER/B_PROTEIN[GENE]
. O
: O
Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O
preservation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O
. O

transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
aortic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
grafts I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

observation O
on O
arterial O
grafts O
in O
dogs B_BIO/B_PERSON
. O

Report O
of O
transplantation O
of O
preserved O
arterial O
grafts O
in O
nine O
human B_PERSON/B_SPECIES[BIO]
cases O
. O

Surg B_LOCATION/B_PERSON
. O
, O
Gyn B_PERSON/B_LOCATION
. O

Obst B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
, O
1949 B_MEASURE
, O
88 B_MEASURE
, O
689 B_MEASURE/B_LOCATION
. O

4 B_PERSON/B_LOCATION
Holman I_PERSON/I_LOCATION
, O
E B_OTHER/B_PERSON
. O
: O
The O
surgery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stenosis B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

experiences B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O
left B_DISEASE/B_PERSON
subclavian I_DISEASE/I_PERSON
. O

to O
left O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
anastomosis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

thorac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
. O

Surg B_PERSON/B_GENE
. O
, O
1949 B_MEASURE
, O
18 B_MEASURE
, O
827 B_MEASURE/B_LOCATION
. O

5 B_PERSON/B_COLOR
Johnson I_PERSON/I_COLOR
, O
J B_OTHER/B_LOCATION
. O
, O
Kirby B_PERSON/B_COLOR
, O
C B_OTHER/B_PERSON
. O

K B_OTHER/B_PROTEIN[GENE]
. O
, O
Greifenstein B_PERSON
, O
F B_OTHER/B_PERSON
. O

E O
. O
, O
and O
Costillo B_LOCATION/B_PERSON
, O
A B_OTHER/B_PERSON
. O
: O
The O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vein B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grafts I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
replace O
defects B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
large B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Surgery B_MEASURE/B_ORGANIZATION
, O
1949 B_MEASURE
, O
26 B_MEASURE
, O
945 B_MEASURE/B_LOCATION
. O

492 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
YALE I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
Journal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
OF O
Biology B_EDU[ORGANIZATION]/B_DISEASE
AND O
Medicine B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

6 B_PERSON/B_COLOR
Lam I_PERSON/I_COLOR
, O
C B_MEASURE/B_GENE
. O

R B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
: O
The O
choice B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
approach B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
in O
operations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
for O
pulmonary B_DISEASE
. O

stenosis B_DISEASE
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

thorac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
. O

Surg B_PERSON/B_GENE
. O
, O
1949 B_MEASURE
, O
18 B_MEASURE
, O
661 B_MEASURE/B_LOCATION
. O

7 B_PERSON/B_LOCATION
Olim I_PERSON/I_LOCATION
, O
C B_OTHER/B_LOCATION
. O

B B_OTHER/B_MEASURE
. O
: O
experiences B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O
congenital B_DISEASE/B_LOCATION
pulmonary I_DISEASE/I_LOCATION
. O

stenosis B_DISEASE
. O

American B_MEASURE/B_PERSON
surgeon I_MEASURE/I_PERSON
, O
1951 B_MEASURE
, O
17 B_MEASURE
, O
245 B_MEASURE
. O

8 B_PERSON/B_COLOR
Paine I_PERSON/I_COLOR
, O
J B_OTHER/B_PERSON
. O

R B_OTHER/B_PROTEIN[GENE]
. O
and O
Varco B_PERSON/B_LOCATION
, O
R B_OTHER/B_PERSON
. O

C B_MEASURE/B_GENE
. O
: O
experiences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
the O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
pul B_DISEASE/B_LOCATION
. O

monic B_DISEASE_ADJECTIVE[DISEASE]
stenosis I_DISEASE_ADJECTIVE[DISEASE]
. O

Surgery B_MEASURE/B_ORGANIZATION
, O
1948 B_MEASURE
, O
24 B_NUMBER[MEASURE]
, O
355 B_MEASURE/B_LOCATION
. O

9 B_PERSON/B_LOCATION
Potts I_PERSON/I_LOCATION
, O
W B_OTHER/B_PERSON
. O

J B_OTHER/B_PROTEIN[GENE]
. O
and O
Smith B_PERSON
, O
S B_OTHER/B_DISEASE
. O
: O
New B_DISEASE_ADJECTIVE[DISEASE]
surgical I_DISEASE_ADJECTIVE[DISEASE]
procedures I_DISEASE_ADJECTIVE[DISEASE]
in O
certain B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cases I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
congenital B_DISEASE
. O

pulmonary B_DISEASE_ADJECTIVE[DISEASE]
stenosis I_DISEASE_ADJECTIVE[DISEASE]
. O

Arch B_LOCATION/B_BIO
. O

Surg B_PERSON/B_GENE
. O
, O
1949 B_MEASURE
, O
59 B_MEASURE
, O
491 B_MEASURE/B_LOCATION
. O

10 B_PERSON/B_LOCATION
Potts I_PERSON/I_LOCATION
, O
W B_OTHER/B_PERSON
. O

J B_OTHER/B_PROTEIN[GENE]
. O
, O
Smith B_LOCATION/B_PERSON
S I_LOCATION/I_PERSON
. O
, O
and O
Gibson B_PERSON/B_COLOR
, O
S B_OTHER/B_LOCATION
. O
: O
anastomosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
of O
the O
aorta B_BODY_PART_OR_ORGAN_COMPONENT
to O
a O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

artery B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
; O
certain B_DISEASE_ADJECTIVE[DISEASE]
types I_DISEASE_ADJECTIVE[DISEASE]
in O
congenital B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
heart I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Am B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

M B_OTHER/B_MEASURE
. O

Ass B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
1946 B_MEASURE
, O
132 B_MEASURE
, O
627 B_MEASURE/B_LOCATION
. O

tissue O
remodeling O
: O
a O
mating O
- O
induced O
differentiation O
program O
for O
the O
Drosophila B_SPECIES[BIO]/B_PERSON
oviduct O
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
both O
vertebrates B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
invertebrates B_SPECIES[BIO]
, O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
an O
epithelial B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
tube I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
surrounded O
by O
visceral B_BODY_PART_OR_ORGAN_COMPONENT
muscles I_BODY_PART_OR_ORGAN_COMPONENT
that O
serves O
as O
a O
conduit B_LOCATION
for O
gamete B_ORGANIZATION/B_LOCATION
transport B_ORGANIZATION/I_LOCATION
between O
the O
ovary B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O
uterus B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

While O
Drosophila O
is O
a O
model O
system O
for O
tubular O
organ O
development O
, O
few O
studies O
have O
addressed O
the O
development O
of O
the O
fly B_SPECIES[BIO]/B_PERSON
' O
s O
oviduct O
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
Drosophila B_SPECIES[BIO]
have O
identified O
mating O
- O
responsive B_GENE
genes I_GENE
and O
proteins B_BIO/B_GENE
whose O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
are O
altered O
by O
mating B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Since O
many B_NUMBER[MEASURE]/B_PERSON
of O
these O
molecules B_BIO/B_GENE
( O
e O
. O
g B_GENE/B_MEASURE
. O
Muscle B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Lim I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
84B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
Coracle B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
Neuroglian B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
have O
known O
roles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O
the O
differentiation B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
of O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
and O
epithelia B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
of O
other B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
organs I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
mating B_BIO/B_PERSON
may O
trigger O
similar B_DISEASE/B_ORGANISM_FUNCTION
differentiation I_DISEASE/I_ORGANISM_FUNCTION
events I_DISEASE/I_ORGANISM_FUNCTION
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

This O
led O
us O
to O
hypothesize O
that O
mating B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediates O
the O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
stages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
oviduct B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
in O
which O
organ B_ENT/B_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specializations I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
arise O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Using O
electron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
and O
confocal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
microscopy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
identified O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
wide B_MEASURE/B_LOCATION
post B_MEASURE/I_LOCATION
- O
mating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
including O
differentiation B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
cellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
junctions I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
remodeling O
of O
extracellular B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
matrix I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
increased O
myofibril B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
and O
increased O
innervation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
once O
- O
and O
twice O
- O
mated O
females B_PERSON/B_BIO
reveals O
that O
some O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
responsive B_PERSON/B_BIO
proteins I_PERSON/I_BIO
respond O
only O
to O
the O
first B_PERSON
mating I_PERSON
, O
while O
others B_PERSON
respond O
to O
both O
matings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

We O
uncovered O
ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
mated B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
roles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
responsive B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
play O
in O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
and O
epithelial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
elsewhere O
. O

This O
suggests O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
triggers O
the O
late B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
we O
suggest O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
responsive B_GENE
proteins I_GENE
that O
respond O
only O
to O
the O
first B_PERSON/B_BIO
mating I_PERSON/I_BIO
are O
involved O
in O
the O
final B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
maturation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
while O
proteins B_BIO/B_GENE
that O
remain O
responsive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
later B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
matings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
are O
also O
involved O
in O
maintenance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O
ongoing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

taken O
together O
, O
our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
establish O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
as O
an O
attractive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
address O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
regulate O
the O
late B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stages B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
differentiation B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
and O
maintenance B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
tubular B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
organ I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Most B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
internal I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
organs I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
including O
the O
vascular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
respiratory B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
systems I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
gastro B_BODY_PART_OR_ORGAN_COMPONENT
- O
intestinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
genital B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tracts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
comprised O
of O
a O
single B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelial I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tube I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O
a O
network B_ORGANIZATION/B_LOCATION
of O
tubes B_BODY_PART_OR_ORGAN_COMPONENT
. O

tubular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
organs I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
serve O
as O
conduits B_LOCATION
for O
the O
transport B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
gases B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
liquids B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
solutes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
serve O
as O
barriers B_LOCATION
between O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compartments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
create O
tubes B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
with O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
barrier B_MEASURE/B_LOCATION
properties I_MEASURE/I_LOCATION
, O
the O
morphology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
tube B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
must O
be O
precisely O
specified O
during O
development B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
modulated O
by O
physiology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

To O
accommodate O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
physiological I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
roles I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programs I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
employed O
at O
the O
last B_LOCATION/B_MEASURE
stages I_LOCATION/I_MEASURE
of O
development B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
. O

While O
much B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
the O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
cellular B_LOCATION/B_GENE
basis I_LOCATION/I_GENE
of O
tube B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
formation I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
6 B_MEASURE
] I_MEASURE
, O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
the O
mechanisms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
regulate O
the O
late B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
stages B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
which O
organ B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specializations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
arise O
. O

The O
conservation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
similarity B_TIME[MEASURE]/B_LOCATION
in O
tubular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
organ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
across O
taxa B_BIO
make O
Drosophila B_SPECIES[BIO]/B_PERSON
an O
excellent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
understanding O
organogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
in O
higher B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
Drosophila B_SPECIES[BIO]/B_PERSON
, O
the O
best B_MEASURE
understood O
tubular B_LOCATION/B_BIO
organs I_LOCATION/I_BIO
from O
a O
developmental B_LOCATION/B_MEASURE
point I_LOCATION/I_MEASURE
of O
view B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
are O
the O
trachea B_BODY_PART_OR_ORGAN_COMPONENT
and O
salivary B_BODY_PART_OR_ORGAN_COMPONENT
gland I_BODY_PART_OR_ORGAN_COMPONENT
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
organs B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
reveal O
a O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
tubular B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
organ I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
development I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
which O
combinatorial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
global B_GENE
patterning I_GENE
genes I_GENE
specifies O
positions B_LOCATION
within O
the O
embryo B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
for O
the O
subsequent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
transcription B_GENE
factors I_GENE
. O

This O
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
results O
in O
the O
activation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
downstream B_GENE
genes I_GENE
involved O
in O
terminal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
organ B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specializations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
as O
the O
cuticle B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
that O
lines O
the O
tracheal B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
lumen I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
[ O
1 B_NUMBER[MEASURE]
, O
2 B_SEQUENCE[MEASURE]
, O
4 B_SEQUENCE[MEASURE]
, O
7 B_SEQUENCE[MEASURE]
- O
9 B_MEASURE
] O
. O

The O
Drosophila B_SPECIES[BIO]/B_PERSON
female O
reproductive O
tract O
is O
another O
tubular O
system O
, O
consisting O
of O
the O
uterus O
and O
a O
common O
oviduct O
( O
the O
main O
tube O
) O
that O
branches O
into O
two O
lateral O
oviducts O
. O

Regional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
are O
observed O
along O
the O
length B_MEASURE/B_LOCATION
of O
the O
tract B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
with O
egg B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation I_ORGANISM_FUNCTION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurring O
largely O
at O
the O
proximal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
end I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
in O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
fertilization B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
occurring O
at O
the O
distal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
end I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
in O
the O
uterus B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
[ O
10 B_NUMBER[MEASURE]
, O
11 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Unlike O
other B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
tubular I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
organs I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
female B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
regional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suggest O
the O
presence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
region B_LOCATION/B_PERSON
- O
specific B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_DISEASE_ADJECTIVE[DISEASE]
programs I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
female B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
Drosophila B_SPECIES[BIO]/B_PERSON
, O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
female B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
behavior I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
physiology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
via O
molecules B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transmitted O
in O
the O
seminal B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
fluid I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
. O

These O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
lead B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
a O
mated O
female B_PERSON/B_LOCATION
state I_PERSON/I_LOCATION
which O
is O
profoundly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
from O
the O
unmated B_PERSON
female I_PERSON
state I_PERSON
. O

While O
an O
unmated B_PERSON/B_BIO
female I_PERSON/I_BIO
lays O
few B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
eggs I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
readily O
accepts O
the O
courtship B_PERSON/B_BIO
efforts I_PERSON/I_BIO
of O
a O
male B_PERSON
, O
a O
mated B_PERSON
female I_PERSON
exhibits I_PERSON
increased O
egg B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
laying O
and O
actively O
rejects O
males B_PERSON/B_BIO
[ O
12 B_MEASURE
- O
19 B_MEASURE
] I_MEASURE
. O

Microarray O
studies O
of O
whole O
flies B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveal O
that O
the O
changes O
in O
egg O
- O
laying O
rate O
are O
accompanied O
by O
a O
change O
in O
gene O
expression O
. O

Within O
three B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
of O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
there O
is O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
expression B_GENE
of O
a O
small B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
genes B_GENE
[ I_GENE
20 I_GENE
, O
21 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
as O
well O
as O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
abundance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
have O
also O
been O
observed O
in O
the O
female B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O
22 B_MEASURE
, O
23 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

In O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
lateral B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
and O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
hereafter O
, O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
immune B_DISEASE/B_ORGANISM_FUNCTION
related O
transcripts B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
down O
regulates O
transcription B_GENE/B_BIO
factors I_GENE/I_BIO
involved O
in O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
growth B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

At O
the O
protein B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
increased O
abundance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
proteins B_BIO/B_GENE
associated O
with O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
assembly B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
cytoskeletal B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
associated O
with O
epithelial B_DISEASE
morphogenesis I_DISEASE
[ O
23 B_DISEASE
] I_DISEASE
. O

Since O
many B_NUMBER[MEASURE]/B_PERSON
of O
these O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
responsive B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
act O
in O
late B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
and O
epithelia B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
elsewhere O
( O
e O
. O
g B_GENE/B_MEASURE
. O
bent B_GENE/B_DISEASE
, O
Muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
Lim I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
protein I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
84B I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
( O
Mlp84B B_GENE/B_BACTERIUM[BIO]
) O
, O
Neuroglian B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
Nrg B_PERSON/B_LOCATION
) O
, O
Coracle B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
( O
Cora B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
) O
) O
, O
we O
hypothesize O
that O
mating B_BIO/B_PERSON
triggers O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

To O
test O
our O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
we O
characterized O
the O
ultrastructure B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
, O
as O
well O
as O
the O
pattern B_MEASURE/B_DISEASE
of O
innervation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
before O
and O
after O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

We O
then O
examined O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimes B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
oviduct B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mating I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
responsive B_MEASURE
cytoskeletal I_MEASURE
proteins I_MEASURE
and O
on O
female B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
reproductive B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
output B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
active B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
tissue B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
remodeling B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
takes O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
musculature B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Furthermore O
, O
we O
found O
a O
striking B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
innervation B_MEASURE
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
after O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
the O
reproductive B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
is O
an O
attractive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
address O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
regulate O
the O
late B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stages B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
tissue B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
tubular B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
organ I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Unlike O
other B_PERSON/B_ORGANISM_FUNCTION
tubular I_PERSON/I_ORGANISM_FUNCTION
organs I_PERSON/I_ORGANISM_FUNCTION
, O
the O
last B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
stage B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
triggered O
by O
an O
extrinsic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
cue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
. O

This O
makes O
it O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
experimentally O
control O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
differentiation B_ORGANISM_FUNCTION/B_GENE
, O
with O
an O
opportunity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
independently O
examine O
the O
effects B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
age B_TIME[MEASURE]/B_PERSON
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
it O
allows O
us O
to O
examine O
processes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
essential I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
reproduction B_DISEASE/B_ORGANISM_FUNCTION
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O
changes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
oviduct B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lumen B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
promotes O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
actin B_GENE/B_BACTERIUM[BIO]
- O
based O
cytoskeletal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
suggests O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
triggers O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
tissue B_DISEASE_ADJECTIVE[DISEASE]
remodeling I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
female B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
reproductive I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
mediate O
its O
progression B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O
a O
mature B_MEASURE/B_LOCATION
functional B_MEASURE/I_LOCATION
stage B_MEASURE/I_LOCATION
[ O
23 B_ORGANISM_FUNCTION/B_BIO
] I_ORGANISM_FUNCTION/I_BIO
. O

To O
gain O
insight B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
underlie O
this O
progression B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
used O
light B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
determine O
the O
morphological B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
status I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O
unmated B_PERSON
and O
mated O
3 B_NUMBER[MEASURE]
- O
day B_PERSON/B_TIME[MEASURE]
old B_PERSON/I_TIME[MEASURE]
females B_PERSON/I_TIME[MEASURE]
. O

In O
nearly O
all O
mated O
reproductive B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processed O
for O
microscopy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
( O
8 B_MEASURE
/ O
9 B_MEASURE
) O
, O
an O
egg B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
located O
in O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
an O
egg B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
was O
never O
observed O
in O
the O
oviduct B_LOCATION/B_MEASURE
of O
unmated B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
reproductive I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tracts I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
5 B_MEASURE
/ O
5 B_NUMBER[MEASURE]
) O
( O
Figure B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
) O
. O

This O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
report O
increased O
ovulation B_ORGANISM_FUNCTION/B_BODY_PART_OR_ORGAN_COMPONENT
and O
egg B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
laying B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
6 B_MEASURE
h O
post B_LOCATION
- O
mating O
[ O
24 B_GENE/B_LOCATION
] I_GENE/I_LOCATION
. O

In O
all O
unmated B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
reproductive I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tracts I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
examined O
, O
the O
region B_LOCATION/B_MEASURE
between O
the O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
oviducts B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
middle B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
the O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
either O
tapered B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
constricted B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
this O
region B_LOCATION/B_MEASURE
appeared O
relaxed B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O
the O
mated B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reproductive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
tract I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
figure B_PROTEIN[GENE]/B_LOCATION
1A I_PROTEIN[GENE]/I_LOCATION
and O
1D B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

These O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
raise O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
lumen B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
is O
narrow B_MEASURE
in O
the O
unmated B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
oviduct I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
and O
larger B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
mated B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
address O
this O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
collected O
serial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
mu B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
m B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
longitudinal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
sections B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
through O
the O
reproductive B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
unmated B_PERSON/B_BIO
and O
mated B_PERSON
females I_PERSON
and O
stained O
these O
sections B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
with O
toluidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
survey O
the O
appearance B_PERSON/B_MEASURE
of O
the O
lumen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
along O
the O
entire B_LOCATION/B_MEASURE
length I_LOCATION/I_MEASURE
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_PROTEIN[GENE]/B_LOCATION
1B I_PROTEIN[GENE]/I_LOCATION
and O
1E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Our O
examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O
that O
, O
in O
unmated B_SPECIES[BIO]/B_PERSON
reproductive I_SPECIES[BIO]/I_PERSON
tracts I_SPECIES[BIO]/I_PERSON
, O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lumen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O
an O
irregular B_DISEASE/B_LOCATION
shape B_DISEASE/I_LOCATION
, O
while O
the O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lumen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appears O
straight O
. O

Moreover O
, O
in O
all O
the O
unmated B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
reproductive B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
tracts B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
sectioned O
, O
we O
detected O
patches B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
darkly O
stained O
material B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
lumen B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
mated B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
reproductive B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
tract B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O
the O
lumen B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
defined O
as O
the O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
oviduct B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
upper B_LOCATION/B_MEASURE
part I_LOCATION/I_MEASURE
of O
the O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
has O
an O
irregular B_DISEASE/B_LOCATION
shape B_DISEASE/I_LOCATION
, O
and O
the O
lumen B_LOCATION/B_PERSON
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
defined O
as O
the O
lower B_LOCATION/B_MEASURE
part I_LOCATION/I_MEASURE
of O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
appears O
straight O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
lumen B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appears O
wider O
in O
mated O
than O
unmated B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
reproductive I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tracts I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
figure B_PROTEIN[GENE]
1c I_PROTEIN[GENE]
and O
1F B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Interestingly O
, O
darkly O
stained B_COLOR/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
material I_COLOR/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
detected O
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lumen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
mated B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
females I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
appears O
to O
be O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
description B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
made O
by O
Mahowald B_PERSON
et I_PERSON
al I_PERSON
. O

[ O
25 B_PERSON/B_LOCATION
] I_PERSON/I_LOCATION
, O
who O
reported O
that O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lumen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
unmated B_SPECIES[BIO]
females I_SPECIES[BIO]
is O
nearly O
filled O
with O
an O
intima B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
like B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
matrix I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
that O
this O
matrix B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
reduced O
after O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Because O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON/B_BIO
mated I_PERSON/I_BIO
females I_PERSON/I_BIO
lay O
eggs B_BIO/B_PERSON
, O
it O
is O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whether O
the O
lack B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
of O
lumenal B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
material I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O
increase O
in O
lumen B_MEASURE
size I_MEASURE
in O
mated B_PERSON/B_BIO
females I_PERSON/I_BIO
occurred O
before O
or O
after O
the O
passage B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
eggs B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
suggest O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
directly O
or O
indirectly O
induces O
morphological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
that O
facilitate O
egg B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
passage B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
through O
the O
duct B_BODY_PART_OR_ORGAN_COMPONENT
. O

taken O
together O
, O
our O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lead O
us O
to O
propose O
that O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lumen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
closed O
and O
/ O
or O
obstructed O
in O
the O
unmated B_SPECIES[BIO]/B_PERSON
reproductive I_SPECIES[BIO]/I_PERSON
tract I_SPECIES[BIO]/I_PERSON
, O
and O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
epithelia B_BODY_PART_OR_ORGAN_COMPONENT
and O
/ O
or O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
that O
' O
open B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lumen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
junctions B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
oviduct B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
is O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

To O
determine O
whether O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
specific B_DISEASE_ADJECTIVE[DISEASE]
morphological I_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
oviduct B_DISEASE/B_PERSON
epithelia I_DISEASE/I_PERSON
post I_DISEASE/I_PERSON
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
we O
next O
examined O
the O
ultrastructure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
unmated B_PERSON/B_BIO
and O
mated O
reproductive B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Since O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
demonstrates O
that O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
associated O
with O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
junctions B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
such B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
as O
alpha B_PROTEIN[GENE]
- O
and O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Spectrin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
Spec B_MEASURE
) O
, O
Cora B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
Nrg B_GENE/B_BACTERIUM[BIO]
[ O
23 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
increase O
post B_DISEASE/B_MEASURE
- O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
first O
determined O
the O
status B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
junctions B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
unmated B_SPECIES[BIO]
females I_SPECIES[BIO]
, O
and O
whether O
these O
junctions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
change O
post B_DISEASE/B_MEASURE
- O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
Drosophila B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
most O
ectodermally O
derived O
epithelia B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
epidermis B_BODY_PART_OR_ORGAN_COMPONENT
and O
trachea B_BODY_PART_OR_ORGAN_COMPONENT
) O
, O
with O
a O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
exceptions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
are O
joined O
apically O
by O
a O
belt B_BODY_PART_OR_ORGAN_COMPONENT
- O
like B_LOCATION/B_MEASURE
adherens I_LOCATION/I_MEASURE
junction I_LOCATION/I_MEASURE
called O
the O
zonal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
adherens I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
junction I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
ZA B_LOCATION/B_PROTEIN[GENE]
) O
followed O
basally O
by O
a O
septate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
junction I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
SJ B_LOCATION
) O
[ O
26 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O
that O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
lined O
, O
along O
its O
entire B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
length I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
, O
by O
a O
monolayered B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
comprised O
of O
squamous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
type B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
region B_LOCATION/B_BIO
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
morphology B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
, O
all O
oviduct B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
examined O
, O
in O
both O
unmated B_PERSON/B_ORGANISM_FUNCTION
and O
mated B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
females I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
are O
joined O
along O
their O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
membranes B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
by O
an O
extensive B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
SJ I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
lack O
an O
apical B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ZA B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
figure B_MEASURE
2 I_MEASURE
) O
. O

SJs B_LOCATION/B_PERSON
and O
ZAs B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
form O
complete B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
belts I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
surround O
the O
epithelial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
thus O
making O
these O
junctions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
easily O
visible B_DISEASE_ADJECTIVE[DISEASE]
in O
transverse B_MEASURE/B_LOCATION
sections B_MEASURE/I_LOCATION
through O
the O
epithelium B_BODY_PART_OR_ORGAN_COMPONENT
. O

Because O
ZAs B_DISEASE/B_PERSON
were O
not O
detected O
in O
our O
transverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sections I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
through O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
this O
implies O
that O
ZAs B_PERSON
never O
formed O
, O
or O
developed O
earlier O
and O
were O
lost O
( O
Figure B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
2D I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Interestingly O
, O
we O
did O
not O
detect O
any O
ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
SJs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
at O
6 B_MEASURE
h O
post B_DISEASE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
but O
we O
did O
uncover O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
SJ B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ultrastructure B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
regions B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Based O
on O
their O
ultrastructure B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
two B_LOCATION/B_MEASURE
types I_LOCATION/I_MEASURE
of O
SJs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O
smooth B_BODY_PART_OR_ORGAN_COMPONENT
and O
pleated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
can O
be O
distinguished O
in O
Drosophila B_SPECIES[BIO]/B_MEASURE
[ I_SPECIES[BIO]/I_MEASURE
26 I_SPECIES[BIO]/I_MEASURE
] I_SPECIES[BIO]/I_MEASURE
. O

smooth B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
SJs I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
distinguished O
by O
the O
lack B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
visible B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
septae B_DISEASE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
the O
appearance B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
electron B_LOCATION/B_BIO
dense I_LOCATION/I_BIO
material I_LOCATION/I_BIO
in O
the O
intercellular B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
space I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
while O
pleated B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
SJs B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
distinguished O
by O
the O
ladder B_LOCATION/B_PRODUCT[OBJECT]
- O
like B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
appearance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
septae B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
. O

In O
the O
lateral B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
oviducts I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
septa B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
were O
not O
detected O
in O
the O
SJ B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
thus O
these O
SJs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
represent O
smooth B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
SJs I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
or O
an O
immature B_MEASURE/B_DISEASE
stage I_MEASURE/I_DISEASE
of O
pleated B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SJ I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
figure B_PROTEIN[GENE]/B_LOCATION
2A I_PROTEIN[GENE]/I_LOCATION
, O
2A B_PROTEIN[GENE]/B_DISEASE
' O
, O
2A B_PROTEIN[GENE]/B_DISEASE
' O
) O
. O

In O
contrast B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
ladder B_LOCATION/B_PRODUCT[OBJECT]
- O
like B_LOCATION
arrangement I_LOCATION
of O
septae B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
was O
often O
visible B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
SJs B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
lower B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
common I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
oviduct I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
Figure B_MEASURE/B_PROTEIN[GENE]
2C I_MEASURE/I_PROTEIN[GENE]
' O
) O
, O
thus O
these O
SJs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
can O
be O
classified O
as O
pleated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Unlike O
the O
smooth B_BODY_PART_OR_ORGAN_COMPONENT
- O
like B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
SJs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
pleated B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
SJs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
followed O
basally O
by O
spot B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
type B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
adherens B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
junction B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
spot B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AJs I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
Figure B_TIME[MEASURE]/B_LOCATION
2B I_TIME[MEASURE]/I_LOCATION
, O
2B B_MEASURE/B_LOCATION
' O
; O
additional B_MEASURE/B_LOCATION
file B_MEASURE/I_LOCATION
1 B_MEASURE/I_LOCATION
) O
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
determine O
if O
the O
SJs B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
upper B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
and O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
represent O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
the O
initial B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SJs B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
as O
well O
as O
spot B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
AJs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
the O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
oviduct I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
are O
mating O
- O
independent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O

This O
raises O
an O
interesting B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
question I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Why O
are O
SJ B_PERSON/B_LOCATION
proteins I_PERSON/I_LOCATION
such I_PERSON/I_LOCATION
as O
Cora B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
Nrg B_PERSON/B_LOCATION
up O
- O
regulated O
post B_DISEASE/B_MEASURE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
if O
SJs B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
are O
formed O
prior B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
increased O
expression B_GENE/B_MEASURE
of O
SJ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
associated O
with O
functional B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
polarized B_DISEASE/B_LOCATION
secretion I_DISEASE/I_LOCATION
post I_DISEASE/I_LOCATION
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
shown O
that O
SJs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
play O
an O
unexpected B_DISEASE_ADJECTIVE[DISEASE]
role I_DISEASE_ADJECTIVE[DISEASE]
in O
regulating O
the O
apical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
specialized B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extracellular B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecules B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
trachea B_BODY_PART_OR_ORGAN_COMPONENT
[ O
27 B_MEASURE
, O
28 B_MEASURE
] I_MEASURE
, O
and O
that O
these O
molecules B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
important B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
regulators I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O
lumen B_MEASURE/B_ORGANISM_FUNCTION
size B_MEASURE/I_ORGANISM_FUNCTION
. O

mating B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
modulates I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
apical O
secretory B_ORGANISM_FUNCTION
activity I_ORGANISM_FUNCTION
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Given O
the O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
extensive B_DISEASE/B_GENE
SJs B_DISEASE/I_GENE
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SJs B_PERSON/B_DISEASE
in O
regulating O
apical B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
secretion I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
of O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
matrix I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
e B_PROTEIN[GENE]/B_DISEASE
. O
g B_GENE/B_MEASURE
. O
trachea B_BODY_PART_OR_ORGAN_COMPONENT
) O
, O
we O
asked O
if O
mating B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
modulates B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
apical B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O
that O
different B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
regions I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
display I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
different I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
apical I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
morphology I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
i O
. O
e B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
microvilli I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O
pleats B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
see O
figures B_MEASURE/B_PERSON
2 I_MEASURE/I_PERSON
and O
additional B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
2A B_TIME[MEASURE]/B_LOCATION
) O
, O
but O
all O
epithelia B_LOCATION
are O
covered O
by O
an O
electron B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dense I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
apical I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
extracellular I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
matrix I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
AECM B_DISEASE/B_PROTEIN[GENE]
) O
and O
a O
thin B_MEASURE/B_LOCATION
layer I_MEASURE/I_LOCATION
of O
cuticle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
found O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
ultrastructural B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
AECM B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
cuticle B_LOCATION
in O
both O
the O
upper B_LOCATION/B_MEASURE
and O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
oviduct B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

In O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
unmated B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
female B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
AECM B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
varies O
in O
thickness B_MEASURE/B_LOCATION
along O
the O
apical B_BODY_PART_OR_ORGAN_COMPONENT
surface I_BODY_PART_OR_ORGAN_COMPONENT
( O
figure B_PROTEIN[GENE]/B_LOCATION
3A I_PROTEIN[GENE]/I_LOCATION
) O
. O

Some O
areas B_LOCATION
have O
little B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
AECM I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
while O
other B_MEASURE/B_PERSON
areas B_MEASURE/I_PERSON
are O
covered O
by O
a O
distinct B_MEASURE/B_LOCATION
layer B_MEASURE/I_LOCATION
of O
AECM B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
~ B_MEASURE
1 I_MEASURE
- O
2 B_MEASURE
Mu I_MEASURE
m I_MEASURE
in O
thickness B_MEASURE/B_LOCATION
; O
Figure B_MEASURE/B_LOCATION
3B I_MEASURE/I_LOCATION
) O
. O

However O
, O
the O
AECM B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
mated B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
females I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
is O
more O
evenly O
distributed O
along O
the O
apical B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
surface I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
( O
~ B_TIME[MEASURE]
2 I_TIME[MEASURE]
Mu I_TIME[MEASURE]
m I_TIME[MEASURE]
in O
thickness B_MEASURE/B_PERSON
; O
Figure B_MEASURE/B_PERSON
3E I_MEASURE/I_PERSON
) O
. O

Strikingly O
, O
the O
AECM B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
cuticle B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
mated B_BIO
females I_BIO
have O
a O
ruffled B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
appearance B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
suggesting O
that O
the O
AECM B_DISEASE/B_LOCATION
and O
cuticle B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
have O
increased O
in O
surface B_MEASURE/B_COLOR
area I_MEASURE/I_COLOR
( O
figure B_LOCATION
3F I_LOCATION
) O
. O

Electron B_LOCATION/B_NUMBER[MEASURE]
dense B_LOCATION/I_NUMBER[MEASURE]
granules I_BIO
up O
to O
~ B_MEASURE
1 I_MEASURE
. O
5 B_TIME[MEASURE]
Mu I_TIME[MEASURE]
m I_TIME[MEASURE]
in O
diameter B_MEASURE
were O
occasionally O
observed O
in O
both O
the O
AECM B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
cell B_LOCATION/B_ORGANIZATION
cytoplasm I_LOCATION/I_ORGANIZATION
( O
Figure B_LOCATION/B_BIO
3F I_LOCATION/I_BIO
) O
. O

Although O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
needed O
to O
determine O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
these O
granules B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
these O
granules B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
participate O
in O
the O
secretion B_ORGANISM_FUNCTION/B_MEASURE
and O
deposition B_DISEASE/B_ORGANISM_FUNCTION
of O
the O
AECM B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

taken O
together O
, O
our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
polarized O
secretion B_ORGANISM_FUNCTION/B_GENE
via O
the O
AECM B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
while O
ongoing O
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
unmated B_PERSON/B_BIO
female B_PERSON/I_BIO
is O
enhanced O
and O
/ O
or O
modulated B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
post I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Post B_LOCATION/B_DISEASE
- O
mating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
AECM B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ultrastructure B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
are O
also O
observed O
in O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
common I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

However O
, O
unlike O
the O
AECM B_DISEASE/B_LOCATION
of O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
, O
the O
AECM B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
well O
developed O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
unmated B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
female B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
AECM B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
consists O
of O
an O
amorphous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
electron I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
dense I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
material I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
is O
unevenly O
distributed O
, O
forming O
a O
thick B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
bulbous B_LOCATION
layer I_LOCATION
above O
the O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
some O
regions B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
( O
additional B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Matrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
like B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
material B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
is O
also O
observed O
in O
the O
lumen B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
but O
this O
material B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
is O
more O
electron B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dense I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
the O
AECM B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
( O
additional B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
2A B_PROTEIN[GENE]/B_DISEASE
) O
. O

In O
the O
mated O
female B_PERSON/B_LOCATION
, O
the O
AECM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
is O
flattened O
against O
the O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
is O
uniformly O
distributed O
along O
the O
apical B_BODY_PART_OR_ORGAN_COMPONENT
surface I_BODY_PART_OR_ORGAN_COMPONENT
( O
additional B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2B I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
2B B_PROTEIN[GENE]
) O
. O

Matrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
like B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
material I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
not O
observed O
in O
the O
center B_LOCATION
of O
the O
lumen B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
but O
small B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pools B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
very O
electron B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dense I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
material I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
detected O
in O
the O
spaces B_LOCATION/B_BIO
between O
the O
epithelial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
folds I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
additional B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2C I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
2C B_MEASURE/B_DISEASE
) O
. O

This O
may O
explain O
why O
lumenal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
matrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
not O
detected O
at O
the O
light B_MEASURE/B_LOCATION
microscopic B_MEASURE/I_LOCATION
level B_MEASURE/I_LOCATION
in O
the O
mated B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
female I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
see O
figure B_PROTEIN[GENE]
1E I_PROTEIN[GENE]
and O
1F B_PROTEIN[GENE]/B_LOCATION
) O
. O

taken O
together O
, O
our O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
site B_LOCATION/B_PERSON
of O
active B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
apical B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
both O
mated B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
unmated B_PERSON
females I_PERSON
, O
and O
that O
matrix B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
particularly O
in O
the O
lumen B_BODY_PART_OR_ORGAN_COMPONENT
, O
is O
reduced O
post B_DISEASE/B_MEASURE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
raise O
the O
intriguing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibility I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
AECM B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
lumenal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
plug B_PRODUCT[OBJECT]/B_LOCATION
in O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
the O
breakdown B_DISEASE/B_ORGANISM_FUNCTION
of O
this O
plug B_PRODUCT[OBJECT]/B_LOCATION
. O

mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
hemi B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
adherens B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
junctions B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
upper B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
modulating O
secretion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
the O
apical B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
, O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
at O
the O
basolateral B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
. O

In O
many B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
steps B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
the O
development B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
layer B_LOCATION/B_MEASURE
of O
extracellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matrix B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ECM B_PROTEIN[GENE]/B_LOCATION
) O
called O
the O
basal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lamina I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
covers O
the O
apical B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
/ O
or O
basal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membranes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
concomitant B_LOCATION/B_ORGANIZATION
development I_LOCATION/I_ORGANIZATION
of O
hemi B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
adherens B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
junctions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
HAJs B_LOCATION/B_ORGANIZATION
) O
. O

HAJs B_PERSON/B_ORGANIZATION
connect O
the O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeleton I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
ECM B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
are O
formed O
at O
virtually O
all O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
surfaces B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O
contact O
an O
ECM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

HAJs B_PERSON/B_ORGANIZATION
can O
be O
distinguished O
at O
the O
ultrastructural B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
level I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
as O
a O
patch B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
like B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
, O
electron B_LOCATION/B_MEASURE
dense I_LOCATION/I_MEASURE
undercoat I_LOCATION/I_MEASURE
of O
the O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
opposes O
the O
basal B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lamina I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
[ B_MEASURE/B_LOCATION
26 I_MEASURE/I_LOCATION
] I_MEASURE/I_LOCATION
; O
Figure B_MEASURE/B_PERSON
3G I_MEASURE/I_PERSON
, O
3H B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
the O
Drosophila B_SPECIES[BIO]/B_PERSON
embryo O
, O
the O
HAJs O
and O
basal O
lamina O
are O
formed O
at O
the O
same O
time O
[ O
26 O
] O
. O

Because O
the O
basal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
lamina B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
is O
established O
at O
a O
time B_TIME[MEASURE]/B_LOCATION
when O
the O
majority B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
matrix I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
actively O
secreted O
[ B_TIME[MEASURE]/B_LOCATION
26 I_TIME[MEASURE]/I_LOCATION
, O
29 B_MEASURE
] I_MEASURE
, O
this O
suggests O
that O
the O
formation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
HAJs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
tightly O
coordinated O
with O
the O
secretion B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_ORGANIZATION
of O
the O
ECM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
the O
most O
striking B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mating O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
the O
appearance B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
numerous B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
HAJs B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
along O
the O
basolateral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_MEASURE/B_PROTEIN[GENE]
3 B_MEASURE/I_PROTEIN[GENE]
) O
. O

The O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HAJs B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
particularly O
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
underscored O
by O
the O
extensive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
infolding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
basolateral B_BODY_PART_OR_ORGAN_COMPONENT
membrane I_BODY_PART_OR_ORGAN_COMPONENT
that O
is O
observed O
in O
both O
unmated B_PERSON
and O
mated O
females B_PERSON/B_BIO
( O
figure B_PROTEIN[GENE]
3A I_PROTEIN[GENE]
and O
3E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
infolded B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gives O
rise B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
highly O
branched O
intercellular B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
space I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
that O
is O
filled O
with O
an O
ECM B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O
figure B_PROTEIN[GENE]/B_LOCATION
3C I_PROTEIN[GENE]/I_LOCATION
and O
3G B_PROTEIN[GENE]/B_LOCATION
) O
. O

This O
ECM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
is O
contiguous B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
with O
the O
basal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lamina I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
surrounds O
the O
epithelia B_BODY_PART_OR_ORGAN_COMPONENT
. O

Few B_NUMBER[MEASURE]/B_PERSON
HAJs B_NUMBER[MEASURE]/I_PERSON
were O
observed O
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
unmated B_PERSON/B_SPECIES[BIO]
female B_PERSON/I_SPECIES[BIO]
, O
and O
these O
were O
largely O
restricted O
to O
the O
basal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
not O
observed O
along O
the O
basolateral B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infolding I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
figure B_PROTEIN[GENE]/B_LOCATION
3C I_PROTEIN[GENE]/I_LOCATION
) O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
numerous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
HAJs I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
appear O
along O
the O
basolateral B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
infolding O
post B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
mating B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
region B_LOCATION/B_MEASURE
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
Figure B_MEASURE/B_PROTEIN[GENE]
3F I_MEASURE/I_PROTEIN[GENE]
- O
3H B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
intercellular B_MEASURE/B_GENE
space I_MEASURE/I_GENE
appears O
wider B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O
figure B_PROTEIN[GENE]/B_LOCATION
3C I_PROTEIN[GENE]/I_LOCATION
- O
3D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
3G B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
, O
suggesting O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
increased O
secretion B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_GENE
and O
/ O
or O
deposition B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
the O
ECM B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
compartment B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
brings O
the O
ECM B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
a O
threshold B_MEASURE/B_LOCATION
concentration B_MEASURE/I_LOCATION
that O
can O
support O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HAJs B_DISEASE/B_ORGANISM_FUNCTION
. O

HAJs B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
were O
also O
detected O
along O
the O
basal B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
they O
were O
not O
detected O
along O
the O
apical B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
even O
though O
this O
membrane B_LOCATION/B_GENE
was O
covered O
by O
an O
ECM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Interestingly O
, O
while O
the O
basolateral B_BODY_PART_OR_ORGAN_COMPONENT
membrane I_BODY_PART_OR_ORGAN_COMPONENT
forms O
very O
shallow B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
folds I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
see O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
file I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
) O
, O
HAJs B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
were O
observed O
along O
this O
membrane B_LOCATION/B_MEASURE
in O
unmated B_MEASURE
reproductive I_MEASURE
tracts I_MEASURE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
, O
thus O
suggesting O
that O
the O
epithelia B_BODY_PART_OR_ORGAN_COMPONENT
is O
more O
differentiated O
in O
this O
region B_LOCATION/B_MEASURE
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
the O
differentiation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
of O
the O
upper B_LOCATION/B_MEASURE
and O
lower B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
under O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

Muscle B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
enhanced O
post B_LOCATION/B_MEASURE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

While O
we O
uncovered O
post B_LOCATION/B_DISEASE
- O
mating O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
oviduct B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
epithelia I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
that O
might O
facilitate O
its O
transition B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
to O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
egg B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
- O
laying O
state B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
this O
transition B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
also O
be O
mediated O
by O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
oviduct B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
muscle B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
properties B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
/ O
or O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
lined O
by O
circular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
fibers I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
with O
supercontractile B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
30 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Our O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
mef2 B_GENE
and O
mlp84B B_GENE/B_BIO
genes I_GENE/I_BIO
that O
regulate O
muscle B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
, O
are O
expressed O
and O
increased O
post B_LOCATION/B_DISEASE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
as O
well O
as O
in O
the O
sperm B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
storage I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
reproductive B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
[ O
22 B_MEASURE
, O
23 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

This O
suggests O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
muscle B_DISEASE/B_ORGANISM_FUNCTION
differentiation I_DISEASE/I_ORGANISM_FUNCTION
in O
the O
reproductive B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

Muscle B_DISEASE/B_LOCATION
differentiation I_DISEASE/I_LOCATION
is O
characterized O
by O
the O
assembly B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
myofilaments B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
into O
bundles B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
called O
myofibrils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O

As O
muscles B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiate O
, O
myofibrils B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
z B_MEASURE/B_PROTEIN[GENE]
- O
bodies B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
appear O
simultaneously O
, O
and O
increase O
in O
number B_MEASURE
until O
the O
cytoplasm B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
is O
filled O
with O
myofibrils B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
[ O
31 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Like O
epithelia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
, O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
steps I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O
muscle B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
is O
the O
secretion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
a O
basal B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lamina I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
surrounds O
the O
muscle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
fiber I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
determine O
if O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O
structural B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
increased O
myofibrils B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O
we O
examined O
the O
ultrastructure B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fibers I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O
lower B_LOCATION/B_MEASURE
parts I_LOCATION/I_MEASURE
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
that O
, O
in O
both O
unmated B_PERSON/B_ORGANISM_FUNCTION
and O
mated O
reproductive B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
are O
highly O
differentiated O
as O
evidenced O
by O
the O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
density I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
myofibrils B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
well O
developed O
and O
aligned O
z B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
bodies B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
secretion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
a O
thick B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
electron B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
dense B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
basal B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
lamina B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
( O
figure B_PROTEIN[GENE]
4E I_PROTEIN[GENE]
and O
4F B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fibers I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
lateral B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
oviducts I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appear O
less O
differentiated B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
evidenced O
by O
the O
lesser B_MEASURE/B_DISEASE
density I_MEASURE/I_DISEASE
of O
myofibrils B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
z B_MEASURE/B_PROTEIN[GENE]
- O
bodies B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
little B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
no O
basal B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lamina I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_PROTEIN[GENE]/B_MEASURE
4A I_PROTEIN[GENE]/I_MEASURE
and O
4B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Moreover O
, O
the O
muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appear O
more O
differentiated B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
mated B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
in O
unmated B_PERSON/B_BIO
reproductive I_PERSON/I_BIO
tracts I_PERSON/I_BIO
( O
figure B_PROTEIN[GENE]
4A I_PROTEIN[GENE]
- O
4D B_NUMBER[MEASURE]/B_LOCATION
) O
. O

Interestingly O
, O
we O
observed O
neighboring B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscle B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibers B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
different B_LOCATION/B_MEASURE
states I_LOCATION/I_MEASURE
of O
differentiation B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
both O
unmated B_PERSON/B_BIO
and O
mated O
reproductive B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
elsewhere O
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
4B I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enhances O
the O
rate B_MEASURE
of O
muscle B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
upper B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
muscle B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
is O
delayed O
in O
the O
upper B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
as O
compared O
to O
the O
lower B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
increased O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
the O
upper B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
is O
not O
dramatic B_DISEASE_ADJECTIVE[DISEASE]
and O
likely O
reflects O
the O
short B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mating B_TIME[MEASURE]
period I_TIME[MEASURE]
examined O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
delayed O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
resembles O
the O
delay B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
onset B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
development B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O
the O
adult B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
thoracic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
abdominal B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
during O
metamorphosis B_ORGANISM_FUNCTION/B_TIME[MEASURE]
[ I_ORGANISM_FUNCTION/I_TIME[MEASURE]
32 I_ORGANISM_FUNCTION/I_TIME[MEASURE]
] I_ORGANISM_FUNCTION/I_TIME[MEASURE]
. O

Since O
the O
ovaries B_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
parts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
reproductive B_BODY_PART_OR_ORGAN_COMPONENT
tract I_BODY_PART_OR_ORGAN_COMPONENT
are O
known O
to O
have O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
segmental B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
origins B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
33 B_ORGANISM_FUNCTION/B_BIO
] I_ORGANISM_FUNCTION/I_BIO
, O
we O
hypothesize O
that O
different B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
parts I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
develop O
at O
different B_TIME[MEASURE]/B_LOCATION
rates I_TIME[MEASURE]/I_LOCATION
or O
begin O
development B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
different B_TIME[MEASURE]/B_ENT
times I_TIME[MEASURE]/I_ENT
. O

increased O
innervation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
the O
oviduct B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Nerve B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
- O
muscle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
interactions I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
play O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
regulating O
adult B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
muscle B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
refining O
the O
final B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
innervation B_DISEASE/B_ORGANISM_FUNCTION
[ B_DISEASE/I_ORGANISM_FUNCTION
34 B_DISEASE/I_ORGANISM_FUNCTION
, O
35 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Given O
that O
oviduct B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
muscle B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
enhanced O
post B_LOCATION/B_MEASURE
- O
mating B_ORGANISM_FUNCTION/B_BIO
, O
we O
predicted O
that O
mating O
either O
directly O
or O
indirectly O
induces O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
innervation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O

To O
address O
this O
prediction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
quantified O
the O
number B_MEASURE
of O
nerve B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
terminals I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
or O
boutons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
innervating O
the O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
oviducts I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
unmated B_PERSON/B_BIO
and O
mated B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
reproductive I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
tracts I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

Studies O
of O
oviduct O
innervation O
in O
Drosophila O
reveal O
that O
the O
fly B_SPECIES[BIO]/B_PERSON
' O
s O
oviduct O
receives O
aminergic O
, O
peptidergic O
and O
glutamatergic O
input O
[ O
30 O
, O
36 O
- O
39 O
] O
. O

In O
both O
larval B_PERSON/B_BIO
and O
adult B_PERSON/B_BIO
Drosophila I_PERSON/I_BIO
, O
different B_LOCATION/B_MEASURE
types I_LOCATION/I_MEASURE
of O
boutons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
formed O
by O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
express O
different B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neurotransmitters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
modulators B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O
40 B_MEASURE
- O
42 B_MEASURE
] I_MEASURE
. O

By O
similarity B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
boutons B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
described O
at O
the O
larval B_PERSON
and O
adult B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
neuromuscular I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
junction I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
Middleton B_LOCATION/B_GENE
et B_LOCATION/I_GENE
al B_LOCATION/I_GENE
. O

[ O
30 O
] O
report O
that O
the O
fly B_SPECIES[BIO]
' O
s O
oviduct O
is O
innervated O
by O
glutamatergic O
type O
I O
boutons O
and O
tyraminergic O
/ O
octopaminergic O
type O
II O
boutons O
. O

Rodgriguez B_PERSON
- O
Valentin B_PERSON/B_LOCATION
et B_PERSON/I_LOCATION
al B_PERSON/I_LOCATION
. O

[ O
43 O
] O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
oviduct B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
express B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
octopamine I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O
give O
rise B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
type B_MEASURE/B_DISEASE
I O
innervation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O
not O
been O
identified O
. O

However O
, O
it O
is O
well O
established O
that O
type B_DISEASE
II I_DISEASE
innervation I_DISEASE
arises O
from O
octopaminergic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
located O
in O
the O
abdominal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglion I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O
30 B_MEASURE
, O
43 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
it O
has O
been O
shown O
that O
some O
or O
all O
of O
these O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
express O
a O
GAL4 B_GENE/B_MEASURE
insertion I_GENE/I_MEASURE
line I_GENE/I_MEASURE
for O
the O
bullwinkle B_SPECIES[BIO]/B_GENE
( O
bwk B_PROTEIN[GENE]/B_DISEASE
) O
gene B_GENE
[ O
43 B_TIME[MEASURE]
] O
. O

Bwk B_GENE/B_DISEASE
encodes O
a O
HMG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
box B_LOCATION/B_MEASURE
containing O
putative B_ENZYME[GENE]/B_LOCATION
transcription I_ENZYME[GENE]/I_LOCATION
factor I_ENZYME[GENE]/I_LOCATION
[ O
44 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

To O
determine O
if O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
any O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
number B_MEASURE/B_LOCATION
of O
type B_DISEASE/B_MEASURE
I O
and O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
innervating O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
used O
the O
pan B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
neural B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marker B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
anti B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
HRP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
label O
all O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
unmated B_PERSON
and O
mated B_PERSON
females I_PERSON
. O

To O
distinguish O
between O
type B_MEASURE/B_PERSON
I O
and O
II B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons O
we O
used O
an O
antibody B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
the O
Disc B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Large I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DLG B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
[ O
45 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

Type B_MEASURE/B_PERSON
I O
boutons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
identified O
by O
their O
DLG B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
postsynaptic I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
staining I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
large B_MEASURE/B_LOCATION
size I_MEASURE/I_LOCATION
( O
> B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
8 B_MEASURE
Mu I_MEASURE
m I_MEASURE
in O
diameter B_MEASURE/B_BIO
) O
( O
figure B_PROTEIN[GENE]
4G I_PROTEIN[GENE]
) O
, O
while O
type B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
boutons I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
distinguished O
by O
their O
absence B_MEASURE/B_DISEASE
of O
DLG B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
smaller B_MEASURE
size I_MEASURE
( O
< B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
Mu I_MEASURE/I_LOCATION
m I_MEASURE/I_LOCATION
) O
( O
figure B_MEASURE
4H I_MEASURE
) O
. O

We O
find O
that O
type B_MEASURE/B_DISEASE
I O
and O
II B_TIME[MEASURE]/B_PROTEIN[GENE]
boutons I_TIME[MEASURE]/I_PROTEIN[GENE]
innervate O
the O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
oviducts I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
the O
type B_MEASURE/B_LOCATION
I O
innervation O
is O
restricted O
to O
a O
few B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
run O
parallel O
to O
the O
length B_MEASURE/B_LOCATION
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
while O
the O
type B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
II I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
innervation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
is O
more O
widespread B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

We O
quantified O
the O
number B_MEASURE/B_LOCATION
of O
boutons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
oviducts I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
and O
observed O
a O
74 B_MEASURE
% I_MEASURE
increase I_MEASURE
in O
bouton B_MEASURE/B_ORGANISM_FUNCTION
number I_MEASURE/I_ORGANISM_FUNCTION
in O
the O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
oviduct B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
a O
66 B_MEASURE
% I_MEASURE
increase I_MEASURE
in O
the O
common B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O
Figure B_MEASURE/B_PROTEIN[GENE]
4I I_MEASURE/I_PROTEIN[GENE]
) O
. O

More B_NUMBER[MEASURE]
over O
, O
we O
observed O
no O
significant B_MEASURE
change I_MEASURE
in O
the O
number B_MEASURE/B_LOCATION
of O
type B_MEASURE/B_DISEASE
I O
boutons O
in O
the O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
oviduct B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
we O
detected O
a O
1 B_MEASURE
. O
5 B_MEASURE
- O
fold B_MEASURE
increase I_MEASURE
in O
the O
number B_MEASURE
of O
type B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
II I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
boutons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
1 B_MEASURE
. O
8 B_MEASURE
- O
fold B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
type B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
innervation I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

dramatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
increases B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
bouton B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
growth B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
also O
observed O
during O
development B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
a O
ten B_NUMBER[MEASURE]
- O
fold B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
bouton B_MEASURE
number I_MEASURE
is O
observed O
at O
the O
neuromuscular B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
junction I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
during O
the O
larval B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
period I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
46 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

To O
determine O
if O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
type B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
innervation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
mating B_PERSON/B_ORGANISM_FUNCTION
or O
reflected O
normal B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
3 B_TIME[MEASURE]
day I_TIME[MEASURE]
- O
old B_PERSON/B_TIME[MEASURE]
females B_PERSON/I_TIME[MEASURE]
, O
we O
quantified O
type B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
I O
and O
II B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
innervation I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
5 B_TIME[MEASURE]
day I_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
females I_PERSON
. O

We O
found O
no O
significant B_MEASURE
difference I_MEASURE
in O
type B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
I O
and O
II B_MEASURE/B_PROTEIN[GENE]
innervation I_MEASURE/I_PROTEIN[GENE]
in O
unmated B_TIME[MEASURE]/B_ENT
3 I_TIME[MEASURE]/I_ENT
day I_TIME[MEASURE]/I_ENT
- O
old B_TIME[MEASURE]/B_PERSON
and O
5 B_MEASURE
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
, O
indicating O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
, O
either O
directly O
or O
indirectly O
, O
induces O
a O
dramatic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
II B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
innervation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
Figure B_LOCATION/B_PROTEIN[GENE]
4I I_LOCATION/I_PROTEIN[GENE]
) O
. O

To O
determine O
if O
the O
post B_LOCATION/B_DISEASE
- O
mating B_MEASURE
increase I_MEASURE
in O
innervation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
unique B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
we O
asked O
if O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
induces O
a O
global B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
change B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
innervation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
quantified O
bouton B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
number B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
adult B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
ventral I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
midline I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
muscles I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
5th B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
abdominal I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
segment I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
muscles B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
innervated O
by O
boutons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
increase O
in O
number B_MEASURE
during O
metamorphosis B_DISEASE/B_ORGANISM_FUNCTION
[ I_DISEASE/I_ORGANISM_FUNCTION
47 I_DISEASE/I_ORGANISM_FUNCTION
] I_DISEASE/I_ORGANISM_FUNCTION
. O

No O
significant B_MEASURE
difference I_MEASURE
in O
bouton B_MEASURE
number I_MEASURE
was O
detected O
at O
these O
muscles B_TIME[MEASURE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
unmated B_PERSON
and O
mated O
females B_PERSON/B_BIO
( O
additional B_MEASURE
file I_MEASURE
3 I_MEASURE
) O
. O

Though O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
needed O
, O
this O
suggests O
that O
the O
post B_LOCATION/B_DISEASE
- O
mating B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
increase B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
innervation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
oviduct B_BIO/B_PERSON
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Because O
the O
type B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
II I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
boutons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
octopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
increased O
type B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
innervation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
result O
in O
increased O
octopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
OA B_PROTEIN[GENE]/B_DISEASE
) O
release B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
support B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
have O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
OA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
released O
in O
the O
oviduct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
post B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O
Heifetz B_PERSON
and O
Wolfner B_PERSON
, O
in O
preparation B_MEASURE
) O
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
locust B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Drosophila B_SPECIES[BIO]
demonstrate O
that O
OA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibits O
oviduct B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
contraction B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
while O
glutamate B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct O
contraction B_DISEASE/B_ORGANISM_FUNCTION
[ O
30 B_MEASURE
, O
43 B_MEASURE
, O
48 B_MEASURE
] I_MEASURE
. O

In O
Drosophila B_SPECIES[BIO]
, O
electrical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
abdominal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
nerve I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
gives O
rise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
a O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
muscle B_DISEASE_ADJECTIVE[DISEASE]
contractions I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
followed O
by O
a O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
muscle B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fatigue I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
relaxation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O
43 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

This O
pattern B_MEASURE/B_DISEASE
of O
muscle B_DISEASE/B_ORGANISM_FUNCTION
contraction I_DISEASE/I_ORGANISM_FUNCTION
and O
relaxation B_DISEASE/B_ORGANISM_FUNCTION
may O
facilitate O
the O
proper B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
movement I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
egg B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
their O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
bwk B_GENE/B_DISEASE
expressing O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O
innervate O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
Rodriguez B_PERSON
- O
Valentin B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
. O

[ O
43 O
] O
show O
that O
OA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
glutamate O
interact B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
produce O
the O
pattern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
oviduct B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contraction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
relaxation B_DISEASE/B_ORGANISM_FUNCTION
described O
above O
. O

It O
is O
therefore O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
post B_DISEASE/B_MEASURE
- O
mating B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
innervation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
plays O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
increased O
rate B_MEASURE
of O
ovulation B_ORGANISM_FUNCTION/B_BODY_PART_OR_ORGAN_COMPONENT
and O
egg B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
laying B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
observed O
post B_LOCATION/B_DISEASE
- O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Female B_DISEASE/B_TIME[MEASURE]
mating I_DISEASE/I_TIME[MEASURE]
history I_DISEASE/I_TIME[MEASURE]
affects O
the O
enrichment B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cytosekeletal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

To O
gain O
insights B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cytoskeletal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
enrichment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
[ O
23 B_MEASURE
] I_MEASURE
; O
additional B_MEASURE
file I_MEASURE
4 I_MEASURE
) O
in O
mediating O
the O
morphological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
we O
examined O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimes B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
cytoskeletal B_MEASURE/B_PERSON
protein B_MEASURE/I_PERSON
abundance B_MEASURE/I_PERSON
. O

We O
focused O
on O
a O
subset B_MEASURE/B_LOCATION
of O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
responsive B_GENE/B_MEASURE
cytoskeletal I_GENE/I_MEASURE
proteins I_GENE/I_MEASURE
with O
well O
established O
roles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O
the O
differentiation B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
of O
muscle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
epithelia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
include O
: O
( O
i B_DISEASE/B_PROTEIN[GENE]
) O
Mlp84B B_GENE/B_BACTERIUM[BIO]
which O
regulates O
the O
late B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
muscle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
49 B_MEASURE
] O
; O
( O
ii B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
Cora B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
Nrg B_GENE/B_PERSON
which O
are O
required O
for O
the O
formation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
septate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
junctions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
epithelia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
[ O
50 B_MEASURE
] I_MEASURE
, O
and O
( O
III B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
Hu B_PERSON/B_LOCATION
- O
li B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
Tai I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
shao I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Hts B_MEASURE/B_PROTEIN[GENE]
) O
, O
also O
known O
as O
adducin B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_PROTEIN[GENE]/B_MEASURE
protein B_PROTEIN[GENE]/I_MEASURE
, O
which O
functions O
in O
assembly B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
cytoskeletal B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
network I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Na B_GENE
+ I_GENE
pump I_GENE
alpha I_GENE
subunit I_GENE
( O
ATP B_PROTEIN[GENE]/B_LOCATION
alpha I_PROTEIN[GENE]/I_LOCATION
) O
, O
another O
protein B_ENZYME[GENE]/B_BACTERIUM[BIO]
associated O
with O
septate B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
junctions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O
epithelia B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
is O
not O
a O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
responsive B_GENE/B_PERSON
protein I_GENE/I_PERSON
and O
was O
used O
as O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Using O
western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blots I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
first O
determined O
the O
abundance B_MEASURE/B_LOCATION
of O
the O
cytoskeletal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_TIME[MEASURE]/B_PERSON
unmated I_TIME[MEASURE]/I_PERSON
and O
mated O
females B_PERSON/B_BIO
at O
6 B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

We O
confirmed O
the O
proteomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Kalpenikov B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al O
. O

[ O
23 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
found O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increases O
the O
abundance B_MEASURE/B_LOCATION
of O
all O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
except O
ATP B_GENE
alpha I_GENE
in O
mated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
oviducts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
relative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
their O
abundance B_MEASURE/B_LOCATION
in O
unmated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
oviducts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
Figure B_MEASURE/B_PERSON
5A I_MEASURE/I_PERSON
) O
. O

To O
determine O
whether O
the O
increased O
abundance B_MEASURE/B_LOCATION
of O
mating B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
responsive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
persists O
for O
longer B_TIME[MEASURE]/B_LOCATION
times I_TIME[MEASURE]/I_LOCATION
post I_TIME[MEASURE]/I_LOCATION
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
we O
examined O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
10 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
that O
mated O
once O
at O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
age B_ORGANISM_FUNCTION
, O
and O
calculated O
the O
abundance B_MEASURE
of O
the O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
- O
responsive B_GENE
proteins I_GENE
relative I_GENE
to O
their O
level B_MEASURE/B_LOCATION
in O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
3 B_MEASURE
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
females I_PERSON
. O

We O
found O
no O
change B_MEASURE
or O
a O
slight B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
relative B_MEASURE/B_LOCATION
abundance I_MEASURE/I_LOCATION
of O
all O
cytoskeletal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
except O
Mlp84B B_GENE/B_BACTERIUM[BIO]
at O
7 B_DISEASE/B_MEASURE
days I_DISEASE/I_MEASURE
post I_DISEASE/I_MEASURE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
Figure B_TIME[MEASURE]/B_PROTEIN[GENE]
5A I_TIME[MEASURE]/I_PROTEIN[GENE]
) O
. O

Strikingly O
, O
the O
level B_MEASURE/B_DISEASE
of O
Mlp84B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
declines B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
by O
7 B_TIME[MEASURE]/B_DISEASE
days B_TIME[MEASURE]/I_DISEASE
post B_TIME[MEASURE]/I_DISEASE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
to O
the O
level B_MEASURE/B_LOCATION
observed O
prior B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
Mlp84B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
levels I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
rise O
and O
fall O
after O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
the O
epithelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
- O
related O
proteins B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
rapidly O
rise O
and O
are O
maintained O
at O
a O
high B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
after O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
raises O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
a O
second B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mating I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
might O
trigger O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
Mlp84B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
expression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
observed O
in O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON/B_BIO
females I_PERSON/I_BIO
at O
6 B_MEASURE
h O
post B_DISEASE/B_MEASURE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

To O
test O
this O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
females B_PERSON/B_SPECIES[BIO]
were O
mated O
twice O
( O
once O
at O
day B_TIME[MEASURE]/B_ORGANISM_FUNCTION
3 I_TIME[MEASURE]/I_ORGANISM_FUNCTION
, O
and O
once O
on O
day B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
age B_TIME[MEASURE]/B_ORGANISM_FUNCTION
) O
, O
and O
their O
oviducts B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
were O
examined O
at O
6 B_TIME[MEASURE]/B_LOCATION
hrs I_TIME[MEASURE]/I_LOCATION
after O
the O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
mating I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

We O
calculated O
the O
abundance B_MEASURE/B_LOCATION
of O
the O
cytoskeletal B_GENE/B_BIO
proteins B_GENE/I_BIO
in O
the O
twice B_BODY_PART_OR_ORGAN_COMPONENT
mated I_BODY_PART_OR_ORGAN_COMPONENT
oviducts I_BODY_PART_OR_ORGAN_COMPONENT
relative I_BODY_PART_OR_ORGAN_COMPONENT
to O
their O
abundance B_MEASURE/B_LOCATION
in O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_TIME[MEASURE]
unmated I_TIME[MEASURE]
females I_TIME[MEASURE]
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
a O
second B_GENE
mating I_GENE
has O
little B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
Mlp84B B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
abundance B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Thus O
, O
Mlp84B B_GENE/B_PERSON
may O
represent O
a O
class B_PERSON/B_LOCATION
of O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
responsive B_GENE/B_MEASURE
proteins I_GENE/I_MEASURE
that O
is O
only O
needed O
after O
the O
first B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mating B_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Interestingly O
, O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
second B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
epithelial B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
- O
related O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
responsive B_PROTEIN[GENE]/B_LOCATION
proteins I_PROTEIN[GENE]/I_LOCATION
appears O
to O
be O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
each O
protein B_BIO/B_PERSON
. O

While O
Cora B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
drop O
to O
the O
level B_MEASURE/B_LOCATION
observed O
in O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
unmated I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
females I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
Nrg B_LOCATION/B_PROTEIN[GENE]
and O
Hts B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
are O
maintained O
at O
a O
high B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
. O

To O
determine O
if O
the O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cytoskeletal B_MEASURE/B_BIO
protein B_MEASURE/I_BIO
abundance B_MEASURE/I_BIO
are O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
we O
measured O
their O
abundance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
the O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
unmated B_NUMBER[MEASURE]
5 I_NUMBER[MEASURE]
- O
and O
10 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
. O

We O
calculated O
their O
abundance B_MEASURE
relative I_MEASURE
to O
their O
level B_MEASURE/B_LOCATION
in O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
of O
unmated B_NUMBER[MEASURE]
3 I_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_TIME[MEASURE]/B_PERSON
females I_TIME[MEASURE]/I_PERSON
( O
Figure B_TIME[MEASURE]/B_PERSON
5B I_TIME[MEASURE]/I_PERSON
) O
. O

We O
rationalized O
that O
if O
the O
change B_MEASURE
in O
cytoskeletal B_MEASURE/B_PERSON
protein B_MEASURE/I_PERSON
abundance B_MEASURE/I_PERSON
is O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
we O
will O
not O
see O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
unmated B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
females B_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
observed O
a O
slow B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
relative B_MEASURE/B_ENT
abundance I_MEASURE/I_ENT
of O
all O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
responsive B_GENE/B_PERSON
proteins I_GENE/I_PERSON
with O
time B_MEASURE/B_LOCATION
post B_MEASURE/I_LOCATION
- O
eclosion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Figure B_MEASURE/B_PROTEIN[GENE]
5B I_MEASURE/I_PROTEIN[GENE]
) O
. O

Because O
unmated B_PERSON/B_BIO
females I_PERSON/I_BIO
lay O
more B_MEASURE/B_LOCATION
eggs B_MEASURE/I_LOCATION
as O
they O
age O
( O
see O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
file I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
5C I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possible I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
increased O
level B_MEASURE/B_PERSON
of O
cytoskeletal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
unmated B_PERSON/B_BIO
females I_PERSON/I_BIO
is O
that O
these O
proteins B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
associated O
with O
an O
intrinsic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
oviduct B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
maturation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
and O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
accelerates O
this O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
maximize O
egg B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
laying O
efficacy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Alternatively O
, O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
slow B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
protein B_MEASURE/B_ORGANISM_FUNCTION
abundance I_MEASURE/I_ORGANISM_FUNCTION
observed O
in O
unmated B_PERSON/B_BIO
females B_PERSON/I_BIO
is O
due O
to O
the O
passage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
eggs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

taken O
together O
, O
our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
fine B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
- O
tune O
the O
levels B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
responsive B_GENE/B_MEASURE
proteins I_GENE/I_MEASURE
examined O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Because O
the O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cytoskeletal B_MEASURE/B_BIO
protein I_MEASURE/I_BIO
abundance I_MEASURE/I_BIO
are O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
unmated B_PERSON
and O
mated B_PERSON/B_DISEASE
females I_PERSON/I_DISEASE
, O
this O
suggests O
that O
the O
post B_DISEASE/B_LOCATION
- O
mating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
mating O
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
we O
suggest O
that O
these O
post B_LOCATION/B_DISEASE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
changes I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
are O
linked O
to O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
oviduct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

Early B_TIME[MEASURE]/B_PERSON
or O
prior B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
mating I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
increases I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
fecundity O
. O

In O
Drosophila B_SPECIES[BIO]/B_PERSON
, O
female B_DISEASE/B_GENE
fecundity I_DISEASE/I_GENE
decreases O
with O
age B_MEASURE/B_PERSON
[ O
51 B_MEASURE
- O
54 B_MEASURE
] I_MEASURE
. O

It O
has O
been O
proposed O
that O
this O
decrease B_DISEASE
is O
due B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
the O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
germline B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O
somatic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
55 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Since O
the O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
oviduct B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytoskeletal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
examined O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
change I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
age B_TIME[MEASURE]/B_ORGANISM_FUNCTION
and O
mating B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experience I_ORGANISM_FUNCTION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
state B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
may O
also O
play O
a O
role B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
fecundity B_ORGANISM_FUNCTION/B_DISEASE
. O

To O
separate O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
age B_ORGANISM_FUNCTION
and O
mating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
, O
we O
measured O
the O
fecundity B_MEASURE
of O
females B_PERSON/B_BIO
that O
mated O
twice O
, O
first O
at O
3 B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
eclosion B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
and O
again O
at O
10 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
and O
compared O
that O
to O
the O
fecundity B_MEASURE
of O
females B_PERSON
that O
mated O
once O
at O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
and O
females B_PERSON
that O
mated O
once O
at O
10 B_ENT/B_TIME[MEASURE]
days B_ENT/I_TIME[MEASURE]
. O

Fecundity B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
measured O
as O
the O
number B_MEASURE
of O
eggs B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laid O
per O
day B_TIME[MEASURE]/B_PERSON
per O
female B_PERSON
during O
the O
first B_TIME[MEASURE]/B_ENT
three I_TIME[MEASURE]/I_ENT
days I_TIME[MEASURE]/I_ENT
after O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Once O
- O
mated O
3 B_MEASURE
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
laid O
nearly O
twice O
as O
many B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
eggs I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
as O
once O
- O
mated O
10 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
during O
the O
three B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
examined O
( O
24 B_MEASURE
. O
5 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
. O
7 B_MEASURE
versus I_MEASURE
13 I_MEASURE
. O
3 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
, O
p O
< B_MEASURE
0 I_MEASURE
. O
0001 B_MEASURE
) O
. O

twice B_NUMBER[MEASURE]/B_PERSON
- O
mated O
10 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
also O
laid O
about O
50 B_MEASURE
% I_MEASURE
more I_MEASURE
eggs I_MEASURE
than O
once O
- O
mated O
females B_PERSON/B_BIO
of O
the O
same B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
age I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
19 B_MEASURE
. O
3 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
versus I_MEASURE
13 I_MEASURE
. O
3 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
, O
p O
< B_NUMBER[MEASURE]/B_LOCATION
0 I_NUMBER[MEASURE]/I_LOCATION
. O
0001 B_MEASURE
) O
, O
but O
about O
20 B_MEASURE
% I_MEASURE
fewer I_MEASURE
than O
laid O
by O
once O
- O
mated O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
during O
the O
three B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
examined O
( O
19 B_MEASURE
. O
3 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
. O
9 B_MEASURE
versus I_MEASURE
24 I_MEASURE
. O
5 B_MEASURE
+/- I_MEASURE
0 I_MEASURE
. O
7 B_MEASURE
, O
p O
< B_MEASURE
0 I_MEASURE
. O
0001 B_MEASURE
) O
( O
figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
6A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
see O
also O
additional B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
file I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5A I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5B B_MEASURE/B_LOCATION
) O
. O

Thus O
, O
the O
difference B_MEASURE
in O
fecundity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
between O
once O
- O
mated O
10 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_TIME[MEASURE]/B_PERSON
and O
once O
- O
mated O
3 B_MEASURE
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
is O
not O
a O
result B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
age B_TIME[MEASURE]/B_PERSON
alone O
. O

Rather O
the O
main B_MEASURE
determinant I_MEASURE
of O
fecundity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
10 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
is O
whether O
there O
had O
been O
a O
prior B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mating I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

We O
also O
calculated O
the O
fertility B_ORGANISM_FUNCTION/B_MEASURE
( O
number B_MEASURE/B_PERSON
of O
adults B_PERSON/B_LOCATION
eclosed O
) O
of O
once O
- O
and O
twice B_NUMBER[MEASURE]/B_LOCATION
- O
mated O
females B_PERSON/B_BIO
. O

Once O
- O
mated O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
are O
more O
fertile B_LOCATION/B_PERSON
than O
once O
- O
mated B_NUMBER[MEASURE]/B_PERSON
10 I_NUMBER[MEASURE]/I_PERSON
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
( O
69 B_MEASURE
. O
5 B_MEASURE
+/- I_MEASURE
1 I_MEASURE
. O
6 B_MEASURE
% I_MEASURE
versus I_MEASURE
56 I_MEASURE
. O
1 B_MEASURE
+/- I_MEASURE
3 I_MEASURE
. O
0 B_MEASURE
% I_MEASURE
, O
p O
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
and O
slightly O
more O
fertile B_LOCATION/B_PERSON
than O
twice O
- O
mated B_NUMBER[MEASURE]/B_PERSON
10 I_NUMBER[MEASURE]/I_PERSON
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
( O
69 B_MEASURE
. O
5 B_MEASURE
+/- I_MEASURE
1 I_MEASURE
. O
6 B_MEASURE
% I_MEASURE
versus I_MEASURE
62 I_MEASURE
. O
7 B_MEASURE
+/- I_MEASURE
2 I_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
p O
< O
0 B_MEASURE
. O
015 B_MEASURE
) O
( O
figure B_MEASURE/B_LOCATION
6B I_MEASURE/I_LOCATION
, O
see O
also O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
file B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
5D B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

Because O
there O
is O
no O
significant B_MEASURE
difference I_MEASURE
in O
fertility B_PERSON/B_ORGANISM_FUNCTION
between O
once O
- O
mated O
and O
twice O
- O
mated O
10 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
, O
this O
suggests O
that O
( O
1 B_TIME[MEASURE]
) O
a O
prior B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mating I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
has O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
fertility B_ORGANISM_FUNCTION
of O
10 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_TIME[MEASURE]/B_PERSON
mated O
females B_PERSON/B_BIO
and O
( O
2 B_NUMBER[MEASURE]
) O
fertility B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
age B_MEASURE/B_PERSON
. O

One B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intriguing B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
that O
an O
early B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fecundity I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
partially O
compensates O
for O
the O
age B_TIME[MEASURE]/B_PERSON
- O
related O
decrease B_DISEASE_ADJECTIVE[DISEASE]
in O
fertility B_PERSON/B_ORGANISM_FUNCTION
. O

Thus O
, O
cytoskeletal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mating I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
responsive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
protein I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O
be O
associated O
with O
structural B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
that O
result O
in O
increased O
fecundity B_ORGANISM_FUNCTION/B_DISEASE
. O

This O
may O
counteract O
the O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
decreased B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fertility I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
reproductive B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
output I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Despite O
the O
use O
of O
Drosophila O
as O
a O
model O
system O
for O
organ O
- O
level O
biology O
and O
the O
emerging O
parallels O
between O
mammalian O
and O
Drosophila B_SPECIES[BIO]
reproductive O
biology O
[ O
56 O
] O
, O
this O
is O
the O
first O
integrative O
tissue O
- O
wide O
study O
of O
post O
- O
mating O
changes O
in O
the O
Drosophila B_SPECIES[BIO]/B_PERSON
oviduct O
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O
several B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
lines I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
at O
the O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
morphological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
physiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
wide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
we O
identify O
ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
mated B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
roles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
some O
of O
the O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
responsive B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
examined O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
e O
. O
g B_GENE/B_MEASURE
. O
Mlp84B B_GENE/B_BACTERIUM[BIO]
, O
Cora B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
Nrg B_GENE/B_BACTERIUM[BIO]
) O
are O
reported O
to O
play O
in O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANISM_FUNCTION
and O
epithelial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
elsewhere O
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
increased O
abundance B_MEASURE
of O
Mlp84B B_GENE/B_BACTERIUM[BIO]
, O
a O
major B_PERSON/B_LOCATION
regulator I_PERSON/I_LOCATION
of O
the O
late B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
muscle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
[ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
49 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
] O
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
increased O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
upper B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Figure B_LOCATION/B_PROTEIN[GENE]
4A I_LOCATION/I_PROTEIN[GENE]
- O
4F B_MEASURE/B_PROTEIN[GENE]
) O
. O

Similarly O
, O
the O
increased O
abundance B_MEASURE/B_LOCATION
of O
Cora B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
Nrg B_GENE/B_BACTERIUM[BIO]
, O
molecules B_BIO/B_GENE
that O
are O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
SJ B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development I_ORGANISM_FUNCTION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
function B_ORGANISM_FUNCTION/B_DISEASE
[ I_ORGANISM_FUNCTION/I_DISEASE
50 I_ORGANISM_FUNCTION/I_DISEASE
] I_ORGANISM_FUNCTION/I_DISEASE
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
SJs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
immature B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
/ O
or O
that O
mating B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
apical B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
extracellular I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
whose O
secretion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
may O
be O
regulated O
, O
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
by O
SJs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
occurs O
in O
the O
trachea B_BODY_PART_OR_ORGAN_COMPONENT
[ O
27 B_MEASURE
, O
28 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
post I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
mating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
indicate O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
wide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
include O
increased O
HAJs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O
the O
basolateral B_BODY_PART_OR_ORGAN_COMPONENT
membrane I_BODY_PART_OR_ORGAN_COMPONENT
and O
increased O
innervation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
protein B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
abundance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
following O
different B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mating I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
regimes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
unmated B_TIME[MEASURE]/B_LOCATION
, O
once O
- O
mated O
, O
twice B_NUMBER[MEASURE]/B_LOCATION
- O
mated O
) O
gave O
us O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insights I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
into O
the O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
roles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
responsive B_GENE/B_LOCATION
proteins I_GENE/I_LOCATION
play O
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
Mlp84B B_GENE/B_BACTERIUM[BIO]
is O
only O
responsive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
first B_PERSON/B_SEQUENCE[MEASURE]
mating I_PERSON/I_SEQUENCE[MEASURE]
, O
while O
the O
epithelial B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
examined O
( O
Cora B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
Nrg B_GENE/B_BACTERIUM[BIO]
and O
Hts B_GENE/B_BIO
) O
are O
responsive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
first B_SEQUENCE[MEASURE]/B_PERSON
and O
second B_SEQUENCE[MEASURE]/B_LOCATION
mating I_SEQUENCE[MEASURE]/I_LOCATION
. O

Furthermore O
, O
the O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
second B_SEQUENCE[MEASURE]/B_PERSON
mating I_SEQUENCE[MEASURE]/I_PERSON
is O
different B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
from O
the O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
first B_TIME[MEASURE]/B_PERSON
mating I_TIME[MEASURE]/I_PERSON
. O

taken O
together O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
Mlp84B B_GENE/B_BACTERIUM[BIO]
is O
required O
for O
the O
final B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maturation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
while O
the O
epithelial B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
proteins I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
examined O
are O
required O
for O
both O
the O
maturation B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
and O
maintenance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
at O
a O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
functional I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
state I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
the O
post B_LOCATION/B_DISEASE
- O
mating O
pattern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
Mlp84B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
supports O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
the O
first B_PERSON/B_BIO
mating B_PERSON/I_BIO
induces O
the O
final B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
maturation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
oviduct B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
rise B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Mlp84B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
abundance I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
after O
the O
first B_PERSON/B_DISEASE
mating B_PERSON/I_DISEASE
( O
Figure B_MEASURE/B_PERSON
5 I_MEASURE/I_PERSON
) O
parallels O
the O
expression B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Mlp84B B_GENE/B_BACTERIUM[BIO]
during O
development B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
where O
peaks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
Mlp84B B_GENE
transcription I_GENE
occur O
during O
periods B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
embryogenesis B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
metamorphosis B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
when O
muscle B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
is O
differentiating O
[ B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
49 I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
] I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Using O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
tested O
whether O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
early B_SEQUENCE[MEASURE]/B_PERSON
mating I_SEQUENCE[MEASURE]/I_PERSON
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
maintenance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reproductive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
output I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
second B_PERSON/B_SPECIES[BIO]
mating I_PERSON/I_SPECIES[BIO]
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
mating O
at O
an O
early B_MEASURE/B_LOCATION
age B_MEASURE/I_LOCATION
is O
essential B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
achieve O
maximum B_MEASURE/B_PERSON
reproductive B_MEASURE/I_PERSON
output B_MEASURE/I_PERSON
( O
i O
. O
e O
. O
high B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
fecundity B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
fertility B_ORGANISM_FUNCTION
) O
. O

Since O
the O
first B_BIO/B_PERSON
mating I_BIO/I_PERSON
increases O
reproductive B_ORGANISM_FUNCTION/B_MEASURE
output I_ORGANISM_FUNCTION/I_MEASURE
( O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
our O
mating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
regime I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
, O
it O
is O
likely B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
ultrastructural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O
in O
mated O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
females I_PERSON
lead O
to O
a O
highly O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
oviduct I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

We O
suggest O
that O
the O
final B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maturation I_ORGANISM_FUNCTION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
oviduct B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
includes O
a O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dependent B_MEASURE/B_LOCATION
stage B_MEASURE/I_LOCATION
. O

We O
propose O
that O
during O
the O
first B_DISEASE/B_MEASURE
few I_DISEASE/I_MEASURE
days I_DISEASE/I_MEASURE
post I_DISEASE/I_MEASURE
- O
eclosion B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
undergoes O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
after O
which O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
is O
developmentally O
poised O
for O
a O
rapid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
an O
extrinsic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
. O

mating B_BIO/B_PERSON
then O
triggers O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
maturation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
tissue B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
remodeling B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
modulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
) O
which O
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
for O
proper B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
function I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
( O
Figure B_LOCATION/B_MEASURE
7 I_LOCATION/I_MEASURE
) O
. O

We O
further O
propose O
that O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
maturation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
consists O
of O
processes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
are O
mating O
- O
independent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
both O
of O
these O
pathways B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
essential B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
produce O
a O
functional B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
initial B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
formation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
SJs B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
occurs O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
mating B_BIO/B_PERSON
- O
independent B_DISEASE_ADJECTIVE[DISEASE]
) O
while O
the O
increased O
apical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
secretion I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
development B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
HAJs B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
mating B_ORGANISM_FUNCTION/B_PERSON
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
oviduct B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
musculature I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
is O
an O
example B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
where O
both O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
independent B_DISEASE_ADJECTIVE[DISEASE]
and O
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
processes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
play O
a O
role B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
highly O
differentiated O
in O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prior I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
muscle B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
is O
ongoing O
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
increases B_DISEASE_ADJECTIVE[DISEASE]
after O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
both O
regions B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
is O
mating O
- O
independent B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
further B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
muscle B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
mating B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
. O

Another O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
on O
oviduct B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
maturation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
is O
that O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
accelerates O
and O
synchronizes O
processes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
maturation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

It O
will O
therefore O
be O
interesting B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
examine O
the O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
older B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
females I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
to O
determine O
the O
status B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
oviduct B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
maturation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
. O

What O
is O
the O
benefit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
differentiation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Unmated B_PERSON
females I_PERSON
are O
capable B_PERSON
of O
laying O
eggs B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
, O
albeit O
at O
a O
reduced O
rate B_MEASURE
as O
compared O
to O
mated O
females B_PERSON/B_BIO
of O
the O
same B_PERSON/B_BIO
age B_PERSON/I_BIO
. O

One B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possible I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
that O
reproduction B_ORGANISM_FUNCTION
is O
energetically O
costly B_DISEASE_ADJECTIVE[DISEASE]
, O
thus O
delaying O
oviduct B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
maturation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
until O
sperm B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
advantageous B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
female B_PERSON/B_BIO
. O

This O
may O
reflect O
the O
evolution B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
mechanism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
optimize O
reproductive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
capacity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
in O
early B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
adulthood I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O
short O
- O
lived O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
summary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
have O
identified O
events B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
the O
cellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
physiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
levels B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
that O
are O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
efficient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
reproduction B_ORGANISM_FUNCTION/B_GENE
. O

Drosophila B_SPECIES[BIO]/B_PERSON
affords O
us O
the O
opportunity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
uncover O
the O
signaling O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
that O
coordinate O
these O
events B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
produce O
a O
physiologically O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organ B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

flies B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Wild O
- O
type O
Canton O
- O
S O
flies B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
for O
the O
fecundity O
/ O
fertility O
experiments O
and O
confocal O
analysis O
. O

Wild O
- O
type O
Canton O
- O
S5 O
[ O
57 O
] O
flies B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
for O
electron O
microscopy O
. O

All O
flies B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
kept O
in O
a O
12 O
hrs O
light O
/ O
dark O
cycle O
at O
23 O
+/- O
2 O
degrees O
C O
. O

Upon O
eclosion B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
, O
females B_PERSON/B_BIO
and O
males B_PERSON/B_BIO
were O
collected O
on O
ice B_LOCATION/B_BIO
and O
held O
separately O
until O
3 B_NUMBER[MEASURE]
( O
females B_PERSON/B_BIO
and O
males B_PERSON
) O
or O
10 B_NUMBER[MEASURE]
( O
females B_PERSON/B_MEASURE
) O
days B_TIME[MEASURE]/B_LOCATION
of O
age B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
preparation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
all O
assays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
unless O
described O
differently O
) O
unmated B_PERSON/B_BIO
females I_PERSON/I_BIO
were O
placed O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON/B_TIME[MEASURE]
unmated I_PERSON/I_TIME[MEASURE]
males I_PERSON/I_TIME[MEASURE]
and O
observed O
until O
mating B_ORGANISM_FUNCTION/B_TIME[MEASURE]
initiated O
. O

At O
the O
end B_LOCATION/B_TIME[MEASURE]
of O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
females B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
were O
aspirated O
into O
fresh B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vials I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
held O
for O
6 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
hrs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

At O
6 B_TIME[MEASURE]
hrs I_TIME[MEASURE]
after O
the O
start B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
females B_PERSON/B_BIO
were O
placed O
on O
ice B_LOCATION/B_BIO
for O
dissection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
molecular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
protein B_GENE
abundance I_GENE
at O
3 B_DISEASE/B_LOCATION
hrs I_DISEASE/I_LOCATION
post I_DISEASE/I_LOCATION
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

We O
hypothesize O
that O
these O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
translate O
into O
morphological B_DISEASE
changes I_DISEASE
in O
the O
next B_BODY_PART_OR_ORGAN_COMPONENT
few I_BODY_PART_OR_ORGAN_COMPONENT
hours I_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
chose O
to O
analyze O
the O
morphology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
mated O
females B_PERSON/B_BIO
at O
6 B_MEASURE
h O
post B_LOCATION/B_DISEASE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
as O
opposed O
to O
later O
times B_TIME[MEASURE]/B_DISEASE
post B_TIME[MEASURE]/I_DISEASE
- O
mating B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
the O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
at O
later B_TIME[MEASURE]/B_ENT
times I_TIME[MEASURE]/I_ENT
may O
be O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
the O
high B_MEASURE/B_LOCATION
rate I_MEASURE/I_LOCATION
of O
eggs B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
passing O
through O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
. O

Electron B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

reproductive O
tracts O
were O
dissected O
in O
Schneider O
' O
s O
Drosophila B_SPECIES[BIO]/B_MEASURE
medium O
( O
Sigma O
) O
on O
ice O
and O
processed O
for O
electron O
microscopy O
as O
described O
in O
[ O
42 O
] O
. O

tracts B_NUMBER[MEASURE]/B_PERSON
were O
flat O
- O
embedded O
between O
two B_LOCATION/B_ENT
sheets I_LOCATION/I_ENT
of O
Aclar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
Electron B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
Sciences I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
which O
allowed O
us O
to O
image O
the O
entire B_BODY_PART_OR_ORGAN_COMPONENT
tract I_BODY_PART_OR_ORGAN_COMPONENT
at O
the O
light B_MEASURE/B_PERSON
microscopic I_MEASURE/I_PERSON
level I_MEASURE/I_PERSON
prior I_MEASURE/I_PERSON
to O
sectioning B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

sections B_LOCATION/B_NUMBER[MEASURE]
were O
cut O
on O
a O
Reichart B_LOCATION
Ultracut I_LOCATION
microtome I_LOCATION
. O

One B_TIME[MEASURE]/B_LOCATION
- O
Mu B_SEQUENCE[MEASURE]
m I_SEQUENCE[MEASURE]
thick I_SEQUENCE[MEASURE]
sections I_SEQUENCE[MEASURE]
were O
stained O
with O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
toluidine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
blue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
viewed O
with O
a O
Zeiss B_PERSON/B_PRODUCT[OBJECT]
Axoplan B_PERSON/I_PRODUCT[OBJECT]
microscope B_PERSON/I_PRODUCT[OBJECT]
. O

Ultrathin B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sections I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
~ B_LOCATION/B_MEASURE
100 I_LOCATION/I_MEASURE
nm I_LOCATION/I_MEASURE
) O
were O
mounted O
on O
formvar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
grids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
stained O
with O
lead B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
citrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
viewed O
with O
a O
Philips B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O
FEI B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Morgagni I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
268 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
TEM I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O
80 B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kV I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
based O
on O
4 B_MEASURE
unmated I_MEASURE
samples I_MEASURE
and O
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mated I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Two B_NUMBER[MEASURE]/B_PERSON
unmated I_NUMBER[MEASURE]/I_PERSON
samples I_NUMBER[MEASURE]/I_PERSON
were O
cut O
in O
the O
longitudinal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
plane I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O
two B_NUMBER[MEASURE]/B_PERSON
additional I_NUMBER[MEASURE]/I_PERSON
unmated I_NUMBER[MEASURE]/I_PERSON
samples I_NUMBER[MEASURE]/I_PERSON
were O
cut O
in O
the O
transverse B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
plane I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
, O
while O
one B_NUMBER[MEASURE]/B_PERSON
mated O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
cut O
in O
the O
longitudinal B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
plane I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
and O
two B_NUMBER[MEASURE]/B_PERSON
additional I_NUMBER[MEASURE]/I_PERSON
mated O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
cut O
in O
the O
transverse B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
plane I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

For O
longitudinal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sections I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
entire B_BODY_PART_OR_ORGAN_COMPONENT
tract I_BODY_PART_OR_ORGAN_COMPONENT
was O
re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
embedded O
and O
cut O
. O

For O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cut O
in O
the O
transverse B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
plane I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
the O
flat O
- O
embedded O
reproductive B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
was O
divided O
into O
three B_LOCATION
regions I_LOCATION
: O
( O
1 B_NUMBER[MEASURE]
) O
lateral B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
oviducts I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviducts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
( O
2 B_NUMBER[MEASURE]
) O
middle B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
( O
3 O
) O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
common I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Each O
region B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
was O
re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
embedded O
and O
sectioned O
. O

It O
is O
beyond O
the O
scope B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
to O
describe O
all O
three B_LOCATION
regions I_LOCATION
, O
and O
our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
focuses O
on O
the O
uppermost B_SEQUENCE[MEASURE]/B_LOCATION
and O
lowermost B_SEQUENCE[MEASURE]/B_LOCATION
regions I_SEQUENCE[MEASURE]/I_LOCATION
. O

immunocytochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

reproductive B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
tracts I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
were O
dissected O
in O
Yamamoto B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
s I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Ringer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
10 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MOPS I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
80 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
0 B_MEASURE
. O
2 B_MEASURE
mm I_MEASURE
MgCl2 I_MEASURE
; O
0 B_MEASURE
. O
1 B_MEASURE
mm I_MEASURE
CaCl2 I_MEASURE
) O
with O
5 B_MEASURE/B_COLOR
% B_MEASURE/I_COLOR
( O
w O
/ O
v O
) O
sucrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
ice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
fixed O
in O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
paraphormaldehyde I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
PBS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
phosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
buffered O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
0 B_MEASURE
. O
85 B_MEASURE
% I_MEASURE
NaCl I_MEASURE
, O
1 B_MEASURE
. O
4 B_MEASURE
mm I_MEASURE
KH2 I_MEASURE
PO4 I_MEASURE
, O
8 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Na2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
HPO4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
pH B_MEASURE/B_LOCATION
7 I_MEASURE/I_LOCATION
. O
4 B_MEASURE
) O
for O
45 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
min I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
then O
washed O
in O
PBS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
reproductive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
then O
incubated O
in O
blocking O
solution B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
0 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
Triton I_MEASURE
x O
- O
100 B_MEASURE/B_BIO
, O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NGS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
BSA I_MEASURE
) O
for O
2 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hrs B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
room B_MEASURE/B_LOCATION
temperature I_MEASURE/I_LOCATION
. O

The O
following O
primary O
antibodies O
, O
reagents O
, O
and O
dilutions O
were O
used O
: O
Cy3 O
- O
conjugated O
goat B_SPECIES[BIO]
anti O
- O
HRP O
, O
1 O
: O
200 O
( O
Jackson O
Immunochemicals O
, O
West O
Grove O
, O
PA O
) O
; O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
Disc O
Large O
( O
DLG O
) O
, O
1 O
: O
1000 O
( O
developmental O
Hybridoma O
Bank O
) O
, O
Alexa O
Fluor O
488 O
- O
phalloidin O
, O
1 O
: O
200 O
( O
Invitrogen O
, O
Molecular O
Probes O
, O
Scotland O
) O
. O

Secondary O
antibodies O
were O
Alexa O
flour O
488 O
- O
conjugated O
Goat B_SPECIES[BIO]/B_GENE
anti O
- O
mouse B_SPECIES[BIO]/B_DISEASE
, O
1 O
: O
200 O
and O
Alexa O
flour O
546 O
- O
conjugated O
Goat B_SPECIES[BIO]/B_GENE
anti O
- O
rabbit B_SPECIES[BIO]
, O
1 O
: O
200 O
( O
Invitrogen O
, O
Molecular O
Probes O
, O
Scotland O
) O
. O

reproductive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
tracts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O
incubated O
with O
the O
different B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
primary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
diluted O
in O
PBS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
+ O
0 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
Triton I_MEASURE
x O
- O
100 B_MEASURE/B_BIO
) O
for O
2 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hr I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
room B_MEASURE/B_LOCATION
temperature I_MEASURE/I_LOCATION
, O
washed O
with O
PBST B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
incubated O
with O
secondary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O
2 B_MEASURE
hrs I_MEASURE
at O
room B_MEASURE/B_LOCATION
temperature B_MEASURE/I_LOCATION
and O
washed O
with O
PBS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

reproductive B_NUMBER[MEASURE]
tracts I_NUMBER[MEASURE]
of O
the O
different B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
mounted O
with O
Antifade B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
media I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
58 B_TIME[MEASURE]/B_LOCATION
] O
on O
a O
multi B_NUMBER[MEASURE]/B_ENT
- O
well O
glass B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
slide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Hendley B_PERSON/B_LOCATION
- O
Essex B_LOCATION/B_PERSON
, O
UK B_LOCATION/B_MEASURE
) O
. O

For O
each O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
unmated B_PERSON/B_MEASURE
, O
mated O
) O
and O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
reagent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
HRP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
DLG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
phalloidin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
a O
minimum B_MEASURE
of O
ten B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
reproductive I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
tracts I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
at O
least O
two B_NUMBER[MEASURE]/B_PERSON
independent I_NUMBER[MEASURE]/I_PERSON
biological I_NUMBER[MEASURE]/I_PERSON
replicates I_NUMBER[MEASURE]/I_PERSON
were O
prepared B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

confocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O

reproductive B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tracts I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
viewed O
with O
a O
Zeiss B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
510 I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
laser I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
scanning I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
confocal I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
microscope I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
using O
20 B_MEASURE/B_LOCATION
x I_MEASURE/I_LOCATION
and O
60 B_MEASURE
x I_MEASURE
objective I_MEASURE
with O
additional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
zooming I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Optical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sections I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
focal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
plans B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
each O
reproductive B_PERSON/B_MEASURE
tract I_PERSON/I_MEASURE
region I_PERSON/I_MEASURE
( O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviducts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
uterus B_BODY_PART_OR_ORGAN_COMPONENT
) O
were O
collected O
and O
projected O
as O
a O
reconstructed B_NUMBER[MEASURE]
three I_NUMBER[MEASURE]
- O
dimensional B_MEASURE/B_LOCATION
image I_MEASURE/I_LOCATION
using O
LSM B_ORGANIZATION
image I_ORGANIZATION
browser I_ORGANIZATION
( O
version B_MEASURE
3 I_MEASURE
, O
5 B_MEASURE
, O
0 B_MEASURE
, O
376 B_MEASURE
) O
software B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Image B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
collections I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
identical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
each O
of O
the O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reproductive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tract I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analyzed O
. O

quantitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
bouton B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
number I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

To O
quantify O
the O
number B_MEASURE/B_LOCATION
of O
boutons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
lateral B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
and O
common B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
oviducts I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
we O
used O
ImageJ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
software I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
1 B_MEASURE/B_LOCATION
. O
37b B_MEASURE
, O
National B_ORGANIZATION/B_LOCATION
Institutes I_ORGANIZATION/I_LOCATION
of O
Health B_PERSON/B_ORGANIZATION
) O
to O
analyze O
confocal B_MEASURE/B_ORGANIZATION
images I_MEASURE/I_ORGANIZATION
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
HRP B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
DLG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labeled O
boutons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
number B_MEASURE/B_LOCATION
of O
boutons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
per O
unit B_MEASURE
area I_MEASURE
was O
quantified O
with O
the O
particle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

briefly O
, O
to O
differentiate O
between O
the O
boutons B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
particle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
requires O
the O
image B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O
be O
a O
' O
binary B_DISEASE/B_TIME[MEASURE]
' O
image B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
i O
. O
e O
. O
, O
black B_COLOR
or O
white B_COLOR
) O
, O
thus O
we O
first O
converted O
the O
images B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
gray B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
then O
set O
a O
' O
threshold B_LOCATION/B_MEASURE
' O
range B_MEASURE
so O
that O
pixels O
in O
the O
image B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whose O
value B_MEASURE/B_LOCATION
lies O
in O
this O
range B_LOCATION/B_MEASURE
are O
converted O
to O
black B_COLOR
; O
pixels B_LOCATION/B_ENT
with O
values B_MEASURE
outside O
this O
range B_LOCATION/B_MEASURE
are O
converted O
to O
white B_COLOR
. O

We O
next O
defined O
a O
region B_LOCATION/B_MEASURE
of O
interest B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ROI B_LOCATION/B_PROTEIN[GENE]
) O
within O
the O
oviduct B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
to O
count O
particles B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
i O
. O
e O
. O
count B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boutons I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

This O
ROI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
saved O
and O
served O
to O
measure O
the O
number B_MEASURE
of O
boutons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
per O
unit B_TIME[MEASURE]/B_PERSON
area I_TIME[MEASURE]/I_PERSON
in O
each O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

For O
each O
oviduct B_BIO/B_PERSON
we O
counted O
the O
number B_MEASURE/B_LOCATION
of O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
HRP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
DLG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labeled O
boutons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
two B_MEASURE/B_LOCATION
ROIs B_MEASURE/I_LOCATION
within O
the O
lateral B_LOCATION/B_PERSON
oviducts I_LOCATION/I_PERSON
and O
two B_NUMBER[MEASURE]/B_PERSON
ROIs I_NUMBER[MEASURE]/I_PERSON
in O
the O
common B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oviduct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

One B_NUMBER[MEASURE]
- O
way B_MEASURE/B_LOCATION
ANOVA I_MEASURE/I_LOCATION
( O
SPSS B_MEASURE
15 I_MEASURE
. O
0 B_MEASURE
) O
was O
used O
to O
measure O
the O
difference B_MEASURE
in O
bouton B_MEASURE
number I_MEASURE
per O
unit B_TIME[MEASURE]/B_PERSON
area B_TIME[MEASURE]/I_PERSON
in O
different B_NUMBER[MEASURE]/B_LOCATION
regions I_NUMBER[MEASURE]/I_LOCATION
of O
the O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
in O
both O
unmated B_PERSON/B_ORGANISM_FUNCTION
and O
mated B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
females B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

quantitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cytoskeleton B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
preparation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
evaluate O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mating B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
the O
abundance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
cytoskeleton B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tested O
, O
females B_PERSON/B_BIO
were O
: O
( O
i O
) O
aged O
for O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
mated O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
males I_PERSON
and O
their O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O
dissected O
after O
6 B_LOCATION/B_DISEASE
hrs I_LOCATION/I_DISEASE
post I_LOCATION/I_DISEASE
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
( O
Once3 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
; O
( O
ii B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
aged O
for O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
mated O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
males I_PERSON
and O
their O
oviducts B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O
dissected O
after O
7 B_TIME[MEASURE]/B_ORGANISM_FUNCTION
days B_TIME[MEASURE]/I_ORGANISM_FUNCTION
( O
Once3 B_PROTEIN[GENE]
day10 I_PROTEIN[GENE]
) O
; O
( O
III B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
aged O
for O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
mated O
first O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
males I_PERSON
and O
held O
singly O
for O
7 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
days I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

At O
10 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
age B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
female B_PERSON/B_BIO
were O
mated O
again O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON/B_TIME[MEASURE]
unmated B_PERSON/I_TIME[MEASURE]
males B_PERSON/I_TIME[MEASURE]
. O

Oviducts B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
were O
dissected O
at O
6 B_NUMBER[MEASURE]/B_LOCATION
hrs I_NUMBER[MEASURE]/I_LOCATION
post I_NUMBER[MEASURE]/I_LOCATION
- O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
mating I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
( O
Twice3 B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
& O
10 B_MEASURE
) O
. O

We O
also O
examined O
5 B_MEASURE
- O
day B_TIME[MEASURE]
- O
old B_TIME[MEASURE]/B_PERSON
and O
10 B_MEASURE
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
females I_PERSON
( O
UM5 B_PROTEIN[GENE]
, O
UM10 B_MEASURE/B_PROTEIN[GENE]
respectively O
) O
. O

SDS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polyacrylamide I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gel I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
SDS B_PROTEIN[GENE]/B_DISEASE
- O
Page B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
each O
mating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
regime I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
sixty B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oviducts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
pooled O
and O
30 B_MEASURE/B_LOCATION
Mu I_MEASURE/I_LOCATION
l I_MEASURE/I_LOCATION
of O
SDS B_MEASURE/B_PROTEIN[GENE]
- O
PAGE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sample I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
buffer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
added O
as O
described O
in O
[ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
59 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
boiled O
, O
and O
then O
frozen O
at O
- O
20 B_MEASURE
degrees I_MEASURE
C I_MEASURE
until O
loading B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

SDS B_PROTEIN[GENE]/B_DISEASE
- O
PAGE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
performed O
on O
12 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polyacrylamide I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gels I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
western B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blotted O
as O
in O
[ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
60 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

proteins B_BIO/B_PERSON
were O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
linked O
to O
the O
filter B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
following O
primary O
antibodies O
and O
dilutions O
were O
used O
: O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
Neuroglian O
( O
kindly O
provided O
by O
M O
. O
Hortsch O
) O
1 O
: O
250 O
; O
Guinea B_SPECIES[BIO]
pig I_SPECIES[BIO]
anti O
- O
Coracle O
( O
kindly O
provided O
by O
R O
. O
G O
. O
Fehon O
) O
1 O
: O
2500 O
; O
rabbit B_SPECIES[BIO]
anti O
- O
Mlp84B O
( O
kindly O
provided O
by O
M O
. O
Beckerle O
) O
1 O
: O
1000 O
; O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
hts O
( O
1B1 O
, O
developmental O
Studies O
Hybridoma O
Bank O
, O
DSHB O
) O
1 O
: O
75 O
; O
mouse B_SPECIES[BIO]/B_DISEASE
anti O
- O
Na O
, O
K O
- O
ATPase O
( O
alpha O
5 O
, O
DSHB O
) O
1 O
: O
100 O
. O

Secondary O
antibodies O
included O
: O
anti O
- O
Guinea B_SPECIES[BIO]
pig I_SPECIES[BIO]
IgG O
( O
peroxidase O
conjugated O
) O
, O
anti O
- O
Rabbit B_SPECIES[BIO]
IgG O
and O
anti O
- O
Mouse B_SPECIES[BIO]/B_DISEASE
IgG O
( O
developed O
in O
goat B_BIO/B_LOCATION
, O
Sigma O
, O
Israel O
) O
1 O
: O
10 O
, O
000 O
. O

proteins B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
visualized O
using O
an O
enhanced B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemiluminescence B_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ecl B_DISEASE/B_PROTEIN[GENE]
) O
detection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Amersham B_LOCATION/B_PERSON
Piscataway I_LOCATION/I_PERSON
, O
NJ B_LOCATION/B_MEASURE
) O
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
developed O
film B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
scanned O
and O
the O
signal B_MEASURE/B_LOCATION
intensity I_MEASURE/I_LOCATION
( O
protein B_LOCATION
abundance I_LOCATION
) O
of O
each O
band B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
determined O
using O
ImageJ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
software I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
1 B_TIME[MEASURE]/B_LOCATION
. O
37d B_TIME[MEASURE]
, O
National B_ORGANIZATION/B_LOCATION
Institutes I_ORGANIZATION/I_LOCATION
of O
Health B_PERSON/B_EDU[ORGANIZATION]
) O
. O

We O
evaluated O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
abundance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O
measuring O
the O
mean B_MEASURE/B_LOCATION
gray I_MEASURE/I_LOCATION
value I_MEASURE/I_LOCATION
of O
a O
specific B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
band B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
mean B_MEASURE/B_LOCATION
gray I_MEASURE/I_LOCATION
value I_MEASURE/I_LOCATION
of O
the O
background B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
then O
subtracted O
from O
that O
of O
the O
measured B_LOCATION/B_COLOR
band I_LOCATION/I_COLOR
. O

relative B_TIME[MEASURE]/B_PERSON
protein I_TIME[MEASURE]/I_PERSON
abundance I_TIME[MEASURE]/I_PERSON
in O
mated B_MEASURE
oviduct I_MEASURE
vs I_MEASURE
. O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_TIME[MEASURE]/B_PERSON
unmated I_TIME[MEASURE]/I_PERSON
oviduct I_TIME[MEASURE]/I_PERSON
was O
then O
calculated O
. O

Four B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independent I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replicates I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
prepared B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
each O
mating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
status I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
reported O
abundance B_MEASURE
( O
see O
figure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
the O
relative B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
( O
mated O
/ O
unmated B_PERSON
or O
unmated B_PERSON/B_MEASURE
/ O
unmated O
) O
of O
at O
least O
three B_NUMBER[MEASURE]/B_PERSON
replicates B_NUMBER[MEASURE]/I_PERSON
that O
showed O
the O
same B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
trend I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Examination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
female B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reproductive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
output I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

mating B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
regimes I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

To O
evaluate O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O
reproductive B_PERSON/B_BIO
output I_PERSON/I_BIO
females I_PERSON/I_BIO
were O
treated O
as O
follows O
: O
( O
i O
) O
aged O
for O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
and O
mated O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
males I_PERSON
( O
Once3 B_MEASURE/B_PROTEIN[GENE]
) O
; O
( O
ii B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
aged O
for O
10 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
and O
mated O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
males I_PERSON
( O
Once10 B_MEASURE
) O
; O
( O
III B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
aged O
for O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
mated O
first O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
males I_PERSON
, O
held O
for O
7 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
and O
mated O
again O
with O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
- O
old B_PERSON
unmated I_PERSON
males I_PERSON
( O
Twice3 B_NUMBER[MEASURE]/B_GENE
& O
10 B_NUMBER[MEASURE]/B_LOCATION
) O
. O

In O
all O
cases B_PERSON/B_LOCATION
male I_PERSON/I_LOCATION
and O
female B_PERSON
pairs I_PERSON
were O
observed O
to O
record O
mating B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
initiation I_ORGANISM_FUNCTION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Following O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
females B_PERSON/B_BIO
were O
aspirated O
into O
fresh B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vials I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
held O
singly O
and O
allowed O
to O
lay O
eggs B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
6 B_TIME[MEASURE]/B_PERSON
hrs I_TIME[MEASURE]/I_PERSON
, O
then O
transferred O
daily O
( O
each O
24 B_TIME[MEASURE]
hrs I_TIME[MEASURE]
) O
to O
fresh B_PERSON/B_BIO
vials I_PERSON/I_BIO
. O

The O
number B_MEASURE
of O
eggs B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laid O
and O
the O
number B_MEASURE/B_LOCATION
of O
eclosed B_BIO/B_PERSON
adults I_BIO/I_PERSON
were O
counted O
from O
vials B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
created O
at O
6 B_MEASURE
hrs I_MEASURE
, O
1 B_TIME[MEASURE]/B_LOCATION
, O
2 B_SEQUENCE[MEASURE]
and O
3 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
post I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

To O
ascertain O
the O
baseline B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
female B_DISEASE/B_BIO
egg B_DISEASE/I_BIO
- O
laying B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
also O
included O
in O
our O
experiment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
unmated O
females B_PERSON/B_BIO
that O
were O
kept O
in O
the O
same B_LOCATION/B_BIO
conditions I_LOCATION/I_BIO
as O
mated B_PERSON/B_LOCATION
females I_PERSON/I_LOCATION
. O

The O
number B_MEASURE/B_PERSON
of O
eggs B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
laid O
by O
unmated B_PERSON/B_BIO
females I_PERSON/I_BIO
was O
counted O
from O
vials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
created O
at O
6 B_MEASURE
hrs I_MEASURE
, O
1 B_SEQUENCE[MEASURE]/B_LOCATION
, O
2 B_SEQUENCE[MEASURE]
and O
3 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
after O
placing O
the O
females B_PERSON/B_BIO
in O
the O
holding O
vials B_PERSON/B_LOCATION
. O

In O
addition B_MEASURE/B_LOCATION
, O
we O
also O
recorded O
the O
pattern B_MEASURE/B_DISEASE
of O
unmated B_PERSON/B_BIO
female B_PERSON/I_BIO
egg B_PERSON/I_BIO
- O
laying B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
10 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

To O
determine O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
different B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mating B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimes B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
female B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
reproductive I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
output I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
i O
. O
e O
. O
fecundity B_ORGANISM_FUNCTION/B_MEASURE
and O
fertility B_ORGANISM_FUNCTION/B_MEASURE
) O
, O
we O
used O
One B_NUMBER[MEASURE]
- O
way B_MEASURE/B_LOCATION
ANOVA I_MEASURE/I_LOCATION
( O
SPSS B_MEASURE
15 I_MEASURE
. O
0 B_MEASURE
) O
. O

Abbreviations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Nrg O
: O
Neuroglian O
; O
Cora O
: O
Coracle O
; O
Spec O
: O
alpha O
- O
and O
beta O
- O
Spectrin O
; O
SJ O
: O
septate O
junction O
; O
SSJ O
: O
smooth O
septate O
junction O
; O
PSJ O
: O
pleated O
septate O
junction O
; O
ZA O
: O
zonal O
adherens O
junction O
; O
AJ O
: O
adherens O
junction O
; O
AECM O
: O
apical O
extracellular O
matrix O
; O
ECM O
: O
extracellular O
matrix O
; O
HAJ O
: O
hemi O
- O
adherens O
junction O
; O
SAJ O
: O
spot O
adherens O
junction O
; O
OA O
: O
Octopamine O
; O
Hts O
: O
Hu O
- O
Li O
Tai O
shao O
; O
ATP O
alpha O
: O
Na O
+ O
pump O
alpha O
subunit O
; O
Mlp84B O
: O
muscle O
Lim O
protein O
at O
84B O
; O
DLG O
: O
Disc O
Large O
; O
HRP O
: O
horseradish B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peroxidas O
; O
um O
: O
unmated O
; O
M O
: O
mated O
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

AK B_LOCATION/B_PERSON
and O
PKR B_LOCATION
contributed O
equally O
to O
this O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

AK B_LOCATION/B_TIME[MEASURE]
, O
PKR B_LOCATION/B_PERSON
and O
YH B_ORGANIZATION/B_PERSON
conceived O
and O
designed O
the O
project B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
analyzed O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

AK B_LOCATION/B_PERSON
performed O
the O
confocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Western B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blots B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fertility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

PKR B_PERSON/B_LOCATION
and O
AK B_LOCATION/B_DISEASE
performed O
the O
light B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

PKR B_PERSON/B_LOCATION
conducted O
the O
electron B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

AK B_LOCATION/B_MEASURE
, O
PKR B_LOCATION
and O
YH B_PERSON/B_LOCATION
wrote O
the O
manuscript B_TIME[MEASURE]/B_ENT
. O

RRH B_PERSON
contributed O
to O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
revision B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
authors B_PERSON
participated O
in O
the O
discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
approval B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
manuscript I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

supplementary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
material I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

Efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
hyaluronan I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
Synvisc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
(R) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
osteoarthritis B_DISEASE
affecting O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
metatarsophalangeal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
joint B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
hallux B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
limitus I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
) O
: O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
randomised O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
controlled O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Osteoarthritis B_DISEASE
of O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metatarsophalangeal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
joint B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
MPJ B_DISEASE/B_PROTEIN[GENE]
) O
of O
the O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
termed O
hallux B_DISEASE/B_BIO
limitus I_DISEASE/I_BIO
, O
is O
common B_DISEASE_ADJECTIVE[DISEASE]
and O
painful B_DISEASE_ADJECTIVE[DISEASE]
. O

Numerous B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
non B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
surgical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interventions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
proposed O
for O
this O
disorder B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
there O
is O
limited B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
their O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Intra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
shown O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
case B_PERSON/B_MEASURE
- O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
osteoarthritis B_DISEASE
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsophalangeal I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
joint I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
no O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O
evaluated O
the O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
using O
a O
randomised B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
placebo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
controlled O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

This O
article O
describes O
the O
design O
of O
a O
randomised O
placebo O
controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
intra O
- O
articular O
hyaluronan O
( O
Synvisc O
(R) O
) O
to O
reduce O
pain O
and O
improve O
function O
in O
people B_PERSON/B_BIO
with O
hallux O
limitus O
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One O
hundred O
and O
fifty O
community O
- O
dwelling O
men B_PERSON
and O
women B_PERSON
aged O
18 O
years O
and O
over O
with O
hallux O
limitus O
( O
who O
satisfy O
inclusion O
and O
exclusion O
criteria O
) O
will O
be O
recruited O
. O

Participants B_PERSON
will O
be O
randomised O
, O
using O
a O
computer O
- O
generated O
random O
number O
sequence O
, O
to O
receive O
a O
single O
intra O
- O
articular O
injection O
of O
up O
to O
1 O
ml O
hyaluronan O
( O
Synvisc O
(R) O
) O
or O
sterile O
saline O
( O
placebo O
) O
into O
the O
first O
MPJ O
. O

The O
injections B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
will O
be O
performed O
by O
an O
interventional B_PERSON
radiologist I_PERSON
using O
fluoroscopy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
ensure O
accurate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
deposition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
joint B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Participants B_PERSON
will O
be O
given O
the O
option O
of O
a O
second O
and O
final O
intra O
- O
articular O
injection O
( O
of O
Synvisc O
(R) O
or O
sterile O
saline O
according O
to O
the O
treatment O
group O
they O
are O
in O
) O
either O
1 O
or O
3 O
months O
post O
- O
treatment O
if O
there O
is O
no O
improvement O
in O
pain O
and O
the O
participant B_PERSON
has O
not O
experienced O
severe O
adverse O
effects O
after O
the O
first O
injection O
. O

The O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
be O
the O
pain B_DISEASE
and O
function B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subscales I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Foot B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
Health I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
Status I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
Questionnaire I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
be O
pain B_DISEASE/B_MEASURE
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
during O
walking O
and O
at O
rest B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
stiffness O
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
passive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
non O
- O
weightbearing O
dorsiflexion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
plantar B_DISEASE/B_MEASURE
flexion I_DISEASE/I_MEASURE
strength I_DISEASE/I_MEASURE
of O
the O
toe B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
flexors B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hallux B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
global B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
satisfaction I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
health B_PERSON/B_DISEASE
- O
related O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
assessed O
using O
the O
Short B_PERSON/B_LOCATION
- O
Form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
36 B_MEASURE
version I_MEASURE
two I_MEASURE
questionnaire I_MEASURE
) O
, O
magnitude B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
symptom B_DISEASE
change I_DISEASE
, O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
pain B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
relieving O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
dynamic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plantar B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pressure B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
distribution B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
maximum B_MEASURE
force I_MEASURE
and O
peak B_MEASURE/B_DISEASE
pressure I_MEASURE/I_DISEASE
) O
during O
walking O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
collected O
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
then O
1 B_SEQUENCE[MEASURE]/B_LOCATION
, O
3 B_MEASURE
and O
6 B_LOCATION/B_MEASURE
months I_LOCATION/I_MEASURE
post I_LOCATION/I_MEASURE
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O
be O
analysed O
using O
the O
intention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
treat O
principle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
randomised I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
placebo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
controlled O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
evaluate O
the O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyaluronan I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Synvisc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
(R) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
osteoarthritis B_DISEASE
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
hallux B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
limitus B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
) O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O
been O
pragmatically O
designed O
to O
ensure O
that O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
implemented O
into O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
practice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
if O
this O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
is O
found O
to O
be O
an O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
registration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Australian B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
New I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Zealand I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Registry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
ACTRN12607000654459 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Osteoarthritis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
OA B_LOCATION/B_PROTEIN[GENE]
) O
is O
a O
degenerative B_DISEASE
joint I_DISEASE
disease I_DISEASE
that O
commonly O
presents O
within O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsophalangeal I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
joint I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MPJ B_DISEASE/B_PROTEIN[GENE]
) O
of O
the O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

The O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hallux O
limitus B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
hallux B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
rigidus B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
have O
frequently O
been O
used O
interchangeably O
to O
describe O
differing O
severities B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pain B_DISEASE
and O
limitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
motion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O
with O
OA B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O
1 B_LOCATION/B_DISEASE
] I_LOCATION/I_DISEASE
. O

Hallux B_DISEASE/B_LOCATION
limitus I_DISEASE/I_LOCATION
is O
a O
progressive B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
osteoarthritic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
condition I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
may O
advance O
to O
an O
end B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stage B_DISEASE/B_MEASURE
presentation I_DISEASE/I_MEASURE
of O
hallux B_DISEASE/B_LOCATION
rigidus I_DISEASE/I_LOCATION
where O
the O
joint B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
fuses O
and O
there O
is O
a O
complete B_DISEASE_ADJECTIVE[DISEASE]
restriction I_DISEASE_ADJECTIVE[DISEASE]
of O
motion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
[ O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
] I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

First B_DISEASE
MPJ I_DISEASE
OA I_DISEASE
is O
the O
second B_SEQUENCE[MEASURE]
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disorder I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
affecting O
the O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
after O
hallux B_DISEASE/B_LOCATION
valgus I_DISEASE/I_LOCATION
[ O
2 B_LOCATION/B_PROTEIN[GENE]
] I_LOCATION/I_PROTEIN[GENE]
. O

The O
prevalence O
of O
the O
condition O
increases O
with O
age O
, O
and O
it O
has O
been O
reported O
that O
radiographic O
changes O
in O
the O
first O
MPJ O
affect O
are O
evident O
in O
approximately O
46 O
% O
of O
women B_PERSON/B_BIO
and O
32 O
% O
of O
men B_PERSON
at O
60 O
years O
of O
age O
[ O
3 O
] O
. O

Osteoarthritis B_DISEASE
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
characterised O
by O
the O
symptoms B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
pain B_DISEASE
and O
stiffness B_DISEASE
at O
the O
joint B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
[ O
1 B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
] I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
. O

Secondary B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
painful I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
symptoms I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
relate O
to O
compensations B_DISEASE_ADJECTIVE[DISEASE]
during O
gait B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
that O
may O
occur O
due O
to O
the O
reduced O
motion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O
1 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
pain B_DISEASE
associated O
with O
first B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_DISEASE_ADJECTIVE[DISEASE]
OA I_DISEASE_ADJECTIVE[DISEASE]
impacts I_DISEASE_ADJECTIVE[DISEASE]
on O
normal B_DISEASE_ADJECTIVE[DISEASE]
walking I_DISEASE_ADJECTIVE[DISEASE]
and O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
4 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
hallux B_DISEASE
limitus I_DISEASE
involves O
conservative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
measures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
physical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
foot B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
orthoses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
footwear B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
modification I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
joint B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
manipulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
[ B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
5 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
] I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
or O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intervention I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
either O
joint B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
salvage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
joint B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
destructive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
) O
[ O
6 B_MEASURE
] I_MEASURE
. O

Pharmacological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
also O
often O
undertaken O
as O
an O
adjunct B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
for O
pain B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
relief I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
management B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
hallux B_DISEASE/B_LOCATION
limitus I_DISEASE/I_LOCATION
[ O
6 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

However O
, O
although O
non B_DISEASE/B_MEASURE
- O
steroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
and O
cyclooxygenase B_GENE
- O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
found O
to O
be O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
management B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
various B_DISEASE_ADJECTIVE[DISEASE]
forms I_DISEASE_ADJECTIVE[DISEASE]
of O
OA B_DISEASE/B_LOCATION
, O
gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O
a O
concern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
[ O
7 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

In O
light B_COLOR/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
these O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
existing O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
an O
alternative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
termed O
' B_LOCATION
viscosupplementation I_LOCATION
' O
- O
the O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O
arthritic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
joints B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
with O
the O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
restoring O
the O
viscoelasticity B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
synovial B_BODY_PART_OR_ORGAN_COMPONENT
fluid I_BODY_PART_OR_ORGAN_COMPONENT
[ O
8 B_MEASURE
] I_MEASURE
- O
has O
been O
proposed O
and O
has O
attracted O
considerable B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attention I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
medical B_LOCATION/B_PERSON
literature I_LOCATION/I_PERSON
as O
a O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
OA B_DISEASE
[ O
9 B_NUMBER[MEASURE]/B_LOCATION
] I_NUMBER[MEASURE]/I_LOCATION
. O

In O
particular B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
both O
the O
American B_LOCATION/B_ORGANIZATION
College B_LOCATION/I_ORGANIZATION
of O
Rheumatology B_DISEASE/B_PERSON
( O
ACR B_ORGANIZATION/B_LOCATION
) O
and O
European B_LOCATION/B_ORGANIZATION
League B_LOCATION/I_ORGANIZATION
Against I_LOCATION
Rheumatism I_LOCATION
( O
EULAR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
recommend O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
the O
management B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
OA B_DISEASE/B_LOCATION
of O
the O
knee B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
[ O
10 B_NUMBER[MEASURE]
, O
11 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Although O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
systematic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigating O
the O
effectiveness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
this O
type B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
knee B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
OA I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
are O
controversial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
most O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
update I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
the O
Cochrane B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
systematic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
evaluating O
viscosupplementation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
knee B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
OA I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
concluded O
that O
viscosupplementation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
both O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
effective B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
OA B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
was O
superior B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
equivalent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
any O
form B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
systemic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
intervention I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
corticosteroids I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O
9 B_MEASURE
, O
12 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Despite O
there O
being O
a O
large B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigating O
the O
effectiveness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
knee B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
OA I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
few B_PERSON
studies I_PERSON
have O
investigated O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
OA B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
the O
first B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
MPJ I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
13 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

In O
a O
case O
- O
series O
retrospective O
study O
, O
14 O
patients B_PERSON
with O
radiographically O
confirmed O
OA O
at O
the O
first O
MPJ O
that O
received O
up O
to O
3 O
intra O
- O
articular O
injections O
of O
1 O
ml O
hyaluronan O
( O
Ostenil O
(R) O
Mini O
) O
( O
sodium O
hyaluronate O
) O
reported O
a O
statistically O
significant O
reduction O
in O
pain O
( O
reported O
using O
a O
visual O
analogue O
scale O
) O
after O
6 O
months O
[ O
14 O
] O
. O

The O
treatment O
was O
well O
tolerated O
, O
with O
3 O
/ O
14 O
( O
21 O
% O
) O
participants B_PERSON
reporting O
mild O
adverse O
reactions O
at O
the O
injection O
site O
. O

In O
another O
study O
, O
Pons O
et O
al O
[ O
13 O
] O
compared O
a O
single O
intra O
- O
articular O
injection O
of O
1 O
ml O
Ostenil O
(R) O
Mini O
( O
sodium O
hyaluronate O
) O
with O
1 O
ml O
Trigon O
depot O
(R) O
( O
triamcinolone O
acetonide O
, O
a O
corticosteroid O
) O
for O
the O
treatment O
of O
painful O
, O
grade O
1 O
hallux O
limitus O
( O
Karasick O
and O
Wapner O
[ O
15 O
] O
scale O
) O
in O
37 O
participants B_PERSON/B_MEASURE
( O
40 O
feet O
) O
[ O
13 O
] O
. O

Both O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
groups I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
showed O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]
reductions I_DISEASE_ADJECTIVE[DISEASE]
in O
pain B_DISEASE/B_MEASURE
at O
rest B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
or O
on O
palpation B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
up O
to O
12 B_NUMBER[MEASURE]/B_LOCATION
weeks I_NUMBER[MEASURE]/I_LOCATION
post I_NUMBER[MEASURE]/I_LOCATION
- O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
, O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
resulted O
in O
a O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
greater I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
pain B_DISEASE/B_MEASURE
during O
walking B_SPORT[ENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
American B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
orthopaedic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
Foot I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
ankle B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
Society I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
AOFAS B_DISEASE/B_ORGANIZATION
) O
hallux B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
MPJ B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
score O
compared O
to O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O
triamcinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
treatment O
with O
hyaluronan O
was O
well O
tolerated O
, O
with O
2 O
/ O
20 O
( O
10 O
% O
) O
participants B_PERSON
reporting O
mild O
adverse O
reactions O
at O
the O
injection O
site O
. O

Although O
both O
of O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyaluronan I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hallux B_DISEASE/B_LOCATION
limitus I_DISEASE/I_LOCATION
, O
neither O
used O
a O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
13 B_MEASURE
, O
14 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

This O
limitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
significant B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
placebo B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
effect I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
can O
account O
for O
79 B_MEASURE
% I_MEASURE
of O
the O
efficacy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hyaluronan I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
[ O
16 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Further O
, O
both O
studies O
are O
limited O
in O
that O
neither O
of O
the O
studies O
used O
blinding O
of O
both O
the O
participants B_PERSON
and O
assessors O
in O
their O
protocols O
. O

It O
is O
therefore O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
positive B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
have O
been O
overestimated O
. O

Accordingly O
, O
the O
aims O
of O
this O
project O
are O
to O
conduct O
a O
double O
blind O
randomised O
controlled O
trial O
to O
determine O
the O
effectiveness O
of O
intra O
- O
articular O
hyaluronan O
( O
Synvisc O
(R) O
) O
on O
( O
i O
) O
foot O
pain O
and O
function O
; O
( O
ii O
) O
the O
range O
of O
motion O
of O
the O
first O
MPJ O
; O
( O
III O
) O
the O
strength O
of O
the O
plantarflexor O
muscles O
of O
the O
first O
MPJ O
; O
( O
IV O
) O
the O
health O
related O
quality O
of O
life O
; O
and O
( O
v O
) O
the O
use O
of O
pain O
- O
relieving O
medications O
in O
people B_PERSON/B_ORGANIZATION
with O
hallux O
limitus O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
presented O
in O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
, O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
with O
the O
recommendations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
Editorial B_PERSON/B_ORGANIZATION
Board I_PERSON/I_ORGANIZATION
of O
BioMed B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Central I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
17 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Design B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study O
is O
a O
parallel O
group O
, O
participant B_PERSON
and O
assessor O
blinded O
, O
randomised O
controlled O
trial O
with O
a O
6 O
month O
follow O
- O
up O
( O
Figure O
1 O
) O
. O

It O
has O
been O
developed O
using O
the O
principles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
described O
by O
Osteoarthritis B_LOCATION/B_ORGANIZATION
Research B_LOCATION/I_ORGANIZATION
Society B_LOCATION/I_ORGANIZATION
International B_LOCATION/I_ORGANIZATION
( O
OARSI B_DISEASE/B_ORGANIZATION
) O
Clinical B_MEASURE
Trials I_MEASURE
Task I_MEASURE
Force I_MEASURE
guidelines I_MEASURE
[ O
18 B_MEASURE
] O
. O

Participants B_PERSON
will O
be O
randomised O
to O
receive O
a O
single O
intra O
- O
articular O
injection O
of O
up O
to O
1 O
ml O
hyaluronan O
( O
Synvisc O
(R) O
) O
or O
sterile O
saline O
( O
placebo O
) O
into O
the O
first O
MPJ O
. O

allocation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
either O
the O
Synvisc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
will O
be O
achieved O
using O
a O
computer B_PRODUCT[OBJECT]/B_PERSON
- O
generated O
random B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
number I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
allocation O
sequence O
will O
be O
generated O
and O
held O
by O
an O
external O
person B_PERSON/B_ORGANIZATION
not O
directly O
involved O
in O
the O
trial O
. O

Concealment O
of O
the O
allocation O
sequence O
will O
be O
ensured O
as O
each O
participant B_PERSON/B_ORGANIZATION
' O
s O
allocation O
will O
be O
contained O
in O
a O
sealed O
opaque O
envelope O
. O

Envelopes B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
made O
opaque B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
by O
using O
a O
sheet B_PRODUCT[OBJECT]/B_LOCATION
of O
aluminium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
foil I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inside O
the O
envelope B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
a O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
using O
carbon B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
paper I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
will O
be O
employed O
so O
the O
details B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
name B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
date B_LOCATION/B_MEASURE
of O
recruitment B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
are O
transferred O
from O
the O
outside B_LOCATION
of O
the O
envelope B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
paper B_PRODUCT[OBJECT]/B_LOCATION
inside O
the O
envelope B_PRODUCT[OBJECT]/B_LOCATION
containing O
the O
allocation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
opening O
the O
seal B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Assessors O
and O
participants B_PERSON
will O
be O
blinded O
to O
group O
allocation O
. O

Participants B_PERSON
will O
be O
given O
the O
option O
of O
a O
second O
and O
final O
intra O
- O
articular O
injection O
( O
of O
Synvisc O
(R) O
or O
sterile O
saline O
according O
to O
the O
treatment O
group O
they O
are O
in O
) O
on O
days O
30 O
or O
90 O
if O
there O
is O
no O
improvement O
in O
pain O
and O
the O
participant B_PERSON
has O
not O
experienced O
severe O
adverse O
effects O
after O
the O
first O
injection O
) O
. O

Participants B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Human B_ORGANIZATION/B_PERSON
Studies I_ORGANIZATION/I_PERSON
Ethics I_ORGANIZATION/I_PERSON
Committee I_ORGANIZATION/I_PERSON
at O
La B_LOCATION/B_ORGANIZATION
Trobe I_LOCATION/I_ORGANIZATION
University I_LOCATION/I_ORGANIZATION
( O
Human B_MEASURE
Ethics I_MEASURE
Committee I_MEASURE
Application I_MEASURE
No I_MEASURE
. O
07 B_MEASURE
- O
45 B_MEASURE
) O
and O
the O
radiation B_PERSON/B_ORGANIZATION
Advisory I_PERSON/I_ORGANIZATION
Committee I_PERSON/I_ORGANIZATION
of O
the O
Victorian B_ORGANIZATION/B_PERSON
Department I_ORGANIZATION/I_PERSON
of O
Human B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Services I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
given O
approval B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Written O
informed O
consent O
will O
be O
obtained O
from O
all O
participants B_PERSON/B_ORGANIZATION
prior O
to O
their O
participation O
. O

People B_PERSON
with O
hallux O
limitus O
will O
be O
recruited O
from O
a O
number O
of O
sources O
: O

( O
i O
) O
advertisements B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
relevant B_LOCATION
Melbourne I_LOCATION
( O
Australia B_LOCATION
) O
newspapers B_LOCATION/B_PERSON
; O

( O
ii B_TIME[MEASURE]
) O
mail B_MEASURE/B_PERSON
- O
out O
advertisements B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
health B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O
care B_PERSON/B_ORGANIZATION
practitioners I_PERSON/I_ORGANIZATION
in O
Melbourne B_LOCATION
; O

( O
iii B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
advertisements B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
relevant B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
internet I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
web I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
- O
sites B_LOCATION/B_ENT
( O
including O
) O
; O

( O
IV B_MEASURE/B_PROTEIN[GENE]
) O
posters B_PERSON/B_LOCATION
displayed O
in O
local B_LOCATION/B_ORGANIZATION
retirement I_LOCATION/I_ORGANIZATION
villages I_LOCATION/I_ORGANIZATION
, O
community B_LOCATION/B_ORGANIZATION
centres I_LOCATION/I_ORGANIZATION
and O
universities B_LOCATION/B_ORGANIZATION
located O
in O
Melbourne B_LOCATION
. O

Respondents B_PERSON/B_BIO
will O
initially O
be O
screened O
by O
telephone B_PERSON/B_ENT
interview I_PERSON/I_ENT
to O
ensure O
they O
are O
suitable B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

suitable B_PERSON
individuals I_PERSON
will O
then O
be O
invited O
to O
participate O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
attend O
an O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

To O
be O
included O
in O
the O
study O
, O
participants B_PERSON
must O
meet O
the O
following O
inclusion O
criteria O
: O

( O
i O
) O
be O
aged O
at O
least O
18 B_TIME[MEASURE]
years I_TIME[MEASURE]
; O

( O
ii B_TIME[MEASURE]
) O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
having O
symptoms B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pain B_DISEASE
, O
during O
walking O
or O
rest B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
in O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
for O
at O
least O
3 B_TIME[MEASURE]
months I_TIME[MEASURE]
; O

( O
III B_MEASURE/B_PROTEIN[GENE]
) O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
having O
pain B_DISEASE/B_MEASURE
rated O
at O
least O
20 B_MEASURE
mm I_MEASURE
on O
a O
100 B_TIME[MEASURE]/B_BIO
mm B_TIME[MEASURE]/I_BIO
visual B_TIME[MEASURE]/I_BIO
analogue B_TIME[MEASURE]/I_BIO
pain B_TIME[MEASURE]/I_BIO
scale B_TIME[MEASURE]/I_BIO
( O
VAPS B_TIME[MEASURE]/B_DISEASE
) O
; O

( O
IV B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
have O
pain B_DISEASE
upon O
palpation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aspect I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
; O

( O
v O
) O
radiographic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
OA B_DISEASE
( O
score B_NUMBER[MEASURE]/B_LOCATION
1 I_NUMBER[MEASURE]/I_LOCATION
or O
2 B_MEASURE
for O
either O
osteophytes B_DISEASE/B_BACTERIUM[BIO]
or O
joint B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
space I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
narrowing O
using O
a O
previously O
published O
radiographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
[ O
19 B_TIME[MEASURE]
] O
at O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

( O
VI B_MEASURE/B_PERSON
) O
able B_TIME[MEASURE]/B_PERSON
to O
walk O
household B_TIME[MEASURE]/B_LOCATION
distances I_TIME[MEASURE]/I_LOCATION
( O
> B_MEASURE
50 B_MEASURE
meters I_MEASURE
) O
without O
the O
aid B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
Walker B_PERSON/B_PRODUCT[OBJECT]
, O
crutches B_DISEASE_ADJECTIVE[DISEASE]/B_PRODUCT[OBJECT]
or O
cane B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O

( O
VII B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
be O
willing B_PERSON
to O
attend O
the O
La B_LOCATION/B_ORGANIZATION
Trobe I_LOCATION/I_ORGANIZATION
University I_LOCATION/I_ORGANIZATION
Medical I_LOCATION/I_ORGANIZATION
Centre I_LOCATION/I_ORGANIZATION
( O
Melbourne B_LOCATION
, O
Australia B_LOCATION/B_PERSON
) O
for O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
either O
Synvisc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
placebo B_LOCATION
( O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
intra B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
attend O
the O
Health B_LOCATION/B_ORGANIZATION
Sciences I_LOCATION/I_ORGANIZATION
Clinic I_LOCATION/I_ORGANIZATION
at O
La B_LOCATION/B_PERSON
Trobe I_LOCATION/I_PERSON
University I_LOCATION/I_PERSON
( O
Melbourne B_LOCATION
, O
Australia B_LOCATION/B_PERSON
) O
for O
the O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
the O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
at O
baseline B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
1 B_MEASURE/B_LOCATION
, O
3 B_NUMBER[MEASURE]
and O
6 B_LOCATION/B_TIME[MEASURE]
months I_LOCATION/I_TIME[MEASURE]
post I_LOCATION/I_TIME[MEASURE]
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
) O
; O

( O
VIII B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
not O
receive O
other B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intra I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
injections I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
into O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O
the O
course B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
apart O
from O
those O
dictated O
by O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
; O

( O
IX B_NUMBER[MEASURE]/B_LOCATION
) O
be O
willing B_PERSON/B_TIME[MEASURE]
to O
discontinue O
taking O
all O
pain B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
relieving O
medications B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
analgesics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
non B_DISEASE/B_MEASURE
- O
steroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
, O
except O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
up O
to O
4 B_MEASURE
g I_MEASURE
/ O
day B_MEASURE
, O
taken O
by O
mouth B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
or O
applied O
topically O
) O
: O

- O
for O
at O
least O
14 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
prior I_TIME[MEASURE]/I_ENT
to O
the O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O

- O
during O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 B_TIME[MEASURE]/B_LOCATION
months B_TIME[MEASURE]/I_LOCATION
after O
the O
final B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O
Synvisc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Participants B_PERSON
who O
do O
take O
paracetamol O
need O
to O
discontinue O
its O
use O
at O
least O
24 O
hours O
prior O
to O
the O
baseline O
assessment O
and O
follow O
- O
up O
assessments O
at O
1 O
, O
3 O
and O
6 O
months O
after O
the O
treatment O
; O

( O
x O
) O
be O
willing B_PERSON
to O
not O
receive O
any O
physical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
on O
the O
involved O
MPJ B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
or O
trial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
shoe B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modifications I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
foot B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
orthoses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
during O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

exclusion O
criteria O
for O
participants B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
study O
will O
be O
: O

( O
i B_DISEASE/B_PROTEIN[GENE]
) O
Severe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
radiographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
OA B_DISEASE
( O
score O
3 B_MEASURE
for O
either O
osteophytes B_DISEASE/B_BACTERIUM[BIO]
or O
joint B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
space I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
narrowing I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
using O
a O
previously O
published O
radiographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
19 B_TIME[MEASURE]/B_PROTEIN[GENE]
] I_TIME[MEASURE]/I_PROTEIN[GENE]
; O

( O
ii B_NUMBER[MEASURE]/B_DISEASE
) O
previous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
; O

( O
III B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
or O
any O
other B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intra I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
previous B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
6 B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
months B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
; O

( O
iv B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
systemic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steroid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
excluding O
inhalation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
topical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steroids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
immunosuppressives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
anticoagulants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
except O
for O
acetylsalicylic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
dosages B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
up O
to O
325 B_MEASURE
mg I_MEASURE
/ O
day B_TIME[MEASURE]
) O
; O

( O
v B_OTHER/B_PROTEIN[GENE]
) O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
joint B_DISEASE/B_MEASURE
infection I_DISEASE/I_MEASURE
( O
s B_OTHER/B_DISEASE
) O
of O
the O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
; O

( O
VI B_TIME[MEASURE]
) O
significant B_DISEASE
deformity I_DISEASE
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
including O
hallux B_DISEASE
abducto I_DISEASE
valgus I_DISEASE
( O
grade B_MEASURE/B_ENT
of O
3 B_SEQUENCE[MEASURE]
or O
4 B_MEASURE
scored O
using O
the O
Manchester B_MEASURE
Scale I_MEASURE
[ O
20 B_TIME[MEASURE]/B_DISEASE
] I_TIME[MEASURE]/I_DISEASE
; O

( O
VII B_NUMBER[MEASURE]
) O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peripheral B_DISEASE
vascular I_DISEASE
disease I_DISEASE
. O

Peripheral B_DISEASE
vascular I_DISEASE
disease I_DISEASE
will O
be O
considered O
to O
be O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O
any O
of O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21 I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O

* B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
past I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
history I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
, O
vascular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
Raynaud B_PERSON/B_LOCATION
' O
s B_DISEASE
phenomenon I_DISEASE
, O
vasculitis B_DISEASE
associated O
with O
connective B_DISEASE
tissue I_DISEASE
diseases I_DISEASE
, O
Buerger B_PERSON/B_DISEASE
' O
s B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
, O
arterial B_DISEASE
emboli I_DISEASE
, O
deep B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
vein B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
thrombosis B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
lower B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
limb I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ulcers I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O

* B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
intermittent B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
claudication I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
rest B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pain I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O

* B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
presence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
atrophy B_DISEASE
, O
ulcers B_DISEASE
or O
significant B_DISEASE
oedema I_DISEASE
; O

* B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
inability I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
to O
palpate O
at O
least O
one B_MEASURE/B_LOCATION
pedal I_MEASURE/I_LOCATION
pulse I_MEASURE/I_LOCATION
; O

* B_MEASURE/B_LOCATION
ankle I_MEASURE/I_LOCATION
Brachial I_MEASURE/I_LOCATION
pressure I_MEASURE/I_LOCATION
Index I_MEASURE/I_LOCATION
< O
0 B_MEASURE
. O
9 B_MEASURE
; O

( O
VIII B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
one B_NUMBER[MEASURE]
or O
more B_NUMBER[MEASURE]/B_LOCATION
conditions I_NUMBER[MEASURE]/I_LOCATION
that O
can O
confound O
pain B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
functional B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessments I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
metatarsalgia B_DISEASE
, O
plantar B_DISEASE
fasciitis I_DISEASE
, O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dislocation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
sprains B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
Achilles B_DISEASE
tendinopathy I_DISEASE
, O
degenerative B_DISEASE
joint I_DISEASE
disease I_DISEASE
of O
the O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
other B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
or O
painful B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corns I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
callus B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
; O

( O
IX B_NUMBER[MEASURE]/B_LOCATION
) O
planning O
to O
undergo O
any O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
or O
receive O
any O
injections B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
apart O
from O
those O
dictated O
by O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
at O
the O
involved O
first B_LOCATION/B_PERSON
MPJ I_LOCATION/I_PERSON
during O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O

( O
x B_MEASURE/B_OTHER
) O
presence B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
systemic B_DISEASE
inflammatory I_DISEASE
condition I_DISEASE
or O
infection B_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
inflammatory B_DISEASE
arthritis I_DISEASE
, O
diagnosed O
with O
rheumatoid B_DISEASE
arthritis I_DISEASE
, O
ankylosing O
spondylitis B_DISEASE
, O
psoriatic B_DISEASE
arthritis I_DISEASE
, O
reactive B_DISEASE
arthritis I_DISEASE
, O
septic B_DISEASE
arthritis I_DISEASE
, O
acute B_DISEASE
pseudogout I_DISEASE
, O
or O
any O
other B_DISEASE/B_PERSON
connective I_DISEASE/I_PERSON
tissue I_DISEASE/I_PERSON
disease I_DISEASE/I_PERSON
; O

( O
Xi B_PERSON/B_NUMBER[MEASURE]
) O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gout B_DISEASE
or O
other B_DISEASE/B_MEASURE
musculoskeletal I_DISEASE/I_MEASURE
disease I_DISEASE/I_MEASURE
other I_DISEASE/I_MEASURE
than O
OA B_DISEASE/B_LOCATION
within O
the O
feet B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
. O

Gout B_PERSON/B_DISEASE
will O
be O
screened O
for O
using O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
physical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
painful B_DISEASE/B_MEASURE
joint I_DISEASE/I_MEASURE
, O
abrupt B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
onset I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
swelling O
) O
, O
radiographic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assessment I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
asymmetrical B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
joint I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
swelling O
, O
subcortical B_DISEASE/B_LOCATION
cysts I_DISEASE/I_LOCATION
without O
erosion B_DISEASE
and O
tophi B_DISEASE
) O
as O
well O
as O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
uric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
hyperuricaemia B_DISEASE_ADJECTIVE[DISEASE]
= O
serum B_DISEASE/B_MEASURE
uric I_DISEASE/I_MEASURE
acid I_DISEASE/I_MEASURE
> O
mean O
+ O
2 B_MEASURE
SD I_MEASURE
from O
normal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
[ O
22 B_MEASURE
] I_MEASURE
; O

( O
xii B_BIO/B_DISEASE
) O
active B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
skin I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
infection B_DISEASE
in O
the O
area B_LOCATION/B_BIO
of O
the O
injection B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O

( O
XIII O
) O
any O
medical O
condition O
that O
, O
in O
the O
opinion O
of O
the O
investigators O
, O
makes O
the O
participant B_PERSON/B_DISEASE
unsuitable O
for O
inclusion O
( O
e O
. O
g O
. O
, O
severe O
progressive O
chronic O
disease O
, O
malignancy O
, O
bleeding O
disorder O
, O
clinically O
important O
pain O
in O
a O
part O
of O
the O
musculoskeletal O
system O
other O
than O
the O
first O
MPJ O
, O
or O
fibromyalgia O
) O
; O

( O
XIV O
) O
pregnant O
or O
lactating O
women B_PERSON
, O
or O
women B_PERSON
who O
are O
of O
child B_PERSON/B_BIO
bearing O
age O
or O
have O
not O
undergone O
menopause O
( O
Synvisc O
(R) O
has O
not O
been O
tested O
in O
pregnant O
women B_PERSON
or O
women B_PERSON
who O
are O
nursing O
) O
; O

( O
XV B_TIME[MEASURE]
) O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
( O
defined O
as O
a O
score B_MEASURE/B_ENT
of O
< O
7 B_MEASURE
on O
the O
Short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
portable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Mental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Status B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Questionnaire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
[ O
23 B_TIME[MEASURE]
] I_TIME[MEASURE]
; O

( O
XVI B_NUMBER[MEASURE]/B_LOCATION
) O
known O
hypersensitivity B_DISEASE
( O
allergy B_DISEASE/B_TIME[MEASURE]
) O
to O
hyaluronan B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
preparations I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
or O
to O
avian O
proteins B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
feathers B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
egg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
; O

( O
xvii B_NUMBER[MEASURE]/B_PERSON
) O
involvement B_PERSON/B_DISEASE
in O
any O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
the O
previous B_TIME[MEASURE]/B_LOCATION
3 B_TIME[MEASURE]/I_LOCATION
months B_TIME[MEASURE]/I_LOCATION
that O
could O
be O
considered O
to O
affect O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
for O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Participants B_PERSON
will O
be O
randomised O
to O
receive O
a O
single O
intra O
- O
articular O
injection O
of O
up O
to O
1 O
ml O
of O
hyaluronan O
( O
Synvisc O
(R) O
; O
Genzyme O
Biosurgery O
, O
Genzyme O
Corporation O
, O
NJ O
, O
USA O
) O
or O
sterile O
saline O
( O
placebo O
) O
into O
the O
first O
MPJ O
. O

Each O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ml I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ampoule I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Synvisc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O
16 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
hylan B_LOCATION/B_PERSON
G I_LOCATION/I_PERSON
- O
F B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
cross B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
linked O
hylan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O
hylan B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
B B_PROTEIN[GENE]/B_DISEASE
) O
, O
17 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_MEASURE
. O
32 B_MEASURE
mg I_MEASURE
disodium I_MEASURE
hydrogen I_MEASURE
phosphate I_MEASURE
, O
0 B_NUMBER[MEASURE]
. O
08 B_MEASURE
mg I_MEASURE
sodium I_MEASURE
dihydrogen I_MEASURE
phosphate I_MEASURE
monohydrate I_MEASURE
. O

The O
hyaluronan O
is O
extracted O
from O
chicken B_BIO
combs O
and O
the O
purified O
material O
has O
an O
average O
molecular O
weight O
of O
6 O
, O
000 O
kDa O
. O

The O
injections B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
performed O
by O
the O
same B_TIME[MEASURE]/B_LOCATION
experienced O
interventional B_PERSON/B_ORGANIZATION
radiologist I_PERSON/I_ORGANIZATION
( O
AEZ B_LOCATION/B_PERSON
) O
using O
fluoroscopic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
ensure O
accurate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
deposition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
the O
joint B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

As O
the O
Synvisc O
(R) O
is O
provided O
in O
ampoules O
that O
are O
labelled O
with O
the O
product O
name O
, O
it O
will O
not O
be O
possible O
to O
blind O
the O
injector O
, O
however O
this O
person B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
involved O
in O
generation O
of O
the O
allocation O
order O
, O
recruitment O
, O
assessment O
or O
data O
analysis O
. O

The O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
will O
be O
performed O
using O
a O
21 B_MEASURE
gauge I_MEASURE
( O
0 B_MEASURE/B_LOCATION
. O
80 B_MEASURE
x O
19 B_TIME[MEASURE]
mm I_TIME[MEASURE]
) O
Surflo B_MEDICAL_DEVICE[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) I_MEDICAL_DEVICE[OBJECT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Terumo B_LOCATION/B_ORGANIZATION
(R) I_LOCATION/I_ORGANIZATION
Corp I_LOCATION/I_ORGANIZATION
. O
, O
Tokyo B_LOCATION/B_ORGANIZATION
, O
Japan B_LOCATION/B_MEASURE
) O
winged O
infusion B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
set O
under O
aseptic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Either O
a O
dorso B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
lateral B_BODY_PART_OR_ORGAN_COMPONENT
or O
dorso B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
medial B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
approach I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
will O
be O
used O
at O
the O
discretion B_LOCATION/B_PERSON
of O
the O
injector B_PERSON
( O
depending O
on O
which O
approach B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
provides O
minimum B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
interference I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
from O
the O
osteophytes B_PERSON/B_BIO
at O
the O
first B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
MPJ B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
joint B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
margins B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
. O

No O
anaesthetic B_PRODUCT[OBJECT]/B_LOCATION
will O
be O
used O
. O

If O
the O
participant B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
has O
bilateral O
painful O
first O
MPJs O
, O
only O
one O
side O
( O
the O
most O
painful O
side O
) O
will O
be O
treated O
and O
used O
for O
data O
collection O
. O

The O
injector B_PRODUCT[OBJECT]/B_ENT
will O
record O
the O
volume B_MEASURE/B_LOCATION
of O
the O
agent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
injected O
. O

Participants B_PERSON
will O
be O
given O
the O
option O
of O
a O
second O
and O
final O
intra O
- O
articular O
injection O
( O
of O
Synvisc O
(R) O
or O
sterile O
saline O
according O
to O
the O
treatment O
group O
they O
are O
in O
) O
on O
days O
30 O
or O
90 O
if O
there O
is O
no O
improvement O
in O
pain O
( O
assessed O
using O
the O
VAPS O
for O
pain O
during O
walking O
or O
at O
rest O
) O
and O
the O
participant B_PERSON
has O
not O
experienced O
severe O
adverse O
effects O
after O
the O
first O
injection O
) O
. O

assessments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

An O
initial O
assessment O
will O
be O
performed O
to O
determine O
the O
eligibility O
of O
participants B_PERSON
for O
this O
study O
. O

demographic O
data O
will O
be O
collected O
including O
the O
age O
, O
gender O
, O
height O
and O
weight O
of O
participants B_PERSON
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O
also O
be O
obtained O
concerning O
the O
presentation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
symptoms B_DISEASE
( O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
affected O
, O
duration B_MEASURE
of O
symptoms B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
. O

If O
the O
participant B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
has O
bilateral O
painful O
first O
MPJs O
, O
the O
most O
painful O
side O
will O
be O
used O
for O
data O
collection O
and O
subsequent O
treatment O
. O

To O
establish O
eligibility O
for O
the O
study O
, O
participants B_PERSON
will O
undergo O
a O
clinical O
assessment O
, O
have O
one O
set O
of O
dorso O
- O
plantar O
and O
lateral O
weight O
- O
bearing O
x O
- O
rays O
taken O
of O
their O
feet O
to O
grade O
the O
severity O
of O
first O
MPJ O
OA O
as O
well O
as O
undergo O
a O
blood O
test O
to O
assess O
serum O
uric O
acid O
levels O
( O
to O
exclude O
gout O
) O
. O

Weightbearing O
dorso O
- O
plantar O
and O
lateral O
radiographic O
views O
will O
be O
obtained O
from O
both O
feet O
with O
the O
participant B_PERSON/B_BIO
standing O
in O
a O
relaxed O
bipedal O
stance O
position O
. O

All O
x B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rays B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
taken O
by O
the O
same B_PERSON/B_LOCATION
medical I_PERSON/I_LOCATION
imaging I_PERSON/I_LOCATION
department I_PERSON/I_LOCATION
using O
a O
Shimadzu B_MEASURE
UD150LRII I_MEASURE
50 I_MEASURE
kW I_MEASURE
/ O
30 B_MEASURE
kHz I_MEASURE
generator I_MEASURE
and O
0 B_TIME[MEASURE]/B_LOCATION
. O
6 B_MEASURE
/ O
1 B_MEASURE
. O
2 B_MEASURE
P18DE I_MEASURE
- O
80s B_NUMBER[MEASURE]/B_SPORT[ENT]
high I_NUMBER[MEASURE]/I_SPORT[ENT]
speed I_NUMBER[MEASURE]/I_SPORT[ENT]
x O
- O
ray B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tube I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
a O
ceiling B_LOCATION/B_MEASURE
suspended O
tube B_LOCATION
mount I_LOCATION
. O

AGFA B_NUMBER[MEASURE]
MD40 I_NUMBER[MEASURE]
CR I_NUMBER[MEASURE]
digital I_NUMBER[MEASURE]
phosphor I_NUMBER[MEASURE]
plates O
in O
a O
24 B_MEASURE
cm I_MEASURE
x O
30 B_MEASURE
cm I_MEASURE
cassette I_MEASURE
will O
be O
used O
. O

For O
dorso B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
plantar B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projections I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
x B_MEASURE
- O
ray B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
tube B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
will O
be O
angled O
15 B_LOCATION/B_MEASURE
degrees I_LOCATION/I_MEASURE
cephalad I_LOCATION/I_MEASURE
and O
centered O
at O
the O
base B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
third B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsal I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
lateral B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projections I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
tube B_BODY_PART_OR_ORGAN_COMPONENT
will O
be O
angled O
90 B_LOCATION/B_MEASURE
degrees I_LOCATION/I_MEASURE
and O
centered O
at O
the O
base B_LOCATION/B_MEASURE
of O
the O
third B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsal I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
film B_MEASURE/B_ENT
focus I_MEASURE/I_ENT
distance I_MEASURE/I_ENT
will O
be O
set O
at O
100 B_MEASURE/B_LOCATION
cm I_MEASURE/I_LOCATION
[ O
19 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Participants B_PERSON
who O
are O
eligible O
for O
the O
study O
will O
be O
invited O
to O
attend O
a O
baseline O
assessment O
. O

During O
the O
baseline O
assessment O
, O
participants B_PERSON
will O
undergo O
primary O
and O
secondary O
outcome O
measurements O
prior O
to O
receiving O
their O
injection O
. O

The O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
been O
developed O
in O
accordance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
recommendations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
OARSI B_ORGANIZATION/B_PERSON
Clinical I_ORGANIZATION/I_PERSON
Trials I_ORGANIZATION/I_PERSON
Task I_ORGANIZATION/I_PERSON
Force I_ORGANIZATION/I_PERSON
guidelines I_ORGANIZATION/I_PERSON
[ O
18 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
and O
secondary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
will O
occur O
at O
four B_NUMBER[MEASURE]/B_ENT
time I_NUMBER[MEASURE]/I_ENT
- O
points B_LOCATION/B_TIME[MEASURE]
at O
baseline B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
1 B_SEQUENCE[MEASURE]/B_LOCATION
, O
3 B_NUMBER[MEASURE]
and O
6 B_TIME[MEASURE]/B_LOCATION
months B_TIME[MEASURE]/I_LOCATION
post B_TIME[MEASURE]/I_LOCATION
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
after O
the O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
Synvisc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
placebo B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
assessor O
performing O
the O
measurements O
will O
be O
blinded O
as O
to O
which O
treatment O
group O
participants B_PERSON/B_LOCATION
have O
been O
allocated O
to O
. O

Participants B_PERSON
who O
receive O
a O
second O
treatment O
at O
day O
30 O
or O
90 O
will O
be O
followed O
for O
a O
further O
30 O
days O
or O
90 O
days O
respectively O
and O
undergo O
outcome O
measurements O
at O
7 O
or O
9 O
months O
respectively O
. O

The O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
be O
the O
Pain B_DISEASE
and O
Function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
subscales B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
Foot B_DISEASE/B_GENE
Health I_DISEASE/I_GENE
Status I_DISEASE/I_GENE
Questionnaire I_DISEASE/I_GENE
( O
FHSQ B_MEASURE/B_DISEASE
) O
[ O
24 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

The O
FHSQ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
includes O
13 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
questions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
assess O
four B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
domains I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
foot B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
health B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, O
Foot B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pain I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
Foot B_DISEASE
function I_DISEASE
, O
Footwear B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
General B_DISEASE_ADJECTIVE[DISEASE]
foot I_DISEASE_ADJECTIVE[DISEASE]
health I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
FHSQ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O
been O
subjected O
to O
an O
extensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
validation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
content B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
criterion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
construct O
validity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

It O
has O
a O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
retest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reliability I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
intraclass B_MEASURE/B_PROTEIN[GENE]
correlation B_MEASURE/I_PROTEIN[GENE]
coefficients B_MEASURE/I_PROTEIN[GENE]
ranging O
from O
0 B_NUMBER[MEASURE]
. O
74 B_MEASURE
to O
0 B_NUMBER[MEASURE]
. O
92 B_MEASURE
) O
and O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
degree I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
internal B_MEASURE
consistency I_MEASURE
( O
Cronbach B_PERSON/B_MEASURE
' O
s B_MEASURE/B_PERSON
alpha I_MEASURE/I_PERSON
ranging O
from O
0 B_NUMBER[MEASURE]
. O
85 B_MEASURE
to O
0 B_NUMBER[MEASURE]
. O
88 B_MEASURE
) O
[ O
24 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

rigorous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reviews I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
rated O
it O
as O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
highest B_SEQUENCE[MEASURE]/B_PERSON
quality I_SEQUENCE[MEASURE]/I_PERSON
foot I_SEQUENCE[MEASURE]/I_PERSON
health I_SEQUENCE[MEASURE]/I_PERSON
status I_SEQUENCE[MEASURE]/I_PERSON
measures I_SEQUENCE[MEASURE]/I_PERSON
currently O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
25 B_MEASURE
- O
27 B_MEASURE
] I_MEASURE
. O

Secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
will O
be O
: O

( O
i O
) O
Severity B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pain B_DISEASE
. O

Severity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
pain B_DISEASE
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O
walking O
, O
and O
during O
rest B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
over O
the O
past B_BODY_PART_OR_ORGAN_COMPONENT
week I_BODY_PART_OR_ORGAN_COMPONENT
will O
be O
assessed O
using O
a O
100 B_MEASURE/B_PERSON
mm B_MEASURE/I_PERSON
visual B_MEASURE/I_PERSON
analogue B_MEASURE/I_PERSON
pain B_MEASURE/I_PERSON
scale B_MEASURE/I_PERSON
. O

The O
left B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
side I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
scale B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
mm I_MEASURE
) O
will O
be O
labelled O
' O
no O
pain B_DISEASE
' O
and O
the O
right B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
side I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
scale B_MEASURE
( O
100 B_MEASURE
mm I_MEASURE
) O
will O
be O
labelled O
' B_DISEASE_ADJECTIVE[DISEASE]
worst I_DISEASE_ADJECTIVE[DISEASE]
pain I_DISEASE_ADJECTIVE[DISEASE]
possible I_DISEASE_ADJECTIVE[DISEASE]
' O
for O
each O
question B_TIME[MEASURE]/B_LOCATION
[ O
25 B_MEASURE
, O
28 B_MEASURE
] I_MEASURE
. O

( O
ii B_SEQUENCE[MEASURE]/B_DISEASE
) O
severity B_MEASURE/B_LOCATION
and O
duration B_MEASURE/B_LOCATION
of O
stiffness B_DISEASE
at O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metatarsophalangeal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
joint B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
severity B_MEASURE
of O
stiffness B_DISEASE
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O
walking O
over O
the O
past B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
week I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
will O
be O
assessed O
using O
a O
100 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visual B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogue B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
left B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
side I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
scale B_MEASURE
( O
0 B_MEASURE
mm I_MEASURE
) O
will O
be O
labelled O
' O
not O
stiff B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O
all O
' O
and O
the O
right B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
side I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
scale B_MEASURE/B_ENT
( O
100 B_MEASURE
mm I_MEASURE
) O
will O
be O
labelled O
' O
most O
stiff B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
possible I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
' O
. O

The O
average B_MEASURE
duration I_MEASURE
of O
stiffness B_DISEASE
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
over O
the O
past B_TIME[MEASURE]/B_LOCATION
week I_TIME[MEASURE]/I_LOCATION
will O
be O
assessed O
using O
a O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
category I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scale I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
response I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
responses B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
: O
' O
none B_TIME[MEASURE]/B_PERSON
' O
, O
' O
1 B_NUMBER[MEASURE]
- O
15 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
' I_TIME[MEASURE]/I_ENT
, O
' O
16 B_MEASURE
- O
30 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
' I_TIME[MEASURE]/I_ENT
and O
' O
greater B_LOCATION/B_MEASURE
than O
30 B_NUMBER[MEASURE]/B_ENT
minutes I_NUMBER[MEASURE]/I_ENT
' I_NUMBER[MEASURE]/I_ENT
[ O
29 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

( O
III B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
passive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
non O
- O
weightbearing O
dorsiflexion B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
motion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metatarsophalangeal I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
joint I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

First B_LOCATION/B_PERSON
MPJ I_LOCATION/I_PERSON
dorsiflexion I_LOCATION/I_PERSON
range I_LOCATION/I_PERSON
of O
motion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
will O
be O
measured O
using O
a O
goniometer B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
maximum B_MEASURE/B_LOCATION
angle I_MEASURE/I_LOCATION
at O
which O
the O
hallux B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cannot I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
be O
passively O
moved O
into O
further B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extension I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
non O
- O
weightbearing O
position B_LOCATION
( O
Figure B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
) O
[ O
30 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
performed O
two B_TIME[MEASURE]/B_LOCATION
times I_TIME[MEASURE]/I_LOCATION
and O
the O
average B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
used O
for O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

This O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
technique I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
shows O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
intra I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
reliability B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ICC B_PROTEIN[GENE]/B_DISEASE
= O
0 B_MEASURE
. O
95 B_MEASURE
, O
standard B_MEASURE/B_LOCATION
error I_MEASURE/I_LOCATION
of O
mean B_MEASURE/B_LOCATION
= O
1 B_MEASURE
. O
3 B_MEASURE
degrees I_MEASURE
) O
[ O
30 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

( O
IV B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
plantar B_DISEASE
flexion I_DISEASE
strength I_DISEASE
of O
the O
toe B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
flexors B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hallux B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Plantar B_NUMBER[MEASURE]/B_PERSON
flexion I_NUMBER[MEASURE]/I_PERSON
strength I_NUMBER[MEASURE]/I_PERSON
of O
the O
toe B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
flexors B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hallux B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
will O
be O
measured O
using O
the O
Mat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scan I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
(R) I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
plantar I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pressure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
device I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
[ O
31 B_TIME[MEASURE]/B_PERSON
] I_TIME[MEASURE]/I_PERSON
. O

Participants B_PERSON
will O
be O
seated O
with O
the O
hip O
, O
knee O
, O
and O
ankle O
at O
90 O
degrees O
and O
their O
foot O
placed O
over O
the O
Mat O
scan O
(R) O
plantar O
pressure O
measurement O
device O
( O
Tekscan O
, O
Boston O
, O
MA O
, O
USA O
) O
( O
Figure O
3a O
) O
. O

This O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
consists O
of O
a O
5 B_MEASURE
- O
mm B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
thick B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
floor B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
mat B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
432 B_MEASURE
x O
368 B_MEASURE
mm I_MEASURE
) O
incorporating O
2288 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resistive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
sensors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
1 B_MEASURE
. O
4 B_MEASURE
sensors I_MEASURE
/ O
cm2 B_MEASURE
) O
sampling B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
at O
a O
rate B_MEASURE
of O
40 B_NUMBER[MEASURE]/B_LOCATION
Hz I_NUMBER[MEASURE]/I_LOCATION
. O

The O
mat O
will O
be O
calibrated O
for O
each O
participant B_PERSON
using O
his O
or O
her O
own O
bodyweight O
before O
each O
testing O
session O
. O

Participants B_PERSON
will O
be O
instructed O
to O
use O
their O
toe O
- O
flexor O
muscles O
to O
maximally O
push O
their O
hallux O
down O
on O
the O
MatScan O
(R) O
device O
and O
forces O
under O
the O
hallux O
will O
be O
recorded O
( O
Figure O
3b O
) O
. O

The O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
performed O
three B_TIME[MEASURE]/B_LOCATION
times I_TIME[MEASURE]/I_LOCATION
for O
the O
hallux B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
the O
maximal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
force B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
used O
for O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O
retest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reliability I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
technique I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
previously O
been O
shown O
to O
be O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
with O
intraclass B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coefficients B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ICCs B_DISEASE/B_LOCATION
) O
= O
0 B_MEASURE
. O
88 B_MEASURE
( O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
0 I_MEASURE
. O
81 B_MEASURE
- O
0 B_MEASURE
. O
93 B_MEASURE
) O
[ O
31 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

( O
VI B_MEASURE
) O
plantar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pressure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

plantar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
be O
recorded O
during O
level B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
barefoot I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
walking O
using O
the O
MatScan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
(R) B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
( O
Tekscan B_MEASURE/B_PERSON
(R) I_MEASURE/I_PERSON
, O
Boston B_LOCATION/B_PERSON
, O
MA B_LOCATION
, O
USA B_LOCATION/B_MEASURE
) O
. O

The O
two B_NUMBER[MEASURE]
- O
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
gait I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
initiation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
will O
be O
used O
to O
obtain O
foot B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
as O
it O
requires O
fewer B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
trials B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
the O
mid B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
gait B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
has O
similar B_LOCATION/B_NUMBER[MEASURE]
re B_LOCATION/I_NUMBER[MEASURE]
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reliability I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
32 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
be O
recorded O
, O
which O
has O
been O
found O
to O
be O
sufficient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
ensure O
adequate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reliability I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
pressure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
32 B_MEASURE
, O
33 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

Following O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
Research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Foot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
(R) I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
version B_MEASURE/B_LOCATION
5 B_MEASURE/I_LOCATION
. O
24 B_MEASURE
) O
will O
be O
used O
to O
construct O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
masks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
determine O
maximum B_MEASURE/B_DISEASE
force I_MEASURE/I_DISEASE
( O
kg B_MEASURE/B_LOCATION
) O
and O
peak B_MEASURE
pressure I_MEASURE
( O
kg B_MEASURE
/ O
cm2 B_MEASURE
) O
under O
seven B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regions B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
: O
hallux B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
lesser B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
toes I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
1st B_BODY_PART_OR_ORGAN_COMPONENT
MPJ I_BODY_PART_OR_ORGAN_COMPONENT
, O
2nd B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
3rd B_SEQUENCE[MEASURE]
to O
5th B_SEQUENCE[MEASURE]/B_PERSON
MPJs I_SEQUENCE[MEASURE]/I_PERSON
, O
midfoot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
heel B_BODY_PART_OR_ORGAN_COMPONENT
( O
Figure B_MEASURE/B_PERSON
4a I_MEASURE/I_PERSON
) O
. O

For O
each O
region B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
median B_MEASURE
of O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
be O
used O
for O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Typical O
plantar O
pressure O
recordings O
from O
a O
participant B_PERSON/B_LOCATION
are O
shown O
in O
Figure O
4b O
. O

( O
VI B_NUMBER[MEASURE]
) O
Global B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
satisfaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Global B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
satisfaction I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
will O
be O
assessed O
using O
a O
5 B_NUMBER[MEASURE]
- O
point B_MEASURE/B_LOCATION
Likert I_MEASURE/I_LOCATION
scale I_MEASURE/I_LOCATION
, O
as O
well O
as O
a O
dichotomous B_BIO/B_MEASURE
( O
yes O
/ O
no O
) O
scale B_MEASURE
. O

The O
five B_NUMBER[MEASURE]/B_DISEASE
point I_NUMBER[MEASURE]/I_DISEASE
- O
Likert B_MEASURE/B_PERSON
scale I_MEASURE/I_PERSON
will O
ask O
' O
How O
satisfied O
are O
you O
with O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
you O
received O
for O
your O
big B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
toe B_DISEASE/B_PERSON
joint B_DISEASE/I_PERSON
pain B_DISEASE/I_PERSON
? O
' O
, O
and O
will O
have O
the O
following O
five B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
' O
Dissatisfied B_PERSON/B_TIME[MEASURE]
' O
, O
' O
Only O
moderately O
satisfied B_TIME[MEASURE]/B_PERSON
' O
, O
' O
fairly O
satisfied B_TIME[MEASURE]/B_PERSON
' O
, O
' O
Clearly O
satisfied B_TIME[MEASURE]/B_PERSON
' O
and O
' O
Very O
satisfied B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O
. O

The O
dichotomous B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
satisfaction B_DISEASE
will O
be O
answered O
as O
' O
Yes O
' O
' O
or O
' O
No O
' O
in O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
question B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
' O
Would O
you O
recommend O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
that O
you O
received O
to O
someone B_PERSON
else O
with O
big B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
toe B_DISEASE
joint I_DISEASE
pain I_DISEASE
' O
. O

( O
VII B_TIME[MEASURE]
) O
Health B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
related O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Short B_PERSON/B_MEASURE
- O
Form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- O
36 B_MEASURE/B_PERSON
( O
version B_LOCATION/B_MEASURE
two I_LOCATION/I_MEASURE
) O
( O
SF B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
36 B_MEASURE
) O
questionnaire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O
be O
used O
to O
assess O
health B_PERSON/B_DISEASE
related O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
SF B_LOCATION/B_DISEASE
- O
36 B_MEASURE
is O
a O
36 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
question I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
survey I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
measures O
eight B_PERSON/B_ORGANIZATION
health I_PERSON/I_ORGANIZATION
concepts I_PERSON/I_ORGANIZATION
most O
affected O
by O
disease B_DISEASE
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
eight B_MEASURE
health I_MEASURE
concepts I_MEASURE
can O
then O
be O
used O
to O
form O
two B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
summary I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Physical B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
health I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
Mental B_DISEASE_ADJECTIVE[DISEASE]
health I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
Short B_LOCATION
Form I_LOCATION
- O
36 B_MEASURE
( O
SF B_LOCATION
- O
36 B_MEASURE
) O
has O
been O
extensively O
validated O
and O
is O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
most O
widely O
used O
instruments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
measure O
health B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
SF B_LOCATION/B_DISEASE
- O
36 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O
content B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
concurrent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
criterion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
construct B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
validity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
reliability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
eight B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concepts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
summary I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
been O
assessed O
using O
both O
internal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consistency I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
retest B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

reliability B_PERSON/B_ORGANIZATION
statistics I_PERSON/I_ORGANIZATION
have O
exceeded O
0 B_MEASURE/B_LOCATION
. O
80 B_MEASURE
[ I_MEASURE
34 I_MEASURE
- O
37 B_MEASURE
] I_MEASURE
. O

( O
VIII B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
Self B_PERSON/B_LOCATION
- O
reported O
magnitude B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
symptom B_DISEASE
change I_DISEASE
. O

Self B_PERSON/B_LOCATION
- O
reported O
magnitude B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
symptom B_DISEASE
change I_DISEASE
will O
be O
measured O
using O
a O
15 B_NUMBER[MEASURE]
- O
point B_MEASURE/B_LOCATION
Likert I_MEASURE/I_LOCATION
scale I_MEASURE/I_LOCATION
. O

The O
scale O
will O
ask O
participants B_PERSON/B_LOCATION
' O
how O
much O
have O
your O
symptoms O
in O
your O
big O
- O
toe O
joint O
have O
changed O
from O
the O
beginning O
of O
the O
study O
to O
now O
? O
' O
. O

The O
fifteen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
range O
from O
' O
A O
very O
great B_DISEASE_ADJECTIVE[DISEASE]
deal I_DISEASE_ADJECTIVE[DISEASE]
better I_DISEASE_ADJECTIVE[DISEASE]
' O
to O
' O
A O
very O
great B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deal I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
worse I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
' O
. O

( O
IX B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
Use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
rescue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
relieve O
pain B_DISEASE
at O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metatarsophalangeal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
joint B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
number O
of O
participants B_PERSON
who O
consumed O
rescue O
medication O
( O
e O
. O
g O
. O
, O
paracetamol O
) O
and O
mean O
consumption O
of O
rescue O
medication O
to O
relieve O
pain O
at O
the O
first O
MPJ O
( O
mean O
grams O
of O
paracetamol O
/ O
participant B_PERSON/B_MEASURE
/ O
month O
] O
will O
be O
assessed O
using O
a O
medications O
diary O
that O
participants B_PERSON
will O
self O
- O
complete O
[ O
38 O
, O
39 O
] O
. O

The O
diary B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
returned O
to O
the O
assessor B_PERSON/B_LOCATION
at O
monthly B_TIME[MEASURE]/B_LOCATION
intervals B_TIME[MEASURE]/I_LOCATION
for O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
x B_OTHER/B_NUMBER[MEASURE]
) O
frequency B_MEASURE
and O
severity B_MEASURE/B_PERSON
of O
adverse B_DISEASE
events I_DISEASE
as O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
frequency O
( O
number O
of O
participants B_PERSON
affected O
and O
number O
of O
cases O
) O
and O
types O
of O
adverse O
events O
( O
including O
adverse O
drug O
reactions O
) O
in O
each O
treatment O
group O
during O
the O
trial O
will O
be O
recorded O
using O
a O
questionnaire O
that O
participants B_PERSON
will O
complete O
during O
the O
follow O
- O
up O
appointments O
at O
1 O
, O
3 O
and O
6 O
months O
post O
- O
treatment O
[ O
40 O
] O
. O

To O
classify O
the O
' O
type B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
' O
of O
adverse B_DISEASE_ADJECTIVE[DISEASE]
event I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
blinded B_PERSON/B_ORGANIZATION
assessor I_PERSON/I_ORGANIZATION
will O
classify O
the O
adverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
event I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
being O
serious B_DISEASE_ADJECTIVE[DISEASE]
or O
non O
- O
serious B_DISEASE_ADJECTIVE[DISEASE]
[ O
40 B_MEASURE/B_PERSON
] B_MEASURE/I_PERSON
. O

Any O
serious B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
, O
defined O
as O
adverse B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
leading O
to O
serious B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disability B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
hospital B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
admission I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
or O
prolongation B_DISEASE/B_TIME[MEASURE]
of O
hospitalisation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
life B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
threatening O
events B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
or O
death B_DISEASE/B_PERSON
) O
will O
be O
further O
classified O
using O
the O
International B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Diseases B_DISEASE
( O
ICD B_DISEASE
) O
codes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O
41 B_NUMBER[MEASURE]
] O
. O

Non B_DISEASE
- O
serious B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
will O
include O
both O
local B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
pain B_DISEASE
, O
effusion B_DISEASE
and O
heat B_DISEASE/B_BIO
, O
with O
each O
classified O
as O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
severe B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
adverse I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
events I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

An O
open O
- O
response O
type O
format O
will O
also O
be O
available O
for O
participant B_PERSON
responses O
. O

sample B_MEASURE
size I_MEASURE
. O

The O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
size I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O
been O
pre B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
specified O
using O
an O
a O
priori B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
power I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O
the O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
pain B_MEASURE
domain I_MEASURE
of O
the O
FHSQ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O
42 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

One O
hundred O
and O
forty O
two O
participants B_PERSON
( O
i O
. O
e O
. O
71 O
per O
group O
) O
will O
provide O
power O
of O
90 O
% O
to O
detect O
a O
minimally O
important O
difference O
in O
the O
pain O
domain O
of O
the O
FHSQ O
( O
i O
. O
e O
. O
14 O
points O
on O
the O
FHSQ O
questionnaire O
) O
with O
the O
significance O
level O
set O
at O
p O
< O
0 O
. O
05 O
. O

A O
difference B_MEASURE/B_LOCATION
of O
14 B_MEASURE
points I_MEASURE
was O
determined O
to O
be O
a O
clinically O
significant B_DISEASE_ADJECTIVE[DISEASE]
difference I_DISEASE_ADJECTIVE[DISEASE]
worth I_DISEASE_ADJECTIVE[DISEASE]
detecting O
[ O
43 B_MEASURE
] I_MEASURE
and O
a O
standard B_MEASURE
deviation I_MEASURE
of O
25 B_NUMBER[MEASURE]
was O
derived O
from O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
44 B_MEASURE
] I_MEASURE
. O

This O
calculation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
included O
a O
5 B_DISEASE
% I_DISEASE
drop I_DISEASE
- O
out O
rate B_MEASURE/B_LOCATION
[ O
13 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

However O
, O
we O
will O
aim O
to O
recruit O
150 O
participants B_PERSON
( O
~ O
75 O
participants B_PERSON
per O
intervention O
group O
) O
. O

Further O
, O
we O
have O
conservatively O
ignored O
the O
extra B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
precision I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
provided O
by O
covariate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
when O
estimating O
the O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
size I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
undertaken O
using O
SPSS B_MEASURE
version I_MEASURE
14 I_MEASURE
. O
0 B_MEASURE
( O
SPSS B_ORGANIZATION/B_LOCATION
Corp I_ORGANIZATION/I_LOCATION
, O
Chicago B_LOCATION
, O
Ill B_LOCATION/B_DISEASE
, O
USA B_LOCATION/B_MEASURE
) O
and O
STATA B_TIME[MEASURE]/B_PERSON
8 I_TIME[MEASURE]/I_PERSON
( O
Stata B_ORGANIZATION/B_LOCATION
Corp B_ORGANIZATION/I_LOCATION
, O
College B_LOCATION/B_PERSON
Station I_LOCATION/I_PERSON
, O
Tex B_PERSON/B_LOCATION
. O
, O
USA B_LOCATION/B_ORGANIZATION
) O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

All O
analyses O
will O
be O
conducted O
on O
an O
intention O
- O
to O
- O
treat O
principle O
using O
all O
randomised O
participants B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
45 O
- O
47 O
] O
. O

Missing O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O
be O
replaced O
with O
the O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
score I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
carried O
forward O
[ O
48 B_MEASURE/B_PERSON
] I_MEASURE/I_PERSON
. O

Standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
distribution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
will O
be O
used O
and O
transformation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
carried O
out O
if O
required O
. O

Demographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
gender B_PERSON/B_MEASURE
, O
age B_MEASURE/B_PERSON
, O
weight B_MEASURE/B_LOCATION
, O
height B_LOCATION/B_MEASURE
, O
body B_MEASURE/B_PERSON
mass I_MEASURE/I_PERSON
index I_MEASURE/I_PERSON
) O
will O
be O
determined O
for O
the O
baseline B_PERSON
visit I_PERSON
for O
each O
treatment B_PERSON/B_LOCATION
group I_PERSON/I_LOCATION
. O

summary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
statistics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
will O
be O
calculated O
for O
duration B_MEASURE
of O
symptoms B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
affected O
( O
left O
, O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O
bilateral B_LOCATION/B_MEASURE
) O
, O
grade B_MEASURE/B_LOCATION
of O
OA B_DISEASE
at O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
[ O
19 B_TIME[MEASURE]/B_LOCATION
] O
as O
well O
as O
all O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
each O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O
be O
conducted O
on O
1 B_TIME[MEASURE]
, O
3 B_SEQUENCE[MEASURE]
and O
6 B_TIME[MEASURE]
month I_TIME[MEASURE]
outcome I_TIME[MEASURE]
measures I_TIME[MEASURE]
. O

The O
continuously O
- O
scored O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
1 B_SEQUENCE[MEASURE]
, O
3 B_NUMBER[MEASURE]
and O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
will O
be O
compared O
using O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
covariance B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
baseline B_MEASURE/B_PERSON
scores I_MEASURE/I_PERSON
and O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
entered O
as O
independent B_MEASURE/B_LOCATION
variables I_MEASURE/I_LOCATION
[ O
49 B_MEASURE
, O
50 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
exception B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
this O
will O
be O
the O
plantar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
which O
will O
be O
analysed O
at O
baseline B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
1 B_SEQUENCE[MEASURE]/B_LOCATION
, O
3 B_SEQUENCE[MEASURE]
and O
6 B_MEASURE/B_LOCATION
months I_MEASURE/I_LOCATION
using O
two B_NUMBER[MEASURE]
- O
way B_LOCATION/B_TIME[MEASURE]
repeated O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
variance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
statistics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Post B_DISEASE/B_LOCATION
- O
hoc B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparisons I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
performed O
using O
Bonferroni B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adjusted O
t B_OTHER/B_DISEASE
- O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

nominal B_TIME[MEASURE]/B_LOCATION
and O
ordinal B_MEASURE
scaled O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O
be O
compared O
at O
1 B_SEQUENCE[MEASURE]
, O
3 B_NUMBER[MEASURE]
and O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
using O
Mann B_PERSON/B_LOCATION
- O
Whitney B_PERSON/B_LOCATION
U I_PERSON/I_LOCATION
- O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
Chi B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
square B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
or O
Fisher B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
s I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exact I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
where O
appropriate B_DISEASE_ADJECTIVE[DISEASE]
) O
respectively O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sizes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
will O
be O
determined O
using O
Cohen B_PERSON/B_MEASURE
' O
s B_PROTEIN[GENE]
d I_PROTEIN[GENE]
( O
continuous B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
scaled O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
or O
odds B_MEASURE/B_LOCATION
ratios I_MEASURE/I_LOCATION
( O
nominal B_MEASURE
scaled O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
ordinal B_MEASURE
scaled O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
as O
appropriate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
outcome O
measurements O
obtained O
at O
7 O
or O
9 O
months O
for O
participants B_PERSON
that O
receive O
a O
second O
and O
final O
intra O
- O
articular O
injection O
( O
of O
Synvisc O
(R) O
or O
sterile O
saline O
according O
to O
the O
treatment O
group O
they O
are O
in O
) O
on O
days O
30 O
or O
90 O
respectively O
, O
will O
also O
be O
analysed O
as O
described O
above O
. O

These O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
classified O
as O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study O
is O
a O
randomised O
placebo O
controlled O
trial O
designed O
to O
investigate O
the O
efficacy O
of O
intra O
- O
articular O
hyaluronan O
( O
Synvisc O
(R) O
) O
to O
reduce O
pain O
and O
improve O
function O
in O
people B_PERSON/B_ORGANIZATION
with O
OA O
of O
the O
first O
MPJ O
( O
hallux O
limitus O
) O
. O

Two B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
previously O
investigated O
the O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
first B_DISEASE
MPJ I_DISEASE
OA I_DISEASE
[ O
13 B_MEASURE
, O
14 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

However O
, O
neither O
of O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
used O
a O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

To O
our O
knowledge B_PERSON/B_DISEASE
, O
this O
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
randomised B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
controlled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
using O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O
OA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
MPJ I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
a O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evaluating O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
therapies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
as O
there O
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
a O
large B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
placebo I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O
to O
the O
injection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
this O
may O
inflate O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
uncontrolled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evaluations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
51 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Indeed O
, O
a O
recent B_DISEASE/B_MEASURE
meta I_DISEASE/I_MEASURE
- O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hyaluronan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
knee B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
OA I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
concluded O
that O
a O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effect I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
accounted O
for O
79 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
efficacy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyaluronan I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
16 B_GENE/B_LOCATION
] I_GENE/I_LOCATION
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
developed O
in O
accordance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
recommendations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
OARSI B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Clinical I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Trials I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Task I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Force I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
guidelines I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
18 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
outcome O
measures O
are O
pain O
and O
function O
subscales O
of O
the O
FHSQ O
, O
pain O
and O
stiffness O
at O
the O
first O
MPJ O
, O
range O
of O
motion O
( O
dorsiflexion O
) O
of O
the O
first O
MPJ O
, O
plantar O
flexion O
strength O
of O
muscles O
of O
the O
first O
MPJ O
, O
generic O
health O
related O
quality O
of O
life O
( O
SF O
- O
36 O
) O
, O
patient B_PERSON
satisfaction O
with O
treatment O
, O
consumption O
of O
rescue O
medication O
as O
well O
as O
frequency O
and O
nature O
of O
adverse O
effects O
. O

These O
outcomes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
will O
be O
measured O
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
then O
at O
1 B_SEQUENCE[MEASURE]
, O
3 B_MEASURE
and O
6 B_SEQUENCE[MEASURE]/B_LOCATION
months I_SEQUENCE[MEASURE]/I_LOCATION
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggests O
that O
the O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hyaluronan I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
persist O
for O
up O
to O
12 B_TIME[MEASURE]
months I_TIME[MEASURE]
following O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
[ I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
9 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
38 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

Thus O
, O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
follow O
- O
up O
assessments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
6 B_TIME[MEASURE]/B_LOCATION
month B_TIME[MEASURE]/I_LOCATION
post B_TIME[MEASURE]/I_LOCATION
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
will O
allow O
us O
to O
determine O
if O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
if O
any O
, O
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
articular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyaluronan I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persist O
in O
the O
longer B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
term I_BODY_PART_OR_ORGAN_COMPONENT/I_TIME[MEASURE]
. O

Participants B_PERSON
will O
be O
given O
the O
option O
of O
a O
second O
and O
final O
intra O
- O
articular O
injection O
( O
of O
Synvisc O
(R) O
or O
sterile O
saline O
according O
to O
the O
treatment O
group O
they O
are O
in O
) O
on O
days O
30 O
or O
90 O
if O
there O
is O
no O
improvement O
in O
their O
symptoms O
. O

Although O
this O
has O
the O
potential B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
complicate O
the O
interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
this O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
included O
as O
it O
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
more O
reflective B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
practice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
14 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
this O
is O
in O
keeping O
with O
the O
pragmatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
summary O
, O
this O
project O
is O
the O
first O
randomised O
controlled O
trial O
to O
be O
conducted O
to O
evaluate O
the O
efficacy O
of O
intra O
- O
articular O
hyaluronan O
for O
reducing O
pain O
and O
improving O
function O
in O
people B_PERSON/B_BIO
with O
hallux O
limitus O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
interventions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
have O
been O
pragmatically O
designed O
to O
ensure O
that O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
generaliseable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
clinical B_PERSON/B_ORGANIZATION
practice I_PERSON/I_ORGANIZATION
. O

recruitment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
will O
commence O
in O
June B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2008 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
we O
expect O
final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
be O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mid B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2010 B_TIME[MEASURE]
. O

competing O
interests B_DISEASE
. O

HBM B_PERSON
and O
KBL B_PERSON/B_ORGANIZATION
are O
Editor B_PERSON
- O
in O
- O
Chief B_PERSON/B_ORGANIZATION
and O
Deputy B_PERSON
Editor I_PERSON
- O
in O
- O
Chief B_PERSON/B_ORGANIZATION
, O
respectively O
, O
of O
Journal B_ORGANIZATION/B_LOCATION
of O
Foot B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
ankle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
Research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

It O
is O
journal B_DISEASE_ADJECTIVE[DISEASE]
policy I_DISEASE_ADJECTIVE[DISEASE]
that O
editors B_PERSON
are O
removed O
from O
the O
peer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
editorial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
decision I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
making O
processes B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
papers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
they O
have O
co B_LOCATION/B_PERSON
- O
authored O
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
contributions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

SEM B_TIME[MEASURE]/B_LOCATION
, O
HBM B_ORGANIZATION/B_LOCATION
, O
KBL B_ORGANIZATION/B_LOCATION
and O
CJH B_ORGANIZATION/B_LOCATION
conceived O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
obtained O
funding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

SEM B_TIME[MEASURE]/B_ORGANIZATION
, O
HBM B_ORGANIZATION/B_LOCATION
, O
KBL B_ORGANIZATION/B_LOCATION
, O
AEZ B_ORGANIZATION/B_LOCATION
and O
JDL B_ORGANIZATION/B_PERSON
designed O
the O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
. O

SEM B_TIME[MEASURE]/B_LOCATION
, O
HBM B_ORGANIZATION/B_LOCATION
, O
KBL B_ORGANIZATION/B_LOCATION
and O
GVZ B_ORGANIZATION/B_LOCATION
drafted O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

All O
authors B_PERSON
have O
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

p8 O
inhibits O
the O
growth O
of O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O
cancer O
cells O
and O
its O
expression O
is O
induced O
through O
pathways O
involved O
in O
growth O
inhibition O
and O
repressed O
by O
factors O
promoting O
cell O
growth O
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

p8 B_GENE
is O
a O
stress B_DISEASE
- O
induced O
protein B_GENE/B_BACTERIUM[BIO]
with O
multiple B_DISEASE_ADJECTIVE[DISEASE]
functions I_DISEASE_ADJECTIVE[DISEASE]
and O
biochemically O
related O
to O
the O
architectural B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HMG I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Y B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
analyzed O
the O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
p8 O
in O
pancreatic B_DISEASE
cancer I_DISEASE
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

expression O
of O
p8 O
was O
silenced O
in O
the O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O
cancer O
cell O
lines O
Panc O
- O
1 O
and O
BxPc O
- O
3 O
by O
infection O
with O
a O
retrovirus O
expressing O
p8 O
RNA O
in O
the O
antisense O
orientation O
. O

Cell B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
growth B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O
measured O
in O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
p8 B_GENE
- O
silenced O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
p8 O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
induction B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathways I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoting O
cellular B_DISEASE_ADJECTIVE[DISEASE]
growth I_DISEASE_ADJECTIVE[DISEASE]
or O
growth B_DISEASE_ADJECTIVE[DISEASE]
arrest I_DISEASE_ADJECTIVE[DISEASE]
was O
monitored O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

p8 O
- O
silenced O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
grew O
more O
rapidly O
than O
control B_PERSON/B_BIO
cells I_PERSON/I_BIO
transfected O
with O
the O
empty B_GENE/B_BIO
retrovirus I_GENE/I_BIO
. O

Activation B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Ras B_GENE/B_DISEASE
--> O
Raf B_GENE/B_DISEASE
--> O
MEK B_GENE/B_LOCATION
--> O
ERK B_GENE
and O
JNK B_GENE
intracellular I_GENE
pathways O
down O
- O
regulated O
p8 B_GENE
expression I_GENE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
MEK1 B_GENE
/ O
2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U0126 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
JNK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SP600125 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
up O
- O
regulates B_MEASURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression I_MEASURE/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
p8 B_GENE
. O

Conversely O
, O
p38 O
or O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_GENE
induced I_GENE
p8 I_GENE
expression I_GENE
whereas O
the O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
p38 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
SB203580 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
down O
- O
regulated O
p8 B_GENE/B_LOCATION
expression I_GENE/I_LOCATION
. O

Finally O
, O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O
in O
part B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediated O
through O
p38 B_GENE
. O

Conclusions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

p8 O
inhibits O
the O
growth O
of O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O
cancer O
cells O
. O

p8 O
expression B_GENE
is O
induced O
through O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
involved O
in O
growth B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
inhibition B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
repressed O
by O
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
promote O
cell B_DISEASE
growth I_DISEASE
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
p8 O
belongs O
to O
a O
pathway B_LOCATION/B_GENE
regulating O
the O
growth B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pancreatic B_DISEASE
cancer I_DISEASE
cells I_DISEASE
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

While O
studying O
the O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
injured B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pancreas I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
we O
identified O
a O
new B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
, O
called O
p8 O
, O
whose O
expression B_GENE
is O
strongly O
induced O
during O
the O
acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
pancreatitis B_DISEASE/B_LOCATION
[ O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
shown O
that O
p8 O
mRNA B_GENE
is O
activated O
in O
almost O
all O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
several B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stresses B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
2 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
, O
including O
minimal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
stresses I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
such I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O
after O
routine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
change I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
culture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
medium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
absence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
any O
added O
substance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O
3 B_MEASURE
] I_MEASURE
, O
indicating O
that O
p8 B_GENE
is O
a O
ubiquitous B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
p8 O
gene O
was O
cloned O
in O
human B_SPECIES[BIO]
, O
rat B_SPECIES[BIO]/B_GENE
, O
mouse B_SPECIES[BIO]/B_DISEASE
, O
and O
Xenopus B_SPECIES[BIO]
laevis I_SPECIES[BIO]
[ O
1 O
, O
4 O
- O
6 O
] O
, O
conceptually O
translated O
from O
the O
Drosophila B_SPECIES[BIO]/B_MEASURE
melanogaster I_SPECIES[BIO]/I_MEASURE
genome O
or O
deduced O
from O
est O
libraries O
( O
Bos B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
taurus I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Xenopus B_SPECIES[BIO]
tropicalis I_SPECIES[BIO]
, O
Zebrafish B_SPECIES[BIO]
, O
Orzzias B_SPECIES[BIO]
latipes I_SPECIES[BIO]
, O
Bombyx B_SPECIES[BIO]
mori I_SPECIES[BIO]
and O
Paralichthys B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
olivaceous I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
overall O
degree O
of O
homology O
with O
human B_SPECIES[BIO]/B_GENE
p8 O
ranged O
from O
81 O
to O
40 O
% O
. O

Secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
structure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
prediction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O
that O
within O
the O
homologous B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
the O
eleven B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
there O
is O
a O
basic B_NUMBER[MEASURE]/B_LOCATION
Helix I_NUMBER[MEASURE]/I_LOCATION
- O
loop B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
helix B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secondary B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
some O
classes B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
transcription B_GENE
factors I_GENE
[ O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Even O
though O
a O
small B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
protein B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
such B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
as O
p8 O
would O
not O
need O
a O
nuclear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
localization I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
signal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
NLS B_LOCATION/B_ORGANIZATION
) O
to O
be O
transported O
to O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
a O
clear B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NLS I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
predicted O
for O
the O
eleven B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
comprising O
a O
bipartite B_LOCATION/B_MEASURE
domain I_LOCATION/I_MEASURE
of O
positively O
charged O
aminoacids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition O
, O
a O
nuclear O
/ O
cytoplasmic O
location O
has O
been O
demonstrated O
for O
human B_SPECIES[BIO]/B_GENE
p8 O
upon O
overexpression O
of O
the O
recombinant O
protein O
and O
immunohistochemistry O
[ O
4 O
] O
, O
and O
for O
recombinant O
Xenopus B_SPECIES[BIO]
laevis I_SPECIES[BIO]
p8 O
fused O
to O
green O
fluorescent O
protein O
[ O
6 O
] O
. O

homology B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
searching O
in O
databases B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
reveal O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
similarity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
p8 O
with O
other B_GENE/B_NUMBER[MEASURE]
proteins I_GENE/I_NUMBER[MEASURE]
of O
known O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

However O
, O
biochemical B_NUMBER[MEASURE]/B_PERSON
properties I_NUMBER[MEASURE]/I_PERSON
of O
the O
mammalian B_GENE/B_BIO
p8 I_GENE/I_BIO
proteins I_GENE/I_BIO
are O
shared O
by O
some O
high B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
mobility I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
group I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
HMG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
[ O
7 B_TIME[MEASURE]/B_BIO
] I_TIME[MEASURE]/I_BIO
, O
particularly O
by O
the O
HMG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
I B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
Y B_PERSON/B_PROTEIN[GENE]
family B_PERSON/I_PROTEIN[GENE]
. O

The O
overall O
identity O
of O
human B_SPECIES[BIO]/B_GENE
p8 O
with O
human B_SPECIES[BIO]
HMG O
- O
I O
/ O
Y O
is O
only O
about O
35 O
% O
, O
but O
the O
molecular O
mass O
, O
isoelectric O
point O
, O
hydrophilicity O
plot O
, O
the O
resistance O
to O
denaturation O
after O
heating O
at O
100 O
degrees O
C O
and O
the O
charge O
separation O
are O
very O
similar O
[ O
8 O
] O
. O

The O
p8 B_GENE
protein I_GENE
seems O
to O
bind O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
weakly O
, O
as O
shown O
by O
electrophoretic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shift I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O
, O
without O
preference B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Finally O
, O
human B_SPECIES[BIO]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p8 O
has O
also O
been O
shown O
to O
be O
a O
substrate O
for O
protein O
kinase O
A O
in O
vitro O
and O
phosphorylated O
p8 O
has O
a O
higher O
content O
of O
secondary O
structure O
and O
binding O
to O
DNA O
is O
highly O
increased O
[ O
8 O
] O
. O

An O
architectural B_DISEASE_ADJECTIVE[DISEASE]
role I_DISEASE_ADJECTIVE[DISEASE]
in O
transcription B_GENE/B_DISEASE
has O
been O
proposed O
for O
this O
protein B_BIO/B_PROTEIN[GENE]
, O
in O
analogy B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
HMG B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O
Y B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
a O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O
to O
confirm O
this O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
[ O
9 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

functions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
p8 B_GENE
appear O
to O
be O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
p8 B_GENE/B_DISEASE
mRNA I_GENE/I_DISEASE
expression I_GENE/I_DISEASE
was O
strongly O
induced O
in O
3T3 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
upon O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
which O
in O
turn B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O
the O
Smad B_GENE
- O
transactivating O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responsible I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
[ O
10 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
also O
found O
that O
p8 O
is O
involved O
in O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
regulation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
since O
p8 O
- O
deficient B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
embryonic B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
fibroblasts B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
grew O
more O
rapidly O
and O
incorporated O
more B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
thymidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
BrdU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O
p8 B_GENE
- O
expressing O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
11 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

Moreover O
, O
expression B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
p8 O
in O
breast B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
seems O
to O
mediate O
the O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
cell B_DISEASE
growth I_DISEASE
induced O
by O
1 B_MEASURE
, O
25 B_MEASURE
- O
Dihydroxyvitamin B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
12 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

On O
the O
contrary B_PERSON/B_LOCATION
, O
we O
also O
reported O
that O
p8 B_GENE
may O
promote O
cell B_DISEASE/B_GENE
growth I_DISEASE/I_GENE
when O
overexpressed O
in O
COS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
7 B_MEASURE
, O
AR42J B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
HeLa B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
1 B_NUMBER[MEASURE]
, O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
p8 B_GENE
seems O
to O
be O
involved O
in O
other B_DISEASE_ADJECTIVE[DISEASE]
intracellular I_DISEASE_ADJECTIVE[DISEASE]
functions I_DISEASE_ADJECTIVE[DISEASE]
such I_DISEASE_ADJECTIVE[DISEASE]
as O
apoptosis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
since O
p8 B_GENE/B_DISEASE
- O
expressing O
fibroblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
are O
more O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
than O
p8 B_GENE
- O
deficient B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fibroblasts I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
the O
apoptosis B_DISEASE
induced O
by O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Also O
, O
p8 B_GENE
is O
required O
for O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
mesangial B_DISEASE
cell I_DISEASE
hypertrophy I_DISEASE
in O
diabetic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
kidney B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
in O
a O
mechanism B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O
ERK B_GENE
, O
JNK B_GENE
and O
PI3 B_GENE
kinase I_GENE
[ I_GENE
13 I_GENE
] I_GENE
. O

p8 O
seems O
to O
play O
a O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
LH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O
embryonic B_ORGANISM_FUNCTION/B_DISEASE_ADJECTIVE[DISEASE]
cell I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
differentiation I_ORGANISM_FUNCTION/I_DISEASE_ADJECTIVE[DISEASE]
[ O
14 B_GENE/B_LOCATION
] I_GENE/I_LOCATION
. O

Moreover O
, O
the O
Drosophila B_SPECIES[BIO]
melanogaster I_SPECIES[BIO]
p8 O
homologue O
is O
involved O
in O
response O
to O
starvation O
and O
might O
be O
activated O
to O
stop O
cell O
growth O
in O
case O
of O
nutrient O
deprivation O
[ O
15 O
] O
. O

Finally O
, O
a O
particularly O
attractive B_PERSON/B_MEASURE
role B_PERSON/I_MEASURE
in O
tumour B_DISEASE/B_GENE
progression I_DISEASE/I_GENE
was O
recently O
proposed O
for O
p8 B_GENE
[ O
16 B_TIME[MEASURE]/B_GENE
] I_TIME[MEASURE]/I_GENE
. O

fibroblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
obtained O
from O
p8 B_GENE
- O
expressing O
or O
p8 B_GENE
- O
deficient B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
animals B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
were O
transformed O
with O
a O
retroviral B_VIRUS[BIO]/B_GENE
vector I_VIRUS[BIO]/I_GENE
expressing O
both O
the O
rasV12 B_GENE
mutated O
protein B_GENE/B_BACTERIUM[BIO]
and O
the O
E1A B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenoviral I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncogene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
soft B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
agar B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
assays B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
transformed O
p8 B_GENE
- O
expressing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
formed O
colonies B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
high B_TIME[MEASURE]/B_LOCATION
frequency I_TIME[MEASURE]/I_LOCATION
, O
as O
expected O
, O
but O
p8 B_GENE
- O
deficient B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transformed O
fibroblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
unable B_DISEASE_ADJECTIVE[DISEASE]
to O
form O
colonies B_LOCATION/B_PERSON
. O

Similarly O
, O
transformed O
p8 O
- O
expressing O
cells O
produced O
tumours O
in O
all O
athymic O
nude B_BIO/B_LOCATION
mice I_BIO/I_LOCATION
when O
injected O
subcutaneously O
or O
intraperitoneally O
, O
whereas O
transformed O
p8 O
- O
deficient O
fibroblasts O
did O
not O
. O

On O
the O
other O
hand O
, O
studies O
by O
another O
laboratory O
revealed O
that O
expression O
of O
the O
Com1 O
protein O
[ O
17 O
] O
, O
which O
is O
identical O
to O
human B_GENE/B_SPECIES[BIO]
p8 O
, O
mediates O
the O
growth O
of O
tumour O
cells O
after O
metastatic O
establishment O
in O
a O
secondary O
organ O
, O
indicating O
that O
activated O
expression O
of O
Com1 O
/ O
p8 O
in O
metastatic O
cells O
is O
required O
for O
tumour O
progression O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strongly O
suggest O
that O
p8 B_GENE
is O
involved O
in O
the O
cellular B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
s B_DISEASE/B_LOCATION
) O
required O
for O
tumour B_DISEASE/B_ORGANISM_FUNCTION
progression I_DISEASE/I_ORGANISM_FUNCTION
and O
metastasis B_DISEASE/B_ORGANISM_FUNCTION
. O

Our O
aim O
is O
to O
check O
the O
relevance O
of O
p8 O
to O
cancer O
progression O
in O
human B_PERSON/B_SPECIES[BIO]
. O

As O
a O
first O
step O
, O
we O
investigated O
in O
the O
present O
study O
the O
function O
of O
p8 O
in O
two O
cell O
lines O
derived O
from O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O
cancer O
. O

We O
observed O
that O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
p8 B_GENE
expression I_GENE
increased O
the O
cells B_MEASURE
growth I_MEASURE
rate I_MEASURE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
activations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
Ras B_GENE/B_PERSON
--> O
Raf B_GENE/B_DISEASE
--> O
MEK B_GENE/B_LOCATION
--> O
ERK B_GENE
and O
JNK B_GENE/B_LOCATION
intracellular I_GENE/I_LOCATION
pathways I_GENE/I_LOCATION
, O
which O
promote O
the O
growth B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
down O
- O
regulated O
p8 B_GENE
expression I_GENE
, O
whereas O
activation B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
p38 B_GENE
or O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_TIME[MEASURE]/B_BIO
, O
which O
inhibit O
cell B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
induced O
its O
expression B_GENE
. O

It O
was O
concluded O
that O
i O
/ O
p8 O
inhibits O
the O
growth O
of O
human B_SPECIES[BIO]/B_NUMBER[MEASURE]
pancreatic O
cancer O
cell O
lines O
, O
ii O
/ O
p8 O
expression O
is O
induced O
through O
pathways O
involved O
in O
growth O
inhibition O
and O
, O
Conversely O
, O
repressed O
by O
factors O
that O
promote O
cell O
growth O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

p8 B_GENE
is O
silenced O
in O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cancer I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
a O
retrovirus B_VIRUS[BIO]/B_GENE
expressing O
p8 O
RNA B_GENE/B_BIO
in O
the O
antisense B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
orientation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

panc B_DISEASE/B_PROTEIN[GENE]
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
3 B_MEASURE
pancreatic I_MEASURE
cells I_MEASURE
were O
chosen O
for O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
, O
on O
the O
one B_PERSON/B_MEASURE
hand I_PERSON/I_MEASURE
, O
both O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
express O
higher B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
level I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
p8 B_GENE
( O
figure B_GENE
1 I_GENE
) O
and O
, O
on O
the O
other B_PERSON/B_NUMBER[MEASURE]
hand B_PERSON/I_NUMBER[MEASURE]
, O
because O
panc B_PROTEIN[GENE]/B_DISEASE
- O
1 B_NUMBER[MEASURE]
is O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
Smad4 B_GENE
/ O
DPC4 B_GENE/B_MEASURE
and O
mutated O
for O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ras B_GENE/B_DISEASE
, O
while O
BxPc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
3 B_NUMBER[MEASURE]
is O
Smad4 B_GENE
/ O
DPC4 B_GENE/B_MEASURE
mutated O
and O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ras B_GENE/B_DISEASE
wild I_GENE/I_DISEASE
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
[ O
18 B_MEASURE
, O
19 B_MEASURE
] I_MEASURE
, O
therefore O
representing O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
transformation B_DISEASE/B_GENE
and O
different B_DISEASE/B_ORGANISM_FUNCTION
genetic I_DISEASE/I_ORGANISM_FUNCTION
backgrounds I_DISEASE/I_ORGANISM_FUNCTION
. O

K B_GENE/B_LOCATION
- O
ras B_GENE/B_DISEASE
and O
Smad4 B_GENE
/ O
DPC4 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
are O
the O
major B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
involved O
in O
pancreatic B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
development I_DISEASE/I_GENE
. O

We O
inhibited O
p8 O
expression B_GENE
in O
both O
panc B_DISEASE/B_PROTEIN[GENE]
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
pancreatic I_MEASURE
cells I_MEASURE
by O
infecting O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
a O
retrovirus B_VIRUS[BIO]/B_GENE
expressing O
the O
p8 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
asRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
antisense B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
carrying O
the O
puromycin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
resistance I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
antibiotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
selected O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O
analyzed O
by O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
evaluate O
the O
intracellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amounts I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
p8 B_GENE
protein I_GENE
. O

As O
shown O
in O
figure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
p8 B_GENE
protein I_GENE
was O
clearly O
visible B_DISEASE_ADJECTIVE[DISEASE]
in O
both O
panc B_DISEASE
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
pancreatic I_MEASURE
cells I_MEASURE
infected O
with O
the O
empty B_VIRUS[BIO]/B_GENE
retrovirus B_VIRUS[BIO]/I_GENE
but O
almost O
undetectable B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infected O
with O
the O
retrovirus B_VIRUS[BIO]/B_GENE
encoding O
the O
p8 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
asRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O
, O
indicating O
that O
our O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
sense B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
strategy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
is O
efficient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
silence O
p8 O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pancreatic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
had O
been O
conducted O
to O
select O
the O
best B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
inhibit O
p8 O
expression B_GENE
. O

We O
compared O
the O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
stable B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transfection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
siRNA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
using O
a O
retroviral B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vector B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
asRNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
described O
above O
. O

In O
our O
hands B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
antisense B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strategy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
worked O
best O
, O
as O
judged O
from O
Western B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
p8 B_GENE
protein I_GENE
expression I_GENE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
not O
shown O
) O
. O

p8 O
- O
silenced O
pancreatic B_DISEASE
cells I_DISEASE
grow O
more O
rapidly O
. O

We O
compared O
in O
the O
two B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines O
the O
influence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
growth B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
blocking O
p8 O
expression B_GENE
with O
the O
p8 O
asRNA B_GENE/B_BIO
. O

figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
3 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O
that O
both O
panc B_DISEASE/B_PROTEIN[GENE]
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
cells I_MEASURE
in O
which O
p8 O
has O
been O
silenced O
grew O
more O
rapidly O
than O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infected O
with O
the O
empty B_GENE/B_LOCATION
vector I_GENE/I_LOCATION
suggesting O
that O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
p8 B_GENE
of O
pancreatic B_DISEASE/B_VIRUS[BIO]
cancer B_DISEASE/I_VIRUS[BIO]
cell B_DISEASE/I_VIRUS[BIO]
growth B_DISEASE/I_VIRUS[BIO]
is O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
from O
the O
mechanism B_MEASURE/B_DISEASE
of O
transformation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Serum B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
cellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
down O
- O
regulates B_TIME[MEASURE]/B_LOCATION
p8 I_TIME[MEASURE]/I_LOCATION
expression I_TIME[MEASURE]/I_LOCATION
. O

Fetal O
calf B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O
, O
which O
contains O
a O
complex O
mix O
of O
growth O
factors O
, O
can O
be O
used O
as O
inductor O
of O
cell O
growth O
. O

As O
shown O
in O
Figure O
4 O
expression O
of O
p8 O
mRNA O
was O
down O
- O
regulated O
in O
both O
Panc O
- O
1 O
and O
BxPc O
- O
3 O
when O
the O
cells O
were O
shifted O
from O
culture O
media O
containing O
0 O
. O
1 O
% O
fetal O
calf B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O
to O
media O
containing O
10 O
% O
FCS O
. O

p8 O
protein B_LOCATION
showed O
a O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
behavior B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O
that O
p8 O
expression B_GENE/B_MEASURE
is O
down O
- O
regulated O
in O
growing O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
Ras B_GENE/B_PERSON
--> O
Raf B_GENE/B_DISEASE
--> O
MEK B_GENE/B_LOCATION
--> O
ERK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
down O
- O
regulates B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
p8 O
expression B_GENE
in O
pancreatic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Most O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
pancreatic O
cancers O
harbor O
mutations O
in O
the O
K O
- O
ras O
oncogene O
, O
which O
happens O
relatively O
early O
in O
pancreatic O
tumorigenesis O
[ O
20 O
] O
. O

The O
oncogenic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
mutation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ras B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
stabilizes O
the O
Ras B_GENE
protein I_GENE
in O
a O
GTP B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O
bound O
form B_LOCATION
, O
which O
is O
constitutively O
active B_DISEASE_ADJECTIVE[DISEASE]
and O
make O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
grow O
more O
rapidly O
. O

contrary B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
activated O
Ras B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
, O
p8 B_GENE
inhibits O
cell B_DISEASE/B_GENE
growth B_DISEASE/I_GENE
( O
figure B_MEASURE/B_GENE
3 B_MEASURE/I_GENE
) O
. O

We O
looked O
whether O
the O
Ras B_GENE/B_PERSON
--> O
Raf B_GENE/B_DISEASE
--> O
MEK B_GENE/B_LOCATION
--> O
ERK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
also O
involved O
in O
the O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
p8 B_GENE
expression I_GENE
, O
and O
which O
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
s O
) O
were O
critical B_DISEASE_ADJECTIVE[DISEASE]
. O

figure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O
that O
expression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
mutated B_MEASURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
form I_MEASURE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O
the O
Ras B_GENE/B_DISEASE
protein I_GENE/I_DISEASE
( O
rasV12 B_GENE/B_DISEASE
) O
in O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O
which O
are O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]
for O
ras B_GENE/B_DISEASE
, O
resulted O
in O
decreased O
p8 B_GENE
mRNA I_GENE
concentration I_GENE
and O
protein B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O
that O
the O
activated O
ras B_GENE/B_DISEASE
inhibits O
p8 O
expression B_GENE
. O

figure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O
that O
overexpression B_GENE
of O
Raf B_GENE/B_DISEASE
, O
but O
not O
of O
Raf301 B_GENE/B_LOCATION
( O
a O
negative B_GENE/B_PERSON
mutant I_GENE/I_PERSON
of O
RAF B_LOCATION/B_GENE
) O
, O
and O
of O
ERK B_GENE/B_LOCATION
also O
inhibited O
the O
expression B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
p8 B_GENE
- O
CAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construct I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Panc B_LOCATION/B_PERSON
- O
1 B_MEASURE
as O
well O
as O
in O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_NUMBER[MEASURE]
. O

Finally O
, O
the O
MEK1 B_GENE
/ O
2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U0126 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activated O
p8 O
mRNA B_GENE
expression I_GENE
in O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
whether O
they O
carry O
mutated B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ras I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
panc B_GENE/B_DISEASE
- O
1 B_NUMBER[MEASURE]
) O
or O
wild B_BIO/B_GENE
- O
type B_GENE/B_DISEASE
( O
BxPc B_LOCATION/B_PERSON
- O
3 B_NUMBER[MEASURE]
) O
. O

Similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
when O
expression B_GENE
of O
the O
p8 B_GENE
protein I_GENE
was O
monitored O
by O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_MEASURE/B_PROTEIN[GENE]
7 B_MEASURE/I_PROTEIN[GENE]
) O
. O

Activation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
JNK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
down O
- O
regulates O
p8 O
expression B_GENE
in O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cancer I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

c O
- O
Jun B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NH2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
terminal B_ENZYME[GENE]
kinase I_ENZYME[GENE]
( O
JNK B_GENE/B_LOCATION
) O
is O
another O
major B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
MAPK I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
which O
converts O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signals I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O
expression B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
target I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O
phosphorylation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
activation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
transcription B_GENE
factors I_GENE
. O

JNK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
implicated O
in O
various B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
often O
opposite B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cellular I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
cell B_DISEASE
proliferation I_DISEASE
, O
transformation B_DISEASE
and O
apoptosis B_DISEASE
. O

As O
shown O
in O
Figure B_MEASURE/B_LOCATION
8 I_MEASURE/I_LOCATION
, O
overexpression B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
JNK B_GENE
down O
- O
regulates O
the O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
reporter B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
p8 B_GENE
- O
CAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construct I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
panc B_PROTEIN[GENE]/B_DISEASE
- O
1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
. O

Similar B_NUMBER[MEASURE]/B_PERSON
results B_NUMBER[MEASURE]/I_PERSON
were O
found O
in O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
cells I_MEASURE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
these O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
with O
the O
JNK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SP600125 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
22 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
up O
- O
regulates B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
p8 B_GENE
mRNA I_GENE
and O
p8 B_GENE
protein B_BIO
( O
Figure B_NUMBER[MEASURE]/B_LOCATION
9 I_NUMBER[MEASURE]/I_LOCATION
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
the O
JNK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
involved O
in O
the O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
p8 O
expression B_GENE
. O

The O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
up O
- O
regulates B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
p8 O
expression B_GENE
in O
pancreatic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transduction I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O
plays O
an O
essential B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
role B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O
regulating O
several B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
including O
growth B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
inflammation B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
differentiation B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
apoptosis B_DISEASE/B_ORGANISM_FUNCTION
. O

In O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
in O
pancreatic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
p38 B_GENE
is O
a O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
inhibitor I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O
proliferation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
[ B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
23 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
] B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
contrary B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O
the O
Ras B_GENE/B_DISEASE
--> O
Raf B_GENE/B_DISEASE
--> O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
--> O
ERK B_GENE/B_LOCATION
and O
JNK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathways I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
therefore O
analyzed O
the O
putative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
regulating O
p8 O
expression B_GENE/B_MEASURE
in O
pancreatic B_DISEASE
cancer I_DISEASE
cells I_DISEASE
. O

figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
10 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
shows O
that O
over O
- O
expression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
plasmid B_GENE
encoding I_GENE
p38 I_GENE
significantly O
increases O
p8 B_GENE/B_LOCATION
- O
CAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
panc B_DISEASE/B_PROTEIN[GENE]
- O
1 B_NUMBER[MEASURE]
as O
well O
as O
in O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE/B_PROTEIN[GENE]
cells I_MEASURE/I_PROTEIN[GENE]
. O

Then O
, O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
treated O
with O
SB203580 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
p38 B_GENE
[ O
24 B_GENE
] I_GENE
, O
and O
p8 O
expression B_GENE
was O
measured O
. O

p8 O
mRNA B_GENE
as O
well O
as O
the O
encoded B_GENE
protein I_GENE
were O
down O
- O
regulated O
after O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
p38 B_GENE
activity I_GENE
( O
figure B_MEASURE/B_GENE
11 B_MEASURE/I_GENE
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
the O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
positive B_PERSON/B_GENE
regulator I_PERSON/I_GENE
of O
p8 O
expression B_GENE
in O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cancer I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_NUMBER[MEASURE]
up O
- O
regulates B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
p8 O
expression B_GENE
in O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cancer I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
most O
prominent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TGF B_PROTEIN[GENE]/B_DISEASE
beta I_PROTEIN[GENE]/I_DISEASE
- O
1 B_NUMBER[MEASURE]
is O
its O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
growth B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
a O
wide B_MEASURE
variety I_MEASURE
of O
cell B_DISEASE
types I_DISEASE
including O
pancreatic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_LOCATION/B_GENE
signals I_LOCATION/I_GENE
are O
sent O
through O
two B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
types I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
transmembrane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
threonine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O

In O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
brings O
together O
the O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O
and O
type B_GENE/B_TIME[MEASURE]
II I_GENE/I_TIME[MEASURE]
receptors I_GENE/I_TIME[MEASURE]
. O

In O
the O
resulting O
complex B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
constitutively O
active B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TGF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
1 B_PROTEIN[GENE]/B_LOCATION
type I_PROTEIN[GENE]/I_LOCATION
II I_PROTEIN[GENE]/I_LOCATION
receptor I_PROTEIN[GENE]/I_LOCATION
phosphorylates O
the O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O
receptor B_GENE
, O
which O
then O
plays O
a O
major B_ENT/B_LOCATION
role I_ENT/I_LOCATION
in O
transducing O
the O
signal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
downstream O
components B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
affect O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
phosphorylation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Smad B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Phosphorylated B_LOCATION/B_MEASURE
receptor I_LOCATION/I_MEASURE
- O
regulated O
SMADs B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
then O
form O
heteromeric B_LOCATION/B_PERSON
complexes I_LOCATION/I_PERSON
with O
the O
common B_GENE
partner I_GENE
SMAD4 I_GENE
. O

These O
heteromeric B_LOCATION/B_GENE
complexes B_LOCATION/I_GENE
then O
move O
to O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
where O
SMAD4 B_GENE/B_PERSON
will O
bind O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
contribute O
to O
transcriptional B_DISEASE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
activation B_DISEASE/I_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

In O
general B_PERSON/B_BIO
, O
pancreatic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
defects B_DISEASE_ADJECTIVE[DISEASE]
in O
TGF B_GENE
beta I_GENE
- O
1 B_PROTEIN[GENE]
signaling I_PROTEIN[GENE]
and O
are O
resistant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
TGF B_GENE
beta I_GENE
- O
1 B_NUMBER[MEASURE]
- O
mediated O
growth B_DISEASE_ADJECTIVE[DISEASE]
suppression I_DISEASE_ADJECTIVE[DISEASE]
. O

Since O
TGF B_GENE
beta I_GENE
- O
1 B_NUMBER[MEASURE]
and O
p8 B_GENE
are O
inhibitors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
pancreatic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
we O
analyzed O
whether O
p8 O
could O
mediate O
, O
at O
least O
in O
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TGF B_GENE
beta I_GENE
- O
1 B_NUMBER[MEASURE]/B_DISEASE
. O

First O
, O
we O
found O
that O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
panc B_PROTEIN[GENE]/B_DISEASE
- O
1 B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
TGF B_GENE/B_LOCATION
beta I_GENE/I_LOCATION
- O
1 B_NUMBER[MEASURE]
increased O
p8 B_GENE
mRNA I_GENE
levels I_GENE
and O
p8 B_GENE
protein I_GENE
as O
judged O
by O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Figure B_MEASURE
12 I_MEASURE
) O
. O

Then O
, O
to O
confirm O
that O
overexpression B_GENE
is O
regulated O
at O
the O
transcriptional B_GENE
level I_GENE
, O
we O
analyzed O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
some O
constructs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expressing O
constitutively O
activated O
type B_MEASURE/B_LOCATION
I O
TGF O
beta B_GENE
receptor I_GENE
, O
dominant B_GENE/B_DISEASE
negative I_GENE/I_DISEASE
type I_GENE/I_DISEASE
II I_GENE/I_DISEASE
TGF I_GENE/I_DISEASE
beta I_GENE/I_DISEASE
receptor I_GENE/I_DISEASE
, O
a O
dominant B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
negative B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
Smad4 B_GENE
and O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_PROTEIN[GENE]/B_MEASURE
Smad4 I_PROTEIN[GENE]/I_MEASURE
on O
the O
p8 B_GENE/B_LOCATION
- O
CAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
expected O
, O
the O
constitutively O
activated O
type B_MEASURE/B_ORGANIZATION
I O
TGF O
beta B_GENE
receptor I_GENE
but O
not O
the O
dominant B_DISEASE/B_GENE
negative B_DISEASE/I_GENE
type B_DISEASE/I_GENE
II B_DISEASE/I_GENE
TGF B_DISEASE/I_GENE
beta B_DISEASE/I_GENE
receptor B_DISEASE/I_GENE
increased O
CAT B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Also O
, O
expression B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
Smad4 B_GENE
, O
contrary B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
of O
the O
negative B_GENE/B_PERSON
mutant I_GENE/I_PERSON
, O
induced O
p8 B_GENE/B_DISEASE
transcription I_GENE/I_DISEASE
( O
figure B_GENE/B_DISEASE
13 I_GENE/I_DISEASE
) O
. O

Together O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
p8 B_GENE/B_DISEASE
is O
positively O
regulated O
by O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_TIME[MEASURE]
. O

Beside O
the O
Smad B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
proteins I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_NUMBER[MEASURE]
also O
activates O
the O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MAPK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
pancreas B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O
which O
may O
play O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_NUMBER[MEASURE]
induced O
genes B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
25 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Therefore O
, O
we O
analyzed O
the O
p38 O
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_TIME[MEASURE]
on O
p8 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transcription B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

As O
shown O
in O
Figure B_MEASURE/B_BIO
13 I_MEASURE/I_BIO
, O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
p38 B_GENE
activity I_GENE
with O
the O
SB203580 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
specific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decreased O
about O
40 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
TGF B_GENE
beta I_GENE
- O
1 B_NUMBER[MEASURE]
on O
the O
p8 B_GENE
promoter I_GENE
indicating O
that O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TGF B_GENE
beta I_GENE
- O
1 B_NUMBER[MEASURE]
on O
p8 B_GENE
promoter I_GENE
is O
mediated O
by O
both O
p38 O
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
p38 B_GENE
- O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
pathways I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pancreatic B_DISEASE
adenocarcinoma I_DISEASE
is O
the O
fourth B_SEQUENCE[MEASURE]/B_LOCATION
leading O
cause B_DISEASE
of O
death B_DISEASE
from O
malignant B_DISEASE
diseases I_DISEASE
[ O
26 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
. O

The O
aggressive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
nature I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
neoplasia B_DISEASE
, O
the O
lack B_DISEASE_ADJECTIVE[DISEASE]
of O
early B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
detection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
and O
the O
limited B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
such I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
radiotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contribute O
to O
the O
high B_DISEASE_ADJECTIVE[DISEASE]
mortality I_DISEASE_ADJECTIVE[DISEASE]
rate I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
disease B_DISEASE/B_PERSON
. O

Therefore O
, O
a O
better B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
molecular B_LOCATION/B_DISEASE
mechanism I_LOCATION/I_DISEASE
leading O
to O
pancreatic B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
remains O
a O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
because O
it O
may O
help O
proposing O
strategies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
earlier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
better B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
most O
commonly O
altered O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pancreatic B_DISEASE
adenocarcinoma I_DISEASE
are O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ras B_GENE/B_PERSON
( O
75 B_MEASURE
to O
100 B_MEASURE
% I_MEASURE
) O
, O
p16INK4a B_GENE
( O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
p53 B_GENE
( O
50 B_MEASURE
to O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
and O
DPC4 B_GENE
( O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
[ O
27 B_MEASURE
- O
31 B_MEASURE
] I_MEASURE
. O

Whereas O
K B_GENE/B_LOCATION
- O
ras B_GENE/B_DISEASE
is O
a O
proto B_DISEASE
- O
oncogene B_GENE/B_DISEASE
all O
the O
others B_PERSON/B_DISEASE
are O
tumour B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
suppressor I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Additional B_NUMBER[MEASURE]/B_PERSON
genes B_NUMBER[MEASURE]/I_PERSON
have O
been O
found O
altered O
at O
lower B_TIME[MEASURE]/B_LOCATION
frequency I_TIME[MEASURE]/I_LOCATION
. O

panc B_DISEASE
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
3 B_NUMBER[MEASURE]
pancreatic I_NUMBER[MEASURE]
cells I_NUMBER[MEASURE]
were O
chosen O
for O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
they O
both O
express O
high B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
levels I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
p8 B_GENE
( O
figure B_GENE
1 I_GENE
) O
and O
because O
they O
present O
with O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
transformation B_DISEASE/B_GENE
and O
genetic B_DISEASE_ADJECTIVE[DISEASE]
backgrounds I_DISEASE_ADJECTIVE[DISEASE]
, O
panc B_PROTEIN[GENE]/B_DISEASE
- O
1 B_NUMBER[MEASURE]
being O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
Smad4 B_GENE
/ O
DPC4 B_GENE/B_MEASURE
but O
mutated O
for O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ras B_GENE/B_DISEASE
and O
BxPc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
3 B_NUMBER[MEASURE]
mutated O
for O
Smad4 B_GENE
/ O
DPC4 B_GENE/B_MEASURE
and O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE/B_MEASURE
for O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ras B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
18 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
19 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

This O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
presents O
evidences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
p8 O
inhibits O
the O
growth B_DISEASE/B_ORGANISM_FUNCTION
rate I_DISEASE/I_ORGANISM_FUNCTION
of O
pancreatic B_DISEASE
cancer I_DISEASE
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
that O
the O
intracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathways I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
promoting O
cell B_DISEASE
growth I_DISEASE
down O
- O
regulate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
p8 O
expression B_GENE
whereas O
those O
promoting O
growth B_DISEASE_ADJECTIVE[DISEASE]
arrest I_DISEASE_ADJECTIVE[DISEASE]
up O
- O
regulate O
its O
expression B_GENE
. O

Together O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
p8 B_GENE
is O
downstream B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
some O
cell B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulators I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
therefore O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
p8 O
expression B_GENE
or O
its O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
used O
as O
a O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
treating O
pancreatic B_DISEASE
cancer I_DISEASE
. O

Silencing B_MEASURE/B_PERSON
p8 B_GENE
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
able B_DISEASE_ADJECTIVE[DISEASE]
to O
strongly O
promote O
cell B_DISEASE
growth I_DISEASE
in O
both O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
panc B_DISEASE
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_NUMBER[MEASURE]
, O
suggesting O
that O
p8 B_GENE
may O
act O
downstream O
of O
the O
ras B_GENE/B_DISEASE
- O
or O
Smad4 B_GENE/B_DISEASE
/ O
DPC4 B_MEASURE/B_PROTEIN[GENE]
- O
dependent B_PERSON/B_GENE
ways B_PERSON/I_GENE
. O

Also O
, O
we O
found O
that O
stimulating O
cell O
growth O
by O
the O
complex O
combination O
of O
growth O
factors O
contained O
in O
fetal O
calf B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O
down O
- O
regulated O
expression O
of O
p8 O
whereas O
, O
on O
the O
contrary O
, O
treating O
the O
cells O
with O
TGF O
beta O
- O
1 O
, O
which O
promotes O
cell O
cycle O
arrest O
, O
stimulates O
p8 O
expression O
. O

Therefore O
, O
p8 O
gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O
to O
be O
regulated O
in O
opposite B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directions I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
mechanisms B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoting O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
growth B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O
cell B_DISEASE/B_ORGANISM_FUNCTION
cycle I_DISEASE/I_ORGANISM_FUNCTION
arrest I_DISEASE/I_ORGANISM_FUNCTION
. O

It O
is O
interesting B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
note O
that O
while O
p8 O
expression B_GENE
is O
under O
the O
control B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
cell B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulatory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
Ras B_GENE/B_PERSON
--> O
Raf B_GENE/B_DISEASE
--> O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
--> O
ERK B_GENE
, O
JNK B_GENE
, O
p38 O
and O
TGF B_GENE
beta I_GENE
- O
1 B_NUMBER[MEASURE]
, O
p8 B_GENE/B_PERSON
can O
affect O
cell B_DISEASE_ADJECTIVE[DISEASE]
cycle I_DISEASE_ADJECTIVE[DISEASE]
progression I_DISEASE_ADJECTIVE[DISEASE]
, O
suggesting O
that O
p8 B_GENE
is O
a O
target B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulating O
pancreatic B_DISEASE
cell I_DISEASE
growth I_DISEASE
. O

A O
mechanism B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
which O
p8 O
could O
regulate O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
progression B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
embryonic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibroblasts I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
previously O
proposed O
[ O
11 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

In O
fact B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
p8 B_GENE
seems O
to O
take O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
upstream O
from O
cyclin B_GENE
- O
dependent B_PROTEIN[GENE]/B_DISEASE
kinases I_PROTEIN[GENE]/I_DISEASE
because O
the O
intracellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
activities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Cdk2 B_GENE
and O
Cdk4 B_GENE
are O
decreased O
when O
p8 B_GENE
is O
expressed O
. O

Concomitantly O
, O
the O
cyclin B_GENE
- O
dependent B_PROTEIN[GENE]
kinase I_PROTEIN[GENE]
inhibitor I_PROTEIN[GENE]
p27 I_PROTEIN[GENE]
is O
expressed O
at O
a O
low B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
in O
p8 B_GENE
- O
deficient B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
which O
may O
explain O
the O
increased O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Cdk2 B_GENE
and O
Cdk4 B_GENE
. O

The O
mechanism B_LOCATION
by O
which O
p8 O
regulates O
the O
intracellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
those O
proteins B_GENE/B_DISEASE
remains O
to O
be O
determined O
. O

However O
, O
because O
p8 O
is O
a O
transcriptional B_GENE/B_PERSON
cofactor I_GENE/I_PERSON
, O
it O
is O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
expression B_GENE
of O
these O
molecules B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
takes O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
at O
least O
in O
part B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
at O
the O
transcription B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
level B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Interestingly O
, O
expression B_GENE
of O
p8 O
mRNA B_GENE/B_LOCATION
seems O
to O
be O
regulated O
in O
a O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
type B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
- O
and O
stimulus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O
, O
for O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
p38 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
induce O
p8 O
expression B_GENE
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
stress B_DISEASE/B_GENE
in O
fibroblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
[ O
3 B_MEASURE
] I_MEASURE
but O
not O
in O
renal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mesangial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
treated O
with O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
13 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
pancreatic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cancer B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
p38 O
seems O
to O
play O
a O
major B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
role B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
since O
it O
is O
involved O
in O
p8 O
activation B_GENE
as O
judged O
by O
transient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
using O
a O
specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p38 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
figures B_NUMBER[MEASURE]
10 I_NUMBER[MEASURE]
and O
11 B_MEASURE
) O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
p38 B_GENE
is O
also O
involved O
in O
TGF B_GENE
beta I_GENE
- O
1 B_NUMBER[MEASURE]
- O
induced O
p8 O
expression B_GENE
because O
about O
40 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
TGF B_GENE
beta I_GENE
- O
1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
abolished O
when O
p38 B_GENE
activity I_GENE
was O
specifically O
blocked O
( O
figure B_GENE
13 I_GENE
) O
. O

On O
the O
other B_PERSON/B_MEASURE
hand I_PERSON/I_MEASURE
, O
ERK B_GENE/B_LOCATION
and O
JNK B_GENE/B_LOCATION
are O
inducers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
p8 O
expression B_GENE
in O
mesangial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
treated O
with O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
but O
not O
involved O
in O
the O
activation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
p8 O
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
stress O
in O
fibroblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
[ O
3 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
even O
repressors B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
figures B_GENE
5 I_GENE
, O
6 B_SEQUENCE[MEASURE]
, O
7 B_SEQUENCE[MEASURE]
, O
8 B_NUMBER[MEASURE]
and O
9 B_NUMBER[MEASURE]
) O
. O

Finally O
, O
PI3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
an O
inducer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
p8 O
expression B_GENE
in O
both O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mediated O
p8 O
activation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
mesangial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
13 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O
pancreatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
not O
shown O
) O
. O

Based O
on O
these O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
overexpression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
p8 O
could O
be O
considered O
a O
possible B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
goal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O
treating O
pancreatic B_DISEASE
tumours I_DISEASE
, O
in O
order B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
limit O
their O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
we O
previously O
reported O
that O
p8 O
repression O
would O
prevent O
rasV12 O
/ O
E1A O
transformed O
fibroblasts O
from O
evolving O
as O
tumours O
in O
nude B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
16 O
] O
. O

This O
apparent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contradiction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
needs O
to O
be O
resolved O
before O
considering O
p8 O
as O
a O
target B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
for O
treating O
cancer B_DISEASE
progression I_DISEASE
. O

Conclusions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
see O
figure B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14 B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
we O
report O
in O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
p8 O
expression B_GENE
by O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
sense B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O
the O
growth B_DISEASE_ADJECTIVE[DISEASE]
rate I_DISEASE_ADJECTIVE[DISEASE]
of O
both O
panc B_DISEASE
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
pancreatic I_MEASURE
cancer I_MEASURE
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

Moreover O
, O
ERK B_GENE
- O
and O
JNK B_GENE
- O
mediated O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
down O
- O
regulate O
p8 O
expression B_GENE
, O
whereas O
p38 B_GENE
and O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_MEASURE/B_LOCATION
pathways I_MEASURE/I_LOCATION
induce O
p8 O
expression B_GENE
. O

Also O
, O
cell O
growth O
triggered O
by O
expression O
of O
a O
RAS O
mutated O
protein O
or O
by O
10 O
% O
fetal O
calf B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O
induces O
down O
- O
regulation O
of O
p8 O
expression O
. O

Together O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
p8 B_GENE
is O
an O
intracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
that O
it O
is O
oppositely O
regulated O
by O
growth B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
promoting O
or O
growth B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
inhibiting O
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
pancreatic B_DISEASE
cancer I_DISEASE
- O
derived O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

Material B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lines I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
cell B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
human B_SPECIES[BIO]
pancreatic O
cancer O
cell O
lines O
Panc O
- O
1 O
and O
BxPc O
- O
3 O
were O
a O
kind O
gift O
of O
Dr O
C O
. O

Susini B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
INSERM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
U B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O
531 B_MEASURE/B_LOCATION
, O
Toulouse B_LOCATION/B_MEASURE
) O
and O
A O
. O

Hajri B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IRCAD B_MEASURE/B_ORGANIZATION
, O
Strasbourg B_LOCATION/B_MEASURE
) O
respectively O
. O

Panc O
- O
1 O
cells O
were O
grown O
in O
Dulbecco O
' O
s O
modified O
Eagle O
' O
s O
medium O
( O
DMEM O
) O
supplemented O
with O
10 O
% O
fetal O
calf B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O
, O
2 O
mm O
L O
- O
glutamine O
, O
100 O
IU O
/ O
ml O
penicilin O
G O
and O
100 O
Mu O
g O
/ O
ml O
streptomycin O
. O

BxPc O
- O
3 O
were O
cultivated O
in O
RPMI O
1640 O
medium O
in O
the O
presence O
of O
2 O
mm O
L O
- O
glutamine O
, O
4 O
. O
5 O
g O
/ O
L O
glucose O
, O
10 O
mm O
Hepes O
, O
1 O
. O
0 O
mm O
sodium O
pyruvate O
, O
10 O
% O
fetal O
calf B_SPECIES[BIO]
serum O
and O
100 O
IU O
/ O
ml O
penicilin O
G O
and O
100 O
Mu O
g O
/ O
ml O
streptomycin O
. O

Human B_PERSON/B_SPECIES[BIO]
recombinant O
TGF O
beta O
- O
1 O
was O
obtained O
from O
Sigma O
, O
and O
specific O
SB203580 O
, O
U0126 O
and O
SP600125 O
inhibitors O
were O
from O
Calbiochem O
and O
utilized O
at O
10 O
Mu O
M O
. O

expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plasmids O
. O

Expression B_GENE/B_BIO
plamids I_GENE
encoding O
p38 B_GENE
( O
pCEFL B_GENE
HA I_GENE
p38 I_GENE
) O
, O
Erk2 B_GENE
( O
pcDNAIII B_GENE
HA I_GENE
ERK2 I_GENE
) O
, O
JNK B_GENE
( O
pcDNAIIIB B_GENE/B_BACTERIUM[BIO]
HA I_GENE/I_BACTERIUM[BIO]
JNK I_GENE/I_BACTERIUM[BIO]
) O
, O
the O
wild B_BIO/B_PROTEIN[GENE]
- O
type B_GENE/B_MEASURE
Raf B_GENE/I_MEASURE
( O
pcDNA B_GENE
Raf I_GENE
BXB I_GENE
) O
and O
the O
Raf B_GENE
dominant I_GENE
negative I_GENE
( O
pcDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Raf I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
301 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
K375W I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
were O
obtained O
from O
O B_LOCATION/B_PERSON
Coso I_LOCATION/I_PERSON
( O
University B_LOCATION
of O
Buenos B_LOCATION
Aires I_LOCATION
) O
. O

Plamids B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding O
the O
constitutively O
activated O
type B_MEASURE/B_ORGANIZATION
I O
TGF O
beta B_GENE
receptor I_GENE
( O
RI B_LOCATION/B_ORGANIZATION
ACT I_LOCATION/I_ORGANIZATION
) O
, O
the O
dominant B_GENE/B_DISEASE
negative I_GENE/I_DISEASE
type I_GENE/I_DISEASE
II I_GENE/I_DISEASE
TGF I_GENE/I_DISEASE
beta I_GENE/I_DISEASE
receptor I_GENE/I_DISEASE
( O
RII B_GENE/B_LOCATION
DN I_GENE/I_LOCATION
) O
and O
the O
Smad4 B_GENE
dominant I_GENE
negative I_GENE
( O
DPC4 B_MEASURE/B_PROTEIN[GENE]
1 I_MEASURE/I_PROTEIN[GENE]
- O
514 B_MEASURE
a O
. O
a O
. O
) O
were O
obtained O
from O
R B_LOCATION/B_PERSON
Urrutia I_LOCATION/I_PERSON
( O
Mayo B_LOCATION
Clinic I_LOCATION
, O
Rochester B_LOCATION
) O
and O
the O
wild B_MEASURE/B_GENE
type I_MEASURE/I_GENE
Smad4 I_MEASURE/I_GENE
was O
from O
C B_LOCATION/B_PERSON
Heldin I_LOCATION/I_PERSON
( O
Ludwig B_LOCATION/B_ORGANIZATION
Institute I_LOCATION/I_ORGANIZATION
, O
Uppsala B_LOCATION
) O
. O

Pancreatic B_GENE
p8 I_GENE
- O
deficient B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

To O
silence O
p8 O
expression O
in O
pancreatic O
cells O
, O
we O
infected O
these O
cells O
with O
a O
retrovirus O
expressing O
human B_SPECIES[BIO]
p8 O
in O
the O
antisense O
orientation O
. O

The O
retroviral O
vector O
was O
constructed O
as O
follows O
: O
human B_SPECIES[BIO]/B_GENE
p8 O
cDNA O
was O
subcloned O
in O
HindIII O
and O
XhoI O
restriction O
sites O
of O
the O
pLPC O
plasmid O
( O
obtained O
from O
S O
. O
Lowe O
) O
in O
the O
antisense O
orientation O
. O

Amphotrope O
human B_PROTEIN[GENE]/B_SPECIES[BIO]
p8 O
expressing O
retrovirus O
was O
then O
generated O
by O
transient O
transfection O
using O
Phoenix O
amphotrope O
packaging O
cells O
. O

Viral B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
supernatant I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O
used O
to O
infect O
panc B_DISEASE/B_PROTEIN[GENE]
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_MEASURE
pancreatic I_MEASURE
cells I_MEASURE
and O
the O
population B_PERSON/B_MEASURE
of O
p8 B_GENE
- O
silenced O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
was O
isolated O
by O
selection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
puromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
1 B_MEASURE/B_LOCATION
Mu I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
ml B_MEASURE/B_PERSON
) O
. O

As O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
infected O
with O
the O
pLPC B_BIO/B_LOCATION
empty I_BIO/I_LOCATION
vector I_BIO/I_LOCATION
. O

p8 O
expression B_GENE
in O
arrested O
and O
growing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

One B_MEASURE/B_LOCATION
million I_MEASURE/I_LOCATION
of O
Panc B_LOCATION/B_PERSON
- O
1 B_NUMBER[MEASURE]
or O
BxPc B_LOCATION
- O
3 B_MEASURE
cells I_MEASURE
were O
cultivated O
on O
10 B_MEASURE
- O
cm B_TIME[MEASURE]/B_BIO
Petri I_TIME[MEASURE]/I_BIO
plates I_TIME[MEASURE]/I_BIO
in O
standard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
with O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FCS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
. O

After O
48 B_TIME[MEASURE]
h O
, O
culture B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
media I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
changed O
for O
fresh B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
media I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
FCS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
restricted O
to O
0 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
, O
in O
order B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
stop O
growth B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
24 O
hours O
of O
growth O
arrest O
, O
culture O
medium O
was O
replaced O
either O
by O
medium O
with O
10 O
% O
fetal O
calf B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
serum O
to O
resume O
cell O
growth O
or O
, O
as O
control O
, O
by O
medium O
with O
0 O
. O
1 O
% O
fetal O
calf B_SPECIES[BIO]
serum O
. O

Twenty B_TIME[MEASURE]/B_ENT
four I_TIME[MEASURE]/I_ENT
hours I_TIME[MEASURE]/I_ENT
later O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
recovered O
and O
RNA B_GENE/B_BIO
and O
protein B_GENE/B_BACTERIUM[BIO]
extracted O
. O

p8 O
expression B_GENE
in O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_NUMBER[MEASURE]
- O
treated O
panc B_DISEASE/B_PROTEIN[GENE]
- O
1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
. O

One B_MEASURE/B_LOCATION
million I_MEASURE/I_LOCATION
of O
panc B_PROTEIN[GENE]/B_DISEASE
- O
1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
were O
cultivated O
in O
10 B_MEASURE
- O
cm B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
culture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
dishes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
48 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
TGF B_GENE/B_DISEASE
beta I_GENE/I_DISEASE
- O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O

Human B_PERSON/B_SPECIES[BIO]
recombinant O
TGF O
beta O
- O
1 O
( O
5 O
ng O
/ O
ml O
) O
was O
added O
to O
cells O
, O
without O
changing O
the O
culture O
medium O
, O
and O
cells O
were O
collected O
12 O
hours O
later O
for O
RNA O
and O
protein O
preparation O
. O

BxPc B_PROTEIN[GENE]/B_MEASURE
- O
3 B_PROTEIN[GENE]/B_LOCATION
rasV12 I_PROTEIN[GENE]/I_LOCATION
- O
expressing O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

pLPC B_PROTEIN[GENE]/B_LOCATION
- O
rasV12 B_PROTEIN[GENE]
and O
pLPC B_MEASURE/B_PERSON
plasmids I_MEASURE/I_PERSON
were O
obtained O
from O
S B_OTHER/B_BIO
. O

Lowe B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O

Phoenix B_NUMBER[MEASURE]/B_PERSON
amphotrope I_NUMBER[MEASURE]/I_PERSON
packaging I_NUMBER[MEASURE]/I_PERSON
cells I_NUMBER[MEASURE]/I_PERSON
( O
106 B_TIME[MEASURE]/B_LOCATION
) O
were O
plated O
in O
a O
6 B_MEASURE/B_LOCATION
- O
well B_MEASURE/B_LOCATION
plate I_MEASURE/I_LOCATION
, O
incubated O
for O
24 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
, O
then O
transfected O
with O
PEI B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O
5 B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mu B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
g B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
retroviral B_GENE
plasmid I_GENE
. O

After O
48 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
virus B_VIRUS[BIO]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
was O
filtered O
( O
0 B_MEASURE/B_LOCATION
. O
45 B_MEASURE
Mu I_MEASURE
m I_MEASURE
filter I_MEASURE
, O
Millipore B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
to O
obtain O
the O
viral B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supernatant B_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Target B_PROTEIN[GENE]/B_LOCATION
BxPc I_PROTEIN[GENE]/I_LOCATION
- O
3 B_MEASURE/B_PRODUCT[OBJECT]
were O
plated O
at O
2 B_MEASURE
x O
105 B_MEASURE
cells I_MEASURE
per O
35 B_MEASURE
- O
mm B_TIME[MEASURE]
dish I_TIME[MEASURE]
and O
incubated O
overnight O
. O

For O
infections B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
culture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
replaced O
by O
an O
appropriate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
mix I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
viral B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
supernatant I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and O
culture B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPECIES[BIO]
medium I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_SPECIES[BIO]
( O
V B_PROTEIN[GENE]/B_LOCATION
/ O
V B_OTHER/B_PROTEIN[GENE]
) O
, O
supplemented O
with O
4 B_MEASURE/B_LOCATION
Mu I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
ml B_MEASURE/B_LOCATION
polybrene I_MEASURE/I_LOCATION
( O
sigma B_PROTEIN[GENE]
) O
, O
and O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
incubated O
at O
37 B_LOCATION/B_MEASURE
degrees I_LOCATION/I_MEASURE
C I_LOCATION/I_MEASURE
. O

BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_GENE
rasV12 I_GENE
- O
expressing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
selected O
with O
puromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
1 B_MEASURE/B_LOCATION
Mu I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
ml B_MEASURE/B_PERSON
) O
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infected O
with O
the O
pLPC B_SPECIES[BIO]/B_GENE
empty I_SPECIES[BIO]/I_GENE
vector I_SPECIES[BIO]/I_GENE
were O
used O
as O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Western B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
blot B_LOCATION
analyses I_LOCATION
. O

One B_MEASURE/B_LOCATION
hundred B_MEASURE/I_LOCATION
Mu B_MEASURE/I_LOCATION
g B_MEASURE/I_LOCATION
of O
total B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
extracted O
from O
cells B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
was O
separated O
with O
standard B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
15 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
SDS I_MEASURE
- O
PAGE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
using O
the O
Mini B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Protean I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
System I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Bio B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
Rad B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
transferred O
to O
a O
nitrocellulose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
membrane I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
sigma B_PROTEIN[GENE]/B_LOCATION
) O
. O

The O
intracellular O
level O
of O
p8 O
was O
estimated O
by O
Western O
blot O
using O
a O
polyclonal O
antibody O
( O
1 O
: O
1000 O
) O
raised O
against O
human B_SPECIES[BIO]
p8 O
[ O
4 O
] O
. O

Growth B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curves I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One B_NUMBER[MEASURE]/B_LOCATION
hundred I_NUMBER[MEASURE]/I_LOCATION
thousand I_NUMBER[MEASURE]/I_LOCATION
cells I_NUMBER[MEASURE]/I_LOCATION
per O
well O
were O
plated O
in O
a O
series B_SPORT[ENT]/B_LOCATION
of O
35 B_MEASURE
- O
mm B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dishes I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cell B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
number I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
estimated O
daily O
in O
triplicate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
during O
1 B_NUMBER[MEASURE]/B_LOCATION
to O
5 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
, O
in O
a O
haemocytometer B_MEASURE/B_LOCATION
. O

Within O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
each O
point B_MEASURE
was O
determined O
at O
least O
two B_TIME[MEASURE]/B_LOCATION
times I_TIME[MEASURE]/I_LOCATION
. O

Cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reporter B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O
. O

Panc B_LOCATION/B_PERSON
- O
1 B_NUMBER[MEASURE]
and O
BxPc B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_NUMBER[MEASURE]
( O
105 B_NUMBER[MEASURE]/B_LOCATION
) O
were O
cultivated O
in O
30 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diameter I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dishes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
24 B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
then O
transiently O
transfected O
with O
0 B_MEASURE
. O
5 B_MEASURE
Mu I_MEASURE
g I_MEASURE
of O
p8 B_GENE
- O
CAT B_GENE/B_MEASURE
reporter I_GENE/I_MEASURE
plasmid O
and O
0 B_MEASURE
. O
5 B_MEASURE
Mu I_MEASURE
g I_MEASURE
of O
pCMV B_GENE/B_BIO
/ O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
to O
control O
transfection B_MEASURE/B_DISEASE
efficiency B_MEASURE/I_DISEASE
) O
using O
the O
Fugene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reagent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
accordance B_TIME[MEASURE]/B_ORGANIZATION
with O
the O
manufacturer B_PERSON/B_ORGANIZATION
' O
s O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
( O
Roche B_MEASURE/B_ORGANIZATION
Molecular I_MEASURE/I_ORGANIZATION
Biochemicals I_MEASURE/I_ORGANIZATION
) O
. O

The O
p8 B_GENE
- O
CAT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasmid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
the O
previously O
reported O
p O
- O
1471 B_MEASURE/B_BIO
/ O
+ B_MEASURE
37p8 I_MEASURE
- O
Cat B_MEASURE/B_GENE
promoter I_MEASURE/I_GENE
construct I_MEASURE/I_GENE
[ O
5 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

Reporter B_PERSON/B_ORGANIZATION
activities I_PERSON/I_ORGANIZATION
were O
measured O
as O
previously O
described O
[ O
5 B_MEASURE/B_GENE
] I_MEASURE/I_GENE
. O

briefly B_TIME[MEASURE]/B_LOCATION
, O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
prepared O
with O
the O
reporter B_GENE
lysis I_GENE
buffer I_GENE
( O
Promega B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
24 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
after O
transfection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
CAT B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
determined O
by O
the O
phase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extraction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
32 B_GENE
] I_GENE
and O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
galactosidase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
performed O
essentially O
as O
described O
in O
Sambrook B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
33 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CAT B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
normalized O
to O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
galactosidase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
carried O
out O
in O
triplicate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
repeated O
at O
least O
two B_TIME[MEASURE]/B_LOCATION
times I_TIME[MEASURE]/I_LOCATION
. O

expression B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
plasmids I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
0 B_MEASURE
. O
5 B_MEASURE
Mu I_MEASURE
g I_MEASURE
) O
were O
co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
transfected O
with O
p8 B_GENE
- O
CAT B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
pCMV B_GENE/B_BIO
/ O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmids I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
indicated O
. O

RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
- O
PCR B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
analysis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

RNA B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
extracted O
using O
the O
Trizol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Life B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
technologies I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Total B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
1 B_PROTEIN[GENE]/B_LOCATION
mu I_PROTEIN[GENE]/I_LOCATION
g I_PROTEIN[GENE]/I_LOCATION
) O
was O
analyzed O
by O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
the O
SuperScript B_NUMBER[MEASURE]/B_PERSON
(TM) I_NUMBER[MEASURE]/I_PERSON
One I_NUMBER[MEASURE]/I_PERSON
- O
step B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
System I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
Platinum B_LOCATION/B_ORGANIZATION
Taq B_LOCATION/I_ORGANIZATION
kit B_LOCATION/I_ORGANIZATION
( O
Life B_PROTEIN[GENE]/B_ORGANIZATION
technologies I_PROTEIN[GENE]/I_ORGANIZATION
) O
. O

RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
using O
different B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
numbers I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
cycles B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
verify O
that O
the O
conditions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
chosen O
were O
within O
the O
linear B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
. O

The O
mRNA B_GENE
coding I_GENE
for O
p8 O
was O
specifically O
amplified O
with O
sense B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
5 B_MEASURE
' O
GAAGAGAGGCAGGGAAGACA B_PROTEIN[GENE]/B_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
' O
) O
and O
antisense B_GENE
( O
5 B_MEASURE
' O
CTGCCGTGCGTGTCTATTTA B_GENE/B_MEASURE
3 B_GENE/I_MEASURE
' O
) O
primers B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
positions B_MEASURE
72 I_MEASURE
and O
643 B_MEASURE
of O
the O
cDNA B_GENE
( O
accession B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
NM B_DISEASE/B_PROTEIN[GENE]
_ I_MEASURE
012385 I_MEASURE
) O
, O
respectively O
. O

As O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
transcript B_GENE
coding I_GENE
for O
the O
ribosomal B_GENE
protein I_GENE
RL3 I_GENE
was O
specifically O
amplified O
for O
22 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cycles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
sense B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
5 B_MEASURE
' O
GAAAGAAGTCGTGGAGGCTG3 B_PROTEIN[GENE]/B_LOCATION
' O
) O
and O
antisense B_GENE
( O
5 B_MEASURE
' O
ATCTCATCCTGCCCAAACAC3 B_PROTEIN[GENE]/B_LOCATION
' O
) O
primers B_GENE/B_LOCATION
, O
in O
positions B_MEASURE
216 I_MEASURE
and O
637 B_MEASURE
of O
the O
cDNA B_GENE
, O
respectively O
. O

Author B_PERSON
' O
s B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributions I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CM B_DISEASE/B_PERSON
prepared O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
retrovirus B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
carried O
out O
RNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blots I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
NL B_LOCATION/B_PERSON
carried O
out O
CAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
SV B_LOCATION/B_ORGANIZATION
participated O
in O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
JLI B_DISEASE/B_LOCATION
participated O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
wrote O
the O
manuscript B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
authors B_PERSON/B_NUMBER[MEASURE]
read O
and O
approved O
the O
final B_TIME[MEASURE]/B_ENT
manuscript B_TIME[MEASURE]/I_ENT
. O

enzymatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
multiplex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
problem B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
reading O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
films B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
been O
reformulated O
using O
an O
easily O
implemented O
, O
multiplex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
version I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
enzymatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

By O
utilizing O
a O
uniquely O
tagged O
primer B_GENE
for O
each O
base B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
the O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O
be O
pooled O
and O
electrophoresed O
in O
a O
single B_LOCATION/B_ORGANIZATION
lane I_LOCATION/I_ORGANIZATION
. O

This O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O
been O
previously O
proposed O
for O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
fluorescently O
labelled O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 B_NUMBER[MEASURE]
) O
, O
and O
is O
analogous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
principle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
in O
four B_NUMBER[MEASURE]/B_COLOR
- O
dye B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fluorescence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequencing O
except O
that O
the O
signals B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
resolved O
following O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_NUMBER[MEASURE]
) O
. O

After O
transfer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
a O
nylon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
membrane I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
images B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
obtained O
separately O
for O
each O
of O
the O
four B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
oligonucleotide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
images B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O
then O
be O
superimposed O
to O
reconstitute O
a O
complete B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pattern I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
way B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
correction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
gel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
distortion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
accurate B_DISEASE/B_MEASURE
band I_DISEASE/I_MEASURE
registration I_DISEASE/I_MEASURE
are O
considerably O
simplified O
, O
as O
each O
of O
the O
four B_LOCATION/B_ORGANIZATION
base I_LOCATION/I_ORGANIZATION
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ladders I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
require O
very O
similar B_MEASURE
corrections I_MEASURE
. O

The O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therefore O
provide O
the O
basis B_PERSON/B_LOCATION
for O
a O
second B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
more O
accurate B_DISEASE_ADJECTIVE[DISEASE]
and O
reliable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
film I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reading I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programs I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
well O
as O
being O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
conventional B_PERSON/B_ENT
multiplex I_PERSON/I_ENT
sequencing I_PERSON/I_ENT
. O

Unlike O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
multiplex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
3 B_TIME[MEASURE]/B_ORGANIZATION
) O
, O
the O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
described O
is O
suitable B_DISEASE_ADJECTIVE[DISEASE]
for O
small B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cloning I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
vectors I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
are O
not O
used O
. O

Although O
more B_MEASURE
than O
one B_NUMBER[MEASURE]/B_LOCATION
vector I_NUMBER[MEASURE]/I_LOCATION
can O
be O
utilized O
, O
only O
a O
library B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fragments B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cloned O
into O
any O
single B_BACTERIUM[BIO]/B_GENE
phage B_BACTERIUM[BIO]/I_GENE
, O
phagemid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
plasmid B_GENE
vector I_GENE
is O
actually O
required O
, O
together O
with O
a O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
tagged O
oligonucleotide B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
primers I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
Images B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nucleic B_NUMBER[MEASURE]/B_LOCATION
acids I_NUMBER[MEASURE]/I_LOCATION
Research I_NUMBER[MEASURE]/I_LOCATION
, O
Vol B_LOCATION/B_PERSON
. O

19 B_MEASURE
, O
No O
. O
12 B_NUMBER[MEASURE]/B_PERSON
3301 I_NUMBER[MEASURE]/I_PERSON
. O

enzymatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
multiplex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Mark B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Chee I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Medical B_LOCATION/B_ORGANIZATION
Research I_LOCATION/I_ORGANIZATION
Council I_LOCATION/I_ORGANIZATION
Laboratory I_LOCATION/I_ORGANIZATION
of O
Molecular B_EDU[ORGANIZATION]/B_LOCATION
Biology I_EDU[ORGANIZATION]/I_LOCATION
, O
Hills B_LOCATION/B_ORGANIZATION
Road I_LOCATION/I_ORGANIZATION
, O
Cambridge B_LOCATION
CB2 I_LOCATION
20H I_LOCATION
, O
UK B_LOCATION
. O

received O
March B_TIME[MEASURE]
15 I_TIME[MEASURE]
, O
1991 B_MEASURE
; O
revised O
and O
accepted O
May B_TIME[MEASURE]
2 I_TIME[MEASURE]
, O
1991 B_MEASURE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
problem B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
reading O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
films B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
been O
reformulated O
using O
an O
easily O
implemented O
, O
multiplex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
version I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
enzymatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

By O
utilizing O
a O
uniquely O
tagged O
primer B_GENE
for O
each O
base B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
the O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O
be O
pooled O
and O
electrophoresed O
in O
a O
single B_LOCATION/B_ORGANIZATION
lane I_LOCATION/I_ORGANIZATION
. O

This O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O
been O
previously O
proposed O
for O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
fluorescently O
labelled O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 B_NUMBER[MEASURE]
) O
, O
and O
is O
analogous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
principle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
in O
four B_NUMBER[MEASURE]/B_COLOR
- O
dye B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fluorescence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequencing O
except O
that O
the O
signals B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
resolved O
following O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_NUMBER[MEASURE]
) O
. O

After O
transfer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
a O
nylon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
membrane I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
images B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
obtained O
separately O
for O
each O
of O
the O
four B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
oligonucleotide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
images B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O
then O
be O
superimposed O
to O
reconstitute O
a O
complete B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pattern I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
way B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
correction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
gel B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
distortion I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
accurate B_DISEASE/B_LOCATION
band I_DISEASE/I_LOCATION
registration I_DISEASE/I_LOCATION
are O
considerably O
simplified O
, O
as O
each O
of O
the O
four B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
basespecific I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ladders I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
require O
very O
similar B_MEASURE
corrections I_MEASURE
. O

The O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therefore O
provide O
the O
basis B_PERSON/B_LOCATION
for O
a O
second B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
more O
accurate B_DISEASE_ADJECTIVE[DISEASE]
and O
reliable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
film I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reading I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programs I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
well O
as O
being O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
conventional B_PERSON/B_ENT
multiplex I_PERSON/I_ENT
sequencing I_PERSON/I_ENT
. O

Unlike O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
multiplex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
3 B_TIME[MEASURE]/B_ORGANIZATION
) O
, O
the O
approach B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
described O
is O
suitable B_DISEASE_ADJECTIVE[DISEASE]
for O
small B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
projects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
cloning I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
vectors I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
are O
not O
used O
. O

Although O
more B_MEASURE
than O
one B_NUMBER[MEASURE]/B_LOCATION
vector I_NUMBER[MEASURE]/I_LOCATION
can O
be O
utilized O
, O
only O
a O
library B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fragments B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cloned O
into O
any O
single B_MEASURE/B_BACTERIUM[BIO]
phage I_MEASURE/I_BACTERIUM[BIO]
. O
phagemid B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
plasmid B_GENE/B_BIO
vector I_GENE/I_BIO
is O
actually O
required O
, O
together O
with O
a O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
tagged O
oligonucleotide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
community B_ORGANIZATION/B_LOCATION
of O
biologists B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
undertaking O
the O
sequencing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
representative B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genomes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
various B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
free I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
living B_BIO/B_LOCATION
organisms I_BIO/I_LOCATION
, O
ranging O
in O
size B_MEASURE/B_LOCATION
from O
Mycoplasma B_BIO
( O
800kb B_MEASURE
) O
to O
mammals B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_MEASURE/B_SPECIES[BIO]
GB I_MEASURE/I_SPECIES[BIO]
) O
( O
4 B_MEASURE
) O
. O

However O
, O
the O
largest B_NUMBER[MEASURE]/B_BIO
contiguous I_NUMBER[MEASURE]/I_BIO
DNA I_NUMBER[MEASURE]/I_BIO
sequences I_NUMBER[MEASURE]/I_BIO
which O
have O
been O
determined O
so O
far O
are O
the O
genomes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
several B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
dsDNA I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
eukaryotic I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
viruses I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
5 B_NUMBER[MEASURE]
, O
6 B_SEQUENCE[MEASURE]
, O
7 B_NUMBER[MEASURE]
, O
8 B_NUMBER[MEASURE]
, O
9 B_NUMBER[MEASURE]
) O
and O
plant B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloroplasts I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_NUMBER[MEASURE]
, O
11 B_NUMBER[MEASURE]
, O
12 B_MEASURE
) O
. O

The O
largest O
of O
these O
is O
the O
229kb O
genome O
of O
human B_SPECIES[BIO]
cytomegalovirus I_SPECIES[BIO]
( O
8 O
) O
. O

The O
difficulty B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
sequencing O
millions B_LOCATION/B_MEASURE
of O
base B_MEASURE/B_DISEASE
pairs I_MEASURE/I_DISEASE
of O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
that O
several B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steps I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
methods B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
are O
relatively O
labour B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensive I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
although O
the O
sequencing O
reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
themselves O
are O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
easily O
performed O
. O

Two B_NUMBER[MEASURE]/B_PERSON
limiting O
steps B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
conventional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
the O
size B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
fractionation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
sequencing O
reaction B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
subsequent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
reading I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ladders B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
former B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
overcome O
by O
multiplexing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
which O
theoretically O
allows O
an O
enormous B_DISEASE_ADJECTIVE[DISEASE]
amount I_DISEASE_ADJECTIVE[DISEASE]
of O
. O

data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
obtained O
from O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
gel I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O
processing O
clones B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
as O
mixtures B_LOCATION
rather O
than O
individually O
( O
3 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Each O
sequence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
mixture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
labelled O
by O
a O
unique B_NUMBER[MEASURE]/B_PERSON
short I_NUMBER[MEASURE]/I_PERSON
oligonucleotide I_NUMBER[MEASURE]/I_PERSON
' I_NUMBER[MEASURE]/I_PERSON
tag I_NUMBER[MEASURE]/I_PERSON
' O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

This O
allows O
the O
mixture B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
be O
resolved O
following O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
the O
superimposed B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequence I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ladders I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
blotted O
from O
the O
gel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
nylon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
membrane I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
detected O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
time B_TIME[MEASURE]/B_LOCATION
by O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
using O
tag B_GENE/B_LOCATION
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
oligonucleotide B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
probes B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

In O
practice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
at O
least O
50 B_NUMBER[MEASURE]
sets I_NUMBER[MEASURE]
of O
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O
be O
obtained O
from O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
gel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
3 B_MEASURE/B_LOCATION
) O
. O

Unfortunately O
, O
a O
bottleneck B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
multiplex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
the O
reading B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
films I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
scale B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
projects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
this O
task B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
performed O
with O
the O
aid B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
sonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
digitizer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
13 B_MEASURE
, O
14 B_MEASURE
) O
. O

Although O
film B_PERSON/B_ORGANIZATION
reading I_PERSON/I_ORGANIZATION
programs I_PERSON/I_ORGANIZATION
have O
been O
under O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
some O
time B_TIME[MEASURE]/B_PERSON
( O
15 B_MEASURE
) O
, O
and O
some O
programs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
commercially O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
their O
error B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
rates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
presently O
more O
variable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
unpredictable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
that O
of O
a O
skilled B_PERSON/B_ENT
person B_PERSON/I_ENT
and O
the O
accurate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
interpretation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
of O
film B_ENT/B_LOCATION
- O
imaged O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
ladders I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
by O
computer B_PERSON/B_ORGANIZATION
programs I_PERSON/I_ORGANIZATION
is O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
achieve O
in O
routine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
practice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Programs B_LOCATION/B_ENT
specifically O
designed O
to O
read O
multiplex B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
films I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
an O
advantage B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
is O
because O
a O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
image I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
can O
be O
used O
as O
an O
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
internal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
standard I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' O
to O
help O
interpret O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
images I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
the O
same B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membrane I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
3 B_TIME[MEASURE]/B_LOCATION
) O
. O

However O
, O
the O
original B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
implementation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
multiplex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
chemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
16 B_MEASURE
) O
, O
which O
yields O
a O
more O
complex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ladder I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O
the O
enzymatic B_TIME[MEASURE]/B_GENE
dideoxynucleotide I_TIME[MEASURE]/I_GENE
chain I_TIME[MEASURE]/I_GENE
- O
termination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
17 B_MEASURE
) O
. O

Most O
successful O
large O
scale O
sequencing O
projects O
have O
used O
the O
chaintermination O
method O
and O
bacteriophage B_BIO/B_DISEASE
M13 I_BIO/I_DISEASE
vectors O
, O
which O
allows O
the O
routine O
production O
of O
clean O
and O
easily O
interpretable O
sequences O
( O
18 O
) O
. O

It O
was O
therefore O
decided O
to O
adapt O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
multiplex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
enzymatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
using O
tagged O
primers B_GENE/B_LOCATION
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Eight B_NUMBER[MEASURE]
oligonucleotide I_NUMBER[MEASURE]
sequencing I_NUMBER[MEASURE]
primers I_NUMBER[MEASURE]
were O
synthesized O
, O
each O
37 B_MEASURE
nucleotides I_MEASURE
in O
length B_MEASURE/B_LOCATION
. O

The O
3 B_NUMBER[MEASURE]
' O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
each O
primer B_GENE/B_LOCATION
consists O
of O
the O
17 B_NUMBER[MEASURE]
nucleotide I_NUMBER[MEASURE]
M13 I_NUMBER[MEASURE]
universal I_NUMBER[MEASURE]
priming I_NUMBER[MEASURE]
sequence I_NUMBER[MEASURE]
[ I_NUMBER[MEASURE]
GTAAAACGACGGCCAGT3 I_NUMBER[MEASURE]
' O
] B_DISEASE/B_PROTEIN[GENE]
. O

The O
5 B_NUMBER[MEASURE]/B_BIO
' O
ends B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
primers B_GENE
bear O
different B_DISEASE_ADJECTIVE[DISEASE]
20mer I_DISEASE_ADJECTIVE[DISEASE]
tag I_DISEASE_ADJECTIVE[DISEASE]
sequences I_DISEASE_ADJECTIVE[DISEASE]
( O
figure B_PROTEIN[GENE]/B_LOCATION
1 I_PROTEIN[GENE]/I_LOCATION
) O
. O

In O
four B_NUMBER[MEASURE]/B_PERSON
of O
the O
primers B_GENE/B_PERSON
, O
UEO1C B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
UPOIC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
UE02C B_DISEASE/B_PROTEIN[GENE]
and O
UP02C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
these O
tags B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
complementary B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
EO1 B_PROTEIN[GENE]/B_LOCATION
, O
PO1 B_PROTEIN[GENE]
, O
E02 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
P02 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
probe I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
respectively O
( O
copied O
from O
the O
original B_NUMBER[MEASURE]/B_PERSON
' O
plex B_DISEASE/B_NUMBER[MEASURE]
' O
vectors B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_TIME[MEASURE]/B_LOCATION
) O
) O
. O

A O
second B_MEASURE/B_LOCATION
set B_MEASURE/I_LOCATION
of O
four B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
primers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
UJOL14C B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
UJOL15C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
UJOL16C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
UJOL17C B_LOCATION/B_PROTEIN[GENE]
, O
have O
the O
following B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
tag B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
: O
5 B_MEASURE
' O
CAAGTTTGAAGGTACTCATT B_GENE/B_MEASURE
, O
TATCAATTAAATTGTllTGAC B_GENE
, O
GTGTTGCTACCCAAGAAGCA B_GENE
, O
and O
TGTCACTAGAGCTGTCACTT B_GENE
, O
respectively O
. O

The B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

? O
= O
) O
1991 B_PERSON/B_MEASURE
Oxford B_PERSON/I_MEASURE
University B_PERSON/I_MEASURE
Press B_PERSON/I_MEASURE
. O

3302 B_NUMBER[MEASURE]/B_ORGANIZATION
Nucleic I_NUMBER[MEASURE]/I_ORGANIZATION
acids I_NUMBER[MEASURE]/I_ORGANIZATION
Research I_NUMBER[MEASURE]/I_ORGANIZATION
, O
Vol B_LOCATION/B_MEASURE
. O

19 O
, O
No O
. O
12 B_NUMBER[MEASURE]
. O

oligonucleotides B_GENE/B_MEASURE
were O
gel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
purified O
( O
19 B_MEASURE
) O
and O
used O
to O
sequence O
ssDNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
templates I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
prepared O
by O
phenol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extraction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 B_MEASURE
) O
or O
SDS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
denaturation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
21 B_MEASURE
) O
. O

Conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reactions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
performed O
as O
previously O
described O
( O
20 B_MEASURE
) O
. O

For O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
experiments I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
radioactively O
labelled O
nucleotides B_GENE/B_DISEASE
were O
omitted O
from O
the O
sequencing O
reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Instead O
, O
the O
21d B_MEASURE
of O
each O
nucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mix I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
added O
to O
the O
reaction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mixture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O
of O
the O
following B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
' O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O
mix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
6 B_MEASURE
. O
25MtM B_MEASURE
dATP I_MEASURE
, O
62 B_MEASURE
. O
5lM B_MEASURE/B_PERSON
ddATP I_MEASURE/I_PERSON
; O
' O
C B_PROTEIN[GENE]/B_LOCATION
' O
mix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
6 B_NUMBER[MEASURE]
. O
25MM B_MEASURE
dCTP I_MEASURE
, O
40MtM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ddCTP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O
' O
G B_PROTEIN[GENE]/B_LOCATION
' O
mix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
6 B_NUMBER[MEASURE]
. O
25MtM B_MEASURE
dGTP I_MEASURE
, O
80MtM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ddGTP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O
' O
T B_PROTEIN[GENE]/B_LOCATION
' O
mix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
6 B_NUMBER[MEASURE]
. O
25MM B_MEASURE
dTTP I_MEASURE
, O
250yM B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ddTTP I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
as O
well O
as O
125MM B_NUMBER[MEASURE]/B_PERSON
of O
each O
of O
the O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
other I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dNTPs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
each O
mix B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
. O

Apart O
from O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
these O
modified O
mixes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
no O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
made O
to O
the O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
procedure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
( O
20 B_TIME[MEASURE]/B_LOCATION
) O
. O

Sequencing B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
reactions I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
were O
pooled O
and O
ethanol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
precipitated O
as O
appropriate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

precipitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
microtitre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
trays I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
carried O
out O
as O
follows O
: O
a O
mixture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
3 B_MEASURE
. O
2M1 B_MEASURE
3M I_MEASURE
NaAc I_MEASURE
pH I_MEASURE
5 I_MEASURE
. O
0 B_MEASURE
and O
112Mi1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
EtOH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
dispensed O
to O
individual B_LOCATION/B_MEASURE
wells I_LOCATION/I_MEASURE
of O
a O
microtitre B_LOCATION
plate I_LOCATION
( O
Falcon B_PERSON/B_LOCATION
3911 I_PERSON/I_LOCATION
or O
Corning B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
25855 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
using O
an O
8 B_NUMBER[MEASURE]/B_LOCATION
- O
channel B_MEDICAL_DEVICE[OBJECT]/B_LOCATION
pipettor I_MEDICAL_DEVICE[OBJECT]/I_LOCATION
. O

Each O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
four B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
added O
to O
the O
EtOH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
NaAc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mixture I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
and O
the O
tray B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sealed O
using O
a O
Falcon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
3073 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
plate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
sealer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
. O

The O
samples B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
mixed O
by O
inversion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
stored O
at O
- O
20 B_MEASURE
? O
C B_MEASURE/B_LOCATION
for O
30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minutes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
DNA B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
was O
collected O
by O
a O
20 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
minute I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
centrifugation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
at O
4 B_MEASURE/B_LOCATION
000 B_MEASURE/I_LOCATION
rpm B_MEASURE/I_LOCATION
in O
an O
IEC B_LOCATION
Centra I_LOCATION
3C I_LOCATION
centrifuge I_LOCATION
. O

The O
sealer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
removed O
, O
and O
the O
plate B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inverted O
to O
discard O
the O
supernatant B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

After O
blotting O
the O
tray B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
tissue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
paper I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
200MI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
95 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
EtOH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
added O
to O
each O
well O
. O

The O
plate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
covered O
with O
a O
plastic B_PRODUCT[OBJECT]/B_LOCATION
lid I_PRODUCT[OBJECT]/I_LOCATION
and O
recentrifuged O
for O
2 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
minutes I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

The O
EtOH B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
discarded O
and O
the O
plate B_BODY_PART_OR_ORGAN_COMPONENT
inverted O
for O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minutes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
tissue B_LOCATION/B_ORGANIZATION
paper I_LOCATION/I_ORGANIZATION
, O
then O
left O
for O
20 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
to O
air O
dry B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Precipitated B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
samples I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
resuspended O
in O
6M1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deionized I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
vortexing O
on O
an O
SMI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
multi B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
tube B_MEDICAL_DEVICE[OBJECT]/B_LOCATION
vortexer I_MEDICAL_DEVICE[OBJECT]/I_LOCATION
for O
1 B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minute B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
denatured O
and O
electrophoresed O
on O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polyacrylamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
buffer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gradient I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
previously O
described O
( O
20 B_MEASURE
) O
. O

Following O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
gel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
transferred O
to O
a O
dry B_LOCATION/B_MEASURE
piece I_LOCATION/I_MEASURE
of O
Whatman B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3MM I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blotting O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
placed O
on O
a O
second B_LOCATION/B_PERSON
sheet I_LOCATION/I_PERSON
of O
blotting O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supported O
on O
a O
glass B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
saturated O
in O
4 B_MEASURE
x O
SSC B_MEASURE
( O
SSC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
150mM B_MEASURE
NaCl I_MEASURE
, O
l5mM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trisodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
citrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

This O
sheet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
wicked O
in O
a O
tray B_LOCATION
containing O
1 B_PERSON/B_LOCATION
litre B_PERSON/I_LOCATION
of O
4 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x O
SSC B_MEASURE/B_LOCATION
. O

The O
DNA B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
transferred O
to O
a O
nylon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
membrane I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
Amersham B_MEASURE
Hybond I_MEASURE
N I_MEASURE
) O
by O
capillary B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
blotting O
overnight O
( O
22 B_TIME[MEASURE]/B_LOCATION
) O
. O

DNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
fixed O
to O
the O
membranes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
U B_OTHER/B_PROTEIN[GENE]
. O
V B_MEASURE/B_LOCATION
. O
crosslinking O
( O
23 B_TIME[MEASURE]/B_LOCATION
) O
. O

Plex B_PERSON
oligonucleotide I_PERSON
probes I_PERSON
were O
a O
kind B_PERSON
gift I_PERSON
of O
Dr B_PERSON/B_LOCATION
. O
George B_PERSON
Church I_PERSON
. O

Probes B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
tailed O
at O
their O
3 B_LOCATION/B_GENE
' I_LOCATION/I_GENE
ends I_LOCATION/I_GENE
using O
[ B_OTHER/B_LOCATION
a O
- O
32P B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O
dCTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
previously O
described O
( O
3 B_MEASURE
) O
. O

For O
the O
preparation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
digoxigenin B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Dig B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
labelled O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
identical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tailing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reactions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
carried O
out O
substituting O
I0pmols B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
Dig B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
II B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dUTP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Boehringer B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
Mannheim I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
for O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
32P B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O
dCTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

membranes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
prehybridized O
for O
at O
least O
10 B_NUMBER[MEASURE]/B_ENT
minutes I_NUMBER[MEASURE]/I_ENT
in O
4 B_MEASURE
x O
SSC B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_MEASURE
x O
Denhardts B_MEASURE/B_LOCATION
' I_MEASURE/I_LOCATION
( O
0 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
( O
w O
/ O
v O
) O
each O
of O
BSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
heated O
at O
80 B_MEASURE
? O
C B_OTHER/B_PROTEIN[GENE]
for O
30 B_TIME[MEASURE]
minutes I_TIME[MEASURE]
to O
inactivate O
any O
alkaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphatase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Ficoll B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Pharmacia B_MEASURE/B_ORGANIZATION
) O
and O
polyvinylpyrrolidone B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
0 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
( O
w B_PROTEIN[GENE]
/ O
v O
) O
SDS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
5mM B_MEASURE/B_LOCATION
NaHPO4 I_MEASURE/I_LOCATION
( O
23 B_MEASURE/B_LOCATION
) O
. O

hybridization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
in O
25 B_MEASURE
- O
50M1 B_MEASURE/B_LOCATION
of O
prehybridization B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
buffer B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
per O
cm2 B_MEASURE/B_LOCATION
of O
membrane B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
probe B_MEASURE/B_LOCATION
concentration I_MEASURE/I_LOCATION
was O
approximately O
lnM O
. O

After O
LH B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
42 B_MEASURE
? O
C B_OTHER/B_PROTEIN[GENE]
, O
unbound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
removed O
by O
five B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minute I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
washes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
room B_MEASURE
temperature I_MEASURE
in O
1 B_MEASURE
x O
SSC B_MEASURE
, O
0 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
SDS I_MEASURE
( O
200MI B_MEASURE/B_LOCATION
/ O
cm2 B_MEASURE
membrane I_MEASURE
) O
. O

radioactive B_PERSON/B_ENT
blots I_PERSON/I_ENT
were O
covered O
in O
Saran B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wrap I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
exposed O
to O
film B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O
. O

Detection B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Dig B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labelled O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
an O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
Dig B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodyalkaline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphatase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
conjugate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Boehringer B_LOCATION/B_DISEASE
Mannheim I_LOCATION/I_DISEASE
) O
according O
to O
the O
manufacturer B_PERSON/B_ORGANIZATION
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
instructions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
except O
that O
all O
volumes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
reduced O
by O
70 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
conjugate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
used O
at O
a O
1 B_MEASURE
: O
10 B_MEASURE
000 I_MEASURE
dilution I_MEASURE
. O

blots B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
developed O
in O
25M1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
100mM B_MEASURE/B_LOCATION
Tris I_MEASURE/I_LOCATION
. O
Cl B_MEASURE/B_LOCATION
pH9 I_MEASURE/I_LOCATION
. O
5 B_MEASURE
, O

mantane4 B_MEASURE
- O
methoxy4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
3 B_MEASURE
' I_MEASURE
- O
phosphoryloxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
phenyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE/B_LOCATION
, O
2 B_NUMBER[MEASURE]
- O
dioxetane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
; O
Tropix B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
/ O
cm2 B_MEASURE/B_SPORT[ENT]
for O
30 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
minutes B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
37 B_TIME[MEASURE]/B_LOCATION
? O
C B_OTHER/B_PROTEIN[GENE]
, O
prior B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
film B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dioxetane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
stripped O
from O
the O
membranes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
by O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
minute I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
washes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
700C B_MEASURE/B_PERSON
with O
0 B_MEASURE
. O
2 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
SDS I_MEASURE/I_PERSON
, O
2mM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
EDTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
200 B_MEASURE
, O
ul B_MEASURE
/ O
cm2 B_MEASURE/B_LOCATION
membrane I_MEASURE/I_LOCATION
) O
. O

The O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
washing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
carried O
out O
in O
plastic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bags I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

However O
, O
washing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steps I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O
also O
been O
performed O
with O
gentle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agitation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
perspex B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
tub B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
( O
43 B_MEASURE
x O
27 B_MEASURE
x O
15cm B_MEASURE
) O
mounted O
on O
a O
reciprocal B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shaker I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
equivalent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
results I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
the O
latter B_TIME[MEASURE]/B_PERSON
case I_TIME[MEASURE]/I_PERSON
a O
minimum B_MEASURE/B_LOCATION
wash I_MEASURE/I_LOCATION
volume I_MEASURE/I_LOCATION
of O
500mls B_MEASURE
was O
used O
. O

The O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
a O
tub B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
is O
more O
convenient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
batch B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
processing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
should O
be O
straightforward B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
automate O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Autoradiograms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
revealed O
no O
difference B_MEASURE
in O
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
quality I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
when O
tagged O
primers B_GENE
were O
used O
instead O
of O
the O
17mer B_MEASURE/B_GENE
universal I_MEASURE/I_GENE
primer I_MEASURE/I_GENE
in O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
[ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
a O
- O
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dATP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
labelled O
sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
in O
multiplex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hybridization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
using O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
- O
32P B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dCTP I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tailed O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
not O
shown O
) O
. O

Experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
then O
conducted O
to O
determine O
the O
feasibility B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
pooling O
the O
four B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
base B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
each O
clone B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
fractionating O
them O
in O
a O
single B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lane B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
obtain O
a O
superimposed O
but O
interpretable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ladders I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
question B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
addressed O
was O
whether O
or O
not O
difficulties B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
band B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
registration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
might O
arise O
as O
a O
result B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
mobility B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
different B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
primer I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
distortion B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
membrane B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
probings B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
relevant B_DISEASE_ADJECTIVE[DISEASE]
that O
an O
automated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
film I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
reader I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
employing O
an O
internal B_MEASURE
standard I_MEASURE
requires O
that O
the O
nylon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
membrane I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
does O
not O
undergo O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distortions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
probings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
george B_LOCATION/B_MEASURE
church I_LOCATION/I_MEASURE
, O
personal B_MEASURE
communication I_MEASURE
) O
. O

Clones B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sequenced O
using O
the O
four B_NUMBER[MEASURE]/B_BIO
tagged O
primers B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
UEOlC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
UPOIC B_LOCATION/B_ORGANIZATION
, O
UE02C B_LOCATION/B_ORGANIZATION
, O
and O
UP02C B_LOCATION/B_ORGANIZATION
, O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
each O
base B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
Figure B_LOCATION/B_MEASURE
1 I_LOCATION/I_MEASURE
) O
. O

The O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
C B_OTHER/B_PROTEIN[GENE]
, O
G B_OTHER/B_PROTEIN[GENE]
and O
T B_LOCATION/B_PROTEIN[GENE]
reactions I_LOCATION/I_PROTEIN[GENE]
for O
each O
clone B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
pooled O
, O
and O
processed O
as O
described O
above O
. O

A O
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
autoradiograms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
obtained O
from O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consecutive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rounds I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
probing O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
32P B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dCTP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
labelled O
oligonucleotides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

alignment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
films B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O
that O
sequence B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
distortion B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
membrane B_LOCATION/B_GENE
between O
probings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
sufficiently O
minor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
allow O
accurate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
registration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
bands B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
hence O
accurate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reading I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

At O
least O
200 B_NUMBER[MEASURE]/B_LOCATION
nucleotides I_NUMBER[MEASURE]/I_LOCATION
of O
sequence B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
read O
accurately O
from O
a O
single B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
simply O
tracing O
the O
four B_LOCATION/B_MEASURE
sets I_LOCATION/I_MEASURE
of O
bands B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
using O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
colours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
overlaying O
the O
tracings B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
reading O
the O
bands B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequentially O
. O

In O
order B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
assess O
the O
practicality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
reading O
the O
sequences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
machine B_PRODUCT[OBJECT]/B_PERSON
, O
the O
images B_ENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
scanned O
to O
provide O
optical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
density I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
figure B_PROTEIN[GENE]/B_DISEASE
2 I_PROTEIN[GENE]/I_DISEASE
) O
. O

These O
profiles B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
overlaid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
and O
were O
found O
to O
be O
sufficiently O
in O
register B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
allow O
accurate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interpretation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
at O
least O
300 B_TIME[MEASURE]
nucleotides I_TIME[MEASURE]
. O

This O
was O
essentially O
the O
limit B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
resolution B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
gel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
accurate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manual I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reading I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
order B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
ensure O
that O
the O
relatively O
minor B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobility B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
between O
the O
four B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
primers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
not O
coincidental B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
the O
oligonucleotides B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
used O
, O
a O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
set I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
four B_NUMBER[MEASURE]
tagged O
M13 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
universal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
primers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
synthesised O
, O
this O
time B_NUMBER[MEASURE]/B_LOCATION
incorporating O
20mer B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
the O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
murine B_LOCATION/B_ORGANIZATION
herpesvirus I_LOCATION/I_ORGANIZATION
- O
68 B_NUMBER[MEASURE]
( O
UJOL14C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
15C B_MEASURE/B_PROTEIN[GENE]
, O
16C B_MEASURE/B_PERSON
, O
17C B_MEASURE/B_PERSON
) O
. O

Sequencing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
performed O
using O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Cx I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dATP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
label O
the O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
directly O
. O

Various B_LOCATION/B_PERSON
templates I_LOCATION/I_PERSON
were O
sequenced O
, O
and O
in O
all O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correctly O
ordered O
sequence B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ladders I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
obtained O
following O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
which O
the O
four B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reactions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
run O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
by O
- O
side B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
( O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
not O
shown O
) O
. O

Initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hybridization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
conducted O
using O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
f O
- O
32P B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

dCTP B_NUMBER[MEASURE]/B_ORGANIZATION
tailed O
oligonucleotide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
probes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

However O
, O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
. O

lOOmM B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaCl I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5OmM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MgC12 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_MEASURE/B_LOCATION
. O
15mM B_MEASURE
AMPPD I_MEASURE
( O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
( O
2 B_NUMBER[MEASURE]
' O
- O
ADA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

B B_OTHER/B_PERSON

C B_OTHER/B_PERSON

' O
Ordinary B_MEASURE/B_PROTEIN[GENE]
' I_PROTEIN[GENE]
Plex B_MEASURE/B_PERSON
' I_MEASURE
4 I_MEASURE
- O
CJ3 B_MEASURE/B_PROTEIN[GENE]
4 I_MEASURE/I_PROTEIN[GENE]
- O
rn B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
. O

Primeir B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
primer I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
. O

' O
All O
' O
C B_PROTEIN[GENE]/B_LOCATION
' O
' O
G B_OTHER/B_LOCATION
' O
' O
T B_OTHER/B_PROTEIN[GENE]
' O
. O

' O
Plex B_PERSON
' O
' O
Ordinary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Pool B_LOCATION/B_PERSON
and O
. O

vector B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
vector I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
fractionate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

resolve O
by O
sequential B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O

hybridizations B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Sequencing O
reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

SequencingreactIo B_SPECIES[BIO]/B_ORGANIZATION
product I_SPECIES[BIO]/I_ORGANIZATION
. O

Sequencing O
reaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

- O
n B_OTHER/B_PERSON
; O

= B_OTHER/B_PROTEIN[GENE]
= O
. O

- B_OTHER/B_PROTEIN[GENE]
= O
. O

- O
n B_MEASURE/B_GENE
: O
= O
. O

Figure B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
. O
approaches B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
enzymatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
multiplex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O
a O
) O
A O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
sequence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
tagged O
vectors B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
used O
. O

The O
tag B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
shown O
in O
red B_COLOR
, O
and O
the O
insert B_GENE/B_LOCATION
to O
be O
sequenced O
in O
blue B_COLOR
. O

However O
, O
the O
original O
plex O
vectors O
( O
3 O
) O
are O
plasmids O
, O
and O
therefore O
amenable O
only O
to O
dsDNA O
sequencing O
. O
sets O
of O
bacteriophage B_NUMBER[MEASURE]/B_BACTERIUM[BIO]
M13 I_NUMBER[MEASURE]/I_BACTERIUM[BIO]
vectors O
have O
been O
constructed O
bearing O
either O
one O
( O
32 O
) O
or O
two O
[ O
Chee O
, O
unpublished O
] O
of O
the O
plex O
tag O
sites O
flanking O
the O
polylinker O
, O
which O
can O
be O
used O
for O
this O
approach O
. O

b O
) O
The O
strategy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
in O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
tag B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
carried O
on O
the O
primer B_GENE
. O

c O
) O
If O
tagged O
primers B_GENE
are O
used O
, O
there O
is O
no O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
impediment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
performing O
each O
base B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O
a O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
primer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
as O
depicted O
. O

The O
reactions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
then O
be O
pooled O
in O
any O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
desired O
. O

The O
configuration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
shown O
, O
in O
which O
the O
four B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reactions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
electrophoresed O
in O
a O
single B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lane I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
designed O
to O
facilitate O
accurate B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
band I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
registration I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
reading O
by O
an O
automatic B_PERSON/B_LOCATION
film I_PERSON/I_LOCATION
reader I_PERSON/I_LOCATION
. O

In O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
read O
the O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
manually O
, O
base B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
would O
be O
run O
side B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
by O
- O
side B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
logistics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
processing O
the O
reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
essentially O
the O
same B_MEASURE/B_LOCATION
with O
either O
configuration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O
the O
same B_MEASURE
number I_MEASURE
of O
probings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
required O
. O

figure B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
. O

Four B_NUMBER[MEASURE]/B_PERSON
overlaid O
one B_NUMBER[MEASURE]
- O
dimensional B_MEASURE/B_LOCATION
optical I_MEASURE/I_LOCATION
density I_MEASURE/I_LOCATION
profiles I_MEASURE/I_LOCATION
for O
a O
single B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
clone I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
shown O
in O
two B_NUMBER[MEASURE]
overlapping O
sections B_LOCATION/B_ENT
. O

The O
optical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
density I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
unprocessed O
, O
except O
for O
a O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transform I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
correct O
for O
the O
relative B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displacement B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
translation B_GENE/B_MEASURE
and O
rotation B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
) O
of O
the O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
images I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O
which O
they O
are O
extracted O
. O

The O
profiles B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
read O
5 B_MEASURE
' O
to O
3 B_MEASURE
' O
from O
right B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
to O
left O
. O

Nucleotides B_MEASURE/B_LOCATION
positions I_MEASURE/I_LOCATION
66 I_MEASURE/I_LOCATION
to O
214 B_MEASURE
from O
the O
start B_LOCATION
of O
the O
universal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
priming I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
shown O
. O

The O
sequence B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
that O
of O
Bluescribe B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M13 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
template B_GENE/B_TIME[MEASURE]
DNA B_GENE/I_TIME[MEASURE]
obtained O
by O
rescue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
with O
M13K07 B_BACTERIUM[BIO]/B_PROTEIN[GENE]
helper B_BACTERIUM[BIO]/I_PROTEIN[GENE]
phage B_BACTERIUM[BIO]/I_PROTEIN[GENE]
( O
30 B_NUMBER[MEASURE]/B_LOCATION
) O
) O
, O
and O
was O
determined O
using O
the O
primers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
UEOIC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
UPOIC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
UE02C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
UP02C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
the O
T B_PROTEIN[GENE]/B_LOCATION
, O
C B_OTHER/B_PROTEIN[GENE]
, O
G B_PROTEIN[GENE]/B_OTHER
and O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

specific B_MEASURE/B_ENT
reactions B_MEASURE/I_ENT
respectively O
. O

Detection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
by O
autoradiography B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
a O
- O
32p B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dCTP I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tailed O
plex B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

A B_OTHER/B_PERSON

Nucleic B_NUMBER[MEASURE]/B_LOCATION
acids I_NUMBER[MEASURE]/I_LOCATION
Research I_NUMBER[MEASURE]/I_LOCATION
, O
Vol B_LOCATION/B_PERSON
. O

19 B_MEASURE
, O
No O
. O
12 B_TIME[MEASURE]
3303 I_TIME[MEASURE]
. O

I B_OTHER/B_PERSON

3304 B_NUMBER[MEASURE]/B_ORGANIZATION
Nucleic I_NUMBER[MEASURE]/I_ORGANIZATION
acids I_NUMBER[MEASURE]/I_ORGANIZATION
Research I_NUMBER[MEASURE]/I_ORGANIZATION
, O
Vol B_LOCATION/B_MEASURE
. O

19 O
, O
No O
. O
12 B_NUMBER[MEASURE]
. O

a B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

175 B_MEASURE
- O
. O
. O
. O

- O
w B_OTHER/B_PERSON
. O

. O
m B_MEASURE/B_OTHER
; O

b B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

182 B_NUMBER[MEASURE]
. O

a B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
. O
. O
. O
. O
. O
. O

F B_MEASURE/B_OTHER
. O
VW B_LOCATION/B_PERSON
. O

an B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

- O
w B_OTHER/B_PERSON
. O

- O
1 B_MEASURE/B_LOCATION
. O

S B_OTHER/B_DISEASE
- O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
~ O
~ O
~ O
~ O
~ O
~ O
~ O
~ O
~ O
~ O
~ B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
~ O
~ O
~ O
~ O
~ O
~ O
~ O
~ O
~ O
i O
. O

' O
F B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
; O
A O
I1 B_LOCATION
' O
CG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

figure B_MEASURE/B_LOCATION
3 I_MEASURE/I_LOCATION
. O

Four B_LOCATION/B_GENE
separate B_LOCATION/I_GENE
base B_LOCATION/I_GENE
- O
specific B_LOCATION/B_PERSON
reactions I_LOCATION/I_PERSON
imaged O
from O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lane I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
using O
chemiluminescent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
detection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
clones B_DISEASE/B_GENE
sequenced O
are O
: O
a O
) O
Bluescribe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
M13 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
obtained O
by O
rescue B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
M13K07 B_BACTERIUM[BIO]/B_GENE
helper B_BACTERIUM[BIO]/I_GENE
phage B_BACTERIUM[BIO]/I_GENE
( O
30 B_MEASURE
) O
) O
and O
b O
) O
an O
M13 B_GENE/B_TIME[MEASURE]
recombinant I_GENE/I_TIME[MEASURE]
clone I_GENE/I_TIME[MEASURE]
prepared O
in O
a O
microtitre B_TIME[MEASURE]/B_PRODUCT[OBJECT]
tray B_TIME[MEASURE]/I_PRODUCT[OBJECT]
( O
21 B_MEASURE
) O
( O
a O
kind B_PERSON
gift I_PERSON
of O
Victoria B_NUMBER[MEASURE]/B_PERSON
Smith I_NUMBER[MEASURE]/I_PERSON
) O
. O

Nucleotide B_LOCATION/B_ORGANIZATION
positions I_LOCATION/I_ORGANIZATION
shown O
on O
the O
figure B_PERSON/B_LOCATION
are O
numbered O
from O
the O
start B_LOCATION/B_MEASURE
of O
the O
universal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
priming I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
clones B_GENE/B_DISEASE
were O
sequenced O
using O
UEOlC B_LOCATION/B_ORGANIZATION
, O
UPOIC B_LOCATION/B_ORGANIZATION
, O
UE02C B_LOCATION/B_ORGANIZATION
, O
and O
UP02C B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
T B_PROTEIN[GENE]/B_LOCATION
, O
C B_PROTEIN[GENE]/B_OTHER
, O
G B_PROTEIN[GENE]/B_LOCATION
and O
A O
specific B_LOCATION/B_PERSON
reactions I_LOCATION/I_PERSON
respectively O
. O

The O
blot B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
probed O
with O
corresponding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Dig I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
11 B_MEASURE/B_LOCATION
- O
dUTP B_MEASURE/B_GENE
labelled I_MEASURE/I_GENE
oligonucleotides I_MEASURE/I_GENE
. O

radioactivity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
the O
scale B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
envisioned O
for O
a O
large B_LOCATION/B_PRODUCT[OBJECT]
sequencing B_LOCATION/I_PRODUCT[OBJECT]
project B_LOCATION/I_PRODUCT[OBJECT]
is O
undesirable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
reasons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
safety B_DISEASE_ADJECTIVE[DISEASE]/B_SPORT[ENT]
. O

The O
relatively O
long B_TIME[MEASURE]
exposure I_TIME[MEASURE]
times I_TIME[MEASURE]
required O
( O
6 B_MEASURE/B_LOCATION
to O
24 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
) O
and O
the O
short B_MEASURE
half I_MEASURE
lives I_MEASURE
of O
the O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O
also O
be O
inconvenient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
has O
been O
shown O
that O
a O
biotin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
streptavidin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
/ O
alkaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
phosphatase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
based O
detection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
used O
in O
conjunction B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
a O
chemiluminescent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dioxetane I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
substrate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
overcomes O
these O
disadvantages B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
24 B_MEASURE
, O
25 B_MEASURE
, O
26 B_MEASURE
) O
. O

We O
utilized O
a O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bridging O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
similar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Digoxigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
( O
Dig B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
labelled B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
oligonucleotide B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
probes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
detected O
using O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
Dig B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
alkaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
conjugates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
chemiluminescent B_LOCATION/B_ENZYME[GENE]
dioxetane B_LOCATION/I_ENZYME[GENE]
substrate B_LOCATION/I_ENZYME[GENE]
. O

exposure B_TIME[MEASURE]
times I_TIME[MEASURE]
of O
10 B_NUMBER[MEASURE]
to O
15 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
were O
typically O
required O
, O
following O
a O
one B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hour I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
preincubation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
period I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Figure B_TIME[MEASURE]/B_LOCATION
3 I_TIME[MEASURE]/I_LOCATION
) O
. O

In O
our O
hands B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
Dig B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bridging O
system B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
sensitivity B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
streptavidin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
based O
system B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
24 B_TIME[MEASURE]/B_LOCATION
) O
, O
and O
the O
practical B_MEASURE/B_LOCATION
lower I_MEASURE/I_LOCATION
limit I_MEASURE/I_LOCATION
of O
template B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ssDNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
required O
in O
order B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
obtain O
an O
easily O
interpretable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
ladder I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
estimated O
to O
be O
in O
the O
range B_LOCATION/B_MEASURE
of O
20 B_NUMBER[MEASURE]
to O
50fmols B_MEASURE/B_PERSON
per O
reaction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

However O
, O
the O
sensitivity B_MEASURE
of O
detection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
limited O
only O
by O
enzymaticallytriggered B_MEASURE/B_LOCATION
background I_MEASURE/I_LOCATION
luminescence I_MEASURE/I_LOCATION
, O
and O
not O
by O
the O
level B_MEASURE
of O
signal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
. O

The O
nonradioactive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
described O
have O
been O
used O
successfully O
in O
an O
8 B_MEASURE/B_PROTEIN[GENE]
- O
plex B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
multiplex I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
based O
on O
a O
set B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O
tagged O
vectors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
3 B_MEASURE/B_BIO
) O
, O
tagged B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
primers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
also O
been O
used O
or O
proposed O
for O
various B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
multiplex B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
George B_MEASURE/B_PERSON
Church I_MEASURE/I_PERSON
, O
personal B_MEASURE
communication I_MEASURE
; O
2 B_MEASURE
, O
27 B_MEASURE
) O
. O

For O
example B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
a O
proposal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
recently O
put O
forward O
for O
multiplex B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O
using O
sequence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
labelled O
primers B_GENE
and O
fluorophor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
labelled O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

( O
1 B_MEASURE
) O
, O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
principle B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
here O
. O

However O
, O
we O
use O
tagged O
primers B_GENE
and O
the O
superposition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
four B_NUMBER[MEASURE]/B_BIO
sequencing O
reactions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
address O
the O
problem B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
reading O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
films B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O
a O
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
solution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
to O
utilize O
M13 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
dideoxynucleotide I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
thereby O
improving O
the O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
be O
analyzed O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
proposal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O
fluorophor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
labelled O
probes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O
not O
take O
into O
consideration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
any O
of O
the O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
addressed O
here O
, O
and O
, O
in O
the O
version B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
described O
, O
remains O
a O
promising B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O
unproven B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
scheme I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
for O
large B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scale I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
are O
several B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advantages B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
tagging O
primers B_GENE
instead O
of O
vectors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

firstly O
, O
there O
is O
no O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
to O
prepare O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
libraries I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
clones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
special B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vectors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

This O
means O
that O
workers B_PERSON/B_ORGANIZATION
can O
use O
vector B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
host B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
combinations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
yield O
good B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
their O
hands B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
an O
increased O
depth B_MEASURE
of O
multiplexing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O
easily O
be O
accomodated O
by O
synthesizing O
more B_ENT/B_LOCATION
primers I_ENT/I_LOCATION
. O

This O
should O
make O
multiplexing O
more O
accessible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
workers B_PERSON/B_ORGANIZATION
undertaking O
smaller B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
projects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
theoretical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disadvantage B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tagged O
primers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
that O
the O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O
only O
be O
multiplexed O
following O
primer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
annealing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
1 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
or O
following O
the O
sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
this O
paper B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
in O
practice B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pooling O
immediately O
after O
the O
annealing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
step I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
might O
lead O
to O
increased O
backgrounds B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
if O
one B_NUMBER[MEASURE]
or O
more B_NUMBER[MEASURE]/B_ENT
primers I_NUMBER[MEASURE]/I_ENT
were O
present B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
excess B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
over O
their O
template B_TIME[MEASURE]/B_LOCATION
DNAs I_TIME[MEASURE]/I_LOCATION
) O
. O

This O
is O
a O
relatively O
late B_DISEASE_ADJECTIVE[DISEASE]
stage I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
original B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
3 B_MEASURE
) O
, O
clones B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O
pooled O
prior B_PERSON
to O
amplification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
by O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
an O
early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
we O
do O
not O
believe O
the O
sacrifice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
be O
of O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
importance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
when O
using O
phage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
vectors I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
our O
experience B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
recombinant B_BIO/B_PERSON
M13 I_BIO/I_PERSON
phage I_BIO/I_PERSON
have O
variable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
competition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
severely O
limit O
the O
number B_MEASURE/B_LOCATION
of O
clones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
can O
usefully O
be O
pooled O
for O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
by O
growing O
clones B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
individually O
, O
the O
depth B_MEASURE
of O
multiplexing O
is O
only O
really O
limited O
by O
probe B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity I_MEASURE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
not O
investigated O
the O
factors B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
influencing O
variability B_MEASURE
in O
phage B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
growth I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
rates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

It O
is O
worth B_LOCATION/B_DISEASE
noting O
that O
reliable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
protocols I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
have O
been O
developed O
for O
growing O
large B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
numbers I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
individual B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
M13 B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
clones B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O
preparing O
high B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
quality I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
ssDNA I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
templates I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
in O
microtitre B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
trays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
28 B_MEASURE
, O
21 B_MEASURE
) O
. O

It O
is O
relatively O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
prepare O
manually O
two B_MEASURE/B_LOCATION
microtitre I_MEASURE/I_LOCATION
trays I_MEASURE/I_LOCATION
of O
ssDNA B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
templates B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
192 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
in O
a O
day B_TIME[MEASURE]/B_LOCATION
. O

sufficient B_PERSON
clones I_PERSON
can O
be O
prepared O
in O
a O
week B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
sequence O
a O
20kb B_GENE/B_MEASURE
fragment I_GENE/I_MEASURE
to O
a O
redundancy B_MEASURE/B_LOCATION
of O
10 B_MEASURE
( O
Victoria B_PERSON/B_BIO
Smith I_PERSON/I_BIO
, O
personal B_MEASURE
communication I_MEASURE
) O
. O

In O
this O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
ssDNA B_BIO/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
now O
prepared O
with O
the O
aid B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
commercially O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
robotic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
workstation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O
21 B_TIME[MEASURE]/B_LOCATION
) O
. O

As O
sequencing O
reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
also O
carried O
out O
in O
microtitre B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
trays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
manually O
or O
robotically O
( O
20 B_MEASURE
, O
29 B_MEASURE
) O
, O
the O
entire B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
M13 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
based O
dideoxynucleotide B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
amenable B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
automation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
( O
29 B_MEASURE
) O
. O

For O
these O
reasons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
we O
see O
little B_DISEASE_ADJECTIVE[DISEASE]
practical I_DISEASE_ADJECTIVE[DISEASE]
advantage I_DISEASE_ADJECTIVE[DISEASE]
in O
pooling O
clones B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early O
. O

Finally O
, O
by O
not O
pooling O
clones B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early O
, O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
easily O
retrieve O
individual B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clones I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
retained O
, O
which O
may O
facilitate O
directed O
sequencing O
later O
in O
a O
project B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
should O
this O
become O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

multiplex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
sequencing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
is O
currently O
limited O
by O
the O
lack B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
robust B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
computer I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O
can O
correct O
for O
the O
large B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variety B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
gel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sequencing O
artefacts B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
normally O
encountered O
. O

The O
foundation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
a O
film B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reading I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
bring O
into O
register B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
precisely O
vertical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arrays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
base B_LOCATION/B_ENT
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bands I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

This O
requires O
the O
ability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
track O
lanes B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
correct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
distortions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
order B_MEASURE
bands I_MEASURE
based O
on O
their O
relative B_MEASURE/B_LOCATION
spacing I_MEASURE/I_LOCATION
. O

A O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sequencing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
has O
successfully O
overcome O
the O
problem B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reading I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
uses O
real B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
time B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
fluorescently O
labelled O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
migrating O
through O
the O
gel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
2 B_MEASURE/B_LOCATION
) O
. O

This O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
also O
utilizes O
the O
principle B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
running O
the O
four B_PRODUCT[OBJECT]/B_LOCATION
base I_PRODUCT[OBJECT]/I_LOCATION
reactions I_PRODUCT[OBJECT]/I_LOCATION
down O
the O
same B_LOCATION/B_PERSON
lane I_LOCATION/I_PERSON
( O
2 B_TIME[MEASURE]/B_LOCATION
) O
. O

However O
, O
bands B_PERSON/B_DISEASE
are O
detected O
at O
a O
fixed B_MEASURE/B_LOCATION
location I_MEASURE/I_LOCATION
. O

in O
space B_LOCATION/B_MEASURE
, O
and O
their O
detection B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
separated O
in O
time B_MEASURE/B_LOCATION
. O

Hence B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
. O

Nucleic B_NUMBER[MEASURE]/B_LOCATION
acids I_NUMBER[MEASURE]/I_LOCATION
Research I_NUMBER[MEASURE]/I_LOCATION
, O
Vol B_LOCATION/B_PERSON
. O

19 B_MEASURE
, O
No O
. O
12 B_NUMBER[MEASURE]/B_PERSON
3305 I_NUMBER[MEASURE]/I_PERSON
. O

problem B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
gel B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
distortion B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
essentially O
avoided O
, O
although O
corrections B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
the O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobilities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
four B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dyes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O
be O
carried O
out O
. O

In O
contrast B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
utilize O
the O
advantages B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
single B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lane I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
address O
the O
problem B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
superimposing O
four B_NUMBER[MEASURE]/B_LOCATION
relatively O
large B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
complex B_NUMBER[MEASURE]
two I_NUMBER[MEASURE]
- O
dimensional B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
images I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Furthermore O
, O
by O
using O
sequence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
tagged O
oligonucleotides B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
are O
detected O
by O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
much O
greater B_MEASURE
depth I_MEASURE
of O
multiplexing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O
realistically O
be O
achieved O
than O
by O
real B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
time B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
two B_NUMBER[MEASURE]
- O
dimensional B_MEASURE/B_LOCATION
colour B_MEASURE/I_LOCATION
traces B_MEASURE/I_LOCATION
to O
depict O
the O
processed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
output I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
a O
film B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reader B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
displaying O
fluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
traces I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
, O
and O
should O
facilitate O
the O
checking B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and O
editing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
sequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
databases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
which O
both O
kinds B_LOCATION/B_DISEASE
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
have O
been O
entered O
. O

The O
sequence B_LOCATION/B_PRODUCT[OBJECT]
compilation B_LOCATION/I_PRODUCT[OBJECT]
programs B_LOCATION/I_PRODUCT[OBJECT]
used O
in O
this O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
which O
are O
already O
capable B_PERSON
of O
handling O
large B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
shotgun I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
databases I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
8 B_MEASURE
, O
31 B_MEASURE
) O
, O
have O
recently O
undergone O
extensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
improvements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O
Rodger B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
Staden I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O
personal B_MEASURE
communication I_MEASURE
) O
. O

There O
is O
now O
an O
interactive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
editor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
which O
allows O
the O
graphical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
display I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
fluorescence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
traces I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
it O
is O
envisaged O
that O
this O
feature B_ENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
extended O
to O
allow O
the O
handling B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
from O
a O
film B_PERSON/B_LOCATION
reader I_PERSON/I_LOCATION
when O
a O
suitable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
machine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
is O
developed O
. O

ACKNOWLEDGEMENTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

I O
am O
particularly O
grateful B_TIME[MEASURE]/B_PERSON
to O
George B_PERSON
Church I_PERSON
for O
thought B_DISEASE
- O
provoking O
discussions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
and O
gifts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
vectors B_PROTEIN[GENE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oligonucleotide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
probes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
to O
John B_PERSON
Sulston I_PERSON
for O
advice B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

I O
also O
thank O
Victoria B_PERSON/B_ORGANIZATION
Smith I_PERSON/I_ORGANIZATION
for O
the O
gift B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
Bart B_PERSON/B_LOCATION
Barrell I_PERSON/I_LOCATION
for O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
support B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
Tom B_PERSON/B_ORGANIZATION
O I_PERSON/I_ORGANIZATION
' I_PERSON/I_ORGANIZATION
Keefe I_PERSON/I_ORGANIZATION
of O
Milligen B_BACTERIUM[BIO]/B_LOCATION
/ O
Biosearch B_PERSON/B_ORGANIZATION
for O
lessons B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
multiplexing O
and O
Amersham B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
International I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
optical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
density I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overlays I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O
in O
figure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

M B_OTHER/B_LOCATION
. O
C B_PROTEIN[GENE]/B_LOCATION
. O

is O
supported O
by O
a O
fellowship B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
Applied B_LOCATION/B_ORGANIZATION
Biosystems I_LOCATION/I_ORGANIZATION
. O

12 B_NUMBER[MEASURE]
. O

Hiratsuka B_PERSON
, O
J B_OTHER/B_LOCATION
. O
, O
Shimada B_PERSON
, O
H B_OTHER/B_LOCATION
. O
, O
Whittier B_PERSON
, O
R B_OTHER/B_LOCATION
. O
, O
Ishibashi B_PERSON
, O
T B_OTHER/B_LOCATION
. O
, O
Sakamoto B_PERSON
, O
M B_OTHER/B_LOCATION
. O
, O
Mori B_PERSON/B_LOCATION
, O

M B_OTHER/B_LOCATION
. O
, O
Kondo B_PERSON/B_LOCATION
, O
C B_OTHER/B_LOCATION
. O
, O
Honju B_PERSON/B_LOCATION
, O
Y B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Sun B_LOCATION/B_PERSON
, O
C B_OTHER/B_PERSON
. O

- O
R B_OTHER/B_PERSON
, O
Meng B_PERSON/B_LOCATION
, O
B B_OTHER/B_PERSON
. O

- O
Y B_OTHER/B_PERSON
, O
Li B_PERSON/B_PROTEIN[GENE]
, O
Y B_OTHER/B_PERSON
. O

- O
Q B_OTHER/B_PERSON
, O
Kanno B_PERSON
, O
A B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Nisizawa B_PERSON/B_LOCATION
, O
Y O
. O
, O
Hirai B_PERSON
, O
A B_OTHER/B_PERSON
. O
, O
Shinozaki B_PERSON
, O
K B_OTHER/B_LOCATION
. O
and O
Sugiura B_PERSON
, O
M B_OTHER/B_PERSON
. O

( O
1989 O
) O
Molecular B_EDU[ORGANIZATION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
General B_EDU[ORGANIZATION]/B_PERSON
genetics I_EDU[ORGANIZATION]/I_PERSON
, O
217 B_MEASURE
, O
185 B_MEASURE
- O
194 B_MEASURE
. O

13 B_NUMBER[MEASURE]
. O

Komaromy B_PERSON
, O
M B_OTHER/B_LOCATION
. O
and O
Govan B_PERSON
, O
H B_OTHER/B_LOCATION
. O

( O
1984 B_MEASURE
) O
Nucleic B_MEASURE/B_LOCATION
acids I_MEASURE/I_LOCATION
Research I_MEASURE/I_LOCATION
, O
12 B_MEASURE
, O
675 B_MEASURE
- O
678 B_MEASURE
. O

14 B_NUMBER[MEASURE]
. O

Staden B_PERSON/B_LOCATION
, O
R B_OTHER/B_PERSON
. O

( O
1984 B_MEASURE
) O
Nucleic B_MEASURE/B_LOCATION
acids I_MEASURE/I_LOCATION
Research I_MEASURE/I_LOCATION
, O
12 B_MEASURE
, O
499 B_MEASURE
- O
503 B_MEASURE
. O

15 B_NUMBER[MEASURE]
. O

Elder B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

K B_OTHER/B_PROTEIN[GENE]
. O
, O
Green B_COLOR/B_PERSON
, O
D B_OTHER/B_PERSON
. O

K B_OTHER/B_PROTEIN[GENE]
. O
and O
Southern B_LOCATION/B_PERSON
, O
E B_OTHER/B_LOCATION
. O

M B_OTHER/B_MEASURE
. O

( O
1986 B_NUMBER[MEASURE]
) O
nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Research B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
14 B_MEASURE
, O
417 B_MEASURE
- O
424 B_MEASURE
. O

16 B_NUMBER[MEASURE]
. O

Maxam B_PERSON/B_COLOR
, O
A O
. O

M B_OTHER/B_MEASURE
. O
and O
Gilbert B_PERSON/B_LOCATION
, O
W B_OTHER/B_PERSON
. O

( O
1977 O
) O
Proceedings B_TIME[MEASURE]/B_PERSON
of O
the O
National B_ORGANIZATION/B_PERSON
Academy I_ORGANIZATION/I_PERSON
. O

of O
Sciences B_ORGANIZATION/B_LOCATION
, O
U B_OTHER/B_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
A B_OTHER/B_PERSON
. O
, O
74 B_MEASURE
, O
560 B_MEASURE
- O
564 B_MEASURE
. O

17 B_NUMBER[MEASURE]
. O

Sanger B_PERSON/B_COLOR
, O
F B_LOCATION/B_DISEASE
. O
, O
Nicklen B_PERSON/B_COLOR
, O
S B_OTHER/B_LOCATION
. O
and O
Coulson B_PERSON
, O
A B_OTHER/B_LOCATION
. O

R B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1977 O
) O
Proceedings B_TIME[MEASURE]/B_PERSON
of O
the O
National B_LOCATION/B_ORGANIZATION
. O

Academy B_LOCATION/B_PERSON
of O
Sciences B_ORGANIZATION/B_LOCATION
, O
U B_OTHER/B_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
A B_OTHER/B_LOCATION
. O
, O
74 B_MEASURE
, O
5463 B_MEASURE
- O
5467 B_MEASURE
. O

18 B_NUMBER[MEASURE]
. O

Sanger B_PERSON/B_COLOR
, O
F B_OTHER/B_LOCATION
. O
, O
Coulson B_PERSON/B_COLOR
, O
A B_OTHER/B_PERSON
. O

R B_OTHER/B_PERSON
. O
, O
Barrell B_PERSON
, O
B B_OTHER/B_LOCATION
. O

G B_OTHER/B_PERSON
. O
, O
Smith B_PERSON
, O
A B_OTHER/B_PERSON
. O

J B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

H B_OTHER/B_PROTEIN[GENE]
. O
and O
Roe B_TIME[MEASURE]/B_PERSON
, O
B B_OTHER/B_PERSON
. O

A B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1980 B_MEASURE
) O
Journal B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Molecular B_EDU[ORGANIZATION]/B_PERSON
Biology I_EDU[ORGANIZATION]/I_PERSON
, O
143 B_MEASURE
, O
161 B_MEASURE
- O
178 B_MEASURE
. O

19 B_NUMBER[MEASURE]
. O

Applied O
Biosystems B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
user I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Bulletin I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1987 B_MEASURE
) O
13 B_MEASURE
, O
11 B_MEASURE
- O
16 B_MEASURE
. O

20 B_NUMBER[MEASURE]
. O

Bankier B_PERSON/B_COLOR
, O
A O
. O

T B_OTHER/B_PERSON
. O
, O
Weston B_PERSON
, O
K B_OTHER/B_PERSON
. O

M B_OTHER/B_PROTEIN[GENE]
. O
and O
Barrell B_PERSON
, O
B B_OTHER/B_PERSON
. O

G B_OTHER/B_GENE
. O

( O
1987 O
) O
Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
. O

Enzymology B_MEASURE
, O
155 B_MEASURE
, O
51 B_MEASURE
- O
93 B_MEASURE
. O

21 B_NUMBER[MEASURE]
. O

Smith B_PERSON/B_COLOR
, O
V B_OTHER/B_LOCATION
. O
, O
Brown B_PERSON/B_COLOR
, O
C B_OTHER/B_LOCATION
. O

M B_OTHER/B_PERSON
. O
, O
Bankier B_PERSON
, O
A B_OTHER/B_LOCATION
. O

T B_PROTEIN[GENE]/B_OTHER
. O
and O
Barrell B_PERSON
, O
B B_OTHER/B_PERSON
. O

G B_OTHER/B_GENE
. O

( O
1990 B_NUMBER[MEASURE]
) O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

sequence B_LOCATION/B_MEASURE
, O
1 B_MEASURE
, O
73 B_MEASURE
- O
78 B_MEASURE
. O

22 B_NUMBER[MEASURE]
. O

Southern B_LOCATION/B_PERSON
, O
E B_OTHER/B_LOCATION
. O

M B_OTHER/B_MEASURE
. O

( O
1975 B_MEASURE
) O
Journal B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Molecular B_EDU[ORGANIZATION]/B_PERSON
Biology I_EDU[ORGANIZATION]/I_PERSON
, O
98 B_MEASURE
, O
503 B_MEASURE
- O
517 B_MEASURE
. O

23 B_NUMBER[MEASURE]
. O

Church B_LOCATION/B_PERSON
, O
G B_OTHER/B_LOCATION
. O

M B_OTHER/B_MEASURE
. O
and O
Gilbert B_PERSON/B_LOCATION
, O
W B_OTHER/B_PERSON
. O

( O
1984 O
) O
Proceedings B_TIME[MEASURE]/B_PERSON
of O
the O
National B_ORGANIZATION/B_PERSON
Academy I_ORGANIZATION/I_PERSON
. O

of O
Sciences B_ORGANIZATION/B_LOCATION
, O
U B_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
A B_OTHER/B_LOCATION
. O
, O
81 B_TIME[MEASURE]/B_LOCATION
, O
1991 B_MEASURE
- O
1995 B_MEASURE
. O

24 B_NUMBER[MEASURE]
. O

Beck B_PERSON/B_COLOR
, O
S B_PROTEIN[GENE]/B_DISEASE
. O
, O
O B_OTHER/B_LOCATION
' O
Keefe B_PERSON
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
, O
Coull B_PERSON
, O
J B_OTHER/B_LOCATION
. O

M B_OTHER/B_PROTEIN[GENE]
. O
and O
Koster B_PERSON/B_LOCATION
, O
H B_OTHER/B_PERSON
. O

( O
1989 B_NUMBER[MEASURE]
) O
nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
17 B_MEASURE
, O
5115 B_MEASURE
- O
5123 B_MEASURE
. O

25 B_NUMBER[MEASURE]
. O

Tizard B_PERSON/B_COLOR
, O
R B_OTHER/B_LOCATION
. O
, O
Cate B_PERSON
, O
R B_OTHER/B_LOCATION
. O

L B_OTHER/B_PERSON
. O
, O
Ramachandran B_PERSON
, O
K B_OTHER/B_PERSON
. O

L B_OTHER/B_PROTEIN[GENE]
. O
, O
Wysk B_PERSON
, O
M B_LOCATION
. O
, O
Voyta B_PERSON/B_LOCATION
, O
J B_OTHER/B_LOCATION
. O

C B_OTHER/B_MEASURE
. O
, O

Murphy B_PERSON/B_MEASURE
, O
0 B_NUMBER[MEASURE]/B_PERSON
. O

J B_OTHER/B_PROTEIN[GENE]
. O
and O
Bronstein B_PERSON
, O
I O
. O

( O
1990 O
) O
Proceedings B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
National B_ORGANIZATION/B_PERSON
Academy I_ORGANIZATION/I_PERSON
of O
Sciences B_EDU[ORGANIZATION]/B_PERSON
, O
U B_OTHER/B_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
A B_OTHER/B_PERSON
. O
, O
87 B_MEASURE
, O
4514 B_MEASURE
- O
4518 B_MEASURE
. O

26 B_NUMBER[MEASURE]
. O

Beck B_PERSON
, O
S B_LOCATION/B_DISEASE
. O
and O
Koster B_PERSON
, O
H B_OTHER/B_LOCATION
. O

( O
1990 B_MEASURE
) O
analytical B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemistry I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
62 B_MEASURE
, O
2558 B_MEASURE
- O
2570 B_MEASURE
. O

27 B_NUMBER[MEASURE]
. O

Jacobson B_PERSON
, O
K B_OTHER/B_PERSON
. O

B B_OTHER/B_PROTEIN[GENE]
. O
, O
Arlinghaus B_PERSON/B_LOCATION
, O
H B_OTHER/B_PERSON
. O

F B_OTHER/B_LOCATION
. O
, O
Schmitt B_PERSON/B_COLOR
, O
H B_OTHER/B_PERSON
. O

W B_OTHER/B_PERSON
. O
, O
Sachleben B_PERSON/B_LOCATION
, O
R B_OTHER/B_PERSON
. O

A B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O

Brown B_PERSON/B_LOCATION
, O
G B_OTHER/B_PERSON
. O

M B_OTHER/B_LOCATION
. O
, O
Thonnard B_PERSON/B_LOCATION
, O
N B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Sloop B_PERSON/B_LOCATION
, O
F B_OTHER/B_PROTEIN[GENE]
. O

V B_OTHER/B_MEASURE
. O
, O
Foote B_PERSON
, O
R B_OTHER/B_PERSON
. O

S B_OTHER/B_PROTEIN[GENE]
. O
, O
Larimer B_PERSON
, O
F B_OTHER/B_PERSON
. O

W B_OTHER/B_PERSON
. O
, O
Woychik B_PERSON/B_COLOR
, O
R B_OTHER/B_PERSON
. O

P B_OTHER/B_PERSON
. O
, O
England B_LOCATION/B_PERSON
, O
M B_OTHER/B_LOCATION
. O

W B_OTHER/B_MEASURE
. O
, O
Burchett B_PERSON
, O
K B_OTHER/B_PERSON
. O

L B_OTHER/B_PROTEIN[GENE]
. O
and O
Jacobson B_PERSON
, O
D B_OTHER/B_PERSON
. O

A B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1991 B_MEASURE
) O
Genomics B_MEASURE/B_ORGANIZATION
, O
9 B_MEASURE
, O
51 B_MEASURE
- O
59 B_MEASURE
. O

28 B_NUMBER[MEASURE]
. O

Eperon B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
I O
. O

C B_OTHER/B_GENE
. O

( O
1986 B_MEASURE
) O
analytical B_TIME[MEASURE]/B_PERSON
Biochemistry I_TIME[MEASURE]/I_PERSON
, O
56 B_MEASURE
, O
406 B_MEASURE
- O
412 B_MEASURE
. O

29 B_NUMBER[MEASURE]
. O

Bankier B_PERSON/B_COLOR
, O
A O
. O

T B_PROTEIN[GENE]/B_OTHER
. O
and O
Barrell B_PERSON
, O
B B_OTHER/B_PERSON
. O

G B_OTHER/B_GENE
. O

( O
1989 O
) O
In O
Howe B_PERSON/B_ORGANIZATION
, O
C B_OTHER/B_PERSON
. O

J B_OTHER/B_PROTEIN[GENE]
. O
and O
Ward B_PERSON/B_LOCATION
, O
E B_OTHER/B_PERSON
. O

S B_OTHER/B_DISEASE
. O

( O
ed O
) O
, O
nucleic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O
: O
a O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

IRL B_NUMBER[MEASURE]/B_PERSON
Press I_NUMBER[MEASURE]/I_PERSON
, O
Oxford B_LOCATION/B_MEASURE
, O
Vol B_LOCATION/B_MEASURE
. O

1 B_NUMBER[MEASURE]
, O
pp O
. O

37 O
- O
78 B_MEASURE
. O

30 B_NUMBER[MEASURE]
. O

Vieira B_PERSON
, O
J B_OTHER/B_LOCATION
. O
and O
messing B_TIME[MEASURE]/B_PERSON
, O
J B_OTHER/B_PERSON
. O

( O
1987 B_MEASURE
) O
Methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
Enzymology B_EDU[ORGANIZATION]/B_DISEASE
, O
153 B_MEASURE
, O
3 B_MEASURE
- O
11 B_MEASURE
. O

31 B_NUMBER[MEASURE]
. O

Davison B_PERSON/B_COLOR
, O
A B_OTHER/B_PERSON
. O

DNA B_MEASURE/B_LOCATION
sequence I_MEASURE/I_LOCATION
, O
in O
press B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

32 B_NUMBER[MEASURE]
. O

Heller B_PERSON/B_COLOR
, O
C B_OTHER/B_LOCATION
. O
, O
Radley B_PERSON
, O
E B_OTHER/B_LOCATION
. O
, O
Khurshid B_PERSON/B_COLOR
, O
F B_OTHER/B_PERSON
. O

A O
. O
and O
Beck B_PERSON
, O
S B_OTHER/B_PERSON
. O

Gene B_PERSON/B_MEASURE
, O
in O
press B_PERSON/B_ENT
. O

references B_PERSON/B_DISEASE
. O

1 B_NUMBER[MEASURE]
. O

Yang B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

M B_OTHER/B_PROTEIN[GENE]
. O
and O
Youvan B_PERSON
, O
D B_OTHER/B_PERSON
. O

C B_OTHER/B_GENE
. O

( O
1989 B_MEASURE
) O
Biotechnology B_MEASURE/B_ORGANIZATION
, O
7 B_MEASURE
, O
576 B_MEASURE
- O
580 B_MEASURE
. O

2 B_NUMBER[MEASURE]
. O

Smith B_PERSON/B_COLOR
, O
L B_OTHER/B_PERSON
. O

M B_OTHER/B_PERSON
. O
, O
Sanders B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

Z B_OTHER/B_PERSON
. O
, O
Kaiser B_PERSON/B_LANGUAGE
, O
R B_OTHER/B_PERSON
. O

J B_OTHER/B_LOCATION
. O
, O
Hughes B_PERSON/B_COLOR
, O
P B_LOCATION
. O
, O
Dodd B_PERSON/B_LOCATION
, O
C B_PROTEIN[GENE]/B_LOCATION
. O
, O
Connell B_PERSON
, O

C B_OTHER/B_GENE
. O

R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Heiner B_PERSON/B_LOCATION
, O
C B_PROTEIN[GENE]/B_LOCATION
. O
, O
Kent B_LOCATION/B_PERSON
, O
S B_OTHER/B_LOCATION
. O

B B_OTHER/B_DISEASE
. O

H B_OTHER/B_PROTEIN[GENE]
. O
and O
Hood B_PERSON/B_COLOR
, O
L B_OTHER/B_PERSON
. O

E B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1986 B_MEASURE
) O
Nature B_MEASURE
, O
321 B_MEASURE
, O
674 B_MEASURE
- O
679 B_MEASURE
. O

3 B_NUMBER[MEASURE]
. O

Church B_LOCATION/B_PERSON
, O
G B_OTHER/B_LOCATION
. O

M B_OTHER/B_PROTEIN[GENE]
. O
and O
Kieffer B_PERSON
- O
Higgins B_PERSON
, O
S B_OTHER/B_PERSON
. O

( O
1988 B_MEASURE
) O
Science B_EDU[ORGANIZATION]/B_MEASURE
, O
240 B_MEASURE
, O
185 B_MEASURE
- O
188 B_MEASURE
. O

4 B_NUMBER[MEASURE]
. O

Watson B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

D B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1990 B_MEASURE
) O
Science B_EDU[ORGANIZATION]/B_MEASURE
, O
248 B_MEASURE
, O
44 B_MEASURE
- O
49 B_MEASURE
. O

5 B_NUMBER[MEASURE]
. O

Baer B_PERSON
, O
R B_OTHER/B_LOCATION
. O
, O
Bankier B_PERSON
, O
A B_OTHER/B_LOCATION
. O

T B_OTHER/B_GENE
. O
, O
Biggin B_PERSON
, O
M B_OTHER/B_PERSON
. O

D B_OTHER/B_LOCATION
. O
, O
Deininger B_PERSON/B_COLOR
, O
P B_OTHER/B_PERSON
. O

L B_OTHER/B_PERSON
. O
, O
Farrell B_PERSON/B_ORGANIZATION
, O
P B_OTHER/B_PERSON
. O

J B_OTHER/B_MEASURE
. O
, O

Gibson B_PERSON
, O
T B_OTHER/B_PERSON
. O

J B_OTHER/B_PROTEIN[GENE]
. O
, O
Hatfull B_PERSON
, O
G B_PROTEIN[GENE]/B_LOCATION
. O
, O
Hudson B_PERSON/B_COLOR
, O
G B_OTHER/B_PERSON
. O

S B_OTHER/B_MEASURE
. O
, O
Satchwell B_PERSON
, O
S B_OTHER/B_PERSON
. O

C B_OTHER/B_PROTEIN[GENE]
. O
, O
Seguin B_PERSON/B_COLOR
, O
C B_PROTEIN[GENE]/B_LOCATION
. O
, O
Tuffnell B_PERSON
, O
P B_OTHER/B_LOCATION
. O

S B_OTHER/B_PROTEIN[GENE]
. O
and O
Barrell B_PERSON
, O
B B_OTHER/B_PERSON
. O

G B_OTHER/B_GENE
. O

( O
1984 B_MEASURE/B_PERSON
) O
Nature B_MEASURE
, O
310 B_MEASURE
, O
207 B_MEASURE
- O
211 B_MEASURE
. O

6 B_NUMBER[MEASURE]
. O

Davison B_PERSON/B_COLOR
, O
A B_OTHER/B_PERSON
. O

J B_OTHER/B_LOCATION
. O
and O
Scott B_PERSON/B_LOCATION
, O
J B_OTHER/B_PERSON
. O

E B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1986 B_MEASURE
) O
Journal B_EDU[ORGANIZATION]/B_TIME[MEASURE]
of O
General B_EDU[ORGANIZATION]/B_PERSON
Virology I_EDU[ORGANIZATION]/I_PERSON
, O
67 B_TIME[MEASURE]/B_PERSON
, O

1759 O
- O
1816 B_TIME[MEASURE]
. O

7 B_NUMBER[MEASURE]
. O

McGeoch B_PERSON
, O
D B_OTHER/B_PERSON
. O

J B_OTHER/B_PERSON
. O
, O
Dalrymple B_PERSON/B_COLOR
, O
M B_OTHER/B_PERSON
. O

A O
. O
, O
Davison B_PERSON
, O
A O
. O

J B_OTHER/B_PERSON
. O
, O
Dolan B_PERSON
, O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
frame B_PERSON
, O

M B_OTHER/B_MEASURE
. O

C B_OTHER/B_PROTEIN[GENE]
. O
, O
McNab B_PERSON/B_COLOR
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Perry B_PERSON/B_COLOR
, O
L B_OTHER/B_LOCATION
. O

J B_OTHER/B_LOCATION
. O
, O
Scott B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

E B_OTHER/B_PROTEIN[GENE]
. O
and O
Taylor B_PERSON/B_COLOR
, O
P B_OTHER/B_PERSON
. O

( O
1988 B_MEASURE
) O
Journal B_EDU[ORGANIZATION]/B_TIME[MEASURE]
of O
General B_EDU[ORGANIZATION]/B_PERSON
Virology I_EDU[ORGANIZATION]/I_PERSON
, O
69 B_MEASURE
, O
1531 B_MEASURE
- O
1574 B_MEASURE
. O

8 B_NUMBER[MEASURE]
. O

Chee B_PERSON/B_LOCATION
, O
M B_OTHER/B_PERSON
. O

S B_OTHER/B_PERSON
. O
, O
Bankier B_PERSON
, O
A B_OTHER/B_LOCATION
. O

T B_OTHER/B_PROTEIN[GENE]
. O
, O
Beck B_PERSON
, O
S B_LOCATION/B_DISEASE
. O
, O
Bohni B_PERSON/B_COLOR
, O
R B_OTHER/B_LOCATION
. O
, O
Brown B_PERSON
, O
C B_OTHER/B_LOCATION
. O

M B_OTHER/B_PERSON
. O
, O
Cerny B_MEASURE/B_LOCATION
, O

R B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Horsnell B_PERSON/B_COLOR
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
, O
Hutchison B_PERSON/B_COLOR
III I_PERSON/I_COLOR
, O
C B_OTHER/B_PERSON
. O

A O
. O
, O
Kouzarides B_PERSON
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
, O
Martignetti B_PERSON
, O
J B_OTHER/B_LOCATION
. O

A O
. O
, O
Satchwell B_PERSON
, O
S B_OTHER/B_PERSON
. O

C B_OTHER/B_PROTEIN[GENE]
. O
, O
Tomlinson B_PERSON/B_COLOR
, O
P B_LOCATION/B_PROTEIN[GENE]
. O
, O
Weston B_PERSON
, O
K B_OTHER/B_LOCATION
. O

M B_OTHER/B_PROTEIN[GENE]
. O
and O
Barrell B_PERSON
, O
B B_OTHER/B_PERSON
. O

G B_OTHER/B_GENE
. O

( O
1990 O
) O
Current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
topics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O
microbiology B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Immunology B_EDU[ORGANIZATION]/B_PERSON
, O
154 B_MEASURE
, O
125 B_MEASURE
- O
169 B_MEASURE
. O

9 B_NUMBER[MEASURE]
. O

Goebel B_PERSON
, O
S B_OTHER/B_PERSON
. O

J B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Johnson B_PERSON/B_COLOR
, O
G B_OTHER/B_PERSON
. O

P B_OTHER/B_PERSON
. O
, O
Perkus B_PERSON
, O
M B_OTHER/B_PERSON
. O

E B_OTHER/B_PERSON
. O
, O
Davis B_PERSON
, O
S B_OTHER/B_PERSON
. O

W B_OTHER/B_PERSON
. O
, O
Winslow B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

P B_OTHER/B_PROTEIN[GENE]
. O
and O
Paoletti B_PERSON/B_LOCATION
, O
E B_OTHER/B_PERSON
. O

( O
1990 B_MEASURE
) O
Virology B_MEASURE
, O
179 B_MEASURE
, O
247 B_MEASURE
- O
266 B_MEASURE
. O

10 B_NUMBER[MEASURE]
. O

Ohyama B_PERSON
, O
K B_OTHER/B_LOCATION
. O
, O
Fukuzawa B_PERSON/B_LOCATION
, O
H B_OTHER/B_LOCATION
. O
, O
Kohchi B_PERSON
, O
T B_OTHER/B_LOCATION
. O
, O
Shirai B_PERSON
, O
H B_OTHER/B_LOCATION
. O
, O
Sano B_PERSON/B_LOCATION
, O
T B_OTHER/B_LOCATION
. O
, O
Sano B_PERSON/B_LOCATION
, O
S B_OTHER/B_LOCATION
. O
, O

Umesono B_PERSON/B_LOCATION
, O
K B_OTHER/B_LOCATION
. O
, O
Shiki B_PERSON/B_LOCATION
, O
Y B_OTHER/B_LOCATION
. O
, O
Takeuchi B_PERSON
, O
M B_OTHER/B_PERSON
. O
, O
Chang B_PERSON
, O
Z B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Aota B_PERSON/B_LOCATION
, O
S B_OTHER/B_LOCATION
. O

- O
I O
, O
Inokuchi B_PERSON/B_LOCATION
, O
H B_OTHER/B_LOCATION
. O
and O
Ozeki B_PERSON
, O
H B_OTHER/B_PERSON
. O

( O
1986 B_MEASURE
) O
Nature B_MEASURE
, O
322 B_MEASURE
, O
572 B_MEASURE
- O
574 B_MEASURE
. O

11 B_NUMBER[MEASURE]
. O

Shinozaki B_PERSON
, O
K B_OTHER/B_LOCATION
. O
, O
Ohme B_PERSON
, O
M B_OTHER/B_LOCATION
. O
, O
Tanaka B_PERSON/B_ORGANIZATION
, O
M B_OTHER/B_LOCATION
. O
, O
Wakasugi B_PERSON
, O
T B_OTHER/B_LOCATION
. O
, O
Hayashida B_PERSON
, O
N B_OTHER/B_LOCATION
. O
, O

Matsubayashi B_PERSON
, O
T B_OTHER/B_LOCATION
. O
, O
Zaita B_PERSON
, O
N B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Chunwongse B_PERSON/B_LOCATION
, O
J B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Obokata B_PERSON
, O
J B_OTHER/B_LOCATION
. O
, O
YamaguchiShinozaki B_PERSON
, O
K B_OTHER/B_LOCATION
. O
, O
Ohto B_PERSON
, O
C B_OTHER/B_PERSON
. O
, O
Torazawa B_PERSON/B_LOCATION
, O
K B_OTHER/B_LOCATION
. O
, O
Meng B_PERSON
, O
B B_OTHER/B_PERSON
. O

Y B_OTHER/B_LOCATION
. O
, O
Sugita B_PERSON
, O
M B_OTHER/B_LOCATION
. O
, O
Deno B_PERSON/B_LOCATION
, O
H B_OTHER/B_LOCATION
. O
, O
Kamogashira B_PERSON
, O
T B_OTHER/B_LOCATION
. O
, O
Yamada B_PERSON
, O
K B_OTHER/B_LOCATION
. O
, O
Kusuda B_PERSON
, O
J B_OTHER/B_LOCATION
. O
, O
Takaiwa B_PERSON/B_LOCATION
, O
F B_OTHER/B_LOCATION
. O
, O
Kato B_PERSON
, O
A B_OTHER/B_LOCATION
. O
, O
Tohdoh B_PERSON/B_LOCATION
, O
N B_OTHER/B_LOCATION
. O
, O
Shimada B_PERSON
, O
H B_OTHER/B_LOCATION
. O
and O
Sugiura B_PERSON
, O
M B_OTHER/B_PERSON
. O

( O
1986 B_MEASURE
) O
EMBO B_TIME[MEASURE]
Journal I_TIME[MEASURE]
, O
5 B_MEASURE
, O
2043 B_MEASURE
- O
2049 B_MEASURE
. O

mapping O
irradiation O
hybrids O
to O
cosmid O
and O
yeast B_SPECIES[BIO]/B_GENE
artificial O
chromosome O
libraries O
by O
direct O
hybridization O
of O
Alu O
- O
PCR O
products O
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
direct O
hybridization O
protocol O
is O
described O
for O
screening O
cosmid O
and O
yeast B_SPECIES[BIO]
artificial O
chromosome O
libraries O
with O
pools O
of O
Alu O
- O
PCR O
products O
from O
somatic O
cell O
or O
irradiation O
hybrids O
. O

This O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
eliminates O
purification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cloning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
each O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
Alu B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
product I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
before O
library B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

A O
series O
of O
human B_NUMBER[MEASURE]/B_SPECIES[BIO]
X O
chromosome O
irradiation O
hybrids O
were O
mapped O
by O
this O
method O
, O
using O
a O
cosmid O
reference O
library O
for O
comparisons O
between O
overlapping O
hybrids O
to O
identify O
interesting O
clones O
for O
further O
analysis O
. O
Images O
. O

Nucleic B_NUMBER[MEASURE]/B_LOCATION
acids I_NUMBER[MEASURE]/I_LOCATION
Research I_NUMBER[MEASURE]/I_LOCATION
, O
Vol B_LOCATION/B_PERSON
. O

19 B_MEASURE
, O
No O
. O
12 B_NUMBER[MEASURE]/B_PERSON
3315 I_NUMBER[MEASURE]/I_PERSON
. O

mapping O
irradiation O
hybrids O
to O
cosmid O
and O
yeast B_SPECIES[BIO]/B_GENE
artificial O
chromosome O
libraries O
by O
direct O
hybridization O
of O
Alu O
- O
PCR O
products O
. O

Anthony B_PERSON/B_BIO
P I_PERSON/I_BIO
. O
Monaco B_LOCATION/B_PERSON
* O
, O
Veronica B_PERSON/B_LOCATION
M I_PERSON/I_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
Lam2 B_PERSON/B_LOCATION
, O
Gunther B_PERSON
Zehetner I_PERSON
, O
Gregory B_PERSON
G I_PERSON
. O
Lennon B_PERSON
, O
Christal B_PERSON
Douglas I_PERSON
, O
Dean B_PERSON
Nizetic I_PERSON
, O
Peter B_PERSON/B_LOCATION
N I_PERSON/I_LOCATION
. O
Goodfellow1 B_PERSON
and O
Hans B_PERSON/B_LOCATION
Lehrach I_PERSON/I_LOCATION
. O

genome B_LOCATION/B_EDU[ORGANIZATION]
Analysis B_LOCATION/I_EDU[ORGANIZATION]
Laboratory B_LOCATION/I_EDU[ORGANIZATION]
and O
' O
Molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Human I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
genetics O
Laboratory B_LOCATION/B_ORGANIZATION
, O
Imperial B_LOCATION/B_ORGANIZATION
Cancer I_LOCATION/I_ORGANIZATION
Research I_LOCATION/I_ORGANIZATION
Fund I_LOCATION/I_ORGANIZATION
, O
44 B_PERSON/B_LOCATION
Lincoln I_PERSON/I_LOCATION
' O
s B_LOCATION
Inn I_LOCATION
Fields I_LOCATION
, O
London B_LOCATION
WC2A I_LOCATION
3PX I_LOCATION
, O
UK B_LOCATION/B_EDU[ORGANIZATION]
and O
2Department B_LOCATION/B_ORGANIZATION
of O
biochemistry B_LOCATION/B_ORGANIZATION
, O
Li B_LOCATION/B_ORGANIZATION
Shu I_LOCATION/I_ORGANIZATION
Fan I_LOCATION/I_ORGANIZATION
Building I_LOCATION/I_ORGANIZATION
, O
Sassoon B_LOCATION
Road I_LOCATION
, O
University B_LOCATION/B_ORGANIZATION
of O
Hong B_LOCATION
Kong I_LOCATION
, O
Hong B_LOCATION/B_PERSON
Kong I_LOCATION/I_PERSON
. O

received O
March B_TIME[MEASURE]
12 I_TIME[MEASURE]
, O
1991 B_MEASURE
; O
revised O
and O
accepted O
May B_TIME[MEASURE]
16 I_TIME[MEASURE]
, O
1991 B_MEASURE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
direct O
hybridization O
protocol O
is O
described O
for O
screening O
cosmid O
and O
yeast B_SPECIES[BIO]
artificial O
chromosome O
libraries O
with O
pools O
of O
Alu O
- O
PCR O
products O
from O
somatic O
cell O
or O
irradiation O
hybrids O
. O

This O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
eliminates O
purification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cloning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
each O
individual B_GENE/B_MEASURE
AluPCR I_GENE/I_MEASURE
product I_GENE/I_MEASURE
before O
library B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
screening I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

A O
series O
of O
human B_NUMBER[MEASURE]/B_SPECIES[BIO]
X O
chromosome O
irradiation O
hybrids O
were O
mapped O
by O
this O
method O
, O
using O
a O
cosmid O
reference O
library O
for O
comparisons O
between O
overlapping O
hybrids O
to O
identify O
interesting O
clones O
for O
further O
analysis O
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
generation O
of O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O
probes O
specific O
for O
individual O
chromosomes O
and O
subregions O
of O
chromosomes O
has O
been O
advanced O
with O
Alu O
- O
sequence O
primed O
polymerase O
chain O
reaction O
amplification O
( O
Alu O
- O
PCR O
, O
1 O
- O
3 O
) O
. O

This O
method O
specifically O
amplifies O
sequences O
between O
Alu O
repeats O
from O
human B_SPECIES[BIO]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
DNA O
in O
somatic O
cell O
hybrids O
and O
yeast B_SPECIES[BIO]
artificial O
chromosomes O
( O
YACs O
, O
4 O
) O
. O

Individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
Alu B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
purified O
from O
agarose B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gels B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
ligated O
into O
plasmid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
vectors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
screen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
for O
single B_DISEASE_ADJECTIVE[DISEASE]
copy I_DISEASE_ADJECTIVE[DISEASE]
sequences I_DISEASE_ADJECTIVE[DISEASE]
. O

unique B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Alu I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
then O
localized O
to O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
chromosome B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
regions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
using O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blots I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
somatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
panels I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Once O
localized O
, O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragments I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
screened O
against O
genomic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
libraries I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
to O
isolate O
longer B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
region B_LOCATION/B_BIO
of O
interest B_PERSON/B_DISEASE
. O

As O
an O
alternative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
this O
multistep B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O
have O
developed O
a O
hybridization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
screening B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
cosmid B_DISEASE/B_GENE
and O
YAC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
libraries I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
directly O
with O
pools B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Two O
new O
human B_SPECIES[BIO]/B_GENE
specific O
Alu O
primers O
were O
used O
to O
generate O
DNA O
probes O
from O
a O
series O
of O
irradiation O
- O
reduced O
hybrids O
containing O
multiple O
human B_SPECIES[BIO]
X O
chromosome O
fragments O
of O
1 O
- O
2000 O
kb O
on O
a O
hamster O
chromosome O
background O
( O
5 O
; O
P O
. O
N O
. O
G O
. O
, O
unpublished O
) O
. O

The O
Alu B_LOCATION/B_PROTEIN[GENE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
hybridized O
as O
a O
pool B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
probes B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
X B_GENE/B_DISEASE
- O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cosmid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
YAC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
libraries I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
after O
. O

competitive O
reassociation O
with O
an O
excess O
of O
human B_PERSON/B_SPECIES[BIO]
DNA O
to O
both O
the O
library O
filters O
and O
radioactively O
labelled O
Alu O
- O
PCR O
products O
. O

Comparisons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
made O
between O
clones B_GENE/B_DISEASE
identified O
by O
overlapping O
irradiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hybrids B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
and O
single B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
copy I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
DNA I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
probes I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
hybridized O
to O
the O
cosmid B_LOCATION/B_DISEASE
and O
YAC B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
libraries B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
Alu O
sequence O
primers O
were O
generated O
which O
were O
shown O
to O
be O
human B_SPECIES[BIO]/B_GENE
specific O
; O
3144 O
from O
the O
3 O
' O
end O
of O
Alu O
: O
5 O
' O
- O
GAGCGAGACTCCGTCTCAAA O
- O
3 O
' O
and O
2729 O
from O
the O
5 O
' O
end O
of O
Alu O
: O
5 O
' O
- O
GTGGATCACCTGAGGTCAGGAGTTC O
- O
3 O
' O
. O

All O
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reactions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
carried O
out O
with O
100 B_MEASURE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ng B_MEASURE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hybrid B_GENE/B_BIO
DNA I_GENE/I_BIO
and O
0 B_MEASURE
. O
7 B_MEASURE
, O
^ B_MEASURE/B_LOCATION
g I_MEASURE/I_LOCATION
of O
a O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Alu I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
primer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
100 B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
d41 I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
0 B_MEASURE
. O
01 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tris I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
HCl B_MEASURE
pH I_MEASURE
8 I_MEASURE
. O
3 B_MEASURE
, O
0 B_MEASURE
. O
0015 B_MEASURE/B_PERSON
M I_MEASURE/I_PERSON
MgCl2 I_MEASURE/I_PERSON
, O
0 B_MEASURE
. O
05 B_MEASURE/B_PERSON
M I_MEASURE/I_PERSON
KCI I_MEASURE/I_PERSON
, O
200 B_NUMBER[MEASURE]/B_LOCATION
AtM I_NUMBER[MEASURE]/I_LOCATION
each O
of O
dNTPs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
% B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dimethlysulfoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
2 B_MEASURE
. O
5 B_MEASURE
units I_MEASURE
of O
Cetus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Taq I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
30 B_MEASURE/B_LOCATION
cycles I_MEASURE/I_LOCATION
of O
94 B_MEASURE
? O
C B_OTHER/B_LOCATION
for O
2 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
, O
57 B_MEASURE
? O
C B_OTHER/B_LOCATION
for O
2 B_MEASURE/B_PERSON
min I_MEASURE/I_PERSON
, O
and O
74 B_MEASURE
? O
C B_OTHER/B_LOCATION
for O
4 B_NUMBER[MEASURE]/B_PERSON
min I_NUMBER[MEASURE]/I_PERSON
followed O
by O
a O
final B_MEASURE/B_LOCATION
extension I_MEASURE/I_LOCATION
time I_MEASURE/I_LOCATION
at O
74 B_MEASURE
? O
C B_OTHER/B_LOCATION
for O
9 B_NUMBER[MEASURE]/B_PERSON
min I_NUMBER[MEASURE]/I_PERSON
. O

reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
products I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
analyzed O
on O
1 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
% I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agarose I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
shown O
to O
contain O
between O
five B_NUMBER[MEASURE]
and O
twenty B_NUMBER[MEASURE]
fragments I_NUMBER[MEASURE]
, O
with O
sizes B_MEASURE
ranging O
from O
0 B_MEASURE/B_LOCATION
. O
1 B_MEASURE
to O
2 B_MEASURE
. O
0 B_MEASURE
kb I_MEASURE
. O

Chinese B_PERSON/B_NUMBER[MEASURE]
hamster B_PERSON/I_NUMBER[MEASURE]
DNA O
and O
no O
DNA O
PCR O
reactions O
were O
done O
to O
control O
for O
non O
- O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
products O
( O
data O
not O
shown O
) O
. O

Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
separated O
from O
Alu B_LOCATION/B_GENE
oligomers B_LOCATION/I_GENE
over O
Qiagen B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
columns B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
and O
approximately O
50 B_MEASURE
- O
100 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
were O
labelled O
by O
random B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hexamer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
priming B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
6 B_TIME[MEASURE]/B_LOCATION
) O
. O

The O
radioactively O
labelled O
pool O
of O
fragments O
was O
prehybridized O
with O
37 O
. O
5 O
, O
^ O
g O
of O
total O
human B_SPECIES[BIO]
DNA O
and O
12 O
. O
5 O
tsg O
of O
hamster O
DNA O
immobilized O
on O
a O
cellulose O
support O
matrix O
, O
prepared O
as O
previously O
described O
( O
7 O
) O
. O

reactions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
at O
65 B_MEASURE/B_LOCATION
? O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
1 B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ml I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
0 B_MEASURE/B_LOCATION
. O
75M B_MEASURE
NaCl I_MEASURE
, O
0 B_MEASURE
. O
05M B_MEASURE
sodium I_MEASURE
phosphate I_MEASURE
pH O
7 B_MEASURE
. O
2 B_MEASURE
, O
0 B_MEASURE
. O
005M B_MEASURE
EDTA I_MEASURE
, O
0 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
sodium I_MEASURE
dodecyl I_MEASURE
sulphate I_MEASURE
( O
SDS B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
heparin I_MEASURE/I_PERSON
, O
and O
100 B_MEASURE/B_PERSON
jig I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
denatured O
salmon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sperm I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
cellulose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
pelleted O
and O
the O
supernatant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
boiled O
for O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
min I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
every O
12 B_NUMBER[MEASURE]
- O
16 B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
( O
three B_TIME[MEASURE]
times I_TIME[MEASURE]
in O
two B_TIME[MEASURE]/B_LOCATION
days I_TIME[MEASURE]/I_LOCATION
) O
. O

Cosmid B_PERSON/B_LOCATION
and O
YAC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
filters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Hybond B_PERSON
N I_PERSON
+ I_PERSON
, O
Amersham B_LOCATION/B_MEASURE
) O
were O
prehybridized O
at O
42 B_MEASURE/B_LOCATION
? O
C B_OTHER/B_MEASURE
for O
16 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
100 B_MEASURE/B_PERSON
jig I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
. O

* B_OTHER/B_PERSON
To O
whom O
correspondence B_NUMBER[MEASURE]/B_PERSON
should O
be O
addressed O
at O
Human B_LOCATION/B_PERSON
genetics I_LOCATION/I_PERSON
Laboratory I_LOCATION/I_PERSON
, O
Imperial B_LOCATION
Cancer I_LOCATION
Research I_LOCATION
Fund I_LOCATION
, O
Institute B_ORGANIZATION/B_LOCATION
of O
Molecular B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Medicine I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
John B_LOCATION/B_ORGANIZATION
Radcliffe I_LOCATION/I_ORGANIZATION
Hospital I_LOCATION/I_ORGANIZATION
, O
Headington B_LOCATION/B_PERSON
, O
Oxford B_LOCATION
OX3 I_LOCATION
9DU I_LOCATION
, O
UK B_LOCATION
. O

1991 B_PERSON/B_LOCATION
Oxford I_PERSON/I_LOCATION
University I_PERSON/I_LOCATION
Press I_PERSON/I_LOCATION
. O

3316 B_NUMBER[MEASURE]/B_ORGANIZATION
Nucleic I_NUMBER[MEASURE]/I_ORGANIZATION
acids I_NUMBER[MEASURE]/I_ORGANIZATION
Research I_NUMBER[MEASURE]/I_ORGANIZATION
, O
Vol B_LOCATION
. O

19 O
, O
No O
. O
12 B_NUMBER[MEASURE]
. O

chromosome B_GENE/B_MEASURE
X I_GENE/I_MEASURE
. O

. O
, O
. O
. O
, O
. O
, O
< B_OTHER/B_LOCATION
. O

_ B_OTHER/B_LOCATION
. O
, O
. O

< B_MEASURE/B_OTHER
. O
, O

* B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
. O
' O
1 B_MEASURE
- O
7 B_MEASURE
- O
_ B_MEASURE/B_OTHER
. O

_ O
- O
_ O
1 B_MEASURE/B_LOCATION
. O

J B_OTHER/B_PERSON

, O
. O
1 B_MEASURE/B_LOCATION
. O
. O

- O
1 B_NUMBER[MEASURE]
, O
_ B_MEASURE/B_DISEASE
i O
- O
_ O
1 B_NUMBER[MEASURE]
. O

1 B_NUMBER[MEASURE]/B_PERSON

1 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
. O

1 B_LOCATION/B_PERSON
1 I_LOCATION/I_PERSON
L I_LOCATION/I_PERSON
L I_LOCATION/I_PERSON
. O

i B_OTHER/B_PERSON

. O
1 B_MEASURE/B_LOCATION
. O

_ B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

1 B_LOCATION/B_MEASURE
1 I_LOCATION/I_MEASURE
s I_LOCATION/I_MEASURE
. O

1 B_MEASURE/B_LOCATION
i O
. O

1 B_MEASURE/B_LOCATION
i O
; O
. O

- O
- O
r B_PROTEIN[GENE]
' O
F B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
. O

1 O
- O
1 B_MEASURE
- O
l B_OTHER/B_MEASURE
. O

j O
i O
- O
_ O
1 B_MEASURE/B_LOCATION
. O

1 B_NUMBER[MEASURE]/B_PERSON

- O
_ O
1 B_MEASURE/B_LOCATION
. O
. O

s B_OTHER/B_PERSON
- O
S B_OTHER/B_LOCATION
. O

i B_OTHER/B_MEASURE
n O
- O
. O

. B_OTHER/B_PERSON
. O

: O
, O
1 B_MEASURE/B_LOCATION
' O
, O
. O

- O
1 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
_ I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
i O
. O

, B_OTHER/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

. O
_ O
_ O
_ B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

G B_OTHER/B_PROTEIN[GENE]
- O
. O


* B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
- O
. O
, O
. O
, O
z O
. O

_ B_OTHER/B_PERSON

_ B_OTHER/B_DISEASE
, O

z O
; O
- O
[ O
X1 B_GENE/B_MEASURE
. O

21 B_NUMBER[MEASURE]/B_PERSON
, O
In O
. O

27 B_TIME[MEASURE]
38 I_TIME[MEASURE]
45 I_TIME[MEASURE]
48 I_TIME[MEASURE]
54 I_TIME[MEASURE]
74 I_TIME[MEASURE]
86 I_TIME[MEASURE]
. O

I O
1 B_TIME[MEASURE]/B_LOCATION
I O
. O

I B_OTHER/B_PERSON

I B_OTHER/B_PERSON

107 B_NUMBER[MEASURE]
. O

MD B_LOCATION/B_DISEASE
. O

I B_OTHER/B_PERSON

: B_OTHER/B_MEASURE
I O
I O
. O

I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
. O

I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
. O

Figur O
2a O
and O
2b O
: O
Hybridization O
of O
Alu O
- O
PCR O
products O
generated O
with O
Alu O
primer O
3144 O
from O
irradiation O
hybrid O
48 O
to O
duplicate O
copies O
of O
22 O
x22cm O
filters O
containing O
9216 O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
X O
chromosome O
cosmids O
( O
8 O
) O
. O

2c O
: O
hybridization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generated O
with O
Alu B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
primer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3144 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
an O
independent B_PERSON/B_LOCATION
hybrid B_PERSON/I_LOCATION
( O
54 B_NUMBER[MEASURE]/B_LOCATION
) O
to O
a O
third B_NUMBER[MEASURE]/B_PERSON
identical B_NUMBER[MEASURE]/I_PERSON
cosmid B_NUMBER[MEASURE]/I_PERSON
filter B_NUMBER[MEASURE]/I_PERSON
. O

Figure O
1 O
: O
A O
schematic O
diagram O
of O
the O
human B_PERSON/B_SPECIES[BIO]
X O
chromosome O
alongside O
the O
approximate O
cytogenetic O
location O
of O
fragments O
identified O
in O
nine O
irradiation O
hybrids O
( O
numbers O
across O
the O
top O
) O
. O

The O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
X O
fragments O
were O
identified O
by O
hybridization O
of O
27 O
known O
DNA O
markers O
( O
indicated O
by O
a O
black O
line O
; O
P O
. O
N O
. O
G O
, O
unpublished O
) O
or O
by O
cosmids O
in O
common O
with O
unique O
X O
chromosome O
probes O
in O
the O
reference O
library O
database O
( O
open O
boxes O
and O
Table O
1 O
) O
. O

The O
size B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
lines B_LOCATION/B_PRODUCT[OBJECT]
and O
boxes B_LOCATION/B_PERSON
relate O
to O
the O
best B_MEASURE/B_ORGANIZATION
cytogenetic I_MEASURE/I_ORGANIZATION
location I_MEASURE/I_ORGANIZATION
of O
the O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
used O
according O
to O
Human B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Gene I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mapping I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
10 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O
5 B_MEASURE
( O
14 B_MEASURE
) O
and O
does O
not O
indicate O
the O
physical B_MEASURE/B_LOCATION
extent I_MEASURE/I_LOCATION
of O
the O
irradiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hybrid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
fragments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O

denatured O
and O
sheared O
total O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPECIES[BIO]
DNA O
in O
50 O
% O
formamide O
, O
4XSSC O
, O
0 O
. O
05 O
M O
sodium O
phosphate O
pH O
7 O
. O
2 O
, O
0 O
. O
001 O
M O
EDTA O
, O
10 O
% O
dextran O
sulphate O
, O
1 O
. O
0 O
% O
SDS O
, O
50 O
isg O
/ O
ml O
denatured O
salmon O
sperm O
DNA O
and O
OxDenhardt O
' O
s O
solution O
. O

The O
radioactively O
labelled O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
denatured O
and O
added O
to O
fresh O
. O

hybridization O
solution O
without O
human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
DNA O
competitor O
at O
1 O
x O
106 O
. O

cpm B_MEASURE/B_LOCATION
/ O
ml B_TIME[MEASURE]/B_PERSON
and O
hybridized O
at O
42 B_TIME[MEASURE]
? O
C B_OTHER/B_MEASURE
for O
16 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

filters B_LOCATION/B_PERSON
were O
washed O
in O
0 B_MEASURE
. O
1 B_MEASURE
xSSC I_MEASURE
and O
1 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
SDS I_MEASURE
, O
twice O
at O
room B_MEASURE
temperature I_MEASURE
and O
twice O
at O
65 B_MEASURE
? O
C B_OTHER/B_PROTEIN[GENE]
for O
30 B_TIME[MEASURE]
min I_TIME[MEASURE]
each O
and O
exposed O
to O
Kodak B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
X B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
OMAT B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
film I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
2 B_NUMBER[MEASURE]/B_LOCATION
- O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
at O
- O
70 B_MEASURE
? O
C B_OTHER/B_MEASURE
with O
an O
intensifying O
screen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
each O
hybridization O
, O
two O
sets O
of O
duplicate O
cosmid O
filters O
were O
used O
from O
the O
ICRF O
reference O
library O
system O
( O
8 O
) O
, O
each O
containing O
9216 O
flow O
- O
sorted O
human B_SPECIES[BIO]/B_MEASURE
X O
chromosome O
cosmid O
clones O
or O
approximately O
2 O
chromosome O
equivalents O
on O
a O
22 O
x O
22 O
cm O
filter O
( O
9 O
) O
. O

The O
coordinates B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
signals B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
positive I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
duplicate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cosmid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
filters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
entered O
into O
the O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
G B_OTHER/B_LOCATION
. O
Z B_OTHER/B_MEASURE
, O
unpublished B_TIME[MEASURE]
) O
using O
a O
digitizing O
tablet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
the O
X B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chromosome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
YAC I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
P B_LOCATION
. O
M B_OTHER/B_LOCATION
. O
and O
H B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_OTHER/B_LOCATION
. O
, O
unpublished B_TIME[MEASURE]/B_LOCATION
) O
, O
about O
420 B_MEASURE/B_GENE
YAC I_MEASURE/I_GENE
colonies I_MEASURE/I_GENE
were O
spotted O
manually O
onto O
filters B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
96 B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O
microtiter B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
dishes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
using O
a O
96 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prong I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
device I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
media I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
3 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
YAC B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
filters I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O
processed O
for O
hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
previously O
described O
( O
10 B_MEASURE
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
panel O
of O
195 O
X O
chromosome O
irradiation O
hybrids O
was O
constructed O
( O
50 O
, O
000 O
rads O
) O
and O
characterized O
by O
DNA O
hybridization O
using O
27 O
X O
chromosome O
markers O
and O
flourescence O
in O
situ O
hybridization O
using O
total O
human B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DNA O
as O
probe O
( O
Benham O
et O
al O
. O
, O
1989 O
; O
P O
. O
N O
. O
G O
. O
, O
unpublished O
) O
. O

This O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
the O
hybrids B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contained O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
small B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
fragments B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
4 B_NUMBER[MEASURE]
- O
10 B_MEASURE/B_LOCATION
fragments B_MEASURE/I_LOCATION
of O
1000 B_MEASURE
- O
5000 B_MEASURE
kb I_MEASURE
each O
) O
with O
a O
preferential B_MEASURE/B_LOCATION
retaining I_MEASURE/I_LOCATION
of O
centromere B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
90 B_MEASURE/B_PROTEIN[GENE]
% B_MEASURE/I_PROTEIN[GENE]
) O
. O

From O
this O
panel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
nine B_LOCATION/B_PERSON
irradiation I_LOCATION/I_PERSON
hybrids I_LOCATION/I_PERSON
were O
chosen O
that O
contained O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
five B_NUMBER[MEASURE]/B_ENT
different I_NUMBER[MEASURE]/I_ENT
regions I_NUMBER[MEASURE]/I_ENT
by O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
probe I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hybridizations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
mostly O
from O
the O
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
X B_GENE
chromosome I_GENE
( O
Fig B_TIME[MEASURE]/B_BIO
1 I_TIME[MEASURE]/I_BIO
) O
. O

All O
nine B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrids I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
in O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reactions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
3 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Alu B_LOCATION/B_PERSON
primer I_LOCATION/I_PERSON
3144 I_LOCATION/I_PERSON
and O
two B_NUMBER[MEASURE]
were O
used O
with O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
Alu B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

Figure O
3 O
: O
Hybridization O
of O
Alu O
- O
PCR O
products O
generated O
with O
Alu O
primer O
3144 O
from O
irradiation O
hybrid O
54 O
to O
a O
filter O
containing O
420 O
YAC O
clones O
from O
the O
human B_PERSON/B_SPECIES[BIO]
X O
chromosome O
. O

The O
positive B_GENE/B_DISEASE
YAC I_GENE/I_DISEASE
was O
also O
identified O
in O
a O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
hybridization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
the O
DMD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
P20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
12 B_NUMBER[MEASURE]
) O
. O

primer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
2729 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

example O
hybridizations O
to O
a O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
X O
chromosome O
cosmid O
filter O
in O
Fig O
2 O
shows O
the O
intensity O
and O
reliability O
of O
positive O
clones O
identified O
on O
duplicate O
filters O
with O
Alu O
- O
PCR O
products O
from O
the O
same O
irradiation O
hybrid O
( O
48 O
) O
and O
the O
independence O
of O
clones O
identified O
with O
Alu O
- O
PCR O
products O
from O
a O
different O
hybrid O
( O
54 O
) O
. O

Fig O
3 O
shows O
a O
single O
positive O
YAC O
clone O
after O
hybridization O
of O
Alu O
- O
PCR O
products O
from O
irradiation O
hybrid O
54 O
to O
a O
filter O
containing O
about O
420 O
YAC O
clones O
specific O
for O
the O
human B_PERSON/B_SPECIES[BIO]
X O
chromosome O
. O

The O
total B_MEASURE/B_PERSON
number B_MEASURE/I_PERSON
of O
cosmids B_BIO/B_GENE
identified O
with O
each O
pool B_LOCATION/B_MEASURE
of O
AluPCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
each O
hybrid B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
shown O
in O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

From O
the O
average B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
cosmids B_BIO/B_GENE
identified O
( O
24 B_MEASURE
) O
in O
four B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
chromosome I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
equivalents I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
screened O
and O
the O
estimated O
average B_MEASURE
DNA I_MEASURE
content I_MEASURE
in O
each O
hybrid B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3000 B_MEASURE
- O
15000 B_MEASURE/B_LOCATION
kb I_MEASURE/I_LOCATION
) O
, O
the O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
products B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
generated O
by O
a O
single B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
primer I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
calculated O
on O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
to O
be O
300 B_MEASURE
- O
1500 B_MEASURE
kb I_MEASURE
apart O
, O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
published O
estimates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 B_MEASURE
, O
2 B_MEASURE
) O
. O

Only O
3 B_MEASURE/B_PROTEIN[GENE]
- O
4 B_GENE/B_MEASURE
cosmids I_GENE/I_MEASURE
were O
identified O
in O
common B_MEASURE
using O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
generated O
with O
either O
3 B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
5 B_MEASURE
' O
Alu B_LOCATION/B_GENE
primers B_LOCATION/I_GENE
( O
3144 B_MEASURE
or O
2729 B_MEASURE
) O
from O
two B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrids I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
38 B_MEASURE
and O
45 B_MEASURE
) O
. O

This O
shows O
that O
separate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
products I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
amplified O
with O
the O
two B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Alu I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
primers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
since O
they O
prime B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
from O
opposite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ends B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
Alu B_GENE
consensus I_GENE
sequence I_GENE
and O
Alu B_MEASURE/B_LOCATION
sequences B_MEASURE/I_LOCATION
are O
oriented O
in O
the O
genome B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
either O
head B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O
head B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O

A B_OTHER/B_PERSON

B B_OTHER/B_PERSON

C B_OTHER/B_PERSON

El B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

I0 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Nucleic B_NUMBER[MEASURE]/B_LOCATION
acids I_NUMBER[MEASURE]/I_LOCATION
Research I_NUMBER[MEASURE]/I_LOCATION
, O
Vol B_LOCATION/B_PERSON
. O

19 B_MEASURE
, O
No O
. O
12 B_NUMBER[MEASURE]/B_PERSON
3317 I_NUMBER[MEASURE]/I_PERSON
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Cosmids B_GENE/B_BACTERIUM[BIO]
identified O
by O
hybrids B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
unique B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
probes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

hybrids B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
21 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
27 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
38 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
38 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
45 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
45 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
48 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
54 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
74 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
86 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
107 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
unique I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

primer O
3144 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3144 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2729 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
2729 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
33144 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
3144 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
probes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

21 B_MEASURE
3144 I_MEASURE
59 I_MEASURE
1 I_MEASURE
27 I_MEASURE
3144 I_MEASURE
7 I_MEASURE
14 I_MEASURE
2 I_MEASURE
38 I_MEASURE
3144 I_MEASURE
3 I_MEASURE
1 I_MEASURE
28 I_MEASURE
2 I_MEASURE
38 I_MEASURE
2729 I_MEASURE
0 I_MEASURE
0 I_MEASURE
4 I_MEASURE
25 I_MEASURE
0 I_MEASURE
45 I_MEASURE
3144 I_MEASURE
13 I_MEASURE
2 I_MEASURE
2 I_MEASURE
0 I_MEASURE
32 I_MEASURE
3 I_MEASURE
45 I_MEASURE
2729 I_MEASURE
1 I_MEASURE
0 I_MEASURE
0 I_MEASURE
0 I_MEASURE
3 I_MEASURE
31 I_MEASURE
0 I_MEASURE
48 I_MEASURE
3144 I_MEASURE
10 I_MEASURE
2 I_MEASURE
4 I_MEASURE
0 I_MEASURE
2 I_MEASURE
0 I_MEASURE
28 I_MEASURE
3 I_MEASURE
54 I_MEASURE
3144 I_MEASURE
11 I_MEASURE
3 I_MEASURE
0 I_MEASURE
0 I_MEASURE
5 I_MEASURE
0 I_MEASURE
5 I_MEASURE
30 I_MEASURE
2 I_MEASURE
74 I_MEASURE
3144 I_MEASURE
5 I_MEASURE
0 I_MEASURE
0 I_MEASURE
0 I_MEASURE
4 I_MEASURE
0 I_MEASURE
5 I_MEASURE
12 I_MEASURE
20 I_MEASURE
3 I_MEASURE
86 I_MEASURE
3144 I_MEASURE
3 I_MEASURE
1 I_MEASURE
0 I_MEASURE
0 I_MEASURE
4 I_MEASURE
1 I_MEASURE
3 I_MEASURE
4 I_MEASURE
3 I_MEASURE
17 I_MEASURE
0 I_MEASURE
107 I_MEASURE
3144 I_MEASURE
1 I_MEASURE
0 I_MEASURE
1 I_MEASURE
1 I_MEASURE
0 I_MEASURE
0 I_MEASURE
3 I_MEASURE
0 I_MEASURE
0 I_MEASURE
0 I_MEASURE
13 I_MEASURE
0 I_MEASURE
. O

tail B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O
tail O
or O
head O
to O
tail B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
relative I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
to O
each O
other B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
by O
using O
the O
3 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
5 B_MEASURE
' O
- O
Alu B_LOCATION/B_GENE
primers B_LOCATION/I_GENE
in O
separate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
reactions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
the O
same B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hybrid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
the O
total B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
cosmid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clones I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
identified O
was O
almost O
doubled O
. O

Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O
indicates O
how O
many B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cosmids I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O
identified O
by O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
other B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrids I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
16 B_PERSON/B_LOCATION
cosmids B_PERSON/I_LOCATION
previously O
identified O
with O
unique B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
probes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

As O
can O
be O
seen O
in O
Fig B_TIME[MEASURE]/B_LOCATION
1 I_TIME[MEASURE]/I_LOCATION
and O
previous B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irradiation I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrid I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
is O
a O
preferential B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
retention I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
centromere B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
2 B_NUMBER[MEASURE]
, O
11 B_MEASURE
) O
. O

However O
, O
there O
were O
no O
cosmids B_BIO/B_GENE
identified O
in O
common B_DISEASE/B_GENE
from O
all O
the O
hybrids B_BIO/B_DISEASE
positive I_BIO/I_DISEASE
with O
centromere B_VIRUS[BIO]/B_GENE
sequences B_VIRUS[BIO]/I_GENE
. O

This O
is O
probably O
due B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
a O
paucity B_DISEASE_ADJECTIVE[DISEASE]
of O
Alu B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repeats I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
correct B_GENE
orientation I_GENE
in O
alphoid B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
centromere B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sequences B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
thus O
few B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
no O
Alu B_LOCATION/B_PROTEIN[GENE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
would O
be O
amplified O
from O
the O
centromere B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Cosmids B_LOCATION/B_PERSON
identified O
in O
common B_MEASURE/B_DISEASE
by O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
irradiation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
hybrids I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
most O
likely B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O
regions B_LOCATION
of O
overlap B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
outside O
the O
centromere B_LOCATION/B_GENE
area I_LOCATION/I_GENE
as O
shown O
by O
the O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
probe I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characterization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Fig B_MEASURE
1 I_MEASURE
) O
. O

The O
overlap B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
hybrids B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O
also O
seen O
by O
16 B_PERSON/B_GENE
cosmids B_PERSON/I_GENE
( O
Table B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Fig B_MEASURE
1 I_MEASURE
) O
that O
were O
hybridization B_MEASURE/B_PERSON
targets B_MEASURE/I_PERSON
of O
unique B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
mapped O
in O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
the O
overlap B_LOCATION/B_BIO
region I_LOCATION/I_BIO
. O

At O
least O
for O
several B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cosmids I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O
showed O
that O
the O
Alu B_LOCATION/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
identified O
target B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cosmids I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
were O
definitely O
from O
the O
expected B_LOCATION/B_BIO
region B_LOCATION/I_BIO
contained O
in O
the O
hybrids B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

For O
example B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
hybrids B_MEASURE
21 I_MEASURE
and O
54 B_MEASURE
were O
both O
shown O
to O
contain O
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O
the O
Duchenne B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
muscular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
dystrophy B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
DMD B_DISEASE/B_PROTEIN[GENE]
) O
locus B_GENE/B_LOCATION
( O
Fig B_MEASURE
1 I_MEASURE
; O
P B_OTHER/B_LOCATION
. O
N B_OTHER/B_PROTEIN[GENE]
. O
G B_OTHER/B_GENE
. O
, O
unpublished B_TIME[MEASURE]
) O
and O
had O
11 B_NUMBER[MEASURE]/B_PERSON
cosmids I_NUMBER[MEASURE]/I_PERSON
in O
common B_DISEASE/B_GENE
, O
including O
one B_NUMBER[MEASURE]/B_PERSON
identified O
by O
the O
probe B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P20 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
deletion B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
hotspot B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
DMD B_GENE/B_BIO
gene I_GENE/I_BIO
( O
12 B_TIME[MEASURE]
) O
. O

In O
Fig B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
hybridization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Alu B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
hybrid B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
54 B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
identified O
a O
YAC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
clone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
was O
also O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
DMD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
P20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
not O
shown O
) O
. O

This O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
identified O
fragments B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
hybrids B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
were O
not O
seen O
in O
the O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characterization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
Fig B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Table B_MEASURE
1 I_MEASURE
) O
. O

Since O
the O
27 B_GENE/B_LOCATION
DNA I_GENE/I_LOCATION
probes I_GENE/I_LOCATION
were O
not O
close B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enough O
to O
each O
other B_NUMBER[MEASURE]/B_PERSON
along O
the O
chromosome B_GENE/B_LOCATION
to O
detect O
all O
possible B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hybrid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragments I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
1000 B_MEASURE
- O
5000 B_MEASURE
kb I_MEASURE
) O
, O
many B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
regions I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
would O
have O
been O
untested B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

For O
example B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
AluPCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
hybrids B_MEASURE
45 I_MEASURE
and O
48 B_MEASURE
identified O
several B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cosmids B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
also O
seen O
by O
the O
cDNA B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
granulomatous B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
disease B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
CYBB B_MEASURE
, O
13 B_NUMBER[MEASURE]/B_LOCATION
) O
in O
Xp2 B_PROTEIN[GENE]/B_MEASURE
1 I_PROTEIN[GENE]/I_MEASURE
. O
1 B_MEASURE
, O
although O
this O
region B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
not O
tested O
in O
the O
original B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hybrid I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characterization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
direct B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hybridization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
somatic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cell B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
hybrids B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O
genomic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
libraries I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
bypass O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
ligation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
fragments B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
into O
plasmid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vectors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
individual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
single B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
copy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
. O

a O
pool B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
ordered O
array B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
libraries I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
flow B_MEASURE/B_SPORT[ENT]
- O
sorted O
X B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
chromosome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cosmid I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
9 B_TIME[MEASURE]/B_LOCATION
) O
, O
allows O
the O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
overlapping O
hybrids B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
pinpoint O
cosmids B_BIO/B_GENE
most O
likely B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
be O
from O
the O
region B_LOCATION/B_BIO
of O
interest B_PERSON/B_TIME[MEASURE]
. O

In O
conjunction B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
library I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
G B_OTHER/B_LOCATION
. O
Z B_OTHER/B_MEASURE
, O
unpublished O
) O
with O
183 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
X I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
chromosome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
probe I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hybridization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
entries I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
cosmids B_BIO/B_GENE
identified O
with O
both O
Alu B_LOCATION/B_PROTEIN[GENE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
uniquely O
mapped O
X B_LOCATION/B_ORGANIZATION
probes I_LOCATION/I_ORGANIZATION
immediately O
map O
them O
to O
the O
region B_LOCATION/B_BIO
of O
interest B_PERSON/B_BIO
and O
proove B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O
worked O
. O

Similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybridization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
four B_NUMBER[MEASURE]
overlapping O
irradiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
hybrids B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
identified O
four B_LOCATION/B_ENT
cosmids I_LOCATION/I_ENT
in O
common B_LOCATION/B_DISEASE
that O
mapped O
to O
the O
region B_LOCATION/B_MEASURE
of O
overlap B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
F B_OTHER/B_LOCATION
. O
Muscatelli B_PERSON
, O
A B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
P B_LOCATION
. O
M B_LOCATION
. O
, O
P B_LOCATION
. O
N B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
G B_LOCATION/B_GENE
. O
, O
H B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_OTHER/B_LOCATION
. O
and O
M B_LOCATION
. O
Fontes B_PERSON
, O
in O
preparation B_MEASURE
) O
. O

Since O
only O
27 O
probes O
from O
the O
X O
chromosome O
were O
used O
to O
initially O
characterize O
the O
hybrids O
and O
the O
length O
of O
individual O
human B_DISEASE/B_GENE
fragments O
in O
the O
irradiation O
hybrids O
is O
about O
1000 O
- O
5000 O
kb O
, O
many O
regions O
could O
have O
been O
undetected O
in O
the O
original O
analysis O
. O

The O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hybridization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
products B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
the O
cosmid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
library B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
detected O
such B_DISEASE/B_GENE
fragments I_DISEASE/I_GENE
since O
they O
identified O
cosmids B_LOCATION/B_PERSON
in O
common B_LOCATION/B_DISEASE
with O
uniquely O
mapped B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
regions B_LOCATION/B_DISEASE
not O
tested O
originally O
( O
Table B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
Fig B_NUMBER[MEASURE]/B_LOCATION
1 I_NUMBER[MEASURE]/I_LOCATION
) O
. O

This O
should O
prove O
to O
be O
a O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
and O
efficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
determine O
content B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
overlap O
of O
irradiation B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hybrids I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
conjunction B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hybridization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
since O
the O
exact O
length O
of O
the O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O
fragments O
for O
each O
hybrid O
and O
the O
spacing O
of O
Alu O
- O
PCR O
products O
along O
the O
chromosome O
is O
not O
known O
, O
it O
is O
difficult O
to O
directly O
correlate O
the O
number O
of O
target O
cosmids O
to O
the O
DNA O
content O
of O
the O
hybrids O
. O

The O
direct B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hybridization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
Alu B_LOCATION/B_PROTEIN[GENE]
- O
PCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
irradiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
somatic B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
cell B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
hybrids B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
to O
total B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genomic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YAC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
libraries I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
will O
be O
especially O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
construct O
long B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
range I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YAC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contigs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
specific B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subregions I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chromosomes B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
dissection O
of O
a O
total O
genomic O
YAC O
library O
by O
this O
method O
may O
be O
more O
efficient O
than O
generating O
chromosome O
specific O
YAC O
libraries O
from O
somatic O
cell O
hybrids O
( O
usually O
a O
haploid O
human B_PERSON/B_SPECIES[BIO]
chromosome O
on O
a O
diploid O
or O
greater O
rodent O
background O
) O
or O
flow O
- O
sorted O
chromosomes O
, O
because O
of O
the O
low O
transformation O
efficiency O
of O
yeast B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

ACKNOWLEDGEMENTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

We O
would O
like O
to O
thank O
Gert B_PERSON
- O
Jan B_PERSON
Van I_PERSON
Ommen I_PERSON
for O
the O
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
P20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
Stuart B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Orkin I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
CYBB B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probe I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
. O
P B_LOCATION
. O
M B_OTHER/B_PERSON
is O
supported O
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
a O
research B_PERSON/B_ORGANIZATION
fellowship I_PERSON/I_ORGANIZATION
from O
the O
muscular B_ORGANIZATION/B_LOCATION
Dystrophy I_ORGANIZATION/I_LOCATION
Association I_ORGANIZATION/I_LOCATION
of O
America B_LOCATION
. O

V B_MEASURE
. O
M B_OTHER/B_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
L B_OTHER/B_LOCATION
. O

is O
supported O
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
the O
Medical B_PERSON/B_ORGANIZATION
Research B_PERSON/I_ORGANIZATION
Grant B_PERSON/I_ORGANIZATION
of O
the O
University B_LOCATION/B_ORGANIZATION
of O
Hong B_LOCATION
Kong I_LOCATION
. O

Reference B_GENE/B_BIO
library I_GENE/I_BIO
filters I_GENE/I_BIO
and O
cosmids B_LOCATION/B_BIO
identified O
by O
Alu B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
products I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
requested O
from O
the O
Reference B_ORGANIZATION/B_LOCATION
Library I_ORGANIZATION/I_LOCATION
Database I_ORGANIZATION/I_LOCATION
, O
ICRF B_LOCATION/B_ORGANIZATION
, O
44 B_PERSON/B_LOCATION
Lincoln I_PERSON/I_LOCATION
' O
s B_LOCATION/B_MEASURE
Inn I_LOCATION/I_MEASURE
Fields I_LOCATION/I_MEASURE
, O
London B_LOCATION
WC2A I_LOCATION
3PX I_LOCATION
, O
U B_OTHER/B_LOCATION
. O
K B_OTHER/B_LOCATION
. O

3318 B_NUMBER[MEASURE]/B_ORGANIZATION
Nucleic I_NUMBER[MEASURE]/I_ORGANIZATION
acids I_NUMBER[MEASURE]/I_ORGANIZATION
Research I_NUMBER[MEASURE]/I_ORGANIZATION
, O
Vol B_LOCATION
. O

19 O
, O
No O
. O
12 B_NUMBER[MEASURE]
. O

references B_PERSON/B_DISEASE
. O

1 B_NUMBER[MEASURE]
. O

Nelson B_PERSON
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_OTHER/B_PROTEIN[GENE]
. O
, O
Ledbetter B_PERSON
, O
S B_LOCATION/B_DISEASE
. O
A B_OTHER/B_LOCATION
. O
, O
Corbo B_PERSON
, O
L B_OTHER/B_PROTEIN[GENE]
. O
, O
Victoria B_PERSON/B_LOCATION
, O
M B_LOCATION
. O
F B_OTHER/B_LOCATION
. O
, O
Ramirez B_PERSON
- O
Solis B_PERSON
, O

R B_OTHER/B_PERSON
. O
, O
Webster B_PERSON
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
D B_OTHER/B_LOCATION
. O
, O
Ledbetter B_PERSON
, O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
H B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Caskey B_PERSON
, O
C B_PROTEIN[GENE]/B_LOCATION
. O
T B_OTHER/B_PROTEIN[GENE]
. O

( O
1989 B_MEASURE
) O
Proc B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Natl B_PERSON/B_BACTERIUM[BIO]
. O

Acad B_LOCATION
. O

Sci B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

USA B_LOCATION/B_EDU[ORGANIZATION]
, O
86 B_MEASURE
: O
6686 B_MEASURE
- O
6690 B_MEASURE
. O

2 B_NUMBER[MEASURE]
. O

Ledbetter B_PERSON
, O
S B_LOCATION/B_DISEASE
. O
A B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Nelson B_PERSON
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_PROTEIN[GENE]/B_LOCATION
. O
, O
Warren B_PERSON
, O
S B_LOCATION/B_DISEASE
. O
T B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Ledbetter B_PERSON
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
H B_OTHER/B_PROTEIN[GENE]
. O

( O
1990 B_MEASURE
) O
. O

Genomics B_MEASURE/B_ORGANIZATION
, O
6 B_MEASURE
: O
475 B_MEASURE
- O
481 B_MEASURE
. O

3 B_NUMBER[MEASURE]
. O

Cotter B_PERSON/B_COLOR
, O
F B_LOCATION/B_DISEASE
. O
E B_OTHER/B_LOCATION
. O
, O
Hampton B_LOCATION/B_PERSON
, O
G B_LOCATION/B_GENE
. O
M B_OTHER/B_LOCATION
. O
, O
Nasipuri B_PERSON/B_LOCATION
, O
S B_OTHER/B_LOCATION
. O
, O
Bodmer B_PERSON
, O
W B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O
F B_OTHER/B_LOCATION
. O
, O
and O
Young B_PERSON
. O

B B_MEASURE/B_DISEASE
. O
D B_OTHER/B_BACTERIUM[BIO]
. O

( O
1990 B_MEASURE
) O
genomics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
7 B_MEASURE
: O
257 B_MEASURE
- O
263 B_MEASURE
. O

4 B_NUMBER[MEASURE]
. O

Burke B_PERSON
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
T B_OTHER/B_PROTEIN[GENE]
. O
, O
Carle B_PERSON
, O
G B_PROTEIN[GENE]/B_LOCATION
. O
F B_OTHER/B_LOCATION
. O
, O
and O
Olson B_PERSON
, O
M B_LOCATION
. O
V B_OTHER/B_LOCATION
. O

( O
1987 B_MEASURE
) O
Science B_EDU[ORGANIZATION]/B_TIME[MEASURE]
, O
236 B_MEASURE
: O
806 B_MEASURE
- O
812 B_MEASURE
. O

5 B_NUMBER[MEASURE]
. O

Benham B_PERSON
, O
F B_OTHER/B_LOCATION
. O
, O
Hart B_PERSON
, O
K B_PROTEIN[GENE]/B_LOCATION
. O
, O
Crolla B_PERSON/B_LOCATION
, O
J B_OTHER/B_LOCATION
. O
, O
Bobrow B_PERSON
, O
M B_LOCATION
. O
, O
Francavilla B_PERSON/B_LOCATION
, O
M B_OTHER/B_LOCATION
. O
, O
and O
. O

Goodfellow B_PERSON
, O
P B_LOCATION
. O
N B_OTHER/B_PERSON
. O

( O
1989 B_MEASURE
) O
Genomics B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
4 B_MEASURE
: O
509 B_MEASURE
- O
517 B_MEASURE
. O

6 B_NUMBER[MEASURE]
. O

Feinberg B_PERSON/B_COLOR
, O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
P B_OTHER/B_LOCATION
. O
, O
and O
Vogelstein B_PERSON
, O
B B_OTHER/B_PERSON
. O

( B_OTHER/B_TIME[MEASURE]
1984 B_MEASURE
) O
Anal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Biochem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
, O
137 B_MEASURE
: O
266 B_MEASURE
- O
267 B_MEASURE
. O

7 B_NUMBER[MEASURE]
. O

Hochgeschwender B_PERSON/B_LOCATION
, O
U B_OTHER/B_PERSON
. O
, O
Sutciffe B_PERSON
, O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
G B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Brennan B_PERSON
, O
M B_LOCATION
. O
B B_OTHER/B_LOCATION
. O

( O
1989 B_MEASURE
) O
Proc B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Natl B_PERSON/B_BACTERIUM[BIO]
. O

Acad B_LOCATION
. O

Sci B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

USA B_LOCATION/B_EDU[ORGANIZATION]
, O
86 B_MEASURE
: O
8482 B_MEASURE
- O
8486 B_MEASURE
. O

8 B_NUMBER[MEASURE]
. O

Lehrach B_PERSON/B_LOCATION
, O
H B_OTHER/B_PROTEIN[GENE]
. O
, O
Drmanac B_PERSON
, O
R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
, O
Hoheisel B_PERSON
, O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Larin B_PERSON
, O
Z B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Lennon B_PERSON
, O
G B_PROTEIN[GENE]/B_LOCATION
. O
, O
Monaco B_LOCATION/B_PERSON
, O

A B_OTHER/B_PERSON
. O
P B_OTHER/B_LOCATION
. O
, O
Nizetic B_PERSON
, O
D B_OTHER/B_PROTEIN[GENE]
. O
, O
Zehetner B_PERSON
, O
G B_OTHER/B_LOCATION
. O
, O
and O
Poustka B_PERSON/B_LOCATION
, O
A B_OTHER/B_PERSON
. O

( O
1990 O
) O
In O
Davies B_PERSON
, O
K B_GENE/B_LOCATION
. O
E B_OTHER/B_PERSON
. O

& O
Tilghman B_PERSON/B_COLOR
, O
S B_PROTEIN[GENE]/B_DISEASE
. O
M B_OTHER/B_PERSON
. O

( O
eds B_PERSON/B_MEASURE
. O
) O
, O
Genome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Volume I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Genetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
and O
Physical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mapping I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cold B_NUMBER[MEASURE]/B_PERSON
Spring I_NUMBER[MEASURE]/I_PERSON
Harbor I_NUMBER[MEASURE]/I_PERSON
Laboratory I_NUMBER[MEASURE]/I_PERSON
Press I_NUMBER[MEASURE]/I_PERSON
, O
Cold B_MEASURE/B_LOCATION
Spring I_MEASURE/I_LOCATION
Harbor I_MEASURE/I_LOCATION
, O
pp B_LOCATION
. O

39 O
- O
81 B_MEASURE
. O

9 B_NUMBER[MEASURE]
. O

Nizetic B_PERSON
, O
D B_OTHER/B_LOCATION
. O
, O
Zehetner B_PERSON
, O
G B_OTHER/B_PROTEIN[GENE]
. O
, O
Monaco B_LOCATION/B_PERSON
, O
A B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
P B_OTHER/B_LOCATION
. O
, O
Gellen B_PERSON
, O
L B_PROTEIN[GENE]/B_LOCATION
. O
, O
Young B_PERSON
, O
B B_LOCATION/B_DISEASE
. O
D B_OTHER/B_LOCATION
. O
, O
and O
. O

Lehrach B_PERSON/B_LOCATION
, O
H B_OTHER/B_PERSON
. O

( O
1991 B_MEASURE
) O
Proc B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Natl B_PERSON/B_BACTERIUM[BIO]
. O

Acad B_LOCATION
. O

Sci B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

USA B_LOCATION/B_MEASURE
, O
88 B_MEASURE
: O
3233 B_MEASURE
- O
3237 B_MEASURE
. O

10 B_NUMBER[MEASURE]
. O

Larin B_PERSON
, O
Z B_OTHER/B_LOCATION
. O
and O
Lehrach B_PERSON/B_LOCATION
, O
H B_OTHER/B_PERSON
. O

( O
1990 B_MEASURE/B_LOCATION
) O
Genet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Res B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
. O

Camb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O
, O
56 B_MEASURE
: O
203 B_MEASURE
- O
208 B_MEASURE
. O

11 B_NUMBER[MEASURE]
. O

Cox B_PERSON
, O
D B_OTHER/B_PERSON
, O
R B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Pritchard B_PERSON/B_COLOR
, O
C B_PROTEIN[GENE]/B_LOCATION
. O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Uglum B_PERSON/B_LOCATION
, O
E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Casher B_PERSON
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Koborl B_PERSON/B_LOCATION
. O

J B_OTHER/B_MEASURE
. O
and O
Myers B_PERSON/B_LOCATION
, O

R B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O
M B_OTHER/B_PERSON
. O

( O
1989 B_MEASURE
) O
Genomics B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
4 B_MEASURE
: O
397 B_MEASURE
- O
407 B_MEASURE
. O

12 B_NUMBER[MEASURE]
. O

Wapenaar B_PERSON/B_LOCATION
, O
M B_LOCATION
. O
C B_OTHER/B_PROTEIN[GENE]
. O
, O
Kievits B_PERSON/B_LOCATION
, O
T B_PROTEIN[GENE]/B_LOCATION
. O
, O
Hart B_PERSON
, O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
A B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O
, O
Abbs B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Blonden B_PERSON/B_COLOR
, O
L B_PROTEIN[GENE]/B_LOCATION
. O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
J B_OTHER/B_PROTEIN[GENE]
. O
, O

denDunnen B_PERSON/B_LOCATION
, O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
T B_OTHER/B_PROTEIN[GENE]
. O
, O
Grootscholten B_PERSON
, O
P B_LOCATION
. O
M B_OTHER/B_LOCATION
. O
, O
Bakker B_PERSON
, O
E B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Verellen B_PERSON
- O
Dumoulin B_PERSON/B_LOCATION
, O
C B_PROTEIN[GENE]/B_LOCATION
. O
, O
Bobrow B_PERSON
, O
M B_PROTEIN[GENE]/B_LOCATION
. O
, O
vanOmmen B_PERSON
, O
G B_PROTEIN[GENE]/B_LOCATION
. O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
B B_OTHER/B_LOCATION
. O
, O
and O
Pearson B_PERSON
, O
P B_LOCATION
. O
L B_OTHER/B_PROTEIN[GENE]
. O

( O
1988 B_MEASURE
) O
Genomics B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
2 B_MEASURE
: O
101 B_MEASURE
- O
108 B_MEASURE
. O

13 B_NUMBER[MEASURE]
. O

Royer B_PERSON
- O
Pokora B_PERSON/B_LOCATION
, O
B B_OTHER/B_LOCATION
. O
, O
Kunkel B_PERSON
, O
L B_PROTEIN[GENE]/B_LOCATION
. O
M B_OTHER/B_LOCATION
. O
, O
Monaco B_LOCATION/B_PERSON
, O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
P B_OTHER/B_LOCATION
. O
, O
Goff B_PERSON
, O
S B_LOCATION/B_DISEASE
. O
C B_OTHER/B_PROTEIN[GENE]
. O
, O
Newburger B_PERSON/B_LOCATION
, O

P B_LOCATION
. O
E B_OTHER/B_LOCATION
. O
, O
Baehner B_PERSON/B_COLOR
, O
R B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_PROTEIN[GENE]/B_LOCATION
. O
, O
cole B_LOCATION
F I_LOCATION
. O
S B_LOCATION/B_DISEASE
. O
, O
Curnette B_LOCATION
J I_LOCATION
. O
T B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Orkin B_PERSON/B_COLOR
, O
S B_LOCATION/B_DISEASE
. O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1986 B_MEASURE
) O
nature B_DISEASE/B_MEASURE
, O
322 B_MEASURE
: O
32 B_MEASURE
- O
38 B_MEASURE
. O

14 B_NUMBER[MEASURE]
. O

Davies B_PERSON
, O
K B_PROTEIN[GENE]/B_LOCATION
. O
E B_OTHER/B_LOCATION
. O
, O
Mandel B_PERSON
, O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_OTHER/B_PROTEIN[GENE]
. O
, O
Monaco B_LOCATION/B_PERSON
, O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
P B_OTHER/B_LOCATION
. O
, O
Nussbaum B_PERSON
, O
R B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_OTHER/B_PROTEIN[GENE]
. O
and O
Willard B_PERSON
, O

H B_PROTEIN[GENE]/B_MEASURE
. O
F B_OTHER/B_DISEASE
. O

( O
1990 B_MEASURE
) O
Cytogenet B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Genet I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

55 O
: O
254 O
- O
313 B_MEASURE
. O

The O
Caenorhabditis B_VIRUS[BIO]/B_DISEASE
elegans I_VIRUS[BIO]/I_DISEASE
genome O
contains O
monomorphic O
minisatellites O
and O
simple O
sequences O
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Many B_BIO/B_PERSON
species I_BIO/I_PERSON
have O
been O
shown O
to O
contain O
tandemly O
repeated O
short B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O
as O
minisatellites B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
motifs B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Due O
to O
allelic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
copy B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
the O
repeat B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unit I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
these O
loci B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
usually O
highly O
polymorphic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Here O
we O
demonstrate O
the O
presence O
of O
sequences O
in O
the O
genome O
of O
the O
nematode O
Caenorhabditis B_SPECIES[BIO]/B_GENE
elegans I_SPECIES[BIO]/I_GENE
which O
are O
homologous O
to O
two O
sets O
of O
short O
sequence O
DNA O
. O

However O
, O
when O
two B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
independent I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
strains I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O
compared O
no O
polymorphism B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
these O
sequences B_DISEASE/B_GENE
could O
be O
detected O
. O
images B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Volume B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
17 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Number I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1989 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nucleic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Caenorhabds B_SPECIES[BIO]/B_MEASURE
elegans I_SPECIES[BIO]/I_MEASURE
genome O
contains O
monomorphic O
minisatellites O
and O
simple O
sequences O
Andrd O
G O
. O
Uitterlinden O
, O
P O
. O
Eline O
Slagboom O
, O
Thomas O
E O
. O
Johnsonl O
and O
Jan O
Vijg O
. O

Department B_ORGANIZATION/B_LOCATION
of O
Molecular B_EDU[ORGANIZATION]/B_PERSON
Biology I_EDU[ORGANIZATION]/I_PERSON
, O
TNO B_ORGANIZATION/B_LOCATION
Institute I_ORGANIZATION/I_LOCATION
for O
Experimental B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Gerontology I_EDU[ORGANIZATION]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Po B_LOCATION
Box I_LOCATION
5815 I_LOCATION
, O
2280 B_LOCATION
HV I_LOCATION
Rijswijk I_LOCATION
, O
The O
Netherlands B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
lInstitute B_LOCATION/B_PERSON
for O
behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
genetics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
University B_LOCATION/B_ORGANIZATION
of O
Colorado B_LOCATION
, O
Boulder B_LOCATION/B_LANGUAGE
, O
CO B_LOCATION
80309 I_LOCATION
, O
USA B_LOCATION/B_MEASURE
. O

received O
October B_TIME[MEASURE]
27 I_TIME[MEASURE]
, O
1989 B_MEASURE
; O
accepted O
November B_TIME[MEASURE]
3 I_TIME[MEASURE]
, O
1989 B_MEASURE
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Many B_BIO/B_PERSON
species I_BIO/I_PERSON
have O
been O
shown O
to O
contain O
tandemly O
repeated O
short B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
DNA I_GENE/I_LOCATION
kinown I_GENE/I_LOCATION
as O
minisatellites B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
motifs B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Due O
to O
allelic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
copy B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
the O
repeat B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unit I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
these O
loci B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
usually O
highly O
polymorphic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Here O
we O
demonstrate O
the O
presence O
of O
sequences O
in O
the O
genome O
of O
the O
nematode O
Caenorhabditis B_SPECIES[BIO]/B_GENE
elegans I_SPECIES[BIO]/I_GENE
which O
are O
homologous O
to O
two O
sets O
of O
short O
sequence O
DNA O
. O

However O
, O
when O
two B_PERSON/B_BIO
independent I_PERSON/I_BIO
strains I_PERSON/I_BIO
were O
compared O
no O
polymorphism B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
these O
sequences B_DISEASE/B_GENE
could O
be O
detected O
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
many B_BIO
species I_BIO
, O
including O
lower B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
organisms I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
contain O
minisatellite B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequences I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
so O
- O
called O
simple B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
1 B_NUMBER[MEASURE]/B_PROTEIN[GENE]
, O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
) O
. O

Due O
to O
extensive B_DISEASE_ADJECTIVE[DISEASE]
variation I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
number B_MEASURE/B_LOCATION
of O
repeat B_BIO/B_GENE
units I_BIO/I_GENE
, O
many B_NUMBER[MEASURE]/B_PERSON
of O
these O
loci B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
shown O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
polymorphic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
markers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
e B_GENE/B_DISEASE
. O
g B_GENE/B_MEASURE
. O
for O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
linkage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
identification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
purposes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Here O
we O
demonstrate O
that O
the O
genome O
of O
the O
nematode O
Caenorhabditis B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
elegans I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
contains O
sequences O
that O
are O
homologous O
to O
the O
minisatellite O
core O
sequence O
33 O
. O
6 O
( O
1 O
) O
and O
to O
the O
simple O
sequence O
motif O
( O
AGC O
) O
n O
. O

surprisingly O
, O
these O
sequences O
did O
not O
display O
polymorphism O
when O
two O
independent O
C B_SPECIES[BIO]/B_LOCATION
. I_SPECIES[BIO]/I_LOCATION
elegans I_SPECIES[BIO]/I_LOCATION
strains O
, O
Bristol O
and O
Bergerac O
, O
were O
compared O
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
METHODS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Genomic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
DNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
from O
nematodes B_BIO/B_DISEASE
. O

Genomic B_DISEASE/B_BACTERIUM[BIO]
DNA B_DISEASE/I_BACTERIUM[BIO]
was O
isolated O
according O
to O
standard B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
the O
two B_LOCATION
strains I_LOCATION
Bergerac I_LOCATION
( O
BO B_PROTEIN[GENE]/B_DISEASE
) O
and O
Bristol B_LOCATION/B_BACTERIUM[BIO]
( O
strain B_LOCATION
N2 I_LOCATION
) O
. O

These O
strains B_BIO
are O
derived O
from O
two B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
different I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
individual I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
worms I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
isolated O
in O
France B_LOCATION
and O
England B_LOCATION
, O
respectively O
. O

Southern B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
blotting I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
. O

Genomic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
digests I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Ag B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
were O
separated O
in O
a O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
agarose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
gel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
1 B_MEASURE
x O
TAE B_MEASURE
( O
40 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tris I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
HCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pH O
7 B_MEASURE
. O
4 B_MEASURE
/ O
20 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
NaEDTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
by O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
75 B_MEASURE/B_LOCATION
V I_MEASURE/I_LOCATION
for O
16 B_MEASURE
h O
. O

separation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patterns I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
transferred O
to O
Zetaprobe B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
membrane I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
BIORAD B_LOCATION/B_ORGANIZATION
) O
in O
0 B_MEASURE
. O
4 B_MEASURE
N I_MEASURE
NaOH I_MEASURE
, O
0 B_MEASURE
. O
6 B_MEASURE
M I_MEASURE
NaCl I_MEASURE
in O
a O
vacu B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
- O
blot B_LOCATION
apparatus I_LOCATION
( O
LKB B_LOCATION/B_PERSON
) O
according O
to O
the O
manufacturer B_PERSON/B_LOCATION
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
instructions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

The O
minisatellite B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
simple B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
probes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
used O
were O
prepared O
essentially O
as O
described O
( O
5 B_MEASURE
) O
. O

The O
Tcl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
probe I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
a O
plasmid B_GENE
containing O
an O
insert B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
the O
transposable B_LOCATION/B_GENE
element B_LOCATION/I_GENE
Tcl B_LOCATION/I_GENE
( O
4 B_NUMBER[MEASURE]/B_BIO
) O
. O

All O
probes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
labelled O
by O
random B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
priming B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

hybridization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
for O
12 B_MEASURE
h O
in O
7 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SDS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_MEASURE
. O
5 B_MEASURE
M I_MEASURE
phosphate I_MEASURE
buffer I_MEASURE
, O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mM I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
Na2EDTA I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
at O
650C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Blots B_PERSON
were O
washed O
twice O
in O
2 B_MEASURE
. O
5 B_MEASURE
x O
SSC B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
650C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O
exposed O
to O
Kodak B_MEASURE/B_PROTEIN[GENE]
XAR I_MEASURE/I_PROTEIN[GENE]
- O
5 B_MEASURE/B_ENT
film I_MEASURE/I_ENT
with O
intensifying O
screens B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

exposure B_TIME[MEASURE]/B_PERSON
times B_TIME[MEASURE]/I_PERSON
are O
indicated O
in O
Fig B_MEASURE/B_LOCATION
. O

1 B_NUMBER[MEASURE]
. O

( O
IRL B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Press I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Volume B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
17 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Number I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
23 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1989 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

9527 B_NUMBER[MEASURE]
. O

nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

C B_PERSON/B_SPECIES[BIO]
. I_PERSON/I_SPECIES[BIO]
elegans I_PERSON/I_SPECIES[BIO]
. O

N B_LOCATION/B_MEASURE
0 B_LOCATION/I_MEASURE
$ O
8 B_MEASURE
. O

_ B_MEASURE/B_GENE
_ I_MEASURE/I_GENE
. O

: B_OTHER/B_PERSON
, O
s O
, O
. O
. O
e O
: O
* O
. O

, O
~ B_OTHER/B_MEASURE
: O
: O
: O
: O
: O

. O
4i B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

. O
t O
_ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
- O
: O
: O
? O
J B_OTHER/B_LOCATION
? O
. O
: O

i B_OTHER/B_DISEASE
- O
. O

. B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
. O

E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
? O
: O
< B_MEASURE/B_OTHER
. O

: B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
y O
: O

* B_GENE/B_MEASURE
01 I_GENE/I_MEASURE
. O

4 B_MEASURE/B_LOCATION
? O
j O
* O
. O

. B_DISEASE/B_GENE
- O
I O
. O

kb B_MEASURE/B_PERSON
- O
27 B_MEASURE/B_LOCATION
. O

- O
9A B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
. O

: B_OTHER/B_MEASURE
. O
: O
: O
. O
. O
. O
. O
. O
. O
. O

Mi B_LOCATION/B_PERSON
. O
. O
. O
. O

- O
4v3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

IC B_MEASURE/B_LOCATION
. O
3 B_TIME[MEASURE]/B_LOCATION
. O

If O
. O
0r B_LOCATION/B_PERSON
. O

MW B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

! O
5 B_PERSON/B_MEASURE
c6 I_PERSON/I_MEASURE
. O

I B_OTHER/B_PERSON

' O
R B_LOCATION/B_PERSON
1d B_LOCATION/I_PERSON
~ B_LOCATION/I_PERSON
! O

; B_OTHER/B_TIME[MEASURE]
, O

figure B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
. O

Southern O
hybridization O
analysis O
of O
Hae O
III O
, O
Rsa O
I O
and O
Eco O
RI O
digested O
genomic O
DNA O
isolated O
from O
the O
two O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
strains O
Bristol O
( O
N O
) O
and O
Bergerac O
( O
B O
) O
. O

The O
probes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
used O
and O
the O
exposure B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
times B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
autoradiograph B_PRODUCT[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
indicated O
below O
the O
figure B_PERSON/B_MEASURE
. O

kb B_MEASURE/B_LOCATION
= O
kilo B_MEASURE/B_PERSON
basepairs I_MEASURE/I_PERSON
. O

9528 B_NUMBER[MEASURE]
. O

* B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
. O
. O
? O
. O
; O
. O

. B_OTHER/B_DISEASE
* O
. O

i B_OTHER/B_LOCATION
. O
. O
. O

: B_OTHER/B_LOCATION
' O
. O

Ann B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
& O
. O

' O
Row B_LOCATION/B_MEASURE
: O
. O
lwmwww O
. O

. O
Ammkw B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O
l B_OTHER/B_LOCATION
. O

4w B_SEQUENCE[MEASURE]/B_PERSON
, O

9 B_NUMBER[MEASURE]/B_PERSON

_ B_OTHER/B_MEASURE
i O
ob O
. O

ill B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
. O

nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
Figure O
1 O
the O
hybridization O
patterns O
are O
shown O
of O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
elegans I_SPECIES[BIO]/I_PERSON
genomic O
DNA O
digested O
with O
Hae O
II O
, O
Rsa O
I O
and O
Eco O
RI O
, O
and O
subsequently O
hybridized O
to O
minisatellite O
core O
probe O
33 O
. O
6 O
, O
the O
simple O
sequence O
probe O
( O
AGC O
) O
n O
and O
Tcl O
. O

The O
latter B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
contains O
a O
member B_PERSON/B_MEASURE
of O
the O
Tcl B_PERSON/B_LOCATION
family I_PERSON/I_LOCATION
of O
transposable B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
is O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
different B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
copy B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
numbers B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
two B_SPECIES[BIO]/B_GENE
different B_SPECIES[BIO]/I_GENE
strains B_SPECIES[BIO]/I_GENE
( O
4 B_TIME[MEASURE]/B_BIO
) O
. O

The O
hybridization B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
patterns I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
probes B_MEASURE/B_PROTEIN[GENE]
33 I_MEASURE/I_PROTEIN[GENE]
. O
6 B_MEASURE
and O
( O
AGC B_MEASURE
) O
n B_OTHER/B_MEASURE
obtained O
after O
Hae B_DISEASE/B_ENZYME[GENE]
Im B_DISEASE/I_ENZYME[GENE]
and O
RSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
I O
digestion O
and O
the O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
intensities B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hybridizing O
bands B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
reminiscent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
fingerprint B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
patterns I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
obtained O
with O
these O
probes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
other B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
species I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
( O
1 B_TIME[MEASURE]
, O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
) O
. O

However O
, O
identical O
hybridization O
patterns O
for O
the O
two O
strains O
with O
the O
three O
enzymes O
tested O
indicated O
that O
in O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
elegans I_SPECIES[BIO]/I_PERSON
these O
sequences O
are O
monomorphic O
( O
Fig O
. O
1 O
) O
. O

Based O
on O
the O
number O
of O
hybridizing O
bands O
we O
estimate O
the O
C B_SPECIES[BIO]/B_MEASURE
. I_SPECIES[BIO]/I_MEASURE
elegans I_SPECIES[BIO]/I_MEASURE
genome O
to O
contain O
about O
30 O
33 O
. O
6 O
homologous O
loci O
and O
about O
20 O
( O
AGC O
) O
n O
homologous O
loci O
. O

Rehybridization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
same B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
blot I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
Tcl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O
extensive B_DISEASE_ADJECTIVE[DISEASE]
RFLPs I_DISEASE_ADJECTIVE[DISEASE]
due O
to O
the O
different B_MEASURE
copy I_MEASURE
number I_MEASURE
of O
the O
transposon B_GENE
in O
the O
two B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
strains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
phenomenon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
which O
has O
been O
described O
previously O
by O
others B_PERSON/B_MEASURE
( O
4 B_MEASURE
) O
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O
in O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
indicate O
that O
polymorphism B_GENE/B_MEASURE
of O
minisatellite B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequences I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
is O
not O
a O
general B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phenomenon I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
animal B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
species I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

So O
far O
, O
only O
some O
species B_BIO
of O
whales B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
have O
displayed O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
monomorphism B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
6 B_MEASURE/B_LOCATION
) O
. O

In O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
species I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
thus O
far O
tested O
both O
minisatellites B_DISEASE_ADJECTIVE[DISEASE]
and O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
display O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
to O
very O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
levels B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
polymorphism B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
should O
be O
noted O
, O
however O
, O
that O
at O
least O
in O
humans B_PERSON/B_SPECIES[BIO]
, O
a O
substantial O
part O
of O
the O
minisatellites O
detected O
by O
core O
probes O
also O
displays O
high O
levels O
of O
monomorphism O
as O
analysed O
by O
cloning O
( O
1 O
) O
or O
by O
two O
- O
dimensional O
DNA O
fingerprinting O
( O
5 O
) O
. O

The O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
nematodes B_BIO/B_PERSON
are O
hermaphrodites B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
and O
thus O
inbred O
, O
might O
be O
a O
contributing O
factor B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
observed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
polymorphism B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

However O
, O
the O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
levels B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
polymorphism B_GENE
detected O
by O
the O
Tcl B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probe I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
do O
not O
indicate O
a O
general B_MEASURE/B_LOCATION
absence B_MEASURE/I_LOCATION
of O
events B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
causing O
genetic B_DISEASE_ADJECTIVE[DISEASE]
variation I_DISEASE_ADJECTIVE[DISEASE]
. O

Indeed O
, O
Eide O
and O
Anderson O
( O
7 O
) O
showed O
that O
tandemly O
repeated O
duplications O
in O
the O
unc O
- O
54 O
gene O
of O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
revert O
at O
high O
frequencies O
. O

Since O
in O
all O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
revertants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
the O
normal B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genomic I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
configuration I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O
suggests O
that O
unequal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
crossing B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O
over B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
does O
occur O
in O
the O
nematode B_BIO/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
. O

A O
more O
likely O
explanation O
for O
the O
monomorphic O
nature O
of O
the O
sequences O
detected O
with O
33 O
. O
6 O
and O
( O
AGC O
) O
n O
in O
C B_SPECIES[BIO]/B_PERSON
. I_SPECIES[BIO]/I_PERSON
elegans I_SPECIES[BIO]/I_PERSON
is O
selection O
against O
sequence O
variants O
at O
these O
loci O
. O

This O
might O
be O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
particular B_LOCATION/B_GENE
subset I_LOCATION/I_GENE
of O
minisatellites B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
/ O
or O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
at O
sites B_LOCATION/B_MEASURE
in O
the O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
this O
organism B_BIO/B_GENE
, O
e O
. O
g B_GENE/B_MEASURE
. O
in O
coding B_BIO/B_GENE
sequences I_BIO/I_GENE
, O
in O
which O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
copy B_MEASURE
number I_MEASURE
of O
repeat B_GENE/B_MEASURE
units I_GENE/I_MEASURE
cannot I_GENE/I_MEASURE
be O
tolerated O
. O

An O
example B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
such O
a O
coding B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
the O
High B_GENE/B_BIO
mobility I_GENE/I_BIO
Group I_GENE/I_BIO
proteins I_GENE/I_BIO
which O
usually O
have O
stretches B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
identical B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
acidic B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
amino B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
acids B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
2 B_MEASURE
, O
8 B_MEASURE
) O
. O

An O
interesting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
this O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
the O
demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
absence B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
any O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
electrophoretic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparisons I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
24 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
enzymes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
the O
Bristol B_LOCATION/B_PERSON
and O
Bergerac B_LOCATION/B_PERSON
strains I_LOCATION/I_PERSON
( O
9 B_MEASURE
) O
. O

An O
important O
step O
in O
understanding O
this O
phenomenon O
will O
therefore O
be O
the O
isolation O
and O
analysis O
of O
individual O
homologous O
minisatellite O
and O
simple O
sequence O
loci O
from O
a O
genomic O
library O
of O
C B_SPECIES[BIO]
. I_SPECIES[BIO]
elegans I_SPECIES[BIO]
. O

references B_PERSON/B_DISEASE
. O

1 B_NUMBER[MEASURE]
. O

Jeffreys B_PERSON/B_COLOR
, O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
J B_OTHER/B_LOCATION
. O
, O
Wilson B_PERSON
, O
V B_LOCATION
. O
, O
and O
Thein B_PERSON/B_COLOR
, O
S B_LOCATION/B_DISEASE
. O
L B_OTHER/B_PROTEIN[GENE]
. O

( O
1985 B_MEASURE
) O
Nature B_MEASURE/B_ORGANIZATION
314 I_MEASURE/I_ORGANIZATION
, O
67 B_MEASURE
- O
73 B_MEASURE
. O

2 B_NUMBER[MEASURE]
. O

Tautz B_PERSON/B_COLOR
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
Trick B_PERSON/B_MEASURE
M I_PERSON/I_MEASURE
. O
, O
and O
Dover B_LOCATION/B_PERSON
, O
G B_PROTEIN[GENE]/B_LOCATION
. O
A B_OTHER/B_MEASURE
. O

( O
1986 B_MEASURE
) O
Nature B_MEASURE/B_LOCATION
322 I_MEASURE/I_LOCATION
, O
652 B_MEASURE
- O
656 B_MEASURE
. O

3 B_NUMBER[MEASURE]
. O

Rogstad B_PERSON/B_LOCATION
, O
S B_OTHER/B_PERSON
. O
H B_OTHER/B_PROTEIN[GENE]
. O
, O
Herwaldt B_PERSON
, O
B B_LOCATION/B_DISEASE
. O
L B_OTHER/B_PROTEIN[GENE]
. O
, O
Schlesinger B_PERSON
, O
P B_PROTEIN[GENE]/B_LOCATION
. O
H B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Krogstad B_PERSON/B_LOCATION
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
J B_OTHER/B_PROTEIN[GENE]
. O

( O
1989 O
) O
nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Res I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

17 B_MEASURE
, O
9 B_MEASURE
, O
3610 B_NUMBER[MEASURE]
. O

4 B_NUMBER[MEASURE]
. O

Emmons B_PERSON
, O
S B_LOCATION/B_DISEASE
. O
W B_OTHER/B_LOCATION
. O
, O
Yesner B_PERSON/B_COLOR
, O
L B_PROTEIN[GENE]/B_LOCATION
. O
, O
Ruan B_PERSON
, O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
and O
Katzenberg B_PERSON
, O
D B_OTHER/B_PERSON
. O

( O
1983 O
) O
Cell B_MEASURE
32 I_MEASURE
, O
55 B_MEASURE
- O
65 B_MEASURE
. O

9529 B_NUMBER[MEASURE]
. O

nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

5 B_NUMBER[MEASURE]
. O

Uitterlinden B_PERSON/B_LOCATION
, O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
G B_OTHER/B_LOCATION
. O
, O
Slagboom B_PERSON
, O
P B_LOCATION
. O
E B_OTHER/B_LOCATION
. O
, O
Knook B_PERSON
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
L B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Vijg B_PERSON/B_COLOR
, O
J B_OTHER/B_PERSON
. O

( O
1989 B_MEASURE
) O
Proc B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Natl B_PERSON/B_BACTERIUM[BIO]
. O

Acad B_LOCATION
. O

USA B_MEASURE/B_LOCATION
86 I_MEASURE/I_LOCATION
, O
2742 B_MEASURE
- O
2746 B_MEASURE
. O

6 B_NUMBER[MEASURE]
. O

Rus B_PERSON
Hoelzel I_PERSON
, O
A B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
and O
Amos B_PERSON
, O
W B_OTHER/B_PERSON
. O

( O
1988 B_MEASURE
) O
Nature B_MEASURE/B_LOCATION
333 I_MEASURE/I_LOCATION
, O
305 B_MEASURE/B_LOCATION
. O

7 B_NUMBER[MEASURE]
. O

Eide B_PERSON/B_COLOR
, O
D B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
and O
Anderson B_PERSON/B_COLOR
, O
P B_OTHER/B_PERSON
. O

( O
1985 B_MEASURE
) O
genetics B_MEASURE
109 I_MEASURE
, O
67 B_MEASURE
- O
79 B_MEASURE
. O

8 B_NUMBER[MEASURE]
. O

Pentecost B_PERSON/B_LOCATION
, O
B B_PROTEIN[GENE]/B_LOCATION
. O
T B_OTHER/B_PERSON
. O
, O
Wright B_PERSON/B_COLOR
, O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
M B_OTHER/B_PROTEIN[GENE]
. O
, O
and O
Dixon B_PERSON/B_ORGANIZATION
, O
G B_PROTEIN[GENE]/B_LOCATION
. O
H B_OTHER/B_PROTEIN[GENE]
. O

( O
1985 O
) O
nucleic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acids I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Res I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

13 B_MEASURE
, O
4871 B_MEASURE
- O
4888 B_MEASURE
. O

9 B_NUMBER[MEASURE]
. O

Butler B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
et I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
al I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

( O
1981 B_MEASURE
) O
J B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Molec B_PERSON/B_DISEASE
. O

Evolution B_MEASURE
18 I_MEASURE
, O
18 B_MEASURE
- O
23 B_MEASURE
. O

9530 B_NUMBER[MEASURE]
. O

This O
article B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
submitted O
on O
disc B_ENT/B_BODY_PART_OR_ORGAN_COMPONENT
, O
has O
been O
automatically O
. O

converted O
into O
this O
typeset B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
format I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
the O
publisher B_PERSON/B_ORGANIZATION
. O

How O
can O
Health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
be O
made O
more O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

abstract B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
paper I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
expresses O
the O
author B_PERSON/B_ORGANIZATION
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
views I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
about O
the O
practical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
utility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
Health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
intervention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
views B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
skeptical B_DISEASE_ADJECTIVE[DISEASE]
and O
perhaps O
even O
a O
bit B_PERSON/B_DISEASE
exaggerated I_PERSON/I_DISEASE
. O

They O
are O
, O
however O
, O
also O
based O
on O
20 B_NUMBER[MEASURE]
- O
plus B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
in O
- O
the O
- O
trenches B_LOCATION/B_ORGANIZATION
research I_LOCATION/I_ORGANIZATION
focused O
on O
improving O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
practice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
through O
research B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
author B_PERSON/B_ORGANIZATION
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
has O
been O
theoretically O
driven O
and O
has O
involved O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
varying O
variables B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
considered O
to O
be O
important B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theoretical I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediators I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
moderators B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
health B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Regretfully O
, O
much B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
has O
found O
these O
variables B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wanting O
in O
basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
scientific I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
merit I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
Behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
Theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
as O
we O
have O
known O
it O
over O
the O
last B_TIME[MEASURE]/B_ENT
25 I_TIME[MEASURE]/I_ENT
years I_TIME[MEASURE]/I_ENT
or O
so O
has O
been O
dominated O
by O
conceptualizations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
behavior B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
change I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
processes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
highlight O
cognitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
decision I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
- O
making B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
much O
of O
health O
behavior O
practice O
targets O
what O
people B_PERSON
do O
rather O
than O
what O
they O
think O
, O
the O
logic O
of O
focusing O
on O
thoughts O
is O
that O
what O
people B_PERSON
think O
about O
is O
the O
key O
to O
what O
they O
will O
do O
in O
the O
future O
, O
and O
that O
interventions O
that O
can O
measure O
and O
harness O
those O
processes O
will O
succeed O
to O
a O
greater O
extent O
than O
those O
that O
do O
not O
. O

Unfortunately O
, O
in O
the O
author B_PERSON/B_LOCATION
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
premise B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cognitive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theories I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
fallen O
short B_PERSON/B_MEASURE
empirically O
in O
a O
number B_MEASURE/B_PERSON
of O
ways B_LOCATION/B_LANGUAGE
. O

The O
cognitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
schemata I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
favored O
by O
most B_PERSON
health I_PERSON
behavior I_PERSON
theories I_PERSON
are O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
measure O
, O
they O
do O
not O
predict O
behavioral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcomes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
very O
well O
, O
there O
is O
little B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
they O
cause O
behavior B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
they O
are O
hard B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O
change O
directly O
. O

summary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
suggested O
that O
health B_PERSON/B_ORGANIZATION
behavior I_PERSON/I_ORGANIZATION
researchers I_PERSON/I_ORGANIZATION
reconsider O
their O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
these O
theories B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
favor B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
models B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whose O
variables B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
more O
accessible B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manipulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
that O
most O
importantly O
have O
strong B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
empirical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
support I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
author B_PERSON/B_LOCATION
has O
been O
conducting O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
on O
behavioral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
obesity B_DISEASE
for O
about O
25 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
. O

During O
that O
time B_TIME[MEASURE]/B_LOCATION
, O
the O
dominant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
conceptual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
guiding O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
development I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O
been O
cognitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
have O
their O
origin B_TIME[MEASURE]/B_DISEASE
in O
psychological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
. O

Those O
most O
often O
cited O
include O
the O
Health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
belief I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
Model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
[ O
1 B_SEQUENCE[MEASURE]/B_LOCATION
] I_SEQUENCE[MEASURE]/I_LOCATION
, O
Protection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
motivation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
Theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
[ O
2 B_NUMBER[MEASURE]/B_LOCATION
] I_NUMBER[MEASURE]/I_LOCATION
, O
Subjective B_DISEASE/B_LOCATION
expected O
utility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
[ O
3 B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
] I_SEQUENCE[MEASURE]/I_PROTEIN[GENE]
, O
the O
Theory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Reasoned B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Action I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
4 B_SEQUENCE[MEASURE]
] I_SEQUENCE[MEASURE]
, O
Social B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
Cognitive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
Theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
[ O
5 B_NUMBER[MEASURE]
] I_NUMBER[MEASURE]
, O
and O
the O
Transtheoretical B_ORGANIZATION/B_LOCATION
Model I_ORGANIZATION/I_LOCATION
[ O
6 B_MEASURE
] I_MEASURE
. O

All O
of O
these O
theories O
are O
concerned O
with O
how O
people B_PERSON/B_BIO
make O
behavioral O
choices O
and O
the O
general O
idea O
is O
that O
people B_PERSON
decide O
what O
to O
do O
based O
on O
the O
extent O
to O
which O
they O
expect O
that O
their O
choices O
will O
produce O
results O
that O
they O
value O
. O

Much B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
content B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
theories B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
concerned O
with O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
may O
affect O
value B_MEASURE/B_DISEASE
/ O
expectancy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calculations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

As O
summarized O
by O
Weinstein B_PERSON
in O
a O
comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
four B_MEASURE
social I_MEASURE
psychological I_MEASURE
theories I_MEASURE
[ O
7 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
, O
variables B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thought O
to O
influence O
value B_TIME[MEASURE]/B_PERSON
/ O
expectancy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
judgments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
include O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
perceived O
rewards B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
current B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
self B_PERSON/B_LOCATION
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
normative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beliefs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
motivation B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
perceived O
consequences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
not O
changing O
behavior B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Weinstein O
' O
s O
summary O
is O
illustrative O
of O
the O
fact O
that O
Health O
behavior O
Theory O
has O
tended O
to O
be O
particularly O
interested O
in O
understanding O
people B_PERSON
' O
s O
motivation O
to O
change O
behavior O
rather O
than O
ability O
to O
change O
. O

Moreover O
, O
motivation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
thought O
to O
be O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
a O
relatively O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
logical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
interpretation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
large B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quantities B_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
information B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O
self B_PERSON/B_LOCATION
and O
environment B_LOCATION/B_PERSON
. O

The O
theories O
that O
Weinstein O
reviewed O
deal O
almost O
exclusively O
with O
behavioral O
decision O
processes O
in O
people B_PERSON
' O
s O
minds O
. O

They O
have O
few B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O
any O
terms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
relating O
to O
how O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
gets O
into O
peoples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
minds I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
how O
subsets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
it O
receive O
more B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
less B_MEASURE
attention I_MEASURE
. O

broader O
health O
behavior O
theories O
such O
as O
Social O
cognitive O
Theory O
or O
the O
Transtheoretical O
model O
have O
addressed O
issues O
and O
variables O
outside O
the O
person B_PERSON
to O
a O
greater O
extent O
, O
but O
the O
fundamental O
interest O
in O
and O
belief O
in O
psychological O
variables O
as O
the O
key O
force O
in O
determining O
health O
behavior O
remains O
. O

The O
implications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
focus B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
psychological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
determinants I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
behavioral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
decision I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
- O
making B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
my O
own B_LOCATION/B_PERSON
research I_LOCATION/I_PERSON
area I_LOCATION/I_PERSON
of O
interest B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
obesity B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
are O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

One B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
is O
the O
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
psychological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
most B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
protocols I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
e O
. O
g B_PROTEIN[GENE]/B_MEASURE
. O
, O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
behavioral B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intentions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
self B_PERSON/B_LOCATION
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
perception B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
barriers B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
change O
, O
perception B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
social B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MENTAL_OR_BEHAVIORAL_DYSFUNCTION[DISEASE]
expectations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MENTAL_OR_BEHAVIORAL_DYSFUNCTION[DISEASE]
) O
. O

A O
second B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
the O
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
elements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
specifically O
target O
psychological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
perceptions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
processes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
independent I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
diet B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
physical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
activity I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
behaviors I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
that O
actually O
produce O
weight B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
e O
. O
g B_GENE/B_MEASURE
. O
, O
how O
to O
deal O
with O
emotional B_DISEASE_ADJECTIVE[DISEASE]
eating I_DISEASE_ADJECTIVE[DISEASE]
, O
how O
to O
deal O
with O
the O
frustration B_DISEASE_ADJECTIVE[DISEASE]
of O
lapses B_DISEASE
and O
relapses B_DISEASE
, O
and O
how O
to O
talk O
to O
yourself O
to O
increase O
self B_PERSON/B_DISEASE
- O
motivation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
) O
. O

A O
third B_SEQUENCE[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
belief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_RELIGION[SOCIAL_CIRCUMSTANCES]
that O
psychological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
treatment B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiences I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
themselves O
are O
very O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
deserve O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Common B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behavioral I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
prescriptions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
frequency B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
self B_PERSON/B_LOCATION
- O
weighing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
exemplary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
i O
. O
e O
. O
, O
recommending O
infrequent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
weighing O
to O
prevent O
discouraging B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
feedback I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O
progress B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
encouraging O
smaller B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
thus O
' O
more O
attainable B_DISEASE_ADJECTIVE[DISEASE]
' I_DISEASE_ADJECTIVE[DISEASE]
behavior I_DISEASE_ADJECTIVE[DISEASE]
and O
weight B_MEASURE/B_LOCATION
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
belief B_RELIGION[SOCIAL_CIRCUMSTANCES]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
they O
will O
be O
more O
motivating O
) O
. O

The O
problem B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
emphasis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
on O
cognitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
weight B_MEASURE/B_PERSON
- O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
that O
they O
have O
so O
far O
failed O
to O
meet O
fundamental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scientific I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
empirical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
verification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Thus O
, O
they O
also O
have O
not O
led O
to O
a O
better B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
process I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
have O
not O
improved O
our O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
predict O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
have O
not O
led O
to O
improvement B_DISEASE_ADJECTIVE[DISEASE]
in O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
methods I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

In O
some O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
it O
is O
even O
arguable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
they O
have O
made O
treatment B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
worse I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

I O
will O
illustrate O
these O
problems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
my O
own B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Like O
most B_PERSON
behavioral I_PERSON
researchers I_PERSON
in O
the O
obesity B_LOCATION
area I_LOCATION
, O
I O
have O
attempted O
to O
measure O
elements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
every O
obesity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intervention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
project I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
have O
ever O
conducted O
. O

I O
have O
assessed O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
behavioral B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
self I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
psychological B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
well O
- O
being O
, O
perceived O
barriers B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
diet B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
physical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
activity I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
change I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
stages B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
of O
- O
change B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
perceived O
social B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
support I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

How O
well O
have O
empirical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
examinations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
of O
these O
factors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
fared O
as O
predictors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
success B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
weight B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
control I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Self B_PERSON/B_LOCATION
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

We O
have O
examined O
the O
predictive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
value I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
self B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
assessments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
several B_NUMBER[MEASURE]
of O
our O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
describe O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
three B_NUMBER[MEASURE]/B_PERSON
of O
these O
here O
in O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detail I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
[ O
8 B_MEASURE
- O
10 B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
. O

In O
the O
first O
study O
, O
self O
- O
efficacy O
was O
assessed O
at O
baseline O
, O
posttreatment O
, O
and O
one O
year O
later O
in O
85 O
men B_PERSON
participating O
in O
a O
15 O
- O
week O
weight O
- O
loss O
program O
[ O
8 O
] O
. O

The O
self B_PERSON/B_MEASURE
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
instrument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
had O
subscales B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
emotional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
states I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
e B_OTHER/B_PROTEIN[GENE]
. O
g B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O
, O
anxiety B_DISEASE/B_PERSON
) O
and O
situations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
e B_PROTEIN[GENE]/B_DISEASE
. O
g B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O
, O
eating O
away O
from O
home B_LOCATION/B_PERSON
) O
. O

Higher B_MEASURE/B_LOCATION
baseline B_MEASURE/I_LOCATION
self B_MEASURE/I_LOCATION
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
on O
both O
subscales B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
associated O
with O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
weight I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
loss I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
and O
at O
1 B_NUMBER[MEASURE]
- O
and O
2 B_NUMBER[MEASURE]
- O
year B_MEASURE/B_LOCATION
follow I_MEASURE/I_LOCATION
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

emotional B_LOCATION/B_DISEASE
self I_LOCATION/I_DISEASE
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
at O
posttreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
did O
not O
predict O
weight B_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
at O
1 B_SEQUENCE[MEASURE]
- O
or O
2 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
follow I_TIME[MEASURE]/I_LOCATION
- O
up B_LOCATION/B_LANGUAGE
. O

Situational B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
self I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
posttreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
predicted O
weight B_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
at O
1 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
but O
not O
2 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
follow I_TIME[MEASURE]/I_LOCATION
- O
up B_LOCATION/B_LANGUAGE
. O

The O
second O
study O
examined O
mood O
and O
situational O
self O
- O
efficacy O
in O
55 O
men B_PERSON
and O
58 O
women B_PERSON/B_BIO
before O
and O
after O
a O
16 O
- O
week O
weight O
- O
loss O
treatment O
with O
a O
1 O
- O
year O
follow O
- O
up O
[ O
9 O
] O
. O

Women B_PERSON/B_BIO
had O
lower O
pretreatment O
self O
- O
efficacy O
than O
men B_PERSON
. O

Self O
- O
efficacy O
was O
predictive O
of O
weight O
loss O
and O
maintenance O
in O
men B_PERSON/B_BIO
but O
not O
in O
women B_PERSON/B_BIO
. O

Change O
in O
self O
- O
efficacy O
over O
time O
was O
positively O
related O
to O
weight O
change O
in O
women B_PERSON/B_BIO
but O
not O
in O
men B_PERSON/B_BIO
. O

The O
third O
study O
examined O
predictors O
of O
weight O
change O
over O
a O
2 O
- O
year O
period O
in O
460 O
men B_PERSON
and O
1172 O
women B_PERSON/B_BIO
who O
received O
a O
low O
- O
intensity O
weight O
- O
loss O
intervention O
delivered O
through O
their O
HMO O
[ O
10 O
] O
. O

The O
self B_PERSON/B_MEASURE
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
the O
WEL B_SEQUENCE[MEASURE]/B_LOCATION
questionnaire I_SEQUENCE[MEASURE]/I_LOCATION
. O

Men B_PERSON
again O
were O
found O
to O
have O
higher O
baseline O
self O
- O
efficacy O
than O
women B_PERSON/B_BIO
. O

Self O
- O
efficacy O
did O
not O
predict O
weight O
change O
in O
men B_PERSON/B_BIO
but O
was O
positively O
, O
though O
weakly O
, O
related O
to O
weight O
change O
at O
6 O
months O
only O
in O
women B_PERSON
. O

Our O
overall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
conclusion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
the O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O
above O
, O
as O
well O
as O
others B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O
pursued O
in O
as O
great B_MEASURE/B_LOCATION
detail I_MEASURE/I_LOCATION
, O
is O
that O
self B_PERSON/B_MEASURE
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
a O
weak B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
predictor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
weight B_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
and O
is O
inconsistent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
populations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
gender B_PERSON/B_LOCATION
. O

It O
tends O
to O
increase O
with O
weight B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
loss I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
efficacy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
not O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
longer B_TIME[MEASURE]/B_LOCATION
- O
term B_TIME[MEASURE]/B_LOCATION
weight I_TIME[MEASURE]/I_LOCATION
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

barriers B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
Adherence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

We O
have O
also O
attempted O
to O
measure O
barriers B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
adherence O
to O
weight B_DISEASE
- O
control B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
behaviors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
many B_NUMBER[MEASURE]
of O
our O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O
11 B_MEASURE
- O
14 B_MEASURE
] I_MEASURE
. O

The O
instruments O
used O
for O
this O
have O
typically O
been O
formatted O
similarly O
to O
efficacy O
questionnaires O
in O
that O
people B_PERSON
are O
asked O
to O
indicate O
how O
difficult O
they O
find O
situational O
, O
knowledge O
, O
and O
motivational O
challenges O
to O
achieving O
diet O
and O
exercise O
changes O
. O

The O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
been O
quite O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

Baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
perceived B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
barriers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
behavior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
change I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
are O
not O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
weight B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Weight B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
associated O
with O
reported O
decreases B_DISEASE_ADJECTIVE[DISEASE]
in O
perceived O
barriers B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
- O
induced O
change B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
perceived O
barriers B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
weight B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
words I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
barrier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perceptions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
we O
have O
measured O
them O
do O
not O
appear O
to O
have O
pragmatic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Weight B_MEASURE
Goals I_MEASURE
. O

Goal O
- O
setting O
has O
long O
been O
of O
interest O
to O
health O
behavior O
theory O
and O
in O
recent O
years O
has O
attracted O
attention O
in O
weight O
- O
loss O
research O
when O
it O
was O
realized O
that O
most O
people B_PERSON
who O
enter O
weight O
- O
loss O
treatments O
want O
to O
lose O
a O
lot O
more O
weight O
than O
is O
realistic O
given O
the O
potency O
of O
current O
weight O
- O
loss O
methodologies O
[ O
15 O
] O
. O

When O
asked O
to O
describe O
weight B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
losses I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
they O
deem O
to O
represent O
' O
dream B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
happy B_DISEASE_ADJECTIVE[DISEASE]
, O
acceptable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
disappointing B_DISEASE_ADJECTIVE[DISEASE]
, O
' O
many B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
individuals I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
fail O
to O
reach O
even O
' O
disappointing B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
' O
weight B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
losses I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O
though O
in O
objective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
medical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
terms I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
the O
results B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
the O
argument B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
failure B_DISEASE
to O
reach O
gratifying O
weight B_MEASURE/B_DISEASE
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
goals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
leads O
to O
psychological B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
distress B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O
lowers O
weight B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
self I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
undermines O
weight B_MEASURE/B_LOCATION
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
has O
become O
popular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
recommend O
counseling O
in O
weight B_MEASURE/B_DISEASE
- O
loss B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
specifically O
targeting O
the O
lowering B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
theoretical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
argument I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
that O
excessive B_PERSON
outcome I_PERSON
expectations I_PERSON
undermine O
behavioral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
efforts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

We O
have O
now O
completed O
three B_MEASURE/B_ENT
sets I_MEASURE/I_ENT
of O
formal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examining O
whether O
weight B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
weight B_MEASURE/B_LOCATION
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
one O
of O
these O
analyses O
the O
relationship O
between O
weight O
- O
loss O
goals O
, O
weight O
- O
loss O
goal O
attainment O
, O
and O
long O
- O
term O
( O
30 O
months O
) O
weight O
- O
loss O
attainment O
and O
psychological O
well O
- O
being O
were O
assessed O
in O
69 O
men B_PERSON
and O
61 O
women B_PERSON/B_BIO
participating O
in O
an O
intensive O
behavioral O
treatment O
program O
[ O
16 O
] O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicated O
that O
weight B_MEASURE/B_PERSON
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
goals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
unrealistically O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
on O
average B_MEASURE/B_PERSON
and O
that O
lower B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goals B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
more O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
reached O
. O

Nevertheless O
, O
weight B_MEASURE/B_LOCATION
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
predict O
either O
short B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
or O
long B_MEASURE/B_LOCATION
- O
term B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
weight I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
losses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
were O
not O
associated O
with O
elevated B_DISEASE_ADJECTIVE[DISEASE]
psychological I_DISEASE_ADJECTIVE[DISEASE]
distress I_DISEASE_ADJECTIVE[DISEASE]
. O

Two B_NUMBER[MEASURE]/B_LOCATION
more O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O
have O
conducted O
looking O
at O
weight B_MEASURE/B_PERSON
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
goals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
predictors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
success B_DISEASE
have O
produced O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
Linde B_PERSON/B_LOCATION
JA I_PERSON/I_LOCATION
, O
Jeffery B_PERSON/B_LOCATION
RW I_PERSON/I_LOCATION
, O
Levy B_LOCATION/B_PERSON
RL I_LOCATION/I_PERSON
, O
Pronk B_LOCATION
NP I_LOCATION
and O
Boyle B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RG I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
unpublished B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
17 B_TIME[MEASURE]
] O
] B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Weight B_MEASURE/B_PERSON
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
goals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
either O
did O
not O
predict O
weight B_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
at O
all O
or O
were O
slightly O
positively O
related O
to O
weight B_MEASURE/B_BIO
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

perceived O
Social B_DISEASE_ADJECTIVE[DISEASE]
Support I_DISEASE_ADJECTIVE[DISEASE]
. O

perceived O
social B_DISEASE_ADJECTIVE[DISEASE]
support I_DISEASE_ADJECTIVE[DISEASE]
is O
another O
psychological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
thought O
to O
influence O
health B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
decision I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
- O
making B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
measured O
social B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
support I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
a O
variety B_ENT/B_MEASURE
of O
ways B_LOCATION/B_LANGUAGE
in O
our O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
ranging O
from O
single B_NUMBER[MEASURE]
- O
item B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
questions I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
multipaged B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
attempting O
to O
differentiate O
among O
informational B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
instrumental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
, O
and O
emotional B_PERSON/B_EDU[ORGANIZATION]
support I_PERSON/I_EDU[ORGANIZATION]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
unfortunately O
, O
have O
closely O
paralleled O
those O
we O
have O
seen O
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
barriers B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
adherence O
. O

assessments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
social B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
prior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
do O
not O
predict O
weight B_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
. O

Average B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
social B_DISEASE
support I_DISEASE
tend O
to O
parallel O
weight B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O
. O

When O
people B_PERSON/B_BIO
lose O
weight O
they O
report O
more O
social O
support O
. O

When O
they O
regain O
, O
they O
report O
less B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
words B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
perceptions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
social B_DISEASE
support I_DISEASE
are O
not O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
success B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
weight B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

frequency B_MEASURE/B_PERSON
Weight B_MEASURE/I_PERSON
Self B_MEASURE/I_PERSON
- O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Self O
- O
monitoring O
of O
health O
behavior O
is O
incorporated O
into O
many O
health O
behavior O
theories O
, O
usually O
as O
part O
of O
a O
person B_PERSON/B_ORGANIZATION
' O
s O
assessment O
of O
achieved O
outcomes O
. O

Although O
self B_PERSON/B_LOCATION
- O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
usually O
considered O
a O
positive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
element I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
adoption B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
health B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
behavior I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
in O
obesity B_PERSON/B_LOCATION
treatment I_PERSON/I_LOCATION
frequent I_PERSON/I_LOCATION
self I_PERSON/I_LOCATION
- O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
weight B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
tended O
to O
be O
down O
- O
played O
or O
even O
discouraged B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
grounds B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
disappointing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
i O
. O
e O
. O
, O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
desired B_MEASURE
weight I_MEASURE
change I_MEASURE
) O
may O
undermine O
motivation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
is O
another O
example B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
which O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behavior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
theory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O
have O
indirectly O
led O
to O
incorrect B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recommendations I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
active B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
discouragement I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
frequent B_PERSON/B_LOCATION
self I_PERSON/I_LOCATION
- O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
weight B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
become O
popular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
the O
premise B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
more O
frequent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
weighting I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
will O
cause O
psychological B_DISEASE/B_MEASURE
stress I_DISEASE/I_MEASURE
and O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
self I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Recently O
, O
we O
have O
examined O
the O
relationship B_PERSON/B_MEASURE
between O
frequency B_MEASURE
of O
self B_PERSON/B_LOCATION
- O
weighing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
body B_MEASURE/B_DISEASE
weight I_MEASURE/I_DISEASE
in O
both O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
have O
found O
, O
somewhat O
to O
our O
surprise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
that O
frequency B_MEASURE
of O
self B_PERSON/B_LOCATION
- O
weighing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
strongest B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
single I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
predictors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
body B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weight B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cross B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
sectionally O
, O
and O
change B_MEASURE
in O
the O
frequency B_MEASURE
of O
self B_PERSON/B_LOCATION
- O
weighing B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
strongest B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
predictors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
weight B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
Linde B_PERSON
JA I_PERSON
, O
Jeffery B_TIME[MEASURE]/B_PERSON
RW I_TIME[MEASURE]/I_PERSON
and O
French B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SA I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
unpublished B_MEASURE/B_LOCATION
data I_MEASURE/I_LOCATION
] I_MEASURE/I_LOCATION
. O

The O
direction B_MEASURE
of O
predictions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
, O
is O
opposite B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
derived O
from O
theory B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

People B_PERSON/B_BIO
who O
weigh O
themselves O
more O
weigh O
less O
and O
are O
more O
successful O
in O
losing O
weight O
. O

Stage B_ENT/B_TIME[MEASURE]
- O
of O
- O
Change B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
failure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
prove O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
weight B_MEASURE/B_PERSON
- O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
relationship B_PERSON/B_MEASURE
between O
a O
stage B_ENT/B_MEASURE
- O
of O
- O
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
adopted O
from O
Prochaska B_PERSON/B_BIO
and O
short B_MEASURE
- O
and O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
18 B_GENE/B_LOCATION
] B_GENE/I_LOCATION
. O

categories B_ORGANIZATION/B_TIME[MEASURE]
of O
precontemplation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
contemplation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
preparation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
defined O
based O
on O
questions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
about O
weight B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intentions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
recent B_MEASURE/B_LOCATION
weight I_MEASURE/I_LOCATION
- O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attempts B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Despite O
a O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sample I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
size I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
excellent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
follow O
- O
up O
rates B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
well O
- O
measured O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
were O
unable B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
demonstrate O
that O
staging O
algorithms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recommended O
by O
proponents B_PERSON
of O
the O
Transtheoretical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
could O
predict O
weight B_MEASURE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Modification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
expectations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Our O
most O
recent B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effort I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
utilize O
health B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
theory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
obesity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
intervention I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
research I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
is O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
attempted O
to O
examine O
the O
effectiveness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
experimentally O
- O
induced O
outcome B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
expectancies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
weight B_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
[ O
Finch B_PERSON
EA I_PERSON
, O
Linde B_PERSON/B_LOCATION
JA B_PERSON/I_LOCATION
, O
Jeffery B_PERSON/B_COLOR
RW I_PERSON/I_COLOR
, O
Rothman B_PERSON/B_COLOR
AJ I_PERSON/I_COLOR
and O
King B_PERSON/B_LOCATION
cm I_PERSON/I_LOCATION
, O
unpublished B_LOCATION/B_MEASURE
data I_LOCATION/I_MEASURE
] I_LOCATION/I_MEASURE
. O

Obese O
men B_PERSON
and O
women B_PERSON
participated O
in O
an O
8 O
- O
week O
weight O
- O
loss O
program O
with O
18 O
- O
month O
follow O
- O
up O
in O
which O
they O
were O
assigned O
to O
one O
of O
two O
expectancy O
groups O
. O

The O
optimistic B_ORGANIZATION/B_PERSON
group B_ORGANIZATION/I_PERSON
was O
told O
that O
focusing O
exclusively O
on O
the O
positive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
weight B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
be O
valuable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
ensuring O
that O
they O
remained O
motivated O
in O
their O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
was O
given O
assignments B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
weekly B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
group I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
sessions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O
homework B_PERSON/B_TIME[MEASURE]
between O
sessions B_TIME[MEASURE]/B_PERSON
to O
reinforce O
this O
optimistic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mindset I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

A O
' B_PERSON
balanced I_PERSON
' O
expectancy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
received O
the O
instructions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
focusing O
on O
both O
the O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
negative B_DISEASE_ADJECTIVE[DISEASE]
aspects I_DISEASE_ADJECTIVE[DISEASE]
of O
weight B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
balanced B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
approach I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
would O
be O
most O
conducive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
maintaining O
weight B_MEASURE/B_LOCATION
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
motivation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
group B_ORGANIZATION/B_PERSON
also O
received O
assignments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
to O
reinforce O
their O
message B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
the O
expectation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
induction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
initially O
but O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
maintain O
in O
the O
face B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
real B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
experience B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
were O
also O
unable B_PERSON/B_LOCATION
to O
show O
that O
experimentally O
- O
induced O
expectations B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influenced O
weight B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
loss B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
success I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

summary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

To O
summarize O
the O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O
above O
, O
I O
have O
had O
considerable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difficulty I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
the O
last B_TIME[MEASURE]/B_ENT
25 I_TIME[MEASURE]/I_ENT
years I_TIME[MEASURE]/I_ENT
in O
confirming O
that O
the O
psychosocial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variables I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
favored O
by O
health B_PERSON
behavior I_PERSON
theory I_PERSON
are O
of O
much B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
value I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
obesity B_PERSON/B_ORGANIZATION
intervention I_PERSON/I_ORGANIZATION
research I_PERSON/I_ORGANIZATION
. O

They O
do O
not O
predict O
weight B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O
, O
either O
as O
mediators B_PERSON/B_ORGANIZATION
or O
moderators B_PERSON/B_ORGANIZATION
. O

There O
is O
little B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
support O
the O
idea B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
that O
targeting O
them O
for O
intervention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
improves O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
, O
of O
course O
, O
arguable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
the O
weak B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relating O
to O
health B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theory I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variables I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O
large B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
part I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
methodological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
weaknesses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
either O
in O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tools I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
their O
frequency B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

I O
would O
argue O
, O
however O
, O
that O
25 B_PERSON/B_ENT
years I_PERSON/I_ENT
is O
long O
enough B_TIME[MEASURE]/B_LOCATION
to O
wait O
for O
improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
that O
it O
is O
time B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
look O
elsewhere O
for O
variables B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
better O
predict O
weight B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
that O
, O
therefore O
, O
may O
form O
a O
better B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
basis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
improving O
future B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

implication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Weight B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
Loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Given O
the O
lack B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
success B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
finding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
cognitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mediators I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
behavior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
weight B_DISEASE/B_PERSON
loss I_DISEASE/I_PERSON
, O
one O
might O
surmise O
that O
progress B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O
improving O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interventions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
the O
last B_TIME[MEASURE]/B_ENT
20 I_TIME[MEASURE]/I_ENT
years I_TIME[MEASURE]/I_ENT
must O
have O
been O
dreary B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indeed O
. O

somewhat O
surprisingly O
, O
however O
, O
that O
is O
not O
the O
case B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
short B_PERSON/B_MEASURE
- O
term B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 B_NUMBER[MEASURE]
to O
12 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
success B_MEASURE/B_DISEASE
of O
weight B_MEASURE/B_DISEASE
- O
loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
approximately O
doubled O
over O
that O
time B_TIME[MEASURE]/B_LOCATION
and O
several B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
variables I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
identified O
that O
reliably O
enhance O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
has O
been O
clearly O
shown O
experimentally O
that O
increasing O
treatment B_MEASURE/B_DISEASE
length B_MEASURE/I_DISEASE
[ O
19 B_MEASURE
] I_MEASURE
, O
prescribing O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
energy B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
intakes I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
20 B_MEASURE
] I_MEASURE
, O
prescribing O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
energy B_MEASURE/B_DISEASE
expenditure I_MEASURE/I_DISEASE
[ O
21 B_MEASURE
] I_MEASURE
, O
using O
a O
deposit B_PERSON/B_ORGANIZATION
contract I_PERSON/I_ORGANIZATION
and O
group B_ORGANIZATION/B_PERSON
- O
based O
reward B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
systems I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
[ O
22 B_MEASURE
] I_MEASURE
, O
and O
simplifying O
adherence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
diet O
through O
meal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
substitutes I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
[ O
23 B_MEASURE
] I_MEASURE
and O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
providing O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
equipment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
24 B_MEASURE
] I_MEASURE
all O
improve O
initial B_DISEASE_ADJECTIVE[DISEASE]
weight I_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
. O

From O
a O
theoretical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perspective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
however O
, O
one B_PERSON/B_LOCATION
thing I_PERSON/I_LOCATION
is O
noteworthy B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
about O
these O
successful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
innovations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
not O
incompatible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
, O
none B_PERSON/B_NUMBER[MEASURE]
of O
them O
are O
specifically O
derived O
from O
cognitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
decision I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
making O
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Indeed O
, O
health B_ORGANIZATION/B_PERSON
behavior I_ORGANIZATION/I_PERSON
theory I_ORGANIZATION/I_PERSON
does O
not O
include O
variables B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O
these O
in O
its O
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Where B_LOCATION
Do O
We O
Go O
From O
Here O
. O

The O
argument B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
above O
about O
the O
practical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
limitations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
popular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
theories I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
health B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
is O
not O
meant O
to O
be O
a O
call B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
abandon O
theory B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

behavior O
scientists O
have O
amassed O
much O
useful O
information O
about O
the O
principles O
underlying O
human B_PERSON/B_SPECIES[BIO]
behavior O
that O
should O
be O
valuable O
for O
health O
behavior O
interventions O
. O

Much O
is O
known O
about O
human B_PERSON/B_SPECIES[BIO]
perception O
, O
learning O
, O
motivation O
, O
and O
responsiveness O
to O
environmental O
opportunities O
and O
contingencies O
. O

Health O
behavior O
intervention O
lies O
at O
the O
interface O
between O
people B_PERSON
and O
their O
environment O
. O

Interventionists O
change O
aspects O
of O
the O
environment O
( O
cues O
, O
information O
, O
behavioral O
contingencies O
) O
with O
the O
intention O
of O
producing O
changes O
in O
how O
people B_PERSON/B_BIO
behave O
. O

What O
is O
needed O
to O
advance O
health B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
behavior I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
intervention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
is O
theory B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
addresses O
relationships B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
modifiable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
environment B_LOCATION/B_PERSON
and O
behavior B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

There O
is O
no O
doubt B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
cognitive B_PERSON
processes I_PERSON
are O
involved O
in O
these O
relationships B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

However O
, O
the O
extent B_MEASURE/B_LOCATION
to O
which O
current B_PERSON/B_LOCATION
theories I_PERSON/I_LOCATION
capture O
this O
is O
questionable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Data O
now O
available O
suggest O
that O
easily O
obtainable O
information O
about O
people B_PERSON
' O
s O
cognitive O
processes O
adds O
little O
to O
our O
ability O
to O
predict O
the O
results O
of O
interventions O
. O

Thus O
, O
it O
may O
be O
wise B_DISEASE_ADJECTIVE[DISEASE]
to O
pay O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
attention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
applied O
theories B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
like O
classical B_EDU[ORGANIZATION]/B_PERSON
behavior I_EDU[ORGANIZATION]/I_PERSON
theory I_EDU[ORGANIZATION]/I_PERSON
[ O
25 B_MEASURE
] I_MEASURE
, O
communications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
theory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
[ O
26 B_MEASURE
] I_MEASURE
, O
and O
learning O
theory B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
27 B_MEASURE
] I_MEASURE
than O
to O
those O
coming O
out O
of O
the O
social B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cognitive I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
traditions I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

competing O
interests B_DISEASE
. O

None B_PERSON
declared O
. O

